Raw Drug,Mechanism Of Action,drug_cleaned,drug_sponsor,standard_drug,synonym_cortellus,flag,synonym_list,drug_cleaned_cortellus,flag_synoymn_list,synonym_list_cleaned,Mapping_flag
nivolumab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,nivolumab,,nivolumab,nivolumab,fexact,"['nivolumab', 'MDX-1106-04', 'Opdivo', 'BMS-936558-01', 'PD-1 checkpoint inhibitor (cancer),/', 'BMS-986298', 'anti-PD-1 antibody (cancer), Ono/Medarex/BMS', 'anti-PD-1 antibody (cancer), Ono//BMS', 'ONO-4538', 'PD-1 checkpoint inhibitor (cancer),/Ono', 'anti-PD-1 antibody (cancer),//BMS', 'BMS-936558', 'NIVO', '89Zr-nivolumab', 'MDX-1106']",nivolumab,fexact,"['nivolumab', 'mdx 1106 04', 'opdivo', 'bms 936558 01', 'pd 1 checkpoint inhibitor cancer', 'bms 986298', 'anti pd 1 antibody cancer ono medarex bms', 'anti pd 1 antibody cancer ono bms', 'ono 4538', 'pd 1 checkpoint inhibitor cancer ono', 'anti pd 1 antibody cancer bms', 'bms 936558', 'nivo', '89zr nivolumab', 'mdx 1106']",correct_mapping
ipilimumab (iv),CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,ipilimumab,,ipilimumab,ipilimumab,fexact,"['BMS-734016', 'MDX-010', 'Winglore', 'MDX-101', 'anti-CTLA4, Medarex', 'Yervoy', 'MDX-CTLA4', 'CTLA-4 checkpoint inhibitor (cancer)', 'anti-CTLA4', 'ipilimumab']",ipilimumab,fexact,"['bms 734016', 'mdx 010', 'winglore', 'mdx 101', 'anti ctla4 medarex', 'yervoy', 'mdx ctla4', 'ctla 4 checkpoint inhibitor cancer', 'anti ctla4', 'ipilimumab']",correct_mapping
pemetrexed disodium,Phosphoribosylglycinamide formyltransferase inhibitor; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor,pemetrexed disodium,,pemetrexed disodium,pemetrexed disodium,fexact,"['NSC-698037', 'multitargeted antifolate', 'Alimta', 'pemetrexed', 'MTA', 'LY-231514', 'IND-40061', 'pemetrexed sodium hydrate', 'pemetrexed disodium']",pemetrexed disodium,fexact,"['nsc 698037', 'multitargeted antifolate', 'alimta', 'pemetrexed', 'mta', 'ly 231514', 'ind 40061', 'pemetrexed sodium hydrate', 'pemetrexed disodium']",correct_mapping
paclitaxel,Beta tubulin inhibitor; Microtubule stimulant; Taxane,paclitaxel,,paclitaxel,paclitaxel,fexact,"['Praxel', 'BMS-181339-01', 'taxol A, NIH', 'paclitaxel, BMS', 'Anzatax', 'Onxal', 'intaxel', 'taxol, BMS', 'taxol, NIH', 'taxol A, BMS', 'paclitaxel, NIH', 'Bristaxol', 'NSC-125973', 'paclitaxel', 'Asotax', 'NSC-673089', 'Taxol']",paclitaxel,fexact,"['praxel', 'bms 181339 01', 'taxol a nih', 'paclitaxel bms', 'anzatax', 'onxal', 'intaxel', 'taxol bms', 'taxol nih', 'taxol a bms', 'paclitaxel nih', 'bristaxol', 'nsc 125973', 'paclitaxel', 'asotax', 'nsc 673089', 'taxol']",correct_mapping
nab-paclitaxel (IV),Beta tubulin inhibitor; Microtubule stimulant; Taxane,nab-paclitaxel,,"paclitaxel (albumin-bound nanoparticle, intravenous)",nab paclitaxel,fexact,"['paclitaxel (albumin-bound nanoparticle, intravenous), Celgene', 'nab-paclitaxel', 'Abraxus', 'paclitaxel (albumin-bound nanoparticle, intravenous), American Bioscience', 'ABI-007', 'Abraxane', 'Capxol', 'paclitaxel (albumin-bound nanoparticle, intravenous), American Pharmaceutical Partners', 'paclitaxel (albumin-bound nanoparticle, intravenous)', 'paclitaxel', 'paclitaxel (albumin-bound nanoparticle, intravenous),/Taiho', 'paclitaxel (albumin-bound nanoparticle, intravenous),/']","paclitaxel (albumin-bound nanoparticle, intravenous)",fexact,"['paclitaxel albumin bound nanoparticle intravenous celgene', 'nab paclitaxel', 'abraxus', 'paclitaxel albumin bound nanoparticle intravenous american bioscience', 'abi 007', 'abraxane', 'capxol', 'paclitaxel albumin bound nanoparticle intravenous american pharmaceutical partners', 'paclitaxel albumin bound nanoparticle intravenous', 'paclitaxel', 'paclitaxel albumin bound nanoparticle intravenous taiho', 'paclitaxel albumin bound nanoparticle intravenous']",correct_mapping
pembrolizumab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,pembrolizumab,,pembrolizumab,pembrolizumab,fexact,"['PD-1 checkpoint inhibitor (cancer), Merck & Co', 'SCH-900475', 'lambrolizumab, Merck', 'MK-3475', 'pembrolizumab', 'lambrolizumab', 'PD-1 checkpoint inhibitor (cancer)', 'Keytruda']",pembrolizumab,fexact,"['pd 1 checkpoint inhibitor cancer merck co', 'sch 900475', 'lambrolizumab merck', 'mk 3475', 'pembrolizumab', 'lambrolizumab', 'pd 1 checkpoint inhibitor cancer', 'keytruda']",correct_mapping
carboplatin (iv),DNA inhibitor,carboplatin,,carboplatin,carboplatin,fexact,"['BMY-26575', 'Paraplatin', 'CBDCA', 'carboplatin']",carboplatin,fexact,"['bmy 26575', 'paraplatin', 'cbdca', 'carboplatin']",correct_mapping
afatinib,EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),afatinib,,afatinib,afatinib,fexact,"['Giotrif', 'afatinib', 'Tomtovok', 'Gilotrif', 'BIBW-2992', 'Tovok', 'dual EGFR/HER2 receptor tyrosine kinase inhibitor (solid tumors)', 'Xovoltib', 'afatinib dimaleate']",afatinib,fexact,"['giotrif', 'afatinib', 'tomtovok', 'gilotrif', 'bibw 2992', 'tovok', 'dual egfr her2 receptor tyrosine kinase inhibitor solid tumors', 'xovoltib', 'afatinib dimaleate']",correct_mapping
ECP-1014,Cyclooxygenase 2 inhibitor,ECP-1014,,,,0,"['chromene COX-2 inhibitors (tablets/capsules, inflammation/acute pain/cancer), Guangzhou Institutes of Biomedicine and Health/', 'chromene cox-2 inhibitors (oral, inflammation/acute pain/cancer)', 'GIBH-1018', 'chromene cox-2 inhibitors (tablets/capsules, inflammation/acute pain/cancer)', 'ECP-1014', 'GIBH-1010', 'GIBH-1008', 'ECP-1012', 'chromene COX-2 inhibitors (oral, inflammation/acute pain/cancer), Guangzhou Institutes of Biomedicine and Health', 'GIBH-1014']",,NER_API,[],0
metformin hydrochloride (extended release),Biguanide; Gluconeogenesis inhibitor,metformin hydrochloride,,metformin hydrochloride,metformin hydrochloride,fexact,"['Gliguanid', 'Metfogamma', 'Diabex', 'LA-6023', 'Glifage IR', 'Metgluco', 'Diaformin', 'Flumamine', 'metformin', 'BMS-207150', 'Glucophage', 'Siofor', 'Diabetosan', 'Fluamine', 'Diabex XR', 'Glifage', 'SMP-862', 'metformin hydrochloride', 'Glucofit']",metformin hydrochloride,fexact,"['gliguanid', 'metfogamma', 'diabex', 'la 6023', 'glifage ir', 'metgluco', 'diaformin', 'flumamine', 'metformin', 'bms 207150', 'glucophage', 'siofor', 'diabetosan', 'fluamine', 'diabex xr', 'glifage', 'smp 862', 'metformin hydrochloride', 'glucofit']",correct_mapping
AZD-7789,PD-1 antagonist; TIM3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,AZD-7789,,AZD-7789,azd 7789,fexact,"['AZD-7789', 'anti-PD-1/anti-TIM-3 bispecific antibody (cancer)', 'PD1-TIM3 bsAb (cancer)', 'dual PD-1 checkpoint inhibitor/TIM-3 checkpoint inhibitor (cancer)']",AZD-7789,fexact,"['azd 7789', 'anti pd 1 anti tim 3 bispecific antibody cancer', 'pd1 tim3 bsab cancer', 'dual pd 1 checkpoint inhibitor tim 3 checkpoint inhibitor cancer']",correct_mapping
telisotuzumab vedotin,Tubulin inhibitor,telisotuzumab vedotin,,telisotuzumab vedotin,telisotuzumab vedotin,fexact,"['telisotuzumab vedotin', 'ABBV-399', 'anti-c-Met-monomethyl auristatin  ADC', 'anti-c-Met-MMAE ADC', 'ABT-399', 'Teliso-V', 'anti-c-Met-monomethyl auristatin E ADC (Intravenous, solid tumors/NSCLC)']",telisotuzumab vedotin,fexact,"['telisotuzumab vedotin', 'abbv 399', 'anti c met monomethyl auristatin adc', 'anti c met mmae adc', 'abt 399', 'teliso v', 'anti c met monomethyl auristatin e adc intravenous solid tumors nsclc']",correct_mapping
undisclosed - chemotherapy,Unidentified pharmacological activity,undisclosed - chemotherapy,,,,0,['undisclosed - chemotherapy'],,0,[],0
"immunotherapy, unspecified",Immuno-oncology therapy,immunotherapy,unspecified,,,0,['immunotherapy'],,0,[],0
capmatinib,MET tyrosine kinase inhibitor,capmatinib,,capmatinib hydrochloride,capmatinib,fexact,"['capmatinib', 'INC-280', 'INCB-028060', 'INCB-28060', 'capmatinib dihydrochloride hydrate', 'capmatinib hydrochloride', 'c-Met tyrosine kinase inhibitor (oral, capsule/tablet, cancer), Novartis', 'Tabrecta', 'c-Met tyrosine kinase inhibitor (oral, capsule/tablet, cancer)']",capmatinib hydrochloride,fexact,"['capmatinib', 'inc 280', 'incb 028060', 'incb 28060', 'capmatinib dihydrochloride hydrate', 'capmatinib hydrochloride', 'c met tyrosine kinase inhibitor oral capsule tablet cancer novartis', 'tabrecta', 'c met tyrosine kinase inhibitor oral capsule tablet cancer']",correct_mapping
sitravatinib,RET tyrosine kinase inhibitor,sitravatinib,,sitravatinib,sitravatinib,fexact,"['MG-516', 'multikinase inhibitor (oral, cancer)', 'sitravatinib', 'multikinase inhibitor (oral, cancer),/', 'multikinase inhibitor (oral, cancer), Mirati Therapeutics/', 'MGCD-516 malate', 'MGCD-516', 'multikinase inhibitor (oral, cancer), Methylgene', 'sitravatinib malate', 'MGCD-0516', 'MG-91516']",sitravatinib,fexact,"['mg 516', 'multikinase inhibitor oral cancer', 'sitravatinib', 'multikinase inhibitor oral cancer', 'multikinase inhibitor oral cancer mirati therapeutics', 'mgcd 516 malate', 'mgcd 516', 'multikinase inhibitor oral cancer methylgene', 'sitravatinib malate', 'mgcd 0516', 'mg 91516']",correct_mapping
brigatinib,EGFR antagonist; Anaplastic lymphoma kinase inhibitor; ROS receptor tyrosine kinase inhibitor,brigatinib,,brigatinib,brigatinib,fexact,"['AP-26113', 'anaplastic lymphoma kinase/EGFR inhibitors (cancer)', 'brigatinib', 'ALK/EGFR inhibitors (cancer)', 'Alunbrig']",brigatinib,fexact,"['ap 26113', 'anaplastic lymphoma kinase egfr inhibitors cancer', 'brigatinib', 'alk egfr inhibitors cancer', 'alunbrig']",correct_mapping
sotorasib,K-Ras inhibitor,sotorasib,,sotorasib,sotorasib,fexact,"['Lumakras', 'sotorasib', 'AMG-510', 'KRAS inhibitor (G12C-mutated solid tumors)']",sotorasib,fexact,"['lumakras', 'sotorasib', 'amg 510', 'kras inhibitor g12c mutated solid tumors']",correct_mapping
almonertinib,EGFR kinase inhibitor,almonertinib,,aumolertinib,almonertinib,fexact,"['aumolertinib', 'AMEILE', 'HS-10296', 'almonertinib', 'omatinib mesylate', 'EQ-143']",aumolertinib,fexact,"['aumolertinib', 'ameile', 'hs 10296', 'almonertinib', 'omatinib mesylate', 'eq 143']",correct_mapping
savolitinib,MET tyrosine kinase inhibitor,savolitinib,,savolitinib,savolitinib,fexact,"['c-Met inhibitor (cancer), Hutchison', 'savolitinib', 'HM-5016504', 'Orpathys', 'Volitinib', 'HMPL-504', 'AZD-6094', 'wolitini', 'c-Met inhibitor (cancer)']",savolitinib,fexact,"['c met inhibitor cancer hutchison', 'savolitinib', 'hm 5016504', 'orpathys', 'volitinib', 'hmpl 504', 'azd 6094', 'wolitini', 'c met inhibitor cancer']",correct_mapping
tislelizumab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,tislelizumab,,tislelizumab,tislelizumab,fexact,"['tislelizumab', 'VDT-482', 'immune checkpoint inhibitor (solid/hematological cancers)', 'PD-1 checkpoint inhibitor (cancer),/', 'mAbs target-7 (solid/hematological cancers)', 'PD-1 checkpoint inhibitor (cancer),/Novartis', 'BGB-A317', 'PD-1 checkpoint inhibitor (solid/hematological cancers)', 'BGB-108', 'PD-1 mAb (solid/hematological cancers)']",tislelizumab,fexact,"['tislelizumab', 'vdt 482', 'immune checkpoint inhibitor solid hematological cancers', 'pd 1 checkpoint inhibitor cancer', 'mabs target 7 solid hematological cancers', 'pd 1 checkpoint inhibitor cancer novartis', 'bgb a317', 'pd 1 checkpoint inhibitor solid hematological cancers', 'bgb 108', 'pd 1 mab solid hematological cancers']",correct_mapping
vinorelbine,Microtubule inhibitor; Tubulin inhibitor; Apoptosis stimulant; Vinca alkaloid,vinorelbine,,vinorelbine,vinorelbine,fexact,"['vinorelbine tartrate', 'KW-2307', 'vinorelbine', 'KW-3407', 'Eunades', 'vinorelbine monotartrate', 'Navelbine']",vinorelbine,fexact,"['vinorelbine tartrate', 'kw 2307', 'vinorelbine', 'kw 3407', 'eunades', 'vinorelbine monotartrate', 'navelbine']",correct_mapping
surufatinib,Colony stimulating factor 1 receptor antagonist; FGF receptor 1 tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Immuno-oncology therapy,surufatinib,,surufatinib,surufatinib,fexact,"['anticancer agents', 'sulfatinib', 'kinase inhibitors (cancer)', 'Sulanda', 'HMPL-012', 'suofantini', 'surufatinib', 'VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer)']",surufatinib,fexact,"['anticancer agents', 'sulfatinib', 'kinase inhibitors cancer', 'sulanda', 'hmpl 012', 'suofantini', 'surufatinib', 'vegfr 1 2 3 and fgfr 1 inhibitor oral cancer']",correct_mapping
"tretinoin, Roche",Microbial collagenase inhibitor; Protein synthesis inhibitor; Retinoic acid receptor agonist,tretinoin,Roche,tretinoin,tretinoin,fexact,"['tretinoin, Roche', 'NSC-122758', 'all-trans retinoic acid, Roche', 'all-trans-Retinoic acid', 'ATRA', 'IDP-121', 'Vesanoid', 'ATRA, Roche', 'tretinoin', 'all-trans retinoic acid']",tretinoin,fexact,"['tretinoin roche', 'nsc 122758', 'all trans retinoic acid roche', 'all trans retinoic acid', 'atra', 'idp 121', 'vesanoid', 'atra roche', 'tretinoin', 'all trans retinoic acid']",correct_mapping
atezolizumab,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,atezolizumab,,atezolizumab,atezolizumab,fexact,"['MPDL-3280A', 'PD-L1 checkpoint inhibitor (cancer),//', 'atezolizumab', 'RG-7746', 'PD-L1 checkpoint inhibitor (cancer), Genentech/Roche/', 'PD-L1 checkpoint inhibitor (cancer),/Roche/', 'RO-5541267', 'anti-PDL1 MAb (solid tumors), Genentech', 'anti-PDL1 MAb (solid tumors)', 'RG-7446', 'Tecentriq']",atezolizumab,fexact,"['mpdl 3280a', 'pd l1 checkpoint inhibitor cancer', 'atezolizumab', 'rg 7746', 'pd l1 checkpoint inhibitor cancer genentech roche', 'pd l1 checkpoint inhibitor cancer roche', 'ro 5541267', 'anti pdl1 mab solid tumors genentech', 'anti pdl1 mab solid tumors', 'rg 7446', 'tecentriq']",correct_mapping
"tumour infiltrating lymphocytes therapy, Shanghai OriginCell Therapeutics",Immuno-oncology therapy,tumour infiltrating lymphocytes therapy,Shanghai OriginCell Therapeutics,,,0,['tumour infiltrating lymphocytes therapy'],,0,[],0
SAR-444245,Interleukin 2 receptor agonist; T cell stimulant,SAR-444245,,THOR-707,sar 444245,fexact,"['THOR-707', 'Synthorin IL-2', 'IL-2 IO synthorin', 'SYTX80-013-A', 'SAR-444245', 'pegylated IL-2 (lyophilized, intravenous, cancer/solid tumor)', 'synthetic IL-2 (cancer)', 'Synthorin cytokine (cancer)']",THOR-707,fexact,"['thor 707', 'synthorin il 2', 'il 2 io synthorin', 'sytx80 013 a', 'sar 444245', 'pegylated il 2 lyophilized intravenous cancer solid tumor', 'synthetic il 2 cancer', 'synthorin cytokine cancer']",correct_mapping
NGM-707,Immuno-oncology therapy; Leukocyte immunoglobulin-like receptor B2 antagonist; ILT2 inhibitor,NGM-707,,NGM-707,ngm 707,fexact,"['dual ILT2/ILT4 checkpoint inhibitor (advanced solid tumors), NGM Biopharmaceuticals/', 'dual LILRB1/LILRB2 checkpoint inhibitor (advanced solid tumors), NGM Biopharmaceuticals/', 'NGM-707', 'dual ILT2/ILT4 checkpoint inhibitor (advanced solid tumors),/', 'dual LILRB1/LILRB2 checkpoint inhibitor (advanced solid tumors),/']",NGM-707,fexact,"['dual ilt2 ilt4 checkpoint inhibitor advanced solid tumors ngm biopharmaceuticals', 'dual lilrb1 lilrb2 checkpoint inhibitor advanced solid tumors ngm biopharmaceuticals', 'ngm 707', 'dual ilt2 ilt4 checkpoint inhibitor advanced solid tumors', 'dual lilrb1 lilrb2 checkpoint inhibitor advanced solid tumors']",correct_mapping
VTP-600,Immuno-oncology therapy,VTP-600,,VTP-600,vtp 600,fexact,['VTP-600'],VTP-600,fexact,['vtp 600'],correct_mapping
osimertinib (tablet),EGFR kinase inhibitor,osimertinib,,osimertinib,osimertinib,fexact,"['osimertinib mesylate', 'AZ-7550', 'osimertinib', 'AZ-5104', 'Tagrisso', 'osimertinib (T790M-mutation-targeting, NSCLC)', 'mereletinib', 'AZD-9291']",osimertinib,fexact,"['osimertinib mesylate', 'az 7550', 'osimertinib', 'az 5104', 'tagrisso', 'osimertinib t790m mutation targeting nsclc', 'mereletinib', 'azd 9291']",correct_mapping
MS-20,Reducing agent; Natural killer cell stimulant,MS-20,,MS-20,ms 20,fexact,"['Chemo Young', 'MS-20', 'MicroSoy-20']",MS-20,fexact,"['chemo young', 'ms 20', 'microsoy 20']",correct_mapping
IBI-323,PD-L1 antagonist; Lymphocyte-activation gene 3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,IBI-323,,IBI-323,ibi 323,fexact,"['dual PD-L1 checkpoint inhibitor/LAG-3 checkpoint inhibitor (cancer)', 'IBI-323', 'anti PD-L1/LAG-3 bispecific monoclonal antibody (cancer)']",IBI-323,fexact,"['dual pd l1 checkpoint inhibitor lag 3 checkpoint inhibitor cancer', 'ibi 323', 'anti pd l1 lag 3 bispecific monoclonal antibody cancer']",correct_mapping
ruxolitinib,Janus kinase 1 inhibitor; Janus kinase 2 inhibitor,ruxolitinib,,"ruxolitinib (sustained release, myelofibrosis)",ruxolitinib,fexact,"['ruxolitinib', 'INCB-018424', 'ruxolitinib (sustained release, myelofibrosis)']","ruxolitinib (sustained release, myelofibrosis)",fexact,"['ruxolitinib', 'incb 018424', 'ruxolitinib sustained release myelofibrosis']",correct_mapping
canakinumab (SC),Interleukin 1b antagonist; Immunosuppressant,canakinumab,,canakinumab,canakinumab,fexact,"['Ilaris', 'ACZ-885', 'anti-IL-1 beta monoclonal antibody (inflammation/COVID-19-induced pneumonia/cytokine release syndrome)', 'canakinumab']",canakinumab,fexact,"['ilaris', 'acz 885', 'anti il 1 beta monoclonal antibody inflammation covid 19 induced pneumonia cytokine release syndrome', 'canakinumab']",correct_mapping
canakinumab (IV),Interleukin 1b antagonist; Immunosuppressant,canakinumab,,canakinumab,canakinumab,fexact,"['Ilaris', 'ACZ-885', 'anti-IL-1 beta monoclonal antibody (inflammation/COVID-19-induced pneumonia/cytokine release syndrome)', 'canakinumab']",canakinumab,fexact,"['ilaris', 'acz 885', 'anti il 1 beta monoclonal antibody inflammation covid 19 induced pneumonia cytokine release syndrome', 'canakinumab']",correct_mapping
MCLA-129,EGFR antagonist; MET tyrosine kinase inhibitor; Immuno-oncology therapy; Immune checkpoint modulator,MCLA-129,,MCLA-129,mcla 129,fexact,"['anti-EGFR/ cMET bispecific antibody\xa0(Biclonics/ GlymaxX, solid tumor),/', 'MCLA-129', 'anti-EGFR/ cMET bispecific antibody\xa0(Biclonics/ GlymaxX, solid tumor), Merus/']",MCLA-129,fexact,"['anti egfr cmet bispecific antibody\xa0 biclonics glymaxx solid tumor', 'mcla 129', 'anti egfr cmet bispecific antibody\xa0 biclonics glymaxx solid tumor merus']",correct_mapping
plinabulin,Angiogenesis inhibitor; Tubulin inhibitor,plinabulin,,plinabulin,plinabulin,fexact,"['halimide', 'anti-microtubule agents (cancer)', 'halimide, UCSD/', 'halimide, Nereus', 'NPI-2350a', 'anticancer agents (marine microbe-isolated), Nereus', 'phenylahistin', '(S)-(-)-phenylahistin', 'KPU-2', 'NPI-2386', 'KPU-35', 'anticancer agents (marine microbe-isolated)', 'phenylahistin series, Nereus', 'NPI-3005', 'KPU-02', 'NPI-2358', 'phenylahistin series', 'NPI-2350', 'NPI-3001', 'anti-microtubule agents (cancer), Nereus', '(-)-phenylahistin', 'NPI-2352', 'NPI-3003', 'halimide, UCSD/Nereus', 'plinabulin', 'NPI-3004']",plinabulin,fexact,"['halimide', 'anti microtubule agents cancer', 'halimide ucsd', 'halimide nereus', 'npi 2350a', 'anticancer agents marine microbe isolated nereus', 'phenylahistin', 's phenylahistin', 'kpu 2', 'npi 2386', 'kpu 35', 'anticancer agents marine microbe isolated', 'phenylahistin series nereus', 'npi 3005', 'kpu 02', 'npi 2358', 'phenylahistin series', 'npi 2350', 'npi 3001', 'anti microtubule agents cancer nereus', 'phenylahistin', 'npi 2352', 'npi 3003', 'halimide ucsd nereus', 'plinabulin', 'npi 3004']",correct_mapping
medical device therapy,Not applicable,medical device therapy,,,,0,['medical device therapy'],,0,[],0
durvalumab,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,durvalumab,,durvalumab,durvalumab,fexact,"['MEDI-4736', 'durvalumab', 'PD-L1 checkpoint inhibitor (cancer), Medarex/', 'Imfinzi']",durvalumab,fexact,"['medi 4736', 'durvalumab', 'pd l1 checkpoint inhibitor cancer medarex', 'imfinzi']",correct_mapping
copanlisib,PI3 kinase alpha inhibitor; PI3 kinase beta inhibitor; PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor,copanlisib,,copanlisib hydrochloride,copanlisib,fexact,"['Aliqopa', 'copanlisib dihydrochloride', 'BAY-80-6946', 'PI3K inhibitor (cancer)', 'copanlisib hydrochloride', 'copanlisib']",copanlisib hydrochloride,fexact,"['aliqopa', 'copanlisib dihydrochloride', 'bay 80 6946', 'pi3k inhibitor cancer', 'copanlisib hydrochloride', 'copanlisib']",correct_mapping
BMS-986340,CC chemokine receptor 8 antagonist; Immuno-oncology therapy,BMS-986340,,BMS-986340,bms 986340,fexact,"['Treg modulator (cancer)', 'nonfucosylated anti-CCR8 mAb (cancer)', 'BMS-986340']",BMS-986340,fexact,"['treg modulator cancer', 'nonfucosylated anti ccr8 mab cancer', 'bms 986340']",correct_mapping
anlotinib hydrochloric,FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor,anlotinib hydrochloric,,,,0,['anlotinib hydrochloric'],,0,[],0
furmonertinib,EGFR kinase inhibitor,furmonertinib,,,,0,"['aifutini mesylate', 'alflutinib mesylate (oral/tablet, cancer),/', 'furmonertinib', 'fumeitini mesylate', 'alflutinib', 'aifutinib mesylate', 'AST-2818', 'alflutinib mesylate (oral/tablet, cancer),/ArriVent Biopharma', 'small molecule therapeutic (oral/tablet, cancer)', 'alflutinib mesylate (oral/tablet, cancer)']",,NER_API,[],0
radiation therapy,Unidentified pharmacological activity,radiation therapy,,,,0,['radiation therapy'],,0,[],0
"PD-L1 inhibitors, undisclosed",PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,PD-L1 inhibitors,undisclosed,,,0,['PD-L1 inhibitors'],,0,[],0
ESG-401,Unidentified pharmacological activity,ESG-401,,ESG-401,esg 401,fexact,"['humanized mAb anti-TROP-2 program (cancer)', 'ESG-401']",ESG-401,fexact,"['humanized mab anti trop 2 program cancer', 'esg 401']",correct_mapping
gemcitabine hydrochloride,DNA synthesis inhibitor; DNA repair enzyme inhibitor; Cell cycle inhibitor,gemcitabine hydrochloride,,gemcitabine,gemcitabine hydrochloride,fexact,"['gemcitabine hydrochloride', 'LY-188011', 'dFdCTP', 'DDFC', 'Gemtro', 'dFdC', 'dFdCyd', 'difluorodeoxycytidine hydrochloride', 'Gemzar', 'gemcitabine', 'NSC-613327']",gemcitabine,fexact,"['gemcitabine hydrochloride', 'ly 188011', 'dfdctp', 'ddfc', 'gemtro', 'dfdc', 'dfdcyd', 'difluorodeoxycytidine hydrochloride', 'gemzar', 'gemcitabine', 'nsc 613327']",correct_mapping
"bevacizumab, Pfizer",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Pfizer,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
BI-1810631,Unidentified pharmacological activity,BI-1810631,,,,0,['BI-1810631'],,NER_API,[],0
IDM-2101,Immuno-oncology therapy,IDM-2101,,OSE-2101,idm 2101,fexact,"['anti-MAGE-3 vaccine, IDM', 'cancer vaccine, IDM', 'OSE-2101', 'anti-MAGE-3 vaccine', 'cancer vaccine', 'IDM-2101', 'EP-2101', 'MAGE-3', 'MAGE-3, IDM', 'Tedopi']",OSE-2101,fexact,"['anti mage 3 vaccine idm', 'cancer vaccine idm', 'ose 2101', 'anti mage 3 vaccine', 'cancer vaccine', 'idm 2101', 'ep 2101', 'mage 3', 'mage 3 idm', 'tedopi']",correct_mapping
PF-07257876,CD47 antagonist; PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,PF-07257876,,,,0,"['dual PD-L1 checkpoint inhibitor/CD47 checkpoint inhibitor (bispecific antibody, solid tumor/NSCLC/SCCHN/ovarian cancer)', 'PF-07257876', 'anti-PD-L1/anti-CD47 bispecific antibody (solid tumor)']",,NER_API,[],0
TAK-676,STING agonist; Immuno-oncology therapy,TAK-676,,TAK-676,tak 676,fexact,"['sting agonist (cancer)', 'TAK-676']",TAK-676,fexact,"['sting agonist cancer', 'tak 676']",correct_mapping
docetaxel,Tubulin inhibitor; Microtubule stimulant; Taxane,docetaxel,,"docetaxel (polymeric micelle, solid tumor)",docetaxel,fexact,"['docetaxel-PM', 'docetaxel (polymeric micelle, solid tumor)', 'Nanoxel-PM', 'docetaxel', 'SYP-0704A', 'Nanoxel']","docetaxel (polymeric micelle, solid tumor)",fexact,"['docetaxel pm', 'docetaxel polymeric micelle solid tumor', 'nanoxel pm', 'docetaxel', 'syp 0704a', 'nanoxel']",correct_mapping
apatinib,RET tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor,apatinib,,rivoceranib mesylate,apatinib,fexact,"['VEGF receptor inhibitor (cancer)', 'Aitan', 'VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang', 'rivoceranib', 'apatinib mesylate', 'apatinib', 'rivoceranib mesylate', 'VEGFR2 receptor inhibitor (uterine/cervical/ovarian cancer), Jiangsu Henrui', 'VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/', 'YN-968D1']",rivoceranib mesylate,fexact,"['vegf receptor inhibitor cancer', 'aitan', 'vegfr2 receptor inhibitor cancer lsk jiangsu henrui bukwang', 'rivoceranib', 'apatinib mesylate', 'apatinib', 'rivoceranib mesylate', 'vegfr2 receptor inhibitor uterine cervical ovarian cancer jiangsu henrui', 'vegfr2 receptor inhibitor cancer lsk jiangsu henrui', 'yn 968d1']",correct_mapping
camrelizumab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,camrelizumab,,camrelizumab,camrelizumab,fexact,"['SHR-1210', 'camrelizumab', 'recombinant humanized anti-PD1 antibody, Jiangsu Hengrui Pharmaceutical', 'PD-1 checkpoint inhibitor (cancer), Shanghai Hengrui Pharmaceutical//Atridia', 'INCSHR-1210', 'PD-1 checkpoint inhibitor (cancer),//Atridia', 'PD-1 checkpoint inhibitor (cancer), Shanghai Hengrui Pharmaceutical/Incyte/Atridia']",camrelizumab,fexact,"['shr 1210', 'camrelizumab', 'recombinant humanized anti pd1 antibody jiangsu hengrui pharmaceutical', 'pd 1 checkpoint inhibitor cancer shanghai hengrui pharmaceutical atridia', 'incshr 1210', 'pd 1 checkpoint inhibitor cancer atridia', 'pd 1 checkpoint inhibitor cancer shanghai hengrui pharmaceutical incyte atridia']",correct_mapping
JY-025,Vascular endothelial growth factor receptor 2 antagonist,JY-025,,JY-025,jy 025,fexact,"['JY-025', 'recombinant anti-VEGFR2 fully human monoclonal antibody (cancer)']",JY-025,fexact,"['jy 025', 'recombinant anti vegfr2 fully human monoclonal antibody cancer']",correct_mapping
palbociclib,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,palbociclib,,palbociclib,palbociclib,fexact,"['PF-332991', 'PD-0332991-00', 'cell cycle regulators', 'PD-0205606', 'palbociclib', 'cell cycle regulators,/Parke-Davis', 'PD-332991', 'palbociclib isethionate', 'PF-0332991', 'Aiboxin', 'PD-991', 'Ibrance', 'cell cycle regulators, Pfizer', 'cell cycle regulators,/', 'cell cycle regulators,/Pfizer', 'PD-0332991']",palbociclib,fexact,"['pf 332991', 'pd 0332991 00', 'cell cycle regulators', 'pd 0205606', 'palbociclib', 'cell cycle regulators parke davis', 'pd 332991', 'palbociclib isethionate', 'pf 0332991', 'aiboxin', 'pd 991', 'ibrance', 'cell cycle regulators pfizer', 'cell cycle regulators', 'cell cycle regulators pfizer', 'pd 0332991']",correct_mapping
binimetinib,Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,binimetinib,,binimetinib,binimetinib,fexact,"['COMBO450', 'ONO-7703', 'MEK-1/2 inhibitors (tablet, inflammation, cancer)', 'Mektovi', 'binimetinib', 'MEK-162', 'ARRY-438162', 'ARRY-162', 'Balimek']",binimetinib,fexact,"['combo450', 'ono 7703', 'mek 1 2 inhibitors tablet inflammation cancer', 'mektovi', 'binimetinib', 'mek 162', 'arry 438162', 'arry 162', 'balimek']",correct_mapping
ociperlimab,TIGIT receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,ociperlimab,,ociperlimab,ociperlimab,fexact,"['anti-TIGIT monoclonal antibody (advanced solid tumors)', 'ociperlimab', 'BGB-A1217', 'TIGIT checkpoint inhibitor (advanced solid tumors)']",ociperlimab,fexact,"['anti tigit monoclonal antibody advanced solid tumors', 'ociperlimab', 'bgb a1217', 'tigit checkpoint inhibitor advanced solid tumors']",correct_mapping
sargramostim,Granulocyte macrophage colony stimulating factor agonist,sargramostim,,sargramostim,sargramostim,fexact,"['GM-CSF,/', 'BI 61.012', 'GM-CSF, Berlex/Schering', 'GM-CSF,/Schering', 'GM-CSF, Immunex', 'GM-CSF, Behringwerke', 'SHL-04023', 'Prokine', 'GM-CSF', 'Leukine', 'sargramostim']",sargramostim,fexact,"['gm csf', 'bi 61 012', 'gm csf berlex schering', 'gm csf schering', 'gm csf immunex', 'gm csf behringwerke', 'shl 04023', 'prokine', 'gm csf', 'leukine', 'sargramostim']",correct_mapping
IBI-188,CD47 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,IBI-188,,letaplimab,ibi 188,fexact,"['CD47 checkpoint inhibitor (intravenous, advanced malignancies/cancer)', 'letaplimab', 'Letaplimab', 'IBI-188', 'CD47 checkpoint inhibitor (intravenous, advanced solid tumor/lymphomas/cancer)']",letaplimab,fexact,"['cd47 checkpoint inhibitor intravenous advanced malignancies cancer', 'letaplimab', 'letaplimab', 'ibi 188', 'cd47 checkpoint inhibitor intravenous advanced solid tumor lymphomas cancer']",correct_mapping
carboplatin,DNA inhibitor,carboplatin,,carboplatin,carboplatin,fexact,"['BMY-26575', 'Paraplatin', 'CBDCA', 'carboplatin']",carboplatin,fexact,"['bmy 26575', 'paraplatin', 'cbdca', 'carboplatin']",correct_mapping
cisplatin,DNA inhibitor; DNA synthesis inhibitor,cisplatin,,,,0,"['demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors),/Orient Europharma', 'cisplatin (injectable, micelle),/Orient Europharma', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors), NanoCarrier/Orient Europharma', 'demplatin pegraglumer', 'cisplatin', 'cisplatin (injectable, micelle), NanoCarrier/', 'Nanoplatin', 'cisplatin (injectable, micelle),/', 'NC-6004', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/nsclc/biliary tract/head and neck/lung cancer/solid tumors)', 'cisplatin (injectable, micelle), NanoCarrier/Orient Europharma', 'cisplatin (injectable, micelle)']",,NER_API,[],0
nab-paclitaxel,Beta tubulin inhibitor; Microtubule stimulant; Taxane,nab-paclitaxel,,"paclitaxel (albumin-bound nanoparticle, intravenous)",nab paclitaxel,fexact,"['paclitaxel (albumin-bound nanoparticle, intravenous), Celgene', 'nab-paclitaxel', 'Abraxus', 'paclitaxel (albumin-bound nanoparticle, intravenous), American Bioscience', 'ABI-007', 'Abraxane', 'Capxol', 'paclitaxel (albumin-bound nanoparticle, intravenous), American Pharmaceutical Partners', 'paclitaxel (albumin-bound nanoparticle, intravenous)', 'paclitaxel', 'paclitaxel (albumin-bound nanoparticle, intravenous),/Taiho', 'paclitaxel (albumin-bound nanoparticle, intravenous),/']","paclitaxel (albumin-bound nanoparticle, intravenous)",fexact,"['paclitaxel albumin bound nanoparticle intravenous celgene', 'nab paclitaxel', 'abraxus', 'paclitaxel albumin bound nanoparticle intravenous american bioscience', 'abi 007', 'abraxane', 'capxol', 'paclitaxel albumin bound nanoparticle intravenous american pharmaceutical partners', 'paclitaxel albumin bound nanoparticle intravenous', 'paclitaxel', 'paclitaxel albumin bound nanoparticle intravenous taiho', 'paclitaxel albumin bound nanoparticle intravenous']",correct_mapping
sintilimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,sintilimab,,sintilimab,sintilimab,fexact,"['anti-PD1 antibody (cancer),/Innovent', 'cindilizumab', 'PD-1 checkpoint inhibitor (cancer), Innovent/', 'PD-1 checkpoint inhibitor (cancer),/', 'xindili', 'anti-PD1 antibody (cancer),/', 'xindi', 'IBI-308', 'sintilimab', 'Tyvyt']",sintilimab,fexact,"['anti pd1 antibody cancer innovent', 'cindilizumab', 'pd 1 checkpoint inhibitor cancer innovent', 'pd 1 checkpoint inhibitor cancer', 'xindili', 'anti pd1 antibody cancer', 'xindi', 'ibi 308', 'sintilimab', 'tyvyt']",correct_mapping
penpulimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,penpulimab,,penpulimab,penpulimab,fexact,"['annike', 'PD-1 checkpoint inhibtor (cancer),/Chi Tai Tianqing Pharmaceutical', 'PD-1 checkpoint inhibitor (cancer)', 'penpulimab', 'AK-105']",penpulimab,fexact,"['annike', 'pd 1 checkpoint inhibtor cancer chi tai tianqing pharmaceutical', 'pd 1 checkpoint inhibitor cancer', 'penpulimab', 'ak 105']",correct_mapping
SNK-01,Immuno-oncology therapy,SNK-01,,SNK-01,snk 01,fexact,"['natural killer cell stimulator (SuperNK, cancer), NKMax America', 'natural killer cell stimulator (SuperNK, iv, cancer/psoriasis), NKMax America', 'autologous NK cell adoptive immunotherapy (SuperNK, iv, cancer/psoriasis/mild cognitive impairment/AD), NKMax America', 'SNK-01', 'autologous NK cell adoptive immunotherapy (SuperNK, iv, cancer/psoriasis/mild cognitive impairment/AD)', 'autologous NK cell adoptive immunotherapy (SuperNK, cancer), NKMax America', 'autologous NK cell adoptive immunotherapy (SuperNK, iv, cancer/psoriasis), NKMax America']",SNK-01,fexact,"['natural killer cell stimulator supernk cancer nkmax america', 'natural killer cell stimulator supernk iv cancer psoriasis nkmax america', 'autologous nk cell adoptive immunotherapy supernk iv cancer psoriasis mild cognitive impairment ad nkmax america', 'snk 01', 'autologous nk cell adoptive immunotherapy supernk iv cancer psoriasis mild cognitive impairment ad', 'autologous nk cell adoptive immunotherapy supernk cancer nkmax america', 'autologous nk cell adoptive immunotherapy supernk iv cancer psoriasis nkmax america']",correct_mapping
alvopem,Phosphoribosylglycinamide formyltransferase inhibitor; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor,alvopem,,,,0,['alvopem'],,0,[],0
aprepitant (capsule),Neurokinin 1 receptor antagonist,aprepitant,,aprepitant,aprepitant,fexact,"['Emend', 'ONO-7436', 'L-754030', 'aprepitant', 'MK-869', 'MK-0869']",aprepitant,fexact,"['emend', 'ono 7436', 'l 754030', 'aprepitant', 'mk 869', 'mk 0869']",correct_mapping
HC-5404-FU,PERK inhibitor,HC-5404-FU,,HC-5404,hc 5404 fu,fexact,"['HC-5404-FU', 'HC-5404', 'hemi fumarate salt of HC-5404', 'protein kinase R–like endoplasmic reticulum kinase inhibitor (oral capsule, advanced solid tumor/renal cell carcinoma/gastric cancer/metastatic breast cancer/small-cell lung cancer)', 'PERK inhibitor (oral capsule, advanced solid tumor/renal cell carcinoma/gastric cancer/metastatic breast cancer/small-cell lung cancer)']",HC-5404,fexact,"['hc 5404 fu', 'hc 5404', 'hemi fumarate salt of hc 5404', 'protein kinase r like endoplasmic reticulum kinase inhibitor oral capsule advanced solid tumor renal cell carcinoma gastric cancer metastatic breast cancer small cell lung cancer', 'perk inhibitor oral capsule advanced solid tumor renal cell carcinoma gastric cancer metastatic breast cancer small cell lung cancer']",correct_mapping
phototherapy,Unidentified pharmacological activity,phototherapy,,,,0,['phototherapy'],,0,[],0
porfimer sodium (IV),Radical formation stimulant,porfimer sodium,,porfimer sodium,porfimer sodium,fexact,"['DHE', 'Photofrin', 'porfimer sodium', 'dihematoporphyrin ether', 'Photofrin 2', 'Photobarr', 'CL-184116']",porfimer sodium,fexact,"['dhe', 'photofrin', 'porfimer sodium', 'dihematoporphyrin ether', 'photofrin 2', 'photobarr', 'cl 184116']",correct_mapping
cytokine-induced killer cells,Unidentified pharmacological activity,cytokine-induced killer cells,,,,0,['cytokine-induced killer cells'],,0,[],0
tiragolumab,TIGIT receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,tiragolumab,,tiragolumab,tiragolumab,fexact,"['TIGIT checkpoint inhibitor (OmniAb, solid tumor)', 'TIGIT checkpoint inhibitor (OmniAb, solid tumor), Genentech', 'MTIG-7192A', 'anti-TIGIT antibody (cancer), Roche', 'RG-6058', 'tiragolumab', 'anti-TIGIT antibody (cancer)', 'RO-7092284']",tiragolumab,fexact,"['tigit checkpoint inhibitor omniab solid tumor', 'tigit checkpoint inhibitor omniab solid tumor genentech', 'mtig 7192a', 'anti tigit antibody cancer roche', 'rg 6058', 'tiragolumab', 'anti tigit antibody cancer', 'ro 7092284']",correct_mapping
EU-101,CD137 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,EU-101,,EU-101,eu 101,fexact,"['4-1BB costimulator (cancer),/', 'EU-101', 'NOV-1801', '4-1BB costimulator (cancer),/Zhejiang Huahai Pharmaceutical']",EU-101,fexact,"['4 1bb costimulator cancer', 'eu 101', 'nov 1801', '4 1bb costimulator cancer zhejiang huahai pharmaceutical']",correct_mapping
fluzoparib,Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor,fluzoparib,,fluazolepali,fluzoparib,fexact,"['PARP1/PARP2 inhibitor (oral, ovarian cancer), Jiangsu Hengrui Medicine', 'SHR-3162', 'fluazolepali', 'PARP1/PARP2 inhibitor (oral, ovarian cancer)', 'airuiyi', 'fluzoparib', 'poly ADP ribose polymerase 1/2 inhibitor (oral, ovarian cancer)', 'small molecule therapeutic (oral/capsule, undisclosed indication)', 'poly ADP ribose polymerase 1/2 inhibitor (oral, ovarian cancer), Jiangsu Hengrui Medicine']",fluazolepali,fexact,"['parp1 parp2 inhibitor oral ovarian cancer jiangsu hengrui medicine', 'shr 3162', 'fluazolepali', 'parp1 parp2 inhibitor oral ovarian cancer', 'airuiyi', 'fluzoparib', 'poly adp ribose polymerase 1 2 inhibitor oral ovarian cancer', 'small molecule therapeutic oral capsule undisclosed indication', 'poly adp ribose polymerase 1 2 inhibitor oral ovarian cancer jiangsu hengrui medicine']",correct_mapping
osimertinib,EGFR kinase inhibitor,osimertinib,,osimertinib,osimertinib,fexact,"['osimertinib mesylate', 'AZ-7550', 'osimertinib', 'AZ-5104', 'Tagrisso', 'osimertinib (T790M-mutation-targeting, NSCLC)', 'mereletinib', 'AZD-9291']",osimertinib,fexact,"['osimertinib mesylate', 'az 7550', 'osimertinib', 'az 5104', 'tagrisso', 'osimertinib t790m mutation targeting nsclc', 'mereletinib', 'azd 9291']",correct_mapping
lazertinib,EGFR kinase inhibitor,lazertinib,,lazertinib,lazertinib,fexact,"['YH-25448', 'pd-l1 checkpoint inhibitor (cancer),/', 'EGFR tyrosine kinase inhibitor (NSCLC), Yuhan/ Janssen Biotech', 'Leclaza', 'egfr tyrosine kinase inhibitor (cancer)', 'EGFR tyrosine kinase inhibitor (NSCLC),/', 'JNJ-1937', 'egfr tyrosine kinase inhibitors (cancer)', 'pd-l1 checkpoint inhibitor (cancer), /yuhan', 'GNS-1480', 'EGFR tyrosine kinase inhibitor (NSCLC), Yuhan/', 'pd-l1 checkpoint inhibitor (cancer),/yuhan', 'JNJ-73841937', 'lazertinib', 'EGFR tyrosine kinase inhibitors (cancer), Yuhan Corp']",lazertinib,fexact,"['yh 25448', 'pd l1 checkpoint inhibitor cancer', 'egfr tyrosine kinase inhibitor nsclc yuhan janssen biotech', 'leclaza', 'egfr tyrosine kinase inhibitor cancer', 'egfr tyrosine kinase inhibitor nsclc', 'jnj 1937', 'egfr tyrosine kinase inhibitors cancer', 'pd l1 checkpoint inhibitor cancer yuhan', 'gns 1480', 'egfr tyrosine kinase inhibitor nsclc yuhan', 'pd l1 checkpoint inhibitor cancer yuhan', 'jnj 73841937', 'lazertinib', 'egfr tyrosine kinase inhibitors cancer yuhan corp']",correct_mapping
CCI-001,Microtubule inhibitor; Tubulin inhibitor,CCI-001,,CCI-001,cci 001,fexact,"['tubulin beta 3 inhibitor (iv infusion, advanced solid tumors)', 'colchicine derivative (iv infusion, advanced solid tumors)', 'CCI-001', 'colchicine derivative (iv infusion, advanced solid tumors),/University of Alberta', 'tubulin beta 3 inhibitor (iv infusion, advanced solid tumors),/University of Alberta']",CCI-001,fexact,"['tubulin beta 3 inhibitor iv infusion advanced solid tumors', 'colchicine derivative iv infusion advanced solid tumors', 'cci 001', 'colchicine derivative iv infusion advanced solid tumors university of alberta', 'tubulin beta 3 inhibitor iv infusion advanced solid tumors university of alberta']",correct_mapping
magrolimab,CD47 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,magrolimab,,magrolimab,magrolimab,fexact,"['humanized anti-CD47 antibody (cancer), Stanford University//Oxford University', 'humanized anti-CD47 antibody (cancer), Stanford University//Oxford University/', 'magrolimab', 'cd47 checkpoint inhibitor (cancer), //oxford university', 'humanized anti-CD47 antibody (cancer), Stanford University//Oxford University/Ono', 'ONO-7913', 'humanized anti-cd47 antibody (cancer), //oxford university', 'CD47 checkpoint inhibitor (cancer), Stanford University//Oxford University', 'Hu5F9-G4', 'GS-4721']",magrolimab,fexact,"['humanized anti cd47 antibody cancer stanford university oxford university', 'humanized anti cd47 antibody cancer stanford university oxford university', 'magrolimab', 'cd47 checkpoint inhibitor cancer oxford university', 'humanized anti cd47 antibody cancer stanford university oxford university ono', 'ono 7913', 'humanized anti cd47 antibody cancer oxford university', 'cd47 checkpoint inhibitor cancer stanford university oxford university', 'hu5f9 g4', 'gs 4721']",correct_mapping
BI-3011441,Mitogen-activated kinase kinase inhibitor,BI-3011441,,BI-3011441,bi 3011441,fexact,"['mitogen-activated protein kinase inhibitor (oral, advanced solid tumor with RAS/BRAF mutation)', 'BI-3011441', 'LNP-3794', 'mitogen-activated protein kinase inhibitor (oral, advanced solid tumor with RAS/BRAF mutation), Lupin']",BI-3011441,fexact,"['mitogen activated protein kinase inhibitor oral advanced solid tumor with ras braf mutation', 'bi 3011441', 'lnp 3794', 'mitogen activated protein kinase inhibitor oral advanced solid tumor with ras braf mutation lupin']",correct_mapping
BI-1701963,K-Ras inhibitor; SOS Ras/Rac guanine nucleotide exchange factor 1 inhibitor,BI-1701963,,BI-1701963,bi 1701963,fexact,['BI-1701963'],BI-1701963,fexact,['bi 1701963'],correct_mapping
acapatamab,CD3 agonist; Immuno-oncology therapy,acapatamab,,AMG-160,acapatamab,fexact,"['acapatamab', 'AMG-160', 'anti-CD3/anti-PSMA bispecific T-cell engager (HLE-BiTE, prostate cancer)']",AMG-160,fexact,"['acapatamab', 'amg 160', 'anti cd3 anti psma bispecific t cell engager hle bite prostate cancer']",correct_mapping
trilaciclib,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,trilaciclib,,trilaciclib dihydrochloride,trilaciclib,fexact,"['trilaciclib', 'trilaciclib  (bone marrow suppression)', 'trilaciclib dihydrochloride', 'bone marrow suppression therapy (oral), G-Zero Therapeutics', 'G1T28-1 (iv, cancer/bone marrow suppression)', 'Cosela', 'G1T-100182', 'CDK4/6 inhibitors (bone marrow suppression), G-Zero Therapeutics', 'CDK4/6 inhibitors (bone marrow suppression)', 'G1T28-1', 'G1T-28']",trilaciclib dihydrochloride,fexact,"['trilaciclib', 'trilaciclib bone marrow suppression', 'trilaciclib dihydrochloride', 'bone marrow suppression therapy oral g zero therapeutics', 'g1t28 1 iv cancer bone marrow suppression', 'cosela', 'g1t 100182', 'cdk4 6 inhibitors bone marrow suppression g zero therapeutics', 'cdk4 6 inhibitors bone marrow suppression', 'g1t28 1', 'g1t 28']",correct_mapping
SHR-A1811,Unidentified pharmacological activity,SHR-A1811,,SHR-A1811,shr a1811,fexact,"['anti-HER2 mAb-cytotoxin conjugate (iv, advanced solid tumor)', 'SHR-A1811']",SHR-A1811,fexact,"['anti her2 mab cytotoxin conjugate iv advanced solid tumor', 'shr a1811']",correct_mapping
selpercatinib,RET tyrosine kinase inhibitor,selpercatinib,,selpercatinib,selpercatinib,fexact,"['RET inhibitor (cancer), Eli Lilly//', 'selpercatinib', 'R-002', 'RET inhibitor (cancer), Eli Lilly/Loxo Oncology at Lilly/', 'Retevmo', 'ret inhibitor (cancer), eli lilly', 'RET inhibitor (cancer), Eli Lilly/Loxo Oncology/', 'LY-3527723', 'Loxo-102', 'R-001', 'LOXO-292']",selpercatinib,fexact,"['ret inhibitor cancer eli lilly', 'selpercatinib', 'r 002', 'ret inhibitor cancer eli lilly loxo oncology at lilly', 'retevmo', 'ret inhibitor cancer eli lilly', 'ret inhibitor cancer eli lilly loxo oncology', 'ly 3527723', 'loxo 102', 'r 001', 'loxo 292']",correct_mapping
dacomitinib,EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),dacomitinib,,dacomitinib,dacomitinib,fexact,"['PF-00299804', 'PF-0299804', 'PF-299804', 'Vizimpro', 'PF-05199265', 'PF-299', 'PF-804', 'dacomitinib (USAN)', 'dacomitinib']",dacomitinib,fexact,"['pf 00299804', 'pf 0299804', 'pf 299804', 'vizimpro', 'pf 05199265', 'pf 299', 'pf 804', 'dacomitinib usan', 'dacomitinib']",correct_mapping
pembrolizumab (SC),PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,pembrolizumab,,pembrolizumab,pembrolizumab,fexact,"['PD-1 checkpoint inhibitor (cancer), Merck & Co', 'SCH-900475', 'lambrolizumab, Merck', 'MK-3475', 'pembrolizumab', 'lambrolizumab', 'PD-1 checkpoint inhibitor (cancer)', 'Keytruda']",pembrolizumab,fexact,"['pd 1 checkpoint inhibitor cancer merck co', 'sch 900475', 'lambrolizumab merck', 'mk 3475', 'pembrolizumab', 'lambrolizumab', 'pd 1 checkpoint inhibitor cancer', 'keytruda']",correct_mapping
spartalizumab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,spartalizumab,,spartalizumab,spartalizumab,fexact,"['pd1 targeting immunotherapy program (cancer)', 'PD-1 checkpoint inhibitor (cancer), Novartis', 'anti-PD-1 antibody (advanced cancer), Novartis', 'spartalizumab', 'PD1 targeting immunotherapy program (cancer), Novartis AG', 'PD-1 checkpoint inhibitor (cancer)', 'PDR-001', 'anti-PD-1 antibody (advanced cancer)']",spartalizumab,fexact,"['pd1 targeting immunotherapy program cancer', 'pd 1 checkpoint inhibitor cancer novartis', 'anti pd 1 antibody advanced cancer novartis', 'spartalizumab', 'pd1 targeting immunotherapy program cancer novartis ag', 'pd 1 checkpoint inhibitor cancer', 'pdr 001', 'anti pd 1 antibody advanced cancer']",correct_mapping
PF-06946860,Growth differentiation factor 15 agonist,PF-06946860,,ponsegromab,pf 06946860,fexact,"['ponsegromab', 'anti-GDF15 mAb (cachexia)', 'growth factor blocker (sc, cachexia/metastatic non-small cell lung cancer)', 'PF-06946860', 'growth factor blocker (sc, cachexia)']",ponsegromab,fexact,"['ponsegromab', 'anti gdf15 mab cachexia', 'growth factor blocker sc cachexia metastatic non small cell lung cancer', 'pf 06946860', 'growth factor blocker sc cachexia']",correct_mapping
cetuximab,EGFR antagonist,cetuximab,,cetuximab,cetuximab,fexact,"['NSC-714692', 'BMS-564717', 'EMD-271786', 'EMR-62202', 'LY-2939777', 'IMC-C 22', 'cetuximab', 'MAb225, ImClone', 'Erbitux', 'MAb225', 'IMC-C225', 'C225']",cetuximab,fexact,"['nsc 714692', 'bms 564717', 'emd 271786', 'emr 62202', 'ly 2939777', 'imc c 22', 'cetuximab', 'mab225 imclone', 'erbitux', 'mab225', 'imc c225', 'c225']",correct_mapping
encorafenib,B-raf kinase inhibitor,encorafenib,,encorafenib,encorafenib,fexact,"['Raf inhibitor (oral, melanoma)', 'PF-07263896', 'encorafenib', 'encorafinib', 'Braftovi', 'LGX-818', 'Raf inhibitor (oral, melanoma), Novartis', 'ONO-7702']",encorafenib,fexact,"['raf inhibitor oral melanoma', 'pf 07263896', 'encorafenib', 'encorafinib', 'braftovi', 'lgx 818', 'raf inhibitor oral melanoma novartis', 'ono 7702']",correct_mapping
lorlatinib,Anaplastic lymphoma kinase inhibitor; ROS receptor tyrosine kinase inhibitor,lorlatinib,,lorlatinib,lorlatinib,fexact,"['lorlatinib', 'Lorbrena', 'ALK/ROS1 inhibitor (oral, cancer), Pfizer', 'ALK/ROS1 inhibitor (oral, cancer)', 'PF-06463922', 'Lorviqua']",lorlatinib,fexact,"['lorlatinib', 'lorbrena', 'alk ros1 inhibitor oral cancer pfizer', 'alk ros1 inhibitor oral cancer', 'pf 06463922', 'lorviqua']",correct_mapping
PF-07284892,"Tyrosine phosphatase, non-receptor type 11 inhibitor",PF-07284892,,PF-07284892,pf 07284892,fexact,"['PF-07284892', 'SHP2 inhibitor (cancer)']",PF-07284892,fexact,"['pf 07284892', 'shp2 inhibitor cancer']",correct_mapping
icotinib hydrochloride,EGFR kinase inhibitor; Tyrosine kinase inhibitor (TKI),icotinib hydrochloride,,icotinib hydrochloride,icotinib hydrochloride,fexact,"['icotinib', 'icotinib hydrochloride', 'Commana', 'BPI-2009-H', 'Conmana', 'Conmanna', 'BPI-2009']",icotinib hydrochloride,fexact,"['icotinib', 'icotinib hydrochloride', 'commana', 'bpi 2009 h', 'conmana', 'conmanna', 'bpi 2009']",correct_mapping
NC-762,B7-H4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,NC-762,,NC-762,nc 762,fexact,"['NC-762', 'B7-H4 checkpoint inhibitor (solid tumor/melanoma)', 'B7-H4 checkpoint inhibitor (advanced solid tumors)']",NC-762,fexact,"['nc 762', 'b7 h4 checkpoint inhibitor solid tumor melanoma', 'b7 h4 checkpoint inhibitor advanced solid tumors']",correct_mapping
ipilimumab,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,ipilimumab,,ipilimumab,ipilimumab,fexact,"['BMS-734016', 'MDX-010', 'Winglore', 'MDX-101', 'anti-CTLA4, Medarex', 'Yervoy', 'MDX-CTLA4', 'CTLA-4 checkpoint inhibitor (cancer)', 'anti-CTLA4', 'ipilimumab']",ipilimumab,fexact,"['bms 734016', 'mdx 010', 'winglore', 'mdx 101', 'anti ctla4 medarex', 'yervoy', 'mdx ctla4', 'ctla 4 checkpoint inhibitor cancer', 'anti ctla4', 'ipilimumab']",correct_mapping
cryotherapy,Not applicable,cryotherapy,,,,0,['cryotherapy'],,0,[],0
etrumadenant,Adenosine A2a receptor antagonist; Adenosine A2b receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,etrumadenant,,,,0,['etrumadenant'],,0,[],0
zimberelimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,zimberelimab,,zimberelimab,zimberelimab,fexact,"['WBP-3055', 'AB-122', 'anti-PD-1 fully human mAb (cancer),/WuXi PharmaTech', 'anti-PD-1 fully human mAb (cancer), Harbin Gloria Pharmaceuticals/WuXi PharmaTech', 'PD-1 checkpoint inhibitor (OmniRat, cancer), Harbin Gloria Pharmaceuticals/WuXi Pharma Tech/', 'GLS-010', 'PD-1 checkpoint inhibitor (OmniRat, cancer),/WuXi Pharma Tech/', 'Zimberelimab', 'zimberelimab', 'GS-0122']",zimberelimab,fexact,"['wbp 3055', 'ab 122', 'anti pd 1 fully human mab cancer wuxi pharmatech', 'anti pd 1 fully human mab cancer harbin gloria pharmaceuticals wuxi pharmatech', 'pd 1 checkpoint inhibitor omnirat cancer harbin gloria pharmaceuticals wuxi pharma tech', 'gls 010', 'pd 1 checkpoint inhibitor omnirat cancer wuxi pharma tech', 'zimberelimab', 'zimberelimab', 'gs 0122']",correct_mapping
domvanalimab,TIGIT receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,domvanalimab,,,,0,['domvanalimab'],,0,[],0
ATL-001,T cell stimulant; Immuno-oncology therapy,ATL-001,,ATL-001,atl 001,fexact,"['autologous clonal neoantigen reactive T cell therapy (iv/infusion, stage IV melanoma)', 'ATL-001', 'cNeTs therapy', 'autologous clonal neoantigen reactive T cell therapy (iv/infusion, stage IV melanoma/NSCLC)']",ATL-001,fexact,"['autologous clonal neoantigen reactive t cell therapy iv infusion stage iv melanoma', 'atl 001', 'cnets therapy', 'autologous clonal neoantigen reactive t cell therapy iv infusion stage iv melanoma nsclc']",correct_mapping
radiosurgery,Not applicable,radiosurgery,,,,0,['radiosurgery'],,0,[],0
"nano-sized gadolinium particles, NH TherAguix",Not applicable,nano-sized gadolinium particles,NH TherAguix,,,0,['nano-sized gadolinium particles'],,0,[],0
pimasertib,Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,pimasertib,,pimasertib hydrochloride,pimasertib,fexact,"['1820', 'pimasertib', 'MEK inhibitor 1, Merck Serono', 'AS-701173', 'MEK inhibitor 1', 'AS-701255', 'pimasertib hydrochloride', 'AS-701820', 'AS-703026', 'MSC-1936369B']",pimasertib hydrochloride,fexact,"['1820', 'pimasertib', 'mek inhibitor 1 merck serono', 'as 701173', 'mek inhibitor 1', 'as 701255', 'pimasertib hydrochloride', 'as 701820', 'as 703026', 'msc 1936369b']",correct_mapping
bintrafusp alfa,Transforming growth factor beta antagonist; PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,bintrafusp alfa,,bintrafusp alfa,bintrafusp alfa,fexact,"['avelumab fc domain/tgf-beta receptor ii fusion protein (solid tumors), baxter oncology', 'bintrafusp alfa', 'dual PD-L1 checkpoint inhibitor/TGF beta inhibitor (bispecific antibody, cancer), Merck KGaA', 'bi-functional immunotherapy (solid tumors), Merck Serono', 'avelumab Fc domain/TGF-beta receptor II fusion protein (solid tumors), Merck KGaA/', 'avelumab Fc domain/TGF-beta receptor II fusion protein (solid tumors), Baxter Oncology/Merck KGaA/', 'MSB-0011359C', 'GSK-4045154', 'avelumab fc domain/tgf-beta receptor ii fusion protein (solid tumors)', 'dual pd-l1 checkpoint inhibitor/tgf beta inhibitor (bispecific antibody, cancer)', 'avelumab Fc domain/TGF-beta receptor II fusion protein (solid tumors), Merck KGaA', 'bifunctional PD-L1 checkpoint inhibitor and TGF-beta trap (solid tumor), EMD Serono', 'anti-PD-L1/TGF-beta trap fusion protein (solid tumor), Merck KGaA', 'anti-pd-l1/tgf-beta trap fusion protein (solid tumor)', 'M-7824']",bintrafusp alfa,fexact,"['avelumab fc domain tgf beta receptor ii fusion protein solid tumors baxter oncology', 'bintrafusp alfa', 'dual pd l1 checkpoint inhibitor tgf beta inhibitor bispecific antibody cancer merck kgaa', 'bi functional immunotherapy solid tumors merck serono', 'avelumab fc domain tgf beta receptor ii fusion protein solid tumors merck kgaa', 'avelumab fc domain tgf beta receptor ii fusion protein solid tumors baxter oncology merck kgaa', 'msb 0011359c', 'gsk 4045154', 'avelumab fc domain tgf beta receptor ii fusion protein solid tumors', 'dual pd l1 checkpoint inhibitor tgf beta inhibitor bispecific antibody cancer', 'avelumab fc domain tgf beta receptor ii fusion protein solid tumors merck kgaa', 'bifunctional pd l1 checkpoint inhibitor and tgf beta trap solid tumor emd serono', 'anti pd l1 tgf beta trap fusion protein solid tumor merck kgaa', 'anti pd l1 tgf beta trap fusion protein solid tumor', 'm 7824']",correct_mapping
ST-067,Interleukin 18 agonist; Immuno-oncology therapy,ST-067,,ST-067,st 067,fexact,"['decoy-resistant il-18 (cancer)', 'ST-067']",ST-067,fexact,"['decoy resistant il 18 cancer', 'st 067']",correct_mapping
pyrotinib dimaleate,EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor,pyrotinib dimaleate,,pyrotinib dimaleate,pyrotinib dimaleate,fexact,"['pyrroltinib maleate (oral tablet, cancer)', 'Airuini', 'receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui', 'pyrotinib', 'pyrotinib (breast cancer), Jiangsu HengRui', 'pyrotinib (breast cancer)', 'pyrroltinib maleate (oral tablet, cancer), Jiangsu Hengrui Medicine', 'SHR1258 dimaleate', 'HTI-1001', 'SHR-1258', 'pyrotinib dimaleate']",pyrotinib dimaleate,fexact,"['pyrroltinib maleate oral tablet cancer', 'airuini', 'receptor tyrosine kinase inhibitors cancer shanghai hengrui', 'pyrotinib', 'pyrotinib breast cancer jiangsu hengrui', 'pyrotinib breast cancer', 'pyrroltinib maleate oral tablet cancer jiangsu hengrui medicine', 'shr1258 dimaleate', 'hti 1001', 'shr 1258', 'pyrotinib dimaleate']",correct_mapping
"paclitaxel micelles, Hangzhou Dihua Biotechnology",Beta tubulin inhibitor; Microtubule stimulant; Taxane,paclitaxel micelles,Hangzhou Dihua Biotechnology,,,0,['paclitaxel micelles'],,0,[],0
IBI-318,PD-1 antagonist; PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,IBI-318,,IBI-318,ibi 318,fexact,"['anti-PD-1/anti-PD-L1  recombinant fully human bispecific antibody (cancer),//Innovent', 'IBI-318', 'anti-PD-1/anti-PD-L1  recombinant fully human bispecific antibody (cancer),/Eli Lilly/Innovent', 'anti-PD-1/anti-PD-L1  recombinant fully human bispecific antibody (cancer),//']",IBI-318,fexact,"['anti pd 1 anti pd l1 recombinant fully human bispecific antibody cancer innovent', 'ibi 318', 'anti pd 1 anti pd l1 recombinant fully human bispecific antibody cancer eli lilly innovent', 'anti pd 1 anti pd l1 recombinant fully human bispecific antibody cancer']",correct_mapping
repotrectinib,Anaplastic lymphoma kinase inhibitor; ROS receptor tyrosine kinase inhibitor; Src inhibitor; TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,repotrectinib,,repotrectinib,repotrectinib,fexact,"['ALK/ROS1/TRK inhibitors (solid tumors), TP Therapeutics/Patheon/INC Research', 'TPX-0005', 'luoputini', 'ropotrectinib', 'repotrectinib']",repotrectinib,fexact,"['alk ros1 trk inhibitors solid tumors tp therapeutics patheon inc research', 'tpx 0005', 'luoputini', 'ropotrectinib', 'repotrectinib']",correct_mapping
toripalimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,toripalimab,,toripalimab,toripalimab,fexact,"['PD-1 checkpoint inhibitor (cancer), Shanghai Junshi Biosciences', 'teriprizumab', 'recombinant humanized anti-PD1 mAb, Shanghai Junshi Biosciences', 'tripleitriumab', 'JS-001', 'recombinant humanized anti-PD1 mAb', 'TeRuiPuLi', 'toripalimab', 'Treipril', 'PD-1 checkpoint inhibitor (cancer)', 'TAB-001', 'Tuoyi']",toripalimab,fexact,"['pd 1 checkpoint inhibitor cancer shanghai junshi biosciences', 'teriprizumab', 'recombinant humanized anti pd1 mab shanghai junshi biosciences', 'tripleitriumab', 'js 001', 'recombinant humanized anti pd1 mab', 'teruipuli', 'toripalimab', 'treipril', 'pd 1 checkpoint inhibitor cancer', 'tab 001', 'tuoyi']",correct_mapping
INBRX-105,CD137 agonist; PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor; Immune checkpoint stimulant,INBRX-105,,INBRX-105,inbrx 105,fexact,"['INBRX-105', 'ES-101', 'dual PD-L1 checkpoint inhibitor/4-1BB costimulator (bispecific antibody, cancer),/', 'anti-4-1BB/PD-L1 tetravalent bispecific antibody (cancer), INHIBRx/', 'dual 4-1BB costimulator + PD-L1 checkpoint inhibitor bispecific antibody (advanced solid tumors),/', 'anti-4-1BB/PD-L1 tetravalent bispecific antibody (cancer),/', 'anti-4-1BB/PD-L1 bispecific antibody (cancer),/', 'dual PD-L1 checkpoint inhibitor/4-1BB costimulator (bispecific antibody, cancer), INHIBRx/', 'dual 4-1BB costimulator + PD-L1 checkpoint inhibitor bispecific antibody (advanced solid tumors), INHIBRx/', 'anti-4-1BB/PD-L1 bispecific antibody (cancer), INHIBRx/']",INBRX-105,fexact,"['inbrx 105', 'es 101', 'dual pd l1 checkpoint inhibitor 4 1bb costimulator bispecific antibody cancer', 'anti 4 1bb pd l1 tetravalent bispecific antibody cancer inhibrx', 'dual 4 1bb costimulator pd l1 checkpoint inhibitor bispecific antibody advanced solid tumors', 'anti 4 1bb pd l1 tetravalent bispecific antibody cancer', 'anti 4 1bb pd l1 bispecific antibody cancer', 'dual pd l1 checkpoint inhibitor 4 1bb costimulator bispecific antibody cancer inhibrx', 'dual 4 1bb costimulator pd l1 checkpoint inhibitor bispecific antibody advanced solid tumors inhibrx', 'anti 4 1bb pd l1 bispecific antibody cancer inhibrx']",correct_mapping
"EGFR-TKI, unspecified",ErbB tyrosine kinase inhibitor,EGFR-TKI,unspecified,,,0,['EGFR-TKI'],,0,[],0
"PD-1 antagonist, undisclosed",PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,PD-1 antagonist,undisclosed,,,0,['PD-1 antagonist'],,0,[],0
MRX-2843,Flt-3 antagonist; Mer tyrosine kinase inhibitor,MRX-2843,,MRX-2843,mrx 2843,fexact,"['Mer tyrosine kinase inhibitors (cancer), Meryx', 'Mer tyrosine kinase inhibitors (cancer), University of North Carolina/University of Colorado at Denver and Health Sciences Center', 'UNC-1062', 'MRX-6361', 'UNC-569A', 'mer-selective inhibitors (cancer/thrombosis), University of North Carolina/University of Colorado', 'mer tyrosine kinase inhibitors (cancer), university of north carolina', 'dual Mer/Flt3-selective inhibitors (cancer/thrombosis)', 'UNC-2881', 'UNC-4203', 'UNC-Mer-TKI-2', 'Mer tyrosine kinase inhibitors (cancer)', 'mer tyrosine kinase inhibitors (cancer)', 'UNC-2371', 'mer-selective inhibitors (cancer/thrombosis), University of North Carolina/', 'dual Mer/Flt3-selective inhibitors (cancer/thrombosis), Meryx', 'mer-selective inhibitors (cancer/thrombosis)', 'dual Mer/Flt3-selective inhibitors (oral capsule, cancer/thrombosis/advanced solid tumors)', 'MRX-2843', 'UNC-Mer-TKI-1', 'UNC-2025', 'dual Mer/Flt3-selective inhibitors (oral capsule, cancer/thrombosis/advanced solid tumors), Meryx', 'Mer-selective inhibitors (cancer/thrombosis)', 'UNC-2250', 'UNC-569', 'Mer-selective inhibitors (cancer/thrombosis), Meryx']",MRX-2843,fexact,"['mer tyrosine kinase inhibitors cancer meryx', 'mer tyrosine kinase inhibitors cancer university of north carolina university of colorado at denver and health sciences center', 'unc 1062', 'mrx 6361', 'unc 569a', 'mer selective inhibitors cancer thrombosis university of north carolina university of colorado', 'mer tyrosine kinase inhibitors cancer university of north carolina', 'dual mer flt3 selective inhibitors cancer thrombosis', 'unc 2881', 'unc 4203', 'unc mer tki 2', 'mer tyrosine kinase inhibitors cancer', 'mer tyrosine kinase inhibitors cancer', 'unc 2371', 'mer selective inhibitors cancer thrombosis university of north carolina', 'dual mer flt3 selective inhibitors cancer thrombosis meryx', 'mer selective inhibitors cancer thrombosis', 'dual mer flt3 selective inhibitors oral capsule cancer thrombosis advanced solid tumors', 'mrx 2843', 'unc mer tki 1', 'unc 2025', 'dual mer flt3 selective inhibitors oral capsule cancer thrombosis advanced solid tumors meryx', 'mer selective inhibitors cancer thrombosis', 'unc 2250', 'unc 569', 'mer selective inhibitors cancer thrombosis meryx']",correct_mapping
alectinib hydrochloride,Anaplastic lymphoma kinase inhibitor,alectinib hydrochloride,,,,0,['alectinib hydrochloride'],,0,[],0
osimertinib (IV),EGFR kinase inhibitor,osimertinib,,osimertinib,osimertinib,fexact,"['osimertinib mesylate', 'AZ-7550', 'osimertinib', 'AZ-5104', 'Tagrisso', 'osimertinib (T790M-mutation-targeting, NSCLC)', 'mereletinib', 'AZD-9291']",osimertinib,fexact,"['osimertinib mesylate', 'az 7550', 'osimertinib', 'az 5104', 'tagrisso', 'osimertinib t790m mutation targeting nsclc', 'mereletinib', 'azd 9291']",correct_mapping
microwave ablation,Not applicable,microwave ablation,,,,0,['microwave ablation'],,0,[],0
ezabenlimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,ezabenlimab,,ezabenlimab,ezabenlimab,fexact,"['PD-1 checkpoint inhibitor (cancer)', 'ezabenlimab', 'anti-PD-1 checkpoint inhibitors (solid tumors/multiple myeloma)', 'BI-754091']",ezabenlimab,fexact,"['pd 1 checkpoint inhibitor cancer', 'ezabenlimab', 'anti pd 1 checkpoint inhibitors solid tumors multiple myeloma', 'bi 754091']",correct_mapping
BI-765049,Unidentified pharmacological activity,BI-765049,,BI-765049,bi 765049,fexact,['BI-765049'],BI-765049,fexact,['bi 765049'],correct_mapping
bozitinib,MET tyrosine kinase inhibitor,bozitinib,,APL-101,bozitinib,fexact,"['CBI-3103', 'APL-101', 'c-met inhibitor (oral, cancer/NSCLC/RCC/HCC/glioblastoma)', 'boruitinib', 'cMET inhibitor (cancer), Crown Bioscience', 'cMET inhibitor (cancer)', 'PLB-1001', 'CBT-101, CBT Pharmaceuticals/Beijing Pearl Biotechnology', 'bozitinib', 'small molecule therapy (oral/enteric-coated capsule)', 'small molecule therapy (oral/enteric-coated capsule), Beijing Purunao Biotech', 'CBT-101']",APL-101,fexact,"['cbi 3103', 'apl 101', 'c met inhibitor oral cancer nsclc rcc hcc glioblastoma', 'boruitinib', 'cmet inhibitor cancer crown bioscience', 'cmet inhibitor cancer', 'plb 1001', 'cbt 101 cbt pharmaceuticals beijing pearl biotechnology', 'bozitinib', 'small molecule therapy oral enteric coated capsule', 'small molecule therapy oral enteric coated capsule beijing purunao biotech', 'cbt 101']",correct_mapping
ABBV-CLS-484,"Tyrosine phosphatase, non-receptor type 2 inhibitor",ABBV-CLS-484,,ABBV-CLS-484,abbv cls 484,fexact,"['PTPN2 inhibitor (oral, advanced solid tumor),/', 'ABBV-CLS-484', 'PTPN2 inhibitor (oral, solid tumor),/', 'PTPN2 inhibitor (oral, advanced solid tumor),/Calico Life Sciences', 'PTPN2 inhibitor (oral, solid tumor),/Calico Life Sciences']",ABBV-CLS-484,fexact,"['ptpn2 inhibitor oral advanced solid tumor', 'abbv cls 484', 'ptpn2 inhibitor oral solid tumor', 'ptpn2 inhibitor oral advanced solid tumor calico life sciences', 'ptpn2 inhibitor oral solid tumor calico life sciences']",correct_mapping
AK-112,Vascular endothelial growth factor (VEGF)receptor antagonist; PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,AK-112,,AK-112,ak 112,fexact,"['AK-112', 'PD-1 checkpoint inhibitor + anti-VEGF (cancer)', 'dual PD-1 checkpoint inhibitor/anti-VEGF (cancer)']",AK-112,fexact,"['ak 112', 'pd 1 checkpoint inhibitor anti vegf cancer', 'dual pd 1 checkpoint inhibitor anti vegf cancer']",correct_mapping
tepotinib (capsule),MET tyrosine kinase inhibitor,tepotinib,,tepotinib,tepotinib,fexact,"['tepotinib hydrochloride hydrate', 'tepotinib hydrochloride', 'Tepmetko', 'tepotinib', 'EMD-1214063', 'c-Met kinase inhibitors (cancer), Merck Serono', 'MSC-2156119J']",tepotinib,fexact,"['tepotinib hydrochloride hydrate', 'tepotinib hydrochloride', 'tepmetko', 'tepotinib', 'emd 1214063', 'c met kinase inhibitors cancer merck serono', 'msc 2156119j']",correct_mapping
SC-43,"Tyrosine phosphatase, non-receptor type 6 inhibitor",SC-43,,SC-43,sc 43,fexact,"['SC-43', 'shp-1 agonist (cancers/liver fibrosis), /taipei veterans general hospital', 'SHP-1 agonist (cancers/liver fibrosis), SupremeCure Pharma/Taipei Veterans General Hospital/National Yang-Ming University', 'SHP-1 agonist (cancers/liver fibrosis), SupremeCure Pharma/Taipei Veterans General Hospital/', 'shp-1 agonist (cancers/liver fibrosis)']",SC-43,fexact,"['sc 43', 'shp 1 agonist cancers liver fibrosis taipei veterans general hospital', 'shp 1 agonist cancers liver fibrosis supremecure pharma taipei veterans general hospital national yang ming university', 'shp 1 agonist cancers liver fibrosis supremecure pharma taipei veterans general hospital', 'shp 1 agonist cancers liver fibrosis']",correct_mapping
hydroxychloroquine sulfate,Immunosuppressant; Disease modifying antirheumatic drug,hydroxychloroquine sulfate,,,,0,"['hydroxychloroquine', 'hydroxychloroquine sulfate (lipin1 disease/rhabdomyolysis)', 'hydroxychloroquine sulfate']",,NER_API,[],0
INBRX-106,CD134 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,INBRX-106,,INBRX-106,inbrx 106,fexact,"['Hexavalent OX-40 agonist antibody, Inhibrx', 'OX40 costimulator (cancer),/', 'OX40 costimulator (cancer), Inhibrx/', 'hexavalent OX40 costimulator (cancer),/Inhibrx', 'anti-OX40 antibody (cancer)', 'hexavalent OX40 costimulator (cancer),/', 'ES-102', 'Hexavalent OX-40 agonist antibody', 'INBRX-106']",INBRX-106,fexact,"['hexavalent ox 40 agonist antibody inhibrx', 'ox40 costimulator cancer', 'ox40 costimulator cancer inhibrx', 'hexavalent ox40 costimulator cancer inhibrx', 'anti ox40 antibody cancer', 'hexavalent ox40 costimulator cancer', 'es 102', 'hexavalent ox 40 agonist antibody', 'inbrx 106']",correct_mapping
bevacizumab,Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
ABBV-637,Unidentified pharmacological activity,ABBV-637,,ABBV-637,abbv 637,fexact,"['ABBV-637', 'apoptosis stimulator (iv, NSCLC)']",ABBV-637,fexact,"['abbv 637', 'apoptosis stimulator iv nsclc']",correct_mapping
furmonertinib (tablet),EGFR kinase inhibitor,furmonertinib,,,,0,"['aifutini mesylate', 'alflutinib mesylate (oral/tablet, cancer),/', 'furmonertinib', 'fumeitini mesylate', 'alflutinib', 'aifutinib mesylate', 'AST-2818', 'alflutinib mesylate (oral/tablet, cancer),/ArriVent Biopharma', 'small molecule therapeutic (oral/tablet, cancer)', 'alflutinib mesylate (oral/tablet, cancer)']",,NER_API,[],0
lenvatinib (capsule),RET tyrosine kinase inhibitor; C-kit inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor; Platelet-derived growth factor receptor alpha kinase inhib; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor; Angiopoietin inhibitor,lenvatinib,,lenvatinib mesylate,lenvatinib,fexact,"['lenvatinib mesylate', 'KN-581', 'Lenvima', 'E-7080', 'lenvatinib', 'MK-7902', 'Kisplyx', 'ER-203492-00']",lenvatinib mesylate,fexact,"['lenvatinib mesylate', 'kn 581', 'lenvima', 'e 7080', 'lenvatinib', 'mk 7902', 'kisplyx', 'er 203492 00']",correct_mapping
tirapazamine (intra-arterial),DNA inhibitor; Reducing agent,tirapazamine,,tirapazamine,tirapazamine,fexact,"['SR-4233', 'Tirazone', 'tirapazamine', 'SR-259075', 'TPZ', 'SR-4330', 'NSC-130181', 'SR-4482', 'SR-4317', 'Win-59075']",tirapazamine,fexact,"['sr 4233', 'tirazone', 'tirapazamine', 'sr 259075', 'tpz', 'sr 4330', 'nsc 130181', 'sr 4482', 'sr 4317', 'win 59075']",correct_mapping
TNO-155,"Tyrosine phosphatase, non-receptor type 11 inhibitor",TNO-155,,TNO-155,tno 155,fexact,"['allosteric inhibitors of oncoprotein cytoplasmic protein Src homology 2 (SHP2) phosphatase (cancer)', 'SHP-099', 'TNO-155', 'SHP-836', 'SHP-504', 'allosteric inhibitors of SHP2 phosphatase (cancer)', 'SHP2 inhibitor (advanced solid tumor)', 'SHP-394']",TNO-155,fexact,"['allosteric inhibitors of oncoprotein cytoplasmic protein src homology 2 shp2 phosphatase cancer', 'shp 099', 'tno 155', 'shp 836', 'shp 504', 'allosteric inhibitors of shp2 phosphatase cancer', 'shp2 inhibitor advanced solid tumor', 'shp 394']",correct_mapping
JDQ-443,K-Ras inhibitor,JDQ-443,,JDQ-443,jdq 443,fexact,"['KRAS G12C inhibitor (advanced solid tumors), Novartis Pharmaceuticals', 'JDQ-443']",JDQ-443,fexact,"['kras g12c inhibitor advanced solid tumors novartis pharmaceuticals', 'jdq 443']",correct_mapping
bifico,Unidentified pharmacological activity,bifico,,Bifico,bifico,fexact,"['bifid-triple viable capsules', 'Bifico']",Bifico,fexact,"['bifid triple viable capsules', 'bifico']",correct_mapping
SHR-1701,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,SHR-1701,,SHR-1701,shr 1701,fexact,"['dual PD-L1 checkpoint inhibitor/TGFbRII inhibitor (advanced solid tumors, metastatic castration-resistant prostate cancer), Jiangsu Hengrui Medicine', 'anti-PD-L1/anti-TGF-beta receptor type 2 therapy (advanced solid tumors, metastatic castration-resistant prostate cancer), Jiangsu Hengrui Medicine', 'SHR-1701', 'anti-PD-L1/anti-TGF-beta receptor II monoclonal antibody (pancreas cancer/advanced cancer),/', 'anti-PD-L1 mAb + TGF-beta receptor II bi-functional fusion protein (advanced solid tumros/mCRPC), Jiangsu Hengrui Medicine', 'anti-PD-L1/anti-TGF-beta receptor type 2 therapy (advanced solid tumors, metastatic castration-resistant prostate cancer)', 'anti-PD-L1/anti-TGF-beta receptor II monoclonal antibody (pancreas cancer/advanced cancer),/Jiangsu Hengrui Medicine', 'dual PD-L1 checkpoint inhibitor/TGFbRII inhibitor (advanced solid tumors, metastatic castration-resistant prostate cancer)', 'anti-PD-L1 mAb + TGF-beta receptor II bi-functional fusion protein (advanced solid tumros/mCRPC)']",SHR-1701,fexact,"['dual pd l1 checkpoint inhibitor tgfbrii inhibitor advanced solid tumors metastatic castration resistant prostate cancer jiangsu hengrui medicine', 'anti pd l1 anti tgf beta receptor type 2 therapy advanced solid tumors metastatic castration resistant prostate cancer jiangsu hengrui medicine', 'shr 1701', 'anti pd l1 anti tgf beta receptor ii monoclonal antibody pancreas cancer advanced cancer', 'anti pd l1 mab tgf beta receptor ii bi functional fusion protein advanced solid tumros mcrpc jiangsu hengrui medicine', 'anti pd l1 anti tgf beta receptor type 2 therapy advanced solid tumors metastatic castration resistant prostate cancer', 'anti pd l1 anti tgf beta receptor ii monoclonal antibody pancreas cancer advanced cancer jiangsu hengrui medicine', 'dual pd l1 checkpoint inhibitor tgfbrii inhibitor advanced solid tumors metastatic castration resistant prostate cancer', 'anti pd l1 mab tgf beta receptor ii bi functional fusion protein advanced solid tumros mcrpc']",correct_mapping
AB-308,TIGIT receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,AB-308,,AB-308,ab 308,fexact,"['anti-TIGIT antibody (FcR-competent, hematological malignancies/solid tumor)', 'AB-308']",AB-308,fexact,"['anti tigit antibody fcr competent hematological malignancies solid tumor', 'ab 308']",correct_mapping
tocilizumab (IV),Interleukin 6 receptor antagonist; Disease modifying antirheumatic drug,tocilizumab,,,,0,"['tocilizumab', 'MSB-11456', 'tocilizumab biosimilar (autoimmune diseases)']",,NER_API,[],0
JAB-8263,BET protein inhibitor,JAB-8263,,JAB-8263,jab 8263,fexact,"['BET inhibitor (oral tablet, solid tumors/myelofibrosis/acute myeloid leukemia/Hematological neoplasm)', 'BET inhibitor (oral tablet, solid tumors/myelofibrosis/acute myeloid leukemia)', 'JAB-8263']",JAB-8263,fexact,"['bet inhibitor oral tablet solid tumors myelofibrosis acute myeloid leukemia hematological neoplasm', 'bet inhibitor oral tablet solid tumors myelofibrosis acute myeloid leukemia', 'jab 8263']",correct_mapping
adagrasib,K-Ras inhibitor,adagrasib,,adagrasib,adagrasib,fexact,"['mutation-specific KRAS G12C inhibitor (oral, NSCLC/CRC),/Mirati Therapeutics', 'adagrasib', 'KRAS G12C inhibitor (oral, lung cancer/colorectal cancer), Mirati Therapeutics/', 'G12C KRAS inhibitors (cancer), Mirati Therapeutics', 'mutation-specific KRAS G12C inhibitor (oral, NSCLC/CRC),/', 'KRAS G12C inhibitor (oral, lung cancer/colorectal cancer),/', 'G12C KRAS inhibitors (cancer)', 'MRTX-849']",adagrasib,fexact,"['mutation specific kras g12c inhibitor oral nsclc crc mirati therapeutics', 'adagrasib', 'kras g12c inhibitor oral lung cancer colorectal cancer mirati therapeutics', 'g12c kras inhibitors cancer mirati therapeutics', 'mutation specific kras g12c inhibitor oral nsclc crc', 'kras g12c inhibitor oral lung cancer colorectal cancer', 'g12c kras inhibitors cancer', 'mrtx 849']",correct_mapping
trastuzumab deruxtecan,DNA topoisomerase I inhibitor,trastuzumab deruxtecan,,trastuzumab deruxtecan,trastuzumab deruxtecan,fexact,"['T-DXd', 'fam-trastuzumab deruxtecan', 'trastuzumab deruxtecan', 'DS-8201a', 'fam-trastuzumab deruxtecan-nxki', 'DS-8201', 'Enhertu']",trastuzumab deruxtecan,fexact,"['t dxd', 'fam trastuzumab deruxtecan', 'trastuzumab deruxtecan', 'ds 8201a', 'fam trastuzumab deruxtecan nxki', 'ds 8201', 'enhertu']",correct_mapping
NC-318,Sialic acid binding lg-like lectin inhibitor; Immuno-oncology therapy,NC-318,,NC-318,nc 318,fexact,"['NC-318', 'siglec-15 checkpoint inhibitor (advanced solid tumors)', 'anti-siglec-15 monoclonal antibody (advanced solid tumors)']",NC-318,fexact,"['nc 318', 'siglec 15 checkpoint inhibitor advanced solid tumors', 'anti siglec 15 monoclonal antibody advanced solid tumors']",correct_mapping
BA-3011,Axl receptor tyrosine kinase inhibitor,BA-3011,,BA-3011,ba 3011,fexact,"['anti-Axl conditionally active biologic antibody-drug conjugate (cancer),/Himalaya', 'anti-AXL antibody-monomethyl auristatin E (MMAE) conjugate (cancer),/Himalaya', 'BA-3011', 'anti-Axl conditionally active biologic antibody-drug conjugate (cancer),/', 'anti-AXL antibody-monomethyl auristatin E (MMAE) conjugate (cancer),/', 'CAB-Axl-ADC']",BA-3011,fexact,"['anti axl conditionally active biologic antibody drug conjugate cancer himalaya', 'anti axl antibody monomethyl auristatin e mmae conjugate cancer himalaya', 'ba 3011', 'anti axl conditionally active biologic antibody drug conjugate cancer', 'anti axl antibody monomethyl auristatin e mmae conjugate cancer', 'cab axl adc']",correct_mapping
"unmodified marrow infiltrating lymphocytes therapy, WindMIL Therapeutics",Immuno-oncology therapy,unmodified marrow infiltrating lymphocytes therapy,WindMIL Therapeutics,,,0,['unmodified marrow infiltrating lymphocytes therapy'],,0,[],0
OMO-103,Myc inhibitor,OMO-103,,OMO-103,omo 103,fexact,"['omomyc cell-penetrating peptide (intravenous, cancer)', 'anti-myc (cancer), //university of sherbrooke', 'OMO-103', 'Omomyc-AF660', 'anti-myc (cancer),//university of sherbrooke', 'omomyc cell-penetrating peptide (cancer)', 'anti-myc (cancer), //university of sherbrooke/universitat autonoma de barcelona', 'anti-myc (intravenous, cancer),//university of sherbrooke', 'anti-myc (intravenous, cancer), /syros pharmaceuticals/university of sherbrooke/universitat autonoma de barcelona', 'anti-myc (cancer), /syros pharmaceuticals/university of sherbrooke/universitat autonoma de barcelona', 'anti-myc (intravenous, cancer), //university of sherbrooke', 'anti-myc (intravenous, cancer), //university of sherbrooke/universitat autonoma de barcelona']",OMO-103,fexact,"['omomyc cell penetrating peptide intravenous cancer', 'anti myc cancer university of sherbrooke', 'omo 103', 'omomyc af660', 'anti myc cancer university of sherbrooke', 'omomyc cell penetrating peptide cancer', 'anti myc cancer university of sherbrooke universitat autonoma de barcelona', 'anti myc intravenous cancer university of sherbrooke', 'anti myc intravenous cancer syros pharmaceuticals university of sherbrooke universitat autonoma de barcelona', 'anti myc cancer syros pharmaceuticals university of sherbrooke universitat autonoma de barcelona', 'anti myc intravenous cancer university of sherbrooke', 'anti myc intravenous cancer university of sherbrooke universitat autonoma de barcelona']",correct_mapping
IBI-939,Immuno-oncology therapy; Immune checkpoint inhibitor,IBI-939,,IBI-939,ibi 939,fexact,"['anti-TIGIT monoclonal antibody (advanced solid cancer)', 'TIGIT checkpoint inhibitor (iv, advanced malignancies)', 'IBI-939']",IBI-939,fexact,"['anti tigit monoclonal antibody advanced solid cancer', 'tigit checkpoint inhibitor iv advanced malignancies', 'ibi 939']",correct_mapping
Sym-021,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,Sym-021,,Sym-021,sym 021,fexact,"['PD-1 checkpoint inhibitor (cancer), Symphogen/', 'Sym-021', 'PD-1 checkpoint inhibitor (cancer), Symphogen/Shire', 'PD-1 checkpoint inhibitor (cancer),/']",Sym-021,fexact,"['pd 1 checkpoint inhibitor cancer symphogen', 'sym 021', 'pd 1 checkpoint inhibitor cancer symphogen shire', 'pd 1 checkpoint inhibitor cancer']",correct_mapping
Sym-024,Immuno-oncology therapy; CD73 antagonist,Sym-024,,Sym-024,sym 024,fexact,"['anti-CD73 mAb (Fc-attenuated, cancer)', 'CD73 checkpoint inhibitor (Fc-attenuated, cancer)', 'Sym-024']",Sym-024,fexact,"['anti cd73 mab fc attenuated cancer', 'cd73 checkpoint inhibitor fc attenuated cancer', 'sym 024']",correct_mapping
SGN-STNV,Unidentified pharmacological activity,SGN-STNV,,SGN-STNV,sgn stnv,fexact,"['anti-sialyltn-vedotin conjugate (solid tumors)', 'SGN-STNV']",SGN-STNV,fexact,"['anti sialyltn vedotin conjugate solid tumors', 'sgn stnv']",correct_mapping
cobolimab,TIM3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,cobolimab,,cobolimab,cobolimab,fexact,"['GSK-4069889', 'GSK-4069889A', 'anti TIM-3 mAbs (cancer immunotherapy)', 'anti TIM-3 mAbs (cancer immunotherapy), TESARO', 'anti T-cell immunoglobulin mucin protein-3 mAbs (cancer immunotherapy)', 'anti T-cell immunoglobulin mucin protein-3 mAbs (cancer immunotherapy), TESARO', 'cobolimab', 'TIM-3 checkpoint inhibitor (SHM-XEL, cancer),/TESARO', 'TIM-3 checkpoint inhibitor (SHM-XEL, cancer),/', 'TSR-022']",cobolimab,fexact,"['gsk 4069889', 'gsk 4069889a', 'anti tim 3 mabs cancer immunotherapy', 'anti tim 3 mabs cancer immunotherapy tesaro', 'anti t cell immunoglobulin mucin protein 3 mabs cancer immunotherapy', 'anti t cell immunoglobulin mucin protein 3 mabs cancer immunotherapy tesaro', 'cobolimab', 'tim 3 checkpoint inhibitor shm xel cancer tesaro', 'tim 3 checkpoint inhibitor shm xel cancer', 'tsr 022']",correct_mapping
dostarlimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,dostarlimab,,dostarlimab,dostarlimab,fexact,"['ANA-011', 'anti-PD-1 mAb program (cancer immunotherapy)', 'TSR-042', 'PD-1 checkpoint inhibitor (SHM-XEL, advanced solid tumors), TESARO', 'ANA-11', 'Jemperli', 'GSK-4057190', 'ANB-011', 'dostarlimab', 'GSK-4057190A', 'PD-1 checkpoint inhibitor (SHM-XEL, advanced solid tumors)', 'dostarlimab-gxly']",dostarlimab,fexact,"['ana 011', 'anti pd 1 mab program cancer immunotherapy', 'tsr 042', 'pd 1 checkpoint inhibitor shm xel advanced solid tumors tesaro', 'ana 11', 'jemperli', 'gsk 4057190', 'anb 011', 'dostarlimab', 'gsk 4057190a', 'pd 1 checkpoint inhibitor shm xel advanced solid tumors', 'dostarlimab gxly']",correct_mapping
datopotamab deruxtecan,DNA topoisomerase I inhibitor,datopotamab deruxtecan,,datopotamab deruxtecan,datopotamab deruxtecan,fexact,"['TROP2 ADC (cancer), Daiichi Sankyo/Institut Gustave Roussy', 'humanized anti-TROP2 Mab (ADC technology, metastatic NSCLC/metastatic TNBC), Daiichi Sankyo', 'humanized anti-TROP2 Mab (ADC technology, metastatic NSCLC/metastatic TNBC)', 'DS-1062a', 'TROP2 ADC (cancer), Daiichi Sankyo', 'datopotamab deruxtecan', 'TROP2 ADC (cancer),/Institut Gustave Roussy', 'Dato-DXd', 'TROP2 ADC (cancer)', 'DS-1062']",datopotamab deruxtecan,fexact,"['trop2 adc cancer daiichi sankyo institut gustave roussy', 'humanized anti trop2 mab adc technology metastatic nsclc metastatic tnbc daiichi sankyo', 'humanized anti trop2 mab adc technology metastatic nsclc metastatic tnbc', 'ds 1062a', 'trop2 adc cancer daiichi sankyo', 'datopotamab deruxtecan', 'trop2 adc cancer institut gustave roussy', 'dato dxd', 'trop2 adc cancer', 'ds 1062']",correct_mapping
atovaquone,Dihydroorotate dehydrogenase inhibitor; Mitochondrial electron transport inhibitor,atovaquone,,atovaquone,atovaquone,fexact,"['BW-A566C', 'Acuvel', 'Samtirel Oral Suspension 15%', 'BW-566C-80', 'Mepron', 'Wellvone', '566C80', 'Metrone', 'atovaquone', 'BW-566C']",atovaquone,fexact,"['bw a566c', 'acuvel', 'samtirel oral suspension 15', 'bw 566c 80', 'mepron', 'wellvone', '566c80', 'metrone', 'atovaquone', 'bw 566c']",correct_mapping
cadonilimab,PD-1 antagonist; CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,cadonilimab,,AK-104,cadonilimab,fexact,"['PD-1 checkpoint inhibitor (bispecific humanized antibody, cancer)', 'cadonilimab', 'AK-104', 'humanized PD-1/CTLA-4 bispecific antibody (advanced solid tumors, gastric or gastroesophageal junction adenocarcinoma)']",AK-104,fexact,"['pd 1 checkpoint inhibitor bispecific humanized antibody cancer', 'cadonilimab', 'ak 104', 'humanized pd 1 ctla 4 bispecific antibody advanced solid tumors gastric or gastroesophageal junction adenocarcinoma']",correct_mapping
naptumomab estafenatox,Immunostimulant; T cell stimulant; Immuno-oncology therapy,naptumomab estafenatox,,naptumomab estafenatox,naptumomab estafenatox,fexact,"['tumor targeted superantigen, NeoTX', 'anticancer antigen,/', 'tumor targeted superantigen,/Pharmacia & Upjohn', 'tumor targeted superantigen', 'anticancer antigen,/Pharmacia & Upjohn', '5T4FabV13-SEA(D227A)', 'TTS-CD3', 'TTS (cancer)', 'naptumomab estafenatox', 'ABR-217620', 'CD-3', 'naptumumab', 'tumor targeted superantigen,/', 'Anyara']",naptumomab estafenatox,fexact,"['tumor targeted superantigen neotx', 'anticancer antigen', 'tumor targeted superantigen pharmacia upjohn', 'tumor targeted superantigen', 'anticancer antigen pharmacia upjohn', '5t4fabv13 sea d227a', 'tts cd3', 'tts cancer', 'naptumomab estafenatox', 'abr 217620', 'cd 3', 'naptumumab', 'tumor targeted superantigen', 'anyara']",correct_mapping
CKD-702,Immuno-oncology therapy,CKD-702,,CKD-702,ckd 702,fexact,"['CKD-702', 'KDDF-201709-11']",CKD-702,fexact,"['ckd 702', 'kddf 201709 11']",correct_mapping
avelumab,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,avelumab,,avelumab,avelumab,fexact,"['anti-PD-L1 mAb (solid tumors)', 'programmed cell death ligand 1 mAb (solid tumors)', 'MSB-0010718C', 'MSB0010682', 'pd-l1 checkpoint inhibitor (cancer), /pfizer', 'pd-l1 checkpoint inhibitor (cancer),/', 'anti-PD-L1 mAb (solid tumors),/ Pfizer', 'anti-PD-L1 mAb (solid tumors),/', 'PF-06834635', 'Bavencio', 'anti-PD-L1 mAb (solid tumors), Merck Serono/ Pfizer', 'anti-PD-L1 mAb (solid tumors), Merck Serono', 'programmed cell death ligand 1 mAb (solid tumors), Merck Serono', 'pd-l1 checkpoint inhibitor (cancer),/pfizer', 'avelumab']",avelumab,fexact,"['anti pd l1 mab solid tumors', 'programmed cell death ligand 1 mab solid tumors', 'msb 0010718c', 'msb0010682', 'pd l1 checkpoint inhibitor cancer pfizer', 'pd l1 checkpoint inhibitor cancer', 'anti pd l1 mab solid tumors pfizer', 'anti pd l1 mab solid tumors', 'pf 06834635', 'bavencio', 'anti pd l1 mab solid tumors merck serono pfizer', 'anti pd l1 mab solid tumors merck serono', 'programmed cell death ligand 1 mab solid tumors merck serono', 'pd l1 checkpoint inhibitor cancer pfizer', 'avelumab']",correct_mapping
cemiplimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,cemiplimab,,cemiplimab,cemiplimab,fexact,"['REGN-2810', 'PD-1 checkpoint inhibitor (cancer),/', 'anti-PD1 mAb (cancer/basal cell carcinoma/metastasis/renal cell carcinoma/multiple myeloma/squamous cell carcinoma/NSCLC/uterine cervix tumor/melanoma/head and neck tumor/advanced prostate cancer),/Sanofi', 'SAR-439684', 'Libtayo', 'PD-1 checkpoint inhibitor (cancer),/Sanofi', 'cemiplimab-rwlc', 'anti-PD1 mAb (cancer/basal cell carcinoma/metastasis/renal cell carcinoma/multiple myeloma/squamous cell carcinoma/NSCLC/uterine cervix tumor/melanoma/head and neck tumor/advanced prostate cancer),/', 'cemiplimab']",cemiplimab,fexact,"['regn 2810', 'pd 1 checkpoint inhibitor cancer', 'anti pd1 mab cancer basal cell carcinoma metastasis renal cell carcinoma multiple myeloma squamous cell carcinoma nsclc uterine cervix tumor melanoma head and neck tumor advanced prostate cancer sanofi', 'sar 439684', 'libtayo', 'pd 1 checkpoint inhibitor cancer sanofi', 'cemiplimab rwlc', 'anti pd1 mab cancer basal cell carcinoma metastasis renal cell carcinoma multiple myeloma squamous cell carcinoma nsclc uterine cervix tumor melanoma head and neck tumor advanced prostate cancer', 'cemiplimab']",correct_mapping
MAGE-A1-TCR-T cells,T cell stimulant; Immuno-oncology therapy,MAGE-A1-TCR-T cells,,,,0,['MAGE-A1-TCR-T cells'],,0,[],0
,,,,,,0,[''],,0,[],0
HL-301,Not applicable,HL-301,,,,0,['HL-301'],,0,[],0
PF-07209960,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,PF-07209960,,PF-07209960,pf 07209960,fexact,"['PD-1 targeted IL-15 mutein (advanced/metastatic solid tumors)', 'PD-1 targeted IL-15 mutein (advanced/metastatic solid tumor/NSCLC/squamous cell carcinoma of the head and neck/renal cell/urothelial/ovarian carcinoma)', 'PD-1 targeting IL-15 fusion protein (advanced/metastatic solid tumors)', 'PD-1 targeting IL-15 fusion protein (advanced/metastatic solid tumor/NSCLC/squamous cell carcinoma of the head and neck/renal cell/urothelial/ovarian carcinoma)', 'PF-07209960']",PF-07209960,fexact,"['pd 1 targeted il 15 mutein advanced metastatic solid tumors', 'pd 1 targeted il 15 mutein advanced metastatic solid tumor nsclc squamous cell carcinoma of the head and neck renal cell urothelial ovarian carcinoma', 'pd 1 targeting il 15 fusion protein advanced metastatic solid tumors', 'pd 1 targeting il 15 fusion protein advanced metastatic solid tumor nsclc squamous cell carcinoma of the head and neck renal cell urothelial ovarian carcinoma', 'pf 07209960']",correct_mapping
tremelimumab,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,tremelimumab,,tremelimumab,tremelimumab,fexact,"['tremelimumab', 'anti-huCTLA4  monoclonal IgG2 antibody (cancer), Pfizer', 'MEDI-1123', 'CTLA-4 checkpoint inhibitor (cancer),//AstraZeneca', 'CTLA-4 checkpoint inhibitor (cancer), Pfizer//AstraZeneca', 'PF-06753388', 'CP-675206', 'anti-huCTLA4  monoclonal IgG2 antibody (cancer)', 'ticilimumab']",tremelimumab,fexact,"['tremelimumab', 'anti huctla4 monoclonal igg2 antibody cancer pfizer', 'medi 1123', 'ctla 4 checkpoint inhibitor cancer astrazeneca', 'ctla 4 checkpoint inhibitor cancer pfizer astrazeneca', 'pf 06753388', 'cp 675206', 'anti huctla4 monoclonal igg2 antibody cancer', 'ticilimumab']",correct_mapping
relatlimab,Lymphocyte-activation gene 3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,relatlimab,,relatlimab,relatlimab,fexact,"['ONO-4482', 'LAG-3 checkpoint inhibitor (iv, solid tumor/non-small cell lung cancer/gastric cancer/esophageal cancer/melanoma/head and neck squamous cell carcinoma/multiple myeloma/hepatocellular carcinoma),/Ono', 'LAG-3 checkpoint inhibitor (cancer/multiple myeloma),/Ono', 'LAG-3 checkpoint inhibitor (iv, solid tumor/non-small cell lung cancer/gastric cancer/esophageal cancer/melanoma/head and neck squamous cell carcinoma/multiple myeloma/hepatocellular carcinoma),/', 'anti-lymphocyte activation gene-3 antibody (cancer), BMS', 'LAG-3 checkpoint inhibitor (cancer),/Ono', 'relatlimab', 'LAG-3 checkpoint inhibitor (cancer/multiple myeloma),/', 'BMS-986016', 'anti-LAG-3 (cancer)', 'LAG-3 checkpoint inhibitor (cancer),/', 'anti-CD223 antibody (oncology)']",relatlimab,fexact,"['ono 4482', 'lag 3 checkpoint inhibitor iv solid tumor non small cell lung cancer gastric cancer esophageal cancer melanoma head and neck squamous cell carcinoma multiple myeloma hepatocellular carcinoma ono', 'lag 3 checkpoint inhibitor cancer multiple myeloma ono', 'lag 3 checkpoint inhibitor iv solid tumor non small cell lung cancer gastric cancer esophageal cancer melanoma head and neck squamous cell carcinoma multiple myeloma hepatocellular carcinoma', 'anti lymphocyte activation gene 3 antibody cancer bms', 'lag 3 checkpoint inhibitor cancer ono', 'relatlimab', 'lag 3 checkpoint inhibitor cancer multiple myeloma', 'bms 986016', 'anti lag 3 cancer', 'lag 3 checkpoint inhibitor cancer', 'anti cd223 antibody oncology']",correct_mapping
tomivosertib,Map kinase interacting serine/threonine kinase 1 inhibitor; Map kinase interacting serine/threonine kinase 2 inhibitor,tomivosertib,,tomivosertib,tomivosertib,fexact,"['eFT-508', 'MNK 1/2 protein kinase inhibitors (oral, cancer)', 'tomivosertib hydrochloride', 'MNK 1/2 protein kinase inhibitors (cancer)', 'tomivosertib']",tomivosertib,fexact,"['eft 508', 'mnk 1 2 protein kinase inhibitors oral cancer', 'tomivosertib hydrochloride', 'mnk 1 2 protein kinase inhibitors cancer', 'tomivosertib']",correct_mapping
patritumab deruxtecan,DNA topoisomerase I inhibitor,patritumab deruxtecan,,patritumab deruxtecan,patritumab deruxtecan,fexact,"['her3-adc (cancer)', 'U3-1402', 'HER3-ADC (cancer),/Institut Gustave Roussy', 'HER3-ADC (cancer)', 'HER3-DXd', 'patritumab deruxtecan']",patritumab deruxtecan,fexact,"['her3 adc cancer', 'u3 1402', 'her3 adc cancer institut gustave roussy', 'her3 adc cancer', 'her3 dxd', 'patritumab deruxtecan']",correct_mapping
PB-103,CC chemokine ligand 16 agonist,PB-103,,,,0,"['PB-103', 'PB-3', 'CCL16 /cancer-targeting monoclonal antibody fusion (cancer)']",,NER_API,[],0
"autologous tumour infiltrating lymphocytes, Iovance Biotherapeutics",Immunostimulant; Immuno-oncology therapy,autologous tumour infiltrating lymphocytes,Iovance Biotherapeutics,,,0,['autologous tumour infiltrating lymphocytes'],,0,[],0
brentuximab vedotin,Tubulin inhibitor,brentuximab vedotin,,brentuximab vedotin,brentuximab vedotin,fexact,"['SGN-35', 'NSC-749710', 'brentuximab vedotin', 'cAC10-SGD-1269', 'anti-CD30 mAb/Auristatin E conjugates', 'auristatin E ADCs, Seattle Genetics', 'auristatin E conjugates, Seattle Genetics', 'anti-CD30 mAb/Auristatin F conjugates, Seattle', '1F6-mafodotin', 'cBR96-Val-Cit-MMAF', 'anti-CD30 mAb/Auristatin  conjugates', 'cAC10-mc-vc-PAB-MMAE', '1F6-mc-MMAF', 'cBR96-vc-MMAF', 'cAC10-mafodotin', '1F6-SGD-1269', 'cAC10-mc-vc-PAB-monomethyl auristatin', 'cAC10 fragment MMAE conjugate (cancer), Seattle', 'antibody-drug conjugates (anticancer), Seattle Genetics', 'cAC10-mc-MMAF', 'Adcetris']",brentuximab vedotin,fexact,"['sgn 35', 'nsc 749710', 'brentuximab vedotin', 'cac10 sgd 1269', 'anti cd30 mab auristatin e conjugates', 'auristatin e adcs seattle genetics', 'auristatin e conjugates seattle genetics', 'anti cd30 mab auristatin f conjugates seattle', '1f6 mafodotin', 'cbr96 val cit mmaf', 'anti cd30 mab auristatin conjugates', 'cac10 mc vc pab mmae', '1f6 mc mmaf', 'cbr96 vc mmaf', 'cac10 mafodotin', '1f6 sgd 1269', 'cac10 mc vc pab monomethyl auristatin', 'cac10 fragment mmae conjugate cancer seattle', 'antibody drug conjugates anticancer seattle genetics', 'cac10 mc mmaf', 'adcetris']",correct_mapping
PF-07248144,Monocytic leukaemia zinc finger inhibitor,PF-07248144,,PF-07248144,pf 07248144,fexact,"['KAT6 inhibitor (cancer)', 'PF-07248144']",PF-07248144,fexact,"['kat6 inhibitor cancer', 'pf 07248144']",correct_mapping
entrectinib,Anaplastic lymphoma kinase inhibitor; ROS receptor tyrosine kinase inhibitor; TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,entrectinib,,entrectinib,entrectinib,fexact,"['ALK inhibitor (cancer), Nerviano Medical Sciences', 'RG-6268', 'Rozlytrek', 'NMS-E628', 'RXDX-101', 'NMS-628', 'ALK inhibitor (cancer)', 'entrectinib']",entrectinib,fexact,"['alk inhibitor cancer nerviano medical sciences', 'rg 6268', 'rozlytrek', 'nms e628', 'rxdx 101', 'nms 628', 'alk inhibitor cancer', 'entrectinib']",correct_mapping
FL-101,Interleukin 1b antagonist,FL-101,,FL-101,fl 101,fexact,"['FL-101', 'IL-1 beta inhibitors (non-small cell lung cancer)', 'IL-1 beta inhibitors (inflammation driven lung cancer)']",FL-101,fexact,"['fl 101', 'il 1 beta inhibitors non small cell lung cancer', 'il 1 beta inhibitors inflammation driven lung cancer']",correct_mapping
amivantamab,EGFR antagonist; Hepatocyte growth factor receptor antagonist; MET tyrosine kinase inhibitor; Immuno-oncology therapy,amivantamab,,amivantamab,amivantamab,fexact,"['Ami-HC-CF', 'anti-EGFR/cMet antibody (intravenous, non-small cell lung cancer),/Janssen', 'EM1-mAb (bispecific EGFR-cMet antibody, cancer)', 'EM1-mAb (bispecific EGFR-cMet antibody, cancer), Janssen Research & Development', 'JNJ-6372', 'Ami-LC-MD', 'Ami-HC', 'anti-EGFR/cMet antibody (intravenous, non-small cell lung cancer),/', 'Ami-LC', 'amivantamab', 'JNJ-372', 'RYBREVANT', 'amivantamab-vmjw', 'CNTO-4424', 'EM1-mAb', 'JNJ-61186372']",amivantamab,fexact,"['ami hc cf', 'anti egfr cmet antibody intravenous non small cell lung cancer janssen', 'em1 mab bispecific egfr cmet antibody cancer', 'em1 mab bispecific egfr cmet antibody cancer janssen research development', 'jnj 6372', 'ami lc md', 'ami hc', 'anti egfr cmet antibody intravenous non small cell lung cancer', 'ami lc', 'amivantamab', 'jnj 372', 'rybrevant', 'amivantamab vmjw', 'cnto 4424', 'em1 mab', 'jnj 61186372']",correct_mapping
memantine hydrochloride,Glutamate release inhibitor; NMDA receptor antagonist,memantine hydrochloride,,memantine hydrochloride,memantine hydrochloride,fexact,"['Akatinol', 'Ebixa', 'Ebix', 'Axura', 'memantine hydrochloride', 'Memary', 'SUN-Y7017', 'D-145', 'memantine', 'Namenda', 'Namenda IR']",memantine hydrochloride,fexact,"['akatinol', 'ebixa', 'ebix', 'axura', 'memantine hydrochloride', 'memary', 'sun y7017', 'd 145', 'memantine', 'namenda', 'namenda ir']",correct_mapping
trastuzumab emtansine,Microtubule inhibitor,trastuzumab emtansine,,trastuzumab emtansine,trastuzumab emtansine,fexact,"['RO-5304020', 'RG-3502', 'trastuzumab MCC mertansine', 'trastuzumab-MCC-DM1', 'ado-trastuzumab emtansine', 'R-3502', 'Kadcyla', 'Herceptin-DM1 conjugate, ImmunoGen/', 'Tmab-MCC-DM1', 'Herceptin-DM1 conjugate, ImmunoGen/Genentech', 'trastuzumab-DM1', 'T-DM1', 'PRO-132365', 'trastuzumab emtansine']",trastuzumab emtansine,fexact,"['ro 5304020', 'rg 3502', 'trastuzumab mcc mertansine', 'trastuzumab mcc dm1', 'ado trastuzumab emtansine', 'r 3502', 'kadcyla', 'herceptin dm1 conjugate immunogen', 'tmab mcc dm1', 'herceptin dm1 conjugate immunogen genentech', 'trastuzumab dm1', 't dm1', 'pro 132365', 'trastuzumab emtansine']",correct_mapping
idasanutlin,MDM2 inhibitor,idasanutlin,,idasanutlin,idasanutlin,fexact,"['MDM2 antagonist (oral, cancer)', 'RO-5503781', 'p53-MDM2 binding inhibitor (oral, cancer)', 'idasanutlin', 'RG-7388', 'MDM2-p53 binding inhibitor (oral, cancer)']",idasanutlin,fexact,"['mdm2 antagonist oral cancer', 'ro 5503781', 'p53 mdm2 binding inhibitor oral cancer', 'idasanutlin', 'rg 7388', 'mdm2 p53 binding inhibitor oral cancer']",correct_mapping
ipatasertib,Protein kinase B inhibitor,ipatasertib,,ipatasertib,ipatasertib,fexact,"['GDC-0068', 'RO-5532961', 'RG-7440', 'ipatasertib', 'ipatasertib dihydrochloride']",ipatasertib,fexact,"['gdc 0068', 'ro 5532961', 'rg 7440', 'ipatasertib', 'ipatasertib dihydrochloride']",correct_mapping
inavolisib,PI3 kinase alpha inhibitor,inavolisib,,inavolisib,inavolisib,fexact,"['RO-7113755', 'RG-6114', 'alpha selective PI3K inhibitors (cancer), Genentech', 'inavolisib', 'GDC-0077']",inavolisib,fexact,"['ro 7113755', 'rg 6114', 'alpha selective pi3k inhibitors cancer genentech', 'inavolisib', 'gdc 0077']",correct_mapping
erlotinib,EGFR kinase inhibitor; Tyrosine kinase inhibitor (TKI),erlotinib,,erlotinib,erlotinib,fexact,"['erlotinib', 'CP-358774-01', 'RG-1415', 'OSI-774', 'erlotinib hydrochloride', 'angiogenesis therapy, OSI//Roche', 'angiogenesis therapy,//', 'angiogenesis therapy, OSI/Genentech/Roche', 'Ro-50-8231', 'NSC-718781', 'CP-358774', 'OSI-744', 'Tarceva', 'R-1415', 'OSI-420', 'angiogenesis therapy, OSI//']",erlotinib,fexact,"['erlotinib', 'cp 358774 01', 'rg 1415', 'osi 774', 'erlotinib hydrochloride', 'angiogenesis therapy osi roche', 'angiogenesis therapy', 'angiogenesis therapy osi genentech roche', 'ro 50 8231', 'nsc 718781', 'cp 358774', 'osi 744', 'tarceva', 'r 1415', 'osi 420', 'angiogenesis therapy osi']",correct_mapping
trastuzumab,ErbB-2 antagonist,trastuzumab,,trastuzumab biosimilar,trastuzumab,fexact,"['trastuzumab biosimilar', 'Trastuzumab BS', 'trastuzumab-qyyp', 'PF-05280014', 'Trazimera', 'trastuzumab']",trastuzumab biosimilar,fexact,"['trastuzumab biosimilar', 'trastuzumab bs', 'trastuzumab qyyp', 'pf 05280014', 'trazimera', 'trastuzumab']",correct_mapping
lapatinib ditosylate,Epidermal growth factor antagonist; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),lapatinib ditosylate,,lapatinib,lapatinib ditosylate,fexact,"['lapatinib ditosylate', 'GW-572016F', 'GW-2016', 'Tykerb', '572016', 'lapatinib ditosylate (USAN)', 'lapatinib', 'Tyverb', 'lapatinib ditosylate monohydrate', 'GW-572016']",lapatinib,fexact,"['lapatinib ditosylate', 'gw 572016f', 'gw 2016', 'tykerb', '572016', 'lapatinib ditosylate usan', 'lapatinib', 'tyverb', 'lapatinib ditosylate monohydrate', 'gw 572016']",correct_mapping
pertuzumab,ErbB-2 antagonist,pertuzumab,,pertuzumab,pertuzumab,fexact,"['anti-2C4, Genentech', 'Perjeta', 'RG-1273', '2C4', 'anti-2C4', 'Herceptin-like antibody, Genentech', 'rhuMAb 2C4', 'R-1273', 'pertuzumab', 'rhuHAb 2C4', 'Omnitarg', 'Herceptin-like antibody', 'RO-4368451']",pertuzumab,fexact,"['anti 2c4 genentech', 'perjeta', 'rg 1273', '2c4', 'anti 2c4', 'herceptin like antibody genentech', 'rhumab 2c4', 'r 1273', 'pertuzumab', 'rhuhab 2c4', 'omnitarg', 'herceptin like antibody', 'ro 4368451']",correct_mapping
everolimus,Immunosuppressant; mTOR kinase inhibitor; Protein kinase inhibitor; Angiogenesis inhibitor; Cell cycle inhibitor,everolimus,,everolimus,everolimus,fexact,"['RAD-001A', 'everolimus', 'Afinitor', 'Afinitor Disperz', 'RAD001C', 'Certican', 'Votubia', 'SDZ-RAD', 'Apinito', 'RAD-001', 'Zortress']",everolimus,fexact,"['rad 001a', 'everolimus', 'afinitor', 'afinitor disperz', 'rad001c', 'certican', 'votubia', 'sdz rad', 'apinito', 'rad 001', 'zortress']",correct_mapping
vemurafenib,B-raf kinase inhibitor; Protein kinase inhibitor,vemurafenib,,vemurafenib,vemurafenib,fexact,"['RG-7204', 'R-7204', 'B-Raf inhibitors (cancer), Plexxikon', 'B-Raf inhibitors (cancer),/Roche', 'B-Raf inhibitors (cancer)', 'vemurafenib', 'PLX-4032', 'PLX-4718', 'Zelboraf', 'B-Raf inhibitors (cancer),/', 'PLX-4720', 'PLx-4735', 'B-Raf inhibitors (cancer), Plexxikon/Roche', 'PLX-3204', 'PLX-3331', 'RO-5185426']",vemurafenib,fexact,"['rg 7204', 'r 7204', 'b raf inhibitors cancer plexxikon', 'b raf inhibitors cancer roche', 'b raf inhibitors cancer', 'vemurafenib', 'plx 4032', 'plx 4718', 'zelboraf', 'b raf inhibitors cancer', 'plx 4720', 'plx 4735', 'b raf inhibitors cancer plexxikon roche', 'plx 3204', 'plx 3331', 'ro 5185426']",correct_mapping
vismodegib,Angiogenesis inhibitor; Hedgehog pathway inhibitor,vismodegib,,vismodegib,vismodegib,fexact,"['Hedgehog antagonists (systemic formulation, cancer),/Genentech/Roche', 'small-molecule hedgehog antagonist (cancer),/Genentech//', 'Hh antagonists (systemic formulation, cancer),/Genentech//', 'NSC-747691', 'Erivedge', 'Hh antagonists (systemic formulation, cancer),///', 'Hedgehog antagonists (systemic formulation, cancer),//', 'R-3616', 'Hedgehog antagonists (systemic formulation, cancer),/Genentech/', 'RG-3616', 'RO-5450815', 'small-molecule hedgehog antagonist (cancer),/Genentech//Roche', 'Hedgehog antagonists (systemic formulation, cancer), Curis/Genentech/Roche', 'small-molecule hedgehog antagonist (cancer),///', 'Hh antagonists (systemic formulation, cancer),/Genentech//Roche', 'vismodegib', 'Hedgehog Antagonist GDC-0449', 'Hh antagonists (systemic formulation, cancer), Curis/Genentech//Roche', 'GDC-0449', 'small-molecule hedgehog antagonist (cancer), Curis/Genentech//Roche']",vismodegib,fexact,"['hedgehog antagonists systemic formulation cancer genentech roche', 'small molecule hedgehog antagonist cancer genentech', 'hh antagonists systemic formulation cancer genentech', 'nsc 747691', 'erivedge', 'hh antagonists systemic formulation cancer', 'hedgehog antagonists systemic formulation cancer', 'r 3616', 'hedgehog antagonists systemic formulation cancer genentech', 'rg 3616', 'ro 5450815', 'small molecule hedgehog antagonist cancer genentech roche', 'hedgehog antagonists systemic formulation cancer curis genentech roche', 'small molecule hedgehog antagonist cancer', 'hh antagonists systemic formulation cancer genentech roche', 'vismodegib', 'hedgehog antagonist gdc 0449', 'hh antagonists systemic formulation cancer curis genentech roche', 'gdc 0449', 'small molecule hedgehog antagonist cancer curis genentech roche']",correct_mapping
cobimetinib,Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,cobimetinib,,cobimetinib,cobimetinib,fexact,"['XL-518', 'MEK inhibitor (oral, cancer),/', 'Cotellic', 'RO-5514041', 'GDC-0973', 'MEK inhibitor (oral, cancer),/Genentech', '[14C]-GDC-0973', 'RG-7421', 'cobimetinib', 'RG-7420 (GDC-0973)', 'cobimetinib butyrate', 'MEK inhibitor (oral, cancer), Exelixis/Genentech', 'cobimetinib fumarate']",cobimetinib,fexact,"['xl 518', 'mek inhibitor oral cancer', 'cotellic', 'ro 5514041', 'gdc 0973', 'mek inhibitor oral cancer genentech', '14c gdc 0973', 'rg 7421', 'cobimetinib', 'rg 7420 gdc 0973', 'cobimetinib butyrate', 'mek inhibitor oral cancer exelixis genentech', 'cobimetinib fumarate']",correct_mapping
ponatinib,Bcr-Abl inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor kinase inhibitor; TIE-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; Angiogenesis inhibitor; Angiopoietin inhibitor,ponatinib,,ponatinib,ponatinib,fexact,"['dual Abl/Src inhibitors (cancer)', 'ponatinib', 'AP-24534', 'oncogenic kinase inhibitors (cancer)', 'ponatinib hydrochloride', 'Iclusig', 'AP-23464', 'AP-24283']",ponatinib,fexact,"['dual abl src inhibitors cancer', 'ponatinib', 'ap 24534', 'oncogenic kinase inhibitors cancer', 'ponatinib hydrochloride', 'iclusig', 'ap 23464', 'ap 24283']",correct_mapping
itacitinib,Janus kinase 1 inhibitor,itacitinib,,itacitinib,itacitinib,fexact,"['INCB-39110', 'INCB-039110', 'IBI-377', 'INCB039110 adipate', 'itacitinib', 'itacitinib adipate']",itacitinib,fexact,"['incb 39110', 'incb 039110', 'ibi 377', 'incb039110 adipate', 'itacitinib', 'itacitinib adipate']",correct_mapping
pemigatinib,FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor,pemigatinib,,pemigatinib,pemigatinib,fexact,"['pemigatinib', 'INCB-054828', 'IBI-375', 'Pemazyre', 'INCB-54828']",pemigatinib,fexact,"['pemigatinib', 'incb 054828', 'ibi 375', 'pemazyre', 'incb 54828']",correct_mapping
JAB-3068,"Tyrosine phosphatase, non-receptor type 11 inhibitor",JAB-3068,,JAB-3068,jab 3068,fexact,"['SHP2 inhibitor (cancer), Jacobio Pharmaceuticals', 'JAB-3068', 'SHP2 inhibitor (cancer)']",JAB-3068,fexact,"['shp2 inhibitor cancer jacobio pharmaceuticals', 'jab 3068', 'shp2 inhibitor cancer']",correct_mapping
MRG-003,Tubulin polymerization inhibitor,MRG-003,,MRG-003,mrg 003,fexact,['MRG-003'],MRG-003,fexact,['mrg 003'],correct_mapping
D-1553,K-Ras inhibitor,D-1553,,D-1553,d 1553,fexact,"['KRAS G12C inhibitor (advanced solid tumor)', 'D-1553']",D-1553,fexact,"['kras g12c inhibitor advanced solid tumor', 'd 1553']",correct_mapping
fulvestrant (IM),Estrogen receptor antagonist; DNA directed DNA polymerase inhibitor; Selective estrogen receptor downregulator,fulvestrant,,fulvestrant,fulvestrant,fexact,"['Faslodex', 'ZD-182780', 'ZM-182780', 'ZD-9238', 'Faslodext', 'ICI-182780', 'fulvestrant']",fulvestrant,fexact,"['faslodex', 'zd 182780', 'zm 182780', 'zd 9238', 'faslodext', 'ici 182780', 'fulvestrant']",correct_mapping
tucatinib,ErbB-2 tyrosine kinase inhibitor,tucatinib,,tucatinib,tucatinib,fexact,"['irbinitinib', 'MK-7119', 'tucatinib', 'ONT-380', 'ErbB-2 kinase inhibitors (breast cancer),/Seagen', 'ErbB-2 inhibitors (cancer), Array BioPharma/ Oncothyreon', 'ErbB-2 kinase inhibitors (breast cancer),/', 'ARRY-333786', 'Tukysa', 'ErbB-2 inhibitors (cancer),/ Oncothyreon', 'ARRY-380', 'ErbB-2 kinase inhibitors (breast cancer), Array Biopharma/Seagen']",tucatinib,fexact,"['irbinitinib', 'mk 7119', 'tucatinib', 'ont 380', 'erbb 2 kinase inhibitors breast cancer seagen', 'erbb 2 inhibitors cancer array biopharma oncothyreon', 'erbb 2 kinase inhibitors breast cancer', 'arry 333786', 'tukysa', 'erbb 2 inhibitors cancer oncothyreon', 'arry 380', 'erbb 2 kinase inhibitors breast cancer array biopharma seagen']",correct_mapping
trastuzumab (IV),ErbB-2 antagonist,trastuzumab,,trastuzumab biosimilar,trastuzumab,fexact,"['trastuzumab biosimilar', 'Trastuzumab BS', 'trastuzumab-qyyp', 'PF-05280014', 'Trazimera', 'trastuzumab']",trastuzumab biosimilar,fexact,"['trastuzumab biosimilar', 'trastuzumab bs', 'trastuzumab qyyp', 'pf 05280014', 'trazimera', 'trastuzumab']",correct_mapping
pucotenlimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,pucotenlimab,,,,0,['pucotenlimab'],,0,[],0
TAK-788 (capsule),EGFR antagonist; ErbB-2 antagonist; Tyrosine kinase inhibitor (TKI),TAK-788,,mobocertinib,tak 788,fexact,"['mobocertinib', 'AP-32788', 'TAK-788']",mobocertinib,fexact,"['mobocertinib', 'ap 32788', 'tak 788']",correct_mapping
gefitinib,EGFR kinase inhibitor,gefitinib,,gefitinib,gefitinib,fexact,"['ZD-1839', 'gefitinib', 'Iressat', 'Iressa']",gefitinib,fexact,"['zd 1839', 'gefitinib', 'iressat', 'iressa']",correct_mapping
ipilimumab (intratumoral),CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,ipilimumab,,ipilimumab,ipilimumab,fexact,"['BMS-734016', 'MDX-010', 'Winglore', 'MDX-101', 'anti-CTLA4, Medarex', 'Yervoy', 'MDX-CTLA4', 'CTLA-4 checkpoint inhibitor (cancer)', 'anti-CTLA4', 'ipilimumab']",ipilimumab,fexact,"['bms 734016', 'mdx 010', 'winglore', 'mdx 101', 'anti ctla4 medarex', 'yervoy', 'mdx ctla4', 'ctla 4 checkpoint inhibitor cancer', 'anti ctla4', 'ipilimumab']",correct_mapping
ulixertinib,Mitogen-activated protein kinase 1 inhibitor; Mitogen-activated protein kinase 3 inhibitor,ulixertinib,,ulixertinib,ulixertinib,fexact,"['ulixertinib hydrochloride', 'BVD-VTX', 'BVD-ERK', 'ulixertinib', 'BVD-ERK/ST', 'BVD-523FB', 'BVD-ERK/HM', 'BVD-523', 'VRT-752271']",ulixertinib,fexact,"['ulixertinib hydrochloride', 'bvd vtx', 'bvd erk', 'ulixertinib', 'bvd erk st', 'bvd 523fb', 'bvd erk hm', 'bvd 523', 'vrt 752271']",correct_mapping
BLU-945,EGFR antagonist,BLU-945,,BLU-945,blu 945,fexact,"['triple mutant EGFR kinase (EGFR+ T790M/C797S) inhibitor (non-small cell lung cancer)', 'BLU-945']",BLU-945,fexact,"['triple mutant egfr kinase egfr t790m c797s inhibitor non small cell lung cancer', 'blu 945']",correct_mapping
PF-07220060,Cyclin-dependent kinase 4 inhibitor,PF-07220060,,PF-07220060,pf 07220060,fexact,['PF-07220060'],PF-07220060,fexact,['pf 07220060'],correct_mapping
PF-07104091,Cyclin-dependent kinase 2 inhibitor,PF-07104091,,PF-07104091,pf 07104091,fexact,"['PF-07104091', 'CDK2 selective next-generation CDK inhibitor (breast cancer, ovarian cancer, NSCLC, SCLC)']",PF-07104091,fexact,"['pf 07104091', 'cdk2 selective next generation cdk inhibitor breast cancer ovarian cancer nsclc sclc']",correct_mapping
IGM-8444,TRAIL receptor 2 agonist; Immuno-oncology therapy,IGM-8444,,IGM-8444,igm 8444,fexact,"['Death Receptor 5', 'multimeric anti-death receptor 5 antibody (cancer)', 'multimeric anti-DR5 antibody (cancer)', 'IGM-8444', 'multimeric IgM antibodies targeting DR5 (cancer)']",IGM-8444,fexact,"['death receptor 5', 'multimeric anti death receptor 5 antibody cancer', 'multimeric anti dr5 antibody cancer', 'igm 8444', 'multimeric igm antibodies targeting dr5 cancer']",correct_mapping
BT-8009,Nectin-4 antagonist,BT-8009,,BT-8009,bt 8009,fexact,"['BT-8009', 'second-generation bicycle toxin conjugate targeting Nectin-4 (iv, solid tumors)', 'bicycle toxin conjugate targeting Nectin-4 (iv, solid tumors), BicycleRD']",BT-8009,fexact,"['bt 8009', 'second generation bicycle toxin conjugate targeting nectin 4 iv solid tumors', 'bicycle toxin conjugate targeting nectin 4 iv solid tumors bicyclerd']",correct_mapping
abemaciclib,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,abemaciclib,,abemaciclib,abemaciclib,fexact,"['abemaciclib', 'Verzenios', 'VerzenioTM', 'Verzenio', 'bemaciclib', 'LY-2835219', 'CDK 4/6 dual inhibitor (oral, cancer)']",abemaciclib,fexact,"['abemaciclib', 'verzenios', 'verzeniotm', 'verzenio', 'bemaciclib', 'ly 2835219', 'cdk 4 6 dual inhibitor oral cancer']",correct_mapping
PF-07284890,B-raf kinase inhibitor,PF-07284890,,PF-07284890,pf 07284890,fexact,"['BRAF BP (melanoma)', 'brain-penetrant V600X BRAF inhibitor (melanoma and other BRAF-driven cancers)', 'ARRY-461', 'PF-07284890', 'B-Raf inhibitor (oral, brain penetrant, advanced solid tumor)']",PF-07284890,fexact,"['braf bp melanoma', 'brain penetrant v600x braf inhibitor melanoma and other braf driven cancers', 'arry 461', 'pf 07284890', 'b raf inhibitor oral brain penetrant advanced solid tumor']",correct_mapping
GNR-051,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,GNR-051,,GNR-051,gnr 051,fexact,"['GNR-051', 'IgG2 anti-PD-1 monoclonal antibody (solid tumor)', 'PD-1 checkpoint inhibitor (solid tumors)']",GNR-051,fexact,"['gnr 051', 'igg2 anti pd 1 monoclonal antibody solid tumor', 'pd 1 checkpoint inhibitor solid tumors']",correct_mapping
temozolomide (oral),DNA inhibitor,temozolomide,,"temozolomide (oral capsule, glioma)",temozolomide,fexact,"['Diqing', 'temozolomide', 'temozolomide (oral capsule, glioma)']","temozolomide (oral capsule, glioma)",fexact,"['diqing', 'temozolomide', 'temozolomide oral capsule glioma']",correct_mapping
famitinib,Vascular endothelial growth factor receptor 1 antagonist; Vascular endothelial growth factor receptor 2 antagonist; Vascular endothelial growth factor receptor 3 antagonist; C-kit inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor kinase inhibitor,famitinib,,famitinib L-malate,famitinib,fexact,"['c-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer)', 'famitinib L-malate', 'famitinib', 'tyrosine-kinase inhibitor (oral, cancer)', 'SHR-1020']",famitinib L-malate,fexact,"['c kit vegfr2 pdgfr vegfr3 flt1 flt3 inhibitor oral cancer', 'famitinib l malate', 'famitinib', 'tyrosine kinase inhibitor oral cancer', 'shr 1020']",correct_mapping
olaparib (tablet),Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor,olaparib,,olaparib,olaparib,fexact,"['KU-0058948', 'TBI-361', 'PARP inhibitors (cancer), KuDOS', 'MRU-868', 'KU-58948', 'NU-1085', 'olaparib', 'MRU-687', 'NU-1025', 'KU-59449', 'KU-0051529', 'KU-0687', 'KU-0059436', 'KU-56186', 'AZD-2281', 'NU-1070', 'PARP inhibitors (cancer), AstraZeneca', 'MK-7339', 'KU-0058684', 'Lipzol', 'PARP inhibitors (cancer)', 'Lynparza', 'KU-59436']",olaparib,fexact,"['ku 0058948', 'tbi 361', 'parp inhibitors cancer kudos', 'mru 868', 'ku 58948', 'nu 1085', 'olaparib', 'mru 687', 'nu 1025', 'ku 59449', 'ku 0051529', 'ku 0687', 'ku 0059436', 'ku 56186', 'azd 2281', 'nu 1070', 'parp inhibitors cancer astrazeneca', 'mk 7339', 'ku 0058684', 'lipzol', 'parp inhibitors cancer', 'lynparza', 'ku 59436']",correct_mapping
mobocertinib,EGFR antagonist; ErbB-2 antagonist; Tyrosine kinase inhibitor (TKI),mobocertinib,,mobocertinib,mobocertinib,fexact,"['mobocertinib', 'AP-32788', 'TAK-788']",mobocertinib,fexact,"['mobocertinib', 'ap 32788', 'tak 788']",correct_mapping
"melatonin, unspecified",Melatonin receptor agonist,melatonin,unspecified,,,0,"['Circadin', 'melatonin (controlled release, insomnia), Neurim', 'KI-1001', 'melatonin (controlled release, insomnia)', 'melatonin', 'melatonin (sustained/immediate release, sleep disorder)', 'Posidorm', 'KI-1001, Kuhnil', 'Circadin–Ped', 'NPC-15', 'Melatobel', 'PedPRM', 'Slenyto']",,Drug_API_mapping,[],0
M-1231,Unidentified pharmacological activity,M-1231,,M-1231,m 1231,fexact,"['antibody drug conjugate (cancer),/', 'EGFR/Mucin 1 bispecific antibody drug conjugate (cancer),/', 'antibody drug conjugate (cancer), Sutro/', 'M-1231', 'EGFR/Mucin 1 bispecific antibody drug conjugate (cancer), Sutro/']",M-1231,fexact,"['antibody drug conjugate cancer', 'egfr mucin 1 bispecific antibody drug conjugate cancer', 'antibody drug conjugate cancer sutro', 'm 1231', 'egfr mucin 1 bispecific antibody drug conjugate cancer sutro']",correct_mapping
KIN-2787,Raf kinase inhibitor,KIN-2787,,KIN-2787,kin 2787,fexact,"['KIN00-2787', 'BRAF inhibitors (melanoma/NSCLC)', 'KIN-2787']",KIN-2787,fexact,"['kin00 2787', 'braf inhibitors melanoma nsclc', 'kin 2787']",correct_mapping
INCB-86550,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,INCB-86550,,INCB-086550,incb 86550,fexact,"['INCB-086550', 'INCB-86550', 'PD-L1 checkpoint inhibitor (advanced solid tumor)']",INCB-086550,fexact,"['incb 086550', 'incb 86550', 'pd l1 checkpoint inhibitor advanced solid tumor']",correct_mapping
GSK-3901961,T cell stimulant; Immuno-oncology therapy,GSK-3901961,,GSK-3901961,gsk 3901961,fexact,"['adoptive T-cell therapy (synovial sarcoma/non small cell lung cancer/advanced tumor)', 'GSK-3901961', 'CD8alpha-expressing anti-NY-ESO-1/LAGE-1a/HLA-A*02:01/HLA-A*02:05/HLA-A*02:06 TCR T-cell therapy (synovial sarcoma/NSCLC/advanced tumor)', 'anti-NY-ESO-1/LAGE-1a/HLA-A*02:01/HLA-A*02:05/HLA-A*02:06 TCR T-cell therapy (synovial sarcoma/NSCLC/advanced tumor)']",GSK-3901961,fexact,"['adoptive t cell therapy synovial sarcoma non small cell lung cancer advanced tumor', 'gsk 3901961', 'cd8alpha expressing anti ny eso 1 lage 1a hla a 02 01 hla a 02 05 hla a 02 06 tcr t cell therapy synovial sarcoma nsclc advanced tumor', 'anti ny eso 1 lage 1a hla a 02 01 hla a 02 05 hla a 02 06 tcr t cell therapy synovial sarcoma nsclc advanced tumor']",correct_mapping
GSK-3845097,T cell stimulant; Immuno-oncology therapy,GSK-3845097,,GSK-3845097,gsk 3845097,fexact,"['GSK-3845097', 'anti-NY-ESO-1/LAGE-1a/HLA-A*02:01/HLA-A*02:05/HLA-A*02:06 TCR T-cell therapy (synovial sarcoma/advanced tumor)', 'adoptive T-cell therapy (synovial sarcoma/advanced tumor)']",GSK-3845097,fexact,"['gsk 3845097', 'anti ny eso 1 lage 1a hla a 02 01 hla a 02 05 hla a 02 06 tcr t cell therapy synovial sarcoma advanced tumor', 'adoptive t cell therapy synovial sarcoma advanced tumor']",correct_mapping
[18F]F-AraG,Radiopharmaceutical,[18F]F-AraG,,[18f]f-arag (cancer),18f f arag,fexact,"['fluorine-18(18f)-radiolabeled-d-arabinofuranosylguanine (cancer)', 'VisAcT', '[18f]f-arag (cancer)', 'F-AraG-[18F]', '[18F]F-AraG (GvHD),//University of California San Francisco', '[18F]F-AraG (cancer),/Standford University/University of California San Francisco', 'fluorine-18(18F)-radiolabeled-D-arabinofuranosylguanine (cancer),/University of California San Francisco/Stanford University', '[18f]f-arag (gvhd)', 'fluorine-18-F-AraG', '[18F]F-AraG', '[18F]F-AraG (GvHD),/Standford University/University of California San Francisco', '[18F]F-AraG (cancer),//University of California San Francisco', 'fluorine-18(18f)-radiolabeled-d-arabinofuranosylguanine (cancer),/university of california san francisco']",[18f]f-arag (cancer),fexact,"['fluorine 18 18f radiolabeled d arabinofuranosylguanine cancer', 'visact', '18f f arag cancer', 'f arag 18f', '18f f arag gvhd university of california san francisco', '18f f arag cancer standford university university of california san francisco', 'fluorine 18 18f radiolabeled d arabinofuranosylguanine cancer university of california san francisco stanford university', '18f f arag gvhd', 'fluorine 18 f arag', '18f f arag', '18f f arag gvhd standford university university of california san francisco', '18f f arag cancer university of california san francisco', 'fluorine 18 18f radiolabeled d arabinofuranosylguanine cancer university of california san francisco']",correct_mapping
OMT-111,Unidentified pharmacological activity,OMT-111,,OMT-110,omt 111,fexact,"['OMT-110', 'OMT-111']",OMT-110,fexact,"['omt 110', 'omt 111']",correct_mapping
fecal bacteriotherapy,"Microbiome modulator, faecal",fecal bacteriotherapy,,,,0,['fecal bacteriotherapy'],,0,[],0
cabozantinib,RET tyrosine kinase inhibitor; Axl receptor tyrosine kinase inhibitor; MET tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor,cabozantinib,,cabozantinib,cabozantinib,fexact,"['Cabometyx', 'XL-184', 'cabozantinib S-malate', 'BMS-907351', 'Cometriq', 'cabozantinib']",cabozantinib,fexact,"['cabometyx', 'xl 184', 'cabozantinib s malate', 'bms 907351', 'cometriq', 'cabozantinib']",correct_mapping
"nivolumab, Mabpharm",PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,nivolumab,Mabpharm,nivolumab,nivolumab,fexact,"['nivolumab', 'MDX-1106-04', 'Opdivo', 'BMS-936558-01', 'PD-1 checkpoint inhibitor (cancer),/', 'BMS-986298', 'anti-PD-1 antibody (cancer), Ono/Medarex/BMS', 'anti-PD-1 antibody (cancer), Ono//BMS', 'ONO-4538', 'PD-1 checkpoint inhibitor (cancer),/Ono', 'anti-PD-1 antibody (cancer),//BMS', 'BMS-936558', 'NIVO', '89Zr-nivolumab', 'MDX-1106']",nivolumab,fexact,"['nivolumab', 'mdx 1106 04', 'opdivo', 'bms 936558 01', 'pd 1 checkpoint inhibitor cancer', 'bms 986298', 'anti pd 1 antibody cancer ono medarex bms', 'anti pd 1 antibody cancer ono bms', 'ono 4538', 'pd 1 checkpoint inhibitor cancer ono', 'anti pd 1 antibody cancer bms', 'bms 936558', 'nivo', '89zr nivolumab', 'mdx 1106']",correct_mapping
SPYK-04,Unidentified pharmacological activity,SPYK-04,,SPYK-04,spyk 04,fexact,['SPYK-04'],SPYK-04,fexact,['spyk 04'],correct_mapping
olmutinib,ErbB tyrosine kinase inhibitor,olmutinib,,olmutinib,olmutinib,fexact,"['Olita', 'HM-61713', 'EMSI (T790M-positive NSCLC)', 'olmutinib', 'olmutinib hydrochloride', 'EGFR mutant selective inhibitor (cancer), Hanmi', 'BI-1482694', 'EMSI (T790M-positive NSCLC), Hanmi', 'olmutinib hydrochloride monohydrate', 'ZL-2303', 'EGFR mutant selective inhibitor (cancer)', 'olmutinib HCl monohydrate']",olmutinib,fexact,"['olita', 'hm 61713', 'emsi t790m positive nsclc', 'olmutinib', 'olmutinib hydrochloride', 'egfr mutant selective inhibitor cancer hanmi', 'bi 1482694', 'emsi t790m positive nsclc hanmi', 'olmutinib hydrochloride monohydrate', 'zl 2303', 'egfr mutant selective inhibitor cancer', 'olmutinib hcl monohydrate']",correct_mapping
RO-5126766,Ras inhibitor; Mitogen-activated kinase kinase inhibitor; Raf kinase inhibitor,RO-5126766,,VS-6766,ro 5126766,fexact,"['dual Raf/MEK protein kinase inhibitor (solid tumors)', 'dual Raf/MEK protein kinase inhibitor (solid tumors), Roche', 'CH-5126766', 'VS-6766', 'RO-5126766', 'R-7304', 'RG-7304', 'CKI-27']",VS-6766,fexact,"['dual raf mek protein kinase inhibitor solid tumors', 'dual raf mek protein kinase inhibitor solid tumors roche', 'ch 5126766', 'vs 6766', 'ro 5126766', 'r 7304', 'rg 7304', 'cki 27']",correct_mapping
defactinib,Focal adhesion kinase inhibitor,defactinib,,defactinib,defactinib,fexact,"['FAK inhibitors (cancer)', 'VS-6063', 'PF-04554878', 'defactinib', 'PF-4554878', 'defactinib hydrochloride', 'PF-941222']",defactinib,fexact,"['fak inhibitors cancer', 'vs 6063', 'pf 04554878', 'defactinib', 'pf 4554878', 'defactinib hydrochloride', 'pf 941222']",correct_mapping
dacomitinib (oral),EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),dacomitinib,,dacomitinib,dacomitinib,fexact,"['PF-00299804', 'PF-0299804', 'PF-299804', 'Vizimpro', 'PF-05199265', 'PF-299', 'PF-804', 'dacomitinib (USAN)', 'dacomitinib']",dacomitinib,fexact,"['pf 00299804', 'pf 0299804', 'pf 299804', 'vizimpro', 'pf 05199265', 'pf 299', 'pf 804', 'dacomitinib usan', 'dacomitinib']",correct_mapping
trametinib,Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,trametinib,,trametinib,trametinib,fexact,"['Mark inhibitor (cancer, inflammation),/', 'JTP-74057 DMSO', 'MEK inhibitor (oral, cancer)', 'Erk inhibitor (cancer, inflammation), Japan Tobacco/', 'trametinib dimethyl sulfoxide', 'Erk inhibitor (cancer, inflammation),/', 'GSK-212', 'trametinib DMSO', 'NSC-763093', 'Mark inhibitor (cancer, inflammation), Japan Tobacco/', 'trametinib', 'TMT-212', 'MEK inhibitor (cancer, inflammation)', 'GSK-1120212', 'Mekinist', 'GSK-1120212B']",trametinib,fexact,"['mark inhibitor cancer inflammation', 'jtp 74057 dmso', 'mek inhibitor oral cancer', 'erk inhibitor cancer inflammation japan tobacco', 'trametinib dimethyl sulfoxide', 'erk inhibitor cancer inflammation', 'gsk 212', 'trametinib dmso', 'nsc 763093', 'mark inhibitor cancer inflammation japan tobacco', 'trametinib', 'tmt 212', 'mek inhibitor cancer inflammation', 'gsk 1120212', 'mekinist', 'gsk 1120212b']",correct_mapping
dabrafenib,B-raf kinase inhibitor,dabrafenib,,dabrafenib,dabrafenib,fexact,"['Tafinlar', 'Rafinlar', 'SB-477790', 'dabrafenib mesylate', 'dabrafenib', 'NSC-763760', 'DRB-436', 'b-Raf inhibitors (cancer)', 'SB-244649', 'GSK-2118436', 'GSK-2118436J', 'GSK-2118436A', 'SB-602330', 'GSK-436', 'SB-590885', 'SB-699393']",dabrafenib,fexact,"['tafinlar', 'rafinlar', 'sb 477790', 'dabrafenib mesylate', 'dabrafenib', 'nsc 763760', 'drb 436', 'b raf inhibitors cancer', 'sb 244649', 'gsk 2118436', 'gsk 2118436j', 'gsk 2118436a', 'sb 602330', 'gsk 436', 'sb 590885', 'sb 699393']",correct_mapping
"ALK inhibitor, unspecified",Anaplastic lymphoma kinase inhibitor,ALK inhibitor,unspecified,,,0,['ALK inhibitor'],,0,[],0
ION-AZ7,Forkhead box P3 inhibitor; Immuno-oncology therapy,ION-AZ7,,AZD-8701,ion az7,fexact,"['Treg modulator (cancer), AstraZenca/Ionis', 'FOXP3 inhibitor (cancer), Astrazenca/Ionis', 'antisense oligonucleotide targeting forkhead Box P3 (cancer), Astrazenca', 'Foxp3-targeting antisense oligonucleotides (cancer), Ionis/', 'Treg modulator (cancer), AstraZenca/', 'FOXP3 inhibitor (cancer), Astrazenca/', 'Foxp3-targeting antisense oligonucleotides (cancer),/', 'ION-AZ7', 'AZD-8701', 'ION-736']",AZD-8701,fexact,"['treg modulator cancer astrazenca ionis', 'foxp3 inhibitor cancer astrazenca ionis', 'antisense oligonucleotide targeting forkhead box p3 cancer astrazenca', 'foxp3 targeting antisense oligonucleotides cancer ionis', 'treg modulator cancer astrazenca', 'foxp3 inhibitor cancer astrazenca', 'foxp3 targeting antisense oligonucleotides cancer', 'ion az7', 'azd 8701', 'ion 736']",correct_mapping
prednisone,Immunosuppressant; Corticosteroid agonist,prednisone,,,,0,"['prednisone (oral microcapsule formulation/Optimum, cancer/acute pain), Orbis Biosciences', 'prednisone (oral microcapsule formulation/Optimum, nephrotic syndrome/asthma/bronchiolitis/eczema/atopic dermatitis/cancer), Orbis Biosciences', 'ORB-101', 'prednisone', 'prednisone (oral microcapsule formulation/Optimum, nephrotic syndrome/asthma/bronchiolitis/eczema/atopic dermatitis/cancer)', 'prednisone (oral microcapsule formulation/Optimum, cancer/acute pain)']",,NER_API,[],0
keynatinib,Protein kinase inhibitor,keynatinib,,MED-1007,keynatinib,fexact,"['kenaitinib', 'TL-007', 'MED-1007', 'keynatinib', 'EGFR inhbitors (lung cancer)', 'EGFR inhbitors (lung cancer), Medolution', 'ML-007']",MED-1007,fexact,"['kenaitinib', 'tl 007', 'med 1007', 'keynatinib', 'egfr inhbitors lung cancer', 'egfr inhbitors lung cancer medolution', 'ml 007']",correct_mapping
ketorolac (IV),Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor,ketorolac,,ketorolac,ketorolac,fexact,"['Lixidol', 'Droal', 'Toradol', 'Toradol Oral', 'ketorolac', 'Tonum', 'RS-37619', 'BPPC', 'BDPC', 'ketorolac tromethamine', 'Findol', 'Tora-Dol', 'Toratex']",ketorolac,fexact,"['lixidol', 'droal', 'toradol', 'toradol oral', 'ketorolac', 'tonum', 'rs 37619', 'bppc', 'bdpc', 'ketorolac tromethamine', 'findol', 'tora dol', 'toratex']",correct_mapping
tocilizumab,Interleukin 6 receptor antagonist; Disease modifying antirheumatic drug,tocilizumab,,,,0,"['tocilizumab', 'MSB-11456', 'tocilizumab biosimilar (autoimmune diseases)']",,NER_API,[],0
CC-1,Unidentified pharmacological activity,CC-1,,,,0,['CC-1'],,0,[],0
tegatrabetan,Unidentified pharmacological activity,tegatrabetan,,tegavivint,tegatrabetan,fexact,"['BC-2059', 'tegatrabetan', 'tegavivint']",tegavivint,fexact,"['bc 2059', 'tegatrabetan', 'tegavivint']",correct_mapping
"immune checkpoint inhibitor, unspecified",Immuno-oncology therapy; Immune checkpoint inhibitor,immune checkpoint inhibitor,unspecified,,,0,['immune checkpoint inhibitor'],,0,[],0
valaciclovir,DNA directed DNA polymerase inhibitor,valaciclovir,,valaciclovir,valaciclovir,fexact,"['Valtrex', 'BW-256U', 'valaciclovir', 'Zelitrex', 'valaciclovir hydrochloride', '256-U-87', 'BW-256', 'valacyclovir', '256U']",valaciclovir,fexact,"['valtrex', 'bw 256u', 'valaciclovir', 'zelitrex', 'valaciclovir hydrochloride', '256 u 87', 'bw 256', 'valacyclovir', '256u']",correct_mapping
aglatimagene besadenovec,Thymidine kinase stimulant; Immunostimulant; DNA directed DNA polymerase inhibitor,aglatimagene besadenovec,,aglatimagene besadenovec,aglatimagene besadenovec,fexact,"['TKS', 'Adv-tk (pancreatic cancer), Advantagene', 'Gene Mediated Cytotoxic Immunotherapy', 'aglatimagene besadenovec (prostate cancer), Advantagene', 'Adv-tk (cancer), Advantagene', 'TK', 'Adv-tk (brain cancer), Advantagene', 'GliAtak', 'PancAtak', 'AdV-tk', 'ProstAtak', 'Adv-tk (prostate cancer), Advantagene', 'CAN-2409', 'Adv-tk (gene therapy, cancer), Advantagene', 'TKC', 'aglatimagene besadenovec', 'GMCI', 'TKR', 'oncolytic adenovirus therapy expressing HSV-tk (cancer), Advantagene']",aglatimagene besadenovec,fexact,"['tks', 'adv tk pancreatic cancer advantagene', 'gene mediated cytotoxic immunotherapy', 'aglatimagene besadenovec prostate cancer advantagene', 'adv tk cancer advantagene', 'tk', 'adv tk brain cancer advantagene', 'gliatak', 'pancatak', 'adv tk', 'prostatak', 'adv tk prostate cancer advantagene', 'can 2409', 'adv tk gene therapy cancer advantagene', 'tkc', 'aglatimagene besadenovec', 'gmci', 'tkr', 'oncolytic adenovirus therapy expressing hsv tk cancer advantagene']",correct_mapping
BAY-1895344,Ataxia telangiectasia Rad3 inhibitor,BAY-1895344,,elimusertib,bay 1895344,fexact,"['elimusertib', 'ATR inhibitor (cancer)', 'BAY-1895344']",elimusertib,fexact,"['elimusertib', 'atr inhibitor cancer', 'bay 1895344']",correct_mapping
CDX-301,Flt-3 agonist,CDX-301,,CDX-301,cdx 301,fexact,"['Flt3L', 'Flt-3/Flk-2 ligand', 'Flt-3 ligand (sc, cancer, NSCLC, stem cell transplantation, B-cell lymphoma, metastatic melanoma, autoimmune disease/prostate cancer)', 'Flt-3 ligand', 'Flt-3 ligand (sc, cancer/NSCLC/stem cell transplantation/B-cell lymphoma/metastatic melanoma/autoimmune disease/pancreatic ductal adenocarcinoma)', 'Flt-3 ligand (stem cell mobilizer)', 'Mobista', 'Mobist', 'CDX-301', 'Flt-3/Flk-2 ligand, Immunex', 'Flt-3 ligand (stem cell mobilizer), Viacell', 'Flt-3 ligand, Immunex', 'Flt-3 ligand (sc, cancer, NSCLC, stem cell transplantation, B-cell lymphoma, metastatic melanoma, autoimmune disease)', 'Moblsta', 'Flt-3 ligand, Amgen', 'rhuFlt3L']",CDX-301,fexact,"['flt3l', 'flt 3 flk 2 ligand', 'flt 3 ligand sc cancer nsclc stem cell transplantation b cell lymphoma metastatic melanoma autoimmune disease prostate cancer', 'flt 3 ligand', 'flt 3 ligand sc cancer nsclc stem cell transplantation b cell lymphoma metastatic melanoma autoimmune disease pancreatic ductal adenocarcinoma', 'flt 3 ligand stem cell mobilizer', 'mobista', 'mobist', 'cdx 301', 'flt 3 flk 2 ligand immunex', 'flt 3 ligand stem cell mobilizer viacell', 'flt 3 ligand immunex', 'flt 3 ligand sc cancer nsclc stem cell transplantation b cell lymphoma metastatic melanoma autoimmune disease', 'moblsta', 'flt 3 ligand amgen', 'rhuflt3l']",correct_mapping
CDX-1140,CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,CDX-1140,,CDX-1140,cdx 1140,fexact,"['CDX-1140', 'human IgG2 CD40 agonist mAb (cancer/melanoma/uveal melanoma/brain tumor)', 'human IgG2 CD40 agonist mAb (cancer/melanoma/uveal melanoma/brain tumor/pancreatic ductal adenocarcinoma)', 'CD40 costimulator (cancer)', 'CD40 agonist antibodies (cancer)']",CDX-1140,fexact,"['cdx 1140', 'human igg2 cd40 agonist mab cancer melanoma uveal melanoma brain tumor', 'human igg2 cd40 agonist mab cancer melanoma uveal melanoma brain tumor pancreatic ductal adenocarcinoma', 'cd40 costimulator cancer', 'cd40 agonist antibodies cancer']",correct_mapping
alpha PD1-MSLN-CAR T cells,Immuno-oncology therapy,alpha PD1-MSLN-CAR T cells,,,,0,['alpha PD1-MSLN-CAR T cells'],,0,[],0
personalized neoantigen vaccine,Unidentified pharmacological activity,personalized neoantigen vaccine,,,,0,['personalized neoantigen vaccine'],,0,[],0
BND-22,Immuno-oncology therapy; Immune checkpoint inhibitor; ILT2 inhibitor,BND-22,,BION-202,bnd 22,fexact,"['BION-202', 'SAR-444881', 'ILT2 checkpoint inhibitor (cancer)', 'LILRB checkpoint inhibitor (cancer)', 'BND-22']",BION-202,fexact,"['bion 202', 'sar 444881', 'ilt2 checkpoint inhibitor cancer', 'lilrb checkpoint inhibitor cancer', 'bnd 22']",correct_mapping
alisertib,Aurora kinase inhibitor; Protein kinase inhibitor; Mitotic inhibitor,alisertib,,alisertib,alisertib,fexact,"['TAK-823', 'MLN-8237', 'alisertib']",alisertib,fexact,"['tak 823', 'mln 8237', 'alisertib']",correct_mapping
sapanisertib,mTORC1 kinase inhibitor; mTORC2 kinase inhibitor,sapanisertib,,sapanisertib,sapanisertib,fexact,"['mTORC1/mTORC2 inhibitors (oral, cancer), Millennium', 'TAK-228', 'INK-128', 'MLN-0128', 'mTORC1/mTORC2 inhibitors (oral, cancer)', 'sapanisertib']",sapanisertib,fexact,"['mtorc1 mtorc2 inhibitors oral cancer millennium', 'tak 228', 'ink 128', 'mln 0128', 'mtorc1 mtorc2 inhibitors oral cancer', 'sapanisertib']",correct_mapping
GC-4711 (intravenous),Superoxide dismutase inhibitor,GC-4711,,GC-4711,gc 4711,fexact,"['GC-4711', 'superoxide dismutase mimetic (iv, NSCLC)']",GC-4711,fexact,"['gc 4711', 'superoxide dismutase mimetic iv nsclc']",correct_mapping
sirpiglenastat,Glutamine antagonist,sirpiglenastat,,sirpiglenastat,sirpiglenastat,fexact,"['JHU-083, John Hopkins University', 'JHU-083', 'DON prodrug (iv, glioblastoma)', 'DON prodrug (cancer)', 'sirpiglenastat', '5c', 'glutamine\xa0antagonist (iv/prodrug, glioblastoma)', 'DRP-104']",sirpiglenastat,fexact,"['jhu 083 john hopkins university', 'jhu 083', 'don prodrug iv glioblastoma', 'don prodrug cancer', 'sirpiglenastat', '5c', 'glutamine\xa0antagonist iv prodrug glioblastoma', 'drp 104']",correct_mapping
pirfenidone,Fibroblast growth factor antagonist; Transforming growth factor beta 1 antagonist; Mitogen-activated protein kinase 14 inhibitor,pirfenidone,,pirfenidone,pirfenidone,fexact,"['Deskar', 'p38 MAP kinase inhibitor (oral, fibrosis/ multiple sclerosis),/', 'S-7701', 'p38 MAP kinase inhibitor (oral, fibrosis/ multiple sclerosis), Marnac/', 'Pirespa', 'RO-0220912', 'Esbriet', 'S-770108', 'pirfenidone', 'p38 MAP kinase inhibitor (oral, fibrosis/ multiple sclerosis), Marnac/ InterMune', 'RG-6062', 'AMR-69']",pirfenidone,fexact,"['deskar', 'p38 map kinase inhibitor oral fibrosis multiple sclerosis', 's 7701', 'p38 map kinase inhibitor oral fibrosis multiple sclerosis marnac', 'pirespa', 'ro 0220912', 'esbriet', 's 770108', 'pirfenidone', 'p38 map kinase inhibitor oral fibrosis multiple sclerosis marnac intermune', 'rg 6062', 'amr 69']",correct_mapping
TPX-0131,Anaplastic lymphoma kinase inhibitor,TPX-0131,,TPX-0131,tpx 0131,fexact,"['ALK inhibitors (non-small cell lung cancer)', 'TPX-0131']",TPX-0131,fexact,"['alk inhibitors non small cell lung cancer', 'tpx 0131']",correct_mapping
VLS-101,Unidentified pharmacological activity,VLS-101,,MK-2140,vls 101,fexact,"['anticancer therapeutic (hematological malignancies)', 'VLS-101', 'anticancer therapeutic (hematological malignancies), VelosBio', ""anti-ROR1 antibody-drug conjugate (Richter's syndrome), VelosBio"", 'anti-ROR1 antibody-drug conjugate (iv, solid tumor/non small cell lung cancer/triple negatve breast cancer) VelosBio', 'MK-2140', ""anti-ROR1 antibody-drug conjugate (Richter's syndrome)""]",MK-2140,fexact,"['anticancer therapeutic hematological malignancies', 'vls 101', 'anticancer therapeutic hematological malignancies velosbio', 'anti ror1 antibody drug conjugate richter s syndrome velosbio', 'anti ror1 antibody drug conjugate iv solid tumor non small cell lung cancer triple negatve breast cancer velosbio', 'mk 2140', 'anti ror1 antibody drug conjugate richter s syndrome']",correct_mapping
axitinib,C-kit inhibitor; Platelet-derived growth factor receptor beta kinase inhib; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,axitinib,,axitinib,axitinib,fexact,"['VEGF/PDGF inhibitor, Agouron/', 'AG-013736', 'AG-13736', 'axitinib', 'Inlyta']",axitinib,fexact,"['vegf pdgf inhibitor agouron', 'ag 013736', 'ag 13736', 'axitinib', 'inlyta']",correct_mapping
GDC-6036,K-Ras inhibitor,GDC-6036,,GDC-6036,gdc 6036,fexact,"['GDC-6036', 'RG-6330']",GDC-6036,fexact,"['gdc 6036', 'rg 6330']",correct_mapping
"bevacizumab, Allergan",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Allergan,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
JMT-101,ErbB antagonist,JMT-101,,nimotuzumab biosimilar,jmt 101,fexact,"['nimotuzumab biosimilar', 'nimotuzumab', 'JMT-101']",nimotuzumab biosimilar,fexact,"['nimotuzumab biosimilar', 'nimotuzumab', 'jmt 101']",correct_mapping
REGN-7075,CD28 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,REGN-7075,,REGN-7075,regn 7075,fexact,"['anti-EGFR/anti-CD28 bispecific antibody (non-small cell lung cancer/head and neck squamous cell carcinoma/cutaneous squamous cell carcinoma/colorectal cancer)', 'dual CD28 costimulator/anti-EGFR antibody (non-small cell lung cancer/head and neck squamous cell carcinoma/cutaneous squamous cell carcinoma/colorectal cancer)', 'EGFRxCD28', 'REGN-7075']",REGN-7075,fexact,"['anti egfr anti cd28 bispecific antibody non small cell lung cancer head and neck squamous cell carcinoma cutaneous squamous cell carcinoma colorectal cancer', 'dual cd28 costimulator anti egfr antibody non small cell lung cancer head and neck squamous cell carcinoma cutaneous squamous cell carcinoma colorectal cancer', 'egfrxcd28', 'regn 7075']",correct_mapping
GLR-2007,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,GLR-2007,,GLR-2007,glr 2007,fexact,"['CDK4 inhibitor (glioblastoma/non small cell lung caner/advanced solid tumors/brain tumor/breast cancer), Gan and Lee Pharmaceuticals', 'GLR2007-237FA', 'cyclin-dependent kinase 4 inhibitor (glioblastoma/non small cell lung caner/advanced solid tumors/brain tumor/breast cancer), Gan and Lee Pharmaceuticals', 'GLR-007', 'cyclin-dependent kinase 6 inhibitor (glioblastoma/non small cell lung caner/advanced solid tumors/brain tumor/breast cancer), Gan and Lee Pharmaceuticals', 'GLR-2007', 'CDK6 inhibitor (glioblastoma/non small cell lung caner/advanced solid tumors/brain tumor/breast cancer), Gan and Lee Pharmaceuticals']",GLR-2007,fexact,"['cdk4 inhibitor glioblastoma non small cell lung caner advanced solid tumors brain tumor breast cancer gan and lee pharmaceuticals', 'glr2007 237fa', 'cyclin dependent kinase 4 inhibitor glioblastoma non small cell lung caner advanced solid tumors brain tumor breast cancer gan and lee pharmaceuticals', 'glr 007', 'cyclin dependent kinase 6 inhibitor glioblastoma non small cell lung caner advanced solid tumors brain tumor breast cancer gan and lee pharmaceuticals', 'glr 2007', 'cdk6 inhibitor glioblastoma non small cell lung caner advanced solid tumors brain tumor breast cancer gan and lee pharmaceuticals']",correct_mapping
vactosertib,Transforming growth factor beta receptor 1 antagonist,vactosertib,,vactosertib,vactosertib,fexact,"['ALK-5 modulator (solid tumor), National OncoVenture', 'TGF-beta type 1 receptor kinase inhibitors (metastasis/fibrosis)', 'TGF-beta type 1 receptor kinase inhibitors (metastasis/fibrosis/solid tumor), MedPacto', 'NOV-1301', 'NOV-130101', 'alk-5 modulator (solid tumor)', 'TEW-7197', 'EW-7197', 'TGF-beta type 1 receptor kinase inhibitors (metastasis/fibrosis/solid tumor)', 'vactosertib']",vactosertib,fexact,"['alk 5 modulator solid tumor national oncoventure', 'tgf beta type 1 receptor kinase inhibitors metastasis fibrosis', 'tgf beta type 1 receptor kinase inhibitors metastasis fibrosis solid tumor medpacto', 'nov 1301', 'nov 130101', 'alk 5 modulator solid tumor', 'tew 7197', 'ew 7197', 'tgf beta type 1 receptor kinase inhibitors metastasis fibrosis solid tumor', 'vactosertib']",correct_mapping
tusamitamab ravtansine,Microtubule inhibitor,tusamitamab ravtansine,,tusamitamab ravtansine,tusamitamab ravtansine,fexact,"['anti-CEACAM5 ADC (intravenous/infusion, colorectal cancer, Metastatic non small cell lung cancer, stomach cancer, solid tumor), Sanofi', 'tusamitamab ravtansine', 'SAR-408701', 'anti-CEACAM5 ADC (intravenous/infusion, colorectal cancer, Metastatic non small cell lung cancer, stomach cancer, solid tumor)']",tusamitamab ravtansine,fexact,"['anti ceacam5 adc intravenous infusion colorectal cancer metastatic non small cell lung cancer stomach cancer solid tumor sanofi', 'tusamitamab ravtansine', 'sar 408701', 'anti ceacam5 adc intravenous infusion colorectal cancer metastatic non small cell lung cancer stomach cancer solid tumor']",correct_mapping
natalizumab,Alpha4 integrin antagonist; Alpha4beta1 integrin antagonist; Alpha4beta7 integrin antagonist; Integrin antagonist,natalizumab,,natalizumab,natalizumab,fexact,"['alpha-4/beta1-integrin mAb, Athena', 'BG-00002', 'mAN100226', 'AN-100226', 'VLA-4 mAb, Athena', 'Tysabri', 'Antegren', 'natalizumab', 'natulizumb']",natalizumab,fexact,"['alpha 4 beta1 integrin mab athena', 'bg 00002', 'man100226', 'an 100226', 'vla 4 mab athena', 'tysabri', 'antegren', 'natalizumab', 'natulizumb']",correct_mapping
BCA-101,EGFR antagonist; Transforming growth factor beta antagonist; Immuno-oncology therapy,BCA-101,,BCA-101,bca 101,fexact,"['EGFR/TGFbeta fusion monoclonal antibody (advanced solid tumors)', 'BCA-101', 'Bifunctional monoclonal antibody (iv, EGFR-driven advanced solid tumors) Bicara Therapeutics']",BCA-101,fexact,"['egfr tgfbeta fusion monoclonal antibody advanced solid tumors', 'bca 101', 'bifunctional monoclonal antibody iv egfr driven advanced solid tumors bicara therapeutics']",correct_mapping
GEN-1044,CD3 agonist; Immuno-oncology therapy,GEN-1044,,GEN-1044,gen 1044,fexact,"['GEN-1044', 'anti-CD3/anti-5T4 bispecific T-cell engager (Fc-silenced DuoBody, cancer)', 'anti-CD3/anti-5T4 bispecific T-cell engager (Fc-silenced DuoBody, cancer), Genmab', 'DuoBody-CD3x5T4']",GEN-1044,fexact,"['gen 1044', 'anti cd3 anti 5t4 bispecific t cell engager fc silenced duobody cancer', 'anti cd3 anti 5t4 bispecific t cell engager fc silenced duobody cancer genmab', 'duobody cd3x5t4']",correct_mapping
HM-06,RET tyrosine kinase inhibitor,HM-06,,TAS-0953,hm 06,fexact,"['HM-06', 'TAS-0953', 'RET inhibitor (advanced solid tumor/metastatic NSCLC),/', 'RET inhibitor (advanced solid tumor/metastatic NSCLC), Taiho Pharmaceutical/']",TAS-0953,fexact,"['hm 06', 'tas 0953', 'ret inhibitor advanced solid tumor metastatic nsclc', 'ret inhibitor advanced solid tumor metastatic nsclc taiho pharmaceutical']",correct_mapping
DF-6002,Interleukin 12 agonist; Immuno-oncology therapy,DF-6002,,DF-6002,df 6002,fexact,"['BMS-986415', 'monovalent human IL-12/Fc fusion protein (subcutaneous, advanced solid tumors)', 'DF-6002']",DF-6002,fexact,"['bms 986415', 'monovalent human il 12 fc fusion protein subcutaneous advanced solid tumors', 'df 6002']",correct_mapping
MVC-101,ErbB antagonist; CD3 agonist; Immuno-oncology therapy,MVC-101,,TAK-186,mvc 101,fexact,"['MVC-101', 'anti-CD3/anti-EGFR bispecific T-cell engager (COBRA, solid tumors)', 'TAK-186']",TAK-186,fexact,"['mvc 101', 'anti cd3 anti egfr bispecific t cell engager cobra solid tumors', 'tak 186']",correct_mapping
dabrafenib (capsule),B-raf kinase inhibitor,dabrafenib,,dabrafenib,dabrafenib,fexact,"['Tafinlar', 'Rafinlar', 'SB-477790', 'dabrafenib mesylate', 'dabrafenib', 'NSC-763760', 'DRB-436', 'b-Raf inhibitors (cancer)', 'SB-244649', 'GSK-2118436', 'GSK-2118436J', 'GSK-2118436A', 'SB-602330', 'GSK-436', 'SB-590885', 'SB-699393']",dabrafenib,fexact,"['tafinlar', 'rafinlar', 'sb 477790', 'dabrafenib mesylate', 'dabrafenib', 'nsc 763760', 'drb 436', 'b raf inhibitors cancer', 'sb 244649', 'gsk 2118436', 'gsk 2118436j', 'gsk 2118436a', 'sb 602330', 'gsk 436', 'sb 590885', 'sb 699393']",correct_mapping
JSI-1187,Mitogen-activated protein kinase 1 inhibitor; Mitogen-activated protein kinase 3 inhibitor,JSI-1187,,JSI-1187,jsi 1187,fexact,['JSI-1187'],JSI-1187,fexact,['jsi 1187'],correct_mapping
RMC-4630,"Tyrosine phosphatase, non-receptor type 11 inhibitor",RMC-4630,,RMC-4630,rmc 4630,fexact,"['SHP2 inhibitor (non-small-cell lung cancer),/Sanofi', 'SAR-442720', 'RMC-4630', 'SHP2 inhibitor (non-small-cell lung cancer),/']",RMC-4630,fexact,"['shp2 inhibitor non small cell lung cancer sanofi', 'sar 442720', 'rmc 4630', 'shp2 inhibitor non small cell lung cancer']",correct_mapping
fruquintinib,VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor,fruquintinib,,fruquintinib,fruquintinib,fexact,"['Elunate', 'fruquintinib', 'aiyoute', 'fukuitini', 'HMPL-013']",fruquintinib,fexact,"['elunate', 'fruquintinib', 'aiyoute', 'fukuitini', 'hmpl 013']",correct_mapping
"elemene, Dalian Holley Kingkong Pharmaceutical Co.",Cell cycle inhibitor,elemene,Dalian Holley Kingkong Pharmaceutical Co.,,,0,['elemene'],,0,[],0
poziotinib,ErbB-3 antagonist; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor,poziotinib,,poziotinib,poziotinib,fexact,"['poziotinib', 'NOV-1201', 'NOV-120101', 'pan-Her/EGFR inhibitors (cancer)', 'HM-78136B']",poziotinib,fexact,"['poziotinib', 'nov 1201', 'nov 120101', 'pan her egfr inhibitors cancer', 'hm 78136b']",correct_mapping
TQ-B3139,Anaplastic lymphoma kinase inhibitor; MET tyrosine kinase inhibitor,TQ-B3139,,TQ-B3139,tq b3139,fexact,['TQ-B3139'],TQ-B3139,fexact,['tq b3139'],correct_mapping
personalized neoantigen cancer vaccine,Unidentified pharmacological activity,personalized neoantigen cancer vaccine,,,,0,['personalized neoantigen cancer vaccine'],,0,[],0
SGN-B6A,Unidentified pharmacological activity,SGN-B6A,,"integrin alpha-v-beta6 antibody-drug conjugate (cancer), Seattle Genetics",sgn b6a,fexact,"['SGN-B6A', 'h15H3-SGD-1269', 'h15H3-mafodotin', 'integrin alpha-v-beta6 antibody-drug conjugate (cancer), Seattle Genetics', 'h15H3-mcMMAF', 'h15H3-vcMMAE']","integrin alpha-v-beta6 antibody-drug conjugate (cancer), Seattle Genetics",fexact,"['sgn b6a', 'h15h3 sgd 1269', 'h15h3 mafodotin', 'integrin alpha v beta6 antibody drug conjugate cancer seattle genetics', 'h15h3 mcmmaf', 'h15h3 vcmmae']",correct_mapping
eprenetapopt,p53 stimulant,eprenetapopt,,eprenetapopt,eprenetapopt,fexact,"['eprenetapopt', 'active moiety 2-methylene-quinuclidin-3-one (iv, cancer)', 'APR-310', 'APR-017', 'APR-305', 'APR-304', 'PRIMA-1-MET', 'p53 modulators (iv, cancer)', 'mutant p53 reactivation compounds (iv, cancer), Karolinksa Institute', 'apoptosis stimulators (iv, cancer)', 'PRIMA-1', 'apoptosis stimulators (iv, cancer), Karolinska Institute', 'APR-246']",eprenetapopt,fexact,"['eprenetapopt', 'active moiety 2 methylene quinuclidin 3 one iv cancer', 'apr 310', 'apr 017', 'apr 305', 'apr 304', 'prima 1 met', 'p53 modulators iv cancer', 'mutant p53 reactivation compounds iv cancer karolinksa institute', 'apoptosis stimulators iv cancer', 'prima 1', 'apoptosis stimulators iv cancer karolinska institute', 'apr 246']",correct_mapping
TAK-981,Immuno-oncology therapy; Small ubiquitin-like modifier inhibitor,TAK-981,,subasumstat,tak 981,fexact,"['antineoplastic agent (iv, relapsed/refractory lymphoma)', 'TAK-981', 'subasumstat']",subasumstat,fexact,"['antineoplastic agent iv relapsed refractory lymphoma', 'tak 981', 'subasumstat']",correct_mapping
"thalidomide, Celgene",Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,thalidomide,Celgene,thalidomide,thalidomide,fexact,"['thalidomide', 'Thalidomide', 'Thalomid', 'Synovir', 'CC-2001', 'Thalidomide Pharmion', 'Thalidomide Celgene']",thalidomide,fexact,"['thalidomide', 'thalidomide', 'thalomid', 'synovir', 'cc 2001', 'thalidomide pharmion', 'thalidomide celgene']",correct_mapping
etoposide (intravenous),DNA inhibitor; DNA topoisomerase II inhibitor; DNA repair enzyme inhibitor; Cell cycle inhibitor,etoposide,,etoposide phosphate,etoposide,fexact,"['Etopophos', 'Eposin', 'NSC-141540', 'etopofos', 'Eposide', 'Nexvep', 'etoposide', 'Vepesid', 'BMY-40481', 'VP-16-213', 'VP-16', 'etoposide phosphate']",etoposide phosphate,fexact,"['etopophos', 'eposin', 'nsc 141540', 'etopofos', 'eposide', 'nexvep', 'etoposide', 'vepesid', 'bmy 40481', 'vp 16 213', 'vp 16', 'etoposide phosphate']",correct_mapping
methotrexate (intrathecal),Immunosuppressant; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Disease modifying antirheumatic drug,methotrexate,,,,0,"['methotrexate', 'repurposed methotrexate (blood cancer)']",,NER_API,[],0
vorinostat,Histone deacetylase inhibitor; Cell cycle inhibitor,vorinostat,,vorinostat (intravenous),vorinostat,fexact,"['MK-0683', 'L-001079038', 'MSK-390', 'suberanilohydroxamic acid (intravenous)', 'SAHA', 'suberoylanilide hydroxamic acid (intravenous)', 'SAHA (intravenous)', 'vorinostat (intravenous), Merck & Co', 'vorinostat', 'vorinostat (intravenous)', 'Suberoylanilide hydroxamic acid']",vorinostat (intravenous),fexact,"['mk 0683', 'l 001079038', 'msk 390', 'suberanilohydroxamic acid intravenous', 'saha', 'suberoylanilide hydroxamic acid intravenous', 'saha intravenous', 'vorinostat intravenous merck co', 'vorinostat', 'vorinostat intravenous', 'suberoylanilide hydroxamic acid']",correct_mapping
undisclosed - influenza vaccine,Immunostimulant,undisclosed - influenza vaccine,,,,0,['undisclosed - influenza vaccine'],,0,[],0
KN-046,PD-L1 antagonist; CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,KN-046,,KN-046,kn 046,fexact,"['KN-046', 'dual CTLA-4 checkpoint inhibitor/PD-L1 checkpoint inhibitor (solid tumor)', 'humanized PD-L1/CTLA-4 bispecific antibody (advanced solid tumor)', 'recombinant humanized anti-PD-L1/anti-CTLA-4 mAb-Fc fusion protein']",KN-046,fexact,"['kn 046', 'dual ctla 4 checkpoint inhibitor pd l1 checkpoint inhibitor solid tumor', 'humanized pd l1 ctla 4 bispecific antibody advanced solid tumor', 'recombinant humanized anti pd l1 anti ctla 4 mab fc fusion protein']",correct_mapping
SIM-0710,Angiogenesis inhibitor,SIM-0710,,PEG-ENDO,sim 0710,fexact,"['SIM-0710', 'PEG-Endostar for Injection', 'PEG-ENDO', 'recombinant human endostatin (pegylated, cancer), shandong simcere medgenn/', 'Endu-PEG injection', 'recombinant human endostatin (pegylated, cancer), shandong simcere medgenn/simcere']",PEG-ENDO,fexact,"['sim 0710', 'peg endostar for injection', 'peg endo', 'recombinant human endostatin pegylated cancer shandong simcere medgenn', 'endu peg injection', 'recombinant human endostatin pegylated cancer shandong simcere medgenn simcere']",correct_mapping
sirolimus,mTOR kinase inhibitor; Protein kinase inhibitor; T cell inhibitor; Cell cycle inhibitor,sirolimus,,"sirolimus (albumin-bound nanoparticle, cancer, intravenous)",sirolimus,fexact,"['sirolimus (albumin-bound nanoparticle, cancer, intravenous)', 'sirolimus (albumin-bound nanoparticle, cancer, intravenous), Celgene', 'Fyarro', 'rapamycin', 'sirolimus (albumin-bound nanoparticle, intravenous)', 'rapamycin (albumin-bound nanoparticle, intravenous)', 'ABI-009', 'nab-rapamycin', 'sirolimus (albumin-bound nanoparticle, intravenous), Abraxis', 'nab-Sirolimus', 'rapamycin (albumin-bound nanoparticle, intravenous), Abraxis', 'sirolimus', 'TARZIFYX']","sirolimus (albumin-bound nanoparticle, cancer, intravenous)",fexact,"['sirolimus albumin bound nanoparticle cancer intravenous', 'sirolimus albumin bound nanoparticle cancer intravenous celgene', 'fyarro', 'rapamycin', 'sirolimus albumin bound nanoparticle intravenous', 'rapamycin albumin bound nanoparticle intravenous', 'abi 009', 'nab rapamycin', 'sirolimus albumin bound nanoparticle intravenous abraxis', 'nab sirolimus', 'rapamycin albumin bound nanoparticle intravenous abraxis', 'sirolimus', 'tarzifyx']",correct_mapping
BMS-986315,Natural killer cell group 2A inhibitor,BMS-986315,,BMS-986315,bms 986315,fexact,"['NKG2A checkpoint inhibitor (advanced solid tumor), Bristol Myers Squibb', 'BMS-986315']",BMS-986315,fexact,"['nkg2a checkpoint inhibitor advanced solid tumor bristol myers squibb', 'bms 986315']",correct_mapping
pegfilgrastim,Granulocyte colony stimulating factor agonist,pegfilgrastim,,pegfilgrastim follow-on biologic,pegfilgrastim,fexact,"['pegfilgrastim', 'PEG-rhGCSF injection', 'pegfilgrastim follow-on biologic', 'Jinyouli', 'PEG-GCSF (neutropenia)', 'PEG-filgrastim (neutropenia)', '津优力']",pegfilgrastim follow-on biologic,fexact,"['pegfilgrastim', 'peg rhgcsf injection', 'pegfilgrastim follow on biologic', 'jinyouli', 'peg gcsf neutropenia', 'peg filgrastim neutropenia', '津优力']",correct_mapping
trametinib (tablet),Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,trametinib,,trametinib,trametinib,fexact,"['Mark inhibitor (cancer, inflammation),/', 'JTP-74057 DMSO', 'MEK inhibitor (oral, cancer)', 'Erk inhibitor (cancer, inflammation), Japan Tobacco/', 'trametinib dimethyl sulfoxide', 'Erk inhibitor (cancer, inflammation),/', 'GSK-212', 'trametinib DMSO', 'NSC-763093', 'Mark inhibitor (cancer, inflammation), Japan Tobacco/', 'trametinib', 'TMT-212', 'MEK inhibitor (cancer, inflammation)', 'GSK-1120212', 'Mekinist', 'GSK-1120212B']",trametinib,fexact,"['mark inhibitor cancer inflammation', 'jtp 74057 dmso', 'mek inhibitor oral cancer', 'erk inhibitor cancer inflammation japan tobacco', 'trametinib dimethyl sulfoxide', 'erk inhibitor cancer inflammation', 'gsk 212', 'trametinib dmso', 'nsc 763093', 'mark inhibitor cancer inflammation japan tobacco', 'trametinib', 'tmt 212', 'mek inhibitor cancer inflammation', 'gsk 1120212', 'mekinist', 'gsk 1120212b']",correct_mapping
ramucirumab,Vascular endothelial growth factor receptor 2 antagonist; Angiogenesis inhibitor,ramucirumab,,ramucirumab,ramucirumab,fexact,"['Cyramza', 'anti-KDR antibodies, ImClone', 'ramucirumab', 'anti-VEGFR2 antibodies', 'anti-KDR antibodies', 'LY-3009806', 'IMC-1121B', 'anti-VEGFR2 antibodies, ImClone']",ramucirumab,fexact,"['cyramza', 'anti kdr antibodies imclone', 'ramucirumab', 'anti vegfr2 antibodies', 'anti kdr antibodies', 'ly 3009806', 'imc 1121b', 'anti vegfr2 antibodies imclone']",correct_mapping
"nitroglycerin, transdermal",Guanylate cyclase stimulant; Nitric oxide stimulant,nitroglycerin,transdermal,nitroglycerin (transdermal),nitroglycerin,fexact,"['Transderm-Nitro', 'nitroglycerin (transdermal)', 'nitroglycerin', 'NITRODERM']",nitroglycerin (transdermal),fexact,"['transderm nitro', 'nitroglycerin transdermal', 'nitroglycerin', 'nitroderm']",correct_mapping
olaparib,Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor,olaparib,,olaparib,olaparib,fexact,"['KU-0058948', 'TBI-361', 'PARP inhibitors (cancer), KuDOS', 'MRU-868', 'KU-58948', 'NU-1085', 'olaparib', 'MRU-687', 'NU-1025', 'KU-59449', 'KU-0051529', 'KU-0687', 'KU-0059436', 'KU-56186', 'AZD-2281', 'NU-1070', 'PARP inhibitors (cancer), AstraZeneca', 'MK-7339', 'KU-0058684', 'Lipzol', 'PARP inhibitors (cancer)', 'Lynparza', 'KU-59436']",olaparib,fexact,"['ku 0058948', 'tbi 361', 'parp inhibitors cancer kudos', 'mru 868', 'ku 58948', 'nu 1085', 'olaparib', 'mru 687', 'nu 1025', 'ku 59449', 'ku 0051529', 'ku 0687', 'ku 0059436', 'ku 56186', 'azd 2281', 'nu 1070', 'parp inhibitors cancer astrazeneca', 'mk 7339', 'ku 0058684', 'lipzol', 'parp inhibitors cancer', 'lynparza', 'ku 59436']",correct_mapping
CBT-502,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,CBT-502,,TQB-2450,cbt 502,fexact,"['CBT-502', 'PD-L1 checkpoint inhibitor (cancer), CBT Pharmaceuticals', 'PD-L1 checkpoint inhibitor (cancer/classical hodgkin lymphoma),/', 'APL-502', 'anti PD-L1 mAb (cancer)', 'TQB-2450', 'anti PD-L1 mAb (cancer), Crown Bioscience', 'PD-L1 checkpoint inhibitor (cancer/classical hodgkin lymphoma),/Chia Tai Tianqing Pharmaceutical Group', 'anti-programmed cell death ligand 1 (PD-L1) (cancer/non-hodgkin lymphoma)']",TQB-2450,fexact,"['cbt 502', 'pd l1 checkpoint inhibitor cancer cbt pharmaceuticals', 'pd l1 checkpoint inhibitor cancer classical hodgkin lymphoma', 'apl 502', 'anti pd l1 mab cancer', 'tqb 2450', 'anti pd l1 mab cancer crown bioscience', 'pd l1 checkpoint inhibitor cancer classical hodgkin lymphoma chia tai tianqing pharmaceutical group', 'anti programmed cell death ligand 1 pd l1 cancer non hodgkin lymphoma']",correct_mapping
AL-2846,Axl receptor tyrosine kinase inhibitor; MET tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Macrophage stimulating protein 1 receptor antagonist,AL-2846,,AL-2846,al 2846,fexact,['AL-2846'],AL-2846,fexact,['al 2846'],correct_mapping
propofol,Membrane permeability inhibitor; Membrane integrity inhibitor,propofol,,,,0,"['propofol', 'propofol (injectable micelle formulation (SmartCelle), general anesthesia)', 'PPI-1502']",,NER_API,[],0
sevoflurane,Membrane permeability inhibitor; Membrane integrity inhibitor,sevoflurane,,sevoflurane,sevoflurane,fexact,"['sevoflurane', 'Sevofrane', 'Sevorane', 'Ultane']",sevoflurane,fexact,"['sevoflurane', 'sevofrane', 'sevorane', 'ultane']",correct_mapping
lidocaine (IV),Membrane integrity inhibitor; Potassium channel antagonist; Voltage-gated sodium channel antagonist,lidocaine,,lidocaine,lidocaine,fexact,"['lidocaine hydrochloride (USAN)', 'Xylocaine', 'Xyloproct', 'Polyamp 0.5%', 'Xylocard', 'lidocaine']",lidocaine,fexact,"['lidocaine hydrochloride usan', 'xylocaine', 'xyloproct', 'polyamp 0 5', 'xylocard', 'lidocaine']",correct_mapping
SHR-1316,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,SHR-1316,,SHR-1316,shr 1316,fexact,"['anti-PD-L1 humanized IgG4 monoclonal antibody (cancer), Jiangsu Hengrui Medicine', 'HTI-1316', 'SHR-1316', 'HTI-1088', 'adebrelimab', 'PD-L1 checkpoint inhibitor (cancer), Jiangsu Hengrui Medicine/', 'anti-PD-L1 humanized IgG4 monoclonal antibody (cancer)', 'PD-L1 checkpoint inhibitor (cancer),/']",SHR-1316,fexact,"['anti pd l1 humanized igg4 monoclonal antibody cancer jiangsu hengrui medicine', 'hti 1316', 'shr 1316', 'hti 1088', 'adebrelimab', 'pd l1 checkpoint inhibitor cancer jiangsu hengrui medicine', 'anti pd l1 humanized igg4 monoclonal antibody cancer', 'pd l1 checkpoint inhibitor cancer']",correct_mapping
GT-103,Unidentified pharmacological activity,GT-103,,GT-103,gt 103,fexact,"['GT-103', 'complement Factor H inhibiting immunoglobulin G-3 antibodies (iv, cancer)', 'complement Factor H inhibiting immunoglobulin G-3 antibodies (iv, cancer), Grid']",GT-103,fexact,"['gt 103', 'complement factor h inhibiting immunoglobulin g 3 antibodies iv cancer', 'complement factor h inhibiting immunoglobulin g 3 antibodies iv cancer grid']",correct_mapping
HBM-4003,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,HBM-4003,,HBM-4003,hbm 4003,fexact,"['HBM-4003', 'ctla-4 checkpoint inhibitor (solid tumor)', 'HBM-4003-2', 'hcabs (solid tumor)']",HBM-4003,fexact,"['hbm 4003', 'ctla 4 checkpoint inhibitor solid tumor', 'hbm 4003 2', 'hcabs solid tumor']",correct_mapping
"nivolumab, ENHANZE sc reformulation",PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,nivolumab,ENHANZE sc reformulation,nivolumab,nivolumab,fexact,"['nivolumab', 'MDX-1106-04', 'Opdivo', 'BMS-936558-01', 'PD-1 checkpoint inhibitor (cancer),/', 'BMS-986298', 'anti-PD-1 antibody (cancer), Ono/Medarex/BMS', 'anti-PD-1 antibody (cancer), Ono//BMS', 'ONO-4538', 'PD-1 checkpoint inhibitor (cancer),/Ono', 'anti-PD-1 antibody (cancer),//BMS', 'BMS-936558', 'NIVO', '89Zr-nivolumab', 'MDX-1106']",nivolumab,fexact,"['nivolumab', 'mdx 1106 04', 'opdivo', 'bms 936558 01', 'pd 1 checkpoint inhibitor cancer', 'bms 986298', 'anti pd 1 antibody cancer ono medarex bms', 'anti pd 1 antibody cancer ono bms', 'ono 4538', 'pd 1 checkpoint inhibitor cancer ono', 'anti pd 1 antibody cancer bms', 'bms 936558', 'nivo', '89zr nivolumab', 'mdx 1106']",correct_mapping
"immunotherapy, ENHANZE sc, Bristol-Myers Squibb",Immuno-oncology therapy,immunotherapy,Bristol-Myers Squibb,,,0,['immunotherapy'],,0,[],0
ipilimumab (sc),CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,ipilimumab,,ipilimumab,ipilimumab,fexact,"['BMS-734016', 'MDX-010', 'Winglore', 'MDX-101', 'anti-CTLA4, Medarex', 'Yervoy', 'MDX-CTLA4', 'CTLA-4 checkpoint inhibitor (cancer)', 'anti-CTLA4', 'ipilimumab']",ipilimumab,fexact,"['bms 734016', 'mdx 010', 'winglore', 'mdx 101', 'anti ctla4 medarex', 'yervoy', 'mdx ctla4', 'ctla 4 checkpoint inhibitor cancer', 'anti ctla4', 'ipilimumab']",correct_mapping
ND-021,CD137 agonist; PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor; Immune checkpoint stimulant,ND-021,,ND-021,nd 021,fexact,"['triple anti-PD-L1/anti-4-1BB/anti-HSA scDb-scFv (scMATCH3, cancer), Numab/', 'PD-L1xCostim scDb-scFv', 'triple anti-PD-L1/anti-4-1BB/anti-HSA scDb-scFv (scMATCH3, cancer),/', 'ND-021', 'trispecific PD-L1 checkpoint inhibitor/4-1BB costimulator/anti-HSA scDb-scFv (cancer)', 'PD-L1/HSA/Costim tri-specific scDb-scFv', 'multispecific antibody fragment-based  (cancer)', 'CS-2006', 'trispecific PD-L1 checkpoint inhibitor/4-1BB costimulator/anti-HSA scDb-scFv (cancer), Numab', 'multispecific antibody fragment-based therapeutics (cancer), Numab', 'multispecific antibody fragment-based therapeutics (cancer)', 'NM21-1480', 'NM21-1186']",ND-021,fexact,"['triple anti pd l1 anti 4 1bb anti hsa scdb scfv scmatch3 cancer numab', 'pd l1xcostim scdb scfv', 'triple anti pd l1 anti 4 1bb anti hsa scdb scfv scmatch3 cancer', 'nd 021', 'trispecific pd l1 checkpoint inhibitor 4 1bb costimulator anti hsa scdb scfv cancer', 'pd l1 hsa costim tri specific scdb scfv', 'multispecific antibody fragment based cancer', 'cs 2006', 'trispecific pd l1 checkpoint inhibitor 4 1bb costimulator anti hsa scdb scfv cancer numab', 'multispecific antibody fragment based therapeutics cancer numab', 'multispecific antibody fragment based therapeutics cancer', 'nm21 1480', 'nm21 1186']",correct_mapping
LY-3214996,Mitogen-activated protein kinase 1 inhibitor; Mitogen-activated protein kinase 3 inhibitor,LY-3214996,,LY-3214996,ly 3214996,fexact,"['ERK 1/2 inhibitor (cancer), Loxo Oncology', 'LY-3214996', 'ERK inhibitor (cancer), Elli Lilly', 'ERK 1/2 inhibitor (cancer)']",LY-3214996,fexact,"['erk 1 2 inhibitor cancer loxo oncology', 'ly 3214996', 'erk inhibitor cancer elli lilly', 'erk 1 2 inhibitor cancer']",correct_mapping
pralsetinib,RET tyrosine kinase inhibitor,pralsetinib,,pralsetinib,pralsetinib,fexact,"['Gavreto', 'RG-6396', 'CS-3009', 'BLU-667', 'X-581238', 'BLU-123244', 'inhibitor of RET kinase mutations and fusions (NSCLC, thyroid cancer)', 'mutant ret kinase inhibitors (cancer)', 'pralsetinib', 'mutant RET kinase inhibitors (cancer)', 'BLU-6864', 'mutant RET kinase inhibitors (cancer),/CStone Pharmaceuticals']",pralsetinib,fexact,"['gavreto', 'rg 6396', 'cs 3009', 'blu 667', 'x 581238', 'blu 123244', 'inhibitor of ret kinase mutations and fusions nsclc thyroid cancer', 'mutant ret kinase inhibitors cancer', 'pralsetinib', 'mutant ret kinase inhibitors cancer', 'blu 6864', 'mutant ret kinase inhibitors cancer cstone pharmaceuticals']",correct_mapping
"endostatin, Simcere",Angiogenesis inhibitor,endostatin,Simcere,endostatin,endostatin,fexact,"['AdEndo', 'NSC-704805', 'endostatin', 'rhEndostatin', 'Endostatin protein']",endostatin,fexact,"['adendo', 'nsc 704805', 'endostatin', 'rhendostatin', 'endostatin protein']",correct_mapping
CimaVax EGF,EGFR antagonist; Immunostimulant,CimaVax EGF,,CimaVax EGF,cimavax egf,fexact,"['cancer vaccine, YM BioSciences', 'recombinant human EGF-rP64K/Montanide ISA 51 vaccine (NSCLC)', 'EGF vaccine (lung cancer), Centro de Immunologica Molecular', 'recombinant human EGF-rP64K/Montanide ISA 51 vaccine (NSCLC), Bioven', 'cancer vaccine', 'EGF vaccine (lung cancer)', 'BVN-NSCLC-003', 'EGF vaccine (cancer), CIMAB/ Micromet/Biocon/Bioven', 'EGF vaccine (cancer), CIMAB/ Micromet//Bioven', 'cancer vaccine, York Medical', 'EGF vaccine (cancer), CIMAB/ Micromet//', 'EGF vaccine (cancer), CIMAB/CancerVax/Biocon', 'EGF vaccine (cancer), CIMAB///', 'EGF vaccine (lung cancer), Cuba Center of Molecular Immunology', 'rEGF-rP64K/Montanide ISA 51 vaccine (NSCLC), Bioven', 'EGF-PTI', 'BVN-NSCLC-002', 'EGF vaccine (cancer), CIMAB/CancerVax/', 'BV-NSCLC-001', 'SAI-EGF', 'EGF vaccine (lung cancer), Biotech Pharmaceutical', 'CimaVax EGF', 'rEGF-rP64K/Montanide ISA 51 vaccine (NSCLC)']",CimaVax EGF,fexact,"['cancer vaccine ym biosciences', 'recombinant human egf rp64k montanide isa 51 vaccine nsclc', 'egf vaccine lung cancer centro de immunologica molecular', 'recombinant human egf rp64k montanide isa 51 vaccine nsclc bioven', 'cancer vaccine', 'egf vaccine lung cancer', 'bvn nsclc 003', 'egf vaccine cancer cimab micromet biocon bioven', 'egf vaccine cancer cimab micromet bioven', 'cancer vaccine york medical', 'egf vaccine cancer cimab micromet', 'egf vaccine cancer cimab cancervax biocon', 'egf vaccine cancer cimab', 'egf vaccine lung cancer cuba center of molecular immunology', 'regf rp64k montanide isa 51 vaccine nsclc bioven', 'egf pti', 'bvn nsclc 002', 'egf vaccine cancer cimab cancervax', 'bv nsclc 001', 'sai egf', 'egf vaccine lung cancer biotech pharmaceutical', 'cimavax egf', 'regf rp64k montanide isa 51 vaccine nsclc']",correct_mapping
crizotinib,Anaplastic lymphoma kinase inhibitor; MET tyrosine kinase inhibitor,crizotinib,,crizotinib,crizotinib,fexact,"['Xalkori', 'PF-2341066', 'crizotinib', 'PF-1066', 'PF-02341066', 'NSC-749005']",crizotinib,fexact,"['xalkori', 'pf 2341066', 'crizotinib', 'pf 1066', 'pf 02341066', 'nsc 749005']",correct_mapping
CC 90011,Lysine (K)-specific demethylase 1A inhibitor,CC 90011,,CC-90011,cc 90011,fexact,"['CC-90011', 'LSD1 inhibitor (solid tumors/SCLC/NSCLC/lymphoma)']",CC-90011,fexact,"['cc 90011', 'lsd1 inhibitor solid tumors sclc nsclc lymphoma']",correct_mapping
necitumumab,EGFR antagonist,necitumumab,,necitumumab,necitumumab,fexact,"['Human EGF antibody vaccine', 'human EGF antibody', 'human EGF antibody, ImClone', 'Portrazza', 'IMC-11F8', 'LY-3012211', 'Human EGF antibody vaccine, ImClone', 'necitumumab']",necitumumab,fexact,"['human egf antibody vaccine', 'human egf antibody', 'human egf antibody imclone', 'portrazza', 'imc 11f8', 'ly 3012211', 'human egf antibody vaccine imclone', 'necitumumab']",correct_mapping
dasatinib,LYN tyrosine kinase inhibitor; Bcr-Abl inhibitor; C-kit inhibitor; EphA receptor kinase inhibitor; Fyn tyrosine kinase inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib; Src inhibitor; Yes tyrosine kinase inhibitor,dasatinib,,dasatinib,dasatinib,fexact,"['NSC-732517', 'Src/Abl kinase inhibitor (cancer), BMS', 'BMS-354825', 'Sprycel', 'Spricel', 'dasatinib (USAN)', 'dasatinib', 'Spraicell']",dasatinib,fexact,"['nsc 732517', 'src abl kinase inhibitor cancer bms', 'bms 354825', 'sprycel', 'spricel', 'dasatinib usan', 'dasatinib', 'spraicell']",correct_mapping
APG-1387,IAP antagonist,APG-1387,,APG-1387,apg 1387,fexact,"['APG-1387', 'SM-1387']",APG-1387,fexact,"['apg 1387', 'sm 1387']",correct_mapping
zanubrutinib,Bruton tyrosine kinase inhibitor,zanubrutinib,,zanubrutinib,zanubrutinib,fexact,"['BGB-3111', 'zanubrutinib', 'target-3 (solid/hematological tumors)', 'BRUKINSA', 'zanubrutinib (COVID-19)', 'BTK inhibitor (solid/hematological tumors)', 'BDB-3111']",zanubrutinib,fexact,"['bgb 3111', 'zanubrutinib', 'target 3 solid hematological tumors', 'brukinsa', 'zanubrutinib covid 19', 'btk inhibitor solid hematological tumors', 'bdb 3111']",correct_mapping
BGB-10188,PI3 kinase delta inhibitor,BGB-10188,,BGB-10188,bgb 10188,fexact,"['PI3Kdelta inhibitor (cancer)', 'BGB-10188']",BGB-10188,fexact,"['pi3kdelta inhibitor cancer', 'bgb 10188']",correct_mapping
Nedaplatin,DNA inhibitor,Nedaplatin,,nedaplatin,nedaplatin,fexact,"['254-S', 'NSC-375101D', 'S-254', 'nedaplatin']",nedaplatin,fexact,"['254 s', 'nsc 375101d', 's 254', 'nedaplatin']",correct_mapping
AL-034,Toll-like receptor 7 agonist,AL-034,,AL-034,al 034,fexact,"['JNJ-4964', 'TLR agonist (hepatitis B), Chia Tai Tianqing/Janssen', 'JNJ-64794964', 'AL-034', 'TQ-A3334, Chia Tai Tianqing Pharmaceutical Group', 'TLR agonist (hepatitis B),/', 'TQ-A3334', 'TLR agonist (hepatitis B),/Janssen']",AL-034,fexact,"['jnj 4964', 'tlr agonist hepatitis b chia tai tianqing janssen', 'jnj 64794964', 'al 034', 'tq a3334 chia tai tianqing pharmaceutical group', 'tlr agonist hepatitis b', 'tq a3334', 'tlr agonist hepatitis b janssen']",correct_mapping
venetoclax,Bcl2 inhibitor; Apoptosis stimulant,venetoclax,,venetoclax,venetoclax,fexact,"['A-1195425.0', 'ABT-199', 'GDC-0199', 'Venclyxto', 'Venclexta', 'venetoclax', 'RG-7601', 'RO-5537382']",venetoclax,fexact,"['a 1195425 0', 'abt 199', 'gdc 0199', 'venclyxto', 'venclexta', 'venetoclax', 'rg 7601', 'ro 5537382']",correct_mapping
tilsotolimod,Toll-like receptor 9 agonist; Immuno-oncology therapy,tilsotolimod,,tilsotolimod,tilsotolimod,fexact,"['IMO-2125', 'IMO (HCV)', 'IMO (hepatitis C virus infection), Hybridon', 'immunomodulatory oligonucleotide (hepatitis C virus infection), Hybridon', 'immunomodulatory oligonucleotide (HCV)', 'tilsotolimod', 'HYB-2125']",tilsotolimod,fexact,"['imo 2125', 'imo hcv', 'imo hepatitis c virus infection hybridon', 'immunomodulatory oligonucleotide hepatitis c virus infection hybridon', 'immunomodulatory oligonucleotide hcv', 'tilsotolimod', 'hyb 2125']",correct_mapping
ABBV-184,CD3 agonist; Immuno-oncology therapy,ABBV-184,,ABBV-184,abbv 184,fexact,"['ABBV-184', 'anti-CD3/anti-survivin bispecific T-cell engager (cancer/AML/NSCLC)']",ABBV-184,fexact,"['abbv 184', 'anti cd3 anti survivin bispecific t cell engager cancer aml nsclc']",correct_mapping
PANDA-VAC,Immunostimulant,PANDA-VAC,,,,0,['PANDA-VAC'],,0,[],0
autogene cevumeran,Immuno-oncology therapy,autogene cevumeran,,autogene cevumeran,autogene cevumeran,fexact,"['individualized Neoantigen-Specific Therapy, Roche/', 'BNT-122', 'RO-7198457', 'autogene cevumeran', 'iNeST, Roche/', 'mRNA-based personalized cancer vaccine (IVAC MUTANOME, iv, solid tumors),/', 'RG-6180', 'mRNA-based personalized cancer vaccine (IVAC MUTANOME, iv, solid tumors), Genentech/']",autogene cevumeran,fexact,"['individualized neoantigen specific therapy roche', 'bnt 122', 'ro 7198457', 'autogene cevumeran', 'inest roche', 'mrna based personalized cancer vaccine ivac mutanome iv solid tumors', 'rg 6180', 'mrna based personalized cancer vaccine ivac mutanome iv solid tumors genentech']",correct_mapping
oleclumab,Immuno-oncology therapy; CD73 antagonist,oleclumab,,oleclumab,oleclumab,fexact,"['oleclumab', 'CD73 checkpoint inhibitor (cancer)', 'CD73 antagonist (cancer)', 'MEDI-9447']",oleclumab,fexact,"['oleclumab', 'cd73 checkpoint inhibitor cancer', 'cd73 antagonist cancer', 'medi 9447']",correct_mapping
UCPVax vaccine,Telomerase stimulant; CD4 agonist; Immuno-oncology therapy,UCPVax vaccine,,,,0,['UCPVax vaccine'],,0,[],0
OC-001,Unidentified pharmacological activity,OC-001,,OC-001,oc 001,fexact,"['tumor necrosis factor inhibitor (intravenous, advanced cancers)', 'TNF inhibitor (intravenous, advanced cancers)', 'OC-001']",OC-001,fexact,"['tumor necrosis factor inhibitor intravenous advanced cancers', 'tnf inhibitor intravenous advanced cancers', 'oc 001']",correct_mapping
RS-0139,Unidentified pharmacological activity,RS-0139,,RS-0139,rs 0139,fexact,['RS-0139'],RS-0139,fexact,['rs 0139'],correct_mapping
rigosertib (oral),Microtubule inhibitor; Polo-like kinase 1 inhibitor; Mcl-1 antagonist; PI3 kinase inhibitor; Cell cycle inhibitor,rigosertib,,,,0,"['Estybon (capsule, myelodysplastic syndrome/solid tumor)', 'rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors),/SymBio', 'rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors), Onconova/SymBio', 'ON-01910 sodium (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'rigosertib', 'Novonex (capsule, myelodysplastic syndrome/solid tumor)', 'SyB-1101 (oral, MDS)', 'Novonex (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'ONO-106 (capsule, myelodysplastic syndrome/solid tumor)', 'rigosertib sodium', 'Estybon (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'ON-01910.Na (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'ON-01910Na', 'ON-1910Na', 'ONO-106 (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'Estybon', 'ON-01910.Na (capsule, myelodysplastic syndrome/solid tumor)', 'ON-1910 sodium', 'ON-01910.Na', 'SyB C-1101', 'SyB-1101 (oral, MDS), SymBio', 'rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors),/', 'Novonex', 'ON-01910 sodium (capsule, myelodysplastic syndrome/solid tumor)']",,NER_API,[],0
YBL-006,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,YBL-006,,YBL-006,ybl 006,fexact,['YBL-006'],YBL-006,fexact,['ybl 006'],correct_mapping
SGN-TGT,TIGIT receptor antagonist,SGN-TGT,,SEA-TGT,sgn tgt,fexact,"['nonfucosylated human IgG antibody (SEA, solid tumor/lymphoma), Seattle Genetics', 'SEA-TGT', 'SGN-TGT']",SEA-TGT,fexact,"['nonfucosylated human igg antibody sea solid tumor lymphoma seattle genetics', 'sea tgt', 'sgn tgt']",correct_mapping
selinexor (tablet),Exportin 1 inhibitor,selinexor,,selinexor,selinexor,fexact,"['ATG-010', 'KCP-330', 'KPT-207', 'XPOVIO', 'nuclear transport inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'selective nuclear export inhibitors (COVID-19), Karyopharm Therapeutics', 'SINE (autoimmune diseases/HIV/cancer)', 'Nexpovio', 'KPT-SINE', 'KPT-185', 'SINE-KPT-330', 'KPT-225', 'KPT-330', 'KPT-XXX', 'Exportin-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'CRM-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease)', 'nuclear transport inhibitors (inflammation/viral diseases/cancer)', 'selective nuclear export inhibitors (autoimmune diseases/HIV/cancer)', 'KPT-249', 'KPT-276', 'Exportin-1 inhibitors (inflammation/viral diseases/cancer)', 'KPT-251', 'selinexor', 'Xpovio', 'selective nuclear export inhibitors (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics', 'SINE (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics', 'CRM-1 inhibitors (inflammation/viral diseases/cancer)', 'ONO-7705', 'selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease), Karyopharm Therapeutics', 'selective nuclear export inhibitors (COVID-19)']",selinexor,fexact,"['atg 010', 'kcp 330', 'kpt 207', 'xpovio', 'nuclear transport inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'selective nuclear export inhibitors covid 19 karyopharm therapeutics', 'sine autoimmune diseases hiv cancer', 'nexpovio', 'kpt sine', 'kpt 185', 'sine kpt 330', 'kpt 225', 'kpt 330', 'kpt xxx', 'exportin 1 inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'crm 1 inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'selective nuclear export inhibitors autoimmune inflammation hiv cancer dermatological disease', 'nuclear transport inhibitors inflammation viral diseases cancer', 'selective nuclear export inhibitors autoimmune diseases hiv cancer', 'kpt 249', 'kpt 276', 'exportin 1 inhibitors inflammation viral diseases cancer', 'kpt 251', 'selinexor', 'xpovio', 'selective nuclear export inhibitors autoimmune diseases hiv cancer karyopharm therapeutics', 'sine autoimmune diseases hiv cancer karyopharm therapeutics', 'crm 1 inhibitors inflammation viral diseases cancer', 'ono 7705', 'selective nuclear export inhibitors autoimmune inflammation hiv cancer dermatological disease karyopharm therapeutics', 'selective nuclear export inhibitors covid 19']",correct_mapping
telaglenastat,Glutaminase inhibitor,telaglenastat,,telaglenastat hydrochloride,telaglenastat,fexact,"['CB-839 HCl', 'glutaminase inhibitors (oral, cancer)', 'CB-839', 'telaglenastat', 'glutaminase inhibitors (oral, cancer/anaplastic astrocytoma)', 'telaglenastat hydrochloride']",telaglenastat hydrochloride,fexact,"['cb 839 hcl', 'glutaminase inhibitors oral cancer', 'cb 839', 'telaglenastat', 'glutaminase inhibitors oral cancer anaplastic astrocytoma', 'telaglenastat hydrochloride']",correct_mapping
guadecitabine,DNA methylase inhibitor,guadecitabine,,guadecitabine sodium,guadecitabine,fexact,"['guadecitabine sodium', 'DNA demethylating agent (myelodysplastic syndrome/hepatocellular carcinoma/ovarian cancer/acute myelogenous leukemia/melanoma/non-small cell lung cancer), Supergen', 'DNA demethylating agent (myelodysplastic syndrome/hepatocellular carcinoma/ovarian cancer/acute myelogenous leukemia), Supergen', 'DNA demethylating agent (myelodysplastic syndrome), Supergen', 'S-110', 'guadecitabine', 'SGI-110']",guadecitabine sodium,fexact,"['guadecitabine sodium', 'dna demethylating agent myelodysplastic syndrome hepatocellular carcinoma ovarian cancer acute myelogenous leukemia melanoma non small cell lung cancer supergen', 'dna demethylating agent myelodysplastic syndrome hepatocellular carcinoma ovarian cancer acute myelogenous leukemia supergen', 'dna demethylating agent myelodysplastic syndrome supergen', 's 110', 'guadecitabine', 'sgi 110']",correct_mapping
GNX-102,Lewis antigen inhibitor,GNX-102,,GNX-102,gnx 102,fexact,"['GNX-102', 'anti-TACAs humanized antibody (advanced solid tumors)', 'anti-tumor-associated carbohydrate antigen mAb (advanced solid tumor)']",GNX-102,fexact,"['gnx 102', 'anti tacas humanized antibody advanced solid tumors', 'anti tumor associated carbohydrate antigen mab advanced solid tumor']",correct_mapping
oritinib,EGFR kinase inhibitor,oritinib,,,,0,['oritinib'],,0,[],0
quaratusugene ozeplasmid,Apoptosis stimulant; Immuno-oncology therapy,quaratusugene ozeplasmid,,quaratusugene ozeplasmid,quaratusugene ozeplasmid,fexact,"['quaratusugene ozeplasmid', 'FUS1 gene therapy (iv nanoparticle formulation, NSCLC)', 'p53 bystander effector, Introgen', 'p53 bystander effector', 'GEN-001', 'DOTAP:chol-FUS1', 'DOTAP:chol-TUSC2', 'Fus-1 tumor suppressor gene therapy (nanoparticles, cancer)', 'Reqorsa', 'INGN-401', 'CNVN-202', 'Oncoprex', 'GPX-001', 'TUSC2 gene therapy (intravenous nanoparticles, NSCLC)', 'FUS1-DOTAP:cholesterol', 'Fus-1 tumor suppressor gene therapy (nanoparticles, cancer), MD Anderson']",quaratusugene ozeplasmid,fexact,"['quaratusugene ozeplasmid', 'fus1 gene therapy iv nanoparticle formulation nsclc', 'p53 bystander effector introgen', 'p53 bystander effector', 'gen 001', 'dotap chol fus1', 'dotap chol tusc2', 'fus 1 tumor suppressor gene therapy nanoparticles cancer', 'reqorsa', 'ingn 401', 'cnvn 202', 'oncoprex', 'gpx 001', 'tusc2 gene therapy intravenous nanoparticles nsclc', 'fus1 dotap cholesterol', 'fus 1 tumor suppressor gene therapy nanoparticles cancer md anderson']",correct_mapping
XMT-1592,NaP2b antagonist,XMT-1592,,XMT-1592,xmt 1592,fexact,"['auristatin/NaPi2b-targeting antibody drug conjugate (Dolasynthen platform, cancer)', 'XMT-1592']",XMT-1592,fexact,"['auristatin napi2b targeting antibody drug conjugate dolasynthen platform cancer', 'xmt 1592']",correct_mapping
enfortumab vedotin,Tubulin inhibitor; Immuno-oncology therapy,enfortumab vedotin,,,,0,"['ASG-22M6E', 'AGS-22M', 'enfortumab vedotin', 'Padcev', 'ASG-22ME', 'ASG-22CE', 'AGS-22M6/monomethyl auristatin E conjugate (solid tumors),/Seattle Genetics', 'AGS-M6', 'AGS-22M6E', 'enfortumab vedotin (iv, cancer),/Seagen', 'enfortumab vedotin (iv, cancer),/', 'enfortumab vedotin-ejfv', 'AGS-22ME', 'AGS-22CE']",,NER_API,[],0
"GEN-001, Genome & Company","Immuno-oncology therapy; Microbiome modulator, live microorganisms",GEN-001,Genome & Company,quaratusugene ozeplasmid,gen 001,fexact,"['quaratusugene ozeplasmid', 'FUS1 gene therapy (iv nanoparticle formulation, NSCLC)', 'p53 bystander effector, Introgen', 'p53 bystander effector', 'GEN-001', 'DOTAP:chol-FUS1', 'DOTAP:chol-TUSC2', 'Fus-1 tumor suppressor gene therapy (nanoparticles, cancer)', 'Reqorsa', 'INGN-401', 'CNVN-202', 'Oncoprex', 'GPX-001', 'TUSC2 gene therapy (intravenous nanoparticles, NSCLC)', 'FUS1-DOTAP:cholesterol', 'Fus-1 tumor suppressor gene therapy (nanoparticles, cancer), MD Anderson']",quaratusugene ozeplasmid,fexact,"['quaratusugene ozeplasmid', 'fus1 gene therapy iv nanoparticle formulation nsclc', 'p53 bystander effector introgen', 'p53 bystander effector', 'gen 001', 'dotap chol fus1', 'dotap chol tusc2', 'fus 1 tumor suppressor gene therapy nanoparticles cancer', 'reqorsa', 'ingn 401', 'cnvn 202', 'oncoprex', 'gpx 001', 'tusc2 gene therapy intravenous nanoparticles nsclc', 'fus1 dotap cholesterol', 'fus 1 tumor suppressor gene therapy nanoparticles cancer md anderson']",correct_mapping
PY-314,TREM-2 antagonist; Immuno-oncology therapy,PY-314,,PY-314,py 314,fexact,"['PI-103 inhibitor (Myeloid Tuning, cancer)', 'PY-314', 'Macrophage modulator (Myeloid Tuning, cancer)', 'anti PI-103 monoclonal antibody (Myeloid Tuning, cancer)', 'TREM2 modulator ((Myeloid Tuning, cancer)', 'anti PI-103 monoclonal antibody (Myeloid Tuning, advanced solid tumor)']",PY-314,fexact,"['pi 103 inhibitor myeloid tuning cancer', 'py 314', 'macrophage modulator myeloid tuning cancer', 'anti pi 103 monoclonal antibody myeloid tuning cancer', 'trem2 modulator myeloid tuning cancer', 'anti pi 103 monoclonal antibody myeloid tuning advanced solid tumor']",correct_mapping
doxorubicin,DNA synthesis inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,doxorubicin,,"doxorubicin (liposomal, STEALTH)",doxorubicin,fexact,"['doxorubicin (liposomal, STEALTH)', 'SL-Dox', 'DOX-SL', 'doxorubicin HCl', 'doxorubicin hydrochloride', 'Caelyx', 'STEALTH (doxorubicin)', 'S-DOX', 'doxorubicin,/Schering', 'NSC-712227', 'doxorubicin,/', 'doxorubicin', 'pegylated liposomal doxorubicin', 'Doxil', 'JNS-002']","doxorubicin (liposomal, STEALTH)",fexact,"['doxorubicin liposomal stealth', 'sl dox', 'dox sl', 'doxorubicin hcl', 'doxorubicin hydrochloride', 'caelyx', 'stealth doxorubicin', 's dox', 'doxorubicin schering', 'nsc 712227', 'doxorubicin', 'doxorubicin', 'pegylated liposomal doxorubicin', 'doxil', 'jns 002']",correct_mapping
ifosfamide,DNA inhibitor; DNA synthesis inhibitor,ifosfamide,,,,0,['ifosfamide'],,0,[],0
vopratelimab,Inducible T-cell costimulator agonist; Immuno-oncology therapy; Immune checkpoint stimulant,vopratelimab,,vopratelimab,vopratelimab,fexact,"['vopratelimab', 'ICOS agonist immunotherapy (solid tumors)', 'JTX-2011', 'ICOS costimulator (cancer)', 'ICOS agonist monoclonal antibody (solid tumors)']",vopratelimab,fexact,"['vopratelimab', 'icos agonist immunotherapy solid tumors', 'jtx 2011', 'icos costimulator cancer', 'icos agonist monoclonal antibody solid tumors']",correct_mapping
pimivalimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,pimivalimab,,JTX-4014,pimivalimab,fexact,"['anti-PD-1 IgG mAb (iv, solid tumors)', 'T effector cell modulator therapy (cancer)', 'PD-1 checkpoint inhibitor (cancer)', 'JTX-4014', 'pimivalimab']",JTX-4014,fexact,"['anti pd 1 igg mab iv solid tumors', 't effector cell modulator therapy cancer', 'pd 1 checkpoint inhibitor cancer', 'jtx 4014', 'pimivalimab']",correct_mapping
hafnium oxide nanoparticle (intratumoral),Immuno-oncology therapy,hafnium oxide nanoparticle,,,,0,['hafnium oxide nanoparticle'],,0,[],0
tepotinib (tablet),MET tyrosine kinase inhibitor,tepotinib,,tepotinib,tepotinib,fexact,"['tepotinib hydrochloride hydrate', 'tepotinib hydrochloride', 'Tepmetko', 'tepotinib', 'EMD-1214063', 'c-Met kinase inhibitors (cancer), Merck Serono', 'MSC-2156119J']",tepotinib,fexact,"['tepotinib hydrochloride hydrate', 'tepotinib hydrochloride', 'tepmetko', 'tepotinib', 'emd 1214063', 'c met kinase inhibitors cancer merck serono', 'msc 2156119j']",correct_mapping
glumetinib,MET tyrosine kinase inhibitor,glumetinib,,glumetinib,glumetinib,fexact,"['small molecule therapeutic (oral/tablet, solid tumor), Shanghai Haihe Pharmaceutical//', 'small molecule therapeutic (oral/tablet, solid tumor), Shanghai Haihe Pharmaceutical/Shanghai Institute of Materia Medica/Shanghai Green Valley Pharmaceutical', 'HH-SCC-244', 'small molecule therapeutic (oral/tablet, solid tumor), Shanghai Haihe Pharmaceutical/Shanghai Institute of Materia Medica/', 'glumetinib', 'SCC-244', 'gumeitini']",glumetinib,fexact,"['small molecule therapeutic oral tablet solid tumor shanghai haihe pharmaceutical', 'small molecule therapeutic oral tablet solid tumor shanghai haihe pharmaceutical shanghai institute of materia medica shanghai green valley pharmaceutical', 'hh scc 244', 'small molecule therapeutic oral tablet solid tumor shanghai haihe pharmaceutical shanghai institute of materia medica', 'glumetinib', 'scc 244', 'gumeitini']",correct_mapping
berzosertib,Ataxia telangiectasia Rad3 inhibitor,berzosertib,,berzosertib,berzosertib,fexact,"['VE-822', 'atr inhibitor (oral, solid tumors)', 'berzosertib', 'VX-970', 'M-66207', 'M-6620']",berzosertib,fexact,"['ve 822', 'atr inhibitor oral solid tumors', 'berzosertib', 'vx 970', 'm 66207', 'm 6620']",correct_mapping
dexamethasone,Immunosuppressant; Corticosteroid agonist,dexamethasone,,ProTmune,dexamethasone,fexact,"['dexamethasone', 'FT-4145', 'ProTmune', 'FT-1050 + FT-4145 modulated mPB (hematologic malignancies)', 'dmPGE2', 'dmPGE2 + dexamethasone modulated mobilized peripheral blood (hematologic malignancies)', 'FT-1050']",ProTmune,fexact,"['dexamethasone', 'ft 4145', 'protmune', 'ft 1050 ft 4145 modulated mpb hematologic malignancies', 'dmpge2', 'dmpge2 dexamethasone modulated mobilized peripheral blood hematologic malignancies', 'ft 1050']",correct_mapping
"vinorelbine, oral",Microtubule inhibitor; Tubulin inhibitor; Apoptosis stimulant; Vinca alkaloid,vinorelbine,oral,vinorelbine,vinorelbine,fexact,"['vinorelbine tartrate', 'KW-2307', 'vinorelbine', 'KW-3407', 'Eunades', 'vinorelbine monotartrate', 'Navelbine']",vinorelbine,fexact,"['vinorelbine tartrate', 'kw 2307', 'vinorelbine', 'kw 3407', 'eunades', 'vinorelbine monotartrate', 'navelbine']",correct_mapping
befortinib mesylate,EGFR kinase inhibitor,befortinib mesylate,,,,0,['befortinib mesylate'],,0,[],0
TY-9591,EGFR kinase inhibitor,TY-9591,,TY-9591,ty 9591,fexact,"['pyrimidine derivative (lung cancer), Guangzhou Boji Medical & Biotechnological/', 'pyrimidine derivate (lung cancer)', 'pyrimidine derivative (lung cancer),/', 'pyrimidine derivate (lung cancer), Tetranov Biopharm', 'TY-9591', 'RUNNOR-9591']",TY-9591,fexact,"['pyrimidine derivative lung cancer guangzhou boji medical biotechnological', 'pyrimidine derivate lung cancer', 'pyrimidine derivative lung cancer', 'pyrimidine derivate lung cancer tetranov biopharm', 'ty 9591', 'runnor 9591']",correct_mapping
retifanlimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,retifanlimab,,retifanlimab,retifanlimab,fexact,"['PD-1 checkpoint inhibitor (cancer), MacroGenics', 'INCMGA-00012', 'INCMGA-0012', 'MGA-012', 'retifanlimab', 'PD-1 checkpoint inhibitor (cancer)']",retifanlimab,fexact,"['pd 1 checkpoint inhibitor cancer macrogenics', 'incmga 00012', 'incmga 0012', 'mga 012', 'retifanlimab', 'pd 1 checkpoint inhibitor cancer']",correct_mapping
CDX-527,CD27 agonist; PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor; Immune checkpoint stimulant,CDX-527,,CDX-527,cdx 527,fexact,"['anti-CD27/anti-PD-L1 bispecific antibodies', 'CDX-527', 'anti-CD27/anti-PD-L1 BsAbs', 'dual PD-L1 checkpoint inhibitor/CD27 costimulator (bispecific antibody, cancer)']",CDX-527,fexact,"['anti cd27 anti pd l1 bispecific antibodies', 'cdx 527', 'anti cd27 anti pd l1 bsabs', 'dual pd l1 checkpoint inhibitor cd27 costimulator bispecific antibody cancer']",correct_mapping
BBP-398,"Tyrosine phosphatase, non-receptor type 11 inhibitor",BBP-398,,BBP-398,bbp 398,fexact,"['SHP-2 inhibitors (cancer), Navire Pharmaceuticals/MD Anderson Cancer Center', 'ptpn11 gene modulator (cancer), navire pharmaceuticals', 'IACS-13909', 'shp-2 inhibitors (cancer), navire pharmaceuticals', 'BBP-398', 'shp-2 inhibitors (cancer/advanced solid tumor/metatsatic non small cell lung cancer), navire pharmaceuticals', 'ptpn11 gene modulator (cancer)', 'shp-2 inhibitors (cancer/advanced solid tumor/metatsatic non small cell lung cancer)', 'PTPN11 gene modulator (cancer), Navire Pharmaceuticals/MD Anderson Cancer Center', 'SHP-2 inhibitors (cancer/advanced solid tumor/metatsatic non small cell lung cancer), Navire Pharmaceuticals/MD Anderson Cancer Center', 'shp-2 inhibitors (cancer)']",BBP-398,fexact,"['shp 2 inhibitors cancer navire pharmaceuticals md anderson cancer center', 'ptpn11 gene modulator cancer navire pharmaceuticals', 'iacs 13909', 'shp 2 inhibitors cancer navire pharmaceuticals', 'bbp 398', 'shp 2 inhibitors cancer advanced solid tumor metatsatic non small cell lung cancer navire pharmaceuticals', 'ptpn11 gene modulator cancer', 'shp 2 inhibitors cancer advanced solid tumor metatsatic non small cell lung cancer', 'ptpn11 gene modulator cancer navire pharmaceuticals md anderson cancer center', 'shp 2 inhibitors cancer advanced solid tumor metatsatic non small cell lung cancer navire pharmaceuticals md anderson cancer center', 'shp 2 inhibitors cancer']",correct_mapping
efineptakin alfa,Interleukin 7 agonist; T cell stimulant; Immuno-oncology therapy,efineptakin alfa,,efineptakin alfa,efineptakin alfa,fexact,"['IL-7-hyFc (lymphopenia/HPV infection/advanced solid tumor)', 'IL-7-hyFc', 'efineptakin alfa', 'GX-17', 'TJ-107', 'IL-7-hyFc (lymphopenia/HPV infection),/ NeoImmuneTech/ I-Mab', 'NT-17', 'NT-I7', 'IL-7-hyFc (lymphopenia/HPV infection),/ NeoImmuneTech/', 'rhIL-7-hyFc', 'IL-7-hyFc (lymphopenia/HPV infection),//', 'IL-7-hyFc (lymphopenia/HPV infection/advanced solid tumor/COVID-19), NeoImmuneTech', 'IL-7-hyFc (lymphopenia/HPV infection/advanced solid tumor/COVID-19)', 'HyLeukin-7', 'NIT-01', 'Hyleukin', '2026634-47-7', 'Hyleukin monotherapy (lymphopenia)', 'IL-7-hyFc (lymphopenia/HPV infection),/NeoImmuneTech', 'Il-7 Hybrid Fc', 'IL-7-hyFc (lymphopenia/HPV infection),/', 'Hyleukin monotherapy (lymphopenia), NeoImmuneTech']",efineptakin alfa,fexact,"['il 7 hyfc lymphopenia hpv infection advanced solid tumor', 'il 7 hyfc', 'efineptakin alfa', 'gx 17', 'tj 107', 'il 7 hyfc lymphopenia hpv infection neoimmunetech i mab', 'nt 17', 'nt i7', 'il 7 hyfc lymphopenia hpv infection neoimmunetech', 'rhil 7 hyfc', 'il 7 hyfc lymphopenia hpv infection', 'il 7 hyfc lymphopenia hpv infection advanced solid tumor covid 19 neoimmunetech', 'il 7 hyfc lymphopenia hpv infection advanced solid tumor covid 19', 'hyleukin 7', 'nit 01', 'hyleukin', '2026634 47 7', 'hyleukin monotherapy lymphopenia', 'il 7 hyfc lymphopenia hpv infection neoimmunetech', 'il 7 hybrid fc', 'il 7 hyfc lymphopenia hpv infection', 'hyleukin monotherapy lymphopenia neoimmunetech']",correct_mapping
autologous-dendritic cells pulsed with antigen,Immunostimulant,autologous-dendritic cells pulsed with antigen,,,,0,['autologous-dendritic cells pulsed with antigen'],,0,[],0
WSD-0922,ErbB antagonist,WSD-0922,,WSD-0922-FU,wsd 0922,fexact,"['WSD-0922', 'egfr inhibitor (nsclc/glioblastoma)', 'egfr inhibitor (nsclc/glioblastoma/head and neck tumor/anaplastic astrocytoma)', 'egfr inhibitor (nsclc/glioblastoma/head and neck tumor)', 'WSD-0922-FU']",WSD-0922-FU,fexact,"['wsd 0922', 'egfr inhibitor nsclc glioblastoma', 'egfr inhibitor nsclc glioblastoma head and neck tumor anaplastic astrocytoma', 'egfr inhibitor nsclc glioblastoma head and neck tumor', 'wsd 0922 fu']",correct_mapping
"anti-PD-1 Ab, unspecified",PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,anti-PD-1 Ab,unspecified,serplulimab,anti pd 1 mab,fuzzy,"['pd-1 checkpoint inhibitor (solid tumor)', 'anti-PD-1 mAb, Shanghai Henlius Biotech', 'PD-1 checkpoint inhibitor (solid tumor), Shanghai Henlius', 'PD-1 checkpoint inhibitor (solid tumor)', 'PD-1 checkpoint inhibitor (solid tumor),/ Kalbe Genexine Biologics', 'serplulimab', 'anti-PD-1 mAb (solid tumor),/ Kalbe Genexine Biologics', 'anti-PD-1 mAb', 'HLX-10', 'anti-pd-1 mab (solid tumor)']",serplulimab,fexact,"['pd 1 checkpoint inhibitor solid tumor', 'anti pd 1 mab shanghai henlius biotech', 'pd 1 checkpoint inhibitor solid tumor shanghai henlius', 'pd 1 checkpoint inhibitor solid tumor', 'pd 1 checkpoint inhibitor solid tumor kalbe genexine biologics', 'serplulimab', 'anti pd 1 mab solid tumor kalbe genexine biologics', 'anti pd 1 mab', 'hlx 10', 'anti pd 1 mab solid tumor']",incorrect_mapping
undisclosed - ROS1 inhibitor,ROS receptor tyrosine kinase inhibitor,undisclosed - ROS1 inhibitor,,,,0,['undisclosed - ROS1 inhibitor'],,0,[],0
autologous cytotoxic T lymphocytes,Immunostimulant,autologous cytotoxic T lymphocytes,,,,0,['autologous cytotoxic T lymphocytes'],,0,[],0
ABM-1310,B-raf kinase inhibitor,ABM-1310,,ABM-1310,abm 1310,fexact,"['ABM-1310', 'b-raf inhibitor (oral capsule, advanced solid tumor)']",ABM-1310,fexact,"['abm 1310', 'b raf inhibitor oral capsule advanced solid tumor']",correct_mapping
cofetuzumab pelidotin,Microtubule inhibitor,cofetuzumab pelidotin,,cofetuzumab pelidotin,cofetuzumab pelidotin,fexact,"['PTK7-ADC', 'PF-7020', 'cofetuzumab pelidotin', 'PTK7-Aur0101', 'PF-06647020', 'ABBV-647', 'anti-PTK7-auristatin']",cofetuzumab pelidotin,fexact,"['ptk7 adc', 'pf 7020', 'cofetuzumab pelidotin', 'ptk7 aur0101', 'pf 06647020', 'abbv 647', 'anti ptk7 auristatin']",correct_mapping
aspirin,Thromboxane synthase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor; Cyclooxygenase inhibitor,aspirin,,,,0,"['aspirin + undisclosed agents (liquid, brain tumor)', 'aspirin', 'acetylsalicylic acid + undisclosed agents (liquid, brain tumor)', 'acetylsalicylic acid', 'acetylsalicylic acid + undisclosed agents (liquid, brain tumor),/University of Portsmouth', 'aspirin + undisclosed agents (liquid, brain tumor),/University of Portsmouth', 'IP-1867B']",,NER_API,[],0
sasanlimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,sasanlimab,,sasanlimab,sasanlimab,fexact,"['PD-1 checkpoint inhibitor (cancer)', 'sasanlimab', 'RN-888', 'PF-06801591']",sasanlimab,fexact,"['pd 1 checkpoint inhibitor cancer', 'sasanlimab', 'rn 888', 'pf 06801591']",correct_mapping
docosahexaenoic acid,Omega 3 fatty acid stimulant,docosahexaenoic acid,,,,0,"['DHA-based cystic fibrosis therapy,/Genzyme', 'docosahexaenoic acid (sickle cell disease/short bowel syndrome)', 'cervnoic acid', 'doconexent', 'docosahexaenoic acid (primary sclerosing cholangitis/sickle cell disease/short bowel syndrome)', 'SC-403', 'DHA-based cystic fibrosis therapy,/', 'SC-411', 'Cervonic acid', 'doconexent (periodontitis)', 'Lumarel', 'Altemia', 'doconexent (primary sclerosing cholangitis/sickle cell disease/short bowel syndrome), Sancilio & Company', 'docosahexaenoic acid', 'docosahexaenoic acid (cystic fibrosis)', 'doconexent (cystic fibrosis)', 'DHA', 'docosahexaenoic acid (primary sclerosing cholangitis/sickle cell disease/short bowel syndrome), Sancilio & Company', 'doconexent (primary sclerosing cholangitis/sickle cell disease/short bowel syndrome)', 'SC-404']",,Drug_API_mapping,[],0
eicosapentaenoic acid,Omega 3 fatty acid stimulant,eicosapentaenoic acid,,,,0,"['icosapent (colorectal polyps)', 'eicosapentaenoic acid (familial adenomatous polyps)', 'icosapent', 'eicosapentaenoic acid,/', 'eicosapentaenoic acid (colorectal polyps)', 'eicosapentaenoic acid, Thallia/', 'eicosapentaenoic acid (oral, familial adenomatous polyposis/inflammatory bowel disease/Crohns disease/COVID-19/ulcerative colitis)', 'eicosapentaenoic acid', 'ALFA', 'eicosapentaenoic acid (oral, familial adenomatous polyposis/inflammatory bowel disease/Crohns disease)', 'icosapent,/', 'EPA, Thallia/', 'icosapent, Thallia/', 'icosapent (familial adenomatous polyposis)', 'EPA,/', 'EPA-FFA', 'EPAspire']",,Drug_API_mapping,[],0
"VSV IFNb NIS, Vyriad",Immuno-oncology therapy,VSV IFNb NIS,Vyriad,VSV-hIFNbeta-NIS,vsv mifn nis,fuzzy,"['BOEC-VSV-IFN-beta', 'VSV-hIFNbeta-NIS', 'recombinant vesicular stomatitis virus (cancer)', 'recombinant vesicular stomatitis virus (cancer), University of Tennessee/', 'VSV-mIFN-NIS', 'oncolytic vsv therapy expressing ifn-beta and sodium-iodide symporter (cancer)', 'oncolytic VSV therapy expressing IFN-beta and sodium-iodide symporter (cancer), University of Tennessee/']",VSV-hIFNbeta-NIS,fexact,"['boec vsv ifn beta', 'vsv hifnbeta nis', 'recombinant vesicular stomatitis virus cancer', 'recombinant vesicular stomatitis virus cancer university of tennessee', 'vsv mifn nis', 'oncolytic vsv therapy expressing ifn beta and sodium iodide symporter cancer', 'oncolytic vsv therapy expressing ifn beta and sodium iodide symporter cancer university of tennessee']",incorrect_mapping
BDC-1001,ErbB-2 antagonist; Immunostimulant; Toll-like receptor 7 agonist; Toll-like receptor 8 agonist; Immuno-oncology therapy,BDC-1001,,BDC-1001,bdc 1001,fexact,"['anti-HER2 TLR7/8 ISAC (cancer)', 'BDC-1001', 'HER2 Boltbody', 'immune-stimulating antibody conjugates (cancer)', 'dendritic cell-activating anti-HER2 antibody (breast cancer).']",BDC-1001,fexact,"['anti her2 tlr7 8 isac cancer', 'bdc 1001', 'her2 boltbody', 'immune stimulating antibody conjugates cancer', 'dendritic cell activating anti her2 antibody breast cancer']",correct_mapping
talazoparib,Poly ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor; Poly ADP ribose polymerase 1 inhibitor,talazoparib,,talazoparib tosylate,talazoparib,fexact,"['talazoparib tosylate', 'MDV-3800', 'talazoparib tosilate', 'talazoparib', 'PARP inhibitors (solid tumors)', 'LT-00673', 'BMN-673', 'BMN-628', 'PF-06944076', 'PARP inhibitors (solid tumors), LEAD Therapeutics', 'LT-673', 'Talzenna']",talazoparib tosylate,fexact,"['talazoparib tosylate', 'mdv 3800', 'talazoparib tosilate', 'talazoparib', 'parp inhibitors solid tumors', 'lt 00673', 'bmn 673', 'bmn 628', 'pf 06944076', 'parp inhibitors solid tumors lead therapeutics', 'lt 673', 'talzenna']",correct_mapping
alkotinib,ROS receptor tyrosine kinase inhibitor,alkotinib,,alkotinib,alkotinib,fexact,"['aokatini', 'small molecule therapeutic (oral/capsule, cancer)', 'ZG-0418', 'ocatinib', 'alkotinib']",alkotinib,fexact,"['aokatini', 'small molecule therapeutic oral capsule cancer', 'zg 0418', 'ocatinib', 'alkotinib']",correct_mapping
SCT-I10A,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,SCT-I10A,,SCT-I10A,sct i10a,fexact,"['PD-1 checkpoint inhibitor (cancer)', 'SCT-I10A']",SCT-I10A,fexact,"['pd 1 checkpoint inhibitor cancer', 'sct i10a']",correct_mapping
BT-5528,EphA receptor kinase inhibitor,BT-5528,,BT-5528,bt 5528,fexact,"['bicycle toxin conjugate targeting EphA2 (cancer)', 'BT-5528']",BT-5528,fexact,"['bicycle toxin conjugate targeting epha2 cancer', 'bt 5528']",correct_mapping
LY-3499446,K-Ras inhibitor,LY-3499446,,LY-3499446,ly 3499446,fexact,"['LY-3499446', 'KRAS G12C inhibitor (cancer)']",LY-3499446,fexact,"['ly 3499446', 'kras g12c inhibitor cancer']",correct_mapping
vibostolimab,TIGIT receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,vibostolimab,,vibostolimab,vibostolimab,fexact,"['TIGIT checkpoint inhibitor (solid tumor)', 'vibostolimab', 'MK-7684']",vibostolimab,fexact,"['tigit checkpoint inhibitor solid tumor', 'vibostolimab', 'mk 7684']",correct_mapping
MK-4830,Leukocyte immunoglobulin-like receptor B2 antagonist,MK-4830,,MK-4830,mk 4830,fexact,"['anti-ILT4-specific mAb (advanced solid tumors),/', 'MK-4830', 'anti-ILT4-specific mAb (advanced solid tumors), Merck/']",MK-4830,fexact,"['anti ilt4 specific mab advanced solid tumors', 'mk 4830', 'anti ilt4 specific mab advanced solid tumors merck']",correct_mapping
MK-5890,CD27 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,MK-5890,,,,0,"['MK-5890', 'CD27 costimulator (cancer/NSCLC)', 'CD27 costimulator (cancer)', 'CD27 agonist (cancer)']",,NER_API,[],0
"Polyphenon E, oral, Polyphenon Pharma",Reducing agent,Polyphenon E,Polyphenon Pharma,,,0,"['topical polyphenols,/MediGene/Mitsui', 'Polyphenon  (topical)', 'topical polyphenols, Epitome/MediGene/Mitsui', 'Veregen', 'sinecatechins (warts), Epitome/MediGene/Mitsui', 'SB-03', 'topical polyphenols,//Mitsui', 'sinecatechins (warts),/MediGene/Mitsui', 'topical polyphenols,//', 'Polyphenon', 'sinecatechins (warts),//Mitsui', 'sinecatechins (warts),//']",,NER_API,[],0
LY-3200882,Transforming growth factor beta receptor 1 antagonist,LY-3200882,,LY-3200882,ly 3200882,fexact,"['TGF beta receptor I inhibitor II (solid tumors/colorectal cancer)', 'TGF-beta-R1 Effort II (solid tumors)', 'LY-3200882', 'TGFbeta RI Kinase inhibitor']",LY-3200882,fexact,"['tgf beta receptor i inhibitor ii solid tumors colorectal cancer', 'tgf beta r1 effort ii solid tumors', 'ly 3200882', 'tgfbeta ri kinase inhibitor']",correct_mapping
TPST-1495,Prostaglandin E2 receptor antagonist; Prostaglandin EP4 receptor antagonist,TPST-1495,,TPST-1495,tpst 1495,fexact,"['E-prostanoid receptor antagonists (cancer)', 'E-prostanoid receptor antagonists (cancer), Tempest Therapeutics', 'E-prostanoid receptor antagonists (cancer), Inception Sciences', 'EP2 receptor antagonists (cancer), Tempest Therapeutics', 'EP2 receptor antagonists (cancer)', 'TPST-1495', 'dual EP2/EP4 antagonists (cancer), Tempest Therapeutics', 'dual EP2/EP4 antagonists (cancer)']",TPST-1495,fexact,"['e prostanoid receptor antagonists cancer', 'e prostanoid receptor antagonists cancer tempest therapeutics', 'e prostanoid receptor antagonists cancer inception sciences', 'ep2 receptor antagonists cancer tempest therapeutics', 'ep2 receptor antagonists cancer', 'tpst 1495', 'dual ep2 ep4 antagonists cancer tempest therapeutics', 'dual ep2 ep4 antagonists cancer']",correct_mapping
ATRC-101,Immuno-oncology therapy,ATRC-101,,ATRC-101,atrc 101,fexact,"['Program 100', 'ATRC-101', 'human antibodies (Immune Repertoire Capture, Driver Antigen Engagement, cancer)']",ATRC-101,fexact,"['program 100', 'atrc 101', 'human antibodies immune repertoire capture driver antigen engagement cancer']",correct_mapping
ZN-c3,Wee-1 tyrosine kinase inhibitor,ZN-c3,,ZN-c3,zn c3,fexact,"['wee-1 protein kinase inhibitor (advanced solid tumors, oral)', 'wee-1 protein kinase inhibitor (advanced solid tumors, oral), /zentalis pharmaceuticals', 'ZN-c3']",ZN-c3,fexact,"['wee 1 protein kinase inhibitor advanced solid tumors oral', 'wee 1 protein kinase inhibitor advanced solid tumors oral zentalis pharmaceuticals', 'zn c3']",correct_mapping
"CXCR5 modified EGFR chimaeric antigen receptor therapy, Guangzhou Bio-gene Technology",T cell stimulant; Immuno-oncology therapy,CXCR5 modified EGFR chimaeric antigen receptor therapy,Guangzhou Bio-gene Technology,,,0,['CXCR5 modified EGFR chimaeric antigen receptor therapy'],,0,[],0
PF-06940434,Alpha/beta integrin antagonist,PF-06940434,,PF-06940434,pf 06940434,fexact,['PF-06940434'],PF-06940434,fexact,['pf 06940434'],correct_mapping
LY-3475070,Immuno-oncology therapy; CD73 antagonist,LY-3475070,,LY-3475070,ly 3475070,fexact,"['CD73 checkpoint inhibitor (oral, advanced solid tumor)', 'CD73 inhibitor (cancer)', 'LY-3475070']",LY-3475070,fexact,"['cd73 checkpoint inhibitor oral advanced solid tumor', 'cd73 inhibitor cancer', 'ly 3475070']",correct_mapping
ensartinib,Anaplastic lymphoma kinase inhibitor; EphA receptor kinase inhibitor; MET tyrosine kinase inhibitor; ROS receptor tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,ensartinib,,ensartinib,ensartinib,fexact,"['X-276', 'anaplastic lymphoma kinase inhibitors (cancer), Xcovery', 'anaplastic lymphoma kinase inhibitors (cancer)', 'ensartinib', 'ALK inhibitors (cancer), Xcovery', 'Ensacove', 'X-376', 'X-396', 'X-353', 'ALK inhibitor (cancer)', 'ALK inhibitors (cancer)']",ensartinib,fexact,"['x 276', 'anaplastic lymphoma kinase inhibitors cancer xcovery', 'anaplastic lymphoma kinase inhibitors cancer', 'ensartinib', 'alk inhibitors cancer xcovery', 'ensacove', 'x 376', 'x 396', 'x 353', 'alk inhibitor cancer', 'alk inhibitors cancer']",correct_mapping
personalized neoantigen-primed dendritic cell vaccine,Immunostimulant,personalized neoantigen-primed dendritic cell vaccine,,,,0,['personalized neoantigen-primed dendritic cell vaccine'],,0,[],0
WX-0593,Unidentified pharmacological activity,WX-0593,,WX-0593,wx 0593,fexact,"['ALK receptor tyrosine kinase inhibitor (non-small-cell lung cancer)', 'yiluaoke', 'WX-0593']",WX-0593,fexact,"['alk receptor tyrosine kinase inhibitor non small cell lung cancer', 'yiluaoke', 'wx 0593']",correct_mapping
AP-001,Unidentified pharmacological activity,AP-001,,,,0,"['interferon alpha 2b, (topical, Biphasix), Helix Biopharma', 'AP-001', 'interferon alpha 2b, (topical, Biphasix)', 'topical interferon alpha 2b', 'AP-004 (topical, Biphasix)', 'Biphasix']",,NER_API,[],0
DCC-3116,ULK kinase inhibitor,DCC-3116,,DCC-3116,dcc 3116,fexact,"['autophagy inhibitors (cancer)', 'DCC-3116', 'ULK kinase inhibitor (cancer)', 'mutant RAS cancer therapy']",DCC-3116,fexact,"['autophagy inhibitors cancer', 'dcc 3116', 'ulk kinase inhibitor cancer', 'mutant ras cancer therapy']",correct_mapping
RO-7247669,PD-1 antagonist; Lymphocyte-activation gene 3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,RO-7247669,,RG-6139,ro 7247669,fexact,"['RG-6139', 'anti PD-1/LAG-3\xa0bispecific antibody (advanced solid tumor/esophageal squamous cell carcinoma)', 'anti PD-1/LAG-3\xa0bispecific antibody (advanced solid tumor)', 'dual PD-1 checkpoint inhibitor/LAG-3 checkpoint inhibitor (advanced solid tumor)', 'anti-PD1 x LAG3 (solid tumors)', 'RO-7247669']",RG-6139,fexact,"['rg 6139', 'anti pd 1 lag 3\xa0bispecific antibody advanced solid tumor esophageal squamous cell carcinoma', 'anti pd 1 lag 3\xa0bispecific antibody advanced solid tumor', 'dual pd 1 checkpoint inhibitor lag 3 checkpoint inhibitor advanced solid tumor', 'anti pd1 x lag3 solid tumors', 'ro 7247669']",correct_mapping
ONC-392,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,ONC-392,,ONC-392,onc 392,fexact,"['CTLA-4 checkpoint inhibitor (cancer)', 'ONC-392', 'anti-CTLA4 humanized monoclonal antibody (cancer)']",ONC-392,fexact,"['ctla 4 checkpoint inhibitor cancer', 'onc 392', 'anti ctla4 humanized monoclonal antibody cancer']",correct_mapping
platinum,Unidentified pharmacological activity,platinum,,,,0,['platinum'],,0,[],0
undisclosed - angiogenesis inhibitor,Angiogenesis inhibitor,undisclosed - angiogenesis inhibitor,,,,0,['undisclosed - angiogenesis inhibitor'],,0,[],0
TAB-004,MUC-1 inhibitor,TAB-004,,TAB-004,tab 004,fexact,"['TAB-004', 'TAB-004/JS-004', 'icatolimab', 'JS-004', 'BTLA checkpoint inhibitor (solid tumors)', 'recombinant humanized anti-BTLA monoclonal antibody (melanoma/lung cancer/lymphoma)']",TAB-004,fexact,"['tab 004', 'tab 004 js 004', 'icatolimab', 'js 004', 'btla checkpoint inhibitor solid tumors', 'recombinant humanized anti btla monoclonal antibody melanoma lung cancer lymphoma']",correct_mapping
BPI-7711,EGFR kinase inhibitor,BPI-7711,,BPI-7711,bpi 7711,fexact,"['EGFR T790M inhibitors (non-small cell lung cancer)', 'BPI-7711', 'rezivertinib', 'BPI-4039']",BPI-7711,fexact,"['egfr t790m inhibitors non small cell lung cancer', 'bpi 7711', 'rezivertinib', 'bpi 4039']",correct_mapping
intensity-modulated radiation therapy,Unidentified pharmacological activity,intensity-modulated radiation therapy,,,,0,['intensity-modulated radiation therapy'],,0,[],0
proton therapy,Unidentified pharmacological activity,proton therapy,,,,0,['proton therapy'],,0,[],0
rogaratinib,FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor,rogaratinib,,rogaratinib,rogaratinib,fexact,"['pan-FGFR inhibitor (cancer)', 'BAY-1163877', 'rogaratinib']",rogaratinib,fexact,"['pan fgfr inhibitor cancer', 'bay 1163877', 'rogaratinib']",correct_mapping
"tyrosine kinase inhibitor, unspecified",Tyrosine kinase inhibitor (TKI),tyrosine kinase inhibitor,unspecified,,,0,['tyrosine kinase inhibitor'],,0,[],0
adavosertib,Wee-1 tyrosine kinase inhibitor,adavosertib,,adavosertib,adavosertib,fexact,"['MK-1775', 'WEE1 kinase inhibitor (cancer), Merck & Co/', 'WEE1 kinase inhibitor (cancer),/', 'adavosertib', 'AZD-1775']",adavosertib,fexact,"['mk 1775', 'wee1 kinase inhibitor cancer merck co', 'wee1 kinase inhibitor cancer', 'adavosertib', 'azd 1775']",correct_mapping
ceralasertib,Ataxia telangiectasia Rad3 inhibitor,ceralasertib,,ceralasertib,ceralasertib,fexact,"['AZD-6738', 'ceralasertib']",ceralasertib,fexact,"['azd 6738', 'ceralasertib']",correct_mapping
AZD-1390,ATM kinase inhibitor,AZD-1390,,AZD-1390,azd 1390,fexact,"['ATM kinase inhibitor (cancer/glioblastoma/metastatic brain cancer)', 'AZD-1390']",AZD-1390,fexact,"['atm kinase inhibitor cancer glioblastoma metastatic brain cancer', 'azd 1390']",correct_mapping
"DNA damage response inhibitor, undisclosed",Not applicable,DNA damage response inhibitor,undisclosed,,,0,['DNA damage response inhibitor'],,0,[],0
HuMax-IL8,Interleukin 8 antagonist; Immuno-oncology therapy,HuMax-IL8,,BMS-986253,humax il8,fexact,"['HuMax-IL8', 'BMS-986253', 'anti-inflammatory antibody, Medarex/Genmab', 'anti-inflammatory antibody,/', 'anti-inflammatory therapeutic, Genmab/Medarex', 'BMS-968253', 'anti-inflammatory therapeutic,/', 'MDX-018', 'anti-inflammatory antibody, Medarex/', 'IL-8 targeting antibody (intravenous, hematological neoplasm/COVID-19 associated respiratory disease)', 'anti-inflammatory therapeutic,/Medarex', 'HuMax-Inflam']",BMS-986253,fexact,"['humax il8', 'bms 986253', 'anti inflammatory antibody medarex genmab', 'anti inflammatory antibody', 'anti inflammatory therapeutic genmab medarex', 'bms 968253', 'anti inflammatory therapeutic', 'mdx 018', 'anti inflammatory antibody medarex', 'il 8 targeting antibody intravenous hematological neoplasm covid 19 associated respiratory disease', 'anti inflammatory therapeutic medarex', 'humax inflam']",correct_mapping
BMS-813160,CC chemokine receptor 5 antagonist; CC chemokine receptor 2 antagonist,BMS-813160,,BMS-813160,bms 813160,fexact,"['BMS-585059', 'CCR2/CCR5 chemokine antagonist (immune disorders, cardiovascular disorders), BMS', 'BMS-813160', 'CCR2/CCR5 dual antagonist (immunology)', 'CCR2/CCR5 dual antagonist (cardiovascular disease)']",BMS-813160,fexact,"['bms 585059', 'ccr2 ccr5 chemokine antagonist immune disorders cardiovascular disorders bms', 'bms 813160', 'ccr2 ccr5 dual antagonist immunology', 'ccr2 ccr5 dual antagonist cardiovascular disease']",correct_mapping
PD1-Vaxx,PD-1 antagonist; PD-L1 antagonist; PD-L2 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,PD1-Vaxx,,PD1-Vaxx,pd1 vaxx,fexact,"['PD-1 checkpoint inhibitor-inducing vaccine (cancer), Medical University of Vienna/', 'APi-2568', 'PD1-Vaxx', 'mimotope immuno-oncologic b-cell peptide vaccine (cancer)', 'IMU-201', 'pd-1-mimotope vaccine (cancer)', 'PD-1-mimotope vaccine (cancer), Medical University of Vienna/', 'pd-1 checkpoint inhibitor-inducing vaccine (cancer)', 'mimotope immuno-oncologic B-cell peptide vaccine (cancer), Medical University of Vienna/']",PD1-Vaxx,fexact,"['pd 1 checkpoint inhibitor inducing vaccine cancer medical university of vienna', 'api 2568', 'pd1 vaxx', 'mimotope immuno oncologic b cell peptide vaccine cancer', 'imu 201', 'pd 1 mimotope vaccine cancer', 'pd 1 mimotope vaccine cancer medical university of vienna', 'pd 1 checkpoint inhibitor inducing vaccine cancer', 'mimotope immuno oncologic b cell peptide vaccine cancer medical university of vienna']",correct_mapping
imiquimod,Immunostimulant,imiquimod,,imiquimod,imiquimod,fexact,"['MTD-39', 'S-26308', 'MLD-39', 'Zyclara', 'Zartra', 'imiquimod', 'Aldara', 'DZ-2636', 'Beselna Cream', 'Vyloma', 'R-837']",imiquimod,fexact,"['mtd 39', 's 26308', 'mld 39', 'zyclara', 'zartra', 'imiquimod', 'aldara', 'dz 2636', 'beselna cream', 'vyloma', 'r 837']",correct_mapping
ultrasound therapy,Not applicable,ultrasound therapy,,,,0,['ultrasound therapy'],,0,[],0
rosiglitazone maleate,Peroxisome proliferator-activated receptor gamma agonist; Insulin sensitizer; Thiazolidinedione,rosiglitazone maleate,,rosiglitazone,rosiglitazone maleate,fexact,"['Avandia', 'rosiglitazone', 'BRL 49653C', 'BRL-49653', 'rosiglitazone maleate']",rosiglitazone,fexact,"['avandia', 'rosiglitazone', 'brl 49653c', 'brl 49653', 'rosiglitazone maleate']",correct_mapping
"metformin, unspecified",Biguanide; Gluconeogenesis inhibitor,metformin,unspecified,metformin hydrochloride,metformin,fexact,"['Gliguanid', 'Metfogamma', 'Diabex', 'LA-6023', 'Glifage IR', 'Metgluco', 'Diaformin', 'Flumamine', 'metformin', 'BMS-207150', 'Glucophage', 'Siofor', 'Diabetosan', 'Fluamine', 'Diabex XR', 'Glifage', 'SMP-862', 'metformin hydrochloride', 'Glucofit']",metformin hydrochloride,fexact,"['gliguanid', 'metfogamma', 'diabex', 'la 6023', 'glifage ir', 'metgluco', 'diaformin', 'flumamine', 'metformin', 'bms 207150', 'glucophage', 'siofor', 'diabetosan', 'fluamine', 'diabex xr', 'glifage', 'smp 862', 'metformin hydrochloride', 'glucofit']",correct_mapping
HLX-55,MET tyrosine kinase inhibitor,HLX-55,,HLX-55,hlx 55,fexact,"['KTN-0216', 'anti-cMET mAb (stomach cancer/glioblastoma), Shanghai Fosun/Shanghai Henlius//', 'HLX-55', 'anti-cMET mAb (stomach cancer/glioblastoma),/Shanghai Henlius//', 'anti-cMET mAb (stomach cancer/glioblastoma), Shanghai Fosun/Shanghai Henlius//Kolltan Pharmaceuticals']",HLX-55,fexact,"['ktn 0216', 'anti cmet mab stomach cancer glioblastoma shanghai fosun shanghai henlius', 'hlx 55', 'anti cmet mab stomach cancer glioblastoma shanghai henlius', 'anti cmet mab stomach cancer glioblastoma shanghai fosun shanghai henlius kolltan pharmaceuticals']",correct_mapping
FT-500,Natural killer cell stimulant; Immuno-oncology therapy,FT-500,,FT-500,ft 500,fexact,"['ipsc-derived nk cell therapy (cancer)', 'iPSC-derived NK cell therapy (cancer),/University of Minnesota', 'FT-500']",FT-500,fexact,"['ipsc derived nk cell therapy cancer', 'ipsc derived nk cell therapy cancer university of minnesota', 'ft 500']",correct_mapping
BDTX-189,EGFR antagonist; ErbB-2 antagonist,BDTX-189,,BDTX-189,bdtx 189,fexact,"['BDTX-189', 'ErbB1 and ErbB2 tyrosine kinase modulators (oral, cancer)']",BDTX-189,fexact,"['bdtx 189', 'erbb1 and erbb2 tyrosine kinase modulators oral cancer']",correct_mapping
ASK-120067,EGFR kinase inhibitor,ASK-120067,,ASK-120067,ask 120067,fexact,"['ASK-120067', 'EGFR tyrosine kinase inhibitor (NSCLC), Jiangsu/Shangai Institute/', 'CCB-120067', 'EGFR tyrosine kinase inhibitor (NSCLC),/Shangai Institute/']",ASK-120067,fexact,"['ask 120067', 'egfr tyrosine kinase inhibitor nsclc jiangsu shangai institute', 'ccb 120067', 'egfr tyrosine kinase inhibitor nsclc shangai institute']",correct_mapping
restorative microbiota therapy (RMT),Microbiome modulator,restorative microbiota therapy,,,,0,['restorative microbiota therapy'],,0,[],0
"GM-CSF, unspecified",Granulocyte macrophage colony stimulating factor agonist,GM-CSF,unspecified,sargramostim,gm csf,fexact,"['GM-CSF,/', 'BI 61.012', 'GM-CSF, Berlex/Schering', 'GM-CSF,/Schering', 'GM-CSF, Immunex', 'GM-CSF, Behringwerke', 'SHL-04023', 'Prokine', 'GM-CSF', 'Leukine', 'sargramostim']",sargramostim,fexact,"['gm csf', 'bi 61 012', 'gm csf berlex schering', 'gm csf schering', 'gm csf immunex', 'gm csf behringwerke', 'shl 04023', 'prokine', 'gm csf', 'leukine', 'sargramostim']",correct_mapping
MT-6035,Protein synthesis inhibitor,MT-6035,,MT-6402,mt 6035,fexact,"['anti-PD-L1/Shiga-like toxin 1 (SLT-1A) MHC class I-antigen-seeding engineered toxin body (melanoma)', 'MT-6402', 'MT-6020-AST (cancer)', 'MT-6035']",MT-6402,fexact,"['anti pd l1 shiga like toxin 1 slt 1a mhc class i antigen seeding engineered toxin body melanoma', 'mt 6402', 'mt 6020 ast cancer', 'mt 6035']",correct_mapping
taletrectinib,ROS receptor tyrosine kinase inhibitor; TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,taletrectinib,,taletrectinib,taletrectinib,fexact,"['NTRK (TrkA)/ROS1 inhibitor (cancer), Innovent Biologics', 'DS-6051', 'NTRK (TrkA)/ROS1 inhibitor (cancer)', 'AB-106', 'NTRK (TrkA)/ROS1 inhibitor (solid tumor/Non small cell lung cancer)', 'taletrectinib', 'DS-6051b']",taletrectinib,fexact,"['ntrk trka ros1 inhibitor cancer innovent biologics', 'ds 6051', 'ntrk trka ros1 inhibitor cancer', 'ab 106', 'ntrk trka ros1 inhibitor solid tumor non small cell lung cancer', 'taletrectinib', 'ds 6051b']",correct_mapping
zenocutuzumab,ErbB-2 antagonist; ErbB-3 antagonist; Immuno-oncology therapy,zenocutuzumab,,zenocutuzumab,zenocutuzumab,fexact,"['PB-4188', 'MCLA-128', 'human therapeutic antibodies (Bispecifics, cancer/viral infections)', 'human bispecific antibodies (Biclonics, cancer)', 'HER family modulators (cancer)', 'zenocutuzumab']",zenocutuzumab,fexact,"['pb 4188', 'mcla 128', 'human therapeutic antibodies bispecifics cancer viral infections', 'human bispecific antibodies biclonics cancer', 'her family modulators cancer', 'zenocutuzumab']",correct_mapping
DSP-107,CD137 agonist; CD47 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor; Immune checkpoint stimulant,DSP-107,,DSP-107,dsp 107,fexact,"['dual CD47 checkpoint inhibitor/4-1BB costimulator (intravenous infusion, metastatic non small cell lung cancer/squamous cell carcinoma/advanced solid tumor)', 'SIRPalpha-4-1BBL', 'DSP-107']",DSP-107,fexact,"['dual cd47 checkpoint inhibitor 4 1bb costimulator intravenous infusion metastatic non small cell lung cancer squamous cell carcinoma advanced solid tumor', 'sirpalpha 4 1bbl', 'dsp 107']",correct_mapping
varlilumab,CD27 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,varlilumab,,varlilumab,varlilumab,fexact,"['CDX-1127', 'CD27-targeting human antibodies (cancer)', 'CD27 costimulator (cancer)', 'varlilumab']",varlilumab,fexact,"['cdx 1127', 'cd27 targeting human antibodies cancer', 'cd27 costimulator cancer', 'varlilumab']",correct_mapping
MIDRIX4-LUNG dendritic cell vaccine,Immunostimulant,MIDRIX4-LUNG dendritic cell vaccine,,,,0,['MIDRIX4-LUNG dendritic cell vaccine'],,0,[],0
MIDRIXNEO-LUNG dendritic cell vaccine,Immunostimulant,MIDRIXNEO-LUNG dendritic cell vaccine,,,,0,['MIDRIXNEO-LUNG dendritic cell vaccine'],,0,[],0
HH-2710,MAP kinase inhibitor,HH-2710,,HH-2710,hh 2710,fexact,"['erk1/2 inhibitor ( oral capsule, advanced tumors), /shanghai institute of materia medica of the chinese academy of sciences', 'erk1/2 inhibitor ( oral capsule, advanced tumors)', 'HH-2710']",HH-2710,fexact,"['erk1 2 inhibitor oral capsule advanced tumors shanghai institute of materia medica of the chinese academy of sciences', 'erk1 2 inhibitor oral capsule advanced tumors', 'hh 2710']",correct_mapping
nidanilimab,Interleukin 1 receptor accessory protein antagonist; Immunostimulant; Immuno-oncology therapy,nidanilimab,,nidanilimab,nidanilimab,fexact,"['nadunolimab', 'CAN-04', 'anti-IL1RAP antibody (leukemia)', 'nidanilimab', 'anti-IL1RAP mAb (leukemia/solid tumor)']",nidanilimab,fexact,"['nadunolimab', 'can 04', 'anti il1rap antibody leukemia', 'nidanilimab', 'anti il1rap mab leukemia solid tumor']",correct_mapping
REGN-5093,MET tyrosine kinase inhibitor,REGN-5093,,REGN-5093,regn 5093,fexact,['REGN-5093'],REGN-5093,fexact,['regn 5093'],correct_mapping
iodine-125 seeds,DNA inhibitor; Radiopharmaceutical,iodine-125 seeds,,,,0,['iodine-125 seeds'],,0,[],0
NGM-120,Growth and differentiation factor 15 antagonist; GDNF alpha like antagonist,NGM-120,,NGM-120,ngm 120,fexact,"['NGM-120', 'GFRAL antagonist monoclonal antibody (cachexia)']",NGM-120,fexact,"['ngm 120', 'gfral antagonist monoclonal antibody cachexia']",correct_mapping
BAY-2416964,Aryl hydrocarbon receptor antagonist,BAY-2416964,,BAY-2416964,bay 2416964,fexact,"['AhR inhibitor (advanced solid tumor)', 'BAY-2416964']",BAY-2416964,fexact,"['ahr inhibitor advanced solid tumor', 'bay 2416964']",correct_mapping
"docetaxel, Samyang",Tubulin inhibitor; Microtubule stimulant; Taxane,docetaxel,Samyang,"docetaxel (polymeric micelle, solid tumor)",docetaxel,fexact,"['docetaxel-PM', 'docetaxel (polymeric micelle, solid tumor)', 'Nanoxel-PM', 'docetaxel', 'SYP-0704A', 'Nanoxel']","docetaxel (polymeric micelle, solid tumor)",fexact,"['docetaxel pm', 'docetaxel polymeric micelle solid tumor', 'nanoxel pm', 'docetaxel', 'syp 0704a', 'nanoxel']",correct_mapping
JAB-3312,"Tyrosine phosphatase, non-receptor type 11 inhibitor",JAB-3312,,JAB-3312,jab 3312,fexact,"['JAB-3312', 'KRAS-MAPK pathway small molecule blocker (capsule formulation)', 'SHP2 inhibitor (oral, solid tumors), Jacobio Pharmaceuticals', 'SHP2 inhibitor (oral, solid tumors)', 'KRAS-MAPK pathway small molecule blocker (capsule formulation), Jacobio Pharmaceuticals']",JAB-3312,fexact,"['jab 3312', 'kras mapk pathway small molecule blocker capsule formulation', 'shp2 inhibitor oral solid tumors jacobio pharmaceuticals', 'shp2 inhibitor oral solid tumors', 'kras mapk pathway small molecule blocker capsule formulation jacobio pharmaceuticals']",correct_mapping
TPX-0046,RET tyrosine kinase inhibitor; Src inhibitor,TPX-0046,,TPX-0046,tpx 0046,fexact,"['TPX-0046', 'RET/SRC inhibitor (advanced solid tumor)']",TPX-0046,fexact,"['tpx 0046', 'ret src inhibitor advanced solid tumor']",correct_mapping
GB-1275,CD11b agonist,GB-1275,,GB-1275,gb 1275,fexact,"['integrin CD11b/CD18 agonists (oral, inflammation/cancer),/', 'ADH-503', 'integrin CD11b/CD18 agonists (oral, inflammation/cancer),/Gossamer', 'leukadherins', 'integrin CD11b/CD18 agonists (inflammation)', 'GB-1275', 'CD11b agonist (oral, inflammation/cancer),/', 'integrin CD11b/CD18 agonists (oral, inflammation/cancer)', 'CD11b agonist (oral, inflammation/cancer),/Gossamer']",GB-1275,fexact,"['integrin cd11b cd18 agonists oral inflammation cancer', 'adh 503', 'integrin cd11b cd18 agonists oral inflammation cancer gossamer', 'leukadherins', 'integrin cd11b cd18 agonists inflammation', 'gb 1275', 'cd11b agonist oral inflammation cancer', 'integrin cd11b cd18 agonists oral inflammation cancer', 'cd11b agonist oral inflammation cancer gossamer']",correct_mapping
donafenib,Raf kinase inhibitor; Tyrosine kinase inhibitor (TKI),donafenib,,"donafenib tosylate (oral tablet, cancer)",donafenib,fexact,"['CM-4307', 'Zepsun', 'donafenib', 'donafenib tosylate', 'zepusheng', 'donafenib tosylate (oral tablet, cancer)']","donafenib tosylate (oral tablet, cancer)",fexact,"['cm 4307', 'zepsun', 'donafenib', 'donafenib tosylate', 'zepusheng', 'donafenib tosylate oral tablet cancer']",correct_mapping
nintedanib,LYN tyrosine kinase inhibitor; FGF receptor tyrosine kinase inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Src inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor,nintedanib,,nintedanib,nintedanib,fexact,"['angiokinase inhibitors (cancer)', 'Vargatef', 'FGF/PDGF/VEGF receptor kinase inhibitors (cancer)', 'intedanib', 'Ofev', 'WeiJiaTe', 'nintedanib esylate', 'nintedanib ethanesulfonate', 'BIBF-1120 ES', 'nintedanib', 'Ofeb', 'BIBF-1120', 'Cyendiv']",nintedanib,fexact,"['angiokinase inhibitors cancer', 'vargatef', 'fgf pdgf vegf receptor kinase inhibitors cancer', 'intedanib', 'ofev', 'weijiate', 'nintedanib esylate', 'nintedanib ethanesulfonate', 'bibf 1120 es', 'nintedanib', 'ofeb', 'bibf 1120', 'cyendiv']",correct_mapping
poziotinib (tablet),ErbB-3 antagonist; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor,poziotinib,,poziotinib,poziotinib,fexact,"['poziotinib', 'NOV-1201', 'NOV-120101', 'pan-Her/EGFR inhibitors (cancer)', 'HM-78136B']",poziotinib,fexact,"['poziotinib', 'nov 1201', 'nov 120101', 'pan her egfr inhibitors cancer', 'hm 78136b']",correct_mapping
SGN-CD228A,Unidentified pharmacological activity,SGN-CD228A,,SGN-CD228A,sgn cd228a,fexact,"['SGN-CD228A', 'hL49-MMAE antibody-drug conjugate (solid tumors), Seattle Genetics', 'anti-CD228A antibody-drug conjugate (solid tumors), Seattle Genetics', 'ADC targeted to CD228 (cancer), Seattle Genetics', 'anti-melanotransferrin antibody drug conjugate (solid tumors), Seattle Genetics']",SGN-CD228A,fexact,"['sgn cd228a', 'hl49 mmae antibody drug conjugate solid tumors seattle genetics', 'anti cd228a antibody drug conjugate solid tumors seattle genetics', 'adc targeted to cd228 cancer seattle genetics', 'anti melanotransferrin antibody drug conjugate solid tumors seattle genetics']",correct_mapping
oxaliplatin,DNA inhibitor,oxaliplatin,,oxaliplatin,oxaliplatin,fexact,"['Dacplat', 'SR-96669', 'Eloxitin', '1670RB', 'Dacotin', 'NSC-266046', 'L-OHP', 'oxaliplatin', 'Elplat', 'RP-54780', 'Eloxatine', 'GSOX', 'Eloxatin', 'RP-54780, 1-OHP']",oxaliplatin,fexact,"['dacplat', 'sr 96669', 'eloxitin', '1670rb', 'dacotin', 'nsc 266046', 'l ohp', 'oxaliplatin', 'elplat', 'rp 54780', 'eloxatine', 'gsox', 'eloxatin', 'rp 54780 1 ohp']",correct_mapping
TPC-064,ErbB antagonist,TPC-064,,TAS-6417,tpc 064,fexact,"['CLN-081', 'mutant-selective egfr inhibitor (oral, cancer)', 'mutant-selective EGFR inhibitor (cancer)', 'mutant-selective egfr inhibitor (oral, cancer), taiho pharmaceutical', 'TAS-6417', 'mutant-selective EGFR inhibitor (cancer), Taiho Pharmaceutical', 'TPC-064']",TAS-6417,fexact,"['cln 081', 'mutant selective egfr inhibitor oral cancer', 'mutant selective egfr inhibitor cancer', 'mutant selective egfr inhibitor oral cancer taiho pharmaceutical', 'tas 6417', 'mutant selective egfr inhibitor cancer taiho pharmaceutical', 'tpc 064']",correct_mapping
ladiratuzumab vedotin,Tubulin inhibitor,ladiratuzumab vedotin,,ladiratuzumab vedotin,ladiratuzumab vedotin,fexact,"['anti-SLC39A6 mAb/monomethyl auristatin E ADC (cancer)', 'anti-Liv-1 antibody-drug conjugate (cancer), Seattle Genetics', 'ladiratuzumab vedotin', 'SGN-LIV1A', 'MK-6440', 'anti-SLC39A6 mAb/monomethyl auristatin E ADC (cancer), Seagen', 'anti-Liv-1 mAb/monomethyl auristatin E ADC (cancer), Seattle Genetics']",ladiratuzumab vedotin,fexact,"['anti slc39a6 mab monomethyl auristatin e adc cancer', 'anti liv 1 antibody drug conjugate cancer seattle genetics', 'ladiratuzumab vedotin', 'sgn liv1a', 'mk 6440', 'anti slc39a6 mab monomethyl auristatin e adc cancer seagen', 'anti liv 1 mab monomethyl auristatin e adc cancer seattle genetics']",correct_mapping
RG-7787,Mesothelin inhibitor,RG-7787,,,,0,"['MSLN-PE cFP', 'RG-7787', 'RO-6927005']",,NER_API,[],0
TmTN-MUC-01,T cell stimulant; Immuno-oncology therapy,TmTN-MUC-01,,,,0,['TmTN-MUC-01'],,0,[],0
ATSP-7041,MDM2 inhibitor; MDM4 inhibitor,ATSP-7041,,ALRN-6924,atsp 7041,fexact,"['dual MDM2/MDMX inhibitors (stapled peptides, p53-dependent cancers),/Roche', 'stapled p53 peptides (cancer),/Roche', 'ALRN-6924', 'dual MDM2/MDMX inhibitors (stapled peptides, p53-dependent cancers),/', 'ATSP-7041', 'stapled p53 peptides (cancer),/']",ALRN-6924,fexact,"['dual mdm2 mdmx inhibitors stapled peptides p53 dependent cancers roche', 'stapled p53 peptides cancer roche', 'alrn 6924', 'dual mdm2 mdmx inhibitors stapled peptides p53 dependent cancers', 'atsp 7041', 'stapled p53 peptides cancer']",correct_mapping
SOT-101,Interleukin 15 agonist,SOT-101,,SOT-101,sot 101,fexact,"['CYP-0150', 'RLI-15', 'SO-C101', 'RLI', 'SOT-101']",SOT-101,fexact,"['cyp 0150', 'rli 15', 'so c101', 'rli', 'sot 101']",correct_mapping
"bevacizumab, Zhejiang Teruisi Biopharma",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Zhejiang Teruisi Biopharma,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
ARS-3248,K-Ras inhibitor,ARS-3248,,ARS-3248,ars 3248,fexact,"['JNJ-74699157', 'K-Ras G12C inhibitor (oral, advanced solid tumors),/', 'ARS-3248', 'K-Ras G12C inhibitor (oral, advanced solid tumors), Araxes Pharma/', 'K-Ras G12C inhibitor (oral, advanced solid tumors), Wellspring Biosciences/']",ARS-3248,fexact,"['jnj 74699157', 'k ras g12c inhibitor oral advanced solid tumors', 'ars 3248', 'k ras g12c inhibitor oral advanced solid tumors araxes pharma', 'k ras g12c inhibitor oral advanced solid tumors wellspring biosciences']",correct_mapping
sonidegib,Hedgehog pathway inhibitor,sonidegib,,sonidegib (oral),sonidegib,fexact,"['LAB-687', 'sonidegib (oral)', 'SMO inhibitor (cancer)', 'NVP-LDE-225', 'LDE-255', 'sonidegib', 'sonidegib phosphate', 'Odomzo', 'erismodegib', 'LDE-225 (oral)', 'smoothened inhibitor (cancer)', 'erismodegib (oral)', 'LDE-225', 'NVP-LDE-225 (oral)']",sonidegib (oral),fexact,"['lab 687', 'sonidegib oral', 'smo inhibitor cancer', 'nvp lde 225', 'lde 255', 'sonidegib', 'sonidegib phosphate', 'odomzo', 'erismodegib', 'lde 225 oral', 'smoothened inhibitor cancer', 'erismodegib oral', 'lde 225', 'nvp lde 225 oral']",correct_mapping
pelcitoclax,Bcl2 inhibitor; Bcl-w inhibitor; Bcl-XL inhibitor,pelcitoclax,,pelcitoclax,pelcitoclax,fexact,"['APG-1252', 'a dual specific Bcl-2/Bcl-xL inhibitor (cancer),/University of Michigan', 'a dual specific bcl-2/bcl-xl inhibitor (cancer)', 'BM-1252', 'pelcitoclax']",pelcitoclax,fexact,"['apg 1252', 'a dual specific bcl 2 bcl xl inhibitor cancer university of michigan', 'a dual specific bcl 2 bcl xl inhibitor cancer', 'bm 1252', 'pelcitoclax']",correct_mapping
radium-223 dichloride,DNA inhibitor; Radiopharmaceutical,radium-223 dichloride,,radium-223 dichloride,radium 223 dichloride,fexact,"['radium-223 dichloride', 'ATI-BC-2', 'radium Ra 223 dichloride', 'BAY-88-8223', 'bone metastases therapy, Anticancer Therapeutic Inventions', 'radium-223 (bone metastases)', '223Ra-based alpha-particle emitting therapy (bone metastases)', 'Radium-223-chloride', '223Ra-chloride', 'Alpharadin', 'Xofigo']",radium-223 dichloride,fexact,"['radium 223 dichloride', 'ati bc 2', 'radium ra 223 dichloride', 'bay 88 8223', 'bone metastases therapy anticancer therapeutic inventions', 'radium 223 bone metastases', '223ra based alpha particle emitting therapy bone metastases', 'radium 223 chloride', '223ra chloride', 'alpharadin', 'xofigo']",correct_mapping
erlotinib (capsule),EGFR kinase inhibitor; Tyrosine kinase inhibitor (TKI),erlotinib,,erlotinib,erlotinib,fexact,"['erlotinib', 'CP-358774-01', 'RG-1415', 'OSI-774', 'erlotinib hydrochloride', 'angiogenesis therapy, OSI//Roche', 'angiogenesis therapy,//', 'angiogenesis therapy, OSI/Genentech/Roche', 'Ro-50-8231', 'NSC-718781', 'CP-358774', 'OSI-744', 'Tarceva', 'R-1415', 'OSI-420', 'angiogenesis therapy, OSI//']",erlotinib,fexact,"['erlotinib', 'cp 358774 01', 'rg 1415', 'osi 774', 'erlotinib hydrochloride', 'angiogenesis therapy osi roche', 'angiogenesis therapy', 'angiogenesis therapy osi genentech roche', 'ro 50 8231', 'nsc 718781', 'cp 358774', 'osi 744', 'tarceva', 'r 1415', 'osi 420', 'angiogenesis therapy osi']",correct_mapping
AB-16B5,IL2-inducible T-cell kinase inhibitor; Clusterin inhibitor; Immuno-oncology therapy,AB-16B5,,AB-16B5,ab 16b5,fexact,"['16B5', 'clusterin-specific antibodies (cancer)', 'clusterin-specific antibodies (cancer), National Research Council Biotechnology Research Institute/', 'secreted clusterin (sCLU)-targeting humanized monoclonal antibody (cancer)', 'clusterin-specific antibodies (cancer), National Research Council Biotechnology Research Institute/ International Biotechnology Center Generium', 'AB-16B5', 'clusterin-specific antibodies (cancer), National Research Council Biotechnology Research Institute', 'clusterin-specific antibodies (cancer), National Research Council of Canada']",AB-16B5,fexact,"['16b5', 'clusterin specific antibodies cancer', 'clusterin specific antibodies cancer national research council biotechnology research institute', 'secreted clusterin sclu targeting humanized monoclonal antibody cancer', 'clusterin specific antibodies cancer national research council biotechnology research institute international biotechnology center generium', 'ab 16b5', 'clusterin specific antibodies cancer national research council biotechnology research institute', 'clusterin specific antibodies cancer national research council of canada']",correct_mapping
serplulimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,serplulimab,,serplulimab,serplulimab,fexact,"['pd-1 checkpoint inhibitor (solid tumor)', 'anti-PD-1 mAb, Shanghai Henlius Biotech', 'PD-1 checkpoint inhibitor (solid tumor), Shanghai Henlius', 'PD-1 checkpoint inhibitor (solid tumor)', 'PD-1 checkpoint inhibitor (solid tumor),/ Kalbe Genexine Biologics', 'serplulimab', 'anti-PD-1 mAb (solid tumor),/ Kalbe Genexine Biologics', 'anti-PD-1 mAb', 'HLX-10', 'anti-pd-1 mab (solid tumor)']",serplulimab,fexact,"['pd 1 checkpoint inhibitor solid tumor', 'anti pd 1 mab shanghai henlius biotech', 'pd 1 checkpoint inhibitor solid tumor shanghai henlius', 'pd 1 checkpoint inhibitor solid tumor', 'pd 1 checkpoint inhibitor solid tumor kalbe genexine biologics', 'serplulimab', 'anti pd 1 mab solid tumor kalbe genexine biologics', 'anti pd 1 mab', 'hlx 10', 'anti pd 1 mab solid tumor']",correct_mapping
HL-085,Mitogen-activated kinase kinase inhibitor,HL-085,,HL-085,hl 085,fexact,"['HL-085', 'MEK inhibitor (cancer), Tianjin Binjiang Pharma']",HL-085,fexact,"['hl 085', 'mek inhibitor cancer tianjin binjiang pharma']",correct_mapping
ADP-A2M4CD8,T cell stimulant; Immuno-oncology therapy,ADP-A2M4CD8,,ADP-A2M4CD8,adp a2m4cd8,fexact,"['ADP-A2M4CD8', 'second-generation ADP-A2M4']",ADP-A2M4CD8,fexact,"['adp a2m4cd8', 'second generation adp a2m4']",correct_mapping
disitamab vedotin,ErbB-2 antagonist; Tubulin inhibitor,disitamab vedotin,,disitamab vedotin,disitamab vedotin,fexact,"['RC48-ADC', 'RC-48', 'anti-HER2 mAb-MMAE ADC (cancer), Yantai Rongchang Biotechnologies', 'anti-HER2 mAb-MMAE antibody drug conjugate (cancer), Yantai Rongchang Biotechnologies', 'aidixi', 'anti-HER2 mAb-MMAE antibody drug conjugate (cancer)', 'anti-HER2 mAb-MMAE ADC (cancer)', 'disitamab vedotin', 'weidixituo']",disitamab vedotin,fexact,"['rc48 adc', 'rc 48', 'anti her2 mab mmae adc cancer yantai rongchang biotechnologies', 'anti her2 mab mmae antibody drug conjugate cancer yantai rongchang biotechnologies', 'aidixi', 'anti her2 mab mmae antibody drug conjugate cancer', 'anti her2 mab mmae adc cancer', 'disitamab vedotin', 'weidixituo']",correct_mapping
Kanglaite injection,Unidentified pharmacological activity,Kanglaite injection,,,,0,['Kanglaite injection'],,0,[],0
undisclosed - platinum antineoplastic,Unidentified pharmacological activity,undisclosed - platinum antineoplastic,,,,0,['undisclosed - platinum antineoplastic'],,0,[],0
DZD-9008,EGFR kinase inhibitor,DZD-9008,,DZD-9008,dzd 9008,fexact,"['DZD-9008', 'EGFR tyrosine kinase inhibitor (cancer)', 'DZ-0586']",DZD-9008,fexact,"['dzd 9008', 'egfr tyrosine kinase inhibitor cancer', 'dz 0586']",correct_mapping
TQ-B3101,Anaplastic lymphoma kinase inhibitor; MET tyrosine kinase inhibitor; ROS receptor tyrosine kinase inhibitor,TQ-B3101,,TQ-B3101,tq b3101,fexact,['TQ-B3101'],TQ-B3101,fexact,['tq b3101'],correct_mapping
XZP-5809,EGFR kinase inhibitor,XZP-5809,,XZP-5809-TT1,xzp 5809,fexact,"['XZP-5809-TT1', 'epithelial growth factor receptor tyrosine kinase inhibitor (lung cancer), Sihuan pharmaceutical holdings group ltd.', 'XZP-5809']",XZP-5809-TT1,fexact,"['xzp 5809 tt1', 'epithelial growth factor receptor tyrosine kinase inhibitor lung cancer sihuan pharmaceutical holdings group ltd', 'xzp 5809']",correct_mapping
pevonedistat,Nedd 8 activating enzyme inhibitor,pevonedistat,,pevonedistat,pevonedistat,fexact,"['TAK-924', 'MLN-4924', 'pevonedistat hydrochloride', 'NAE inhibitor (cancer), Millennium', 'pevonedistat', 'NEDD8 activating enzyme inhibitor (cancer), Millennium']",pevonedistat,fexact,"['tak 924', 'mln 4924', 'pevonedistat hydrochloride', 'nae inhibitor cancer millennium', 'pevonedistat', 'nedd8 activating enzyme inhibitor cancer millennium']",correct_mapping
BI-754111,Lymphocyte-activation gene 3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,BI-754111,,BI-754111,bi 754111,fexact,"['LAG-3 checkpoint inhibitor (cancer)', 'miptenalimab', 'BI-754111']",BI-754111,fexact,"['lag 3 checkpoint inhibitor cancer', 'miptenalimab', 'bi 754111']",correct_mapping
BI-907828,MDM2 inhibitor,BI-907828,,BI-907828,bi 907828,fexact,"['MDM2 inhibitor (solid tumor)', 'BI-907828']",BI-907828,fexact,"['mdm2 inhibitor solid tumor', 'bi 907828']",correct_mapping
sacituzumab govitecan,DNA topoisomerase I inhibitor,sacituzumab govitecan,,sacituzumab govitecan,sacituzumab govitecan,fexact,"['humanized anti-TROP-2-SN-38 conjugate (cancer), Immunomedics', 'GS-0132', 'CL2-SN-38', 'sacituzumab govitecan', 'anti-EGP-1 mAB/SN-38 conjugate (cancer)', 'isactuzumab govitecan', 'hRS7-CL2A-SN-38', 'RS7-SN38', 'anti-EGP-1 mAB/SN-38 conjugate (cancer), Immunomedics', 'IMMU-132', 'hRS7-SN-38 conjugate', 'humanized anti-TROP-2-SN-38 conjugate (cancer)', 'hRS7-SN-38 (antibody conjugate, cancer)', 'sacituzumab govitecan-hziy', 'anti-TROP-2-SN-38', 'hRS7-SN-38 (antibody conjugate, cancer), Immunomedics', 'Trodelvy']",sacituzumab govitecan,fexact,"['humanized anti trop 2 sn 38 conjugate cancer immunomedics', 'gs 0132', 'cl2 sn 38', 'sacituzumab govitecan', 'anti egp 1 mab sn 38 conjugate cancer', 'isactuzumab govitecan', 'hrs7 cl2a sn 38', 'rs7 sn38', 'anti egp 1 mab sn 38 conjugate cancer immunomedics', 'immu 132', 'hrs7 sn 38 conjugate', 'humanized anti trop 2 sn 38 conjugate cancer', 'hrs7 sn 38 antibody conjugate cancer', 'sacituzumab govitecan hziy', 'anti trop 2 sn 38', 'hrs7 sn 38 antibody conjugate cancer immunomedics', 'trodelvy']",correct_mapping
autologous natural killer cells,Immunostimulant,autologous natural killer cells,,,,0,['autologous natural killer cells'],,0,[],0
zoledronic acid,Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor,zoledronic acid,,zoledronic acid,zoledronic acid,fexact,"['zoledronic acid', 'Aclasta', 'Reclast', 'CGP-42446', 'CGP-42446A', 'zoledronate disodium', 'ZOL-446', 'Zometa', 'AK-156', 'zoledronate', 'zoledronate trisodium']",zoledronic acid,fexact,"['zoledronic acid', 'aclasta', 'reclast', 'cgp 42446', 'cgp 42446a', 'zoledronate disodium', 'zol 446', 'zometa', 'ak 156', 'zoledronate', 'zoledronate trisodium']",correct_mapping
denosumab,RANKL antagonist; Osteoclast inhibitor; Bone resorption inhibitor,denosumab,,denosumab,denosumab,fexact,"['denosumab', 'Xgeva', 'anti-RANK-L mAb (bone diseases, rheumatoid arthritis)', 'RANK-L antagonist (monoclonal antibody)', 'Pralia', 'Ranmark', 'Prolia', 'AMG-162']",denosumab,fexact,"['denosumab', 'xgeva', 'anti rank l mab bone diseases rheumatoid arthritis', 'rank l antagonist monoclonal antibody', 'pralia', 'ranmark', 'prolia', 'amg 162']",correct_mapping
SGN-CD47M,Unidentified pharmacological activity,SGN-CD47M,,SGN-CD47M,sgn cd47m,fexact,"['SGN-CD47M', 'CD47 checkpoint inhibitor (solid tumors), Seattle Genetics']",SGN-CD47M,fexact,"['sgn cd47m', 'cd47 checkpoint inhibitor solid tumors seattle genetics']",correct_mapping
TPX-0022,Colony stimulating factor 1 receptor antagonist; MET tyrosine kinase inhibitor; Src inhibitor; Immuno-oncology therapy,TPX-0022,,TPX-0022,tpx 0022,fexact,"['TPX-02226', 'MET/CSF1R/SRC inhibitor (advanced solid tumor)', 'TPX-0022']",TPX-0022,fexact,"['tpx 02226', 'met csf1r src inhibitor advanced solid tumor', 'tpx 0022']",correct_mapping
"bevacizumab, Henlius Biopharmaceuticals",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Henlius Biopharmaceuticals,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
SLATE-001,T cell stimulant; Immuno-oncology therapy,SLATE-001,,SLATE-001,slate 001,fexact,"['tumor-specific neo-antigen therapy (cancer)', 'GRT-C903', 'SLATE', 'personalized shared neoantigen-based prime-boost cancer vaccine (im, advanced solid tumor)', 'GRT-C903/GRT-R904', 'GRT-R904', 'SLATE-001']",SLATE-001,fexact,"['tumor specific neo antigen therapy cancer', 'grt c903', 'slate', 'personalized shared neoantigen based prime boost cancer vaccine im advanced solid tumor', 'grt c903 grt r904', 'grt r904', 'slate 001']",correct_mapping
PD-1 monoclonal antibody-activated autologous peripheral blood T-lymphocyte,Unidentified pharmacological activity,PD-1 monoclonal antibody-activated autologous peripheral blood T-lymphocyte,,,,0,['PD-1 monoclonal antibody-activated autologous peripheral blood T-lymphocyte'],,0,[],0
romiplostim (SC),Thrombopoietin agonist,romiplostim,,romiplostim,romiplostim,fexact,"['thrombopoietin agonist peptibody (thrombocytopenia)', 'Romiplate', 'romiplostim', 'Mpl-binding peptibody (thrombocytopenia)', 'Nplate', 'AMG-531']",romiplostim,fexact,"['thrombopoietin agonist peptibody thrombocytopenia', 'romiplate', 'romiplostim', 'mpl binding peptibody thrombocytopenia', 'nplate', 'amg 531']",correct_mapping
"PSCA targeted bispecific antibody, GEMoaB Monoclonals",Immuno-oncology therapy,PSCA targeted bispecific antibody,GEMoaB Monoclonals,,,0,['PSCA targeted bispecific antibody'],,0,[],0
GEN-1046,CD137 agonist; PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor; Immune checkpoint stimulant,GEN-1046,,GEN-1046,gen 1046,fexact,"['BNT-311', 'dual PD-L1 checkpoint inhibitor/4-1BB costimulator (DuoBody, cancer), Genmab/', 'DuoBody-PD-L1x4-1BB', 'dual PD-L1 checkpoint inhibitor/4-1BB costimulator (DuoBody, cancer),/', 'bispecific PD-L1 x 4-1BB targeting antibody (DuoBody, cancer),/', 'GEN-1046', 'bispecific PD-L1 x 4-1BB targeting antibody (DuoBody, cancer), Genmab/']",GEN-1046,fexact,"['bnt 311', 'dual pd l1 checkpoint inhibitor 4 1bb costimulator duobody cancer genmab', 'duobody pd l1x4 1bb', 'dual pd l1 checkpoint inhibitor 4 1bb costimulator duobody cancer', 'bispecific pd l1 x 4 1bb targeting antibody duobody cancer', 'gen 1046', 'bispecific pd l1 x 4 1bb targeting antibody duobody cancer genmab']",correct_mapping
MK-0482,Unidentified pharmacological activity,MK-0482,,MK-0482,mk 0482,fexact,"['MK-0482', 'anticancer mAb (iv, advanced solid tumors)']",MK-0482,fexact,"['mk 0482', 'anticancer mab iv advanced solid tumors']",correct_mapping
BDB-001,Toll-like receptor (TLR) agonist; Immuno-oncology therapy,BDB-001,,BDB-1,bdb 001,fexact,"['anti-human complement factor C5a monoclonal antibody (intravenous infusion/IFX-1, hidradenitis suppurativa/coronavirus disease 19 infection)', 'BDB-001', 'BDB-1', 'anti-C5aR monoclonal antibody (intravenous infusion/IFX-1, hidradenitis suppurativa/COVID-19/advanced solid tumors)', 'anti-C5aR monoclonal antibody (intravenous infusion/IFX-1, hidradenitis suppurativa/COVID-19)']",BDB-1,fexact,"['anti human complement factor c5a monoclonal antibody intravenous infusion ifx 1 hidradenitis suppurativa coronavirus disease 19 infection', 'bdb 001', 'bdb 1', 'anti c5ar monoclonal antibody intravenous infusion ifx 1 hidradenitis suppurativa covid 19 advanced solid tumors', 'anti c5ar monoclonal antibody intravenous infusion ifx 1 hidradenitis suppurativa covid 19']",correct_mapping
APG-2449,Anaplastic lymphoma kinase inhibitor; Focal adhesion kinase inhibitor; ROS receptor tyrosine kinase inhibitor,APG-2449,,APG-2449,apg 2449,fexact,['APG-2449'],APG-2449,fexact,['apg 2449'],correct_mapping
MK-6018,CD66a antagonist; Immuno-oncology therapy,MK-6018,,CM-24,mk 6018,fexact,"['humanized monoclonal IgG4 antibody (non small cell lung cancer/Metastatic pancreas cancer/Stage IV melanoma/Metastatic colorectal cancer/Metastatic ovary cancer/Papillary thyroid tumor/Adenocarcinoma), Purple Biotech', 'CEACAM-1 checkpoint inhibitor (cancer), cCAM Biotherapeutics', 'humanized monoclonal IgG4 antibody (non small cell lung cancer), Kitov Pharmaceuticals', 'Anti-CEACAM1 antibody (cancer), cCAM', 'CM-10', 'ceacam-1 checkpoint inhibitor (cancer)', 'CM-24', 'MK-6018', 'humanized monoclonal IgG4 antibody (cancer)', 'Anti-CEACAM1 antibody (cancer)', 'humanized monoclonal IgG4 antibody (non small cell lung cancer/Metastatic pancreas cancer/Stage IV melanoma/Metastatic colorectal cancer/Metastatic ovary cancer/Papillary thyroid tumor/Adenocarcinoma)', 'humanized monoclonal IgG4 antibody (cancer), cCAM']",CM-24,fexact,"['humanized monoclonal igg4 antibody non small cell lung cancer metastatic pancreas cancer stage iv melanoma metastatic colorectal cancer metastatic ovary cancer papillary thyroid tumor adenocarcinoma purple biotech', 'ceacam 1 checkpoint inhibitor cancer ccam biotherapeutics', 'humanized monoclonal igg4 antibody non small cell lung cancer kitov pharmaceuticals', 'anti ceacam1 antibody cancer ccam', 'cm 10', 'ceacam 1 checkpoint inhibitor cancer', 'cm 24', 'mk 6018', 'humanized monoclonal igg4 antibody cancer', 'anti ceacam1 antibody cancer', 'humanized monoclonal igg4 antibody non small cell lung cancer metastatic pancreas cancer stage iv melanoma metastatic colorectal cancer metastatic ovary cancer papillary thyroid tumor adenocarcinoma', 'humanized monoclonal igg4 antibody cancer ccam']",correct_mapping
losartan potassium (tablet),Angiotensin II 1 antagonist,losartan potassium,,losartan,losartan potassium,fexact,"['Cozaar', 'Avastar', 'Entrizen', 'MK-954', 'E-3340', 'E-3174', 'losartan', 'EXP-3174', 'Cozaar Plus F', 'losartan potassium', 'MK-0954', 'DuP-753', 'DUP-89', 'Nu-Lotan']",losartan,fexact,"['cozaar', 'avastar', 'entrizen', 'mk 954', 'e 3340', 'e 3174', 'losartan', 'exp 3174', 'cozaar plus f', 'losartan potassium', 'mk 0954', 'dup 753', 'dup 89', 'nu lotan']",correct_mapping
"personalized mRNA tumour vaccine, Stemirna Therapeutics",Immunostimulant,personalized mRNA tumour vaccine,Stemirna Therapeutics,,,0,['personalized mRNA tumour vaccine'],,0,[],0
SY-5609,Cyclin-dependent kinase 7 inhibitor,SY-5609,,SY-5609,sy 5609,fexact,"['SY-5102', 'cdk7 inhibitor (oral, cancer)', 'cdk7 inhibitor (oral, breast cancer)', 'SY-5609']",SY-5609,fexact,"['sy 5102', 'cdk7 inhibitor oral cancer', 'cdk7 inhibitor oral breast cancer', 'sy 5609']",correct_mapping
anti PD-1 antibody-activated TILs,Unidentified pharmacological activity,anti PD-1 antibody-activated TILs,,,,0,['anti PD-1 antibody-activated TILs'],,0,[],0
SL-279252,Tumour necrosis factor ligand 4 agonist; PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor; Immune checkpoint stimulant,SL-279252,,SL-279252,sl 279252,fexact,"['dual PD-L1 checkpoint inhibitor/OX40 costimulator (ARC, cancer),/Takeda', 'TAK-252', 'SL-279252', 'PD-1 x OX40L (Agonist Redirected Checkpoint, cancer),/Takeda', 'PD1-Fc-OX40L (cancer)', 'dual PD-L1 checkpoint inhibitor/OX40 costimulator (ARC, cancer),/', 'PD-1 x OX40L (Agonist Redirected Checkpoint, cancer),/']",SL-279252,fexact,"['dual pd l1 checkpoint inhibitor ox40 costimulator arc cancer takeda', 'tak 252', 'sl 279252', 'pd 1 x ox40l agonist redirected checkpoint cancer takeda', 'pd1 fc ox40l cancer', 'dual pd l1 checkpoint inhibitor ox40 costimulator arc cancer', 'pd 1 x ox40l agonist redirected checkpoint cancer']",correct_mapping
budigalimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,budigalimab,,budigalimab,budigalimab,fexact,"['budigalimab', 'anticancer monoclonal antibody (iv, ovarian cancer/solid tumor/SCLC)', 'anticancer mabs (iv, ovarian cancer/solid tumor)', 'budigalimab (HIV-1 infection)', 'budigalimab (cancer)', 'PD-1 checkpoint inhibitor (cancer)', 'ABBV-181']",budigalimab,fexact,"['budigalimab', 'anticancer monoclonal antibody iv ovarian cancer solid tumor sclc', 'anticancer mabs iv ovarian cancer solid tumor', 'budigalimab hiv 1 infection', 'budigalimab cancer', 'pd 1 checkpoint inhibitor cancer', 'abbv 181']",correct_mapping
ABBV-368,CD134 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,ABBV-368,,ABBV-368,abbv 368,fexact,"['ABBV-368', 'revdofilimab', 'OX40 costimulator (solid tumor)']",ABBV-368,fexact,"['abbv 368', 'revdofilimab', 'ox40 costimulator solid tumor']",correct_mapping
ABBV-927 (intravenous),CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,ABBV-927,,ABBV-927,abbv 927,fexact,"['ABBV-927', 'giloralimab', 'CD40 costimulator (solid tumors)', 'anti-CD40 monoclonal antibody (solid tumors)']",ABBV-927,fexact,"['abbv 927', 'giloralimab', 'cd40 costimulator solid tumors', 'anti cd40 monoclonal antibody solid tumors']",correct_mapping
DKY-709,IKAROS family zinc finger 2 inhibitor,DKY-709,,DKY-709,dky 709,fexact,"['DKY-709', 'IKZF2 degrader (advanced solid tumor)']",DKY-709,fexact,"['dky 709', 'ikzf2 degrader advanced solid tumor']",correct_mapping
SRK-181,Transforming growth factor beta 1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,SRK-181,,SRK-181,srk 181,fexact,"['tgf-beta-1 inhibitors (cancer)', 'SRK-181', 'tgf-beta-1 inhibitors (cancer), scholar rock']",SRK-181,fexact,"['tgf beta 1 inhibitors cancer', 'srk 181', 'tgf beta 1 inhibitors cancer scholar rock']",correct_mapping
BBT-176,Pellino E3 ubiquitin protein ligase 1 inhibitor,BBT-176,,BBT-176,bbt 176,fexact,"['epidermal growth factor receptor-tyrosine kinase inhibitor (oral, NSCLC)', 'epidermal growth factor receptor-tyrosine kinase inhibitor (NSCLC), Korea Research Institute of Chemical Technology/', 'BBT-176', 'epidermal growth factor receptor-tyrosine kinase inhibitor (nsclc)']",BBT-176,fexact,"['epidermal growth factor receptor tyrosine kinase inhibitor oral nsclc', 'epidermal growth factor receptor tyrosine kinase inhibitor nsclc korea research institute of chemical technology', 'bbt 176', 'epidermal growth factor receptor tyrosine kinase inhibitor nsclc']",correct_mapping
vitamin A,Reducing agent,vitamin A,,,,0,['vitamin A'],,0,[],0
SBT-6050,Toll-like receptor 8 agonist; Immuno-oncology therapy,SBT-6050,,SBT-6050,sbt 6050,fexact,"['TLR8 agonist\xa0conjugated mAb (systemic, HER2-expressing tumors)', 'SBT-6050']",SBT-6050,fexact,"['tlr8 agonist\xa0conjugated mab systemic her2 expressing tumors', 'sbt 6050']",correct_mapping
GEN-011,T cell stimulant; Immuno-oncology therapy,GEN-011,,GEN-011,gen 011,fexact,"['adoptive T-cell therapy (cancer)', 'GEN-011']",GEN-011,fexact,"['adoptive t cell therapy cancer', 'gen 011']",correct_mapping
CPL-304-110,FGF receptor tyrosine kinase inhibitor,CPL-304-110,,CPL-304-110,cpl 304 110,fexact,"['CPL-304-110', 'fibroblast growth factor receptor inhibitor (gastric cancer/bladder cancer/squamous non-small cell lung cancer/cholangiocarcinoma/sarcoma/endometrial/ovarian cancer)', 'fibroblast growth factor receptor inhibitor (advanced solid malignancies)', 'PG-19']",CPL-304-110,fexact,"['cpl 304 110', 'fibroblast growth factor receptor inhibitor gastric cancer bladder cancer squamous non small cell lung cancer cholangiocarcinoma sarcoma endometrial ovarian cancer', 'fibroblast growth factor receptor inhibitor advanced solid malignancies', 'pg 19']",correct_mapping
cobicistat,Cytochrome P450 inhibitor,cobicistat,,cobicistat,cobicistat,fexact,"['Tybost', 'GS-9350', 'antiretroviral boosting agent,/ Japan Tobacco', 'antiretroviral boosting agent,/', 'antiretroviral boosting agent', 'cobicistat']",cobicistat,fexact,"['tybost', 'gs 9350', 'antiretroviral boosting agent japan tobacco', 'antiretroviral boosting agent', 'antiretroviral boosting agent', 'cobicistat']",correct_mapping
abivertinib,ErbB tyrosine kinase inhibitor,abivertinib,,abivertinib,abivertinib,fexact,"['ACEA-0010', 'AC-0010-MA', 'abivertinib', 'AC-010', 'aiweitini', 'avitinib', 'EGFR inhibitors (oral, cancer)', 'AC-0010', 'abivertinib maleate', 'STI-5656']",abivertinib,fexact,"['acea 0010', 'ac 0010 ma', 'abivertinib', 'ac 010', 'aiweitini', 'avitinib', 'egfr inhibitors oral cancer', 'ac 0010', 'abivertinib maleate', 'sti 5656']",correct_mapping
PF-06939999,Protein arginine methyltransferase 5 inhibitor,PF-06939999,,PF-06939999,pf 06939999,fexact,"['PF-06939999', 'PF-06855800', 'PRMT5 inhibitors (cancer)']",PF-06939999,fexact,"['pf 06939999', 'pf 06855800', 'prmt5 inhibitors cancer']",correct_mapping
SG-001,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,SG-001,,SG-001,sg 001,fexact,"['PD-1 checkpoint inhibitor (advanced solid tumors),/', 'PD-1 checkpoint inhibitor (advanced solid tumors),/Hangzhou Sumgen Biotechnology', 'SYSA-1802', 'PD-1 checkpoint inhibitor (cancer)', 'SG-001', 'PD-1 checkpoint inhibitor (cancer), Hangzhou Sumgen Biotechnology']",SG-001,fexact,"['pd 1 checkpoint inhibitor advanced solid tumors', 'pd 1 checkpoint inhibitor advanced solid tumors hangzhou sumgen biotechnology', 'sysa 1802', 'pd 1 checkpoint inhibitor cancer', 'sg 001', 'pd 1 checkpoint inhibitor cancer hangzhou sumgen biotechnology']",correct_mapping
vorolanib,Colony stimulating factor 1 receptor antagonist; Platelet-derived growth factor receptor kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor,vorolanib,,vorolanib,vorolanib,fexact,"['vegfr and pdgfr tyrosine kinase inhibitor (age-related macular degeneration), /xcovery vision', 'X-82', 'vegfr and pdgfr tyrosine kinase inhibitor (age-related macular degeneration)', 'EYP-1901', 'CM-082', 'vorolanib', 'vegfr and pdgfr tyrosine kinase inhibitor (age-related macular degeneration),/xcovery vision', 'VEGFR and PDGFR tyrosine kinase inhibitor (age-related macular degeneration), Tyrogenex/Xcovery Vision']",vorolanib,fexact,"['vegfr and pdgfr tyrosine kinase inhibitor age related macular degeneration xcovery vision', 'x 82', 'vegfr and pdgfr tyrosine kinase inhibitor age related macular degeneration', 'eyp 1901', 'cm 082', 'vorolanib', 'vegfr and pdgfr tyrosine kinase inhibitor age related macular degeneration xcovery vision', 'vegfr and pdgfr tyrosine kinase inhibitor age related macular degeneration tyrogenex xcovery vision']",correct_mapping
obinutuzumab,CD20 antagonist; Immuno-oncology therapy,obinutuzumab,,obinutuzumab,obinutuzumab,fexact,"['GA-101', 'Gazyva', 'Gasseba', 'afutuzumab', 'Gazyvaro', 'anti-CD20 humanized mAb (GlycoMAb)', 'anti-CD20 humanized mAb (GlycoMAb), Glycart', 'R-7159', 'RO-5072759', 'obinutuzumab', 'RG-7159']",obinutuzumab,fexact,"['ga 101', 'gazyva', 'gasseba', 'afutuzumab', 'gazyvaro', 'anti cd20 humanized mab glycomab', 'anti cd20 humanized mab glycomab glycart', 'r 7159', 'ro 5072759', 'obinutuzumab', 'rg 7159']",correct_mapping
rucaparib,Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor; Poly ADP ribose polymerase 3 inhibitor,rucaparib,,"rucaparib camsylate (oral, solid tumors)",rucaparib,fexact,"['rucaparib camsylate (oral, solid tumors)', 'rucaparib camsylate (oral, solid tumors), Clovis', 'Rubraca', 'rucaparib camsylate', 'rucaparib', 'CO-338']","rucaparib camsylate (oral, solid tumors)",fexact,"['rucaparib camsylate oral solid tumors', 'rucaparib camsylate oral solid tumors clovis', 'rubraca', 'rucaparib camsylate', 'rucaparib', 'co 338']",correct_mapping
LR-19125,Immunostimulant; Immuno-oncology therapy,LR-19125,,,,0,['LR-19125'],,0,[],0
monalizumab,Natural killer cell group 2A inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor,monalizumab,,monalizumab,monalizumab,fexact,"['Natural killer cell agonist (NK Platform, cancer),/Novo Nordisk', 'NKG2A checkpoint inhibitor (iv, cancer),/', 'NN-8765', 'NKG2A checkpoint inhibitor (iv, cancer)', 'IPH-22XX', 'NNC-0141-0000-0100', 'Anti-NKG2a (rheumatoid athritis),/', 'Natural killer cell agonist (NK Platform, cancer),/', 'Natural killer cell agonist (NK Platform, cancer), Innate Pharma/Novo Nordisk', 'NNC-141-0100', 'Anti-NKG2a (rheumatoid athritis), Novo Nordisk/Innate', 'monalizumab', 'NKG2A checkpoint inhibitor (iv, metastatic HER2 positive breast cancer)', 'IPH-2201', 'NKG2A checkpoint inhibitor (iv, cancer), Innate Pharma/', 'NN8765-3658', 'Anti-NKG2a (rheumatoid athritis), Novo Nordisk/']",monalizumab,fexact,"['natural killer cell agonist nk platform cancer novo nordisk', 'nkg2a checkpoint inhibitor iv cancer', 'nn 8765', 'nkg2a checkpoint inhibitor iv cancer', 'iph 22xx', 'nnc 0141 0000 0100', 'anti nkg2a rheumatoid athritis', 'natural killer cell agonist nk platform cancer', 'natural killer cell agonist nk platform cancer innate pharma novo nordisk', 'nnc 141 0100', 'anti nkg2a rheumatoid athritis novo nordisk innate', 'monalizumab', 'nkg2a checkpoint inhibitor iv metastatic her2 positive breast cancer', 'iph 2201', 'nkg2a checkpoint inhibitor iv cancer innate pharma', 'nn8765 3658', 'anti nkg2a rheumatoid athritis novo nordisk']",correct_mapping
lenvatinib,RET tyrosine kinase inhibitor; C-kit inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor; Platelet-derived growth factor receptor alpha kinase inhib; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor; Angiopoietin inhibitor,lenvatinib,,lenvatinib mesylate,lenvatinib,fexact,"['lenvatinib mesylate', 'KN-581', 'Lenvima', 'E-7080', 'lenvatinib', 'MK-7902', 'Kisplyx', 'ER-203492-00']",lenvatinib mesylate,fexact,"['lenvatinib mesylate', 'kn 581', 'lenvima', 'e 7080', 'lenvatinib', 'mk 7902', 'kisplyx', 'er 203492 00']",correct_mapping
TPST-1120,Peroxisome proliferator-activated receptor alpha antagonist,TPST-1120,,TPST-1120,tpst 1120,fexact,"['TPST-1120', 'NXT-629', 'PPAR alpha antagonist (cancer), Inception Sciences', 'PPAR alpha antagonist (cancer)', 'PPAR alpha antagonist (cancer), Tempest Therapeutics']",TPST-1120,fexact,"['tpst 1120', 'nxt 629', 'ppar alpha antagonist cancer inception sciences', 'ppar alpha antagonist cancer', 'ppar alpha antagonist cancer tempest therapeutics']",correct_mapping
papaverine,Phosphodiesterase inhibitor,papaverine,,,,0,['papaverine'],,0,[],0
monalizumab (IV),Natural killer cell group 2A inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor,monalizumab,,monalizumab,monalizumab,fexact,"['Natural killer cell agonist (NK Platform, cancer),/Novo Nordisk', 'NKG2A checkpoint inhibitor (iv, cancer),/', 'NN-8765', 'NKG2A checkpoint inhibitor (iv, cancer)', 'IPH-22XX', 'NNC-0141-0000-0100', 'Anti-NKG2a (rheumatoid athritis),/', 'Natural killer cell agonist (NK Platform, cancer),/', 'Natural killer cell agonist (NK Platform, cancer), Innate Pharma/Novo Nordisk', 'NNC-141-0100', 'Anti-NKG2a (rheumatoid athritis), Novo Nordisk/Innate', 'monalizumab', 'NKG2A checkpoint inhibitor (iv, metastatic HER2 positive breast cancer)', 'IPH-2201', 'NKG2A checkpoint inhibitor (iv, cancer), Innate Pharma/', 'NN8765-3658', 'Anti-NKG2a (rheumatoid athritis), Novo Nordisk/']",monalizumab,fexact,"['natural killer cell agonist nk platform cancer novo nordisk', 'nkg2a checkpoint inhibitor iv cancer', 'nn 8765', 'nkg2a checkpoint inhibitor iv cancer', 'iph 22xx', 'nnc 0141 0000 0100', 'anti nkg2a rheumatoid athritis', 'natural killer cell agonist nk platform cancer', 'natural killer cell agonist nk platform cancer innate pharma novo nordisk', 'nnc 141 0100', 'anti nkg2a rheumatoid athritis novo nordisk innate', 'monalizumab', 'nkg2a checkpoint inhibitor iv metastatic her2 positive breast cancer', 'iph 2201', 'nkg2a checkpoint inhibitor iv cancer innate pharma', 'nn8765 3658', 'anti nkg2a rheumatoid athritis novo nordisk']",correct_mapping
AFM-24_I,EGFR antagonist; CD16 antagonist; Immuno-oncology therapy,AFM-24_I,,,,0,"['anti-CD16A/anti-EGFR bispecific NK-cell engager (TandAb, cancer)', 'EGFR/CD16A antibodies (solid tumors), Affimed GmbH', 'anti-CD16A/anti-EGFR bispecific immune-cell engager (TandAb, cancer)', 'ICE (Affimed’s innate cell engager)', 'AFM-24']",,Drug_API_mapping,[],0
danvatirsen,STAT transcription factor 3 inhibitor,danvatirsen,,danvatirsen,danvatirsen,fexact,"['IONIS-STAT3-2.5Rx', 'AZD-9150', 'STAT-3-targeting antisense oligonucleotide (cancer), Ionis Pharmaceuticals', 'STAT-3-targeting antisense oligonucleotide (cancer)', 'ISIS-STAT3Rx', 'danvatirsen', 'ISIS-481464', 'STAT-3-targeting antisense oligonucleotide (cancer), Isis', 'STAT3-ASO', 'ISIS-STAT3-2.5Rx']",danvatirsen,fexact,"['ionis stat3 2 5rx', 'azd 9150', 'stat 3 targeting antisense oligonucleotide cancer ionis pharmaceuticals', 'stat 3 targeting antisense oligonucleotide cancer', 'isis stat3rx', 'danvatirsen', 'isis 481464', 'stat 3 targeting antisense oligonucleotide cancer isis', 'stat3 aso', 'isis stat3 2 5rx']",correct_mapping
MEDI-5752,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,MEDI-5752,,tovetumab,medi 575,fuzzy,"['anti-PDGFR-alpha modulators (iv infusion, cancer)', 'platelet derived growth factor receptor alpha modulators (cancer)', 'tovetumab', 'MEDI-575']",tovetumab,fexact,"['anti pdgfr alpha modulators iv infusion cancer', 'platelet derived growth factor receptor alpha modulators cancer', 'tovetumab', 'medi 575']",incorrect_mapping
MEDI-7247,DNA inhibitor,MEDI-7247,,MEDI-7247,medi 7247,fexact,"['anti-ASCT2 mAb-tesirine', 'anti-ASCT2 mAb-SG-3249', 'MEDI-7247']",MEDI-7247,fexact,"['anti asct2 mab tesirine', 'anti asct2 mab sg 3249', 'medi 7247']",correct_mapping
cyclophosphamide,Immunosuppressant; DNA inhibitor,cyclophosphamide,,cyclophosphamide monohydrate,cyclophosphamide,fexact,"['Endoxan', 'cyclophosphamide monohydrate', 'cyclophosphamide']",cyclophosphamide monohydrate,fexact,"['endoxan', 'cyclophosphamide monohydrate', 'cyclophosphamide']",correct_mapping
TVB-2640,Fatty acid synthase inhibitor,TVB-2640,,TVB-2640,tvb 2640,fexact,"['TVB-3199', 'FASN inhibitors (HCV infection), 3-V Biosciences Inc', 'TVB-3150', 'TVB-3693', 'fatty acid synthase modulators (HCV infection), 3-V Biosciences Inc', 'ASC-40', 'TVB-3166', 'FASN inhibitors (cancer/HCV/RSV/HSV infection), 3-V Biosciences Inc', 'TVB-3664', 'small molecule inhibitor (viral infection), 3-V Biosciences', 'TVB-2640']",TVB-2640,fexact,"['tvb 3199', 'fasn inhibitors hcv infection 3 v biosciences inc', 'tvb 3150', 'tvb 3693', 'fatty acid synthase modulators hcv infection 3 v biosciences inc', 'asc 40', 'tvb 3166', 'fasn inhibitors cancer hcv rsv hsv infection 3 v biosciences inc', 'tvb 3664', 'small molecule inhibitor viral infection 3 v biosciences', 'tvb 2640']",correct_mapping
"bevacizumab, Innovent Biologics",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Innovent Biologics,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
vitamin C,Reducing agent; Vitamin C agonist,vitamin C,,,,0,['vitamin C'],,0,[],0
"bevacizumab, Sinocelltech",Vascular endothelial growth factor (VEGF)receptor antagonist,bevacizumab,Sinocelltech,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
palupiprant,Prostaglandin EP4 receptor antagonist,palupiprant,,,,0,['palupiprant'],,0,[],0
Agerafenib,EGFR antagonist; RET tyrosine kinase inhibitor; B-raf kinase inhibitor,Agerafenib,,agerafenib hydrochloride,agerafenib,fexact,"['agerafenib hydrochloride', 'AB-024', 'RXDX-105', 'B-RAF kinase inhibitors (melanoma),/', 'B-RAF kinase inhibitors (melanoma),/Cephalon', 'CEP-32496', 'agerafenib']",agerafenib hydrochloride,fexact,"['agerafenib hydrochloride', 'ab 024', 'rxdx 105', 'b raf kinase inhibitors melanoma', 'b raf kinase inhibitors melanoma cephalon', 'cep 32496', 'agerafenib']",correct_mapping
savolitinib (tablet),MET tyrosine kinase inhibitor,savolitinib,,savolitinib,savolitinib,fexact,"['c-Met inhibitor (cancer), Hutchison', 'savolitinib', 'HM-5016504', 'Orpathys', 'Volitinib', 'HMPL-504', 'AZD-6094', 'wolitini', 'c-Met inhibitor (cancer)']",savolitinib,fexact,"['c met inhibitor cancer hutchison', 'savolitinib', 'hm 5016504', 'orpathys', 'volitinib', 'hmpl 504', 'azd 6094', 'wolitini', 'c met inhibitor cancer']",correct_mapping
TCR-T cells,Immunostimulant; Immuno-oncology therapy,TCR-T cells,,,,0,['TCR-T cells'],,0,[],0
BOS-172738,RET tyrosine kinase inhibitor,BOS-172738,,BOS-172738,bos 172738,fexact,"['ret inhibitor (cancer), daiichi sankyo', 'ret inhibitor (cancer)', 'DS-5010', 'BOS-172738']",BOS-172738,fexact,"['ret inhibitor cancer daiichi sankyo', 'ret inhibitor cancer', 'ds 5010', 'bos 172738']",correct_mapping
SCT-200,EGFR antagonist; Immuno-oncology therapy,SCT-200,,SCT-200,sct 200,fexact,"['SCT-200', 'recombinant humanized anti-hEGFR mAb', 'recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody']",SCT-200,fexact,"['sct 200', 'recombinant humanized anti hegfr mab', 'recombinant humanized anti human epidermal growth factor receptor monoclonal antibody']",correct_mapping
sugemalimab,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,sugemalimab,,sugemalimab,sugemalimab,fexact,"['WBP-3155', 'sugemalimab', 'pd-l1 checkpoint inhibitor (cancer)', 'recombinant anti-pd-l1 mab', 'pd-l1 targeting human igg mab (solid tumor/hodgkin lymphoma)', 'CS-1001']",sugemalimab,fexact,"['wbp 3155', 'sugemalimab', 'pd l1 checkpoint inhibitor cancer', 'recombinant anti pd l1 mab', 'pd l1 targeting human igg mab solid tumor hodgkin lymphoma', 'cs 1001']",correct_mapping
NBF-006,Glutathione S transferase inhibitor; Gene expression inhibitor,NBF-006,,NBF-006,nbf 006,fexact,"['NBF-006', 'glutathione S-transferase-P inhibitors (cancer)']",NBF-006,fexact,"['nbf 006', 'glutathione s transferase p inhibitors cancer']",correct_mapping
genolimzumab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,genolimzumab,,geptanolimab,genolimzumab,fexact,"['jienuo mAb', 'CBT-501', 'PD-1 checkpoint inhibitor (cancer),/', 'geptanolimab', 'GB-226', 'PD-1 checkpoint inhibitor (cancer),/Genor BioPharm', 'jeno mAb (intravenous, cancer), CBT Pharmaceuticals//', 'PD-1 checkpoint inhibitor (cancer), CBT Pharmaceuticals/Genor Biopharma', 'jienuo mAb, Genor Biopharma', 'anti PD-1 mAb (cancer), Crown Bioscience', 'jeno mAb (intravenous, cancer), CBT Pharmaceuticals/Crown Bioscience/Genor Biopharma', 'APL-501', 'PD-1 checkpoint inhibitor (cancer), CBT Pharmaceuticals/', 'anti PD-1 mAb (cancer)', 'genolimzumab', 'jeno mAb (intravenous, cancer), CBT Pharmaceuticals//Genor Biopharma']",geptanolimab,fexact,"['jienuo mab', 'cbt 501', 'pd 1 checkpoint inhibitor cancer', 'geptanolimab', 'gb 226', 'pd 1 checkpoint inhibitor cancer genor biopharm', 'jeno mab intravenous cancer cbt pharmaceuticals', 'pd 1 checkpoint inhibitor cancer cbt pharmaceuticals genor biopharma', 'jienuo mab genor biopharma', 'anti pd 1 mab cancer crown bioscience', 'jeno mab intravenous cancer cbt pharmaceuticals crown bioscience genor biopharma', 'apl 501', 'pd 1 checkpoint inhibitor cancer cbt pharmaceuticals', 'anti pd 1 mab cancer', 'genolimzumab', 'jeno mab intravenous cancer cbt pharmaceuticals genor biopharma']",correct_mapping
fruquintinib (tablet),VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor,fruquintinib,,fruquintinib,fruquintinib,fexact,"['Elunate', 'fruquintinib', 'aiyoute', 'fukuitini', 'HMPL-013']",fruquintinib,fexact,"['elunate', 'fruquintinib', 'aiyoute', 'fukuitini', 'hmpl 013']",correct_mapping
rucaparib (oral),Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor; Poly ADP ribose polymerase 3 inhibitor,rucaparib,,"rucaparib camsylate (oral, solid tumors)",rucaparib,fexact,"['rucaparib camsylate (oral, solid tumors)', 'rucaparib camsylate (oral, solid tumors), Clovis', 'Rubraca', 'rucaparib camsylate', 'rucaparib', 'CO-338']","rucaparib camsylate (oral, solid tumors)",fexact,"['rucaparib camsylate oral solid tumors', 'rucaparib camsylate oral solid tumors clovis', 'rubraca', 'rucaparib camsylate', 'rucaparib', 'co 338']",correct_mapping
ningetinib,Axl receptor tyrosine kinase inhibitor; Flt-3 antagonist; Mer tyrosine kinase inhibitor; MET tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Macrophage stimulating protein 1 receptor antagonist,ningetinib,,ningetinib tosilate,ningetinib,fexact,"['ningetinib tosilate', 'CT-053PTSA', 'ningetinib toluenesulfonate', 'CT-053', 'ningetinib', 'ninggetini']",ningetinib tosilate,fexact,"['ningetinib tosilate', 'ct 053ptsa', 'ningetinib toluenesulfonate', 'ct 053', 'ningetinib', 'ninggetini']",correct_mapping
citoplurikin,Immunostimulant; Immuno-oncology therapy,citoplurikin,,IRX-2,citoplurikin,fexact,"['IRX-2', 'cytokines containing adjuvant Th1 agonist  (sc, solid tumors)', 'citoplurikin']",IRX-2,fexact,"['irx 2', 'cytokines containing adjuvant th1 agonist sc solid tumors', 'citoplurikin']",correct_mapping
PTZ-522,Glucocorticoid-induced TNFR-related protein agonist; Immuno-oncology therapy; Immune checkpoint stimulant,PTZ-522,,ASP-1951,ptz 522,fexact,"['antibody targeting immuno-regulatory pathway (cancer), Potenza/', 'GITR costimulator (cancer), Potenza/', 'GITR costimulator (cancer),/', 'PTZ-522', 'ASP-1951', 'antibody targeting immuno-regulatory pathway (cancer),/']",ASP-1951,fexact,"['antibody targeting immuno regulatory pathway cancer potenza', 'gitr costimulator cancer potenza', 'gitr costimulator cancer', 'ptz 522', 'asp 1951', 'antibody targeting immuno regulatory pathway cancer']",correct_mapping
anamorelin hydrochloride (tablet),Growth hormone secretagogue receptor agonist,anamorelin hydrochloride,,anamorelin,anamorelin hydrochloride,fexact,"['anamorelin hydrochloride', 'NSAC, Rejuvenon/', 'ONO-7643', 'NSAC,/', 'gastrointestinal system agent (tablet/oral formulation, aging/bone injury/anorexia nervosa/cachexia)', 'NSAC, Rejuvenon/Novo Nordisk', 'growth hormone secretagogues, Rejuvenon/', 'growth hormone secretagogues, Sapphire/Novo Nordisk', 'RC-1291 hydrochloride', 'ONO-07643', 'anamorelin', 'growth hormone secretagogues, Sapphire/', 'growth hormone secretagogues,/', 'RC-1291', 'gastrointestinal system agent (tablet/oral formulation, aging/bone injury/anorexia nervosa/cachexia), Ono', 'ghrelin agonist', 'NSAC, Sapphire/', 'NSAC, Sapphire/Novo Nordisk', 'ghrelin agonist, Helsinn', 'RC-1291 HCl', 'ghrelin agonist, Rejuvenon', 'Adlumiz', 'growth hormone secretagogues, Rejuvenon/Novo Nordisk']",anamorelin,fexact,"['anamorelin hydrochloride', 'nsac rejuvenon', 'ono 7643', 'nsac', 'gastrointestinal system agent tablet oral formulation aging bone injury anorexia nervosa cachexia', 'nsac rejuvenon novo nordisk', 'growth hormone secretagogues rejuvenon', 'growth hormone secretagogues sapphire novo nordisk', 'rc 1291 hydrochloride', 'ono 07643', 'anamorelin', 'growth hormone secretagogues sapphire', 'growth hormone secretagogues', 'rc 1291', 'gastrointestinal system agent tablet oral formulation aging bone injury anorexia nervosa cachexia ono', 'ghrelin agonist', 'nsac sapphire', 'nsac sapphire novo nordisk', 'ghrelin agonist helsinn', 'rc 1291 hcl', 'ghrelin agonist rejuvenon', 'adlumiz', 'growth hormone secretagogues rejuvenon novo nordisk']",correct_mapping
feladilimab,Inducible T-cell costimulator agonist; Immuno-oncology therapy; Immune checkpoint stimulant,feladilimab,,feladilimab,feladilimab,fexact,"['GSK-3359609', 'H2L5 IgG4PE (cancer)', 'ICOS costimulator (cancer)', 'GSK-609', 'feladilimab', 'H2L5 IgG4PE (cancer, metastatic head and neck cancer, squamous cell carcinoma, pharynx tumor, larynx tumor)']",feladilimab,fexact,"['gsk 3359609', 'h2l5 igg4pe cancer', 'icos costimulator cancer', 'gsk 609', 'feladilimab', 'h2l5 igg4pe cancer metastatic head and neck cancer squamous cell carcinoma pharynx tumor larynx tumor']",correct_mapping
ceritinib,Anaplastic lymphoma kinase inhibitor,ceritinib,,ceritinib,ceritinib,fexact,"['LDK-378', 'ALK inhibitor (oral, cancer)', 'Zykadia', 'ceritinib']",ceritinib,fexact,"['ldk 378', 'alk inhibitor oral cancer', 'zykadia', 'ceritinib']",correct_mapping
MGC-018,Protein synthesis inhibitor; Immune checkpoint inhibitor,MGC-018,,MGC-018,mgc 018,fexact,"['MGC-018', 'duocarmycin analog-anti-B7-H3 antibody conjugate (solid tumor)', 'B7-H3 checkpoint inhibitor (solid tumor)', 'humanized B7-H3 antibody drug conjugate']",MGC-018,fexact,"['mgc 018', 'duocarmycin analog anti b7 h3 antibody conjugate solid tumor', 'b7 h3 checkpoint inhibitor solid tumor', 'humanized b7 h3 antibody drug conjugate']",correct_mapping
erdafitinib,FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor,erdafitinib,,erdafitinib,erdafitinib,fexact,"['FGFR inhibitors (cancer),/', 'JNJ-493', 'FGFR inhibitors (cancer),/Janssen Biotech', 'fibroblast growth factor receptor inhibitors (cancer), Ortho Biotech', 'FGFR inhibitors (cancer)', 'fibroblast growth factor receptor inhibitors (cancer)', 'Balversa', 'FGFR inhibitors (cancer),/Centocor Ortho Biotech', 'JNJ-42756493', 'erdafitinib']",erdafitinib,fexact,"['fgfr inhibitors cancer', 'jnj 493', 'fgfr inhibitors cancer janssen biotech', 'fibroblast growth factor receptor inhibitors cancer ortho biotech', 'fgfr inhibitors cancer', 'fibroblast growth factor receptor inhibitors cancer', 'balversa', 'fgfr inhibitors cancer centocor ortho biotech', 'jnj 42756493', 'erdafitinib']",correct_mapping
EVAX-01,Immunostimulant,EVAX-01,,EVX-01,evx 01,fuzzy,"['NeoPepVac', 'EVAX-01-CAF09b', 'NPV-ds001-CAF09b', 'NPV-ds001', 'EVX-01']",EVX-01,fexact,"['neopepvac', 'evax 01 caf09b', 'npv ds001 caf09b', 'npv ds001', 'evx 01']",incorrect_mapping
BT-001,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,BT-001,,BT-001,bt 001,fexact,"['CTLA-4 checkpoint inhibitor (oncolytic vaccinia virus delivery, Invir.IOTM/n-CoDeR/FIRST, solid tumor), Transgene/', 'Treg (oncolytic vaccinia virus delivery, Invir.IOTM/n-CoDER/FIRST, solid tumor), Transgene/', 'VV-α-CTLA-4', 'Treg (oncolytic vaccinia virus delivery, Invir.IOTM/n-CoDER/FIRST, solid tumor),/', 'CTLA-4 checkpoint inhibitor (oncolytic vaccinia virus delivery, Invir.IOTM/n-CoDeR/FIRST, solid tumor),/', 'BT-001']",BT-001,fexact,"['ctla 4 checkpoint inhibitor oncolytic vaccinia virus delivery invir iotm n coder first solid tumor transgene', 'treg oncolytic vaccinia virus delivery invir iotm n coder first solid tumor transgene', 'vv α ctla 4', 'treg oncolytic vaccinia virus delivery invir iotm n coder first solid tumor', 'ctla 4 checkpoint inhibitor oncolytic vaccinia virus delivery invir iotm n coder first solid tumor', 'bt 001']",correct_mapping
BI-1808,Tumour necrosis factor receptor 2 antagonist; Immuno-oncology therapy,BI-1808,,BI-1808,bi 1808,fexact,"['anti-TNFR2 antibody (solid tumor)', 'Treg modulator (n-CoDeR/F.I.R.S.T., solid tumor)', 'anti-TNFR2 antibody (n-CoDeR/F.I.R.S.T., solid tumor)', 'anti-TNFRS antibody (n-CoDeR/F.I.R.S.T., solid tumor)', 'BI-1808', 'regulatory t cells modulatory program (cancer)', 'FIRST alphaTreg', 'regulatory T cells modulatory program (cancer),/University of Southampton', 't reg immuno-modulatory program (cancer)', 'T reg immuno-modulatory program (cancer),/University of Southampton']",BI-1808,fexact,"['anti tnfr2 antibody solid tumor', 'treg modulator n coder f i r s t solid tumor', 'anti tnfr2 antibody n coder f i r s t solid tumor', 'anti tnfrs antibody n coder f i r s t solid tumor', 'bi 1808', 'regulatory t cells modulatory program cancer', 'first alphatreg', 'regulatory t cells modulatory program cancer university of southampton', 't reg immuno modulatory program cancer', 't reg immuno modulatory program cancer university of southampton']",correct_mapping
surgical intervention,Not applicable,surgical intervention,,,,0,['surgical intervention'],,0,[],0
metformin hydrochloride,Insulin sensitizer; Biguanide; Gluconeogenesis inhibitor,metformin hydrochloride,,metformin hydrochloride,metformin hydrochloride,fexact,"['Gliguanid', 'Metfogamma', 'Diabex', 'LA-6023', 'Glifage IR', 'Metgluco', 'Diaformin', 'Flumamine', 'metformin', 'BMS-207150', 'Glucophage', 'Siofor', 'Diabetosan', 'Fluamine', 'Diabex XR', 'Glifage', 'SMP-862', 'metformin hydrochloride', 'Glucofit']",metformin hydrochloride,fexact,"['gliguanid', 'metfogamma', 'diabex', 'la 6023', 'glifage ir', 'metgluco', 'diaformin', 'flumamine', 'metformin', 'bms 207150', 'glucophage', 'siofor', 'diabetosan', 'fluamine', 'diabex xr', 'glifage', 'smp 862', 'metformin hydrochloride', 'glucofit']",correct_mapping
RO-7121661,PD-1 antagonist; TIM3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,RO-7121661,,RG-7769,ro 7121661,fexact,"['anti-PD-1/TIM-3 bispecific antibody (intravenous, advanced solid tumor/esophageal squamous cell carcinoma)', 'anti-PD-1/TIM-3 bispecific antibody (intravenous, advanced solid tumor)', 'anti-PD-1/TIM-3 bispecific antibody (intravenous, NSCLC/stage IV melanoma/advanced solid tumor/esophageal squamous cell carcinoma)', 'RG-7769', 'dual PD-1/TIM-3 checkpoint inhibitor (intravenous, NSCLC/stage IV melanoma/advanced solid tumor)', 'dual PD-1 checkpoint inhibitor/TIM-3 checkpoint inhibitor (NSCLC/melanoma/solid tumor)', 'RO-7121661']",RG-7769,fexact,"['anti pd 1 tim 3 bispecific antibody intravenous advanced solid tumor esophageal squamous cell carcinoma', 'anti pd 1 tim 3 bispecific antibody intravenous advanced solid tumor', 'anti pd 1 tim 3 bispecific antibody intravenous nsclc stage iv melanoma advanced solid tumor esophageal squamous cell carcinoma', 'rg 7769', 'dual pd 1 tim 3 checkpoint inhibitor intravenous nsclc stage iv melanoma advanced solid tumor', 'dual pd 1 checkpoint inhibitor tim 3 checkpoint inhibitor nsclc melanoma solid tumor', 'ro 7121661']",correct_mapping
letetresgene-autoleucel,T cell stimulant; Immuno-oncology therapy,letetresgene-autoleucel,,letetresgene autoleucel,letetresgene autoleucel,fexact,"['anti-NY-ESOc259T SLLMWITQC/HLA‐A*0201 TCR T-cell therapy (cancer),/', 'NY-ESO-1 TCR-T', 'anti-LAGE-1/HLA‐A*0201 TCR T-cell therapy (cancer),/GlaxoSmithKline', ""GSK'794"", 'genetically engineered NY-ESO-1-specific (c259)  cells  (cancer)', 'GSK-3377794', 'NY-ESO SPEAR T-cell therapy (cancer)', 'lete-cel', 'NY-ESOc259T', '3377794', 'HLA‐A*0201‐SLLMWITQC TCR T-cell therapy (cancer),/', 'anti-LAGE-1/HLA‐A*0201 TCR T-cell therapy (cancer),/', 'enhanced TCR-transduced autologous  cells (cancer)', 'adoptive T-cell therapy (cancer)', 'anti-NY-ESO/HLA‐A*0201 TCR T-cell therapy (cancer),/', 'genetically engineered NY-ESO-1-specific (c259) T cells  (cancer)', 'NY-ESO-1 TCR-engineered T-Cells', 'NY-ESO-1c259 SPEAR T-cells', 'letetresgene autoleucel', 'anti-NY-ESO/HLA‐A*0201 TCR T-cell therapy (cancer),/GlaxoSmithKline', 'anti-NY-ESOc259T SLLMWITQC/HLA‐A*0201 TCR T-cell therapy (cancer),/GlaxoSmithKline', 'enhanced TCR-transduced autologous T cells (cancer)', 'adoptive T-cell therapy (multiple myeloma, synovial sarcoma, melanoma)', 'HLA‐A*0201‐SLLMWITQC TCR T-cell therapy (cancer),/GlaxoSmithKline', 'NY-ESO TCR']",letetresgene autoleucel,fexact,"['anti ny esoc259t sllmwitqc hla a 0201 tcr t cell therapy cancer', 'ny eso 1 tcr t', 'anti lage 1 hla a 0201 tcr t cell therapy cancer glaxosmithkline', 'gsk 794', 'genetically engineered ny eso 1 specific c259 cells cancer', 'gsk 3377794', 'ny eso spear t cell therapy cancer', 'lete cel', 'ny esoc259t', '3377794', 'hla a 0201 sllmwitqc tcr t cell therapy cancer', 'anti lage 1 hla a 0201 tcr t cell therapy cancer', 'enhanced tcr transduced autologous cells cancer', 'adoptive t cell therapy cancer', 'anti ny eso hla a 0201 tcr t cell therapy cancer', 'genetically engineered ny eso 1 specific c259 t cells cancer', 'ny eso 1 tcr engineered t cells', 'ny eso 1c259 spear t cells', 'letetresgene autoleucel', 'anti ny eso hla a 0201 tcr t cell therapy cancer glaxosmithkline', 'anti ny esoc259t sllmwitqc hla a 0201 tcr t cell therapy cancer glaxosmithkline', 'enhanced tcr transduced autologous t cells cancer', 'adoptive t cell therapy multiple myeloma synovial sarcoma melanoma', 'hla a 0201 sllmwitqc tcr t cell therapy cancer glaxosmithkline', 'ny eso tcr']",correct_mapping
darleukin (IV),Interleukin 2 receptor agonist; Immunostimulant; T cell stimulant,darleukin,,L19-IL-2 fusion protein,darleukin,fexact,"['Darleukin', 'L19-IL-2 fusion protein, Philogen', 'L19-IL-2 fusion protein', 'immunocytokine fusion protein', 'immunocytokine fusion protein, Philogen']",L19-IL-2 fusion protein,fexact,"['darleukin', 'l19 il 2 fusion protein philogen', 'l19 il 2 fusion protein', 'immunocytokine fusion protein', 'immunocytokine fusion protein philogen']",correct_mapping
nutritional supplement,Reducing agent; Free radical scavenger,nutritional supplement,,,,0,['nutritional supplement'],,0,[],0
TS-1 (oral capsule),DNA synthesis inhibitor; Orotate phosphoribosyltransferase inhibitor; Thymidylate synthase inhibitor; Dihydropyrimidine dehydrogenase inhibitor,TS-1,,,,0,"['tegafur + gimeracil + oxonate potassium', 'ts-1', 'tegafur + gimeracil + oteracil potassium', 'S-1, Sanofi', 'T-20', 'T-20, Taiho', 'TS-1', 'Cefesone', 'pp2a activators (cancer),/', 'TS-1 combination capsule T20', 'BMS-247616', 'P-selectin glycoprotein ligand-1, Genetics Institute', 'S-1', 'rPSGL-Ig', 'vitamin e succinate derivatives (cancer), / technology commercialization and knowledge transfer', 'pp2a activators (cancer), / technology commercialization and knowledge transfer', ""P-selectin glycoprotein ligand-1, Y's Therapeutics"", 'P-selectin glycoprotein ligand-1', 'rPSGL-Ig, Genetics Institute', 'rpsgl-ig', 'YSPSL', 'P-selectin glycoprotein ligand-1, Wyeth BioPharma', 'rPSGL-Ig, Wyeth BioPharma', 'p-selectin glycoprotein ligand-1', 'TS-1 combination capsule T25', 'T-25', 'TS-ONE', ""rPSGL-Ig, Y's Therapeutics"", 'Teysuno', 'vitamin e succinate derivatives (cancer),/', 'TS-1, Sanofi']",,Drug_API_mapping,[],0
L-DOS-47,Urease stimulant,L-DOS-47,,L-DOS47,l dos47,fuzzy,"['Tumour Defence Breaker', 'antibody-targeted urease (cancer),/Canadian Research Council', 'L-DOS47']",L-DOS47,fexact,"['tumour defence breaker', 'antibody targeted urease cancer canadian research council', 'l dos47']",incorrect_mapping
grapiprant,Prostaglandin EP4 receptor antagonist,grapiprant,,grapiprant (oral),grapiprant,fexact,"['grapiprant', 'ARY-007', 'IK-007', 'NB-002', 'AAT-007', 'RQ-00000007', 'RQ-00000007 (oral)', 'NB-002, Ningbo NewBay Medical Technology', '3D-1002', 'CJ-023423', 'RQ-7', 'RMX-1002', 'grapiprant (oral)']",grapiprant (oral),fexact,"['grapiprant', 'ary 007', 'ik 007', 'nb 002', 'aat 007', 'rq 00000007', 'rq 00000007 oral', 'nb 002 ningbo newbay medical technology', '3d 1002', 'cj 023423', 'rq 7', 'rmx 1002', 'grapiprant oral']",correct_mapping
depoxythilone,Beta tubulin inhibitor; Microtubule stimulant; Taxane,depoxythilone,,depoxythilone,depoxythilone,fexact,"['BGE-5', 'UTD-1', 'utidelone', 'youtidelong', 'depoxythilone']",depoxythilone,fexact,"['bge 5', 'utd 1', 'utidelone', 'youtidelong', 'depoxythilone']",correct_mapping
Careseng 1370,Unidentified pharmacological activity,Careseng 1370,,,,0,['Careseng 1370'],,0,[],0
IO-112,Arginase stimulant; T cell stimulant; Immuno-oncology therapy,IO-112,,IO-112,io 112,fexact,"['arginase derived peptide vaccine (arginase-positive solid tumor)', 'arginase-i modulator (solid tumor)', 'IO-112']",IO-112,fexact,"['arginase derived peptide vaccine arginase positive solid tumor', 'arginase i modulator solid tumor', 'io 112']",correct_mapping
GSK-095,Receptor-interacting protein 1 kinase inhibitor,GSK-095,,GSK-3145095,gsk 095,fexact,"['GSK-3145095', ""GSK'095"", 'GSK-095', 'RIPK1 inhibitor (oral/tablet/capsule, pancreatic ductal adenocarcinoma/advanced solid tumors)']",GSK-3145095,fexact,"['gsk 3145095', 'gsk 095', 'gsk 095', 'ripk1 inhibitor oral tablet capsule pancreatic ductal adenocarcinoma advanced solid tumors']",correct_mapping
chlorogenic acid,Unidentified pharmacological activity,chlorogenic acid,,"chlorogenic acid (intramuscular, cancer)",chlorogenic acid,fexact,"['LAG-3 checkpoint inhibitor (cancer)', 'lvyuansuan', 'chlorogenic acid', 'chlorogenic acid (intramuscular, cancer)', 'CD223 checkpoint inhibitor (cancer)']","chlorogenic acid (intramuscular, cancer)",fexact,"['lag 3 checkpoint inhibitor cancer', 'lvyuansuan', 'chlorogenic acid', 'chlorogenic acid intramuscular cancer', 'cd223 checkpoint inhibitor cancer']",correct_mapping
prolgolimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,prolgolimab,,,,0,"['anti PD-1 monoclonal antibody (cancer)', 'prolgolimab (iv, advanced solid tumor/renal cell carcinoma/stage III melanoma/stage IV melanoma/metastatic non-small cell lung cancer/lung tumor/squamous carcinoma/cervical cancer)', 'BCD-100', 'prolgolimab', 'anti PD-1 mAb (cancer)', 'prolgolimab (iv, advanced solid tumor/renal cell carcinoma/stage III melanoma/stage IV melanoma/metastatic non-small cell lung cancer/lung tumor)', 'PD-1 checkpoint inhibitor (solid tumor)', 'Forteca']",,NER_API,[],0
"bevacizumab, Celltrion",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Celltrion,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
PF-06936308,Immuno-oncology therapy,PF-06936308,,PF-06936308,pf 06936308,fexact,"['PF-06801591 + tremelimumab + undisclosed components  (NSCLC/TNBC)', 'PF-06936308', 'PF-06936308 + tremelimumab + other (undisclosed) therapeutics (NSCLC, TNBC)', 'vaccine-based immunotherapy regimen-2 (VBIR-2, NSCLC/TNBC)', 'CTLA-4 checkpoint inhibitor + PD-1 checkpoint inhibitor + undisclosed components  (NSCLC/TNBC)']",PF-06936308,fexact,"['pf 06801591 tremelimumab undisclosed components nsclc tnbc', 'pf 06936308', 'pf 06936308 tremelimumab other undisclosed therapeutics nsclc tnbc', 'vaccine based immunotherapy regimen 2 vbir 2 nsclc tnbc', 'ctla 4 checkpoint inhibitor pd 1 checkpoint inhibitor undisclosed components nsclc tnbc']",correct_mapping
EMB-01,Immuno-oncology therapy,EMB-01,,EMB-01,emb 01,fexact,"['FIT-013a', 'EMB-01', 'cMET/EGFR bispecific antibody (cancer)']",EMB-01,fexact,"['fit 013a', 'emb 01', 'cmet egfr bispecific antibody cancer']",correct_mapping
mirdametinib,Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,mirdametinib,,mirdametinib,mirdametinib,fexact,"['second generation MAP/ERK kinase [MEK]-1 inhibitor', 'second generation MEK 1/2 inhibitor (oral, type 1 neurofibromatosis/advanced solid tumors), SpringWorks', 'PD-325901', 'PD-0325901', 'mirdametinib', 'second generation MEK 1/2 inhibitor (oral, type 1 neurofibromatosis/advanced solid tumors)']",mirdametinib,fexact,"['second generation map erk kinase mek 1 inhibitor', 'second generation mek 1 2 inhibitor oral type 1 neurofibromatosis advanced solid tumors springworks', 'pd 325901', 'pd 0325901', 'mirdametinib', 'second generation mek 1 2 inhibitor oral type 1 neurofibromatosis advanced solid tumors']",correct_mapping
lifirafenib,B-raf kinase inhibitor,lifirafenib,,lifirafenib,lifirafenib,fexact,"['lifirafenib sesqui-maleate', 'BGB-283 sesqui-maleate', 'BRAF kinase inhibitor (cancer),/Merck KGaA', 'BGB-283', 'lifirafenib maleate', 'lifirafenib', 'BeiGene-283', 'BRAF and EGFR dual inhibitor (cancer),/Merck KGaA']",lifirafenib,fexact,"['lifirafenib sesqui maleate', 'bgb 283 sesqui maleate', 'braf kinase inhibitor cancer merck kgaa', 'bgb 283', 'lifirafenib maleate', 'lifirafenib', 'beigene 283', 'braf and egfr dual inhibitor cancer merck kgaa']",correct_mapping
crizotinib (capsule),Anaplastic lymphoma kinase inhibitor; MET tyrosine kinase inhibitor,crizotinib,,crizotinib,crizotinib,fexact,"['Xalkori', 'PF-2341066', 'crizotinib', 'PF-1066', 'PF-02341066', 'NSC-749005']",crizotinib,fexact,"['xalkori', 'pf 2341066', 'crizotinib', 'pf 1066', 'pf 02341066', 'nsc 749005']",correct_mapping
maveropepimut-S,Immunostimulant,maveropepimut-S,,maveropepimut-S,maveropepimut s,fexact,"['Survivin-expressing tumor vaccine (solid tumors)', 'Survivin-expressing tumor vaccine (solid tumors), Merck Serono', 'DPX-Survivac', 'DPX-R9F', 'survivin-expressing tumor vaccine (solid tumors)', 'Survivin-expressing tumor vaccine (solid tumors), Survac', 'Survivin-expressing tumor vaccine (DepoVax, solid tumors), Immunovaccine', 'maveropepimut-S', 'Survivin-expressing tumor vaccine (solid tumors), Merck KGaA', 'Survivac', 'Survivin-expressing tumor vaccine (DepoVax, solid tumors)']",maveropepimut-S,fexact,"['survivin expressing tumor vaccine solid tumors', 'survivin expressing tumor vaccine solid tumors merck serono', 'dpx survivac', 'dpx r9f', 'survivin expressing tumor vaccine solid tumors', 'survivin expressing tumor vaccine solid tumors survac', 'survivin expressing tumor vaccine depovax solid tumors immunovaccine', 'maveropepimut s', 'survivin expressing tumor vaccine solid tumors merck kgaa', 'survivac', 'survivin expressing tumor vaccine depovax solid tumors']",correct_mapping
GSK-3368715,Protein arginine methyltransferase 1 inhibitor,GSK-3368715,,GSK-3368715,gsk 3368715,fexact,"['GSK-3368715', 'protein arginine N-methyltransferase 1 inhibitor (oral capsule, diffuse large B-cell lymphoma/solid tumors), GlaxoSmithKline', ""GSK'715"", 'protein arginine N-methyltransferase 1 inhibitor (oral capsule, diffuse large B-cell lymphoma/solid tumors)']",GSK-3368715,fexact,"['gsk 3368715', 'protein arginine n methyltransferase 1 inhibitor oral capsule diffuse large b cell lymphoma solid tumors glaxosmithkline', 'gsk 715', 'protein arginine n methyltransferase 1 inhibitor oral capsule diffuse large b cell lymphoma solid tumors']",correct_mapping
etoposide,DNA inhibitor; DNA topoisomerase II inhibitor; DNA repair enzyme inhibitor; Cell cycle inhibitor,etoposide,,etoposide phosphate,etoposide,fexact,"['Etopophos', 'Eposin', 'NSC-141540', 'etopofos', 'Eposide', 'Nexvep', 'etoposide', 'Vepesid', 'BMY-40481', 'VP-16-213', 'VP-16', 'etoposide phosphate']",etoposide phosphate,fexact,"['etopophos', 'eposin', 'nsc 141540', 'etopofos', 'eposide', 'nexvep', 'etoposide', 'vepesid', 'bmy 40481', 'vp 16 213', 'vp 16', 'etoposide phosphate']",correct_mapping
itraconazole,Cell wall synthesis inhibitor; Sterol demethylase inhibitor,itraconazole,,itraconazole,itraconazole,fexact,"['Itorizoru', 'Oromyc', 'Itranax', 'R-51211', 'Orungal', 'Sempera', 'Itrizole Injection 1%', 'Sporanox', 'JK-1211', 'Sporal', 'Itrizole', 'itraconazole', 'Intiazol', 'Itrizol', 'oriconazole']",itraconazole,fexact,"['itorizoru', 'oromyc', 'itranax', 'r 51211', 'orungal', 'sempera', 'itrizole injection 1', 'sporanox', 'jk 1211', 'sporal', 'itrizole', 'itraconazole', 'intiazol', 'itrizol', 'oriconazole']",correct_mapping
TQB-3456,EGFR kinase inhibitor,TQB-3456,,TQB-3456,tqb 3456,fexact,['TQB-3456'],TQB-3456,fexact,['tqb 3456'],correct_mapping
SLC-391,Axl receptor tyrosine kinase inhibitor; Mer tyrosine kinase inhibitor,SLC-391,,SLC-391,slc 391,fexact,"['AXL tyrosine kinase receptor inhibitors (cancer, advanced solid tumors)', 'AXL tyrosine kinase receptor inhibitors (metastatic non-small cell lung cancer)', 'axl checkpoint inhibitor (cancer)', 'SLC-0211', 'SLC-366', 'SLC-391', 'AXL tyrosine kinase receptor inhibitors (cancer)']",SLC-391,fexact,"['axl tyrosine kinase receptor inhibitors cancer advanced solid tumors', 'axl tyrosine kinase receptor inhibitors metastatic non small cell lung cancer', 'axl checkpoint inhibitor cancer', 'slc 0211', 'slc 366', 'slc 391', 'axl tyrosine kinase receptor inhibitors cancer']",correct_mapping
CCCR-NK92 cells,Not applicable,CCCR-NK92 cells,,,,0,['CCCR-NK92 cells'],,0,[],0
zorifertinib,EGFR kinase inhibitor,zorifertinib,,zorifertinib,zorifertinib,fexact,"['zorifertinib', 'AZD-3759']",zorifertinib,fexact,"['zorifertinib', 'azd 3759']",correct_mapping
VSV IFNb NIS (intravenous),Immuno-oncology therapy,VSV IFNb NIS,,VSV-hIFNbeta-NIS,vsv mifn nis,fuzzy,"['BOEC-VSV-IFN-beta', 'VSV-hIFNbeta-NIS', 'recombinant vesicular stomatitis virus (cancer)', 'recombinant vesicular stomatitis virus (cancer), University of Tennessee/', 'VSV-mIFN-NIS', 'oncolytic vsv therapy expressing ifn-beta and sodium-iodide symporter (cancer)', 'oncolytic VSV therapy expressing IFN-beta and sodium-iodide symporter (cancer), University of Tennessee/']",VSV-hIFNbeta-NIS,fexact,"['boec vsv ifn beta', 'vsv hifnbeta nis', 'recombinant vesicular stomatitis virus cancer', 'recombinant vesicular stomatitis virus cancer university of tennessee', 'vsv mifn nis', 'oncolytic vsv therapy expressing ifn beta and sodium iodide symporter cancer', 'oncolytic vsv therapy expressing ifn beta and sodium iodide symporter cancer university of tennessee']",incorrect_mapping
infiltrating lymphocytes,Immunosuppressant,infiltrating lymphocytes,,,,0,['infiltrating lymphocytes'],,0,[],0
lifileucel,Immunostimulant; Immuno-oncology therapy,lifileucel,,lifileucel,lifileucel,fexact,"['autologous tumor infiltrating lymphocyte cell therapy (cancer), Genesis Biopharma', 'LN-144', 'Contego', 'autologous tumor infiltrating lymphocyte cell therapy (cancer)', 'LN-145', 'lifileucel']",lifileucel,fexact,"['autologous tumor infiltrating lymphocyte cell therapy cancer genesis biopharma', 'ln 144', 'contego', 'autologous tumor infiltrating lymphocyte cell therapy cancer', 'ln 145', 'lifileucel']",correct_mapping
ilixadencel,Immuno-oncology therapy,ilixadencel,,ilixadencel,ilixadencel,fexact,"['INTUVAX RCC', 'INTUVAX-GIST', 'dendritic cell vaccine (cancer)', 'INTUVAX-HCC', 'COMBIG-MEL', 'dendritic cell  (cancer)', 'COMBIG-vaccine (cancer)', 'COMBIG-RCC', 'COMBIG-DC', 'INTUVAC-RCC', 'INTUVAC', 'INTUVAX', 'ilixadencel']",ilixadencel,fexact,"['intuvax rcc', 'intuvax gist', 'dendritic cell vaccine cancer', 'intuvax hcc', 'combig mel', 'dendritic cell cancer', 'combig vaccine cancer', 'combig rcc', 'combig dc', 'intuvac rcc', 'intuvac', 'intuvax', 'ilixadencel']",correct_mapping
anamorelin hydrochloride,Growth hormone secretagogue receptor agonist,anamorelin hydrochloride,,anamorelin,anamorelin hydrochloride,fexact,"['anamorelin hydrochloride', 'NSAC, Rejuvenon/', 'ONO-7643', 'NSAC,/', 'gastrointestinal system agent (tablet/oral formulation, aging/bone injury/anorexia nervosa/cachexia)', 'NSAC, Rejuvenon/Novo Nordisk', 'growth hormone secretagogues, Rejuvenon/', 'growth hormone secretagogues, Sapphire/Novo Nordisk', 'RC-1291 hydrochloride', 'ONO-07643', 'anamorelin', 'growth hormone secretagogues, Sapphire/', 'growth hormone secretagogues,/', 'RC-1291', 'gastrointestinal system agent (tablet/oral formulation, aging/bone injury/anorexia nervosa/cachexia), Ono', 'ghrelin agonist', 'NSAC, Sapphire/', 'NSAC, Sapphire/Novo Nordisk', 'ghrelin agonist, Helsinn', 'RC-1291 HCl', 'ghrelin agonist, Rejuvenon', 'Adlumiz', 'growth hormone secretagogues, Rejuvenon/Novo Nordisk']",anamorelin,fexact,"['anamorelin hydrochloride', 'nsac rejuvenon', 'ono 7643', 'nsac', 'gastrointestinal system agent tablet oral formulation aging bone injury anorexia nervosa cachexia', 'nsac rejuvenon novo nordisk', 'growth hormone secretagogues rejuvenon', 'growth hormone secretagogues sapphire novo nordisk', 'rc 1291 hydrochloride', 'ono 07643', 'anamorelin', 'growth hormone secretagogues sapphire', 'growth hormone secretagogues', 'rc 1291', 'gastrointestinal system agent tablet oral formulation aging bone injury anorexia nervosa cachexia ono', 'ghrelin agonist', 'nsac sapphire', 'nsac sapphire novo nordisk', 'ghrelin agonist helsinn', 'rc 1291 hcl', 'ghrelin agonist rejuvenon', 'adlumiz', 'growth hormone secretagogues rejuvenon novo nordisk']",correct_mapping
"DCVax-Direct Adjuvant, Northwest",Immunostimulant,DCVax-Direct Adjuvant,Northwest,,,0,['DCVax-Direct Adjuvant'],,0,[],0
BGB-A425,TIM3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,BGB-A425,,BGB-A425,bgb a425,fexact,"['Tim-3 mAb (cancer)', 'BGB-A425', 'TIM-3 checkpoint inhibitor (cancer)']",BGB-A425,fexact,"['tim 3 mab cancer', 'bgb a425', 'tim 3 checkpoint inhibitor cancer']",correct_mapping
camidanlumab tesirine,DNA inhibitor,camidanlumab tesirine,,camidanlumab tesirine,camidanlumab tesirine,fexact,"['ADCT-301', 'camidanlumab tesirine', 'HuMax-TAC-ADC', 'Cami-T', 'SUR-301', 'HuMax-TAC-drug conjugate (leukemia/lymphoma, pyrrolobenzodiazepine (PBD)-based warhead), Genmab /', 'IL-2RA-targeting antibody (NHL/HL/DLBCL/AML/advanced solid tumors/myelodysplastic syndrome/myeloproliferative neoplasms)', 'HuMax-TAC-drug conjugate (leukemia/lymphoma, pyrrolobenzodiazepine (PBD)-based warhead),/']",camidanlumab tesirine,fexact,"['adct 301', 'camidanlumab tesirine', 'humax tac adc', 'cami t', 'sur 301', 'humax tac drug conjugate leukemia lymphoma pyrrolobenzodiazepine pbd based warhead genmab', 'il 2ra targeting antibody nhl hl dlbcl aml advanced solid tumors myelodysplastic syndrome myeloproliferative neoplasms', 'humax tac drug conjugate leukemia lymphoma pyrrolobenzodiazepine pbd based warhead']",correct_mapping
alrizomadlin,MDM2 inhibitor,alrizomadlin,,APG-115,alrizomadlin,fexact,"['alrizomadlin', 'APG-115']",APG-115,fexact,"['alrizomadlin', 'apg 115']",correct_mapping
lobaplatin,DNA inhibitor,lobaplatin,,lobaplatin,lobaplatin,fexact,"['D-19466', 'lobaplatin']",lobaplatin,fexact,"['d 19466', 'lobaplatin']",correct_mapping
dalpiciclib,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,dalpiciclib,,,,0,"['dalpiciclib', 'dalpiciclib (CDK4/6 inhibitor, oral, cancer)', 'SHR-6390', 'CDK4/6 inhibitor (oral, cancer)']",,NER_API,[],0
mirzotamab clezutoclax,Bcl-XL inhibitor,mirzotamab clezutoclax,,mirzotamab clezutoclax,mirzotamab clezutoclax,fexact,"['Bcl-xL inhibitor antibody-drug conjugate (cancer)', 'huAb13.1a', 'Bcl-xL inhibitor ADC (cancer)', 'ABBV-155', 'antineoplastic agent (iv, advanced solid tumour)', 'B7-H3 antibody-Bcl-xl inhibitor conjugate (cancer)', 'mirzotamab clezutoclax', 'huAb13v1', 'B7-H3 antibody-clezutoclax conjugate (cancer)', 'P01-18-P10-18']",mirzotamab clezutoclax,fexact,"['bcl xl inhibitor antibody drug conjugate cancer', 'huab13 1a', 'bcl xl inhibitor adc cancer', 'abbv 155', 'antineoplastic agent iv advanced solid tumour', 'b7 h3 antibody bcl xl inhibitor conjugate cancer', 'mirzotamab clezutoclax', 'huab13v1', 'b7 h3 antibody clezutoclax conjugate cancer', 'p01 18 p10 18']",correct_mapping
BAY-1834942,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 in; Immuno-oncology therapy; Immune checkpoint modulator,BAY-1834942,,tinurilimab,bay 1834942,fexact,"['BAY-1834942', 'tinurilimab', 'BAY-942', 'CD66c antagonist (cancer),/Cologne/German Cancer Research Center', 'CEACAM6 fb antibody (cancer)']",tinurilimab,fexact,"['bay 1834942', 'tinurilimab', 'bay 942', 'cd66c antagonist cancer cologne german cancer research center', 'ceacam6 fb antibody cancer']",correct_mapping
DS-1205c,Axl receptor tyrosine kinase inhibitor,DS-1205c,,DS-1205c,ds 1205c,fexact,"['DS-1205c', 'DS-1205b', 'AXL tyrosine kinase inhibitor (NSCLC), Daiichi Sankyo', 'DS-1205', 'AXL tyrosine kinase inhibitor (NSCLC)', 'AB-329']",DS-1205c,fexact,"['ds 1205c', 'ds 1205b', 'axl tyrosine kinase inhibitor nsclc daiichi sankyo', 'ds 1205', 'axl tyrosine kinase inhibitor nsclc', 'ab 329']",correct_mapping
ADXS-503,Immuno-oncology therapy,ADXS-503,,ADXS-503,adxs 503,fexact,"['ADXS-HOT program (non-small-cell lung cancer)', 'ADXS-503', 'HOT-Lung']",ADXS-503,fexact,"['adxs hot program non small cell lung cancer', 'adxs 503', 'hot lung']",correct_mapping
KY-1044,Inducible T-cell costimulator agonist; Immuno-oncology therapy; Immune checkpoint stimulant,KY-1044,,KY-1044,ky 1044,fexact,"['ICOS costimulator (Kymouse, cancer), Wellcome Trust Sanger Institute/', 'KY-1044', 'icos costimulator (kymouse, cancer)']",KY-1044,fexact,"['icos costimulator kymouse cancer wellcome trust sanger institute', 'ky 1044', 'icos costimulator kymouse cancer']",correct_mapping
mRNA-5671,K-Ras inhibitor,mRNA-5671,,mRNA-5671,mrna 5671,fexact,"['V-941', 'KRAS vaccine (cancer), ModeRNA Therapeutics/', 'mRNA-5671', 'kras vaccine (cancer)']",mRNA-5671,fexact,"['v 941', 'kras vaccine cancer moderna therapeutics', 'mrna 5671', 'kras vaccine cancer']",correct_mapping
selumetinib,Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,selumetinib,,selumetinib sulfate,selumetinib,fexact,"['MEK inhibitors (cancer)', 'MK-5618', 'selumetinib hyd-sulfate', 'neurodegenerative disease therapeutics', 'kinase inhibitors (cancer)', 'selumetinib sulfate', 'AZD-6244 hydrogen sulfate', 'NSC-748727', 'IND-77782', 'ARRY-886', 'AZD-6244', 'ARRY-142886', 'selumetinib', 'Koselugo', 'AZD-6244 hyd-sulfate']",selumetinib sulfate,fexact,"['mek inhibitors cancer', 'mk 5618', 'selumetinib hyd sulfate', 'neurodegenerative disease therapeutics', 'kinase inhibitors cancer', 'selumetinib sulfate', 'azd 6244 hydrogen sulfate', 'nsc 748727', 'ind 77782', 'arry 886', 'azd 6244', 'arry 142886', 'selumetinib', 'koselugo', 'azd 6244 hyd sulfate']",correct_mapping
REGN-4659,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,REGN-4659,,REGN-4659,regn 4659,fexact,"['CTLA-4 checkpoint inhibitor (metastatic non-small-cell lung cancer),/', 'CTLA-4 checkpoint inhibitor (cancer),/', 'anti-CTLA-4 mAbs (cancer),/Sanofi', 'CTLA-4 checkpoint inhibitor (metastatic non-small-cell lung cancer),/Sanofi', 'REGN-4659', 'CTLA-4 checkpoint inhibitor (cancer),/Sanofi', 'anti-CTLA-4 mAbs (cancer),/']",REGN-4659,fexact,"['ctla 4 checkpoint inhibitor metastatic non small cell lung cancer', 'ctla 4 checkpoint inhibitor cancer', 'anti ctla 4 mabs cancer sanofi', 'ctla 4 checkpoint inhibitor metastatic non small cell lung cancer sanofi', 'regn 4659', 'ctla 4 checkpoint inhibitor cancer sanofi', 'anti ctla 4 mabs cancer']",correct_mapping
abexinostat,Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,abexinostat,,abexinostat,abexinostat,fexact,"['CRA-024781', 'abexinostat', 'histone deacetylase inhibitors (anticancer), Pharmacyclics', 'HDAC inhibitors (anticancer)', 'CRA-026440', 'histone deacetylase inhibitors (anticancer)', 'S-78454', 'PCI-24781', 'HDAC inhibitors (anticancer), Pharmacyclics', 'CG-781', 'abexinostat hydrochloride']",abexinostat,fexact,"['cra 024781', 'abexinostat', 'histone deacetylase inhibitors anticancer pharmacyclics', 'hdac inhibitors anticancer', 'cra 026440', 'histone deacetylase inhibitors anticancer', 's 78454', 'pci 24781', 'hdac inhibitors anticancer pharmacyclics', 'cg 781', 'abexinostat hydrochloride']",correct_mapping
nimotuzumab,EGFR antagonist,nimotuzumab,,nimotuzumab biosimilar,nimotuzumab,fexact,"['nimotuzumab biosimilar', 'nimotuzumab', 'JMT-101']",nimotuzumab biosimilar,fexact,"['nimotuzumab biosimilar', 'nimotuzumab', 'jmt 101']",correct_mapping
pirotinib,ErbB-3 antagonist; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor,pirotinib,,Pirotinib,pirotinib,fexact,"['5209', 'KBP-5209', 'Pirotinib']",Pirotinib,fexact,"['5209', 'kbp 5209', 'pirotinib']",correct_mapping
"high-affinity Natural Killer cells, NantKwest",CD16 antagonist; Interleukin 2 receptor agonist; Immuno-oncology therapy,high-affinity Natural Killer cells,NantKwest,,,0,['high-affinity Natural Killer cells'],,0,[],0
PTZ-329,T cell inhibitor; NRP 1 antagonist; Immuno-oncology therapy,PTZ-329,,ASP-1948,ptz 329,fexact,"['antibody targeting immuno-regulatory pathway (cancer),/', 'PTZ-329', 'ASP-1948', 'antibody targeting immuno-regulatory pathway (cancer), Potenza/']",ASP-1948,fexact,"['antibody targeting immuno regulatory pathway cancer', 'ptz 329', 'asp 1948', 'antibody targeting immuno regulatory pathway cancer potenza']",correct_mapping
VMD-928,TrkA tyrosine kinase inhibitor,VMD-928,,VMD-928,vmd 928,fexact,"['VMD-928', 'TrkA antagonist (pancreatic cancer)', 'TrkA antagonist (oral, pancreatic cancer/advanced solid tumor/lymphoma)']",VMD-928,fexact,"['vmd 928', 'trka antagonist pancreatic cancer', 'trka antagonist oral pancreatic cancer advanced solid tumor lymphoma']",correct_mapping
pegilodecakin,Interleukin 10 agonist,pegilodecakin,,pegilodecakin,pegilodecakin,fexact,"['rHuIL-10', 'LY-3500518', 'interleukin-10, Schering-Plough', 'peg-IL-10', 'ilodecakin', 'IL-10, Schering-Plough', 'IL-10', 'PEGylated human IL-10', 'Tenovil', 'pegilodecakin', 'interleukin-10', 'Sch-52000', 'rHuIL-10, Schering-Plough', 'AM-0010']",pegilodecakin,fexact,"['rhuil 10', 'ly 3500518', 'interleukin 10 schering plough', 'peg il 10', 'ilodecakin', 'il 10 schering plough', 'il 10', 'pegylated human il 10', 'tenovil', 'pegilodecakin', 'interleukin 10', 'sch 52000', 'rhuil 10 schering plough', 'am 0010']",correct_mapping
YE-NEO-001,Unidentified pharmacological activity,YE-NEO-001,,YE-NEO-001,ye neo 001,fexact,"['neoepitope yeast vaccine (cancer)', 'YE-NEO-011', 'YE-NEO-001', 'neoepitope-based personalized yeast vaccine (cancer)']",YE-NEO-001,fexact,"['neoepitope yeast vaccine cancer', 'ye neo 011', 'ye neo 001', 'neoepitope based personalized yeast vaccine cancer']",correct_mapping
EDP-1503,"Immuno-oncology therapy; Microbiome modulator, live microorganisms",EDP-1503,,EDP-1503,edp 1503,fexact,"['monoclonal microbial developed from bifidobacteria (cancer),/University of Chicago', 'EDP-1503', 'microbiome based immunotherapy (cancer)', 'microbiome based immunotherapy (cancer),/University of Chicago', 'monoclonal microbial developed from bifidobacteria (cancer)', 'monoclonal microbial (cancer)']",EDP-1503,fexact,"['monoclonal microbial developed from bifidobacteria cancer university of chicago', 'edp 1503', 'microbiome based immunotherapy cancer', 'microbiome based immunotherapy cancer university of chicago', 'monoclonal microbial developed from bifidobacteria cancer', 'monoclonal microbial cancer']",correct_mapping
MRx-518,"Toll-like receptor 5 agonist; Immuno-oncology therapy; Microbiome modulator, live microorganisms",MRx-518,,MRx-518,mrx 518,fexact,"['live biotherapeutic preparation (MicroRx, cancer)', 'live biotherapeutic preparation (oral, cancer)', 'MRx-518', 'MRx-0518']",MRx-518,fexact,"['live biotherapeutic preparation microrx cancer', 'live biotherapeutic preparation oral cancer', 'mrx 518', 'mrx 0518']",correct_mapping
NZV-930,Immuno-oncology therapy; CD73 antagonist,NZV-930,,NZV-930,nzv 930,fexact,"['SRF-373', 'NZV-930', 'anti-CD73 human monoclonal antibody (cancer), Surface Oncology/', 'anti-cd73 human monoclonal antibody (cancer)', 'CD73 checkpoint inhibitor (cancer), Surface Oncology', 'cd73 checkpoint inhibitor (cancer)']",NZV-930,fexact,"['srf 373', 'nzv 930', 'anti cd73 human monoclonal antibody cancer surface oncology', 'anti cd73 human monoclonal antibody cancer', 'cd73 checkpoint inhibitor cancer surface oncology', 'cd73 checkpoint inhibitor cancer']",correct_mapping
autologous dendritic cell-adenovirus CCL21 vaccine,Immunostimulant,autologous dendritic cell-adenovirus CCL21 vaccine,,,,0,['autologous dendritic cell-adenovirus CCL21 vaccine'],,0,[],0
vancomycin,Cell wall synthesis inhibitor,vancomycin,,vancomycin,vancomycin,fexact,"['vancomycin', 'vancomycin hydrochloride (bacterial infection),///Shionogi/', 'vancomycin hydrochloride (bacterial infection),//Flynn Pharma/Shionogi/Searchlight Pharma', 'Vancocin', 'vancomycin hydrochloride (bacterial infection),////', 'Vancocin Pulvules', 'vancomycin hydrochloride', 'vancomycin hydrochloride (bacterial infection), Eli Lilly//Flynn Pharma/Shionogi/Searchlight Pharma', 'vancomycin hydrochloride (bacterial infection),///Shionogi/Searchlight Pharma']",vancomycin,fexact,"['vancomycin', 'vancomycin hydrochloride bacterial infection shionogi', 'vancomycin hydrochloride bacterial infection flynn pharma shionogi searchlight pharma', 'vancocin', 'vancomycin hydrochloride bacterial infection', 'vancocin pulvules', 'vancomycin hydrochloride', 'vancomycin hydrochloride bacterial infection eli lilly flynn pharma shionogi searchlight pharma', 'vancomycin hydrochloride bacterial infection shionogi searchlight pharma']",correct_mapping
INCAGN-2385,Lymphocyte-activation gene 3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,INCAGN-2385,,INCAGN-2385,incagn 2385,fexact,"['INCAGN-02385', 'lag-3 targeted antibody program', 'LAG-3 targeted antibody program (cancer),/', 'LAG-3 targeted antibody program (cancer),/Ludwig Institute for Cancer Research', 'LAG-3 targeted antibody program,/Ludwig Institute for Cancer Research', 'INCAGN-2385', 'lag-3 targeted antibody program (cancer)', 'LAG-3 targeted antibody program (cancer),/ Incyte', 'LAG-3 checkpoint inhibitor (cancer),/', 'LAG-3 checkpoint inhibitor (cancer),/Incyte']",INCAGN-2385,fexact,"['incagn 02385', 'lag 3 targeted antibody program', 'lag 3 targeted antibody program cancer', 'lag 3 targeted antibody program cancer ludwig institute for cancer research', 'lag 3 targeted antibody program ludwig institute for cancer research', 'incagn 2385', 'lag 3 targeted antibody program cancer', 'lag 3 targeted antibody program cancer incyte', 'lag 3 checkpoint inhibitor cancer', 'lag 3 checkpoint inhibitor cancer incyte']",correct_mapping
"PD-1 knockout CAR-T-cells, Guangzhou Anjie Biomed Tech Co",PD-1 antagonist; T cell stimulant; Immuno-oncology therapy,PD-1 knockout CAR-T-cells,Guangzhou Anjie Biomed Tech Co,,,0,['PD-1 knockout CAR-T-cells'],,0,[],0
"anti-MUC1 CAR-T cells, Guangzhou Anjie Biomedical Tech Co",MUC-1 inhibitor; Immuno-oncology therapy,anti-MUC1 CAR-T cells,Guangzhou Anjie Biomedical Tech Co,,,0,['anti-MUC1 CAR-T cells'],,0,[],0
ALT-803,Interleukin 15 agonist; Immuno-oncology therapy,ALT-803,,nogapendekin alfa,alt 803,fexact,"['modified human IL-15 (malaria)', 'nogapendekin alfa', 'N-803', 'Anktiva', 'ALT-803', 'IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer)']",nogapendekin alfa,fexact,"['modified human il 15 malaria', 'nogapendekin alfa', 'n 803', 'anktiva', 'alt 803', 'il 15 agonist il 15r alpha fc fusion complex cancer']",correct_mapping
methotrexate (oral),Immunosuppressant; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Disease modifying antirheumatic drug,methotrexate,,,,0,"['methotrexate', 'repurposed methotrexate (blood cancer)']",,NER_API,[],0
regorafenib,RET tyrosine kinase inhibitor; C-kit inhibitor; FGF receptor tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Raf kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,regorafenib,,regorafenib,regorafenib,fexact,"['BAY-81-1557', 'fluoro-sorafenib', 'dual acting kinase inhibitor (cancer)', 'dual acting multikinase inhibitor (cancer)', 'regorafenib', 'BAY-73-4506', 'DAST inhibitor (cancer)', 'Bai Wan Ge', 'DAST (cancer)', 'DAST inhibitor', 'dual acting signal transduction inhibitor (cancer)', 'Stivarga']",regorafenib,fexact,"['bay 81 1557', 'fluoro sorafenib', 'dual acting kinase inhibitor cancer', 'dual acting multikinase inhibitor cancer', 'regorafenib', 'bay 73 4506', 'dast inhibitor cancer', 'bai wan ge', 'dast cancer', 'dast inhibitor', 'dual acting signal transduction inhibitor cancer', 'stivarga']",correct_mapping
INCAGN-2390,TIM3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,INCAGN-2390,,INCAGN-2390,incagn 2390,fexact,"['tim-3 targeted antibody program (cancer)', 'TIM-3 checkpoint inhibitor (cancer),/', 'TIM-3 targeted antibody program (cancer),/Ludwig Institute for Cancer Research', 'TIM-3 targeted antibody program (cancer),/ Incyte', 'TIM-3 checkpoint inhibitor (cancer),/Incyte', 'INCAGN-02390', 'TIM-3 targeted antibody program (cancer),/', 'tim-3 targeted antibody program', 'TIM-3 targeted antibody program,/Ludwig Institute for Cancer Research', 'INCAGN-2390']",INCAGN-2390,fexact,"['tim 3 targeted antibody program cancer', 'tim 3 checkpoint inhibitor cancer', 'tim 3 targeted antibody program cancer ludwig institute for cancer research', 'tim 3 targeted antibody program cancer incyte', 'tim 3 checkpoint inhibitor cancer incyte', 'incagn 02390', 'tim 3 targeted antibody program cancer', 'tim 3 targeted antibody program', 'tim 3 targeted antibody program ludwig institute for cancer research', 'incagn 2390']",correct_mapping
MGD-019,PD-1 antagonist; CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,MGD-019,,MGD-019,mgd 019,fexact,"['tetravalent PD-1 x CTLA-4 bispecific DARTi protein (cancer)', 'dual CTLA-4 checkpoint inhibitor/PD-1 checkpoint inhibitor (cancer)', 'PD-1/CTLA4 bispecific antibodies (cancer)', 'MGD-019', 'trivalent PD-1 x CTLA-4 TRIDENTi protein (cancer)']",MGD-019,fexact,"['tetravalent pd 1 x ctla 4 bispecific darti protein cancer', 'dual ctla 4 checkpoint inhibitor pd 1 checkpoint inhibitor cancer', 'pd 1 ctla4 bispecific antibodies cancer', 'mgd 019', 'trivalent pd 1 x ctla 4 tridenti protein cancer']",correct_mapping
XmAb-841,CTLA4 antagonist; Lymphocyte-activation gene 3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,XmAb-841,,,,0,['XmAb-841'],,0,[],0
favezelimab,Lymphocyte-activation gene 3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,favezelimab,,MK-4280,favezelimab,fexact,"['MK-4280', 'mavezelimab', 'LAG-3 checkpoint inhibitor (solid tumor)', 'favezelimab', 'MK-4280A']",MK-4280,fexact,"['mk 4280', 'mavezelimab', 'lag 3 checkpoint inhibitor solid tumor', 'favezelimab', 'mk 4280a']",correct_mapping
quavonlimab,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,quavonlimab,,,,0,['quavonlimab'],,0,[],0
nazartinib,EGFR kinase inhibitor,nazartinib,,nazartinib,nazartinib,fexact,"['mutant-selective EGFR inhibitor (T790M-mutated NSCLC)', 'nazartinib', 'EGF-816']",nazartinib,fexact,"['mutant selective egfr inhibitor t790m mutated nsclc', 'nazartinib', 'egf 816']",correct_mapping
"immune killer cells, Ivy Life Sciences",Immunostimulant,immune killer cells,Ivy Life Sciences,,,0,['immune killer cells'],,0,[],0
anti-PD-L1 antibody,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,anti-PD-L1 antibody,,,,0,['anti-PD-L1 antibody'],,Drug_API_mapping,[],0
"anti-CTLA4, unspecified",CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,anti-CTLA4,unspecified,ipilimumab,anti ctla4,fexact,"['BMS-734016', 'MDX-010', 'Winglore', 'MDX-101', 'anti-CTLA4, Medarex', 'Yervoy', 'MDX-CTLA4', 'CTLA-4 checkpoint inhibitor (cancer)', 'anti-CTLA4', 'ipilimumab']",ipilimumab,fexact,"['bms 734016', 'mdx 010', 'winglore', 'mdx 101', 'anti ctla4 medarex', 'yervoy', 'mdx ctla4', 'ctla 4 checkpoint inhibitor cancer', 'anti ctla4', 'ipilimumab']",correct_mapping
sotigalimab,CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,sotigalimab,,APX-005M,sotigalimab,fexact,"['anti-CD40 humanized monoclonal antibody (RabMab/MLG, myeloma/CLL/NHL/metastatic melanoma/ esophageal cancer)', 'anti-CD40 humanized monoclonal antibody (RabMab/MLG, myeloma/CLL/NHL), Epitomics', 'EPI-0050', 'APX-005', 'CD40 costimulator (cancer)', 'anti-CD40 humanized monoclonal antibody (RabMab/MLG, myeloma/CLL/NHL)', 'APX-005M', 'sotigalimab', 'anti-CD40 humanized monoclonal antibody (RabMab/MLG, myeloma/CLL/NHL/metastatic melanoma)']",APX-005M,fexact,"['anti cd40 humanized monoclonal antibody rabmab mlg myeloma cll nhl metastatic melanoma esophageal cancer', 'anti cd40 humanized monoclonal antibody rabmab mlg myeloma cll nhl epitomics', 'epi 0050', 'apx 005', 'cd40 costimulator cancer', 'anti cd40 humanized monoclonal antibody rabmab mlg myeloma cll nhl', 'apx 005m', 'sotigalimab', 'anti cd40 humanized monoclonal antibody rabmab mlg myeloma cll nhl metastatic melanoma']",correct_mapping
BA-3021,Unidentified pharmacological activity,BA-3021,,BA-3021,ba 3021,fexact,"['ROR-2 conditionally active biologic antibody based drug conjugate (cancer),/Himalaya', 'CAB-Ror2-ADC', 'BA-3021', 'RoR-2 conditionally active biologic antibody-drug conjugate (triple-negative breast cancer),/', 'ROR-2 conditionally active biologic antibody based drug conjugate (cancer),/', 'RoR-2 conditionally active biologic antibody-drug conjugate (triple-negative breast cancer),/Himalaya']",BA-3021,fexact,"['ror 2 conditionally active biologic antibody based drug conjugate cancer himalaya', 'cab ror2 adc', 'ba 3021', 'ror 2 conditionally active biologic antibody drug conjugate triple negative breast cancer', 'ror 2 conditionally active biologic antibody based drug conjugate cancer', 'ror 2 conditionally active biologic antibody drug conjugate triple negative breast cancer himalaya']",correct_mapping
pegargiminase,Unidentified pharmacological activity,pegargiminase,,pegargiminase,pegargiminase,fexact,"['Melanocid', 'ADI-SS PEG 20,000 mw', 'ADI-PEG-20', 'ZK-207342', 'ADI-SS', 'PEGylated arginine deiminase, Schering AG/Phoenix', 'PEGylated arginine deiminase, Schering AG/', 'PEGylated arginine deiminase', 'PEGylated ADI', 'pegargiminase', 'PEGylated ADI, Phoenix', 'Hepacid', 'PEGylated arginine deiminase, Phoenix']",pegargiminase,fexact,"['melanocid', 'adi ss peg 20 000 mw', 'adi peg 20', 'zk 207342', 'adi ss', 'pegylated arginine deiminase schering ag phoenix', 'pegylated arginine deiminase schering ag', 'pegylated arginine deiminase', 'pegylated adi', 'pegargiminase', 'pegylated adi phoenix', 'hepacid', 'pegylated arginine deiminase phoenix']",correct_mapping
tipifarnib,Farnesyltransferase inhibitor; Angiogenesis inhibitor; Apoptosis stimulant,tipifarnib,,tipifarnib,tipifarnib,fexact,"['NSC-702818', 'ras farnesyl inibitor', 'Zarnestra', 'R-115777', 'tipifarnib', 'ras farnesyl inibitor, Janssen']",tipifarnib,fexact,"['nsc 702818', 'ras farnesyl inibitor', 'zarnestra', 'r 115777', 'tipifarnib', 'ras farnesyl inibitor janssen']",correct_mapping
"rhGM-CSF, unspecified",Immunostimulant,rhGM-CSF,unspecified,filgrastim,rhg csf,fuzzy,"['CSF', 'r-metHuG-CSF', 'hG-CSF', 'KRN-8601E', 'pluripoietin', 'Neupogen', 'rhG-CSF', 'Nupogen', 'G-CSF', 'filgrastim', 'KRN-8601', 'Grasin', 'filgrastim (HemaGel ER formulation, RxKinetix)', 'Granulokine', 'Neutropoietin', 'CSF-G', 'NSC-614629', 'GRAN']",filgrastim,fexact,"['csf', 'r methug csf', 'hg csf', 'krn 8601e', 'pluripoietin', 'neupogen', 'rhg csf', 'nupogen', 'g csf', 'filgrastim', 'krn 8601', 'grasin', 'filgrastim hemagel er formulation rxkinetix', 'granulokine', 'neutropoietin', 'csf g', 'nsc 614629', 'gran']",incorrect_mapping
berberine,Unidentified pharmacological activity,berberine,,,,0,"['berberine chloride (type 2 diabetes/hyperlipidemia), Shenyang No.1 Pharmaceutical/', 'AC-701', 'berberine', 'berberine hydrochloride (oral/tablet, type 2 diabetes/hyperlipidemia)', 'IL-1 alpha/IL-8 release inhibitor (topical gel, rosacea/skin rash), TWi Pharmaceuticals', 'berberine (topical gel formulation, skin rash), TWi Pharmaceuticals', 'berberine + ursodeoxycholate', 'berberine chloride (type 2 diabetes/hyperlipidemia),/', 'berberine + ursodeoxycholate (primary sclerosing cholangitis), Shenzhen HighTide Biopharmaceutical', 'berberine (transdermal, hypercholesterolemia/hypertriglyceridemia)', 'berberine hydrochloride (oral/tablet, type 2 diabetes/hyperlipidemia), Shenyang No.1 Pharmaceutical', 'berberine chloride', 'berberine + ursodeoxycholic acid', 'HTD-2802']",,Drug_API_mapping,[],0
tisotumab vedotin,Tubulin inhibitor,tisotumab vedotin,,tisotumab vedotin,tisotumab vedotin,fexact,"['tisotumab', 'HuMax-TF', 'TF-011-monomethyl auristatin', 'tisotumab vedotin', 'HuMax-TF-ADC', 'anti-tissue factor human antibody (cancer)', 'TF-011-MMAE']",tisotumab vedotin,fexact,"['tisotumab', 'humax tf', 'tf 011 monomethyl auristatin', 'tisotumab vedotin', 'humax tf adc', 'anti tissue factor human antibody cancer', 'tf 011 mmae']",correct_mapping
Compound 121564,Unidentified pharmacological activity,Compound 121564,,,,0,['Compound 121564'],,0,[],0
BI-836880 (iv),Angiopoietin-2 inhibitor,BI-836880,,BI-836880,bi 836880,fexact,"['nanobody therapeutics (cancer),/ Boehringer Ingelheim', 'BI-836880', 'nanobody therapeutics (cancer),/', 'anti-VEGF/Ang-2 nanobody therapeutic (solid tumor)', 'anti-VEGF/Ang-2 nanobody therapeutic (solid tumor), Boehringer Ingelheim']",BI-836880,fexact,"['nanobody therapeutics cancer boehringer ingelheim', 'bi 836880', 'nanobody therapeutics cancer', 'anti vegf ang 2 nanobody therapeutic solid tumor', 'anti vegf ang 2 nanobody therapeutic solid tumor boehringer ingelheim']",correct_mapping
navarixin,CXC chemokine receptor 1 antagonist; Chemokine receptor antagonist; CXC chemokine receptor 2 antagonist,navarixin,,navarixin,navarixin,fexact,"['CXCR2 antagonist (chronic obstructive pulmonary disorder), Schering-Plough/', 'SCH-527123', 'PS-938285', 'respiratory disease therapeutics, Schering-Plough/Pharmacopeia', 'navarixin (USAN)', 'respiratory disease therapeutics,/', 'SCH-N', 'CXCR2 receptor antagonist (COPD)', 'navarixin', 'respiratory disease therapeutics, Schering-Plough/', 'CXCR2 antagonist (chronic obstructive pulmonary disorder), Schering-Plough/Pharmacopeia', 'CXCR2 antagonist (chronic obstructive pulmonary disorder),/', 'PS-291822', 'MK-7123', 'CXCR2 antagonist (chronic obstructive pulmonary disorder)', 'PS-140430']",navarixin,fexact,"['cxcr2 antagonist chronic obstructive pulmonary disorder schering plough', 'sch 527123', 'ps 938285', 'respiratory disease therapeutics schering plough pharmacopeia', 'navarixin usan', 'respiratory disease therapeutics', 'sch n', 'cxcr2 receptor antagonist copd', 'navarixin', 'respiratory disease therapeutics schering plough', 'cxcr2 antagonist chronic obstructive pulmonary disorder schering plough pharmacopeia', 'cxcr2 antagonist chronic obstructive pulmonary disorder', 'ps 291822', 'mk 7123', 'cxcr2 antagonist chronic obstructive pulmonary disorder', 'ps 140430']",correct_mapping
"interleukin-2, unspecified",Interleukin receptor agonist,interleukin-2,unspecified,,,0,"['IL-2 follow-on biologic', 'IL-2', 'Leuferon 2', 'interleukin-2 biosimilar API', 'interleukin-2 (sublingual, Mycobacterium tuberculosis infection)', 'rhIL-2', 'interleukin-2 follow-on biologic', 'interleukin-2 biosimilar', 'Xin  Er', 'IL-2 biosimilar', 'Yintekang', 'IL-2 biosimilar API', 'IL-2, Roche', 'interleukin-2, Roche', 'interleukin-2, Immunex', 'Ro-23-6019', 'IL-2, Immunex', 'interleukin-2']",,Drug_API_mapping,[],0
cosibelimab,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,cosibelimab,,cosibelimab,cosibelimab,fexact,"['TG-1501', 'anti PD-L1 antibody (hematological malignancies),/TG Therapeutics', 'cosibelimab', 'anti PD-L1 antibody (cancer)', 'anti PD-L1 antibody (cancer), Dana-Farber', 'anti PD-L1 antibody (cancer),/ TG Therapeutics', 'anti PD-L1 antibody (cancer),/', 'PD-L1 checkpoint inhibitor (cancer),/', 'PD-L1 checkpoint inhibitor (cancer), TG Therapeutics/', 'CK-301', 'anti PD-L1 antibody (hematological malignancies),/']",cosibelimab,fexact,"['tg 1501', 'anti pd l1 antibody hematological malignancies tg therapeutics', 'cosibelimab', 'anti pd l1 antibody cancer', 'anti pd l1 antibody cancer dana farber', 'anti pd l1 antibody cancer tg therapeutics', 'anti pd l1 antibody cancer', 'pd l1 checkpoint inhibitor cancer', 'pd l1 checkpoint inhibitor cancer tg therapeutics', 'ck 301', 'anti pd l1 antibody hematological malignancies']",correct_mapping
CX-2029,CD71 antagonist,CX-2029,,CX-2029,cx 2029,fexact,"['Probody drug conjugates targeting CD-71 (cancer), CytomX', 'Probody drug conjugates targeting CD-71 (cancer),/', 'Probody drug conjugates targeting CD-71 (cancer), CytomX/', 'anti-CD71 probody drug conjugate (cancer), CytomX/', 'ABBV-2029', 'ABBV-CX-2029', 'anti-CD71 probody drug conjugate (cancer),/', 'CX-2029', 'Probody drug conjugates targeting CD-71 (cancer)']",CX-2029,fexact,"['probody drug conjugates targeting cd 71 cancer cytomx', 'probody drug conjugates targeting cd 71 cancer', 'probody drug conjugates targeting cd 71 cancer cytomx', 'anti cd71 probody drug conjugate cancer cytomx', 'abbv 2029', 'abbv cx 2029', 'anti cd71 probody drug conjugate cancer', 'cx 2029', 'probody drug conjugates targeting cd 71 cancer']",correct_mapping
IO-102,"Indoleamine 2,3-dioxygenase inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor",IO-102,,IO-102,io 102,fexact,"['IDO-derived peptide vaccine (cancer)', 'Treg modulator (cancer)', 'IO-102']",IO-102,fexact,"['ido derived peptide vaccine cancer', 'treg modulator cancer', 'io 102']",correct_mapping
eftilagimod alfa,Lymphocyte-activation gene 3 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,eftilagimod alfa,,eftilagimod alfa,eftilagimod alfa,fexact,"['Efti', 'Eftilagimod Alpha', 'soluble CD223 (ImmuFact, cancer)', 'EOC-202', 'soluble LAG-3 (ImmuFact, cancer)', 'eftilagimod alfa', 'IMP-321', 'EDP-202', 'soluble LAG-3 (ImmuFact, cancer), Immutep', 'Soluble LAG-3Ig', 'soluble CD223 (ImmuFact, cancer), Immutep']",eftilagimod alfa,fexact,"['efti', 'eftilagimod alpha', 'soluble cd223 immufact cancer', 'eoc 202', 'soluble lag 3 immufact cancer', 'eftilagimod alfa', 'imp 321', 'edp 202', 'soluble lag 3 immufact cancer immutep', 'soluble lag 3ig', 'soluble cd223 immufact cancer immutep']",correct_mapping
"endostatin, unspecified",Angiogenesis inhibitor,endostatin,unspecified,endostatin,endostatin,fexact,"['AdEndo', 'NSC-704805', 'endostatin', 'rhEndostatin', 'Endostatin protein']",endostatin,fexact,"['adendo', 'nsc 704805', 'endostatin', 'rhendostatin', 'endostatin protein']",correct_mapping
TS-1,DNA synthesis inhibitor; Orotate phosphoribosyltransferase inhibitor; Thymidylate synthase inhibitor; Dihydropyrimidine dehydrogenase inhibitor,TS-1,,,,0,"['tegafur + gimeracil + oxonate potassium', 'ts-1', 'tegafur + gimeracil + oteracil potassium', 'S-1, Sanofi', 'T-20', 'T-20, Taiho', 'TS-1', 'Cefesone', 'pp2a activators (cancer),/', 'TS-1 combination capsule T20', 'BMS-247616', 'P-selectin glycoprotein ligand-1, Genetics Institute', 'S-1', 'rPSGL-Ig', 'vitamin e succinate derivatives (cancer), / technology commercialization and knowledge transfer', 'pp2a activators (cancer), / technology commercialization and knowledge transfer', ""P-selectin glycoprotein ligand-1, Y's Therapeutics"", 'P-selectin glycoprotein ligand-1', 'rPSGL-Ig, Genetics Institute', 'rpsgl-ig', 'YSPSL', 'P-selectin glycoprotein ligand-1, Wyeth BioPharma', 'rPSGL-Ig, Wyeth BioPharma', 'p-selectin glycoprotein ligand-1', 'TS-1 combination capsule T25', 'T-25', 'TS-ONE', ""rPSGL-Ig, Y's Therapeutics"", 'Teysuno', 'vitamin e succinate derivatives (cancer),/', 'TS-1, Sanofi']",,Drug_API_mapping,[],0
"MSC-1, Northern Biologics",Leukaemic inhibitory factor  antagonist,MSC-1,Northern Biologics,MSC-1,msc 1,fexact,"['anti-LIF mAb (intravenous, cancer)', 'anti-LIF mAb (intravenous, cancer), Northern Biologics/', 'anti-LIF mAb (intravenous, cancer), Northern Biologics', 'MSC-1 (cancer), Mosaic Biomedicals', 'MSC-1, Northern Biologics/', 'anti-LIF mAb (intravenous, cancer),/', 'anti-leukemia inhibitory factor mAb (intravenous, cancer), Northern Biologics', 'MSC-1, Northern Biologics', 'anti-leukemia inhibitory factor mAb (intravenous, cancer)', 'MSC-1,/', 'MSC-1', 'MSC-1, Northern Biologics/Celgene', 'msc-1 (cancer)']",MSC-1,fexact,"['anti lif mab intravenous cancer', 'anti lif mab intravenous cancer northern biologics', 'anti lif mab intravenous cancer northern biologics', 'msc 1 cancer mosaic biomedicals', 'msc 1 northern biologics', 'anti lif mab intravenous cancer', 'anti leukemia inhibitory factor mab intravenous cancer northern biologics', 'msc 1 northern biologics', 'anti leukemia inhibitory factor mab intravenous cancer', 'msc 1', 'msc 1', 'msc 1 northern biologics celgene', 'msc 1 cancer']",correct_mapping
anetumab ravtansine,Microtubule inhibitor,anetumab ravtansine,,anetumab ravtansine,anetumab ravtansine,fexact,"['anti-mesothelin antibody-DM4 conjugate (cancer)', 'mesothelin-ADC (cancer)', 'anti-mesothelin antibody-maytansinoid conjugate (cancer)', 'BAY-94-9343', 'anti-mesothelin immunoconjugates (cancer)', 'anetumab ravtansine']",anetumab ravtansine,fexact,"['anti mesothelin antibody dm4 conjugate cancer', 'mesothelin adc cancer', 'anti mesothelin antibody maytansinoid conjugate cancer', 'bay 94 9343', 'anti mesothelin immunoconjugates cancer', 'anetumab ravtansine']",correct_mapping
AZD-4205,Janus kinase 1 inhibitor,AZD-4205,,DZD-4205,azd 4205,fexact,"['NC-0322', 'JAK1 kinase inhibitor (cancer)', 'AZ-3', 'AZD-4205', 'DZD-4205', 'JAK1 kinase inhibitor (inflammatory bowel disease), Dizal (Jiangsu) Pharmaceutical']",DZD-4205,fexact,"['nc 0322', 'jak1 kinase inhibitor cancer', 'az 3', 'azd 4205', 'dzd 4205', 'jak1 kinase inhibitor inflammatory bowel disease dizal jiangsu pharmaceutical']",correct_mapping
KP-673,EGFR kinase inhibitor,KP-673,,ZN-e4,kp 673,fexact,"['EGFR inhibitor (oral, non-small-cell lung cancer), Zentalis/SciClone Pharmaceuticals', 'EGFR inhibitor (oral, non-small-cell lung cancer),/SciClone Pharmaceuticals', 'KP-673', 'ZN-e4']",ZN-e4,fexact,"['egfr inhibitor oral non small cell lung cancer zentalis sciclone pharmaceuticals', 'egfr inhibitor oral non small cell lung cancer sciclone pharmaceuticals', 'kp 673', 'zn e4']",correct_mapping
IMA-202,T cell stimulant; Immuno-oncology therapy,IMA-202,,IMA-202,ima 202,fexact,"['TCR T-cell therapy (solid tumor/NSCLC/hepatocellular carcinoma)', 'IMA-202']",IMA-202,fexact,"['tcr t cell therapy solid tumor nsclc hepatocellular carcinoma', 'ima 202']",correct_mapping
ARB-1598 (intratumoral),Immunostimulant; Toll-like receptor 9 agonist,ARB-1598,,vidutolimod,arb 1598,fexact,"['Derp-1-Qbeta', 'CpG-A oligonucleotide (sc, stage IV skin melanoma/non-small cell lung cancer/metastatic colorectal cancer), Checkmate', 'CMP-001', 'TLR-9 agonist (HBV infection), Tekmira', 'CYT-003-QbG10', 'Immunodrug vaccines (allergy/asthma), Cytos', 'CYT-003', 'Qa-Derp1, Cytos', 'CYT-001-DerQb', 'CMP-001, Checkmate Pharmaceuticals', 'vidutolimod', 'AlphaVaccine (allergy/asthma), Cytos', 'allergy/asthma vaccine, Cytos Biotechnology', 'ARB-1598', 'QbG10 Immunodrug carrier (allergy/asthma), Cytos', 'CpG-A oligonucleotide (sc, stage IV skin melanoma/non-small cell lung cancer/metastatic colorectal cancer)', 'cmp-001', 'Immunodrug']",vidutolimod,fexact,"['derp 1 qbeta', 'cpg a oligonucleotide sc stage iv skin melanoma non small cell lung cancer metastatic colorectal cancer checkmate', 'cmp 001', 'tlr 9 agonist hbv infection tekmira', 'cyt 003 qbg10', 'immunodrug vaccines allergy asthma cytos', 'cyt 003', 'qa derp1 cytos', 'cyt 001 derqb', 'cmp 001 checkmate pharmaceuticals', 'vidutolimod', 'alphavaccine allergy asthma cytos', 'allergy asthma vaccine cytos biotechnology', 'arb 1598', 'qbg10 immunodrug carrier allergy asthma cytos', 'cpg a oligonucleotide sc stage iv skin melanoma non small cell lung cancer metastatic colorectal cancer', 'cmp 001', 'immunodrug']",correct_mapping
ARB-1598 (SC),Immunostimulant; Toll-like receptor 9 agonist,ARB-1598,,vidutolimod,arb 1598,fexact,"['Derp-1-Qbeta', 'CpG-A oligonucleotide (sc, stage IV skin melanoma/non-small cell lung cancer/metastatic colorectal cancer), Checkmate', 'CMP-001', 'TLR-9 agonist (HBV infection), Tekmira', 'CYT-003-QbG10', 'Immunodrug vaccines (allergy/asthma), Cytos', 'CYT-003', 'Qa-Derp1, Cytos', 'CYT-001-DerQb', 'CMP-001, Checkmate Pharmaceuticals', 'vidutolimod', 'AlphaVaccine (allergy/asthma), Cytos', 'allergy/asthma vaccine, Cytos Biotechnology', 'ARB-1598', 'QbG10 Immunodrug carrier (allergy/asthma), Cytos', 'CpG-A oligonucleotide (sc, stage IV skin melanoma/non-small cell lung cancer/metastatic colorectal cancer)', 'cmp-001', 'Immunodrug']",vidutolimod,fexact,"['derp 1 qbeta', 'cpg a oligonucleotide sc stage iv skin melanoma non small cell lung cancer metastatic colorectal cancer checkmate', 'cmp 001', 'tlr 9 agonist hbv infection tekmira', 'cyt 003 qbg10', 'immunodrug vaccines allergy asthma cytos', 'cyt 003', 'qa derp1 cytos', 'cyt 001 derqb', 'cmp 001 checkmate pharmaceuticals', 'vidutolimod', 'alphavaccine allergy asthma cytos', 'allergy asthma vaccine cytos biotechnology', 'arb 1598', 'qbg10 immunodrug carrier allergy asthma cytos', 'cpg a oligonucleotide sc stage iv skin melanoma non small cell lung cancer metastatic colorectal cancer', 'cmp 001', 'immunodrug']",correct_mapping
BVD-CNV (intratumoral),Immuno-oncology therapy,BVD-CNV,,,,0,['BVD-CNV'],,0,[],0
autologous central memory T (Tcm) cells immunotherapy,Immuno-oncology therapy,autologous central memory T  cells immunotherapy,,,,0,['autologous central memory T  cells immunotherapy'],,0,[],0
FCN-411,ErbB tyrosine kinase inhibitor,FCN-411,,FCN-411,fcn 411,fexact,['FCN-411'],FCN-411,fexact,['fcn 411'],correct_mapping
BNT-411,Toll-like receptor 7 agonist,BNT-411,,BNT-411,bnt 411,fexact,"['BNT-411', 'TLR agonists (cancer immunotherapy),/BioNTech', 'TLR agonists (cancer immunotherapy),/', 'TLR agonists (CIT)', 'SC-2', '4SC-CIT', 'SC-1.2', 'SC-1']",BNT-411,fexact,"['bnt 411', 'tlr agonists cancer immunotherapy biontech', 'tlr agonists cancer immunotherapy', 'tlr agonists cit', 'sc 2', '4sc cit', 'sc 1 2', 'sc 1']",correct_mapping
linrodostat,"Indoleamine 2,3-dioxygenase inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor",linrodostat,,linrodostat,linrodostat,fexact,"['IDO-1 checkpoint inhibitor (cancer),/', 'IDO-1 checkpoint inhibitor (cancer),/Ono', 'FLX-B', 'IDO-1 inhibitors (cancer), Flexus Biosciences', 'IDO-1 inhibitors (cancer)', 'cancer immunotherapy program 1, Flexus Biosciences', 'linrodostat', 'linrodostat mesylate', 'cancer immunotherapy program 1', 'BMS-986205', 'ONO-7701', 'IDO checkpoint inhibitor (cancer)', 'F-001287', 'IDO inhibitors (cancer)']",linrodostat,fexact,"['ido 1 checkpoint inhibitor cancer', 'ido 1 checkpoint inhibitor cancer ono', 'flx b', 'ido 1 inhibitors cancer flexus biosciences', 'ido 1 inhibitors cancer', 'cancer immunotherapy program 1 flexus biosciences', 'linrodostat', 'linrodostat mesylate', 'cancer immunotherapy program 1', 'bms 986205', 'ono 7701', 'ido checkpoint inhibitor cancer', 'f 001287', 'ido inhibitors cancer']",correct_mapping
"T-cell receptor therapy, Ziopharm Oncology",Immunostimulant; T cell stimulant; Immuno-oncology therapy,T-cell receptor therapy,Ziopharm Oncology,,,0,['T-cell receptor therapy'],,0,[],0
aldesleukin,Interleukin 2 agonist; Immunostimulant; T cell stimulant,aldesleukin,,aldesleukin,aldesleukin,fexact,"['aldesleukin', 'Proleukin', 'recombinant IL-2', 'rhIL-2', 'Macrolin IL-2', 'NSC-373364']",aldesleukin,fexact,"['aldesleukin', 'proleukin', 'recombinant il 2', 'rhil 2', 'macrolin il 2', 'nsc 373364']",correct_mapping
TCR transduced autologous peripheral blood lymphocytes,Immuno-oncology therapy,TCR transduced autologous peripheral blood lymphocytes,,,,0,['TCR transduced autologous peripheral blood lymphocytes'],,0,[],0
TAS-0728,ErbB-2 antagonist,TAS-0728,,TAS-0728,tas 0728,fexact,"['TAS-0728', 'mutant HER2 inhibitor (cancer), Taiho Pharmaceuticals', 'TPC-107']",TAS-0728,fexact,"['tas 0728', 'mutant her2 inhibitor cancer taiho pharmaceuticals', 'tpc 107']",correct_mapping
BIO-11006,Myristoylated alanine-rich C kinase substrate inhibitor,BIO-11006,,BIO-11006 Inhalation Solution,bio 11006,fexact,"['BIO-11006 Inhalation Solution', 'BIO-11006']",BIO-11006 Inhalation Solution,fexact,"['bio 11006 inhalation solution', 'bio 11006']",correct_mapping
Chinese traditional medicine XH1,Unidentified pharmacological activity,Chinese traditional medicine XH1,,,,0,['Chinese traditional medicine XH1'],,0,[],0
Sheng Bai oral liquid,Unidentified pharmacological activity,Sheng Bai oral liquid,,,,0,['Sheng Bai oral liquid'],,0,[],0
cintirorgon,RORC RAR-related orphan receptor C gamma-t inhibitor; Immuno-oncology therapy,cintirorgon,,cintirorgon,cintirorgon,fexact,"['LYC-55716', 'cintirorgon']",cintirorgon,fexact,"['lyc 55716', 'cintirorgon']",correct_mapping
ASN-007,Mitogen-activated protein kinase 1 inhibitor; Mitogen-activated protein kinase 3 inhibitor,ASN-007,,ASN-007,asn 007,fexact,"['ASN-007', 'ERK inhibitors (cancer)', 'ERAS-007']",ASN-007,fexact,"['asn 007', 'erk inhibitors cancer', 'eras 007']",correct_mapping
"bevacizumab, Prestige BioPharma-1",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Prestige BioPharma-1,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
simlukafusp alfa,Interleukin 2 receptor agonist; Immuno-oncology therapy,simlukafusp alfa,,simlukafusp alfa,simlukafusp alfa,fexact,"['simlukafusp alfa', 'GA-501', 'FAP-targeted IL-2v antibody (solid tumor/RCC/metastatic melanoma), Hoffmann-La Roche', 'FAP-IL2v', 'RG-7461', 'RO-6874281', 'FAP-targeted IL-2v antibody (cancer), Hoffmann-La Roche']",simlukafusp alfa,fexact,"['simlukafusp alfa', 'ga 501', 'fap targeted il 2v antibody solid tumor rcc metastatic melanoma hoffmann la roche', 'fap il2v', 'rg 7461', 'ro 6874281', 'fap targeted il 2v antibody cancer hoffmann la roche']",correct_mapping
palbociclib (capsule),Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,palbociclib,,palbociclib,palbociclib,fexact,"['PF-332991', 'PD-0332991-00', 'cell cycle regulators', 'PD-0205606', 'palbociclib', 'cell cycle regulators,/Parke-Davis', 'PD-332991', 'palbociclib isethionate', 'PF-0332991', 'Aiboxin', 'PD-991', 'Ibrance', 'cell cycle regulators, Pfizer', 'cell cycle regulators,/', 'cell cycle regulators,/Pfizer', 'PD-0332991']",palbociclib,fexact,"['pf 332991', 'pd 0332991 00', 'cell cycle regulators', 'pd 0205606', 'palbociclib', 'cell cycle regulators parke davis', 'pd 332991', 'palbociclib isethionate', 'pf 0332991', 'aiboxin', 'pd 991', 'ibrance', 'cell cycle regulators pfizer', 'cell cycle regulators', 'cell cycle regulators pfizer', 'pd 0332991']",correct_mapping
CT-0508,ErbB-2 antagonist; T cell stimulant; Immuno-oncology therapy,CT-0508,,CT-0508,ct 0508,fexact,"['CARMA-0508', 'anti-her2 car macrophage therapy (advanced solid tumor)', 'car macrophage therapy (carma, solid tumor)', 'CT-0508']",CT-0508,fexact,"['carma 0508', 'anti her2 car macrophage therapy advanced solid tumor', 'car macrophage therapy carma solid tumor', 'ct 0508']",correct_mapping
FLX-475,T cell inhibitor; CC chemokine receptor 4 antagonist; Immuno-oncology therapy,FLX-475,,FLX-475,flx 475,fexact,"['FLX CCR4 antagonists (cancer), RAPT Therapeutics', 'FLX CCR4 antagonists (cancer), FLX Bio', 'FLX CCR4 antagonists (cancer)', 'Treg modulator (cancer)', 'Treg modulator (cancer), RAPT Therapeutics', 'FLX-475']",FLX-475,fexact,"['flx ccr4 antagonists cancer rapt therapeutics', 'flx ccr4 antagonists cancer flx bio', 'flx ccr4 antagonists cancer', 'treg modulator cancer', 'treg modulator cancer rapt therapeutics', 'flx 475']",correct_mapping
NEO-PV-01,Immuno-oncology therapy,NEO-PV-01,,NEO-PV-01,neo pv 01,fexact,"['NEO-PV-01', 'cancer vaccine, Neon Therapeutics', 'personal neoantigen vaccine (melanoma/NSCLC/bladder cancer), Neon Therapeutics', 'personal neoantigen vaccine (melanoma/NSCLC/bladder cancer)']",NEO-PV-01,fexact,"['neo pv 01', 'cancer vaccine neon therapeutics', 'personal neoantigen vaccine melanoma nsclc bladder cancer neon therapeutics', 'personal neoantigen vaccine melanoma nsclc bladder cancer']",correct_mapping
nintedanib (soft capsule),LYN tyrosine kinase inhibitor; FGF receptor tyrosine kinase inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Src inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor,nintedanib,,nintedanib,nintedanib,fexact,"['angiokinase inhibitors (cancer)', 'Vargatef', 'FGF/PDGF/VEGF receptor kinase inhibitors (cancer)', 'intedanib', 'Ofev', 'WeiJiaTe', 'nintedanib esylate', 'nintedanib ethanesulfonate', 'BIBF-1120 ES', 'nintedanib', 'Ofeb', 'BIBF-1120', 'Cyendiv']",nintedanib,fexact,"['angiokinase inhibitors cancer', 'vargatef', 'fgf pdgf vegf receptor kinase inhibitors cancer', 'intedanib', 'ofev', 'weijiate', 'nintedanib esylate', 'nintedanib ethanesulfonate', 'bibf 1120 es', 'nintedanib', 'ofeb', 'bibf 1120', 'cyendiv']",correct_mapping
RP-1,Immuno-oncology therapy,RP-1,,,,0,"['gamma-RP-1', 'kinocidin derivatives (bacterial infection)', 'RP-1']",,Drug_API_mapping,[],0
devimistat,Alpha ketoglutarate dehydrogenase inhibitor; Pyruvate dehydrogenase inhibitor,devimistat,,devimistat,devimistat,fexact,"['thioctans (injectable, cancer), Rafael Pharmaceuticals', 'ONO-7912', 'thioctans (injectable, cancer), Cornerstone Pharmaceuticals', 'CPI-613', 'devimistat', 'thioctoids (cancer), Cornerstone Pharmaceuticals', 'thioctans (injectable, cancer)', 'CPI-1410', 'lipoic acid derviatives (injectable, cancer), Rafael Pharmaceuticals', 'lipoic acid derviatives (injectable, cancer), Cornerstone Pharmaceuticals', 'thioctoids (cancer), Rafael Pharmaceuticals', 'lipoic acid derviatives (injectable, cancer)', 'thioctoids (cancer)']",devimistat,fexact,"['thioctans injectable cancer rafael pharmaceuticals', 'ono 7912', 'thioctans injectable cancer cornerstone pharmaceuticals', 'cpi 613', 'devimistat', 'thioctoids cancer cornerstone pharmaceuticals', 'thioctans injectable cancer', 'cpi 1410', 'lipoic acid derviatives injectable cancer rafael pharmaceuticals', 'lipoic acid derviatives injectable cancer cornerstone pharmaceuticals', 'thioctoids cancer rafael pharmaceuticals', 'lipoic acid derviatives injectable cancer', 'thioctoids cancer']",correct_mapping
isatuximab,CD38 antagonist; Immunostimulant; Immuno-oncology therapy,isatuximab,,isatuximab,isatuximab,fexact,"['SAR-650984', 'anti-CD38 monoclonal antibody (leukemia), ImmunoGen/sanofi-aventis', 'Sarclisa', 'isatuximab-irfc', 'isatuximab', 'anti-CD38 monoclonal antibody (leukemia),/sanofi-aventis']",isatuximab,fexact,"['sar 650984', 'anti cd38 monoclonal antibody leukemia immunogen sanofi aventis', 'sarclisa', 'isatuximab irfc', 'isatuximab', 'anti cd38 monoclonal antibody leukemia sanofi aventis']",correct_mapping
haploidentical natural killer cells,Immunostimulant,haploidentical natural killer cells,,,,0,['haploidentical natural killer cells'],,0,[],0
Dendritic Cells - Cytokine Induced Killer Cells,Immuno-oncology therapy,Dendritic Cells - Cytokine Induced Killer Cells,,,,0,['Dendritic Cells - Cytokine Induced Killer Cells'],,0,[],0
epacadostat,"Indoleamine 2,3-dioxygenase inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor",epacadostat,,epacadostat,epacadostat,fexact,"['INCB-24360', 'epacadostat', 'indoleamine 2,3-dioxygenase 1 inhibitors (cancer)', 'INCB-024360', 'IDO checkpoint inhibitor (cancer)', 'INCB-24360-203']",epacadostat,fexact,"['incb 24360', 'epacadostat', 'indoleamine 2 3 dioxygenase 1 inhibitors cancer', 'incb 024360', 'ido checkpoint inhibitor cancer', 'incb 24360 203']",correct_mapping
numidargistat,Arginase inhibitor; Immuno-oncology therapy,numidargistat,,numidargistat,numidargistat,fexact,"['INCB-01158', 'CB-1158', 'arginase inhibitors (oral, cancer)', 'arginase 1 and 2 inhibitor (oral, cancer/advanced solid tumor/colorectal/endometrioid/biliary/esophagus/ovary/multiple myeloma)', 'INCB-001158', 'numidargistat', 'arginase 1 and 2 inhibitor (oral, cancer/advanced solid tumor/colorectal/endometrioid/biliary/esophagus/ovary/multiple myeloma), Incyte']",numidargistat,fexact,"['incb 01158', 'cb 1158', 'arginase inhibitors oral cancer', 'arginase 1 and 2 inhibitor oral cancer advanced solid tumor colorectal endometrioid biliary esophagus ovary multiple myeloma', 'incb 001158', 'numidargistat', 'arginase 1 and 2 inhibitor oral cancer advanced solid tumor colorectal endometrioid biliary esophagus ovary multiple myeloma incyte']",correct_mapping
BCD-135,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,BCD-135,,BCD-135,bcd 135,fexact,"['anti PD-L1 monoclonal antibody (advanced solid tumor)', 'BCD-135', 'manelimab', 'anti PD-L1 mAb (advanced solid tumor)', 'PD-L1 checkpoint inhibitor (advanced solid tumor)']",BCD-135,fexact,"['anti pd l1 monoclonal antibody advanced solid tumor', 'bcd 135', 'manelimab', 'anti pd l1 mab advanced solid tumor', 'pd l1 checkpoint inhibitor advanced solid tumor']",correct_mapping
"bevacizumab, Luye pharma",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Luye pharma,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
autologous lung cancer specific cytotoxic lymphocytes,Unidentified pharmacological activity,autologous lung cancer specific cytotoxic lymphocytes,,,,0,['autologous lung cancer specific cytotoxic lymphocytes'],,0,[],0
lodapolimab,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,lodapolimab,,lodapolimab,lodapolimab,fexact,"['PD-L1 checkpoint inhibitor (solid tumor)', 'PD-L1 antibody + LY combo (cancer)', 'LY-3300054', 'anti-PD-L1 antibody (solid tumors)', 'PD-L1 mAb (cancer)', 'lodapolimab']",lodapolimab,fexact,"['pd l1 checkpoint inhibitor solid tumor', 'pd l1 antibody ly combo cancer', 'ly 3300054', 'anti pd l1 antibody solid tumors', 'pd l1 mab cancer', 'lodapolimab']",correct_mapping
LY-3381916,"Indoleamine 2,3-dioxygenase inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor",LY-3381916,,LY-3381916,ly 3381916,fexact,"['LY-3381916', 'IDO-1 checkpoint inhibitor (solid tumor)', 'indoleamine 2,3-dioxygenase 1 inhibitor (oral, solid tumor)', 'IDO1 inhibitor (cancer)', 'IDO checkpoint inhibitor (solid tumor)']",LY-3381916,fexact,"['ly 3381916', 'ido 1 checkpoint inhibitor solid tumor', 'indoleamine 2 3 dioxygenase 1 inhibitor oral solid tumor', 'ido1 inhibitor cancer', 'ido checkpoint inhibitor solid tumor']",correct_mapping
COM-701,PVRIG antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,COM-701,,COM-701,com 701,fexact,"['CGEN-15051', 'CGEN-15021T (recombinant fusion protein, autoimmune diseases)', 'COM-701', 'CGEN-15027', 'CGEN-15029', 'CGEN-15091', 'CGEN-15029 checkpoint inhibitor (cancer)', 'CGEN-15031', 'CGEN-15092', 'PVRIG-checkpoint inhibitor (cancer)', 'CGEN-15021']",COM-701,fexact,"['cgen 15051', 'cgen 15021t recombinant fusion protein autoimmune diseases', 'com 701', 'cgen 15027', 'cgen 15029', 'cgen 15091', 'cgen 15029 checkpoint inhibitor cancer', 'cgen 15031', 'cgen 15092', 'pvrig checkpoint inhibitor cancer', 'cgen 15021']",correct_mapping
ciforadenant,Adenosine A2a receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,ciforadenant,,ciforadenant,ciforadenant,fexact,"['VER-6623', 'Parkinsons therapeutics, Vernalis/Biogen Idec', 'Parkinsons therapeutics,/Biogen Idec', 'V-81444', 'checkpoint inhibitor A (oral, cancer)', 'A2aR checkpoint inhibitor (cancer/infectious disease/autoimmune diseases), Corvus/', 'A2aR checkpoint inhibitor (cancer/infectious disease/autoimmune diseases),/', 'Parkinsons therapeutics, Vernalis', 'A2aR checkpoint inhibitor (cancer), Vernalis/Corvus', 'A2aR checkpoint inhibitor (cancer), Vernalis/', 'adenosine A2a antagonists (Parkinsons disease), Vernalis', 'adenosine A2a antagonists (Parkinsons disease),/Biogen Idec', 'CPI-444', 'ciforadenant', 'checkpoint inhibitor A (oral, cancer), Corvus Pharmaceuticals', 'VER-4187', 'adenosine A2a antagonists (Parkinsons disease), Vernalis/Biogen Idec', 'A2aR checkpoint inhibitor (cancer),/', 'Parkinsons therapeutics', 'adenosine A2a antagonists (Parkinsons disease)']",ciforadenant,fexact,"['ver 6623', 'parkinsons therapeutics vernalis biogen idec', 'parkinsons therapeutics biogen idec', 'v 81444', 'checkpoint inhibitor a oral cancer', 'a2ar checkpoint inhibitor cancer infectious disease autoimmune diseases corvus', 'a2ar checkpoint inhibitor cancer infectious disease autoimmune diseases', 'parkinsons therapeutics vernalis', 'a2ar checkpoint inhibitor cancer vernalis corvus', 'a2ar checkpoint inhibitor cancer vernalis', 'adenosine a2a antagonists parkinsons disease vernalis', 'adenosine a2a antagonists parkinsons disease biogen idec', 'cpi 444', 'ciforadenant', 'checkpoint inhibitor a oral cancer corvus pharmaceuticals', 'ver 4187', 'adenosine a2a antagonists parkinsons disease vernalis biogen idec', 'a2ar checkpoint inhibitor cancer', 'parkinsons therapeutics', 'adenosine a2a antagonists parkinsons disease']",correct_mapping
"anti-CD73 MAb, Corvus Pharmaceuticals",Immuno-oncology therapy; CD73 antagonist,anti-CD73 MAb,Corvus Pharmaceuticals,,,0,['anti-CD73 MAb'],,0,[],0
linagliptin,Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue,linagliptin,,linagliptin,linagliptin,fexact,"['Trajenta', 'Trazenta', 'BI-1356', 'linagliptine', 'Trayenta', 'linagliptin', 'Ondero', 'BI-1356-BS', 'Tradjenta']",linagliptin,fexact,"['trajenta', 'trazenta', 'bi 1356', 'linagliptine', 'trayenta', 'linagliptin', 'ondero', 'bi 1356 bs', 'tradjenta']",correct_mapping
motixafortide,CXC chemokine receptor 4 antagonist,motixafortide,,motixafortide,motixafortide,fexact,"['BKT-140', 'BKT-140 (sc, cancer/stem cell mobilization)', 'motixafortide', 'BL-8040', 'CXCR4 antagonist (cancer/COVID-19 associated ARDS), Biokine', 'BKT-140 (sc, cancer/stem cell mobilization), Biokine', 'CXCR4 antagonist (cancer/COVID-19 associated ARDS)']",motixafortide,fexact,"['bkt 140', 'bkt 140 sc cancer stem cell mobilization', 'motixafortide', 'bl 8040', 'cxcr4 antagonist cancer covid 19 associated ards biokine', 'bkt 140 sc cancer stem cell mobilization biokine', 'cxcr4 antagonist cancer covid 19 associated ards']",correct_mapping
tazemetostat,Enhancer of zeste homolog 2 inhibitor,tazemetostat,,tazemetostat hydrobromide,tazemetostat,fexact,"['EPZ-005687', 'tazemetostat hydrobromide', 'E-7438', 'EZH2 inhibitors (cancer),/', 'tazemetostat', 'EPZ-6438', 'EPZ-5687', 'EZH2 inhibitors (cancer), EpiZyme/', 'Tazverik']",tazemetostat hydrobromide,fexact,"['epz 005687', 'tazemetostat hydrobromide', 'e 7438', 'ezh2 inhibitors cancer', 'tazemetostat', 'epz 6438', 'epz 5687', 'ezh2 inhibitors cancer epizyme', 'tazverik']",correct_mapping
cobimetinib (IV),Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,cobimetinib,,cobimetinib,cobimetinib,fexact,"['XL-518', 'MEK inhibitor (oral, cancer),/', 'Cotellic', 'RO-5514041', 'GDC-0973', 'MEK inhibitor (oral, cancer),/Genentech', '[14C]-GDC-0973', 'RG-7421', 'cobimetinib', 'RG-7420 (GDC-0973)', 'cobimetinib butyrate', 'MEK inhibitor (oral, cancer), Exelixis/Genentech', 'cobimetinib fumarate']",cobimetinib,fexact,"['xl 518', 'mek inhibitor oral cancer', 'cotellic', 'ro 5514041', 'gdc 0973', 'mek inhibitor oral cancer genentech', '14c gdc 0973', 'rg 7421', 'cobimetinib', 'rg 7420 gdc 0973', 'cobimetinib butyrate', 'mek inhibitor oral cancer exelixis genentech', 'cobimetinib fumarate']",correct_mapping
cibisatamab,CD3 agonist; Immuno-oncology therapy,cibisatamab,,cibisatamab,cibisatamab,fexact,"['anti-CD3/anti-CEA bispecific T-cell engager (TCB, solid tumors)', 'cibisatamab', 'RG-7802', 'RO-6958688', 'CEA-TCB', 'anti-CD3/anti-CEA bispecific T-cell engager (TCB, solid tumors), Roche', 'T-cell bispecific antibody (iv, solid tumors), Roche', 'T-cell bispecific antibody (iv, solid tumors)']",cibisatamab,fexact,"['anti cd3 anti cea bispecific t cell engager tcb solid tumors', 'cibisatamab', 'rg 7802', 'ro 6958688', 'cea tcb', 'anti cd3 anti cea bispecific t cell engager tcb solid tumors roche', 't cell bispecific antibody iv solid tumors roche', 't cell bispecific antibody iv solid tumors']",correct_mapping
"PD-L1 CAR-T cells, Guangzhou Yiyang Biological Technology Co., Ltd",Immuno-oncology therapy,PD-L1 CAR-T cells,Ltd,,,0,['PD-L1 CAR-T cells'],,0,[],0
"bevacizumab, Bio-Thera Solutions",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Bio-Thera Solutions,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
cediranib,C-kit inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,cediranib,,cediranib,cediranib,fexact,"['Zemfirza', 'cediranib  maleate', 'cediranib', 'Recentin', 'AZD-2171']",cediranib,fexact,"['zemfirza', 'cediranib maleate', 'cediranib', 'recentin', 'azd 2171']",correct_mapping
vistusertib,mTORC1 kinase inhibitor; mTORC2 kinase inhibitor,vistusertib,,vistusertib,vistusertib,fexact,"['mTOR inhibitors (cancer), KuDOS', 'AZD-2014', 'mTOR inhibitors (cancer)', 'KU-63794', 'vistusertib', 'KU-0063794']",vistusertib,fexact,"['mtor inhibitors cancer kudos', 'azd 2014', 'mtor inhibitors cancer', 'ku 63794', 'vistusertib', 'ku 0063794']",correct_mapping
gavocabtagene autoleucel,T cell stimulant; Immuno-oncology therapy,gavocabtagene autoleucel,,gavocabtagene autoleucel,gavocabtagene autoleucel,fexact,"['anti-mesothelin TCR T-cell therapy (TRuC, solid tumor), TCR2\xa0Therapeutics', 'TC-210', 'gavocabtagene autoleucel', 'gavocabtagene autoleucel (solid tumor)', 'anti-mesothelin TRuC T-cell therapy (solid tumor)', 'mesothelin-TRuC-T cell therapy', 'Gavo-cel', 'TC-210 + PD1 Switch', 'MSLN-e-TRuC']",gavocabtagene autoleucel,fexact,"['anti mesothelin tcr t cell therapy truc solid tumor tcr2\xa0therapeutics', 'tc 210', 'gavocabtagene autoleucel', 'gavocabtagene autoleucel solid tumor', 'anti mesothelin truc t cell therapy solid tumor', 'mesothelin truc t cell therapy', 'gavo cel', 'tc 210 pd1 switch', 'msln e truc']",correct_mapping
"ASN-004, Asana BioSciences",Unidentified pharmacological activity,ASN-004,Asana BioSciences,ASN-004,asn 004,fexact,['ASN-004'],ASN-004,fexact,['asn 004'],correct_mapping
"adegramotide and nelatimotide, Boston Biomedical",Immunostimulant; T cell stimulant; Immuno-oncology therapy,adegramotide and nelatimotide,Boston Biomedical,ombipepimut-S,adegramotide nelatimotide,fuzzy,"['adegramotide acetate + nelatimotide triflutate', 'adegramotide + nelatimotide', 'elatipepimut-S triflutate + adegramotide acetate', 'adegrapepimut-S acetate + nelatimotide triflutate', 'DSP-7888', 'elatipepimut-S + adegramotide', 'nelatimotide triflutate + adegramotide acetate', 'ombipepimut-S', 'nelatimotide + adegramotide', 'nelatimotide trifluoroacetate+ adegramotide acetate', 'adegrapepimut-S + nelatimotide']",ombipepimut-S,fexact,"['adegramotide acetate nelatimotide triflutate', 'adegramotide nelatimotide', 'elatipepimut s triflutate adegramotide acetate', 'adegrapepimut s acetate nelatimotide triflutate', 'dsp 7888', 'elatipepimut s adegramotide', 'nelatimotide triflutate adegramotide acetate', 'ombipepimut s', 'nelatimotide adegramotide', 'nelatimotide trifluoroacetate adegramotide acetate', 'adegrapepimut s nelatimotide']",incorrect_mapping
BI-765063,Immuno-oncology therapy; Signal regulatory protein alpha antagonist; Immune checkpoint inhibitor,BI-765063,,BI-765063,bi 765063,fexact,"['BI-765063', 'Effi-DEM', 'sirpa checkpoint inhibitor (cancer)', 'OSE-172', 'SIRPa checkpoint inhibitor (cancer), OSE Immunotherapeutics']",BI-765063,fexact,"['bi 765063', 'effi dem', 'sirpa checkpoint inhibitor cancer', 'ose 172', 'sirpa checkpoint inhibitor cancer ose immunotherapeutics']",correct_mapping
mesenchymal stromal cells expressing TRAIL,TRAIL receptor agonist,mesenchymal stromal cells expressing TRAIL,,,,0,['mesenchymal stromal cells expressing TRAIL'],,0,[],0
"bevacizumab, Mabxience",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Mabxience,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
PT-112,Apoptosis stimulant,PT-112,,imifoplatin,pt 112,fexact,"['imifoplatin', 'phosphaplatin compounds (cancer), Phosplatin', 'phosphaplatin compounds (cancer)', 'PT-112 and its analogs (cancer)', 'PT-112', 'PT-112 and its analogs (cancer), Phosplatin']",imifoplatin,fexact,"['imifoplatin', 'phosphaplatin compounds cancer phosplatin', 'phosphaplatin compounds cancer', 'pt 112 and its analogs cancer', 'pt 112', 'pt 112 and its analogs cancer phosplatin']",correct_mapping
zalifrelimab,CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,zalifrelimab,,zalifrelimab,zalifrelimab,fexact,"['zalifrelimab', 'ctla-4 targeted antibody program (cancer, nsclc)', 'fully human antibodies (cancer, NSCLC), Agenus', 'CTLA-4 checkpoint inhibitor (Retrocyte, cancer/NSCLC)', 'fully human antibodies (cancer, NSCLC)', 'CTLA-4 targeted antibody program (cancer, NSCLC),/Ludwig Institute for Cancer Research', 'AGEN-1884', 'CTLA-4 checkpoint inhibitor (Retrocyte,/NSCLC)']",zalifrelimab,fexact,"['zalifrelimab', 'ctla 4 targeted antibody program cancer nsclc', 'fully human antibodies cancer nsclc agenus', 'ctla 4 checkpoint inhibitor retrocyte cancer nsclc', 'fully human antibodies cancer nsclc', 'ctla 4 targeted antibody program cancer nsclc ludwig institute for cancer research', 'agen 1884', 'ctla 4 checkpoint inhibitor retrocyte nsclc']",correct_mapping
PBF-1129,Adenosine A2b receptor antagonist,PBF-1129,,PBF-1129,pbf 1129,fexact,"['PBF-1129', 'PBF-1250', 'A2bR checkpoint inhibitor (cancer/idiopathic pulmonary fibrosis)']",PBF-1129,fexact,"['pbf 1129', 'pbf 1250', 'a2br checkpoint inhibitor cancer idiopathic pulmonary fibrosis']",correct_mapping
JinFuKang,Unidentified pharmacological activity,JinFuKang,,,,0,['JinFuKang'],,0,[],0
molibresib,BET protein inhibitor,molibresib,,molibresib,molibresib,fexact,"['GSK-525762C', 'molibresib', 'BET inhibitor (oral, cancer)', 'I-BET-726', 'GSK-525762', 'GSK-525762A', '525762', ""GSK'762"", 'GSK-1324726A', 'I-BET-762', 'ApoA1 upregulating agents (atherosclerosis), GSK']",molibresib,fexact,"['gsk 525762c', 'molibresib', 'bet inhibitor oral cancer', 'i bet 726', 'gsk 525762', 'gsk 525762a', '525762', 'gsk 762', 'gsk 1324726a', 'i bet 762', 'apoa1 upregulating agents atherosclerosis gsk']",correct_mapping
TAK-931 (tablet),Cdc7 kinase inhibitor,TAK-931,,simurosertib hydrate,tak 931,fexact,"['TAK-931', 'simurosertib', 'simurosertib hydrate']",simurosertib hydrate,fexact,"['tak 931', 'simurosertib', 'simurosertib hydrate']",correct_mapping
idelalisib,Protein kinase inhibitor; PI3 kinase delta inhibitor; CC chemokine ligand antagonist,idelalisib,,idelalisib,idelalisib,fexact,"['CAL-101', 'PI3K delta inhibitors (inflammation/cancer),/', 'GS-1101', 'lipid kinase inhibitors', 'idelalisib (inflammation/autoimmunity/cancer)', 'p110 delta PI3 kinase inhibitors (inflammation/cancer)', 'idelalisib (inflammation/autoimmunity/cancer), ICOS', 'lipid kinase inhibitors, ICOS', 'Zydelig', 'IC-980033', 'PI3K delta inhibitors (inflammation/cancer), ICOS/', 'P13K delta inhibitors (inflammation/cancer)', 'lipid kinase inhibitors (inflammation/autoimmunity/cancer), ICOS', 'idelalisib', 'p110 delta PI3 kinase inhibitors (inflammation/cancer), ICOS', 'IC-87114', 'lipid kinase inhibitors (inflammation/autoimmunity/cancer)', 'P13K delta inhibitors (inflammation/cancer), Eli Lilly']",idelalisib,fexact,"['cal 101', 'pi3k delta inhibitors inflammation cancer', 'gs 1101', 'lipid kinase inhibitors', 'idelalisib inflammation autoimmunity cancer', 'p110 delta pi3 kinase inhibitors inflammation cancer', 'idelalisib inflammation autoimmunity cancer icos', 'lipid kinase inhibitors icos', 'zydelig', 'ic 980033', 'pi3k delta inhibitors inflammation cancer icos', 'p13k delta inhibitors inflammation cancer', 'lipid kinase inhibitors inflammation autoimmunity cancer icos', 'idelalisib', 'p110 delta pi3 kinase inhibitors inflammation cancer icos', 'ic 87114', 'lipid kinase inhibitors inflammation autoimmunity cancer', 'p13k delta inhibitors inflammation cancer eli lilly']",correct_mapping
lerociclib,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,lerociclib,,lerociclib,lerociclib,fexact,"['GB-491', 'lerociclib', 'G1T-38', 'G1T38-1']",lerociclib,fexact,"['gb 491', 'lerociclib', 'g1t 38', 'g1t38 1']",correct_mapping
DBPR-112,Unidentified pharmacological activity,DBPR-112,,DBPR-112,dbpr 112,fexact,['DBPR-112'],DBPR-112,fexact,['dbpr 112'],correct_mapping
INCAGN-1949,CD134 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,INCAGN-1949,,INCAGN-1949,incagn 1949,fexact,"['anti-OX40 agonist monoclonal antibody (cancer),/Ludwig Institute/Memorial Sloan-Kettering Cancer Center', 'anti-ox40 agonist monoclonal antibody (cancer)', 'INCAGN-1949', 'INCAGN-01949', 'OX40 costimulator (Retrocyte, cancer),/', 'OX40 costimulator (Retrocyte, cancer),/Incyte', 'anti-OX40 agonist monoclonal antibody (cancer),//Memorial Sloan-Kettering Cancer Center']",INCAGN-1949,fexact,"['anti ox40 agonist monoclonal antibody cancer ludwig institute memorial sloan kettering cancer center', 'anti ox40 agonist monoclonal antibody cancer', 'incagn 1949', 'incagn 01949', 'ox40 costimulator retrocyte cancer', 'ox40 costimulator retrocyte cancer incyte', 'anti ox40 agonist monoclonal antibody cancer memorial sloan kettering cancer center']",correct_mapping
VB10.NEO,Immunostimulant; Immuno-oncology therapy,VB10.NEO,,VB-10.NEO,vb 10 neo,fuzzy,"['VB-10.NEO', 'therapeutic dna vaccines (prostate cancer/melanoma)', 'therapeutic DNA vaccines (prostate cancer/melanoma), Vaccibody/University of Southampton', 'therapeutic DNA vaccines (advanced or metastatic solid tumors)', 'therapeutic dna vaccines (prostate cancer/melanoma), vaccibody', 'therapeutic DNA vaccines (advanced or metastatic solid tumors), Vaccibody']",VB-10.NEO,fexact,"['vb 10 neo', 'therapeutic dna vaccines prostate cancer melanoma', 'therapeutic dna vaccines prostate cancer melanoma vaccibody university of southampton', 'therapeutic dna vaccines advanced or metastatic solid tumors', 'therapeutic dna vaccines prostate cancer melanoma vaccibody', 'therapeutic dna vaccines advanced or metastatic solid tumors vaccibody']",incorrect_mapping
targinine,Inducible nitric oxide synthase inhibitor,targinine,,,,0,"['BW-546C88', 'tilarginine', 'targinine', '546C88', 'L-NMMA HCl', 'nitric oxide inhibitor']",,NER_API,[],0
tetrahydrouridine,Cytidine deaminase inhibitor,tetrahydrouridine,,5-Fluoro-2-deoxycytidine,tetrahydrouridine,fexact,"['5-Fluoro-2-deoxycytidine', 'FdCyd', 'tetrahydrouridine', ""5-Fluoro-2'-deoxycytidine""]",5-Fluoro-2-deoxycytidine,fexact,"['5 fluoro 2 deoxycytidine', 'fdcyd', 'tetrahydrouridine', '5 fluoro 2 deoxycytidine']",correct_mapping
decitabine (oral),DNA methylase inhibitor,decitabine,,decitabine,decitabine,fexact,"['NSC-127716', 'IND-50733', '5-aza-CdR', ""5-aza-2'-deoxycytidine"", '5-aza-2-deoxycytidine', 'decitabine (intravenous, myelodysplastic syndromes/acute myeloid leukemia)', 'Dacogen', 'Dakogen', 'DAC', 'decitabine', 'E-7373', 'decitabine (intravenous, myelodysplastic syndromes/acute myeloid leukemia), Eisai', '5-CdR', '5-azadeoxycytidine', 'AZA-DC', 'JNJ-30979754']",decitabine,fexact,"['nsc 127716', 'ind 50733', '5 aza cdr', '5 aza 2 deoxycytidine', '5 aza 2 deoxycytidine', 'decitabine intravenous myelodysplastic syndromes acute myeloid leukemia', 'dacogen', 'dakogen', 'dac', 'decitabine', 'e 7373', 'decitabine intravenous myelodysplastic syndromes acute myeloid leukemia eisai', '5 cdr', '5 azadeoxycytidine', 'aza dc', 'jnj 30979754']",correct_mapping
serclutamab talirine,EGFR antagonist,serclutamab talirine,,serclutamab talirine,serclutamab talirine,fexact,"['ABBV-321', 'serclutamab talirine', 'EGFR-targeting antibody-drug conjugate (iv, advanced solid tumors)']",serclutamab talirine,fexact,"['abbv 321', 'serclutamab talirine', 'egfr targeting antibody drug conjugate iv advanced solid tumors']",correct_mapping
avdoralimab,C5a inhibitor; Immuno-oncology therapy,avdoralimab,,,,0,"['NN-8210', 'NNC-0215-0384', 'avdoralimab', 'anti-C5aR-215']",,NER_API,[],0
ALT-803 (SC),Interleukin 15 agonist; Immuno-oncology therapy,ALT-803,,nogapendekin alfa,alt 803,fexact,"['modified human IL-15 (malaria)', 'nogapendekin alfa', 'N-803', 'Anktiva', 'ALT-803', 'IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer)']",nogapendekin alfa,fexact,"['modified human il 15 malaria', 'nogapendekin alfa', 'n 803', 'anktiva', 'alt 803', 'il 15 agonist il 15r alpha fc fusion complex cancer']",correct_mapping
trigriluzole,Dopamine receptor agonist; Glutamate antagonist; Sodium channel antagonist,trigriluzole,,troriluzole hydrochloride,trigriluzole,fexact,"['troriluzole', 'trigriluzole', 'riluzole prodrug (spinocerebellar ataxia/anxiety disorder/mood disorder/depression), Biohaven Pharmaceutical', 'BHV-4157', 'FC-4157', 'riluzole prodrug (spinocerebellar ataxia), Biohaven Pharmaceutical', 'troriluzole hydrochloride', 'riluzole prodrug (spinocerebellar ataxia/anxiety disorder/mood disorder/depression)', 'riluzole prodrug (spinocerebellar ataxia/anxiety disorder/mood disorder/depression/Alzheimer disease), Biohaven Pharmaceutical', 'riluzole prodrug (spinocerebellar ataxia/anxiety disorder/mood disorder/depression/Alzheimer disease)', 'riluzole prodrug (spinocerebellar ataxia)']",troriluzole hydrochloride,fexact,"['troriluzole', 'trigriluzole', 'riluzole prodrug spinocerebellar ataxia anxiety disorder mood disorder depression biohaven pharmaceutical', 'bhv 4157', 'fc 4157', 'riluzole prodrug spinocerebellar ataxia biohaven pharmaceutical', 'troriluzole hydrochloride', 'riluzole prodrug spinocerebellar ataxia anxiety disorder mood disorder depression', 'riluzole prodrug spinocerebellar ataxia anxiety disorder mood disorder depression alzheimer disease biohaven pharmaceutical', 'riluzole prodrug spinocerebellar ataxia anxiety disorder mood disorder depression alzheimer disease', 'riluzole prodrug spinocerebellar ataxia']",correct_mapping
"IL-2 iv gene therapy, Urigen",Interleukin 2 agonist; Immunostimulant; Interferon receptor agonist,IL-2 iv gene therapy,Urigen,,,0,['IL-2 iv gene therapy'],,0,[],0
mocetinostat,Histone deacetylase inhibitor; Cell cycle inhibitor,mocetinostat,,mocetinostat dihydrobromide,mocetinostat,fexact,"['HDAC inhibitors (cancer)', 'mocetinostat dihydrobromide', 'histone deacetylase inhibitor (cancer),/Taiho/', 'MGCD-0103 (oral),//', 'histone deacetylase inhibitor (cancer), MethylGene/ Taiho/ Pharmion', 'histone deacetylase inhibitor (cancer),/ Taiho/', 'MG-4230', 'HDAC inhibitors (cancer), MethylGene', 'MGCD-3650', 'MGCD-0103 (oral),/Taiho/Pharmion', 'MG-5026', 'MGCD-0103 (oral), MethylGene/Taiho/', 'histone deacetylase inhibitor (cancer),/ Taiho/ Pharmion', 'MG-0103', 'MGCD-0103', 'MGCD-0103 (oral),/Taiho/', 'histone deacetylase inhibitor (cancer),//', 'histone deacetylase inhibitor (cancer), MethylGene/Taiho/', 'MGCD-103', 'mocetinostat', 'MGCD-0103 (oral), MethylGene/Taiho/Pharmion', 'MG-4915']",mocetinostat dihydrobromide,fexact,"['hdac inhibitors cancer', 'mocetinostat dihydrobromide', 'histone deacetylase inhibitor cancer taiho', 'mgcd 0103 oral', 'histone deacetylase inhibitor cancer methylgene taiho pharmion', 'histone deacetylase inhibitor cancer taiho', 'mg 4230', 'hdac inhibitors cancer methylgene', 'mgcd 3650', 'mgcd 0103 oral taiho pharmion', 'mg 5026', 'mgcd 0103 oral methylgene taiho', 'histone deacetylase inhibitor cancer taiho pharmion', 'mg 0103', 'mgcd 0103', 'mgcd 0103 oral taiho', 'histone deacetylase inhibitor cancer', 'histone deacetylase inhibitor cancer methylgene taiho', 'mgcd 103', 'mocetinostat', 'mgcd 0103 oral methylgene taiho pharmion', 'mg 4915']",correct_mapping
"tumour infiltrating lymphocytes, Iovance Biotherapeutics-1",Immunostimulant; Immuno-oncology therapy,tumour infiltrating lymphocytes,Iovance Biotherapeutics-1,,,0,['tumour infiltrating lymphocytes'],,0,[],0
I-010,EGFR antagonist,I-010,,SPH-1188-11,i 010,fexact,"['SPH-1188', 'I-010', 'SPH-1188-11', 'small molecule therapeutic (oral/tablet, NSCLC)']",SPH-1188-11,fexact,"['sph 1188', 'i 010', 'sph 1188 11', 'small molecule therapeutic oral tablet nsclc']",correct_mapping
PBF-509,Adenosine A2a receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,PBF-509,,taminadenant,pbf 509,fexact,"['taminadenant', ""adenosine A2a antagonist (oral, Parkinson's disease)"", 'A2aR checkpoint inhibitor (solid tumor), Palobiofarma/', 'A2aR checkpoint inhibitor (solid tumor),/', 'PBF-509', ""adenosine A2a antagonist (Parkinson's disease)"", ""adenosine A2a antagonist (oral, Parkinson's disease), Palobiofarma"", 'NIR-178', ""adenosine A2a antagonist (Parkinson's disease), Palobiofarma""]",taminadenant,fexact,"['taminadenant', 'adenosine a2a antagonist oral parkinson s disease', 'a2ar checkpoint inhibitor solid tumor palobiofarma', 'a2ar checkpoint inhibitor solid tumor', 'pbf 509', 'adenosine a2a antagonist parkinson s disease', 'adenosine a2a antagonist oral parkinson s disease palobiofarma', 'nir 178', 'adenosine a2a antagonist parkinson s disease palobiofarma']",correct_mapping
Neo-MASCT,Immuno-oncology therapy,Neo-MASCT,,,,0,['Neo-MASCT'],,0,[],0
NK immunotherapy,Immunostimulant,NK immunotherapy,,,,0,['NK immunotherapy'],,0,[],0
"natural killer T cell therapy, Shanghai Houchao Biotechnology",Immunostimulant; T cell stimulant; Natural killer cell stimulant; Natural Killer T cell stimulant; Immuno-oncology therapy,natural killer T cell therapy,Shanghai Houchao Biotechnology,,,0,['natural killer T cell therapy'],,0,[],0
Huaier Granule,Unidentified pharmacological activity,Huaier Granule,,,,0,['Huaier Granule'],,0,[],0
"bevacizumab, Qilu",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Qilu,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
"TTI-101, Tvardi Therapeutics",STAT transcription factor 3 inhibitor,TTI-101,Tvardi Therapeutics,TTI-101,tti 101,fexact,"['C-188-9', 'MM-206', 'stat3 inhibitor (cancer),//tvardi therapeutics', 'TTI-101', 'STAT3 inhibitor (oral, advanced solid tumors)', 'STAT3 inhibitor (oral, advanced solid tumors), Tvardi Therapeutics', 'C-188', 'stat3 inhibitor (cancer),//', 'stat3 inhibitor (cancer), stemmed//tvardi therapeutics']",TTI-101,fexact,"['c 188 9', 'mm 206', 'stat3 inhibitor cancer tvardi therapeutics', 'tti 101', 'stat3 inhibitor oral advanced solid tumors', 'stat3 inhibitor oral advanced solid tumors tvardi therapeutics', 'c 188', 'stat3 inhibitor cancer', 'stat3 inhibitor cancer stemmed tvardi therapeutics']",correct_mapping
"high efficient killing cell therapy, Shanghai Houchao Biotechnology",Immunostimulant; Immuno-oncology therapy,high efficient killing cell therapy,Shanghai Houchao Biotechnology,,,0,"['HEKT cell therapy', 'high efficient killing cell therapy']",,Drug_API_mapping,[],0
ABI-009 (IV),Immunosuppressant; mTOR kinase inhibitor; Protein kinase inhibitor; Angiogenesis inhibitor; T cell inhibitor; Cell cycle inhibitor,ABI-009,,"sirolimus (albumin-bound nanoparticle, cancer, intravenous)",abi 009,fexact,"['sirolimus (albumin-bound nanoparticle, cancer, intravenous)', 'sirolimus (albumin-bound nanoparticle, cancer, intravenous), Celgene', 'Fyarro', 'rapamycin', 'sirolimus (albumin-bound nanoparticle, intravenous)', 'rapamycin (albumin-bound nanoparticle, intravenous)', 'ABI-009', 'nab-rapamycin', 'sirolimus (albumin-bound nanoparticle, intravenous), Abraxis', 'nab-Sirolimus', 'rapamycin (albumin-bound nanoparticle, intravenous), Abraxis', 'sirolimus', 'TARZIFYX']","sirolimus (albumin-bound nanoparticle, cancer, intravenous)",fexact,"['sirolimus albumin bound nanoparticle cancer intravenous', 'sirolimus albumin bound nanoparticle cancer intravenous celgene', 'fyarro', 'rapamycin', 'sirolimus albumin bound nanoparticle intravenous', 'rapamycin albumin bound nanoparticle intravenous', 'abi 009', 'nab rapamycin', 'sirolimus albumin bound nanoparticle intravenous abraxis', 'nab sirolimus', 'rapamycin albumin bound nanoparticle intravenous abraxis', 'sirolimus', 'tarzifyx']",correct_mapping
carotuximab,CD105 antagonist,carotuximab,,carotuximab,carotuximab,fexact,"['anti-CD105 antibody (cancer)', '66Ga-NOTA-TRC-105', 'endoglin-targeting monoclonal antibody (cancer)', 'anti-CD105 antibody (cancer), TRACON Pharmaceuticals', '64Cu-NOTA-GO-TRC-105', 'endoglin MAbs, TRACON', '64Cu-TRC-105', 'TRC-105', '64Cu-NOTA-TRC-105-800CW', 'SN6j', '66Ga-NOTA-GO-TRC-105', 'SN6k', 'P3-2G8', '66Ga-TRC-105', 'Y4-2F1', 'K4-2C10', 'endoglin-targeting monoclonal antibody (cancer), TRACON Pharmaceuticals', 'SN6a', 'endoglin MAbs', 'SN6f', '177Lu-DTPA-TRC-105', 'carotuximab']",carotuximab,fexact,"['anti cd105 antibody cancer', '66ga nota trc 105', 'endoglin targeting monoclonal antibody cancer', 'anti cd105 antibody cancer tracon pharmaceuticals', '64cu nota go trc 105', 'endoglin mabs tracon', '64cu trc 105', 'trc 105', '64cu nota trc 105 800cw', 'sn6j', '66ga nota go trc 105', 'sn6k', 'p3 2g8', '66ga trc 105', 'y4 2f1', 'k4 2c10', 'endoglin targeting monoclonal antibody cancer tracon pharmaceuticals', 'sn6a', 'endoglin mabs', 'sn6f', '177lu dtpa trc 105', 'carotuximab']",correct_mapping
lipo-flurbiprofen,Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor,lipo-flurbiprofen,,,,0,['lipo-flurbiprofen'],,0,[],0
personalized synthetic long peptide vaccine,Unidentified pharmacological activity,personalized synthetic long peptide vaccine,,,,0,['personalized synthetic long peptide vaccine'],,0,[],0
BI891065,IAP antagonist,BI891065,,BI-891065,bi 891065,fuzzy,"['SMAC mimetics (cancer)', 'BI-891065', 'BI-5']",BI-891065,fexact,"['smac mimetics cancer', 'bi 891065', 'bi 5']",incorrect_mapping
CV-9202,Unidentified pharmacological activity,CV-9202,,BI-1361849,cv 9202,fexact,"['BI-1361849', 'CV-9202']",BI-1361849,fexact,"['bi 1361849', 'cv 9202']",correct_mapping
tarlatamab,CD3 agonist; Immuno-oncology therapy,tarlatamab,,AMG-757,tarlatamab,fexact,"['anti-CD3/anti-DLL3 bispecific T-cell engager (HLE-BiTE, solid tumor)', 'DLL3-BiTE', 'tarlatamab', 'AMG-757', 'delta-like ligand-3 bispecific T-cell engager antibody construct (small-cell lung cancer)', 'HLE DLL3-BiTE']",AMG-757,fexact,"['anti cd3 anti dll3 bispecific t cell engager hle bite solid tumor', 'dll3 bite', 'tarlatamab', 'amg 757', 'delta like ligand 3 bispecific t cell engager antibody construct small cell lung cancer', 'hle dll3 bite']",correct_mapping
AMG-404,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,AMG-404,,AMG-404,amg 404,fexact,"['AMG-404', 'anti-PD-1 mAb (iv, advanced solid tumor/B-cell acute lymphoblastic leukemia/glioblastoma)', 'anti-PD-1 mAb (solid tumor)', 'PD-1 checkpoint inhibitor (iv, advanced solid tumor/B-cell acute lymphoblastic leukemia/glioblastoma)', 'PD-1 checkpoint inhibitor (advanced solid tumor)']",AMG-404,fexact,"['amg 404', 'anti pd 1 mab iv advanced solid tumor b cell acute lymphoblastic leukemia glioblastoma', 'anti pd 1 mab solid tumor', 'pd 1 checkpoint inhibitor iv advanced solid tumor b cell acute lymphoblastic leukemia glioblastoma', 'pd 1 checkpoint inhibitor advanced solid tumor']",correct_mapping
topotecan,DNA topoisomerase I inhibitor,topotecan,,topotecan,topotecan,fexact,"['nogitecan HCl', 'nogitecan', 'SKFS-104864-A', 'Evotopin', 'SKF-104864', 'NSC-609699', 'Hycamtim', 'hycaptamine', 'Hycamtin', 'hycamptamine', 'topotecan lactone', 'SKF-104864-A', 'NK-211', 'topotecan', 'Hicamtin']",topotecan,fexact,"['nogitecan hcl', 'nogitecan', 'skfs 104864 a', 'evotopin', 'skf 104864', 'nsc 609699', 'hycamtim', 'hycaptamine', 'hycamtin', 'hycamptamine', 'topotecan lactone', 'skf 104864 a', 'nk 211', 'topotecan', 'hicamtin']",correct_mapping
SH-3809,"Tyrosine phosphatase, non-receptor type 11 inhibitor",SH-3809,,SH-3809,sh 3809,fexact,['SH-3809'],SH-3809,fexact,['sh 3809'],correct_mapping
SI-B003,PD-1 antagonist; CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,SI-B003,,SI-B-003,si b 003,fuzzy,['SI-B-003'],SI-B-003,fexact,['si b 003'],incorrect_mapping
tidutamab,CD3 agonist; Immuno-oncology therapy,tidutamab,,tidutamab,tidutamab,fexact,"['XmAb-18087', 'tidutamab', 'anti-CD3/anti-SSTR2 bispecific T-cell engager (neuroendocrine tumor/GIST)']",tidutamab,fexact,"['xmab 18087', 'tidutamab', 'anti cd3 anti sstr2 bispecific t cell engager neuroendocrine tumor gist']",correct_mapping
AL-8326,Fibroblast growth factor receptor antagonist; Vascular endothelial growth factor (VEGF)receptor antagonist; Aurora kinase inhibitor,AL-8326,,AL-8326,al 8326,fexact,['AL-8326'],AL-8326,fexact,['al 8326'],correct_mapping
BMS-986253 (intravenous),Interleukin 8 antagonist; Immuno-oncology therapy,BMS-986253,,BMS-986253,bms 986253,fexact,"['HuMax-IL8', 'BMS-986253', 'anti-inflammatory antibody, Medarex/Genmab', 'anti-inflammatory antibody,/', 'anti-inflammatory therapeutic, Genmab/Medarex', 'BMS-968253', 'anti-inflammatory therapeutic,/', 'MDX-018', 'anti-inflammatory antibody, Medarex/', 'IL-8 targeting antibody (intravenous, hematological neoplasm/COVID-19 associated respiratory disease)', 'anti-inflammatory therapeutic,/Medarex', 'HuMax-Inflam']",BMS-986253,fexact,"['humax il8', 'bms 986253', 'anti inflammatory antibody medarex genmab', 'anti inflammatory antibody', 'anti inflammatory therapeutic genmab medarex', 'bms 968253', 'anti inflammatory therapeutic', 'mdx 018', 'anti inflammatory antibody medarex', 'il 8 targeting antibody intravenous hematological neoplasm covid 19 associated respiratory disease', 'anti inflammatory therapeutic medarex', 'humax inflam']",correct_mapping
"barasertib, AstraZeneca",Aurora kinase inhibitor; Protein kinase inhibitor; Mitotic inhibitor,barasertib,AstraZeneca,barasertib,barasertib,fexact,"['AZD-1152-hQPA', 'AZD-1152', 'barasertib', 'AZD-1152-hydroxyQPA', 'aurora kinase inhibitors']",barasertib,fexact,"['azd 1152 hqpa', 'azd 1152', 'barasertib', 'azd 1152 hydroxyqpa', 'aurora kinase inhibitors']",correct_mapping
vedolizumab,Immunosuppressant; Alpha4beta7 integrin antagonist; Integrin antagonist,vedolizumab,,vedolizumab,vedolizumab,fexact,"['vedolizumab', 'integrin antagonists, Millennium/', 'Kintelles', 'MLN-02', 'anti alpha-4/beta-7 integrin antibody', 'anti alpha-4/beta-7 integrin antibody, Millennium/', 'MLN-0002', 'Entyvio', 'Kynteles', 'LDP-02', 'anti alpha-4/beta-7 integrin antibody, LeukoSite']",vedolizumab,fexact,"['vedolizumab', 'integrin antagonists millennium', 'kintelles', 'mln 02', 'anti alpha 4 beta 7 integrin antibody', 'anti alpha 4 beta 7 integrin antibody millennium', 'mln 0002', 'entyvio', 'kynteles', 'ldp 02', 'anti alpha 4 beta 7 integrin antibody leukosite']",correct_mapping
infliximab,Tumour necrosis factor alpha antagonist,infliximab,,infliximab,infliximab,fexact,"['Remicade', 'anti-TNF-alpha MAb', 'CenTNF', 'cA2 antibody', 'SCH-215596', 'Avakine', 'Remicad', 'anti-TNF-alpha MAb, Tanabe', 'infliximab', 'TA-650']",infliximab,fexact,"['remicade', 'anti tnf alpha mab', 'centnf', 'ca2 antibody', 'sch 215596', 'avakine', 'remicad', 'anti tnf alpha mab tanabe', 'infliximab', 'ta 650']",correct_mapping
"avasopasem manganese, Galera Therapeutics",Superoxide dismutase stimulant,avasopasem manganese,Galera Therapeutics,avasopasem manganese,avasopasem manganese,fexact,"['imisopasem manganese enantiomer (cancer), Kereos', 'anticancer agent', 'anticancer agent, Kereos', 'SC-72325A', 'imisopasem manganese enantiomer (cancer)', 'GC-4419 dichloro', 'KM-4419', 'M-40419', 'GC-4419', 'avasopasem manganese']",avasopasem manganese,fexact,"['imisopasem manganese enantiomer cancer kereos', 'anticancer agent', 'anticancer agent kereos', 'sc 72325a', 'imisopasem manganese enantiomer cancer', 'gc 4419 dichloro', 'km 4419', 'm 40419', 'gc 4419', 'avasopasem manganese']",correct_mapping
PL-0264,DNA topoisomerase I inhibitor; Hypoxia-inducible factor 1 alpha antagonist,PL-0264,,PLX-038,pl 0264,fexact,"['DFP-13318', 'pegylated SN-38 prodrug (cancer),/', 'PL-0264', 'PEG-SN-38 (cancer), ProLynx/', 'PEG-SN-38 (cancer), ProLynx', 'pegylated SN-38 prodrug (cancer)', 'PLX-0264', 'PEG-SN-38 (cancer),/', 'pegylated SN-38 prodrug (cancer), ProLynx', 'PLX-038', 'PEG-SN-38 (cancer)', 'pegylated SN-38 prodrug (cancer), ProLynx/']",PLX-038,fexact,"['dfp 13318', 'pegylated sn 38 prodrug cancer', 'pl 0264', 'peg sn 38 cancer prolynx', 'peg sn 38 cancer prolynx', 'pegylated sn 38 prodrug cancer', 'plx 0264', 'peg sn 38 cancer', 'pegylated sn 38 prodrug cancer prolynx', 'plx 038', 'peg sn 38 cancer', 'pegylated sn 38 prodrug cancer prolynx']",correct_mapping
"pegfilgrastim, Jiangsu Hengrui Medicine",Granulocyte colony stimulating factor agonist,pegfilgrastim,Jiangsu Hengrui Medicine,pegfilgrastim follow-on biologic,pegfilgrastim,fexact,"['pegfilgrastim', 'PEG-rhGCSF injection', 'pegfilgrastim follow-on biologic', 'Jinyouli', 'PEG-GCSF (neutropenia)', 'PEG-filgrastim (neutropenia)', '津优力']",pegfilgrastim follow-on biologic,fexact,"['pegfilgrastim', 'peg rhgcsf injection', 'pegfilgrastim follow on biologic', 'jinyouli', 'peg gcsf neutropenia', 'peg filgrastim neutropenia', '津优力']",correct_mapping
"topotecan, Fujifilm Toyama Chemical",DNA topoisomerase inhibitor,topotecan,Fujifilm Toyama Chemical,topotecan,topotecan,fexact,"['nogitecan HCl', 'nogitecan', 'SKFS-104864-A', 'Evotopin', 'SKF-104864', 'NSC-609699', 'Hycamtim', 'hycaptamine', 'Hycamtin', 'hycamptamine', 'topotecan lactone', 'SKF-104864-A', 'NK-211', 'topotecan', 'Hicamtin']",topotecan,fexact,"['nogitecan hcl', 'nogitecan', 'skfs 104864 a', 'evotopin', 'skf 104864', 'nsc 609699', 'hycamtim', 'hycaptamine', 'hycamtin', 'hycamptamine', 'topotecan lactone', 'skf 104864 a', 'nk 211', 'topotecan', 'hicamtin']",correct_mapping
"pneumococcal polyvalent polysaccharide vaccine, Merck",Immunostimulant,pneumococcal polyvalent polysaccharide vaccine,Merck,,,0,['pneumococcal polyvalent polysaccharide vaccine'],,0,[],0
"pneumococcal vaccine, 13-valent, Wyeth",Immunostimulant,pneumococcal vaccine,Wyeth,,,0,['pneumococcal vaccine'],,0,[],0
"talabostat, BioXcel Therapeutics",Growth factor receptor agonist; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Dipeptidyl peptidase 8 (DPP VIII) inhibitor; Dipeptidyl peptidase 9 (DPP IX) inhibitor; Fibroblast activation protein inhibitor; Serine protease inhibitor; Immuno-oncology therapy,talabostat,BioXcel Therapeutics,talabostat,talabostat,fexact,"['boroproline compounds, Point Therapeutics', 'boroproline compounds, DARA BioSciences', 'PT-100', 'talabostat', 'Val-boro-Pro', 'talabostat mesylate']",talabostat,fexact,"['boroproline compounds point therapeutics', 'boroproline compounds dara biosciences', 'pt 100', 'talabostat', 'val boro pro', 'talabostat mesylate']",correct_mapping
ZSP-1602,Unidentified pharmacological activity,ZSP-1602,,ZSP-1602,zsp 1602,fexact,"['ZSYM-004', 'ZSP-1602']",ZSP-1602,fexact,"['zsym 004', 'zsp 1602']",correct_mapping
thymalfasin,Angiogenesis stimulant; Thymosin fraction A1 agonist,thymalfasin,,thymalfasin,thymalfasin,fexact,"['ST-1472', 'thymosin alpha 1', 'Zadaxin', 'Timosina', 'Talpha 1', 'thymosin alpha1 human', 'thymalfasin']",thymalfasin,fexact,"['st 1472', 'thymosin alpha 1', 'zadaxin', 'timosina', 'talpha 1', 'thymosin alpha1 human', 'thymalfasin']",correct_mapping
TAEST-16001,T cell stimulant; Immuno-oncology therapy,TAEST-16001,,TAEST-16001,taest 16001,fexact,"['anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy (NSCLC/sarcoma)', 'anticancer immunotherapy (solid tumors)', 'TAEST-16001', 'anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy (NSCLC/sarcoma), Guangzhou Xiangxue Pharmaceutical', 'anticancer immunotherapy (solid tumors), Guangzhou Xiangxue Pharmaceutical']",TAEST-16001,fexact,"['anti ny eso 1 hla a 0201 tcr t cell therapy nsclc sarcoma', 'anticancer immunotherapy solid tumors', 'taest 16001', 'anti ny eso 1 hla a 0201 tcr t cell therapy nsclc sarcoma guangzhou xiangxue pharmaceutical', 'anticancer immunotherapy solid tumors guangzhou xiangxue pharmaceutical']",correct_mapping
FT-1238,Immunostimulant; Immuno-oncology therapy,FT-1238,,,,0,['FT-1238'],,0,[],0
ß-elemene,Unidentified pharmacological activity,ß-elemene,,,,0,['ß-elemene'],,0,[],0
3D-CRT,Unidentified pharmacological activity,3D-CRT,,,,0,['3D-CRT'],,0,[],0
selinexor,Exportin 1 inhibitor,selinexor,,selinexor,selinexor,fexact,"['ATG-010', 'KCP-330', 'KPT-207', 'XPOVIO', 'nuclear transport inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'selective nuclear export inhibitors (COVID-19), Karyopharm Therapeutics', 'SINE (autoimmune diseases/HIV/cancer)', 'Nexpovio', 'KPT-SINE', 'KPT-185', 'SINE-KPT-330', 'KPT-225', 'KPT-330', 'KPT-XXX', 'Exportin-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'CRM-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease)', 'nuclear transport inhibitors (inflammation/viral diseases/cancer)', 'selective nuclear export inhibitors (autoimmune diseases/HIV/cancer)', 'KPT-249', 'KPT-276', 'Exportin-1 inhibitors (inflammation/viral diseases/cancer)', 'KPT-251', 'selinexor', 'Xpovio', 'selective nuclear export inhibitors (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics', 'SINE (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics', 'CRM-1 inhibitors (inflammation/viral diseases/cancer)', 'ONO-7705', 'selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease), Karyopharm Therapeutics', 'selective nuclear export inhibitors (COVID-19)']",selinexor,fexact,"['atg 010', 'kcp 330', 'kpt 207', 'xpovio', 'nuclear transport inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'selective nuclear export inhibitors covid 19 karyopharm therapeutics', 'sine autoimmune diseases hiv cancer', 'nexpovio', 'kpt sine', 'kpt 185', 'sine kpt 330', 'kpt 225', 'kpt 330', 'kpt xxx', 'exportin 1 inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'crm 1 inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'selective nuclear export inhibitors autoimmune inflammation hiv cancer dermatological disease', 'nuclear transport inhibitors inflammation viral diseases cancer', 'selective nuclear export inhibitors autoimmune diseases hiv cancer', 'kpt 249', 'kpt 276', 'exportin 1 inhibitors inflammation viral diseases cancer', 'kpt 251', 'selinexor', 'xpovio', 'selective nuclear export inhibitors autoimmune diseases hiv cancer karyopharm therapeutics', 'sine autoimmune diseases hiv cancer karyopharm therapeutics', 'crm 1 inhibitors inflammation viral diseases cancer', 'ono 7705', 'selective nuclear export inhibitors autoimmune inflammation hiv cancer dermatological disease karyopharm therapeutics', 'selective nuclear export inhibitors covid 19']",correct_mapping
rovalpituzumab tesirine,DNA inhibitor,rovalpituzumab tesirine,,rovalpituzumab tesirine,rovalpituzumab tesirine,fexact,"['rovalpituzumab tesirine', 'D6.5', 'SC16LD6.5', 'Rova-T']",rovalpituzumab tesirine,fexact,"['rovalpituzumab tesirine', 'd6 5', 'sc16ld6 5', 'rova t']",correct_mapping
"bevacizumab, Genor Biopharma",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Genor Biopharma,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
"dulanermin, Shanghai Gebade Biotechnology",TRAIL receptor 1 agonist; TRAIL receptor 2 agonist; Apoptosis stimulant,dulanermin,Shanghai Gebade Biotechnology,dulanermin,dulanermin,fexact,"['TRAIL protein, Immunex', 'TRAIL/Apo2L,/', 'APO2L/tumor necrosis factor-related apoptosis inducing ligand (cancer),/Genentech', 'rhApo2L/TRAIL (cancer),/Genentech', 'Apo2L/TRAIL (cell death signaling),/Genentech', 'RG-3639', 'TRAIL/Apo2L (Cancer), Genentech/', 'dulanermin', 'TRAIL/Apo2L (Cancer),/', 'Apo2L/TRAIL (cancer),/Genentech', 'Apo2L/TRAIL (cell death signaling),/', 'AMG-951', 'PRO-1762', 'rhApo2L/TRAIL (cancer),/', 'Apo2L/TRAIL (cancer),/', 'TRAIL/Apo2L,/Immunex', 'APO2L/tumor necrosis factor-related apoptosis inducing ligand (cancer),/', 'TRAIL/Apo2L, Genentech/Immunex', 'rhApo2L/TRAIL', 'TRAIL protein']",dulanermin,fexact,"['trail protein immunex', 'trail apo2l', 'apo2l tumor necrosis factor related apoptosis inducing ligand cancer genentech', 'rhapo2l trail cancer genentech', 'apo2l trail cell death signaling genentech', 'rg 3639', 'trail apo2l cancer genentech', 'dulanermin', 'trail apo2l cancer', 'apo2l trail cancer genentech', 'apo2l trail cell death signaling', 'amg 951', 'pro 1762', 'rhapo2l trail cancer', 'apo2l trail cancer', 'trail apo2l immunex', 'apo2l tumor necrosis factor related apoptosis inducing ligand cancer', 'trail apo2l genentech immunex', 'rhapo2l trail', 'trail protein']",correct_mapping
taselisib,PI3 kinase alpha inhibitor,taselisib,,taselisib,taselisib,fexact,"['RG-7604', 'taselisib', 'GDC-0326', 'GDC-0032', 'RO-5537381']",taselisib,fexact,"['rg 7604', 'taselisib', 'gdc 0326', 'gdc 0032', 'ro 5537381']",correct_mapping
18F-fludeoxyglucose,Unidentified pharmacological activity,18F-fludeoxyglucose,,,,0,['18F-fludeoxyglucose'],,0,[],0
BAY-94-9392,Radiopharmaceutical,BAY-94-9392,,florilglutamic acid (18F),bay 94 9392,fexact,"['18F-florilglutamic acid', 'FSPG', '18F-FSPG', 'cysteine glutamate transporter-targeted PET tracer (cancer/inflammation), Piramal', 'BAY-94-9392', 'cysteine glutamate transporter-targeted PET tracer (cancer/inflammation)', 'florilglutamic acid (18F)', 'Fluorine-18-florilglutamic acid']",florilglutamic acid (18F),fexact,"['18f florilglutamic acid', 'fspg', '18f fspg', 'cysteine glutamate transporter targeted pet tracer cancer inflammation piramal', 'bay 94 9392', 'cysteine glutamate transporter targeted pet tracer cancer inflammation', 'florilglutamic acid 18f', 'fluorine 18 florilglutamic acid']",correct_mapping
nelfinavir mesylate,HIV protease inhibitor,nelfinavir mesylate,,nelfinavir,nelfinavir mesylate,fexact,"['AG-1346', 'nelfinavir', 'nelfinavir mesylate', 'LY-312857', 'AG-1343', 'Viracept']",nelfinavir,fexact,"['ag 1346', 'nelfinavir', 'nelfinavir mesylate', 'ly 312857', 'ag 1343', 'viracept']",correct_mapping
naquotinib,EGFR kinase inhibitor,naquotinib,,naquotinib mesylate,naquotinib,fexact,"['naquotinib mesylate', 'ASP-8273', 'naquotinib']",naquotinib mesylate,fexact,"['naquotinib mesylate', 'asp 8273', 'naquotinib']",correct_mapping
bempegaldesleukin,Interleukin 2 receptor agonist; Immunostimulant; Immuno-oncology therapy; Immune checkpoint stimulant,bempegaldesleukin,,bempegaldesleukin,bempegaldesleukin,fexact,"['BMS-986321', 'il-2 (pegylated, cancer), /bms', 'ONO-7911', 'IL-2 (PEGylated, cancer), Nektar Therapeutics/BMS', 'il-2 (pegylated, bladder cancer),/bms', 'NKTR-214', 'il-2 (pegylated, cancer),/bms', 'il-2 (pegylated, bladder cancer), /bms', 'BEMPEG', 'bempegaldesleukin', 'IL-2 (PEGylated, bladder cancer), Nektar Therapeutics/BMS']",bempegaldesleukin,fexact,"['bms 986321', 'il 2 pegylated cancer bms', 'ono 7911', 'il 2 pegylated cancer nektar therapeutics bms', 'il 2 pegylated bladder cancer bms', 'nktr 214', 'il 2 pegylated cancer bms', 'il 2 pegylated bladder cancer bms', 'bempeg', 'bempegaldesleukin', 'il 2 pegylated bladder cancer nektar therapeutics bms']",correct_mapping
ABBV-927 (intratumoral),CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,ABBV-927,,ABBV-927,abbv 927,fexact,"['ABBV-927', 'giloralimab', 'CD40 costimulator (solid tumors)', 'anti-CD40 monoclonal antibody (solid tumors)']",ABBV-927,fexact,"['abbv 927', 'giloralimab', 'cd40 costimulator solid tumors', 'anti cd40 monoclonal antibody solid tumors']",correct_mapping
AT-406,IAP antagonist,AT-406,,xevinapant,at 406,fexact,"['Smac mimetic (cancer)', 'D-1143', 'SM-163', 'SM-157', 'SM-102', 'SM-164', 'AT-406', 'SM-173', 'SM-130', 'SM-186', 'SM-406', 'Smac mimetic (cancer), Ascenta', 'smac mimetic (cancer)', 'SM-1253', 'smac mimetic (cancer), Merck KGaA', 'SM-165', 'Debio-1143', 'SH-122', 'SM-122', 'SM-231', 'xevinapant', 'SM-1252', 'Smac mimetic SM-227']",xevinapant,fexact,"['smac mimetic cancer', 'd 1143', 'sm 163', 'sm 157', 'sm 102', 'sm 164', 'at 406', 'sm 173', 'sm 130', 'sm 186', 'sm 406', 'smac mimetic cancer ascenta', 'smac mimetic cancer', 'sm 1253', 'smac mimetic cancer merck kgaa', 'sm 165', 'debio 1143', 'sh 122', 'sm 122', 'sm 231', 'xevinapant', 'sm 1252', 'smac mimetic sm 227']",correct_mapping
ixazomib citrate (oral),Transcription factor NF-kappaB inhibitor; Proteasome inhibitor,ixazomib citrate,,ixazomib citrate,ixazomib citrate,fexact,"['enlairui', 'MLN-9708', 'proteasome inhibitor (oral, cancer), Millennium', 'ixazomib citrate (oral, multiple myeloma/amyloidosis)', 'Ninlaro', 'MLN-9708 (oral, multiple myeloma/amyloidosis), Millennium', 'ixazomib citrate', 'MLN-9708 (oral, cancer), Millennium']",ixazomib citrate,fexact,"['enlairui', 'mln 9708', 'proteasome inhibitor oral cancer millennium', 'ixazomib citrate oral multiple myeloma amyloidosis', 'ninlaro', 'mln 9708 oral multiple myeloma amyloidosis millennium', 'ixazomib citrate', 'mln 9708 oral cancer millennium']",correct_mapping
iadademstat,Lysine (K)-specific demethylase 1A inhibitor,iadademstat,,iadademstat dihydrochloride,iadademstat,fexact,"['LSD-1 inhibitors (HSV infection/blood cancer)', 'LSD-1 inhibitors (oral, small cell lung cancer/acute myeloid leukemia)', 'iadademstat', 'ORY-1001', 'RG-6016', 'iadademstat dihydrochloride', 'RO-7051790']",iadademstat dihydrochloride,fexact,"['lsd 1 inhibitors hsv infection blood cancer', 'lsd 1 inhibitors oral small cell lung cancer acute myeloid leukemia', 'iadademstat', 'ory 1001', 'rg 6016', 'iadademstat dihydrochloride', 'ro 7051790']",correct_mapping
IMA-101,Immunostimulant; T cell stimulant; Immuno-oncology therapy,IMA-101,,IMA-101,ima 101,fexact,"['IMA-101', 'autologous adoptive T-cell therapy (ACTolog, cancer)']",IMA-101,fexact,"['ima 101', 'autologous adoptive t cell therapy actolog cancer']",correct_mapping
prexasertib,Checkpoint kinase 1 inhibitor; Checkpoint kinase 2 inhibitor,prexasertib,,prexasertib,prexasertib,fexact,"['LY-2606368 MsOH H2O', 'ACR-368', 'prexasertib', 'back-up checkpoint kinase 1 inhibitor (cancer)', 'prexasertib mesylate monohydrate', 'back-up Chk1 inhibitor (cancer), Eli Lilly', 'LY-2606368 mesylate monohydrate', 'LY-2606368', 'back-up Chk1 inhibitor (cancer)', 'Chk1 Inhibitor II (cancer), Elil Lilly', 'back-up checkpoint kinase 1 inhibitor (cancer), Eli Lilly', 'LCI-1']",prexasertib,fexact,"['ly 2606368 msoh h2o', 'acr 368', 'prexasertib', 'back up checkpoint kinase 1 inhibitor cancer', 'prexasertib mesylate monohydrate', 'back up chk1 inhibitor cancer eli lilly', 'ly 2606368 mesylate monohydrate', 'ly 2606368', 'back up chk1 inhibitor cancer', 'chk1 inhibitor ii cancer elil lilly', 'back up checkpoint kinase 1 inhibitor cancer eli lilly', 'lci 1']",correct_mapping
"bevacizumab, Biocon",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Biocon,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
undisclosed - anaesthetic,Unidentified pharmacological activity,undisclosed - anaesthetic,,,,0,['undisclosed - anaesthetic'],,0,[],0
nabilone,Cannabinoid CB1 receptor agonist,nabilone,,nabilone,nabilone,fexact,"['nabilone, Lilly', 'nabilone', 'Cesamet']",nabilone,fexact,"['nabilone lilly', 'nabilone', 'cesamet']",correct_mapping
PD-1 knockout T-cells,Immuno-oncology therapy,PD-1 knockout T-cells,,,,0,['PD-1 knockout T-cells'],,0,[],0
89Zr-pembrolizumab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,89Zr-pembrolizumab,,,,0,['89Zr-pembrolizumab'],,0,[],0
darleukin,Interleukin 2 receptor agonist; Immunostimulant; T cell stimulant,darleukin,,L19-IL-2 fusion protein,darleukin,fexact,"['Darleukin', 'L19-IL-2 fusion protein, Philogen', 'L19-IL-2 fusion protein', 'immunocytokine fusion protein', 'immunocytokine fusion protein, Philogen']",L19-IL-2 fusion protein,fexact,"['darleukin', 'l19 il 2 fusion protein philogen', 'l19 il 2 fusion protein', 'immunocytokine fusion protein', 'immunocytokine fusion protein philogen']",correct_mapping
PP-CSF,Unidentified pharmacological activity,PP-CSF,,,,0,['PP-CSF'],,0,[],0
birabresib,Bromodomain containing 4 inhibitor; Bromodomain containing 2 inhibitor; Bromodomain containing 3 inhibitor,birabresib,,birabresib dihydrate,birabresib,fexact,"['birabresib dihydrate', 'OTX-015', 'birabresib', 'y-803 (hematological cancer)', 'Y-803', 'MK-8628', 'BRD 2/3/4 selective inhibitor (oral, cancer), OncoEthix', 'Y-803 (hematological cancer), OncoEthix', 'brd 2/3/4 selective inhibitor (oral, cancer)']",birabresib dihydrate,fexact,"['birabresib dihydrate', 'otx 015', 'birabresib', 'y 803 hematological cancer', 'y 803', 'mk 8628', 'brd 2 3 4 selective inhibitor oral cancer oncoethix', 'y 803 hematological cancer oncoethix', 'brd 2 3 4 selective inhibitor oral cancer']",correct_mapping
dabrafenib (tablet),B-raf kinase inhibitor,dabrafenib,,dabrafenib,dabrafenib,fexact,"['Tafinlar', 'Rafinlar', 'SB-477790', 'dabrafenib mesylate', 'dabrafenib', 'NSC-763760', 'DRB-436', 'b-Raf inhibitors (cancer)', 'SB-244649', 'GSK-2118436', 'GSK-2118436J', 'GSK-2118436A', 'SB-602330', 'GSK-436', 'SB-590885', 'SB-699393']",dabrafenib,fexact,"['tafinlar', 'rafinlar', 'sb 477790', 'dabrafenib mesylate', 'dabrafenib', 'nsc 763760', 'drb 436', 'b raf inhibitors cancer', 'sb 244649', 'gsk 2118436', 'gsk 2118436j', 'gsk 2118436a', 'sb 602330', 'gsk 436', 'sb 590885', 'sb 699393']",correct_mapping
JNJ-61610588,V-set immunoregulatory receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,JNJ-61610588,,onvatilimab,jnj 61610588,fexact,"['VISTA checkpoint inhibitor (cancer), ImmuNext/Janssen Biotech', 'VISTA checkpoint inhibitor (cancer),/Janssen Biotech', 'VISTA pathway antagonists (cancer),/Janssen Biotech', 'anti-VISTA (cancer),/', 'anti-VISTA (cancer),/Janssen Biotech', 'JNJ-61610588', 'CI-8993', '13-F-3', 'VISTA pathway antagonists (cancer), ImmuNext/Janssen Biotech', 'onvatilimab', 'anti-VISTA (cancer), ImmuNext/Janssen Biotech', 'VISTA checkpoint inhibitor (cancer),/', 'VISTA pathway antagonists (cancer),/']",onvatilimab,fexact,"['vista checkpoint inhibitor cancer immunext janssen biotech', 'vista checkpoint inhibitor cancer janssen biotech', 'vista pathway antagonists cancer janssen biotech', 'anti vista cancer', 'anti vista cancer janssen biotech', 'jnj 61610588', 'ci 8993', '13 f 3', 'vista pathway antagonists cancer immunext janssen biotech', 'onvatilimab', 'anti vista cancer immunext janssen biotech', 'vista checkpoint inhibitor cancer', 'vista pathway antagonists cancer']",correct_mapping
PEN-221,Somatostatin receptor 2 antagonist,PEN-221,,PEN-221,pen 221,fexact,"['cytotoxic DM1 program (neuroendocrine tumor/small cell lung cancer)', '(Tyr3,Cys8) octreotate-DM1 conjugate', 'PEN-221', '(Tyr3,Cys8) octreotate-mertansinse conjugate', 'SSTR2 targeted peptide-DM1 conjugate (neuroendocrine tumor/small cell lung cancer)']",PEN-221,fexact,"['cytotoxic dm1 program neuroendocrine tumor small cell lung cancer', 'tyr3 cys8 octreotate dm1 conjugate', 'pen 221', 'tyr3 cys8 octreotate mertansinse conjugate', 'sstr2 targeted peptide dm1 conjugate neuroendocrine tumor small cell lung cancer']",correct_mapping
enapotamab vedotin,Tubulin inhibitor,enapotamab vedotin,,enapotamab vedotin,enapotamab vedotin,fexact,"['Axl-ADCs', 'enapotamab vedotin', 'AXL modulator human antibody (cancer)', 'HuMax-AXL-ADC', 'AXL-107-MMAE']",enapotamab vedotin,fexact,"['axl adcs', 'enapotamab vedotin', 'axl modulator human antibody cancer', 'humax axl adc', 'axl 107 mmae']",correct_mapping
poly-ICLC,Immunostimulant; Natural killer cell stimulant,poly-ICLC,,Poly-ICLC,poly iclc,fexact,"['Hiltonol', 'interferon inducer (cancer/viral diseases)', 'polyinosinic-polycytidilic acid', 'Poly-ICLC', 'NSC-301463']",Poly-ICLC,fexact,"['hiltonol', 'interferon inducer cancer viral diseases', 'polyinosinic polycytidilic acid', 'poly iclc', 'nsc 301463']",correct_mapping
CDX-1401,Immunostimulant; Immuno-oncology therapy,CDX-1401,,CDX-1401,cdx 1401,fexact,"['CDX-1401', 'CD205 modulator (vaccine/mAb, solid tumor)', 'rasdegafusp alfa', 'DEC-205-NY-ESO-1 vaccine (solid tumor)']",CDX-1401,fexact,"['cdx 1401', 'cd205 modulator vaccine mab solid tumor', 'rasdegafusp alfa', 'dec 205 ny eso 1 vaccine solid tumor']",correct_mapping
irinotecan (IV),DNA topoisomerase I inhibitor,irinotecan,,irinotecan,irinotecan,fexact,"['Camptothecin 11 hydrochloride', 'DQ-2805', 'camptothecin II', 'irinotecan hydrochloride hydrate', 'camptothecin II hydrochloride', 'Topotecin', 'NSC-616348', 'irinotecan', 'camptothecin', 'camptothecin  hydrochloride', 'Camptothecin 11', 'Campto', 'irinotecan hydrochloride', 'Camptosar']",irinotecan,fexact,"['camptothecin 11 hydrochloride', 'dq 2805', 'camptothecin ii', 'irinotecan hydrochloride hydrate', 'camptothecin ii hydrochloride', 'topotecin', 'nsc 616348', 'irinotecan', 'camptothecin', 'camptothecin hydrochloride', 'camptothecin 11', 'campto', 'irinotecan hydrochloride', 'camptosar']",correct_mapping
JCAR-024,T cell stimulant; Immuno-oncology therapy,JCAR-024,,,,0,"['anti-ROR-1 CAR T-cell therapy (cancer)', 'JCAR-024', 'anti-ROR-1 CAR T-cell therapy (cancer), Juno Therapeutics']",,NER_API,[],0
bavituximab,Phosphatidylserine inhibitor; Immuno-oncology therapy,bavituximab,,bavituximab,bavituximab,fexact,"['anti-PS antibodies,/Peregrine', 'anti-phosphatidylserine antibodies, University of Texas/Peregrine', 'anti-PS antibodies,/', 'anti-phosphatidylserine antibodies (VTA), Peregrine', 'Tarvacin', 'anti-PS antibodies, University of Texas/Peregrine', 'PGN-401', 'bavituximab', 'anti-PS antibodies, University of Texas/', 'anti-phosphatidylserine antibodies,/Peregrine', 'anti-phosphatidylserine antibodies,/', '9D2', 'anti-phosphatidylserine antibodies, University of Texas/', '3G4']",bavituximab,fexact,"['anti ps antibodies peregrine', 'anti phosphatidylserine antibodies university of texas peregrine', 'anti ps antibodies', 'anti phosphatidylserine antibodies vta peregrine', 'tarvacin', 'anti ps antibodies university of texas peregrine', 'pgn 401', 'bavituximab', 'anti ps antibodies university of texas', 'anti phosphatidylserine antibodies peregrine', 'anti phosphatidylserine antibodies', '9d2', 'anti phosphatidylserine antibodies university of texas', '3g4']",correct_mapping
"genistein, Humanetics",Transcription factor NF-kappaB inhibitor,genistein,Humanetics,,,0,"['genistein (oral/capsule, osteoporosis), Zhongzhu Holding//', ""genistein (oral/capsule, osteoporosis), Zhongzhu Holding//Xi'an Hengtai Herbal Medicine Technology"", 'genistein']",,NER_API,[],0
natural killer T cells,Immunostimulant,natural killer T cells,,,,0,['natural killer T cells'],,0,[],0
orlotamab,CD3 agonist; Immuno-oncology therapy; Immune checkpoint inhibitor,orlotamab,,orlotamab,orlotamab,fexact,"['anti-CD3 + anti-CD276 bispecific antibody (solid tumors)', 'orlotamab', 'anti-CD3/anti-B7-H3 T-cell engager (DART, solid tumors)', 'anti-CD3 + anti-B7-H3 bispecific antibody (solid tumors)', 'MGD-009']",orlotamab,fexact,"['anti cd3 anti cd276 bispecific antibody solid tumors', 'orlotamab', 'anti cd3 anti b7 h3 t cell engager dart solid tumors', 'anti cd3 anti b7 h3 bispecific antibody solid tumors', 'mgd 009']",correct_mapping
methoxyamine,DNA repair enzyme inhibitor,methoxyamine,,"TRC-102 (oral, cancer)",methoxyamine,fexact,"['TRC-102', 'methoxyamine (oral, chemotherapy resistance),/TRACON', 'TRC-102 (oral, cancer)', 'methoxyamine (oral, chemotherapy resistance),/', 'methoxyamine', 'TRC-102 (oral, cancer), Tracon']","TRC-102 (oral, cancer)",fexact,"['trc 102', 'methoxyamine oral chemotherapy resistance tracon', 'trc 102 oral cancer', 'methoxyamine oral chemotherapy resistance', 'methoxyamine', 'trc 102 oral cancer tracon']",correct_mapping
talimogene laherparepvec (intratumoral),Granulocyte macrophage colony stimulating factor agonist; Immuno-oncology therapy,talimogene laherparepvec,,talimogene laherparepvec,talimogene laherparepvec,fexact,"['T-VEC', 'OncoVEX therapies (cancer)', 'talminogene laherparepvec', 'Imlygic', 'talimogene laherparepvec', 'OncoVEX-TNF-alpha', 'ICP34.5-null herpes simplex virus-1', 'oncolytic HSV1 therapy expressing GM-CSF (OncoVEX platform, melanoma)', 'OncoVEX-TNF-alpha+GM-CSF', 'OncoVEX', 'ICP34.5-null herpes simplex virus-1, BioVex', 'JS1 34.5-hGMCSF 47-pA-', 'OncoVEX GM-CSF vaccine']",talimogene laherparepvec,fexact,"['t vec', 'oncovex therapies cancer', 'talminogene laherparepvec', 'imlygic', 'talimogene laherparepvec', 'oncovex tnf alpha', 'icp34 5 null herpes simplex virus 1', 'oncolytic hsv1 therapy expressing gm csf oncovex platform melanoma', 'oncovex tnf alpha gm csf', 'oncovex', 'icp34 5 null herpes simplex virus 1 biovex', 'js1 34 5 hgmcsf 47 pa', 'oncovex gm csf vaccine']",correct_mapping
CA-170,PD-L1 antagonist; V-set immunoregulatory receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,CA-170,,CA-170,ca 170,fexact,"['PD-L1, VISTA checkpoint inhibitor (cancer),/', 'programmed death ligand 1 antagonist (cancer),/', 'VISTA, PD-L1 checkpoint inhibitor (cancer),/Curis', 'CA-170', 'VISTA, PD-L1 checkpoint inhibitor (cancer),/', 'AUPM-170', 'VISTA and PD-L1 checkpoint inhibitor (cancer),/', 'dual PD-L1 checkpoint inhibitor/VISTA checkpoint inhibitor (cancer),/', 'dual PD-L1 checkpoint inhibitor/VISTA checkpoint inhibitor (cancer),/Curis', 'programmed death ligand 1 antagonist (cancer)', 'PD-L1, VISTA checkpoint inhibitor (cancer),/Curis', 'VISTA and PD-L1 checkpoint inhibitor (cancer),/Curis', 'programmed death ligand 1 antagonist (cancer),/Curis']",CA-170,fexact,"['pd l1 vista checkpoint inhibitor cancer', 'programmed death ligand 1 antagonist cancer', 'vista pd l1 checkpoint inhibitor cancer curis', 'ca 170', 'vista pd l1 checkpoint inhibitor cancer', 'aupm 170', 'vista and pd l1 checkpoint inhibitor cancer', 'dual pd l1 checkpoint inhibitor vista checkpoint inhibitor cancer', 'dual pd l1 checkpoint inhibitor vista checkpoint inhibitor cancer curis', 'programmed death ligand 1 antagonist cancer', 'pd l1 vista checkpoint inhibitor cancer curis', 'vista and pd l1 checkpoint inhibitor cancer curis', 'programmed death ligand 1 antagonist cancer curis']",correct_mapping
SC-002,Unidentified pharmacological activity,SC-002,,SC-002,sc 002,fexact,"['antibody-drug conjugate (SCLC), Stemcentrx', 'antibody-drug conjugate (SCLC)', 'SC-002', 'Rova-T Next-Gen', 'SC-002, Stemcentrx']",SC-002,fexact,"['antibody drug conjugate sclc stemcentrx', 'antibody drug conjugate sclc', 'sc 002', 'rova t next gen', 'sc 002 stemcentrx']",correct_mapping
gilteritinib,Axl receptor tyrosine kinase inhibitor; Flt-3 antagonist,gilteritinib,,gilteritinib,gilteritinib,fexact,"['ASP-2215 hemifumarate', 'gilteritinib', 'Xospata', 'gilteritinib fumarate', 'ASP-2215']",gilteritinib,fexact,"['asp 2215 hemifumarate', 'gilteritinib', 'xospata', 'gilteritinib fumarate', 'asp 2215']",correct_mapping
INCB-028060 (Tablet),MET tyrosine kinase inhibitor,INCB-028060,,capmatinib hydrochloride,incb 028060,fexact,"['capmatinib', 'INC-280', 'INCB-028060', 'INCB-28060', 'capmatinib dihydrochloride hydrate', 'capmatinib hydrochloride', 'c-Met tyrosine kinase inhibitor (oral, capsule/tablet, cancer), Novartis', 'Tabrecta', 'c-Met tyrosine kinase inhibitor (oral, capsule/tablet, cancer)']",capmatinib hydrochloride,fexact,"['capmatinib', 'inc 280', 'incb 028060', 'incb 28060', 'capmatinib dihydrochloride hydrate', 'capmatinib hydrochloride', 'c met tyrosine kinase inhibitor oral capsule tablet cancer novartis', 'tabrecta', 'c met tyrosine kinase inhibitor oral capsule tablet cancer']",correct_mapping
radiofrequency ablation,Not applicable,radiofrequency ablation,,,,0,['radiofrequency ablation'],,0,[],0
fosaprepitant dimeglumine,Neurokinin 1 receptor antagonist,fosaprepitant dimeglumine,,fosaprepitant,fosaprepitant dimeglumine,fexact,"['Proemend for Injection', 'c-9280', 'Emend for Injection', 'fosaprepitant dimeglumine', 'fosaprepitant', 'Ivemend', 'ONO-7847', 'Proemend', 'MK-517', 'L-758298', 'MK-0517', 'Emend IV']",fosaprepitant,fexact,"['proemend for injection', 'c 9280', 'emend for injection', 'fosaprepitant dimeglumine', 'fosaprepitant', 'ivemend', 'ono 7847', 'proemend', 'mk 517', 'l 758298', 'mk 0517', 'emend iv']",correct_mapping
vistusertib (tablet),mTORC1 kinase inhibitor; mTORC2 kinase inhibitor,vistusertib,,vistusertib,vistusertib,fexact,"['mTOR inhibitors (cancer), KuDOS', 'AZD-2014', 'mTOR inhibitors (cancer)', 'KU-63794', 'vistusertib', 'KU-0063794']",vistusertib,fexact,"['mtor inhibitors cancer kudos', 'azd 2014', 'mtor inhibitors cancer', 'ku 63794', 'vistusertib', 'ku 0063794']",correct_mapping
entinostat,Histone deacetylase inhibitor; Cell cycle inhibitor,entinostat,,entinostat,entinostat,fexact,"['histone deacetylase inhibitors, Schering AG', 'EOC-103', 'MS-27-275', 'histone deacetylase inhibitors, Mitsui Pharmaceuticals', 'entinostat', 'KHK-2375', 'histone deacetylase inhibitors (oral), Syndax Pharmaceuticals', 'histone deacetylase inhibitors (oral)', 'MS-275', 'Treg modulator (cancer), Sydax Pharmaceuticals', 'SNDX-275', 'histone deacetylase inhibitors', 'EDP 103']",entinostat,fexact,"['histone deacetylase inhibitors schering ag', 'eoc 103', 'ms 27 275', 'histone deacetylase inhibitors mitsui pharmaceuticals', 'entinostat', 'khk 2375', 'histone deacetylase inhibitors oral syndax pharmaceuticals', 'histone deacetylase inhibitors oral', 'ms 275', 'treg modulator cancer sydax pharmaceuticals', 'sndx 275', 'histone deacetylase inhibitors', 'edp 103']",correct_mapping
enoblituzumab,B7-H3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,enoblituzumab,,enoblituzumab,enoblituzumab,fexact,"['B7-H3 checkpoint inhibitor (solid tumors)', 'enoblituzumab', 'MGA-271', 'B7-H3 checkpoint inhibitor (solid tumors), MacroGenics', 'Anti-B7-H3']",enoblituzumab,fexact,"['b7 h3 checkpoint inhibitor solid tumors', 'enoblituzumab', 'mga 271', 'b7 h3 checkpoint inhibitor solid tumors macrogenics', 'anti b7 h3']",correct_mapping
BAY-1238097,BET protein inhibitor,BAY-1238097,,"bet inhibitors (oral, cancer)",bay 1238097,fexact,"['BAY-1238097', 'BET-BAY-002', 'BAY-671', 'BAY-356', 'bet inhibitors (oral, cancer)']","bet inhibitors (oral, cancer)",fexact,"['bay 1238097', 'bet bay 002', 'bay 671', 'bay 356', 'bet inhibitors oral cancer']",correct_mapping
seribantumab,ErbB-3 antagonist; Immuno-oncology therapy,seribantumab,,seribantumab,seribantumab,fexact,"['ErbB antibodies (cancer)', 'EGFR antibodies (cancer)', 'EGFR antibodies (cancer), Merrimack', 'EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC),/sanofi-aventis', 'SAR-256212', 'seribantumab', 'ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC),/sanofi-aventis', 'MM-1x1 program (iv, cancer)', 'ErbB antibodies (cancer), Merrimack', 'ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis', 'EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis', 'MM-121', 'MM-1x1 program (iv, cancer), Merrimack']",seribantumab,fexact,"['erbb antibodies cancer', 'egfr antibodies cancer', 'egfr antibodies cancer merrimack', 'egfr family tyrosine kinase receptor inhibitor intravenous formulation monoclonal antibody cancer nsclc sanofi aventis', 'sar 256212', 'seribantumab', 'erbb3 tyrosine kinase receptor modulator intravenous formulation monoclonal antibody cancer nsclc sanofi aventis', 'mm 1x1 program iv cancer', 'erbb antibodies cancer merrimack', 'erbb3 tyrosine kinase receptor modulator intravenous formulation monoclonal antibody cancer nsclc merrimack pharmaceuticals sanofi aventis', 'egfr family tyrosine kinase receptor inhibitor intravenous formulation monoclonal antibody cancer nsclc merrimack pharmaceuticals sanofi aventis', 'mm 121', 'mm 1x1 program iv cancer merrimack']",correct_mapping
selumetinib (capsule),Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,selumetinib,,selumetinib sulfate,selumetinib,fexact,"['MEK inhibitors (cancer)', 'MK-5618', 'selumetinib hyd-sulfate', 'neurodegenerative disease therapeutics', 'kinase inhibitors (cancer)', 'selumetinib sulfate', 'AZD-6244 hydrogen sulfate', 'NSC-748727', 'IND-77782', 'ARRY-886', 'AZD-6244', 'ARRY-142886', 'selumetinib', 'Koselugo', 'AZD-6244 hyd-sulfate']",selumetinib sulfate,fexact,"['mek inhibitors cancer', 'mk 5618', 'selumetinib hyd sulfate', 'neurodegenerative disease therapeutics', 'kinase inhibitors cancer', 'selumetinib sulfate', 'azd 6244 hydrogen sulfate', 'nsc 748727', 'ind 77782', 'arry 886', 'azd 6244', 'arry 142886', 'selumetinib', 'koselugo', 'azd 6244 hyd sulfate']",correct_mapping
[F-18] VM4-037,Radiopharmaceutical,[F-18] VM4-037,,F-18-VM4-037,f 18 vm4 037,fexact,"['F-18-labelled VM4-037', 'F-18-VM4-037', 'F-18-labelled imaging agent (Cancer), Siemens Molecular Imaging']",F-18-VM4-037,fexact,"['f 18 labelled vm4 037', 'f 18 vm4 037', 'f 18 labelled imaging agent cancer siemens molecular imaging']",correct_mapping
modafinil,Alpha 1 adrenoreceptor agonist,modafinil,,modafinil,modafinil,fexact,"['Vigil', 'AFT-801', 'Alertec', 'Modasomil', 'GRL-40476', 'Sparlon', 'CN-801', 'Modiodal', 'Provigil', 'modafinil', 'Modavigil', 'Attenace', 'Vigil, Cephalon']",modafinil,fexact,"['vigil', 'aft 801', 'alertec', 'modasomil', 'grl 40476', 'sparlon', 'cn 801', 'modiodal', 'provigil', 'modafinil', 'modavigil', 'attenace', 'vigil cephalon']",correct_mapping
PG-2,Immunostimulant,PG-2,,PG-2,pg 2,fexact,"['PHN-013', 'PHN-011', 'PHN-015', 'PG-2', 'PHN-014', 'PHN-012', 'XueBao']",PG-2,fexact,"['phn 013', 'phn 011', 'phn 015', 'pg 2', 'phn 014', 'phn 012', 'xuebao']",correct_mapping
CC-90003,Mitogen-activated protein kinase 1 inhibitor; Mitogen-activated protein kinase 3 inhibitor,CC-90003,,CC-90003,cc 90003,fexact,"['MAPK inhibitor (cancer)', 'extracellular signal-regulated kinase inhibitor (cancer)', 'CC-90003', 'ERK inhibitor (cancer)', 'mitogen-activated protein kinase inhibitor (cancer)']",CC-90003,fexact,"['mapk inhibitor cancer', 'extracellular signal regulated kinase inhibitor cancer', 'cc 90003', 'erk inhibitor cancer', 'mitogen activated protein kinase inhibitor cancer']",correct_mapping
etirinotecan pegol,DNA topoisomerase I inhibitor,etirinotecan pegol,,etirinotecan pegol,etirinotecan pegol,fexact,"['PEG-irinotecan', 'etirinotecan pegol tetratriflutate', 'Onzeald', 'NKTR-102', 'PEG-irinotecan, Nektar', 'PEGylated irinotecan prodrug (iv, cancer), Nektar', 'PEGylated irinotecan prodrug (iv, cancer)', 'etirinotecan pegol', 'etirinotecan pegol tetrahydrochloride']",etirinotecan pegol,fexact,"['peg irinotecan', 'etirinotecan pegol tetratriflutate', 'onzeald', 'nktr 102', 'peg irinotecan nektar', 'pegylated irinotecan prodrug iv cancer nektar', 'pegylated irinotecan prodrug iv cancer', 'etirinotecan pegol', 'etirinotecan pegol tetrahydrochloride']",correct_mapping
rociletinib,EGFR kinase inhibitor,rociletinib,,rociletinib,rociletinib,fexact,"['790M mutant-targeting, non-small-cell lung cancer), Celgene/', 'EMSI (oral, T790M mutant-targeting, NSCLC),/Clovis Oncology', 'Xegafri', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC),/', 'rociletinib', 'rociletinib hydrobromide', 'AVL-301', 'EGFR mutant-selective inhibitor (tablet, NSCLC), Celgene/', 'epidermal growth factor receptor mutant-selective inhibitor (oral, T790M mutant-targeting, non-small-cell lung cancer),/Clovis Oncology', 'rociletinib (T790M-mutation-targeting, NSCLC), Clovis', 'EMSI (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Celgene/', 'EMSI (oral, T790M mutant-targeting, NSCLC),/', 'CO-1686', 'rociletinib (T790M-mutation-targeting, NSCLC)', 'CNX-419', '790M mutant-targeting, non-small-cell lung cancer), Celgene/Clovis Oncology', 'EMSI (oral, T790M mutant-targeting, NSCLC), Celgene/', 'EGFR mutant-selective inhibitor (tablet, NSCLC), Celgene/Clovis Oncology', 'epidermal growth factor receptor mutant-selective inhibitor (oral, T790M mutant-targeting, non-small-cell lung cancer),/', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC),/Clovis Oncology']",rociletinib,fexact,"['790m mutant targeting non small cell lung cancer celgene', 'emsi oral t790m mutant targeting nsclc clovis oncology', 'xegafri', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc', 'rociletinib', 'rociletinib hydrobromide', 'avl 301', 'egfr mutant selective inhibitor tablet nsclc celgene', 'epidermal growth factor receptor mutant selective inhibitor oral t790m mutant targeting non small cell lung cancer clovis oncology', 'rociletinib t790m mutation targeting nsclc clovis', 'emsi oral t790m mutant targeting nsclc celgene clovis oncology', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc celgene clovis oncology', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc celgene', 'emsi oral t790m mutant targeting nsclc', 'co 1686', 'rociletinib t790m mutation targeting nsclc', 'cnx 419', '790m mutant targeting non small cell lung cancer celgene clovis oncology', 'emsi oral t790m mutant targeting nsclc celgene', 'egfr mutant selective inhibitor tablet nsclc celgene clovis oncology', 'epidermal growth factor receptor mutant selective inhibitor oral t790m mutant targeting non small cell lung cancer', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc clovis oncology']",correct_mapping
STM-434,"Inhibin, beta A inhibitor; Activin receptor type II antagonist",STM-434,,STM-434,stm 434,fexact,"['STM-434/s', 'STM-434', 'recombinant human soluble activin type 2B receptor Fc fusion protein (cancer),/', 'STM-217', 'recombinant human soluble activin type 2B receptor Fc fusion protein (cancer),/Atara Biotherapeutics']",STM-434,fexact,"['stm 434 s', 'stm 434', 'recombinant human soluble activin type 2b receptor fc fusion protein cancer', 'stm 217', 'recombinant human soluble activin type 2b receptor fc fusion protein cancer atara biotherapeutics']",correct_mapping
ganetespib,Heat shock protein 90 antagonist,ganetespib,,ganetespib,ganetespib,fexact,"['Hsp90 inhibitor (intravenous, cancer)', 'ADX-1612', 'Hsp90 inhibitor (intravenous, cancer), Madrigal', 'Hsp90 inhibitor (intravenous, cancer), Synta', 'STA-9090', 'ganetespib']",ganetespib,fexact,"['hsp90 inhibitor intravenous cancer', 'adx 1612', 'hsp90 inhibitor intravenous cancer madrigal', 'hsp90 inhibitor intravenous cancer synta', 'sta 9090', 'ganetespib']",correct_mapping
momelotinib (tablet),Activin receptor-like kinase 2 inhibitor; Janus kinase 1 inhibitor; Janus kinase 2 inhibitor,momelotinib,,momelotinib,momelotinib,fexact,"['JAK2 tyrosine kinase inhibitors (cardiovascular disease)', 'JAK2 tyrosine kinase inhibitors (cancer/cardiovascular disease/myeloproliferative disorder)', 'JAK tyrosine kinase inhibitors (cardiovascular disease),/Myomatrix', 'CYT-387', 'JAK2 tyrosine kinase inhibitors (cardiovascular disease),/Myomatrix', 'GS-0387', 'momelotinib', 'momelotinib dihydrochloride']",momelotinib,fexact,"['jak2 tyrosine kinase inhibitors cardiovascular disease', 'jak2 tyrosine kinase inhibitors cancer cardiovascular disease myeloproliferative disorder', 'jak tyrosine kinase inhibitors cardiovascular disease myomatrix', 'cyt 387', 'jak2 tyrosine kinase inhibitors cardiovascular disease myomatrix', 'gs 0387', 'momelotinib', 'momelotinib dihydrochloride']",correct_mapping
sibrotuzumab,Fibroblast activation protein inhibitor,sibrotuzumab,,sibrotuzumab,sibrotuzumab,fexact,"['F19 antibody (humanized), Ludwig/', 'BIBH-1', 'F19 antibody (humanized),/', 'anti-FAP antibody (humanized),/', 'sibrotuzumab', 'anti-FAP antibody (humanized), Ludwig/']",sibrotuzumab,fexact,"['f19 antibody humanized ludwig', 'bibh 1', 'f19 antibody humanized', 'anti fap antibody humanized', 'sibrotuzumab', 'anti fap antibody humanized ludwig']",correct_mapping
BIWA-4,DNA inhibitor; Chondroitin sulfate proteoglycan inhibitor; Radiopharmaceutical,BIWA-4,,,,0,"['bivatuzumab', 'anti CD44 monoclonals,/Sloan Kettering/Ludwig', 'BIWA-4', 'anti-CD44']",,NER_API,[],0
TPI 287 (IV),Beta tubulin inhibitor; Microtubule stimulant; Taxane,TPI 287,,,,0,['TPI 287'],,0,[],0
"thioredoxin reductase inhibitor, unspecified",Thioredoxin reductase inhibitor,thioredoxin reductase inhibitor,unspecified,,,0,['thioredoxin reductase inhibitor'],,0,[],0
vorinostat (oral),Histone deacetylase inhibitor; Cell cycle inhibitor,vorinostat,,vorinostat (intravenous),vorinostat,fexact,"['MK-0683', 'L-001079038', 'MSK-390', 'suberanilohydroxamic acid (intravenous)', 'SAHA', 'suberoylanilide hydroxamic acid (intravenous)', 'SAHA (intravenous)', 'vorinostat (intravenous), Merck & Co', 'vorinostat', 'vorinostat (intravenous)', 'Suberoylanilide hydroxamic acid']",vorinostat (intravenous),fexact,"['mk 0683', 'l 001079038', 'msk 390', 'suberanilohydroxamic acid intravenous', 'saha', 'suberoylanilide hydroxamic acid intravenous', 'saha intravenous', 'vorinostat intravenous merck co', 'vorinostat', 'vorinostat intravenous', 'suberoylanilide hydroxamic acid']",correct_mapping
IDB-1016,Estrogen receptor antagonist; Reducing agent,IDB-1016,,,,0,"['silybinin phosphatidylcholine complex', 'IdB-1016', 'Silipide', 'Siliphos', 'silybin phosphatidylcholine complex']",,NER_API,[],0
nelfinavir (tablet),HIV protease inhibitor,nelfinavir,,nelfinavir,nelfinavir,fexact,"['AG-1346', 'nelfinavir', 'nelfinavir mesylate', 'LY-312857', 'AG-1343', 'Viracept']",nelfinavir,fexact,"['ag 1346', 'nelfinavir', 'nelfinavir mesylate', 'ly 312857', 'ag 1343', 'viracept']",correct_mapping
Oshadi D,Unidentified pharmacological activity,Oshadi D,,,,0,['Oshadi D'],,0,[],0
Oshadi R,Unidentified pharmacological activity,Oshadi R,,,,0,['Oshadi R'],,0,[],0
certolizumab pegol (SC),Tumour necrosis factor alpha antagonist,certolizumab pegol,,certolizumab pegol,certolizumab pegol,fexact,"['Perstymab', 'CDP-870', 'Cimzia', 'certolizumab pegol']",certolizumab pegol,fexact,"['perstymab', 'cdp 870', 'cimzia', 'certolizumab pegol']",correct_mapping
abemaciclib (capsule),Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,abemaciclib,,abemaciclib,abemaciclib,fexact,"['abemaciclib', 'Verzenios', 'VerzenioTM', 'Verzenio', 'bemaciclib', 'LY-2835219', 'CDK 4/6 dual inhibitor (oral, cancer)']",abemaciclib,fexact,"['abemaciclib', 'verzenios', 'verzeniotm', 'verzenio', 'bemaciclib', 'ly 2835219', 'cdk 4 6 dual inhibitor oral cancer']",correct_mapping
enadenotucirev (IV),Immuno-oncology therapy,enadenotucirev,,enadenotucirev,enadenotucirev,fexact,"['oncolytic Ad11/Ad3 chimeric group B adenovirus (cancer), PsiOxus', 'oncolytic adenovirus therapy (solid tumor)', 'oncolytic adenovirus therapy (solid tumor), PsiOxus', 'ColoAd1', 'oncolytic Ad11/Ad3 chimeric group B adenovirus (cancer)', 'enadenotucirev']",enadenotucirev,fexact,"['oncolytic ad11 ad3 chimeric group b adenovirus cancer psioxus', 'oncolytic adenovirus therapy solid tumor', 'oncolytic adenovirus therapy solid tumor psioxus', 'coload1', 'oncolytic ad11 ad3 chimeric group b adenovirus cancer', 'enadenotucirev']",correct_mapping
enadenotucirev (intratumoral),Immuno-oncology therapy,enadenotucirev,,enadenotucirev,enadenotucirev,fexact,"['oncolytic Ad11/Ad3 chimeric group B adenovirus (cancer), PsiOxus', 'oncolytic adenovirus therapy (solid tumor)', 'oncolytic adenovirus therapy (solid tumor), PsiOxus', 'ColoAd1', 'oncolytic Ad11/Ad3 chimeric group B adenovirus (cancer)', 'enadenotucirev']",enadenotucirev,fexact,"['oncolytic ad11 ad3 chimeric group b adenovirus cancer psioxus', 'oncolytic adenovirus therapy solid tumor', 'oncolytic adenovirus therapy solid tumor psioxus', 'coload1', 'oncolytic ad11 ad3 chimeric group b adenovirus cancer', 'enadenotucirev']",correct_mapping
foretinib,Axl receptor tyrosine kinase inhibitor; C-kit inhibitor; Flt-3 antagonist; MET tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; TIE-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor,foretinib,,foretinib,foretinib,fexact,"['kinase inhibitor (oral, cancer)', 'GSK-1363089G', 'kinase inhibitor (cancer)', 'foretinib', 'XL-880', 'EXEL-2880', 'kinase inhibitor (oral, cancer), GlaxoSmithKline', '1363089', 'GSK-089', 'GSK-1363089']",foretinib,fexact,"['kinase inhibitor oral cancer', 'gsk 1363089g', 'kinase inhibitor cancer', 'foretinib', 'xl 880', 'exel 2880', 'kinase inhibitor oral cancer glaxosmithkline', '1363089', 'gsk 089', 'gsk 1363089']",correct_mapping
"ONC-201, Oncoceutics",Dopamine D2 receptor antagonist; ClpP agonist,ONC-201,Oncoceutics,,,0,"['PI3K inhibitors (cancer)', 'ONC-201,/', 'ONC-201, Oncoceutics/', 'ONC-206', 'TIC-10', 'imidazolinopyrimidinones (cancer), Oncoceutics', 'imidazolinopyrimidinones (cancer)', 'ONC-200 series (cancer), Oncoceutics', 'ONC-200 series (cancer)', 'ONC-201, Oncoceutics', 'ONC-201 dihydrochloride', 'PI3K inhibitors (cancer), Oncalis', 'ONC-201, Oncoceutics/ Ohara Pharmaceutical', 'OP-10', 'ONC-201', 'NSC-350625']",,Drug_API_mapping,[],0
sonidegib (oral),Hedgehog pathway inhibitor,sonidegib,,sonidegib (oral),sonidegib,fexact,"['LAB-687', 'sonidegib (oral)', 'SMO inhibitor (cancer)', 'NVP-LDE-225', 'LDE-255', 'sonidegib', 'sonidegib phosphate', 'Odomzo', 'erismodegib', 'LDE-225 (oral)', 'smoothened inhibitor (cancer)', 'erismodegib (oral)', 'LDE-225', 'NVP-LDE-225 (oral)']",sonidegib (oral),fexact,"['lab 687', 'sonidegib oral', 'smo inhibitor cancer', 'nvp lde 225', 'lde 255', 'sonidegib', 'sonidegib phosphate', 'odomzo', 'erismodegib', 'lde 225 oral', 'smoothened inhibitor cancer', 'erismodegib oral', 'lde 225', 'nvp lde 225 oral']",correct_mapping
cabazitaxel (IV),Microtubule inhibitor; Taxane,cabazitaxel,,cabazitaxel,cabazitaxel,fexact,"['cabazitaxel', '116258', 'Jevtana', 'taxoid (cancer), sanofi-aventis', '106258', 'TXD-258', 'RPR-116258A', 'XRP-6258']",cabazitaxel,fexact,"['cabazitaxel', '116258', 'jevtana', 'taxoid cancer sanofi aventis', '106258', 'txd 258', 'rpr 116258a', 'xrp 6258']",correct_mapping
emibetuzumab,MET tyrosine kinase inhibitor,emibetuzumab,,emibetuzumab,emibetuzumab,fexact,"['LA-480', 'bispecific c-Met monoclonal antibody (cancer)', 'LY-2875358', 'c-Met mAb (cancer)', 'emibetuzumab', 'anti-c-Met antibody (cancer)']",emibetuzumab,fexact,"['la 480', 'bispecific c met monoclonal antibody cancer', 'ly 2875358', 'c met mab cancer', 'emibetuzumab', 'anti c met antibody cancer']",correct_mapping
tiomolibdate diammonium,Chelating agent,tiomolibdate diammonium,,"tetrathiomolybdate, Adeona Pharmaceuticals",tiomolibdate diammonium,fexact,"['tetrathiomolybdate', 'Oral TTM', 'tetrathiomolybdate, Adeona Pharmaceuticals', 'Coprexa', 'tm', 'TTM', 'tetrathiomolybdate, Pipex Pharmaceuticals', 'tiomolibdate diammonium', 'TM, University of Michigan', 'tiomolibdic acid']","tetrathiomolybdate, Adeona Pharmaceuticals",fexact,"['tetrathiomolybdate', 'oral ttm', 'tetrathiomolybdate adeona pharmaceuticals', 'coprexa', 'tm', 'ttm', 'tetrathiomolybdate pipex pharmaceuticals', 'tiomolibdate diammonium', 'tm university of michigan', 'tiomolibdic acid']",correct_mapping
dovitinib lactate,Fibroblast growth factor receptor 1 antagonist; Fibroblast growth factor receptor 3 antagonist; C-kit inhibitor; EGFR kinase inhibitor; FGF receptor tyrosine kinase inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,dovitinib lactate,,dovitinib,dovitinib lactate,fexact,"['VEGF receptor kinase inhibitor (cancer)', 'dovitinib lactate (USAN)', 'dovitinib, Allarity Therapeutics', 'GFKI, Novartis', 'VEGF/FGF/PDGF receptor kinase inhibitor', 'CHIR-258', 'dovitinib lactate', 'VEGF receptor kinase inhibitor (cancer), Novartis', 'VEGFR kinase inhibitor, Novartis', 'growth factor kinase inhibitor', 'TKI-258', 'growth factor kinase inhibitor, Novartis', 'Dovitinib DPR', 'GFKI-258', 'GFKI', 'VEGFR kinase inhibitor', 'VEGF/FGF/PDGF receptor kinase inhibitor, Novartis', 'dovitinib', 'TK-1258']",dovitinib,fexact,"['vegf receptor kinase inhibitor cancer', 'dovitinib lactate usan', 'dovitinib allarity therapeutics', 'gfki novartis', 'vegf fgf pdgf receptor kinase inhibitor', 'chir 258', 'dovitinib lactate', 'vegf receptor kinase inhibitor cancer novartis', 'vegfr kinase inhibitor novartis', 'growth factor kinase inhibitor', 'tki 258', 'growth factor kinase inhibitor novartis', 'dovitinib dpr', 'gfki 258', 'gfki', 'vegfr kinase inhibitor', 'vegf fgf pdgf receptor kinase inhibitor novartis', 'dovitinib', 'tk 1258']",correct_mapping
luminespib,Heat shock protein 90 antagonist,luminespib,,luminespib,luminespib,fexact,"['Hsp 90 inhibitors (cancer), Vernalis/Novartis', 'VER-28535', 'AUY-922', 'Hsp 90 inhibitors, RiboTargets/Institute of Cancer Research', 'luminespib mesylate', 'CCT-066952', 'Hsp 90 inhibitors (cancer),/', 'CCT-0669963', 'RBT-0028535', 'CCT-066950', 'Hsp 90 inhibitors,/', 'VER-49009', 'VER-49537', 'Hsp 90 inhibitors, Institute of Cancer Research/Vernalis', 'CCT-072440', 'CCT-018159', 'G-3129', 'VER-27129', 'luminespib', 'VER-50589', 'Hsp 90 inhibitors,/Vernalis', 'VER-510747', 'RBT-0036283', 'Hsp 90 inhibitors (cancer), Vernalis/', 'VER-51000', 'CCT-066965', 'RBT-0045856', 'G-3130', 'VER-52296', 'VER-45864', 'PH-3', 'RBT-0027129', 'NVP-AUY-922', 'Hsp 90 inhibitors, RiboTargets/']",luminespib,fexact,"['hsp 90 inhibitors cancer vernalis novartis', 'ver 28535', 'auy 922', 'hsp 90 inhibitors ribotargets institute of cancer research', 'luminespib mesylate', 'cct 066952', 'hsp 90 inhibitors cancer', 'cct 0669963', 'rbt 0028535', 'cct 066950', 'hsp 90 inhibitors', 'ver 49009', 'ver 49537', 'hsp 90 inhibitors institute of cancer research vernalis', 'cct 072440', 'cct 018159', 'g 3129', 'ver 27129', 'luminespib', 'ver 50589', 'hsp 90 inhibitors vernalis', 'ver 510747', 'rbt 0036283', 'hsp 90 inhibitors cancer vernalis', 'ver 51000', 'cct 066965', 'rbt 0045856', 'g 3130', 'ver 52296', 'ver 45864', 'ph 3', 'rbt 0027129', 'nvp auy 922', 'hsp 90 inhibitors ribotargets']",correct_mapping
taladegib (capsule),Hedgehog pathway inhibitor,taladegib,,"taladegib (oral, cancer)",taladegib,fexact,"['taladegib (oral, cancer)', 'taladegib (oral, cancer), Ignyta', 'taladegib', 'smoothened receptor antagonist (oral, cancer)', 'hedgehog/SMO antagonist (cancer)', 'LY-2940680']","taladegib (oral, cancer)",fexact,"['taladegib oral cancer', 'taladegib oral cancer ignyta', 'taladegib', 'smoothened receptor antagonist oral cancer', 'hedgehog smo antagonist cancer', 'ly 2940680']",correct_mapping
MUC1 peptide-poly-ICLC adjuvant vaccine,Immunostimulant,MUC1 peptide-poly-ICLC adjuvant vaccine,,,,0,['MUC1 peptide-poly-ICLC adjuvant vaccine'],,0,[],0
desipramine,Adrenergic transmitter uptake inhibitor; Tricyclic antidepressant,desipramine,,,,0,"['desipramine', 'desipramine hydrochloride (Rett syndrome)', 'desipramine hydrochloride (Rett syndrome), ORPHELIA Pharma', 'ORP-002', 'desipramine  hydrochloride', 'desipramine hydrochloride (Rett syndrome), TargeOn', 'desipramine chlorhydrate']",,NER_API,[],0
TSR-011 (controlled-release),Anaplastic lymphoma kinase inhibitor; TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,TSR-011,,TSR-011,tsr 011,fexact,"['ALK inhibitors (oral, non-small cell lung cancer),/TESARO', 'anaplastic lymphoma kinase inhibitors (oral, non-small cell lung cancer)', 'ALK inhibitors (oral, non-small cell lung cancer),/', 'anaplastic lymphoma kinase inhibitors (oral, non-small cell lung cancer), TESARO', 'TSR-011', 'belizatinib', 'TRK inhibitor', 'TSR-012']",TSR-011,fexact,"['alk inhibitors oral non small cell lung cancer tesaro', 'anaplastic lymphoma kinase inhibitors oral non small cell lung cancer', 'alk inhibitors oral non small cell lung cancer', 'anaplastic lymphoma kinase inhibitors oral non small cell lung cancer tesaro', 'tsr 011', 'belizatinib', 'trk inhibitor', 'tsr 012']",correct_mapping
TSR-011 (capsule),Anaplastic lymphoma kinase inhibitor; TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,TSR-011,,TSR-011,tsr 011,fexact,"['ALK inhibitors (oral, non-small cell lung cancer),/TESARO', 'anaplastic lymphoma kinase inhibitors (oral, non-small cell lung cancer)', 'ALK inhibitors (oral, non-small cell lung cancer),/', 'anaplastic lymphoma kinase inhibitors (oral, non-small cell lung cancer), TESARO', 'TSR-011', 'belizatinib', 'TRK inhibitor', 'TSR-012']",TSR-011,fexact,"['alk inhibitors oral non small cell lung cancer tesaro', 'anaplastic lymphoma kinase inhibitors oral non small cell lung cancer', 'alk inhibitors oral non small cell lung cancer', 'anaplastic lymphoma kinase inhibitors oral non small cell lung cancer tesaro', 'tsr 011', 'belizatinib', 'trk inhibitor', 'tsr 012']",correct_mapping
dovitinib lactate (capsule),Fibroblast growth factor receptor 1 antagonist; Fibroblast growth factor receptor 3 antagonist; C-kit inhibitor; EGFR kinase inhibitor; FGF receptor tyrosine kinase inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,dovitinib lactate,,dovitinib,dovitinib lactate,fexact,"['VEGF receptor kinase inhibitor (cancer)', 'dovitinib lactate (USAN)', 'dovitinib, Allarity Therapeutics', 'GFKI, Novartis', 'VEGF/FGF/PDGF receptor kinase inhibitor', 'CHIR-258', 'dovitinib lactate', 'VEGF receptor kinase inhibitor (cancer), Novartis', 'VEGFR kinase inhibitor, Novartis', 'growth factor kinase inhibitor', 'TKI-258', 'growth factor kinase inhibitor, Novartis', 'Dovitinib DPR', 'GFKI-258', 'GFKI', 'VEGFR kinase inhibitor', 'VEGF/FGF/PDGF receptor kinase inhibitor, Novartis', 'dovitinib', 'TK-1258']",dovitinib,fexact,"['vegf receptor kinase inhibitor cancer', 'dovitinib lactate usan', 'dovitinib allarity therapeutics', 'gfki novartis', 'vegf fgf pdgf receptor kinase inhibitor', 'chir 258', 'dovitinib lactate', 'vegf receptor kinase inhibitor cancer novartis', 'vegfr kinase inhibitor novartis', 'growth factor kinase inhibitor', 'tki 258', 'growth factor kinase inhibitor novartis', 'dovitinib dpr', 'gfki 258', 'gfki', 'vegfr kinase inhibitor', 'vegf fgf pdgf receptor kinase inhibitor novartis', 'dovitinib', 'tk 1258']",correct_mapping
neratinib (tablet),EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),neratinib,,neratinib,neratinib,fexact,"['neratinib', 'PF-5208767', 'PF-05208767', 'CAN-030', 'PB-272', 'HKI-272', 'Nerlynx']",neratinib,fexact,"['neratinib', 'pf 5208767', 'pf 05208767', 'can 030', 'pb 272', 'hki 272', 'nerlynx']",correct_mapping
trebananib,TIE-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Angiopoietin-1 inhibitor; Angiopoietin-2 inhibitor,trebananib,,trebananib,trebananib,fexact,"['tie-2 tyrosine kinase receptor antagonists (cancer),/', 'Ab536', 'tie-2 tyrosine kinase receptor antagonists,/', 'Angiopoietin-2 antagonists (cancer),/', 'tie-2 tyrosine kinase receptor antagonists,/Takeda', '2xCon4C', 'tie-2 receptor antagonists,/', 'Ang-2 antagonists (cancer),/Takeda', 'tie-2 tyrosine kinase receptor antagonists (cancer),/Takeda', 'AMG-386', 'Peptidobody tie-2 tyrosine kinase receptor antagonists', 'tie-2 receptor antagonists,/Takeda', 'Ang-2 antagonists (cancer),/', 'Angiopoietin-2 antagonists (cancer),/Takeda', 'L1-7', 'trebananib']",trebananib,fexact,"['tie 2 tyrosine kinase receptor antagonists cancer', 'ab536', 'tie 2 tyrosine kinase receptor antagonists', 'angiopoietin 2 antagonists cancer', 'tie 2 tyrosine kinase receptor antagonists takeda', '2xcon4c', 'tie 2 receptor antagonists', 'ang 2 antagonists cancer takeda', 'tie 2 tyrosine kinase receptor antagonists cancer takeda', 'amg 386', 'peptidobody tie 2 tyrosine kinase receptor antagonists', 'tie 2 receptor antagonists takeda', 'ang 2 antagonists cancer', 'angiopoietin 2 antagonists cancer takeda', 'l1 7', 'trebananib']",correct_mapping
exemestane,Aromatase inhibitor,exemestane,,exemestane,exemestane,fexact,"['exemestane', 'Aromasin', 'PNU-155971', 'FCE-24304', 'Nikidess', 'PNU-971-ONC-0028']",exemestane,fexact,"['exemestane', 'aromasin', 'pnu 155971', 'fce 24304', 'nikidess', 'pnu 971 onc 0028']",correct_mapping
boanmycin,Unidentified pharmacological activity,boanmycin,,"boanmycin hydrochloride (intramuscular, intravenous, head and neck tumor)",boanmycin,fexact,"['boanmycin HCl', 'boanmycin', 'boanmycin hydrochloride', 'boanmycin hydrochloride (intramuscular, intravenous, head and neck tumor)', 'boanmycin hydrochloride (intramuscular, intravenous, head and neck tumor), Tianjin Taihe Pharmaceutical', 'Ye Li Ning']","boanmycin hydrochloride (intramuscular, intravenous, head and neck tumor)",fexact,"['boanmycin hcl', 'boanmycin', 'boanmycin hydrochloride', 'boanmycin hydrochloride intramuscular intravenous head and neck tumor', 'boanmycin hydrochloride intramuscular intravenous head and neck tumor tianjin taihe pharmaceutical', 'ye li ning']",correct_mapping
veliparib (capsule),Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor,veliparib,,veliparib,veliparib,fexact,"['ABT-888', 'PARP inhibitor (cancer), Abbott/NIH', 'PARP inhibitor (cancer),/NIH', 'NSC-737664', 'PARP inhibitor (testicular cancer/germ cell and embryonic cancer/seminoma)', 'ABT-620223', 'veliparib']",veliparib,fexact,"['abt 888', 'parp inhibitor cancer abbott nih', 'parp inhibitor cancer nih', 'nsc 737664', 'parp inhibitor testicular cancer germ cell and embryonic cancer seminoma', 'abt 620223', 'veliparib']",correct_mapping
cixutumumab,Insulin-like growth factor 1 antagonist,cixutumumab,,cixutumumab,cixutumumab,fexact,"['NSC-742460', 'IMC-A12', 'IGF-R1 antibodies (cancer)', 'cixutumumab', 'LY-3012217', 'IMCL-A12']",cixutumumab,fexact,"['nsc 742460', 'imc a12', 'igf r1 antibodies cancer', 'cixutumumab', 'ly 3012217', 'imcl a12']",correct_mapping
18F-FLT,Unidentified pharmacological activity,18F-FLT,,,,0,"['18F-FLT', 'Fluorine 18-FLT', 'FLT-[18F]', '[18F] FLT PET agent (acute lymphoblastic leukemia), Advanced Imaging Projects', 'Fluorine 18-fluorothymidine', 'AIP-104', 'fluorothymidine-[18F]', '18F-fluorothymidine']",,NER_API,[],0
apatorsen,Heat shock protein 27 antagonist,apatorsen,,apatorsen sodium,apatorsen,fexact,"['OGX-427', 'apatorsen', 'apatorsen sodium', 'Hsp27 inhibitors (cancer), OncoGenex', 'Hsp27 inhibitors (cancer)']",apatorsen sodium,fexact,"['ogx 427', 'apatorsen', 'apatorsen sodium', 'hsp27 inhibitors cancer oncogenex', 'hsp27 inhibitors cancer']",correct_mapping
DS-3078,mTORC1 kinase inhibitor; mTORC2 kinase inhibitor,DS-3078,,DS-3078,ds 3078,fexact,"['DS-3078a', 'mTORC1/2 inhibitor (oral, cancer)', 'DS-3078', 'dual TORC1/2 inhibitor (oral, cancer)']",DS-3078,fexact,"['ds 3078a', 'mtorc1 2 inhibitor oral cancer', 'ds 3078', 'dual torc1 2 inhibitor oral cancer']",correct_mapping
pazopanib (tablet),B-raf kinase inhibitor; C-kit inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,pazopanib,,pazopanib,pazopanib,fexact,"['GW-786034B', 'PZP-115891', 'pazopanib (oral, cancer), Novartis', 'Armala', 'pazopanib (oral, cancer)', 'GW-786034', 'Patorma', 'pazopanib', '786034', 'pazopanib hydrochloride', 'Votrient']",pazopanib,fexact,"['gw 786034b', 'pzp 115891', 'pazopanib oral cancer novartis', 'armala', 'pazopanib oral cancer', 'gw 786034', 'patorma', 'pazopanib', '786034', 'pazopanib hydrochloride', 'votrient']",correct_mapping
CVA-21 (IV),Immuno-oncology therapy,CVA-21,,Cavatak,cva21,fuzzy,"['Cavatak', 'Coxsackievirus A21 (cancer), Viralytics', 'Coxsackievirus A21 (cancer)', 'CVA21', 'cav-21 (coe strain, coxsackievirus a21, enterovirus) cancer therapy', 'oncolytic coxsackievirus therapy (cancer)', 'V-937', 'CAV21 (coe strain, Coxsackievirus A21, enterovirus) cancer therapy, ViroTarg', 'CAV21 (coe strain, Coxsackievirus A21, enterovirus) cancer therapy', 'oncolytic coxsackievirus therapy (cancer), Viralytics', 'Coxsackievirus A21 (cancer), Psiron']",Cavatak,fexact,"['cavatak', 'coxsackievirus a21 cancer viralytics', 'coxsackievirus a21 cancer', 'cva21', 'cav 21 coe strain coxsackievirus a21 enterovirus cancer therapy', 'oncolytic coxsackievirus therapy cancer', 'v 937', 'cav21 coe strain coxsackievirus a21 enterovirus cancer therapy virotarg', 'cav21 coe strain coxsackievirus a21 enterovirus cancer therapy', 'oncolytic coxsackievirus therapy cancer viralytics', 'coxsackievirus a21 cancer psiron']",incorrect_mapping
MM-151,EGFR antagonist,MM-151,,MM-151,mm 151,fexact,['MM-151'],MM-151,fexact,['mm 151'],correct_mapping
HS-110,Immunostimulant,HS-110,,viagenpumatucel-L,hs 110,fexact,"['gp96-Ig secreting adenocarcinoma cell-based vaccine (intradermal, advanced solid tumor)', 'viagenpumatucel-L', 'gp96-Ig secreting adenocarcinoma cell-based vaccine (NSCLC, HeatShock/ImPACT)', 'Ad100-gp96Ig-HLA A1', 'HS-110', 'HS-L1']",viagenpumatucel-L,fexact,"['gp96 ig secreting adenocarcinoma cell based vaccine intradermal advanced solid tumor', 'viagenpumatucel l', 'gp96 ig secreting adenocarcinoma cell based vaccine nsclc heatshock impact', 'ad100 gp96ig hla a1', 'hs 110', 'hs l1']",correct_mapping
"nicotine replacement therapy, unspecified",Unidentified pharmacological activity,nicotine replacement therapy,unspecified,,,0,['nicotine replacement therapy'],,0,[],0
"nicotine transdermal patch, unspecified",Unidentified pharmacological activity,nicotine transdermal patch,unspecified,,,0,"['Niquitin CQ', 'Nicomed', 'Nicoderm CQ', 'Nicotell TTS', 'Nicotrol inhaler', 'Nicotinell', 'nicotine transdermal, Kabi', 'Nicoderm', 'transdermal nicotine', 'nicotine transdermal', 'nicotinell TTS', 'Habitrol', 'nicotine transdermal, Warner', 'Nicabate TTS', 'Nicabate', 'Nicotrol', 'nicotine transdermal, Marion', 'TS-Nicotine', 'nicotine', 'Nicorette inhaler', 'Nicorette', 'Niquitin Clear', 'Nicopatch']",,Drug_API_mapping,[],0
bimagrumab,Activin receptor type II antagonist,bimagrumab,,bimagrumab,bimagrumab,fexact,"['anti-activin type IIB monoclonal antibody (cachexia/myositis)', 'BYM-338', 'HuCAL-derived monoclonal antibody (myositis/cachexia)', 'hucal-derived monoclonal antibody (myositis/cachexia)', 'bimagrumab', 'anti-activin type IIB monoclonal antibody (cachexia/myositis), Novartis', 'HuCAL-derived monoclonal antibody (myositis/cachexia), Novartis']",bimagrumab,fexact,"['anti activin type iib monoclonal antibody cachexia myositis', 'bym 338', 'hucal derived monoclonal antibody myositis cachexia', 'hucal derived monoclonal antibody myositis cachexia', 'bimagrumab', 'anti activin type iib monoclonal antibody cachexia myositis novartis', 'hucal derived monoclonal antibody myositis cachexia novartis']",correct_mapping
pasireotide LAR,Somatostatin receptor 1 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 3 agonist; Somatostatin receptor 5 agonist,pasireotide LAR,,,,0,"['pasireotide pamoate', 'SOM-230C', 'pasireotide LAR', 'Signifol', 'Signifolo', 'pasireotide', 'pasireotide pamoate (sustained release)', 'Signifore LAR', 'Signifor LAR']",,Drug_API_mapping,[],0
[18F]FPRGD2,Not applicable,[18F]FPRGD2,,"peptide-based pet radiotracer (breast cancer), medical center",18f fpprgd2,fuzzy,"['PEG3-E[c(RGDyk)]2', '18F-FPPRGD2', 'peptide-based pet radiotracer (breast cancer), medical center']","peptide-based pet radiotracer (breast cancer), medical center",fexact,"['peg3 e c rgdyk 2', '18f fpprgd2', 'peptide based pet radiotracer breast cancer medical center']",incorrect_mapping
[18F]FPPRGD2,Not applicable,[18F]FPPRGD2,,"peptide-based pet radiotracer (breast cancer), medical center",18f fpprgd2,fexact,"['PEG3-E[c(RGDyk)]2', '18F-FPPRGD2', 'peptide-based pet radiotracer (breast cancer), medical center']","peptide-based pet radiotracer (breast cancer), medical center",fexact,"['peg3 e c rgdyk 2', '18f fpprgd2', 'peptide based pet radiotracer breast cancer medical center']",correct_mapping
gedatolisib,mTOR kinase inhibitor; PI3 kinase inhibitor,gedatolisib,,gedatolisib,gedatolisib,fexact,"['PF-384', 'PF-05212384', 'gedatolisib', 'PKI-587']",gedatolisib,fexact,"['pf 384', 'pf 05212384', 'gedatolisib', 'pki 587']",correct_mapping
PF-04691502,mTOR kinase inhibitor; PI3 kinase alpha inhibitor; PI3 kinase beta inhibitor; PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor,PF-04691502,,PF-4691502,pf 04691502,fexact,"['PF-4691502', 'PF-06465603', 'PF-502', 'PI3K/mTOR inhibitor (cancer)', 'PF-04691502', 'PF-0', 'PF-04691503']",PF-4691502,fexact,"['pf 4691502', 'pf 06465603', 'pf 502', 'pi3k mtor inhibitor cancer', 'pf 04691502', 'pf 0', 'pf 04691503']",correct_mapping
belagenpumatucel-L,Transforming growth factor beta 2 antagonist; Immunostimulant; Immuno-oncology therapy,belagenpumatucel-L,,belagenpumatucel-L,belagenpumatucel l,fexact,"['Lucanix', 'lung cancer/ astrocytoma vaccine, NovaRx', 'belagenpumatucel-L', 'antisense (TGFbeta) lung cancer/ astrocytoma vaccine, NovaRx']",belagenpumatucel-L,fexact,"['lucanix', 'lung cancer astrocytoma vaccine novarx', 'belagenpumatucel l', 'antisense tgfbeta lung cancer astrocytoma vaccine novarx']",correct_mapping
romidepsin (IV),Histone deacetylase inhibitor; Cell cycle inhibitor,romidepsin,,romidepsin,romidepsin,fexact,"['depsipeptide, NCI/', 'romidepsin', 'Istodax', 'depsipeptide, NCI/Fujisawa']",romidepsin,fexact,"['depsipeptide nci', 'romidepsin', 'istodax', 'depsipeptide nci fujisawa']",correct_mapping
veliparib,Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor,veliparib,,veliparib,veliparib,fexact,"['ABT-888', 'PARP inhibitor (cancer), Abbott/NIH', 'PARP inhibitor (cancer),/NIH', 'NSC-737664', 'PARP inhibitor (testicular cancer/germ cell and embryonic cancer/seminoma)', 'ABT-620223', 'veliparib']",veliparib,fexact,"['abt 888', 'parp inhibitor cancer abbott nih', 'parp inhibitor cancer nih', 'nsc 737664', 'parp inhibitor testicular cancer germ cell and embryonic cancer seminoma', 'abt 620223', 'veliparib']",correct_mapping
belinostat,Histone deacetylase inhibitor; Cell cycle inhibitor,belinostat,,"belinostat (oral, cancer)",belinostat,fexact,"['PX-089344', 'belinostat (oral, solid tumors),/', 'belinostat (oral, cancer), TopoTarget/Spectrum', 'belinostat (oral, cancer)', 'belinostat (oral, cancer), BioAlliance Pharma/Spectrum', 'histone deacetylase inhibitor (oral, solid tumors), TopoTarget/', 'belinostat (oral, cancer),/Spectrum', 'PXD-101 (oral, solid tumors), TopoTarget/', 'belinostat (oral, cancer),/', 'HDAC inhibitor (oral, solid tumors),/', 'histone deacetylase inhibitor (oral, solid tumors),/', 'belinostat', 'belinostat (oral, cancer), Onxeo', 'belinostat (oral, cancer), BioAlliance Pharma/', 'belinostat (oral, cancer), TopoTarget/', 'belinostat (oral, cancer), Onxeo/Spectrum', 'PXD-101 (oral, solid tumors),/', 'belinostat (oral, solid tumors), TopoTarget/', 'PXD-101', 'HDAC inhibitor (oral, solid tumors), TopoTarget/']","belinostat (oral, cancer)",fexact,"['px 089344', 'belinostat oral solid tumors', 'belinostat oral cancer topotarget spectrum', 'belinostat oral cancer', 'belinostat oral cancer bioalliance pharma spectrum', 'histone deacetylase inhibitor oral solid tumors topotarget', 'belinostat oral cancer spectrum', 'pxd 101 oral solid tumors topotarget', 'belinostat oral cancer', 'hdac inhibitor oral solid tumors', 'histone deacetylase inhibitor oral solid tumors', 'belinostat', 'belinostat oral cancer onxeo', 'belinostat oral cancer bioalliance pharma', 'belinostat oral cancer topotarget', 'belinostat oral cancer onxeo spectrum', 'pxd 101 oral solid tumors', 'belinostat oral solid tumors topotarget', 'pxd 101', 'hdac inhibitor oral solid tumors topotarget']",correct_mapping
tivantinib,MET tyrosine kinase inhibitor; Angiogenesis inhibitor,tivantinib,,tivantinib,tivantinib,fexact,"['CO-650', 'ARQ-707', '650RP', 'tivantinib', 'ARQ-650RP', 'cancer survival protein modulation program', 'ARQ-650', 'ARQ-197', 'CO-650 series (cancer)', 'cancer survival protein modulation product']",tivantinib,fexact,"['co 650', 'arq 707', '650rp', 'tivantinib', 'arq 650rp', 'cancer survival protein modulation program', 'arq 650', 'arq 197', 'co 650 series cancer', 'cancer survival protein modulation product']",correct_mapping
azacitidine (iv),DNA synthesis inhibitor; DNA methylase inhibitor; RNA synthesis inhibitor,azacitidine,,"azacytidine (inhaled aerosol, lung cancer)",azacitidine,fexact,"['azacitidine', 'azacytidine (inhaled aerosol, lung cancer)', '5-azacytidine (inhaled aerosol, lung cancer)', '5-azacitidine']","azacytidine (inhaled aerosol, lung cancer)",fexact,"['azacitidine', 'azacytidine inhaled aerosol lung cancer', '5 azacytidine inhaled aerosol lung cancer', '5 azacitidine']",correct_mapping
pazopanib,Vascular endothelial growth factor (VEGF)receptor antagonist; B-raf kinase inhibitor; C-kit inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,pazopanib,,pazopanib,pazopanib,fexact,"['GW-786034B', 'PZP-115891', 'pazopanib (oral, cancer), Novartis', 'Armala', 'pazopanib (oral, cancer)', 'GW-786034', 'Patorma', 'pazopanib', '786034', 'pazopanib hydrochloride', 'Votrient']",pazopanib,fexact,"['gw 786034b', 'pzp 115891', 'pazopanib oral cancer novartis', 'armala', 'pazopanib oral cancer', 'gw 786034', 'patorma', 'pazopanib', '786034', 'pazopanib hydrochloride', 'votrient']",correct_mapping
palifosfamide-tris (IV),DNA inhibitor; DNA synthesis inhibitor,palifosfamide-tris,,palifosfamide,palifosfamide tris,fexact,"['lysine-isophosphoramide mustard (L-IPM)', 'ZIO-203', 'ifosfamide analogs,/', 'palifosfamide-tris', 'palifosfamide lysine', '4-hydroperoxyifosfamide', 'lysine-isophosphoramide mustard (cancer), ZIOPHARM', 'L-IPM (cancer)', 'ZIO-201-T', 'lysine-isophosphoramide mustard (cancer)', 'ifosfamide analogs, ZIOPHARM/', 'Zymafos', 'ZIO-201', 'IPM-L', 'L-IPM', 'lysine-isophosphoramide mustard', 'HO-IFOS', 'ifosfamide analogs', 'IPM', 'Isophosphoramide mustard', 'palifosfamide-T', 'palifosfamide', 'palifosfamide tromethamine', 'L-IPM (cancer), ZIOPHARM', 'ZIO-202']",palifosfamide,fexact,"['lysine isophosphoramide mustard l ipm', 'zio 203', 'ifosfamide analogs', 'palifosfamide tris', 'palifosfamide lysine', '4 hydroperoxyifosfamide', 'lysine isophosphoramide mustard cancer ziopharm', 'l ipm cancer', 'zio 201 t', 'lysine isophosphoramide mustard cancer', 'ifosfamide analogs ziopharm', 'zymafos', 'zio 201', 'ipm l', 'l ipm', 'lysine isophosphoramide mustard', 'ho ifos', 'ifosfamide analogs', 'ipm', 'isophosphoramide mustard', 'palifosfamide t', 'palifosfamide', 'palifosfamide tromethamine', 'l ipm cancer ziopharm', 'zio 202']",correct_mapping
BMS-690514,EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,BMS-690514,,BMS-690514,bms 690514,fexact,"['BMS-690514', 'BMS-399626', 'BMS-655875', 'ErbB/VEGF inhibitor (cancer), BMS', 'panHER/VEGFR-2 kinase inhibitor (cancer)', 'panHER/VEGFR-2 kinase inhibitor (cancer), BMS']",BMS-690514,fexact,"['bms 690514', 'bms 399626', 'bms 655875', 'erbb vegf inhibitor cancer bms', 'panher vegfr 2 kinase inhibitor cancer', 'panher vegfr 2 kinase inhibitor cancer bms']",correct_mapping
PRAME ASCI,Preferential antigen of melanoma inhibitor; Immuno-oncology therapy,PRAME ASCI,,,,0,['PRAME ASCI'],,0,[],0
temsirolimus (IV),Immunosuppressant; mTOR kinase inhibitor; Protein kinase inhibitor; Cell cycle inhibitor,temsirolimus,,temsirolimus,temsirolimus,fexact,"['Torisel', 'NSC-683864', 'CCI-779', 'temsirolimus']",temsirolimus,fexact,"['torisel', 'nsc 683864', 'cci 779', 'temsirolimus']",correct_mapping
buparlisib,Protein kinase inhibitor; PI3 kinase inhibitor,buparlisib,,buparlisib,buparlisib,fexact,"['buparlisib hydrochloride', 'BKM-120', 'buparlisib', 'AN-2025', 'phosphatidylinositol-3-kinase inhibitor (cancer), Novartis', 'PI3K inhibitor (cancer)', 'PI3K inhibitor (cancer), Novartis', 'NVP-BKM-120', 'BKM-210', 'phosphatidylinositol-3-kinase inhibitor (cancer), Adlai Nortye Biopharma', 'phosphatidylinositol-3-kinase inhibitor (cancer)']",buparlisib,fexact,"['buparlisib hydrochloride', 'bkm 120', 'buparlisib', 'an 2025', 'phosphatidylinositol 3 kinase inhibitor cancer novartis', 'pi3k inhibitor cancer', 'pi3k inhibitor cancer novartis', 'nvp bkm 120', 'bkm 210', 'phosphatidylinositol 3 kinase inhibitor cancer adlai nortye biopharma', 'phosphatidylinositol 3 kinase inhibitor cancer']",correct_mapping
racotumomab (SC),Immunostimulant,racotumomab,,racotumomab,racotumomab,fexact,"['vaxira (lung cancer)', '1E10', '1E10 anti-idiotypic MAb', 'P3 MAb, CIM', 'Vaxira (lung cancer), Recombio', '1E10 anti-idiotypic MAb, Center of Molecular Immunology', 'racotumomab']",racotumomab,fexact,"['vaxira lung cancer', '1e10', '1e10 anti idiotypic mab', 'p3 mab cim', 'vaxira lung cancer recombio', '1e10 anti idiotypic mab center of molecular immunology', 'racotumomab']",correct_mapping
celecoxib,Cyclooxygenase 2 inhibitor,celecoxib,,celecoxib,celecoxib,fexact,"['Celecox', 'Onsenal', 'YM-74177', 'celecoxib FAP', 'YM-177', 'SC-58635', 'Celebrex', 'Celebra', 'celecoxib']",celecoxib,fexact,"['celecox', 'onsenal', 'ym 74177', 'celecoxib fap', 'ym 177', 'sc 58635', 'celebrex', 'celebra', 'celecoxib']",correct_mapping
"sodium thiosulfate, Adherex",Not applicable,sodium thiosulfate,Adherex,,,0,"['sodium thiosulfate (calciphylaxis)', 'sodium thiosulfate (otoprotectant)', 'sodium thiosulfate (otoprotectant), Adherex', 'STS', 'PEDMARK', 'sodium thiosulfate', 'STS, Adherex', 'sodium thiosulfate (calciphylaxis/toxicity/dermatomyositis)']",,Drug_API_mapping,[],0
cisplatin (intra-arterial),DNA inhibitor; DNA synthesis inhibitor,cisplatin,,,,0,"['demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors),/Orient Europharma', 'cisplatin (injectable, micelle),/Orient Europharma', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors), NanoCarrier/Orient Europharma', 'demplatin pegraglumer', 'cisplatin', 'cisplatin (injectable, micelle), NanoCarrier/', 'Nanoplatin', 'cisplatin (injectable, micelle),/', 'NC-6004', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/nsclc/biliary tract/head and neck/lung cancer/solid tumors)', 'cisplatin (injectable, micelle), NanoCarrier/Orient Europharma', 'cisplatin (injectable, micelle)']",,NER_API,[],0
sepantronium bromide,Survivin inhibitor,sepantronium bromide,,sepantronium bromide,sepantronium bromide,fexact,"['PC-002', 'survivin expression inhibitor, Yamanouchi', 'sepantronium bromide', 'YM-155', 'survivin expression inhibitor']",sepantronium bromide,fexact,"['pc 002', 'survivin expression inhibitor yamanouchi', 'sepantronium bromide', 'ym 155', 'survivin expression inhibitor']",correct_mapping
litronesib,Kinesin inhibitor,litronesib,,litronesib,litronesib,fexact,"['mitotic kinesin Eg5 inhibitor (cancer), Kyowa Hakko Kogyo/', 'litronesib', 'K-858', 'mitotic kinesin Eg5 inhibitor (cancer), Kyowa Hakko Kirin/', 'mitotic kinesin Eg5 inhibitor (cancer),/', 'KF-89617', 'Eg5 inhibitor (cancer)', 'LY-2523355']",litronesib,fexact,"['mitotic kinesin eg5 inhibitor cancer kyowa hakko kogyo', 'litronesib', 'k 858', 'mitotic kinesin eg5 inhibitor cancer kyowa hakko kirin', 'mitotic kinesin eg5 inhibitor cancer', 'kf 89617', 'eg5 inhibitor cancer', 'ly 2523355']",correct_mapping
"doxorubicin, Stealth",DNA synthesis inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,doxorubicin,Stealth,"doxorubicin (liposomal, STEALTH)",doxorubicin,fexact,"['doxorubicin (liposomal, STEALTH)', 'SL-Dox', 'DOX-SL', 'doxorubicin HCl', 'doxorubicin hydrochloride', 'Caelyx', 'STEALTH (doxorubicin)', 'S-DOX', 'doxorubicin,/Schering', 'NSC-712227', 'doxorubicin,/', 'doxorubicin', 'pegylated liposomal doxorubicin', 'Doxil', 'JNS-002']","doxorubicin (liposomal, STEALTH)",fexact,"['doxorubicin liposomal stealth', 'sl dox', 'dox sl', 'doxorubicin hcl', 'doxorubicin hydrochloride', 'caelyx', 'stealth doxorubicin', 's dox', 'doxorubicin schering', 'nsc 712227', 'doxorubicin', 'doxorubicin', 'pegylated liposomal doxorubicin', 'doxil', 'jns 002']",correct_mapping
IMO-2055,Toll-like receptor 9 agonist,IMO-2055,,IMO-2055,imo 2055,fexact,"['oligonucleotide (inflammation),/Institut Pasteur', 'oligonucleotide (anti IL-5), Insitut Pasteur/', 'IMOxine', 'oligonucleotide (asthma),/Institut Pasteur', 'IMO program', 'immunomodulatory oligonucleotides (cancer)', 'immunomodulatory oligonucleotides', 'IMO program, Hybridon', 'oligonucleotide (asthma), Hybridon/Institut Pasteur', 'synthetic immunomodulatory oligonucleotides (IMO)', 'HYB-2055', 'immunomodulatory oligonucleotides (cancer), Merck Serono', 'IMO-2055', 'oligonucleotide (anti IL-5), Institut Pasteur/Hybridon', 'oligonucleotide (allergy),/Institut Pasteur', 'EMD-1201081', 'oligonucleotide (allergy), Hybridon/Institut Pasteur', 'oligonucleotide (inflammation), Hybridon/Institut Pasteur', 'oligonucleotides (immune disorders)', 'synthetic immunomodulatory oligonucleotides (IMO), Hybridon', 'oligonucleotides (immune disorders), Hybridon']",IMO-2055,fexact,"['oligonucleotide inflammation institut pasteur', 'oligonucleotide anti il 5 insitut pasteur', 'imoxine', 'oligonucleotide asthma institut pasteur', 'imo program', 'immunomodulatory oligonucleotides cancer', 'immunomodulatory oligonucleotides', 'imo program hybridon', 'oligonucleotide asthma hybridon institut pasteur', 'synthetic immunomodulatory oligonucleotides imo', 'hyb 2055', 'immunomodulatory oligonucleotides cancer merck serono', 'imo 2055', 'oligonucleotide anti il 5 institut pasteur hybridon', 'oligonucleotide allergy institut pasteur', 'emd 1201081', 'oligonucleotide allergy hybridon institut pasteur', 'oligonucleotide inflammation hybridon institut pasteur', 'oligonucleotides immune disorders', 'synthetic immunomodulatory oligonucleotides imo hybridon', 'oligonucleotides immune disorders hybridon']",correct_mapping
dichloroacetate (oral),Unidentified pharmacological activity,dichloroacetate,,,,0,"['sodium dichloroacetate', 'Dichloroacetate', 'CPC-211', 'DCA', 'Ceresine']",,Drug_API_mapping,[],0
sunitinib,Colony stimulating factor 1 receptor antagonist; RET tyrosine kinase inhibitor; C-kit inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor alpha kinase inhib; Platelet-derived growth factor receptor beta kinase inhib; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,sunitinib,,sunitinib,sunitinib,fexact,"['SU-11248', 'SU-010398', 'SU-12662', 'SU-11248J', 'sunitinib malate', 'SU-011248', 'PHA-290940AD', 'PDGF TK antagonist (cancer), SUGEN', 'Sutent', 'PDGF TK antagonist (cancer)', 'sunitinib', 'SU-012662', 'Sutene']",sunitinib,fexact,"['su 11248', 'su 010398', 'su 12662', 'su 11248j', 'sunitinib malate', 'su 011248', 'pha 290940ad', 'pdgf tk antagonist cancer sugen', 'sutent', 'pdgf tk antagonist cancer', 'sunitinib', 'su 012662', 'sutene']",correct_mapping
racotumomab (intradermal),Immunostimulant,racotumomab,,racotumomab,racotumomab,fexact,"['vaxira (lung cancer)', '1E10', '1E10 anti-idiotypic MAb', 'P3 MAb, CIM', 'Vaxira (lung cancer), Recombio', '1E10 anti-idiotypic MAb, Center of Molecular Immunology', 'racotumomab']",racotumomab,fexact,"['vaxira lung cancer', '1e10', '1e10 anti idiotypic mab', 'p3 mab cim', 'vaxira lung cancer recombio', '1e10 anti idiotypic mab center of molecular immunology', 'racotumomab']",correct_mapping
PX-866,Protein kinase B inhibitor; PI3 kinase inhibitor; PTEN inhibitor,PX-866,,"sonolisib (oral, cancer)",px 866,fexact,"['PX-866', 'DJM-166', 'sonolisib', 'PX-2000', 'sonolisib (oral, cancer)', 'phosphatidylinositol-3-kinase inhibitors (cancer), Biomira', 'sonolisib (oral, cancer), Oncothyreon', 'phosphatidylinositol-3-kinase inhibitor (oral, cancer), Oncothyreon']","sonolisib (oral, cancer)",fexact,"['px 866', 'djm 166', 'sonolisib', 'px 2000', 'sonolisib oral cancer', 'phosphatidylinositol 3 kinase inhibitors cancer biomira', 'sonolisib oral cancer oncothyreon', 'phosphatidylinositol 3 kinase inhibitor oral cancer oncothyreon']",correct_mapping
saracatinib,Abl receptor tyrosine kinase inhibitor; Src inhibitor,saracatinib,,saracatinib,saracatinib,fexact,"['ADZ-0530', 'saracatinib', 'AZ-10353926', 'saracatinib difumarate', 'AZD-O530', 'NSC-735464', 'AZ-0530', 'AZD-0530']",saracatinib,fexact,"['adz 0530', 'saracatinib', 'az 10353926', 'saracatinib difumarate', 'azd o530', 'nsc 735464', 'az 0530', 'azd 0530']",correct_mapping
AT-101,Bcl2 inhibitor; Bcl-XL inhibitor; Mcl-1 antagonist,AT-101,,AT-101,at 101,fexact,"['NSC-726190', 'BL-193', 'bcl-2/bcl-xl inhibitors (cancer, tablet/natural product)', '(-)-gossypol (anticancer)', 'TW-37', '(-)-gossypol (anticancer), Ascenta', '(-)-gossypol', 'gossypol analogs, nci', 'R-(-)-gossypol acetic acid', '(-)-gossypol, NCI/University of Michigan', 'pan-Bcl-2 inhibitor (cancer), Ascenta/', 'Bcl-2/Bcl-xl inhibitors (cancer, tablet/natural product), University of Michigan/Ascenta', 'AT-101', 'pan-Bcl-2 inhibitor (cancer),/', 'Bcl-2/Bcl-xl inhibitors (cancer, tablet/natural product), University of Michigan/', 'gossypol analogs, NCI/University of Michigan', '(-)-gossypol, nci']",AT-101,fexact,"['nsc 726190', 'bl 193', 'bcl 2 bcl xl inhibitors cancer tablet natural product', 'gossypol anticancer', 'tw 37', 'gossypol anticancer ascenta', 'gossypol', 'gossypol analogs nci', 'r gossypol acetic acid', 'gossypol nci university of michigan', 'pan bcl 2 inhibitor cancer ascenta', 'bcl 2 bcl xl inhibitors cancer tablet natural product university of michigan ascenta', 'at 101', 'pan bcl 2 inhibitor cancer', 'bcl 2 bcl xl inhibitors cancer tablet natural product university of michigan', 'gossypol analogs nci university of michigan', 'gossypol nci']",correct_mapping
fluorouracil,DNA synthesis inhibitor; Thymidylate synthase inhibitor; RNA synthesis inhibitor,fluorouracil,,,,0,"['microsponge (5-fluorouracil), AP Pharma/', '5-Fluorouracil', 'Carac', 'microsponge (fluorouracil), AP Pharma/', 'fluorouracil', 'microsponge (keratosis), Advanced Polymer Systems/', '5-FU', 'microsponge (5-FU), Advanced Polymer Systems/']",,NER_API,[],0
AZD-4547,Fibroblast growth factor receptor antagonist; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor,AZD-4547,,AZD-4547,azd 4547,fexact,"['FGF receptor antagonist (cancer),/', 'ABSK-091', 'FGF receptor antagonist (cancer), AstraZeneca/', 'AZD-4547']",AZD-4547,fexact,"['fgf receptor antagonist cancer', 'absk 091', 'fgf receptor antagonist cancer astrazeneca', 'azd 4547']",correct_mapping
rosuvastatin calcium,HMGCoA reductase inhibitor,rosuvastatin calcium,,rosuvastatin,rosuvastatin calcium,fexact,"['keding', 'AZD-4522', 'S-4522', 'Crestor', 'ZD-4522', 'rosuvastatin', 'rosuvastatin calcium']",rosuvastatin,fexact,"['keding', 'azd 4522', 's 4522', 'crestor', 'zd 4522', 'rosuvastatin', 'rosuvastatin calcium']",correct_mapping
CBP-501,Calmodulin antagonist; G2 checkpoint inhibitor,CBP-501,,CBP-501,cbp 501,fexact,"['G2 checkpoint abrogator peptide,/Takeda', 'CBP-501', 'calmodulin modulator peptide (mesothelioma/NSCLC)', 'G2 checkpoint abrogator peptide,/']",CBP-501,fexact,"['g2 checkpoint abrogator peptide takeda', 'cbp 501', 'calmodulin modulator peptide mesothelioma nsclc', 'g2 checkpoint abrogator peptide']",correct_mapping
sorafenib,RET tyrosine kinase inhibitor; B-raf kinase inhibitor; C-kit inhibitor; C-raf kinase inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor beta kinase inhib; Raf kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,sorafenib,,sorafenib,sorafenib,fexact,"['raf kinase inhibitor,/Onyx', 'Nexavar', 'sorafenib', 'sorafenib analogs, Bayer', 'sorafenib tosylate', 'raf kinase inhibitor, Bayer/Onyx', 'BAY-54-9085', 'raf kinase inhibitor,/', 'sorafenib analogs', 'BAY-43-9006']",sorafenib,fexact,"['raf kinase inhibitor onyx', 'nexavar', 'sorafenib', 'sorafenib analogs bayer', 'sorafenib tosylate', 'raf kinase inhibitor bayer onyx', 'bay 54 9085', 'raf kinase inhibitor', 'sorafenib analogs', 'bay 43 9006']",correct_mapping
cilengitide,Angiogenesis inhibitor; Alphavbeta3 integrin antagonist; Alphavbeta5 integrin antagonist; Integrin antagonist,cilengitide,,cilengitide,cilengitide,fexact,"['EspoiR-003', 'EMD-121974', 'EMD-85189', 'NSC-707544', 'cilengitide']",cilengitide,fexact,"['espoir 003', 'emd 121974', 'emd 85189', 'nsc 707544', 'cilengitide']",correct_mapping
filgrastim (IV),Granulocyte colony stimulating factor agonist,filgrastim,,filgrastim biosimilar,filgrastim,fexact,"['Zarxio', 'filgrastim-sndz', 'Zarzio', 'filgrastim biosimilar, Hexal', 'Filgrastim Hexal', 'filgrastim biosimilar', 'filgrastim', 'EP-2006', 'Filgrastim BS']",filgrastim biosimilar,fexact,"['zarxio', 'filgrastim sndz', 'zarzio', 'filgrastim biosimilar hexal', 'filgrastim hexal', 'filgrastim biosimilar', 'filgrastim', 'ep 2006', 'filgrastim bs']",correct_mapping
Selectikine,Interleukin 2 receptor agonist; Immuno-oncology therapy; Immune checkpoint stimulant,Selectikine,,NHS-IL2-LT,selectikine,fexact,"['NHS-IL2-LT', 'immunocytokine (solid tumors)', 'Selectikine', 'EMD-521873', 'NHS-IL-2(D20T) immunocytokine', 'immunocytokine (solid tumors), Merck Serono', 'MSB-0010445']",NHS-IL2-LT,fexact,"['nhs il2 lt', 'immunocytokine solid tumors', 'selectikine', 'emd 521873', 'nhs il 2 d20t immunocytokine', 'immunocytokine solid tumors merck serono', 'msb 0010445']",correct_mapping
"NGR-TNF, MolMed",Angiogenesis inhibitor; Tumour necrosis factor alpha agonist,NGR-TNF,MolMed,,,0,['NGR-TNF'],,0,[],0
topotecan (oral),DNA topoisomerase I inhibitor,topotecan,,topotecan,topotecan,fexact,"['nogitecan HCl', 'nogitecan', 'SKFS-104864-A', 'Evotopin', 'SKF-104864', 'NSC-609699', 'Hycamtim', 'hycaptamine', 'Hycamtin', 'hycamptamine', 'topotecan lactone', 'SKF-104864-A', 'NK-211', 'topotecan', 'Hicamtin']",topotecan,fexact,"['nogitecan hcl', 'nogitecan', 'skfs 104864 a', 'evotopin', 'skf 104864', 'nsc 609699', 'hycamtim', 'hycaptamine', 'hycamtin', 'hycamptamine', 'topotecan lactone', 'skf 104864 a', 'nk 211', 'topotecan', 'hicamtin']",correct_mapping
cytarabine,DNA synthesis inhibitor,cytarabine,,,,0,"['cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/', 'DepoFoam (cytarabine)', 'DepoCyt', 'NS-101', 'Savedar', 'cytarabine (sustained release, DepoFoam), SkyePharma', 'DTC-101', 'cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical', 'Cytosar-U', 'cytarabine (SR formulation), DepoTech/', 'Cytosar', 'cytarabine', 'DepoCyte', 'cytarabine (sustained release, DepoFoam),/Sigma-Tau/Pfizer/', 'cytarabine (sustained release, DepoFoam),///', 'Ara-C', 'cytarabine (sustained release, DepoFoam),/Sigma-Tau//']",,NER_API,[],0
olaratumab,Platelet-derived growth factor (PDGF) receptor antagonist,olaratumab,,olaratumab,olaratumab,fexact,"['IMC-3G3', 'PDGF mAb (cancer)', 'LY-3012207', 'PDGFRa mAb (cancer)', '3G3 mAb (cancer)', 'PDGF-alpha monoclonal antibody (cancer), ImClone/', 'PDGF mAb (cancer), ImClone', '3G3 mAb (cancer), ImClone', 'PDGF-alpha monoclonal antibody (cancer),/', 'Lartruvo', 'olaratumab']",olaratumab,fexact,"['imc 3g3', 'pdgf mab cancer', 'ly 3012207', 'pdgfra mab cancer', '3g3 mab cancer', 'pdgf alpha monoclonal antibody cancer imclone', 'pdgf mab cancer imclone', '3g3 mab cancer imclone', 'pdgf alpha monoclonal antibody cancer', 'lartruvo', 'olaratumab']",correct_mapping
ridaforolimus (oral),Vascular endothelial growth factor (VEGF)receptor antagonist; Immunosuppressant; mTOR kinase inhibitor; Protein kinase inhibitor; Angiogenesis inhibitor; Cell cycle inhibitor,ridaforolimus,,ridaforolimus,ridaforolimus,fexact,"['ridaforolimus (oral, cancer),/', 'ridaforolimus (oral, cancer),/Merck', 'AP-23573 (oral),/', 'AP-23573 (oral),/Merck & Co', 'MK-8669', 'Taltorvic', 'deforolimus', 'Jenzyl', 'deforolimus (oral),/Merck & Co', 'deforolimus (oral),/', 'ridaforolimus', 'AP-23573']",ridaforolimus,fexact,"['ridaforolimus oral cancer', 'ridaforolimus oral cancer merck', 'ap 23573 oral', 'ap 23573 oral merck co', 'mk 8669', 'taltorvic', 'deforolimus', 'jenzyl', 'deforolimus oral merck co', 'deforolimus oral', 'ridaforolimus', 'ap 23573']",correct_mapping
siltuximab,Interleukin 6 antagonist,siltuximab,,siltuximab,siltuximab,fexact,"['cCLB8', 'anti-IL-6 monoclonal antibody (Castlemans disease/multiple myeloma/COVID-19),/', 'Sylvant', 'anti-IL-6 monoclonal antibody (Castlemans disease/multiple myeloma/COVID-19), Janssen Biotech/', 'CNTO-328', 'anti-IL-6 monoclonal antibody (Castlemans disease/multiple myeloma/COVID-19), Janssen Biotech/EUSA', 'MAb (IL-6), Centocor', 'siltuximab', 'monoclonal antibody (IL-6), Centocor Janssen/EUSA', 'monoclonal antibody (IL-6), Centocor Janssen/', 'monoclonal antibody (IL-6), Centocor']",siltuximab,fexact,"['cclb8', 'anti il 6 monoclonal antibody castlemans disease multiple myeloma covid 19', 'sylvant', 'anti il 6 monoclonal antibody castlemans disease multiple myeloma covid 19 janssen biotech', 'cnto 328', 'anti il 6 monoclonal antibody castlemans disease multiple myeloma covid 19 janssen biotech eusa', 'mab il 6 centocor', 'siltuximab', 'monoclonal antibody il 6 centocor janssen eusa', 'monoclonal antibody il 6 centocor janssen', 'monoclonal antibody il 6 centocor']",correct_mapping
glesatinib,Flt-3 antagonist; MET tyrosine kinase inhibitor; TIE-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Macrophage stimulating protein 1 receptor antagonist; Angiogenesis inhibitor,glesatinib,,glesatinib glycolate,glesatinib,fexact,"['multikinase inhibitors (cancer)', 'glesatinib glycolate', 'glesatinib', 'MGCD-265']",glesatinib glycolate,fexact,"['multikinase inhibitors cancer', 'glesatinib glycolate', 'glesatinib', 'mgcd 265']",correct_mapping
vandetanib,RET tyrosine kinase inhibitor; EGFR kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor,vandetanib,,vandetanib,vandetanib,fexact,"['Caprelsa', 'Zictifa', 'ZD-6474', 'Zactima', 'vandetanib', 'AZD-6474']",vandetanib,fexact,"['caprelsa', 'zictifa', 'zd 6474', 'zactima', 'vandetanib', 'azd 6474']",correct_mapping
apricoxib,Cyclooxygenase 2 inhibitor,apricoxib,,apricoxib,apricoxib,fexact,"['apricoxib', 'TG-01 (inflammation), Tragara', 'Capoxigem', 'Kymena', 'TG-01', 'TP-2001', 'CS-706', 'R-109339', 'TG-01 (oral, cancer), Tragara', 'TP-1001']",apricoxib,fexact,"['apricoxib', 'tg 01 inflammation tragara', 'capoxigem', 'kymena', 'tg 01', 'tp 2001', 'cs 706', 'r 109339', 'tg 01 oral cancer tragara', 'tp 1001']",correct_mapping
"tretinoin, unspecified",Retinoic acid receptor agonist,tretinoin,unspecified,tretinoin,tretinoin,fexact,"['tretinoin, Roche', 'NSC-122758', 'all-trans retinoic acid, Roche', 'all-trans-Retinoic acid', 'ATRA', 'IDP-121', 'Vesanoid', 'ATRA, Roche', 'tretinoin', 'all-trans retinoic acid']",tretinoin,fexact,"['tretinoin roche', 'nsc 122758', 'all trans retinoic acid roche', 'all trans retinoic acid', 'atra', 'idp 121', 'vesanoid', 'atra roche', 'tretinoin', 'all trans retinoic acid']",correct_mapping
pioglitazone hydrochloride,Peroxisome proliferator-activated receptor gamma agonist; Insulin sensitizer; Thiazolidinedione,pioglitazone hydrochloride,,pioglitazone,pioglitazone hydrochloride,fexact,"['Actos OD', 'AD-4833', 'Actos', 'pioglitazone hydrochloride', 'TOMM40', 'Glustin', '72107', 'pioglitazone', 'U 72107', 'U-72107A']",pioglitazone,fexact,"['actos od', 'ad 4833', 'actos', 'pioglitazone hydrochloride', 'tomm40', 'glustin', '72107', 'pioglitazone', 'u 72107', 'u 72107a']",correct_mapping
Yttrium-90 (Y-90) chimeric T84.66 (cT84.66) anti-CEA antibody,Carcinoembryonic antigen inhibitor,Yttrium-90  anti-CEA antibody,,,,0,['Yttrium-90  anti-CEA antibody'],,0,[],0
dinaciclib,Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 5 inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Apoptosis stimulant; Cell cycle inhibitor,dinaciclib,,dinaciclib,dinaciclib,fexact,"['dinaciclib', 'NSC-727135', 'PS-095760', 'CDK inhibitor (cancer), Schering-Plough', 'SCH-727965', 'CDK 1/2/9 inhibitor (cancer), Schering-Plough/Pharmacopeia', 'CDK 1/2/9 inhibitor (cancer),/', 'CDK inhibitor (cancer)', 'MK-7965', 'CDK 1/2/9 inhibitor (cancer), Schering-Plough/']",dinaciclib,fexact,"['dinaciclib', 'nsc 727135', 'ps 095760', 'cdk inhibitor cancer schering plough', 'sch 727965', 'cdk 1 2 9 inhibitor cancer schering plough pharmacopeia', 'cdk 1 2 9 inhibitor cancer', 'cdk inhibitor cancer', 'mk 7965', 'cdk 1 2 9 inhibitor cancer schering plough']",correct_mapping
dalotuzumab,Insulin-like growth factor 1 antagonist,dalotuzumab,,dalotuzumab,dalotuzumab,fexact,"['anti-IGF-1R monoclonal antibody (cancer),/', '7H2HM', 'cancer immunotherapy, Pierre Fabre', 'cancer immunotherapy', 'anti-IGF-1R mAb (cancer)', 'dalotuzumab', 'anti-IGF-1R monoclonal antibody (cancer),/Pierre Fabre', 'h7C10', 'F-50035', 'A2CHM', 'MK-0646']",dalotuzumab,fexact,"['anti igf 1r monoclonal antibody cancer', '7h2hm', 'cancer immunotherapy pierre fabre', 'cancer immunotherapy', 'anti igf 1r mab cancer', 'dalotuzumab', 'anti igf 1r monoclonal antibody cancer pierre fabre', 'h7c10', 'f 50035', 'a2chm', 'mk 0646']",correct_mapping
satraplatin,DNA inhibitor,satraplatin,,satraplatin,satraplatin,fexact,"['JM-383', 'POplat', 'diacetatodichloroplatinum compound (cancer),/Yakult Honsha/', 'JM-216', 'BMY-45594', 'satraplatin', 'diacetatodichloroplatinum compound (cancer),/Yakult Honsha/Celgene', 'diacetatodichloroplatinum compound (cancer), GPC Biotech/Yakult Honsha/', 'Orplatna', 'diacetatodichloroplatinum compound (cancer),//', 'JM-118', 'diacetatodichloroplatinum compound (cancer), GPC Biotech/Yakult Honsha/Celgene', 'JM-518', 'BMS-182751']",satraplatin,fexact,"['jm 383', 'poplat', 'diacetatodichloroplatinum compound cancer yakult honsha', 'jm 216', 'bmy 45594', 'satraplatin', 'diacetatodichloroplatinum compound cancer yakult honsha celgene', 'diacetatodichloroplatinum compound cancer gpc biotech yakult honsha', 'orplatna', 'diacetatodichloroplatinum compound cancer', 'jm 118', 'diacetatodichloroplatinum compound cancer gpc biotech yakult honsha celgene', 'jm 518', 'bms 182751']",correct_mapping
ixabepilone,Microtubule inhibitor,ixabepilone,,ixabepilone,ixabepilone,fexact,"['Ixempra', 'ixabepilone', 'NSC-710428', 'anticancer agents, BMS/GBF', 'BMS-747550', 'BMS-247550', 'epothilone, BMS/GBF']",ixabepilone,fexact,"['ixempra', 'ixabepilone', 'nsc 710428', 'anticancer agents bms gbf', 'bms 747550', 'bms 247550', 'epothilone bms gbf']",correct_mapping
"tuberculosis vaccine (Mw), Cadila",Immunostimulant,tuberculosis vaccine,Cadila,,,0,"['Corixa/GlaxoSmithKline', 'tuberculosis vaccine,/GlaxoSmithKline', 'tuberculosis vaccine, GlaxoSmithKline', 'MTB72F vaccine (tuberculosis), Bill & Melinda Gates MRI', 'SB-692342', 'MTB72F vaccine (tuberculosis), GSK/ IAVI', 'tuberculosis', 'rAd5-TB vaccine (tuberculosis), GlaxoSmithKline/', 'tuberculosis vaccine,/SB', 'GSK-692342', 'Mtb antigens,/', 'vaccine (tuberculosis),/GlaxoSmithKline', 'M72/AS01E', 'rAd5-TB vaccine (tuberculosis),/', 'tuberculosis vaccine,/', 'vaccine (tuberculosis), Corixa/GlaxoSmithKline', 'Mtb antigens,/GlaxoSmithKline', 'Mtb8.4, Corixa/GlaxoSmithKline', 'GSK-M72', 'tuberculosis vaccine, Corixa/SB', 'Mtb72F/AS02A', 'M-72', 'M72/AS-01', 'tuberculosis vaccine', 'Mtb8.4,/GlaxoSmithKline', 'MTB72F vaccine (tuberculosis), GSK/', 'Mtb antigens, Corixa/GlaxoSmithKline', 'Mtb8.4,/', 'vaccine (tuberculosis),/', 'tuberculosis vaccine, Corixa/GlaxoSmithKline']",,Drug_API_mapping,[],0
GI-4000,Immunostimulant,GI-4000,,GI-4000,gi 4000,fexact,"['GI-4000 series (anticancer vaccine)', 'GI-4000 series (anticancer vaccine), NantCell', 'GI-4000 series (Ras), NantCell', 'GI-4000', 'CERES-Vax vaccine delivery system (cancer)', 'vaccine delivery system (cancer)', 'GI-4000 series (anticancer vaccine, Tarmogen)', 'GI-4016', 'GI-4000 series (Ras)', 'GI-4014', 'GI-4015']",GI-4000,fexact,"['gi 4000 series anticancer vaccine', 'gi 4000 series anticancer vaccine nantcell', 'gi 4000 series ras nantcell', 'gi 4000', 'ceres vax vaccine delivery system cancer', 'vaccine delivery system cancer', 'gi 4000 series anticancer vaccine tarmogen', 'gi 4016', 'gi 4000 series ras', 'gi 4014', 'gi 4015']",correct_mapping
BTH-1677,Immunostimulant; Macrophage stimulant; Natural killer cell stimulant; Immuno-oncology therapy,BTH-1677,,Imprime PGG,bth 1677,fexact,"['Betafectin', 'Imprime PGG', 'BTH-1677', 'IRI-1677', 'fcgriia activator/cr3 activator (cancer)', 'Imprime', 'cd32a activator/complement receptor 3 activator (cancer)', 'PGG-Betafectin']",Imprime PGG,fexact,"['betafectin', 'imprime pgg', 'bth 1677', 'iri 1677', 'fcgriia activator cr3 activator cancer', 'imprime', 'cd32a activator complement receptor 3 activator cancer', 'pgg betafectin']",correct_mapping
oxaliplatin (IV),DNA inhibitor,oxaliplatin,,oxaliplatin,oxaliplatin,fexact,"['Dacplat', 'SR-96669', 'Eloxitin', '1670RB', 'Dacotin', 'NSC-266046', 'L-OHP', 'oxaliplatin', 'Elplat', 'RP-54780', 'Eloxatine', 'GSOX', 'Eloxatin', 'RP-54780, 1-OHP']",oxaliplatin,fexact,"['dacplat', 'sr 96669', 'eloxitin', '1670rb', 'dacotin', 'nsc 266046', 'l ohp', 'oxaliplatin', 'elplat', 'rp 54780', 'eloxatine', 'gsox', 'eloxatin', 'rp 54780 1 ohp']",correct_mapping
figitumumab,Insulin-like growth factor 1 antagonist,figitumumab,,figitumumab,figitumumab,fexact,"['anti-insulin-like growth factor 1 receptor mAbs (cancer)', 'IGF-1R human mAbs (cancer)', 'figitumumab', 'CP-751871', 'PINT-8A1', 'PINT-9A2', 'PINT-11A4', 'IGF-1R human mAbs (rheumatoid arthritis)']",figitumumab,fexact,"['anti insulin like growth factor 1 receptor mabs cancer', 'igf 1r human mabs cancer', 'figitumumab', 'cp 751871', 'pint 8a1', 'pint 9a2', 'pint 11a4', 'igf 1r human mabs rheumatoid arthritis']",correct_mapping
panobinostat (oral),Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,panobinostat,,panobinostat (oral),panobinostat,fexact,"['Faridak', 'LBH-589 (oral)', 'LBH-589', 'LBH-589B', 'Farydak', 'NVP-LBH-589', 'panobinostat (oral)', 'panobinostat']",panobinostat (oral),fexact,"['faridak', 'lbh 589 oral', 'lbh 589', 'lbh 589b', 'farydak', 'nvp lbh 589', 'panobinostat oral', 'panobinostat']",correct_mapping
Betamarc,Unidentified pharmacological activity,Betamarc,,Betamarc,betamarc,fexact,"['Betamarc', 'appetite stimulant (cachexia/appetite loss)']",Betamarc,fexact,"['betamarc', 'appetite stimulant cachexia appetite loss']",correct_mapping
SPC-512,Unidentified pharmacological activity,SPC-512,,,,0,['SPC-512'],,0,[],0
sargramostim (IV),Granulocyte macrophage colony stimulating factor agonist,sargramostim,,sargramostim,sargramostim,fexact,"['GM-CSF,/', 'BI 61.012', 'GM-CSF, Berlex/Schering', 'GM-CSF,/Schering', 'GM-CSF, Immunex', 'GM-CSF, Behringwerke', 'SHL-04023', 'Prokine', 'GM-CSF', 'Leukine', 'sargramostim']",sargramostim,fexact,"['gm csf', 'bi 61 012', 'gm csf berlex schering', 'gm csf schering', 'gm csf immunex', 'gm csf behringwerke', 'shl 04023', 'prokine', 'gm csf', 'leukine', 'sargramostim']",correct_mapping
aerosolized sargramostim,Granulocyte macrophage colony stimulating factor agonist; Immunostimulant,aerosolized sargramostim,,,,0,['aerosolized sargramostim'],,0,[],0
paclitaxel polyglumex,Beta tubulin inhibitor; Microtubule stimulant; Taxane,paclitaxel polyglumex,,paclitaxel poliglumex,paclitaxel poliglumex,fuzzy,"['CHC-12103', 'polyglutamate paclitaxel', 'Opaxio', 'PG-paclitaxel', 'PPX', 'drug delivery system, paclitaxel, Cell Therapeutics', 'Xyotax', 'PG-TXL', 'paclitaxel poliglumex', 'drug delivery system, paclitaxel', 'paclitaxel', 'CT-2103']",paclitaxel poliglumex,fexact,"['chc 12103', 'polyglutamate paclitaxel', 'opaxio', 'pg paclitaxel', 'ppx', 'drug delivery system paclitaxel cell therapeutics', 'xyotax', 'pg txl', 'paclitaxel poliglumex', 'drug delivery system paclitaxel', 'paclitaxel', 'ct 2103']",incorrect_mapping
tinzaparin (SC),Indirect Factor Xa inhibitor; Indirect thrombin inhibitor; Heparin stimulant,tinzaparin,,,,0,['tinzaparin'],,0,[],0
drozitumab,TRAIL receptor 2 agonist; Apoptosis stimulant,drozitumab,,drozitumab,drozitumab,fexact,"['DR5 receptor mab (iv, cancer)', 'drozitumab', 'RG-7425', 'Apomab', 'PRO-95780']",drozitumab,fexact,"['dr5 receptor mab iv cancer', 'drozitumab', 'rg 7425', 'apomab', 'pro 95780']",correct_mapping
enzastaurin hydrochloride,Protein kinase C beta inhibitor; Protein kinase B inhibitor; Angiogenesis inhibitor; Apoptosis stimulant; PI3 kinase inhibitor,enzastaurin hydrochloride,,enzastaurin,enzastaurin hydrochloride,fexact,"['317615.2HCl', 'PKC-beta inhibitor, Lilly', 'enzastaurin hydrochloride', 'Kinenza', 'AR-101', 'DB-102', 'PKC-beta inhibitor', 'LY-317615', 'enzastaurin']",enzastaurin,fexact,"['317615 2hcl', 'pkc beta inhibitor lilly', 'enzastaurin hydrochloride', 'kinenza', 'ar 101', 'db 102', 'pkc beta inhibitor', 'ly 317615', 'enzastaurin']",correct_mapping
simvastatin,HMGCoA reductase inhibitor,simvastatin,,simvastatin,simvastatin,fexact,"['Zocor', 'MK-0733', 'MK-733', 'simvastatin', 'Lipovas']",simvastatin,fexact,"['zocor', 'mk 0733', 'mk 733', 'simvastatin', 'lipovas']",correct_mapping
aflibercept (IV),Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,aflibercept,,,,0,"['aflibercept', 'aflibercept biosimilar', 'SCD-411']",,NER_API,[],0
topotecan (IV),DNA topoisomerase I inhibitor,topotecan,,topotecan,topotecan,fexact,"['nogitecan HCl', 'nogitecan', 'SKFS-104864-A', 'Evotopin', 'SKF-104864', 'NSC-609699', 'Hycamtim', 'hycaptamine', 'Hycamtin', 'hycamptamine', 'topotecan lactone', 'SKF-104864-A', 'NK-211', 'topotecan', 'Hicamtin']",topotecan,fexact,"['nogitecan hcl', 'nogitecan', 'skfs 104864 a', 'evotopin', 'skf 104864', 'nsc 609699', 'hycamtim', 'hycaptamine', 'hycamtin', 'hycamptamine', 'topotecan lactone', 'skf 104864 a', 'nk 211', 'topotecan', 'hicamtin']",correct_mapping
PR-104,Unidentified pharmacological activity,PR-104,,SN-29222,pr 104,fexact,"['hypoxia-activated anticancer prodrugs, University of Auckland', 'SN-27858', 'SN-25341', 'SN-23862', 'hypoxia-activated anticancer prodrugs', 'PR-104M', 'hypoxia-activated anticancer prodrugs, Proacta', 'SN-27686', 'SN-29222', 'PR-104', 'PR-104A', 'bioreductive cytotoxins (cancer)', 'SN-23816', 'NSC-646394', 'PR-104H', 'SN-29546', 'SN-24927', 'bioreductive cytotoxins (cancer), University of Auckland']",SN-29222,fexact,"['hypoxia activated anticancer prodrugs university of auckland', 'sn 27858', 'sn 25341', 'sn 23862', 'hypoxia activated anticancer prodrugs', 'pr 104m', 'hypoxia activated anticancer prodrugs proacta', 'sn 27686', 'sn 29222', 'pr 104', 'pr 104a', 'bioreductive cytotoxins cancer', 'sn 23816', 'nsc 646394', 'pr 104h', 'sn 29546', 'sn 24927', 'bioreductive cytotoxins cancer university of auckland']",correct_mapping
bortezomib (IV),Transcription factor NF-kappaB inhibitor; Apoptosis stimulant; Proteasome inhibitor,bortezomib,,bortezomib,bortezomib,fexact,"['bortezomib', 'NSC-681239', 'PDP-341', 'LDP-341', 'PS-341', 'MLN-341', 'JNJ-26866138', 'Velcade', 'MG-341']",bortezomib,fexact,"['bortezomib', 'nsc 681239', 'pdp 341', 'ldp 341', 'ps 341', 'mln 341', 'jnj 26866138', 'velcade', 'mg 341']",correct_mapping
"bexarotene, oral, Eisai",Retinoid X alpha receptor agonist; Retinoid X beta receptor agonist; Retinoid X gamma receptor agonist,bexarotene,Eisai,,,0,"['bexarotene (aerosolized, lung cancer), / nci', 'bexarotene', 'bexarotene (aerosolized, lung cancer),/']",,NER_API,[],0
mapatumumab,TRAIL receptor 1 agonist; Apoptosis stimulant,mapatumumab,,mapatumumab,mapatumumab,fexact,"['TI-1', 'TRAIL receptor-1 mAbs, HGS', 'mapatumumab', 'Trail-R1 mAb', 'TRAIL-R1 mAb, HGS/', 'TRAIL-R1 mAb, HGS', 'TAK-799', 'TRM-1', 'HGS-ETR1', 'TRAIL-R1 mAb, HGS/Takeda']",mapatumumab,fexact,"['ti 1', 'trail receptor 1 mabs hgs', 'mapatumumab', 'trail r1 mab', 'trail r1 mab hgs', 'trail r1 mab hgs', 'tak 799', 'trm 1', 'hgs etr1', 'trail r1 mab hgs takeda']",correct_mapping
XL-281,B-raf kinase inhibitor; C-raf kinase inhibitor; Protein kinase inhibitor; Raf kinase inhibitor,XL-281,,XL-281,xl 281,fexact,"['EXEL-2819', 'Raf kinase inhibitors (cancer)', 'Raf kinase inhibitors (cancer), Exelixis', 'BMS-908662', 'Raf kinase inhibitor (cancer)', 'XL-281']",XL-281,fexact,"['exel 2819', 'raf kinase inhibitors cancer', 'raf kinase inhibitors cancer exelixis', 'bms 908662', 'raf kinase inhibitor cancer', 'xl 281']",correct_mapping
retaspimycin (IV),Apoptosis stimulant; Heat shock protein 90 antagonist,retaspimycin,,"retaspimycin (iv, cancer)",retaspimycin,fexact,"['retaspimycin hydrochloride (iv, cancer),/', 'retaspimycin hydrochloride', 'IPI-504 (intravenous),/', 'retaspimycin (iv, cancer),/', 'retaspimycin', 'hsp90 inhibitor (iv, cancer),/MedImmune', 'retaspimycin hydrochloride (iv, cancer),/MedImmune', 'retaspimycin (iv, cancer),/MedImmune', 'IPI-504', 'MEDI-561', 'IPI-504 (intravenous),/MedImmune', 'retaspimycin (iv, cancer)', 'hsp90 inhibitor (iv, cancer),/']","retaspimycin (iv, cancer)",fexact,"['retaspimycin hydrochloride iv cancer', 'retaspimycin hydrochloride', 'ipi 504 intravenous', 'retaspimycin iv cancer', 'retaspimycin', 'hsp90 inhibitor iv cancer medimmune', 'retaspimycin hydrochloride iv cancer medimmune', 'retaspimycin iv cancer medimmune', 'ipi 504', 'medi 561', 'ipi 504 intravenous medimmune', 'retaspimycin iv cancer', 'hsp90 inhibitor iv cancer']",correct_mapping
aldoxorubicin,DNA topoisomerase II inhibitor,aldoxorubicin,,aldoxorubicin (cancer),aldoxorubicin,fexact,"['aldoxorubicin hydrochloride', 'aldoxorubicin', 'doxorubicin (hydrazone derivative), University of Freiburg', 'INNO-206', 'DOXO-EMCH, University of Freiburg', 'tumor-targeted doxorubicin conjugate', 'aldoxorubicin (cancer)', 'aldoxorubicin (cancer), NantCell', 'aldoxorubicin (cancer), ImmunityBio', 'DOXO-EMCH', 'doxorubicin prodrug, University of Freiburg', 'Doxorubicin-EMCH']",aldoxorubicin (cancer),fexact,"['aldoxorubicin hydrochloride', 'aldoxorubicin', 'doxorubicin hydrazone derivative university of freiburg', 'inno 206', 'doxo emch university of freiburg', 'tumor targeted doxorubicin conjugate', 'aldoxorubicin cancer', 'aldoxorubicin cancer nantcell', 'aldoxorubicin cancer immunitybio', 'doxo emch', 'doxorubicin prodrug university of freiburg', 'doxorubicin emch']",correct_mapping
motexafin gadolinium,Radical formation stimulant; Thioredoxin reductase inhibitor; Apoptosis stimulant; Thioredoxin inhibitor,motexafin gadolinium,,motexafin gadolinium,motexafin gadolinium,fexact,"['PCI-0120', 'Xcytrin', 'gadolinium texaphyrin', 'Gd-Tex', 'motexafin gadolinium']",motexafin gadolinium,fexact,"['pci 0120', 'xcytrin', 'gadolinium texaphyrin', 'gd tex', 'motexafin gadolinium']",correct_mapping
eribulin mesylate,Microtubule inhibitor; Tubulin inhibitor,eribulin mesylate,,"eribulin mesylate (liposomal formulation, cancer)",eribulin mesylate,fexact,"['eribulin mesylate (liposomal formulation, cancer)', 'E-7389-LF', 'eribulin mesylate', 'Halaven (liposomal, cancer)', 'Halaven']","eribulin mesylate (liposomal formulation, cancer)",fexact,"['eribulin mesylate liposomal formulation cancer', 'e 7389 lf', 'eribulin mesylate', 'halaven liposomal cancer', 'halaven']",correct_mapping
astuprotimut-r,Immunostimulant,astuprotimut-r,,zastumotide,astuprotimut r,fexact,"['GSK-1203486A', 'astuprotimut-R', 'MAGE-3 ASCI', 'melanoma vaccine', 'melanoma vaccine, SmithKline Beecham', 'GSK-249553', 'pharmaccine (MAGE-3 + SBAS-2)', '249553', 'astuprotimut-r', 'recMAGE-A3', 'GSK-2132231A', 'MAGE-A3 ASCI', 'Zumagev', 'zastumotide', 'MAGE-3/Vaximmune vaccine, GSK', 'MAGE-3 vaccine', 'MAGE-3 antigen specific cancer immunotherapeutic', 'SB-249553', 'GSK-1572932A', 'melanoma/lung cancer vaccine']",zastumotide,fexact,"['gsk 1203486a', 'astuprotimut r', 'mage 3 asci', 'melanoma vaccine', 'melanoma vaccine smithkline beecham', 'gsk 249553', 'pharmaccine mage 3 sbas 2', '249553', 'astuprotimut r', 'recmage a3', 'gsk 2132231a', 'mage a3 asci', 'zumagev', 'zastumotide', 'mage 3 vaximmune vaccine gsk', 'mage 3 vaccine', 'mage 3 antigen specific cancer immunotherapeutic', 'sb 249553', 'gsk 1572932a', 'melanoma lung cancer vaccine']",correct_mapping
"pyrazoloacridine, Parke-Davis",DNA topoisomerase I inhibitor; DNA topoisomerase II inhibitor,pyrazoloacridine,Parke-Davis,PD-115934,pyrazoloacridine,fexact,"['PD-115934', 'pyrazoloacridine', 'NSC-366140']",PD-115934,fexact,"['pd 115934', 'pyrazoloacridine', 'nsc 366140']",correct_mapping
VX-001,Unidentified pharmacological activity,VX-001,,Vx-001,vx 001,fexact,"['Vx-001', 'HLA-A2 monopeptide vaccine (cancer)', 'hTERT572Y peptide vaccine (cancer)', 'TERT572 + TERT572Y peptide (cancer)']",Vx-001,fexact,"['vx 001', 'hla a2 monopeptide vaccine cancer', 'htert572y peptide vaccine cancer', 'tert572 tert572y peptide cancer']",correct_mapping
vinflunine (iv),Microtubule inhibitor; Tubulin inhibitor; Vinca alkaloid,vinflunine,,vinflunine,vinflunine,fexact,"['L-0070', 'Javlor', 'BMS-710485', 'vinflunine', 'F-12158', 'vinflunine ditartrate', 'F-13667', 'F-13840']",vinflunine,fexact,"['l 0070', 'javlor', 'bms 710485', 'vinflunine', 'f 12158', 'vinflunine ditartrate', 'f 13667', 'f 13840']",correct_mapping
pomalidomide,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,pomalidomide,,pomalidomide,pomalidomide,fexact,"['IMiD-1', 'pomalidomide', 'Pomalyst', 'ENMD-0995', 'CC-4047', 'S-3APG', 'Actimid', 'Actimid (current lead)', 'Imnovid']",pomalidomide,fexact,"['imid 1', 'pomalidomide', 'pomalyst', 'enmd 0995', 'cc 4047', 's 3apg', 'actimid', 'actimid current lead', 'imnovid']",correct_mapping
motesanib diphosphate,RET tyrosine kinase inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,motesanib diphosphate,,motesanib diphosphate,motesanib diphosphate,fexact,"['motesanib', 'AMG-706', 'motesanib diphosphate', 'oral selective VEGFR/PDGFR/Kit kinase inhibitor (solid tumors)']",motesanib diphosphate,fexact,"['motesanib', 'amg 706', 'motesanib diphosphate', 'oral selective vegfr pdgfr kit kinase inhibitor solid tumors']",correct_mapping
allogeneic lymphocytes,Immunostimulant,allogeneic lymphocytes,,,,0,['allogeneic lymphocytes'],,0,[],0
ABT-751,Microtubule inhibitor; PABA antagonist; Dihydropteroate synthase inhibitor; Tubulin inhibitor,ABT-751,,ABT-751,abt 751,fexact,"['E-7010', 'E-7010 analogs', 'ABT-751', 'ER-67865', 'ER-67487', 'ER-67880']",ABT-751,fexact,"['e 7010', 'e 7010 analogs', 'abt 751', 'er 67865', 'er 67487', 'er 67880']",correct_mapping
darbepoetin alfa,Erythropoietin receptor agonist,darbepoetin alfa,,darbepoetin alfa,darbepoetin alfa,fexact,"['KRN-321', 'NESP', 'KER-321', 'recombinant erythropoietin analog', 'darbepoetin alfa', 'novel erythropoiesis stimulating protein', 'Aranesp', 'Nespo']",darbepoetin alfa,fexact,"['krn 321', 'nesp', 'ker 321', 'recombinant erythropoietin analog', 'darbepoetin alfa', 'novel erythropoiesis stimulating protein', 'aranesp', 'nespo']",correct_mapping
capecitabine,DNA synthesis inhibitor; Thymidylate synthase inhibitor; RNA synthesis inhibitor,capecitabine,,capecitabine,capecitabine,fexact,"['Ro-09-1978', 'R-340', 'Xeloda', 'capecitabine', 'RG-340']",capecitabine,fexact,"['ro 09 1978', 'r 340', 'xeloda', 'capecitabine', 'rg 340']",correct_mapping
lenalidomide,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,lenalidomide,,lenalidomide,lenalidomide,fexact,"['CDC-501', 'IMiD-1', 'IND-70116', 'IMiD-3', 'Revlimid', 'lenalidomide', 'CC-5013', 'NSC-703813', 'ENMD-0997', 'Revimid', 'CDC-5013']",lenalidomide,fexact,"['cdc 501', 'imid 1', 'ind 70116', 'imid 3', 'revlimid', 'lenalidomide', 'cc 5013', 'nsc 703813', 'enmd 0997', 'revimid', 'cdc 5013']",correct_mapping
mitomycin C,DNA inhibitor,mitomycin C,,,,0,"['mitomycin C (nanoparticles, bladder cancer)', 'mitomycin C (sustained release/RTGel, upper tract urothelial carcinoma)', 'mitomycin C (sustained release/RTGel, upper tract urothelial carcinoma), Urogen Pharma', 'Mitomycin', 'mitomycin C (nanoparticle, soild tumors)', 'Mitozytrex', 'MMC-GAG', 'UGN-102', 'mitomycin (nanoparticle, soild tumors)', 'Jelmyto', 'mitomycin (injection/powdered, bladder cancer)', 'mitomycin', 'VesiGel', 'mitomycin (injection/powdered, bladder cancer), Speciality European Pharma', 'magnetic targeted carrier (mitomycin)', 'Optomycin', 'MitoGel', 'mitomycin C (high-dose/sustained release intravesical formulation/RTGel, low grade non-muscle invasive bladder cancer)', 'mitomycin C (high-dose/sustained release/RTGel, bladder cancer)', 'MMC-NP', 'mitomycin (reformulated, Extra), SuperGen', 'MitoExtra', 'mitomycin (nanoparticles, bladder cancer)', 'mitomycin C (ophthalmic)', 'antifibrotic agent delivery system (corneal disease)', 'mitomycin C (reformulated, Extra), SuperGen', 'Mitem', 'mitomycin (injection/powdered, bladder cancer), Substipharm', 'MMC-Gel', 'UGN-101', 'MagneTarg mitomycin', 'Mitomycin C', 'mitomycin (magnetic targeted carrier)', 'mitomycin (ophthalmic)', 'MTC-mitomycin', 'Mitosol', 'MTC-MMC']",,Drug_API_mapping,[],0
CDP-791,Vascular endothelial growth factor receptor 2 antagonist; Angiogenesis inhibitor,CDP-791,,alacizumab pegol,cdp 791,fexact,"['CDP-791', 'alacizumab pegol']",alacizumab pegol,fexact,"['cdp 791', 'alacizumab pegol']",correct_mapping
agatolimod (sc),Immunostimulant; Toll-like receptor 9 agonist,agatolimod,,agatolimod,agatolimod,fexact,"['agatolimod sodium', 'Vaximmune', 'TLR9 agonists', 'CpG-8916', 'CpG-8954', 'PF-676', 'ProMune', 'CpG DNA, CpG ImmunoPharmaceuticals', 'CpG-7909', 'CpG DNA', 'agatolimod', 'PF-3512676']",agatolimod,fexact,"['agatolimod sodium', 'vaximmune', 'tlr9 agonists', 'cpg 8916', 'cpg 8954', 'pf 676', 'promune', 'cpg dna cpg immunopharmaceuticals', 'cpg 7909', 'cpg dna', 'agatolimod', 'pf 3512676']",correct_mapping
talotrexin ammonium,Dihydrofolate reductase inhibitor,talotrexin ammonium,,talotrexin,talotrexin ammonium,fexact,"['PT-523', 'talotrexin ammonium', '10-deaza-PT-523', 'NSC-633713', 'NSC-712783', 'PT-633', 'Talvesta', 'talotrexin']",talotrexin,fexact,"['pt 523', 'talotrexin ammonium', '10 deaza pt 523', 'nsc 633713', 'nsc 712783', 'pt 633', 'talvesta', 'talotrexin']",correct_mapping
cositecan (oral),DNA topoisomerase I inhibitor,cositecan,,cositecan (oral),cositecan,fexact,"['BNP-1350 (oral), BioNumerik', 'Karenitecin', 'cositecan (oral)', 'BNP-1350 (oral)', 'BNP-1350', 'cositecan (oral), BioNumerik', 'MCC-12824', 'cositecan']",cositecan (oral),fexact,"['bnp 1350 oral bionumerik', 'karenitecin', 'cositecan oral', 'bnp 1350 oral', 'bnp 1350', 'cositecan oral bionumerik', 'mcc 12824', 'cositecan']",correct_mapping
"camptothecin, Calando",Hypoxia-inducible factor 2 alpha antagonist; DNA topoisomerase I inhibitor; Hypoxia-inducible factor 1 alpha antagonist,camptothecin,Calando,irinotecan,camptothecin,fexact,"['Camptothecin 11 hydrochloride', 'DQ-2805', 'camptothecin II', 'irinotecan hydrochloride hydrate', 'camptothecin II hydrochloride', 'Topotecin', 'NSC-616348', 'irinotecan', 'camptothecin', 'camptothecin  hydrochloride', 'Camptothecin 11', 'Campto', 'irinotecan hydrochloride', 'Camptosar']",irinotecan,fexact,"['camptothecin 11 hydrochloride', 'dq 2805', 'camptothecin ii', 'irinotecan hydrochloride hydrate', 'camptothecin ii hydrochloride', 'topotecin', 'nsc 616348', 'irinotecan', 'camptothecin', 'camptothecin hydrochloride', 'camptothecin 11', 'campto', 'irinotecan hydrochloride', 'camptosar']",correct_mapping
amifostine (SC),Oxygen scavenger; Reducing agent; Free radical scavenger,amifostine,,amifostine,amifostine,fexact,"['WR-2721C', 'NSC-296961', 'WR-2721', 'Ethiofos', 'Gammaphos', 'YM-08310', 'amifostine', 'Ethyol']",amifostine,fexact,"['wr 2721c', 'nsc 296961', 'wr 2721', 'ethiofos', 'gammaphos', 'ym 08310', 'amifostine', 'ethyol']",correct_mapping
celecoxib (capsule),Cyclooxygenase 2 inhibitor,celecoxib,,celecoxib,celecoxib,fexact,"['Celecox', 'Onsenal', 'YM-74177', 'celecoxib FAP', 'YM-177', 'SC-58635', 'Celebrex', 'Celebra', 'celecoxib']",celecoxib,fexact,"['celecox', 'onsenal', 'ym 74177', 'celecoxib fap', 'ym 177', 'sc 58635', 'celebrex', 'celebra', 'celecoxib']",correct_mapping
SGN-15,DNA topoisomerase II inhibitor,SGN-15,,SGN-15,sgn 15,fexact,"['doxorubicin-BR96 conjugate, BMS', 'BR96-DOX', 'SGN-15', 'doxorubicin-anti Lewis-Y related antigen antibody conjugate, BMS', 'hBR96', 'BMS-182248-01', 'BMS-182248']",SGN-15,fexact,"['doxorubicin br96 conjugate bms', 'br96 dox', 'sgn 15', 'doxorubicin anti lewis y related antigen antibody conjugate bms', 'hbr96', 'bms 182248 01', 'bms 182248']",correct_mapping
Y-90-labetuzumab,DNA inhibitor; Immunostimulant; Carcinoembryonic antigen inhibitor; Radiopharmaceutical,Y-90-labetuzumab,,labetuzumab,90y labetuzumab,fuzzy,"['labetuzumab', 'IMMU-111', 'hMN-14', 'ImmuRAIT-CEA(I-131)', 'yttrium-90-labetuzumab', 'IMMU-100', '131I-labetuzumab', 'hCEA-Y-90', 'hCEA-I-131', 'hAFP antibody', 'CEA-Cide', 'hCEA antibody', 'CEA-Cide(Y-90)', 'MN-14', 'IMMU-101', '90Y-labetuzumab', 'ImmuRAIT-AFP(I-131)', 'iodine-131-labetuzumab']",labetuzumab,fexact,"['labetuzumab', 'immu 111', 'hmn 14', 'immurait cea i 131', 'yttrium 90 labetuzumab', 'immu 100', '131i labetuzumab', 'hcea y 90', 'hcea i 131', 'hafp antibody', 'cea cide', 'hcea antibody', 'cea cide y 90', 'mn 14', 'immu 101', '90y labetuzumab', 'immurait afp i 131', 'iodine 131 labetuzumab']",incorrect_mapping
epoetin beta pegol (SC),Erythropoietin receptor agonist,epoetin beta pegol,,methoxy polyethylene glycol-epoetin beta,epoetin beta pegol,fexact,"['methoxy polyethylene glycol-epoetin beta', 'CERA,/Shearwater', 'epoetin beta pegol (genetic recombinant)', 'monopegylated epoetin beta', 'second generation EPO', 'R-744', 'Mircera', 'RG-744', 'continuous erythropoietin receptor activator', 'epoetin beta pegol', 'PEG-680-Ala-[30-Asn,32-Thr,87-Val,88-Asn,90-Thr]erythropoietin(human)-(1-165)', 'Ro-50-3821', 'pegdarbepoetin beta', 'CERA, Roche/Shearwater', 'second generation EPO, Roche', 'CERA,/Nektar', 'CERA, Roche/Nektar']",methoxy polyethylene glycol-epoetin beta,fexact,"['methoxy polyethylene glycol epoetin beta', 'cera shearwater', 'epoetin beta pegol genetic recombinant', 'monopegylated epoetin beta', 'second generation epo', 'r 744', 'mircera', 'rg 744', 'continuous erythropoietin receptor activator', 'epoetin beta pegol', 'peg 680 ala 30 asn 32 thr 87 val 88 asn 90 thr erythropoietin human 1 165', 'ro 50 3821', 'pegdarbepoetin beta', 'cera roche shearwater', 'second generation epo roche', 'cera nektar', 'cera roche nektar']",correct_mapping
"epothilone D, Kosan",Microtubule stabilizer,epothilone D,Kosan,KOS-862,epothilone d,fexact,"['epothilone B analog,/Roche', 'dEpoB analog, Koson/', 'desoxyepothilone', 'epothilone', 'NSC-703147', 'epothilone D,/Roche', 'desoxyepothilone B analog,/', 'epothilone D,/', 'desoxyepothilone B analog,/Roche', 'KOS-862', 'R-1492', 'epothilone D', 'dEpoB analog, Koson/Roche', 'epothilone B analog,/']",KOS-862,fexact,"['epothilone b analog roche', 'depob analog koson', 'desoxyepothilone', 'epothilone', 'nsc 703147', 'epothilone d roche', 'desoxyepothilone b analog', 'epothilone d', 'desoxyepothilone b analog roche', 'kos 862', 'r 1492', 'epothilone d', 'depob analog koson roche', 'epothilone b analog']",correct_mapping
oblimersen (IV),Bcl2 inhibitor; Apoptosis stimulant,oblimersen,,oblimersen,oblimersen,fexact,"['Genasense', 'G-3139', 'anticode (bcl-2),/La Jolla', 'antisense oligonucleotides (bcl-2)', 'oblimersen', 'oblimersen sodium', 'antisense oligonucleotides (bcl-2), Genta', 'augmerosen', 'anticode (bcl-2), Genta/La Jolla']",oblimersen,fexact,"['genasense', 'g 3139', 'anticode bcl 2 la jolla', 'antisense oligonucleotides bcl 2', 'oblimersen', 'oblimersen sodium', 'antisense oligonucleotides bcl 2 genta', 'augmerosen', 'anticode bcl 2 genta la jolla']",correct_mapping
zileuton,5 Lipoxygenase inhibitor; Leucotriene synthesis inhibitor,zileuton,,zileuton,zileuton,fexact,"['Leutrol', 'zileuton', 'Zyflo', 'Filmtab', 'Zyflo Filmtab', 'A-64077']",zileuton,fexact,"['leutrol', 'zileuton', 'zyflo', 'filmtab', 'zyflo filmtab', 'a 64077']",correct_mapping
muparfostat (SC),Fibroblast growth factor 1 antagonist; Fibroblast growth factor 2 antagonist; Vascular endothelial growth factor (VEGF)receptor antagonist; Heparanase inhibitor; Angiogenesis inhibitor; Heparinase inhibitor,muparfostat,,muparfostat sodium,muparfostat,fexact,"['heparanase inhibitor (cancer), Progen/Australian National University', 'phosphomannopentaose sulfate', 'sulfated oligosaccharides (cancer), Progen/Australian National University', 'muparfostat sodium', 'sulfated mannopentaose phosphate', 'muparfostat', 'PI-88']",muparfostat sodium,fexact,"['heparanase inhibitor cancer progen australian national university', 'phosphomannopentaose sulfate', 'sulfated oligosaccharides cancer progen australian national university', 'muparfostat sodium', 'sulfated mannopentaose phosphate', 'muparfostat', 'pi 88']",correct_mapping
custirsen,Clusterin inhibitor,custirsen,,custirsen,custirsen,fexact,"['custirsen sodium', 'OGX-011', 'TV-1011', 'antisense clusterin inhibitor (anticancer),/Isis', 'custirsen', 'ISIS-112989', 'antisense clusterin inhibitor (anticancer), OncoGenex/Isis']",custirsen,fexact,"['custirsen sodium', 'ogx 011', 'tv 1011', 'antisense clusterin inhibitor anticancer isis', 'custirsen', 'isis 112989', 'antisense clusterin inhibitor anticancer oncogenex isis']",correct_mapping
canfosfamide hydrochloride,DNA inhibitor; Glutathione S transferase inhibitor; Caspase 3 stimulant; Apoptosis stimulant,canfosfamide hydrochloride,,canfosfamide,canfosfamide hydrochloride,fexact,"['TLK-286', 'canfosfamide', 'canfosfamide hydrochloride', 'TER-296', 'TER-332', 'canglustratide hydrochloride', 'TER-286', 'TER-324', 'Telcyta', 'TER-338']",canfosfamide,fexact,"['tlk 286', 'canfosfamide', 'canfosfamide hydrochloride', 'ter 296', 'ter 332', 'canglustratide hydrochloride', 'ter 286', 'ter 324', 'telcyta', 'ter 338']",correct_mapping
KRN-7000,Immunosuppressant; T cell stimulant; CD1D agonist,KRN-7000,,RGI-2001,krn 7000,fexact,"['RGI-7000', 'RGI-2001', 'ToleroVax', 'T-cell modulator (transplant rejection/autoimmune disease)', 'krn-7000, liposomal formulation (autoimmune disease)', 'Multivax platform', 'KRN-7000']",RGI-2001,fexact,"['rgi 7000', 'rgi 2001', 'tolerovax', 't cell modulator transplant rejection autoimmune disease', 'krn 7000 liposomal formulation autoimmune disease', 'multivax platform', 'krn 7000']",correct_mapping
LOR-2040 (IV),Ribonucleoside triphosphate reductase inhibitor,LOR-2040,,LOR-2040,lor 2040,fexact,"['GTI-2040', 'R2 ribonucleotide reductase mRNA antisense oligo, Lorus', 'LOR-2040']",LOR-2040,fexact,"['gti 2040', 'r2 ribonucleotide reductase mrna antisense oligo lorus', 'lor 2040']",correct_mapping
"suramin hexasodium, PD",DNA synthesis inhibitor; Angiogenesis inhibitor,suramin hexasodium,PD,"suramin sodium (low-dose, cancer)",suramin hexasodium,fexact,"['suramin', 'suramin sodium', 'suramin sodium (low-dose, cancer)', 'suramin hexasodium', 'suramin (low-dose, cancer)']","suramin sodium (low-dose, cancer)",fexact,"['suramin', 'suramin sodium', 'suramin sodium low dose cancer', 'suramin hexasodium', 'suramin low dose cancer']",correct_mapping
UCN-01,Protein kinase C inhibitor; 3-phosphoinositide-dependent kinase 1 inhibitor; Cyclin-dependent kinase inhibitor; Protein kinase B inhibitor; Protein kinase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,UCN-01,,UCN-01,ucn 01,fexact,"['UCN 01-Pr', '7-hydroxystaurosporine', 'KW-2401', 'KRX-0601', 'UCN-01-Me', 'UCN-02', 'NSC-638850', 'UCN-01']",UCN-01,fexact,"['ucn 01 pr', '7 hydroxystaurosporine', 'kw 2401', 'krx 0601', 'ucn 01 me', 'ucn 02', 'nsc 638850', 'ucn 01']",correct_mapping
adenovirus p53,p53 stimulant,adenovirus p53,,,,0,['adenovirus p53'],,0,[],0
Triapine (IV),Ribonucleoside diphosphate reductase inhibitor,Triapine,,"Triapine (intravenous, cancer)",triapine,fexact,"['5-fluoro-ortho-phosphate-3AP', '3-AP, Vion', 'triapine (intravenous, cancer)', 'Triapine (intravenous, cancer), Ology Bioservices', 'Triapine (intravenous, cancer)', 'Triapine (intravenous, cancer), National Resilience Inc', 'Triapine (intravenous, cancer), Nanotherapeutics', 'OCX-191', 'Triapine (intravenous, cancer), Vion', '3-AMP', '5-fluoro-ortho-phosphate-3AP, Vion', 'ortho-3AP', 'Triapine', 'NTO-1151', 'Triapine (myeloproliferative disorder)', 'Triapine (myeloproliferative disorder), Vion', '3-AP']","Triapine (intravenous, cancer)",fexact,"['5 fluoro ortho phosphate 3ap', '3 ap vion', 'triapine intravenous cancer', 'triapine intravenous cancer ology bioservices', 'triapine intravenous cancer', 'triapine intravenous cancer national resilience inc', 'triapine intravenous cancer nanotherapeutics', 'ocx 191', 'triapine intravenous cancer vion', '3 amp', '5 fluoro ortho phosphate 3ap vion', 'ortho 3ap', 'triapine', 'nto 1151', 'triapine myeloproliferative disorder', 'triapine myeloproliferative disorder vion', '3 ap']",correct_mapping
mesna disulfide (IV),Tubulin inhibitor; Tubulin stimulant,mesna disulfide,,,,0,['mesna disulfide'],,0,[],0
filgrastim (SC),Granulocyte colony stimulating factor agonist,filgrastim,,filgrastim biosimilar,filgrastim,fexact,"['Zarxio', 'filgrastim-sndz', 'Zarzio', 'filgrastim biosimilar, Hexal', 'Filgrastim Hexal', 'filgrastim biosimilar', 'filgrastim', 'EP-2006', 'Filgrastim BS']",filgrastim biosimilar,fexact,"['zarxio', 'filgrastim sndz', 'zarzio', 'filgrastim biosimilar hexal', 'filgrastim hexal', 'filgrastim biosimilar', 'filgrastim', 'ep 2006', 'filgrastim bs']",correct_mapping
"arsenic trioxide, Cephalon",Cysteine protease stimulant; Apoptosis stimulant,arsenic trioxide,Cephalon,"arsenic trioxide (oral, acute promyelocytic leukemia)",arsenic trioxide,fexact,"['ORH-2014', 'arsenic trioxide', 'SY-2101, Syros Pharmaceuticals', 'sy-2101', 'arsenic trioxide (oral, acute promyelocytic leukemia)']","arsenic trioxide (oral, acute promyelocytic leukemia)",fexact,"['orh 2014', 'arsenic trioxide', 'sy 2101 syros pharmaceuticals', 'sy 2101', 'arsenic trioxide oral acute promyelocytic leukemia']",correct_mapping
milataxel (IV),Beta tubulin inhibitor; Microtubule stimulant; Taxane,milataxel,,milataxel,milataxel,fexact,"['MAC-321', 'TL-139', 'TL-00139 (injectable),/', 'MAC-321 (injectable),/', 'milataxel', 'TL-139 (injectable),/', 'MAC-321 (injectable),/Wyeth', 'TL-139 (injectable),/Wyeth', 'TL-00139', 'TL-00139 (injectable),/Wyeth', 'M-10']",milataxel,fexact,"['mac 321', 'tl 139', 'tl 00139 injectable', 'mac 321 injectable', 'milataxel', 'tl 139 injectable', 'mac 321 injectable wyeth', 'tl 139 injectable wyeth', 'tl 00139', 'tl 00139 injectable wyeth', 'm 10']",correct_mapping
tirapazamine (intravenous),DNA inhibitor; Reducing agent,tirapazamine,,tirapazamine,tirapazamine,fexact,"['SR-4233', 'Tirazone', 'tirapazamine', 'SR-259075', 'TPZ', 'SR-4330', 'NSC-130181', 'SR-4482', 'SR-4317', 'Win-59075']",tirapazamine,fexact,"['sr 4233', 'tirazone', 'tirapazamine', 'sr 259075', 'tpz', 'sr 4330', 'nsc 130181', 'sr 4482', 'sr 4317', 'win 59075']",correct_mapping
p53 peptides,Immunostimulant,p53 peptides,,,,0,"['peptide p53-hdm2 antagonists (cancer)', 'p53 peptides', 'CGP-84700']",,Drug_API_mapping,[],0
Ras peptide vaccine,Immunostimulant,Ras peptide vaccine,,mutant ras vaccine,ras peptide vaccine,fexact,"['13 mer ras peptide', 'ras peptide vaccine', 'mutant ras vaccine']",mutant ras vaccine,fexact,"['13 mer ras peptide', 'ras peptide vaccine', 'mutant ras vaccine']",correct_mapping
Peptide-Activated Lymphocytes,Immunostimulant,Peptide-Activated Lymphocytes,,,,0,['Peptide-Activated Lymphocytes'],,0,[],0
CBT-1,General pump inhibitor; P glycoprotein inhibitor,CBT-1,,CBT-1,cbt 1,fexact,"['CBT-1', 'p-glycoprotein inhibitor (cancer)']",CBT-1,fexact,"['cbt 1', 'p glycoprotein inhibitor cancer']",correct_mapping
undisclosed - investigational drug,Unidentified pharmacological activity,undisclosed - investigational drug,,,,0,['undisclosed - investigational drug'],,0,[],0
vitamin E,Reducing agent; Vitamin E agonist,vitamin E,,,,0,['vitamin E'],,0,[],0
aprinocarsen sodium,Protein kinase C alpha inhibitor; Protein synthesis inhibitor,aprinocarsen sodium,,aprinocarsen,aprinocarsen sodium,fexact,"['Affinitac', 'antisense oligonucleotide (PKC alpha)', 'aprinocarsen', 'antisense oligonucleotide (PKC alpha), Isis/', 'ISIS-3521', 'LY-900003', 'CGP-64128A', 'antisense oligonucleotide (PKC alpha), Isis/Novartis', 'ISI-641A', 'ISI-641', 'aprinocarsen sodium', 'Affinitak']",aprinocarsen,fexact,"['affinitac', 'antisense oligonucleotide pkc alpha', 'aprinocarsen', 'antisense oligonucleotide pkc alpha isis', 'isis 3521', 'ly 900003', 'cgp 64128a', 'antisense oligonucleotide pkc alpha isis novartis', 'isi 641a', 'isi 641', 'aprinocarsen sodium', 'affinitak']",correct_mapping
tariquidar,P glycoprotein inhibitor; MRP inhibitor,tariquidar,,tariquidar,tariquidar,fexact,"['tariquidar', 'XR-9351 series', 'XR-9576']",tariquidar,fexact,"['tariquidar', 'xr 9351 series', 'xr 9576']",correct_mapping
exisulind,Phosphodiesterase 2 inhibitor; Phosphodiesterase 5 inhibitor; Apoptosis stimulant,exisulind,,exisulind,exisulind,fexact,"['CP-246', 'Aptosyn', 'exisulind', 'FGN-1', 'sulindac sulfone', 'Prevatac']",exisulind,fexact,"['cp 246', 'aptosyn', 'exisulind', 'fgn 1', 'sulindac sulfone', 'prevatac']",correct_mapping
selenium,Platelet aggregation inhibitor; Reducing agent,selenium,,,,0,['selenium'],,0,[],0
vinblastine,Microtubule inhibitor; Vinca alkaloid,vinblastine,,,,0,['vinblastine'],,0,[],0
vindesine,Microtubule inhibitor; Tubulin inhibitor; Vinca alkaloid,vindesine,,,,0,['vindesine'],,0,[],0
cositecan (IV),DNA topoisomerase I inhibitor,cositecan,,cositecan (oral),cositecan,fexact,"['BNP-1350 (oral), BioNumerik', 'Karenitecin', 'cositecan (oral)', 'BNP-1350 (oral)', 'BNP-1350', 'cositecan (oral), BioNumerik', 'MCC-12824', 'cositecan']",cositecan (oral),fexact,"['bnp 1350 oral bionumerik', 'karenitecin', 'cositecan oral', 'bnp 1350 oral', 'bnp 1350', 'cositecan oral bionumerik', 'mcc 12824', 'cositecan']",correct_mapping
peptide pulsed dendritic cell vaccine,Immunostimulant,peptide pulsed dendritic cell vaccine,,,,0,['peptide pulsed dendritic cell vaccine'],,0,[],0
lurbinectedin,DNA inhibitor; RNA polymerase inhibitor,lurbinectedin,,lurbinectedin,lurbinectedin,fexact,"['anticancer agents (natural product)', 'PM-1183', 'PM-01183', 'anticancer agents (natural product), PharmaMar', 'tryptamicidin', 'PM-00113', 'PM-050489', 'Zepzelca', 'LY-01017', 'lurbinectedin', 'PM-01120', 'Zepsyre']",lurbinectedin,fexact,"['anticancer agents natural product', 'pm 1183', 'pm 01183', 'anticancer agents natural product pharmamar', 'tryptamicidin', 'pm 00113', 'pm 050489', 'zepzelca', 'ly 01017', 'lurbinectedin', 'pm 01120', 'zepsyre']",correct_mapping
mirtazapine,Alpha 2 adrenoreceptor antagonist; 5 Hydroxytryptamine 2 receptor antagonist; 5 Hydroxytryptamine 3 receptor antagonist,mirtazapine,,mirtazapine,mirtazapine,fexact,"['Org-3770', 'Zispin Soltab', 'Remeron Soltab', 'mirtazapine', 'Promyrtil', 'Rexer', 'Norset', 'Remeron', 'Zispin', 'ME-2040', 'Remergil', '6-azamianserin', 'mepirzepine', 'Reflex']",mirtazapine,fexact,"['org 3770', 'zispin soltab', 'remeron soltab', 'mirtazapine', 'promyrtil', 'rexer', 'norset', 'remeron', 'zispin', 'me 2040', 'remergil', '6 azamianserin', 'mepirzepine', 'reflex']",correct_mapping
RMC-5552,mTORC1 kinase inhibitor,RMC-5552,,RMC-5552,rmc 5552,fexact,"['RMC-5552', 'mTORC1 inhibitors (cancer)', 'RM-001', 'RMC-6272', 'RM-006']",RMC-5552,fexact,"['rmc 5552', 'mtorc1 inhibitors cancer', 'rm 001', 'rmc 6272', 'rm 006']",correct_mapping
mirvetuximab soravtansine,Microtubule inhibitor,mirvetuximab soravtansine,,mirvetuximab soravtansine,mirvetuximab soravtansine,fexact,"['mirvetuximab soravtansine', 'HDM-2002', 'M9346A-sulfo-SPDB-DM4', 'FOLR1-targeting DM4 conjugates (cancer)', 'MIRV', 'FOLR1-targeting DM4 conjugates (cancer), Immunogen', 'huFR107-SPDB-DM4', 'IMGN-853']",mirvetuximab soravtansine,fexact,"['mirvetuximab soravtansine', 'hdm 2002', 'm9346a sulfo spdb dm4', 'folr1 targeting dm4 conjugates cancer', 'mirv', 'folr1 targeting dm4 conjugates cancer immunogen', 'hufr107 spdb dm4', 'imgn 853']",correct_mapping
SI-B001,Immuno-oncology therapy,SI-B001,,SI-B-001,si b 001,fuzzy,['SI-B-001'],SI-B-001,fexact,['si b 001'],incorrect_mapping
LP-002,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,LP-002,,LP-002,lp 002,fexact,"['LP-002', 'PD-L1 chekcpoint inhibitor (advanced solid tumor)', 'anti-PD-L1 recombinant humanized monoclonal antibody (advanced solid tumor)']",LP-002,fexact,"['lp 002', 'pd l1 chekcpoint inhibitor advanced solid tumor', 'anti pd l1 recombinant humanized monoclonal antibody advanced solid tumor']",correct_mapping
TTX-080,Immuno-oncology therapy,TTX-080,,TTX-080,ttx 080,fexact,"['anti-HLA-G antibody (cancer)', 'TTX-080', 'immune checkpoint inhibitor (cancer)']",TTX-080,fexact,"['anti hla g antibody cancer', 'ttx 080', 'immune checkpoint inhibitor cancer']",correct_mapping
"alphalex-exatecan, Cybrexa Therapeutics",DNA topoisomerase I inhibitor,alphalex-exatecan,Cybrexa Therapeutics,,,0,"['exatecan', 'exatecan (intracellular/alphalex, solid tumors)', 'alphalex-exatecan', 'CBX-12']",,Drug_API_mapping,[],0
"anticancer vaccine, Elicio-1",K-Ras inhibitor; Immuno-oncology therapy,anticancer vaccine,Elicio-1,,,0,['anticancer vaccine'],,0,[],0
GEN-1042,CD137 agonist; CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,GEN-1042,,GEN-1042,gen 1042,fexact,"['bispecific anti-CD40/anti-CDw137 antibody (DuoBody, cancer),/', 'BNT-312', 'dual CD40 costimulator/4-1BB costimulator (DuoBody, cancer),/', 'bispecific anti-CD40/anti-CDw137 antibody (DuoBody, cancer),/Genmab', 'dual CD40 costimulator/4-1BB costimulator (DuoBody, cancer),/Genmab', 'DuoBody-CD40x41BB', 'GEN-1042']",GEN-1042,fexact,"['bispecific anti cd40 anti cdw137 antibody duobody cancer', 'bnt 312', 'dual cd40 costimulator 4 1bb costimulator duobody cancer', 'bispecific anti cd40 anti cdw137 antibody duobody cancer genmab', 'dual cd40 costimulator 4 1bb costimulator duobody cancer genmab', 'duobody cd40x41bb', 'gen 1042']",correct_mapping
niraparib,Poly ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor; Poly ADP ribose polymerase 1 inhibitor,niraparib,,niraparib,niraparib,fexact,"['niraparib', 'GSK-3985771', 'PARP-1/-2 inhibitor (oral, cancer),/TESARO', 'PARP-1/-2 inhibitor (oral, cancer),/', 'PARP-1/-2 inhibitor (oral, cancer), Merck & Co/TESARO', 'MK-4827', 'ZL-2306', 'Zejula', 'JNJ-64091742', 'niraparib tosilate monohydrate', '1038915-60-4']",niraparib,fexact,"['niraparib', 'gsk 3985771', 'parp 1 2 inhibitor oral cancer tesaro', 'parp 1 2 inhibitor oral cancer', 'parp 1 2 inhibitor oral cancer merck co tesaro', 'mk 4827', 'zl 2306', 'zejula', 'jnj 64091742', 'niraparib tosilate monohydrate', '1038915 60 4']",correct_mapping
"PEG-filgrastim, CSPC Pharmaceutical",Granulocyte colony stimulating factor agonist,PEG-filgrastim,CSPC Pharmaceutical,pegfilgrastim follow-on biologic,pegfilgrastim,fuzzy,"['pegfilgrastim', 'PEG-rhGCSF injection', 'pegfilgrastim follow-on biologic', 'Jinyouli', 'PEG-GCSF (neutropenia)', 'PEG-filgrastim (neutropenia)', '津优力']",pegfilgrastim follow-on biologic,fexact,"['pegfilgrastim', 'peg rhgcsf injection', 'pegfilgrastim follow on biologic', 'jinyouli', 'peg gcsf neutropenia', 'peg filgrastim neutropenia', '津优力']",incorrect_mapping
"Microneedle arrays containing doxorubicin (D-MNA), SkinJect",DNA synthesis inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,Microneedle arrays containing doxorubicin,SkinJect,,,0,['Microneedle arrays containing doxorubicin'],,0,[],0
pamiparib,Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor,pamiparib,,pamiparib,pamiparib,fexact,"['pamiparib', 'PARP inhibitor (cancer),/Merck Serono', 'PARP 1/2 inhibitor (oral, cancer)', 'PARP inhibitor (cancer),/', 'BGB-290']",pamiparib,fexact,"['pamiparib', 'parp inhibitor cancer merck serono', 'parp 1 2 inhibitor oral cancer', 'parp inhibitor cancer', 'bgb 290']",correct_mapping
"bevacizumab, Mabworks Biotech",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Mabworks Biotech,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
naloxegol,Opioid mu receptor antagonist,naloxegol,,naloxegol,naloxegol,fexact,"['PEG-naloxol (oral, opioid-induced constipation)', 'Moventig', 'PEG-naloxol (oral, opioid-induced constipation), Nektar', 'NKTR-118 oxalate', 'Movantik', 'naloxegol', 'PEG-naloxol (oral, opioid-induced constipation),/', 'AZ-13337019 oxalate', 'PEG-naloxol (oral, opioid-induced constipation),/RedHill', 'NKTR-118', 'naloxegol oxalate']",naloxegol,fexact,"['peg naloxol oral opioid induced constipation', 'moventig', 'peg naloxol oral opioid induced constipation nektar', 'nktr 118 oxalate', 'movantik', 'naloxegol', 'peg naloxol oral opioid induced constipation', 'az 13337019 oxalate', 'peg naloxol oral opioid induced constipation redhill', 'nktr 118', 'naloxegol oxalate']",correct_mapping
naquotinib mesylate (capsule),EGFR kinase inhibitor,naquotinib mesylate,,naquotinib mesylate,naquotinib mesylate,fexact,"['naquotinib mesylate', 'ASP-8273', 'naquotinib']",naquotinib mesylate,fexact,"['naquotinib mesylate', 'asp 8273', 'naquotinib']",correct_mapping
naquotinib mesylate (tablet),EGFR kinase inhibitor,naquotinib mesylate,,naquotinib mesylate,naquotinib mesylate,fexact,"['naquotinib mesylate', 'ASP-8273', 'naquotinib']",naquotinib mesylate,fexact,"['naquotinib mesylate', 'asp 8273', 'naquotinib']",correct_mapping
metformin 500mg,Biguanide; Gluconeogenesis inhibitor,metformin 500mg,,,,0,['metformin 500mg'],,0,[],0
cabozantinib (tablet),RET tyrosine kinase inhibitor; Axl receptor tyrosine kinase inhibitor; MET tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor,cabozantinib,,cabozantinib,cabozantinib,fexact,"['Cabometyx', 'XL-184', 'cabozantinib S-malate', 'BMS-907351', 'Cometriq', 'cabozantinib']",cabozantinib,fexact,"['cabometyx', 'xl 184', 'cabozantinib s malate', 'bms 907351', 'cometriq', 'cabozantinib']",correct_mapping
allogeneic DRibble vaccine,Immunostimulant,allogeneic DRibble vaccine,,,,0,['allogeneic DRibble vaccine'],,0,[],0
lentiviral transduced huCART-meso cells,Immuno-oncology therapy,lentiviral transduced huCART-meso cells,,,,0,['lentiviral transduced huCART-meso cells'],,0,[],0
upifitamab rilsodotin,NaP2b antagonist,upifitamab rilsodotin,,upifitamab rilsodotin,upifitamab rilsodotin,fexact,"['auristatin-MERS-67 drug conjugate (cancer)', 'auristatin/NaPi2b-targeting-antibody drug conjugate (cancer)', 'upifitamab rilsodotin', 'auristatin-upifitamab drug conjugate (cancer)', 'upri', 'auristatin-XMT-1535 drug conjugate (cancer)', 'XMT-1536']",upifitamab rilsodotin,fexact,"['auristatin mers 67 drug conjugate cancer', 'auristatin napi2b targeting antibody drug conjugate cancer', 'upifitamab rilsodotin', 'auristatin upifitamab drug conjugate cancer', 'upri', 'auristatin xmt 1535 drug conjugate cancer', 'xmt 1536']",correct_mapping
daratumumab (IV),CD38 antagonist; Immuno-oncology therapy,daratumumab,,daratumumab,daratumumab,fexact,"['Darzalex', 'HuMax-CD38', 'daratumumab', '3003-005', 'HuMax, multiple myeloma', 'JNJ-54767414', 'IgG1kappa antibody (multiple myeloma)']",daratumumab,fexact,"['darzalex', 'humax cd38', 'daratumumab', '3003 005', 'humax multiple myeloma', 'jnj 54767414', 'igg1kappa antibody multiple myeloma']",correct_mapping
"liposomal paclitaxel, Nanjing Cisco",Beta tubulin inhibitor; Microtubule stimulant; Taxane,liposomal paclitaxel,Nanjing Cisco,,,0,['liposomal paclitaxel'],,0,[],0
"thymosin alpha 1 (sc), unspecified",Angiogenesis stimulant; Thymosin fraction A1 agonist,thymosin alpha 1,unspecified,thymalfasin,thymosin alpha 1,fexact,"['ST-1472', 'thymosin alpha 1', 'Zadaxin', 'Timosina', 'Talpha 1', 'thymosin alpha1 human', 'thymalfasin']",thymalfasin,fexact,"['st 1472', 'thymosin alpha 1', 'zadaxin', 'timosina', 'talpha 1', 'thymosin alpha1 human', 'thymalfasin']",correct_mapping
azacitidine (sc),DNA synthesis inhibitor; DNA methylase inhibitor; RNA synthesis inhibitor,azacitidine,,"azacytidine (inhaled aerosol, lung cancer)",azacitidine,fexact,"['azacitidine', 'azacytidine (inhaled aerosol, lung cancer)', '5-azacytidine (inhaled aerosol, lung cancer)', '5-azacitidine']","azacytidine (inhaled aerosol, lung cancer)",fexact,"['azacitidine', 'azacytidine inhaled aerosol lung cancer', '5 azacytidine inhaled aerosol lung cancer', '5 azacitidine']",correct_mapping
INCB-59872,Lysine (K)-specific demethylase 1A inhibitor,INCB-59872,,INCB-59872,incb 59872,fexact,"['lsd1 inhibitor (oral tablet, small cell lung cancer/ ewing sarcoma/ neuroendocrine tumors/ acute myeloid leukemia/ myelodysplastic syndrome/ myelofibrosis)', 'INCB-59872', 'lsd1 inhibitor (oral tablet, small cell lung cancer/ ewing sarcoma/ neuroendocrine tumors/ acute myeloid leukemia/ myelodysplastic syndrome/ myelofibrosis/ sickle cell anemia)', 'INCB-059872']",INCB-59872,fexact,"['lsd1 inhibitor oral tablet small cell lung cancer ewing sarcoma neuroendocrine tumors acute myeloid leukemia myelodysplastic syndrome myelofibrosis', 'incb 59872', 'lsd1 inhibitor oral tablet small cell lung cancer ewing sarcoma neuroendocrine tumors acute myeloid leukemia myelodysplastic syndrome myelofibrosis sickle cell anemia', 'incb 059872']",correct_mapping
INCB-057643,BET protein inhibitor,INCB-057643,,INCB-057643,incb 057643,fexact,"['INCB-057643', 'INCB-57643', 'bet inhibitors (advanced tumor)']",INCB-057643,fexact,"['incb 057643', 'incb 57643', 'bet inhibitors advanced tumor']",correct_mapping
ABBV-428,CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,ABBV-428,,ABBV-428,abbv 428,fexact,"['dual CD40 costimulator/anti-mesothelin (solid tumors)', 'ABBV-428', 'anti-CD40/anti-mesothelin bispecific antibody (solid tumors)']",ABBV-428,fexact,"['dual cd40 costimulator anti mesothelin solid tumors', 'abbv 428', 'anti cd40 anti mesothelin bispecific antibody solid tumors']",correct_mapping
2-fluorofucose,Immunostimulant; Immuno-oncology therapy,2-fluorofucose,,SGN-2FF,2 fluorofucose,fexact,"['SGD-2083', 'SGN-2FF', '2-flurofucose, Seattle Genetics', '2-fluorofucose', 'protein fucosylation inhibitor (cancer), Seattle Genetics']",SGN-2FF,fexact,"['sgd 2083', 'sgn 2ff', '2 flurofucose seattle genetics', '2 fluorofucose', 'protein fucosylation inhibitor cancer seattle genetics']",correct_mapping
BMS-986012,Unidentified pharmacological activity,BMS-986012,,BMS-986012,bms 986012,fexact,"['BMS-986012', 'anti-fucosyl GM1 antibody (cancer), BMS', 'anti-fucosyl GM1 (oncology)']",BMS-986012,fexact,"['bms 986012', 'anti fucosyl gm1 antibody cancer bms', 'anti fucosyl gm1 oncology']",correct_mapping
cetrelimab,PD-1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,cetrelimab,,cetrelimab,cetrelimab,fexact,"['JNJ-3283', 'JNJ-63723283', 'JNJ-283', 'PD-1 checkpoint inhibitor (cancer)', 'cetrelimab']",cetrelimab,fexact,"['jnj 3283', 'jnj 63723283', 'jnj 283', 'pd 1 checkpoint inhibitor cancer', 'cetrelimab']",correct_mapping
"bevacizumab, Cipla BioTec",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Cipla BioTec,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
ADU-214,Immunostimulant,ADU-214,,JNJ-64041757,adu 214,fexact,"['JNJ-1757', 'JNJ-64041757', 'pemlimogene merolisbac', 'ADU-214', 'JNJ-757']",JNJ-64041757,fexact,"['jnj 1757', 'jnj 64041757', 'pemlimogene merolisbac', 'adu 214', 'jnj 757']",correct_mapping
TAK-659 (solution),Flt-3 antagonist; Syk tyrosine kinase inhibitor,TAK-659,,mivavotinib,tak 659,fexact,"['mivavotinib monocitrate', 'mivavotinib', 'TAK-659 citrate', 'mivavotinib citrate', 'TAK-659']",mivavotinib,fexact,"['mivavotinib monocitrate', 'mivavotinib', 'tak 659 citrate', 'mivavotinib citrate', 'tak 659']",correct_mapping
napabucasin,STAT transcription factor 3 inhibitor; Apoptosis stimulant,napabucasin,,napabucasin,napabucasin,fexact,"['GB-201', 'napabucasin', 'BBI-608', 'GB-608', 'BB-608']",napabucasin,fexact,"['gb 201', 'napabucasin', 'bbi 608', 'gb 608', 'bb 608']",correct_mapping
chidamide,Histone deacetylase inhibitor; Cell cycle inhibitor,chidamide,,tucidinostat,chidamide,fexact,"['Epidaza', 'Chidamide', 'HBI-8000', 'CS-055', 'HDAC1 antagonist (colon/lung cancers)', 'tucidinostat', 'HDAC1 antagonist (colon/lung cancers), Shenzhen Chipscreen Biosciences']",tucidinostat,fexact,"['epidaza', 'chidamide', 'hbi 8000', 'cs 055', 'hdac1 antagonist colon lung cancers', 'tucidinostat', 'hdac1 antagonist colon lung cancers shenzhen chipscreen biosciences']",correct_mapping
nicorandil,Potassium channel agonist,nicorandil,,nicorandil,nicorandil,fexact,"['SG-75', 'Ikorel', 'Adancor', 'nicorandil', 'SG-86', 'Dancor', 'Sigmart', 'U-64417']",nicorandil,fexact,"['sg 75', 'ikorel', 'adancor', 'nicorandil', 'sg 86', 'dancor', 'sigmart', 'u 64417']",correct_mapping
"Plasmodium immunotherapy, CAS Lamvac Biotech",Immuno-oncology therapy,Plasmodium immunotherapy,CAS Lamvac Biotech,,,0,['Plasmodium immunotherapy'],,0,[],0
"bevacizumab, Samsung Bioepis",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; Immuno-oncology therapy,bevacizumab,Samsung Bioepis,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
TG4010 (SC),Interleukin 2 receptor agonist; MUC-1 inhibitor,TG4010,,TG-4010,tg 4010,fuzzy,"['MVA-Muc1-IL-2', 'TG-4010', 'MUC1/IL-2 antigen therapy (gene transfer system, cancer)', 'MVA-TG-9931 (frozen suspension)']",TG-4010,fexact,"['mva muc1 il 2', 'tg 4010', 'muc1 il 2 antigen therapy gene transfer system cancer', 'mva tg 9931 frozen suspension']",incorrect_mapping
rineterkib,Mitogen-activated protein kinase 1 inhibitor; Mitogen-activated protein kinase 3 inhibitor,rineterkib,,rineterkib,rineterkib,fexact,"['LTT-462', 'rineterkib']",rineterkib,fexact,"['ltt 462', 'rineterkib']",correct_mapping
"adjuvanted neoantigen peptide vaccine, Genocea Biosciences",Immuno-oncology therapy,adjuvanted neoantigen peptide vaccine,Genocea Biosciences,,,0,['adjuvanted neoantigen peptide vaccine'],,0,[],0
ragifilimab,Glucocorticoid-induced TNFR-related protein agonist; Immuno-oncology therapy; Immune checkpoint stimulant,ragifilimab,,INCAGN-1876,ragifilimab,fexact,"['ragifilimab', 'INCAGN-01876', 'anti-GITR antibody (solid tumors), Incyte Corp', 'anti-gitr antibody (solid tumors)', 'INCAGN-1876']",INCAGN-1876,fexact,"['ragifilimab', 'incagn 01876', 'anti gitr antibody solid tumors incyte corp', 'anti gitr antibody solid tumors', 'incagn 1876']",correct_mapping
"cisplatin, oral, Ethypharm",DNA inhibitor; DNA synthesis inhibitor,cisplatin,Ethypharm,,,0,"['demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors),/Orient Europharma', 'cisplatin (injectable, micelle),/Orient Europharma', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors), NanoCarrier/Orient Europharma', 'demplatin pegraglumer', 'cisplatin', 'cisplatin (injectable, micelle), NanoCarrier/', 'Nanoplatin', 'cisplatin (injectable, micelle),/', 'NC-6004', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/nsclc/biliary tract/head and neck/lung cancer/solid tumors)', 'cisplatin (injectable, micelle), NanoCarrier/Orient Europharma', 'cisplatin (injectable, micelle)']",,NER_API,[],0
tocotrienol,Unidentified pharmacological activity,tocotrienol,,,,0,"['tocotrienols (cancer), Bionutrics', 'tocotrienol (cancer)', 'tocotrienol']",,Drug_API_mapping,[],0
pirfenidone (capsule),Fibroblast growth factor antagonist; Transforming growth factor beta 1 antagonist; Mitogen-activated protein kinase 14 inhibitor,pirfenidone,,pirfenidone,pirfenidone,fexact,"['Deskar', 'p38 MAP kinase inhibitor (oral, fibrosis/ multiple sclerosis),/', 'S-7701', 'p38 MAP kinase inhibitor (oral, fibrosis/ multiple sclerosis), Marnac/', 'Pirespa', 'RO-0220912', 'Esbriet', 'S-770108', 'pirfenidone', 'p38 MAP kinase inhibitor (oral, fibrosis/ multiple sclerosis), Marnac/ InterMune', 'RG-6062', 'AMR-69']",pirfenidone,fexact,"['deskar', 'p38 map kinase inhibitor oral fibrosis multiple sclerosis', 's 7701', 'p38 map kinase inhibitor oral fibrosis multiple sclerosis marnac', 'pirespa', 'ro 0220912', 'esbriet', 's 770108', 'pirfenidone', 'p38 map kinase inhibitor oral fibrosis multiple sclerosis marnac intermune', 'rg 6062', 'amr 69']",correct_mapping
istiratumab,ErbB-3 antagonist; Insulin-like growth factor 1 antagonist; Immuno-oncology therapy,istiratumab,,istiratumab,istiratumab,fexact,"['istiratumab', 'MM-141']",istiratumab,fexact,"['istiratumab', 'mm 141']",correct_mapping
GSK-3174998,CD134 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,GSK-3174998,,GSK-3174998,gsk 3174998,fexact,"['OX40 agonist antibodies (cancer),/', 'OX40 costimulator (cancer),/', 'OX40 costimulator (cancer),/MD Anderson', 'OX40 agonist antibodies (iv,/d solid tumors)', ""GSK'998"", 'OX40 agonist antibodies (cancer),/MD Anderson', 'GSK-3174998', 'OX40 agonist antibodies (iv, cancer/d solid tumors)']",GSK-3174998,fexact,"['ox40 agonist antibodies cancer', 'ox40 costimulator cancer', 'ox40 costimulator cancer md anderson', 'ox40 agonist antibodies iv d solid tumors', 'gsk 998', 'ox40 agonist antibodies cancer md anderson', 'gsk 3174998', 'ox40 agonist antibodies iv cancer d solid tumors']",correct_mapping
ImmuniCell,Not applicable,ImmuniCell,,ImmuniCell,immunicell,fexact,"['ImmuniCell', 'autologous gamma delta T-cell therapy (cancer)']",ImmuniCell,fexact,"['immunicell', 'autologous gamma delta t cell therapy cancer']",correct_mapping
AMG-228,Glucocorticoid-induced TNFR-related protein agonist; Immuno-oncology therapy; Immune checkpoint stimulant,AMG-228,,AMG-228,amg 228,fexact,"['AMG-228', 'GITR costimulator (solid tumor)']",AMG-228,fexact,"['amg 228', 'gitr costimulator solid tumor']",correct_mapping
BAY-1143269,Map kinase interacting serine/threonine kinase 1 inhibitor,BAY-1143269,,BAY-1143269,bay 1143269,fexact,"['MKNK1 inhibitor (cancer), Bayer Pharma', 'MAP kinase-interacting serine/threonine-protein kinase 1 (cancer), Bayer Pharma', 'BAY-1143269']",BAY-1143269,fexact,"['mknk1 inhibitor cancer bayer pharma', 'map kinase interacting serine threonine protein kinase 1 cancer bayer pharma', 'bay 1143269']",correct_mapping
temozolomide,DNA inhibitor,temozolomide,,"temozolomide (oral capsule, glioma)",temozolomide,fexact,"['Diqing', 'temozolomide', 'temozolomide (oral capsule, glioma)']","temozolomide (oral capsule, glioma)",fexact,"['diqing', 'temozolomide', 'temozolomide oral capsule glioma']",correct_mapping
BMS-986148,Unidentified pharmacological activity,BMS-986148,,BMS-986148,bms 986148,fexact,['BMS-986148'],BMS-986148,fexact,['bms 986148'],correct_mapping
"menadione, Talon",Phosphatase inhibitor,menadione,Talon,"menadione (topical, skin rash)",menadione,fexact,"['menadione (topical, skin rash), Talon', 'menadione (topical, skin rash), Spectrum Pharmaceuticals', 'menadione', 'vitamin K3 (topical, skin rash), Hana', 'menadione (topical, skin rash)', 'menadione (topical, skin rash), Hana']","menadione (topical, skin rash)",fexact,"['menadione topical skin rash talon', 'menadione topical skin rash spectrum pharmaceuticals', 'menadione', 'vitamin k3 topical skin rash hana', 'menadione topical skin rash', 'menadione topical skin rash hana']",correct_mapping
bupropion,Norepinephrine/dopamine dual reuptake inhibitor,bupropion,,,,0,"['BVF-033 + antidepressant (depression)', 'BVF-045', 'bupropion', 'bupropion (enhanced-absorption salt) + antidepressant (depression)']",,NER_API,[],0
"minocycline, Lederle",Protein 30S ribosomal subunit inhibitor,minocycline,Lederle,minocycline,minocycline,fexact,"['minocycline hydrochloride', 'minocycline', 'Minocin']",minocycline,fexact,"['minocycline hydrochloride', 'minocycline', 'minocin']",correct_mapping
armodafinil,Alpha 1 adrenoreceptor agonist,armodafinil,,armodafinil,armodafinil,fexact,"['R-modafinil', 'Nuvigil', 'R-isomer modafinil', 'armodafinil', 'CEP-10953']",armodafinil,fexact,"['r modafinil', 'nuvigil', 'r isomer modafinil', 'armodafinil', 'cep 10953']",correct_mapping
curcumin,Thromboxane synthase inhibitor; Platelet aggregation inhibitor; Reducing agent; Free radical scavenger,curcumin,,,,0,"['reformulated curcumin (cancer/inflammation)', 'Lipocurc', 'liposomal curcumin (iv,/COVID-19), Sign Path Pharma', 'curcumin', 'IMX-109', 'nuclear factor kappab inhibitor (intravenous/nanoparticle/liposome formulation, cancer), sign path', 'curcuminoids (oral, cystic fibrosis),/ CFFTI', 'VOLT-3', 'liposomal curcumin (iv, cancer)', ""liposomal curcumin (iv,/Parkinson's disease/sepsis), Sign Path Pharma"", 'nuclear factor kappab inhibitor (intravenous/nanoparticle/liposome formulation, cancer)', 'VOLT-03', 'reformulated curcumin (cancer/inflammation), Renascense Pharmaceuticals', 'liposomal curcumin (iv, cancer), Sign Path Pharma', 'reformulated curcumin (cancer/inflammation), Voltarra', 'nf-kappab inhibitor (intravenous/nanoparticle/liposome formulation, cancer), sign path pharma', 'sp-01', 'nf-kappab inhibitor (intravenous/nanoparticle/liposome formulation, cancer)', 'curcuminoids (oral, cystic fibrosis), SEER Pharmaceuticals/ CFFTI', ""liposomal curcumin (iv,/parkinson's disease/sepsis)"", 'diferuloylmethane', 'SP-01, Sign Path Pharma', 'liposomal curcumin (iv,/covid-19)', 'SPP1003', 'curcumin (nanoformulation, neurodegenerative/age-related diseases)']",,Drug_API_mapping,[],0
"doxycycline (capsule), unspecified",Protein 30S ribosomal subunit inhibitor,doxycycline,unspecified,doxycycline hyclate,doxycycline,fexact,"['Vibramycin', 'Vibramicina', 'doxycycline', 'doxycycline hyclate', 'VIBRA-TABS']",doxycycline hyclate,fexact,"['vibramycin', 'vibramicina', 'doxycycline', 'doxycycline hyclate', 'vibra tabs']",correct_mapping
tacrolimus,Immunosuppressant; Calcineurin inhibitor; T cell inhibitor,tacrolimus,,tacrolimus,tacrolimus,fexact,"['FK-506 (oral)', 'Hecoria', 'tacrolimus (oral), Fujisawa', 'tacrolimus (oral)', 'Prograf granule', 'tacrolimus (injectable)', 'Adbagraf', 'FK-506 (oral), Fujisawa', 'Prograf', 'fujimycin', 'tsukubaenolide', 'Prograf injection', 'Prograf capsule', 'L-679934', 'Modigraf', 'tacrolimus', 'FR-900506', 'tacrolimus (injectable), Fujisawa', 'FK-506']",tacrolimus,fexact,"['fk 506 oral', 'hecoria', 'tacrolimus oral fujisawa', 'tacrolimus oral', 'prograf granule', 'tacrolimus injectable', 'adbagraf', 'fk 506 oral fujisawa', 'prograf', 'fujimycin', 'tsukubaenolide', 'prograf injection', 'prograf capsule', 'l 679934', 'modigraf', 'tacrolimus', 'fr 900506', 'tacrolimus injectable fujisawa', 'fk 506']",correct_mapping
EF5,Unidentified pharmacological activity,EF5,,,,0,['EF5'],,0,[],0
lutetium texaphyrin,Radical formation stimulant,lutetium texaphyrin,,motexafin lutetium,lutetium texaphyrin,fexact,"['Optrin', 'Antrin', 'PCI-0123', 'lutetium texaphyrin', 'Lu-Tex', 'PCI-0123 hydrate', 'Lutrin', 'Motexafin lutetium hydrate', 'motexafin lutetium']",motexafin lutetium,fexact,"['optrin', 'antrin', 'pci 0123', 'lutetium texaphyrin', 'lu tex', 'pci 0123 hydrate', 'lutrin', 'motexafin lutetium hydrate', 'motexafin lutetium']",correct_mapping
iodixanol,Not applicable,iodixanol,,,,0,"['Visipaque', 'VISIPAQUE 270', 'iodixanol', 'DU-6807', '2-5410-3A', 'Acupaque', 'VISIPAQUE 320']",,NER_API,[],0
iohexol,Not applicable,iohexol,,iohexol,iohexol,fexact,"['iohexol', 'Omnipaque']",iohexol,fexact,"['iohexol', 'omnipaque']",correct_mapping
nicotine,Nicotinic receptor agonist,nicotine,,nicotine,nicotine,fexact,"['nicotine transdermal, Warner', 'Nicorette inhaler', 'nicotine', 'nicotine transdermal', 'Nicorette', 'nicotine transdermal, Kabi', 'Nicotrol', 'Nicotrol inhaler']",nicotine,fexact,"['nicotine transdermal warner', 'nicorette inhaler', 'nicotine', 'nicotine transdermal', 'nicorette', 'nicotine transdermal kabi', 'nicotrol', 'nicotrol inhaler']",correct_mapping
irinotecan hydrochloride,DNA topoisomerase I inhibitor,irinotecan hydrochloride,,irinotecan,irinotecan hydrochloride,fexact,"['Camptothecin 11 hydrochloride', 'DQ-2805', 'camptothecin II', 'irinotecan hydrochloride hydrate', 'camptothecin II hydrochloride', 'Topotecin', 'NSC-616348', 'irinotecan', 'camptothecin', 'camptothecin  hydrochloride', 'Camptothecin 11', 'Campto', 'irinotecan hydrochloride', 'Camptosar']",irinotecan,fexact,"['camptothecin 11 hydrochloride', 'dq 2805', 'camptothecin ii', 'irinotecan hydrochloride hydrate', 'camptothecin ii hydrochloride', 'topotecin', 'nsc 616348', 'irinotecan', 'camptothecin', 'camptothecin hydrochloride', 'camptothecin 11', 'campto', 'irinotecan hydrochloride', 'camptosar']",correct_mapping
"docetaxel, BIND Biosciences",Tubulin inhibitor; Microtubule stimulant; Taxane,docetaxel,BIND Biosciences,"docetaxel (polymeric micelle, solid tumor)",docetaxel,fexact,"['docetaxel-PM', 'docetaxel (polymeric micelle, solid tumor)', 'Nanoxel-PM', 'docetaxel', 'SYP-0704A', 'Nanoxel']","docetaxel (polymeric micelle, solid tumor)",fexact,"['docetaxel pm', 'docetaxel polymeric micelle solid tumor', 'nanoxel pm', 'docetaxel', 'syp 0704a', 'nanoxel']",correct_mapping
lumretuzumab,ErbB-3 antagonist,lumretuzumab,,lumretuzumab,lumretuzumab,fexact,"['glycoengineered anti-HER3 monoclonal antibody (solid tumors)', 'RO-5479599', 'anti-HER3 monoclonal antibody (solid tumors)', 'RG-7116', 'GE-huMAb HER3 (solid tumors)', 'lumretuzumab']",lumretuzumab,fexact,"['glycoengineered anti her3 monoclonal antibody solid tumors', 'ro 5479599', 'anti her3 monoclonal antibody solid tumors', 'rg 7116', 'ge humab her3 solid tumors', 'lumretuzumab']",correct_mapping
YangzhengXiaoji,Unidentified pharmacological activity,YangzhengXiaoji,,,,0,['YangzhengXiaoji'],,0,[],0
ID-LV305,Unidentified pharmacological activity,ID-LV305,,LV-305,id lv305,fexact,"['DC-NILV-based cancer vaccine', 'dendritic cell-targeted lentiviral vector expressing NY-ESO-1 gene', 'LV-305', 'ID-LV based cancer vaccine', 'ID-LV305']",LV-305,fexact,"['dc nilv based cancer vaccine', 'dendritic cell targeted lentiviral vector expressing ny eso 1 gene', 'lv 305', 'id lv based cancer vaccine', 'id lv305']",correct_mapping
glembatumumab vedotin,Tubulin inhibitor,glembatumumab vedotin,,glembatumumab vedotin,glembatumumab vedotin,fexact,"['glembatumumab vedotin', 'CR-011-mc-vc-PAB-MMAE', 'CR-011-MMAE (iv, cancer), Curagen', 'CR-011-vedotin', 'anti-glycoprotein NMB monoclonal antibody + monomethy-Auristatin E (cancer)', 'CR011-vcMMAE', 'anti-gpNMB mAb- MMAE (iv, cancer), Curagen', 'CR-011-MMAE (iv, cancer)', 'anti-glycoprotein NMB monoclonal antibody + monomethy-Auristatin E (cancer), Curagen', 'anti-gpNMB mAb- MMAE (iv, cancer)', 'glembatumumab-mc-vc-PAB-MMAE', 'anti-glycoprotein NMB monoclonal antibody + monomethy-Auristatin  (cancer)', 'CDX-011']",glembatumumab vedotin,fexact,"['glembatumumab vedotin', 'cr 011 mc vc pab mmae', 'cr 011 mmae iv cancer curagen', 'cr 011 vedotin', 'anti glycoprotein nmb monoclonal antibody monomethy auristatin e cancer', 'cr011 vcmmae', 'anti gpnmb mab mmae iv cancer curagen', 'cr 011 mmae iv cancer', 'anti glycoprotein nmb monoclonal antibody monomethy auristatin e cancer curagen', 'anti gpnmb mab mmae iv cancer', 'glembatumumab mc vc pab mmae', 'anti glycoprotein nmb monoclonal antibody monomethy auristatin cancer', 'cdx 011']",correct_mapping
GSK-2879552,Lysine (K)-specific demethylase 1A inhibitor,GSK-2879552,,GSK-2879552,gsk 2879552,fexact,"['GSK-519', 'GSK-2879552', 'GSK-690', 'LSD-1 inhibitors (cancer)']",GSK-2879552,fexact,"['gsk 519', 'gsk 2879552', 'gsk 690', 'lsd 1 inhibitors cancer']",correct_mapping
PLX-8394,B-raf kinase inhibitor,PLX-8394,,FORE-8394,plx 8394,fexact,"['FORE-8394', 'PLX-8394']",FORE-8394,fexact,"['fore 8394', 'plx 8394']",correct_mapping
"mifepristone, Corcept Therapeutics",Progesterone receptor antagonist; Glucocorticoid antagonist,mifepristone,Corcept Therapeutics,,,0,"['mifepristone, Population Council', 'mifepristone, Roussel Uclaf', 'Mifegymiso', 'RU-486', 'RU-486-6', 'Mifegyne', 'R-38486', 'Mifeprex', 'Mifezone', 'RU-38486', 'mifepristone']",,NER_API,[],0
tepotinib,MET tyrosine kinase inhibitor,tepotinib,,tepotinib,tepotinib,fexact,"['tepotinib hydrochloride hydrate', 'tepotinib hydrochloride', 'Tepmetko', 'tepotinib', 'EMD-1214063', 'c-Met kinase inhibitors (cancer), Merck Serono', 'MSC-2156119J']",tepotinib,fexact,"['tepotinib hydrochloride hydrate', 'tepotinib hydrochloride', 'tepmetko', 'tepotinib', 'emd 1214063', 'c met kinase inhibitors cancer merck serono', 'msc 2156119j']",correct_mapping
"folate-tubulysin B hydrazide conjugate, Endocyte",Folate antagonist; Microtubule inhibitor,folate-tubulysin B hydrazide conjugate,Endocyte,,,0,['folate-tubulysin B hydrazide conjugate'],,0,[],0
selinexor (suspension),Exportin 1 inhibitor,selinexor,,selinexor,selinexor,fexact,"['ATG-010', 'KCP-330', 'KPT-207', 'XPOVIO', 'nuclear transport inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'selective nuclear export inhibitors (COVID-19), Karyopharm Therapeutics', 'SINE (autoimmune diseases/HIV/cancer)', 'Nexpovio', 'KPT-SINE', 'KPT-185', 'SINE-KPT-330', 'KPT-225', 'KPT-330', 'KPT-XXX', 'Exportin-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'CRM-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease)', 'nuclear transport inhibitors (inflammation/viral diseases/cancer)', 'selective nuclear export inhibitors (autoimmune diseases/HIV/cancer)', 'KPT-249', 'KPT-276', 'Exportin-1 inhibitors (inflammation/viral diseases/cancer)', 'KPT-251', 'selinexor', 'Xpovio', 'selective nuclear export inhibitors (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics', 'SINE (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics', 'CRM-1 inhibitors (inflammation/viral diseases/cancer)', 'ONO-7705', 'selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease), Karyopharm Therapeutics', 'selective nuclear export inhibitors (COVID-19)']",selinexor,fexact,"['atg 010', 'kcp 330', 'kpt 207', 'xpovio', 'nuclear transport inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'selective nuclear export inhibitors covid 19 karyopharm therapeutics', 'sine autoimmune diseases hiv cancer', 'nexpovio', 'kpt sine', 'kpt 185', 'sine kpt 330', 'kpt 225', 'kpt 330', 'kpt xxx', 'exportin 1 inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'crm 1 inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'selective nuclear export inhibitors autoimmune inflammation hiv cancer dermatological disease', 'nuclear transport inhibitors inflammation viral diseases cancer', 'selective nuclear export inhibitors autoimmune diseases hiv cancer', 'kpt 249', 'kpt 276', 'exportin 1 inhibitors inflammation viral diseases cancer', 'kpt 251', 'selinexor', 'xpovio', 'selective nuclear export inhibitors autoimmune diseases hiv cancer karyopharm therapeutics', 'sine autoimmune diseases hiv cancer karyopharm therapeutics', 'crm 1 inhibitors inflammation viral diseases cancer', 'ono 7705', 'selective nuclear export inhibitors autoimmune inflammation hiv cancer dermatological disease karyopharm therapeutics', 'selective nuclear export inhibitors covid 19']",correct_mapping
rSIFN-co,Immunostimulant,rSIFN-co,,,,0,['rSIFN-co'],,0,[],0
buparlisib (capsule),Protein kinase inhibitor; PI3 kinase inhibitor,buparlisib,,buparlisib,buparlisib,fexact,"['buparlisib hydrochloride', 'BKM-120', 'buparlisib', 'AN-2025', 'phosphatidylinositol-3-kinase inhibitor (cancer), Novartis', 'PI3K inhibitor (cancer)', 'PI3K inhibitor (cancer), Novartis', 'NVP-BKM-120', 'BKM-210', 'phosphatidylinositol-3-kinase inhibitor (cancer), Adlai Nortye Biopharma', 'phosphatidylinositol-3-kinase inhibitor (cancer)']",buparlisib,fexact,"['buparlisib hydrochloride', 'bkm 120', 'buparlisib', 'an 2025', 'phosphatidylinositol 3 kinase inhibitor cancer novartis', 'pi3k inhibitor cancer', 'pi3k inhibitor cancer novartis', 'nvp bkm 120', 'bkm 210', 'phosphatidylinositol 3 kinase inhibitor cancer adlai nortye biopharma', 'phosphatidylinositol 3 kinase inhibitor cancer']",correct_mapping
AZD-8186,PI3 kinase beta inhibitor; PI3 kinase delta inhibitor,AZD-8186,,AZD-8186,azd 8186,fexact,['AZD-8186'],AZD-8186,fexact,['azd 8186'],correct_mapping
FP-1039,Fibroblast growth factor receptor 1 antagonist; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,FP-1039,,FP-1039,fp 1039,fexact,"['modified growth factor receptor (cancer), FivePrime Therapeutics', 'GSK-3052230', 'FGFR-1c antagonist (protein fusion/, cancer), FivePrime Therapeutics/ Human Genome Sciences', 'FGFR-1c antagonist (protein fusion/, cancer), FivePrime Therapeutics/', 'FP-1039', 'FGFR-1c antagonist (protein fusion/, cancer), FivePrime Therapeutics', '3052330', 'FPT-039', 'HGS-1036']",FP-1039,fexact,"['modified growth factor receptor cancer fiveprime therapeutics', 'gsk 3052230', 'fgfr 1c antagonist protein fusion cancer fiveprime therapeutics human genome sciences', 'fgfr 1c antagonist protein fusion cancer fiveprime therapeutics', 'fp 1039', 'fgfr 1c antagonist protein fusion cancer fiveprime therapeutics', '3052330', 'fpt 039', 'hgs 1036']",correct_mapping
tivozanib,VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor,tivozanib,,tivozanib,tivozanib,fexact,"['Fotivda', 'quinoline-urea-derived VEGF inhibitor (oral, cancer), AVEO Pharmaceuticals', 'quinoline-urea-derived VEGF inhibitor (cancer)', 'tivozanib hydrochloride', 'ASP-4130', 'AV-951', 'quinoline-urea-derived VEGF inhibitor (oral, cancer), Kirin// Astellas', 'Tivopath', 'quinoline-urea-derived VEGF inhibitor (oral, cancer), Kirin//', 'KRN-951', 'quinoline-urea-derived VEGF inhibitor (oral, cancer),//', 'tivozanib', 'quinoline-urea-derived VEGF inhibitor (cancer), Kirin']",tivozanib,fexact,"['fotivda', 'quinoline urea derived vegf inhibitor oral cancer aveo pharmaceuticals', 'quinoline urea derived vegf inhibitor cancer', 'tivozanib hydrochloride', 'asp 4130', 'av 951', 'quinoline urea derived vegf inhibitor oral cancer kirin astellas', 'tivopath', 'quinoline urea derived vegf inhibitor oral cancer kirin', 'krn 951', 'quinoline urea derived vegf inhibitor oral cancer', 'tivozanib', 'quinoline urea derived vegf inhibitor cancer kirin']",correct_mapping
samotolisib,mTOR kinase inhibitor; PI3 kinase inhibitor,samotolisib,,samotolisib,samotolisib,fexact,"['PI3 kinase/mTOR dual inhibitor (cancer)', 'samotolisib', 'LY-3023414']",samotolisib,fexact,"['pi3 kinase mtor dual inhibitor cancer', 'samotolisib', 'ly 3023414']",correct_mapping
buparlisib (tablet),Protein kinase inhibitor; PI3 kinase inhibitor,buparlisib,,buparlisib,buparlisib,fexact,"['buparlisib hydrochloride', 'BKM-120', 'buparlisib', 'AN-2025', 'phosphatidylinositol-3-kinase inhibitor (cancer), Novartis', 'PI3K inhibitor (cancer)', 'PI3K inhibitor (cancer), Novartis', 'NVP-BKM-120', 'BKM-210', 'phosphatidylinositol-3-kinase inhibitor (cancer), Adlai Nortye Biopharma', 'phosphatidylinositol-3-kinase inhibitor (cancer)']",buparlisib,fexact,"['buparlisib hydrochloride', 'bkm 120', 'buparlisib', 'an 2025', 'phosphatidylinositol 3 kinase inhibitor cancer novartis', 'pi3k inhibitor cancer', 'pi3k inhibitor cancer novartis', 'nvp bkm 120', 'bkm 210', 'phosphatidylinositol 3 kinase inhibitor cancer adlai nortye biopharma', 'phosphatidylinositol 3 kinase inhibitor cancer']",correct_mapping
Nerium olander extract (sublingual),Fibroblast growth factor 2 antagonist; Fibroblast growth factor receptor 2 antagonist; mTOR kinase inhibitor; Protein kinase B inhibitor; Protein kinase inhibitor; Na+ K+ transporting ATPase inhibitor; Transcription factor NF-kappaB inhibitor,Nerium olander extract,,,,0,['Nerium olander extract'],,0,[],0
turgenpumatucel-L,Immunostimulant,turgenpumatucel-L,,tergenpumatucel-L,tergenpumatucel l,fuzzy,"['HyperAcute vaccine (intradermal, lung cancer)', 'HyperAcute vaccine (lung cancer)', 'tergenpumatucel-L', 'HyperAcute-Lung', 'HAL']",tergenpumatucel-L,fexact,"['hyperacute vaccine intradermal lung cancer', 'hyperacute vaccine lung cancer', 'tergenpumatucel l', 'hyperacute lung', 'hal']",incorrect_mapping
"picropodophyllin, Axelar",Mitotic inhibitor,picropodophyllin,Axelar,,,0,"['IGF-1R inhibitor (cancer), Karolinska', 'insulin-like growth factor 1 inhibitors,/', 'picropodophyllin', 'IGF-1 inhibitors,/', 'picropodophyllin (oral suspension, cancer)', 'picropodophyllin,/', 'picropodophyllin (oral suspension, cancer),/ Cadila', 'picropodophyllin (oral suspension, cancer),/', 'picropodophyllin (cancer), Karolinska', 'picropodophyllin,/Biovitrum', 'picropodophyllin (cancer)', 'PPP', 'cyclolignan picropodophyllin', 'IGF-1 inhibitors,/Biovitrum', 'insulin-like growth factor 1 inhibitors,/Biovitrum', 'IGF-1 inhibitors, Karolinska/Biovitrum', 'BVT-51004', 'IGF-1 inhibitors, Karolinska/', 'AXL-1717']",,Drug_API_mapping,[],0
zalutumumab,EGFR antagonist,zalutumumab,,zalutumumab,zalutumumab,fexact,"['HuMax-EGFr', 'zalutumumab', 'SF8', '2F8']",zalutumumab,fexact,"['humax egfr', 'zalutumumab', 'sf8', '2f8']",correct_mapping
Re-188 P2045,Somatostatin receptor 2 agonist; Radiopharmaceutical,Re-188 P2045,,,,0,['Re-188 P2045'],,0,[],0
amatuximab,Immunostimulant; Mesothelin inhibitor,amatuximab,,amatuximab,amatuximab,fexact,"['MORAb-009', 'monoclonal antibody (cancer)', 'amatuximab', '64Cu-MORAb-009', 'monoclonal antibody (cancer), Morphotek']",amatuximab,fexact,"['morab 009', 'monoclonal antibody cancer', 'amatuximab', '64cu morab 009', 'monoclonal antibody cancer morphotek']",correct_mapping
cyclin B1 peptide pulsed dendritic cell vaccine,Immunostimulant,cyclin B1 peptide pulsed dendritic cell vaccine,,,,0,['cyclin B1 peptide pulsed dendritic cell vaccine'],,0,[],0
sodium aurothiomalate,Immunosuppressant; Disease modifying antirheumatic drug,sodium aurothiomalate,,,,0,['sodium aurothiomalate'],,0,[],0
gemcitabine elaidate (IV),DNA synthesis inhibitor; DNA repair enzyme inhibitor; Apoptosis stimulant; Cell cycle inhibitor,gemcitabine elaidate,,"gemcitabine elaidate (iv lipid vector, cancer)",gemcitabine elaidate,fexact,"['fatty acid gemcitabine prodrug (iv, lipid vector technology, cancer), Clavis', 'CP-4126 (iv, lipid vector technology, cancer), Clavis Pharma', 'gemcitabine elaidate (iv lipid vector, cancer)', 'CP-4126 (intravenous, lipid vector technology, cancer), Clavis Pharma/', 'gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology', 'CP-4126 (intravenous, lipid vector technology, cancer), Clavis Pharma/Clovis Oncology', 'gemcitabine elaidate (intravenous, lipid vector technology), Clavis Pharma/', 'CO-1.01', 'CO-101', 'CO-101 (intravenous, lipid vector technology), Clavis Pharma/Clovis Oncology', 'CP-4126', 'gemcitabine elaidate (intravenous, lipid vector technology), Clavis Pharma/Clovis Oncology', 'CO-101 (intravenous, lipid vector technology), Clavis Pharma/', 'gemcitabine elaidate']","gemcitabine elaidate (iv lipid vector, cancer)",fexact,"['fatty acid gemcitabine prodrug iv lipid vector technology cancer clavis', 'cp 4126 iv lipid vector technology cancer clavis pharma', 'gemcitabine elaidate iv lipid vector cancer', 'cp 4126 intravenous lipid vector technology cancer clavis pharma', 'gemcitabine elaidate iv lipid vector cancer clovis oncology', 'cp 4126 intravenous lipid vector technology cancer clavis pharma clovis oncology', 'gemcitabine elaidate intravenous lipid vector technology clavis pharma', 'co 1 01', 'co 101', 'co 101 intravenous lipid vector technology clavis pharma clovis oncology', 'cp 4126', 'gemcitabine elaidate intravenous lipid vector technology clavis pharma clovis oncology', 'co 101 intravenous lipid vector technology clavis pharma', 'gemcitabine elaidate']",correct_mapping
MK-2206,Protein kinase B inhibitor,MK-2206,,MK-2206,mk 2206,fexact,"['MK-2206', 'AKT inhibitors (cancer),/Rutgers', 'NSC-749607']",MK-2206,fexact,"['mk 2206', 'akt inhibitors cancer rutgers', 'nsc 749607']",correct_mapping
utomilumab,CD137 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,utomilumab,,utomilumab,utomilumab,fexact,"['4-1BB agonist (iv, cancer)', 'anti-4-1BB (iv, cancer)', 'utomilumab', 'TNFRSF9 agonist  (iv, cancer)', 'PF-2566', 'MOR-7483', 'MOR-7480', 'PFE-1 antibody (HuCAL, cancer),/MorphoSys', 'PFE-05082566', 'CD137 agonist (iv, cancer)', '4-1BB costimulator (HuCAL, cancer),/Morphosys', 'PF-05082566']",utomilumab,fexact,"['4 1bb agonist iv cancer', 'anti 4 1bb iv cancer', 'utomilumab', 'tnfrsf9 agonist iv cancer', 'pf 2566', 'mor 7483', 'mor 7480', 'pfe 1 antibody hucal cancer morphosys', 'pfe 05082566', 'cd137 agonist iv cancer', '4 1bb costimulator hucal cancer morphosys', 'pf 05082566']",correct_mapping
acetyl-L-carnitine (oral),Carnitine O-acetyltransferase stimulant,acetyl-L-carnitine,,acetyl-L-carnitine hydrochloride,acetyl l carnitine,fexact,"['Zibren', 'acetyl-L-carnitine hydrochloride', 'Neuroactil', 'acetyl-L-carnitine', 'ST-200', 'Ceredon', 'TA-803', 'levacecarnine', 'L-Branigen', 'levocarnitine acetate hydrochloride']",acetyl-L-carnitine hydrochloride,fexact,"['zibren', 'acetyl l carnitine hydrochloride', 'neuroactil', 'acetyl l carnitine', 'st 200', 'ceredon', 'ta 803', 'levacecarnine', 'l branigen', 'levocarnitine acetate hydrochloride']",correct_mapping
tamibarotene (tablet),Retinoic acid alpha receptor agonist; Retinoic acid beta receptor agonist,tamibarotene,,tamibarotene,tamibarotene,fexact,"['Tamibaro', 'TM-411', 'Amnolake', 'oral tamibarotene (oncological/inflammatory indications), Nippon Shinyaku/R&R/TMRC//Choongwae', 'tamibarotene', 'oral tamibarotene (oncological/inflammatory indications),//TMRC//Choongwae', 'OP-09', 'oral tamibarotene (oncological/inflammatory indications),/R&R/TMRC//Choongwae', 'RR-110', 'oral tamibarotene (oncological/inflammatory indications), Nippon Shinyaku/R&R/TMRC/Innovive/Choongwae', 'INNO-507', 'OMSO-728', 'TOS-80T', 'Amnoid', 'AM-80', 'oral tamibarotene (oncological/inflammatory indications),////Choongwae', 'SY-1425', 'oral tamibarotene (oncological/inflammatory indications), Nippon Shinyaku/R&R/TMRC/CytRx/Choongwae', 'Z-208']",tamibarotene,fexact,"['tamibaro', 'tm 411', 'amnolake', 'oral tamibarotene oncological inflammatory indications nippon shinyaku r r tmrc choongwae', 'tamibarotene', 'oral tamibarotene oncological inflammatory indications tmrc choongwae', 'op 09', 'oral tamibarotene oncological inflammatory indications r r tmrc choongwae', 'rr 110', 'oral tamibarotene oncological inflammatory indications nippon shinyaku r r tmrc innovive choongwae', 'inno 507', 'omso 728', 'tos 80t', 'amnoid', 'am 80', 'oral tamibarotene oncological inflammatory indications choongwae', 'sy 1425', 'oral tamibarotene oncological inflammatory indications nippon shinyaku r r tmrc cytrx choongwae', 'z 208']",correct_mapping
farletuzumab,Folate binding protein inhibitor; Folate receptor antagonist,farletuzumab,,farletuzumab,farletuzumab,fexact,"['monoclonal antibody (ovarian cancer)', 'monoclonal antibody (ovarian cancer), Morphotek', 'MORAb-003', 'farletuzumab']",farletuzumab,fexact,"['monoclonal antibody ovarian cancer', 'monoclonal antibody ovarian cancer morphotek', 'morab 003', 'farletuzumab']",correct_mapping
IO-101,"Indoleamine 2,3-dioxygenase inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor",IO-101,,IO-101,io 101,fexact,['IO-101'],IO-101,fexact,['io 101'],correct_mapping
SB-AS15,Immunostimulant,SB-AS15,,AS-15 adjuvant,sb as15,fexact,"['AS-15 adjuvant', 'SB-AS15', 'QS-21 + MPL + CpG (vaccination), GSK']",AS-15 adjuvant,fexact,"['as 15 adjuvant', 'sb as15', 'qs 21 mpl cpg vaccination gsk']",correct_mapping
GSK-2241658A,Immunostimulant; Immuno-oncology therapy,GSK-2241658A,,GSK-2241658A,gsk 2241658a,fexact,"['NY-ESO-1 ASCI (melanoma), GSK', '2241658A', 'recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma)', 'GSK-2241658A']",GSK-2241658A,fexact,"['ny eso 1 asci melanoma gsk', '2241658a', 'recombinant ny eso 1 antigen immunotherapeutic vaccine melanoma', 'gsk 2241658a']",correct_mapping
duligotuzumab,ErbB-3 antagonist,duligotuzumab,,duligotuzumab,duligotuzumab,fexact,"['MEHD-7945A', 'RG-7597', 'anti-HER3 EGFR DAF MAb', 'duligotuzumab', 'duligotumab', 'EGFR/HER3 dual monoclonal antibody']",duligotuzumab,fexact,"['mehd 7945a', 'rg 7597', 'anti her3 egfr daf mab', 'duligotuzumab', 'duligotumab', 'egfr her3 dual monoclonal antibody']",correct_mapping
efatutazone,Peroxisome proliferator-activated receptor gamma agonist,efatutazone,,efatutazone,efatutazone,fexact,"['inolitazone', 'ppar gamma agonist (cancer)', 'PPAR gamma agonist (cancer),/Daiichi Sankyo Inc', 'efatutazone', 'RS-5444', 'CS-7017']",efatutazone,fexact,"['inolitazone', 'ppar gamma agonist cancer', 'ppar gamma agonist cancer daiichi sankyo inc', 'efatutazone', 'rs 5444', 'cs 7017']",correct_mapping
RG-4733,Secretase gamma inhibitor; Notch pathway inhibitor,RG-4733,,RO-4929097,rg 4733,fexact,"['Gamma-secretase inhibitor (oral, solid tumor)', 'Notch signalling inhibitor (oral, solid tumor)', 'R-4733', 'NSC-749225', 'RG-4733', 'RO-4929097']",RO-4929097,fexact,"['gamma secretase inhibitor oral solid tumor', 'notch signalling inhibitor oral solid tumor', 'r 4733', 'nsc 749225', 'rg 4733', 'ro 4929097']",correct_mapping
belinostat (oral),Histone deacetylase inhibitor; Cell cycle inhibitor,belinostat,,"belinostat (oral, cancer)",belinostat,fexact,"['PX-089344', 'belinostat (oral, solid tumors),/', 'belinostat (oral, cancer), TopoTarget/Spectrum', 'belinostat (oral, cancer)', 'belinostat (oral, cancer), BioAlliance Pharma/Spectrum', 'histone deacetylase inhibitor (oral, solid tumors), TopoTarget/', 'belinostat (oral, cancer),/Spectrum', 'PXD-101 (oral, solid tumors), TopoTarget/', 'belinostat (oral, cancer),/', 'HDAC inhibitor (oral, solid tumors),/', 'histone deacetylase inhibitor (oral, solid tumors),/', 'belinostat', 'belinostat (oral, cancer), Onxeo', 'belinostat (oral, cancer), BioAlliance Pharma/', 'belinostat (oral, cancer), TopoTarget/', 'belinostat (oral, cancer), Onxeo/Spectrum', 'PXD-101 (oral, solid tumors),/', 'belinostat (oral, solid tumors), TopoTarget/', 'PXD-101', 'HDAC inhibitor (oral, solid tumors), TopoTarget/']","belinostat (oral, cancer)",fexact,"['px 089344', 'belinostat oral solid tumors', 'belinostat oral cancer topotarget spectrum', 'belinostat oral cancer', 'belinostat oral cancer bioalliance pharma spectrum', 'histone deacetylase inhibitor oral solid tumors topotarget', 'belinostat oral cancer spectrum', 'pxd 101 oral solid tumors topotarget', 'belinostat oral cancer', 'hdac inhibitor oral solid tumors', 'histone deacetylase inhibitor oral solid tumors', 'belinostat', 'belinostat oral cancer onxeo', 'belinostat oral cancer bioalliance pharma', 'belinostat oral cancer topotarget', 'belinostat oral cancer onxeo spectrum', 'pxd 101 oral solid tumors', 'belinostat oral solid tumors topotarget', 'pxd 101', 'hdac inhibitor oral solid tumors topotarget']",correct_mapping
F16-IL2,Interleukin 2 receptor agonist; Immunostimulant,F16-IL2,,,,0,['F16-IL2'],,0,[],0
panobinostat (IV),Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,panobinostat,,panobinostat (oral),panobinostat,fexact,"['Faridak', 'LBH-589 (oral)', 'LBH-589', 'LBH-589B', 'Farydak', 'NVP-LBH-589', 'panobinostat (oral)', 'panobinostat']",panobinostat (oral),fexact,"['faridak', 'lbh 589 oral', 'lbh 589', 'lbh 589b', 'farydak', 'nvp lbh 589', 'panobinostat oral', 'panobinostat']",correct_mapping
CUDC-101 (iv),EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI); Histone deacetylase inhibitor; Apoptosis stimulant,CUDC-101,,,,0,"['CUDC-101 (iv/Captisol, cancer),/', 'CUDC-101 (iv/Captisol, cancer),/Ligand', 'CUDC-101']",,NER_API,[],0
lorvotuzumab mertansine,Microtubule inhibitor,lorvotuzumab mertansine,,lorvotuzumab mertansine,lorvotuzumab mertansine,fexact,"['lorvotuzumab-DM1', 'huN901-DM1', 'NCAM1-targeted MAb-DM1 conjugate', 'lorvotuzumab mertansine', 'CD56-targeted MAb-DM1 conjugate', 'IMGN-901', 'BB-10901']",lorvotuzumab mertansine,fexact,"['lorvotuzumab dm1', 'hun901 dm1', 'ncam1 targeted mab dm1 conjugate', 'lorvotuzumab mertansine', 'cd56 targeted mab dm1 conjugate', 'imgn 901', 'bb 10901']",correct_mapping
iniparib,DNA repair enzyme inhibitor; Poly ADP ribose polymerase 1 inhibitor,iniparib,,iniparib,iniparib,fexact,"['PARP-1 inhibitors (cancer)', 'MS-292', 'iniparib', 'iniparib, Octamer', 'BSI-201', 'SAR-240550']",iniparib,fexact,"['parp 1 inhibitors cancer', 'ms 292', 'iniparib', 'iniparib octamer', 'bsi 201', 'sar 240550']",correct_mapping
amrubicin (IV),DNA topoisomerase II inhibitor,amrubicin,,amrubicin,amrubicin,fexact,"['Calsed', 'amrubicin', 'S-5887', 'SM-5887', 'CNF-3140', 'amrubicin hydrochloride']",amrubicin,fexact,"['calsed', 'amrubicin', 's 5887', 'sm 5887', 'cnf 3140', 'amrubicin hydrochloride']",correct_mapping
URLC10 peptide,Immunostimulant,URLC10 peptide,,,,0,['URLC10 peptide'],,0,[],0
"Vigil, Gradalis",Granulocyte macrophage colony stimulating factor agonist; Transforming growth factor beta 1 antagonist; Transforming growth factor beta 2 antagonist; Immuno-oncology therapy,Vigil,Gradalis,gemogenovatucel-T,vigil,fexact,"['Personalized Vaccine', 'Vigil', 'Vigil EATC', 'bi-shRNAfurin and GMCSF augmented autologous tumor cell immunotherapy', 'FANG vaccine', 'IND-14205', 'personalized cancer vaccine', 'gemogenovatucel-T', 'autologous GMCSF + bi-shRNAfurin expressing vaccine (cancer)']",gemogenovatucel-T,fexact,"['personalized vaccine', 'vigil', 'vigil eatc', 'bi shrnafurin and gmcsf augmented autologous tumor cell immunotherapy', 'fang vaccine', 'ind 14205', 'personalized cancer vaccine', 'gemogenovatucel t', 'autologous gmcsf bi shrnafurin expressing vaccine cancer']",correct_mapping
panitumumab,EGFR antagonist,panitumumab,,panitumumab,panitumumab,fexact,"['anti-EGFr antibody,/Immunex', 'anti-EGFr antibody,/Amgen', 'rHuMAb-EGFr, Amgen/', 'ABX-EGF', 'rHuMAb-EGFr,/', 'Vectibix', 'panitumumab', 'anti-EGFr antibody,/']",panitumumab,fexact,"['anti egfr antibody immunex', 'anti egfr antibody amgen', 'rhumab egfr amgen', 'abx egf', 'rhumab egfr', 'vectibix', 'panitumumab', 'anti egfr antibody']",correct_mapping
ganitumab,Insulin-like growth factor 1 antagonist,ganitumab,,ganitumab,ganitumab,fexact,"['IGF-1R antagonist (cancer),/Takeda', 'IGF-1R antagonist (cancer),/', 'AMG-479', 'ganitumab', 'insulin-like growth factor 1 antagonist (cancer),/Takeda', 'insulin-like growth factor 1 antagonist (cancer),/']",ganitumab,fexact,"['igf 1r antagonist cancer takeda', 'igf 1r antagonist cancer', 'amg 479', 'ganitumab', 'insulin like growth factor 1 antagonist cancer takeda', 'insulin like growth factor 1 antagonist cancer']",correct_mapping
linsitinib,IGF-1 receptor tyrosine kinase inhibitor,linsitinib,,linsitinib,linsitinib,fexact,"['IGF-1R tyrosine kinase inhibitor (cancer)', 'OSI-906AA', 'insulin-like growth factor receptor-1 tyrosine kinase inhibitor (cancer)', 'insulin-like growth factor receptor-1 tyrosine kinase inhibitor (cancer), OSI Pharmaceuticals', 'apoptosis inhibitor (solid tumors, small molecule therapeutic), OSI Pharmaceuticals', 'IGF-1R tyrosine kinase inhibitor (cancer), OSI Pharmaceuticals', 'ASP-7487', 'linsitinib', 'OSI-906', 'apoptosis inhibitor (solid tumors, small molecule therapeutic)']",linsitinib,fexact,"['igf 1r tyrosine kinase inhibitor cancer', 'osi 906aa', 'insulin like growth factor receptor 1 tyrosine kinase inhibitor cancer', 'insulin like growth factor receptor 1 tyrosine kinase inhibitor cancer osi pharmaceuticals', 'apoptosis inhibitor solid tumors small molecule therapeutic osi pharmaceuticals', 'igf 1r tyrosine kinase inhibitor cancer osi pharmaceuticals', 'asp 7487', 'linsitinib', 'osi 906', 'apoptosis inhibitor solid tumors small molecule therapeutic']",correct_mapping
"paclitaxel, Samyang-1",Beta tubulin inhibitor; Microtubule stimulant; Taxane,paclitaxel,Samyang-1,paclitaxel,paclitaxel,fexact,"['Praxel', 'BMS-181339-01', 'taxol A, NIH', 'paclitaxel, BMS', 'Anzatax', 'Onxal', 'intaxel', 'taxol, BMS', 'taxol, NIH', 'taxol A, BMS', 'paclitaxel, NIH', 'Bristaxol', 'NSC-125973', 'paclitaxel', 'Asotax', 'NSC-673089', 'Taxol']",paclitaxel,fexact,"['praxel', 'bms 181339 01', 'taxol a nih', 'paclitaxel bms', 'anzatax', 'onxal', 'intaxel', 'taxol bms', 'taxol nih', 'taxol a bms', 'paclitaxel nih', 'bristaxol', 'nsc 125973', 'paclitaxel', 'asotax', 'nsc 673089', 'taxol']",correct_mapping
"paclitaxel, Samyang",Beta tubulin inhibitor; Microtubule stimulant; Taxane,paclitaxel,Samyang,paclitaxel,paclitaxel,fexact,"['Praxel', 'BMS-181339-01', 'taxol A, NIH', 'paclitaxel, BMS', 'Anzatax', 'Onxal', 'intaxel', 'taxol, BMS', 'taxol, NIH', 'taxol A, BMS', 'paclitaxel, NIH', 'Bristaxol', 'NSC-125973', 'paclitaxel', 'Asotax', 'NSC-673089', 'Taxol']",paclitaxel,fexact,"['praxel', 'bms 181339 01', 'taxol a nih', 'paclitaxel bms', 'anzatax', 'onxal', 'intaxel', 'taxol bms', 'taxol nih', 'taxol a bms', 'paclitaxel nih', 'bristaxol', 'nsc 125973', 'paclitaxel', 'asotax', 'nsc 673089', 'taxol']",correct_mapping
belotecan hydrochloride (IV),DNA topoisomerase I inhibitor,belotecan hydrochloride,,belotecan (injectable),belotecan hydrochloride,fexact,"['CKD 602', 'CKD-602 (injectable)', 'belotecan (injectable)', 'camptothecin analogs', 'belotecan', 'belotecan hydrochloride', 'Camtobell Inj', 'CRD-602']",belotecan (injectable),fexact,"['ckd 602', 'ckd 602 injectable', 'belotecan injectable', 'camptothecin analogs', 'belotecan', 'belotecan hydrochloride', 'camtobell inj', 'crd 602']",correct_mapping
cabozantinib (capsule),RET tyrosine kinase inhibitor; Axl receptor tyrosine kinase inhibitor; MET tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor,cabozantinib,,cabozantinib,cabozantinib,fexact,"['Cabometyx', 'XL-184', 'cabozantinib S-malate', 'BMS-907351', 'Cometriq', 'cabozantinib']",cabozantinib,fexact,"['cabometyx', 'xl 184', 'cabozantinib s malate', 'bms 907351', 'cometriq', 'cabozantinib']",correct_mapping
bendamustine,DNA inhibitor; Apoptosis stimulant,bendamustine,,bendamustine,bendamustine,fexact,"['Cytostasan', 'SDX-105', 'SyB L-0501', 'Benda', 'bendamustine', 'Inno-P08001', 'Treakisym', 'Innomustine', 'SyB L-0501RI', 'Treanda', 'bendamustine hydrochloride', 'Levact', 'Ribomustin', 'SyBL-0501', 'Ribovact', 'Symbenda']",bendamustine,fexact,"['cytostasan', 'sdx 105', 'syb l 0501', 'benda', 'bendamustine', 'inno p08001', 'treakisym', 'innomustine', 'syb l 0501ri', 'treanda', 'bendamustine hydrochloride', 'levact', 'ribomustin', 'sybl 0501', 'ribovact', 'symbenda']",correct_mapping
BIIB-022,Insulin-like growth factor 1 antagonist,BIIB-022,,BIIB-022,biib 022,fexact,"['Anti-IGF-1R', 'BIIB-022']",BIIB-022,fexact,"['anti igf 1r', 'biib 022']",correct_mapping
pictilisib,PI3 kinase alpha inhibitor; PI3 kinase beta inhibitor; PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor,pictilisib,,pictilisib,pictilisib,fexact,"['PI-103 series', 'PI3K inhibitors (immune-inflammation), PIramed', 'PI3K inhibitors (cancer), PIramed', 'PI-540', 'GNE-151', 'GNE-126', 'phosphatidyinositol-3-kinase inhibitors (cancer)', 'PI3K inhibitors, PIramed', 'GNE-380', 'PI-516', 'PI-509', 'PI3K inhibitors', 'GDC-0941', 'PI3Kalpha inhibitors,/', 'GNE-123', 'PI-620', 'RG-7321', 'PI-PFP', 'GNE-477', 'PI-103', 'GNE-390', 'GNE-493', 'PI3Kalpha inhibitors, PIramed/', 'PI-IM', 'pictrelisib', 'phosphatidyinositol-3-kinase inhibitors (cancer), PIramed', 'pictilisib', 'PI3Kalpha inhibitors, PIramed/Genentech', 'GNE-317', 'PI3K inhibitors (immune-inflammation)', 'PI3K inhibitors (cancer)', 'PI-103 series, PIramed']",pictilisib,fexact,"['pi 103 series', 'pi3k inhibitors immune inflammation piramed', 'pi3k inhibitors cancer piramed', 'pi 540', 'gne 151', 'gne 126', 'phosphatidyinositol 3 kinase inhibitors cancer', 'pi3k inhibitors piramed', 'gne 380', 'pi 516', 'pi 509', 'pi3k inhibitors', 'gdc 0941', 'pi3kalpha inhibitors', 'gne 123', 'pi 620', 'rg 7321', 'pi pfp', 'gne 477', 'pi 103', 'gne 390', 'gne 493', 'pi3kalpha inhibitors piramed', 'pi im', 'pictrelisib', 'phosphatidyinositol 3 kinase inhibitors cancer piramed', 'pictilisib', 'pi3kalpha inhibitors piramed genentech', 'gne 317', 'pi3k inhibitors immune inflammation', 'pi3k inhibitors cancer', 'pi 103 series piramed']",correct_mapping
fostamatinib disodium,Syk tyrosine kinase inhibitor,fostamatinib disodium,,fostamatinib disodium,fostamatinib disodium,fexact,"['R-788', 'R-935788', 'R-950091', 'Syk kinase inhibitors (rheumatoid arthritis)', 'Tavlesse', 'fostamatinib disodium hexahydrate', 'tamatinib fosdium', 'Tavalisse', 'R-091', 'fostamatinib disodium', 'R-935788 sodium', 'R-406', 'Syk kinase inhibitors (rheumatoid arthritis), Rigel', 'R-406/788', 'fostamatinib']",fostamatinib disodium,fexact,"['r 788', 'r 935788', 'r 950091', 'syk kinase inhibitors rheumatoid arthritis', 'tavlesse', 'fostamatinib disodium hexahydrate', 'tamatinib fosdium', 'tavalisse', 'r 091', 'fostamatinib disodium', 'r 935788 sodium', 'r 406', 'syk kinase inhibitors rheumatoid arthritis rigel', 'r 406 788', 'fostamatinib']",correct_mapping
enobosarm,Androgen receptor agonist; Selective androgen receptor modulator,enobosarm,,enobosarm,enobosarm,fexact,"['SARM (muscle-wasting), Merck & Co', 'selective androgen receptor modulator (muscle-wasting)', 'VERU-024', 'enobosarm', 'Ostarine', 'GTx-024', 'SARM (muscle-wasting)', 'S-22', 'selective androgen receptor modulator (muscle-wasting), Merck & Co', 'MK-2866']",enobosarm,fexact,"['sarm muscle wasting merck co', 'selective androgen receptor modulator muscle wasting', 'veru 024', 'enobosarm', 'ostarine', 'gtx 024', 'sarm muscle wasting', 's 22', 'selective androgen receptor modulator muscle wasting merck co', 'mk 2866']",correct_mapping
measles vaccine (live attenuated),Immunostimulant,measles vaccine,,,,0,['measles vaccine'],,Drug_API_mapping,[],0
DNA-transfected semi-allogeneic human fibroblasts (MRC-5),Immunostimulant,DNA-transfected semi-allogeneic human fibroblasts,,,,0,['DNA-transfected semi-allogeneic human fibroblasts'],,0,[],0
varenicline tartrate,Neuronal nicotinic receptor agonist,varenicline tartrate,,varenicline,varenicline tartrate,fexact,"['varenicline tartrate', 'CP-526555', 'Chantix', 'Champix', 'varenicline', 'CP 526555-18', 'KKM-164R', 'alpha4/beta2 nicotinic receptor partial agonist']",varenicline,fexact,"['varenicline tartrate', 'cp 526555', 'chantix', 'champix', 'varenicline', 'cp 526555 18', 'kkm 164r', 'alpha4 beta2 nicotinic receptor partial agonist']",correct_mapping
"nicotine (gum), unspecified",Nicotinic receptor agonist,nicotine,unspecified,nicotine,nicotine,fexact,"['nicotine transdermal, Warner', 'Nicorette inhaler', 'nicotine', 'nicotine transdermal', 'Nicorette', 'nicotine transdermal, Kabi', 'Nicotrol', 'Nicotrol inhaler']",nicotine,fexact,"['nicotine transdermal warner', 'nicorette inhaler', 'nicotine', 'nicotine transdermal', 'nicorette', 'nicotine transdermal kabi', 'nicotrol', 'nicotrol inhaler']",correct_mapping
teprotumumab,Insulin-like growth factor 1 antagonist,teprotumumab,,,,0,"['teprotumumab', 'teprotumumab + hyaluronidase (sc Enhanze, thyroid eye disease)', 'teprotumumab (sc Enhanze, thyroid eye disease)']",,NER_API,[],0
valproic acid,GABA receptor agonist; Voltage-gated sodium channel antagonist; Histone deacetylase inhibitor,valproic acid,,divalproex sodium (oral extended-release),valproic acid,fexact,"['Epilim Chronosphere', 'Deprakine', 'Depakine Chrono', 'Depakine', 'valproic acid (oral extended-release), Sanofi', 'Ergenyl', 'Depakote', 'valproate semisodium', 'ABT-711', 'valproic acid', 'Depakene', 'semisodium valproate', 'Micropakine', 'Epilim', 'Valproex', 'Depakote Chronosphere', 'divalproex sodium', 'Depakote ER', 'Epilim Chrono', 'Ergenyl Retard', 'Abbott-50711', 'Deprakote', 'Depakine Chronosphere', 'Epival', 'Depakote Sprinkle', 'Depacon', 'Deprakine Retard', 'divalproex sodium (oral extended-release), Sanofi', 'divalproex sodium (oral extended-release)', 'valproic acid (oral extended-release)', 'valcote', 'Depakon', 'Depakote Chrono']",divalproex sodium (oral extended-release),fexact,"['epilim chronosphere', 'deprakine', 'depakine chrono', 'depakine', 'valproic acid oral extended release sanofi', 'ergenyl', 'depakote', 'valproate semisodium', 'abt 711', 'valproic acid', 'depakene', 'semisodium valproate', 'micropakine', 'epilim', 'valproex', 'depakote chronosphere', 'divalproex sodium', 'depakote er', 'epilim chrono', 'ergenyl retard', 'abbott 50711', 'deprakote', 'depakine chronosphere', 'epival', 'depakote sprinkle', 'depacon', 'deprakine retard', 'divalproex sodium oral extended release sanofi', 'divalproex sodium oral extended release', 'valproic acid oral extended release', 'valcote', 'depakon', 'depakote chrono']",correct_mapping
dacarbazine,DNA inhibitor,dacarbazine,,,,0,['dacarbazine'],,0,[],0
melatonin (oral),Melatonin receptor agonist,melatonin,,,,0,"['Circadin', 'melatonin (controlled release, insomnia), Neurim', 'KI-1001', 'melatonin (controlled release, insomnia)', 'melatonin', 'melatonin (sustained/immediate release, sleep disorder)', 'Posidorm', 'KI-1001, Kuhnil', 'Circadin–Ped', 'NPC-15', 'Melatobel', 'PedPRM', 'Slenyto']",,Drug_API_mapping,[],0
vadimezan,Angiogenesis inhibitor,vadimezan,,vadimezan,vadimezan,fexact,"['ASA-404', 'R-1564', '5,6-dimethylxanthenone-4-acetic acid', '[14C]ASA-404', 'NSC-640488', 'vadimezan', '5,6-MeXAA', 'DMXAA', 'NSC-649488', 'AS-1404']",vadimezan,fexact,"['asa 404', 'r 1564', '5 6 dimethylxanthenone 4 acetic acid', '14c asa 404', 'nsc 640488', 'vadimezan', '5 6 mexaa', 'dmxaa', 'nsc 649488', 'as 1404']",correct_mapping
volociximab,Angiogenesis inhibitor; Alpha5beta1 integrin antagonist; Integrin antagonist,volociximab,,volociximab,volociximab,fexact,"['anti-AAB1 antibody, Protein Design Labs', 'M-200', 'anti-alpha-5/beta-1 integrin Ab (cancer), PDL', 'anti-AAB1 antibody (AMD), Ophthotech', 'Eos-200-4', 'anti-alpha-5/beta-1 integrin Ab (cancer), PDL/Biogen Idec', 'anti-AAB1 antibody, PDL/Biogen Idec', 'anti-alpha-5/beta-1 integrin Ab (cancer), Facet Biotech/Biogen Idec', 'anti-AAB1 antibody, Protein Design Labs/Biogen Idec', 'volociximab', 'anti-alpha-5/beta-1 integrin Ab (cancer)', 'anti-AAB1 antibody,/Biogen Idec', 'anti-AAB1 antibody (cancer), PDL', 'anti-AAB1 antibody (cancer)', 'anti-AAB1 antibody (cancer), EOS', 'anti-alpha-5/beta-1 integrin Ab (cancer),/Biogen Idec', 'anti-alpha-5/beta-1 integrin Ab (AMD), Ophthotech']",volociximab,fexact,"['anti aab1 antibody protein design labs', 'm 200', 'anti alpha 5 beta 1 integrin ab cancer pdl', 'anti aab1 antibody amd ophthotech', 'eos 200 4', 'anti alpha 5 beta 1 integrin ab cancer pdl biogen idec', 'anti aab1 antibody pdl biogen idec', 'anti alpha 5 beta 1 integrin ab cancer facet biotech biogen idec', 'anti aab1 antibody protein design labs biogen idec', 'volociximab', 'anti alpha 5 beta 1 integrin ab cancer', 'anti aab1 antibody biogen idec', 'anti aab1 antibody cancer pdl', 'anti aab1 antibody cancer', 'anti aab1 antibody cancer eos', 'anti alpha 5 beta 1 integrin ab cancer biogen idec', 'anti alpha 5 beta 1 integrin ab amd ophthotech']",correct_mapping
vorinostat (IV),Histone deacetylase inhibitor; Cell cycle inhibitor,vorinostat,,vorinostat (intravenous),vorinostat,fexact,"['MK-0683', 'L-001079038', 'MSK-390', 'suberanilohydroxamic acid (intravenous)', 'SAHA', 'suberoylanilide hydroxamic acid (intravenous)', 'SAHA (intravenous)', 'vorinostat (intravenous), Merck & Co', 'vorinostat', 'vorinostat (intravenous)', 'Suberoylanilide hydroxamic acid']",vorinostat (intravenous),fexact,"['mk 0683', 'l 001079038', 'msk 390', 'suberanilohydroxamic acid intravenous', 'saha', 'suberoylanilide hydroxamic acid intravenous', 'saha intravenous', 'vorinostat intravenous merck co', 'vorinostat', 'vorinostat intravenous', 'suberoylanilide hydroxamic acid']",correct_mapping
sirolimus (tablet),mTOR kinase inhibitor; Protein kinase inhibitor; T cell inhibitor; Cell cycle inhibitor,sirolimus,,"sirolimus (albumin-bound nanoparticle, cancer, intravenous)",sirolimus,fexact,"['sirolimus (albumin-bound nanoparticle, cancer, intravenous)', 'sirolimus (albumin-bound nanoparticle, cancer, intravenous), Celgene', 'Fyarro', 'rapamycin', 'sirolimus (albumin-bound nanoparticle, intravenous)', 'rapamycin (albumin-bound nanoparticle, intravenous)', 'ABI-009', 'nab-rapamycin', 'sirolimus (albumin-bound nanoparticle, intravenous), Abraxis', 'nab-Sirolimus', 'rapamycin (albumin-bound nanoparticle, intravenous), Abraxis', 'sirolimus', 'TARZIFYX']","sirolimus (albumin-bound nanoparticle, cancer, intravenous)",fexact,"['sirolimus albumin bound nanoparticle cancer intravenous', 'sirolimus albumin bound nanoparticle cancer intravenous celgene', 'fyarro', 'rapamycin', 'sirolimus albumin bound nanoparticle intravenous', 'rapamycin albumin bound nanoparticle intravenous', 'abi 009', 'nab rapamycin', 'sirolimus albumin bound nanoparticle intravenous abraxis', 'nab sirolimus', 'rapamycin albumin bound nanoparticle intravenous abraxis', 'sirolimus', 'tarzifyx']",correct_mapping
bupropion SR,Adrenergic transmitter uptake inhibitor; Norepinephrine/dopamine dual reuptake inhibitor,bupropion SR,,,,0,"['Elontril', 'bupropion (oral sustained release), GlaxoSmithKline', 'amfebutamone (oral sustained release)', 'amfebutamone (oral extended release), GlaxoSmithKline/', 'BW-323U', 'Zyban', 'bupropion hydrochloride', 'Wellbutrin', 'Wellbutrin Retard', '323U66', 'bupropion', 'amfebutamone (extended release)', 'bupropion (oral sustained release)', 'amfebutamone (oral extended release), GlaxoSmithKline/Biovail', 'bupropion SR', 'Voxra', 'bupropion (oral extended release), GlaxoSmithKline/Biovail', 'amfebutamone', 'bupropion XL', 'bupropion (extended release), GSK', 'bupropion (oral extended release), GlaxoSmithKline/', 'amfebutamone (oral extended release),/', 'Wellbutrin XR', 'amfebutamone (oral sustained release), GlaxoSmithKline', 'Wellbutrin SR', 'bupropion (oral extended release),/', 'Wellbutrin XL']",,Drug_API_mapping,[],0
"sodium selenite, Pharma Nord",Unidentified pharmacological activity,sodium selenite,Pharma Nord,"sodium selenite (oral, prostate cancer)",sodium selenite,fexact,"['sk-03014', 'selenious acid disodium salt', 'sodium selenite (oral, prostate cancer)', 'sodium selenite']","sodium selenite (oral, prostate cancer)",fexact,"['sk 03014', 'selenious acid disodium salt', 'sodium selenite oral prostate cancer', 'sodium selenite']",correct_mapping
ombrabulin,Angiogenesis inhibitor; Tubulin inhibitor; Apoptosis stimulant,ombrabulin,,ombrabulin,ombrabulin,fexact,"['AVE-8062A', 'combretastatin A4 analog,/sanofi-aventis', 'AC-7700', 'ombrabulin', 'AC-7739', 'RPR-258063', 'AVE-8062']",ombrabulin,fexact,"['ave 8062a', 'combretastatin a4 analog sanofi aventis', 'ac 7700', 'ombrabulin', 'ac 7739', 'rpr 258063', 'ave 8062']",correct_mapping
salirasib,Immunosuppressant; Ras inhibitor; mTOR kinase inhibitor; Protein kinase inhibitor; Cell cycle inhibitor,salirasib,,salirasib,salirasib,fexact,"['farnesylthiosalicyclic acid (oral, cancer)', 'Th-101', 'ONO-7056', 'FTS, Thyreos', 'trans-farnesylthiosalicylic acid', 'S-trans', 'farnesylthiosalicyclic acid', 'salirasib', 'FTS', 'FTS (oral, cancer),/', 'FTS (oral, cancer)', 'ras antagonists, Thyreos', 'KD-032', 'FTS (oral, cancer),/Ono', 'Ras-inhibitors (cancer)', 'ras antagonists']",salirasib,fexact,"['farnesylthiosalicyclic acid oral cancer', 'th 101', 'ono 7056', 'fts thyreos', 'trans farnesylthiosalicylic acid', 's trans', 'farnesylthiosalicyclic acid', 'salirasib', 'fts', 'fts oral cancer', 'fts oral cancer', 'ras antagonists thyreos', 'kd 032', 'fts oral cancer ono', 'ras inhibitors cancer', 'ras antagonists']",correct_mapping
selenomethionine,Unidentified pharmacological activity,selenomethionine,,,,0,['selenomethionine'],,0,[],0
XL-999,Fibroblast growth factor receptor 1 antagonist; Fibroblast growth factor receptor 3 antagonist; C-kit inhibitor; EGFR kinase inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor alpha kinase inhib; Platelet-derived growth factor receptor beta kinase inhib; Src inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,XL-999,,XL-999,xl 999,fexact,"['XL-999', 'EXEL-0999']",XL-999,fexact,"['xl 999', 'exel 0999']",correct_mapping
vincristine,Microtubule inhibitor; Vinca alkaloid,vincristine,,vincristine sulfate (liposomal injection),vincristine,fexact,"['VSLI, Inex', 'transmembrane carrier system (vincristine), Inex', 'vincristine sulfate liposomes for injection, Inex', 'vincristine sulfate (liposomal injection), Talon', 'vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals', 'vincristine sulfate', 'VSLI', 'vincristine sulfate liposomes for injection, Hana', 'vincristine sulfate (liposomal injection), Spectrum /', 'vincristine sulfate (liposomal injection, Optisome)', 'vincristine-TCS, Hana', 'vincristine sulfate (liposomal injection), Spectrum / CASI Pharmaceuticals', 'vincristine', 'vincristine sulfate (liposomal injection), Hana', 'transmembrane carrier system (vincristine)', 'vincristine sulfate (liposomal injection, Optisome), Inex', 'vincristine-TCS, Inex', 'vincristine sulfate (liposomal injection)', 'Marqibo', 'vincristine sulfate liposomes for injection', 'vincristine-TCS', 'Onco-TCS', 'transmembrane carrier system (vincristine), Hana', 'VSLI, Hana', 'vincristine sulfate (liposomal injection),/']",vincristine sulfate (liposomal injection),fexact,"['vsli inex', 'transmembrane carrier system vincristine inex', 'vincristine sulfate liposomes for injection inex', 'vincristine sulfate liposomal injection talon', 'vincristine sulfate liposomal injection spectrum pharmaceuticals', 'vincristine sulfate', 'vsli', 'vincristine sulfate liposomes for injection hana', 'vincristine sulfate liposomal injection spectrum', 'vincristine sulfate liposomal injection optisome', 'vincristine tcs hana', 'vincristine sulfate liposomal injection spectrum casi pharmaceuticals', 'vincristine', 'vincristine sulfate liposomal injection hana', 'transmembrane carrier system vincristine', 'vincristine sulfate liposomal injection optisome inex', 'vincristine tcs inex', 'vincristine sulfate liposomal injection', 'marqibo', 'vincristine sulfate liposomes for injection', 'vincristine tcs', 'onco tcs', 'transmembrane carrier system vincristine hana', 'vsli hana', 'vincristine sulfate liposomal injection']",correct_mapping
syngeneic gene-modified CD8 T cells,Immunostimulant,syngeneic gene-modified CD8 T cells,,,,0,['syngeneic gene-modified CD8 T cells'],,0,[],0
Detox-B,Immunostimulant,Detox-B,,,,0,['Detox-B'],,0,[],0
phenethyl isothiocyanate,Aldehyde dehydrogenase inhibitor,phenethyl isothiocyanate,,PEITC,phenethyl isothiocyanate,fexact,"['phenethyl-isothiocyanate', 'PEITC']",PEITC,fexact,"['phenethyl isothiocyanate', 'peitc']",correct_mapping
phosphorus P32,Unidentified pharmacological activity,phosphorus P32,,,,0,['phosphorus P32'],,0,[],0
imatinib mesilate,Bcr-Abl inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Apoptosis stimulant,imatinib mesilate,,imatinib,imatinib mesilate,fexact,"['Ruvise', 'QTI-517', 'Gleevec', 'CGP-57148B', 'Glivec', 'CGP-57148', 'Abl tyrosine protein kinase inhibitors', 'STI-571A', 'Abl tyrosine protein kinase inhibitors, Novartis', 'CGS-57148', 'imatinib mesylate', 'imatinib mesilate', 'QTI-571', 'STI-571', 'NSC-716051', 'imatinib']",imatinib,fexact,"['ruvise', 'qti 517', 'gleevec', 'cgp 57148b', 'glivec', 'cgp 57148', 'abl tyrosine protein kinase inhibitors', 'sti 571a', 'abl tyrosine protein kinase inhibitors novartis', 'cgs 57148', 'imatinib mesylate', 'imatinib mesilate', 'qti 571', 'sti 571', 'nsc 716051', 'imatinib']",correct_mapping
talactoferrin alfa (oral),Granulocyte macrophage colony stimulating factor agonist; Chelating agent; Immunostimulant; Cell wall synthesis inhibitor; Angiogenesis inhibitor; Reducing agent,talactoferrin alfa,,talactoferrin alfa,talactoferrin alfa,fexact,"['lactoferrin', 'talactoferrin alpha', 'Lactoferrin (human recombinant)', 'lactoferrin (NSCLC/nosocomial infection/renal cell carcinoma/sepsis)', 'talactoferrin alfa', 'talactoferrin', 'rhLF', 'rh lactoferrin']",talactoferrin alfa,fexact,"['lactoferrin', 'talactoferrin alpha', 'lactoferrin human recombinant', 'lactoferrin nsclc nosocomial infection renal cell carcinoma sepsis', 'talactoferrin alfa', 'talactoferrin', 'rhlf', 'rh lactoferrin']",correct_mapping
crenolanib,Flt-3 antagonist; Platelet-derived growth factor receptor alpha kinase inhib; Platelet-derived growth factor receptor beta kinase inhib; Angiogenesis inhibitor,crenolanib,,crenolanib,crenolanib,fexact,"['CP-868596-26', 'CP-868596', 'ARO-002', 'crenolanib besylate', 'crenolanib', 'plarotinib', 'PDGFR inhibitor (solid tumors)', 'PDGFR inhibitor (solid tumors), Pfizer']",crenolanib,fexact,"['cp 868596 26', 'cp 868596', 'aro 002', 'crenolanib besylate', 'crenolanib', 'plarotinib', 'pdgfr inhibitor solid tumors', 'pdgfr inhibitor solid tumors pfizer']",correct_mapping
Sm153 lexidronam,Chelating agent; DNA inhibitor; Radiopharmaceutical,Sm153 lexidronam,,,,0,['Sm153 lexidronam'],,0,[],0
strontium-89 chloride,DNA inhibitor; Radiopharmaceutical,strontium-89 chloride,,,,0,['strontium-89 chloride'],,0,[],0
seliciclib,Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor; Apoptosis stimulant,seliciclib,,seliciclib,seliciclib,fexact,"['CYC-202', 'CYC-200', 'CYC-204', '(R)-roscovitine', 'seliciclib', 'CYC-200 series', 'CYC-201', '(R)-roscovitine, Cyclacel', 'CDK inhibitors', 'NSC-701554', 'CDK inhibitors, Cyclacel', 'Roscovitine']",seliciclib,fexact,"['cyc 202', 'cyc 200', 'cyc 204', 'r roscovitine', 'seliciclib', 'cyc 200 series', 'cyc 201', 'r roscovitine cyclacel', 'cdk inhibitors', 'nsc 701554', 'cdk inhibitors cyclacel', 'roscovitine']",correct_mapping
tesevatinib,EGFR kinase inhibitor; EphB receptor kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Src inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor,tesevatinib,,tesevatinib,tesevatinib,fexact,"['tesevatinib (oral, NSCLC/prostate cancer/breast cancer/autosomal recessive and dormant polycystic kidney disease, glioblastoma)', 'XL-647', 'tesevatinib (oral, NSCLC/prostate cancer/breast cancer/autosomal recessive and dormant polycystic kidney disease)', 'tesevatinib', 'tesevatinib (oral, NSCLC/prostate cancer/breast cancer/autosomal recessive and dormant polycystic kidney disease, glioblastoma), Kadmon Pharmaceuticals', 'KD-019', 'EXEL-7647', 'tesevatinib (cancer), Kadmon Pharmaceuticals', 'tesevatinib (oral, NSCLC/prostate cancer/breast cancer/autosomal recessive and dormant polycystic kidney disease), Kadmon Pharmaceuticals', 'tesevatinib (cancer)', 'KD-020']",tesevatinib,fexact,"['tesevatinib oral nsclc prostate cancer breast cancer autosomal recessive and dormant polycystic kidney disease glioblastoma', 'xl 647', 'tesevatinib oral nsclc prostate cancer breast cancer autosomal recessive and dormant polycystic kidney disease', 'tesevatinib', 'tesevatinib oral nsclc prostate cancer breast cancer autosomal recessive and dormant polycystic kidney disease glioblastoma kadmon pharmaceuticals', 'kd 019', 'exel 7647', 'tesevatinib cancer kadmon pharmaceuticals', 'tesevatinib oral nsclc prostate cancer breast cancer autosomal recessive and dormant polycystic kidney disease kadmon pharmaceuticals', 'tesevatinib cancer', 'kd 020']",correct_mapping
antineoplaston A10 (IV),DNA inhibitor,antineoplaston A10,,"antineoplaston A-10, Burzynski Institute",antineoplaston a 10,fuzzy,"['atengenal', 'antineoplaston A-10', 'NSC-648539', 'antineoplaston A-10, Burzynski Institute']","antineoplaston A-10, Burzynski Institute",fexact,"['atengenal', 'antineoplaston a 10', 'nsc 648539', 'antineoplaston a 10 burzynski institute']",incorrect_mapping
antineoplaston AS2-1 (IV),DNA methylase inhibitor; Protein synthesis inhibitor,antineoplaston AS2-1,,"antineoplaston AS2-1, Burzynski Institute",antineoplaston as2 1,fexact,"['NSC-620621', 'antineoplaston AS2-1, Burzynski Institute', 'astugenal', 'antineoplaston AS2-1']","antineoplaston AS2-1, Burzynski Institute",fexact,"['nsc 620621', 'antineoplaston as2 1 burzynski institute', 'astugenal', 'antineoplaston as2 1']",correct_mapping
vatalanib,C-kit inhibitor; ErbB-4 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,vatalanib,,vatalanib,vatalanib,fexact,"['PTK/ZK, Novartis/', 'vatalanib', 'DE-00268', 'angiogenesis inhibitor, Novartis/', 'angiogenesis inhibitor,/', 'CGP-79787', 'VEGF-RKI', 'ZK-22584', 'VEGF-TK inhibitor,/', 'PTK/ZK', 'VEGR-TKI', 'CGP-79787D', 'pynasunate', 'VEGF-TK inhibitor, Novartis/', 'PTK/ZK,/', 'ZK-222584', 'finasunate', 'PTK-787A', 'PTK-787']",vatalanib,fexact,"['ptk zk novartis', 'vatalanib', 'de 00268', 'angiogenesis inhibitor novartis', 'angiogenesis inhibitor', 'cgp 79787', 'vegf rki', 'zk 22584', 'vegf tk inhibitor', 'ptk zk', 'vegr tki', 'cgp 79787d', 'pynasunate', 'vegf tk inhibitor novartis', 'ptk zk', 'zk 222584', 'finasunate', 'ptk 787a', 'ptk 787']",correct_mapping
sagopilone,Tubulin inhibitor; Microtubule stimulant,sagopilone,,sagopilone,sagopilone,fexact,"['DE-03757', 'ZK-epothilone', 'ZK-219477', 'BAY-86-5302', 'EPO-477', 'SH-Y-03757', 'SH-Y03757A', 'epothilone analogs', 'sagopilone', 'ZK-EPO', 'epothilone analogs, Schering AG']",sagopilone,fexact,"['de 03757', 'zk epothilone', 'zk 219477', 'bay 86 5302', 'epo 477', 'sh y 03757', 'sh y03757a', 'epothilone analogs', 'sagopilone', 'zk epo', 'epothilone analogs schering ag']",correct_mapping
"paclitaxel-DHA, Luitpold",Beta tubulin inhibitor; Microtubule stimulant; Omega 3 fatty acid stimulant; Taxane,paclitaxel-DHA,Luitpold,,,0,['paclitaxel-DHA'],,0,[],0
L9NC,DNA topoisomerase I inhibitor,L9NC,,L9NC,l9nc,fexact,"['9-Nitro-20(S)-camptothecin', 'L9NC', 'aerosolized liposomal 9 nitro-20 (S) camptothecin']",L9NC,fexact,"['9 nitro 20 s camptothecin', 'l9nc', 'aerosolized liposomal 9 nitro 20 s camptothecin']",correct_mapping
emepepimut-S,Immunostimulant,emepepimut-S,,emepepimut-S,emepepimut s,fexact,"['encapsulated MUC-1 peptide vaccine (cancer), Oncothyreon', 'BLP-25 liposome vaccine', 'BP-24', 'encapsulated MUC-1 peptide vaccine (cancer), Biomira', 'Stimuvax', 'ONO-7165', 'L-BLP-25', 'BLP-25', 'emepepimut-S', 'EMD 531444', 'tecemotide', '531444']",emepepimut-S,fexact,"['encapsulated muc 1 peptide vaccine cancer oncothyreon', 'blp 25 liposome vaccine', 'bp 24', 'encapsulated muc 1 peptide vaccine cancer biomira', 'stimuvax', 'ono 7165', 'l blp 25', 'blp 25', 'emepepimut s', 'emd 531444', 'tecemotide', '531444']",correct_mapping
L-Vax (intradermal),Immunostimulant,L-Vax,,LungVax,l vax,fexact,"['vaccine (myeloid leukemia)', 'L-Vax', 'AC vaccine (lung cancer),/University of Pennsylvania', 'LungVax']",LungVax,fexact,"['vaccine myeloid leukemia', 'l vax', 'ac vaccine lung cancer university of pennsylvania', 'lungvax']",correct_mapping
Exherin,Angiogenesis inhibitor; N-cadherin inhibitor,Exherin,,ADH-1,exherin,fexact,"['ADH-1', 'Exherin', 'peptide N-cadherin antagonist (cancer)', 'cadherin antagonist, Adherex', 'peptide N-cadherin antagonist (cancer), Shire Pharmaceuticals', 'peptide N-cadherin antagonist (cancer, intravenous/peptide), Adherex', 'peptide N-cadherin antagonist (cancer), BioChem Pharma']",ADH-1,fexact,"['adh 1', 'exherin', 'peptide n cadherin antagonist cancer', 'cadherin antagonist adherex', 'peptide n cadherin antagonist cancer shire pharmaceuticals', 'peptide n cadherin antagonist cancer intravenous peptide adherex', 'peptide n cadherin antagonist cancer biochem pharma']",correct_mapping
lomustine,DNA inhibitor; DNA synthesis inhibitor,lomustine,,,,0,['lomustine'],,0,[],0
ispinesib mesylate,Kinesin inhibitor,ispinesib mesylate,,ispinesib,ispinesib mesylate,fexact,"['715992', 'ispinesib mesylate', 'SB-715992', 'ispinesib', 'SB-715992S', 'CK-0238273']",ispinesib,fexact,"['715992', 'ispinesib mesylate', 'sb 715992', 'ispinesib', 'sb 715992s', 'ck 0238273']",correct_mapping
decitabine (IV),DNA methylase inhibitor,decitabine,,decitabine,decitabine,fexact,"['NSC-127716', 'IND-50733', '5-aza-CdR', ""5-aza-2'-deoxycytidine"", '5-aza-2-deoxycytidine', 'decitabine (intravenous, myelodysplastic syndromes/acute myeloid leukemia)', 'Dacogen', 'Dakogen', 'DAC', 'decitabine', 'E-7373', 'decitabine (intravenous, myelodysplastic syndromes/acute myeloid leukemia), Eisai', '5-CdR', '5-azadeoxycytidine', 'AZA-DC', 'JNJ-30979754']",decitabine,fexact,"['nsc 127716', 'ind 50733', '5 aza cdr', '5 aza 2 deoxycytidine', '5 aza 2 deoxycytidine', 'decitabine intravenous myelodysplastic syndromes acute myeloid leukemia', 'dacogen', 'dakogen', 'dac', 'decitabine', 'e 7373', 'decitabine intravenous myelodysplastic syndromes acute myeloid leukemia eisai', '5 cdr', '5 azadeoxycytidine', 'aza dc', 'jnj 30979754']",correct_mapping
"calcitriol, Transcept",Vitamin D agonist,calcitriol,Transcept,,,0,"['calcitriol', 'calcitriol (chemotherapy-induced alopecia), Cytotech Labs', 'API-31543', 'calcitriol (API-31543, drug-induced alopecia), Cytotech Labs', 'calcitriol (topical, chemotherapy-induced alopecia)', 'BPM-31543']",,NER_API,[],0
pralatrexate,Dihydrofolate reductase inhibitor,pralatrexate,,pralatrexate,pralatrexate,fexact,"['DHFR inhibitor (anticancer), Allos', 'Folotyn', 'pralatrexate', 'PDX', 'DHFR inhibitor (anticancer)', 'DHFR inhibitor (anticancer), Memorial Sloan-Kettering', 'PDX, Allos', '10-propargyl-10-deazaaminopterin', 'Difolta']",pralatrexate,fexact,"['dhfr inhibitor anticancer allos', 'folotyn', 'pralatrexate', 'pdx', 'dhfr inhibitor anticancer', 'dhfr inhibitor anticancer memorial sloan kettering', 'pdx allos', '10 propargyl 10 deazaaminopterin', 'difolta']",correct_mapping
marimastat,Matrix metalloproteinase inhibitor; Angiogenesis inhibitor,marimastat,,marimastat,marimastat,fexact,"['BB-2516', 'TA-2516', 'marimastat']",marimastat,fexact,"['bb 2516', 'ta 2516', 'marimastat']",correct_mapping
tucotuzumab celmoleukin,Interleukin 2 agonist; Interleukin 2 receptor agonist; Epithelial cell adhesion molecule inhibitor,tucotuzumab celmoleukin,,tucotuzumab celmoleukin,tucotuzumab celmoleukin,fexact,"['fusion protein-directed IL-2 therapy, Scripps/', 'EMD-273066', 'huKS1/4-IL-2', 'KS-IL-2', 'tucotuzumab celmoleukin', 'IL-2 fusion protein, Scripps/', 'hKS1/4-IL-2', 'huKS-IL-2']",tucotuzumab celmoleukin,fexact,"['fusion protein directed il 2 therapy scripps', 'emd 273066', 'huks1 4 il 2', 'ks il 2', 'tucotuzumab celmoleukin', 'il 2 fusion protein scripps', 'hks1 4 il 2', 'huks il 2']",correct_mapping
oltipraz,Membrane integrity inhibitor; Glutathione S transferase stimulant; Membrane permeability enhancer; Angiogenesis inhibitor,oltipraz,,oltipraz,oltipraz,fexact,"['RP-35972', 'oltipraz']",oltipraz,fexact,"['rp 35972', 'oltipraz']",correct_mapping
interleukin-12,Immunostimulant,interleukin-12,,pegilodecakin,interleukin 10,fuzzy,"['rHuIL-10', 'LY-3500518', 'interleukin-10, Schering-Plough', 'peg-IL-10', 'ilodecakin', 'IL-10, Schering-Plough', 'IL-10', 'PEGylated human IL-10', 'Tenovil', 'pegilodecakin', 'interleukin-10', 'Sch-52000', 'rHuIL-10, Schering-Plough', 'AM-0010']",pegilodecakin,fexact,"['rhuil 10', 'ly 3500518', 'interleukin 10 schering plough', 'peg il 10', 'ilodecakin', 'il 10 schering plough', 'il 10', 'pegylated human il 10', 'tenovil', 'pegilodecakin', 'interleukin 10', 'sch 52000', 'rhuil 10 schering plough', 'am 0010']",incorrect_mapping
Viscum album,Immunostimulant,Viscum album,,,,0,['Viscum album'],,0,[],0
pivaloyloxymethyl butyrate,Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,pivaloyloxymethyl butyrate,,AN-9,pivaloyloxymethyl butyrate,fexact,"['pivaloyloxymethyl butyrate', 'Pivanex', 'AN-9', 'Pivanex Injection']",AN-9,fexact,"['pivaloyloxymethyl butyrate', 'pivanex', 'an 9', 'pivanex injection']",correct_mapping
GVAX lung cancer vaccine,Granulocyte macrophage colony stimulating factor agonist; Immunostimulant,GVAX lung cancer vaccine,,,,0,['GVAX lung cancer vaccine'],,0,[],0
autologous dendritic cells,Immunostimulant,autologous dendritic cells,,,,0,['autologous dendritic cells'],,0,[],0
L-alanosine,Unidentified pharmacological activity,L-alanosine,,L-alanosine,l alanosine,fexact,"['SDX-102', 'L-alanosine', 'alanosine']",L-alanosine,fexact,"['sdx 102', 'l alanosine', 'alanosine']",correct_mapping
ortataxel (IV),Tubulin inhibitor; Microtubule stimulant; Taxane,ortataxel,,"ortataxel (intravenous, cancer)",ortataxel,fexact,"['ortataxel', 'SB-T-101144', 'BAY-59-8862', 'taxane analog (intravenous, anticancer)', 'IDN-5109', 'ortataxel (intravenous, cancer), Spectrum', 'ortataxel (intravenous, cancer)', 'SB-T-101141', 'SB-T-101131', 'IDN-5111', 'ortataxel (iv)', 'BAY-55-8862']","ortataxel (intravenous, cancer)",fexact,"['ortataxel', 'sb t 101144', 'bay 59 8862', 'taxane analog intravenous anticancer', 'idn 5109', 'ortataxel intravenous cancer spectrum', 'ortataxel intravenous cancer', 'sb t 101141', 'sb t 101131', 'idn 5111', 'ortataxel iv', 'bay 55 8862']",correct_mapping
amifostine (IV),Oxygen scavenger; Reducing agent; Free radical scavenger,amifostine,,amifostine,amifostine,fexact,"['WR-2721C', 'NSC-296961', 'WR-2721', 'Ethiofos', 'Gammaphos', 'YM-08310', 'amifostine', 'Ethyol']",amifostine,fexact,"['wr 2721c', 'nsc 296961', 'wr 2721', 'ethiofos', 'gammaphos', 'ym 08310', 'amifostine', 'ethyol']",correct_mapping
acridine carboxamide,DNA topoisomerase I inhibitor; DNA topoisomerase II inhibitor,acridine carboxamide,,,,0,['acridine carboxamide'],,0,[],0
batabulin sodium,Microtubule inhibitor; Beta tubulin inhibitor; Radiopharmaceutical,batabulin sodium,,,,0,['batabulin sodium'],,0,[],0
tacedinaline,Histone deacetylase inhibitor; Cell cycle inhibitor,tacedinaline,,tacedinaline,tacedinaline,fexact,"['PD-123654', 'PD-130636', 'N-acetyldinaline', 'acetyldinaline', 'CI-994', 'tacedinaline', 'Goe-5549']",tacedinaline,fexact,"['pd 123654', 'pd 130636', 'n acetyldinaline', 'acetyldinaline', 'ci 994', 'tacedinaline', 'goe 5549']",correct_mapping
ICON-2,Immuno-oncology therapy,ICON-2,,XB-002,icon 2,fexact,"['XB-002', 'anti-tissue factor monoclonal antibody-drug conjugate (ZymeLink ADC, solid tumors)', 'anti-tissue factor monoclonal antibody-drug conjugate (ZymeLink ADC, solid tumors), Iconic Therapeutics', 'anti-tissue factor monoclonal antibody-drug conjugate (ZymeLink ADC, solid tumors), Exelixis', 'ICON-2']",XB-002,fexact,"['xb 002', 'anti tissue factor monoclonal antibody drug conjugate zymelink adc solid tumors', 'anti tissue factor monoclonal antibody drug conjugate zymelink adc solid tumors iconic therapeutics', 'anti tissue factor monoclonal antibody drug conjugate zymelink adc solid tumors exelixis', 'icon 2']",correct_mapping
"autologous anti-PD-L1 armoured CD22-targeting CAR-T cells, Hebei Senlang Biotechnology",T cell stimulant; Immuno-oncology therapy; Immune checkpoint inhibitor,autologous anti-PD-L1 armoured CD22-targeting CAR-T cells,Hebei Senlang Biotechnology,,,0,['autologous anti-PD-L1 armoured CD22-targeting CAR-T cells'],,0,[],0
BI-764532,Unidentified pharmacological activity,BI-764532,,BI-764532,bi 764532,fexact,"['anti-CD3/anti-DLL3 bispecific T-cell engager (HLE-BiTE, small-cell lung cancer)', 'anti-CD3/anti-DLL3 BiTE (half-life extended, small-cell lung cancer)', 'BI-764532', 'anti-CD3/anti-DLL3 bispecific T-cell engager (small-cell lung cancer)', 'delta-like Ligand 3/CD3 IgG-like T cell engager (small-cell lung cancer)', 'anti-CD3/anti-DLL3 BiTE (small-cell lung cancer)']",BI-764532,fexact,"['anti cd3 anti dll3 bispecific t cell engager hle bite small cell lung cancer', 'anti cd3 anti dll3 bite half life extended small cell lung cancer', 'bi 764532', 'anti cd3 anti dll3 bispecific t cell engager small cell lung cancer', 'delta like ligand 3 cd3 igg like t cell engager small cell lung cancer', 'anti cd3 anti dll3 bite small cell lung cancer']",correct_mapping
"NeoTCR-P1 adoptive cell therapy, PACT Pharma",T cell stimulant; Immuno-oncology therapy; Genome editing,NeoTCR-P1 adoptive cell therapy,PACT Pharma,,,0,['NeoTCR-P1 adoptive cell therapy'],,0,[],0
ONM-100,Not applicable,ONM-100,,,,0,['ONM-100'],,0,[],0
"bupivacaine, DepoFoamdep",Sodium channel antagonist,bupivacaine,DepoFoamdep,bupivacaine,bupivacaine,fexact,"['DUR-843', 'Sensorcaine', 'bupivacaine, AstraZeneca', 'bupivacaine', 'Marcaine']",bupivacaine,fexact,"['dur 843', 'sensorcaine', 'bupivacaine astrazeneca', 'bupivacaine', 'marcaine']",correct_mapping
FT-516,Natural Killer T cell stimulant; Immuno-oncology therapy,FT-516,,FT-516,ft 516,fexact,"['hnCD16-expressing iPSC-derived NK cell therapy (cancer),/University of Minnesota', 'hnCD16-iNK', 'hncd16-expressing ipsc-derived nk cell therapy (cancer)', 'FT-516', 'allogeneic natural killer cell therapy (cancer)', 'ipsc-derived targeted immunotherapy (cancer/acute myelogenous leukemia/non-hodgkin lymphoma/multiple myeloma)', 'iPSC-derived targeted immunotherapy (cancer/acute myelogenous leukemia/non-hodgkin lymphoma/multiple myeloma),/University of Minnesota', 'allogeneic natural killer cell therapy (cancer),/ University of Minnesota']",FT-516,fexact,"['hncd16 expressing ipsc derived nk cell therapy cancer university of minnesota', 'hncd16 ink', 'hncd16 expressing ipsc derived nk cell therapy cancer', 'ft 516', 'allogeneic natural killer cell therapy cancer', 'ipsc derived targeted immunotherapy cancer acute myelogenous leukemia non hodgkin lymphoma multiple myeloma', 'ipsc derived targeted immunotherapy cancer acute myelogenous leukemia non hodgkin lymphoma multiple myeloma university of minnesota', 'allogeneic natural killer cell therapy cancer university of minnesota']",correct_mapping
omeprazole,H+ K+ transporting ATPase inhibitor,omeprazole,,omeprazole,omeprazole,fexact,"['Omeprazone', 'Omeprazon', 'Ulcid', 'Losec', 'Prilosec', 'Omepral', 'Mopral', 'Antra', 'omeprazole', 'Antra MUPS']",omeprazole,fexact,"['omeprazone', 'omeprazon', 'ulcid', 'losec', 'prilosec', 'omepral', 'mopral', 'antra', 'omeprazole', 'antra mups']",correct_mapping
177-Lu-DOTA-octreotate,Somatostatin receptor agonist; Radiopharmaceutical,177-Lu-DOTA-octreotate,,,,0,['177-Lu-DOTA-octreotate'],,0,[],0
fucoidan,Reducing agent,fucoidan,,,,0,['fucoidan'],,0,[],0
GEN-1029,TRAIL receptor 2 agonist,GEN-1029,,,,0,"['MR-009E', 'HexaBody-DR5', 'Hx-DR5-01/05', 'DR5-targeting mAb (HexaBody, cancer)', 'IDD-004', 'GEN-1029', 'HexaBody-DR5/DR5', 'Hx-DR5-01', 'Hx-DR5-05', 'benufutamab']",,NER_API,[],0
ADCT-502,ErbB-2 antagonist,ADCT-502,,,,0,"['engineered trastuzumab + pyrrolobenzodiazepine\xa0dimer cytotoxin (iv infusion, solid tumors)', 'ADCT-502', 'antibody drug conjugate (solid tumors)']",,NER_API,[],0
AVID-100,ErbB antagonist; Immunostimulant; Immuno-oncology therapy,AVID-100,,AVID-100,avid 100,fexact,"['AVID-100', 'ADC (EGFR modulator), Formation Biologics', 'antibody-drug conjugate (EGFR modulator), Formation Biologics', 'ADC (EGFR modulator), AvidBiologics', 'antibody-drug conjugate (EGFR modulator), AvidBiologics']",AVID-100,fexact,"['avid 100', 'adc egfr modulator formation biologics', 'antibody drug conjugate egfr modulator formation biologics', 'adc egfr modulator avidbiologics', 'antibody drug conjugate egfr modulator avidbiologics']",correct_mapping
PLB-1003,Anaplastic lymphoma kinase inhibitor,PLB-1003,,PLB-1003,plb 1003,fexact,"['ALK Inhibitor (oral capsule, non-small cell lung cancer)', 'PLB-1003']",PLB-1003,fexact,"['alk inhibitor oral capsule non small cell lung cancer', 'plb 1003']",correct_mapping
Zeushield cytotoxic T lymphocytes (Z-CTLs),Immuno-oncology therapy,Zeushield cytotoxic T lymphocytes,,,,0,['Zeushield cytotoxic T lymphocytes'],,0,[],0
rilotumumab,Hepatocyte growth factor receptor antagonist; MET tyrosine kinase inhibitor,rilotumumab,,rilotumumab,rilotumumab,fexact,"['AMG-102', 'antibody 2.12.1', 'rilotumumab', 'anti-HGF/SF monoclonal antibody (cancer)', 'NSC-750009']",rilotumumab,fexact,"['amg 102', 'antibody 2 12 1', 'rilotumumab', 'anti hgf sf monoclonal antibody cancer', 'nsc 750009']",correct_mapping
HDC-SN-38,DNA topoisomerase inhibitor; Heat shock protein 90 antagonist,HDC-SN-38,,PEN-866,hdc sn 38,fexact,"['STA-8666', 'Hsp90 inhibitor-SN-38 conjugate (cancer)', 'Hsp90 inhibitor-SN-38 conjugate (cancer), Synta', 'HDC SN-38', 'STA-12-8666', 'PEN-866']",PEN-866,fexact,"['sta 8666', 'hsp90 inhibitor sn 38 conjugate cancer', 'hsp90 inhibitor sn 38 conjugate cancer synta', 'hdc sn 38', 'sta 12 8666', 'pen 866']",correct_mapping
bosutinib,Abl receptor tyrosine kinase inhibitor; Bcr-Abl inhibitor; Src inhibitor; Apoptosis stimulant,bosutinib,,bosutinib,bosutinib,fexact,"['SKI-971', 'PF-05208763', 'PF-5208763', 'Src kinase inhibitors (oral)', 'Bcr-Abl kinase inhibitors, Wyeth', 'Src kinase inhibitors (oral), Wyeth', 'SKI-758', 'Bosulif', 'SKI-606', 'Boslif', 'SKI-015', 'Bcr-Abl kinase inhibitors, Pfizer', 'Bcr-Abl kinase inhibitors', 'Src kinase inhibitors (oral), Wyeth-Ayerst', 'Src kinase inhibitors (oral), Pfizer', 'bosutinib']",bosutinib,fexact,"['ski 971', 'pf 05208763', 'pf 5208763', 'src kinase inhibitors oral', 'bcr abl kinase inhibitors wyeth', 'src kinase inhibitors oral wyeth', 'ski 758', 'bosulif', 'ski 606', 'boslif', 'ski 015', 'bcr abl kinase inhibitors pfizer', 'bcr abl kinase inhibitors', 'src kinase inhibitors oral wyeth ayerst', 'src kinase inhibitors oral pfizer', 'bosutinib']",correct_mapping
BT-1718,Metalloproteinase-1 inhibitor; Immuno-oncology therapy,BT-1718,,BT-1718,bt 1718,fexact,"['bicyclic peptides (cancer)', 'BT-1718', 'bicycles program (peptide, cancer)', 'BTBCD-9', 'BDC-17', 'BDC-9']",BT-1718,fexact,"['bicyclic peptides cancer', 'bt 1718', 'bicycles program peptide cancer', 'btbcd 9', 'bdc 17', 'bdc 9']",correct_mapping
high activity natural killer immunotherapy,Immuno-oncology therapy,high activity natural killer immunotherapy,,,,0,['high activity natural killer immunotherapy'],,0,[],0
pimitespib,Heat shock protein 90 antagonist,pimitespib,,pimitespib,pimitespib,fexact,"['pimitespib', 'THS-1593', 'TAS-116', 'ATP-competitive Hsp90alpha/beta inhibitor (oral, gastrointestinal stromal tumor/advanced solid tumor)']",pimitespib,fexact,"['pimitespib', 'ths 1593', 'tas 116', 'atp competitive hsp90alpha beta inhibitor oral gastrointestinal stromal tumor advanced solid tumor']",correct_mapping
copper gluconate,Unidentified pharmacological activity,copper gluconate,,,,0,['copper gluconate'],,0,[],0
disulfiram,Aldehyde dehydrogenase inhibitor,disulfiram,,,,0,"['liposomal disulfiram (cataract), Pharmacia', 'liposomal disulfiram (cataract)', 'disulfiram, Pharmacia', 'disulfiram', 'disulfiram (liposome formulation)']",,NER_API,[],0
undisclosed - targeted therapy,Unidentified pharmacological activity,undisclosed - targeted therapy,,,,0,['undisclosed - targeted therapy'],,0,[],0
RGX-104,Liver X receptor agonist; Immuno-oncology therapy,RGX-104,,RGX-104,rgx 104,fexact,"['RGX-101', 'RGX-104']",RGX-104,fexact,"['rgx 101', 'rgx 104']",correct_mapping
merestinib,MET tyrosine kinase inhibitor,merestinib,,merestinib,merestinib,fexact,"['LY-2801653', 'merestinib', 'MET, RON, ROS1, AXL, MERTK, Tie2/TEK and MKNK1/2 inhibitor (cancer)', 'dual Axl checkpoint inhibitor/Mer checkpoint inhibitor (oral, cancer)']",merestinib,fexact,"['ly 2801653', 'merestinib', 'met ron ros1 axl mertk tie2 tek and mknk1 2 inhibitor cancer', 'dual axl checkpoint inhibitor mer checkpoint inhibitor oral cancer']",correct_mapping
"oncolytic measles virus, Vyriad",Immuno-oncology therapy,oncolytic measles virus,Vyriad,,,0,['oncolytic measles virus'],,0,[],0
LY-3295668,Aurora kinase inhibitor,LY-3295668,,LY-3295668 erbumine,ly 3295668,fexact,"['aur A kinase inhibitor (cancer)', 'solid tumor therapeutic, / eli lilly', 'aur A kinase inhibitor (cancer), Eli Lilly', 'solid tumor therapeutic,/', 'AK-01', 'aurora A inhibitor (Rb-deficient tumors)', 'AUR-A selective inhibitor (Rb-deficient tumors), Eli Lilly', 'aur A kin inh (cancer)', 'LY-3295668', 'aurora A inhibitor (Rb-deficient tumors), Eli Lilly', 'LY-3295668 erbumine', 'aur A kin inh (cancer), Eli Lilly', 'AUR-A selective inhibitor (Rb-deficient tumors)']",LY-3295668 erbumine,fexact,"['aur a kinase inhibitor cancer', 'solid tumor therapeutic eli lilly', 'aur a kinase inhibitor cancer eli lilly', 'solid tumor therapeutic', 'ak 01', 'aurora a inhibitor rb deficient tumors', 'aur a selective inhibitor rb deficient tumors eli lilly', 'aur a kin inh cancer', 'ly 3295668', 'aurora a inhibitor rb deficient tumors eli lilly', 'ly 3295668 erbumine', 'aur a kin inh cancer eli lilly', 'aur a selective inhibitor rb deficient tumors']",correct_mapping
KJgpc3-001,T cell stimulant; Immuno-oncology therapy,KJgpc3-001,,CSG-GPC3,kjgpc3 001,fexact,"['anti-GPC3 CAR T-cell therapy (HCC/LSCC)', 'KJgpc3-001', 'CSG-GPC3', 'CAR-GPC3 T-cells', 'genetically-modified chimeric antigen receptor-T cell therapy (hepatocellular carcinoma/lung cancer)', 'CT-0180', 'genetically-modified CAR T-cell therapy (hepatocellular carcinoma/lung cancer)']",CSG-GPC3,fexact,"['anti gpc3 car t cell therapy hcc lscc', 'kjgpc3 001', 'csg gpc3', 'car gpc3 t cells', 'genetically modified chimeric antigen receptor t cell therapy hepatocellular carcinoma lung cancer', 'ct 0180', 'genetically modified car t cell therapy hepatocellular carcinoma lung cancer']",correct_mapping
"Reishi mushroom extract, unspecified",Immunostimulant,Reishi mushroom extract,unspecified,,,0,['Reishi mushroom extract'],,0,[],0
"MUC1 CAR-pNK cell therapy, PersonGen Biomedicine",T cell stimulant; Immuno-oncology therapy,MUC1 CAR-pNK cell therapy,PersonGen Biomedicine,,,0,['MUC1 CAR-pNK cell therapy'],,0,[],0
bupivacaine,Sodium channel antagonist,bupivacaine,,bupivacaine,bupivacaine,fexact,"['DUR-843', 'Sensorcaine', 'bupivacaine, AstraZeneca', 'bupivacaine', 'Marcaine']",bupivacaine,fexact,"['dur 843', 'sensorcaine', 'bupivacaine astrazeneca', 'bupivacaine', 'marcaine']",correct_mapping
undisclosed - opioids,Opioid receptor agonist,undisclosed - opioids,,,,0,['undisclosed - opioids'],,0,[],0
isoflurane,Membrane permeability inhibitor; Membrane integrity inhibitor,isoflurane,,,,0,"['isoflurane (intravenous, anesthesia)', 'isoflurane']",,NER_API,[],0
ADC1013 (Intravenous),CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,ADC1013,,mitazalimab,adc 1013,fuzzy,"['immunotherapeutic (antibody, cancer) Alligator Bioscience/', 'JNJ-7107', 'CD40 costimulator (prostate tumor)', 'immunotherapeutic (antibody, cancer) Alligator Bioscience/BioInvent', 'JNJ-64457107', 'ADC-1013', 'mitazalimab', 'CD40 costimulator (prostate tumor), Janssen']",mitazalimab,fexact,"['immunotherapeutic antibody cancer alligator bioscience', 'jnj 7107', 'cd40 costimulator prostate tumor', 'immunotherapeutic antibody cancer alligator bioscience bioinvent', 'jnj 64457107', 'adc 1013', 'mitazalimab', 'cd40 costimulator prostate tumor janssen']",incorrect_mapping
"bevacizumab, Fujifilm Kyowa Kirin Biologics",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Fujifilm Kyowa Kirin Biologics,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
XingZaoRuanJian,Unidentified pharmacological activity,XingZaoRuanJian,,,,0,['XingZaoRuanJian'],,0,[],0
abiraterone (tablet),"Steroid synthesis inhibitor; 17,20 lyase inhibitor",abiraterone,,abiraterone,abiraterone,fexact,"['CB-7598', 'piraterone', 'abiraterone', 'abiraterone acetate', 'JNJ-212082', 'CB-7630', 'Zytiga', 'JNJ-589485']",abiraterone,fexact,"['cb 7598', 'piraterone', 'abiraterone', 'abiraterone acetate', 'jnj 212082', 'cb 7630', 'zytiga', 'jnj 589485']",correct_mapping
imaradenant,Adenosine A2a receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,imaradenant,,imaradenant,imaradenant,fexact,"['A2a receptor antagonist (cancer),/', 'AZD-4635', 'A2a receptor antagonist (cancer), Heptares/', 'A2a receptor antagonist (attention deficit hyperactivity disorder), Heptares', 'A2a receptor antagonist (Parkinsons disease), Shire', 'A2aR checkpoint inhibitor (solid tumor),/', 'A2aR checkpoint inhibitor (solid tumor), Heptares/', 'HTL-1071', 'A2a receptor antagonist (Parkinsons disease)', 'A2aR checkpoint inhibitor (solid tumor), Sosei Heptares/', 'A2a receptor antagonist (Parkinsons disease), Heptares', 'imaradenant', 'HTL-001071', 'A2a receptor antagonist (attention deficit hyperactivity disorder)']",imaradenant,fexact,"['a2a receptor antagonist cancer', 'azd 4635', 'a2a receptor antagonist cancer heptares', 'a2a receptor antagonist attention deficit hyperactivity disorder heptares', 'a2a receptor antagonist parkinsons disease shire', 'a2ar checkpoint inhibitor solid tumor', 'a2ar checkpoint inhibitor solid tumor heptares', 'htl 1071', 'a2a receptor antagonist parkinsons disease', 'a2ar checkpoint inhibitor solid tumor sosei heptares', 'a2a receptor antagonist parkinsons disease heptares', 'imaradenant', 'htl 001071', 'a2a receptor antagonist attention deficit hyperactivity disorder']",correct_mapping
"autologous tumour lysate-pulsed DC-CIK, Shenzhen Hornetcorn",Immunostimulant,autologous tumour lysate-pulsed DC-CIK,Shenzhen Hornetcorn,,,0,['autologous tumour lysate-pulsed DC-CIK'],,0,[],0
ABTL-0812,mTORC1 kinase inhibitor; mTORC2 kinase inhibitor; Protein kinase B inhibitor; PI3 kinase inhibitor,ABTL-0812,,ABTL-0812,abtl 0812,fexact,"['LP-10218', 'ABTL-0812', 'LP-182A1', 'sodium 2-hydroxylinoleic (oral, cancer)']",ABTL-0812,fexact,"['lp 10218', 'abtl 0812', 'lp 182a1', 'sodium 2 hydroxylinoleic oral cancer']",correct_mapping
selumetinib (tablet),Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,selumetinib,,selumetinib sulfate,selumetinib,fexact,"['MEK inhibitors (cancer)', 'MK-5618', 'selumetinib hyd-sulfate', 'neurodegenerative disease therapeutics', 'kinase inhibitors (cancer)', 'selumetinib sulfate', 'AZD-6244 hydrogen sulfate', 'NSC-748727', 'IND-77782', 'ARRY-886', 'AZD-6244', 'ARRY-142886', 'selumetinib', 'Koselugo', 'AZD-6244 hyd-sulfate']",selumetinib sulfate,fexact,"['mek inhibitors cancer', 'mk 5618', 'selumetinib hyd sulfate', 'neurodegenerative disease therapeutics', 'kinase inhibitors cancer', 'selumetinib sulfate', 'azd 6244 hydrogen sulfate', 'nsc 748727', 'ind 77782', 'arry 886', 'azd 6244', 'arry 142886', 'selumetinib', 'koselugo', 'azd 6244 hyd sulfate']",correct_mapping
azacitidine (oral),DNA synthesis inhibitor; DNA methylase inhibitor; RNA synthesis inhibitor,azacitidine,,"azacytidine (inhaled aerosol, lung cancer)",azacitidine,fexact,"['azacitidine', 'azacytidine (inhaled aerosol, lung cancer)', '5-azacytidine (inhaled aerosol, lung cancer)', '5-azacitidine']","azacytidine (inhaled aerosol, lung cancer)",fexact,"['azacitidine', 'azacytidine inhaled aerosol lung cancer', '5 azacytidine inhaled aerosol lung cancer', '5 azacitidine']",correct_mapping
onalespib,Heat shock protein 90 antagonist,onalespib,,onalespib,onalespib,fexact,"['AT-13387AU', 'onalespib lactate', 'AT-13387', 'Hsp 90 inhibitors (iv/infusion, cancer)', 'onalespib', 'AT-12128', 'AT13387A']",onalespib,fexact,"['at 13387au', 'onalespib lactate', 'at 13387', 'hsp 90 inhibitors iv infusion cancer', 'onalespib', 'at 12128', 'at13387a']",correct_mapping
axalimogene filolisbac,Immuno-oncology therapy,axalimogene filolisbac,,axalimogene filolisbac,axalimogene filolisbac,fexact,"['Lm-LLO-E7', 'Raligize', 'AXAL', 'axalimogene filolisbac', 'listeriolysin-O (LLO)/HPV-16 E7 antigen fusion (HPV)', 'ADXS-HPV', 'Lovaxin', 'ADXS11-001', 'HPV E7 cancer vaccine (Listeria vector)']",axalimogene filolisbac,fexact,"['lm llo e7', 'raligize', 'axal', 'axalimogene filolisbac', 'listeriolysin o llo hpv 16 e7 antigen fusion hpv', 'adxs hpv', 'lovaxin', 'adxs11 001', 'hpv e7 cancer vaccine listeria vector']",correct_mapping
ALT-803 (IV),Interleukin 15 agonist; Immuno-oncology therapy,ALT-803,,nogapendekin alfa,alt 803,fexact,"['modified human IL-15 (malaria)', 'nogapendekin alfa', 'N-803', 'Anktiva', 'ALT-803', 'IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer)']",nogapendekin alfa,fexact,"['modified human il 15 malaria', 'nogapendekin alfa', 'n 803', 'anktiva', 'alt 803', 'il 15 agonist il 15r alpha fc fusion complex cancer']",correct_mapping
navitoclax,Bcl2 inhibitor; Apoptosis stimulant; Bcl-XL inhibitor,navitoclax,,navitoclax,navitoclax,fexact,"['cancer therapeutics (Bcl-2/Bcl-xL inhibitors)', 'Bax modulators (anticancer), Idun/', 'Bax modulators (anticancer),/', 'ABT-263', 'A-438744', 'A-371191', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors),/Idun', 'navitoclax dihydrochloride', 'Bcl-2/Bcl-xL inhibitors (anticancer),/Idun', 'RG-7433', 'Bcl-2/Bcl-xL inhibitors (anticancer), Abbott/Idun', 'Bax modulators (anticancer), Idun/Abbott', 'Bcl-2/Bcl-xL inhibitors (anticancer),/', 'Bcl-2/Bcl-xL inhibitors (anticancer)', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors),/', 'navitoclax', 'A-385358', 'Bax modulators (anticancer, oral), Abbott', 'Bax modulators (anticancer, oral)', 'A-855071.0', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott/Idun', 'A-317267', 'Bcl-2/Bcl-xL inhibitors (anticancer), Abbott', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott']",navitoclax,fexact,"['cancer therapeutics bcl 2 bcl xl inhibitors', 'bax modulators anticancer idun', 'bax modulators anticancer', 'abt 263', 'a 438744', 'a 371191', 'cancer therapeutics bcl 2 bcl xl inhibitors idun', 'navitoclax dihydrochloride', 'bcl 2 bcl xl inhibitors anticancer idun', 'rg 7433', 'bcl 2 bcl xl inhibitors anticancer abbott idun', 'bax modulators anticancer idun abbott', 'bcl 2 bcl xl inhibitors anticancer', 'bcl 2 bcl xl inhibitors anticancer', 'cancer therapeutics bcl 2 bcl xl inhibitors', 'navitoclax', 'a 385358', 'bax modulators anticancer oral abbott', 'bax modulators anticancer oral', 'a 855071 0', 'cancer therapeutics bcl 2 bcl xl inhibitors abbott idun', 'a 317267', 'bcl 2 bcl xl inhibitors anticancer abbott', 'cancer therapeutics bcl 2 bcl xl inhibitors abbott']",correct_mapping
clarithromycin,Protein 50S ribosomal subunit inhibitor,clarithromycin,,clarithromycin,clarithromycin,fexact,"['Biaxin', 'antibiotic A-56268', 'Velcam', 'Macladin', 'Zaclar', 'acladin', 'Cyllind', 'Klacid SR', 'Klaricid XL', 'Kofron', 'Claricid', 'Klacid LA', 'clarithromycin', 'TE-031', 'Clarith', 'A-56268', 'Biclar', 'antibiotic TE-31', 'Klacid', 'Klaricid']",clarithromycin,fexact,"['biaxin', 'antibiotic a 56268', 'velcam', 'macladin', 'zaclar', 'acladin', 'cyllind', 'klacid sr', 'klaricid xl', 'kofron', 'claricid', 'klacid la', 'clarithromycin', 'te 031', 'clarith', 'a 56268', 'biclar', 'antibiotic te 31', 'klacid', 'klaricid']",correct_mapping
treosulfan,DNA inhibitor,treosulfan,,treosulfan,treosulfan,fexact,"['Ovastat', 'Trecondi', 'treosulfan', 'Trecondyv', 'NSC-39069', 'Treograft']",treosulfan,fexact,"['ovastat', 'trecondi', 'treosulfan', 'trecondyv', 'nsc 39069', 'treograft']",correct_mapping
"CD40LGVAX vaccine, Cellular Biomedicine Group",Granulocyte colony stimulating factor agonist; CD40 ligand agonist; T cell stimulant; Immuno-oncology therapy,CD40LGVAX vaccine,Cellular Biomedicine Group,,,0,['CD40LGVAX vaccine'],,0,[],0
leramilimab,Lymphocyte-activation gene 3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,leramilimab,,LAG-525,ieramilimab,fuzzy,"['anti-membrane bound LAG-3 monoclonal antibody (ImmuTune, cancer/infectious disease)', 'LAG-3 checkpoint inhibitor (cancer)', 'LAG-525', 'ieramilimab', 'anti-membrane bound LAG-3 monoclonal antibody (ImmuTune, cancer/infectious disease), Immutep', 'IMP-701', 'LAG-3 checkpoint inhibitor (cancer), Novartis', 'anti-LAG-3 antibody (cancer), Novartis', 'anti-LAG-3 antibody (cancer)']",LAG-525,fexact,"['anti membrane bound lag 3 monoclonal antibody immutune cancer infectious disease', 'lag 3 checkpoint inhibitor cancer', 'lag 525', 'ieramilimab', 'anti membrane bound lag 3 monoclonal antibody immutune cancer infectious disease immutep', 'imp 701', 'lag 3 checkpoint inhibitor cancer novartis', 'anti lag 3 antibody cancer novartis', 'anti lag 3 antibody cancer']",incorrect_mapping
acalabrutinib,Bruton tyrosine kinase inhibitor,acalabrutinib,,acalabrutinib,acalabrutinib,fexact,"['acalabrutinib', 'acalabrutinib maleate', 'Benzamide', 'Calquence', 'ACP-196', 'ACP-5862']",acalabrutinib,fexact,"['acalabrutinib', 'acalabrutinib maleate', 'benzamide', 'calquence', 'acp 196', 'acp 5862']",correct_mapping
SAR-125844,MET tyrosine kinase inhibitor,SAR-125844,,SAR-125844,sar 125844,fexact,"['SAR-125844', 'met inhibitor (iv, cancer), sanofi-aventis']",SAR-125844,fexact,"['sar 125844', 'met inhibitor iv cancer sanofi aventis']",correct_mapping
MGCD-265 (tablet),Flt-3 antagonist; MET tyrosine kinase inhibitor; TIE-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Macrophage stimulating protein 1 receptor antagonist; Angiogenesis inhibitor,MGCD-265,,glesatinib glycolate,mgcd 265,fexact,"['multikinase inhibitors (cancer)', 'glesatinib glycolate', 'glesatinib', 'MGCD-265']",glesatinib glycolate,fexact,"['multikinase inhibitors cancer', 'glesatinib glycolate', 'glesatinib', 'mgcd 265']",correct_mapping
S-588410,Immunostimulant,S-588410,,S-588410,s 588410,fexact,"['asudemotide', 'S-488403', 'S-588410', 'peptide vaccine (bladder cancer)', 'S-488410', 'peptide vaccine (lung/ esophagael cancer), Shionogi', 'peptide vaccine (lung/ esophagael cancer)', 'S-488402', 'peptide vaccine (bladder cancer), Shionogi', 'peptide vaccine (lung/ esophagael cancer/gastric cancer)', 'S-288310', 'S-488401']",S-588410,fexact,"['asudemotide', 's 488403', 's 588410', 'peptide vaccine bladder cancer', 's 488410', 'peptide vaccine lung esophagael cancer shionogi', 'peptide vaccine lung esophagael cancer', 's 488402', 'peptide vaccine bladder cancer shionogi', 'peptide vaccine lung esophagael cancer gastric cancer', 's 288310', 's 488401']",correct_mapping
autologous ex vivo-expanded NK cell-enriched lymphocytes,Immunostimulant,autologous ex vivo-expanded NK cell-enriched lymphocytes,,,,0,['autologous ex vivo-expanded NK cell-enriched lymphocytes'],,0,[],0
mavelertinib,EGFR kinase inhibitor,mavelertinib,,mavelertinib,mavelertinib,fexact,"['mavelertinib', 'PF-6459988', 'epidermal growth factor receptor (EGFR) T790M inhibitor (NSCLC)', 'PF-06747775', 'PF-7775']",mavelertinib,fexact,"['mavelertinib', 'pf 6459988', 'epidermal growth factor receptor egfr t790m inhibitor nsclc', 'pf 06747775', 'pf 7775']",correct_mapping
"irinotecan, unspecified",DNA topoisomerase I inhibitor,irinotecan,unspecified,irinotecan,irinotecan,fexact,"['Camptothecin 11 hydrochloride', 'DQ-2805', 'camptothecin II', 'irinotecan hydrochloride hydrate', 'camptothecin II hydrochloride', 'Topotecin', 'NSC-616348', 'irinotecan', 'camptothecin', 'camptothecin  hydrochloride', 'Camptothecin 11', 'Campto', 'irinotecan hydrochloride', 'Camptosar']",irinotecan,fexact,"['camptothecin 11 hydrochloride', 'dq 2805', 'camptothecin ii', 'irinotecan hydrochloride hydrate', 'camptothecin ii hydrochloride', 'topotecin', 'nsc 616348', 'irinotecan', 'camptothecin', 'camptothecin hydrochloride', 'camptothecin 11', 'campto', 'irinotecan hydrochloride', 'camptosar']",correct_mapping
pepinemab,Semaphorin antagonist; Immuno-oncology therapy,pepinemab,,pepinemab,pepinemab,fexact,"['anti-semaphorin 4D monoclonal antibody (autoimmune disease/cancer), Vaccinex', 'anti-SEMA4D antibody, Vaccinex', 'plexin B1 antagonist (autoimmune disease/cancer), Vaccinex', 'anti-semaphorin 4D monoclonal antibody (autoimmune disease/cancer)', 'plexin B1 antagonist (autoimmune disease/cancer)', 'anti-SEMA4D antibody', 'VX-15', 'anti-CD100 MAb (autoimmune disease/cancer)', 'anti-CD100 MAb (autoimmune disease/cancer), Vaccinex', 'VX-15/2503', 'pepinemab']",pepinemab,fexact,"['anti semaphorin 4d monoclonal antibody autoimmune disease cancer vaccinex', 'anti sema4d antibody vaccinex', 'plexin b1 antagonist autoimmune disease cancer vaccinex', 'anti semaphorin 4d monoclonal antibody autoimmune disease cancer', 'plexin b1 antagonist autoimmune disease cancer', 'anti sema4d antibody', 'vx 15', 'anti cd100 mab autoimmune disease cancer', 'anti cd100 mab autoimmune disease cancer vaccinex', 'vx 15 2503', 'pepinemab']",correct_mapping
18F Flotegatide,Unidentified pharmacological activity,18F Flotegatide,,flotegatide (18F),18f flotegatide,fexact,"['flotegatide (18F)', 'SMIBR-K5-[18F]', 'cyclic triazole bearing RGD peptide integrin alpha-v beta-3 imaging agent (cancer)', 'RGD-K5-[18F]', 'fluorine-18-flotegatide', 'fluorine-18-SMIBR-K5', '18F-flotegatide', '18F-RGD-K5', '18F-SMIBR-K5', 'SMIBR-K5']",flotegatide (18F),fexact,"['flotegatide 18f', 'smibr k5 18f', 'cyclic triazole bearing rgd peptide integrin alpha v beta 3 imaging agent cancer', 'rgd k5 18f', 'fluorine 18 flotegatide', 'fluorine 18 smibr k5', '18f flotegatide', '18f rgd k5', '18f smibr k5', 'smibr k5']",correct_mapping
ibrutinib (capsule),Bruton tyrosine kinase inhibitor,ibrutinib,,ibrutinib,ibrutinib,fexact,"['Btk inhibitor (cancer), Pharmacyclics/', 'JNJ-54179060', 'Yi Ke', 'PCI-32765', 'Btk inhibitors (autoimmune disease, lymphoma), Pharmacyclics', 'Btk inhibitors (autoimmune disease, lymphoma)', 'B-cell associated tyrosine kinase inhibitors (lymphoma, autoimmune disease)', 'B-cell-associated tyrosine kinase inhibitors (lymphoma, autoimmune disease)', 'PCI-45261', 'CRA-032765', 'Imbruvica', 'B-cell-associated tyrosine kinase inhibitor (cancer),/', 'B-cell-associated tyrosine kinase inhibitor (cancer), Pharmacyclics/', 'Btk inhibitor (cancer), Pharmacyclics/Janssen Biotech', 'B-cell-associated tyrosine kinase inhibitors (lymphoma, autoimmune disease), Celera', 'B-cell associated tyrosine kinase inhibitors (lymphoma, autoimmune disease), Pharmacyclics', 'ibrutinib', 'B-cell-associated tyrosine kinase inhibitor (cancer), Pharmacyclics/Janssen Biotech', 'PCI-31523', 'Btk inhibitor (cancer),/']",ibrutinib,fexact,"['btk inhibitor cancer pharmacyclics', 'jnj 54179060', 'yi ke', 'pci 32765', 'btk inhibitors autoimmune disease lymphoma pharmacyclics', 'btk inhibitors autoimmune disease lymphoma', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease', 'pci 45261', 'cra 032765', 'imbruvica', 'b cell associated tyrosine kinase inhibitor cancer', 'b cell associated tyrosine kinase inhibitor cancer pharmacyclics', 'btk inhibitor cancer pharmacyclics janssen biotech', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease celera', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease pharmacyclics', 'ibrutinib', 'b cell associated tyrosine kinase inhibitor cancer pharmacyclics janssen biotech', 'pci 31523', 'btk inhibitor cancer']",correct_mapping
amifostine,Oxygen scavenger; Reducing agent; Free radical scavenger,amifostine,,amifostine,amifostine,fexact,"['WR-2721C', 'NSC-296961', 'WR-2721', 'Ethiofos', 'Gammaphos', 'YM-08310', 'amifostine', 'Ethyol']",amifostine,fexact,"['wr 2721c', 'nsc 296961', 'wr 2721', 'ethiofos', 'gammaphos', 'ym 08310', 'amifostine', 'ethyol']",correct_mapping
captopril,Angiotensin I converting enzyme inhibitor,captopril,,captopril,captopril,fexact,"['captopril', 'Lopril']",captopril,fexact,"['captopril', 'lopril']",correct_mapping
tetracycline,Protein 30S ribosomal subunit inhibitor,tetracycline,,,,0,"['Pylera', 'biskalcitrate + metronidazole + tetracycline hydrochloride', 'biskalcitrate potassium + metronidazole + tetracycline HCl (H pylori infection),/ NewBridge/ NovaMedica', 'bismuth citrate + metronidazole + tetracycline', 'Helizide', 'biskalcitrate potassium + metronidazole + tetracycline hydrochloride (H pylori infection),/ NewBridge', 'biskalcitrate potassium + metronidazole + tetracycline hcl (h pylori infection)', 'Helicide', 'H pylori combination therapy, Axcan', 'bismuth subcitrate potassium', 'biskalcitrate potassium + metronidazole + tetracycline hydrochloride (H pylori infection)', 'biskalcitrate potassium + metronidazole + tetracycline HCl (H pylori infection),// NovaMedica', 'tetracycline', 'bismuth subcitrate potassium +  metronidazole + tetracycline hydrochloride', 'bismuth citrate + metronidazole + tetracycline (H pylori infection), Axcan', 'biskalcitrate potassium + metronidazole + tetracycline hydrochloride (H pylori infection),/', 'biskalcitrate potassium + metronidazole + tetracycline hydrochloride (H pylori infection), Axcan']",,NER_API,[],0
recombinant human thrombopoietin (rhTPO),Unidentified pharmacological activity,recombinant human thrombopoietin,,epoetin beta,recombinant human erythropoietin,fuzzy,"['Epogin', 'recombinant human erythropoietin, Chugai', 'erythropoietin, Genetics Institute//', 'Marogen', 'rHuEPO, Genetics Inst//', 'erythropoietin, Genetics Institute//Roche', 'epoetin beta, Roche', 'NeoRecormon', 'recombinant human erythropoietin', 'Recormon', 'epoetin beta, Genetics Inst//', 'EPOCH', 'erythropoietin, Genetics Institute/Chugai/Roche', 'RO-2053859', 'rHuEPO, Genetics Inst/Chugai/', 'epoetin beta, Genetics Inst/Chugai/', 'epoetin beta', 'Epogin Subcutaneous Injection Syringe 24000']",epoetin beta,fexact,"['epogin', 'recombinant human erythropoietin chugai', 'erythropoietin genetics institute', 'marogen', 'rhuepo genetics inst', 'erythropoietin genetics institute roche', 'epoetin beta roche', 'neorecormon', 'recombinant human erythropoietin', 'recormon', 'epoetin beta genetics inst', 'epoch', 'erythropoietin genetics institute chugai roche', 'ro 2053859', 'rhuepo genetics inst chugai', 'epoetin beta genetics inst chugai', 'epoetin beta', 'epogin subcutaneous injection syringe 24000']",incorrect_mapping
"hydroxycarbamide, NCI",Ribonucleoside triphosphate reductase inhibitor,hydroxycarbamide,NCI,"hydroxycarbamide (sickle cell anemia, thrombocythemia, polycythemia), BMS",hydroxycarbamide,fexact,"['Hydrea', 'Hydura', 'hydroxyurea, BMS', 'Biosuppressin', 'Hydreia', 'Litalir', 'hydroxyurea', 'SQ-1089', 'hydroxycarbamide (sickle cell anemia, thrombocythemia, polycythemia), BMS', 'hydroxycarbamide', 'Onco-carbide', 'Droxia', 'Hidrix', 'NSC-32065']","hydroxycarbamide (sickle cell anemia, thrombocythemia, polycythemia), BMS",fexact,"['hydrea', 'hydura', 'hydroxyurea bms', 'biosuppressin', 'hydreia', 'litalir', 'hydroxyurea', 'sq 1089', 'hydroxycarbamide sickle cell anemia thrombocythemia polycythemia bms', 'hydroxycarbamide', 'onco carbide', 'droxia', 'hidrix', 'nsc 32065']",correct_mapping
roniciclib (tablet),Cyclin-dependent kinase inhibitor,roniciclib,,roniciclib,roniciclib,fexact,"['cyclin-dependent kinase inhibitors (anticancer)', 'BAY-1000394', 'CDK inhibitors (anticancer)', 'BAY-80-3000', 'roniciclib']",roniciclib,fexact,"['cyclin dependent kinase inhibitors anticancer', 'bay 1000394', 'cdk inhibitors anticancer', 'bay 80 3000', 'roniciclib']",correct_mapping
auranofin,Immunosuppressant; Prostaglandin synthase inhibitor; Disease modifying antirheumatic drug,auranofin,,,,0,"['auranofin', 'repurposed auranofin (ovarian cancer)']",,NER_API,[],0
rociletinib (tablet),EGFR kinase inhibitor,rociletinib,,rociletinib,rociletinib,fexact,"['790M mutant-targeting, non-small-cell lung cancer), Celgene/', 'EMSI (oral, T790M mutant-targeting, NSCLC),/Clovis Oncology', 'Xegafri', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC),/', 'rociletinib', 'rociletinib hydrobromide', 'AVL-301', 'EGFR mutant-selective inhibitor (tablet, NSCLC), Celgene/', 'epidermal growth factor receptor mutant-selective inhibitor (oral, T790M mutant-targeting, non-small-cell lung cancer),/Clovis Oncology', 'rociletinib (T790M-mutation-targeting, NSCLC), Clovis', 'EMSI (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Celgene/', 'EMSI (oral, T790M mutant-targeting, NSCLC),/', 'CO-1686', 'rociletinib (T790M-mutation-targeting, NSCLC)', 'CNX-419', '790M mutant-targeting, non-small-cell lung cancer), Celgene/Clovis Oncology', 'EMSI (oral, T790M mutant-targeting, NSCLC), Celgene/', 'EGFR mutant-selective inhibitor (tablet, NSCLC), Celgene/Clovis Oncology', 'epidermal growth factor receptor mutant-selective inhibitor (oral, T790M mutant-targeting, non-small-cell lung cancer),/', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC),/Clovis Oncology']",rociletinib,fexact,"['790m mutant targeting non small cell lung cancer celgene', 'emsi oral t790m mutant targeting nsclc clovis oncology', 'xegafri', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc', 'rociletinib', 'rociletinib hydrobromide', 'avl 301', 'egfr mutant selective inhibitor tablet nsclc celgene', 'epidermal growth factor receptor mutant selective inhibitor oral t790m mutant targeting non small cell lung cancer clovis oncology', 'rociletinib t790m mutation targeting nsclc clovis', 'emsi oral t790m mutant targeting nsclc celgene clovis oncology', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc celgene clovis oncology', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc celgene', 'emsi oral t790m mutant targeting nsclc', 'co 1686', 'rociletinib t790m mutation targeting nsclc', 'cnx 419', '790m mutant targeting non small cell lung cancer celgene clovis oncology', 'emsi oral t790m mutant targeting nsclc celgene', 'egfr mutant selective inhibitor tablet nsclc celgene clovis oncology', 'epidermal growth factor receptor mutant selective inhibitor oral t790m mutant targeting non small cell lung cancer', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc clovis oncology']",correct_mapping
ruxolitinib (oral),Janus kinase 1 inhibitor; Janus kinase 2 inhibitor,ruxolitinib,,"ruxolitinib (sustained release, myelofibrosis)",ruxolitinib,fexact,"['ruxolitinib', 'INCB-018424', 'ruxolitinib (sustained release, myelofibrosis)']","ruxolitinib (sustained release, myelofibrosis)",fexact,"['ruxolitinib', 'incb 018424', 'ruxolitinib sustained release myelofibrosis']",correct_mapping
antroquinonol,Ras inhibitor,antroquinonol,,antroquinonol,antroquinonol,fexact,"['GHCovid-2-001', 'antroquinonol', 'GHAML-2-001', 'fungal extract (cancer)', 'fungal extract (cancer), Golden Biotechnology', 'Hocena']",antroquinonol,fexact,"['ghcovid 2 001', 'antroquinonol', 'ghaml 2 001', 'fungal extract cancer', 'fungal extract cancer golden biotechnology', 'hocena']",correct_mapping
onartuzumab,Hepatocyte growth factor receptor antagonist,onartuzumab,,onartuzumab,onartuzumab,fexact,"['HGF/c-Met antagonist', 'RG-3638', '5D5 Fab (cancer)', 'HGF/c-Met antagonist, Genentech', 'RO-5490258', '5D5 Fab (cancer), Genentech', 'PRO-143966', 'MetMAb', 'onartuzumab']",onartuzumab,fexact,"['hgf c met antagonist', 'rg 3638', '5d5 fab cancer', 'hgf c met antagonist genentech', 'ro 5490258', '5d5 fab cancer genentech', 'pro 143966', 'metmab', 'onartuzumab']",correct_mapping
G-305,Toll-like receptor 4 agonist,G-305,,G-305,g 305,fexact,"['ID-G305', 'NY-ESO-1 protein + GLA-SE', 'GLA-SE + melanoma antigens (cancer)', 'G-305', 'IDC-G305', 'GLA-SE + NY-ESO-1 protein', 'therapeutic vaccine (GLA adjuvanted, cancer)', 'baloramotide']",G-305,fexact,"['id g305', 'ny eso 1 protein gla se', 'gla se melanoma antigens cancer', 'g 305', 'idc g305', 'gla se ny eso 1 protein', 'therapeutic vaccine gla adjuvanted cancer', 'baloramotide']",correct_mapping
lucanthone,DNA topoisomerase II inhibitor; Apurinic/apyrimidinic endonuclease 1 inhibitor,lucanthone,,lucanthone,lucanthone,fexact,"['lucanthone hydrochloride', 'lucanthone']",lucanthone,fexact,"['lucanthone hydrochloride', 'lucanthone']",correct_mapping
bemcentinib,Axl receptor tyrosine kinase inhibitor,bemcentinib,,bemcentinib,bemcentinib,fexact,"['R-428', 'Axl receptor tyrosine kinase inhibitors (cancer)', 'BGB-324', 'bemcentinib', 'Axl receptor tyrosine kinase inhibitor (cancer)', 'Axl checkpoint inhibitor (oral, cancer)']",bemcentinib,fexact,"['r 428', 'axl receptor tyrosine kinase inhibitors cancer', 'bgb 324', 'bemcentinib', 'axl receptor tyrosine kinase inhibitor cancer', 'axl checkpoint inhibitor oral cancer']",correct_mapping
lifastuzumab vedotin,Unidentified pharmacological activity,lifastuzumab vedotin,,lifastuzumab vedotin,lifastuzumab vedotin,fexact,"['anti-NaPi2b antibody-MMAE conjugate', 'RG-7599', 'anti-NaPi2b antibody-cytotoxic agent conjugate (ovarian cancer/NSCLC)', 'anti-NaPi2b antibody-vedotin conjugate', 'lifastuzumab vedotin', 'antibody-drug conjugate (NSCLC/ovarian cancer)', 'DNIB-0600A']",lifastuzumab vedotin,fexact,"['anti napi2b antibody mmae conjugate', 'rg 7599', 'anti napi2b antibody cytotoxic agent conjugate ovarian cancer nsclc', 'anti napi2b antibody vedotin conjugate', 'lifastuzumab vedotin', 'antibody drug conjugate nsclc ovarian cancer', 'dnib 0600a']",correct_mapping
"NY-ESO-1 T cell therapy, Kite Pharma",Immunostimulant; T cell stimulant; Immuno-oncology therapy,NY-ESO-1 T cell therapy,Kite Pharma,,,0,['NY-ESO-1 T cell therapy'],,0,[],0
vantictumab,Wnt pathway inhibitor,vantictumab,,vantictumab,vantictumab,fexact,"['Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals', 'OMP-18R5', 'Wnt inhibitors (mAb, cancer)', 'vantictumab', 'frizzled-7 receptor targeted mAb (cancer), Oncomed/', 'frizzled-7 receptor targeted mAb (cancer),/']",vantictumab,fexact,"['wnt inhibitors mab cancer oncomed pharmaceuticals', 'omp 18r5', 'wnt inhibitors mab cancer', 'vantictumab', 'frizzled 7 receptor targeted mab cancer oncomed', 'frizzled 7 receptor targeted mab cancer']",correct_mapping
soy isoflavones,Isoflavone agonist,soy isoflavones,,,,0,['soy isoflavones'],,0,[],0
CDCA1 peptide,Immunostimulant,CDCA1 peptide,,,,0,['CDCA1 peptide'],,0,[],0
KIF20A peptide,Immunostimulant,KIF20A peptide,,,,0,['KIF20A peptide'],,0,[],0
PF-06263507,Tubulin polymerization inhibitor,PF-06263507,,PF-06263507,pf 06263507,fexact,['PF-06263507'],PF-06263507,fexact,['pf 06263507'],correct_mapping
apatorsen (IV),Heat shock protein 27 antagonist,apatorsen,,apatorsen sodium,apatorsen,fexact,"['OGX-427', 'apatorsen', 'apatorsen sodium', 'Hsp27 inhibitors (cancer), OncoGenex', 'Hsp27 inhibitors (cancer)']",apatorsen sodium,fexact,"['ogx 427', 'apatorsen', 'apatorsen sodium', 'hsp27 inhibitors cancer oncogenex', 'hsp27 inhibitors cancer']",correct_mapping
temoporfin,Radical formation stimulant,temoporfin,,temoporfin,temoporfin,fexact,"['EF-9', 'Foscan', 'm-THPC', 'temoporfin', 'KW-2345']",temoporfin,fexact,"['ef 9', 'foscan', 'm thpc', 'temoporfin', 'kw 2345']",correct_mapping
"quinacrine, Cleveland",DNA inhibitor; Acetylcholinesterase inhibitor; mTOR kinase inhibitor; Protein kinase B inhibitor; Transcription factor NF-kappaB inhibitor; Apoptosis stimulant; p53 stimulant; PI3 kinase inhibitor,quinacrine,Cleveland,,,0,"['mepacrine (oral, liver/prostate cancer), Incuron', 'mepacrine (Ebola infection/Marburg infection)', 'curaxin CBLC-102', 'CBLC-101', 'mepacrine (oral, cancer),/Incuron', 'mepacrine (oral, cancer),/', 'quinacrine', 'mepacrine (oral, liver/prostate cancer)', 'CBL0-102', 'CBLC-102', 'mepacrine', 'quinacrine (Ebola infection/Marburg infection)']",,Drug_API_mapping,[],0
MRX-01,MicroRNA stimulant,MRX-01,,MRX-34,mrx 01,fexact,"['MiR-Rx34', 'MRX-34', 'miR-34a mimetic (lung cancer)', 'MRX-01']",MRX-34,fexact,"['mir rx34', 'mrx 34', 'mir 34a mimetic lung cancer', 'mrx 01']",correct_mapping
alternative medicine,Unidentified pharmacological activity,alternative medicine,,,,0,['alternative medicine'],,0,[],0
"bevacizumab, Biocad",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Biocad,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
"itraconazole, Mayne Pharma",Cell wall synthesis inhibitor; Sterol demethylase inhibitor,itraconazole,Mayne Pharma,itraconazole,itraconazole,fexact,"['Itorizoru', 'Oromyc', 'Itranax', 'R-51211', 'Orungal', 'Sempera', 'Itrizole Injection 1%', 'Sporanox', 'JK-1211', 'Sporal', 'Itrizole', 'itraconazole', 'Intiazol', 'Itrizol', 'oriconazole']",itraconazole,fexact,"['itorizoru', 'oromyc', 'itranax', 'r 51211', 'orungal', 'sempera', 'itrizole injection 1', 'sporanox', 'jk 1211', 'sporal', 'itrizole', 'itraconazole', 'intiazol', 'itrizol', 'oriconazole']",correct_mapping
depatuxizumab mafodotin,Immuno-oncology therapy,depatuxizumab mafodotin,,depatuxizumab mafodotin,depatuxizumab mafodotin,fexact,"['EGFR-ADC (cancer), Abbott', 'EGFR antibody-drug conjugate (cancer), Abbott', 'EGFR-ADC (cancer)', 'Depatux-M', 'EGFR antibody-drug conjugate (cancer)', 'ABBV-414', 'ABT-806-MMAF conjugate', 'andepatuzumab mafodotin', 'ABT-414', 'anti-EGFR antibody-MMAF conjugate', 'depatuxizumab mafodotin']",depatuxizumab mafodotin,fexact,"['egfr adc cancer abbott', 'egfr antibody drug conjugate cancer abbott', 'egfr adc cancer', 'depatux m', 'egfr antibody drug conjugate cancer', 'abbv 414', 'abt 806 mmaf conjugate', 'andepatuzumab mafodotin', 'abt 414', 'anti egfr antibody mmaf conjugate', 'depatuxizumab mafodotin']",correct_mapping
interleukin-15,Interleukin 15 agonist,interleukin-15,,pegilodecakin,interleukin 10,fuzzy,"['rHuIL-10', 'LY-3500518', 'interleukin-10, Schering-Plough', 'peg-IL-10', 'ilodecakin', 'IL-10, Schering-Plough', 'IL-10', 'PEGylated human IL-10', 'Tenovil', 'pegilodecakin', 'interleukin-10', 'Sch-52000', 'rHuIL-10, Schering-Plough', 'AM-0010']",pegilodecakin,fexact,"['rhuil 10', 'ly 3500518', 'interleukin 10 schering plough', 'peg il 10', 'ilodecakin', 'il 10 schering plough', 'il 10', 'pegylated human il 10', 'tenovil', 'pegilodecakin', 'interleukin 10', 'sch 52000', 'rhuil 10 schering plough', 'am 0010']",incorrect_mapping
"interferon alpha-2b, unspecified",Interferon receptor agonist,interferon alpha-2b,unspecified,interferon alfa-2b,interferon alpha 2b,fexact,"['Virtron', 'Intron A', 'interferon alpha-2b', 'interferon alfa-2b', 'Intron', 'Viraferon', 'Alfatronol']",interferon alfa-2b,fexact,"['virtron', 'intron a', 'interferon alpha 2b', 'interferon alfa 2b', 'intron', 'viraferon', 'alfatronol']",correct_mapping
Gendicine,p53 stimulant,Gendicine,,Gendicine,gendicine,fexact,"['rAd-p53', 'adenoviral gene therapy (cancer)', 'Genkaxin', 'adenoviral gene therapy (p53)', 'Gendicine']",Gendicine,fexact,"['rad p53', 'adenoviral gene therapy cancer', 'genkaxin', 'adenoviral gene therapy p53', 'gendicine']",correct_mapping
roniciclib,Cyclin-dependent kinase inhibitor,roniciclib,,roniciclib,roniciclib,fexact,"['cyclin-dependent kinase inhibitors (anticancer)', 'BAY-1000394', 'CDK inhibitors (anticancer)', 'BAY-80-3000', 'roniciclib']",roniciclib,fexact,"['cyclin dependent kinase inhibitors anticancer', 'bay 1000394', 'cdk inhibitors anticancer', 'bay 80 3000', 'roniciclib']",correct_mapping
CUDC-305,Heat shock protein 90 antagonist,CUDC-305,,CTXT-102,cudc 305,fexact,"['CUDC-0303', 'CU-0305', 'CUDC-305', 'CTXT-102', 'HDAC/Hsp 90 inhibitors (cancer/CNS)', 'HDAC/Hsp 90 inhibitors (cancer/CNS), Debiopharm', 'Debio-0932']",CTXT-102,fexact,"['cudc 0303', 'cu 0305', 'cudc 305', 'ctxt 102', 'hdac hsp 90 inhibitors cancer cns', 'hdac hsp 90 inhibitors cancer cns debiopharm', 'debio 0932']",correct_mapping
DKN-01,DKK-1 inhibitor; Immuno-oncology therapy,DKN-01,,DKN-01,dkn 01,fexact,"['anti-Dkk1 mAb (multiple myeloma/cancer/bone fractures),/Dekkun Corp', 'DKN-01', 'Mab B3 (anti-Dickkopf-1 chimeric mAb, bone disease/cancer), Eli Lilly', 'LY-2812176', 'biological therapy (cancer) 1, Eli Lilly', 'anti-Dkk1 mAb (multiple myeloma/cancer/bone fractures), Eli Lilly/Dekkun Corp', 'biological therapy (cancer) 1', 'Mab B3 (anti-Dickkopf-1 chimeric mAb, bone disease/cancer)']",DKN-01,fexact,"['anti dkk1 mab multiple myeloma cancer bone fractures dekkun corp', 'dkn 01', 'mab b3 anti dickkopf 1 chimeric mab bone disease cancer eli lilly', 'ly 2812176', 'biological therapy cancer 1 eli lilly', 'anti dkk1 mab multiple myeloma cancer bone fractures eli lilly dekkun corp', 'biological therapy cancer 1', 'mab b3 anti dickkopf 1 chimeric mab bone disease cancer']",correct_mapping
alpelisib,PI3 kinase alpha inhibitor,alpelisib,,alpelisib,alpelisib,fexact,"['PI3K-alpha inhibitor (cancer)', 'Piqray', 'BYL-719', 'alpelisib', 'NVP-BYL719', 'phosphoinositide 3-kinase alpha inhibitor (cancer)']",alpelisib,fexact,"['pi3k alpha inhibitor cancer', 'piqray', 'byl 719', 'alpelisib', 'nvp byl719', 'phosphoinositide 3 kinase alpha inhibitor cancer']",correct_mapping
CCL21 expressing tumor cells,T cell stimulant; Chemokine ligand agonist,CCL21 expressing tumor cells,,,,0,['CCL21 expressing tumor cells'],,0,[],0
Pentostatin,Adenosine deaminase inhibitor,Pentostatin,,pentostatin,pentostatin,fexact,"['pentostatin, GvH disease', 'NSC-218321', 'pentostatin', 'PD-81565', 'CI-825', 'pentostatin, rheumatoid arthritis', 'Nipent']",pentostatin,fexact,"['pentostatin gvh disease', 'nsc 218321', 'pentostatin', 'pd 81565', 'ci 825', 'pentostatin rheumatoid arthritis', 'nipent']",correct_mapping
SS1(dsFV)-PE38,Protein synthesis inhibitor; Translation elongation factor 2 inhibitor,SS1-PE38,,SS (dsFv) PE38 immunotoxin,ss1 pe38,fexact,"['SS1P, Enzon/NCI', 'SS1-PE38', 'SS (dsFv) PE38 immunotoxin, NCI', 'SS1P,/NCI', 'SS1(dsFv)-PE38', 'SS (dsFv) PE38 immunotoxin', 'SS1P,/', 'CAT-5001']",SS (dsFv) PE38 immunotoxin,fexact,"['ss1p enzon nci', 'ss1 pe38', 'ss dsfv pe38 immunotoxin nci', 'ss1p nci', 'ss1 dsfv pe38', 'ss dsfv pe38 immunotoxin', 'ss1p', 'cat 5001']",correct_mapping
parsatuzumab,EGFL7 inhibitor,parsatuzumab,,parsatuzumab,parsatuzumab,fexact,"['anticancer agent (iv, cancer), Genentech', 'anti-EGFL7 fully humanized monoclonal antibody (cancer)', 'parsatuzumab', 'anticancer agent (iv, cancer)', 'RO-5490248', 'anti-EGFL7 fully humanized monoclonal antibody (cancer), Genentech', 'RG-7414', 'MEGF-0444A']",parsatuzumab,fexact,"['anticancer agent iv cancer genentech', 'anti egfl7 fully humanized monoclonal antibody cancer', 'parsatuzumab', 'anticancer agent iv cancer', 'ro 5490248', 'anti egfl7 fully humanized monoclonal antibody cancer genentech', 'rg 7414', 'megf 0444a']",correct_mapping
TNX-832,Factor III inhibitor,TNX-832,,ALT-836,tnx 832,fexact,"['tissue factor monoclonals (cardiovascular disease)', 'TNX-832', 'tissue factor monoclonals (cardiovascular disease), Sunol', 'tissue factor antagonist antibodies (ARDS/ALI), Genentech/', 'Sunol-cH36', 'IgG4 antibody (cardiovascular disease)', 'TF antagonist antibodies (ARDS/ALI),/', 'ALT-836', 'tissue factor antagonist antibodies (ARDS/ALI),/', 'IgG4 antibody (cardiovascular disease), Sunol', 'Factor X binding inhibitor', 'Factor  binding inhibitor', 'tissue factor antagonist antibodies (acute respiratory distress syndrome/acute lung injury), Genentech/', 'TF antagonist antibodies (ARDS/ALI), Genentech/', 'TF antagonist antibodies (acute respiratory distress syndrome/acute lung injury),/', 'tissue factor antagonist antibodies (acute respiratory distress syndrome/acute lung injury),/', 'Factor X binding inhibitor, Sunol', 'TF antagonist antibodies (acute respiratory distress syndrome/acute lung injury), Genentech/']",ALT-836,fexact,"['tissue factor monoclonals cardiovascular disease', 'tnx 832', 'tissue factor monoclonals cardiovascular disease sunol', 'tissue factor antagonist antibodies ards ali genentech', 'sunol ch36', 'igg4 antibody cardiovascular disease', 'tf antagonist antibodies ards ali', 'alt 836', 'tissue factor antagonist antibodies ards ali', 'igg4 antibody cardiovascular disease sunol', 'factor x binding inhibitor', 'factor binding inhibitor', 'tissue factor antagonist antibodies acute respiratory distress syndrome acute lung injury genentech', 'tf antagonist antibodies ards ali genentech', 'tf antagonist antibodies acute respiratory distress syndrome acute lung injury', 'tissue factor antagonist antibodies acute respiratory distress syndrome acute lung injury', 'factor x binding inhibitor sunol', 'tf antagonist antibodies acute respiratory distress syndrome acute lung injury genentech']",correct_mapping
tovetumab,Platelet-derived growth factor alpha receptor antagonist; Platelet-derived growth factor receptor alpha kinase inhib,tovetumab,,tovetumab,tovetumab,fexact,"['anti-PDGFR-alpha modulators (iv infusion, cancer)', 'platelet derived growth factor receptor alpha modulators (cancer)', 'tovetumab', 'MEDI-575']",tovetumab,fexact,"['anti pdgfr alpha modulators iv infusion cancer', 'platelet derived growth factor receptor alpha modulators cancer', 'tovetumab', 'medi 575']",correct_mapping
LY-2275796,Translation initiation factor 4E inhibitor; Angiogenesis inhibitor,LY-2275796,,ISIS-EIF4ERx,ly 2275796,fexact,"['eIF-4E-targeting antisense oligonucleotide (cancer)', 'LY-2275796', 'ISIS-183750', 'ISIS-EIF4ERx', 'eIF-4E-targeting antisense oligonucleotides (cancer),/Isis', 'eIF-4E ASO (cancer),/Isis']",ISIS-EIF4ERx,fexact,"['eif 4e targeting antisense oligonucleotide cancer', 'ly 2275796', 'isis 183750', 'isis eif4erx', 'eif 4e targeting antisense oligonucleotides cancer isis', 'eif 4e aso cancer isis']",correct_mapping
Lu-177-labeled IMP-288,Not applicable,Lu-177-labeled IMP-288,,,,0,['Lu-177-labeled IMP-288'],,0,[],0
TF2,Unidentified pharmacological activity,TF2,,,,0,['TF2'],,0,[],0
patritumab,ErbB-3 antagonist,patritumab,,patritumab,patritumab,fexact,"['anti-Her-3 human monoclonal antibody (epithelial-derived cancers), U3 Pharma/', 'U3-1287', 'anti-Her-3 human monoclonal antibody (epithelial-derived cancers),/', 'AMG-888', 'anti-Her-3 human monoclonal antibody (epithelial-derived cancers), U3 Pharma/Amgen', 'patritumab']",patritumab,fexact,"['anti her 3 human monoclonal antibody epithelial derived cancers u3 pharma', 'u3 1287', 'anti her 3 human monoclonal antibody epithelial derived cancers', 'amg 888', 'anti her 3 human monoclonal antibody epithelial derived cancers u3 pharma amgen', 'patritumab']",correct_mapping
"nitroglycerin (transdermal), unspecified",Guanylate cyclase stimulant; Nitric oxide stimulant,nitroglycerin,unspecified,nitroglycerin (transdermal),nitroglycerin,fexact,"['Transderm-Nitro', 'nitroglycerin (transdermal)', 'nitroglycerin', 'NITRODERM']",nitroglycerin (transdermal),fexact,"['transderm nitro', 'nitroglycerin transdermal', 'nitroglycerin', 'nitroderm']",correct_mapping
rabusertib,Checkpoint kinase 1 inhibitor,rabusertib,,rabusertib,rabusertib,fexact,"['cell cycle checkpoint/DNA repair antagonists,/Oregon Health', 'cell cycle regulator,/Oregon Health', 'lead Chk-1 inhibitor (cancer), Eli Lilly', 'cell cycle checkpoint/DNA repair antagonists, Eli Lilly/Oregon Health', 'cell cycle checkpoint/DNA repair antagonists, ICOS/Oregon Health', 'IC-83', 'cell cycle regulator, ICOS/Oregon Health', 'Atr gene inhibitors,/Oregon Health', 'lead Chk-1 inhibitor (cancer)', 'Atr gene inhibitors, ICOS/Oregon Health', 'rabusertib', 'LY-2603618']",rabusertib,fexact,"['cell cycle checkpoint dna repair antagonists oregon health', 'cell cycle regulator oregon health', 'lead chk 1 inhibitor cancer eli lilly', 'cell cycle checkpoint dna repair antagonists eli lilly oregon health', 'cell cycle checkpoint dna repair antagonists icos oregon health', 'ic 83', 'cell cycle regulator icos oregon health', 'atr gene inhibitors oregon health', 'lead chk 1 inhibitor cancer', 'atr gene inhibitors icos oregon health', 'rabusertib', 'ly 2603618']",correct_mapping
radretumab,DNA inhibitor; Radiopharmaceutical,radretumab,,,,0,['radretumab'],,0,[],0
Montanide ISA-51,Immunostimulant,Montanide ISA-51,,,,0,['Montanide ISA-51'],,0,[],0
AZD-1480,Janus kinase 2 inhibitor,AZD-1480,,AZD-1480,azd 1480,fexact,"['Jak tyrosine kinase inhibitors (cancer)', 'AZD-1480']",AZD-1480,fexact,"['jak tyrosine kinase inhibitors cancer', 'azd 1480']",correct_mapping
gadopentetic acid,Not applicable,gadopentetic acid,,,,0,['gadopentetic acid'],,0,[],0
tigatuzumab,TRAIL receptor 2 agonist; Apoptosis stimulant,tigatuzumab,,tigatuzumab,tigatuzumab,fexact,"['TRA-8', 'CS-1008', 'tigatuzumab', 'R-161460', 'DR5 mAb']",tigatuzumab,fexact,"['tra 8', 'cs 1008', 'tigatuzumab', 'r 161460', 'dr5 mab']",correct_mapping
padeliporfin,Radical formation stimulant,padeliporfin,,padeliporfin potassium,padeliporfin,fexact,"['padeliporfin photodynamic therapy (age-related macular degeneration/cancer), Weizmann Institute', 'palladium-bacteriopheophorbide monolysine taurine', 'padeliporfin ImPACT', 'padeliporfin', 'Tookad', 'padeliporfin photodynamic therapy (age-related macular degeneration/cancer)', 'Pd-bacteriopheophorbide monolysine taurine', 'Stakel', 'Tookad (Soluble)', 'padeliporfin di-potassium', 'WST-11', 'padeliporfin potassium']",padeliporfin potassium,fexact,"['padeliporfin photodynamic therapy age related macular degeneration cancer weizmann institute', 'palladium bacteriopheophorbide monolysine taurine', 'padeliporfin impact', 'padeliporfin', 'tookad', 'padeliporfin photodynamic therapy age related macular degeneration cancer', 'pd bacteriopheophorbide monolysine taurine', 'stakel', 'tookad soluble', 'padeliporfin di potassium', 'wst 11', 'padeliporfin potassium']",correct_mapping
crizotinib (tablet),Anaplastic lymphoma kinase inhibitor; MET tyrosine kinase inhibitor,crizotinib,,crizotinib,crizotinib,fexact,"['Xalkori', 'PF-2341066', 'crizotinib', 'PF-1066', 'PF-02341066', 'NSC-749005']",crizotinib,fexact,"['xalkori', 'pf 2341066', 'crizotinib', 'pf 1066', 'pf 02341066', 'nsc 749005']",correct_mapping
enoxaparin (SC),Indirect Factor Xa inhibitor; Indirect thrombin inhibitor; Heparin stimulant,enoxaparin,,,,0,"['low molecular weight heparin (patch, thrombosis)', 'enoxaparin', 'Kalbenox', 'LMW heparin (patch, thrombosis)', 'Kalparin', 'enoxaparin follow-on biologic', 'low-molecular-weight heparin (inhalant, COVID-19)', 'enoxaparin (patch, thrombosis)', 'enoxaparin (inhalant, COVID-19)']",,Drug_API_mapping,[],0
vismodegib (oral),Angiogenesis inhibitor; Hedgehog pathway inhibitor,vismodegib,,vismodegib,vismodegib,fexact,"['Hedgehog antagonists (systemic formulation, cancer),/Genentech/Roche', 'small-molecule hedgehog antagonist (cancer),/Genentech//', 'Hh antagonists (systemic formulation, cancer),/Genentech//', 'NSC-747691', 'Erivedge', 'Hh antagonists (systemic formulation, cancer),///', 'Hedgehog antagonists (systemic formulation, cancer),//', 'R-3616', 'Hedgehog antagonists (systemic formulation, cancer),/Genentech/', 'RG-3616', 'RO-5450815', 'small-molecule hedgehog antagonist (cancer),/Genentech//Roche', 'Hedgehog antagonists (systemic formulation, cancer), Curis/Genentech/Roche', 'small-molecule hedgehog antagonist (cancer),///', 'Hh antagonists (systemic formulation, cancer),/Genentech//Roche', 'vismodegib', 'Hedgehog Antagonist GDC-0449', 'Hh antagonists (systemic formulation, cancer), Curis/Genentech//Roche', 'GDC-0449', 'small-molecule hedgehog antagonist (cancer), Curis/Genentech//Roche']",vismodegib,fexact,"['hedgehog antagonists systemic formulation cancer genentech roche', 'small molecule hedgehog antagonist cancer genentech', 'hh antagonists systemic formulation cancer genentech', 'nsc 747691', 'erivedge', 'hh antagonists systemic formulation cancer', 'hedgehog antagonists systemic formulation cancer', 'r 3616', 'hedgehog antagonists systemic formulation cancer genentech', 'rg 3616', 'ro 5450815', 'small molecule hedgehog antagonist cancer genentech roche', 'hedgehog antagonists systemic formulation cancer curis genentech roche', 'small molecule hedgehog antagonist cancer', 'hh antagonists systemic formulation cancer genentech roche', 'vismodegib', 'hedgehog antagonist gdc 0449', 'hh antagonists systemic formulation cancer curis genentech roche', 'gdc 0449', 'small molecule hedgehog antagonist cancer curis genentech roche']",correct_mapping
VEGFR2 peptide,Immunostimulant,VEGFR2 peptide,,,,0,['VEGFR2 peptide'],,0,[],0
VEGFR1 peptide,Immunostimulant,VEGFR1 peptide,,,,0,['VEGFR1 peptide'],,0,[],0
clazakizumab (IV),Interleukin 6 antagonist,clazakizumab,,clazakizumab,clazakizumab,fexact,"['ALD-518', 'anti-IL6 mAb (rheumatoid arthritis/cancer),/', 'BMS-945429', 'clazakizumab', 'anti-IL6 monoclonal antibody (rheumatoid arthritis/cancer),/BMS', 'anti-IL6 mAb (rheumatoid arthritis/cancer),/Bristol-Myers Squibb']",clazakizumab,fexact,"['ald 518', 'anti il6 mab rheumatoid arthritis cancer', 'bms 945429', 'clazakizumab', 'anti il6 monoclonal antibody rheumatoid arthritis cancer bms', 'anti il6 mab rheumatoid arthritis cancer bristol myers squibb']",correct_mapping
autologous DRibble vaccine,Immunostimulant,autologous DRibble vaccine,,,,0,['autologous DRibble vaccine'],,0,[],0
voxtalisib,mTOR kinase inhibitor; Protein kinase inhibitor; PI3 kinase alpha inhibitor; Cell cycle inhibitor,voxtalisib,,voxtalisib,voxtalisib,fexact,"['voxtalisib', 'phosphoinositide-3 kinase/mTOR inhibitor (cancer)', 'SAR-245409', 'XL-765', 'PI3K/mTOR inhibitor (cancer)', 'PI3K/mTOR inhibitor (cancer), sanofi-aventis']",voxtalisib,fexact,"['voxtalisib', 'phosphoinositide 3 kinase mtor inhibitor cancer', 'sar 245409', 'xl 765', 'pi3k mtor inhibitor cancer', 'pi3k mtor inhibitor cancer sanofi aventis']",correct_mapping
KOC1 peptide,Immunostimulant,KOC1 peptide,,,,0,['KOC1 peptide'],,0,[],0
TTK peptide,Immunostimulant,TTK peptide,,,,0,['TTK peptide'],,0,[],0
"nitroglycerin, unspecified",Guanylate cyclase stimulant; Nitric oxide stimulant,nitroglycerin,unspecified,nitroglycerin (transdermal),nitroglycerin,fexact,"['Transderm-Nitro', 'nitroglycerin (transdermal)', 'nitroglycerin', 'NITRODERM']",nitroglycerin (transdermal),fexact,"['transderm nitro', 'nitroglycerin transdermal', 'nitroglycerin', 'nitroderm']",correct_mapping
"nicotine (inhaled), undisclosed",Nicotinic receptor agonist,nicotine,undisclosed,nicotine,nicotine,fexact,"['nicotine transdermal, Warner', 'Nicorette inhaler', 'nicotine', 'nicotine transdermal', 'Nicorette', 'nicotine transdermal, Kabi', 'Nicotrol', 'Nicotrol inhaler']",nicotine,fexact,"['nicotine transdermal warner', 'nicorette inhaler', 'nicotine', 'nicotine transdermal', 'nicorette', 'nicotine transdermal kabi', 'nicotrol', 'nicotrol inhaler']",correct_mapping
MGCD-265 (capsule),Flt-3 antagonist; MET tyrosine kinase inhibitor; TIE-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Macrophage stimulating protein 1 receptor antagonist; Angiogenesis inhibitor,MGCD-265,,glesatinib glycolate,mgcd 265,fexact,"['multikinase inhibitors (cancer)', 'glesatinib glycolate', 'glesatinib', 'MGCD-265']",glesatinib glycolate,fexact,"['multikinase inhibitors cancer', 'glesatinib glycolate', 'glesatinib', 'mgcd 265']",correct_mapping
allogeneic tumor cell vaccine,Immunostimulant,allogeneic tumor cell vaccine,,,,0,['allogeneic tumor cell vaccine'],,0,[],0
vintafolide,Microtubule inhibitor; DNA synthesis inhibitor; Vinca alkaloid; Folate receptor antagonist,vintafolide,,vintafolide,vintafolide,fexact,"['MK-8109', 'EC-0255', 'EC-145', 'Vynfinit', 'EC-0260', 'vintafolide']",vintafolide,fexact,"['mk 8109', 'ec 0255', 'ec 145', 'vynfinit', 'ec 0260', 'vintafolide']",correct_mapping
MelCancerVac,Immunostimulant,MelCancerVac,,MelCancerVac,melcancervac,fexact,"['MCV', 'dendritic cell vaccine (cancer)', 'ENOB-DB-01', 'ENO-4001', 'MelCancerVac', 'MelCancerVax']",MelCancerVac,fexact,"['mcv', 'dendritic cell vaccine cancer', 'enob db 01', 'eno 4001', 'melcancervac', 'melcancervax']",correct_mapping
tumor lysate-pulsed dendritic cells,Immunostimulant,tumor lysate-pulsed dendritic cells,,,,0,['tumor lysate-pulsed dendritic cells'],,0,[],0
inositol,Unidentified pharmacological activity,inositol,,,,0,['inositol'],,0,[],0
imetelstat,Telomerase inhibitor; RNA binder,imetelstat,,imetelstat,imetelstat,fexact,"['GRN-719', 'GRN-163 (modified)', 'telomere modulators,/Pharmacia/', 'GRN-163L', 'telomerase inhibitors', 'telomerase inhibitors,//', 'telomere modulators,//', 'telomerase modulators', 'telomere modulators,/Pharmacia/Kyowa Hakko', 'JNJ-63935937', 'telomerase inhibitors,/Pharmacia/Kyowa Hakko', 'telomerase inhibitors,/Pharmacia/', 'IND-110934', 'imetelstat', 'NSC-754228', 'GRN-163', 'imetelstat sodium']",imetelstat,fexact,"['grn 719', 'grn 163 modified', 'telomere modulators pharmacia', 'grn 163l', 'telomerase inhibitors', 'telomerase inhibitors', 'telomere modulators', 'telomerase modulators', 'telomere modulators pharmacia kyowa hakko', 'jnj 63935937', 'telomerase inhibitors pharmacia kyowa hakko', 'telomerase inhibitors pharmacia', 'ind 110934', 'imetelstat', 'nsc 754228', 'grn 163', 'imetelstat sodium']",correct_mapping
epirubicin,DNA synthesis inhibitor; Radical formation stimulant; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,epirubicin,,epirubicin,epirubicin,fexact,"[""4'-epiadriamycin"", 'Farmorubicin', 'Ellence', 'epirubicin', 'Pharmorubicin', 'IMI-28', ""4'-epi-doxorubicin HCl"", 'epirubicin hydrochloride']",epirubicin,fexact,"['4 epiadriamycin', 'farmorubicin', 'ellence', 'epirubicin', 'pharmorubicin', 'imi 28', '4 epi doxorubicin hcl', 'epirubicin hydrochloride']",correct_mapping
aminocamptothecin (IV),DNA topoisomerase I inhibitor,aminocamptothecin,,9-aminocamptothecin,9 aminocamptothecin,fuzzy,"['9-aminocamptothecin', '9-amino-20 (S)-camptothecin', '9-AC', 'NSC-603071']",9-aminocamptothecin,fexact,"['9 aminocamptothecin', '9 amino 20 s camptothecin', '9 ac', 'nsc 603071']",incorrect_mapping
donepezil hydrochloride,Acetylcholinesterase inhibitor,donepezil hydrochloride,,donepezil hydrochloride,donepezil hydrochloride,fexact,"['donepezil (oral jelly formulation)', 'E-2020 (Rapid Disintegration Tablet), Eisai', 'donepezil hydrochloride (dry syrup, Alzheimers disease), Eisai', 'donepezil hydrochloride', 'E-2020 (liquid formulation), Eisai', 'donepezil', 'donepexil', 'MF-5844', 'donepezil hydrochloride (fine granules, Alzheimers disease), Eisai', 'E-2020 (RDT), Eisai', 'donepezil hydrochloride (dry syrup, Alzheimers disease)', 'donepezil (Rapid Disintegration Tablet), Eisai', 'donepezil (RDT), Eisai', 'donepezil (tablet formulation), Eisai', 'E-2020', 'E-2020 (Rapid Disintegration Tablet)', 'donepezil (liquid formulation), Eisai', 'Aricept Evess', 'donepezil hydrochloride (fine granules, Alzheimers disease)', 'donepezil (oral jelly formulation), Eisai', 'Aricep', 'donepezil (oral sustained release formulation), Eisai', 'donepezil (Rapid Disintegration Tablet)', 'Aricept', 'Eranz', 'Aricept SR', 'donepezil (liquid formulation)', 'E-2020 (liquid formulation)', 'E-2020 (tablet formulation)', 'E-2020 (RDT)', 'donepezil (tablet formulation)', 'donepexil hydrochloride', 'donepezil (oral sustained release formulation)', 'E-2020 (tablet formulation), Eisai', 'donepezil (RDT)']",donepezil hydrochloride,fexact,"['donepezil oral jelly formulation', 'e 2020 rapid disintegration tablet eisai', 'donepezil hydrochloride dry syrup alzheimers disease eisai', 'donepezil hydrochloride', 'e 2020 liquid formulation eisai', 'donepezil', 'donepexil', 'mf 5844', 'donepezil hydrochloride fine granules alzheimers disease eisai', 'e 2020 rdt eisai', 'donepezil hydrochloride dry syrup alzheimers disease', 'donepezil rapid disintegration tablet eisai', 'donepezil rdt eisai', 'donepezil tablet formulation eisai', 'e 2020', 'e 2020 rapid disintegration tablet', 'donepezil liquid formulation eisai', 'aricept evess', 'donepezil hydrochloride fine granules alzheimers disease', 'donepezil oral jelly formulation eisai', 'aricep', 'donepezil oral sustained release formulation eisai', 'donepezil rapid disintegration tablet', 'aricept', 'eranz', 'aricept sr', 'donepezil liquid formulation', 'e 2020 liquid formulation', 'e 2020 tablet formulation', 'e 2020 rdt', 'donepezil tablet formulation', 'donepexil hydrochloride', 'donepezil oral sustained release formulation', 'e 2020 tablet formulation eisai', 'donepezil rdt']",correct_mapping
glufosfamide,DNA inhibitor,glufosfamide,,glufosfamide,glufosfamide,fexact,"['glufosfamide (iv, pancreatic tumor) , Eleison Pharmaceuticals/ China Oncology Focus', 'beta-D-GLU-IPM', 'Glufosamide', 'glufosfamide (iv, pancreatic tumor) ,/', 'glufosfamide (iv, pancreatic tumor) , Eleison Pharmaceuticals/', 'D-19575', 'glufosfamide']",glufosfamide,fexact,"['glufosfamide iv pancreatic tumor eleison pharmaceuticals china oncology focus', 'beta d glu ipm', 'glufosamide', 'glufosfamide iv pancreatic tumor', 'glufosfamide iv pancreatic tumor eleison pharmaceuticals', 'd 19575', 'glufosfamide']",correct_mapping
rofecoxib,Cyclooxygenase 2 inhibitor,rofecoxib,,rofecoxib,rofecoxib,fexact,"['L-001069957', 'MK-0966', 'Vioxx', 'MK-966', 'rofecoxib']",rofecoxib,fexact,"['l 001069957', 'mk 0966', 'vioxx', 'mk 966', 'rofecoxib']",correct_mapping
agatolimod,Immunostimulant; Toll-like receptor 9 agonist,agatolimod,,agatolimod,agatolimod,fexact,"['agatolimod sodium', 'Vaximmune', 'TLR9 agonists', 'CpG-8916', 'CpG-8954', 'PF-676', 'ProMune', 'CpG DNA, CpG ImmunoPharmaceuticals', 'CpG-7909', 'CpG DNA', 'agatolimod', 'PF-3512676']",agatolimod,fexact,"['agatolimod sodium', 'vaximmune', 'tlr9 agonists', 'cpg 8916', 'cpg 8954', 'pf 676', 'promune', 'cpg dna cpg immunopharmaceuticals', 'cpg 7909', 'cpg dna', 'agatolimod', 'pf 3512676']",correct_mapping
nadroparin (SC),Indirect Factor Xa inhibitor; Indirect thrombin inhibitor; Heparin stimulant,nadroparin,,nadroparin calcium,nadroparin,fexact,"['Fraxodi', 'nadroparin calcium', 'nadroparin', 'Fraxiparine', 'Calciparine']",nadroparin calcium,fexact,"['fraxodi', 'nadroparin calcium', 'nadroparin', 'fraxiparine', 'calciparine']",correct_mapping
digoxin,Na+ K+ transporting ATPase inhibitor,digoxin,,,,0,"['digoxin', 'repurposed digoxin (amyotrophic lateral sclerosis)']",,NER_API,[],0
MKC-1,Microtubule inhibitor; mTOR kinase inhibitor; Protein kinase B inhibitor; Ribosomal S6 kinase inhibitor; Beta tubulin inhibitor; Apoptosis stimulant,MKC-1,,MKC-1,mkc 1,fexact,"['Ro-27-4006', 'cell cycle inhibitor', 'R-440', 'MKC-1', 'cell cycle inhibitor (cancer), Miikana', 'cell cycle inhibitor (cancer)', 'cell cycle inhibitor, Roche', 'Ro-27-0997', 'Ro-27-0431', 'Ro-27-1050', 'Ro-31-7453', 'Ro-28-0351']",MKC-1,fexact,"['ro 27 4006', 'cell cycle inhibitor', 'r 440', 'mkc 1', 'cell cycle inhibitor cancer miikana', 'cell cycle inhibitor cancer', 'cell cycle inhibitor roche', 'ro 27 0997', 'ro 27 0431', 'ro 27 1050', 'ro 31 7453', 'ro 28 0351']",correct_mapping
eniluracil (oral tablet),Dihydropyrimidine dehydrogenase inhibitor,eniluracil,,eniluracil,eniluracil,fexact,"['5-EU', 'GW-776', 'ADH-300004', '776C85', 'eniluracil', '5-ethynyluracil', 'PCS-6422', 'BW-776-C85']",eniluracil,fexact,"['5 eu', 'gw 776', 'adh 300004', '776c85', 'eniluracil', '5 ethynyluracil', 'pcs 6422', 'bw 776 c85']",correct_mapping
denileukin diftitox (IV),Translation elongation factor 2 inhibitor,denileukin diftitox,,denileukin diftitox,denileukin diftitox,fexact,"['interleukin-2 fusion toxin, Eisai', 'Onzar', 'IL-2 fusion toxin, Ligand', 'Ontak', 'interleukin-2 fusion toxin, Ligand', 'IL-2 fusion toxin, Eisai', 'IL-2 fusion toxin', 'interleukin-2 fusion toxin, Seragen', 'E-7272', 'DAB389-IL-2', 'interleukin-2 fusion toxin', 'denileukin diftitox', 'IL-2 fusion toxin, Seragen', 'E-7777', 'E-7272 + E-7777', 'Remitoro', 'LY-335348']",denileukin diftitox,fexact,"['interleukin 2 fusion toxin eisai', 'onzar', 'il 2 fusion toxin ligand', 'ontak', 'interleukin 2 fusion toxin ligand', 'il 2 fusion toxin eisai', 'il 2 fusion toxin', 'interleukin 2 fusion toxin seragen', 'e 7272', 'dab389 il 2', 'interleukin 2 fusion toxin', 'denileukin diftitox', 'il 2 fusion toxin seragen', 'e 7777', 'e 7272 e 7777', 'remitoro', 'ly 335348']",correct_mapping
"T cells, HER2 specific",Immunostimulant,T cells,HER2 specific,,,0,['T cells'],,0,[],0
belinostat (IV),Histone deacetylase inhibitor; Cell cycle inhibitor,belinostat,,"belinostat (oral, cancer)",belinostat,fexact,"['PX-089344', 'belinostat (oral, solid tumors),/', 'belinostat (oral, cancer), TopoTarget/Spectrum', 'belinostat (oral, cancer)', 'belinostat (oral, cancer), BioAlliance Pharma/Spectrum', 'histone deacetylase inhibitor (oral, solid tumors), TopoTarget/', 'belinostat (oral, cancer),/Spectrum', 'PXD-101 (oral, solid tumors), TopoTarget/', 'belinostat (oral, cancer),/', 'HDAC inhibitor (oral, solid tumors),/', 'histone deacetylase inhibitor (oral, solid tumors),/', 'belinostat', 'belinostat (oral, cancer), Onxeo', 'belinostat (oral, cancer), BioAlliance Pharma/', 'belinostat (oral, cancer), TopoTarget/', 'belinostat (oral, cancer), Onxeo/Spectrum', 'PXD-101 (oral, solid tumors),/', 'belinostat (oral, solid tumors), TopoTarget/', 'PXD-101', 'HDAC inhibitor (oral, solid tumors), TopoTarget/']","belinostat (oral, cancer)",fexact,"['px 089344', 'belinostat oral solid tumors', 'belinostat oral cancer topotarget spectrum', 'belinostat oral cancer', 'belinostat oral cancer bioalliance pharma spectrum', 'histone deacetylase inhibitor oral solid tumors topotarget', 'belinostat oral cancer spectrum', 'pxd 101 oral solid tumors topotarget', 'belinostat oral cancer', 'hdac inhibitor oral solid tumors', 'histone deacetylase inhibitor oral solid tumors', 'belinostat', 'belinostat oral cancer onxeo', 'belinostat oral cancer bioalliance pharma', 'belinostat oral cancer topotarget', 'belinostat oral cancer onxeo spectrum', 'pxd 101 oral solid tumors', 'belinostat oral solid tumors topotarget', 'pxd 101', 'hdac inhibitor oral solid tumors topotarget']",correct_mapping
picoplatin (IV),DNA inhibitor; Apoptosis stimulant,picoplatin,,picoplatin,picoplatin,fexact,"['NX-473', 'picoplatin', 'JM-473', 'AMD-473', 'ZD-0473', 'Nexplatin']",picoplatin,fexact,"['nx 473', 'picoplatin', 'jm 473', 'amd 473', 'zd 0473', 'nexplatin']",correct_mapping
"iloprost trometamol, oral",Platelet aggregation inhibitor; Prostaglandin IP2 receptor agonist,iloprost trometamol,oral,,,0,['iloprost trometamol'],,0,[],0
LMB-9 immunotoxin,Unidentified pharmacological activity,LMB-9 immunotoxin,,,,0,['LMB-9 immunotoxin'],,0,[],0
tasidotin hydrochloride (IV),Microtubule inhibitor; Tubulin inhibitor,tasidotin hydrochloride,,tasidotin HCl (intravenous),tasidotin hydrochloride,fexact,"['ILX-651', 'synthadotin', 'LU-223651', 'tasidotin HCl', 'tasidotin hydrochloride', 'tasidotin HCl (intravenous), Genzyme', 'BSF-223651', 'syn-D', 'tasidotin HCl (intravenous)', 'tasidotin']",tasidotin HCl (intravenous),fexact,"['ilx 651', 'synthadotin', 'lu 223651', 'tasidotin hcl', 'tasidotin hydrochloride', 'tasidotin hcl intravenous genzyme', 'bsf 223651', 'syn d', 'tasidotin hcl intravenous', 'tasidotin']",correct_mapping
S-3304,Matrix metalloproteinase inhibitor,S-3304,,S-3304,s 3304,fexact,"['S-3304', 'MMP inhibitors', 'BPHA', 'matrix metalloproteinase inhibitor']",S-3304,fexact,"['s 3304', 'mmp inhibitors', 'bpha', 'matrix metalloproteinase inhibitor']",correct_mapping
canertinib dihydrochloride (oral),ErbB-3 antagonist; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),canertinib dihydrochloride,,canertinib,canertinib dihydrochloride,fexact,"['SN-26606', 'CI-1033', 'PD-183805', 'canertinib', 'PD-0183805', 'canertinib dihydrochloride']",canertinib,fexact,"['sn 26606', 'ci 1033', 'pd 183805', 'canertinib', 'pd 0183805', 'canertinib dihydrochloride']",correct_mapping
CAI,Vascular endothelial growth factor (VEGF)receptor antagonist; Interleukin 8 antagonist; Calcium channel antagonist; Angiogenesis inhibitor,CAI,,,,0,"['CAI', 'carboxyamidotriazole', 'L-651582', 'NSC-609974']",,Drug_API_mapping,[],0
BBR-3464,DNA inhibitor,BBR-3464,,BBR-3464,bbr 3464,fexact,"['trinuclear platinum complex, Roche/', 'trinuclear platinum complex, Roche/Novuspharma', 'trinuclear platinum complex, Roche/Cell Therapeutics', 'trinuclear platinum complex,/Cell Therapeutics', 'trinuclear platinum complex', 'BBR-3464', 'trinuclear platinum complex,/', 'triplatin tetranitrate']",BBR-3464,fexact,"['trinuclear platinum complex roche', 'trinuclear platinum complex roche novuspharma', 'trinuclear platinum complex roche cell therapeutics', 'trinuclear platinum complex cell therapeutics', 'trinuclear platinum complex', 'bbr 3464', 'trinuclear platinum complex', 'triplatin tetranitrate']",correct_mapping
ABT-510,Angiogenesis inhibitor; Thrombospondin 1 agonist,ABT-510,,ABT-510,abt 510,fexact,"['thrombospondin-1 peptide mimetics', 'DI-TSP', 'ABT-526', 'DI-TSPa', 'ABT-510']",ABT-510,fexact,"['thrombospondin 1 peptide mimetics', 'di tsp', 'abt 526', 'di tspa', 'abt 510']",correct_mapping
St. John`s Wort,Catechol O methyltransferase inhibitor; Neurotransmitter uptake inhibitor,St. John`s Wort,,,,0,['St. John`s Wort'],,0,[],0
efaproxiral sodium,Haemoglobin oxygen release stimulant,efaproxiral sodium,,efaproxiral,efaproxiral sodium,fexact,"['Revaproxyn', 'RSR-4', 'efaproxiral', 'RSR-13', 'Efaproxyn', 'efaproxiral sodium']",efaproxiral,fexact,"['revaproxyn', 'rsr 4', 'efaproxiral', 'rsr 13', 'efaproxyn', 'efaproxiral sodium']",correct_mapping
ALVAC-CEA-B7.1 vaccine,Immunostimulant; Carcinoembryonic antigen inhibitor,ALVAC-CEA-B7.1 vaccine,,,,0,['ALVAC-CEA-B7.1 vaccine'],,0,[],0
vaccinia-TRICOM vaccine,Immunostimulant; Carcinoembryonic antigen inhibitor,vaccinia-TRICOM vaccine,,,,0,['vaccinia-TRICOM vaccine'],,0,[],0
MAGE-12.Cw7 (170-178) peptide,Immunostimulant,MAGE-12.Cw7  peptide,,,,0,['MAGE-12.Cw7  peptide'],,0,[],0
11D10 anti-idiotype vaccine (SC),Immunostimulant,11D10 anti-idiotype vaccine,,,,0,['11D10 anti-idiotype vaccine'],,0,[],0
CeaVac,Immunostimulant; Carcinoembryonic antigen inhibitor,CeaVac,,,,0,"['monoclonal antibody (cancer)', 'CeaVac', 'idiotypic vaccine (CEA)']",,NER_API,[],0
11D10 anti-idiotype vaccine (intradermal),Immunostimulant,11D10 anti-idiotype vaccine,,,,0,['11D10 anti-idiotype vaccine'],,0,[],0
dalteparin sodium,Indirect Factor Xa inhibitor; Indirect thrombin inhibitor; Heparin stimulant,dalteparin sodium,,dalteparin sodium,dalteparin sodium,fexact,"['FR-860', 'Fragmin', 'K-2165', 'dalteparin sodium', 'LigoFragmin', 'Boxol', 'Fragmine', 'Fragmin 5000 IU', 'KABI-2165']",dalteparin sodium,fexact,"['fr 860', 'fragmin', 'k 2165', 'dalteparin sodium', 'ligofragmin', 'boxol', 'fragmine', 'fragmin 5000 iu', 'kabi 2165']",correct_mapping
"interferon alpha, unspecified",Interferon receptor agonist,interferon alpha,unspecified,interferon alfa-2b,interferon alpha 2b,fuzzy,"['Virtron', 'Intron A', 'interferon alpha-2b', 'interferon alfa-2b', 'Intron', 'Viraferon', 'Alfatronol']",interferon alfa-2b,fexact,"['virtron', 'intron a', 'interferon alpha 2b', 'interferon alfa 2b', 'intron', 'viraferon', 'alfatronol']",incorrect_mapping
"interferon, Genentech (gamma1b) (SC)",Immunostimulant; Interferon gamma 1b agonist; T helper cell stimulant,interferon,Genentech,,,0,['interferon'],,0,[],0
autologous tumor cells,Immunostimulant,autologous tumor cells,,,,0,['autologous tumor cells'],,0,[],0
GNC-039,Immuno-oncology therapy; Immune checkpoint inhibitor,GNC-039,,GNC-039,gnc 039,fexact,['GNC-039'],GNC-039,fexact,['gnc 039'],correct_mapping
lamivudine,Nucleoside reverse transcriptase inhibitor,lamivudine,,lamivudine,lamivudine,fexact,"['GG-714', 'GR-109714', 'NGPB-21', 'Epivir', 'Heptovir', 'GR-109714X', 'Heptodin', 'Epivir-HBV', '(-)-BCH-189', '3TC', 'Zefix', 'lamivudine', 'Zeffix', 'BCH-790', 'GR-103665']",lamivudine,fexact,"['gg 714', 'gr 109714', 'ngpb 21', 'epivir', 'heptovir', 'gr 109714x', 'heptodin', 'epivir hbv', 'bch 189', '3tc', 'zefix', 'lamivudine', 'zeffix', 'bch 790', 'gr 103665']",correct_mapping
LB-100,Protein phosphatase 2A inhibitor,LB-100,,LB-100,lb 100,fexact,"['Protein phosphatase 2A inhibitor (achondroplasia)', 'LB-100']",LB-100,fexact,"['protein phosphatase 2a inhibitor achondroplasia', 'lb 100']",correct_mapping
TTX-030,CD39 antagonist; Immuno-oncology therapy,TTX-030,,TTX-030,ttx 030,fexact,"['anti-CD39 monoclonal antibodies', 'CD39 checkpoint inhibitor (cancer/solid tumor/lymphoma), Trishula Therapeutics', 'TTX-030', 'CD39 checkpoint inhibitor (cancer/solid tumor/lymphoma)', 'anti-CD39 monoclonal antibodies, Trishula Therapeutics', 'CD39 checkpoint inhibitor (cancer)']",TTX-030,fexact,"['anti cd39 monoclonal antibodies', 'cd39 checkpoint inhibitor cancer solid tumor lymphoma trishula therapeutics', 'ttx 030', 'cd39 checkpoint inhibitor cancer solid tumor lymphoma', 'anti cd39 monoclonal antibodies trishula therapeutics', 'cd39 checkpoint inhibitor cancer']",correct_mapping
irinotecan,DNA topoisomerase I inhibitor,irinotecan,,irinotecan,irinotecan,fexact,"['Camptothecin 11 hydrochloride', 'DQ-2805', 'camptothecin II', 'irinotecan hydrochloride hydrate', 'camptothecin II hydrochloride', 'Topotecin', 'NSC-616348', 'irinotecan', 'camptothecin', 'camptothecin  hydrochloride', 'Camptothecin 11', 'Campto', 'irinotecan hydrochloride', 'Camptosar']",irinotecan,fexact,"['camptothecin 11 hydrochloride', 'dq 2805', 'camptothecin ii', 'irinotecan hydrochloride hydrate', 'camptothecin ii hydrochloride', 'topotecin', 'nsc 616348', 'irinotecan', 'camptothecin', 'camptothecin hydrochloride', 'camptothecin 11', 'campto', 'irinotecan hydrochloride', 'camptosar']",correct_mapping
BGB-3245,RAF dimer inhibitor,BGB-3245,,BGB-3245,bgb 3245,fexact,"['RAF dimer inhibitor', 'BGB-3245']",BGB-3245,fexact,"['raf dimer inhibitor', 'bgb 3245']",correct_mapping
leucovorin,Unidentified pharmacological activity,leucovorin,,calcium levofolinate,s leucovorin,fuzzy,"['calcium levofolinate', 'levoleucovorin', 'Isovorin', '(S)-Leucovorin', 'Khapzory', 'levofolinic acid', 'LFA', 'levoleucovorin calcium', 'Fusilev', 'L-Folinic acid']",calcium levofolinate,fexact,"['calcium levofolinate', 'levoleucovorin', 'isovorin', 's leucovorin', 'khapzory', 'levofolinic acid', 'lfa', 'levoleucovorin calcium', 'fusilev', 'l folinic acid']",incorrect_mapping
liposomal irinotecan,DNA topoisomerase inhibitor,liposomal irinotecan,,,,0,['liposomal irinotecan'],,0,[],0
"Ad-p53, MultiVir (intra-arterial)",Immuno-oncology therapy,Ad-p53,MultiVir,contusugene ladenovec,ad p53,fexact,"['Ad-p53 (head and neck tumor), p53', 'oncolytic adenovirus therapy expressing p53 (cancer), MultiVir', 'INGN-201', 'Ad-p53 (intratumoral, colorectal liver metastasis/head and neck tumor)', 'Ad-p53 (intratumoral, colorectal liver metastasis/head and neck tumor), MultiVir', 'Ad-p53, Introgen', 'Ad5CMV-p53', 'Ad-p53 (colorectal liver metastasis), MultiVir', 'Ad-p53 (colorectal liver metastasis)', 'Advexin', 'oncolytic adenovirus therapy expressing p53 (cancer)', 'INGN-004', 'Ad-p53', 'oncolytic adenovirus therapy expressing p53 (solid tumor), Introgen', 'oncolytic adenovirus therapy expressing p53 (solid tumor)', 'contusugene ladenovec']",contusugene ladenovec,fexact,"['ad p53 head and neck tumor p53', 'oncolytic adenovirus therapy expressing p53 cancer multivir', 'ingn 201', 'ad p53 intratumoral colorectal liver metastasis head and neck tumor', 'ad p53 intratumoral colorectal liver metastasis head and neck tumor multivir', 'ad p53 introgen', 'ad5cmv p53', 'ad p53 colorectal liver metastasis multivir', 'ad p53 colorectal liver metastasis', 'advexin', 'oncolytic adenovirus therapy expressing p53 cancer', 'ingn 004', 'ad p53', 'oncolytic adenovirus therapy expressing p53 solid tumor introgen', 'oncolytic adenovirus therapy expressing p53 solid tumor', 'contusugene ladenovec']",correct_mapping
ZW-49,ErbB-2 antagonist,ZW-49,,ZW-49,zw 49,fexact,"['zanidatamab zovodotin', 'ZW-49', 'cytotoxic payload-linked bispecific anti-HER2 ADC (ZymeLink/Azymetric, HER2-expressing cancers/breast cancer)', 'cytotoxic payload-linked bispecific anti-HER2 ADC (ZymeLink/Azymetric, HER2-expressing cancers/breast cancer), Zymeworks']",ZW-49,fexact,"['zanidatamab zovodotin', 'zw 49', 'cytotoxic payload linked bispecific anti her2 adc zymelink azymetric her2 expressing cancers breast cancer', 'cytotoxic payload linked bispecific anti her2 adc zymelink azymetric her2 expressing cancers breast cancer zymeworks']",correct_mapping
galunisertib,Protein kinase inhibitor; Transforming growth factor beta receptor 1 antagonist,galunisertib,,galunisertib,galunisertib,fexact,"['TGF beta inhibitor (cancer)', 'galunisertib', 'LY-2109761', 'TGF beta receptor I inhibitors (solid tumors)', 'LY-566592', 'LY-2021154', 'LY-580276', 'LY-364947', 'LY-2157299', 'LY-550410']",galunisertib,fexact,"['tgf beta inhibitor cancer', 'galunisertib', 'ly 2109761', 'tgf beta receptor i inhibitors solid tumors', 'ly 566592', 'ly 2021154', 'ly 580276', 'ly 364947', 'ly 2157299', 'ly 550410']",correct_mapping
"eribulin mesylate, liposomal",Microtubule inhibitor; Tubulin inhibitor,eribulin mesylate,liposomal,"eribulin mesylate (liposomal formulation, cancer)",eribulin mesylate,fexact,"['eribulin mesylate (liposomal formulation, cancer)', 'E-7389-LF', 'eribulin mesylate', 'Halaven (liposomal, cancer)', 'Halaven']","eribulin mesylate (liposomal formulation, cancer)",fexact,"['eribulin mesylate liposomal formulation cancer', 'e 7389 lf', 'eribulin mesylate', 'halaven liposomal cancer', 'halaven']",correct_mapping
GPC3-CAR-T cells,Immuno-oncology therapy,GPC3-CAR-T cells,,,,0,['GPC3-CAR-T cells'],,0,[],0
trabectedin,DNA inhibitor; DNA repair enzyme inhibitor; Apoptosis stimulant; Cell cycle inhibitor,trabectedin,,trabectedin,trabectedin,fexact,"['Ect-743', 'phthalascidin', 'trabectedin', 'ET-743, University of Illinois', 'Yondelis', 'et-743', 'Pt-650', 'ecteinascidin-743']",trabectedin,fexact,"['ect 743', 'phthalascidin', 'trabectedin', 'et 743 university of illinois', 'yondelis', 'et 743', 'pt 650', 'ecteinascidin 743']",correct_mapping
iNKT cells,Natural Killer T cell stimulant; Immuno-oncology therapy,iNKT cells,,,,0,['iNKT cells'],,0,[],0
MEDI-5083,CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,MEDI-5083,,MEDI-5083,medi 5083,fexact,"['CD40 costimulator (advanced solid tumor)', 'CD40 ligand-antibody fragment fusion protein (advanced solid tumor)', 'MEDI-5083']",MEDI-5083,fexact,"['cd40 costimulator advanced solid tumor', 'cd40 ligand antibody fragment fusion protein advanced solid tumor', 'medi 5083']",correct_mapping
RXDX-106,Axl receptor tyrosine kinase inhibitor; Mer tyrosine kinase inhibitor; MET tyrosine kinase inhibitor; TYRO3 protein tyrosine kinase inhibitor,RXDX-106,,RXDX-106,rxdx 106,fexact,"['CEP-40783', 'triple Axl checkpoint inhibitor/Mer checkpoint inhibitor/Tyro3 checkpoint inhibitor (advanced solid tumors)', 'RXDX-106', 'triple Axl checkpoint inhibitor/Mer checkpoint inhibitor/Tyro3 checkpoint inhibitor (advanced solid tumors), Ignyta']",RXDX-106,fexact,"['cep 40783', 'triple axl checkpoint inhibitor mer checkpoint inhibitor tyro3 checkpoint inhibitor advanced solid tumors', 'rxdx 106', 'triple axl checkpoint inhibitor mer checkpoint inhibitor tyro3 checkpoint inhibitor advanced solid tumors ignyta']",correct_mapping
DV-281,Toll-like receptor 9 agonist; Immuno-oncology therapy,DV-281,,DV-281,dv 281,fexact,"['DV-281', 'SD-101 (inhaled, lung cancer)', 'VR-347']",DV-281,fexact,"['dv 281', 'sd 101 inhaled lung cancer', 'vr 347']",correct_mapping
SD-101,Toll-like receptor 9 agonist; Immuno-oncology therapy,SD-101,,SD-101,sd 101,fexact,"['SD-101, TriSalus', 'HCV vaccine (ISS),/Symphony Dynamo', 'HCV vaccine (ISS),/', 'TLR9 agonist (CpG-C class oligodeoxynucleotide vaccine, advanced solid tumors)', 'SD-101', 'TLR9 agonist (CpG-C class oligodeoxynucleotide vaccine, advanced solid tumors), TriSalus', 'HCV-ISS']",SD-101,fexact,"['sd 101 trisalus', 'hcv vaccine iss symphony dynamo', 'hcv vaccine iss', 'tlr9 agonist cpg c class oligodeoxynucleotide vaccine advanced solid tumors', 'sd 101', 'tlr9 agonist cpg c class oligodeoxynucleotide vaccine advanced solid tumors trisalus', 'hcv iss']",correct_mapping
[14C] AC0010,Unidentified pharmacological activity,[14C] AC0010,,,,0,['[14C] AC0010'],,0,[],0
BPI9016M,Axl receptor tyrosine kinase inhibitor; MET tyrosine kinase inhibitor,BPI9016M,,BPI-9016M,bpi 9016m,fuzzy,"['BPI-9016M', 'c-met and Axl tyrosine kinase inhibitor(oral/tablet, cancer), Beta Pharma', 'BPI-9016', 'BPI-9000']",BPI-9016M,fexact,"['bpi 9016m', 'c met and axl tyrosine kinase inhibitor oral tablet cancer beta pharma', 'bpi 9016', 'bpi 9000']",incorrect_mapping
"irinotecan, PharmaEngine",DNA topoisomerase I inhibitor,irinotecan,PharmaEngine,irinotecan,irinotecan,fexact,"['Camptothecin 11 hydrochloride', 'DQ-2805', 'camptothecin II', 'irinotecan hydrochloride hydrate', 'camptothecin II hydrochloride', 'Topotecin', 'NSC-616348', 'irinotecan', 'camptothecin', 'camptothecin  hydrochloride', 'Camptothecin 11', 'Campto', 'irinotecan hydrochloride', 'Camptosar']",irinotecan,fexact,"['camptothecin 11 hydrochloride', 'dq 2805', 'camptothecin ii', 'irinotecan hydrochloride hydrate', 'camptothecin ii hydrochloride', 'topotecin', 'nsc 616348', 'irinotecan', 'camptothecin', 'camptothecin hydrochloride', 'camptothecin 11', 'campto', 'irinotecan hydrochloride', 'camptosar']",correct_mapping
furetinib succinate,Anaplastic lymphoma kinase inhibitor; ROS receptor tyrosine kinase inhibitor,furetinib succinate,,SAF-189s,furuitinib succinate,fuzzy,"['ALK/ROS1 inhibitor (oral, non-small cell lung cancer/solid tumor)', 'dingersuan furuitini', 'foritinib succinate (oral, non-small cell lung cancer/solid tumor),/Shanghai Fosun Pharmaceutical (Group)', 'SAF-189', 'furuitinib succinate', 'ALK inhibitor (oral/capsule, cancer),/Shanghai Institute of Materia Medica', 'FC-110', 'SAF-189s', 'SAT-189', 'ALK inhibitor (oral/capsule, cancer),/', 'foritinib succinate']",SAF-189s,fexact,"['alk ros1 inhibitor oral non small cell lung cancer solid tumor', 'dingersuan furuitini', 'foritinib succinate oral non small cell lung cancer solid tumor shanghai fosun pharmaceutical group', 'saf 189', 'furuitinib succinate', 'alk inhibitor oral capsule cancer shanghai institute of materia medica', 'fc 110', 'saf 189s', 'sat 189', 'alk inhibitor oral capsule cancer', 'foritinib succinate']",incorrect_mapping
anastrozole,Aromatase inhibitor,anastrozole,,anastrozole,anastrozole,fexact,"['D-1033', 'ICI-D-1033', 'ZD-1033', 'Arimidex', 'anastrozole']",anastrozole,fexact,"['d 1033', 'ici d 1033', 'zd 1033', 'arimidex', 'anastrozole']",correct_mapping
GRANITE-001,T cell stimulant; Immuno-oncology therapy,GRANITE-001,,GRANITE-001,granite 001,fexact,"['GRT-C901', 'rna-based personalized neoantigen immunotherapies (lipid nanoparticle, cancer)', 'GRANITE', 'GRT-R902', 'GRANITE-001', 'GRT-C901/GRT-R902']",GRANITE-001,fexact,"['grt c901', 'rna based personalized neoantigen immunotherapies lipid nanoparticle cancer', 'granite', 'grt r902', 'granite 001', 'grt c901 grt r902']",correct_mapping
quisinostat,Histone deacetylase inhibitor,quisinostat,,quisinostat,quisinostat,fexact,"['quisinostat', 'second-generation pan-histone deacetylase inhibitors (cancer), J&J', 'quisinostat hydrochloride', 'second-generation pan-HDAC inhibitors (cancer), Ortho Biotech Oncology Research & Development', 'JNJ-26481585', 'second-generation pan-hdac inhibitors (cancer)']",quisinostat,fexact,"['quisinostat', 'second generation pan histone deacetylase inhibitors cancer j j', 'quisinostat hydrochloride', 'second generation pan hdac inhibitors cancer ortho biotech oncology research development', 'jnj 26481585', 'second generation pan hdac inhibitors cancer']",correct_mapping
motolimod (SC),Immunostimulant; Toll-like receptor 8 agonist,motolimod,,motolimod,motolimod,fexact,"['toll-like receptor modulators,/', 'VTX-378', 'toll-like receptor modulators (cancer, allergy), VentiRx/ Celgene', 'motolimod', 'toll-like receptor modulators (cancer, allergy), VentiRx/', 'TLR modulators (cancer, allergy),/', 'VTX-2337', 'TLR modulators (cancer, allergy), VentiRx/', 'toll-like receptor modulators, VentiRx/ Celgene', 'toll-like receptor modulators, VentiRx/', 'toll-like receptor modulators (cancer, allergy), VentiRx/Bristol-Myers Squibb', 'toll-like receptor modulators (cancer, allergy),/']",motolimod,fexact,"['toll like receptor modulators', 'vtx 378', 'toll like receptor modulators cancer allergy ventirx celgene', 'motolimod', 'toll like receptor modulators cancer allergy ventirx', 'tlr modulators cancer allergy', 'vtx 2337', 'tlr modulators cancer allergy ventirx', 'toll like receptor modulators ventirx celgene', 'toll like receptor modulators ventirx', 'toll like receptor modulators cancer allergy ventirx bristol myers squibb', 'toll like receptor modulators cancer allergy']",correct_mapping
"cyclophosphamide (IV), unspecified",DNA inhibitor,cyclophosphamide,unspecified,cyclophosphamide monohydrate,cyclophosphamide,fexact,"['Endoxan', 'cyclophosphamide monohydrate', 'cyclophosphamide']",cyclophosphamide monohydrate,fexact,"['endoxan', 'cyclophosphamide monohydrate', 'cyclophosphamide']",correct_mapping
LCL-161,IAP antagonist,LCL-161,,LCL-161,lcl 161,fexact,['LCL-161'],LCL-161,fexact,['lcl 161'],correct_mapping
parsaclisib,PI3 kinase delta inhibitor,parsaclisib,,parsaclisib,parsaclisib,fexact,"['parsaclisib hydrochloride', 'INCB-50465', 'IBI-376', 'parsaclisib', 'PI3K delta inhibitor (2) (oral, B-cell lymphoma/ALL/Pemphigus)', 'INCB-050465', 'PI3K delta inhibitor (2) (B-cell lymphoma)']",parsaclisib,fexact,"['parsaclisib hydrochloride', 'incb 50465', 'ibi 376', 'parsaclisib', 'pi3k delta inhibitor 2 oral b cell lymphoma all pemphigus', 'incb 050465', 'pi3k delta inhibitor 2 b cell lymphoma']",correct_mapping
desloratadine,Histamine H1 receptor antagonist,desloratadine,,,,0,"['MK-4117', 'DCL', 'Clarinex', 'descarboethoxyloratadine', 'Erius', 'desloratadine', 'Neoclarityn', 'Aerius', 'Sch-34117', 'Neoclaritin', 'Desalex', 'Azomyr', 'DCL, Sepracor', 'DCL, Sunovion']",,NER_API,[],0
metatinib,Vascular endothelial growth factor receptor 2 antagonist; MET tyrosine kinase inhibitor,metatinib,,,,0,"['modified gefitinib, Beijing Labsolutions Pharmaceutical Co Ltd', 'Metatinib', 'BL-001']",,Drug_API_mapping,[],0
"anti-MUC1 CAR-T cells, PersonGen Biomedicine",T cell stimulant; Immuno-oncology therapy,anti-MUC1 CAR-T cells,PersonGen Biomedicine,,,0,['anti-MUC1 CAR-T cells'],,0,[],0
H-101,Immuno-oncology therapy,H-101,,H-101,h 101,fexact,"['Oncorine', 'oncolytic adenovirus therapy (E1B-deficient, cancer), Shanghai Sunway', 'oncolytic adenovirus therapy (E1B-deficient, cancer)', 'H-101']",H-101,fexact,"['oncorine', 'oncolytic adenovirus therapy e1b deficient cancer shanghai sunway', 'oncolytic adenovirus therapy e1b deficient cancer', 'h 101']",correct_mapping
indocyanine green,Unidentified pharmacological activity,indocyanine green,,,,0,['indocyanine green'],,0,[],0
ripretinib,C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor,ripretinib,,ripretinib,ripretinib,fexact,"['DP-3429', 'DP-3975', 'ZL-2307', 'DCC-2618', 'Qinlock', 'DP-3636', 'c-kit inhibitors (cancer)', 'DP-2976', 'DP-4444', 'ripretinib', 'DP-3407']",ripretinib,fexact,"['dp 3429', 'dp 3975', 'zl 2307', 'dcc 2618', 'qinlock', 'dp 3636', 'c kit inhibitors cancer', 'dp 2976', 'dp 4444', 'ripretinib', 'dp 3407']",correct_mapping
larotrectinib (capsule),TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,larotrectinib,,larotrectinib sulfate,larotrectinib,fexact,"['larotrectinib sulfate', 'BAY-2757556', 'tyrosine kinase inhibitor (oral, cancer),/', 'oncogenic activating mutation-targeting compound (cancer),/', 'oncogenic activating mutation-targeting compound (cancer),/ Loxo Oncology', 'Vitrakvi', 'LOXO-101', 'larotrectinib', 'tyrosine kinase inhibitor (oral, cancer),/Loxo Oncology']",larotrectinib sulfate,fexact,"['larotrectinib sulfate', 'bay 2757556', 'tyrosine kinase inhibitor oral cancer', 'oncogenic activating mutation targeting compound cancer', 'oncogenic activating mutation targeting compound cancer loxo oncology', 'vitrakvi', 'loxo 101', 'larotrectinib', 'tyrosine kinase inhibitor oral cancer loxo oncology']",correct_mapping
"risperidone, ValiSeek",Alpha 1 adrenoreceptor antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 2A receptor agonist,risperidone,ValiSeek,,,0,"['Resperidal', 'Risperdal Quicklet', 'risperidone', 'Risperdal OD', 'Belivon', 'R-064766', 'Risperdal M-Tab', 'Risperdal', 'Rispedal', 'Rispolept', 'R-64766']",,NER_API,[],0
RRx-001,CD47 antagonist; Immuno-oncology therapy; Signal regulatory protein alpha antagonist; Immune checkpoint inhibitor,RRx-001,,RRx-001,rrx 001,fexact,"['ABDNAZ', 'dual CD47 checkpoint inhibitor/SIRPa checkpoint inhibitor (cancer)', 'dinitroazetidines (radiation sensitizer, cancer), RadioRx', 'RRx-001']",RRx-001,fexact,"['abdnaz', 'dual cd47 checkpoint inhibitor sirpa checkpoint inhibitor cancer', 'dinitroazetidines radiation sensitizer cancer radiorx', 'rrx 001']",correct_mapping
ulocuplumab,Radical formation stimulant; CXC chemokine receptor 4 antagonist,ulocuplumab,,ulocuplumab,ulocuplumab,fexact,"['ulocuplumab', 'BMS-936564', 'MDX-1338']",ulocuplumab,fexact,"['ulocuplumab', 'bms 936564', 'mdx 1338']",correct_mapping
indoximod,"Indoleamine 2,3-dioxygenase inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor",indoximod,,indoximod hydrochloride,indoximod,fexact,"['Indoximod Prostate', 'Indoximod Breast', 'indoximod hydrochloride', 'indoximod', '1-methyltryptophan', 'NLG-001', 'D-1-methyltryptophan', 'NLG-8189', 'IDO checkpoint inhibitor (cancer)', 'D-1MT', '1-methyl-D-tryptophan', 'indoleamine 2,3-dioxygenase inhibitors (solid tumor)']",indoximod hydrochloride,fexact,"['indoximod prostate', 'indoximod breast', 'indoximod hydrochloride', 'indoximod', '1 methyltryptophan', 'nlg 001', 'd 1 methyltryptophan', 'nlg 8189', 'ido checkpoint inhibitor cancer', 'd 1mt', '1 methyl d tryptophan', 'indoleamine 2 3 dioxygenase inhibitors solid tumor']",correct_mapping
RG-7842,Mitogen-activated protein kinase 1 inhibitor; Mitogen-activated protein kinase 3 inhibitor,RG-7842,,ravoxertinib,rg 7842,fexact,"['RG-7842', 'ravoxertinib', 'GDC-0094', 'GDC-0994']",ravoxertinib,fexact,"['rg 7842', 'ravoxertinib', 'gdc 0094', 'gdc 0994']",correct_mapping
pexidartinib,Colony stimulating factor 1 receptor antagonist; C-kit inhibitor; Flt-3 antagonist; Immuno-oncology therapy,pexidartinib,,,,0,"['PLX-3397', 'pexidartinib hydrochloride  (cancer/inflammatory disease)', 'Fms/Kit/Flt-3-ITD inhibitor (cancer/inflammatory disease), Plexxikon', 'pexidartinib hydrochloride  (cancer/inflammatory disease), Plexxikon', 'Fms/Kit/Flt-3-ITD inhibitor (cancer/inflammatory disease)', 'Turalio', 'PLX3397 hydrochloride', 'FP-113', 'pexidartinib hydrochloride', 'pexidartinib']",,NER_API,[],0
SEA-CD40,CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,SEA-CD40,,SEA-CD40,sea cd40,fexact,"['SEA-CD40', 'CD40 costimulator (SEA technology, solid tumor/hematological neoplasm), Seattle Genetics', 'SEA-m1C10', 'CD40-targeted antibody (solid tumors/hematological malignancies), Seattle Genetics']",SEA-CD40,fexact,"['sea cd40', 'cd40 costimulator sea technology solid tumor hematological neoplasm seattle genetics', 'sea m1c10', 'cd40 targeted antibody solid tumors hematological malignancies seattle genetics']",correct_mapping
INCB-54329,BET protein inhibitor,INCB-54329,,INCB-054329,incb 54329,fexact,"['INCB-54329', 'INCB-054329']",INCB-054329,fexact,"['incb 54329', 'incb 054329']",correct_mapping
amantadine,Unidentified pharmacological activity,amantadine,,,,0,"['Osmolex ER', 'amantadine hydrochloride (extended release/oral tablet formulation, Parkinson’s disease/dyskinesia)', 'amantadine (extended release/oral tablet formulation, Parkinson’s disease/dyskinesia), Osmotica', 'amantadine (extended release/immediate release/oral tablet formulation, Parkinson’s disease/drug-induced extrapyramidal reactions), Osmotica', 'amantadine (extended release/immediate release/oral tablet formulation, Parkinson’s disease/drug-induced extrapyramidal reactions)', 'amantadine (extended release/oral tablet formulation, Parkinson’s disease/dyskinesia)', 'amantadine hydrochloride', 'amantadine', 'OS-320', 'amantadine hydrochloride (extended release/oral tablet formulation, Parkinson’s disease/dyskinesia), Osmotica']",,NER_API,[],0
BAY-86-9596,Radiopharmaceutical,BAY-86-9596,,BAY-86-9596,bay 86 9596,fexact,"['D-18F-fluoromethyl tyrosine', '18F-labeled PET imaging agent (cancer), Bayer Schering Pharma', 'diagnostic 18F-labeled PET tracer', '18-F PET tracer (diagnostic imaging)', 'D-fluoromethyl tyrosine-[18F]', 'BAY-86-9596', 'D-FMT']",BAY-86-9596,fexact,"['d 18f fluoromethyl tyrosine', '18f labeled pet imaging agent cancer bayer schering pharma', 'diagnostic 18f labeled pet tracer', '18 f pet tracer diagnostic imaging', 'd fluoromethyl tyrosine 18f', 'bay 86 9596', 'd fmt']",correct_mapping
palifermin,Fibroblast growth factor 7 agonist,palifermin,,palifermin,palifermin,fexact,"['palifermin', 'rhKGF', 'Kepivance', 'human keratinocyte growth factor (recombinant)', 'rHuKGF', 'FGF-7']",palifermin,fexact,"['palifermin', 'rhkgf', 'kepivance', 'human keratinocyte growth factor recombinant', 'rhukgf', 'fgf 7']",correct_mapping
isoquercetin,Unidentified pharmacological activity,isoquercetin,,,,0,['isoquercetin'],,0,[],0
lisinopril,Angiotensin I converting enzyme inhibitor,lisinopril,,lisinopril,lisinopril,fexact,"['Aceday', 'Zestril', 'Lipril', 'Acerbon', 'Listen', 'lisinopril dihydrate', 'lisinopril (USAN)', 'lisinopril', 'Prinivil', 'Acemin', 'Longes']",lisinopril,fexact,"['aceday', 'zestril', 'lipril', 'acerbon', 'listen', 'lisinopril dihydrate', 'lisinopril usan', 'lisinopril', 'prinivil', 'acemin', 'longes']",correct_mapping
pentoxifylline,Platelet aggregation inhibitor,pentoxifylline,,pentoxifylline,pentoxifylline,fexact,"['Pentoxil', 'Trental', 'pentoxifylline', 'Torental LP']",pentoxifylline,fexact,"['pentoxil', 'trental', 'pentoxifylline', 'torental lp']",correct_mapping
budesonide,Immunosuppressant; Glucocorticoid agonist,budesonide,,budesonide (inhaled formulations),budesonide,fexact,"['Budecort Aqua', 'Rhinocort Aqua', 'Inflammide', 'budesonide (inhaled formulations), AstraZeneca', 'budesonide, controlled release', 'Betactin', 'budesonide', 'Pulmicort Flexhaler', 'Rhinocort', 'Pulmicort', 'eudragit L-100-55', 'Naricort', 'Pulmicort Turbuhaler', 'S-1320', 'Horacort', 'Budoxis', 'Preferid', 'Rhinocort Turbuhaler', 'Pulmaxan Turbuhaler', 'budesonide (inhaled formulations)', 'Pulmicort Respules']",budesonide (inhaled formulations),fexact,"['budecort aqua', 'rhinocort aqua', 'inflammide', 'budesonide inhaled formulations astrazeneca', 'budesonide controlled release', 'betactin', 'budesonide', 'pulmicort flexhaler', 'rhinocort', 'pulmicort', 'eudragit l 100 55', 'naricort', 'pulmicort turbuhaler', 's 1320', 'horacort', 'budoxis', 'preferid', 'rhinocort turbuhaler', 'pulmaxan turbuhaler', 'budesonide inhaled formulations', 'pulmicort respules']",correct_mapping
selicrelumab,CD40 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,selicrelumab,,,,0,"['RO-7009789', 'CD40 iMAb (solid tumors/non-hodgkin lymphoma)', 'CD40 iMAb (solid tumors)', 'CD40 costimulator (solid tumor/NHL)', 'selicrelumab', 'RG-7876']",,NER_API,[],0
"miR-16, EDV nanocells, EnGeneIC",Immunostimulant,miR-16,EnGeneIC,,,0,['miR-16'],,0,[],0
PF-06664178,Unidentified pharmacological activity,PF-06664178,,PF-06664178,pf 06664178,fexact,"['RN-927C', 'PF-06664178']",PF-06664178,fexact,"['rn 927c', 'pf 06664178']",correct_mapping
ficlatuzumab,Hepatocyte growth factor receptor antagonist,ficlatuzumab,,ficlatuzumab,ficlatuzumab,fexact,"['AVEO-299', 'humanized anti-human growth factor monoclonal antibody (iv, cancer),/', 'anti-HGF (cancer), Merck & Co/', 'anti-HGF (cancer), Schering-Plough/', 'ficlatuzumab', 'SCH-900105', 'humanized anti-human growth factor monoclonal antibody (iv, cancer),/Merck & Co', 'AV-299', 'anti-HGF (cancer),/']",ficlatuzumab,fexact,"['aveo 299', 'humanized anti human growth factor monoclonal antibody iv cancer', 'anti hgf cancer merck co', 'anti hgf cancer schering plough', 'ficlatuzumab', 'sch 900105', 'humanized anti human growth factor monoclonal antibody iv cancer merck co', 'av 299', 'anti hgf cancer']",correct_mapping
finasteride,5 Alpha reductase Type II inhibitor,finasteride,,finasteride,finasteride,fexact,"['Eutiz', 'Procure', 'Andozac', 'MK-906', 'Finastid', 'YM-152', 'Chibro-Proscar', 'MK-0906', 'Finaspros', 'Prodel', 'Prostide', 'Proscar', 'finasteride']",finasteride,fexact,"['eutiz', 'procure', 'andozac', 'mk 906', 'finastid', 'ym 152', 'chibro proscar', 'mk 0906', 'finaspros', 'prodel', 'prostide', 'proscar', 'finasteride']",correct_mapping
Iscomatrix,Immunostimulant,Iscomatrix,,ISCOMATRIX,iscomatrix,fexact,"['ISCOPREP703', 'ISCOMATRIX', 'vaccine adjuvants', 'ISCOM']",ISCOMATRIX,fexact,"['iscoprep703', 'iscomatrix', 'vaccine adjuvants', 'iscom']",correct_mapping
H1299 lysate vaccine,Immunostimulant,H1299 lysate vaccine,,,,0,['H1299 lysate vaccine'],,0,[],0
omaveloxolone (capsule),Transcription factor Nrf2 stimulant,omaveloxolone,,,,0,"['AIMs (CNS disease/respiratory disease/autoimmune disease), Reata/', '[14C]-RTA 408', 'Nrf2 activators (CNS disease/respiratory disease/autoimmune disease),/', 'AIMs (CNS disease/respiratory disease/autoimmune disease), Reata', 'CDDO-EA', 'aims (cns disease/respiratory disease/autoimmune disease)', 'AIMs (CNS disease/respiratory disease/autoimmune disease), Dartmouth College', 'RTA-408', 'AIMs (CNS disease/respiratory disease/autoimmune disease)', 'AIMs (CNS disease/respiratory disease/autoimmune disease), Reata/Abbott', 'omaveloxolone', 'AIMs (CNS disease/respiratory disease/autoimmune disease),/', 'Nrf2 activators (CNS disease/respiratory disease/autoimmune disease), Reata Pharmaceuticals/', '[14C]-Omaveloxolone']",,NER_API,[],0
carfilzomib,Protease/peptidase inhibitor; Apoptosis stimulant; Proteasome inhibitor,carfilzomib,,carfilzomib,carfilzomib,fexact,"['epoxomicin derivative (anticancer), Proteolix', 'epoxomicin derivative (anticancer)', 'ONO-7057', 'carfilzomib (intravenous/Captisol-enabled, cancer), Onyx/Ligand', 'Kyprolis', 'proteasome inhibitors (hematological malignancies)', 'proteasome inhibitors (hematological malignancies), Proteolix', 'carfilzomib', 'carfilzomib (intravenous/Captisol-enabled, cancer),/Ligand', 'PR-171']",carfilzomib,fexact,"['epoxomicin derivative anticancer proteolix', 'epoxomicin derivative anticancer', 'ono 7057', 'carfilzomib intravenous captisol enabled cancer onyx ligand', 'kyprolis', 'proteasome inhibitors hematological malignancies', 'proteasome inhibitors hematological malignancies proteolix', 'carfilzomib', 'carfilzomib intravenous captisol enabled cancer ligand', 'pr 171']",correct_mapping
bortezomib (SC),Transcription factor NF-kappaB inhibitor; Apoptosis stimulant; Proteasome inhibitor,bortezomib,,bortezomib,bortezomib,fexact,"['bortezomib', 'NSC-681239', 'PDP-341', 'LDP-341', 'PS-341', 'MLN-341', 'JNJ-26866138', 'Velcade', 'MG-341']",bortezomib,fexact,"['bortezomib', 'nsc 681239', 'pdp 341', 'ldp 341', 'ps 341', 'mln 341', 'jnj 26866138', 'velcade', 'mg 341']",correct_mapping
"pentamidine isethionate, Oncozyme",DNA repair enzyme inhibitor; Nuclease unspecified inhibitor,pentamidine isethionate,Oncozyme,"pentamidine isethionate (cancer), Oncozyme Pharma",pentamidine isethionate,fexact,"['pentamidine isethionate', 'pentamidine', 'pentamidine isethionate (cancer), Oncozyme Pharma', 'OCZ103-OS']","pentamidine isethionate (cancer), Oncozyme Pharma",fexact,"['pentamidine isethionate', 'pentamidine', 'pentamidine isethionate cancer oncozyme pharma', 'ocz103 os']",correct_mapping
UV1,Telomerase inhibitor; Immunostimulant,UV1,,,,0,['UV1'],,0,[],0
"anti-GM2 antibody, KHK",Ganglioside antigen GM2 antagonist; Immuno-oncology therapy,anti-GM2 antibody,KHK,,,0,['anti-GM2 antibody'],,0,[],0
imgatuzumab,EGFR antagonist,imgatuzumab,,imgatuzumab,imgatuzumab,fexact,"['anticancer agent (iv, solid tumor/NHL/HL)', 'R-7160', 'RO-5083945', 'imgatuzumab', '89Zr-imgatuzumab', 'Glycoengineered anti-EGFR antibody (GlycoMAb, injectable, solid tumor)', 'EGFR-targeting antibody (glycoengineered, solid tumor)', 'RG-7160', 'GA-201', 'Glycoengineered anti-EGFR antibody (GlycoMAb, injectable, solid tumor), Glycart']",imgatuzumab,fexact,"['anticancer agent iv solid tumor nhl hl', 'r 7160', 'ro 5083945', 'imgatuzumab', '89zr imgatuzumab', 'glycoengineered anti egfr antibody glycomab injectable solid tumor', 'egfr targeting antibody glycoengineered solid tumor', 'rg 7160', 'ga 201', 'glycoengineered anti egfr antibody glycomab injectable solid tumor glycart']",correct_mapping
pelareorep (IV),Immuno-oncology therapy,pelareorep,,pelareorep (cancer),pelareorep,fexact,"['pelareorep (cancer), Oncolytics', 'Reosyn', 'oncolytic retrovirus therapy (cancer), Oncolytics', 'P-BB0209', 'IND-13370', 'cancer therapy (reovirus)', 'Reolysin', 'oncolytic retrovirus therapy (cancer)', 'cancer therapy (reovirus), Oncolytics', 'pelareorep', 'pelareorep (cancer)', 'AN-1004', 'NSC-729968']",pelareorep (cancer),fexact,"['pelareorep cancer oncolytics', 'reosyn', 'oncolytic retrovirus therapy cancer oncolytics', 'p bb0209', 'ind 13370', 'cancer therapy reovirus', 'reolysin', 'oncolytic retrovirus therapy cancer', 'cancer therapy reovirus oncolytics', 'pelareorep', 'pelareorep cancer', 'an 1004', 'nsc 729968']",correct_mapping
fulvestrant (IV),Estrogen receptor antagonist; DNA directed DNA polymerase inhibitor; Selective estrogen receptor downregulator,fulvestrant,,fulvestrant,fulvestrant,fexact,"['Faslodex', 'ZD-182780', 'ZM-182780', 'ZD-9238', 'Faslodext', 'ICI-182780', 'fulvestrant']",fulvestrant,fexact,"['faslodex', 'zd 182780', 'zm 182780', 'zd 9238', 'faslodext', 'ici 182780', 'fulvestrant']",correct_mapping
"lithium, unspecified",Unidentified pharmacological activity,lithium,unspecified,,,0,['lithium'],,0,[],0
QBKPN,Immunostimulant; Immuno-oncology therapy,QBKPN,,QBKPN,qbkpn,fexact,"['site-specific immunotherapeutic (lung cancer)', 'lung SSI', 'QBKPN-01', 'QBKPN', 'QBKPN SSI']",QBKPN,fexact,"['site specific immunotherapeutic lung cancer', 'lung ssi', 'qbkpn 01', 'qbkpn', 'qbkpn ssi']",correct_mapping
"cancer vaccine, DRibble, UbiVac",T cell stimulant; Immuno-oncology therapy,cancer vaccine,UbiVac,HER-2 peptide vaccine (cancer),cancer vaccine,fexact,"['trastuzumab like and pertuzumab-like HER-2 vaccine (cancer), Ohio State University', 'HER-2 peptide vaccine (cancer), Ohio State University', 'peptide vaccines, Ohio State University', 'peptide vaccines', 'her-2 peptide vaccine (cancer)', 'HER-2 628-647', 'HER-2 peptide vaccine (cancer)', 'cancer vaccine', 'MVF HER-2 (597-626)', 'cancer vaccine, Ohio State University', 'MVF HER2', 'trastuzumab like and pertuzumab-like her-2 vaccine (cancer)', 'B-Vaxx', 'MVF HER-2 (266-296)', 'HER-2 316-339']",HER-2 peptide vaccine (cancer),fexact,"['trastuzumab like and pertuzumab like her 2 vaccine cancer ohio state university', 'her 2 peptide vaccine cancer ohio state university', 'peptide vaccines ohio state university', 'peptide vaccines', 'her 2 peptide vaccine cancer', 'her 2 628 647', 'her 2 peptide vaccine cancer', 'cancer vaccine', 'mvf her 2 597 626', 'cancer vaccine ohio state university', 'mvf her2', 'trastuzumab like and pertuzumab like her 2 vaccine cancer', 'b vaxx', 'mvf her 2 266 296', 'her 2 316 339']",correct_mapping
"doxorubicin, Celsion",DNA topoisomerase II inhibitor,doxorubicin,Celsion,"doxorubicin (liposomal, STEALTH)",doxorubicin,fexact,"['doxorubicin (liposomal, STEALTH)', 'SL-Dox', 'DOX-SL', 'doxorubicin HCl', 'doxorubicin hydrochloride', 'Caelyx', 'STEALTH (doxorubicin)', 'S-DOX', 'doxorubicin,/Schering', 'NSC-712227', 'doxorubicin,/', 'doxorubicin', 'pegylated liposomal doxorubicin', 'Doxil', 'JNS-002']","doxorubicin (liposomal, STEALTH)",fexact,"['doxorubicin liposomal stealth', 'sl dox', 'dox sl', 'doxorubicin hcl', 'doxorubicin hydrochloride', 'caelyx', 'stealth doxorubicin', 's dox', 'doxorubicin schering', 'nsc 712227', 'doxorubicin', 'doxorubicin', 'pegylated liposomal doxorubicin', 'doxil', 'jns 002']",correct_mapping
tarloxotinib,EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor,tarloxotinib,,,,0,['tarloxotinib'],,0,[],0
"sclc vaccine, MabVax",Immunostimulant,sclc vaccine,MabVax,,,0,['sclc vaccine'],,0,[],0
SB injection,Unidentified pharmacological activity,SB injection,,,,0,"['saponins (cancer)', 'SB-31', 'Injection']",,Drug_API_mapping,[],0
sotatercept (SC),Transforming growth factor beta antagonist; Activin A receptor type 2A ligand trap,sotatercept,,sotatercept,sotatercept,fexact,"['ACE-011', 'activin IIa receptor antagonist (anemia, bone loss),/', 'ActRIIA-IgG1', 'bone loss therapy', 'sotatercept', 'activin IIa receptor antagonist (anemia, bone loss),/Bristol-Myers Squibb', 'activin IIa receptor antagonist (anemia, bone loss)', 'RAP-011', 'ACE-011d']",sotatercept,fexact,"['ace 011', 'activin iia receptor antagonist anemia bone loss', 'actriia igg1', 'bone loss therapy', 'sotatercept', 'activin iia receptor antagonist anemia bone loss bristol myers squibb', 'activin iia receptor antagonist anemia bone loss', 'rap 011', 'ace 011d']",correct_mapping
"pemetrexed, Jiangsu Stockhausen",Phosphoribosylglycinamide formyltransferase inhibitor; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor,pemetrexed,Jiangsu Stockhausen,pemetrexed disodium,pemetrexed,fexact,"['NSC-698037', 'multitargeted antifolate', 'Alimta', 'pemetrexed', 'MTA', 'LY-231514', 'IND-40061', 'pemetrexed sodium hydrate', 'pemetrexed disodium']",pemetrexed disodium,fexact,"['nsc 698037', 'multitargeted antifolate', 'alimta', 'pemetrexed', 'mta', 'ly 231514', 'ind 40061', 'pemetrexed sodium hydrate', 'pemetrexed disodium']",correct_mapping
demcizumab,Immunostimulant; Delta-like 4 antagonist,demcizumab,,demcizumab,demcizumab,fexact,"['demcizumab', 'tumor stem cell-targeting humanized monoclonal antibodies (cancer)', 'OMP-21M18', 'OMP-90R210', 'anti-DLL4 humanized monoclonal antibodies (cancer)', 'tumor stem cell-targeting humanized mAbs (cancer)']",demcizumab,fexact,"['demcizumab', 'tumor stem cell targeting humanized monoclonal antibodies cancer', 'omp 21m18', 'omp 90r210', 'anti dll4 humanized monoclonal antibodies cancer', 'tumor stem cell targeting humanized mabs cancer']",correct_mapping
tivantinib (tablet),MET tyrosine kinase inhibitor; Angiogenesis inhibitor,tivantinib,,tivantinib,tivantinib,fexact,"['CO-650', 'ARQ-707', '650RP', 'tivantinib', 'ARQ-650RP', 'cancer survival protein modulation program', 'ARQ-650', 'ARQ-197', 'CO-650 series (cancer)', 'cancer survival protein modulation product']",tivantinib,fexact,"['co 650', 'arq 707', '650rp', 'tivantinib', 'arq 650rp', 'cancer survival protein modulation program', 'arq 650', 'arq 197', 'co 650 series cancer', 'cancer survival protein modulation product']",correct_mapping
onatasertib (capsule),mTORC1 kinase inhibitor; mTORC2 kinase inhibitor,onatasertib,,onatasertib,onatasertib,fexact,"['TORC1/2 inhibitor (oral, solid tumors/hematological malignancies)', 'mTOR kinase inhibitors, Celgene', 'mTOR kinase inhibitors', 'CC-223', 'TORC1/2 inhibitor (oral, solid tumors/hematological malignancies), Bristol-Myers Squibb', 'TORKi CC-223', 'onatasertib', 'ATG-008']",onatasertib,fexact,"['torc1 2 inhibitor oral solid tumors hematological malignancies', 'mtor kinase inhibitors celgene', 'mtor kinase inhibitors', 'cc 223', 'torc1 2 inhibitor oral solid tumors hematological malignancies bristol myers squibb', 'torki cc 223', 'onatasertib', 'atg 008']",correct_mapping
sodium metaarsenite,DNA inhibitor,sodium metaarsenite,,,,0,['sodium metaarsenite'],,0,[],0
AlloStim (ID),Immunostimulant; Immuno-oncology therapy; Immune checkpoint stimulant,AlloStim,,"allostim (infusion formulation, hematological neoplasms)",allostim,fexact,"['activated T-Stim cells (iv infusion, hematological neoplasms)', 'activated mismatched CD4+ memory  cells (hematological malignancies)', 'AlloStim', 'AlloStim (infusion formulation, hematological neoplasms)', 'AlloStim (infusion formulation, hematological neoplasms),/ Robert H Lurie Cancer Center', 'InSituVax', 'allostim (infusion formulation, hematological neoplasms)', 'AlloStim-9 infusion + AlloStim-8 booster infusions (hematological cancers)', 'activated mismatched CD4+ memory T cells (hematological malignancies)', 'StimVax']","allostim (infusion formulation, hematological neoplasms)",fexact,"['activated t stim cells iv infusion hematological neoplasms', 'activated mismatched cd4 memory cells hematological malignancies', 'allostim', 'allostim infusion formulation hematological neoplasms', 'allostim infusion formulation hematological neoplasms robert h lurie cancer center', 'insituvax', 'allostim infusion formulation hematological neoplasms', 'allostim 9 infusion allostim 8 booster infusions hematological cancers', 'activated mismatched cd4 memory t cells hematological malignancies', 'stimvax']",correct_mapping
AlloStim (intratumoral),Immunostimulant; Immuno-oncology therapy; Immune checkpoint stimulant,AlloStim,,"allostim (infusion formulation, hematological neoplasms)",allostim,fexact,"['activated T-Stim cells (iv infusion, hematological neoplasms)', 'activated mismatched CD4+ memory  cells (hematological malignancies)', 'AlloStim', 'AlloStim (infusion formulation, hematological neoplasms)', 'AlloStim (infusion formulation, hematological neoplasms),/ Robert H Lurie Cancer Center', 'InSituVax', 'allostim (infusion formulation, hematological neoplasms)', 'AlloStim-9 infusion + AlloStim-8 booster infusions (hematological cancers)', 'activated mismatched CD4+ memory T cells (hematological malignancies)', 'StimVax']","allostim (infusion formulation, hematological neoplasms)",fexact,"['activated t stim cells iv infusion hematological neoplasms', 'activated mismatched cd4 memory cells hematological malignancies', 'allostim', 'allostim infusion formulation hematological neoplasms', 'allostim infusion formulation hematological neoplasms robert h lurie cancer center', 'insituvax', 'allostim infusion formulation hematological neoplasms', 'allostim 9 infusion allostim 8 booster infusions hematological cancers', 'activated mismatched cd4 memory t cells hematological malignancies', 'stimvax']",correct_mapping
AlloStim (IV),Immunostimulant; Immuno-oncology therapy; Immune checkpoint stimulant,AlloStim,,"allostim (infusion formulation, hematological neoplasms)",allostim,fexact,"['activated T-Stim cells (iv infusion, hematological neoplasms)', 'activated mismatched CD4+ memory  cells (hematological malignancies)', 'AlloStim', 'AlloStim (infusion formulation, hematological neoplasms)', 'AlloStim (infusion formulation, hematological neoplasms),/ Robert H Lurie Cancer Center', 'InSituVax', 'allostim (infusion formulation, hematological neoplasms)', 'AlloStim-9 infusion + AlloStim-8 booster infusions (hematological cancers)', 'activated mismatched CD4+ memory T cells (hematological malignancies)', 'StimVax']","allostim (infusion formulation, hematological neoplasms)",fexact,"['activated t stim cells iv infusion hematological neoplasms', 'activated mismatched cd4 memory cells hematological malignancies', 'allostim', 'allostim infusion formulation hematological neoplasms', 'allostim infusion formulation hematological neoplasms robert h lurie cancer center', 'insituvax', 'allostim infusion formulation hematological neoplasms', 'allostim 9 infusion allostim 8 booster infusions hematological cancers', 'activated mismatched cd4 memory t cells hematological malignancies', 'stimvax']",correct_mapping
AlloStim (intraperitoneal),Immunostimulant; Immuno-oncology therapy; Immune checkpoint stimulant,AlloStim,,"allostim (infusion formulation, hematological neoplasms)",allostim,fexact,"['activated T-Stim cells (iv infusion, hematological neoplasms)', 'activated mismatched CD4+ memory  cells (hematological malignancies)', 'AlloStim', 'AlloStim (infusion formulation, hematological neoplasms)', 'AlloStim (infusion formulation, hematological neoplasms),/ Robert H Lurie Cancer Center', 'InSituVax', 'allostim (infusion formulation, hematological neoplasms)', 'AlloStim-9 infusion + AlloStim-8 booster infusions (hematological cancers)', 'activated mismatched CD4+ memory T cells (hematological malignancies)', 'StimVax']","allostim (infusion formulation, hematological neoplasms)",fexact,"['activated t stim cells iv infusion hematological neoplasms', 'activated mismatched cd4 memory cells hematological malignancies', 'allostim', 'allostim infusion formulation hematological neoplasms', 'allostim infusion formulation hematological neoplasms robert h lurie cancer center', 'insituvax', 'allostim infusion formulation hematological neoplasms', 'allostim 9 infusion allostim 8 booster infusions hematological cancers', 'activated mismatched cd4 memory t cells hematological malignancies', 'stimvax']",correct_mapping
AlloStim (intrapleural),Immunostimulant; Immuno-oncology therapy; Immune checkpoint stimulant,AlloStim,,"allostim (infusion formulation, hematological neoplasms)",allostim,fexact,"['activated T-Stim cells (iv infusion, hematological neoplasms)', 'activated mismatched CD4+ memory  cells (hematological malignancies)', 'AlloStim', 'AlloStim (infusion formulation, hematological neoplasms)', 'AlloStim (infusion formulation, hematological neoplasms),/ Robert H Lurie Cancer Center', 'InSituVax', 'allostim (infusion formulation, hematological neoplasms)', 'AlloStim-9 infusion + AlloStim-8 booster infusions (hematological cancers)', 'activated mismatched CD4+ memory T cells (hematological malignancies)', 'StimVax']","allostim (infusion formulation, hematological neoplasms)",fexact,"['activated t stim cells iv infusion hematological neoplasms', 'activated mismatched cd4 memory cells hematological malignancies', 'allostim', 'allostim infusion formulation hematological neoplasms', 'allostim infusion formulation hematological neoplasms robert h lurie cancer center', 'insituvax', 'allostim infusion formulation hematological neoplasms', 'allostim 9 infusion allostim 8 booster infusions hematological cancers', 'activated mismatched cd4 memory t cells hematological malignancies', 'stimvax']",correct_mapping
"suramin, Optimum Therapeutics",DNA synthesis inhibitor; Angiogenesis inhibitor,suramin,Optimum Therapeutics,"suramin sodium (low-dose, cancer)",suramin,fexact,"['suramin', 'suramin sodium', 'suramin sodium (low-dose, cancer)', 'suramin hexasodium', 'suramin (low-dose, cancer)']","suramin sodium (low-dose, cancer)",fexact,"['suramin', 'suramin sodium', 'suramin sodium low dose cancer', 'suramin hexasodium', 'suramin low dose cancer']",correct_mapping
"docetaxel, Azaya",Tubulin inhibitor; Microtubule stimulant; Taxane,docetaxel,Azaya,"docetaxel (polymeric micelle, solid tumor)",docetaxel,fexact,"['docetaxel-PM', 'docetaxel (polymeric micelle, solid tumor)', 'Nanoxel-PM', 'docetaxel', 'SYP-0704A', 'Nanoxel']","docetaxel (polymeric micelle, solid tumor)",fexact,"['docetaxel pm', 'docetaxel polymeric micelle solid tumor', 'nanoxel pm', 'docetaxel', 'syp 0704a', 'nanoxel']",correct_mapping
SVV-001,Immuno-oncology therapy,SVV-001,,SVV-001,svv 001,fexact,"['TEM-8 targeting oncolytic virus therapy (solid tumors)', 'TEM-8 targeting oncolytic virus therapy (solid tumors), Seneca Therapeutics', 'oncolytic Seneca Valley virus therapy (iv, cancer)', 'SVV-001', 'NTX-010']",SVV-001,fexact,"['tem 8 targeting oncolytic virus therapy solid tumors', 'tem 8 targeting oncolytic virus therapy solid tumors seneca therapeutics', 'oncolytic seneca valley virus therapy iv cancer', 'svv 001', 'ntx 010']",correct_mapping
robatumumab,Insulin-like growth factor 1 antagonist,robatumumab,,robatumumab,robatumumab,fexact,"['anti-IGF-1R (cancer)', 'anti-IR3 antibodies', 'MAb-391', 'anti-IGF-1R (cancer), Schering-Plough', 'SCH-717454', 'anti-IGFR1 antibodies (cancer)', 'anti-IR3 antibodies, Schering-Plough', 'anti-IGFR1 antibodies (cancer), Schering-Plough', 'robatumumab', '19D12']",robatumumab,fexact,"['anti igf 1r cancer', 'anti ir3 antibodies', 'mab 391', 'anti igf 1r cancer schering plough', 'sch 717454', 'anti igfr1 antibodies cancer', 'anti ir3 antibodies schering plough', 'anti igfr1 antibodies cancer schering plough', 'robatumumab', '19d12']",correct_mapping
sapacitabine,DNA synthesis inhibitor; DNA directed DNA polymerase inhibitor; Cell cycle inhibitor,sapacitabine,,sapacitabine,sapacitabine,fexact,"['CYC-682', 'CNDAC prodrug (cancer)', 'CNDAU', 'sapacitabine', 'CS-682', 'CNDAC']",sapacitabine,fexact,"['cyc 682', 'cndac prodrug cancer', 'cndau', 'sapacitabine', 'cs 682', 'cndac']",correct_mapping
bortezomib,Transcription factor NF-kappaB inhibitor; Apoptosis stimulant; Proteasome inhibitor,bortezomib,,bortezomib,bortezomib,fexact,"['bortezomib', 'NSC-681239', 'PDP-341', 'LDP-341', 'PS-341', 'MLN-341', 'JNJ-26866138', 'Velcade', 'MG-341']",bortezomib,fexact,"['bortezomib', 'nsc 681239', 'pdp 341', 'ldp 341', 'ps 341', 'mln 341', 'jnj 26866138', 'velcade', 'mg 341']",correct_mapping
"imexon, AmpliMed",Immunosuppressant; Immunostimulant; Apoptosis stimulant,imexon,AmpliMed,imexon (injectable),imexon,fexact,"['Amplimexon', 'AMP-404', 'imexon (injectable)', 'imexon analogs', 'AMP-019', 'imexon']",imexon (injectable),fexact,"['amplimexon', 'amp 404', 'imexon injectable', 'imexon analogs', 'amp 019', 'imexon']",correct_mapping
evofosfamide,DNA inhibitor; DNA synthesis inhibitor,evofosfamide,,evofosfamide,evofosfamide,fexact,"['hypoxia-activated daunorubicin prodrugs (cancer), Threshold', 'HAP-302', 'TH-302', 'evofosfamide', 'hypoxia-activated daunorubicin prodrugs (cancer)', 'dibromo isophosphoramide mustard', 'hypoxia-activated daunorubicin prodrugs (cancer), Molecular', 'TH-63']",evofosfamide,fexact,"['hypoxia activated daunorubicin prodrugs cancer threshold', 'hap 302', 'th 302', 'evofosfamide', 'hypoxia activated daunorubicin prodrugs cancer', 'dibromo isophosphoramide mustard', 'hypoxia activated daunorubicin prodrugs cancer molecular', 'th 63']",correct_mapping
linifanib,Colony stimulating factor 1 receptor antagonist; Macrophage colony stimulating factor antagonist; Platelet-derived growth factor receptor kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,linifanib,,linifanib,linifanib,fexact,"['ABT-869', 'AL-39324', 'tyrosine kinase inhibitors (cancer)', 'linifanib', 'RG-3635']",linifanib,fexact,"['abt 869', 'al 39324', 'tyrosine kinase inhibitors cancer', 'linifanib', 'rg 3635']",correct_mapping
AEG-35156,Caspase stimulant; IAP antagonist,AEG-35156,,AEG-35156,aeg 35156,fexact,"['GEM-640', 'X-linked inhibitory apoptosis protein (antisense),/', 'AEG-35156', 'X-linked inhibitory apoptosis protein (antisense),/Idera', 'XIAP antisense (anticancer),/', 'AEG-161', 'XIAP-AS', 'X-linked inhibitory apoptosis protein (antisense)', 'XIAP antisense (anticancer),/Hybridon', 'AEG-351569', 'XIAP antisense (anticancer),/Idera', 'X-linked inhibitory apoptosis protein (antisense), Apoptogen']",AEG-35156,fexact,"['gem 640', 'x linked inhibitory apoptosis protein antisense', 'aeg 35156', 'x linked inhibitory apoptosis protein antisense idera', 'xiap antisense anticancer', 'aeg 161', 'xiap as', 'x linked inhibitory apoptosis protein antisense', 'xiap antisense anticancer hybridon', 'aeg 351569', 'xiap antisense anticancer idera', 'x linked inhibitory apoptosis protein antisense apoptogen']",correct_mapping
pexastimogene devacirepvec (IV),Granulocyte macrophage colony stimulating factor agonist; Immuno-oncology therapy,pexastimogene devacirepvec,,pexastimogene devacirepvec,pexastimogene devacirepvec,fexact,"['oncolytic vaccinia virus therapy expressing GM-CSF (cancer),/Green Cross', 'TG-6006', 'oncolytic vaccinia virus therapy expressing GM-CSF (cancer), Jennerex/Green Cross', 'pexastimogene devacirepvec', 'Pexa-Vec', 'JX-594']",pexastimogene devacirepvec,fexact,"['oncolytic vaccinia virus therapy expressing gm csf cancer green cross', 'tg 6006', 'oncolytic vaccinia virus therapy expressing gm csf cancer jennerex green cross', 'pexastimogene devacirepvec', 'pexa vec', 'jx 594']",correct_mapping
conatumumab,TRAIL receptor 2 agonist; Apoptosis stimulant,conatumumab,,conatumumab,conatumumab,fexact,"['TRAIL receptor-2 mAb (cancer),/Takeda', 'TRAIL receptor-2 mAb (cancer),/', 'AMG-655', 'conatumumab', 'TRAIL-R2 mAb']",conatumumab,fexact,"['trail receptor 2 mab cancer takeda', 'trail receptor 2 mab cancer', 'amg 655', 'conatumumab', 'trail r2 mab']",correct_mapping
1650-G,Immunostimulant,1650-G,,allogeneic cell vaccine (non-small cell lung cancer),1650 g,fexact,"['allogeneic cell vaccine (non-small cell lung cancer)', '1650-G']",allogeneic cell vaccine (non-small cell lung cancer),fexact,"['allogeneic cell vaccine non small cell lung cancer', '1650 g']",correct_mapping
BI-2536,Polo-like kinase 1 inhibitor; Protein kinase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,BI-2536,,BI-2536,bi 2536,fexact,"['BI-2536-BS', 'BI-2536']",BI-2536,fexact,"['bi 2536 bs', 'bi 2536']",correct_mapping
CALAA-01,Ribonucleoside triphosphate reductase inhibitor; Gene expression inhibitor,CALAA-01,,CALAA-01,calaa 01,fexact,"['ribonucleotide reductase M2 subunit (RRM2)-targeted siRNA agent (RONDEL, intravenous, cancer)', 'CALAA-01']",CALAA-01,fexact,"['ribonucleotide reductase m2 subunit rrm2 targeted sirna agent rondel intravenous cancer', 'calaa 01']",correct_mapping
antineoplaston A10 (capsule),DNA inhibitor,antineoplaston A10,,"antineoplaston A-10, Burzynski Institute",antineoplaston a 10,fuzzy,"['atengenal', 'antineoplaston A-10', 'NSC-648539', 'antineoplaston A-10, Burzynski Institute']","antineoplaston A-10, Burzynski Institute",fexact,"['atengenal', 'antineoplaston a 10', 'nsc 648539', 'antineoplaston a 10 burzynski institute']",incorrect_mapping
antineoplaston AS2-1 (oral),DNA methylase inhibitor; Protein synthesis inhibitor,antineoplaston AS2-1,,"antineoplaston AS2-1, Burzynski Institute",antineoplaston as2 1,fexact,"['NSC-620621', 'antineoplaston AS2-1, Burzynski Institute', 'astugenal', 'antineoplaston AS2-1']","antineoplaston AS2-1, Burzynski Institute",fexact,"['nsc 620621', 'antineoplaston as2 1 burzynski institute', 'astugenal', 'antineoplaston as2 1']",correct_mapping
dulanermin,TRAIL receptor 1 agonist; TRAIL receptor 2 agonist; Apoptosis stimulant,dulanermin,,dulanermin,dulanermin,fexact,"['TRAIL protein, Immunex', 'TRAIL/Apo2L,/', 'APO2L/tumor necrosis factor-related apoptosis inducing ligand (cancer),/Genentech', 'rhApo2L/TRAIL (cancer),/Genentech', 'Apo2L/TRAIL (cell death signaling),/Genentech', 'RG-3639', 'TRAIL/Apo2L (Cancer), Genentech/', 'dulanermin', 'TRAIL/Apo2L (Cancer),/', 'Apo2L/TRAIL (cancer),/Genentech', 'Apo2L/TRAIL (cell death signaling),/', 'AMG-951', 'PRO-1762', 'rhApo2L/TRAIL (cancer),/', 'Apo2L/TRAIL (cancer),/', 'TRAIL/Apo2L,/Immunex', 'APO2L/tumor necrosis factor-related apoptosis inducing ligand (cancer),/', 'TRAIL/Apo2L, Genentech/Immunex', 'rhApo2L/TRAIL', 'TRAIL protein']",dulanermin,fexact,"['trail protein immunex', 'trail apo2l', 'apo2l tumor necrosis factor related apoptosis inducing ligand cancer genentech', 'rhapo2l trail cancer genentech', 'apo2l trail cell death signaling genentech', 'rg 3639', 'trail apo2l cancer genentech', 'dulanermin', 'trail apo2l cancer', 'apo2l trail cancer genentech', 'apo2l trail cell death signaling', 'amg 951', 'pro 1762', 'rhapo2l trail cancer', 'apo2l trail cancer', 'trail apo2l immunex', 'apo2l tumor necrosis factor related apoptosis inducing ligand cancer', 'trail apo2l genentech immunex', 'rhapo2l trail', 'trail protein']",correct_mapping
BMS-275183,Beta tubulin inhibitor; Microtubule stimulant; Taxane,BMS-275183,,BMS-275183,bms 275183,fexact,"['BMS-198246', 'oral taxane (cancer)', 'BMS-275183', 'oral taxane (cancer), BMS']",BMS-275183,fexact,"['bms 198246', 'oral taxane cancer', 'bms 275183', 'oral taxane cancer bms']",correct_mapping
tozasertib lactate,Aurora kinase inhibitor; Bcr-Abl inhibitor; Flt-3 antagonist; Janus kinase 2 inhibitor; Mitotic inhibitor,tozasertib lactate,,tozasertib,tozasertib lactate,fexact,"['multi-kinase inhibitor (Aurora, ABL, Flt3)', 'tozasertib', 'MK-0457', 'VRT-960', 'tozasertib lactate', 'VRT-426', 'VX-680']",tozasertib,fexact,"['multi kinase inhibitor aurora abl flt3', 'tozasertib', 'mk 0457', 'vrt 960', 'tozasertib lactate', 'vrt 426', 'vx 680']",correct_mapping
"vinorelbine, Adventrx",Microtubule inhibitor; Tubulin inhibitor; Vinca alkaloid,vinorelbine,Adventrx,vinorelbine,vinorelbine,fexact,"['vinorelbine tartrate', 'KW-2307', 'vinorelbine', 'KW-3407', 'Eunades', 'vinorelbine monotartrate', 'Navelbine']",vinorelbine,fexact,"['vinorelbine tartrate', 'kw 2307', 'vinorelbine', 'kw 3407', 'eunades', 'vinorelbine monotartrate', 'navelbine']",correct_mapping
talabostat mesylate,Growth factor receptor agonist; Immunostimulant; Dipeptidyl peptidase 8 (DPP VIII) inhibitor; Dipeptidyl peptidase 9 (DPP IX) inhibitor; Fibroblast activation protein inhibitor; Serine protease inhibitor,talabostat mesylate,,talabostat,talabostat mesylate,fexact,"['boroproline compounds, Point Therapeutics', 'boroproline compounds, DARA BioSciences', 'PT-100', 'talabostat', 'Val-boro-Pro', 'talabostat mesylate']",talabostat,fexact,"['boroproline compounds point therapeutics', 'boroproline compounds dara biosciences', 'pt 100', 'talabostat', 'val boro pro', 'talabostat mesylate']",correct_mapping
"NY-ESO-1 vaccine, PowderMed",Immunostimulant,NY-ESO-1 vaccine,PowderMed,,,0,['NY-ESO-1 vaccine'],,0,[],0
hyperthermia,Not applicable,hyperthermia,,,,0,['hyperthermia'],,0,[],0
ING-1 (SC),Epithelial cell adhesion molecule inhibitor,ING-1,,ING-1,ing 1,fexact,"['ING-1 (heMAb)', 'ING-1 mAb', 'ING-1']",ING-1,fexact,"['ing 1 hemab', 'ing 1 mab', 'ing 1']",correct_mapping
matuzumab,EGFR antagonist,matuzumab,,matuzumab,matuzumab,fexact,"['matuzumab', 'anti-epidermal growth factor receptor humanized antibody (iv, cancer),/ takeda pharmaceuticals', 'anti-egfr humanized mab (iv, cancer),/ takeda pharmaceuticals', 'EMD-72000', 'anti-egf receptor humanized antibody (iv, cancer), / takeda pharmaceuticals', 'anti-egfr humanized mab (iv, cancer), / takeda pharmaceuticals', 'anti-egf receptor humanized antibody (iv, cancer),/ takeda pharmaceuticals', 'EMD-62000', 'anti-epidermal growth factor receptor humanized antibody (iv, cancer), / takeda pharmaceuticals']",matuzumab,fexact,"['matuzumab', 'anti epidermal growth factor receptor humanized antibody iv cancer takeda pharmaceuticals', 'anti egfr humanized mab iv cancer takeda pharmaceuticals', 'emd 72000', 'anti egf receptor humanized antibody iv cancer takeda pharmaceuticals', 'anti egfr humanized mab iv cancer takeda pharmaceuticals', 'anti egf receptor humanized antibody iv cancer takeda pharmaceuticals', 'emd 62000', 'anti epidermal growth factor receptor humanized antibody iv cancer takeda pharmaceuticals']",correct_mapping
perifosine,Protein kinase B inhibitor; Protein kinase inhibitor; PI3 kinase inhibitor,perifosine,,perifosine,perifosine,fexact,"['IND-58156', 'perifosin', 'KRX-0401', 'perifosine', 'D-21266', 'AEZS-104', 'YHI-1003', 'ASTA-D21266', 'NSC-639966']",perifosine,fexact,"['ind 58156', 'perifosin', 'krx 0401', 'perifosine', 'd 21266', 'aezs 104', 'yhi 1003', 'asta d21266', 'nsc 639966']",correct_mapping
pelitrexol,Phosphoribosylglycinamide formyltransferase inhibitor,pelitrexol,,pelitrexol,pelitrexol,fexact,"['AG-2037', 'pelitrexol']",pelitrexol,fexact,"['ag 2037', 'pelitrexol']",correct_mapping
CEA-TRICOM,Immunostimulant; Carcinoembryonic antigen inhibitor,CEA-TRICOM,,,,0,['CEA-TRICOM'],,0,[],0
sargramostim (SC),Granulocyte macrophage colony stimulating factor agonist,sargramostim,,sargramostim,sargramostim,fexact,"['GM-CSF,/', 'BI 61.012', 'GM-CSF, Berlex/Schering', 'GM-CSF,/Schering', 'GM-CSF, Immunex', 'GM-CSF, Behringwerke', 'SHL-04023', 'Prokine', 'GM-CSF', 'Leukine', 'sargramostim']",sargramostim,fexact,"['gm csf', 'bi 61 012', 'gm csf berlex schering', 'gm csf schering', 'gm csf immunex', 'gm csf behringwerke', 'shl 04023', 'prokine', 'gm csf', 'leukine', 'sargramostim']",correct_mapping
diflomotecan (IV),DNA topoisomerase I inhibitor,diflomotecan,,diflomotecan,diflomotecan,fexact,"['diflomotecan', 'R-1536', 'anticancer homocamptothecins, beafour-ipsen', 'BN-80942', 'BN-90915', 'topoisomerase inhibitors, beaufour- (biomeasure/institut henri beaufour)', 'BN-80362', 'BN-80915']",diflomotecan,fexact,"['diflomotecan', 'r 1536', 'anticancer homocamptothecins beafour ipsen', 'bn 80942', 'bn 90915', 'topoisomerase inhibitors beaufour biomeasure institut henri beaufour', 'bn 80362', 'bn 80915']",correct_mapping
vitespen (sc),Immunostimulant,vitespen,,vitespen,vitespen,fexact,"['HSPPC-96-GH', 'Oncophage', 'Prophage M-200', 'Prophage G-200', 'Prophage R-200', 'Prophage M-100', 'gp96 vaccine, Antigenics', 'NP-150', 'Prophage R-100', 'vitespen', 'HSPPC-96', 'Prophage G-100', 'Prophage NP-150', 'HSPPC-96-C']",vitespen,fexact,"['hsppc 96 gh', 'oncophage', 'prophage m 200', 'prophage g 200', 'prophage r 200', 'prophage m 100', 'gp96 vaccine antigenics', 'np 150', 'prophage r 100', 'vitespen', 'hsppc 96', 'prophage g 100', 'prophage np 150', 'hsppc 96 c']",correct_mapping
"lurtotecan hydrochloride, OSI",DNA topoisomerase I inhibitor,lurtotecan hydrochloride,OSI,lurtotecan (liposomal),lurtotecan dihydrochloride,fuzzy,"['lurtotecan dihydrochloride', 'NX-211', 'lurtotecan (liposomal), OSI', 'GG211 (liposomal),/', 'lurtotecan (liposomal), NeXstar/Glaxo Wellcome', 'lurtotecan (liposomal),/Glaxo Wellcome', 'GG211 (liposomal), NeXstar/GlaxoSmithKline', 'lurtotecan (liposomal)', 'GG211 (liposomal),/Glaxo Wellcome', 'lurtotecan (liposomal), NeXstar/GlaxoSmithKline', 'OSI-211', 'GG211 (liposomal), NeXstar/', 'GG211 (liposomal), NeXstar/Glaxo Wellcome', 'lurtotecan (liposomal),/', 'lurtotecan (liposomal), NeXstar/', 'GI 147211C']",lurtotecan (liposomal),fexact,"['lurtotecan dihydrochloride', 'nx 211', 'lurtotecan liposomal osi', 'gg211 liposomal', 'lurtotecan liposomal nexstar glaxo wellcome', 'lurtotecan liposomal glaxo wellcome', 'gg211 liposomal nexstar glaxosmithkline', 'lurtotecan liposomal', 'gg211 liposomal glaxo wellcome', 'lurtotecan liposomal nexstar glaxosmithkline', 'osi 211', 'gg211 liposomal nexstar', 'gg211 liposomal nexstar glaxo wellcome', 'lurtotecan liposomal', 'lurtotecan liposomal nexstar', 'gi 147211c']",incorrect_mapping
orantinib (oral),Fibroblast growth factor receptor antagonist; Vascular endothelial growth factor (VEGF)receptor antagonist; FGF receptor 1 tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Apoptosis stimulant,orantinib,,orantinib,orantinib,fexact,"['SU-6668', 'TSU-68', 'orantinib', 'SU-006668']",orantinib,fexact,"['su 6668', 'tsu 68', 'orantinib', 'su 006668']",correct_mapping
nelipepimut-S,Immunostimulant; ErbB-2 tyrosine kinase inhibitor; Immuno-oncology therapy,nelipepimut-S,,,,0,"['HER2/neu peptide vaccine (breast cancer)', 'E75 peptide', 'HER2/neu peptide vaccine (breast cancer), SELLAS Life Sciences', 'nelipepimut-s', 'Her2/neu (E75) prostate cancer vaccine,/', 'Her2/neu (E75) prostate cancer vaccine, Henry M Jackson Foundation/', 'Her2/neu (E75) prostate cancer vaccine, Henry M Jackson Foundation/Galena', 'NeuVax']",,NER_API,[],0
"doxorubicin, inhaled",DNA topoisomerase II inhibitor,doxorubicin,inhaled,"doxorubicin (liposomal, STEALTH)",doxorubicin,fexact,"['doxorubicin (liposomal, STEALTH)', 'SL-Dox', 'DOX-SL', 'doxorubicin HCl', 'doxorubicin hydrochloride', 'Caelyx', 'STEALTH (doxorubicin)', 'S-DOX', 'doxorubicin,/Schering', 'NSC-712227', 'doxorubicin,/', 'doxorubicin', 'pegylated liposomal doxorubicin', 'Doxil', 'JNS-002']","doxorubicin (liposomal, STEALTH)",fexact,"['doxorubicin liposomal stealth', 'sl dox', 'dox sl', 'doxorubicin hcl', 'doxorubicin hydrochloride', 'caelyx', 'stealth doxorubicin', 's dox', 'doxorubicin schering', 'nsc 712227', 'doxorubicin', 'doxorubicin', 'pegylated liposomal doxorubicin', 'doxil', 'jns 002']",correct_mapping
romidepsin,Histone deacetylase inhibitor; Cell cycle inhibitor,romidepsin,,romidepsin,romidepsin,fexact,"['depsipeptide, NCI/', 'romidepsin', 'Istodax', 'depsipeptide, NCI/Fujisawa']",romidepsin,fexact,"['depsipeptide nci', 'romidepsin', 'istodax', 'depsipeptide nci fujisawa']",correct_mapping
bryostatin-1,Protein kinase C stimulant; T cell stimulant,bryostatin-1,,bryostatin-1,bryostatin 1,fexact,"['bryolog', 'NSC-339555', 'bryostatin-1', 'Bryol', 'BMY-45618', 'bryostatin']",bryostatin-1,fexact,"['bryolog', 'nsc 339555', 'bryostatin 1', 'bryol', 'bmy 45618', 'bryostatin']",correct_mapping
soblidotin,Microtubule inhibitor; Tubulin inhibitor,soblidotin,,soblidotin,soblidotin,fexact,"['dolastatin derivative', 'TZT-1027', 'soblidotin', 'YHI-501', 'auristatin PE', 'ZT-1027']",soblidotin,fexact,"['dolastatin derivative', 'tzt 1027', 'soblidotin', 'yhi 501', 'auristatin pe', 'zt 1027']",correct_mapping
lonafarnib,Farnesyltransferase inhibitor; P glycoprotein inhibitor; MRP inhibitor,lonafarnib,,lonafarnib,lonafarnib,fexact,"['MK-6336', 'SCH-066336', 'ras farnesyl protein transferase inhibitor (lead)', 'Zokinvy', 'Sch-704742', 'lonafarnib', 'FPT inhibitor (lead, progeria)', 'ras farnesyl protein transferase inhibitor (lead), Schering-Plough', 'FPT inhibitor (lead, progeria), Schering-Plough', 'Sch-66336']",lonafarnib,fexact,"['mk 6336', 'sch 066336', 'ras farnesyl protein transferase inhibitor lead', 'zokinvy', 'sch 704742', 'lonafarnib', 'fpt inhibitor lead progeria', 'ras farnesyl protein transferase inhibitor lead schering plough', 'fpt inhibitor lead progeria schering plough', 'sch 66336']",correct_mapping
megestrol,Progesterone receptor agonist; DNA inhibitor,megestrol,,,,0,"['megestrol', 'megestrol acetate (nanosuspension formulation, eating disorder)', 'megestrol  (nanosuspension formulation, eating disorder)', 'megestrol acetate', 'DW-ES(B)', 'Daewon-ES(B)']",,NER_API,[],0
CI-1040,Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,CI-1040,,PD-184352,ci 1040,fexact,"['CI-1040', 'PD-184352', 'PD-318088', 'PD-170611']",PD-184352,fexact,"['ci 1040', 'pd 184352', 'pd 318088', 'pd 170611']",correct_mapping
"sodium phenylbutyrate, Access",Histone deacetylase inhibitor; Cell cycle inhibitor,sodium phenylbutyrate,Access,,,0,"['sodium 4-phenylbutyrate (cancer), Virium/Access Pharmaceuticals', 'sodium 4-phenylbutyrate (cancer),/', 'sodium phenylbutyrate (cancer), Virium/Access Pharmaceuticals', 'sodium phenylbutyrate (cancer), MacroChem/Access', 'sodium 4-phenylbutyrate (cancer), Virium/', 'sodium 4-phenyibutyrate (cancer), MacroChem/Access', 'sodium phenylbutyrate, Elan', 'sodium phenylbutyrate', 'sodium 4-phenyibutyrate (cancer),/Access', 'sodium phenylbutyrate (cancer),/Access Pharmaceuticals', 'sodium 4-phenylbutyrate, Elan', 'sodium phenylbutyrate (cancer), Virium/ Somanta', 'EL-532', 'sodium 4-phenylbutyrate (cancer),/Access Pharmaceuticals', 'sodium phenylbutyrate (cancer),/Access', 'sodium 4-phenylbutyrate', 'sodium phenylbutyrate (cancer), Virium/', 'sodium 4-phenylbutyrate (cancer), Virium/ Somanta', 'VP-101', 'sodium phenylbutyrate (cancer),/']",,NER_API,[],0
becatecarin,DNA topoisomerase I inhibitor; DNA topoisomerase II inhibitor,becatecarin,,becatecarin,becatecarin,fexact,"['BMY-27557', 'BMY-27557-14', 'NSC-D640199', 'NSC-655649', 'rebeccamycin analog,/BMS', 'rebeccamycin analog, Exelixis/BMS', 'BMS-181176', 'becatecarin', 'XL-119']",becatecarin,fexact,"['bmy 27557', 'bmy 27557 14', 'nsc d640199', 'nsc 655649', 'rebeccamycin analog bms', 'rebeccamycin analog exelixis bms', 'bms 181176', 'becatecarin', 'xl 119']",correct_mapping
porfimer sodium,Radical formation stimulant,porfimer sodium,,porfimer sodium,porfimer sodium,fexact,"['DHE', 'Photofrin', 'porfimer sodium', 'dihematoporphyrin ether', 'Photofrin 2', 'Photobarr', 'CL-184116']",porfimer sodium,fexact,"['dhe', 'photofrin', 'porfimer sodium', 'dihematoporphyrin ether', 'photofrin 2', 'photobarr', 'cl 184116']",correct_mapping
Lipiodol,Unidentified pharmacological activity,Lipiodol,,,,0,['Lipiodol'],,0,[],0
INCB-106385,Adenosine A2a receptor antagonist; Adenosine A2b receptor antagonist,INCB-106385,,INCB-106385,incb 106385,fexact,"['INCB-106385', 'A2a/A2b adenosine receptor antagonist (cancer)', 'A2aR checkpoint inhibitor/A2bR checkpoint inhibitor (cancer)']",INCB-106385,fexact,"['incb 106385', 'a2a a2b adenosine receptor antagonist cancer', 'a2ar checkpoint inhibitor a2br checkpoint inhibitor cancer']",correct_mapping
senaparib,DNA repair enzyme inhibitor; Poly ADP ribose polymerase 1 inhibitor,senaparib,,senaparib,senaparib,fexact,"['IMP-04297', 'JS-109', 'IMP-427', 'IMP-4297', 'PARP-1 inhibitor (cancer)', 'senaparib']",senaparib,fexact,"['imp 04297', 'js 109', 'imp 427', 'imp 4297', 'parp 1 inhibitor cancer', 'senaparib']",correct_mapping
SYHA-1807,Lysine (K)-specific demethylase 1A inhibitor,SYHA-1807,,SYHA-1807,syha 1807,fexact,"['LSD1 inhibitor (cancer)', 'SYHA-1807', 'lysine specific demethylase 1 inhibitor (cancer)']",SYHA-1807,fexact,"['lsd1 inhibitor cancer', 'syha 1807', 'lysine specific demethylase 1 inhibitor cancer']",correct_mapping
ACE-1702,ErbB-2 antagonist; Immuno-oncology therapy,ACE-1702,,ACE-1702,ace 1702,fexact,"['JWACE-002', 'oNK program (recurrent ovarian/endometrial/breast cancers)', 'ACE-1702', 'Antibody mediated effector T-cell therapies (cancer)']",ACE-1702,fexact,"['jwace 002', 'onk program recurrent ovarian endometrial breast cancers', 'ace 1702', 'antibody mediated effector t cell therapies cancer']",correct_mapping
SGM-101,Radiopharmaceutical,SGM-101,,SGM-101,sgm 101,fexact,['SGM-101'],SGM-101,fexact,['sgm 101'],correct_mapping
HPN-328,CD3 agonist; Immuno-oncology therapy,HPN-328,,HPN-328,hpn 328,fexact,"['anti-CD3/anti-DLL3/anti-albumin trispecific T-cell engager (TriTAC, small-cell lung cancer)', 'HPN-328', 'triple anti-CD3/anti-DLL3/anti-HSA T-cell engager (small cell lung cancer)', 'triple anti-CD3/anti-DLL3/anti-HSA T-cell engager (iv, advanced cancers/small cell lung cancer)', 'anti-CD3/anti-DLL3/anti-albumin trispecific T-cell engager (iv, TriTAC, advanced cancers/small-cell lung cancer)']",HPN-328,fexact,"['anti cd3 anti dll3 anti albumin trispecific t cell engager tritac small cell lung cancer', 'hpn 328', 'triple anti cd3 anti dll3 anti hsa t cell engager small cell lung cancer', 'triple anti cd3 anti dll3 anti hsa t cell engager iv advanced cancers small cell lung cancer', 'anti cd3 anti dll3 anti albumin trispecific t cell engager iv tritac advanced cancers small cell lung cancer']",correct_mapping
"temozolomide (capsule), Jiangsu Tasly Diyi Pharmaceutical Co.",DNA inhibitor,temozolomide,Jiangsu Tasly Diyi Pharmaceutical Co.,"temozolomide (oral capsule, glioma)",temozolomide,fexact,"['Diqing', 'temozolomide', 'temozolomide (oral capsule, glioma)']","temozolomide (oral capsule, glioma)",fexact,"['diqing', 'temozolomide', 'temozolomide oral capsule glioma']",correct_mapping
acetazolamide,Carbonic anhydrase inhibitor,acetazolamide,,,,0,"['repurposed acetazolamide (vancomycin-resistant enterococci infection)', 'acetazolamide']",,NER_API,[],0
PF-06821497,Enhancer of zeste homolog 2 inhibitor,PF-06821497,,PF-06821497,pf 06821497,fexact,"['EZH2 inhibitor (prostate cancer)', 'PF-06821497']",PF-06821497,fexact,"['ezh2 inhibitor prostate cancer', 'pf 06821497']",correct_mapping
bicalutamide,Androgen receptor antagonist,bicalutamide,,bicalutamide,bicalutamide,fexact,"['ICI-176334', 'Casodex', 'Cosudex', 'bicalutamide', 'ICI176334-1']",bicalutamide,fexact,"['ici 176334', 'casodex', 'cosudex', 'bicalutamide', 'ici176334 1']",correct_mapping
degarelix (SC),Luteinizing hormone releasing hormone (LHRH) antagonist,degarelix,,degarelix,degarelix,fexact,"['Gonax', 'degarelix ART', 'ASP-3550', 'Firmagon', 'degarelix', 'FE-200486', 'degarelix acetate']",degarelix,fexact,"['gonax', 'degarelix art', 'asp 3550', 'firmagon', 'degarelix', 'fe 200486', 'degarelix acetate']",correct_mapping
aflibercept ophthalmic solution,Placental growth factor inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,aflibercept ophthalmic solution,,,,0,['aflibercept ophthalmic solution'],,0,[],0
SM-08502,CDC like kinase 2 inhibitor; CDC like kinase 3 inhibitor; Wnt pathway inhibitor,SM-08502,,SM-08502,sm 08502,fexact,"['SM-08502', 'CLK3 inhibitor (oral, advanced solid tumors)', 'CDC-like kinase inhibitor (pancreatic cancer/gastrointestinal tumor/advanced solid tumors)', 'CLK2 inhibitor (oral, advanced solid tumors)', 'CDC-like kinase inhibitor (pancreatic cancer)', 'wnt-pathway inhibitor (oral tablet, advanced solid tumor)', 'cirtuvivint', 'Clk inhibitor (pancreatic cancer)']",SM-08502,fexact,"['sm 08502', 'clk3 inhibitor oral advanced solid tumors', 'cdc like kinase inhibitor pancreatic cancer gastrointestinal tumor advanced solid tumors', 'clk2 inhibitor oral advanced solid tumors', 'cdc like kinase inhibitor pancreatic cancer', 'wnt pathway inhibitor oral tablet advanced solid tumor', 'cirtuvivint', 'clk inhibitor pancreatic cancer']",correct_mapping
galinpepimut-S,Immunostimulant; T cell stimulant; Immuno-oncology therapy,galinpepimut-S,,galinpepimut-S,galinpepimut s,fexact,"['anti-WT1 T-cells vaccine (cancer)', 'anti-WT1 T-cells vaccine (cancer), CytRx', 'WT-1 cancer vaccine, Sellas', 'galinpepimut-S', 'WT-1 122 long', 'WT1 heteroclitic peptide (cancer)', 'WT1 heteroclitic peptide (cancer), CytRx', 'WT1 heteroclitic peptide (cancer), Innovive', 'WT-1 A1 + WT-1 122 long + WT-1 427 long + WT-1 331 long', 'WT1 T-cell vaccine (cancer), Innovive', 'WT-1 cancer vaccine', 'anti-WT1 T-cells vaccine (cancer), Innovive', 'WT-1 331 long', 'WT1 T-cell vaccine (cancer)', 'WT1 T-cell vaccine (cancer), CytRx', 'GPS', 'WT-1 A1', 'WT-1 427 long', 'SLS-001', 'INNO-305']",galinpepimut-S,fexact,"['anti wt1 t cells vaccine cancer', 'anti wt1 t cells vaccine cancer cytrx', 'wt 1 cancer vaccine sellas', 'galinpepimut s', 'wt 1 122 long', 'wt1 heteroclitic peptide cancer', 'wt1 heteroclitic peptide cancer cytrx', 'wt1 heteroclitic peptide cancer innovive', 'wt 1 a1 wt 1 122 long wt 1 427 long wt 1 331 long', 'wt1 t cell vaccine cancer innovive', 'wt 1 cancer vaccine', 'anti wt1 t cells vaccine cancer innovive', 'wt 1 331 long', 'wt1 t cell vaccine cancer', 'wt1 t cell vaccine cancer cytrx', 'gps', 'wt 1 a1', 'wt 1 427 long', 'sls 001', 'inno 305']",correct_mapping
sufentanil,Opioid mu receptor agonist,sufentanil,,,,0,"['sufentanil', 'sufentanil (transdermal patch/bio-d3 transdermal drug delivery system, pain)', 'NAL-1241']",,NER_API,[],0
dexamethasone sodium phosphate,Arachidonic acid inhibitor; Glucocorticoid agonist,dexamethasone sodium phosphate,,,,0,"['ProDex', 'dexamethasone (sustained release liposomal/BioSeizer, osteoarthritis)', 'TLC-599', 'dexamethasone sodium phosphate', 'dexamethasone sodium phosphate (sustained release liposomal/BioSeizer, osteoarthritis pain)', 'dexamethasone']",,NER_API,[],0
dinutuximab,Ganglioside antigen GD2 antagonist; Immuno-oncology therapy,dinutuximab,,dinutuximab,dinutuximab,fexact,"['ch14.18 (intravenous),/', 'ch14.18 (intravenous), United Therapeutics/', 'dinutuximab', 'ch14.18-UTC', 'OP-08', 'Unituxin']",dinutuximab,fexact,"['ch14 18 intravenous', 'ch14 18 intravenous united therapeutics', 'dinutuximab', 'ch14 18 utc', 'op 08', 'unituxin']",correct_mapping
LY-3143921,Cdc7 kinase inhibitor,LY-3143921,,LY-3143921 hydrate,ly 3143921,fexact,"['LY-3143921', 'LY-3143921 hydrate', 'CDC7 inhibitors (advanced solid tumors)']",LY-3143921 hydrate,fexact,"['ly 3143921', 'ly 3143921 hydrate', 'cdc7 inhibitors advanced solid tumors']",correct_mapping
GRN-1201,Immuno-oncology therapy,GRN-1201,,GRN-1201,grn 1201,fexact,['GRN-1201'],GRN-1201,fexact,['grn 1201'],correct_mapping
NRX-4204,Retinoid X receptor agonist,NRX-4204,,IRX-4204,nrx 4204,fexact,"['VTP-4204', 'rexinoid receptor agonist (cancer)', 'RXR agonists,/Parke-Davis', 'NRX-194204', 'AGN-192870', 'retinoid X receptor agonists, ALRT', 'AGN-195393', 'IRX-4204', 'VTP-194204', 'AGN-191183', 'ALRT-4204', 'NRX-194202', 'AGN-192599', 'AGN-192509', 'RXR ligands, ALRT', 'AGN-191701', 'receptor agonists', 'AGN-194204', 'AGN-192326', 'RXR agonists (cancer/ diabetes)', 'AGN-194277', 'rexinoid receptor agonist (cancer), NuRx', 'AGN-190205', 'retinoid X receptor agonists', 'RXR ligands', 'LGD-4204', 'RXR agonists,/Pfizer', 'ALRT-326', 'AGN-4204', 'RXR agonists,/', 'AGN-191659', 'LGD-4326', 'NRX-4204', 'RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals', 'AGN-4202', 'AGN-192327', 'X receptor agonists']",IRX-4204,fexact,"['vtp 4204', 'rexinoid receptor agonist cancer', 'rxr agonists parke davis', 'nrx 194204', 'agn 192870', 'retinoid x receptor agonists alrt', 'agn 195393', 'irx 4204', 'vtp 194204', 'agn 191183', 'alrt 4204', 'nrx 194202', 'agn 192599', 'agn 192509', 'rxr ligands alrt', 'agn 191701', 'receptor agonists', 'agn 194204', 'agn 192326', 'rxr agonists cancer diabetes', 'agn 194277', 'rexinoid receptor agonist cancer nurx', 'agn 190205', 'retinoid x receptor agonists', 'rxr ligands', 'lgd 4204', 'rxr agonists pfizer', 'alrt 326', 'agn 4204', 'rxr agonists', 'agn 191659', 'lgd 4326', 'nrx 4204', 'rxr agonists cancer diabetes vitae pharmaceuticals', 'agn 4202', 'agn 192327', 'x receptor agonists']",correct_mapping
LXH-254,Raf kinase inhibitor,LXH-254,,naporafenib,lxh 254,fexact,"['naporafenib', 'LXH-254', 'pan-RAF inhibitor (oral/tablet, advanced solid tumors/NSCLC/melanoma/ovarian cancer/colorectal)']",naporafenib,fexact,"['naporafenib', 'lxh 254', 'pan raf inhibitor oral tablet advanced solid tumors nsclc melanoma ovarian cancer colorectal']",correct_mapping
ibrutinib,Bruton tyrosine kinase inhibitor,ibrutinib,,ibrutinib,ibrutinib,fexact,"['Btk inhibitor (cancer), Pharmacyclics/', 'JNJ-54179060', 'Yi Ke', 'PCI-32765', 'Btk inhibitors (autoimmune disease, lymphoma), Pharmacyclics', 'Btk inhibitors (autoimmune disease, lymphoma)', 'B-cell associated tyrosine kinase inhibitors (lymphoma, autoimmune disease)', 'B-cell-associated tyrosine kinase inhibitors (lymphoma, autoimmune disease)', 'PCI-45261', 'CRA-032765', 'Imbruvica', 'B-cell-associated tyrosine kinase inhibitor (cancer),/', 'B-cell-associated tyrosine kinase inhibitor (cancer), Pharmacyclics/', 'Btk inhibitor (cancer), Pharmacyclics/Janssen Biotech', 'B-cell-associated tyrosine kinase inhibitors (lymphoma, autoimmune disease), Celera', 'B-cell associated tyrosine kinase inhibitors (lymphoma, autoimmune disease), Pharmacyclics', 'ibrutinib', 'B-cell-associated tyrosine kinase inhibitor (cancer), Pharmacyclics/Janssen Biotech', 'PCI-31523', 'Btk inhibitor (cancer),/']",ibrutinib,fexact,"['btk inhibitor cancer pharmacyclics', 'jnj 54179060', 'yi ke', 'pci 32765', 'btk inhibitors autoimmune disease lymphoma pharmacyclics', 'btk inhibitors autoimmune disease lymphoma', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease', 'pci 45261', 'cra 032765', 'imbruvica', 'b cell associated tyrosine kinase inhibitor cancer', 'b cell associated tyrosine kinase inhibitor cancer pharmacyclics', 'btk inhibitor cancer pharmacyclics janssen biotech', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease celera', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease pharmacyclics', 'ibrutinib', 'b cell associated tyrosine kinase inhibitor cancer pharmacyclics janssen biotech', 'pci 31523', 'btk inhibitor cancer']",correct_mapping
BPI-15086,EGFR kinase inhibitor,BPI-15086,,BPI-15000,bpi 15086,fexact,"['BPI-15086', 'BPI-15000']",BPI-15000,fexact,"['bpi 15086', 'bpi 15000']",correct_mapping
"cisplatin, unspecified",DNA inhibitor; DNA synthesis inhibitor,cisplatin,unspecified,,,0,"['demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors),/Orient Europharma', 'cisplatin (injectable, micelle),/Orient Europharma', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors), NanoCarrier/Orient Europharma', 'demplatin pegraglumer', 'cisplatin', 'cisplatin (injectable, micelle), NanoCarrier/', 'Nanoplatin', 'cisplatin (injectable, micelle),/', 'NC-6004', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/nsclc/biliary tract/head and neck/lung cancer/solid tumors)', 'cisplatin (injectable, micelle), NanoCarrier/Orient Europharma', 'cisplatin (injectable, micelle)']",,NER_API,[],0
DC-preT cells,Unidentified pharmacological activity,DC-preT cells,,,,0,['DC-preT cells'],,0,[],0
Ad-MAGEA3,Immuno-oncology therapy,Ad-MAGEA3,,,,0,['Ad-MAGEA3'],,0,[],0
MG1-MAGEA3,Immuno-oncology therapy,MG1-MAGEA3,,MG1MA3,mg1 magea3,fexact,"['MG1-MAGEA3', 'Ad-MG1-MAGEA3', 'MG1 Maraba/MAGE-A3', 'cancer vaccine (Maraba virus, lung cancer)', 'MG1MA3']",MG1MA3,fexact,"['mg1 magea3', 'ad mg1 magea3', 'mg1 maraba mage a3', 'cancer vaccine maraba virus lung cancer', 'mg1ma3']",correct_mapping
"valacyclovir, unspecified",DNA directed DNA polymerase inhibitor,valacyclovir,unspecified,valaciclovir,valacyclovir,fexact,"['Valtrex', 'BW-256U', 'valaciclovir', 'Zelitrex', 'valaciclovir hydrochloride', '256-U-87', 'BW-256', 'valacyclovir', '256U']",valaciclovir,fexact,"['valtrex', 'bw 256u', 'valaciclovir', 'zelitrex', 'valaciclovir hydrochloride', '256 u 87', 'bw 256', 'valacyclovir', '256u']",correct_mapping
EPZ-015666,Protein arginine methyltransferase 5 inhibitor,EPZ-015666,,pemrametostat,epz 015666,fexact,"['EPZ-015666', '3326595', 'protein arginine methyltransferase 5 inhibitors (oral, non-Hodgkin lymphoma/breast adenocarcinoma/acute myelogenous leukemia/chronic myelomonocytic leukemia/solid tumor)', 'protein arginine methyltransferase 5 inhibitors (oral, non-Hodgkin lymphoma/breast adenocarcinoma/acute myelogenous leukemia/chronic myelomonocytic leukemia/solid tumor), GlaxoSmithKline', 'EPZ-015866', 'PRMT5 inhibitors (cancer),/GlaxoSmithKline', 'protein arginine methyltransferase 5 inhibitors (oral, cancer)', 'EPZ015866', 'PRMT5 inhibitors (cancer),/', 'protein arginine methyltransferase 5 inhibitors (Non-Hodgkin lymphoma),/GlaxoSmithKline', 'GSK-3326595', 'EPZ-015938', 'EPZ015938', 'protein arginine methyltransferase 5 inhibitors (Non-Hodgkin lymphoma),/', 'GSK-595', 'GSK-591', 'GSK-3235025', 'YQ-3628', 'protein arginine methyltransferase 5 inhibitors (oral, cancer), GlaxoSmithKline', 'GSK-3203591', 'pemrametostat', ""GSK'595""]",pemrametostat,fexact,"['epz 015666', '3326595', 'protein arginine methyltransferase 5 inhibitors oral non hodgkin lymphoma breast adenocarcinoma acute myelogenous leukemia chronic myelomonocytic leukemia solid tumor', 'protein arginine methyltransferase 5 inhibitors oral non hodgkin lymphoma breast adenocarcinoma acute myelogenous leukemia chronic myelomonocytic leukemia solid tumor glaxosmithkline', 'epz 015866', 'prmt5 inhibitors cancer glaxosmithkline', 'protein arginine methyltransferase 5 inhibitors oral cancer', 'epz015866', 'prmt5 inhibitors cancer', 'protein arginine methyltransferase 5 inhibitors non hodgkin lymphoma glaxosmithkline', 'gsk 3326595', 'epz 015938', 'epz015938', 'protein arginine methyltransferase 5 inhibitors non hodgkin lymphoma', 'gsk 595', 'gsk 591', 'gsk 3235025', 'yq 3628', 'protein arginine methyltransferase 5 inhibitors oral cancer glaxosmithkline', 'gsk 3203591', 'pemrametostat', 'gsk 595']",correct_mapping
conteltinib,Anaplastic lymphoma kinase inhibitor; Focal adhesion kinase inhibitor; IGF-1 receptor tyrosine kinase inhibitor,conteltinib,,,,0,['conteltinib'],,0,[],0
rocapuldencel T,Immunostimulant; T cell stimulant; Immuno-oncology therapy,rocapuldencel T,,rocapuldencel-T,rocapuldencel t,fexact,"['dendritic cell vaccine (Arcelis, melanoma/renal tumor),/Kirin', 'tumor antigen transfected dendritic cells (melanoma/renal tumor),/', 'RNA-loaded dendritic cell vaccine (melanoma/renal tumor),/Kyowa Hakko Kirin', 'RNA-loaded dendritic cell vaccine (intradermal, renal cell carcinoma),/', 'cancer vaccine (tumor RNA), Merix', 'RNA-loaded dendritic cell vaccine (melanoma/renal tumor),/', 'CMN-001', 'RNA-loaded dendritic cell vaccine (melanoma/renal tumor),/Kirin', 'dendritic cell vaccine (Arcelis, melanoma/renal tumor), Argos Therapeutics/Kirin', 'melanoma/renal tumor vaccine (tumor RNA), Argos Therapeutics/Kirin', 'RNA-loaded dendritic cell vaccine (melanoma/renal tumor), Argos Therapeutics/Kyowa Hakko Kirin', 'RNA-loaded dendritic cell vaccine (intradermal, renal cell carcinoma), Argos Therapeutics/Medinet', 'RNA-loaded dendritic cell vaccine (cancer), Merix', 'AGS-003', 'tumor antigen transfected dendritic cells (melanoma/renal tumor), Argos Therapeutics/Kirin', 'tumor antigen transfected dendritic cells (melanoma/renal tumor),/Kirin', 'dendritic cell vaccine (Arcelis, melanoma/renal tumor),/', 'melanoma/renal tumor vaccine (tumor RNA),/', 'melanoma/renal tumor vaccine (tumor RNA),/Kirin', 'rocapuldencel-T', 'RNA-loaded dendritic cell vaccine (melanoma/renal tumor), Argos Therapeutics/Kirin', 'MB-002', 'tumor antigen transfected dendritic cells (cancer), Merix', 'RNA-loaded dendritic cell vaccine (intradermal, renal cell carcinoma),/Medinet']",rocapuldencel-T,fexact,"['dendritic cell vaccine arcelis melanoma renal tumor kirin', 'tumor antigen transfected dendritic cells melanoma renal tumor', 'rna loaded dendritic cell vaccine melanoma renal tumor kyowa hakko kirin', 'rna loaded dendritic cell vaccine intradermal renal cell carcinoma', 'cancer vaccine tumor rna merix', 'rna loaded dendritic cell vaccine melanoma renal tumor', 'cmn 001', 'rna loaded dendritic cell vaccine melanoma renal tumor kirin', 'dendritic cell vaccine arcelis melanoma renal tumor argos therapeutics kirin', 'melanoma renal tumor vaccine tumor rna argos therapeutics kirin', 'rna loaded dendritic cell vaccine melanoma renal tumor argos therapeutics kyowa hakko kirin', 'rna loaded dendritic cell vaccine intradermal renal cell carcinoma argos therapeutics medinet', 'rna loaded dendritic cell vaccine cancer merix', 'ags 003', 'tumor antigen transfected dendritic cells melanoma renal tumor argos therapeutics kirin', 'tumor antigen transfected dendritic cells melanoma renal tumor kirin', 'dendritic cell vaccine arcelis melanoma renal tumor', 'melanoma renal tumor vaccine tumor rna', 'melanoma renal tumor vaccine tumor rna kirin', 'rocapuldencel t', 'rna loaded dendritic cell vaccine melanoma renal tumor argos therapeutics kirin', 'mb 002', 'tumor antigen transfected dendritic cells cancer merix', 'rna loaded dendritic cell vaccine intradermal renal cell carcinoma medinet']",correct_mapping
dubermatinib,Axl receptor tyrosine kinase inhibitor,dubermatinib,,dubermatinib,dubermatinib,fexact,"['dubermatinib tartrate', 'HCI-2084', 'TP-0903', 'Huntsman Cancer Institute-2084', 'dubermatinib']",dubermatinib,fexact,"['dubermatinib tartrate', 'hci 2084', 'tp 0903', 'huntsman cancer institute 2084', 'dubermatinib']",correct_mapping
mifepristone,Progesterone receptor antagonist; Glucocorticoid antagonist,mifepristone,,,,0,"['mifepristone, Population Council', 'mifepristone, Roussel Uclaf', 'Mifegymiso', 'RU-486', 'RU-486-6', 'Mifegyne', 'R-38486', 'Mifeprex', 'Mifezone', 'RU-38486', 'mifepristone']",,NER_API,[],0
NEO-201,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 in; Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 in; Immuno-oncology therapy,NEO-201,,NEO-201,neo 201,fexact,"['NEO-201', 'h16C3', 'tumor-specific variants of carcinoembryonic antigen-related cell adhesion molecules 5/6-targeted humanized monoclonal antibody (cancer), Precision Biologics', 'dual CEACAM-5/CEACAM-6 checkpoint inhibitor (cancer)', 'tumor-specific variants of carcinoembryonic antigen-related cell adhesion molecules 5/6-targeted humanized monoclonal antibody (cancer)', 'tumor-specific variants of CEACAM 5/6-targeted hmAb (cancer), Precision Biologics', '16C3', 'tumor-specific variants of CEACAM 5/6-targeted hmAb (cancer)']",NEO-201,fexact,"['neo 201', 'h16c3', 'tumor specific variants of carcinoembryonic antigen related cell adhesion molecules 5 6 targeted humanized monoclonal antibody cancer precision biologics', 'dual ceacam 5 ceacam 6 checkpoint inhibitor cancer', 'tumor specific variants of carcinoembryonic antigen related cell adhesion molecules 5 6 targeted humanized monoclonal antibody cancer', 'tumor specific variants of ceacam 5 6 targeted hmab cancer precision biologics', '16c3', 'tumor specific variants of ceacam 5 6 targeted hmab cancer']",correct_mapping
AMB-051,Colony stimulating factor 1 receptor antagonist; Immuno-oncology therapy,AMB-051,,AMG-820,amb 051,fexact,"['AMB-05X', 'AMB-051', 'AMG-820']",AMG-820,fexact,"['amb 05x', 'amb 051', 'amg 820']",correct_mapping
nadaplatin,DNA inhibitor,nadaplatin,,,,0,['nadaplatin'],,0,[],0
sabatolimab,TIM3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,sabatolimab,,sabatolimab,sabatolimab,fexact,"['TIM-3 mAb (cancer), Novartis', 'MGB-453', 'TIM-3 checkpoint inhibitor (cancer)', 'HAVCR2 mAb (cancer), Novartis', 'TIM-3 antagonist (cancer), Novartis', 'sabatolimab', 'TIM-3 checkpoint inhibitor (cancer), Novartis', 'HAVCR2 mAb (cancer)', 'HAVCR2 antagonist (cancer)', 'TIM-3 antagonist (cancer)', 'TIM-3 mAb (cancer)', 'HAVCR2 antagonist (cancer), Novartis', 'MBG-453']",sabatolimab,fexact,"['tim 3 mab cancer novartis', 'mgb 453', 'tim 3 checkpoint inhibitor cancer', 'havcr2 mab cancer novartis', 'tim 3 antagonist cancer novartis', 'sabatolimab', 'tim 3 checkpoint inhibitor cancer novartis', 'havcr2 mab cancer', 'havcr2 antagonist cancer', 'tim 3 antagonist cancer', 'tim 3 mab cancer', 'havcr2 antagonist cancer novartis', 'mbg 453']",correct_mapping
lirilumab,Natural killer cell stimulant; KIR-mediated natural killer cell inhibition antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,lirilumab,,lirilumab,lirilumab,fexact,"['IPH-2102', 'KIR checkpoint inhibitor (cancer),//', 'anti-killer cell immunoglobulin-like receptor monoclonal antibody (hematological cancers), Innate Pharma/', 'anti-killer cell immunoglobulin-like receptor monoclonal antibody (hematological cancers),/', 'anti-KIR mAb (hematological cancers), Innate Pharma/BMS', 'anti-KIR mAb (hematological cancers),/BMS', 'lirilumab', 'BMS-986015', 'ONO-4483', 'KIR checkpoint inhibitor (cancer), Innate Pharma//Ono', 'KIR checkpoint inhibitor (cancer),//Ono', 'anti-KIR (oncology)']",lirilumab,fexact,"['iph 2102', 'kir checkpoint inhibitor cancer', 'anti killer cell immunoglobulin like receptor monoclonal antibody hematological cancers innate pharma', 'anti killer cell immunoglobulin like receptor monoclonal antibody hematological cancers', 'anti kir mab hematological cancers innate pharma bms', 'anti kir mab hematological cancers bms', 'lirilumab', 'bms 986015', 'ono 4483', 'kir checkpoint inhibitor cancer innate pharma ono', 'kir checkpoint inhibitor cancer ono', 'anti kir oncology']",correct_mapping
"PEGPH20, Halozyme",Hyaluronidase stimulant,PEGPH20,Halozyme,,,0,"['PEGylated hyaluronidase (cancer/stroke)', 'PEGylated vorhyaluronidase (solid tumor/pancreatic cancer, Enhanze)', 'PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer)', 'PEGH-20', 'PEGPH20', 'PH-20', 'hyaluronidase (human recombinant)', 'vorhyaluronidase alfa', 'hyaluronidase PH-20 human pegylated', 'PEGylated hyaluronidase vorhyaluronidase alfa (intravenous, stroke/cancer)', 'rHuPH-20', 'PEGylated recombinant human hyaluronidase (stroke/cancer)', 'pegvorhyaluronidase alfa', 'PEG-rHuPH-20', 'PEG-vorhyaluronidase alfa']",,NER_API,[],0
eganelisib,PI3 kinase gamma inhibitor; Immuno-oncology therapy,eganelisib,,eganelisib,eganelisib,fexact,"['PI3K-gamma inhibitor (oral, solid tumor)', 'eganelisib', 'IPI-549']",eganelisib,fexact,"['pi3k gamma inhibitor oral solid tumor', 'eganelisib', 'ipi 549']",correct_mapping
PNT-737,Checkpoint kinase 1 inhibitor,PNT-737,,SRA-737,pnt 737,fexact,"['CCT-245737', 'SAR-020106', 'PNT-737', 'SRA-737', 'selective Chk1 inhibitors (cancer), Sareum/ Institute of Cancer Research/', 'CCT-244747', 'selective Chk1 inhibitors (cancer), ProNai', 'selective Chk1 inhibitors (cancer),//', 'SRA-737737', 'selective Chk1 inhibitors (cancer), Sareum//']",SRA-737,fexact,"['cct 245737', 'sar 020106', 'pnt 737', 'sra 737', 'selective chk1 inhibitors cancer sareum institute of cancer research', 'cct 244747', 'selective chk1 inhibitors cancer pronai', 'selective chk1 inhibitors cancer', 'sra 737737', 'selective chk1 inhibitors cancer sareum']",correct_mapping
Hemay-020,EGFR kinase inhibitor,Hemay-020,,Hemay-020,hemay 020,fexact,['Hemay-020'],Hemay-020,fexact,['hemay 020'],correct_mapping
niacinamide,Reducing agent; Poly ADP ribose polymerase inhibitor; Vitamin B3 agonist,niacinamide,,,,0,['niacinamide'],,0,[],0
JTCR-016,Immunostimulant; Immuno-oncology therapy,JTCR-016,,JTCR-016,jtcr 016,fexact,"['anti-WT1/HLA-A*0201 TCR T-cell therapy (AML/MDS/CML/NSCLC/mesothelioma), Fred Hutchinson/', 'JTCR-016', 'anti-WT1/HLA-A*0201 TCR T-cell therapy (AML/MDS/CML/NSCLC/mesothelioma),/Juno Therapeutics', 'anti-WT1/HLA-A*0201 TCR T-cell therapy (AML/MDS/CML/NSCLC/mesothelioma), Fred Hutchinson/Juno Therapeutics', 'anti-WT1/HLA-A*0201 TCR T-cell therapy (AML/MDS/CML/NSCLC/mesothelioma),/']",JTCR-016,fexact,"['anti wt1 hla a 0201 tcr t cell therapy aml mds cml nsclc mesothelioma fred hutchinson', 'jtcr 016', 'anti wt1 hla a 0201 tcr t cell therapy aml mds cml nsclc mesothelioma juno therapeutics', 'anti wt1 hla a 0201 tcr t cell therapy aml mds cml nsclc mesothelioma fred hutchinson juno therapeutics', 'anti wt1 hla a 0201 tcr t cell therapy aml mds cml nsclc mesothelioma']",correct_mapping
serabelisib,PI3 kinase alpha inhibitor; PI3 kinase beta inhibitor,serabelisib,,serabelisib,serabelisib,fexact,"['serabelisib', 'phosphoinositide-3 kinase alpha inhibitor (solid tumor), Takeda Oncology', 'phosphoinositide-3 kinase alpha inhibitor (solid tumor), Petra Pharma', 'PI3Kalpha inhibitors (cancer)', 'INK-1117', 'TAK-117', 'PETRA-06', 'MLN-1117', 'phosphoinositide-3 kinase alpha inhibitor (solid tumor), Millennium', 'phosphoinositide-3 kinase alpha inhibitors (cancer)', 'phosphoinositide-3 kinase alpha inhibitor (solid tumor)']",serabelisib,fexact,"['serabelisib', 'phosphoinositide 3 kinase alpha inhibitor solid tumor takeda oncology', 'phosphoinositide 3 kinase alpha inhibitor solid tumor petra pharma', 'pi3kalpha inhibitors cancer', 'ink 1117', 'tak 117', 'petra 06', 'mln 1117', 'phosphoinositide 3 kinase alpha inhibitor solid tumor millennium', 'phosphoinositide 3 kinase alpha inhibitors cancer', 'phosphoinositide 3 kinase alpha inhibitor solid tumor']",correct_mapping
mivebresib,BET protein inhibitor,mivebresib,,mivebresib,mivebresib,fexact,"['ABBV-075', 'mivebresib']",mivebresib,fexact,"['abbv 075', 'mivebresib']",correct_mapping
mogamulizumab-kpkc,CC chemokine receptor 4 antagonist; Immuno-oncology therapy,mogamulizumab-kpkc,,mogamulizumab,mogamulizumab kpkc,fexact,"['mogamulizumab', 'KM-8761', 'Poteligeo', 'CCR4 modulator (allergy + cancer, POTELLIGENT), Kyowa Hakko Kogyo', 'anti-CCR4 humanized mAb ( allergy)', 'KW-0761', 'CCR4 modulator (allergy + cancer, POTELLIGENT)', 'CC chemokine receptor-4 modulator (allergy + cancer, POTELLIGENT), Kyowa Hakko Kirin', 'KW-0761 (allergy)', 'CC chemokine receptor-4 modulator (allergy + cancer, POTELLIGENT), Kyowa Hakko Kogyo', 'mogamulizumab-kpkc', 'CC chemokine receptor-4 modulator (allergy + cancer, POTELLIGENT)', 'AMG-761', 'Poteligio']",mogamulizumab,fexact,"['mogamulizumab', 'km 8761', 'poteligeo', 'ccr4 modulator allergy cancer potelligent kyowa hakko kogyo', 'anti ccr4 humanized mab allergy', 'kw 0761', 'ccr4 modulator allergy cancer potelligent', 'cc chemokine receptor 4 modulator allergy cancer potelligent kyowa hakko kirin', 'kw 0761 allergy', 'cc chemokine receptor 4 modulator allergy cancer potelligent kyowa hakko kogyo', 'mogamulizumab kpkc', 'cc chemokine receptor 4 modulator allergy cancer potelligent', 'amg 761', 'poteligio']",correct_mapping
navoximod,"Indoleamine 2,3-dioxygenase inhibitor; Immuno-oncology therapy; Immune checkpoint inhibitor",navoximod,,navoximod,navoximod,fexact,"['GDC-0919', 'IDO-IN-7', 'RG-6078', 'indoleamine 2,3-dioxygenase pathway inhibitors (cancer)', 'NLG-919', 'IDO checkpoint inhibitor (solid tumor), NewLink Genetics', 'G-6078', 'RO-7077339', 'indoleamine 2,3-dioxygenase pathway inhibitors (cancer), NewLink Genetics', 'IDO pathway inhibitors (solid tumor)', 'navoximod', 'IDO pathway inhibitors (solid tumor), NewLink Genetics', 'IDO checkpoint inhibitor (solid tumor)']",navoximod,fexact,"['gdc 0919', 'ido in 7', 'rg 6078', 'indoleamine 2 3 dioxygenase pathway inhibitors cancer', 'nlg 919', 'ido checkpoint inhibitor solid tumor newlink genetics', 'g 6078', 'ro 7077339', 'indoleamine 2 3 dioxygenase pathway inhibitors cancer newlink genetics', 'ido pathway inhibitors solid tumor', 'navoximod', 'ido pathway inhibitors solid tumor newlink genetics', 'ido checkpoint inhibitor solid tumor']",correct_mapping
pacritinib,Colony stimulating factor 1 receptor antagonist; C-kit inhibitor; Flt-3 antagonist; Interleukin-1 receptor associated protein kinase inhibitor; Janus kinase 2 inhibitor; Immuno-oncology therapy,pacritinib,,pacritinib,pacritinib,fexact,"['JAK2/IRAK-1/CSF1R/Fit3 tyrosine kinase inhibitors (oral, graft versus host disease/thrombocytopenia/myelofibrosis/lymphoma/COVID-19/respiratory distress syndrome), CTI Biopharma Corp', 'Epjevy', 'JAK-2 kinase inhibitors (oral, myeloproliferative disorders/hematological neoplasms)', 'EX58  JAK2i', 'pacritinib citrate', 'BAX-2201', 'JAK-2 kinase inhibitors (oral, COVID-19)', 'jak2/irak-1/csf1r/fit3 tyrosine kinase inhibitors (oral, graft versus host disease/thrombocytopenia/myelofibrosis/lymphoma/covid-19/respiratory distress syndrome)', 'ONX-0803', 'SB-1518', 'JAK-2 kinase inhibitors (oral, myeloproliferative disorders/hematological neoplasms), S*Bio', 'JAK-2 kinase inhibitors (oral, COVID-19), S*Bio', 'pacritinib', 'Enpaxiq']",pacritinib,fexact,"['jak2 irak 1 csf1r fit3 tyrosine kinase inhibitors oral graft versus host disease thrombocytopenia myelofibrosis lymphoma covid 19 respiratory distress syndrome cti biopharma corp', 'epjevy', 'jak 2 kinase inhibitors oral myeloproliferative disorders hematological neoplasms', 'ex58 jak2i', 'pacritinib citrate', 'bax 2201', 'jak 2 kinase inhibitors oral covid 19', 'jak2 irak 1 csf1r fit3 tyrosine kinase inhibitors oral graft versus host disease thrombocytopenia myelofibrosis lymphoma covid 19 respiratory distress syndrome', 'onx 0803', 'sb 1518', 'jak 2 kinase inhibitors oral myeloproliferative disorders hematological neoplasms s bio', 'jak 2 kinase inhibitors oral covid 19 s bio', 'pacritinib', 'enpaxiq']",correct_mapping
FolateImmune,Immunostimulant,FolateImmune,,,,0,"['FolateImmune', 'keyhole-limpet hemocyanin fluorescein isothiocyanate conjugate', 'folate-targeted immunotherapy (cancer)', 'KLH-FITC', 'EC-90', 'EC90 + EC17 + GPI-0100 (cancer)']",,NER_API,[],0
CSC-loaded DC vaccines,Immunostimulant,CSC-loaded DC vaccines,,,,0,['CSC-loaded DC vaccines'],,0,[],0
PF-04518600,CD134 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,PF-04518600,,ivuxolimab,pf 04518600,fexact,"['ivuxolimab', 'PF-8600', 'PF-04518600', 'OX40 costimulator (cancer)']",ivuxolimab,fexact,"['ivuxolimab', 'pf 8600', 'pf 04518600', 'ox40 costimulator cancer']",correct_mapping
PF-06459988,EGFR antagonist,PF-06459988,,PF-06459988,pf 06459988,fexact,['PF-06459988'],PF-06459988,fexact,['pf 06459988'],correct_mapping
"bevacizumab, Boehringer Ingelheim",Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,bevacizumab,Boehringer Ingelheim,bevacizumab biosimilar,bevacizumab,fexact,"['bevacizumab', 'Onbevzi', 'AYBINTIO', 'SB-8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar, Samsung Bioepis']",bevacizumab biosimilar,fexact,"['bevacizumab', 'onbevzi', 'aybintio', 'sb 8', '615', 'bevacizumab biosimilar', 'bevacizumab biosimilar samsung bioepis']",correct_mapping
AST-VAC2,Immunostimulant; Immuno-oncology therapy,AST-VAC2,,,,0,['AST-VAC2'],,0,[],0
crizotinib (IV),Anaplastic lymphoma kinase inhibitor; MET tyrosine kinase inhibitor,crizotinib,,crizotinib,crizotinib,fexact,"['Xalkori', 'PF-2341066', 'crizotinib', 'PF-1066', 'PF-02341066', 'NSC-749005']",crizotinib,fexact,"['xalkori', 'pf 2341066', 'crizotinib', 'pf 1066', 'pf 02341066', 'nsc 749005']",correct_mapping
131I-BIBH-1,DNA inhibitor; Fibroblast activation protein inhibitor,131I-BIBH-1,,,,0,['131I-BIBH-1'],,0,[],0
capivasertib,Protein kinase B inhibitor; Protein kinase inhibitor; Ribosomal S6 kinase inhibitor,capivasertib,,capivasertib,capivasertib,fexact,"['Akt inhibitor (cancer),/ICR//', 'capivasertib', 'AZD-5363', 'Akt inhibitor (cancer),/ICR/Cancer Research/', 'Akt inhibitor (cancer),/ICR/Cancer Research/AstraZeneca']",capivasertib,fexact,"['akt inhibitor cancer icr', 'capivasertib', 'azd 5363', 'akt inhibitor cancer icr cancer research', 'akt inhibitor cancer icr cancer research astrazeneca']",correct_mapping
PLX-7486,TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,PLX-7486,,,,0,"['dual tropomyosin receptor kinase/colony stimulating factor inhibitors (cancer)', 'PLX-7486-TsOH', 'TRK/FMS inhibitors (cancer)', 'PLX-7486']",,NER_API,[],0
futibatinib,FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor,futibatinib,,futibatinib,futibatinib,fexact,"['FGFR inhibitor (cancer/Endometrial carcinoma/hepatocellular carcinoma)', 'TAS-2985', 'TAS-120', 'FGFR infibitor (oral, Breast cancer/Endometrial carcinoma/hepatocellular carcinoma/Esophageal cancer/Stomach cancer/Cholangiocarcinoma/Solid tumor) Taiho', 'irreversible FGFR inhibitor (oral, cancer), Taiho Pharmaceutical/', 'FGFR infibitor (oral, Breast cancer/endometrial carcinoma/hepatocellular carcinoma/esophageal cancer/stomach cancer/cholangiocarcinoma/solid tumor/urothelial carcinoma) Taiho', 'irreversible FGFR inhibitor (oral, cancer),/', 'FGFR inhibitors (cancer), Taiho Pharmaceutical Co Ltd', 'fgfr inhibitors (cancer)', 'futibatinib']",futibatinib,fexact,"['fgfr inhibitor cancer endometrial carcinoma hepatocellular carcinoma', 'tas 2985', 'tas 120', 'fgfr infibitor oral breast cancer endometrial carcinoma hepatocellular carcinoma esophageal cancer stomach cancer cholangiocarcinoma solid tumor taiho', 'irreversible fgfr inhibitor oral cancer taiho pharmaceutical', 'fgfr infibitor oral breast cancer endometrial carcinoma hepatocellular carcinoma esophageal cancer stomach cancer cholangiocarcinoma solid tumor urothelial carcinoma taiho', 'irreversible fgfr inhibitor oral cancer', 'fgfr inhibitors cancer taiho pharmaceutical co ltd', 'fgfr inhibitors cancer', 'futibatinib']",correct_mapping
lucitanib,FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor alpha kinase inhib; Platelet-derived growth factor receptor beta kinase inhib; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor,lucitanib,,lucitanib hydrochloride,lucitanib,fexact,"['delitinib (oral capsule, cancer),/', 'E-3810', '3800 project', 'delitinib (oral capsule, cancer), SFFT Developing/Shanghai Institute of Materia Medica', 'lucitanib hydrochloride', 'CO-3810', 'lucitanib', 'S-80881', 'delitinib (oral capsule, cancer),/Shanghai Institute of Materia Medica', 'AL-3810']",lucitanib hydrochloride,fexact,"['delitinib oral capsule cancer', 'e 3810', '3800 project', 'delitinib oral capsule cancer sfft developing shanghai institute of materia medica', 'lucitanib hydrochloride', 'co 3810', 'lucitanib', 's 80881', 'delitinib oral capsule cancer shanghai institute of materia medica', 'al 3810']",correct_mapping
neratinib,EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),neratinib,,neratinib,neratinib,fexact,"['neratinib', 'PF-5208767', 'PF-05208767', 'CAN-030', 'PB-272', 'HKI-272', 'Nerlynx']",neratinib,fexact,"['neratinib', 'pf 5208767', 'pf 05208767', 'can 030', 'pb 272', 'hki 272', 'nerlynx']",correct_mapping
"cisplatin, Medicelle",DNA inhibitor,cisplatin,Medicelle,,,0,"['demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors),/Orient Europharma', 'cisplatin (injectable, micelle),/Orient Europharma', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/NSCLC/biliary tract/head and neck/lung cancer/solid tumors), NanoCarrier/Orient Europharma', 'demplatin pegraglumer', 'cisplatin', 'cisplatin (injectable, micelle), NanoCarrier/', 'Nanoplatin', 'cisplatin (injectable, micelle),/', 'NC-6004', 'demplatin pegraglumer (injectable/micelle, pancreatic/bladder/nsclc/biliary tract/head and neck/lung cancer/solid tumors)', 'cisplatin (injectable, micelle), NanoCarrier/Orient Europharma', 'cisplatin (injectable, micelle)']",,NER_API,[],0
PF-4929113 (capsule),Heat shock protein 90 antagonist,PF-4929113,,"SNX-5422 (oral, cancer)",pf 4929113,fexact,"['SC-105422', 'SC-107881', 'SC-102112', 'SNX-5542', 'SNX-5422', 'PF-4929113 (oral, cancer)', 'PF-04928473', 'PF-4929113', 'SNX-5422 (oral, cancer)', 'PF-4929113 (oral, cancer), Pfizer', 'SNX-5422 (oral, cancer), Pfizer', 'Hsp90 inhibitors (oral, cancer), Serenex', 'SN-5422', 'SNX-2112', 'SNX-5422 (oral, cancer), Serenex', 'PF-4928473', 'PF-04929113', 'Hsp90 inhibitors (oral, cancer)']","SNX-5422 (oral, cancer)",fexact,"['sc 105422', 'sc 107881', 'sc 102112', 'snx 5542', 'snx 5422', 'pf 4929113 oral cancer', 'pf 04928473', 'pf 4929113', 'snx 5422 oral cancer', 'pf 4929113 oral cancer pfizer', 'snx 5422 oral cancer pfizer', 'hsp90 inhibitors oral cancer serenex', 'sn 5422', 'snx 2112', 'snx 5422 oral cancer serenex', 'pf 4928473', 'pf 04929113', 'hsp90 inhibitors oral cancer']",correct_mapping
"levoleucovorin calcium, Spectrum",Unidentified pharmacological activity,levoleucovorin calcium,Spectrum,calcium levofolinate,levoleucovorin calcium,fexact,"['calcium levofolinate', 'levoleucovorin', 'Isovorin', '(S)-Leucovorin', 'Khapzory', 'levofolinic acid', 'LFA', 'levoleucovorin calcium', 'Fusilev', 'L-Folinic acid']",calcium levofolinate,fexact,"['calcium levofolinate', 'levoleucovorin', 'isovorin', 's leucovorin', 'khapzory', 'levofolinic acid', 'lfa', 'levoleucovorin calcium', 'fusilev', 'l folinic acid']",correct_mapping
simotinib,EGFR kinase inhibitor,simotinib,,simotinib hydrochloride,simotinib,fexact,"['simotinib hydrochloride', 'AL-6802', 'ximotini', 'EGFR modulators (cancer),/Simcere', 'EGFR modulators (cancer),/', 'SIM-6802', 'simotinib']",simotinib hydrochloride,fexact,"['simotinib hydrochloride', 'al 6802', 'ximotini', 'egfr modulators cancer simcere', 'egfr modulators cancer', 'sim 6802', 'simotinib']",correct_mapping
"docetaxel, Onkovis",Tubulin inhibitor; Microtubule stimulant; Taxane,docetaxel,Onkovis,"docetaxel (polymeric micelle, solid tumor)",docetaxel,fexact,"['docetaxel-PM', 'docetaxel (polymeric micelle, solid tumor)', 'Nanoxel-PM', 'docetaxel', 'SYP-0704A', 'Nanoxel']","docetaxel (polymeric micelle, solid tumor)",fexact,"['docetaxel pm', 'docetaxel polymeric micelle solid tumor', 'nanoxel pm', 'docetaxel', 'syp 0704a', 'nanoxel']",correct_mapping
Camcolit,Unidentified pharmacological activity,Camcolit,,,,0,['Camcolit'],,0,[],0
dasatinib (tablet),LYN tyrosine kinase inhibitor; Bcr-Abl inhibitor; C-kit inhibitor; EphA receptor kinase inhibitor; Fyn tyrosine kinase inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib; Src inhibitor; Yes tyrosine kinase inhibitor,dasatinib,,dasatinib,dasatinib,fexact,"['NSC-732517', 'Src/Abl kinase inhibitor (cancer), BMS', 'BMS-354825', 'Sprycel', 'Spricel', 'dasatinib (USAN)', 'dasatinib', 'Spraicell']",dasatinib,fexact,"['nsc 732517', 'src abl kinase inhibitor cancer bms', 'bms 354825', 'sprycel', 'spricel', 'dasatinib usan', 'dasatinib', 'spraicell']",correct_mapping
M2ES,Angiogenesis inhibitor,M2ES,,M2ES,m2es,fexact,"['M2ES', 'PEGylated recombinant human endostatin (cancer),/Tsinghua University', 'CRB-0401', 'pegylated recombinant human endostatin (cancer)']",M2ES,fexact,"['m2es', 'pegylated recombinant human endostatin cancer tsinghua university', 'crb 0401', 'pegylated recombinant human endostatin cancer']",correct_mapping
LY-2510924,CXC chemokine receptor 4 antagonist,LY-2510924,,LY-2510924,ly 2510924,fexact,"['LY-2510924', 'CXCR4 peptide inhibitor (cancer)']",LY-2510924,fexact,"['ly 2510924', 'cxcr4 peptide inhibitor cancer']",correct_mapping
sovateltide,Angiogenesis stimulant; Endothelin B receptor agonist,sovateltide,,sovateltide,sovateltide,fexact,"['ENDG-5010', 'ENDG-4020', 'SPI-1620', 'PMZ-1620', 'endothelin B agonists, Spectrum/', 'Sovateltide', 'IRL-1620', 'endothelin B agonists,/', 'sovateltide']",sovateltide,fexact,"['endg 5010', 'endg 4020', 'spi 1620', 'pmz 1620', 'endothelin b agonists spectrum', 'sovateltide', 'irl 1620', 'endothelin b agonists', 'sovateltide']",correct_mapping
calcitriol,Vitamin D agonist,calcitriol,,,,0,"['calcitriol', 'calcitriol (chemotherapy-induced alopecia), Cytotech Labs', 'API-31543', 'calcitriol (API-31543, drug-induced alopecia), Cytotech Labs', 'calcitriol (topical, chemotherapy-induced alopecia)', 'BPM-31543']",,NER_API,[],0
rociletinib (capsule),EGFR kinase inhibitor,rociletinib,,rociletinib,rociletinib,fexact,"['790M mutant-targeting, non-small-cell lung cancer), Celgene/', 'EMSI (oral, T790M mutant-targeting, NSCLC),/Clovis Oncology', 'Xegafri', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC),/', 'rociletinib', 'rociletinib hydrobromide', 'AVL-301', 'EGFR mutant-selective inhibitor (tablet, NSCLC), Celgene/', 'epidermal growth factor receptor mutant-selective inhibitor (oral, T790M mutant-targeting, non-small-cell lung cancer),/Clovis Oncology', 'rociletinib (T790M-mutation-targeting, NSCLC), Clovis', 'EMSI (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Celgene/', 'EMSI (oral, T790M mutant-targeting, NSCLC),/', 'CO-1686', 'rociletinib (T790M-mutation-targeting, NSCLC)', 'CNX-419', '790M mutant-targeting, non-small-cell lung cancer), Celgene/Clovis Oncology', 'EMSI (oral, T790M mutant-targeting, NSCLC), Celgene/', 'EGFR mutant-selective inhibitor (tablet, NSCLC), Celgene/Clovis Oncology', 'epidermal growth factor receptor mutant-selective inhibitor (oral, T790M mutant-targeting, non-small-cell lung cancer),/', 'EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC),/Clovis Oncology']",rociletinib,fexact,"['790m mutant targeting non small cell lung cancer celgene', 'emsi oral t790m mutant targeting nsclc clovis oncology', 'xegafri', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc', 'rociletinib', 'rociletinib hydrobromide', 'avl 301', 'egfr mutant selective inhibitor tablet nsclc celgene', 'epidermal growth factor receptor mutant selective inhibitor oral t790m mutant targeting non small cell lung cancer clovis oncology', 'rociletinib t790m mutation targeting nsclc clovis', 'emsi oral t790m mutant targeting nsclc celgene clovis oncology', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc celgene clovis oncology', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc celgene', 'emsi oral t790m mutant targeting nsclc', 'co 1686', 'rociletinib t790m mutation targeting nsclc', 'cnx 419', '790m mutant targeting non small cell lung cancer celgene clovis oncology', 'emsi oral t790m mutant targeting nsclc celgene', 'egfr mutant selective inhibitor tablet nsclc celgene clovis oncology', 'epidermal growth factor receptor mutant selective inhibitor oral t790m mutant targeting non small cell lung cancer', 'egfr mutant selective inhibitor oral t790m mutant targeting nsclc clovis oncology']",correct_mapping
dactolisib,mTORC1 kinase inhibitor; mTORC2 kinase inhibitor; Protein kinase inhibitor; PI3 kinase inhibitor,dactolisib,,dactolisib,dactolisib,fexact,"['dactolisib tosylate', 'mTORC1 inhibitors (respiratory tract infection), resTORbio', 'NVP-BEZ235', 'PI3K/mTOR inhibitor (cancer), Novartis', 'BEZ-235', 'dactolisib', 'NVP-BEZ235-NX', 'NVP-BEZ235-ANA', 'phosphatidylinositol-3-kinase/mTOR inhibitor (cancer), Novartis', 'mTORC1 inhibitors (respiratory tract infection)', 'PI3K/mTOR inhibitor (cancer)', 'RTB-101', 'phosphatidylinositol-3-kinase/mTOR inhibitor (cancer)']",dactolisib,fexact,"['dactolisib tosylate', 'mtorc1 inhibitors respiratory tract infection restorbio', 'nvp bez235', 'pi3k mtor inhibitor cancer novartis', 'bez 235', 'dactolisib', 'nvp bez235 nx', 'nvp bez235 ana', 'phosphatidylinositol 3 kinase mtor inhibitor cancer novartis', 'mtorc1 inhibitors respiratory tract infection', 'pi3k mtor inhibitor cancer', 'rtb 101', 'phosphatidylinositol 3 kinase mtor inhibitor cancer']",correct_mapping
"s-pindolol, PsiOxus",Beta adrenoreceptor antagonist,s-pindolol,PsiOxus,ACM-001,s pindolol,fexact,"['espindolol', 'S-pindolol', 'espindolol, PsiOxus', 'MT-102, Myotec', 'ACM-001', 'MT-102', 'MT-102, PsiOxus']",ACM-001,fexact,"['espindolol', 's pindolol', 'espindolol psioxus', 'mt 102 myotec', 'acm 001', 'mt 102', 'mt 102 psioxus']",correct_mapping
tivantinib (capsule),MET tyrosine kinase inhibitor; Angiogenesis inhibitor,tivantinib,,tivantinib,tivantinib,fexact,"['CO-650', 'ARQ-707', '650RP', 'tivantinib', 'ARQ-650RP', 'cancer survival protein modulation program', 'ARQ-650', 'ARQ-197', 'CO-650 series (cancer)', 'cancer survival protein modulation product']",tivantinib,fexact,"['co 650', 'arq 707', '650rp', 'tivantinib', 'arq 650rp', 'cancer survival protein modulation program', 'arq 650', 'arq 197', 'co 650 series cancer', 'cancer survival protein modulation product']",correct_mapping
LY-2584702,Ribosomal S6 kinase inhibitor,LY-2584702,,LY-2584702,ly 2584702,fexact,"['LY-S6K1', 'LY-2584702', 'p70 S6 kinase inhibitor (cancer)', 'LY-S6K1 tosylate', 'LY-S6K1 HCl']",LY-2584702,fexact,"['ly s6k1', 'ly 2584702', 'p70 s6 kinase inhibitor cancer', 'ly s6k1 tosylate', 'ly s6k1 hcl']",correct_mapping
IMN-1207,RNA directed DNA polymerase inhibitor; Glutathione synthase stimulant,IMN-1207,,,,0,['IMN-1207'],,0,[],0
[F-18]RGD-K5,Not applicable,[F-18]RGD-K5,,,,0,['[F-18]RGD-K5'],,0,[],0
"ATL-101, ATLAB Pharma",Prostate-specific membrane antigen inhibitor; Radiopharmaceutical,ATL-101,ATLAB Pharma,177Lu-rosopatamab tetraxetan,atl 101,fexact,"['MLN-591RL', '177Lu-J-591', 'Lutetium-177-MLN-591', 'lutetium-177-J591', 'lutetium-177-MLN-591', 'MLN-591-[177Lu]', 'DOTA-rosopatamab-[177Lu]', 'Lutetium-177-rosopatamab tetraxetan', 'anti-PSMA', 'J-591', '177Lu-DOTA-TLX591-CHO', 'J-591-[177Lu]', '111In-J591', '177Lu-J591', 'anti-PSMA, Millennium/BZL Biologics', 'J591', '177Lu-rosopatamab tetraxetan, Telix Pharma', 'MLN-591', '90Y-J591', '177Lu-DOTA-rosopatamab, Telix Pharma', 'TX-591', 'huJ591', '177Lu-rosopatamab tetraxetan', 'Lutetium-177-J-591', 'MLN-5591RL', 'anti-PSMA, Millennium', '177Lu-MLN-591', 'anti-PSMA, Millennium/', 'Lutetium-177-DOTA-rosopatamab', 'yttrium-90-J591', '90Y-MLN-591', 'TLX-591', 'ATL-101', 'rosopatamab tetraxetan-[177Lu]', '177Lu-DOTA-rosopatamab', 'yttrium-90-MLN-591']",177Lu-rosopatamab tetraxetan,fexact,"['mln 591rl', '177lu j 591', 'lutetium 177 mln 591', 'lutetium 177 j591', 'lutetium 177 mln 591', 'mln 591 177lu', 'dota rosopatamab 177lu', 'lutetium 177 rosopatamab tetraxetan', 'anti psma', 'j 591', '177lu dota tlx591 cho', 'j 591 177lu', '111in j591', '177lu j591', 'anti psma millennium bzl biologics', 'j591', '177lu rosopatamab tetraxetan telix pharma', 'mln 591', '90y j591', '177lu dota rosopatamab telix pharma', 'tx 591', 'huj591', '177lu rosopatamab tetraxetan', 'lutetium 177 j 591', 'mln 5591rl', 'anti psma millennium', '177lu mln 591', 'anti psma millennium', 'lutetium 177 dota rosopatamab', 'yttrium 90 j591', '90y mln 591', 'tlx 591', 'atl 101', 'rosopatamab tetraxetan 177lu', '177lu dota rosopatamab', 'yttrium 90 mln 591']",correct_mapping
anastrozole (tablet),Aromatase inhibitor,anastrozole,,anastrozole,anastrozole,fexact,"['D-1033', 'ICI-D-1033', 'ZD-1033', 'Arimidex', 'anastrozole']",anastrozole,fexact,"['d 1033', 'ici d 1033', 'zd 1033', 'arimidex', 'anastrozole']",correct_mapping
"docetaxel, SK Holdings",Tubulin inhibitor; Microtubule stimulant; Taxane,docetaxel,SK Holdings,"docetaxel (polymeric micelle, solid tumor)",docetaxel,fexact,"['docetaxel-PM', 'docetaxel (polymeric micelle, solid tumor)', 'Nanoxel-PM', 'docetaxel', 'SYP-0704A', 'Nanoxel']","docetaxel (polymeric micelle, solid tumor)",fexact,"['docetaxel pm', 'docetaxel polymeric micelle solid tumor', 'nanoxel pm', 'docetaxel', 'syp 0704a', 'nanoxel']",correct_mapping
pegdinetanib,Vascular endothelial growth factor receptor 2 antagonist; Angiogenesis inhibitor,pegdinetanib,,pegdinetanib,pegdinetanib,fexact,"['TRINECTINs', 'Trinectin binding proteins, Compound Therapeutics/Phylos', 'CT-322', 'VEGF R-2 Adnectin (oncology), Bristol-Myers Squibb', 'BMS-844203', 'Angiocept', 'AdNectin VEGFR-2 inhibitor (anti-angiogenesis), Compound Therapeutics', 'AdNectin VEGFR-2 inhibitor (anti-angiogenesis)', 'Trinectins (anti-angiogenesis)', 'pegdinetanib', 'Trinectin binding proteins, Compound Therapeutics/', 'Adnectin', 'Trinectins (anti-angiogenesis), Compound Therapeutics']",pegdinetanib,fexact,"['trinectins', 'trinectin binding proteins compound therapeutics phylos', 'ct 322', 'vegf r 2 adnectin oncology bristol myers squibb', 'bms 844203', 'angiocept', 'adnectin vegfr 2 inhibitor anti angiogenesis compound therapeutics', 'adnectin vegfr 2 inhibitor anti angiogenesis', 'trinectins anti angiogenesis', 'pegdinetanib', 'trinectin binding proteins compound therapeutics', 'adnectin', 'trinectins anti angiogenesis compound therapeutics']",correct_mapping
volasertib,Polo-like kinase 1 inhibitor; Protein kinase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,volasertib,,volasertib,volasertib,fexact,"['volasertib', 'BI-6727']",volasertib,fexact,"['volasertib', 'bi 6727']",correct_mapping
V934,Telomerase stimulant; Immunostimulant,V934,,,,0,['V934'],,0,[],0
V935,Telomerase stimulant; Immunostimulant,V935,,,,0,['V935'],,0,[],0
pilaralisib (tablet),Protein kinase inhibitor; PI3 kinase inhibitor,pilaralisib,,pilaralisib,pilaralisib,fexact,"['SAR-245408', 'XL-147', 'PI3K/EGFR inhibitor (cancer), sanofi-aventis', 'pilaralisib', 'PI3K/EGFR inhibitor (cancer)', 'phosphoinositide-3 kinase/epidermal growth factor receptor inhibito (cancer)']",pilaralisib,fexact,"['sar 245408', 'xl 147', 'pi3k egfr inhibitor cancer sanofi aventis', 'pilaralisib', 'pi3k egfr inhibitor cancer', 'phosphoinositide 3 kinase epidermal growth factor receptor inhibito cancer']",correct_mapping
pilaralisib (gelcap),Protein kinase inhibitor; PI3 kinase inhibitor,pilaralisib,,pilaralisib,pilaralisib,fexact,"['SAR-245408', 'XL-147', 'PI3K/EGFR inhibitor (cancer), sanofi-aventis', 'pilaralisib', 'PI3K/EGFR inhibitor (cancer)', 'phosphoinositide-3 kinase/epidermal growth factor receptor inhibito (cancer)']",pilaralisib,fexact,"['sar 245408', 'xl 147', 'pi3k egfr inhibitor cancer sanofi aventis', 'pilaralisib', 'pi3k egfr inhibitor cancer', 'phosphoinositide 3 kinase epidermal growth factor receptor inhibito cancer']",correct_mapping
MFEz T cells,Immunostimulant,MFEz T cells,,,,0,['MFEz T cells'],,0,[],0
fosbretabulin,Microtubule inhibitor; Angiogenesis inhibitor; Tubulin inhibitor; Apoptosis stimulant; VE-cadherin antagonist; Immuno-oncology therapy,fosbretabulin,,"fosbretabulin (iv, cancer)",fosbretabulin,fexact,"['fosbretabulin (iv, melanoma), Mateon Therapeutics', 'CA4DP', 'fosbretabulin tromethamine', 'fosbretabulin (iv, cancer)', 'fosbretabulin', 'combretastatin A4 prodrug (cancer/diabetes), OXiGENE', 'combretastatin, /oxigene', 'fosbretabulin (iv, cancer), Mateon Therapeutics Inc', 'fosbretabulin (iv, cancer), OXiGENE', 'Zybrestat', 'CA4P, OXiGENE/', 'fosbretabulin disodium', 'fosbretabulin (iv formulation)', 'combretastatin A4 phosphate', 'combretastatin a-4 prodrug, oxigene', 'fosbretabulin (iv, melanoma)', 'CA4P', 'combretastatin,/oxigene', 'combretastatin A4 disodium phosphate', 'Zybrestat (iv formulation)', 'fosbretabulin disodium (cancer/diabetes), OXiGENE', 'combretastatin A4 prodrug']","fosbretabulin (iv, cancer)",fexact,"['fosbretabulin iv melanoma mateon therapeutics', 'ca4dp', 'fosbretabulin tromethamine', 'fosbretabulin iv cancer', 'fosbretabulin', 'combretastatin a4 prodrug cancer diabetes oxigene', 'combretastatin oxigene', 'fosbretabulin iv cancer mateon therapeutics inc', 'fosbretabulin iv cancer oxigene', 'zybrestat', 'ca4p oxigene', 'fosbretabulin disodium', 'fosbretabulin iv formulation', 'combretastatin a4 phosphate', 'combretastatin a 4 prodrug oxigene', 'fosbretabulin iv melanoma', 'ca4p', 'combretastatin oxigene', 'combretastatin a4 disodium phosphate', 'zybrestat iv formulation', 'fosbretabulin disodium cancer diabetes oxigene', 'combretastatin a4 prodrug']",correct_mapping
solitomab,CD3 agonist; Immuno-oncology therapy,solitomab,,AMG-110,solitomab,fexact,"['muS110', 'MT-110', 'AMG-110', 'bispecific EpCAM/CD3 antibody (BiTE, cancer),/', 'bispecific EpCAM/CD3 antibody (BiTE, cancer), Micromet/', 'anti-CD3/anti-EpCAM bispecific T-cell engager (BiTE, solid tumor)', 'solitomab']",AMG-110,fexact,"['mus110', 'mt 110', 'amg 110', 'bispecific epcam cd3 antibody bite cancer', 'bispecific epcam cd3 antibody bite cancer micromet', 'anti cd3 anti epcam bispecific t cell engager bite solid tumor', 'solitomab']",correct_mapping
Ad5-endostatin,Angiogenesis inhibitor,Ad5-endostatin,,,,0,['Ad5-endostatin'],,0,[],0
brivanib alaninate,FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,brivanib alaninate,,brivanib alaninate,brivanib alaninate,fexact,"['BMS-540215', 'brivanib', 'brivanib alaninate', 'ZL-2301', 'VEGFR-2 kinase inhibitor (cancer), BMS', 'Kdr/Flk-1 kinase inhibitors (cancer), BMS', 'vascular endothelial growth factor receptor 2 kinase inhibitors']",brivanib alaninate,fexact,"['bms 540215', 'brivanib', 'brivanib alaninate', 'zl 2301', 'vegfr 2 kinase inhibitor cancer bms', 'kdr flk 1 kinase inhibitors cancer bms', 'vascular endothelial growth factor receptor 2 kinase inhibitors']",correct_mapping
nicotine lozenge,Neuronal nicotinic receptor agonist,nicotine lozenge,,,,0,"['nicotine (oral transmucosal)', 'nicotine (oral transmucosal), Watson', 'nicotine lozenge', 'nicotine', 'nicotine-OTM', 'nicotine lozenge, Watson']",,Drug_API_mapping,[],0
"N-acetylcysteine, IV",Reducing agent,N-acetylcysteine,IV,,,0,"['N-acetylcysteine (ProGelz matrix, oral mucositis), RxKinetix', 'N-acetylcysteine (ProGelz matrix, oral mucositis)', 'RK-0505', 'acetylcysteine, Adherex', 'RK-0202', 'N-acetylcysteine', 'EN-3285', 'oral mucositis therapy,/', 'acetylcysteine (ProGelz matrix, oral mucositis), RxKinetix', 'NAC', 'acetylcysteine (ProGelz matrix, oral mucositis)', 'N-acetylcysteine (ototoxicity), Oregon Health & Science University', 'ACER-003', 'acetylcysteine', 'repurposed N-acetylcysteine (systemic sclerosis)', 'N-acetylcysteine (ProGelz matrix enema, proctitis)', 'acetylcysteine (ProGelz matrix enema, proctitis)', 'N-acetyl cysteine', 'oral mucositis therapy,/RxKinetix']",,Drug_API_mapping,[],0
"mesothelin vaccine, Aduro",Immunostimulant,mesothelin vaccine,Aduro,,,0,['mesothelin vaccine'],,0,[],0
OSI-930,C-kit inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor,OSI-930,,OSI-930,osi 930,fexact,"['Thiophenib', 'OSI-817', 'c-kit/KDR dual inhibitors (cancer), OSI Pharmaceuticals', 'SIM-81', 'OSI-930', 'c-kit/KDR dual inhibitors (cancer)']",OSI-930,fexact,"['thiophenib', 'osi 817', 'c kit kdr dual inhibitors cancer osi pharmaceuticals', 'sim 81', 'osi 930', 'c kit kdr dual inhibitors cancer']",correct_mapping
"fentanyl (sublingual), Insys",Opioid delta receptor agonist; Opioid kappa receptor agonist; Opioid mu receptor agonist,fentanyl,Insys,"fentanyl (sublingual spray, pain)",fentanyl,fexact,"['fentanyl (sublingual spray, pain), Insys Therapeutics', 'fentanyl', 'fentanyl (sublingual spray, pain), Lunatus', 'Fentanyl SL spray', 'Subsys', 'fentanyl (sublingual spray, pain)']","fentanyl (sublingual spray, pain)",fexact,"['fentanyl sublingual spray pain insys therapeutics', 'fentanyl', 'fentanyl sublingual spray pain lunatus', 'fentanyl sl spray', 'subsys', 'fentanyl sublingual spray pain']",correct_mapping
urelumab,CD137 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,urelumab,,urelumab,urelumab,fexact,"['4-1BB costimulator (UlitMAb, cancer),/Ono', 'BMS-554271', 'urelumab', '4-1BB MAb, BMS', '4-1BB costimulator (UlitMAb, cancer),/', 'CD137 MAb', 'BMS-469492', 'ONO-4481', 'BMS-66513', 'anti-CD137 monoclonal antibody, BMS', 'BMS-663513']",urelumab,fexact,"['4 1bb costimulator ulitmab cancer ono', 'bms 554271', 'urelumab', '4 1bb mab bms', '4 1bb costimulator ulitmab cancer', 'cd137 mab', 'bms 469492', 'ono 4481', 'bms 66513', 'anti cd137 monoclonal antibody bms', 'bms 663513']",correct_mapping
gataparsen,Apoptosis stimulant; Survivin inhibitor,gataparsen,,gataparsen,gataparsen,fexact,"['survivin mRNA-targeting antisense oligonucleotides (cancer), Isis', 'survivin-targeting antisense oligonucleotides (cancer)', 'survivin ASO', 'gataparsen sodium', 'gataparsen', 'ISIS-23722', 'LY-2181308']",gataparsen,fexact,"['survivin mrna targeting antisense oligonucleotides cancer isis', 'survivin targeting antisense oligonucleotides cancer', 'survivin aso', 'gataparsen sodium', 'gataparsen', 'isis 23722', 'ly 2181308']",correct_mapping
"camptothecin prodrug, Mersana",DNA topoisomerase I inhibitor,camptothecin prodrug,Mersana,,,0,"['PQ-1003', 'camptothecin prodrug', 'Camptofos']",,Drug_API_mapping,[],0
tosedostat,Peptidase inhibitor,tosedostat,,tosedostat,tosedostat,fexact,"['aminopeptidase inhibitor (oral, cancer), Chroma', 'CHR-79888', 'aminopeptidase inhibitor (oral, cancer)', 'CHR-2797', 'tosedostat']",tosedostat,fexact,"['aminopeptidase inhibitor oral cancer chroma', 'chr 79888', 'aminopeptidase inhibitor oral cancer', 'chr 2797', 'tosedostat']",correct_mapping
KOS-1584,Microtubule stimulant,KOS-1584,,KOS-1584,kos 1584,fexact,"['KOS-1584', 'second-generation epothilone D analog (iv, cancer),/Roche', '(E)-9,10-didehydroepothilone D', '9,10-didehydroepothilone D (iv, cancer),/', 'second-generation epothilone D analog (iv, cancer), Bristol-Myer Squibb', '9,10-didehydroepothilone D (iv, cancer), Bristol-Myer Squibb', 'R-1645', '9,10-didehydroepothilone D (iv, cancer),/Roche', '9,10-didehydroepothilone D', 'second-generation epothilone D analog (iv, cancer), Kosan/Roche', '9,10-didehydroepothilone D (iv, cancer), Kosan/Roche', 'second-generation epothilone D analog (iv, cancer),/']",KOS-1584,fexact,"['kos 1584', 'second generation epothilone d analog iv cancer roche', 'e 9 10 didehydroepothilone d', '9 10 didehydroepothilone d iv cancer', 'second generation epothilone d analog iv cancer bristol myer squibb', '9 10 didehydroepothilone d iv cancer bristol myer squibb', 'r 1645', '9 10 didehydroepothilone d iv cancer roche', '9 10 didehydroepothilone d', 'second generation epothilone d analog iv cancer kosan roche', '9 10 didehydroepothilone d iv cancer kosan roche', 'second generation epothilone d analog iv cancer']",correct_mapping
brachytherapy,Unidentified pharmacological activity,brachytherapy,,,,0,['brachytherapy'],,0,[],0
ezatiostat hydrochloride (tablet),Glutathione S transferase inhibitor; Immunostimulant,ezatiostat hydrochloride,,ezatiostat (oral),ezatiostat hydrochloride,fexact,"['ezatiostat', 'Telintra (oral), Telik', 'ezatiostat (oral)', 'Telintra', 'TLK-199', 'TLK-199 (oral), Telik', 'ezatiostat hydrochloride (oral), Telik', 'ezatiostat (oral), Telik', 'ezatiostat hydrochloride']",ezatiostat (oral),fexact,"['ezatiostat', 'telintra oral telik', 'ezatiostat oral', 'telintra', 'tlk 199', 'tlk 199 oral telik', 'ezatiostat hydrochloride oral telik', 'ezatiostat oral telik', 'ezatiostat hydrochloride']",correct_mapping
tertomotide,Telomerase inhibitor; Immunostimulant; T cell stimulant; Immuno-oncology therapy,tertomotide,,tertomotide,tertomotide,fexact,"['telomerase vaccine (cancer, injectable/peptide)', 'KDDF-201609-02', 'GV-1001', 'telomerase vaccine (cancer, injectable/peptide), KAEL-GemVax', 'hTERT611-626', 'Riavax', 'HR-2822', 'tertomotide', 'HR-2802']",tertomotide,fexact,"['telomerase vaccine cancer injectable peptide', 'kddf 201609 02', 'gv 1001', 'telomerase vaccine cancer injectable peptide kael gemvax', 'htert611 626', 'riavax', 'hr 2822', 'tertomotide', 'hr 2802']",correct_mapping
sulindac,Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor,sulindac,,,,0,"['sulindac', 'repurposed sulindac (oral, fragile X syndrome)']",,NER_API,[],0
tasisulam,Apoptosis stimulant,tasisulam,,tasisulam,tasisulam,fexact,"['Apoptosis stimulator (cancer)', 'LY-573636Na', 'LY-573636', 'LY-573636 sodium', 'tasisulam', 'tasisulam sodium']",tasisulam,fexact,"['apoptosis stimulator cancer', 'ly 573636na', 'ly 573636', 'ly 573636 sodium', 'tasisulam', 'tasisulam sodium']",correct_mapping
radioactive iodine,Unidentified pharmacological activity,radioactive iodine,,,,0,['radioactive iodine'],,0,[],0
Pulmicort,Immunosuppressant; Glucocorticoid agonist,Pulmicort,,budesonide (inhaled formulations),pulmicort,fexact,"['Budecort Aqua', 'Rhinocort Aqua', 'Inflammide', 'budesonide (inhaled formulations), AstraZeneca', 'budesonide, controlled release', 'Betactin', 'budesonide', 'Pulmicort Flexhaler', 'Rhinocort', 'Pulmicort', 'eudragit L-100-55', 'Naricort', 'Pulmicort Turbuhaler', 'S-1320', 'Horacort', 'Budoxis', 'Preferid', 'Rhinocort Turbuhaler', 'Pulmaxan Turbuhaler', 'budesonide (inhaled formulations)', 'Pulmicort Respules']",budesonide (inhaled formulations),fexact,"['budecort aqua', 'rhinocort aqua', 'inflammide', 'budesonide inhaled formulations astrazeneca', 'budesonide controlled release', 'betactin', 'budesonide', 'pulmicort flexhaler', 'rhinocort', 'pulmicort', 'eudragit l 100 55', 'naricort', 'pulmicort turbuhaler', 's 1320', 'horacort', 'budoxis', 'preferid', 'rhinocort turbuhaler', 'pulmaxan turbuhaler', 'budesonide inhaled formulations', 'pulmicort respules']",correct_mapping
pravastatin,HMGCoA reductase inhibitor,pravastatin,,pravastatin,pravastatin,fexact,"['CS-514E', 'Epastatin sodium', 'CS-514', 'Pravachol', 'Selectin', 'CS-514S', 'SQ-31000', 'eptastatin', 'Sanaprav', 'Mevalotin', 'pravastatin', 'ravaselect', 'HMG-CoA reductase inhibitor (hypercholestrolemia),/', 'Lipostat', 'HMG-CoA reductase inhibitor (hypercholestrolemia),/ Merck Serono', 'eptastatin sodium', 'Vasten', 'pravastatin sodium', 'Liplat', 'lavastatin', 'Elisor']",pravastatin,fexact,"['cs 514e', 'epastatin sodium', 'cs 514', 'pravachol', 'selectin', 'cs 514s', 'sq 31000', 'eptastatin', 'sanaprav', 'mevalotin', 'pravastatin', 'ravaselect', 'hmg coa reductase inhibitor hypercholestrolemia', 'lipostat', 'hmg coa reductase inhibitor hypercholestrolemia merck serono', 'eptastatin sodium', 'vasten', 'pravastatin sodium', 'liplat', 'lavastatin', 'elisor']",correct_mapping
"KLH, Intracel",Immunostimulant,KLH,Intracel,,,0,['KLH'],,0,[],0
methoxsalen,Immunosuppressant,methoxsalen,,,,0,['methoxsalen'],,0,[],0
transimmunization,Immunostimulant,transimmunization,,,,0,['transimmunization'],,0,[],0
vosaroxin,DNA-dependent protein kinase inhibitor; DNA topoisomerase II inhibitor; Apoptosis stimulant; Cell cycle inhibitor,vosaroxin,,vosaroxin,vosaroxin,fexact,"['AT-3639', 'SPC-595', 'SNS-595', 'Qinprezo', 'DB-106', 'vosaroxin', 'voreloxin', 'naphthyridines (anticancer)', 'AG-7352', 'naphthyridines (anticancer), Sunesis']",vosaroxin,fexact,"['at 3639', 'spc 595', 'sns 595', 'qinprezo', 'db 106', 'vosaroxin', 'voreloxin', 'naphthyridines anticancer', 'ag 7352', 'naphthyridines anticancer sunesis']",correct_mapping
neratinib (capsule),EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),neratinib,,neratinib,neratinib,fexact,"['neratinib', 'PF-5208767', 'PF-05208767', 'CAN-030', 'PB-272', 'HKI-272', 'Nerlynx']",neratinib,fexact,"['neratinib', 'pf 5208767', 'pf 05208767', 'can 030', 'pb 272', 'hki 272', 'nerlynx']",correct_mapping
alvocidib,Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,alvocidib,,alvocidib,alvocidib,fexact,"['alvocidib hydrochloride', 'MDL-107826A', 'HMR-1275', 'DSP-2033', 'alvocidib', 'flavopiridol', 'NSC-649890', 'L-868275']",alvocidib,fexact,"['alvocidib hydrochloride', 'mdl 107826a', 'hmr 1275', 'dsp 2033', 'alvocidib', 'flavopiridol', 'nsc 649890', 'l 868275']",correct_mapping
recombinant fowlpox-GM-CSF (sc),Granulocyte macrophage colony stimulating factor agonist; Immunostimulant,recombinant fowlpox-GM-CSF,,,,0,['recombinant fowlpox-GM-CSF'],,0,[],0
epoetin alfa (SC),Erythropoietin receptor agonist,epoetin alfa,,epoetin alfa (Epogen),epoetin alfa,fexact,"['epoetin alfa', 'Globuren', 'KRN-5702E', 'EPO', 'erythropoietin', 'Erypo', 'Epoade', 'epoetin alfa (Epogen)', 'Epogen', 'Espo']",epoetin alfa (Epogen),fexact,"['epoetin alfa', 'globuren', 'krn 5702e', 'epo', 'erythropoietin', 'erypo', 'epoade', 'epoetin alfa epogen', 'epogen', 'espo']",correct_mapping
elesclomol,Apoptosis stimulant; Heat shock protein 70 agonist,elesclomol,,elesclomol sodium,elesclomol,fexact,"['immunomodulatory taxane enhancer (cancer)', 'STA-5370', 'elesclomol sodium', 'immunomodulatory taxane enhancer (cancer), Madrigal', 'elesclomol', 'immunomodulatory taxane enhancer (cancer), Synta', 'STA-4783']",elesclomol sodium,fexact,"['immunomodulatory taxane enhancer cancer', 'sta 5370', 'elesclomol sodium', 'immunomodulatory taxane enhancer cancer madrigal', 'elesclomol', 'immunomodulatory taxane enhancer cancer synta', 'sta 4783']",correct_mapping
rubitecan,DNA topoisomerase I inhibitor,rubitecan,,"rubitecan (oral), SuperGen",rubitecan,fexact,"['9NC', 'Camptogen', '9-nitrocamptothecin', 'RFS-2000', 'rubitecan (oral), SuperGen', 'Orathecin', 'rubitecan']","rubitecan (oral), SuperGen",fexact,"['9nc', 'camptogen', '9 nitrocamptothecin', 'rfs 2000', 'rubitecan oral supergen', 'orathecin', 'rubitecan']",correct_mapping
CAT-3888,Protein synthesis inhibitor,CAT-3888,,BL-22,cat 3888,fexact,"['CAT-3888', 'NSC-691237', 'RFB4(dsFv)-PE38', 'PE38-conjugated anti-CD22 immunotoxin, NCI//AstraZeneca', 'PE38-conjugated anti-CD22 immunotoxin,//AstraZeneca', 'GCR-3888', 'BL-22']",BL-22,fexact,"['cat 3888', 'nsc 691237', 'rfb4 dsfv pe38', 'pe38 conjugated anti cd22 immunotoxin nci astrazeneca', 'pe38 conjugated anti cd22 immunotoxin astrazeneca', 'gcr 3888', 'bl 22']",correct_mapping
LMB-2,Protein synthesis inhibitor,LMB-2,,LMB-2,lmb 2,fexact,"['LMB-2a', 'immunotoxin (cancer)', 'alpha Tac-Fv-M18-PE24', 'AntiTac(Fv)-PE38', 'LMB-2']",LMB-2,fexact,"['lmb 2a', 'immunotoxin cancer', 'alpha tac fv m18 pe24', 'antitac fv pe38', 'lmb 2']",correct_mapping
MDNA-55,Interleukin 4 receptor antagonist; Protein synthesis inhibitor; Immuno-oncology therapy,MDNA-55,,MDNA-55,mdna 55,fexact,"['IL-4 fusion toxin (cancer)', 'Interleukin-4 (circularly permuted) + endotoxin, NCI/', 'IL4-PE', 'Interleukin-4 (circularly permuted) + endotoxin, NCI/Neurocrine', 'INxin', 'PRX-321', 'IL4(38-37)-PE38KDEL', 'IL-4 targeting fusion protein (intratumoral, bladder cancer/glioblastoma/prostrate tumor), Medicenna BioPharma', 'MDNA-55', 'IL-4 fusion toxin, NIH/', 'IL-4 fusion toxin, NIH/Neurocrine', 'NBI-3001', 'IL-4 fusion toxin (cancer), Sophiris']",MDNA-55,fexact,"['il 4 fusion toxin cancer', 'interleukin 4 circularly permuted endotoxin nci', 'il4 pe', 'interleukin 4 circularly permuted endotoxin nci neurocrine', 'inxin', 'prx 321', 'il4 38 37 pe38kdel', 'il 4 targeting fusion protein intratumoral bladder cancer glioblastoma prostrate tumor medicenna biopharma', 'mdna 55', 'il 4 fusion toxin nih', 'il 4 fusion toxin nih neurocrine', 'nbi 3001', 'il 4 fusion toxin cancer sophiris']",correct_mapping
MVF-HER-2(628-647)-CRL 1005 vaccine,Immunostimulant,MVF-HER-2-CRL 1005 vaccine,,,,0,['MVF-HER-2-CRL 1005 vaccine'],,0,[],0
"interferon-ß gene therapy, Biogen",Interferon beta 1 agonist,interferon-ß gene therapy,Biogen,,,0,['interferon-ß gene therapy'],,0,[],0
OSI-632,Vascular endothelial growth factor (VEGF)receptor antagonist; Vascular endothelial growth factor receptor 2 antagonist; Angiogenesis inhibitor,OSI-632,,OSI-632,osi 632,fexact,"['OSI-632', 'CP-564959', 'CP-547632']",OSI-632,fexact,"['osi 632', 'cp 564959', 'cp 547632']",correct_mapping
etalocib,Leucotriene B4 antagonist; Leucotriene receptor antagonist; 5 Lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist,etalocib,,etalocib,etalocib,fexact,"['VML-295', 'LY-293111Na', 'VML-495', 'LY-293111', 'etalocib']",etalocib,fexact,"['vml 295', 'ly 293111na', 'vml 495', 'ly 293111', 'etalocib']",correct_mapping
mitumomab,Immunostimulant,mitumomab,,mitumomab,mitumomab,fexact,"['MelVax', 'mitumomab', 'BEC-2', 'melanoma vaccine', 'GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering', 'LuVax', 'IMC-BEC2', 'EMD-60205', 'antimetastatic agents,/Merck KGaA', 'GD3 ganglioside (vaccine 1)', 'antimelanoma antibody,/Merck KGaA', 'melanoma vaccine,/Merck KGaA', 'antimelanoma antibody', 'antimetastatic agents']",mitumomab,fexact,"['melvax', 'mitumomab', 'bec 2', 'melanoma vaccine', 'gd3 ganglioside vaccine 1 memorial sloan kettering', 'luvax', 'imc bec2', 'emd 60205', 'antimetastatic agents merck kgaa', 'gd3 ganglioside vaccine 1', 'antimelanoma antibody merck kgaa', 'melanoma vaccine merck kgaa', 'antimelanoma antibody', 'antimetastatic agents']",correct_mapping
TheraCys (ID),Immunostimulant,TheraCys,,,,0,['TheraCys'],,0,[],0
biricodar dicitrate,P glycoprotein inhibitor; MRP inhibitor,biricodar dicitrate,,biricodar,biricodar dicitrate,fexact,"['Incel', 'VX-710', 'biricodar', 'biricodar dicitrate', 'VX-710-3']",biricodar,fexact,"['incel', 'vx 710', 'biricodar', 'biricodar dicitrate', 'vx 710 3']",correct_mapping
exatecan mesylate,DNA topoisomerase I inhibitor,exatecan mesylate,,exatecan,exatecan mesylate,fexact,"['UM-1', 'DX-8951', 'exatecan', 'DX-8951a', 'UM-2', 'exatecan hydrochloride', 'DX-8951f', 'exatecan mesylate']",exatecan,fexact,"['um 1', 'dx 8951', 'exatecan', 'dx 8951a', 'um 2', 'exatecan hydrochloride', 'dx 8951f', 'exatecan mesylate']",correct_mapping
chlorsulfaquinoxalone,Immunosuppressant; DNA topoisomerase II inhibitor,chlorsulfaquinoxalone,,,,0,['chlorsulfaquinoxalone'],,0,[],0
"angiostatin (SC), Entremed",Angiogenesis inhibitor,angiostatin,Entremed,Angiostatin,angiostatin,fexact,"['angiostatin protein', 'K1-4', 'rhuAngiostatin, EntreMed', 'angiogenesis inhibitor, Entremed/BMS', 'recombinant human angiostatin, EntreMed', 'rhuAngiostatin,/CMCC', 'recombinant human angiostatin,/CMCC', 'angiogenesis inhibitor,/CMCC', 'Angiostatin']",Angiostatin,fexact,"['angiostatin protein', 'k1 4', 'rhuangiostatin entremed', 'angiogenesis inhibitor entremed bms', 'recombinant human angiostatin entremed', 'rhuangiostatin cmcc', 'recombinant human angiostatin cmcc', 'angiogenesis inhibitor cmcc', 'angiostatin']",correct_mapping
infliximab (iv),Tumour necrosis factor alpha antagonist,infliximab,,infliximab,infliximab,fexact,"['Remicade', 'anti-TNF-alpha MAb', 'CenTNF', 'cA2 antibody', 'SCH-215596', 'Avakine', 'Remicad', 'anti-TNF-alpha MAb, Tanabe', 'infliximab', 'TA-650']",infliximab,fexact,"['remicade', 'anti tnf alpha mab', 'centnf', 'ca2 antibody', 'sch 215596', 'avakine', 'remicad', 'anti tnf alpha mab tanabe', 'infliximab', 'ta 650']",correct_mapping
"irinotecan hydrochloride, Luye Pharma",DNA topoisomerase I inhibitor,irinotecan hydrochloride,Luye Pharma,irinotecan,irinotecan hydrochloride,fexact,"['Camptothecin 11 hydrochloride', 'DQ-2805', 'camptothecin II', 'irinotecan hydrochloride hydrate', 'camptothecin II hydrochloride', 'Topotecin', 'NSC-616348', 'irinotecan', 'camptothecin', 'camptothecin  hydrochloride', 'Camptothecin 11', 'Campto', 'irinotecan hydrochloride', 'Camptosar']",irinotecan,fexact,"['camptothecin 11 hydrochloride', 'dq 2805', 'camptothecin ii', 'irinotecan hydrochloride hydrate', 'camptothecin ii hydrochloride', 'topotecin', 'nsc 616348', 'irinotecan', 'camptothecin', 'camptothecin hydrochloride', 'camptothecin 11', 'campto', 'irinotecan hydrochloride', 'camptosar']",correct_mapping
zotatifin,Translation initiation factor 4A inhibitor,zotatifin,,zotatifin,zotatifin,fexact,"['eFT-226', 'eIF4A inhibitors (cancer)', 'zotatifin', 'eukaryotic initiation factor 4A inhibitors (cancer)']",zotatifin,fexact,"['eft 226', 'eif4a inhibitors cancer', 'zotatifin', 'eukaryotic initiation factor 4a inhibitors cancer']",correct_mapping
methylprednisolone suleptanate,Glucocorticoid agonist,methylprednisolone suleptanate,,,,0,"['methylprednisolone suleptanate', 'PNU-67590A', 'Medrosol', 'Promedrol', 'U-67590A']",,NER_API,[],0
SC-011,Unidentified pharmacological activity,SC-011,,ABBV-011,sc 011,fexact,"['antibody-drug conjugate (SCLC)', 'SEZ6 ADC', 'SC-011', 'ABBV-011', 'anti-SEZ6 antibody-calicheamicin conjugate', 'antineoplastic agent (iv, SCLC)']",ABBV-011,fexact,"['antibody drug conjugate sclc', 'sez6 adc', 'sc 011', 'abbv 011', 'anti sez6 antibody calicheamicin conjugate', 'antineoplastic agent iv sclc']",correct_mapping
PLX-2853,Bromodomain containing 4 inhibitor,PLX-2853,,PLX-2853,plx 2853,fexact,"['BRD4 inhibitor (oral tablet, advanced malignancies)', 'bromodomain containing protein inhibitor (oral tablet, advanced malignancies)', 'BRD4 inhibitor (oral tablet, advanced malignancies/hematological malignancies)', 'PLX-2853']",PLX-2853,fexact,"['brd4 inhibitor oral tablet advanced malignancies', 'bromodomain containing protein inhibitor oral tablet advanced malignancies', 'brd4 inhibitor oral tablet advanced malignancies hematological malignancies', 'plx 2853']",correct_mapping
AZD-4785,K-Ras inhibitor,AZD-4785,,AZD-4785,azd 4785,fexact,"['IONIS-KRAS-2.5', 'IONIS-651987', 'IONIS-KRAS-2.5Rx', 'AZD-4785']",AZD-4785,fexact,"['ionis kras 2 5', 'ionis 651987', 'ionis kras 2 5rx', 'azd 4785']",correct_mapping
"docetaxel, Merrimack",Tubulin inhibitor; Microtubule stimulant; Taxane,docetaxel,Merrimack,"docetaxel (polymeric micelle, solid tumor)",docetaxel,fexact,"['docetaxel-PM', 'docetaxel (polymeric micelle, solid tumor)', 'Nanoxel-PM', 'docetaxel', 'SYP-0704A', 'Nanoxel']","docetaxel (polymeric micelle, solid tumor)",fexact,"['docetaxel pm', 'docetaxel polymeric micelle solid tumor', 'nanoxel pm', 'docetaxel', 'syp 0704a', 'nanoxel']",correct_mapping
MP-0250,Hepatocyte growth factor receptor antagonist; Vascular endothelial growth factor (VEGF)receptor antagonist,MP-0250,,MP-0250,mp 0250,fexact,"['MP-0250 DARPin', 'anti-VEGF/HGF DARPins (cancer)', 'MP-0250', 'designed ankyrin repeat proteins (cancer)']",MP-0250,fexact,"['mp 0250 darpin', 'anti vegf hgf darpins cancer', 'mp 0250', 'designed ankyrin repeat proteins cancer']",correct_mapping
"ephrin-B4 soluble receptor, VasGene",EphB receptor kinase inhibitor,ephrin-B4 soluble receptor,VasGene,,,0,['ephrin-B4 soluble receptor'],,0,[],0
afamitresgene autoleucel,T cell stimulant; Immuno-oncology therapy,afamitresgene autoleucel,,,,0,['afamitresgene autoleucel'],,0,[],0
IMA-201,Immunostimulant; T cell stimulant; Immuno-oncology therapy,IMA-201,,,,0,"['CAR T-cell therapy (autologous, ACTengine, cancer)', 'IMA-201', 'anti-MAGE-A4/A8 CAR T-cell therapy (cancer), Inmatics']",,Drug_API_mapping,[],0
ASN-003,B-raf kinase inhibitor; PI3 kinase inhibitor,ASN-003,,ASN-003,asn 003,fexact,"['EN-3352', 'ASN-003']",ASN-003,fexact,"['en 3352', 'asn 003']",correct_mapping
ADXS-NEO,Immuno-oncology therapy,ADXS-NEO,,ADXS-NEO,adxs neo,fexact,"['ADXS-NEO', 'neoepitope-based immunotherapy (cancer, Lm), Amgen', 'neoepitope-based immunotherapy (cancer, Lm)', 'Lm based vaccine (infusion, metastatic colon cancer/metastatic NSCLC/metastatic head and neck cancer) Amgen']",ADXS-NEO,fexact,"['adxs neo', 'neoepitope based immunotherapy cancer lm amgen', 'neoepitope based immunotherapy cancer lm', 'lm based vaccine infusion metastatic colon cancer metastatic nsclc metastatic head and neck cancer amgen']",correct_mapping
zanidatamab,ErbB-2 antagonist,zanidatamab,,zanidatamab,zanidatamab,fexact,"['bi-specific Azymetric antibody (ZymeCAD, cancer), Zymeworks', 'HER-2 inhibitor (iv, cancers', 'bi-specific antibody (cancer), Zymeworks', 'HER-2 modulator (breast cancer)', 'bi-specific Azymetric antibody (ZymeCAD, cancer)', 'HER-2 modulator (breast cancer), Zymeworks', 'zanidatamab', 'ZW-25', 'bi-specific antibody (cancer)', 'HER-2 inhibitor (iv, cancers, Zymeworks']",zanidatamab,fexact,"['bi specific azymetric antibody zymecad cancer zymeworks', 'her 2 inhibitor iv cancers', 'bi specific antibody cancer zymeworks', 'her 2 modulator breast cancer', 'bi specific azymetric antibody zymecad cancer', 'her 2 modulator breast cancer zymeworks', 'zanidatamab', 'zw 25', 'bi specific antibody cancer', 'her 2 inhibitor iv cancers zymeworks']",correct_mapping
XmAb-20717,PD-1 antagonist; CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,XmAb-20717,,XmAb-20717,xmab 20717,fexact,"['dual CTLA-4 checkpoint inhibitor/PD-1 checkpoint inhibitor (FcRn-mediated half-life extension/Xtend, cancer)', 'XmAb-20717', 'PD-1 x CTLA-4 bispecific antibodies (cancer)', 'vudalimab', 'XENP-20053']",XmAb-20717,fexact,"['dual ctla 4 checkpoint inhibitor pd 1 checkpoint inhibitor fcrn mediated half life extension xtend cancer', 'xmab 20717', 'pd 1 x ctla 4 bispecific antibodies cancer', 'vudalimab', 'xenp 20053']",correct_mapping
TAS-114,Deoxyuridine 5'-triphosphate nucleotidohydrolase inhibitor; Dihydropyrimidine dehydrogenase inhibitor,TAS-114,,TAS-114,tas 114,fexact,"['deoxyuridine 5-triphosphate nucleotidehydrolase inhibitor as dihydropyrimidine dehydrogenase inhibitor potentiator (oral, solid tumor)', 'TAS-114', 'fluoropyrimidine enhancer (oral, solid tumor)', 'deoxyuridine 5-triphosphate nucleotidehydrolase inhibitor as dihydropyrimidine dehydrogenase inhibitor potentiator (oral, solid tumor), Taiho Pharmaceutical/', 'dUTPase inhibitor as DPD inhibitor potentiator (oral, solid tumor)', 'deoxyuridine 5-triphosphate nucleotidehydrolase inhibitor as dihydropyrimidine dehydrogenase inhibitor potentiator (oral, solid tumor),/']",TAS-114,fexact,"['deoxyuridine 5 triphosphate nucleotidehydrolase inhibitor as dihydropyrimidine dehydrogenase inhibitor potentiator oral solid tumor', 'tas 114', 'fluoropyrimidine enhancer oral solid tumor', 'deoxyuridine 5 triphosphate nucleotidehydrolase inhibitor as dihydropyrimidine dehydrogenase inhibitor potentiator oral solid tumor taiho pharmaceutical', 'dutpase inhibitor as dpd inhibitor potentiator oral solid tumor', 'deoxyuridine 5 triphosphate nucleotidehydrolase inhibitor as dihydropyrimidine dehydrogenase inhibitor potentiator oral solid tumor']",correct_mapping
"hTERT peptide-based vaccine, Invectys",Telomerase stimulant; CD4 agonist; Immuno-oncology therapy,hTERT peptide-based vaccine,Invectys,,,0,['hTERT peptide-based vaccine'],,0,[],0
"regorafenib, unspecified",Vascular endothelial growth factor (VEGF)receptor antagonist; RET tyrosine kinase inhibitor; C-kit inhibitor; FGF receptor tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Raf kinase inhibitor; Angiogenesis inhibitor,regorafenib,unspecified,regorafenib,regorafenib,fexact,"['BAY-81-1557', 'fluoro-sorafenib', 'dual acting kinase inhibitor (cancer)', 'dual acting multikinase inhibitor (cancer)', 'regorafenib', 'BAY-73-4506', 'DAST inhibitor (cancer)', 'Bai Wan Ge', 'DAST (cancer)', 'DAST inhibitor', 'dual acting signal transduction inhibitor (cancer)', 'Stivarga']",regorafenib,fexact,"['bay 81 1557', 'fluoro sorafenib', 'dual acting kinase inhibitor cancer', 'dual acting multikinase inhibitor cancer', 'regorafenib', 'bay 73 4506', 'dast inhibitor cancer', 'bai wan ge', 'dast cancer', 'dast inhibitor', 'dual acting signal transduction inhibitor cancer', 'stivarga']",correct_mapping
praluzatamab ravtansine,CD166 antagonist; Immuno-oncology therapy,praluzatamab ravtansine,,praluzatamab ravtansine,praluzatamab ravtansine,fexact,"['DM4 tubulin inhibitor conjugated, CD166-targeted, antibody prodrug (Probody, cancer)', 'CX-2009', 'praluzatamab ravtansine']",praluzatamab ravtansine,fexact,"['dm4 tubulin inhibitor conjugated cd166 targeted antibody prodrug probody cancer', 'cx 2009', 'praluzatamab ravtansine']",correct_mapping
olafertinib,EGFR kinase inhibitor,olafertinib,,olafertinib,olafertinib,fexact,"['olafertinib', 'CK-101', 'RX-518']",olafertinib,fexact,"['olafertinib', 'ck 101', 'rx 518']",correct_mapping
dendritic cell vaccine,Immunostimulant,dendritic cell vaccine,,,,0,['dendritic cell vaccine'],,0,[],0
"ginsenoside H dripping pills, Tasly Pharmaceutical",Unidentified pharmacological activity,ginsenoside H dripping pills,Tasly Pharmaceutical,,,0,['ginsenoside H dripping pills'],,0,[],0
XmAb-104,PD-1 antagonist; Inducible T-cell costimulator agonist; Immuno-oncology therapy; Immune checkpoint inhibitor; Immune checkpoint stimulant,XmAb-104,,,,0,"['XmAb-23104', 'dual PD-1 checkpoint inhibitor/ICOS costimulator (FcRn-mediated half-life extension/Xtend, cancer)', 'PD1/ICOS bispecific mAbs (cancer)', 'XmAb-104']",,NER_API,[],0
XMT-1522,ErbB-2 antagonist,XMT-1522,,XMT-1522,xmt 1522,fexact,"['XMT-1522', 'trastuzumab-dolaflexin', 'anti-HER-2 ADC (cancer),/', 'antibody-drug conjugates (cancer), Mersana/', 'antibody-drug conjugates (cancer), Mersana Therapeutics', 'auristatin-polymer conjugates (cancer)', 'Dolaflexin', 'anti-HER2 antibody-auristatin conjugates (cancer), Mersana Therapeutics/ Endo International', 'antibody-drug conjugates (cancer)', 'auristatin-polymer conjugates (cancer), Mersana Therapeutics', 'TAK-522', 'anti-HER-2 ADC (cancer), Mersana/', 'anti-HER2 antibody-auristatin conjugates (cancer),/', 'anti-HER2 antibody-auristatin conjugates (cancer), Mersana Therapeutics/', 'antibody-drug conjugates (cancer),/']",XMT-1522,fexact,"['xmt 1522', 'trastuzumab dolaflexin', 'anti her 2 adc cancer', 'antibody drug conjugates cancer mersana', 'antibody drug conjugates cancer mersana therapeutics', 'auristatin polymer conjugates cancer', 'dolaflexin', 'anti her2 antibody auristatin conjugates cancer mersana therapeutics endo international', 'antibody drug conjugates cancer', 'auristatin polymer conjugates cancer mersana therapeutics', 'tak 522', 'anti her 2 adc cancer mersana', 'anti her2 antibody auristatin conjugates cancer', 'anti her2 antibody auristatin conjugates cancer mersana therapeutics', 'antibody drug conjugates cancer']",correct_mapping
BMS-986205 (oral),"Indoleamine 2,3-dioxygenase inhibitor",BMS-986205,,linrodostat,bms 986205,fexact,"['IDO-1 checkpoint inhibitor (cancer),/', 'IDO-1 checkpoint inhibitor (cancer),/Ono', 'FLX-B', 'IDO-1 inhibitors (cancer), Flexus Biosciences', 'IDO-1 inhibitors (cancer)', 'cancer immunotherapy program 1, Flexus Biosciences', 'linrodostat', 'linrodostat mesylate', 'cancer immunotherapy program 1', 'BMS-986205', 'ONO-7701', 'IDO checkpoint inhibitor (cancer)', 'F-001287', 'IDO inhibitors (cancer)']",linrodostat,fexact,"['ido 1 checkpoint inhibitor cancer', 'ido 1 checkpoint inhibitor cancer ono', 'flx b', 'ido 1 inhibitors cancer flexus biosciences', 'ido 1 inhibitors cancer', 'cancer immunotherapy program 1 flexus biosciences', 'linrodostat', 'linrodostat mesylate', 'cancer immunotherapy program 1', 'bms 986205', 'ono 7701', 'ido checkpoint inhibitor cancer', 'f 001287', 'ido inhibitors cancer']",correct_mapping
PF-06671008,CD3 agonist; Immuno-oncology therapy,PF-06671008,,PF-06671008,pf 06671008,fexact,"['anti-CD3/anti-cadherin 3 bispecific T-cell engager (DART, cancer),/', 'PF-06671008', 'anti-CD3/anti-p-cadherin bispecific T-cell engager (DART, cancer),/Pfizer', 'P-cadherin LP-DART', 'anti-CD3/anti-p-cadherin bispecific T-cell engager (DART, cancer),/', 'anti-CD3/anti-cadherin 3 bispecific T-cell engager (DART, cancer),/Pfizer']",PF-06671008,fexact,"['anti cd3 anti cadherin 3 bispecific t cell engager dart cancer', 'pf 06671008', 'anti cd3 anti p cadherin bispecific t cell engager dart cancer pfizer', 'p cadherin lp dart', 'anti cd3 anti p cadherin bispecific t cell engager dart cancer', 'anti cd3 anti cadherin 3 bispecific t cell engager dart cancer pfizer']",correct_mapping
Sym-015,MET tyrosine kinase inhibitor,Sym-015,,Sym-015,sym 015,fexact,"['tumor and stromal targeting recombinant mAbs (cancer)', 'recombinant mAbs mixture (cancer)', 'Sym-015', 'recombinant mAbs mixture (advanced solid tumors/advanced NSCLC)']",Sym-015,fexact,"['tumor and stromal targeting recombinant mabs cancer', 'recombinant mabs mixture cancer', 'sym 015', 'recombinant mabs mixture advanced solid tumors advanced nsclc']",correct_mapping
citarinostat,Histone deacetylase inhibitor,citarinostat,,citarinostat,citarinostat,fexact,"['CC-96241', 'ACY-241', 'citarinostat']",citarinostat,fexact,"['cc 96241', 'acy 241', 'citarinostat']",correct_mapping
para-toluenesulfonamide (intratumoral),Unidentified pharmacological activity,para-toluenesulfonamide,,"para-toluenesulfonamide (intratumoral, cancer)",para toluenesulfonamide,fexact,"['PTS', 'para-toluenesulfonamide (intratumoral, adenoid cystic carcinoma/hepatocellular carcinom/non small cell lung cancer), PTS International', 'PTS-500', 'para-toluenesulfonamide (intratumoral, cancer), PTS International', 'PTS-302', 'para-toluenesulfonamide (intratumoral, adenoid cystic carcinoma/hepatocellular carcinom/non small cell lung cancer)', 'para-toluenesulfonamide', 'para-toluenesulfonamide (intratumoral, cancer)', 'PTS-100', 'PTS-02', 'p-toluene sulfonamide']","para-toluenesulfonamide (intratumoral, cancer)",fexact,"['pts', 'para toluenesulfonamide intratumoral adenoid cystic carcinoma hepatocellular carcinom non small cell lung cancer pts international', 'pts 500', 'para toluenesulfonamide intratumoral cancer pts international', 'pts 302', 'para toluenesulfonamide intratumoral adenoid cystic carcinoma hepatocellular carcinom non small cell lung cancer', 'para toluenesulfonamide', 'para toluenesulfonamide intratumoral cancer', 'pts 100', 'pts 02', 'p toluene sulfonamide']",correct_mapping
undisclosed - antiretroviral (ARV) agent,Unidentified pharmacological activity,undisclosed - antiretroviral  agent,,,,0,['undisclosed - antiretroviral  agent'],,0,[],0
fresolimumab,Transforming growth factor beta antagonist,fresolimumab,,fresolimumab,fresolimumab,fexact,"['anti-TGF beta antibodies, Genzyme/Cambridge Antibody Technologies', 'fresolimumab', 'GC-1000 series, Genzyme/Cambridge Antibody Technologies', 'GC-1008', 'fresolumimab', 'anti-TGF beta antibodies,/Cambridge Antibody Technologies', 'GZ-402669', 'GC-1000 series,/Cambridge Antibody Technologies']",fresolimumab,fexact,"['anti tgf beta antibodies genzyme cambridge antibody technologies', 'fresolimumab', 'gc 1000 series genzyme cambridge antibody technologies', 'gc 1008', 'fresolumimab', 'anti tgf beta antibodies cambridge antibody technologies', 'gz 402669', 'gc 1000 series cambridge antibody technologies']",correct_mapping
PD-0360324,Macrophage colony stimulating factor antagonist,PD-0360324,,PD-360324,pd 0360324,fexact,"['PD-0360324', 'MCSF mAb (cutaneous lupus erythematosus, RA)', 'PD-360324', 'macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis, CLE)']",PD-360324,fexact,"['pd 0360324', 'mcsf mab cutaneous lupus erythematosus ra', 'pd 360324', 'macrophage colony stimulating factor monoclonal antibody rheumatoid arthritis cle']",correct_mapping
"paclitaxel micellar injection, Shanghai Yizhong Biotechnology",Beta tubulin inhibitor; Microtubule stimulant; Taxane,paclitaxel micellar injection,Shanghai Yizhong Biotechnology,,,0,['paclitaxel micellar injection'],,0,[],0
"MAGE A-10 T cells, Adaptimmune",Immunostimulant; T cell stimulant; Immuno-oncology therapy,MAGE A-10 T cells,Adaptimmune,,,0,['MAGE A-10 T cells'],,0,[],0
"MVAp53 vaccine, Tara Immuno-Oncology",p53 stimulant; Immuno-oncology therapy,MVAp53 vaccine,Tara Immuno-Oncology,MVA-p53 vaccine,mva p53 vaccine,fuzzy,"['MVA-p53 vaccine, Tara Immuno-Oncology', 'p53mva vaccine, /national cancer institute', 'p53mva vaccine,/national cancer institute', 'MVA-p53 vaccine']",MVA-p53 vaccine,fexact,"['mva p53 vaccine tara immuno oncology', 'p53mva vaccine national cancer institute', 'p53mva vaccine national cancer institute', 'mva p53 vaccine']",incorrect_mapping
gamma-delta T cells,Immunostimulant,gamma-delta T cells,,,,0,['gamma-delta T cells'],,0,[],0
belapectin,Galectin-3 antagonist; Galectin-1 antagonist,belapectin,,belapectin,belapectin,fexact,"['GR-MD-02', 'belapectin', 'galactoarabino-rhamnogalacturonate']",belapectin,fexact,"['gr md 02', 'belapectin', 'galactoarabino rhamnogalacturonate']",correct_mapping
alisertib (tablet),Aurora kinase inhibitor; Protein kinase inhibitor; Mitotic inhibitor,alisertib,,alisertib,alisertib,fexact,"['TAK-823', 'MLN-8237', 'alisertib']",alisertib,fexact,"['tak 823', 'mln 8237', 'alisertib']",correct_mapping
losatuxizumab vedotin,EGFR antagonist,losatuxizumab vedotin,,ABBV-221,losatuxizumab vedotin,fexact,"['anti-EGFR antibody-drug conjugate (solid tumors)', 'ABBV-221', 'anti-EGFR ADC (solid tumors)', 'losatuxizumab vedotin']",ABBV-221,fexact,"['anti egfr antibody drug conjugate solid tumors', 'abbv 221', 'anti egfr adc solid tumors', 'losatuxizumab vedotin']",correct_mapping
gefitinib (capsule),EGFR kinase inhibitor,gefitinib,,gefitinib,gefitinib,fexact,"['ZD-1839', 'gefitinib', 'Iressat', 'Iressa']",gefitinib,fexact,"['zd 1839', 'gefitinib', 'iressat', 'iressa']",correct_mapping
betamethasone dipropionate,Corticosteroid agonist,betamethasone dipropionate,,"beclomethasone dipropionate, (CFC-free)",beclomethasone dipropionate,fuzzy,"['Qvar Digihaler', 'beclomethasone dipropionate', 'beclomethasone dipropionate (inhaled)', 'Qvar RediHaler', 'Qvar BAI', 'HFA-BDP extrafine aerosol', 'beclometasone (inhaled, CFC-free), Teva', 'beclomethasone dipropionate (Easi-Breathe), Ivax', 'Qvar', 'Aerobec Ventolair', 'beclomethasone dipropionate, (CFC-free), Teva', 'beclomethasone dipropionate, (CFC-free)', 'AeroBec Autohaler', 'beclomethasone dipropionate (Easi-Breathe)', 'beclometasone (inhaled, CFC-free)', 'beclomethasone dipropionate (MDI formulation)', 'TMP-96', 'HFA-134a BDP, HMR']","beclomethasone dipropionate, (CFC-free)",fexact,"['qvar digihaler', 'beclomethasone dipropionate', 'beclomethasone dipropionate inhaled', 'qvar redihaler', 'qvar bai', 'hfa bdp extrafine aerosol', 'beclometasone inhaled cfc free teva', 'beclomethasone dipropionate easi breathe ivax', 'qvar', 'aerobec ventolair', 'beclomethasone dipropionate cfc free teva', 'beclomethasone dipropionate cfc free', 'aerobec autohaler', 'beclomethasone dipropionate easi breathe', 'beclometasone inhaled cfc free', 'beclomethasone dipropionate mdi formulation', 'tmp 96', 'hfa 134a bdp hmr']",incorrect_mapping
loperamide,Opioid receptor agonist,loperamide,,,,0,"['loperamide (nanoparticle formulation, diarrhea)', 'loperamide']",,NER_API,[],0
tiotropium bromide,Long-acting muscarinic antagonist; Muscarinic M3 receptor antagonist,tiotropium bromide,,tiotropium bromide,tiotropium bromide,fexact,"['Favint Respimat', 'Spiriva Respima', 'Respimat (tiotropium), BI', 'Ba-679 BR', 'tiotropium bromide', 'Spiriva', 'BA-679', 'Spiriva HandiHaler', 'Spiriva Respimat', 'Tiotropium Respimat']",tiotropium bromide,fexact,"['favint respimat', 'spiriva respima', 'respimat tiotropium bi', 'ba 679 br', 'tiotropium bromide', 'spiriva', 'ba 679', 'spiriva handihaler', 'spiriva respimat', 'tiotropium respimat']",correct_mapping
filgrastim,Granulocyte colony stimulating factor agonist,filgrastim,,filgrastim biosimilar,filgrastim,fexact,"['Zarxio', 'filgrastim-sndz', 'Zarzio', 'filgrastim biosimilar, Hexal', 'Filgrastim Hexal', 'filgrastim biosimilar', 'filgrastim', 'EP-2006', 'Filgrastim BS']",filgrastim biosimilar,fexact,"['zarxio', 'filgrastim sndz', 'zarzio', 'filgrastim biosimilar hexal', 'filgrastim hexal', 'filgrastim biosimilar', 'filgrastim', 'ep 2006', 'filgrastim bs']",correct_mapping
isotretinoin,Microbial collagenase inhibitor; Protein synthesis inhibitor; Retinoic acid receptor agonist,isotretinoin,,isotretinoin,isotretinoin,fexact,"['Roacutan', 'isotretinoin', 'Accutane', 'Roaccutane']",isotretinoin,fexact,"['roacutan', 'isotretinoin', 'accutane', 'roaccutane']",correct_mapping
ribociclib,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor,ribociclib,,ribociclib,ribociclib,fexact,"['cyclin-dependent kinase 4/6 inhibitor (cancer), Astrex/', 'cyclin-dependent kinase 4/6 inhibitor (cancer), Astrex/Novartis', 'ribociclib succinate', 'ribociclib', 'Kisqali Femara Co-Pack', 'Kisqali', 'CDK4/6 inhibitor (cancer), Novartis/Astrex', 'LEE-011', 'CDK4/6 inhibitor (cancer),/Astrex']",ribociclib,fexact,"['cyclin dependent kinase 4 6 inhibitor cancer astrex', 'cyclin dependent kinase 4 6 inhibitor cancer astrex novartis', 'ribociclib succinate', 'ribociclib', 'kisqali femara co pack', 'kisqali', 'cdk4 6 inhibitor cancer novartis astrex', 'lee 011', 'cdk4 6 inhibitor cancer astrex']",correct_mapping
aflibercept,Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,aflibercept,,,,0,"['aflibercept', 'aflibercept biosimilar', 'SCD-411']",,NER_API,[],0
xentuzumab,Insulin-like growth factor 1 antagonist; Insulin-like growth factor 2 antagonist,xentuzumab,,xentuzumab,xentuzumab,fexact,"['xentuzumab', 'BI-836845', 'IGF pathway modulator (iv, cancer)']",xentuzumab,fexact,"['xentuzumab', 'bi 836845', 'igf pathway modulator iv cancer']",correct_mapping
ID-CMB305,Immunostimulant; Toll-like receptor 4 agonist; Immuno-oncology therapy,ID-CMB305,,CMB-305,id cmb305,fexact,"['CMB-305', 'LV-305 + G-305', 'ID-CMB305']",CMB-305,fexact,"['cmb 305', 'lv 305 g 305', 'id cmb305']",correct_mapping
sapitinib,EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor,sapitinib,,sapitinib,sapitinib,fexact,"['sapitinib', 'AZD-8931']",sapitinib,fexact,"['sapitinib', 'azd 8931']",correct_mapping
AZD-5363 (capsule),Protein kinase B inhibitor; Protein kinase inhibitor; Ribosomal S6 kinase inhibitor,AZD-5363,,capivasertib,azd 5363,fexact,"['Akt inhibitor (cancer),/ICR//', 'capivasertib', 'AZD-5363', 'Akt inhibitor (cancer),/ICR/Cancer Research/', 'Akt inhibitor (cancer),/ICR/Cancer Research/AstraZeneca']",capivasertib,fexact,"['akt inhibitor cancer icr', 'capivasertib', 'azd 5363', 'akt inhibitor cancer icr cancer research', 'akt inhibitor cancer icr cancer research astrazeneca']",correct_mapping
"theophylline, unspecified",Adenosine A1 receptor antagonist; Adenosine A2a receptor antagonist; Phosphodiesterase inhibitor,theophylline,unspecified,theophylline,theophylline,fexact,"['theophylline, Mitsubishi Pharma', 'Theodur', 'theophylline']",theophylline,fexact,"['theophylline mitsubishi pharma', 'theodur', 'theophylline']",correct_mapping
Sulijia,Angiogenesis inhibitor,Sulijia,,,,0,"['DB-108', 'Sulijia', 'recombinant human endostatin (intravenous, advanced non-small cell lung cancer), Wuzhong Group', 'endostatin human', 'recombinant human endostatin (iv, NSCLC),/Wuzhong Group']",,NER_API,[],0
DP-4978,B-raf kinase inhibitor; C-raf kinase inhibitor,DP-4978,,LY-3009120,dp 4978,fexact,"['selective B-Raf inhibitors (cancer),/Eli Lilly', 'DP-2743', 'Pan-Raf inhibitor (cancer), Eli Lilly', 'dual B-RAF and C-RAF inhibitor (cancer)', 'DP-2854', 'DP-2512', 'Pan-Raf inhibitor (cancer)', 'DP-4978', 'DP-3346', 'LY-3009120', 'LSN-3074753', 'DP-2874', 'selective B-Raf inhibitors (cancer),/']",LY-3009120,fexact,"['selective b raf inhibitors cancer eli lilly', 'dp 2743', 'pan raf inhibitor cancer eli lilly', 'dual b raf and c raf inhibitor cancer', 'dp 2854', 'dp 2512', 'pan raf inhibitor cancer', 'dp 4978', 'dp 3346', 'ly 3009120', 'lsn 3074753', 'dp 2874', 'selective b raf inhibitors cancer']",correct_mapping
5-azacitidine (inhaled),DNA synthesis inhibitor; DNA methylase inhibitor; RNA synthesis inhibitor,5-azacitidine,,"azacytidine (inhaled aerosol, lung cancer)",5 azacitidine,fexact,"['azacitidine', 'azacytidine (inhaled aerosol, lung cancer)', '5-azacytidine (inhaled aerosol, lung cancer)', '5-azacitidine']","azacytidine (inhaled aerosol, lung cancer)",fexact,"['azacitidine', 'azacytidine inhaled aerosol lung cancer', '5 azacytidine inhaled aerosol lung cancer', '5 azacitidine']",correct_mapping
"Ypegylated filgrastim, Amoytop",Granulocyte colony stimulating factor agonist,Ypegylated filgrastim,Amoytop,pegfilgrastim,pegylated filgrastim,fuzzy,"['pegfilgrastim', 'r-metHuG-CSF-SD/01', 'KRN-125', 'Neulastim', 'Ristempa', 'PEG-GCSF,/', 'PEG-GCSF,/Roche', 'SD-01', 'PEGylated filgrastim', 'Neupopeg', 'Filgrastim SD-01', 'G-Lasta', 'Neulasta Onpro', 'R-1471', 'Peglasta', 'Neulasta', 'Neupogen (sustained release)']",pegfilgrastim,fexact,"['pegfilgrastim', 'r methug csf sd 01', 'krn 125', 'neulastim', 'ristempa', 'peg gcsf', 'peg gcsf roche', 'sd 01', 'pegylated filgrastim', 'neupopeg', 'filgrastim sd 01', 'g lasta', 'neulasta onpro', 'r 1471', 'peglasta', 'neulasta', 'neupogen sustained release']",incorrect_mapping
ASP-5878,FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor,ASP-5878,,ASP-5878,asp 5878,fexact,['ASP-5878'],ASP-5878,fexact,['asp 5878'],correct_mapping
Gossypol,Apoptosis stimulant,Gossypol,,AT-101,gossypol,fexact,"['NSC-726190', 'BL-193', 'bcl-2/bcl-xl inhibitors (cancer, tablet/natural product)', '(-)-gossypol (anticancer)', 'TW-37', '(-)-gossypol (anticancer), Ascenta', '(-)-gossypol', 'gossypol analogs, nci', 'R-(-)-gossypol acetic acid', '(-)-gossypol, NCI/University of Michigan', 'pan-Bcl-2 inhibitor (cancer), Ascenta/', 'Bcl-2/Bcl-xl inhibitors (cancer, tablet/natural product), University of Michigan/Ascenta', 'AT-101', 'pan-Bcl-2 inhibitor (cancer),/', 'Bcl-2/Bcl-xl inhibitors (cancer, tablet/natural product), University of Michigan/', 'gossypol analogs, NCI/University of Michigan', '(-)-gossypol, nci']",AT-101,fexact,"['nsc 726190', 'bl 193', 'bcl 2 bcl xl inhibitors cancer tablet natural product', 'gossypol anticancer', 'tw 37', 'gossypol anticancer ascenta', 'gossypol', 'gossypol analogs nci', 'r gossypol acetic acid', 'gossypol nci university of michigan', 'pan bcl 2 inhibitor cancer ascenta', 'bcl 2 bcl xl inhibitors cancer tablet natural product university of michigan ascenta', 'at 101', 'pan bcl 2 inhibitor cancer', 'bcl 2 bcl xl inhibitors cancer tablet natural product university of michigan', 'gossypol analogs nci university of michigan', 'gossypol nci']",correct_mapping
"anti-CTLA-4 antibody, unspecified",CTLA4 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,anti-CTLA-4 antibody,unspecified,,,0,['anti-CTLA-4 antibody'],,0,[],0
PF-4929113 (tablet),Heat shock protein 90 antagonist,PF-4929113,,"SNX-5422 (oral, cancer)",pf 4929113,fexact,"['SC-105422', 'SC-107881', 'SC-102112', 'SNX-5542', 'SNX-5422', 'PF-4929113 (oral, cancer)', 'PF-04928473', 'PF-4929113', 'SNX-5422 (oral, cancer)', 'PF-4929113 (oral, cancer), Pfizer', 'SNX-5422 (oral, cancer), Pfizer', 'Hsp90 inhibitors (oral, cancer), Serenex', 'SN-5422', 'SNX-2112', 'SNX-5422 (oral, cancer), Serenex', 'PF-4928473', 'PF-04929113', 'Hsp90 inhibitors (oral, cancer)']","SNX-5422 (oral, cancer)",fexact,"['sc 105422', 'sc 107881', 'sc 102112', 'snx 5542', 'snx 5422', 'pf 4929113 oral cancer', 'pf 04928473', 'pf 4929113', 'snx 5422 oral cancer', 'pf 4929113 oral cancer pfizer', 'snx 5422 oral cancer pfizer', 'hsp90 inhibitors oral cancer serenex', 'sn 5422', 'snx 2112', 'snx 5422 oral cancer serenex', 'pf 4928473', 'pf 04929113', 'hsp90 inhibitors oral cancer']",correct_mapping
monosialoganglioside GM1,Nerve growth factor agonist,monosialoganglioside GM1,,,,0,['monosialoganglioside GM1'],,0,[],0
tarextumab,Notch pathway inhibitor,tarextumab,,tarextumab,tarextumab,fexact,"['notch 2/3 receptor inhibitor (mAb, solid tumors)', 'notch receptor modulator (mAb, solid tumor), Oncomed/', 'notch receptor modulator (mAb, solid tumor),/', 'notch 2/3 receptor inhibitor (mAb, solid tumors), Oncomed pharmaceuticals', 'tarextumab', 'OMP-59R5', 'Tarextumumab']",tarextumab,fexact,"['notch 2 3 receptor inhibitor mab solid tumors', 'notch receptor modulator mab solid tumor oncomed', 'notch receptor modulator mab solid tumor', 'notch 2 3 receptor inhibitor mab solid tumors oncomed pharmaceuticals', 'tarextumab', 'omp 59r5', 'tarextumumab']",correct_mapping
methoxyamine (oral),DNA repair enzyme inhibitor,methoxyamine,,"TRC-102 (oral, cancer)",methoxyamine,fexact,"['TRC-102', 'methoxyamine (oral, chemotherapy resistance),/TRACON', 'TRC-102 (oral, cancer)', 'methoxyamine (oral, chemotherapy resistance),/', 'methoxyamine', 'TRC-102 (oral, cancer), Tracon']","TRC-102 (oral, cancer)",fexact,"['trc 102', 'methoxyamine oral chemotherapy resistance tracon', 'trc 102 oral cancer', 'methoxyamine oral chemotherapy resistance', 'methoxyamine', 'trc 102 oral cancer tracon']",correct_mapping
IMGN-289,Unidentified pharmacological activity,IMGN-289,,IMGN-289,imgn 289,fexact,"['laprituximab emtansine', 'anti-EGFR-DM1', 'IMGN-289', 'EGFR-targeted MAb-DM1 conjugate', 'J-2898-A-DM1 conjugate']",IMGN-289,fexact,"['laprituximab emtansine', 'anti egfr dm1', 'imgn 289', 'egfr targeted mab dm1 conjugate', 'j 2898 a dm1 conjugate']",correct_mapping
GS-5745 (IV),Matrix metalloproteinase-9 inhibitor,GS-5745,,andecaliximab,gs 5745,fexact,"['andecaliximab', 'GS-5745', 'matrix metalloproteinase-9 inhibitor (rheumatoid arthritis)']",andecaliximab,fexact,"['andecaliximab', 'gs 5745', 'matrix metalloproteinase 9 inhibitor rheumatoid arthritis']",correct_mapping
MORAb-066,Factor III inhibitor,MORAb-066,,MORAb-066,morab 066,fexact,"['anti-tissue factor monoclonal antibody (pancreatic tumor)', 'anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek', 'MORAb-066']",MORAb-066,fexact,"['anti tissue factor monoclonal antibody pancreatic tumor', 'anti tissue factor monoclonal antibody pancreatic tumor morphotek', 'morab 066']",correct_mapping
etoposide toniribate,DNA topoisomerase II inhibitor,etoposide toniribate,,etoposide toniribate,etoposide toniribate,fexact,"['topoisomerase inhibitors (cancer)', 'topoisomerase II inhibitor (Prodrug, cancer)', 'GP-7.1', 'CAP-7.1', 'etoposide toniribate', 'pro-CAP-7.1', 'EDO-S7.1', 'topoisomerase inhibitors (cancer), GenPat77']",etoposide toniribate,fexact,"['topoisomerase inhibitors cancer', 'topoisomerase ii inhibitor prodrug cancer', 'gp 7 1', 'cap 7 1', 'etoposide toniribate', 'pro cap 7 1', 'edo s7 1', 'topoisomerase inhibitors cancer genpat77']",correct_mapping
genistein,Immunosuppressant; Histidine kinase inhibitor; Tyrosine kinase inhibitor (TKI); Angiogenesis inhibitor; Reducing agent; Isoflavone agonist,genistein,,,,0,"['genistein (oral/capsule, osteoporosis), Zhongzhu Holding//', ""genistein (oral/capsule, osteoporosis), Zhongzhu Holding//Xi'an Hengtai Herbal Medicine Technology"", 'genistein']",,NER_API,[],0
S-488410,Immunostimulant,S-488410,,S-588410,s 488410,fexact,"['asudemotide', 'S-488403', 'S-588410', 'peptide vaccine (bladder cancer)', 'S-488410', 'peptide vaccine (lung/ esophagael cancer), Shionogi', 'peptide vaccine (lung/ esophagael cancer)', 'S-488402', 'peptide vaccine (bladder cancer), Shionogi', 'peptide vaccine (lung/ esophagael cancer/gastric cancer)', 'S-288310', 'S-488401']",S-588410,fexact,"['asudemotide', 's 488403', 's 588410', 'peptide vaccine bladder cancer', 's 488410', 'peptide vaccine lung esophagael cancer shionogi', 'peptide vaccine lung esophagael cancer', 's 488402', 'peptide vaccine bladder cancer shionogi', 'peptide vaccine lung esophagael cancer gastric cancer', 's 288310', 's 488401']",correct_mapping
GV-1001 (intradermal),Telomerase inhibitor; Immunostimulant; T cell stimulant; Immuno-oncology therapy,GV-1001,,tertomotide,gv 1001,fexact,"['telomerase vaccine (cancer, injectable/peptide)', 'KDDF-201609-02', 'GV-1001', 'telomerase vaccine (cancer, injectable/peptide), KAEL-GemVax', 'hTERT611-626', 'Riavax', 'HR-2822', 'tertomotide', 'HR-2802']",tertomotide,fexact,"['telomerase vaccine cancer injectable peptide', 'kddf 201609 02', 'gv 1001', 'telomerase vaccine cancer injectable peptide kael gemvax', 'htert611 626', 'riavax', 'hr 2822', 'tertomotide', 'hr 2802']",correct_mapping
retaspimycin,Apoptosis stimulant; Heat shock protein 90 antagonist,retaspimycin,,"retaspimycin (iv, cancer)",retaspimycin,fexact,"['retaspimycin hydrochloride (iv, cancer),/', 'retaspimycin hydrochloride', 'IPI-504 (intravenous),/', 'retaspimycin (iv, cancer),/', 'retaspimycin', 'hsp90 inhibitor (iv, cancer),/MedImmune', 'retaspimycin hydrochloride (iv, cancer),/MedImmune', 'retaspimycin (iv, cancer),/MedImmune', 'IPI-504', 'MEDI-561', 'IPI-504 (intravenous),/MedImmune', 'retaspimycin (iv, cancer)', 'hsp90 inhibitor (iv, cancer),/']","retaspimycin (iv, cancer)",fexact,"['retaspimycin hydrochloride iv cancer', 'retaspimycin hydrochloride', 'ipi 504 intravenous', 'retaspimycin iv cancer', 'retaspimycin', 'hsp90 inhibitor iv cancer medimmune', 'retaspimycin hydrochloride iv cancer medimmune', 'retaspimycin iv cancer medimmune', 'ipi 504', 'medi 561', 'ipi 504 intravenous medimmune', 'retaspimycin iv cancer', 'hsp90 inhibitor iv cancer']",correct_mapping
pioglitazone hydrochloride (tablet),Peroxisome proliferator-activated receptor gamma agonist; Insulin sensitizer; Thiazolidinedione,pioglitazone hydrochloride,,pioglitazone,pioglitazone hydrochloride,fexact,"['Actos OD', 'AD-4833', 'Actos', 'pioglitazone hydrochloride', 'TOMM40', 'Glustin', '72107', 'pioglitazone', 'U 72107', 'U-72107A']",pioglitazone,fexact,"['actos od', 'ad 4833', 'actos', 'pioglitazone hydrochloride', 'tomm40', 'glustin', '72107', 'pioglitazone', 'u 72107', 'u 72107a']",correct_mapping
DS-2248,Heat shock protein 90 antagonist,DS-2248,,DS-2248,ds 2248,fexact,['DS-2248'],DS-2248,fexact,['ds 2248'],correct_mapping
amuvatinib (lipid suspension capsule),RET tyrosine kinase inhibitor; C-kit inhibitor; Flt-3 antagonist; MET tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; DNA repair enzyme inhibitor; RAD51 expression inhibitor,amuvatinib,,amuvatinib,amuvatinib,fexact,"['amuvatinib', 'MP-470 hydrochloride', 'amuvatinib hydrochloride', 'MP-470']",amuvatinib,fexact,"['amuvatinib', 'mp 470 hydrochloride', 'amuvatinib hydrochloride', 'mp 470']",correct_mapping
AC-480 (IV),ErbB-3 antagonist; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor,AC-480,,"AC-480 (iv, cancer)",ac 480,fexact,"['AC-480 (iv, cancer)', 'HER-1, 2, 3, 4 tyrosine kinase inhibitor (iv, solid tumors)', 'AC-480', 'AC-480IV']","AC-480 (iv, cancer)",fexact,"['ac 480 iv cancer', 'her 1 2 3 4 tyrosine kinase inhibitor iv solid tumors', 'ac 480', 'ac 480iv']",correct_mapping
ranpirnase,Ribonuclease stimulant; RNA binder; Apoptosis stimulant,ranpirnase,,ranpirnase,ranpirnase,fexact,"['RanTop', 'TMR-004', 'ranpirnase', 'proapoptotic amphibian ribonuclease (cancer/ HIV), Tamir', 'proapoptotic amphibian ribonuclease (cancer/ HIV)', 'proapoptotic amphibian ribonuclease (cancer/ HIV), Alfacell', 'Onconase']",ranpirnase,fexact,"['rantop', 'tmr 004', 'ranpirnase', 'proapoptotic amphibian ribonuclease cancer hiv tamir', 'proapoptotic amphibian ribonuclease cancer hiv', 'proapoptotic amphibian ribonuclease cancer hiv alfacell', 'onconase']",correct_mapping
PKI-179,mTOR kinase inhibitor; PI3 kinase inhibitor,PKI-179,,PKI-179,pki 179,fexact,"['pi3k inhibitor (cancer, oral)', 'phosphoinositide 3-kinase inhibitor (cancer, oral)', 'phosphoinositide 3-kinase inhibitor (cancer, oral), Wyeth', 'PI3K inhibitor (cancer, oral), Wyeth', 'PKI-179']",PKI-179,fexact,"['pi3k inhibitor cancer oral', 'phosphoinositide 3 kinase inhibitor cancer oral', 'phosphoinositide 3 kinase inhibitor cancer oral wyeth', 'pi3k inhibitor cancer oral wyeth', 'pki 179']",correct_mapping
5-fluoro-2-deoxycytidine,DNA methylase inhibitor,5-fluoro-2-deoxycytidine,,5-Fluoro-2-deoxycytidine,5 fluoro 2 deoxycytidine,fexact,"['5-Fluoro-2-deoxycytidine', 'FdCyd', 'tetrahydrouridine', ""5-Fluoro-2'-deoxycytidine""]",5-Fluoro-2-deoxycytidine,fexact,"['5 fluoro 2 deoxycytidine', 'fdcyd', 'tetrahydrouridine', '5 fluoro 2 deoxycytidine']",correct_mapping
"chloroquine, Ace Pharmaceuticals",Immunosuppressant,chloroquine,Ace Pharmaceuticals,,,0,"['repurposed chloroquine (cancer), university of leuven/globalcures', 'repurposed chloroquine (cancer), university of leuven', 'chloroquine']",,NER_API,[],0
CV-9201,Immunostimulant,CV-9201,,CV-9201,cv 9201,fexact,"['CV-9201-1', 'CV-9201-4', 'CV-9201-2', 'CV-9201-5', 'RNActive RNA-based vaccine (NY-ESO-1, MAGE-C1/CT7, MAGE-C2/CT10, NSCLC)', 'CV-9201-3', 'CV-9201']",CV-9201,fexact,"['cv 9201 1', 'cv 9201 4', 'cv 9201 2', 'cv 9201 5', 'rnactive rna based vaccine ny eso 1 mage c1 ct7 mage c2 ct10 nsclc', 'cv 9201 3', 'cv 9201']",correct_mapping
CLR-1404,DNA inhibitor; Radiopharmaceutical,CLR-1404,,,,0,"['CLR-1401', 'NM-404', 'CLR-1404', 'COLD (cancer), Novelos']",,NER_API,[],0
ixazomib citrate (IV),Transcription factor NF-kappaB inhibitor; Proteasome inhibitor,ixazomib citrate,,ixazomib citrate,ixazomib citrate,fexact,"['enlairui', 'MLN-9708', 'proteasome inhibitor (oral, cancer), Millennium', 'ixazomib citrate (oral, multiple myeloma/amyloidosis)', 'Ninlaro', 'MLN-9708 (oral, multiple myeloma/amyloidosis), Millennium', 'ixazomib citrate', 'MLN-9708 (oral, cancer), Millennium']",ixazomib citrate,fexact,"['enlairui', 'mln 9708', 'proteasome inhibitor oral cancer millennium', 'ixazomib citrate oral multiple myeloma amyloidosis', 'ninlaro', 'mln 9708 oral multiple myeloma amyloidosis millennium', 'ixazomib citrate', 'mln 9708 oral cancer millennium']",correct_mapping
beta-glucan (oral),Immunostimulant; Macrophage stimulant; Natural killer cell stimulant,beta-glucan,,,,0,['beta-glucan'],,0,[],0
sildenafil (IR),Phosphodiesterase 5 inhibitor,sildenafil,,sildenafil citrate,sildenafil,fexact,"['Patrex', 'Viagra', 'Revatio', 'UK 92480-10', 'UK-92480', 'sildenafil citrate', 'sildenafil']",sildenafil citrate,fexact,"['patrex', 'viagra', 'revatio', 'uk 92480 10', 'uk 92480', 'sildenafil citrate', 'sildenafil']",correct_mapping
zibotentan,Endothelin A receptor antagonist,zibotentan,,zibotentan,zibotentan,fexact,"['ZD-4054', 'zibotentan', 'AZ-11922817', 'AZD-4054']",zibotentan,fexact,"['zd 4054', 'zibotentan', 'az 11922817', 'azd 4054']",correct_mapping
marizomib (IV),Apoptosis stimulant; Proteasome inhibitor,marizomib,,,,0,"['NPI-0052', 'marizomib (iv, cancer), Triphase', 'marizomib (iv, cancer), Triphase/', 'marizomib (iv, cancer),/', 'marizomib (iv, cancer)', 'salinosporamide', 'marizomib (iv, cancer), Triphase/Celgene', 'marizomib (iv, cancer), Celgene', 'marizomib', 'salinosporamide A, UCSD', 'salinosporamide A']",,NER_API,[],0
indinavir sulfate,HIV protease inhibitor,indinavir sulfate,,indinavir,indinavir sulfate,fexact,"['L-735524', 'indinavir', 'Crixivan', 'indinavir sulfate', 'MK-639', 'Compound J']",indinavir,fexact,"['l 735524', 'indinavir', 'crixivan', 'indinavir sulfate', 'mk 639', 'compound j']",correct_mapping
ritonavir,Cytochrome P450 inhibitor; HIV protease inhibitor,ritonavir,,ritonavir,ritonavir,fexact,"['ritonavir', 'ABT-538', 'A-84538', 'Abbott-84538', 'novir', 'Norvir']",ritonavir,fexact,"['ritonavir', 'abt 538', 'a 84538', 'abbott 84538', 'novir', 'norvir']",correct_mapping
peginesatide (SC),Erythropoietin receptor agonist,peginesatide,,peginesatide,peginesatide,fexact,"['peginesatide', 'EPO mimetic (systemic, anemia),/Takeda', 'Omontys', 'erythropoietin mimetic (systemic, anemia),/Takeda', 'AF-37702', 'erythropoietin mimetic (systemic, anemia),/', 'EPO mimetic (systemic, anemia),/', 'Hematide']",peginesatide,fexact,"['peginesatide', 'epo mimetic systemic anemia takeda', 'omontys', 'erythropoietin mimetic systemic anemia takeda', 'af 37702', 'erythropoietin mimetic systemic anemia', 'epo mimetic systemic anemia', 'hematide']",correct_mapping
Anti-CD3 x Anti-EGFR-Armed Activated T-Cells,EGFR antagonist,Anti-CD3 x Anti-EGFR-Armed Activated T-Cells,,,,0,['Anti-CD3 x Anti-EGFR-Armed Activated T-Cells'],,0,[],0
linifanib (tablet),Colony stimulating factor 1 receptor antagonist; Macrophage colony stimulating factor antagonist; Platelet-derived growth factor receptor kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor,linifanib,,linifanib,linifanib,fexact,"['ABT-869', 'AL-39324', 'tyrosine kinase inhibitors (cancer)', 'linifanib', 'RG-3635']",linifanib,fexact,"['abt 869', 'al 39324', 'tyrosine kinase inhibitors cancer', 'linifanib', 'rg 3635']",correct_mapping
fondaparinux sodium,Indirect Factor Xa inhibitor; Serine protease inhibitor,fondaparinux sodium,,fondaparinux sodium,fondaparinux sodium,fexact,"['Arixtra', 'Quixidar', 'Arixtra®', 'SR-90107', 'pentasaccharide', 'fondaparin sodium', 'SR-90107A', 'GSK-576428', 'fondaparinux', 'Xantidar', 'pentasaccharide, Sanofi-Synthelabo/Organon', 'pentasaccharide, Sanofi-Synthelabo/', 'Org-31540', 'IC-851589', 'fondaparinux sodium']",fondaparinux sodium,fexact,"['arixtra', 'quixidar', 'arixtra', 'sr 90107', 'pentasaccharide', 'fondaparin sodium', 'sr 90107a', 'gsk 576428', 'fondaparinux', 'xantidar', 'pentasaccharide sanofi synthelabo organon', 'pentasaccharide sanofi synthelabo', 'org 31540', 'ic 851589', 'fondaparinux sodium']",correct_mapping
"topotecan TCS, Tekmira",DNA topoisomerase I inhibitor,topotecan TCS,Tekmira,,,0,['topotecan TCS'],,0,[],0
escitalopram oxalate,5 Hydroxytryptamine uptake inhibitor,escitalopram oxalate,,escitalopram,escitalopram oxalate,fexact,"['Entact', 'S-citalopram', 'escitalopram', 'Sipralex', 'citalopram enantiomer,/', 'Cipralex', 'Seroplex', 'Sipralexa', 'citalopram enantiomer, Actavis/', 'Esertia', 'escitalopram oxalate', 'LU-26-054', 'Lexapro', 'citalopram enantiomer, Actavis/Lundbeck', 'citalopram enantiomer, Forest/Lundbeck', 'MLD-55', 'Cipralex Meltz', 'citalopram enantiomer,/Lundbeck']",escitalopram,fexact,"['entact', 's citalopram', 'escitalopram', 'sipralex', 'citalopram enantiomer', 'cipralex', 'seroplex', 'sipralexa', 'citalopram enantiomer actavis', 'esertia', 'escitalopram oxalate', 'lu 26 054', 'lexapro', 'citalopram enantiomer actavis lundbeck', 'citalopram enantiomer forest lundbeck', 'mld 55', 'cipralex meltz', 'citalopram enantiomer lundbeck']",correct_mapping
obatoclax (iv),Bcl2 inhibitor; Mcl-1 antagonist,obatoclax,,obatoclax,obatoclax,fexact,"['GX-015 series, Gemin X', 'obatoclax mesylate', 'GX-011', 'GX-15-003', 'GX-022', 'GX-015-034', 'Bcl-2 pan-inhibitors (cancer)', 'GX-01 series, Gemin X', 'Bcl-2 inhibitors (cancer)', 'obatoclax', 'GX-01 series', 'GX-015 series', 'Bcl-2 inhibitors (cancer), Gemin X', 'GX-15-070MS', 'GX-15-000', 'CEP-41601', 'Bcl-2 pan-inhibitors (cancer), Gemin X', 'NSC-729280', 'GX-15-070', 'GX-015-000', 'GX-015-003', 'GX-15-034', 'GX-015-070']",obatoclax,fexact,"['gx 015 series gemin x', 'obatoclax mesylate', 'gx 011', 'gx 15 003', 'gx 022', 'gx 015 034', 'bcl 2 pan inhibitors cancer', 'gx 01 series gemin x', 'bcl 2 inhibitors cancer', 'obatoclax', 'gx 01 series', 'gx 015 series', 'bcl 2 inhibitors cancer gemin x', 'gx 15 070ms', 'gx 15 000', 'cep 41601', 'bcl 2 pan inhibitors cancer gemin x', 'nsc 729280', 'gx 15 070', 'gx 015 000', 'gx 015 003', 'gx 15 034', 'gx 015 070']",correct_mapping
131-I-TM-601 (IV),DNA inhibitor; Angiogenesis inhibitor; Radiopharmaceutical,131-I-TM-601,,131I-TM-601,131i tm 601,fuzzy,"['TM-602', 'TM-603', 'glioma therapy, Transmolecular', 'TM-803', 'solid tumor imaging', 'toxin-based anticancers', 'iodine-131-TM-601', 'solid tumor imaging, TransMolecular', 'toxin-based anticancers, Transmolecular', 'glioma therapy', '131I-TM-601']",131I-TM-601,fexact,"['tm 602', 'tm 603', 'glioma therapy transmolecular', 'tm 803', 'solid tumor imaging', 'toxin based anticancers', 'iodine 131 tm 601', 'solid tumor imaging transmolecular', 'toxin based anticancers transmolecular', 'glioma therapy', '131i tm 601']",incorrect_mapping
"disulfiram, Ora Bio",Angiogenesis inhibitor,disulfiram,Ora Bio,,,0,"['liposomal disulfiram (cataract), Pharmacia', 'liposomal disulfiram (cataract)', 'disulfiram, Pharmacia', 'disulfiram', 'disulfiram (liposome formulation)']",,NER_API,[],0
patupilone,Tubulin inhibitor; Microtubule stimulant,patupilone,,patupilone,patupilone,fexact,"['EPO-906A', 'epothilone B', 'EPO-906', 'patupilone']",patupilone,fexact,"['epo 906a', 'epothilone b', 'epo 906', 'patupilone']",correct_mapping
detoxPC,Immunostimulant,detoxPC,,,,0,['detoxPC'],,0,[],0
RAV12,Unidentified pharmacological activity,RAV12,,RAV-12,rav 12,fuzzy,"['RAV-12', 'KID-3 antibody (cancer), Raven', 'KID-3 antibody (cancer)', 'anti-RAAG12 monoclonal antibody', 'anti-RAAG12 mab']",RAV-12,fexact,"['rav 12', 'kid 3 antibody cancer raven', 'kid 3 antibody cancer', 'anti raag12 monoclonal antibody', 'anti raag12 mab']",incorrect_mapping
IG-002,Beta tubulin inhibitor; Microtubule stimulant; Taxane,IG-002,,,,0,['IG-002'],,0,[],0
sulfamethoxazole,Sulfonamide antibiotic,sulfamethoxazole,,,,0,['sulfamethoxazole'],,0,[],0
trimethoprim,Dihydrofolate reductase inhibitor,trimethoprim,,,,0,['trimethoprim'],,0,[],0
ciprofloxacin (tablet),DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,ciprofloxacin,,ciprofloxacin hydrochloride,ciprofloxacin,fexact,"['Ciprobay', 'Uniflox', 'Ciproxina', 'ciprofloxacin', 'Ciflox', 'BAY-Q-3939', 'Baycip', 'Cipro', 'Ciproxine', 'Ciloxan', 'Ciproxan', 'Ciproxin', 'ciprofloxacin hydrochloride']",ciprofloxacin hydrochloride,fexact,"['ciprobay', 'uniflox', 'ciproxina', 'ciprofloxacin', 'ciflox', 'bay q 3939', 'baycip', 'cipro', 'ciproxine', 'ciloxan', 'ciproxan', 'ciproxin', 'ciprofloxacin hydrochloride']",correct_mapping
tanespimycin,Heat shock protein 90 antagonist,tanespimycin,,tanespimycin (HALT technology),tanespimycin,fexact,"['EC-5', 'EC-71', 'EC4', 'HSP90 modulators (HALT technology)', '17-AAG', 'tanespimycin', 'CNF-1010, Conforma', 'HSP90 modulators (HALT technology), Conforma', 'tanespimycin (HALT technology)', 'EC-69', 'CNF-1010']",tanespimycin (HALT technology),fexact,"['ec 5', 'ec 71', 'ec4', 'hsp90 modulators halt technology', '17 aag', 'tanespimycin', 'cnf 1010 conforma', 'hsp90 modulators halt technology conforma', 'tanespimycin halt technology', 'ec 69', 'cnf 1010']",correct_mapping
pelitinib,EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI),pelitinib,,pelitinib,pelitinib,fexact,"['EKB-569', 'WAY-EKB-569', 'EKI-569', 'pelitinib']",pelitinib,fexact,"['ekb 569', 'way ekb 569', 'eki 569', 'pelitinib']",correct_mapping
irofulven,DNA inhibitor; DNA synthesis inhibitor; Apoptosis stimulant; RNA polymerase inhibitor,irofulven,,irofulven,irofulven,fexact,"['Irofulven-1', 'HMAF', 'NSC-683863', 'hydroxymethylacylfulvene', 'MGI-114', 'IND-55804', 'acylfulvenes, MGI', 'Irofulven DRP', 'LP-100, Lantern Pharma', 'LP-100', 'hydroxymethylacylfulvene, MGI', 'acylfulvenes', 'Acylfulvene', 'E-7850', 'Irofulven, Allarity Therapeutics', 'irofulven']",irofulven,fexact,"['irofulven 1', 'hmaf', 'nsc 683863', 'hydroxymethylacylfulvene', 'mgi 114', 'ind 55804', 'acylfulvenes mgi', 'irofulven drp', 'lp 100 lantern pharma', 'lp 100', 'hydroxymethylacylfulvene mgi', 'acylfulvenes', 'acylfulvene', 'e 7850', 'irofulven allarity therapeutics', 'irofulven']",correct_mapping
prinomastat,Matrix metalloproteinase inhibitor; Angiogenesis inhibitor,prinomastat,,prinomastat,prinomastat,fexact,"['AG-3362', 'AG-2393', 'prinomastat', 'AG-3354', 'AG-3340']",prinomastat,fexact,"['ag 3362', 'ag 2393', 'prinomastat', 'ag 3354', 'ag 3340']",correct_mapping
folic acid,Unidentified pharmacological activity,folic acid,,,,0,['folic acid'],,0,[],0
lometrexol,Phosphoribosylglycinamide formyltransferase inhibitor,lometrexol,,lometrexol,lometrexol,fexact,"['GARFT inhibitors', 'lometrexol', 'DDATHF', 'LY-264618', 'lometrexol sodium', 'T-64', 'LY-249543']",lometrexol,fexact,"['garft inhibitors', 'lometrexol', 'ddathf', 'ly 264618', 'lometrexol sodium', 't 64', 'ly 249543']",correct_mapping
fluoxetine,5 Hydroxytryptamine uptake inhibitor,fluoxetine,,fluoxetine hydrochloride,fluoxetine,fexact,"['LY-110140', 'Prozac Weekly', 'fluoxetine hydrochloride', 'fluoxetine', 'Sarafem', 'Prozac']",fluoxetine hydrochloride,fexact,"['ly 110140', 'prozac weekly', 'fluoxetine hydrochloride', 'fluoxetine', 'sarafem', 'prozac']",correct_mapping
rebimastat,Matrix metalloproteinase-2 inhibitor; Matrix metalloproteinase-9 inhibitor; Angiogenesis inhibitor,rebimastat,,rebimastat,rebimastat,fexact,"['BMS-275291', 'rebimastat', 'D-2163']",rebimastat,fexact,"['bms 275291', 'rebimastat', 'd 2163']",correct_mapping
Neovastat,Vascular endothelial growth factor receptor 2 antagonist; Matrix metalloproteinase inhibitor; Angiogenesis inhibitor; Apoptosis stimulant,Neovastat,,AE-941,neovastat,fexact,"['Neoretna', 'Psovascar', 'Neovastat', 'Arthrovas', 'AE-941']",AE-941,fexact,"['neoretna', 'psovascar', 'neovastat', 'arthrovas', 'ae 941']",correct_mapping
GC-012F,T cell stimulant; Immuno-oncology therapy,GC-012F,,GC-012,gc 012f,fexact,"['anti-BCMA + anti-CD19 CAR T-cell therapy (multiple myeloma)', 'GC-012F', 'dual anti-BCMA/undisclosed target CAR T-cell therapy (multiple myeloma)', 'Dual CAR-BCMA-19', 'dual anti-BCMA/CD19 CAR T-cell therapy (multiple myeloma)', 'GC-012', 'anti-BCMA + anti-undisclosed target CAR T-cell therapy (multiple myeloma)']",GC-012,fexact,"['anti bcma anti cd19 car t cell therapy multiple myeloma', 'gc 012f', 'dual anti bcma undisclosed target car t cell therapy multiple myeloma', 'dual car bcma 19', 'dual anti bcma cd19 car t cell therapy multiple myeloma', 'gc 012', 'anti bcma anti undisclosed target car t cell therapy multiple myeloma']",correct_mapping
melphalan,DNA inhibitor,melphalan,,,,0,"['melphalan (percutaneous hepatic perfusion, liver cancer),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma/cholangiocarcinoma),/', 'melphalan (percutaneous hepatic perfusion, liver cancer),/', 'melphalan (hepatic delivery system)', 'melphalan (Chemosat, liver cancer),/', 'melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma),/', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma),/', 'HEPZATO', 'CHEMOSAT', 'melphalan (Chemosat, liver cancer),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma/cholangiocarcinoma),/NCI', 'melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma),/NCI', 'melphalan', 'Melblez']",,NER_API,[],0
iberdomide,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,iberdomide,,iberdomide,iberdomide,fexact,"['CC-10062', 'CC-12025', 'TNF alpha synthesis inhibitor (oral, SLE/MM/lymphomas)', 'Immunomodulatory drugs', 'IMiD-2', 'CC-220', 'CC-5098', 'CC-3052', 'CC-5031', 'iberdomide hydrochloride', 'IMiDs', 'Immunomodulatory drugs, Celgene', 'IMiDs, Celgene', 'CC-5022', 'CC-10015', 'IMiD-5', 'CC-10095', 'iberdomide', 'CC-4059']",iberdomide,fexact,"['cc 10062', 'cc 12025', 'tnf alpha synthesis inhibitor oral sle mm lymphomas', 'immunomodulatory drugs', 'imid 2', 'cc 220', 'cc 5098', 'cc 3052', 'cc 5031', 'iberdomide hydrochloride', 'imids', 'immunomodulatory drugs celgene', 'imids celgene', 'cc 5022', 'cc 10015', 'imid 5', 'cc 10095', 'iberdomide', 'cc 4059']",correct_mapping
daratumumab,CD38 antagonist; Immuno-oncology therapy,daratumumab,,daratumumab,daratumumab,fexact,"['Darzalex', 'HuMax-CD38', 'daratumumab', '3003-005', 'HuMax, multiple myeloma', 'JNJ-54767414', 'IgG1kappa antibody (multiple myeloma)']",daratumumab,fexact,"['darzalex', 'humax cd38', 'daratumumab', '3003 005', 'humax multiple myeloma', 'jnj 54767414', 'igg1kappa antibody multiple myeloma']",correct_mapping
ciltacabtagene autoleucel,T cell stimulant; Immuno-oncology therapy,ciltacabtagene autoleucel,,ciltacabtagene autoleucel,ciltacabtagene autoleucel,fexact,"['JNJ-4528', 'anti-BCMA CAR T-cell therapy (multiple myeloma)', 'anti-BCMA CAR T-cell therapy (multiple myeloma), Nanjing Legend Biotech', 'ciltacabtagene autoleucel', 'LCAR-B38M', 'JNJ-68284528', 'cilta-cel']",ciltacabtagene autoleucel,fexact,"['jnj 4528', 'anti bcma car t cell therapy multiple myeloma', 'anti bcma car t cell therapy multiple myeloma nanjing legend biotech', 'ciltacabtagene autoleucel', 'lcar b38m', 'jnj 68284528', 'cilta cel']",correct_mapping
cevostamab,CD3 agonist; Immuno-oncology therapy,cevostamab,,cevostamab,cevostamab,fexact,"['anti-CD3/anti-FcRH5 bispecific T-cell engager (TDB, multiple myeloma)', 'cevostamab', 'RO-7187797', 'FcRH5-TDB', 'anti-FcRH5/anti-CD3 bispecific antibody (multiple myeloma)', 'RG-6160', 'BFCR-4350A']",cevostamab,fexact,"['anti cd3 anti fcrh5 bispecific t cell engager tdb multiple myeloma', 'cevostamab', 'ro 7187797', 'fcrh5 tdb', 'anti fcrh5 anti cd3 bispecific antibody multiple myeloma', 'rg 6160', 'bfcr 4350a']",correct_mapping
belantamab mafodotin,Tubulin polymerization inhibitor; Immuno-oncology therapy,belantamab mafodotin,,belantamab mafodotin,belantamab mafodotin,fexact,"['humanized Fc-engineered anti-B cell maturation antigen-MMAF mAb-drug conjugate (cancer), GlaxoSmithKline/', 'humanized Fc-engineered anti-B cell maturation antigen-MMAF mAb-drug conjugate (cancer),/', 'belantamab mafodotin-blmf', 'BLENREP', 'belantamab mafodotin', 'Blenrep', 'J6M0-mcMMAF', 'GSK-2857916', ""GSK'916""]",belantamab mafodotin,fexact,"['humanized fc engineered anti b cell maturation antigen mmaf mab drug conjugate cancer glaxosmithkline', 'humanized fc engineered anti b cell maturation antigen mmaf mab drug conjugate cancer', 'belantamab mafodotin blmf', 'blenrep', 'belantamab mafodotin', 'blenrep', 'j6m0 mcmmaf', 'gsk 2857916', 'gsk 916']",correct_mapping
lemzoparlimab,CD47 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,lemzoparlimab,,lemzoparlimab,lemzoparlimab,fexact,"['TJ-011133', 'lemzoparlimab', 'CD47 checkpoint inhibitor (cancer), I-Mab Biopharma', 'TJC-4', 'cd47 checkpoint inhibitor (cancer)']",lemzoparlimab,fexact,"['tj 011133', 'lemzoparlimab', 'cd47 checkpoint inhibitor cancer i mab biopharma', 'tjc 4', 'cd47 checkpoint inhibitor cancer']",correct_mapping
SLAMF7 BATs,SLAMF7 antagonist; Immuno-oncology therapy,SLAMF7 BATs,,,,0,['SLAMF7 BATs'],,0,[],0
hyperbaric oxygen,Unidentified pharmacological activity,hyperbaric oxygen,,,,0,['hyperbaric oxygen'],,0,[],0
crenigacestat,Secretase gamma inhibitor; Notch pathway inhibitor,crenigacestat,,crenigacestat,crenigacestat,fexact,"['notch inhibitor II (cancer)', 'crenigacestat', 'JSMD-194', 'gamma secretase inhibitor (notch pathway, cancer), Eli Lilly', 'LY-3039478', 'notch signalling inhibitor (gamma secretase SMI, cancer)', 'gamma secretase inhibitor (notch pathway, cancer)', 'notch inhibitor II (cancer), Eli Lilly', 'notch signalling inhibitor (gamma secretase SMI, cancer), Eli Lilly']",crenigacestat,fexact,"['notch inhibitor ii cancer', 'crenigacestat', 'jsmd 194', 'gamma secretase inhibitor notch pathway cancer eli lilly', 'ly 3039478', 'notch signalling inhibitor gamma secretase smi cancer', 'gamma secretase inhibitor notch pathway cancer', 'notch inhibitor ii cancer eli lilly', 'notch signalling inhibitor gamma secretase smi cancer eli lilly']",correct_mapping
idecabtagene vicleucel,T cell stimulant; Immuno-oncology therapy,idecabtagene vicleucel,,idecabtagene vicleucel,idecabtagene vicleucel,fexact,"['anti-BCMA CAR T-cell therapy (hematological malignancies), bluebird bio/', 'idecabtagene vicleucel', 'anti B-cell maturation antigen-targeting chimeric antigen receptor T-cells (hematological malignancies), bluebird bio', 'BCMA-targeting CAR T-cells (hematological malignancies)', 'anti-BCMA CAR T-cell therapy (hematological malignancies),/', 'bb-2121', 'Abecma', 'BCMA-targeting CAR T-cells (hematological malignancies), bluebird bio', 'ide-cel', 'anti-BCMA CAR T-cell therapy (hematological malignancies), bluebird bio/Celgene', 'anti B-cell maturation antigen-targeting chimeric antigen receptor T-cells (hematological malignancies)']",idecabtagene vicleucel,fexact,"['anti bcma car t cell therapy hematological malignancies bluebird bio', 'idecabtagene vicleucel', 'anti b cell maturation antigen targeting chimeric antigen receptor t cells hematological malignancies bluebird bio', 'bcma targeting car t cells hematological malignancies', 'anti bcma car t cell therapy hematological malignancies', 'bb 2121', 'abecma', 'bcma targeting car t cells hematological malignancies bluebird bio', 'ide cel', 'anti bcma car t cell therapy hematological malignancies bluebird bio celgene', 'anti b cell maturation antigen targeting chimeric antigen receptor t cells hematological malignancies']",correct_mapping
"metformin HCl, once-daily, BMS",Insulin sensitizer; Biguanide; Gluconeogenesis inhibitor,metformin HCl,BMS,,,0,['metformin HCl'],,0,[],0
ixazomib citrate,Transcription factor NF-kappaB inhibitor; Proteasome inhibitor,ixazomib citrate,,ixazomib citrate,ixazomib citrate,fexact,"['enlairui', 'MLN-9708', 'proteasome inhibitor (oral, cancer), Millennium', 'ixazomib citrate (oral, multiple myeloma/amyloidosis)', 'Ninlaro', 'MLN-9708 (oral, multiple myeloma/amyloidosis), Millennium', 'ixazomib citrate', 'MLN-9708 (oral, cancer), Millennium']",ixazomib citrate,fexact,"['enlairui', 'mln 9708', 'proteasome inhibitor oral cancer millennium', 'ixazomib citrate oral multiple myeloma amyloidosis', 'ninlaro', 'mln 9708 oral multiple myeloma amyloidosis millennium', 'ixazomib citrate', 'mln 9708 oral cancer millennium']",correct_mapping
selinexor (capsule),Exportin 1 inhibitor,selinexor,,selinexor,selinexor,fexact,"['ATG-010', 'KCP-330', 'KPT-207', 'XPOVIO', 'nuclear transport inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'selective nuclear export inhibitors (COVID-19), Karyopharm Therapeutics', 'SINE (autoimmune diseases/HIV/cancer)', 'Nexpovio', 'KPT-SINE', 'KPT-185', 'SINE-KPT-330', 'KPT-225', 'KPT-330', 'KPT-XXX', 'Exportin-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'CRM-1 inhibitors (inflammation/viral diseases/cancer), Karyopharm Therapeutics', 'selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease)', 'nuclear transport inhibitors (inflammation/viral diseases/cancer)', 'selective nuclear export inhibitors (autoimmune diseases/HIV/cancer)', 'KPT-249', 'KPT-276', 'Exportin-1 inhibitors (inflammation/viral diseases/cancer)', 'KPT-251', 'selinexor', 'Xpovio', 'selective nuclear export inhibitors (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics', 'SINE (autoimmune diseases/HIV/cancer), Karyopharm Therapeutics', 'CRM-1 inhibitors (inflammation/viral diseases/cancer)', 'ONO-7705', 'selective nuclear export inhibitors (autoimmune/inflammation/HIV/cancer/dermatological disease), Karyopharm Therapeutics', 'selective nuclear export inhibitors (COVID-19)']",selinexor,fexact,"['atg 010', 'kcp 330', 'kpt 207', 'xpovio', 'nuclear transport inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'selective nuclear export inhibitors covid 19 karyopharm therapeutics', 'sine autoimmune diseases hiv cancer', 'nexpovio', 'kpt sine', 'kpt 185', 'sine kpt 330', 'kpt 225', 'kpt 330', 'kpt xxx', 'exportin 1 inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'crm 1 inhibitors inflammation viral diseases cancer karyopharm therapeutics', 'selective nuclear export inhibitors autoimmune inflammation hiv cancer dermatological disease', 'nuclear transport inhibitors inflammation viral diseases cancer', 'selective nuclear export inhibitors autoimmune diseases hiv cancer', 'kpt 249', 'kpt 276', 'exportin 1 inhibitors inflammation viral diseases cancer', 'kpt 251', 'selinexor', 'xpovio', 'selective nuclear export inhibitors autoimmune diseases hiv cancer karyopharm therapeutics', 'sine autoimmune diseases hiv cancer karyopharm therapeutics', 'crm 1 inhibitors inflammation viral diseases cancer', 'ono 7705', 'selective nuclear export inhibitors autoimmune inflammation hiv cancer dermatological disease karyopharm therapeutics', 'selective nuclear export inhibitors covid 19']",correct_mapping
elotuzumab,SLAMF7 antagonist; Immuno-oncology therapy,elotuzumab,,elotuzumab,elotuzumab,fexact,"['anti-CS1 antibody (cancer), BMS/PDL', 'CS1 targeting humanized monoclonal antibody (mab, multiple myeloma), PDL', 'anti-CD37 mAb (multiple myeloma), Bristol-Myers Squibb', 'CS1 targeting humanized mAb (multiple myeloma), Bristol-Myers Squibb', 'anti-CD37 mAb (multiple myeloma)', 'HuLuc63', 'anti-CS1 antibody (cancer), BMS/', 'BMS-901608', 'PDL-063', 'elotuzumab', 'Empliciti', 'CS1 targeting humanized monoclonal antibody (mab, multiple myeloma)', 'CS1 targeting humanized mAb (multiple myeloma), Facet', 'CS1 targeting humanized mAb (multiple myeloma)']",elotuzumab,fexact,"['anti cs1 antibody cancer bms pdl', 'cs1 targeting humanized monoclonal antibody mab multiple myeloma pdl', 'anti cd37 mab multiple myeloma bristol myers squibb', 'cs1 targeting humanized mab multiple myeloma bristol myers squibb', 'anti cd37 mab multiple myeloma', 'huluc63', 'anti cs1 antibody cancer bms', 'bms 901608', 'pdl 063', 'elotuzumab', 'empliciti', 'cs1 targeting humanized monoclonal antibody mab multiple myeloma', 'cs1 targeting humanized mab multiple myeloma facet', 'cs1 targeting humanized mab multiple myeloma']",correct_mapping
LAVA-051,T cell stimulant; Immuno-oncology therapy; CD1D agonist,LAVA-051,,LAVA-051,lava 051,fexact,"['anti-TCR/anti-CD1d bispecific gamma-delta T-cell engager (hematological malignancies),/Leiden University Medical Center', 'CD1d-Vd2 bispecific VHH', 'anti-TCR/anti-CD1d bispecific T-cell engager (hematological malignancies),/Leiden University Medical Center', 'LAVA-051', 'CD1d-Vd2 bsVHH', 'CD1d-VHH + Vd2-VHH']",LAVA-051,fexact,"['anti tcr anti cd1d bispecific gamma delta t cell engager hematological malignancies leiden university medical center', 'cd1d vd2 bispecific vhh', 'anti tcr anti cd1d bispecific t cell engager hematological malignancies leiden university medical center', 'lava 051', 'cd1d vd2 bsvhh', 'cd1d vhh vd2 vhh']",correct_mapping
CM-313,CD38 antagonist; Immuno-oncology therapy,CM-313,,CM-313,cm 313,fexact,['CM-313'],CM-313,fexact,['cm 313'],correct_mapping
Descartes-08,T cell stimulant; Immuno-oncology therapy,Descartes-08,,Descartes-08,descartes 08,fexact,"['cd8+ anti-bcma car t-cell therapy (multiple myeloma), /harvard medical school', 'Descartes-08', 'cd8+ anti-bcma car t-cell therapy (multiple myeloma)']",Descartes-08,fexact,"['cd8 anti bcma car t cell therapy multiple myeloma harvard medical school', 'descartes 08', 'cd8 anti bcma car t cell therapy multiple myeloma']",correct_mapping
ciclosporin,Immunosuppressant; Calcineurin inhibitor; T cell inhibitor,ciclosporin,,ciclosporin,ciclosporin,fexact,"['cyclosporin', 'cyclosporin A', 'Sandimmun', 'OLO-400', 'ciclosporin', 'Neoral', 'Sandimmune', 'cyclosporine', 'Sandimmun Neoral']",ciclosporin,fexact,"['cyclosporin', 'cyclosporin a', 'sandimmun', 'olo 400', 'ciclosporin', 'neoral', 'sandimmune', 'cyclosporine', 'sandimmun neoral']",correct_mapping
LNA-i-miR-221,MicroRNA inhibitor,LNA-i-miR-221,,,,0,['LNA-i-miR-221'],,0,[],0
OPD-5,Unidentified pharmacological activity,OPD-5,,OPD-5,opd 5,fexact,"['OPD-5', 'peptide conjugated alkylator (peptide-drug conjugate (PDC) platform, multiple myeloma)']",OPD-5,fexact,"['opd 5', 'peptide conjugated alkylator peptide drug conjugate pdc platform multiple myeloma']",correct_mapping
elranatamab,CD3 agonist; Immuno-oncology therapy,elranatamab,,elranatamab,elranatamab,fexact,"['elranatamab', 'B-cell maturation antigen (BCMA) CD3 bi-specific (relapsed/refractory multiple myeloma)', 'anti-CD3/anti-BCMA bispecific T-cell engager (multiple myeloma)', 'PF-06863135', 'BMCA + CD3 therapeutic (triple MM/double MM)']",elranatamab,fexact,"['elranatamab', 'b cell maturation antigen bcma cd3 bi specific relapsed refractory multiple myeloma', 'anti cd3 anti bcma bispecific t cell engager multiple myeloma', 'pf 06863135', 'bmca cd3 therapeutic triple mm double mm']",correct_mapping
"BCMA CAR-T cells, Chongqing Precision Biotech",T cell stimulant; Immuno-oncology therapy,BCMA CAR-T cells,Chongqing Precision Biotech,PRG-1801,bcma car t cells,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma), Pregene (Shenzhen) Biotechnology/ Henan Province Hospital', 'anti-BCMA CAR T-cell therapy (multiple myeloma),/ Henan Province Hospital', 'BCMA CAR-T cells', 'PRG-1801']",PRG-1801,fexact,"['anti bcma car t cell therapy multiple myeloma pregene shenzhen biotechnology henan province hospital', 'anti bcma car t cell therapy multiple myeloma henan province hospital', 'bcma car t cells', 'prg 1801']",correct_mapping
talquetamab,CD3 agonist; Immuno-oncology therapy,talquetamab,,talquetamab,talquetamab,fexact,"['anti-CD3/anti-GPRC5D bispecific T-cell engager (DuoBody, multiple myeloma),/Genmab', 'talquetamab', 'anti-CD3/anti-GPRC5D bispecific mAb (relapsed or refractory multiple myeloma), Genmab/', 'CD3xGPRC5D bispecific mAb (relapsed or refractory multiple myeloma), Genmab/', 'JNJ-64407564', 'DuoBody CD3xGPRC5D bispecific antibody (multiple myeloma), Genmab/', 'JNJ-7564']",talquetamab,fexact,"['anti cd3 anti gprc5d bispecific t cell engager duobody multiple myeloma genmab', 'talquetamab', 'anti cd3 anti gprc5d bispecific mab relapsed or refractory multiple myeloma genmab', 'cd3xgprc5d bispecific mab relapsed or refractory multiple myeloma genmab', 'jnj 64407564', 'duobody cd3xgprc5d bispecific antibody multiple myeloma genmab', 'jnj 7564']",correct_mapping
LP-118,Unidentified pharmacological activity,LP-118,,LP-118,lp 118,fexact,"['dual Bcl-2/Bcl-xL inhibitor (oral tablet, cancer)', 'LP-118']",LP-118,fexact,"['dual bcl 2 bcl xl inhibitor oral tablet cancer', 'lp 118']",correct_mapping
GEN-3014,CD38 antagonist; Immuno-oncology therapy,GEN-3014,,HexaBody-CD38,gen 3014,fexact,"['GEN-3014', 'HexaBody-CD38']",HexaBody-CD38,fexact,"['gen 3014', 'hexabody cd38']",correct_mapping
EMB-06,CD3 agonist; B-cell maturation antigen antagonist; Immuno-oncology therapy,EMB-06,,EMB-06,emb 06,fexact,"['EMB-06', 'undisclosed target bispecific T-cell engager (FIT-Ig, cancer)', 'anti-CD3/anti-BCMA bispecific T-cell engager (multiple myeloma)']",EMB-06,fexact,"['emb 06', 'undisclosed target bispecific t cell engager fit ig cancer', 'anti cd3 anti bcma bispecific t cell engager multiple myeloma']",correct_mapping
piperine,Unidentified pharmacological activity,piperine,,,,0,"['piperine analogs (vitiligo), King`s College', 'rCHP', 'piperine analogs (vitiligo), OHSU', 'AD-8001', 'piperine analogs (vitiligo), BTG/King`s College', 'piperine', 'THP', 'piperine analogs (vitilgo), BTG', 'piperine analogs (vitiligo)', 'piperine analogs (vitiligo), Oregon Health and Science University', 'piperine analogs (vitiligo),/King`s College', 'CHP', 'piperine analogs (vitilgo)']",,Drug_API_mapping,[],0
CFT-7455,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,CFT-7455,,transcription factor protein degraders (hematological malignancies),cft 7455,fexact,"['transcription factor protein degraders (hematological malignancies)', 'CFT-7455']",transcription factor protein degraders (hematological malignancies),fexact,"['transcription factor protein degraders hematological malignancies', 'cft 7455']",correct_mapping
CXCR4 modified anti-BCMA CAR T cells,T cell stimulant; CXC chemokine receptor 4 antagonist; Immuno-oncology therapy,CXCR4 modified anti-BCMA CAR T cells,,,,0,['CXCR4 modified anti-BCMA CAR T cells'],,0,[],0
teclistamab,CD3 agonist; Immuno-oncology therapy,teclistamab,,teclistamab,teclistamab,fexact,"['anti-CD3/anti-BCMA bispecific T-cell engager (DuoBody, multiple myeloma)', 'anti-CD3/anti-BCMA bispecific T-cell engager (DuoBody, hematological neoplasm)', 'JNJ-7957', 'JNJ-957', 'BCMA x CD3 DuoBody bispecific antibody (hematological neoplasm), Janssen Biotech/ Genmab', 'JNJ-64007957', 'Ab-957', 'teclistamab', 'AB-957']",teclistamab,fexact,"['anti cd3 anti bcma bispecific t cell engager duobody multiple myeloma', 'anti cd3 anti bcma bispecific t cell engager duobody hematological neoplasm', 'jnj 7957', 'jnj 957', 'bcma x cd3 duobody bispecific antibody hematological neoplasm janssen biotech genmab', 'jnj 64007957', 'ab 957', 'teclistamab', 'ab 957']",correct_mapping
HB10101,B-cell maturation antigen antagonist; Immuno-oncology therapy,HB10101,,,,0,['HB10101'],,0,[],0
CBG-002,T cell stimulant; Immuno-oncology therapy,CBG-002,,CBG-002,cbg 002,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma)', 'CBG-002']",CBG-002,fexact,"['anti bcma car t cell therapy multiple myeloma', 'cbg 002']",correct_mapping
S-64315,Mcl-1 antagonist,S-64315,,S-64315,s 64315,fexact,"['Mcl-1 inhibitors (cancer), Servier/', 'MIK-665', 'mcl-1 inhibitors (cancer)', 'S-64315', 'S-63845']",S-64315,fexact,"['mcl 1 inhibitors cancer servier', 'mik 665', 'mcl 1 inhibitors cancer', 's 64315', 's 63845']",correct_mapping
S-65487,Bcl2 inhibitor,S-65487,,VOB-560,s 65487,fexact,"['S-65487', 'Bcl-2 inhibitor (cancer)', 'VOB-560']",VOB-560,fexact,"['s 65487', 'bcl 2 inhibitor cancer', 'vob 560']",correct_mapping
C-4-29,T cell stimulant; Immuno-oncology therapy,C-4-29,,C-4-29,c 4 29,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma)', 'C-4-29']",C-4-29,fexact,"['anti bcma car t cell therapy multiple myeloma', 'c 4 29']",correct_mapping
TEG-002,T cell stimulant; Immuno-oncology therapy,TEG-002,,GDT-002,teg 002,fexact,"['GDT-002', 'TEG-002', 'autologous T-cells expressing gamma delta T-cell receptor (breast tumor)', 'autologous T cells transduced\xa0with a specific gamma delta T-cell receptor (infusion, multiple myeloma)', 'TCR T-cell therapy (multiple myeloma)', 'TCR gamma delta T-cell therapy (multiple myeloma)']",GDT-002,fexact,"['gdt 002', 'teg 002', 'autologous t cells expressing gamma delta t cell receptor breast tumor', 'autologous t cells transduced\xa0with a specific gamma delta t cell receptor infusion multiple myeloma', 'tcr t cell therapy multiple myeloma', 'tcr gamma delta t cell therapy multiple myeloma']",correct_mapping
uproleselan,E-selectin antagonist,uproleselan,,uproleselan sodium,uproleselan,fexact,"['E-selectin antagonists (metastasis/pancreas cancer/thromboembolism)', 'E-Selectin antagonists (oral, diabetic angiopathy)', 'uproleselan sodium', 'E-selectin antagonists (metastasis/pancreas cancer/thromboembolism), GlycoMimetics', 'E-Selectin antagonists (oral, diabetic angiopathy), GlycoMimetics', 'APL-106', 'uproleselan', 'GMI-1271']",uproleselan sodium,fexact,"['e selectin antagonists metastasis pancreas cancer thromboembolism', 'e selectin antagonists oral diabetic angiopathy', 'uproleselan sodium', 'e selectin antagonists metastasis pancreas cancer thromboembolism glycomimetics', 'e selectin antagonists oral diabetic angiopathy glycomimetics', 'apl 106', 'uproleselan', 'gmi 1271']",correct_mapping
JWCAR-129,T cell stimulant; Immuno-oncology therapy,JWCAR-129,,JWCAR-129,jwcar 129,fexact,"['JWCAR-129', 'anti-BCMA CAR-T cell therapy (multiple myeloma),/', 'anti-BCMA CAR-T cell therapy (multiple myeloma), JW Therapeutics (Shanghai)/Juno Therapeutics', 'anti-BCMA CAR-T cell therapy (multiple myeloma), JW Therapeutics (Shanghai)/', 'anti-BCMA CAR-T cell therapy (multiple myeloma), JW Therapeutics (Shanghai)/Celgene', 'anti-BCMA CAR-T cell therapy (multiple myeloma),/Juno Therapeutics']",JWCAR-129,fexact,"['jwcar 129', 'anti bcma car t cell therapy multiple myeloma', 'anti bcma car t cell therapy multiple myeloma jw therapeutics shanghai juno therapeutics', 'anti bcma car t cell therapy multiple myeloma jw therapeutics shanghai', 'anti bcma car t cell therapy multiple myeloma jw therapeutics shanghai celgene', 'anti bcma car t cell therapy multiple myeloma juno therapeutics']",correct_mapping
CC-95266,Unidentified pharmacological activity,CC-95266,,CC-95266,cc 95266,fexact,['CC-95266'],CC-95266,fexact,['cc 95266'],correct_mapping
daratumumab (SC),CD38 antagonist; Immuno-oncology therapy,daratumumab,,daratumumab,daratumumab,fexact,"['Darzalex', 'HuMax-CD38', 'daratumumab', '3003-005', 'HuMax, multiple myeloma', 'JNJ-54767414', 'IgG1kappa antibody (multiple myeloma)']",daratumumab,fexact,"['darzalex', 'humax cd38', 'daratumumab', '3003 005', 'humax multiple myeloma', 'jnj 54767414', 'igg1kappa antibody multiple myeloma']",correct_mapping
fludarabine (IV),DNA synthesis inhibitor; Ribonucleoside diphosphate reductase inhibitor; DNA repair enzyme inhibitor,fludarabine,,fludarabine,fludarabine,fexact,"['Oforta', '2-F-AraAMP', 'SH-537', 'SH-L-573A', 'SHT-586', 'Fludara iv', 'Fludara Oral', 'SH-586', 'fludarabine phosphate', 'BAY-86-4864', 'Beneflur', 'NSC-312887', 'Fludara', 'fludarabine', 'SH-584']",fludarabine,fexact,"['oforta', '2 f araamp', 'sh 537', 'sh l 573a', 'sht 586', 'fludara iv', 'fludara oral', 'sh 586', 'fludarabine phosphate', 'bay 86 4864', 'beneflur', 'nsc 312887', 'fludara', 'fludarabine', 'sh 584']",correct_mapping
"bispecific chimaeric antigen receptor -T cells therapy, Wuhan Si'an Medical Technology",T cell stimulant; Immuno-oncology therapy,bispecific chimaeric antigen receptor -T cells therapy,Wuhan Si'an Medical Technology,,,0,['bispecific chimaeric antigen receptor -T cells therapy'],,0,[],0
"CD70 chimaeric antigen receptor-T cell therapy, Yake Biotechnology",T cell stimulant; Immuno-oncology therapy,CD70 chimaeric antigen receptor-T cell therapy,Yake Biotechnology,,,0,['CD70 chimaeric antigen receptor-T cell therapy'],,0,[],0
CERC-007,Interleukin 18 antagonist; Immuno-oncology therapy,CERC-007,,CERC-007,cerc 007,fexact,"['anti-IL-18 mAb (inflammation)', 'auto-inflammatory disease therapy', 'MEDI-2338', ""70636 anti-IL-18-mAb (iv, Still's disease/ juvenile idiopathic arthritis/multiple myelom)"", 'AEVI-007', 'CERC-007', 'interleukin 18-targeted monoclonal antibody (inflammation), MedImmune', 'interleukin 18-targeted monoclonal antibody (inflammation)', 'anti-IL-18 mAb (inflammation), MedImmune']",CERC-007,fexact,"['anti il 18 mab inflammation', 'auto inflammatory disease therapy', 'medi 2338', '70636 anti il 18 mab iv still s disease juvenile idiopathic arthritis multiple myelom', 'aevi 007', 'cerc 007', 'interleukin 18 targeted monoclonal antibody inflammation medimmune', 'interleukin 18 targeted monoclonal antibody inflammation', 'anti il 18 mab inflammation medimmune']",correct_mapping
"APRIL chimaeric antigen receptor-T cell therapy, Yake Biotechnology",T cell stimulant; Immuno-oncology therapy,APRIL chimaeric antigen receptor-T cell therapy,Yake Biotechnology,,,0,['APRIL chimaeric antigen receptor-T cell therapy'],,0,[],0
SG-301,Unidentified pharmacological activity,SG-301,,SG-301,sg 301,fexact,"['humanized anti-CD38 mAb (multiple myeloma)', 'SG-301']",SG-301,fexact,"['humanized anti cd38 mab multiple myeloma', 'sg 301']",correct_mapping
lisaftoclax,Bcl2 inhibitor,lisaftoclax,,lisaftoclax,lisaftoclax,fexact,"['APG-2575', 'lisaftoclax', 'Bcl-2 inhibitor (oral, B-cell malignancies)']",lisaftoclax,fexact,"['apg 2575', 'lisaftoclax', 'bcl 2 inhibitor oral b cell malignancies']",correct_mapping
"BCMA CAR-T cell therapy, PersonGen BioTherapeutics",T cell stimulant; Immuno-oncology therapy,BCMA CAR-T cell therapy,PersonGen BioTherapeutics,CT-053,anti bcma car t cell therapy,fuzzy,"['anti-BCMA CAR T-cell therapy (intravenous infusion, multiple myeloma)', 'anti-BCMA CAR T-cell therapy', 'CT-053']",CT-053,fexact,"['anti bcma car t cell therapy intravenous infusion multiple myeloma', 'anti bcma car t cell therapy', 'ct 053']",incorrect_mapping
OPC-415,T cell stimulant; Immuno-oncology therapy,OPC-415,,OPC-415,opc 415,fexact,"['anti-integrin beta-7 car t-cell therapy (multiple myeloma), /otsuka pharmaceutical', 'OPC-415', 'anti-integrin beta-7 car t-cell therapy (multiple myeloma),/', 'mmg49 car t-cell therapy (multiple myeloma),/', 'mmg49 car t-cell therapy (multiple myeloma), /otsuka pharmaceutical', 'MMG49 CAR T-cell therapy']",OPC-415,fexact,"['anti integrin beta 7 car t cell therapy multiple myeloma otsuka pharmaceutical', 'opc 415', 'anti integrin beta 7 car t cell therapy multiple myeloma', 'mmg49 car t cell therapy multiple myeloma', 'mmg49 car t cell therapy multiple myeloma otsuka pharmaceutical', 'mmg49 car t cell therapy']",correct_mapping
SAR-439459,Transforming growth factor beta antagonist,SAR-439459,,SAR-439459,sar 439459,fexact,"['anti-TGF beta monoclonal antibody (intravenous, solid tumor)', 'SAR-439459']",SAR-439459,fexact,"['anti tgf beta monoclonal antibody intravenous solid tumor', 'sar 439459']",correct_mapping
"BCMA CAR-T therapy, Yake Biotechnology",T cell stimulant; Immuno-oncology therapy,BCMA CAR-T therapy,Yake Biotechnology,,,0,['BCMA CAR-T therapy'],,0,[],0
BCMA-CAR-T cells,B-cell maturation antigen antagonist; Immuno-oncology therapy,BCMA-CAR-T cells,,PRG-1801,bcma car t cells,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma), Pregene (Shenzhen) Biotechnology/ Henan Province Hospital', 'anti-BCMA CAR T-cell therapy (multiple myeloma),/ Henan Province Hospital', 'BCMA CAR-T cells', 'PRG-1801']",PRG-1801,fexact,"['anti bcma car t cell therapy multiple myeloma pregene shenzhen biotechnology henan province hospital', 'anti bcma car t cell therapy multiple myeloma henan province hospital', 'bcma car t cells', 'prg 1801']",correct_mapping
"BCMA chimaeric antigen receptor therapy, Hebei Senlang Biotechnology",T cell stimulant; Immuno-oncology therapy,BCMA chimaeric antigen receptor therapy,Hebei Senlang Biotechnology,,,0,['BCMA chimaeric antigen receptor therapy'],,0,[],0
INCB-00928,Activin receptor-like kinase 2 inhibitor,INCB-00928,,INCB-00928,incb 00928,fexact,"['ALK2 inhibitors (fibrodysplasia ossificans progressiva/myelofibrosis)', 'activin receptor-like kinase-2 inhibitors (fibrodysplasia ossificans progressiva/myelofibrosis)', 'INCB-000928', 'INCB-00928']",INCB-00928,fexact,"['alk2 inhibitors fibrodysplasia ossificans progressiva myelofibrosis', 'activin receptor like kinase 2 inhibitors fibrodysplasia ossificans progressiva myelofibrosis', 'incb 000928', 'incb 00928']",correct_mapping
eftozanermin alfa,TRAIL receptor agonist,eftozanermin alfa,,eftozanermin alfa,eftozanermin alfa,fexact,"['ABBV-621', 'TRAIL receptor agonists (solid tumor),/AbbbVie', 'APG-880', 'TRAIL receptor agonist (iv, solid tumors/hematological malignancies)', 'eftozanermin alfa', 'TRAIL receptor agonists (solid tumor), Apogenix/AbbbVie', 'APG-350', 'HERA-TRAIL']",eftozanermin alfa,fexact,"['abbv 621', 'trail receptor agonists solid tumor abbbvie', 'apg 880', 'trail receptor agonist iv solid tumors hematological malignancies', 'eftozanermin alfa', 'trail receptor agonists solid tumor apogenix abbbvie', 'apg 350', 'hera trail']",correct_mapping
CellProtect,Not applicable,CellProtect,,CellProtect,cellprotect,fexact,"['CellProtect', 'expanded autologous NK cell therapy (CellProtect, multiple myeloma),/Karolinska', 'natural killer cell therapy (autologus, multiple myeloma/acute myeloid leukemia/neuroblastoma),/Karolinska Institute', 'natural killer cell therapy (autologous, multiple myeloma),/Karolinska Institute', 'expanded autologous NK cell therapy (CellProtect, multiple myeloma),/', 'natural killer cell therapy (autologous, multiple myeloma),/', 'natural killer cell therapy (autologus, multiple myeloma/acute myeloid leukemia/neuroblastoma),/']",CellProtect,fexact,"['cellprotect', 'expanded autologous nk cell therapy cellprotect multiple myeloma karolinska', 'natural killer cell therapy autologus multiple myeloma acute myeloid leukemia neuroblastoma karolinska institute', 'natural killer cell therapy autologous multiple myeloma karolinska institute', 'expanded autologous nk cell therapy cellprotect multiple myeloma', 'natural killer cell therapy autologous multiple myeloma', 'natural killer cell therapy autologus multiple myeloma acute myeloid leukemia neuroblastoma']",correct_mapping
RO-7425781,Unidentified pharmacological activity,RO-7425781,,RO-7425781,ro 7425781,fexact,"['RG-6234', 'RO-7425781']",RO-7425781,fexact,"['rg 6234', 'ro 7425781']",correct_mapping
ET-150,T cell stimulant; Immuno-oncology therapy,ET-150,,,,0,['ET-150'],,0,[],0
PRT-1419,Mcl-1 antagonist,PRT-1419,,PRT-1419,prt 1419,fexact,"['PRT-1419', 'myeloid leukemia cell differentiation protein 1 inhibitor (hematological neoplasm)']",PRT-1419,fexact,"['prt 1419', 'myeloid leukemia cell differentiation protein 1 inhibitor hematological neoplasm']",correct_mapping
"CS1-chimaeric antigen receptor-T cell therapy, Yake Biotechnology",T cell stimulant; Immuno-oncology therapy,CS1-chimaeric antigen receptor-T cell therapy,Yake Biotechnology,,,0,['CS1-chimaeric antigen receptor-T cell therapy'],,0,[],0
IM-21,T cell stimulant; Immuno-oncology therapy,IM-21,,IM-21,im 21,fexact,"['IM21 CART', 'IM-21', 'anti-BCMA CAR T-cell therapy (multiple myeloma), Peking Union Medical College Hospital/', 'anti-BCMA CAR T-cell therapy (multiple myeloma)']",IM-21,fexact,"['im21 cart', 'im 21', 'anti bcma car t cell therapy multiple myeloma peking union medical college hospital', 'anti bcma car t cell therapy multiple myeloma']",correct_mapping
melphalan flufenamide,DNA inhibitor; Angiogenesis inhibitor,melphalan flufenamide,,melphalan flufenamide hydrochloride,melphalan flufenamide,fexact,"['dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor)', 'Pepaxto', 'mel-flufen', 'melphalan flufenamide hydrochloride', 'CK-1535', 'melflufen hydrochloride', 'J-1', 'melphalan flufenamide', 'Ygalo']",melphalan flufenamide hydrochloride,fexact,"['dipeptide conjugated melphalan prodrug iv formulation ovary tumor', 'pepaxto', 'mel flufen', 'melphalan flufenamide hydrochloride', 'ck 1535', 'melflufen hydrochloride', 'j 1', 'melphalan flufenamide', 'ygalo']",correct_mapping
leflunomide,Immunosuppressant; Dihydroorotate dehydrogenase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Disease modifying antirheumatic drug,leflunomide,,leflunomide,leflunomide,fexact,"['RS-34821', 'RS-61980', 'Arava', 'leflunomide', 'HWA-486']",leflunomide,fexact,"['rs 34821', 'rs 61980', 'arava', 'leflunomide', 'hwa 486']",correct_mapping
spCART-269,Immuno-oncology therapy,spCART-269,,spCART-269,spcart 269,fexact,"['spCART-269', 'PD-1 knock-down anti-CD269 CAR T-cell therapy (lymphoma)', 'anti-BCMA CAR T-cell therapy (multiple myeloma)']",spCART-269,fexact,"['spcart 269', 'pd 1 knock down anti cd269 car t cell therapy lymphoma', 'anti bcma car t cell therapy multiple myeloma']",correct_mapping
211At-OKT10-B10,Unidentified pharmacological activity,211At-OKT10-B10,,211[At]-OKT10-B10,211 at okt10 b10,fuzzy,"['211-at labelled anti-cd38 monoclonal antibody (multiple myeloma)', 'At211-OKT10-B10', 'Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10', 'Astatine At 211 Anti-CD38 MoAb OKT10-B10', '211[At]-OKT10-B10', 'Astatine-211-OKT10-B10']",211[At]-OKT10-B10,fexact,"['211 at labelled anti cd38 monoclonal antibody multiple myeloma', 'at211 okt10 b10', 'astatine 211 labeled anti cd38 monoclonal antibody okt10 b10', 'astatine at 211 anti cd38 moab okt10 b10', '211 at okt10 b10', 'astatine 211 okt10 b10']",incorrect_mapping
TNB-383B,CD3 agonist; Immuno-oncology therapy,TNB-383B,,TNB-383B,tnb 383b,fexact,"['TNB-383B', 'anti-CD3/anti-BCMA bispecific T-cell engager (TeneoSeek, multiple myeloma)', 'anti-CD3 + anti-BCMA bispecific antibody (TeneoSeek, multiple myeloma)', 'anti-BCMAxCD3 (TeneoSeek, multiple myeloma), TenBio']",TNB-383B,fexact,"['tnb 383b', 'anti cd3 anti bcma bispecific t cell engager teneoseek multiple myeloma', 'anti cd3 anti bcma bispecific antibody teneoseek multiple myeloma', 'anti bcmaxcd3 teneoseek multiple myeloma tenbio']",correct_mapping
AO-176,CD47 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,AO-176,,AO-176,ao 176,fexact,"['Ti-061', 'cd47 checkpoint inhibitor (advanced solid tumors)', 'cd47 checkpoint inhibitor (hypertension/tissue ischemia/organ transplants/leukemia)', 'Ti-108', 'anti-cd47 mabs (hypertension/tissue ischemia/organ transplants/leukemia/solid tumor)', 'Vx-1004', 'Ti-176', 'AO-176', 'Vx-1000R', 'anti-CD47 mAbs (hypertension/tissue ischemia/organ transplants/leukemia), Tioma Therapeutics', 'AO-104', 'AO-108', 'Ti-104', 'anti-CD47 mAbs (hypertension/tissue ischemia/organ transplants/leukemia), Vasculox']",AO-176,fexact,"['ti 061', 'cd47 checkpoint inhibitor advanced solid tumors', 'cd47 checkpoint inhibitor hypertension tissue ischemia organ transplants leukemia', 'ti 108', 'anti cd47 mabs hypertension tissue ischemia organ transplants leukemia solid tumor', 'vx 1004', 'ti 176', 'ao 176', 'vx 1000r', 'anti cd47 mabs hypertension tissue ischemia organ transplants leukemia tioma therapeutics', 'ao 104', 'ao 108', 'ti 104', 'anti cd47 mabs hypertension tissue ischemia organ transplants leukemia vasculox']",correct_mapping
GSK-2636771,PI3 kinase beta inhibitor,GSK-2636771,,GSK-2636771,gsk 2636771,fexact,"['GSK-2636771A', 'GSK-2636771', 'GSK-2636771B']",GSK-2636771,fexact,"['gsk 2636771a', 'gsk 2636771', 'gsk 2636771b']",correct_mapping
Descartes-011,T cell stimulant; Immuno-oncology therapy,Descartes-011,,Descartes-011,descartes 011,fexact,"['Descartes-11', 'cd8-positive anti-bcma car t-cell therapy (multiple myeloma/rna armory platform)', 'Descartes-011']",Descartes-011,fexact,"['descartes 11', 'cd8 positive anti bcma car t cell therapy multiple myeloma rna armory platform', 'descartes 011']",correct_mapping
RO-7297089,CD16 antagonist; B-cell maturation antigen antagonist,RO-7297089,,RO-7297089,ro 7297089,fexact,"['RG-6296', 'AFM-26', 'anti-CD16A/anti-BCMA bispecific NK-cell engager (multiple myeloma),/Genentech/Roche', 'anti-CD16A/anti-BCMA bispecific NK-cell engager (multiple myeloma),//Roche', 'RO-7297089', 'anti-CD16A/anti-BCMA bispecific immune-cell engager (multiple myeloma)']",RO-7297089,fexact,"['rg 6296', 'afm 26', 'anti cd16a anti bcma bispecific nk cell engager multiple myeloma genentech roche', 'anti cd16a anti bcma bispecific nk cell engager multiple myeloma roche', 'ro 7297089', 'anti cd16a anti bcma bispecific immune cell engager multiple myeloma']",correct_mapping
SAR-442257,CD38 antagonist; CD3 antagonist; CD28 antagonist; Immuno-oncology therapy; Immune checkpoint stimulant,SAR-442257,,SAR-442257,sar 442257,fexact,"['dual anti-CD3/anti-CD38 T-cell engager/CD28 costimulator (multiple myeloma)', 'SAR-442257', 'CD3/CD38/CD28 trispecific T-cell engager/costimulator (multiple myeloma)']",SAR-442257,fexact,"['dual anti cd3 anti cd38 t cell engager cd28 costimulator multiple myeloma', 'sar 442257', 'cd3 cd38 cd28 trispecific t cell engager costimulator multiple myeloma']",correct_mapping
ION-251,Interferon regulatory factor 4 inhibitor,ION-251,,ION-251,ion 251,fexact,"['IONIS-IRF4-2.5Rx', 'antisense oligonucleotides (multiple myeloma), Isis', 'ION-251', 'antisense oligonucleotides (multiple myeloma)']",ION-251,fexact,"['ionis irf4 2 5rx', 'antisense oligonucleotides multiple myeloma isis', 'ion 251', 'antisense oligonucleotides multiple myeloma']",correct_mapping
TAK-573,Interferon alpha agonist; Immuno-oncology therapy,TAK-573,,TAK-573,tak 573,fexact,"['modakafusp alfa', 'CD38-attenukine (intravenous, infusion, advanced solid tumors/NSCLC/CRPC/multiple myeloma),/Teva', 'CD38-attenukine (intravenous, infusion, advanced solid tumors/NSCLC/CRPC/multiple myeloma),/', 'TEV-48573', 'TAK-573', 'CD38-Attenukine']",TAK-573,fexact,"['modakafusp alfa', 'cd38 attenukine intravenous infusion advanced solid tumors nsclc crpc multiple myeloma teva', 'cd38 attenukine intravenous infusion advanced solid tumors nsclc crpc multiple myeloma', 'tev 48573', 'tak 573', 'cd38 attenukine']",correct_mapping
CC-98633,T cell stimulant; Immuno-oncology therapy,CC-98633,,CC-98633,cc 98633,fexact,"['anti-BCMA NEX-T CAR T-cell therapy (multiple myeloma), Juno Therapeutics', 'anti-BCMA CAR T-cell therapy (NEX-T, multiple myeloma)', 'anti-BCMA CAR T-cell therapy (NEX-T, multiple myeloma), Juno Therapeutics', 'anti-BCMA NEX-T CAR T-cell therapy (multiple myeloma)', 'CC-98633', 'anti-bcma nex-t car t-cell therapy (multiple myeloma)']",CC-98633,fexact,"['anti bcma nex t car t cell therapy multiple myeloma juno therapeutics', 'anti bcma car t cell therapy nex t multiple myeloma', 'anti bcma car t cell therapy nex t multiple myeloma juno therapeutics', 'anti bcma nex t car t cell therapy multiple myeloma', 'cc 98633', 'anti bcma nex t car t cell therapy multiple myeloma']",correct_mapping
agenT-797,Natural Killer T cell stimulant; Immuno-oncology therapy,agenT-797,,agenT-797,agent 797,fexact,"[""allogeneic iNKT cell-based immunotherapy (multiple myeloma/chronic lymphocytic leukemia/small lymphocytic lymphoma/non-hodgkin's lymphoma/follicular lymphoma/marginal zone lymphoma/diffuse large B-cell lymphoma/solid tumor)"", 'allogeneic iNKT cell-based immunotherapy (MM/CLL/small lymphocytic lymphoma/NHL/follicular lymphoma/marginal zone lymphoma/DLBCL/solid tumors/COVID-19/inflammation)', 'agenT-797']",agenT-797,fexact,"['allogeneic inkt cell based immunotherapy multiple myeloma chronic lymphocytic leukemia small lymphocytic lymphoma non hodgkin s lymphoma follicular lymphoma marginal zone lymphoma diffuse large b cell lymphoma solid tumor', 'allogeneic inkt cell based immunotherapy mm cll small lymphocytic lymphoma nhl follicular lymphoma marginal zone lymphoma dlbcl solid tumors covid 19 inflammation', 'agent 797']",correct_mapping
CYAD-211,T cell stimulant; Immuno-oncology therapy,CYAD-211,,CYAD-211,cyad 211,fexact,"['anti-bcma car t-cell therapy (multiple myeloma)', 'anti-bcma car t-cell therapy (tcr knock-out shrna smartvector platform, multiple myeloma)', 'CYAD-211']",CYAD-211,fexact,"['anti bcma car t cell therapy multiple myeloma', 'anti bcma car t cell therapy tcr knock out shrna smartvector platform multiple myeloma', 'cyad 211']",correct_mapping
anti-SLAMF7 CAR-T cells,SLAMF7 antagonist; Immuno-oncology therapy,anti-SLAMF7 CAR-T cells,,,,0,['anti-SLAMF7 CAR-T cells'],,0,[],0
INCB-053914,Pim kinase inhibitor,INCB-053914,,uzansertib,incb 053914,fexact,"['pan-PIM kinase inhibitors (cancer)', 'uzansertib', 'INCB-53914', 'INCB-053914']",uzansertib,fexact,"['pan pim kinase inhibitors cancer', 'uzansertib', 'incb 53914', 'incb 053914']",correct_mapping
FT-538,Natural Killer T cell stimulant; Immuno-oncology therapy,FT-538,,FT-538,ft 538,fexact,"['iPSC-derived hnCD16/CD38null NK cells (multiple myeloma),/University of Minnesota', 'il-15rf and hncd16-expressing ipsc-derived nk cell therapy with cd38 knock out (cancer)', 'ipsc-derived hncd16/cd38null nk cells (multiple myeloma)', 'FT-538', 'IL-15RF and hnCD16-expressing iPSC-derived NK cell therapy with CD38 knock out (cancer),/University of Minnesota']",FT-538,fexact,"['ipsc derived hncd16 cd38null nk cells multiple myeloma university of minnesota', 'il 15rf and hncd16 expressing ipsc derived nk cell therapy with cd38 knock out cancer', 'ipsc derived hncd16 cd38null nk cells multiple myeloma', 'ft 538', 'il 15rf and hncd16 expressing ipsc derived nk cell therapy with cd38 knock out cancer university of minnesota']",correct_mapping
temsirolimus,Immunosuppressant; mTOR kinase inhibitor; Protein kinase inhibitor; Cell cycle inhibitor,temsirolimus,,temsirolimus,temsirolimus,fexact,"['Torisel', 'NSC-683864', 'CCI-779', 'temsirolimus']",temsirolimus,fexact,"['torisel', 'nsc 683864', 'cci 779', 'temsirolimus']",correct_mapping
"anti BCMA CAR-T cell therapy, Cellular Biomedicine Group",T cell stimulant; Immuno-oncology therapy,anti BCMA CAR-T cell therapy,Cellular Biomedicine Group,CT-053,anti bcma car t cell therapy,fexact,"['anti-BCMA CAR T-cell therapy (intravenous infusion, multiple myeloma)', 'anti-BCMA CAR T-cell therapy', 'CT-053']",CT-053,fexact,"['anti bcma car t cell therapy intravenous infusion multiple myeloma', 'anti bcma car t cell therapy', 'ct 053']",correct_mapping
PHE-885,T cell stimulant; Immuno-oncology therapy,PHE-885,,PHE-885,phe 885,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma)', 'PHE-885']",PHE-885,fexact,"['anti bcma car t cell therapy multiple myeloma', 'phe 885']",correct_mapping
CARTBCMA ARI0002h,T cell stimulant; Immuno-oncology therapy,CARTBCMA ARI0002h,,,,0,['CARTBCMA ARI0002h'],,0,[],0
taniraleucel,Natural killer cell stimulant; Immuno-oncology therapy,taniraleucel,,taniraleucel,taniraleucel,fexact,"['allogeneic NK cell therapy (COVID-19/ARDS),/Lung Biotech', 'CYNK-001', 'human placental hematopoietic stem cell derived natural killer cells (cryopreserved formulation, hematologic cancers/solid tumors)', 'taniraleucel', 'allogeneic NK cell therapy (COVID-19),/Sorrento Therapeutics', 'allogeneic NK cell therapy (COVID-19),/', 'allogeneic NK cell therapy (COVID-19/ARDS),/', 'PNK-007 (cryopreserved formulation, hematologic cancers/solid tumors)']",taniraleucel,fexact,"['allogeneic nk cell therapy covid 19 ards lung biotech', 'cynk 001', 'human placental hematopoietic stem cell derived natural killer cells cryopreserved formulation hematologic cancers solid tumors', 'taniraleucel', 'allogeneic nk cell therapy covid 19 sorrento therapeutics', 'allogeneic nk cell therapy covid 19', 'allogeneic nk cell therapy covid 19 ards', 'pnk 007 cryopreserved formulation hematologic cancers solid tumors']",correct_mapping
"busulfan, Otsuka",DNA inhibitor,busulfan,Otsuka,Busulfex,busulfan,fexact,"['busulfan, MD Anderson', 'KRN-246', 'KER-246', 'Myleran', 'busulfan, Orphan Medical', 'Busilvex', 'busulfan', 'Busulfex', 'Busulfanex']",Busulfex,fexact,"['busulfan md anderson', 'krn 246', 'ker 246', 'myleran', 'busulfan orphan medical', 'busilvex', 'busulfan', 'busulfex', 'busulfanex']",correct_mapping
KPG-818,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,KPG-818,,KPG-818,kpg 818,fexact,"['Cullin-RING E3 ubiquitin ligase complex modulator (SLE/DLBCL/MCL/FCL/MM/hematological malignancies)', 'Cullin-RING E3 ubiquitin ligase complex modulator (COVID-19)', 'KPG-818']",KPG-818,fexact,"['cullin ring e3 ubiquitin ligase complex modulator sle dlbcl mcl fcl mm hematological malignancies', 'cullin ring e3 ubiquitin ligase complex modulator covid 19', 'kpg 818']",correct_mapping
TQB-3602,Proteasome inhibitor,TQB-3602,,TQB-3602,tqb 3602,fexact,"['TQB-3602', 'proteasome inhibitor (oral capsule, relapsed/refractory multiple myeloma)']",TQB-3602,fexact,"['tqb 3602', 'proteasome inhibitor oral capsule relapsed refractory multiple myeloma']",correct_mapping
tasquinimod,Angiogenesis inhibitor; Immuno-oncology therapy,tasquinimod,,tasquinimod,tasquinimod,fexact,"['ABR-215050', 'prostate cancer therapeutic', 'tasquinimod', 'TASQ project', 'quinoline-3-carboxamide derivatives']",tasquinimod,fexact,"['abr 215050', 'prostate cancer therapeutic', 'tasquinimod', 'tasq project', 'quinoline 3 carboxamide derivatives']",correct_mapping
CTX-120,T cell stimulant; Immuno-oncology therapy; Genome editing,CTX-120,,CTX-120,ctx 120,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma)', 'CTX-120']",CTX-120,fexact,"['anti bcma car t cell therapy multiple myeloma', 'ctx 120']",correct_mapping
ditiocarb sodium,Immunostimulant,ditiocarb sodium,,,,0,"['Imuthiol', 'dithiocarb', 'ditiocarb sodium', 'soxinol-esl', 'kupral', 'cupral', 'DTC']",,NER_API,[],0
AUTO-8,T cell stimulant; Immuno-oncology therapy,AUTO-8,,,,0,"['dual anti-BCMA/undisclosed target CAR T-cell therapy (multiple myeloma)', 'AUTO-8']",,NER_API,[],0
AZD-0466,Bcl2 inhibitor; Bcl-XL inhibitor,AZD-0466,,AZD-0466,azd 0466,fexact,"['dual Bcl-2/Bcl-xL inhibitor (solid tumor/hematological neoplasm)', 'AZD-0466']",AZD-0466,fexact,"['dual bcl 2 bcl xl inhibitor solid tumor hematological neoplasm', 'azd 0466']",correct_mapping
mycophenolate mofetil,Immunosuppressant; Inosine monophosphate dehydrogenase inhibitor,mycophenolate mofetil,,mycophenolate mofetil,mycophenolate mofetil,fexact,"['mycophenolate mofetil hydrochloride', 'ME-MPA', 'CellCept Cap', 'mycophenolate mofetil', 'RS-61443', 'R-99, Roche', 'R-99', 'mycofenolate mofetil', 'CellCept', 'Munoloc', 'RS-6143', 'MMF']",mycophenolate mofetil,fexact,"['mycophenolate mofetil hydrochloride', 'me mpa', 'cellcept cap', 'mycophenolate mofetil', 'rs 61443', 'r 99 roche', 'r 99', 'mycofenolate mofetil', 'cellcept', 'munoloc', 'rs 6143', 'mmf']",correct_mapping
"CD19 specific CAR T cells, unspecified",CD19 antagonist; Immuno-oncology therapy,CD19 specific CAR T cells,unspecified,,,0,['CD19 specific CAR T cells'],,0,[],0
"CAR-T cell therapy, Timmune Biotech",T cell stimulant; Immuno-oncology therapy,CAR-T cell therapy,Timmune Biotech,,,0,['CAR-T cell therapy'],,0,[],0
"BCMA-CAR-T cells, PersonGen Biomedicine",T cell stimulant; Immuno-oncology therapy,BCMA-CAR-T cells,PersonGen Biomedicine,PRG-1801,bcma car t cells,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma), Pregene (Shenzhen) Biotechnology/ Henan Province Hospital', 'anti-BCMA CAR T-cell therapy (multiple myeloma),/ Henan Province Hospital', 'BCMA CAR-T cells', 'PRG-1801']",PRG-1801,fexact,"['anti bcma car t cell therapy multiple myeloma pregene shenzhen biotechnology henan province hospital', 'anti bcma car t cell therapy multiple myeloma henan province hospital', 'bcma car t cells', 'prg 1801']",correct_mapping
ABBV-467,Mcl-1 antagonist,ABBV-467,,,,0,"['Mcl-1 inhibitors (cancer)', 'A-1210477', 'Mcl-1 inhibitors (cancer/multiple myeloma), Abbott', 'ABBV-467', 'Mcl-1 inhibitors (cancer/multiple myeloma)']",,NER_API,[],0
RAPA-201,T cell stimulant; Immuno-oncology therapy,RAPA-201,,RAPA-201,rapa 201,fexact,"['rapa-201 autologous t cells (multiple myeloma), rapa therapeutics', 'rapa-201 autologous t cells (multiple myeloma)', 'autologous rapamycin-resistant th1/tc1 cells (multiple myeloma), rapa therapeutics', 'autologous rapamycin-resistant th1/tc1 cells (multiple myeloma)', 'RAPA-201', 'RAPA-201 cells']",RAPA-201,fexact,"['rapa 201 autologous t cells multiple myeloma rapa therapeutics', 'rapa 201 autologous t cells multiple myeloma', 'autologous rapamycin resistant th1 tc1 cells multiple myeloma rapa therapeutics', 'autologous rapamycin resistant th1 tc1 cells multiple myeloma', 'rapa 201', 'rapa 201 cells']",correct_mapping
nirogacestat,Secretase gamma inhibitor,nirogacestat,,nirogacestat hydrobromide,nirogacestat,fexact,"['gamma secretase inhibitor (cancer)', 'nirogacestat dihydrobromide', 'PF-03084014', 'PF-3084014', 'nirogacestat', 'nirogacestat hydrobromide']",nirogacestat hydrobromide,fexact,"['gamma secretase inhibitor cancer', 'nirogacestat dihydrobromide', 'pf 03084014', 'pf 3084014', 'nirogacestat', 'nirogacestat hydrobromide']",correct_mapping
PBCAR-269A,T cell stimulant; Immuno-oncology therapy,PBCAR-269A,,PBCAR-269A,pbcar 269a,fexact,"['anti-BCMA CAR T-cell therapy (ARCUS, multiple myeloma)', 'allogeneic CAR T-cell therapy (ARCUS, multiple myeloma)', 'PBCAR-269A']",PBCAR-269A,fexact,"['anti bcma car t cell therapy arcus multiple myeloma', 'allogeneic car t cell therapy arcus multiple myeloma', 'pbcar 269a']",correct_mapping
BCMA-PD1-CART cells,PD-L1 antagonist; B-cell maturation antigen antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,BCMA-PD1-CART cells,,,,0,['BCMA-PD1-CART cells'],,0,[],0
"BCMA-CD19 cCAR T cells, iCell Gene Therapeutics",T cell stimulant; Immuno-oncology therapy,BCMA-CD19 cCAR T cells,iCell Gene Therapeutics,,,0,['BCMA-CD19 cCAR T cells'],,0,[],0
TSK-011010,CD38 antagonist; Immuno-oncology therapy,TSK-011010,,CID-103,tsk 011010,fexact,"['fully human anti‐CD38 antibodies (cancer)', 'TSK-011010', 'CD38 checkpoint inhibitor (multiple myeloma/solid tumors)', 'CD38 checkpoint inhibitor (cancer), CASI Pharmaceuticals', 'CID-103', 'CD38 checkpoint inhibitor (cancer)', 'CD38 checkpoint inhibitor (cancer), Tusk Therapeutics', 'fully human anti‐CD38 antibodies (cancer), Tusk Therapeutics']",CID-103,fexact,"['fully human anti cd38 antibodies cancer', 'tsk 011010', 'cd38 checkpoint inhibitor multiple myeloma solid tumors', 'cd38 checkpoint inhibitor cancer casi pharmaceuticals', 'cid 103', 'cd38 checkpoint inhibitor cancer', 'cd38 checkpoint inhibitor cancer tusk therapeutics', 'fully human anti cd38 antibodies cancer tusk therapeutics']",correct_mapping
"chimeric-antigen receptor B cell maturation antigen-dd, Arcellx",T cell stimulant; Immuno-oncology therapy,chimeric-antigen receptor B cell maturation antigen-dd,Arcellx,,,0,['chimeric-antigen receptor B cell maturation antigen-dd'],,0,[],0
"prednisolone, unspecified",Arachidonic acid inhibitor; Immunosuppressant; Glucocorticoid agonist,prednisolone,unspecified,,,0,"['prednisolone', 'prednisolone (oral controlled release formulation/csds)', 'prednisolone (oral controlled release formulation/colon specific drug delivery system)']",,NER_API,[],0
panobinostat,Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,panobinostat,,panobinostat (oral),panobinostat,fexact,"['Faridak', 'LBH-589 (oral)', 'LBH-589', 'LBH-589B', 'Farydak', 'NVP-LBH-589', 'panobinostat (oral)', 'panobinostat']",panobinostat (oral),fexact,"['faridak', 'lbh 589 oral', 'lbh 589', 'lbh 589b', 'farydak', 'nvp lbh 589', 'panobinostat oral', 'panobinostat']",correct_mapping
pomalidomide (capsule),Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,pomalidomide,,pomalidomide,pomalidomide,fexact,"['IMiD-1', 'pomalidomide', 'Pomalyst', 'ENMD-0995', 'CC-4047', 'S-3APG', 'Actimid', 'Actimid (current lead)', 'Imnovid']",pomalidomide,fexact,"['imid 1', 'pomalidomide', 'pomalyst', 'enmd 0995', 'cc 4047', 's 3apg', 'actimid', 'actimid current lead', 'imnovid']",correct_mapping
WVT-078,Unidentified pharmacological activity,WVT-078,,WVT-078,wvt 078,fexact,"['anti-CD3/anti-BCMA T-cell engager (intravenous, multiple myeloma)', 'CD3/BCMA bispecific T-cell engager antibody (intravenous, multiple myeloma)', 'WVT-078']",WVT-078,fexact,"['anti cd3 anti bcma t cell engager intravenous multiple myeloma', 'cd3 bcma bispecific t cell engager antibody intravenous multiple myeloma', 'wvt 078']",correct_mapping
undisclosed - anti-thymocyte globulin,Immunosuppressant,undisclosed - anti-thymocyte globulin,,,,0,['undisclosed - anti-thymocyte globulin'],,0,[],0
fludarabine,DNA synthesis inhibitor; Ribonucleoside diphosphate reductase inhibitor; DNA repair enzyme inhibitor,fludarabine,,fludarabine,fludarabine,fexact,"['Oforta', '2-F-AraAMP', 'SH-537', 'SH-L-573A', 'SHT-586', 'Fludara iv', 'Fludara Oral', 'SH-586', 'fludarabine phosphate', 'BAY-86-4864', 'Beneflur', 'NSC-312887', 'Fludara', 'fludarabine', 'SH-584']",fludarabine,fexact,"['oforta', '2 f araamp', 'sh 537', 'sh l 573a', 'sht 586', 'fludara iv', 'fludara oral', 'sh 586', 'fludarabine phosphate', 'bay 86 4864', 'beneflur', 'nsc 312887', 'fludara', 'fludarabine', 'sh 584']",correct_mapping
anakinra (IV),Interleukin 1 receptor antagonist,anakinra,,anakinra,anakinra,fexact,"['Antril', 'Kineret', 'anakinra', 'IL-1 antagonist, InSite Vision', 'IL-1ra']",anakinra,fexact,"['antril', 'kineret', 'anakinra', 'il 1 antagonist insite vision', 'il 1ra']",correct_mapping
REGN-5459,CD3 agonist; Immuno-oncology therapy,REGN-5459,,REGN-5459,regn 5459,fexact,"['REGN-5459', 'anti-CD3/anti-BCMA bispecific T-cell engager (multiple myeloma)', 'BCMAxCD3 bispecific antibody (intravenous, multiple myeloma)']",REGN-5459,fexact,"['regn 5459', 'anti cd3 anti bcma bispecific t cell engager multiple myeloma', 'bcmaxcd3 bispecific antibody intravenous multiple myeloma']",correct_mapping
karonudib,MutT human homolog 1 inhibitor,karonudib,,TH-1579,karonudib,fexact,"['karonudib', 'MTH1 protein inhibitor (oral solution, cancer), Thomas Helleday Foundation', 'TH-1579']",TH-1579,fexact,"['karonudib', 'mth1 protein inhibitor oral solution cancer thomas helleday foundation', 'th 1579']",correct_mapping
KP-1237,CD38 antagonist; Immuno-oncology therapy,KP-1237,,KP-1237,kp 1237,fexact,"['KP-1237', 'CD38 targeting antibody recruiting molecule (short acting, relapsed/refractory multiple myeloma),/PeptiDream', 'CD38 targeting antibody recruiting molecule (short acting, relapsed/refractory multiple myeloma),/', 'CD38-ARM']",KP-1237,fexact,"['kp 1237', 'cd38 targeting antibody recruiting molecule short acting relapsed refractory multiple myeloma peptidream', 'cd38 targeting antibody recruiting molecule short acting relapsed refractory multiple myeloma', 'cd38 arm']",correct_mapping
M-3258,proteasome subunit beta type-8 inhibitor,M-3258,,M-3258,m 3258,fexact,"['M-3258', 'inhibitor of lmp7 subunit of the immunoproteasome (multiple myeloma)', 'lmp7 inhibitor (oral, multiple myeloma)']",M-3258,fexact,"['m 3258', 'inhibitor of lmp7 subunit of the immunoproteasome multiple myeloma', 'lmp7 inhibitor oral multiple myeloma']",correct_mapping
CCS-1477,CREB binding protein inhibitor; P300 inhibitor,CCS-1477,,CCS-1477,ccs 1477,fexact,"['hat inhibitors (castrate resistant prostate cancer, lung cancer)', 'p300/CBP inhibitors (oral capsule, castrate resistant prostate cancer/lung cancer/bladder cancer)', 'CCS-1477', 'p300/CBP inhibitor (oral, CRPC/lung cancer/bladder cancer/hemotoogical neoplasms)', 'histone acetyltransferase inhibitors (castrate resistant prostate cancer, lung cancer)', 'p300/CBP inhibitors (oral, castrate resistant prostate cancer/lung cancer/bladder cancer)']",CCS-1477,fexact,"['hat inhibitors castrate resistant prostate cancer lung cancer', 'p300 cbp inhibitors oral capsule castrate resistant prostate cancer lung cancer bladder cancer', 'ccs 1477', 'p300 cbp inhibitor oral crpc lung cancer bladder cancer hemotoogical neoplasms', 'histone acetyltransferase inhibitors castrate resistant prostate cancer lung cancer', 'p300 cbp inhibitors oral castrate resistant prostate cancer lung cancer bladder cancer']",correct_mapping
"pegylated G-CSF, Green Cross",Granulocyte colony stimulating factor agonist,pegylated G-CSF,Green Cross,,,0,['pegylated G-CSF'],,0,[],0
CC-99712,B-cell maturation antigen antagonist; Immuno-oncology therapy,CC-99712,,CC-99712,cc 99712,fexact,"['antibody drug conjugate (BCMA inhibitor, multiple myeloma),/', 'antibody drug conjugate (cancer),/', 'antibody drug conjugate (cancer), Sutro/Celgene', 'antibody drug conjugate (cancer), Sutro/', 'antibody drug conjugate (BCMA, multiple myeloma), Sutro/Celgene', 'antibody drug conjugate (BCMA, multiple myeloma), Sutro/', 'antibody drug conjugate (BCMA inhibitor, multiple myeloma), Sutro/', 'antibody drug conjugate (BCMA, multiple myeloma),/', 'CC-99712']",CC-99712,fexact,"['antibody drug conjugate bcma inhibitor multiple myeloma', 'antibody drug conjugate cancer', 'antibody drug conjugate cancer sutro celgene', 'antibody drug conjugate cancer sutro', 'antibody drug conjugate bcma multiple myeloma sutro celgene', 'antibody drug conjugate bcma multiple myeloma sutro', 'antibody drug conjugate bcma inhibitor multiple myeloma sutro', 'antibody drug conjugate bcma multiple myeloma', 'cc 99712']",correct_mapping
allogeneic stem cells,Not applicable,allogeneic stem cells,,,,0,['allogeneic stem cells'],,0,[],0
HRAIN-002,T cell stimulant; Immuno-oncology therapy,HRAIN-002,,,,0,"['HRAIN-002', 'bispecific anti-CD19/anti-BCMA CAR T-cell therapy (multiple myeloma)', 'dual anti-CD19/anti-BCMA CAR T-cell therapy (multiple myeloma)']",,NER_API,[],0
SAR-442085,CD38 antagonist; Immuno-oncology therapy,SAR-442085,,SAR-442085,sar 442085,fexact,"['anti-CD38 Fc engineered mAb (multiple myeloma)', 'SAR-442085']",SAR-442085,fexact,"['anti cd38 fc engineered mab multiple myeloma', 'sar 442085']",correct_mapping
CYT-0851,RAD51 expression inhibitor,CYT-0851,,CYT-0851,cyt 0851,fexact,"['CYT-01A', 'C-1523', 'CYT-0178', 'CYT-0851', 'CYT-0853', 'RAD51 inhibitors (cancer/autoimmune diseases)', 'CYT-01B']",CYT-0851,fexact,"['cyt 01a', 'c 1523', 'cyt 0178', 'cyt 0851', 'cyt 0853', 'rad51 inhibitors cancer autoimmune diseases', 'cyt 01b']",correct_mapping
CC-92480,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,CC-92480,,CC-92480,cc 92480,fexact,"['cereblon E3  ligase modulator (oral, multiple myeloma)', 'cereblon modulator (multiple myeloma)', 'CC-92480', 'cereblon modulator (multiple myeloma), Celgene']",CC-92480,fexact,"['cereblon e3 ligase modulator oral multiple myeloma', 'cereblon modulator multiple myeloma', 'cc 92480', 'cereblon modulator multiple myeloma celgene']",correct_mapping
TAK-079 (subcutaneous),CD38 antagonist; Immuno-oncology therapy,TAK-079,,mezagitamab,tak 079,fexact,"['TAK-079', 'mezagitamab', 'anti-CD38 mAb (intravenous/subcutaneous, multiple myeloma/systemic lupus erythematosus/ myasthenia gravis/primary immune thrombocytopenia/)', 'anti-CD38 mAb (intravenous/subcutaneous, multiple myeloma/systemic lupus erythematosus/autoimmune disease)']",mezagitamab,fexact,"['tak 079', 'mezagitamab', 'anti cd38 mab intravenous subcutaneous multiple myeloma systemic lupus erythematosus myasthenia gravis primary immune thrombocytopenia', 'anti cd38 mab intravenous subcutaneous multiple myeloma systemic lupus erythematosus autoimmune disease']",correct_mapping
"BCMA-CAR-T cells, CARsgen Therapeutics",T cell stimulant; B-cell maturation antigen antagonist; Immuno-oncology therapy,BCMA-CAR-T cells,CARsgen Therapeutics,PRG-1801,bcma car t cells,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma), Pregene (Shenzhen) Biotechnology/ Henan Province Hospital', 'anti-BCMA CAR T-cell therapy (multiple myeloma),/ Henan Province Hospital', 'BCMA CAR-T cells', 'PRG-1801']",PRG-1801,fexact,"['anti bcma car t cell therapy multiple myeloma pregene shenzhen biotechnology henan province hospital', 'anti bcma car t cell therapy multiple myeloma henan province hospital', 'bcma car t cells', 'prg 1801']",correct_mapping
NEXI-002,Immuno-oncology therapy,NEXI-002,,NEXI-002,nexi 002,fexact,"['anti-WT1/HLA-A0201 + anti-CD138/HLA-A0201 + anti-NY-ESO-1/HLA-A0201 + anti-CS1/HLA-A0201 adoptive T-cell therapy (AIM ACT, multiple myeloma)', 'NEXI-002', 'aAPC-based adoptive cell therapy (AIM, multiple myeloma)', 'artificial antigen-presenting cell-based adoptive cell therapy (AIM, multiple myeloma)', 'adoptive T-cell therapy (AIM ACT, multiple myeloma)']",NEXI-002,fexact,"['anti wt1 hla a0201 anti cd138 hla a0201 anti ny eso 1 hla a0201 anti cs1 hla a0201 adoptive t cell therapy aim act multiple myeloma', 'nexi 002', 'aapc based adoptive cell therapy aim multiple myeloma', 'artificial antigen presenting cell based adoptive cell therapy aim multiple myeloma', 'adoptive t cell therapy aim act multiple myeloma']",correct_mapping
"BCMA CAR-NK 92 cell therapy, Asclepius Technology Company",T cell stimulant; Natural killer cell stimulant; Immuno-oncology therapy,BCMA CAR-NK 92 cell therapy,Asclepius Technology Company,,,0,['BCMA CAR-NK 92 cell therapy'],,0,[],0
pegylated liposomal doxorubicin,DNA synthesis inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,pegylated liposomal doxorubicin,,"doxorubicin (liposomal, STEALTH)",pegylated liposomal doxorubicin,fexact,"['doxorubicin (liposomal, STEALTH)', 'SL-Dox', 'DOX-SL', 'doxorubicin HCl', 'doxorubicin hydrochloride', 'Caelyx', 'STEALTH (doxorubicin)', 'S-DOX', 'doxorubicin,/Schering', 'NSC-712227', 'doxorubicin,/', 'doxorubicin', 'pegylated liposomal doxorubicin', 'Doxil', 'JNS-002']","doxorubicin (liposomal, STEALTH)",fexact,"['doxorubicin liposomal stealth', 'sl dox', 'dox sl', 'doxorubicin hcl', 'doxorubicin hydrochloride', 'caelyx', 'stealth doxorubicin', 's dox', 'doxorubicin schering', 'nsc 712227', 'doxorubicin', 'doxorubicin', 'pegylated liposomal doxorubicin', 'doxil', 'jns 002']",correct_mapping
MGTA-M100,CXC chemokine receptor 4 antagonist; CXC chemokine receptor 2 agonist,MGTA-M100,,MGTA-145,mgta m100,fexact,"['MGTA-145', 'MGTA-M100', 'GRObetaT (stem cell mobilization)']",MGTA-145,fexact,"['mgta 145', 'mgta m100', 'grobetat stem cell mobilization']",correct_mapping
MDG-1021,T cell stimulant; Immuno-oncology therapy,MDG-1021,,MDG-1021,mdg 1021,fexact,"['HA-1 TCR transduced virus-specific T-cells', 'anti-ha-1/hla-a*0201 tcr t-cell therapy (hematological cancer/solid tumor),  (lumc)/medigene', 'anti-ha-1/hla-a*0201 tcr t-cell therapy (hematological cancer/solid tumor),  (lumc)/', 'MDG-1021']",MDG-1021,fexact,"['ha 1 tcr transduced virus specific t cells', 'anti ha 1 hla a 0201 tcr t cell therapy hematological cancer solid tumor lumc medigene', 'anti ha 1 hla a 0201 tcr t cell therapy hematological cancer solid tumor lumc', 'mdg 1021']",correct_mapping
abiraterone acetate,"Steroid synthesis inhibitor; 17,20 lyase inhibitor",abiraterone acetate,,abiraterone,abiraterone acetate,fexact,"['CB-7598', 'piraterone', 'abiraterone', 'abiraterone acetate', 'JNJ-212082', 'CB-7630', 'Zytiga', 'JNJ-589485']",abiraterone,fexact,"['cb 7598', 'piraterone', 'abiraterone', 'abiraterone acetate', 'jnj 212082', 'cb 7630', 'zytiga', 'jnj 589485']",correct_mapping
enzalutamide,Androgen receptor antagonist,enzalutamide,,enzalutamide,enzalutamide,fexact,"['MDVN-311', 'RD-162', 'MDVN-312', 'prostate cancer therapeutics, Medivation', 'Xtandi', ""RD-162'"", 'enzalutamide', 'ASP-9785', 'MDV-3100', 'MDVN-300', 'MDV-300', 'prostate cancer therapeutics']",enzalutamide,fexact,"['mdvn 311', 'rd 162', 'mdvn 312', 'prostate cancer therapeutics medivation', 'xtandi', 'rd 162', 'enzalutamide', 'asp 9785', 'mdv 3100', 'mdvn 300', 'mdv 300', 'prostate cancer therapeutics']",correct_mapping
Temferon,Interferon alpha antagonist; Immuno-oncology therapy,Temferon,,Temferon,temferon,fexact,"['HIV-derived lentivirus delivered gene therapy (solid tumor)', 'Temferon']",Temferon,fexact,"['hiv derived lentivirus delivered gene therapy solid tumor', 'temferon']",correct_mapping
felzartamab,CD38 antagonist; Immuno-oncology therapy,felzartamab,,felzartamab,felzartamab,fexact,"['MOR-202', 'HuCAL-mAb3', 'HuCAL-mAb2, MorphoSys', 'felzartamab', 'anti-cd38 fully human monoclonal antibody (recrurrent/refractory multiple myeloma), /morphosys', 'HuCAL-mAb1', 'MOR-03087', 'HuCAL-mAb2', 'TJ-202', 'anti-CD38 antibodies, MorphoSys', 'HuCAL-mAb1, MorphoSys', 'anti-CD38 fully human monoclonal antibody (recrurrent/refractory multiple myeloma), I-Mab Biopharma/MorphoSys', 'anti-CD38 antibodies', 'HuCAL-mAb3, MorphoSys', 'anti-cd38 fully human monoclonal antibody (recrurrent/refractory multiple myeloma),/']",felzartamab,fexact,"['mor 202', 'hucal mab3', 'hucal mab2 morphosys', 'felzartamab', 'anti cd38 fully human monoclonal antibody recrurrent refractory multiple myeloma morphosys', 'hucal mab1', 'mor 03087', 'hucal mab2', 'tj 202', 'anti cd38 antibodies morphosys', 'hucal mab1 morphosys', 'anti cd38 fully human monoclonal antibody recrurrent refractory multiple myeloma i mab biopharma morphosys', 'anti cd38 antibodies', 'hucal mab3 morphosys', 'anti cd38 fully human monoclonal antibody recrurrent refractory multiple myeloma']",correct_mapping
Thymoglobulin,Immunosuppressant; T cell inhibitor,Thymoglobulin,,Thymoglobulin,thymoglobulin,fexact,"['Thymoglobuline', 'Thymoglobulin', 'anti-Thymocyte-globulin (rabbit)', 'GZ-427051']",Thymoglobulin,fexact,"['thymoglobuline', 'thymoglobulin', 'anti thymocyte globulin rabbit', 'gz 427051']",correct_mapping
melphalan (oral),DNA inhibitor,melphalan,,,,0,"['melphalan (percutaneous hepatic perfusion, liver cancer),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma/cholangiocarcinoma),/', 'melphalan (percutaneous hepatic perfusion, liver cancer),/', 'melphalan (hepatic delivery system)', 'melphalan (Chemosat, liver cancer),/', 'melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma),/', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma),/', 'HEPZATO', 'CHEMOSAT', 'melphalan (Chemosat, liver cancer),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma/cholangiocarcinoma),/NCI', 'melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma),/NCI', 'melphalan', 'Melblez']",,NER_API,[],0
PD-L1 peptide vaccine,Immunostimulant; Immuno-oncology therapy,PD-L1 peptide vaccine,,,,0,['PD-L1 peptide vaccine'],,0,[],0
Myelovax,Immunostimulant,Myelovax,,,,0,['Myelovax'],,0,[],0
GM-CSF vaccine,Granulocyte macrophage colony stimulating factor agonist,GM-CSF vaccine,,,,0,['GM-CSF vaccine'],,Drug_API_mapping,[],0
CAR-T cell therapy,Immuno-oncology therapy,CAR-T cell therapy,,,,0,['CAR-T cell therapy'],,0,[],0
BI-836909,CD3 agonist; Immuno-oncology therapy,BI-836909,,AMG-420,bi 836909,fexact,"['anti-CD3/anti-BCMA bispecific T-cell engager (BiTE, multiple myeloma),//', 'anti-CD3/anti-BCMA bispecific T-cell engager (BiTE, multiple myeloma), Micromet//', 'pacanalotamab', 'AMG-420', 'anti-CD3/anti-BCMA bispecific T-cell engager (BiTE, multiple myeloma), Micromet//Boehringer Ingelheim', 'BI-836909']",AMG-420,fexact,"['anti cd3 anti bcma bispecific t cell engager bite multiple myeloma', 'anti cd3 anti bcma bispecific t cell engager bite multiple myeloma micromet', 'pacanalotamab', 'amg 420', 'anti cd3 anti bcma bispecific t cell engager bite multiple myeloma micromet boehringer ingelheim', 'bi 836909']",correct_mapping
REGN-5458,CD3 agonist; Immuno-oncology therapy,REGN-5458,,REGN-5458,regn 5458,fexact,"['anti-CD3/anti-BCMA bispecific T-cell engager (cancer)', 'BCMAxCD3 bispecific antibody (cancer)', 'REGN-5458', 'anti-CD3/anti-BCMA bispecific T-cell engager (cancer),/Sanofi']",REGN-5458,fexact,"['anti cd3 anti bcma bispecific t cell engager cancer', 'bcmaxcd3 bispecific antibody cancer', 'regn 5458', 'anti cd3 anti bcma bispecific t cell engager cancer sanofi']",correct_mapping
CVD908ssb-TXSVN,Immunostimulant,CVD908ssb-TXSVN,,cvd908delta-ssb-based svn and mycn vaccines (cancer),cvd908ssb txsvn,fexact,"['CVD908ssb-TXSVN', 'cancer vaccine (attenuated salmonella strain), university of maryland school of medicine', 'cancer vaccine (attenuated salmonella strain)', 'cvd908delta-ssb-based svn and mycn vaccines (cancer), university of maryland school of medicine', 'cvd908delta-ssb-based svn and mycn vaccines (cancer)']",cvd908delta-ssb-based svn and mycn vaccines (cancer),fexact,"['cvd908ssb txsvn', 'cancer vaccine attenuated salmonella strain university of maryland school of medicine', 'cancer vaccine attenuated salmonella strain', 'cvd908delta ssb based svn and mycn vaccines cancer university of maryland school of medicine', 'cvd908delta ssb based svn and mycn vaccines cancer']",correct_mapping
"chimeric-antigen receptor B cell maturation antigen-CS1, iCell Gene Therapeutics",T cell stimulant; Immuno-oncology therapy,chimeric-antigen receptor B cell maturation antigen-CS1,iCell Gene Therapeutics,,,0,['chimeric-antigen receptor B cell maturation antigen-CS1'],,0,[],0
"BCMA-UCART, Shanghai Bioray Laboratory",T cell stimulant; B-cell maturation antigen antagonist; Immuno-oncology therapy,BCMA-UCART,Shanghai Bioray Laboratory,BCMA-UCART,bcma ucart,fexact,"['anti-BCMA CAR T-cell therapy (allogeneic, UCAR technology, multiple myeloma)', 'BCMA-UCART']",BCMA-UCART,fexact,"['anti bcma car t cell therapy allogeneic ucar technology multiple myeloma', 'bcma ucart']",correct_mapping
UCARTCS1,T cell stimulant; Immuno-oncology therapy; Genome editing,UCARTCS1,,UCART-CS1,ucart cs1,fuzzy,"['UCART-CS1', 'anti-cs1 car t-cell therapy (multiple myeloma/all)', 'UCART-CS1A', 'anti-CS1 CAR T-cell therapy (multiple myeloma/ALL),/MD Anderson Cancer Center']",UCART-CS1,fexact,"['ucart cs1', 'anti cs1 car t cell therapy multiple myeloma all', 'ucart cs1a', 'anti cs1 car t cell therapy multiple myeloma all md anderson cancer center']",incorrect_mapping
rimiducid,Immunostimulant,rimiducid,,rimiducid,rimiducid,fexact,"['AP-1903', 'AP-1903 + ARGENT (GvHD),//Washington/', 'AP-1903 + ARGENT (GvHD),/Genovo/Washington/Raffaele', 'AP-1903 + ARGENT (GvHD),///', 'AP-1966', 'Dimerizer Drug, AP-1903', 'rimiducid', 'AP-1903 + ARGENT (GvHD),//Washington/Raffaele', 'AP-1889']",rimiducid,fexact,"['ap 1903', 'ap 1903 argent gvhd washington', 'ap 1903 argent gvhd genovo washington raffaele', 'ap 1903 argent gvhd', 'ap 1966', 'dimerizer drug ap 1903', 'rimiducid', 'ap 1903 argent gvhd washington raffaele', 'ap 1889']",correct_mapping
HPN-217,CD3 agonist; B-cell maturation antigen antagonist; Immuno-oncology therapy,HPN-217,,HPN-217,hpn 217,fexact,"['anti-CD3/anti-BCMA/anti-albumin trispecific T-cell engager (TriTAC, multiple myeloma)', 'HPN-217']",HPN-217,fexact,"['anti cd3 anti bcma anti albumin trispecific t cell engager tritac multiple myeloma', 'hpn 217']",correct_mapping
enasidenib,Isocitrate dehydrogenase 2 inhibitor,enasidenib,,enasidenib,enasidenib,fexact,"['AG-221', 'isocitrate dehydrogenase-2 inhibitor (oral, cancer/type II D-2 hydroxyglutaric aciduria),/', 'enasidenib mesylate', 'AGI-12910', 'isocitrate dehydrogenase-2 inhibitor (oral, cancer/type II D-2 hydroxyglutaric aciduria),/Celgene', 'AG-221 mesylate', 'CC-90007', 'Idhifa', 'enasidenib', 'AGI-6780', 'AGI-12026']",enasidenib,fexact,"['ag 221', 'isocitrate dehydrogenase 2 inhibitor oral cancer type ii d 2 hydroxyglutaric aciduria', 'enasidenib mesylate', 'agi 12910', 'isocitrate dehydrogenase 2 inhibitor oral cancer type ii d 2 hydroxyglutaric aciduria celgene', 'ag 221 mesylate', 'cc 90007', 'idhifa', 'enasidenib', 'agi 6780', 'agi 12026']",correct_mapping
MB-104,T cell stimulant; Immuno-oncology therapy,MB-104,,MB-104,mb 104,fexact,"['anti-cs1 car t-cell therapy (multiple myeloma),/nci/', 'anti-cs1 car t-cell therapy (multiple myeloma),/', 'cs1-car t-cell therapy (multiple myeloma),/nci', 'anti-cs1 car t-cell therapy (multiple myeloma),/nci', 'anti-cs1 car t-cell therapy (multiple myeloma), /nci/mustang bio', 'anti-cs1 car t-cell therapy (multiple myeloma),//', 'cs1-car t-cell therapy (multiple myeloma),/', 'MB-104', 'cs1-car t-cell therapy (multiple myeloma), /nci', 'anti-cs1 car t-cell therapy (multiple myeloma), /nci']",MB-104,fexact,"['anti cs1 car t cell therapy multiple myeloma nci', 'anti cs1 car t cell therapy multiple myeloma', 'cs1 car t cell therapy multiple myeloma nci', 'anti cs1 car t cell therapy multiple myeloma nci', 'anti cs1 car t cell therapy multiple myeloma nci mustang bio', 'anti cs1 car t cell therapy multiple myeloma', 'cs1 car t cell therapy multiple myeloma', 'mb 104', 'cs1 car t cell therapy multiple myeloma nci', 'anti cs1 car t cell therapy multiple myeloma nci']",correct_mapping
tinostamustine,Histone deacetylase inhibitor,tinostamustine,,tinostamustine,tinostamustine,fexact,"['NL-101 (cancer),//', 'tinostamustine (cancer), Northlake Biosciences/Mundipharma/Hangzhou Minsheng', 'tinostamustine (cancer), Northlake Biosciences/Mundipharma/', 'tinostamustine (intravenous, hematological cancer/solid tumors),//', 'NL-101 (cancer), Northlake Biosciences/Mundipharma/Hangzhou Minsheng', 'tinostamustine', 'tinostamustine (intravenous, hematological cancer/solid tumors), Northlake Biosciences//', 'NL-101', 'EDO-S101', 'tinostamustine (cancer), Northlake Biosciences//', 'NL-101 (cancer), Northlake Biosciences//', 'tinostamustine (intravenous, hematological cancer/solid tumors), Northlake Biosciences/Mundipharma/Hangzhou Minsheng', 'tinostamustine (intravenous, hematological cancer/solid tumors), Northlake Biosciences/Mundipharma/', 'tinostamustine (cancer),//', 'CY-190602', 'NL-101 (cancer), Northlake Biosciences/Mundipharma/']",tinostamustine,fexact,"['nl 101 cancer', 'tinostamustine cancer northlake biosciences mundipharma hangzhou minsheng', 'tinostamustine cancer northlake biosciences mundipharma', 'tinostamustine intravenous hematological cancer solid tumors', 'nl 101 cancer northlake biosciences mundipharma hangzhou minsheng', 'tinostamustine', 'tinostamustine intravenous hematological cancer solid tumors northlake biosciences', 'nl 101', 'edo s101', 'tinostamustine cancer northlake biosciences', 'nl 101 cancer northlake biosciences', 'tinostamustine intravenous hematological cancer solid tumors northlake biosciences mundipharma hangzhou minsheng', 'tinostamustine intravenous hematological cancer solid tumors northlake biosciences mundipharma', 'tinostamustine cancer', 'cy 190602', 'nl 101 cancer northlake biosciences mundipharma']",correct_mapping
ALLO-715,T cell stimulant; Immuno-oncology therapy; Genome editing,ALLO-715,,ALLO-715,allo 715,fexact,"['Anti-BCMA AlloCAR  Therapy', 'anti-BCMA engineered\xa0allogenic chimeric antigen receptor (CAR) T-cell therapy (iv, relapsed/refractory multiple myeloma),/Pfizer', 'UCART-BCMA', 'BCMA-targeted allogenic CAR T-cell therapy (iv, relapsed/refractory multiple myeloma),/Cellectis', 'anti-BCMA engineered\xa0allogenic chimeric antigen receptor (CAR) T-cell therapy (iv, relapsed/refractory multiple myeloma),/', 'BCMA-targeted allogenic CAR T-cell therapy (iv, relapsed/refractory multiple myeloma),/', 'ALLO-715', 'anti-BCMA CAR T-cell therapy (multiple myeloma), Cellectis/Pfizer', 'anti-BCMA CAR T-cell therapy (multiple myeloma),/Pfizer', 'anti-BCMA CAR T-cell therapy (multiple myeloma),/']",ALLO-715,fexact,"['anti bcma allocar therapy', 'anti bcma engineered\xa0allogenic chimeric antigen receptor car t cell therapy iv relapsed refractory multiple myeloma pfizer', 'ucart bcma', 'bcma targeted allogenic car t cell therapy iv relapsed refractory multiple myeloma cellectis', 'anti bcma engineered\xa0allogenic chimeric antigen receptor car t cell therapy iv relapsed refractory multiple myeloma', 'bcma targeted allogenic car t cell therapy iv relapsed refractory multiple myeloma', 'allo 715', 'anti bcma car t cell therapy multiple myeloma cellectis pfizer', 'anti bcma car t cell therapy multiple myeloma pfizer', 'anti bcma car t cell therapy multiple myeloma']",correct_mapping
ALLO-647,CD52 antagonist,ALLO-647,,ALLO-647,allo 647,fexact,"['anti-CD52 monoclonal antibody (lymphodepletion agent/CAR  persisitence)', 'anti-CD52 monoclonal antibody (lymphodepletion agent/CAR T persisitence)', 'ALLO-647', 'CAR T-cell therapy (cancer),/ Pfizer', 'UCART-S1', 'CAR T-cell therapy (cancer),/', 'CAR T-cell therapy (cancer), Cellectis/ Pfizer', 'CAR T-cell therapy (cancer), Cellectis/']",ALLO-647,fexact,"['anti cd52 monoclonal antibody lymphodepletion agent car persisitence', 'anti cd52 monoclonal antibody lymphodepletion agent car t persisitence', 'allo 647', 'car t cell therapy cancer pfizer', 'ucart s1', 'car t cell therapy cancer', 'car t cell therapy cancer cellectis pfizer', 'car t cell therapy cancer cellectis']",correct_mapping
"LCAR-B4822M-02 CAR-T cell immunotherapy, Nanjing Legend Biotech",T cell stimulant; Immuno-oncology therapy,LCAR-B4822M-02 CAR-T cell immunotherapy,Nanjing Legend Biotech,,,0,['LCAR-B4822M-02 CAR-T cell immunotherapy'],,0,[],0
CART-138 cells,Immuno-oncology therapy,CART-138 cells,,,,0,['CART-138 cells'],,0,[],0
osalmid,Ribonucleoside diphosphate reductase inhibitor,osalmid,,,,0,['osalmid'],,0,[],0
"BCMA chimaeric antigen receptor therapy, Pregene",T cell stimulant; Immuno-oncology therapy,BCMA chimaeric antigen receptor therapy,Pregene,,,0,['BCMA chimaeric antigen receptor therapy'],,0,[],0
FOR-46,Unidentified pharmacological activity,FOR-46,,FOR-46,for 46,fexact,"['anti-CD46 antibody-drug conjugate (metastatic castration-resistant prostate cancer)', 'anti-CD46 antibody-drug conjugate (metastatic castration-resistant prostate cancer and multiple myeloma)', 'FOR-46']",FOR-46,fexact,"['anti cd46 antibody drug conjugate metastatic castration resistant prostate cancer', 'anti cd46 antibody drug conjugate metastatic castration resistant prostate cancer and multiple myeloma', 'for 46']",correct_mapping
cytokine-treated veto cells,Unidentified pharmacological activity,cytokine-treated veto cells,,,,0,['cytokine-treated veto cells'],,0,[],0
bisthianostat,Histone deacetylase inhibitor,bisthianostat,,BGT-001,bisthianostat,fexact,"['beisainuota', 'bisthianostat', 'BGT-001', 'small molecule therapeutic (oral/tablet, cancer)']",BGT-001,fexact,"['beisainuota', 'bisthianostat', 'bgt 001', 'small molecule therapeutic oral tablet cancer']",correct_mapping
"cannabidiol, Leaf Vertical",Adenosine uptake inhibitor; Cannabinoid CB1 receptor inverse agonist; Vanilloid receptor 1 agonist; GPR55 antagonist,cannabidiol,Leaf Vertical,,,0,"['RLS-102', 'cannabidiol', 'cannabidiol (oral capsule, agitation)', 'Cannabidiol SNAC capsule']",,NER_API,[],0
dendritic cell DKK1 vaccine,Immunostimulant,dendritic cell DKK1 vaccine,,,,0,['dendritic cell DKK1 vaccine'],,0,[],0
"humanized non-fucosylated anti-BCMA antibody, Seattle Genetics",B-cell maturation antigen antagonist; Immuno-oncology therapy,humanized non-fucosylated anti-BCMA antibody,Seattle Genetics,,,0,['humanized non-fucosylated anti-BCMA antibody'],,0,[],0
carmustine,DNA inhibitor,carmustine,,,,0,"['NSC 409962', 'injectable carmustine', 'DTI-015', 'Carmustin', 'BCNU', 'carmustine', 'NSC 409962', 'injectable carmustine', 'DTI-015', 'Carmustin', 'BCNU', 'carmustine']",,NER_API,[],0
MTV-273,T cell stimulant; Immuno-oncology therapy,MTV-273,,MCM-998,mtv 273,fexact,"['MCM-998', 'anti-bcma car t-cell therapy (multiple myeloma)', 'CART-BCMA', 'anti-BCMA CAR T-cell therapy (multiple myeloma), University of Pennsylvania/', 'MTV-273']",MCM-998,fexact,"['mcm 998', 'anti bcma car t cell therapy multiple myeloma', 'cart bcma', 'anti bcma car t cell therapy multiple myeloma university of pennsylvania', 'mtv 273']",correct_mapping
rituximab,CD20 antagonist,rituximab,,rituximab biosimilar,rituximab,fexact,"['GP-2013', 'Riximyo', 'Rixathon', 'rituximab biosimilar', 'Rituximab BS', 'rituximab', 'rituximab biosimilar, Sandoz']",rituximab biosimilar,fexact,"['gp 2013', 'riximyo', 'rixathon', 'rituximab biosimilar', 'rituximab bs', 'rituximab', 'rituximab biosimilar sandoz']",correct_mapping
haploidentical hematopoietic stem cell transplantation,Not applicable,haploidentical hematopoietic stem cell transplantation,,,,0,['haploidentical hematopoietic stem cell transplantation'],,0,[],0
CD56-enriched donor lymphocyte infusion,Unidentified pharmacological activity,CD56-enriched donor lymphocyte infusion,,,,0,['CD56-enriched donor lymphocyte infusion'],,0,[],0
NKTR-255,Interleukin 15 agonist; Immuno-oncology therapy,NKTR-255,,NKTR-255,nktr 255,fexact,"['il-15 receptor agonist (cancer)', 'NKTR-255']",NKTR-255,fexact,"['il 15 receptor agonist cancer', 'nktr 255']",correct_mapping
HG-146,Histone deacetylase inhibitor; Immuno-oncology therapy,HG-146,,HG-146,hg 146,fexact,['HG-146'],HG-146,fexact,['hg 146'],correct_mapping
RV-NYESO TCR PBMC,Immuno-oncology therapy,RV-NYESO TCR PBMC,,,,0,['RV-NYESO TCR PBMC'],,0,[],0
orvacabtagene autoleucel,T cell stimulant; Immuno-oncology therapy,orvacabtagene autoleucel,,orvacabtagene autoleucel,orvacabtagene autoleucel,fexact,"['BCMA-125', 'ET-140', '125-BBz', 'JCARH-125', 'anti-BCMA CAR T-cell therapy (lentiviral vector, multiple myeloma), MSKCC//Juno Therapeutics', 'Orva-cel', 'orvacabtagene autoleucel', 'anti-BCMA CAR T-cell therapy (lentiviral vector, multiple myeloma), MSKCC/Eureka/Juno Therapeutics', 'JCAR-125', 'anti-BCMA CAR T-cell therapy (lentiviral vector, multiple myeloma), MSKCC//']",orvacabtagene autoleucel,fexact,"['bcma 125', 'et 140', '125 bbz', 'jcarh 125', 'anti bcma car t cell therapy lentiviral vector multiple myeloma mskcc juno therapeutics', 'orva cel', 'orvacabtagene autoleucel', 'anti bcma car t cell therapy lentiviral vector multiple myeloma mskcc eureka juno therapeutics', 'jcar 125', 'anti bcma car t cell therapy lentiviral vector multiple myeloma mskcc']",correct_mapping
"BCMA-CAR T cells, Shanghai Bioray Laboratory",T cell stimulant; Immuno-oncology therapy,BCMA-CAR T cells,Shanghai Bioray Laboratory,PRG-1801,bcma car t cells,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma), Pregene (Shenzhen) Biotechnology/ Henan Province Hospital', 'anti-BCMA CAR T-cell therapy (multiple myeloma),/ Henan Province Hospital', 'BCMA CAR-T cells', 'PRG-1801']",PRG-1801,fexact,"['anti bcma car t cell therapy multiple myeloma pregene shenzhen biotechnology henan province hospital', 'anti bcma car t cell therapy multiple myeloma henan province hospital', 'bcma car t cells', 'prg 1801']",correct_mapping
MEDI-2228,DNA inhibitor; B-cell maturation antigen antagonist,MEDI-2228,,MEDI-2228,medi 2228,fexact,"['MEDI-2228', 'pyrrolobenzodiazepine-linked antibody drug conjugate (BCMA, multiple myeloma),/Dana-Farber Cancer Institute']",MEDI-2228,fexact,"['medi 2228', 'pyrrolobenzodiazepine linked antibody drug conjugate bcma multiple myeloma dana farber cancer institute']",correct_mapping
tacrolimus (capsule),Immunosuppressant; Calcineurin inhibitor; T cell inhibitor,tacrolimus,,tacrolimus,tacrolimus,fexact,"['FK-506 (oral)', 'Hecoria', 'tacrolimus (oral), Fujisawa', 'tacrolimus (oral)', 'Prograf granule', 'tacrolimus (injectable)', 'Adbagraf', 'FK-506 (oral), Fujisawa', 'Prograf', 'fujimycin', 'tsukubaenolide', 'Prograf injection', 'Prograf capsule', 'L-679934', 'Modigraf', 'tacrolimus', 'FR-900506', 'tacrolimus (injectable), Fujisawa', 'FK-506']",tacrolimus,fexact,"['fk 506 oral', 'hecoria', 'tacrolimus oral fujisawa', 'tacrolimus oral', 'prograf granule', 'tacrolimus injectable', 'adbagraf', 'fk 506 oral fujisawa', 'prograf', 'fujimycin', 'tsukubaenolide', 'prograf injection', 'prograf capsule', 'l 679934', 'modigraf', 'tacrolimus', 'fr 900506', 'tacrolimus injectable fujisawa', 'fk 506']",correct_mapping
tacrolimus (IV),Immunosuppressant; Calcineurin inhibitor; T cell inhibitor,tacrolimus,,tacrolimus,tacrolimus,fexact,"['FK-506 (oral)', 'Hecoria', 'tacrolimus (oral), Fujisawa', 'tacrolimus (oral)', 'Prograf granule', 'tacrolimus (injectable)', 'Adbagraf', 'FK-506 (oral), Fujisawa', 'Prograf', 'fujimycin', 'tsukubaenolide', 'Prograf injection', 'Prograf capsule', 'L-679934', 'Modigraf', 'tacrolimus', 'FR-900506', 'tacrolimus (injectable), Fujisawa', 'FK-506']",tacrolimus,fexact,"['fk 506 oral', 'hecoria', 'tacrolimus oral fujisawa', 'tacrolimus oral', 'prograf granule', 'tacrolimus injectable', 'adbagraf', 'fk 506 oral fujisawa', 'prograf', 'fujimycin', 'tsukubaenolide', 'prograf injection', 'prograf capsule', 'l 679934', 'modigraf', 'tacrolimus', 'fr 900506', 'tacrolimus injectable fujisawa', 'fk 506']",correct_mapping
"G-CSF, unspecified",Granulocyte colony stimulating factor agonist,G-CSF,unspecified,lenograstim,g csf,fexact,"['Granocyte', 'CSF', 'hG-CSF', 'hG-CSF, Chugai', 'rHuG-CSF', 'G-CSF, Rhone-Poulenc Rorer', 'Neutrogin', 'G-CSF', 'Myelostim', 'CSF, Chugai', 'lenograstim', 'rHuG-CSF, Chugai', 'G-CSF, Chugai']",lenograstim,fexact,"['granocyte', 'csf', 'hg csf', 'hg csf chugai', 'rhug csf', 'g csf rhone poulenc rorer', 'neutrogin', 'g csf', 'myelostim', 'csf chugai', 'lenograstim', 'rhug csf chugai', 'g csf chugai']",correct_mapping
murizatoclax,Mcl-1 antagonist,murizatoclax,,murizatoclax,murizatoclax,fexact,"['PPI inhibitor (hematological malignancies)', 'AMG-397', 'AM-2721', 'murizatoclax', ""protein-protein interaction inhibitor (multiple myeloma/non-Hodgkin's lymphoma/acute myeloid leukemia)""]",murizatoclax,fexact,"['ppi inhibitor hematological malignancies', 'amg 397', 'am 2721', 'murizatoclax', 'protein protein interaction inhibitor multiple myeloma non hodgkin s lymphoma acute myeloid leukemia']",correct_mapping
abatacept (IV),CD86 antagonist; T cell inhibitor; CD80 antagonist; Immune checkpoint inhibitor,abatacept,,abatacept,abatacept,fexact,"['abatacept', 'BMS-188667', 'Orencia', 'ONO-4164IV', 'ONO-4164', 'BMS-188667SC', 'ONO-4164SC', 'BMS-188667IV', 'CTLA4-Ig, BMS', 'BMS-1888667', 'Orenica']",abatacept,fexact,"['abatacept', 'bms 188667', 'orencia', 'ono 4164iv', 'ono 4164', 'bms 188667sc', 'ono 4164sc', 'bms 188667iv', 'ctla4 ig bms', 'bms 1888667', 'orenica']",correct_mapping
abatacept (SC),CD86 antagonist; T cell inhibitor; CD80 antagonist; Immune checkpoint inhibitor,abatacept,,abatacept,abatacept,fexact,"['abatacept', 'BMS-188667', 'Orencia', 'ONO-4164IV', 'ONO-4164', 'BMS-188667SC', 'ONO-4164SC', 'BMS-188667IV', 'CTLA4-Ig, BMS', 'BMS-1888667', 'Orenica']",abatacept,fexact,"['abatacept', 'bms 188667', 'orencia', 'ono 4164iv', 'ono 4164', 'bms 188667sc', 'ono 4164sc', 'bms 188667iv', 'ctla4 ig bms', 'bms 1888667', 'orenica']",correct_mapping
"ECT-001-expanded cord blood cells, ExCellThera",Not applicable,ECT-001-expanded cord blood cells,ExCellThera,,,0,['ECT-001-expanded cord blood cells'],,0,[],0
lisocabtagene maraleucel,T cell stimulant; Immuno-oncology therapy,lisocabtagene maraleucel,,lisocabtagene maraleucel,lisocabtagene maraleucel,fexact,"['anti-CD19 CAR T-cell therapy (leukemia), Juno Therapeutics', 'anti-CD19 CAR T-cell therapy (leukemia)', 'SCRI-CAR19v1', 'liso-cel', 'Breyanzi', 'anti-cd19 car t-cell therapy (iv/infusion, b-cell malignancies)', 'JCAR-017', 'anti-CD19 CAR T-cell therapy (iv/infusion, B-cell malignancies), Celgene Corp', 'lisocabtagene maraleucel']",lisocabtagene maraleucel,fexact,"['anti cd19 car t cell therapy leukemia juno therapeutics', 'anti cd19 car t cell therapy leukemia', 'scri car19v1', 'liso cel', 'breyanzi', 'anti cd19 car t cell therapy iv infusion b cell malignancies', 'jcar 017', 'anti cd19 car t cell therapy iv infusion b cell malignancies celgene corp', 'lisocabtagene maraleucel']",correct_mapping
"cyclophosphamide, Baxter",DNA inhibitor,cyclophosphamide,Baxter,cyclophosphamide monohydrate,cyclophosphamide,fexact,"['Endoxan', 'cyclophosphamide monohydrate', 'cyclophosphamide']",cyclophosphamide monohydrate,fexact,"['endoxan', 'cyclophosphamide monohydrate', 'cyclophosphamide']",correct_mapping
"melphalan, Cydex",DNA inhibitor,melphalan,Cydex,,,0,"['melphalan (percutaneous hepatic perfusion, liver cancer),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma/cholangiocarcinoma),/', 'melphalan (percutaneous hepatic perfusion, liver cancer),/', 'melphalan (hepatic delivery system)', 'melphalan (Chemosat, liver cancer),/', 'melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma),/', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma),/', 'HEPZATO', 'CHEMOSAT', 'melphalan (Chemosat, liver cancer),/NCI', 'melphalan (percutaneous hepatic perfusion, liver cancer/hepatocellular carcinoma/cholangiocarcinoma),/NCI', 'melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma),/NCI', 'melphalan', 'Melblez']",,NER_API,[],0
filgrastim-bflm (SC),Granulocyte colony stimulating factor agonist,filgrastim-bflm,,,,0,['filgrastim-bflm'],,0,[],0
plerixafor,CXC chemokine receptor 4 antagonist; Chemokine receptor antagonist,plerixafor,,plerixafor,plerixafor,fexact,"['plerixafor octahydrochloride', 'AMD-3100', 'SDZ-SID-791', 'SID-791', 'Mozobil', 'GZ316455', 'JM-3100', 'plerixafor']",plerixafor,fexact,"['plerixafor octahydrochloride', 'amd 3100', 'sdz sid 791', 'sid 791', 'mozobil', 'gz316455', 'jm 3100', 'plerixafor']",correct_mapping
"NY-ESO-1 TCR therapy, Tmunity Therapeutics",T cell stimulant; Immuno-oncology therapy; Genome editing,NY-ESO-1 TCR therapy,Tmunity Therapeutics,,,0,['NY-ESO-1 TCR therapy'],,0,[],0
TAK-169,Protein synthesis inhibitor,TAK-169,,TAK-169,tak 169,fexact,"['TAK-169', 'CD38-targeted second-generation Engineered Toxin Bodies (multiple myeloma),/', 'CD38-targeted second-generation Engineered Toxin Bodies (multiple myeloma),/Takeda', 'CD38 ETB']",TAK-169,fexact,"['tak 169', 'cd38 targeted second generation engineered toxin bodies multiple myeloma', 'cd38 targeted second generation engineered toxin bodies multiple myeloma takeda', 'cd38 etb']",correct_mapping
FCARH-143,T cell stimulant; Immuno-oncology therapy,FCARH-143,,FCARH-143,fcarh 143,fexact,"['anti-BCMA CAR T-cell therapy (lentiviral vector, multiple myeloma), Juno Therapeutics', 'FCARH-143', 'anti-BCMA CAR T-cell therapy (lentiviral vector, multiple myeloma)']",FCARH-143,fexact,"['anti bcma car t cell therapy lentiviral vector multiple myeloma juno therapeutics', 'fcarh 143', 'anti bcma car t cell therapy lentiviral vector multiple myeloma']",correct_mapping
"hyaluronidase, recombinant, Halozyme",Hyaluronidase stimulant,hyaluronidase,Halozyme,,,0,"['hyaluronidase', 'orgelase', 'recombinant hyaluronidase']",,NER_API,[],0
"filgrastim, Teva",Granulocyte colony stimulating factor agonist,filgrastim,Teva,filgrastim biosimilar,filgrastim,fexact,"['Zarxio', 'filgrastim-sndz', 'Zarzio', 'filgrastim biosimilar, Hexal', 'Filgrastim Hexal', 'filgrastim biosimilar', 'filgrastim', 'EP-2006', 'Filgrastim BS']",filgrastim biosimilar,fexact,"['zarxio', 'filgrastim sndz', 'zarzio', 'filgrastim biosimilar hexal', 'filgrastim hexal', 'filgrastim biosimilar', 'filgrastim', 'ep 2006', 'filgrastim bs']",correct_mapping
cobimetinib (oral tablet),Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase 2 inhibitor,cobimetinib,,cobimetinib,cobimetinib,fexact,"['XL-518', 'MEK inhibitor (oral, cancer),/', 'Cotellic', 'RO-5514041', 'GDC-0973', 'MEK inhibitor (oral, cancer),/Genentech', '[14C]-GDC-0973', 'RG-7421', 'cobimetinib', 'RG-7420 (GDC-0973)', 'cobimetinib butyrate', 'MEK inhibitor (oral, cancer), Exelixis/Genentech', 'cobimetinib fumarate']",cobimetinib,fexact,"['xl 518', 'mek inhibitor oral cancer', 'cotellic', 'ro 5514041', 'gdc 0973', 'mek inhibitor oral cancer genentech', '14c gdc 0973', 'rg 7421', 'cobimetinib', 'rg 7420 gdc 0973', 'cobimetinib butyrate', 'mek inhibitor oral cancer exelixis genentech', 'cobimetinib fumarate']",correct_mapping
CSG-CD19,T cell stimulant; Immuno-oncology therapy,CSG-CD19,,CSG-CD19,csg cd19,fexact,"['CSG-CD19', 'CT-032', 'anti-CD19 CAR T-cell therapy (blood cancer)']",CSG-CD19,fexact,"['csg cd19', 'ct 032', 'anti cd19 car t cell therapy blood cancer']",correct_mapping
CT-041,T cell stimulant; Immuno-oncology therapy,CT-041,,CT-041,ct 041,fexact,"['anti-Claudin18.2 CAR T-cell therapy (gastric cancer/pancreatic cancer)', 'CT-041', 'Claudin18.2-targeted chimeric antigen receptor redirected autologous T-cell therapy (gastric cancerrcinoma/pancreatic cancer)', 'CAR-CLD18 T-cell therapy (gastric cancer/pancreatic cancer)', 'CLDN18.2-CAR-T cells', 'CAR-CLD18 T-cells']",CT-041,fexact,"['anti claudin18 2 car t cell therapy gastric cancer pancreatic cancer', 'ct 041', 'claudin18 2 targeted chimeric antigen receptor redirected autologous t cell therapy gastric cancerrcinoma pancreatic cancer', 'car cld18 t cell therapy gastric cancer pancreatic cancer', 'cldn18 2 car t cells', 'car cld18 t cells']",correct_mapping
pavurutamab,CD3 agonist; Immuno-oncology therapy,pavurutamab,,AMG-701,pavurutamab,fexact,"['anti-CD3/anti-BCMA bispecific T-cell engager (HLE-BiTE, multiple myeloma)', 'anti-BCMA HLE BiTE', 'pavurutamab', 'AMG-701']",AMG-701,fexact,"['anti cd3 anti bcma bispecific t cell engager hle bite multiple myeloma', 'anti bcma hle bite', 'pavurutamab', 'amg 701']",correct_mapping
BB-21217,T cell stimulant; B-cell maturation antigen antagonist; Immuno-oncology therapy,BB-21217,,bb-21217,bb 21217,fexact,"['bb-2121 matured ex vivo with bb-007', 'anti B-cell maturation antigen-targeting chimeric antigen receptor T-cells (bb-007, hematological malignancies), bluebird bio', 'anti-BCMA CAR T-cell therapy (bb-007, hematological malignancies), bluebird bio/Celgene', 'bb-21217', 'BCMA-targeting CAR T-cells (bb-007, hematological malignancies)', 'anti B-cell maturation antigen-targeting chimeric antigen receptor T-cells (bb-007, hematological malignancies)', 'anti-BCMA CAR T-cell therapy (bb-007, hematological malignancies),/', 'anti-BCMA CAR T-cell therapy (bb-007, hematological malignancies), bluebird bio/', 'BCMA-targeting CAR T-cells (bb-007, hematological malignancies), bluebird bio']",bb-21217,fexact,"['bb 2121 matured ex vivo with bb 007', 'anti b cell maturation antigen targeting chimeric antigen receptor t cells bb 007 hematological malignancies bluebird bio', 'anti bcma car t cell therapy bb 007 hematological malignancies bluebird bio celgene', 'bb 21217', 'bcma targeting car t cells bb 007 hematological malignancies', 'anti b cell maturation antigen targeting chimeric antigen receptor t cells bb 007 hematological malignancies', 'anti bcma car t cell therapy bb 007 hematological malignancies', 'anti bcma car t cell therapy bb 007 hematological malignancies bluebird bio', 'bcma targeting car t cells bb 007 hematological malignancies bluebird bio']",correct_mapping
ACTR-087,T cell stimulant; Immuno-oncology therapy,ACTR-087,,,,0,"['ACTR-087 + trastuzumab', 'ACTR-087', 'ATTCK-20', 'anti-HER2 mAb + CD16 anti-Fc CAR T-cell therapy (HER2-positive solid tumor), Unum Therapeutics', 'anti-HER2 monoclonal antibody + chimeric CD16V-41BB-CD3zeta receptor T cells (HER2-positive solid tumor), Unum Therapeutics', 'anti-HER2 mAb + CD16V-BB-zeta T cells (HER2-positive solid tumor), Unum Therapeutics']",,NER_API,[],0
AZD-4573,Cyclin-dependent kinase 9 inhibitor,AZD-4573,,AZD-4573,azd 4573,fexact,"['cyclin-dependent kinase 9 inhibitors (inflammatory diseases), Probiodrug', 'CDK9 inhibitors (inflammatory diseases), Probiodrug', 'AZ-13810325', 'CDK9 inhibitors (inflammatory diseases/ cancer)', 'AZD-4753', 'AZ-5576', 'cyclin-dependent kinase 9 inhibitors (inflammatory diseases/ cancer)', 'AZD-4573', 'AZD-5576', 'PC-585']",AZD-4573,fexact,"['cyclin dependent kinase 9 inhibitors inflammatory diseases probiodrug', 'cdk9 inhibitors inflammatory diseases probiodrug', 'az 13810325', 'cdk9 inhibitors inflammatory diseases cancer', 'azd 4753', 'az 5576', 'cyclin dependent kinase 9 inhibitors inflammatory diseases cancer', 'azd 4573', 'azd 5576', 'pc 585']",correct_mapping
STRO-001,CD74 antagonist; Immuno-oncology therapy,STRO-001,,STRO-001,stro 001,fexact,"['SP-7219', 'CD74 targeting antibody drug conjugates (cancer)', 'SP-7676', 'antibody drug conjugates (cancer)', 'anti-CD74 antibody-maytansinoid conjugate (B-cell malignancies', 'STRO-001', 'SP-7675']",STRO-001,fexact,"['sp 7219', 'cd74 targeting antibody drug conjugates cancer', 'sp 7676', 'antibody drug conjugates cancer', 'anti cd74 antibody maytansinoid conjugate b cell malignancies', 'stro 001', 'sp 7675']",correct_mapping
inebilizumab (IV),CD19 antagonist; Immuno-oncology therapy,inebilizumab,,inebilizumab,inebilizumab,fexact,"['B-cell depleting anti-CD19 monoclonal antibody, MedImmune', 'b-cell depleting anti-cd19 monoclonal antibody', 'B-cell depleting anti-CD19 monoclonal antibody, Viela Bio', 'VIB-0551', 'CD19-1aFuc', 'B-cell depleting anti-CD19 monoclonal antibody', 'MEDI-551', 'inebilizumab-cdon', 'Uplizna', 'inebilizumab', 'MT-0551']",inebilizumab,fexact,"['b cell depleting anti cd19 monoclonal antibody medimmune', 'b cell depleting anti cd19 monoclonal antibody', 'b cell depleting anti cd19 monoclonal antibody viela bio', 'vib 0551', 'cd19 1afuc', 'b cell depleting anti cd19 monoclonal antibody', 'medi 551', 'inebilizumab cdon', 'uplizna', 'inebilizumab', 'mt 0551']",correct_mapping
mycophenolate mofetil (IV),Immunosuppressant; Inosine monophosphate dehydrogenase inhibitor,mycophenolate mofetil,,mycophenolate mofetil,mycophenolate mofetil,fexact,"['mycophenolate mofetil hydrochloride', 'ME-MPA', 'CellCept Cap', 'mycophenolate mofetil', 'RS-61443', 'R-99, Roche', 'R-99', 'mycofenolate mofetil', 'CellCept', 'Munoloc', 'RS-6143', 'MMF']",mycophenolate mofetil,fexact,"['mycophenolate mofetil hydrochloride', 'me mpa', 'cellcept cap', 'mycophenolate mofetil', 'rs 61443', 'r 99 roche', 'r 99', 'mycofenolate mofetil', 'cellcept', 'munoloc', 'rs 6143', 'mmf']",correct_mapping
GSK-2816126,Enhancer of zeste homolog 2 inhibitor,GSK-2816126,,GSK-2816126,gsk 2816126,fexact,"['GSK-2816126A', 'GSK-2816126', 'GSK-9726', 'GSK-641', 'EZH2 inhibitor (cancer)', 'GSK-126 (EZH2)', 'GSK-343']",GSK-2816126,fexact,"['gsk 2816126a', 'gsk 2816126', 'gsk 9726', 'gsk 641', 'ezh2 inhibitor cancer', 'gsk 126 ezh2', 'gsk 343']",correct_mapping
TTI-622,CD47 antagonist; Signal regulatory protein alpha agonist; Immuno-oncology therapy; Immune checkpoint inhibitor,TTI-622,,TTI-622,tti 622,fexact,"['TTI-622', 'SIRPalpha Fc (multiple myeloma, lymphoma)', 'dual CD47 checkpoint inhibitor/modest FcgR activator (cancer/lymphoma/myeloma)', 'dual CD47 checkpoint inhibitor/modest FcgR activator (Hodgkins lymphoma/multiple myleoma)']",TTI-622,fexact,"['tti 622', 'sirpalpha fc multiple myeloma lymphoma', 'dual cd47 checkpoint inhibitor modest fcgr activator cancer lymphoma myeloma', 'dual cd47 checkpoint inhibitor modest fcgr activator hodgkins lymphoma multiple myleoma']",correct_mapping
blinatumomab,CD3 agonist; Immuno-oncology therapy,blinatumomab,,blinatumomab,blinatumomab,fexact,"['Blincyto', 'blinatumomab', 'blinatumomab (cancer, BiTE),/', 'anti-CD3/anti-CD19 bispecific T-cell engager (BiTE, acute lymphoblastic leukemia),/Astellas', 'MT-103 (cancer, BiTE),/', 'bscCD19xCD3 (cancer, BiTE), Micromet/MedImmune', 'anti-CD3/anti-CD19 bispecific T-cell engager (BiTE, acute lymphoblastic leukemia),/', 'bscCD19xCD3 (cancer, BiTE), Micromet/', 'L01XC19', 'AMG-103', 'MT-103 (cancer, BiTE), Micromet/MedImmune', 'MEDI-538', 'MT-103', 'MT-103, MedImmune', 'MT-103 (cancer, BiTE)', 'bscCD19xCD3 (cancer, BiTE)', 'blinatumomab (cancer, BiTE), Micromet/MedImmune', 'MT-103 (cancer, BiTE), Micromet/', 'blinatumomab (cancer, BiTE), Micromet/', 'CD19XCD3', 'bscCD19xCD3 (cancer, BiTE),/']",blinatumomab,fexact,"['blincyto', 'blinatumomab', 'blinatumomab cancer bite', 'anti cd3 anti cd19 bispecific t cell engager bite acute lymphoblastic leukemia astellas', 'mt 103 cancer bite', 'bsccd19xcd3 cancer bite micromet medimmune', 'anti cd3 anti cd19 bispecific t cell engager bite acute lymphoblastic leukemia', 'bsccd19xcd3 cancer bite micromet', 'l01xc19', 'amg 103', 'mt 103 cancer bite micromet medimmune', 'medi 538', 'mt 103', 'mt 103 medimmune', 'mt 103 cancer bite', 'bsccd19xcd3 cancer bite', 'blinatumomab cancer bite micromet medimmune', 'mt 103 cancer bite micromet', 'blinatumomab cancer bite micromet', 'cd19xcd3', 'bsccd19xcd3 cancer bite']",correct_mapping
lenalidomide (tablet),Tumour necrosis factor alpha antagonist; Angiogenesis inhibitor,lenalidomide,,lenalidomide,lenalidomide,fexact,"['CDC-501', 'IMiD-1', 'IND-70116', 'IMiD-3', 'Revlimid', 'lenalidomide', 'CC-5013', 'NSC-703813', 'ENMD-0997', 'Revimid', 'CDC-5013']",lenalidomide,fexact,"['cdc 501', 'imid 1', 'ind 70116', 'imid 3', 'revlimid', 'lenalidomide', 'cc 5013', 'nsc 703813', 'enmd 0997', 'revimid', 'cdc 5013']",correct_mapping
"CD38 CAR-T cell therapy, Sorrento Therapeutics",CD38 antagonist; T cell stimulant; Immuno-oncology therapy,CD38 CAR-T cell therapy,Sorrento Therapeutics,,,0,['CD38 CAR-T cell therapy'],,0,[],0
cabiralizumab,Colony stimulating factor 1 receptor antagonist; Immuno-oncology therapy,cabiralizumab,,cabiralizumab,cabiralizumab,fexact,"['FPA-008', 'cabiralizumab', 'anti-CSF1R hmAb (autoimmune disease), FivePrime Therapeutics', 'anti-colony stimulating factor 1 receptor humanized monoclonal antibody (autoimmune disease), FivePrime Therapeutics', 'BMS-986227', 'ONO-4687']",cabiralizumab,fexact,"['fpa 008', 'cabiralizumab', 'anti csf1r hmab autoimmune disease fiveprime therapeutics', 'anti colony stimulating factor 1 receptor humanized monoclonal antibody autoimmune disease fiveprime therapeutics', 'bms 986227', 'ono 4687']",correct_mapping
CKD-581,Histone deacetylase inhibitor,CKD-581,,"CKD-581 (iv, cancer)",ckd 581,fexact,"['alteminostat mesylate', 'histone deacetylase inhibitor (solid tumor)', 'CKD-581 (iv, cancer)', 'CKD-581', 'alteminostat', 'HDAC inhibitor (solid tumor)']","CKD-581 (iv, cancer)",fexact,"['alteminostat mesylate', 'histone deacetylase inhibitor solid tumor', 'ckd 581 iv cancer', 'ckd 581', 'alteminostat', 'hdac inhibitor solid tumor']",correct_mapping
HDP-101,B-cell maturation antigen antagonist,HDP-101,,HDP-101,hdp 101,fexact,"['amanitin-BCMA antibody drug conjugate (multiple myeloma)', 'HDP-101', 'BCMA-ATAC', 'HDP-101-ATAC', 'HD-101', 'amanitin-B cell maturation antigen antibody drug conjugate (multiple myeloma)']",HDP-101,fexact,"['amanitin bcma antibody drug conjugate multiple myeloma', 'hdp 101', 'bcma atac', 'hdp 101 atac', 'hd 101', 'amanitin b cell maturation antigen antibody drug conjugate multiple myeloma']",correct_mapping
AZD-5991,Mcl-1 antagonist,AZD-5991,,AZD-5991,azd 5991,fexact,"['Mcl-1 inhibitors (hematological malignancies)', 'AZD-5991', 'AZ-MC1']",AZD-5991,fexact,"['mcl 1 inhibitors hematological malignancies', 'azd 5991', 'az mc1']",correct_mapping
busulfan (oral),DNA inhibitor,busulfan,,Busulfex,busulfan,fexact,"['busulfan, MD Anderson', 'KRN-246', 'KER-246', 'Myleran', 'busulfan, Orphan Medical', 'Busilvex', 'busulfan', 'Busulfex', 'Busulfanex']",Busulfex,fexact,"['busulfan md anderson', 'krn 246', 'ker 246', 'myleran', 'busulfan orphan medical', 'busilvex', 'busulfan', 'busulfex', 'busulfanex']",correct_mapping
CJM-112,Interleukin 17A antagonist,CJM-112,,CJM-112,cjm 112,fexact,['CJM-112'],CJM-112,fexact,['cjm 112'],correct_mapping
AUTO-2,T cell stimulant; B-cell maturation antigen antagonist; TACI antagonist; Immuno-oncology therapy,AUTO-2,,AUTO-2,auto 2,fexact,"['APRIL-CAR', 'dual anti-BCMA/anti-TACI CAR T-cell therapy (APRIL-based, cancer)', 'CAR T-cell therapy (cancer)', 'AUTO-2', 'chimeric antigen receptor T-cell therapy (cancer)']",AUTO-2,fexact,"['april car', 'dual anti bcma anti taci car t cell therapy april based cancer', 'car t cell therapy cancer', 'auto 2', 'chimeric antigen receptor t cell therapy cancer']",correct_mapping
RG-6146,BET protein inhibitor,RG-6146,,RG-6146,rg 6146,fexact,"['TEN-010', '(S)-JQ35', 'RG-6146', 'bromodomain inhibitors (cancer), Tensha', 'bromodomain inhibitors (cancer)', 'RO-6870810']",RG-6146,fexact,"['ten 010', 's jq35', 'rg 6146', 'bromodomain inhibitors cancer tensha', 'bromodomain inhibitors cancer', 'ro 6870810']",correct_mapping
KITE-585,T cell stimulant; Immuno-oncology therapy; Immune checkpoint stimulant,KITE-585,,KITE-585,kite 585,fexact,"['KITE-585', 'anti-BCMA CAR T-cell therapy (multiple myeloma)']",KITE-585,fexact,"['kite 585', 'anti bcma car t cell therapy multiple myeloma']",correct_mapping
GBR-1342,CD3 agonist; Immuno-oncology therapy,GBR-1342,,ISB-1342,gbr 1342,fexact,"['anti-cd3/anti-cd38 bispecific tcell engager (bsab/beat, cancer)', 'CD38/CD3 bispecific monoclonal antibody (cancer/multiple myeloma)', 'ISB-1342', 'anti-CD3/anti-CD38 bispecific Tcell engager (bsAb/BEAT, cancer), Ichnos Sciences', 'anti-CD3/anti-CD38 bispecific Tcell engager (bsAb/BEAT, cancer)', 'cd38/cd3 bispecific monoclonal antibody (cancer/multiple myeloma)', 'GBR-1342', 'CD38/CD3 bispecific monoclonal antibody (cancer/multiple myeloma), Ichnos Sciences']",ISB-1342,fexact,"['anti cd3 anti cd38 bispecific tcell engager bsab beat cancer', 'cd38 cd3 bispecific monoclonal antibody cancer multiple myeloma', 'isb 1342', 'anti cd3 anti cd38 bispecific tcell engager bsab beat cancer ichnos sciences', 'anti cd3 anti cd38 bispecific tcell engager bsab beat cancer', 'cd38 cd3 bispecific monoclonal antibody cancer multiple myeloma', 'gbr 1342', 'cd38 cd3 bispecific monoclonal antibody cancer multiple myeloma ichnos sciences']",correct_mapping
KRT-232,MDM2 inhibitor,KRT-232,,KRT-232,krt 232,fexact,"['MDM2 inhibitor (myelofibrosis/polycythemia vera/merkel cell lymphoma/acute myeloid leukemia)', 'MDM2 inhibitor (solid tumor/melanoma),/GlaxoSmithkline', 'Mouse double minute 2 homolog inhibitor (solid tumor/melanoma),/GlaxoSmithkline', 'AMG-232', 'MDM2 inhibitor (myelofibrosis/polycythemia vera/merkel cell lymphoma/acute myeloid leukemia), Kartos Therapeutics', 'KRT-232']",KRT-232,fexact,"['mdm2 inhibitor myelofibrosis polycythemia vera merkel cell lymphoma acute myeloid leukemia', 'mdm2 inhibitor solid tumor melanoma glaxosmithkline', 'mouse double minute 2 homolog inhibitor solid tumor melanoma glaxosmithkline', 'amg 232', 'mdm2 inhibitor myelofibrosis polycythemia vera merkel cell lymphoma acute myeloid leukemia kartos therapeutics', 'krt 232']",correct_mapping
CC-93269,CD3 agonist; Immuno-oncology therapy,CC-93269,,CC-93269,cc 93269,fexact,"['anti-CD3/anti-BCMA T-cell bispecific antibody (multiple myeloma), Celgene', 'alnuctamab', 'anti-CD3/anti-BCMA bispecific T-cell engager (TCB, multiple myeloma)', 'EM-901', 'CC-93269']",CC-93269,fexact,"['anti cd3 anti bcma t cell bispecific antibody multiple myeloma celgene', 'alnuctamab', 'anti cd3 anti bcma bispecific t cell engager tcb multiple myeloma', 'em 901', 'cc 93269']",correct_mapping
GDA-201,Immunostimulant; Immuno-oncology therapy,GDA-201,,GDA-201,gda 201,fexact,"['NK cell program (cancer)', 'natural killer cell program (cancer)', 'NAM-NK', 'GDA-201']",GDA-201,fexact,"['nk cell program cancer', 'natural killer cell program cancer', 'nam nk', 'gda 201']",correct_mapping
CAR-CD44v6,T cell stimulant; Immuno-oncology therapy,CAR-CD44v6,,CAR-CD44v6,car cd44v6,fexact,"['CD44v6CAR.28z', 'CAR-T CD44v6', 'CD44 variant 6 targeting T-cell therapy (cancer), San Raffaele Scientific Institute/MolMed', 'CAR-CD44v6', 'anti-CD44v6 CAR T-cell therapy (cancer), San Raffaele Scientific Institute/MolMed']",CAR-CD44v6,fexact,"['cd44v6car 28z', 'car t cd44v6', 'cd44 variant 6 targeting t cell therapy cancer san raffaele scientific institute molmed', 'car cd44v6', 'anti cd44v6 car t cell therapy cancer san raffaele scientific institute molmed']",correct_mapping
lintuzumab-Ac-225,DNA inhibitor; Radiopharmaceutical,lintuzumab-Ac-225,,225Ac-lintuzumab,lintuzumab ac225,fuzzy,"['actinium-225-HuM-195', 'HuM-195-Ac-225', '225Ac-HuM-195', 'lintuzumab satetraxetan [225Ac]', 'SMART 225Ac-M195', 'HuM-195 [225Ac]', 'Actimab-M', '225Ac-lintuzumab', 'actinium-225-M195', 'lintuzumab-Ac225', '225Ac- lintuzumab satetraxetan', '(225Ac) lintuzumab satetraxetan', 'SMART actinium-225-M195', 'Actimab-A', 'Actimab-MDS']",225Ac-lintuzumab,fexact,"['actinium 225 hum 195', 'hum 195 ac 225', '225ac hum 195', 'lintuzumab satetraxetan 225ac', 'smart 225ac m195', 'hum 195 225ac', 'actimab m', '225ac lintuzumab', 'actinium 225 m195', 'lintuzumab ac225', '225ac lintuzumab satetraxetan', '225ac lintuzumab satetraxetan', 'smart actinium 225 m195', 'actimab a', 'actimab mds']",incorrect_mapping
"tacrolimus, unspecified",Interleukin 2 antagonist; Immunosuppressant; Calcineurin inhibitor; T cell inhibitor,tacrolimus,unspecified,tacrolimus,tacrolimus,fexact,"['FK-506 (oral)', 'Hecoria', 'tacrolimus (oral), Fujisawa', 'tacrolimus (oral)', 'Prograf granule', 'tacrolimus (injectable)', 'Adbagraf', 'FK-506 (oral), Fujisawa', 'Prograf', 'fujimycin', 'tsukubaenolide', 'Prograf injection', 'Prograf capsule', 'L-679934', 'Modigraf', 'tacrolimus', 'FR-900506', 'tacrolimus (injectable), Fujisawa', 'FK-506']",tacrolimus,fexact,"['fk 506 oral', 'hecoria', 'tacrolimus oral fujisawa', 'tacrolimus oral', 'prograf granule', 'tacrolimus injectable', 'adbagraf', 'fk 506 oral fujisawa', 'prograf', 'fujimycin', 'tsukubaenolide', 'prograf injection', 'prograf capsule', 'l 679934', 'modigraf', 'tacrolimus', 'fr 900506', 'tacrolimus injectable fujisawa', 'fk 506']",correct_mapping
"cyclophosphamide, unspecified",DNA inhibitor,cyclophosphamide,unspecified,cyclophosphamide monohydrate,cyclophosphamide,fexact,"['Endoxan', 'cyclophosphamide monohydrate', 'cyclophosphamide']",cyclophosphamide monohydrate,fexact,"['endoxan', 'cyclophosphamide monohydrate', 'cyclophosphamide']",correct_mapping
"mycophenolate mofetil, unspecified",Immunosuppressant; Inosine monophosphate dehydrogenase inhibitor,mycophenolate mofetil,unspecified,mycophenolate mofetil,mycophenolate mofetil,fexact,"['mycophenolate mofetil hydrochloride', 'ME-MPA', 'CellCept Cap', 'mycophenolate mofetil', 'RS-61443', 'R-99, Roche', 'R-99', 'mycofenolate mofetil', 'CellCept', 'Munoloc', 'RS-6143', 'MMF']",mycophenolate mofetil,fexact,"['mycophenolate mofetil hydrochloride', 'me mpa', 'cellcept cap', 'mycophenolate mofetil', 'rs 61443', 'r 99 roche', 'r 99', 'mycofenolate mofetil', 'cellcept', 'munoloc', 'rs 6143', 'mmf']",correct_mapping
TAS-4464,Nedd 8 activating enzyme inhibitor,TAS-4464,,TAS-4464,tas 4464,fexact,"['NEDD8 activating enzyme E1 inhibitors (cancer)', 'TAS-4464', 'NAE inhibitors (cancer)']",TAS-4464,fexact,"['nedd8 activating enzyme e1 inhibitors cancer', 'tas 4464', 'nae inhibitors cancer']",correct_mapping
P-BCMA-101,T cell stimulant; Immuno-oncology therapy,P-BCMA-101,,P-BCMA-101,p bcma 101,fexact,"['anti-BCMA CAR T-cell therapy (multiple myeloma)', 'P-BCMA-101']",P-BCMA-101,fexact,"['anti bcma car t cell therapy multiple myeloma', 'p bcma 101']",correct_mapping
pomalidomide (tablet),Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,pomalidomide,,pomalidomide,pomalidomide,fexact,"['IMiD-1', 'pomalidomide', 'Pomalyst', 'ENMD-0995', 'CC-4047', 'S-3APG', 'Actimid', 'Actimid (current lead)', 'Imnovid']",pomalidomide,fexact,"['imid 1', 'pomalidomide', 'pomalyst', 'enmd 0995', 'cc 4047', 's 3apg', 'actimid', 'actimid current lead', 'imnovid']",correct_mapping
recombinant human interleukin-2,Unidentified pharmacological activity,recombinant human interleukin-2,,,,0,['recombinant human interleukin-2'],,0,[],0
PNK-007,Immuno-oncology therapy,PNK-007,,PNK-007,pnk 007,fexact,"['placental natural killer (PNK) cell therapy (AML/MM/GBM)', 'PNK-007', 'placental natural killer (PNK) cell therapy (AML/MM/GBM), Celularity']",PNK-007,fexact,"['placental natural killer pnk cell therapy aml mm gbm', 'pnk 007', 'placental natural killer pnk cell therapy aml mm gbm celularity']",correct_mapping
SGN-CD48A,Tubulin inhibitor,SGN-CD48A,,SGN-CD48A,sgn cd48a,fexact,"['CD48-targeting ADC (PEGylated MMAE, multiple myeloma), Seattle Genetics', 'SGN-CD48A']",SGN-CD48A,fexact,"['cd48 targeting adc pegylated mmae multiple myeloma seattle genetics', 'sgn cd48a']",correct_mapping
ABBV-838,SLAMF7 antagonist; Immuno-oncology therapy,ABBV-838,,ABBV-838,abbv 838,fexact,"['anti-CS1 antibody-drug conjugate (solid tumors)', 'azintuxizumab vedotin', 'ABBV-838', 'anti-CS1 ADC (solid tumors)']",ABBV-838,fexact,"['anti cs1 antibody drug conjugate solid tumors', 'azintuxizumab vedotin', 'abbv 838', 'anti cs1 adc solid tumors']",correct_mapping
oprozomib,Proteasome inhibitor,oprozomib,,oprozomib,oprozomib,fexact,"['proteasome inhibitor program (oral, cancer),/', 'PR-047', 'proteasome inhibitor (oral, cancer), Proteolix Inc/Onyx Pharmaceuticals Inc', 'proteasome inhibitor program (oral, cancer), Onyx Pharmaceuticals/', 'oprozomib', 'PR-928', 'PR-141', 'PR-924', 'proteasome inhibitor (oral, cancer)', 'ONX-0912', 'proteasome inhibitor program (oral, cancer), Onyx Pharmaceuticals/Ono Pharmaceutical', 'ONO-7058', 'ONX-012', 'proteasome inhibitor (oral, cancer), proteolix inc']",oprozomib,fexact,"['proteasome inhibitor program oral cancer', 'pr 047', 'proteasome inhibitor oral cancer proteolix inc onyx pharmaceuticals inc', 'proteasome inhibitor program oral cancer onyx pharmaceuticals', 'oprozomib', 'pr 928', 'pr 141', 'pr 924', 'proteasome inhibitor oral cancer', 'onx 0912', 'proteasome inhibitor program oral cancer onyx pharmaceuticals ono pharmaceutical', 'ono 7058', 'onx 012', 'proteasome inhibitor oral cancer proteolix inc']",correct_mapping
MegaFasL,Apoptosis stimulant; Fas agonist,MegaFasL,,APO-010,megafasl,fexact,"['cancer therapeutics (FasL)', 'Soluble FasL (Mega-Ligand)', 'MegaFasL', 'APO-010 DRP', 'Soluble FasL (Mega-Ligand), TopoTarget', 'APO-010', 'anticancer therapeutics (FasL)', 'soluble FasL (Mega-Ligand)']",APO-010,fexact,"['cancer therapeutics fasl', 'soluble fasl mega ligand', 'megafasl', 'apo 010 drp', 'soluble fasl mega ligand topotarget', 'apo 010', 'anticancer therapeutics fasl', 'soluble fasl mega ligand']",correct_mapping
methotrexate,Immunosuppressant; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Disease modifying antirheumatic drug,methotrexate,,,,0,"['methotrexate', 'repurposed methotrexate (blood cancer)']",,NER_API,[],0
captisol enabled melphalan,Unidentified pharmacological activity,captisol enabled melphalan,,,,0,['captisol enabled melphalan'],,0,[],0
MCARH-171,T cell stimulant; Immuno-oncology therapy,MCARH-171,,MCARH-171,mcarh 171,fexact,"['anti-BCMA scFv(171)/CD8a hinge/4-1BB/CD3zeta CAR T-cells (retroviral vector, multiple myeloma), MSKCC/', 'anti-BCMA scFv(171)/CD8a hinge/4-1BB/CD3zeta CAR T-cells (retroviral vector, multiple myeloma), MSKCC/Juno Therapeutics', 'EGFRt/BCMA-41BBz', '183-BBz', 'MCARH-171', 'BCMA-171', 'anti-BCMA CAR T-cell therapy (retroviral vector, multiple myeloma), MSKCC/', 'BCMA-137', '130-BBz', '171-BBz', 'EGFRt/hBCMA-41BBz', 'BCMA-183', 'anti-BCMA CAR T-cell therapy (retroviral vector, multiple myeloma), MSKCC/Juno Therapeutics', 'BCMA-130', '137-BBz']",MCARH-171,fexact,"['anti bcma scfv 171 cd8a hinge 4 1bb cd3zeta car t cells retroviral vector multiple myeloma mskcc', 'anti bcma scfv 171 cd8a hinge 4 1bb cd3zeta car t cells retroviral vector multiple myeloma mskcc juno therapeutics', 'egfrt bcma 41bbz', '183 bbz', 'mcarh 171', 'bcma 171', 'anti bcma car t cell therapy retroviral vector multiple myeloma mskcc', 'bcma 137', '130 bbz', '171 bbz', 'egfrt hbcma 41bbz', 'bcma 183', 'anti bcma car t cell therapy retroviral vector multiple myeloma mskcc juno therapeutics', 'bcma 130', '137 bbz']",correct_mapping
BION-1301,APRIL inhibitor; Immuno-oncology therapy,BION-1301,,BION-1301,bion 1301,fexact,"['human APRIL.01A', 'hA.03A', 'BION-1301', 'anti-APRIL monoclonal antibodies (cancer), Aduro BioTech Europe', 'anti-APRIL monoclonal antibodies (IgA nephropathy/ cancer), Aduro BioTech Europe', 'hA.01A', 'anti-APRIL monoclonal antibodies (cancer), BioNovion', 'human APRIL.03A']",BION-1301,fexact,"['human april 01a', 'ha 03a', 'bion 1301', 'anti april monoclonal antibodies cancer aduro biotech europe', 'anti april monoclonal antibodies iga nephropathy cancer aduro biotech europe', 'ha 01a', 'anti april monoclonal antibodies cancer bionovion', 'human april 03a']",correct_mapping
"anticancer therapeutic peptide vaccine, OncoPep",Immunostimulant,anticancer therapeutic peptide vaccine,OncoPep,,,0,['anticancer therapeutic peptide vaccine'],,0,[],0
TTI-621,CD47 antagonist; Macrophage stimulant; Signal regulatory protein alpha agonist; Immuno-oncology therapy; Immune checkpoint inhibitor,TTI-621,,TTI-621,tti 621,fexact,"['CD47 checkpoint inhibitor (cancer), Trillium Therapeutics', 'SIRPa-IgG1 Fc, Trillium Therapeutics', 'dual CD47 checkpoint inhibitor/strong FcgR activator (cancer), Trillium Therapeutics', 'sirpa-igg1 fc', 'ontorpacept', 'sirpalpha fc (acute myeloid leukemia)', 'dual cd47 checkpoint inhibitor/strong fcgr activator (cancer)', 'TTI-621', 'cd47 checkpoint inhibitor (cancer)', 'SIRPaFc', 'SIRPalpha Fc (acute myeloid leukemia), Trillium Therapeutics']",TTI-621,fexact,"['cd47 checkpoint inhibitor cancer trillium therapeutics', 'sirpa igg1 fc trillium therapeutics', 'dual cd47 checkpoint inhibitor strong fcgr activator cancer trillium therapeutics', 'sirpa igg1 fc', 'ontorpacept', 'sirpalpha fc acute myeloid leukemia', 'dual cd47 checkpoint inhibitor strong fcgr activator cancer', 'tti 621', 'cd47 checkpoint inhibitor cancer', 'sirpafc', 'sirpalpha fc acute myeloid leukemia trillium therapeutics']",correct_mapping
"doxorubicin citrate, GP Pharm",DNA topoisomerase II inhibitor,doxorubicin citrate,GP Pharm,,,0,['doxorubicin citrate'],,0,[],0
plitidepsin,Epidermal growth factor agonist; DNA synthesis inhibitor; VEGFR-1 tyrosine kinase inhibitor; Ornithine decarboxylase inhibitor; Elongation factor-1alpha inhibitor; Apoptosis stimulant; Palmitoyl-protein thioesterase inhibitor; Cell cycle inhibitor,plitidepsin,,plitidepsin,plitidepsin,fexact,"['Aplidine', 'Aplidin', 'eukaryotic translation elongation factor 1 alpha 2 inhibitor (COVID-19), PharmaMar', 'eukaryotic translation elongation factor 1 alpha 2 inhibitor (COVID-19)', 'Aplidina', 'plitidepsin', 'dehydrodidemnin', 'DDB, PharmaMar', 'DDB', 'Aplidin(R)']",plitidepsin,fexact,"['aplidine', 'aplidin', 'eukaryotic translation elongation factor 1 alpha 2 inhibitor covid 19 pharmamar', 'eukaryotic translation elongation factor 1 alpha 2 inhibitor covid 19', 'aplidina', 'plitidepsin', 'dehydrodidemnin', 'ddb pharmamar', 'ddb', 'aplidin r']",correct_mapping
survivin transfected dendritic cells,Immunostimulant,survivin transfected dendritic cells,,,,0,['survivin transfected dendritic cells'],,0,[],0
"pneumococcal vaccine, 13-valent (IM), Wyeth",Immunostimulant,pneumococcal vaccine,Wyeth,,,0,['pneumococcal vaccine'],,0,[],0
"granulocyte colony stimulating factor, unspecified",Granulocyte colony stimulating factor agonist,granulocyte colony stimulating factor,unspecified,,,0,['granulocyte colony stimulating factor'],,0,[],0
SGN-CD352A,DNA inhibitor,SGN-CD352A,,SGN-CD352A,sgn cd352a,fexact,"['SGN-CD352A', 'CD352-targeted antibody-drug conjugate (cancer), Seattle Genetics', 'SGN-352A']",SGN-CD352A,fexact,"['sgn cd352a', 'cd352 targeted antibody drug conjugate cancer seattle genetics', 'sgn 352a']",correct_mapping
tisagenlecleucel-t,T cell stimulant; Immuno-oncology therapy,tisagenlecleucel-t,,tisagenlecleucel,tisagenlecleucel t,fexact,"['tisagenlecleucel', 'anti-CD19 CAR T-cell therapy (B-cell leukemia/lymphoma), Novartis', 'tisagenlecleucel-T', 'CART-19', 'anti-cd19-car-transduced autologous t cells (b-cell leukemia/lymphoma)', 'CTL-019', 'Kymriah', 'anti-cd19-car-transduced autologous  cells (b-cell leukemia/lymphoma)', 'anti-CD19 CAR T-cell therapy (B-cell leukemia/lymphoma)']",tisagenlecleucel,fexact,"['tisagenlecleucel', 'anti cd19 car t cell therapy b cell leukemia lymphoma novartis', 'tisagenlecleucel t', 'cart 19', 'anti cd19 car transduced autologous t cells b cell leukemia lymphoma', 'ctl 019', 'kymriah', 'anti cd19 car transduced autologous cells b cell leukemia lymphoma', 'anti cd19 car t cell therapy b cell leukemia lymphoma']",correct_mapping
rivogenlecleucel,T cell stimulant; Immuno-oncology therapy,rivogenlecleucel,,rivogenlecleucel,rivogenlecleucel,fexact,"['BPZ-1001', 'allodepleted T cells transduced with inducible caspase 9 suicide gene + rimiducid (infusion, graft versus host disease)', 'CaspaCIDe', 'CaspaCIDe DLI (graft versus host disease)', 'CaspaCIDe donor lymphocyte infusion (graft versus host disease)', 'BPX-501', 'rivo-cel', 'rivogenlecleucel']",rivogenlecleucel,fexact,"['bpz 1001', 'allodepleted t cells transduced with inducible caspase 9 suicide gene rimiducid infusion graft versus host disease', 'caspacide', 'caspacide dli graft versus host disease', 'caspacide donor lymphocyte infusion graft versus host disease', 'bpx 501', 'rivo cel', 'rivogenlecleucel']",correct_mapping
nilotinib,Abl receptor tyrosine kinase inhibitor; Bcr-Abl inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor,nilotinib,,nilotinib,nilotinib,fexact,"['nilotinib', 'BBT-594', 'nilotinib hydrochloride monohydrate', 'Tasigna', 'AMN-107', 'AFG-210', 'BCG-463', 'AHT-202']",nilotinib,fexact,"['nilotinib', 'bbt 594', 'nilotinib hydrochloride monohydrate', 'tasigna', 'amn 107', 'afg 210', 'bcg 463', 'aht 202']",correct_mapping
"trastuzumab, Enhanze",ErbB-2 antagonist,trastuzumab,Enhanze,trastuzumab biosimilar,trastuzumab,fexact,"['trastuzumab biosimilar', 'Trastuzumab BS', 'trastuzumab-qyyp', 'PF-05280014', 'Trazimera', 'trastuzumab']",trastuzumab biosimilar,fexact,"['trastuzumab biosimilar', 'trastuzumab bs', 'trastuzumab qyyp', 'pf 05280014', 'trazimera', 'trastuzumab']",correct_mapping
apixaban,Direct Factor Xa inhibitor; Factor Xa inhibitor; Serine protease inhibitor,apixaban,,apixaban,apixaban,fexact,"['razaxaban follow-on compound,/', 'Factor Xa antagonist (follow-on),/Pfizer', 'BMS-562247', 'razaxaban follow-on compound,/Pfizer', 'Eliquis', 'apixaban', 'Factor Xa antagonist (follow-on),/']",apixaban,fexact,"['razaxaban follow on compound', 'factor xa antagonist follow on pfizer', 'bms 562247', 'razaxaban follow on compound pfizer', 'eliquis', 'apixaban', 'factor xa antagonist follow on']",correct_mapping
CYAD-01,T cell stimulant; Immuno-oncology therapy,CYAD-01,,CYAD-01,cyad 01,fexact,"['NKR-2', 'chNKG2D T-cell therapy (cancer), OnCyte', 'NKG2D-expressing CAR T-cell therapy (cancer)', 'chnkg2d t-cell therapy (cancer)', 'anti-nkg2d-ligand car t-cell therapy (autologous, cancer)', 'anti-NKG2D-ligand CAR T-cell therapy (autologous, cancer), Celyad Oncology', 'CAR-T NKG2D (autologous)', 'chNKG2D T-cell therapy (cancer),/OnCyte', 'CM-CS1', 'extracellular nkg2d + transmembrane dap10 + intracellular cd3 zeta car t-cell therapy (cancer)', 'CYAD-01', 'CAR-NKG2D', 'extracellular NKG2D + transmembrane DAP10 + intracellular CD3 zeta CAR T-cell therapy (cancer), Celyad Oncology', 'NKRx']",CYAD-01,fexact,"['nkr 2', 'chnkg2d t cell therapy cancer oncyte', 'nkg2d expressing car t cell therapy cancer', 'chnkg2d t cell therapy cancer', 'anti nkg2d ligand car t cell therapy autologous cancer', 'anti nkg2d ligand car t cell therapy autologous cancer celyad oncology', 'car t nkg2d autologous', 'chnkg2d t cell therapy cancer oncyte', 'cm cs1', 'extracellular nkg2d transmembrane dap10 intracellular cd3 zeta car t cell therapy cancer', 'cyad 01', 'car nkg2d', 'extracellular nkg2d transmembrane dap10 intracellular cd3 zeta car t cell therapy cancer celyad oncology', 'nkrx']",correct_mapping
allogeneic natural killer cells,Immunostimulant,allogeneic natural killer cells,,,,0,['allogeneic natural killer cells'],,0,[],0
umbilical cord blood transplant,Unidentified pharmacological activity,umbilical cord blood transplant,,,,0,['umbilical cord blood transplant'],,0,[],0
peptide vaccine (personalized),Immunostimulant,peptide vaccine,,HER-2 peptide vaccine (cancer),peptide vaccines,fuzzy,"['trastuzumab like and pertuzumab-like HER-2 vaccine (cancer), Ohio State University', 'HER-2 peptide vaccine (cancer), Ohio State University', 'peptide vaccines, Ohio State University', 'peptide vaccines', 'her-2 peptide vaccine (cancer)', 'HER-2 628-647', 'HER-2 peptide vaccine (cancer)', 'cancer vaccine', 'MVF HER-2 (597-626)', 'cancer vaccine, Ohio State University', 'MVF HER2', 'trastuzumab like and pertuzumab-like her-2 vaccine (cancer)', 'B-Vaxx', 'MVF HER-2 (266-296)', 'HER-2 316-339']",HER-2 peptide vaccine (cancer),fexact,"['trastuzumab like and pertuzumab like her 2 vaccine cancer ohio state university', 'her 2 peptide vaccine cancer ohio state university', 'peptide vaccines ohio state university', 'peptide vaccines', 'her 2 peptide vaccine cancer', 'her 2 628 647', 'her 2 peptide vaccine cancer', 'cancer vaccine', 'mvf her 2 597 626', 'cancer vaccine ohio state university', 'mvf her2', 'trastuzumab like and pertuzumab like her 2 vaccine cancer', 'b vaxx', 'mvf her 2 266 296', 'her 2 316 339']",incorrect_mapping
PGV-001,Immunostimulant; Immuno-oncology therapy,PGV-001,,PGV-001,pgv 001,fexact,"['personalized peptide vaccine (solid tumors)', 'mutation-derived tumor antigen based personalized vaccine (glioblastoma), Mount Sinai School of Medicine', 'Personalized Genome Vaccine 001', 'MTA-based personalized vaccine (glioblastoma), Mount Sinai School of Medicine', 'PGV-001']",PGV-001,fexact,"['personalized peptide vaccine solid tumors', 'mutation derived tumor antigen based personalized vaccine glioblastoma mount sinai school of medicine', 'personalized genome vaccine 001', 'mta based personalized vaccine glioblastoma mount sinai school of medicine', 'pgv 001']",correct_mapping
XmAb-15426,CD3 agonist; Immuno-oncology therapy,XmAb-15426,,XmAb-698,xmab 15426,fexact,"['anti-CD3/anti-CD38 bispecific T-cell engager (XmAb, multiple myeloma),/', 'bispecific CD3/CD38 targeting antibody program (multiple myeloma)', 'XmAb-13551', 'XmAb-698', 'anti-CD3/anti-CD38 bispecific T-cell engager (XmAb, multiple myeloma), Xencor/', 'AMG-424', 'XmAb-13243', 'bispecific antibody program (CD3 x CD38 target, cancer)', 'bispecific antibody program (CD3 x CD38 target, cancer), Xencor', 'XmAb-15426']",XmAb-698,fexact,"['anti cd3 anti cd38 bispecific t cell engager xmab multiple myeloma', 'bispecific cd3 cd38 targeting antibody program multiple myeloma', 'xmab 13551', 'xmab 698', 'anti cd3 anti cd38 bispecific t cell engager xmab multiple myeloma xencor', 'amg 424', 'xmab 13243', 'bispecific antibody program cd3 x cd38 target cancer', 'bispecific antibody program cd3 x cd38 target cancer xencor', 'xmab 15426']",correct_mapping
"dexamethasone, KRKA",Immunosuppressant; Glucocorticoid agonist,dexamethasone,KRKA,ProTmune,dexamethasone,fexact,"['dexamethasone', 'FT-4145', 'ProTmune', 'FT-1050 + FT-4145 modulated mPB (hematologic malignancies)', 'dmPGE2', 'dmPGE2 + dexamethasone modulated mobilized peripheral blood (hematologic malignancies)', 'FT-1050']",ProTmune,fexact,"['dexamethasone', 'ft 4145', 'protmune', 'ft 1050 ft 4145 modulated mpb hematologic malignancies', 'dmpge2', 'dmpge2 dexamethasone modulated mobilized peripheral blood hematologic malignancies', 'ft 1050']",correct_mapping
larotrectinib,TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor,larotrectinib,,larotrectinib sulfate,larotrectinib,fexact,"['larotrectinib sulfate', 'BAY-2757556', 'tyrosine kinase inhibitor (oral, cancer),/', 'oncogenic activating mutation-targeting compound (cancer),/', 'oncogenic activating mutation-targeting compound (cancer),/ Loxo Oncology', 'Vitrakvi', 'LOXO-101', 'larotrectinib', 'tyrosine kinase inhibitor (oral, cancer),/Loxo Oncology']",larotrectinib sulfate,fexact,"['larotrectinib sulfate', 'bay 2757556', 'tyrosine kinase inhibitor oral cancer', 'oncogenic activating mutation targeting compound cancer', 'oncogenic activating mutation targeting compound cancer loxo oncology', 'vitrakvi', 'loxo 101', 'larotrectinib', 'tyrosine kinase inhibitor oral cancer loxo oncology']",correct_mapping
AMG-176,Mcl-1 antagonist,AMG-176,,"tapotoclax (intravenous, cancer)",amg 176,fexact,"['tapotoclax (intravenous, cancer)', 'MCL-1 inhibitor (intravenous, cancer)', 'tapotoclax', 'AMG-176']","tapotoclax (intravenous, cancer)",fexact,"['tapotoclax intravenous cancer', 'mcl 1 inhibitor intravenous cancer', 'tapotoclax', 'amg 176']",correct_mapping
thiotepa,Microtubule inhibitor; DNA inhibitor,thiotepa,,,,0,"['thiotepa', 'DSP-1958', 'RITHIO', 'thiotepa (hematopoietic stem cell transplantation)', 'Rethio', '52-24-4']",,NER_API,[],0
allopurinol,Xanthine oxidase inhibitor,allopurinol,,,,0,"['allopurinol', 'allopurinol sodium', 'allopurinol sodium (perinatal asphyxia)', 'allopurinol sodium (perinatal asphyxia/brain injury)']",,NER_API,[],0
GO-203-2c,MUC-1 inhibitor,GO-203-2c,,GO-203-2C,go 203 2c,fexact,"['GO-203', 'mucin 1 inhibitors (cancer)', 'GO-201', 'MUC1 inhibitor (iv, cancer)', 'GO-203-2C', 'MUC1 inhibitors (cancer)']",GO-203-2C,fexact,"['go 203', 'mucin 1 inhibitors cancer', 'go 201', 'muc1 inhibitor iv cancer', 'go 203 2c', 'muc1 inhibitors cancer']",correct_mapping
"SIRPa-Fc, Trillium Therapeutics (intravenous)",CD47 antagonist; Macrophage stimulant; Signal regulatory protein alpha agonist; Immuno-oncology therapy; Immune checkpoint inhibitor,SIRPa-Fc,Trillium Therapeutics,TTI-621,sirpafc,fuzzy,"['CD47 checkpoint inhibitor (cancer), Trillium Therapeutics', 'SIRPa-IgG1 Fc, Trillium Therapeutics', 'dual CD47 checkpoint inhibitor/strong FcgR activator (cancer), Trillium Therapeutics', 'sirpa-igg1 fc', 'ontorpacept', 'sirpalpha fc (acute myeloid leukemia)', 'dual cd47 checkpoint inhibitor/strong fcgr activator (cancer)', 'TTI-621', 'cd47 checkpoint inhibitor (cancer)', 'SIRPaFc', 'SIRPalpha Fc (acute myeloid leukemia), Trillium Therapeutics']",TTI-621,fexact,"['cd47 checkpoint inhibitor cancer trillium therapeutics', 'sirpa igg1 fc trillium therapeutics', 'dual cd47 checkpoint inhibitor strong fcgr activator cancer trillium therapeutics', 'sirpa igg1 fc', 'ontorpacept', 'sirpalpha fc acute myeloid leukemia', 'dual cd47 checkpoint inhibitor strong fcgr activator cancer', 'tti 621', 'cd47 checkpoint inhibitor cancer', 'sirpafc', 'sirpalpha fc acute myeloid leukemia trillium therapeutics']",incorrect_mapping
eltanexor,Exportin 1 inhibitor,eltanexor,,eltanexor,eltanexor,fexact,"['eltanexor', 'KPTI 8602', 'ONO-7706', 'KPT-8602', 'ATG-016']",eltanexor,fexact,"['eltanexor', 'kpti 8602', 'ono 7706', 'kpt 8602', 'atg 016']",correct_mapping
"fluticasone propionate, inhaled",Lipocortin synthesis stimulant; Glucocorticoid agonist,fluticasone propionate,inhaled,fluticasone propionate,fluticasone propionate,fexact,"['Flonase', 'fluticasone', 'Flovent Diskus', 'Flixotide Evohaler', 'SN-411', 'Axotide', 'SN-411A', 'CCI-18781', 'SN-410', 'Flovent', 'Flunase', 'Flutide', 'Flutide Diskus', 'fluticasone propionate', 'Flutide Evohaler', 'Flovent HFA', 'FN-25']",fluticasone propionate,fexact,"['flonase', 'fluticasone', 'flovent diskus', 'flixotide evohaler', 'sn 411', 'axotide', 'sn 411a', 'cci 18781', 'sn 410', 'flovent', 'flunase', 'flutide', 'flutide diskus', 'fluticasone propionate', 'flutide evohaler', 'flovent hfa', 'fn 25']",correct_mapping
milademetan,MDM2 inhibitor,milademetan,,milademetan monotosylate monohydrate,milademetan,fexact,"['ubiquitination pathway inhibitors (cancer/inflammation), Rigel/', 'E-3 ubiquitin ligase inhibitors, Rigel/', 'ubiquitination pathway inhibitors (cancer)', 'milademetan', 'E-2 ubiquitin ligase inhibitors,/', 'RAIN-32', 'ubiquitination pathway inhibitors (cancer/inflammation),/', 'E-3 ubiquitin ligase inhibitors,/', 'E-2 ubiquitin ligase inhibitors, Rigel/', 'DS-3032', 'DS-3032b', 'milademetan monotosylate monohydrate']",milademetan monotosylate monohydrate,fexact,"['ubiquitination pathway inhibitors cancer inflammation rigel', 'e 3 ubiquitin ligase inhibitors rigel', 'ubiquitination pathway inhibitors cancer', 'milademetan', 'e 2 ubiquitin ligase inhibitors', 'rain 32', 'ubiquitination pathway inhibitors cancer inflammation', 'e 3 ubiquitin ligase inhibitors', 'e 2 ubiquitin ligase inhibitors rigel', 'ds 3032', 'ds 3032b', 'milademetan monotosylate monohydrate']",correct_mapping
"doxorubicin HCL, liposomal, unspecified",DNA synthesis inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,doxorubicin HCL,unspecified,"doxorubicin (liposomal, STEALTH)",doxorubicin hcl,fexact,"['doxorubicin (liposomal, STEALTH)', 'SL-Dox', 'DOX-SL', 'doxorubicin HCl', 'doxorubicin hydrochloride', 'Caelyx', 'STEALTH (doxorubicin)', 'S-DOX', 'doxorubicin,/Schering', 'NSC-712227', 'doxorubicin,/', 'doxorubicin', 'pegylated liposomal doxorubicin', 'Doxil', 'JNS-002']","doxorubicin (liposomal, STEALTH)",fexact,"['doxorubicin liposomal stealth', 'sl dox', 'dox sl', 'doxorubicin hcl', 'doxorubicin hydrochloride', 'caelyx', 'stealth doxorubicin', 's dox', 'doxorubicin schering', 'nsc 712227', 'doxorubicin', 'doxorubicin', 'pegylated liposomal doxorubicin', 'doxil', 'jns 002']",correct_mapping
REC-2282,Protein kinase B inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor,REC-2282,,REC-2282,rec 2282,fexact,"['AR-42', 'pan-histone deacetylase inhibitor (neurofibromatosis type 2)', 'AR-42 (cancer)', 's-HDAC-42', 'VAD-20', 'REC-2282', 'HDAC-42', 'pan-histone deacetylase inhibitor (neurofibromatosis type 2), Recursion', 'OSU-HDAC-42', 'NSC-736012', 'histone deacetylase inhibitors, Ohio State University', 'NSC-D736012', 'VAD-18', 'NSC-731438', 'histone deacetylase inhibitors']",REC-2282,fexact,"['ar 42', 'pan histone deacetylase inhibitor neurofibromatosis type 2', 'ar 42 cancer', 's hdac 42', 'vad 20', 'rec 2282', 'hdac 42', 'pan histone deacetylase inhibitor neurofibromatosis type 2 recursion', 'osu hdac 42', 'nsc 736012', 'histone deacetylase inhibitors ohio state university', 'nsc d736012', 'vad 18', 'nsc 731438', 'histone deacetylase inhibitors']",correct_mapping
"influenza vaccine, high-dose, Sanofi Pasteur",Immunostimulant,influenza vaccine,Sanofi Pasteur,,,0,['influenza vaccine'],,0,[],0
opaganib,Sphingosine kinase 2 inhibitor,opaganib,,opaganib,opaganib,fexact,"['SKI-I', 'sphingosine kinase inhibitors (cancer/coronavirus disease 19 infection), RedHill', 'sphingosine kinase inhibitors (cancer/COVID-19), RedHill', 'opaganib', 'sphingosine kinase inhibitors (cancer/coronavirus disease 19 infection)', 'sphingosine kinase inhibitors (cancer)', 'SKI-V', 'sphingosine kinase inhibitors (cancer/COVID-19)', 'Yeliva', 'ABC-294640', 'ABC-747080', 'ABC-294735', 'SKI-II']",opaganib,fexact,"['ski i', 'sphingosine kinase inhibitors cancer coronavirus disease 19 infection redhill', 'sphingosine kinase inhibitors cancer covid 19 redhill', 'opaganib', 'sphingosine kinase inhibitors cancer coronavirus disease 19 infection', 'sphingosine kinase inhibitors cancer', 'ski v', 'sphingosine kinase inhibitors cancer covid 19', 'yeliva', 'abc 294640', 'abc 747080', 'abc 294735', 'ski ii']",correct_mapping
AMG-224,Microtubule inhibitor,AMG-224,,AMG-224,amg 224,fexact,['AMG-224'],AMG-224,fexact,['amg 224'],correct_mapping
BI-836909 (IV),CD3 agonist; Immuno-oncology therapy,BI-836909,,AMG-420,bi 836909,fexact,"['anti-CD3/anti-BCMA bispecific T-cell engager (BiTE, multiple myeloma),//', 'anti-CD3/anti-BCMA bispecific T-cell engager (BiTE, multiple myeloma), Micromet//', 'pacanalotamab', 'AMG-420', 'anti-CD3/anti-BCMA bispecific T-cell engager (BiTE, multiple myeloma), Micromet//Boehringer Ingelheim', 'BI-836909']",AMG-420,fexact,"['anti cd3 anti bcma bispecific t cell engager bite multiple myeloma', 'anti cd3 anti bcma bispecific t cell engager bite multiple myeloma micromet', 'pacanalotamab', 'amg 420', 'anti cd3 anti bcma bispecific t cell engager bite multiple myeloma micromet boehringer ingelheim', 'bi 836909']",correct_mapping
anakinra (SC),Interleukin 1 receptor antagonist,anakinra,,anakinra,anakinra,fexact,"['Antril', 'Kineret', 'anakinra', 'IL-1 antagonist, InSite Vision', 'IL-1ra']",anakinra,fexact,"['antril', 'kineret', 'anakinra', 'il 1 antagonist insite vision', 'il 1ra']",correct_mapping
N-methyl-pyrrolidone,Immunostimulant,N-methyl-pyrrolidone,,"nmp (oral, cancer)",n methyl 2 pyrrolidone,fuzzy,"['N-methyl-2-pyrrolidone', 'n-methylpyrrolidone compounds (cancer)', 'nmp (oral, cancer)', 'NMP']","nmp (oral, cancer)",fexact,"['n methyl 2 pyrrolidone', 'n methylpyrrolidone compounds cancer', 'nmp oral cancer', 'nmp']",incorrect_mapping
CWP-232291,Wnt pathway inhibitor,CWP-232291,,CWP-291,cwp 232291,fexact,"['KDDF-201408-09', 'CWP-232291', 'CWP-231', 'KDDF-201310-14', 'CWP-291', 'CW-231', 'CWP-231A']",CWP-291,fexact,"['kddf 201408 09', 'cwp 232291', 'cwp 231', 'kddf 201310 14', 'cwp 291', 'cw 231', 'cwp 231a']",correct_mapping
BI-505,Protein synthesis inhibitor; ICAM 1 antagonist; Apoptosis stimulant,BI-505,,BI-505,bi 505,fexact,"['BI-505', 'ICAM-1-targeting antibody (FIRST, cancer)']",BI-505,fexact,"['bi 505', 'icam 1 targeting antibody first cancer']",correct_mapping
filanesib,Kinesin inhibitor,filanesib,,filanesib,filanesib,fexact,"['KSP inhibitors (cancer)', 'ARRY-649', 'filanesib hydrochloride', 'filanesib', 'ARRY-520', 'kinesin spindle protein inhibitors (cancer)']",filanesib,fexact,"['ksp inhibitors cancer', 'arry 649', 'filanesib hydrochloride', 'filanesib', 'arry 520', 'kinesin spindle protein inhibitors cancer']",correct_mapping
"anti-survivin cancer vaccine, MimiVax",Survivin inhibitor; Immuno-oncology therapy,anti-survivin cancer vaccine,MimiVax,,,0,['anti-survivin cancer vaccine'],,0,[],0
CBLC-137 (IV),DNA inhibitor; mTOR kinase inhibitor; Protein kinase B inhibitor; Transcription factor NF-kappaB inhibitor; Apoptosis stimulant; p53 stimulant; PI3 kinase inhibitor,CBLC-137,,"CBL-0137 (iv, cancer)",cblc 137,fexact,"['curaxin (iv, cancer)', 'CBL-137', 'CBL-0137', 'CBLC-137', 'CBL-0137 (iv, cancer)', 'CBLC-137 (iv, cancer)', 'curaxin-137', 'CBLC-137 (iv, cancer), Incuron', 'CBLB-137', 'CBL-0137 (iv, cancer), Incuron', 'curaxin (iv, cancer), Incuron']","CBL-0137 (iv, cancer)",fexact,"['curaxin iv cancer', 'cbl 137', 'cbl 0137', 'cblc 137', 'cbl 0137 iv cancer', 'cblc 137 iv cancer', 'curaxin 137', 'cblc 137 iv cancer incuron', 'cblb 137', 'cbl 0137 iv cancer incuron', 'curaxin iv cancer incuron']",correct_mapping
ACP-319,PI3 kinase delta inhibitor,ACP-319,,ACP-319,acp 319,fexact,"['ACP-319', 'PIK3 delta inhibitor (cancer, oral)']",ACP-319,fexact,"['acp 319', 'pik3 delta inhibitor cancer oral']",correct_mapping
romiplostim,Thrombopoietin agonist,romiplostim,,romiplostim,romiplostim,fexact,"['thrombopoietin agonist peptibody (thrombocytopenia)', 'Romiplate', 'romiplostim', 'Mpl-binding peptibody (thrombocytopenia)', 'Nplate', 'AMG-531']",romiplostim,fexact,"['thrombopoietin agonist peptibody thrombocytopenia', 'romiplate', 'romiplostim', 'mpl binding peptibody thrombocytopenia', 'nplate', 'amg 531']",correct_mapping
TAA-specific cytotoxic T lymphocytes,Immunostimulant,TAA-specific cytotoxic T lymphocytes,,,,0,['TAA-specific cytotoxic T lymphocytes'],,0,[],0
gabapentin,Calcium channel antagonist,gabapentin,,,,0,"['gabapentin', 'Goe-3450', 'Neurontin', 'Goe-2450', 'Go-3450', 'CI-945', 'Gabapen']",,NER_API,[],0
amitriptyline,5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Serotonin and norepinephrine reuptake inhibitor; Tricyclic antidepressant,amitriptyline,,,,0,"['nav1.7 subunit sodium channel inhbitor (peripheral neuropathy/erythromelalgia)', 'amitriptyline', 'nav1.9 subunit sodium channel inhbitor (peripheral neuropathy/erythromelalgia)', 'nav1.8 subunit sodium channel inhbitor (peripheral neuropathy/erythromelalgia)', 'ATX-01']",,NER_API,[],0
pregabalin,Calcium channel antagonist,pregabalin,,pregabalin,pregabalin,fexact,"['pregabalin', 'Lyrica', 'Lyrica Capsules', 'PD-144723', 'Lyrica OD Tablets', 'S-isobutylGABA', 'PGB', 'CI-1008']",pregabalin,fexact,"['pregabalin', 'lyrica', 'lyrica capsules', 'pd 144723', 'lyrica od tablets', 's isobutylgaba', 'pgb', 'ci 1008']",correct_mapping
"mesenchymal stromal cells, unspecified",Not applicable,mesenchymal stromal cells,unspecified,,,0,['mesenchymal stromal cells'],,0,[],0
VLX-1570,Ubiquitin-specific protease inhibitor; Apoptosis inhibitor,VLX-1570,,VLX-1570,vlx 1570,fexact,"['b-AP15', 'deubiquitinase inhibitors (multiple myeloma)', 'deubiquitinase inhibitors (multiple myeloma), Vivolux', 'VLX-1570']",VLX-1570,fexact,"['b ap15', 'deubiquitinase inhibitors multiple myeloma', 'deubiquitinase inhibitors multiple myeloma vivolux', 'vlx 1570']",correct_mapping
BB-MPI-03,T cell stimulant,BB-MPI-03,,BB-MPI-03,bb mpi 03,fexact,['BB-MPI-03'],BB-MPI-03,fexact,['bb mpi 03'],correct_mapping
afuresertib,Protein kinase B inhibitor,afuresertib,,afuresertib,afuresertib,fexact,"['pan AKT protein kinase inhibitor (cancer), Laekna Therapeutics', 'afuresertib hydrochloride', 'GSK-2110183', 'AKT protein kinase inhibitor (cancer)', 'afuresertib', 'ASB-183', '2110183', 'LAE-002', 'pan AKT protein kinase inhibitor (cancer)']",afuresertib,fexact,"['pan akt protein kinase inhibitor cancer laekna therapeutics', 'afuresertib hydrochloride', 'gsk 2110183', 'akt protein kinase inhibitor cancer', 'afuresertib', 'asb 183', '2110183', 'lae 002', 'pan akt protein kinase inhibitor cancer']",correct_mapping
CB-5083,p97 inhibitor,CB-5083,,CB-5083,cb 5083,fexact,"['CL-974386', 'CB-5083', 'CL-974521', 'CL-974039', 'CL-973134', 'p97 inhibitors (cancer), Cleave Biosciences', 'CL-970294']",CB-5083,fexact,"['cl 974386', 'cb 5083', 'cl 974521', 'cl 974039', 'cl 973134', 'p97 inhibitors cancer cleave biosciences', 'cl 970294']",correct_mapping
"chimeric antigen receptor modified T-cells, Celdara (intrahepatic)",T cell stimulant; Immuno-oncology therapy,chimeric antigen receptor modified T-cells,Celdara,,,0,['chimeric antigen receptor modified T-cells'],,0,[],0
ricolinostat,Histone deacetylase 6 inhibitor,ricolinostat,,ricolinostat,ricolinostat,fexact,"['HDAC-6 inhibitors (cancer, inflammatory disease)', 'HDAC-6 inhibitors (rheumatoid arthritis), Acetylon', 'HDAC-6 inhibitors (rheumatoid arthritis),/Bristol-Myers Squibb', 'ACY-63', 'HDAC-6 inhibitors (cancer, inflammatory disease), Acetylon', 'NK-308', 'HDAC-6 inhibitors (multiple myeloma), Acetylon', 'rocilinostat', 'HDAC-6 inhibitors (multiple myeloma)', 'HDAC-6 inhibitors (rheumatoid arthritis)', 'ACY-1215', 'HDAC-6 inhibitors (rheumatoid arthritis), Regenacy Pharmaceuticals/Bristol-Myers Squibb', 'HDAC-6 inhibitors (rheumatoid arthritis),/', 'ricolinostat']",ricolinostat,fexact,"['hdac 6 inhibitors cancer inflammatory disease', 'hdac 6 inhibitors rheumatoid arthritis acetylon', 'hdac 6 inhibitors rheumatoid arthritis bristol myers squibb', 'acy 63', 'hdac 6 inhibitors cancer inflammatory disease acetylon', 'nk 308', 'hdac 6 inhibitors multiple myeloma acetylon', 'rocilinostat', 'hdac 6 inhibitors multiple myeloma', 'hdac 6 inhibitors rheumatoid arthritis', 'acy 1215', 'hdac 6 inhibitors rheumatoid arthritis regenacy pharmaceuticals bristol myers squibb', 'hdac 6 inhibitors rheumatoid arthritis', 'ricolinostat']",correct_mapping
lenograstim,Granulocyte colony stimulating factor agonist,lenograstim,,lenograstim,lenograstim,fexact,"['Granocyte', 'CSF', 'hG-CSF', 'hG-CSF, Chugai', 'rHuG-CSF', 'G-CSF, Rhone-Poulenc Rorer', 'Neutrogin', 'G-CSF', 'Myelostim', 'CSF, Chugai', 'lenograstim', 'rHuG-CSF, Chugai', 'G-CSF, Chugai']",lenograstim,fexact,"['granocyte', 'csf', 'hg csf', 'hg csf chugai', 'rhug csf', 'g csf rhone poulenc rorer', 'neutrogin', 'g csf', 'myelostim', 'csf chugai', 'lenograstim', 'rhug csf chugai', 'g csf chugai']",correct_mapping
sodium selenite,Unidentified pharmacological activity,sodium selenite,,"sodium selenite (oral, prostate cancer)",sodium selenite,fexact,"['sk-03014', 'selenious acid disodium salt', 'sodium selenite (oral, prostate cancer)', 'sodium selenite']","sodium selenite (oral, prostate cancer)",fexact,"['sk 03014', 'selenious acid disodium salt', 'sodium selenite oral prostate cancer', 'sodium selenite']",correct_mapping
LGH-447,Pim kinase inhibitor,LGH-447,,PIM-447,lgh 447,fexact,"['LGH-447', 'PIM-447', 'LGH-477']",PIM-447,fexact,"['lgh 447', 'pim 447', 'lgh 477']",correct_mapping
"busulfan (IV), unspecified",DNA inhibitor,busulfan,unspecified,Busulfex,busulfan,fexact,"['busulfan, MD Anderson', 'KRN-246', 'KER-246', 'Myleran', 'busulfan, Orphan Medical', 'Busilvex', 'busulfan', 'Busulfex', 'Busulfanex']",Busulfex,fexact,"['busulfan md anderson', 'krn 246', 'ker 246', 'myleran', 'busulfan orphan medical', 'busilvex', 'busulfan', 'busulfex', 'busulfanex']",correct_mapping
tagraxofusp,Translation elongation factor 2 inhibitor,tagraxofusp,,tagraxofusp,tagraxofusp,fexact,"['tagraxofusp-erzs', 'DT388IL-3', 'Elzonris', 'SL-401', 'tagraxofusp']",tagraxofusp,fexact,"['tagraxofusp erzs', 'dt388il 3', 'elzonris', 'sl 401', 'tagraxofusp']",correct_mapping
vitamin B6,Unidentified pharmacological activity,vitamin B6,,,,0,['vitamin B6'],,0,[],0
pyridoxine (IV),Unidentified pharmacological activity,pyridoxine,,,,0,['pyridoxine'],,0,[],0
"calcium phosphate (oral rinse), EUSA Pharma",Phosphate antagonist,calcium phosphate,EUSA Pharma,,,0,['calcium phosphate'],,0,[],0
"glutamine, unspecified",Unidentified pharmacological activity,glutamine,unspecified,"glutamine (oral, short bowel syndrome)",glutamine,fexact,"['NutreStore', 'glutamine', 'L-glutamine (oral, short bowel syndrome)', 'glutamine (oral, short bowel syndrome)']","glutamine (oral, short bowel syndrome)",fexact,"['nutrestore', 'glutamine', 'l glutamine oral short bowel syndrome', 'glutamine oral short bowel syndrome']",correct_mapping
rituximab (IV),CD20 antagonist,rituximab,,rituximab biosimilar,rituximab,fexact,"['GP-2013', 'Riximyo', 'Rixathon', 'rituximab biosimilar', 'Rituximab BS', 'rituximab', 'rituximab biosimilar, Sandoz']",rituximab biosimilar,fexact,"['gp 2013', 'riximyo', 'rixathon', 'rituximab biosimilar', 'rituximab bs', 'rituximab', 'rituximab biosimilar sandoz']",correct_mapping
treosulfan (IV),DNA inhibitor,treosulfan,,treosulfan,treosulfan,fexact,"['Ovastat', 'Trecondi', 'treosulfan', 'Trecondyv', 'NSC-39069', 'Treograft']",treosulfan,fexact,"['ovastat', 'trecondi', 'treosulfan', 'trecondyv', 'nsc 39069', 'treograft']",correct_mapping
ATG-Fresenius,Immunosuppressant,ATG-Fresenius,,,,0,['ATG-Fresenius'],,0,[],0
burixafor,CXC chemokine receptor 4 antagonist,burixafor,,burixafor,burixafor,fexact,"['CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology', 'bulishafu', 'CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant)', 'burixafor', 'TG-0054']",burixafor,fexact,"['cxcr4 binding inhibitor cell mobilizer iv stem cell transplant taigen biotechnology', 'bulishafu', 'cxcr4 binding inhibitor cell mobilizer iv stem cell transplant', 'burixafor', 'tg 0054']",correct_mapping
DCR-M1711,Myc inhibitor,DCR-M1711,,DCR-M1711,dcr m1711,fexact,"['anti-Myc DsiRNAs (cancer)', 'DCR-MYC', 'DCR-M1711']",DCR-M1711,fexact,"['anti myc dsirnas cancer', 'dcr myc', 'dcr m1711']",correct_mapping
S-55746,Bcl2 inhibitor,S-55746,,BCL-201,s 55746,fexact,"['Servier1', 'bcl-2 inhibitors (cancer),/', 'servier1', 'bcl-2 inhibitors (cancer), /vernalis', 'BCL-201', 'S-055746', 'Bcl-2 inhibitors (cancer), Servier/Vernalis/', 'S-55746']",BCL-201,fexact,"['servier1', 'bcl 2 inhibitors cancer', 'servier1', 'bcl 2 inhibitors cancer vernalis', 'bcl 201', 's 055746', 'bcl 2 inhibitors cancer servier vernalis', 's 55746']",correct_mapping
pidilizumab,Unidentified pharmacological activity,pidilizumab,,pidilizumab,pidilizumab,fexact,"['MDV-9300', 'pidilizumab', 'humanized immunomodulatory mAb', 'StimuMab', 'CT-011', 'BAT-1', 'BAT antibody']",pidilizumab,fexact,"['mdv 9300', 'pidilizumab', 'humanized immunomodulatory mab', 'stimumab', 'ct 011', 'bat 1', 'bat antibody']",correct_mapping
"dexamethasone, Enceladus",Arachidonic acid inhibitor; Glucocorticoid agonist,dexamethasone,Enceladus,ProTmune,dexamethasone,fexact,"['dexamethasone', 'FT-4145', 'ProTmune', 'FT-1050 + FT-4145 modulated mPB (hematologic malignancies)', 'dmPGE2', 'dmPGE2 + dexamethasone modulated mobilized peripheral blood (hematologic malignancies)', 'FT-1050']",ProTmune,fexact,"['dexamethasone', 'ft 4145', 'protmune', 'ft 1050 ft 4145 modulated mpb hematologic malignancies', 'dmpge2', 'dmpge2 dexamethasone modulated mobilized peripheral blood hematologic malignancies', 'ft 1050']",correct_mapping
MAGE-A3 peptide,Immunostimulant,MAGE-A3 peptide,,,,0,['MAGE-A3 peptide'],,0,[],0
WT1-encoding electroporated dendritic cells,Immunostimulant,WT1-encoding electroporated dendritic cells,,,,0,['WT1-encoding electroporated dendritic cells'],,0,[],0
CT-7,Immunostimulant,CT-7,,,,0,['CT-7'],,0,[],0
"fenofibrate (capsule), unspecified",Lipase clearing factor stimulant; Peroxisome proliferator-activated receptor alpha agonist,fenofibrate,unspecified,,,0,"['FP-250', 'fenofibrate', 'fenofibrate (PEG/oral solid dispersion, hyperlipidemia)', 'FP-0250']",,NER_API,[],0
"cyclosporine A, unspecified",Immunosuppressant; Calcineurin inhibitor; T cell inhibitor,cyclosporine A,unspecified,ciclosporin,cyclosporin a,fuzzy,"['cyclosporin', 'cyclosporin A', 'Sandimmun', 'OLO-400', 'ciclosporin', 'Neoral', 'Sandimmune', 'cyclosporine', 'Sandimmun Neoral']",ciclosporin,fexact,"['cyclosporin', 'cyclosporin a', 'sandimmun', 'olo 400', 'ciclosporin', 'neoral', 'sandimmune', 'cyclosporine', 'sandimmun neoral']",incorrect_mapping
LCL-161 (tablet),IAP antagonist,LCL-161,,LCL-161,lcl 161,fexact,['LCL-161'],LCL-161,fexact,['lcl 161'],correct_mapping
G-CSF (SC),Granulocyte colony stimulating factor agonist,G-CSF,,lenograstim,g csf,fexact,"['Granocyte', 'CSF', 'hG-CSF', 'hG-CSF, Chugai', 'rHuG-CSF', 'G-CSF, Rhone-Poulenc Rorer', 'Neutrogin', 'G-CSF', 'Myelostim', 'CSF, Chugai', 'lenograstim', 'rHuG-CSF, Chugai', 'G-CSF, Chugai']",lenograstim,fexact,"['granocyte', 'csf', 'hg csf', 'hg csf chugai', 'rhug csf', 'g csf rhone poulenc rorer', 'neutrogin', 'g csf', 'myelostim', 'csf chugai', 'lenograstim', 'rhug csf chugai', 'g csf chugai']",correct_mapping
pelabresib,BET protein inhibitor,pelabresib,,pelabresib,pelabresib,fexact,"['CPI-232', 'CPI-203', 'BET inhibitors (cancer)', 'CPI-0610', 'BET bromodomain inhibitors (cancer)', 'CPI-267203', 'pelabresib']",pelabresib,fexact,"['cpi 232', 'cpi 203', 'bet inhibitors cancer', 'cpi 0610', 'bet bromodomain inhibitors cancer', 'cpi 267203', 'pelabresib']",correct_mapping
spanlecortemlocel,Not applicable,spanlecortemlocel,,spanlecortemlocel,spanlecortemlocel,fexact,"['LFU-835-expanded umbilical cord stem cell therapy (hematopoetic stem cell transplant), Novartis', 'umbilical cord stem cell therapy (hematological cancer), Novartis', 'LFU-835-expanded umbilical cord stem cell therapy (hematopoetic stem cell transplant)', 'StemRegenin 1', 'SR1', 'spanlecortemlocel', 'LFU-835-expanded umbilical cord stem cell therapy (hematopoetic stem cell transplant/ inherited metabolic disorder)', 'LFU-835', 'umbilical cord stem cell therapy (hematological cancer)', 'HSC-835', 'MGTA-456', 'umbilical cord stem cell therapy (hematopoetic stem cell transplant/ inherited metabolic disorder)']",spanlecortemlocel,fexact,"['lfu 835 expanded umbilical cord stem cell therapy hematopoetic stem cell transplant novartis', 'umbilical cord stem cell therapy hematological cancer novartis', 'lfu 835 expanded umbilical cord stem cell therapy hematopoetic stem cell transplant', 'stemregenin 1', 'sr1', 'spanlecortemlocel', 'lfu 835 expanded umbilical cord stem cell therapy hematopoetic stem cell transplant inherited metabolic disorder', 'lfu 835', 'umbilical cord stem cell therapy hematological cancer', 'hsc 835', 'mgta 456', 'umbilical cord stem cell therapy hematopoetic stem cell transplant inherited metabolic disorder']",correct_mapping
roflumilast (oral),Phosphodiesterase 4 inhibitor,roflumilast,,roflumilast,roflumilast,fexact,"['roflumist', 'Libertek', 'BYK-20869', 'B9302-107', 'roflumilast', 'BY-217', 'APTA-2217', 'Xevex', 'Dalveza', 'Daliresp', 'Daxas']",roflumilast,fexact,"['roflumist', 'libertek', 'byk 20869', 'b9302 107', 'roflumilast', 'by 217', 'apta 2217', 'xevex', 'dalveza', 'daliresp', 'daxas']",correct_mapping
"L-glutamine, Emmaus",Glutamate antagonist,L-glutamine,Emmaus,,,0,"['l-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia)', 'pharmaceutical grade L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia/diabetes)', 'Saforis', 'L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia)', 'BKR-013', 'L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia/diabetes)', 'glutamine (suppository, type 2 diabetes),/', 'L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia),/University of California Los Angeles', 'hypoglycemic agent (type 2 diabetes)', 'glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia)', 'L-glutamine (oral, short bowel syndrome)', 'PGLG', 'AES-14', 'L-glutamine (topical, chemotherapy-induced mucositis)', 'L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia/diabetes/diverticulosis)', 'Xyndari', 'glutamine (suppository, type 2 diabetes),/Mayo Clinic', 'Aesgen-14', 'Endari', 'L-glutamine', 'NutreStore', 'glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia),/University of California Los Angeles', 'E-6014', 'glutamine (oral, short bowel syndrome)', 'glutamine (Phloral, oral pill, type 2 diabetes)', 'glutamine', 'levoglutamide (sickle cell disease)']",,Drug_API_mapping,[],0
roneparstat,Heparanase inhibitor,roneparstat,,roneparstat,roneparstat,fexact,"['SST-0001', 'roneparstat', 'LB-401']",roneparstat,fexact,"['sst 0001', 'roneparstat', 'lb 401']",correct_mapping
WT1-CTL,T cell stimulant,WT1-CTL,,WT1-CTL,wt1 ctl,fexact,"['WT-1 analog peptide vaccine (acute myeloid leukemia/mesothelioma/cancer), Formula Pharmaceuticals Inc(US)/ Memorial Sloan-Kettering Cancer Center', 'WT-1 therapeutic vaccine (cancer)', 'FPI-01', 'WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals', 'WT1-CTL', 'wt-1 analog peptide vaccine (acute myeloid leukemia/mesothelioma/cancer), (us)', 'wt-1 analog peptide vaccine (acute myeloid leukemia/mesothelioma/cancer), (us)/ memorial sloan-kettering cancer center', 'ATA-520']",WT1-CTL,fexact,"['wt 1 analog peptide vaccine acute myeloid leukemia mesothelioma cancer formula pharmaceuticals inc us memorial sloan kettering cancer center', 'wt 1 therapeutic vaccine cancer', 'fpi 01', 'wt 1 therapeutic vaccine cancer formula pharmaceuticals', 'wt1 ctl', 'wt 1 analog peptide vaccine acute myeloid leukemia mesothelioma cancer us', 'wt 1 analog peptide vaccine acute myeloid leukemia mesothelioma cancer us memorial sloan kettering cancer center', 'ata 520']",correct_mapping
leuprolide acetate,Luteinizing hormone releasing hormone (LHRH) agonist,leuprolide acetate,,leuprorelin acetate,leuprolide acetate,fexact,"['Lucrin Depot', 'Prostap', 'leuprorelin', 'Lucrin', 'Lupron Depot', 'leuprorelin acetate', 'Lupron Depot-PED', 'Leuplin PRO', 'Leuplin', 'leuprolide acetate', 'Lupron', 'Leuplin 3M DPS', 'Enanton', 'Leuplin SR', 'Procren Depot', 'Sixantone', 'leuprorelin SR', 'Abbott-43818', 'TAP-144SR', 'Trenantone', 'TAP-144', 'Enantone']",leuprorelin acetate,fexact,"['lucrin depot', 'prostap', 'leuprorelin', 'lucrin', 'lupron depot', 'leuprorelin acetate', 'lupron depot ped', 'leuplin pro', 'leuplin', 'leuprolide acetate', 'lupron', 'leuplin 3m dps', 'enanton', 'leuplin sr', 'procren depot', 'sixantone', 'leuprorelin sr', 'abbott 43818', 'tap 144sr', 'trenantone', 'tap 144', 'enantone']",correct_mapping
umbilical cord blood derived-NK cells,Immunostimulant,umbilical cord blood derived-NK cells,,,,0,['umbilical cord blood derived-NK cells'],,0,[],0
anti-LewisY chimaeric receptor gene,Lewis Y antigen inhibitor,anti-LewisY chimaeric receptor gene,,,,0,['anti-LewisY chimaeric receptor gene'],,0,[],0
ALT-801,Interleukin 2 receptor agonist; Immuno-oncology therapy,ALT-801,,,,0,"['SP-1373', 'VPD-107', 'GLP1/glucagon receptor agonist (sc, type II diabetes/non-alcoholic steatohepatitis/obesity/non-alcoholic fatty liver disease)', 'GLP1/glucagon receptor agonist (Subcutaneous formulation, type II diabetes/non-alcoholic steatohepatitis/obesity)', 'ALT-801']",,NER_API,[],0
PRLX-93936,Ion channel antagonist,PRLX-93936,,PRLX-93936,prlx 93936,fexact,"['PRLX-93936', 'erastin', 'PRLX-82845', 'selectively cytotoxic anti-cancer compounds,/', 'PRLX-82845 series', 'PRLX-82845 series, Prolexys', 'selectively cytotoxic anti-cancer compounds, Prolexys/Whitehead Institute', 'selectively cytotoxic anti-cancer compounds,/Whitehead Institute']",PRLX-93936,fexact,"['prlx 93936', 'erastin', 'prlx 82845', 'selectively cytotoxic anti cancer compounds', 'prlx 82845 series', 'prlx 82845 series prolexys', 'selectively cytotoxic anti cancer compounds prolexys whitehead institute', 'selectively cytotoxic anti cancer compounds whitehead institute']",correct_mapping
regulatory T lymphocytes,Immunosuppressant,regulatory T lymphocytes,,,,0,['regulatory T lymphocytes'],,0,[],0
epoetin zeta,Erythropoietin receptor agonist,epoetin zeta,,epoetin beta,epoetin beta,fuzzy,"['Epogin', 'recombinant human erythropoietin, Chugai', 'erythropoietin, Genetics Institute//', 'Marogen', 'rHuEPO, Genetics Inst//', 'erythropoietin, Genetics Institute//Roche', 'epoetin beta, Roche', 'NeoRecormon', 'recombinant human erythropoietin', 'Recormon', 'epoetin beta, Genetics Inst//', 'EPOCH', 'erythropoietin, Genetics Institute/Chugai/Roche', 'RO-2053859', 'rHuEPO, Genetics Inst/Chugai/', 'epoetin beta, Genetics Inst/Chugai/', 'epoetin beta', 'Epogin Subcutaneous Injection Syringe 24000']",epoetin beta,fexact,"['epogin', 'recombinant human erythropoietin chugai', 'erythropoietin genetics institute', 'marogen', 'rhuepo genetics inst', 'erythropoietin genetics institute roche', 'epoetin beta roche', 'neorecormon', 'recombinant human erythropoietin', 'recormon', 'epoetin beta genetics inst', 'epoch', 'erythropoietin genetics institute chugai roche', 'ro 2053859', 'rhuepo genetics inst chugai', 'epoetin beta genetics inst chugai', 'epoetin beta', 'epogin subcutaneous injection syringe 24000']",incorrect_mapping
tabalumab (IV),B-cell activating factor inhibitor,tabalumab,,tabalumab,tabalumab,fexact,"['anti-BAFF humanized monoclonal antibody (rheumatoid arthritis/lupus)', 'BAFF antibody (RA/lupus)', 'LY-2127399', 'tabalumab']",tabalumab,fexact,"['anti baff humanized monoclonal antibody rheumatoid arthritis lupus', 'baff antibody ra lupus', 'ly 2127399', 'tabalumab']",correct_mapping
anti-transferrin receptor mAb A27.15,Unidentified pharmacological activity,anti-transferrin receptor mAb A27.15,,,,0,['anti-transferrin receptor mAb A27.15'],,0,[],0
anti-transferrin receptor mAb E2.3,Unidentified pharmacological activity,anti-transferrin receptor mAb E2.3,,,,0,['anti-transferrin receptor mAb E2.3'],,0,[],0
"sirolimus, unspecified",mTOR kinase inhibitor; Protein kinase inhibitor; T cell inhibitor; Cell cycle inhibitor,sirolimus,unspecified,"sirolimus (albumin-bound nanoparticle, cancer, intravenous)",sirolimus,fexact,"['sirolimus (albumin-bound nanoparticle, cancer, intravenous)', 'sirolimus (albumin-bound nanoparticle, cancer, intravenous), Celgene', 'Fyarro', 'rapamycin', 'sirolimus (albumin-bound nanoparticle, intravenous)', 'rapamycin (albumin-bound nanoparticle, intravenous)', 'ABI-009', 'nab-rapamycin', 'sirolimus (albumin-bound nanoparticle, intravenous), Abraxis', 'nab-Sirolimus', 'rapamycin (albumin-bound nanoparticle, intravenous), Abraxis', 'sirolimus', 'TARZIFYX']","sirolimus (albumin-bound nanoparticle, cancer, intravenous)",fexact,"['sirolimus albumin bound nanoparticle cancer intravenous', 'sirolimus albumin bound nanoparticle cancer intravenous celgene', 'fyarro', 'rapamycin', 'sirolimus albumin bound nanoparticle intravenous', 'rapamycin albumin bound nanoparticle intravenous', 'abi 009', 'nab rapamycin', 'sirolimus albumin bound nanoparticle intravenous abraxis', 'nab sirolimus', 'rapamycin albumin bound nanoparticle intravenous abraxis', 'sirolimus', 'tarzifyx']",correct_mapping
alemtuzumab (IV),Immunosuppressant; CD52 antagonist,alemtuzumab,,alemtuzumab,alemtuzumab,fexact,"['BAY-86-5045', 'GZ-402673', 'CAMPATH-1H', 'Lemtrada', 'LDP-03', 'MabCampath', 'CAMPATH-1', 'CAMPATH', 'anti-CD52 mAb, Millennium//', 'alemtuzumab', 'anti-CD52 mAb, Millennium//Schering', 'DE-04188', 'ZK-217699', 'MabCampath-1H', 'anti-CD52 mAb, Millennium/ILEX/Schering']",alemtuzumab,fexact,"['bay 86 5045', 'gz 402673', 'campath 1h', 'lemtrada', 'ldp 03', 'mabcampath', 'campath 1', 'campath', 'anti cd52 mab millennium', 'alemtuzumab', 'anti cd52 mab millennium schering', 'de 04188', 'zk 217699', 'mabcampath 1h', 'anti cd52 mab millennium ilex schering']",correct_mapping
anti-CD45 monoclonal antibody BC8,CD45 antagonist,anti-CD45 monoclonal antibody BC8,,,,0,['anti-CD45 monoclonal antibody BC8'],,0,[],0
BMS-936559,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,BMS-936559,,BMS-936559,bms 936559,fexact,"['anti-PD-L1 humanized mAb (solid tumors)', 'MDX-1105', 'anti-programmed cell death-ligand1 humanized mAb (solid tumors)', 'anti-programmed cell death-ligand1 humanized mAb (solid tumors), Medarex', 'BMS-936559', 'anti-PD-L1 humanized mAb (solid tumors), Medarex']",BMS-936559,fexact,"['anti pd l1 humanized mab solid tumors', 'mdx 1105', 'anti programmed cell death ligand1 humanized mab solid tumors', 'anti programmed cell death ligand1 humanized mab solid tumors medarex', 'bms 936559', 'anti pd l1 humanized mab solid tumors medarex']",correct_mapping
chloroquine,Unidentified pharmacological activity,chloroquine,,,,0,"['repurposed chloroquine (cancer), university of leuven/globalcures', 'repurposed chloroquine (cancer), university of leuven', 'chloroquine']",,NER_API,[],0
DFRF-4539A,Unidentified pharmacological activity,DFRF-4539A,,RG-7598,dfrf 4539a,fexact,"['RG-7598', 'DFRF-4539A', 'antibody-drug conjugate (multiple myeloma)']",RG-7598,fexact,"['rg 7598', 'dfrf 4539a', 'antibody drug conjugate multiple myeloma']",correct_mapping
"Id-KLH vaccine, unspecified",Immunostimulant,Id-KLH vaccine,unspecified,,,0,['Id-KLH vaccine'],,0,[],0
avadomide,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,avadomide,,avadomide,avadomide,fexact,"['avadomide', 'CC-122 HCl', 'pleiotropic pathway modulator (oral, cancer)', 'CC-122', 'pleiotropic pathway modulator (oral, cancer), Celgene', 'avadomide hydrochloride', 'CC-122 hydrochloride', 'pleiotropic pathway modulator (oral, cancer), Bristol-Myers Squib', 'CC-16057', 'pleiotropic pathway modifiers (inflammatory disease), Celgene', 'pleiotropic pathway modifiers (inflammatory disease)']",avadomide,fexact,"['avadomide', 'cc 122 hcl', 'pleiotropic pathway modulator oral cancer', 'cc 122', 'pleiotropic pathway modulator oral cancer celgene', 'avadomide hydrochloride', 'cc 122 hydrochloride', 'pleiotropic pathway modulator oral cancer bristol myers squib', 'cc 16057', 'pleiotropic pathway modifiers inflammatory disease celgene', 'pleiotropic pathway modifiers inflammatory disease']",correct_mapping
balixafortide,CXC chemokine receptor 4 antagonist; Immuno-oncology therapy,balixafortide,,balixafortide,balixafortide,fexact,"['CXCR4 antagonists (cancer/HIV)', 'epitope mimetics (HIV fusion)', 'CXCR4 antagonists (intravenous, cancer/HIV/COVID-19)', 'POL-3026', 'CXCR4 antagonists', 'POL-2438', 'balixafortide', 'POL-6326']",balixafortide,fexact,"['cxcr4 antagonists cancer hiv', 'epitope mimetics hiv fusion', 'cxcr4 antagonists intravenous cancer hiv covid 19', 'pol 3026', 'cxcr4 antagonists', 'pol 2438', 'balixafortide', 'pol 6326']",correct_mapping
methoxyamine (IV),DNA repair enzyme inhibitor,methoxyamine,,"TRC-102 (oral, cancer)",methoxyamine,fexact,"['TRC-102', 'methoxyamine (oral, chemotherapy resistance),/TRACON', 'TRC-102 (oral, cancer)', 'methoxyamine (oral, chemotherapy resistance),/', 'methoxyamine', 'TRC-102 (oral, cancer), Tracon']","TRC-102 (oral, cancer)",fexact,"['trc 102', 'methoxyamine oral chemotherapy resistance tracon', 'trc 102 oral cancer', 'methoxyamine oral chemotherapy resistance', 'methoxyamine', 'trc 102 oral cancer tracon']",correct_mapping
indatuximab ravtansine,Microtubule inhibitor,indatuximab ravtansine,,,,0,"['nBT062-SPP-DM1', 'BT-062', 'anti-CD138 mAb (multiple myeloma)', 'nBT062-SMCC-DM1', 'indatuximab ravtansine (multiple myeloma/solid tumors)', 'nBT062-SPDB-DM4', 'indatuximab ravtansine']",,NER_API,[],0
buffy coat cell infusions,Immunostimulant,buffy coat cell infusions,,,,0,['buffy coat cell infusions'],,0,[],0
tadalafil (tablet),Phosphodiesterase 5 inhibitor,tadalafil,,tadalafil,tadalafil,fexact,"['PDE 5 inhibitor,/', 'ICOS-351', 'LY-450190', 'Cialis', 'PDE V inhibitor,/ICOS', 'GG-960', 'PDE V inhibitor,/', 'Adcirca', 'Zalutia', 'IC-351', 'Tadalafil', 'GF-196960', 'PDE 5 inhibitor, ICOS/', 'tadalafil', 'ICI-351']",tadalafil,fexact,"['pde 5 inhibitor', 'icos 351', 'ly 450190', 'cialis', 'pde v inhibitor icos', 'gg 960', 'pde v inhibitor', 'adcirca', 'zalutia', 'ic 351', 'tadalafil', 'gf 196960', 'pde 5 inhibitor icos', 'tadalafil', 'ici 351']",correct_mapping
CC-115,DNA-dependent protein kinase inhibitor; mTORC1 kinase inhibitor; mTORC2 kinase inhibitor,CC-115,,CC-115,cc 115,fexact,"['CC-0483115', 'CC-115', 'dual DNA-PK/mTOR inhibitor (oral, cancer), Celgene', 'dual DNA-PK/mTOR inhibitor (oral, cancer)']",CC-115,fexact,"['cc 0483115', 'cc 115', 'dual dna pk mtor inhibitor oral cancer celgene', 'dual dna pk mtor inhibitor oral cancer']",correct_mapping
"MAGE-A3 T cells, Adaptimmune",T cell stimulant; Immuno-oncology therapy,MAGE-A3 T cells,Adaptimmune,,,0,['MAGE-A3 T cells'],,0,[],0
OPB-51602,STAT transcription factor 3 inhibitor,OPB-51602,,OPB-51602,opb 51602,fexact,"['OPB-51602', 'OPB-51822']",OPB-51602,fexact,"['opb 51602', 'opb 51822']",correct_mapping
"methylprednisolone (IV), unspecified",Arachidonic acid inhibitor; Glucocorticoid agonist,methylprednisolone,unspecified,methylprednisolone (Pfizer),methylprednisolone,fexact,"['methylprednisolone sodium succinate', 'methylprednisolone acetate', 'Depo-Medrol', 'DEPO-MEDRONE', 'Solu-Medrol', 'methylprednisolone (Pfizer)', 'PF-00345299', 'methylprednisolone', 'Medrol']",methylprednisolone (Pfizer),fexact,"['methylprednisolone sodium succinate', 'methylprednisolone acetate', 'depo medrol', 'depo medrone', 'solu medrol', 'methylprednisolone pfizer', 'pf 00345299', 'methylprednisolone', 'medrol']",correct_mapping
131I-BB4 antibody,Unidentified pharmacological activity,131I-BB4 antibody,,,,0,['131I-BB4 antibody'],,0,[],0
Bcl-2 peptides,Immunostimulant,Bcl-2 peptides,,,,0,['Bcl-2 peptides'],,0,[],0
low molecular weight heparin,Serine protease inhibitor; Indirect thrombin inhibitor; Heparin stimulant,low molecular weight heparin,,,,0,"['LMWH [BEODAS]', 'LMWH', 'low molecular weight heparin', 'heparin [LMW]']",,Drug_API_mapping,[],0
vitamin K,Unidentified pharmacological activity,vitamin K,,,,0,"['menatetrenone', 'Glakay', 'Kaytwo', 'E-0167', 'vitamin K', 'Ea0167']",,Drug_API_mapping,[],0
pirarubicin,DNA topoisomerase II inhibitor,pirarubicin,,pirarubicin,pirarubicin,fexact,"['1609RB', 'tirarubicin', 'Berirubin', 'Theprubicine', 'Therarubicin', 'pirarubicin', 'Pinorubin']",pirarubicin,fexact,"['1609rb', 'tirarubicin', 'berirubin', 'theprubicine', 'therarubicin', 'pirarubicin', 'pinorubin']",correct_mapping
IPH-2101,Natural killer cell stimulant; KIR-mediated natural killer cell inhibition antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,IPH-2101,,IPH-2101,iph 2101,fexact,"['anti-KIR mAb (hematological cancer), Novo Nordisk', 'NN-1975', 'IPH-2101', 'anti-killer cell immunoglobulin-like receptor monoclonal antibody (hematological cancer)', 'KIR checkpoint inhibitor (hematological cancer),/', 'KIR checkpoint inhibitor (hematological cancer)', 'anti-killer cell immunoglobulin-like receptor monoclonal antibody (hematological cancer), Innate Pharma', 'anti-killer cell immunoglobulin-like receptor monoclonal antibody (hematological cancer), Novo Nordisk', 'KIR checkpoint inhibitor (hematological cancer), Innate Pharma/', 'anti-KIR mAb (hematological cancer)', '1-7F9', 'anti-KIR mAb (hematological cancer), Innate Pharma']",IPH-2101,fexact,"['anti kir mab hematological cancer novo nordisk', 'nn 1975', 'iph 2101', 'anti killer cell immunoglobulin like receptor monoclonal antibody hematological cancer', 'kir checkpoint inhibitor hematological cancer', 'kir checkpoint inhibitor hematological cancer', 'anti killer cell immunoglobulin like receptor monoclonal antibody hematological cancer innate pharma', 'anti killer cell immunoglobulin like receptor monoclonal antibody hematological cancer novo nordisk', 'kir checkpoint inhibitor hematological cancer innate pharma', 'anti kir mab hematological cancer', '1 7f9', 'anti kir mab hematological cancer innate pharma']",correct_mapping
BHQ-880,Bone resorption inhibitor; DKK-1 inhibitor,BHQ-880,,BHQ-880,bhq 880,fexact,"['BHQ-880A', 'HuCAL-derived monoclonal antibody (multiple mylenoma), Novartis', 'HuCAL-derived monoclonal antibody (multiple mylenoma)', 'anti-DKK1 monoclonal antibody (multiple myeloma)', 'BHQ-880', 'anti-DKK1 monoclonal antibody (multiple myeloma), Novartis']",BHQ-880,fexact,"['bhq 880a', 'hucal derived monoclonal antibody multiple mylenoma novartis', 'hucal derived monoclonal antibody multiple mylenoma', 'anti dkk1 monoclonal antibody multiple myeloma', 'bhq 880', 'anti dkk1 monoclonal antibody multiple myeloma novartis']",correct_mapping
biropepimut-S,Immunostimulant,biropepimut-S,,biropepimut-S,biropepimut s,fexact,"['MAGE-A3 peptide antigen cancer vaccine', 'GL-0817', 'biropepimut-S', 'MAGE-A3 Trojan Peptide Vaccine']",biropepimut-S,fexact,"['mage a3 peptide antigen cancer vaccine', 'gl 0817', 'biropepimut s', 'mage a3 trojan peptide vaccine']",correct_mapping
pamidronate (IV),Hypocalcaemic agent; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor,pamidronate,,pamidronate disodium,pamidronate,fexact,"['APD', 'CGP-23339A', 'Aminomax', 'pamidronate', 'pamidronate disodium', 'Pamidronic Acid Disodium Salt', 'CGP-23339', 'amidronate', 'PD', 'Aredia', 'pamidronic acid', 'disodium pamidronate', 'PD, Henkel', 'APD, Henkel']",pamidronate disodium,fexact,"['apd', 'cgp 23339a', 'aminomax', 'pamidronate', 'pamidronate disodium', 'pamidronic acid disodium salt', 'cgp 23339', 'amidronate', 'pd', 'aredia', 'pamidronic acid', 'disodium pamidronate', 'pd henkel', 'apd henkel']",correct_mapping
masitinib (tablet),Colony stimulating factor 1 receptor antagonist; FGF receptor 3 tyrosine kinase inhibitor,masitinib,,masitinib,masitinib,fexact,"['Alsitek', 'Masican', 'Kinaction', 'Masipro', 'Masiviera', 'c-kit inhibitor (mastocytosis/GIST)', 'AB-1010', 'masitinib']",masitinib,fexact,"['alsitek', 'masican', 'kinaction', 'masipro', 'masiviera', 'c kit inhibitor mastocytosis gist', 'ab 1010', 'masitinib']",correct_mapping
silmitasertib,Casein kinase 2 inhibitor; Hedgehog pathway inhibitor,silmitasertib,,silmitasertib,silmitasertib,fexact,"['silmitasertib', 'CK2 inhibitor (oral, cancer/COVID-19), Senhwa Biosciences', 'CX-4945', 'CK2 inhibitor (oral, cancer)', 'CK2 inhibitor (oral, cancer/COVID-19)']",silmitasertib,fexact,"['silmitasertib', 'ck2 inhibitor oral cancer covid 19 senhwa biosciences', 'cx 4945', 'ck2 inhibitor oral cancer', 'ck2 inhibitor oral cancer covid 19']",correct_mapping
zotiraciclib,Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Flt-3 antagonist; Janus kinase 2 inhibitor; Mitogen-activated protein kinase 7 inhibitor,zotiraciclib,,zotiraciclib citrate,zotiraciclib,fexact,"['EX45 CDK/Flt3i', 'SB-1317', 'multi-kinase program (oral, cancer), S*Bio Pte Ltd/Tragara Pharmaceuticals', 'Jak2 tyrosine kinase inhibitor/ERK 5 inhibitor (oral, cancer), S*Bio Pte Ltd', 'zotiraciclib', 'Sbio-300 series', 'multi-kinase program (oral, cancer), /tragara pharmaceuticals', 'jak2 tyrosine kinase inhibitor/erk 5 inhibitor (oral, cancer)', 'TG-02', 'cyclin dependent+Flt3 tyrosine kinase inhibitors (oral, cancer), S*Bio Pte Ltd/Tragara Pharamceuticals', 'cyclin dependent+flt3 tyrosine kinase inhibitors (oral, cancer)', 'zotiraciclib citrate', 'cyclin dependent+flt3 tyrosine kinase inhibitors (oral, cancer), /tragara pharamceuticals', 'CDK/FLT3 inhibitors (oral, cancer),/Tragara Pharmaceuticals', 'cyclin dependent+Flt3 tyrosine kinase inhibitors (oral, cancer), S*Bio Pte Ltd/', 'CDK/FLT3 inhibitors (oral, cancer), S*BIO/Tragara Pharmaceuticals']",zotiraciclib citrate,fexact,"['ex45 cdk flt3i', 'sb 1317', 'multi kinase program oral cancer s bio pte ltd tragara pharmaceuticals', 'jak2 tyrosine kinase inhibitor erk 5 inhibitor oral cancer s bio pte ltd', 'zotiraciclib', 'sbio 300 series', 'multi kinase program oral cancer tragara pharmaceuticals', 'jak2 tyrosine kinase inhibitor erk 5 inhibitor oral cancer', 'tg 02', 'cyclin dependent flt3 tyrosine kinase inhibitors oral cancer s bio pte ltd tragara pharamceuticals', 'cyclin dependent flt3 tyrosine kinase inhibitors oral cancer', 'zotiraciclib citrate', 'cyclin dependent flt3 tyrosine kinase inhibitors oral cancer tragara pharamceuticals', 'cdk flt3 inhibitors oral cancer tragara pharmaceuticals', 'cyclin dependent flt3 tyrosine kinase inhibitors oral cancer s bio pte ltd', 'cdk flt3 inhibitors oral cancer s bio tragara pharmaceuticals']",correct_mapping
domatinostat,Histone deacetylase inhibitor; Lysine (K)-specific demethylase 1A inhibitor,domatinostat,,domatinostat tosylate,domatinostat,fexact,"['SC-85958', 'domatinostat', 'histone deacetylase inhibitor (cancer)', 'HDAC isoenzymes 1, 2, 3 inhibitor/mitotic inhibitor (oral tablet, cancer/hematological neoplasms)', 'domatinostat tosylate', '4SC-202']",domatinostat tosylate,fexact,"['sc 85958', 'domatinostat', 'histone deacetylase inhibitor cancer', 'hdac isoenzymes 1 2 3 inhibitor mitotic inhibitor oral tablet cancer hematological neoplasms', 'domatinostat tosylate', '4sc 202']",correct_mapping
PAT-SM6,GRP78 antagonist,PAT-SM6,,PAT-SM6,pat sm6,fexact,"['human monoclonal IgM antibody (multiple myeloma/melanoma/cancer)', 'human monoclonal IgM antibody (pancreatic cancer), Patrys', 'human Immunoglobulin-M antibody (pancreatic cancer)', 'human monoclonal  IgM antibody (pancreatic cancer)', 'SAM-6', 'PAT-SAM6', 'PAT-SM6', 'human monoclonal IgM antibody (multiple myeloma/melanoma/cancer), Patrys', 'human monoclonal IgM antibody (pancreatic cancer)']",PAT-SM6,fexact,"['human monoclonal igm antibody multiple myeloma melanoma cancer', 'human monoclonal igm antibody pancreatic cancer patrys', 'human immunoglobulin m antibody pancreatic cancer', 'human monoclonal igm antibody pancreatic cancer', 'sam 6', 'pat sam6', 'pat sm6', 'human monoclonal igm antibody multiple myeloma melanoma cancer patrys', 'human monoclonal igm antibody pancreatic cancer']",correct_mapping
delanzomib,Proteasome inhibitor,delanzomib,,delanzomib,delanzomib,fexact,"['CT-18770', 'proteasome inhibitors,/Novuspharma', 'delanzomib', 'CEP-1612', 'proteasome inhibitors,/Cell Therapeutics', 'CEP-1508', 'CEP-18770', 'CEP-28331', 'proteasome inhibitors, Cephalon/Cell Therapeutics', 'proteasome inhibitors', 'proteasome inhibitors,/', 'CEP-3117', 'proteasome inhibitors, Cephalon/Novuspharma', 'proteasome inhibitors, Cephalon']",delanzomib,fexact,"['ct 18770', 'proteasome inhibitors novuspharma', 'delanzomib', 'cep 1612', 'proteasome inhibitors cell therapeutics', 'cep 1508', 'cep 18770', 'cep 28331', 'proteasome inhibitors cephalon cell therapeutics', 'proteasome inhibitors', 'proteasome inhibitors', 'cep 3117', 'proteasome inhibitors cephalon novuspharma', 'proteasome inhibitors cephalon']",correct_mapping
autologous lymphocytes,Unidentified pharmacological activity,autologous lymphocytes,,,,0,['autologous lymphocytes'],,0,[],0
filgrastim-sndz,Granulocyte colony stimulating factor agonist,filgrastim-sndz,,filgrastim biosimilar,filgrastim sndz,fexact,"['Zarxio', 'filgrastim-sndz', 'Zarzio', 'filgrastim biosimilar, Hexal', 'Filgrastim Hexal', 'filgrastim biosimilar', 'filgrastim', 'EP-2006', 'Filgrastim BS']",filgrastim biosimilar,fexact,"['zarxio', 'filgrastim sndz', 'zarzio', 'filgrastim biosimilar hexal', 'filgrastim hexal', 'filgrastim biosimilar', 'filgrastim', 'ep 2006', 'filgrastim bs']",correct_mapping
TXA-127,Unidentified pharmacological activity,TXA-127,,TXA-127,txa 127,fexact,"['angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome/pulmonary arterial hypertension), Tarix', 'angiotensin ii 1-7 (sc, thrombocytopenia)', 'angiotensin II 1-7 (COVID-19)', 'angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome/pulmonary arterial hypertension)', 'angiotensin II 1-7 (sc, thrombocytopenia), University of Southern California', 'angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome/pulmonary arterial hypertension/Marfan syndrome), Tarix', 'angiotensin II 1-7 (sc, duchenne dystrophy/muscular dystrophy/motor neurone disease/peripheral vascular disease/stem cell transplantation/Marfan syndrome/epidermolysis bullosa dystrophica/stroke/diabetes mellitus)', 'angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome), Tarix', 'angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome)', 'angiotensin (1-7)', 'angiotensin II 1-7 (sc, thrombocytopenia/stem cell transplantation/HIV-related lymphocytopenia/acute respiratory distress syndrome/pulmonary arterial hypertension/Marfan syndrome)', 'TXA-127']",TXA-127,fexact,"['angiotensin ii 1 7 sc thrombocytopenia stem cell transplantation hiv related lymphocytopenia acute respiratory distress syndrome pulmonary arterial hypertension tarix', 'angiotensin ii 1 7 sc thrombocytopenia', 'angiotensin ii 1 7 covid 19', 'angiotensin ii 1 7 sc thrombocytopenia stem cell transplantation hiv related lymphocytopenia acute respiratory distress syndrome pulmonary arterial hypertension', 'angiotensin ii 1 7 sc thrombocytopenia university of southern california', 'angiotensin ii 1 7 sc thrombocytopenia stem cell transplantation hiv related lymphocytopenia acute respiratory distress syndrome pulmonary arterial hypertension marfan syndrome tarix', 'angiotensin ii 1 7 sc duchenne dystrophy muscular dystrophy motor neurone disease peripheral vascular disease stem cell transplantation marfan syndrome epidermolysis bullosa dystrophica stroke diabetes mellitus', 'angiotensin ii 1 7 sc thrombocytopenia stem cell transplantation hiv related lymphocytopenia acute respiratory distress syndrome tarix', 'angiotensin ii 1 7 sc thrombocytopenia stem cell transplantation hiv related lymphocytopenia acute respiratory distress syndrome', 'angiotensin 1 7', 'angiotensin ii 1 7 sc thrombocytopenia stem cell transplantation hiv related lymphocytopenia acute respiratory distress syndrome pulmonary arterial hypertension marfan syndrome', 'txa 127']",correct_mapping
olaptesed pegol (IV),Stromal cell-derived factor 1 antagonist; Angiogenesis inhibitor,olaptesed pegol,,olaptesed pegol,olaptesed pegol,fexact,"['CXCL12 inhibitor (spiegelmer, diabetic retinopathy/AMD/stem cell transplantation/pancreatic cancer/colorectal cancer)', 'olaptesed pegol', 'SDF-1 inhbitor (spiegelmer, stem cell transplantation)', 'ocular antineovascularisation agent/angiogenesis inhibitor (diabetic retinopathy/AMD)', 'NOX-A12']",olaptesed pegol,fexact,"['cxcl12 inhibitor spiegelmer diabetic retinopathy amd stem cell transplantation pancreatic cancer colorectal cancer', 'olaptesed pegol', 'sdf 1 inhbitor spiegelmer stem cell transplantation', 'ocular antineovascularisation agent angiogenesis inhibitor diabetic retinopathy amd', 'nox a12']",correct_mapping
SNS-01,Translation initiation factor 5 inhibitor; Apoptosis stimulant,SNS-01,,,,0,"['Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, MM/MCL/DLBCL), Senesco', 'SNS-01', 'Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, multiple myeloma), Senesco', 'SNS-101', 'Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, multiple myeloma/ mantle cell lymphoma/diffuse large B-cell lymphoma), Senesco', 'SNS-01-T', 'Factor 5A siRNA + Factor 5A plasmid nanoparticle (in vivo-jetPEI, iv, MM/MCL/DLBCL), Sevion Therapeutics']",,NER_API,[],0
RG-7444,Fibroblast growth factor receptor 3 antagonist,RG-7444,,RG-7444,rg 7444,fexact,"['RG-7444', 'MFGR-1877S', 'anti-FGFR3 humanized mAb (multiple myeloma/bladder cancer)', 'R3Mab']",RG-7444,fexact,"['rg 7444', 'mfgr 1877s', 'anti fgfr3 humanized mab multiple myeloma bladder cancer', 'r3mab']",correct_mapping
clofarabine (IV),DNA synthesis inhibitor; Ribonucleoside triphosphate reductase inhibitor; DNA repair enzyme inhibitor,clofarabine,,clofarabine (oral),clofarabine,fexact,"['Clolar', 'clofarabine (oral),/', 'clofarabine', 'clofarabine (oral)', 'GZ-393590', 'clofarabine (oral),/ILEX', 'clofarabine (oral), Genzyme', 'SAR-393590']",clofarabine (oral),fexact,"['clolar', 'clofarabine oral', 'clofarabine', 'clofarabine oral', 'gz 393590', 'clofarabine oral ilex', 'clofarabine oral genzyme', 'sar 393590']",correct_mapping
sodium chloride 0.9%,Unidentified pharmacological activity,sodium chloride 0.9%,,,,0,['sodium chloride 0.9%'],,0,[],0
KW-2478,Heat shock protein 90 antagonist,KW-2478,,KW-2478,kw 2478,fexact,"['HSP-90 inhibitor (intravenous, cancer)', 'KW-2478']",KW-2478,fexact,"['hsp 90 inhibitor intravenous cancer', 'kw 2478']",correct_mapping
GVAX myeloma vaccine,Granulocyte macrophage colony stimulating factor agonist; Immunostimulant; Immuno-oncology therapy,GVAX myeloma vaccine,,,,0,['GVAX myeloma vaccine'],,0,[],0
AT-9283,Aurora kinase inhibitor; Janus kinase 2 inhibitor; Protein kinase inhibitor; Mitotic inhibitor,AT-9283,,"AT-9283 (iv, cancer)",at 9283,fexact,"['aurora kinase inhibitors (cancer)', 'AT-9283 (iv, cancer), SuperGen', 'AT-9283', 'AT-9283 (iv, cancer)', 'AT-9283 (iv, cancer), Otsuka']","AT-9283 (iv, cancer)",fexact,"['aurora kinase inhibitors cancer', 'at 9283 iv cancer supergen', 'at 9283', 'at 9283 iv cancer', 'at 9283 iv cancer otsuka']",correct_mapping
"melphalan hydrochloride, Unspecified",DNA inhibitor,melphalan hydrochloride,Unspecified,,,0,"['Melphalan', 'melphalan (intravenous/Captisol, multiple myeloma), CyDex Pharmaceuticals', 'melphalan (intravenous/Captisol, multiple myeloma), Spectrum /', 'melphalan (intravenous/Captisol, multiple myeloma),/', 'melphalan (intravenous/Captisol, multiple myeloma), Spectrum Pharmaceuticals', 'CE Melphalan', 'Evomela', 'Captisol-enabled Melphalan', 'melphalan (intravenous/Captisol, multiple myeloma)', 'melphalan (intravenous/Captisol, multiple myeloma), Spectrum / CASI Pharmaceuticals', 'melphalan hydrochloride', 'CDX-353', 'melphalan']",,Drug_API_mapping,[],0
dalantercept,Activin receptor-like kinase 1 inhibitor; Angiogenesis inhibitor,dalantercept,,dalantercept,dalantercept,fexact,"['Alk1-Fc', 'dalantercept', 'ACE-041', 'recombinant ALK-1 signaling inhibitor (angiogenesis)', 'RAP-041', 'chimeric receptor TGF beta antagonist (sc, solid tumors/multiple myeloma/AMD)']",dalantercept,fexact,"['alk1 fc', 'dalantercept', 'ace 041', 'recombinant alk 1 signaling inhibitor angiogenesis', 'rap 041', 'chimeric receptor tgf beta antagonist sc solid tumors multiple myeloma amd']",correct_mapping
"idiotype-pulsed dendritic cells, Stanford",Immunostimulant,idiotype-pulsed dendritic cells,Stanford,,,0,['idiotype-pulsed dendritic cells'],,0,[],0
Agaricus blazei Murill mushroom extract,Unidentified pharmacological activity,Agaricus blazei Murill mushroom extract,,,,0,['Agaricus blazei Murill mushroom extract'],,0,[],0
iodochlorhydroxyquin,Chelating agent; Beta amyloid protein antagonist,iodochlorhydroxyquin,,,,0,"['clioquinol (Alzheimers), Prana', 'iodochlorhydroxyquin (Alzheimers), Prana', 'PBT-1, Prana Biotechnology', 'Iodochlorhydroxyquin', 'clioquinol']",,Drug_API_mapping,[],0
CD20Bi-ATC,CD2 antagonist,CD20Bi-ATC,,,,0,['CD20Bi-ATC'],,0,[],0
allogeneic dendritic cells,Immunostimulant,allogeneic dendritic cells,,,,0,['allogeneic dendritic cells'],,0,[],0
autologous dendritic cells (SC),Immunostimulant,autologous dendritic cells,,,,0,['autologous dendritic cells'],,0,[],0
omega-3 fatty acids,Omega 3 fatty acid stimulant,omega-3 fatty acids,,,,0,"['omega-3 acid ethyl esters 90', 'Lotriga', 'Seacor', 'omega-3 fatty acids, Pronova', 'GSK-2212836', 'Omacor', 'Esapent', 'TAK-085', 'Eskim', 'K-85', 'Lovaza', 'omega-3 fatty acids', 'Zodin', 'doconexent ethyl + icosapent ethyl', 'omega-3-acid ethyl esters']",,Drug_API_mapping,[],0
"resveratrol, Sirtris",Sirtuin 1 stimulant,resveratrol,Sirtris,,,0,"['resveratrol (Alzheimer’s disease), Georgetown University', 'resveratrol (Alzheimer’s disease)', 'resveratrol (alzheimer’s disease)', 'AIC-101', 'resveratrol']",,NER_API,[],0
allogeneic umbilical cord blood-derived T cells,Unidentified pharmacological activity,allogeneic umbilical cord blood-derived T cells,,,,0,['allogeneic umbilical cord blood-derived T cells'],,0,[],0
romyelocel-L,Not applicable,romyelocel-L,,romyelocel,romyelocel,fuzzy,"['myeloid progenitor cells (neutropenia/acute radiation syndrome/cord blood transfusion)', 'stem cell therapy (neutropenia)', 'CLT-008', 'romyelocel']",romyelocel,fexact,"['myeloid progenitor cells neutropenia acute radiation syndrome cord blood transfusion', 'stem cell therapy neutropenia', 'clt 008', 'romyelocel']",incorrect_mapping
XL-139,Angiogenesis inhibitor; Hedgehog pathway inhibitor,XL-139,,XL-139,xl 139,fexact,"['smoothened 7TM receptor inhibitor (cancer), BMS/', 'BMS-833923', 'SMO inhibitor (cancer),/', 'XL-139', 'SMO antagonist (cancer), BMS/Exelixis', 'smoothened 7TM receptor inhibitor (cancer), BMS/Exelixis', 'SMO antagonist (cancer), BMS/', 'SMO inhibitor (cancer),/Exelixis']",XL-139,fexact,"['smoothened 7tm receptor inhibitor cancer bms', 'bms 833923', 'smo inhibitor cancer', 'xl 139', 'smo antagonist cancer bms exelixis', 'smoothened 7tm receptor inhibitor cancer bms exelixis', 'smo antagonist cancer bms', 'smo inhibitor cancer exelixis']",correct_mapping
autologous CAR-Kappa CTL,T cell stimulant; Immuno-oncology therapy,autologous CAR-Kappa CTL,,,,0,['autologous CAR-Kappa CTL'],,0,[],0
ganciclovir,DNA synthesis inhibitor; DNA directed DNA polymerase inhibitor,ganciclovir,,"ganciclovir (oral), Roche Bioscience",ganciclovir,fexact,"['RS-21592', 'Cymevene', 'ganciclovir (oral), Roche Bioscience', 'Cytovene', 'ganciclovir']","ganciclovir (oral), Roche Bioscience",fexact,"['rs 21592', 'cymevene', 'ganciclovir oral roche bioscience', 'cytovene', 'ganciclovir']",correct_mapping
CD34-TK75 transduced donor lymphocytes,Immunostimulant,CD34-TK75 transduced donor lymphocytes,,,,0,['CD34-TK75 transduced donor lymphocytes'],,0,[],0
danusertib,Aurora kinase inhibitor; Bcr-Abl inhibitor,danusertib,,danusertib,danusertib,fexact,"['PHA-739358', 'PHA-816359', 'PHA-680632', 'danusertib', 'PHA-680626', 'Aurora kinase inhibitors (iv, chronic myeloid leukemia/solid tumors)']",danusertib,fexact,"['pha 739358', 'pha 816359', 'pha 680632', 'danusertib', 'pha 680626', 'aurora kinase inhibitors iv chronic myeloid leukemia solid tumors']",correct_mapping
"pegylated liposomal doxorubicin, Sun Pharma",DNA topoisomerase II inhibitor,pegylated liposomal doxorubicin,Sun Pharma,"doxorubicin (liposomal, STEALTH)",pegylated liposomal doxorubicin,fexact,"['doxorubicin (liposomal, STEALTH)', 'SL-Dox', 'DOX-SL', 'doxorubicin HCl', 'doxorubicin hydrochloride', 'Caelyx', 'STEALTH (doxorubicin)', 'S-DOX', 'doxorubicin,/Schering', 'NSC-712227', 'doxorubicin,/', 'doxorubicin', 'pegylated liposomal doxorubicin', 'Doxil', 'JNS-002']","doxorubicin (liposomal, STEALTH)",fexact,"['doxorubicin liposomal stealth', 'sl dox', 'dox sl', 'doxorubicin hcl', 'doxorubicin hydrochloride', 'caelyx', 'stealth doxorubicin', 's dox', 'doxorubicin schering', 'nsc 712227', 'doxorubicin', 'doxorubicin', 'pegylated liposomal doxorubicin', 'doxil', 'jns 002']",correct_mapping
rigosertib (IV),Microtubule inhibitor; Polo-like kinase 1 inhibitor; Mcl-1 antagonist; PI3 kinase inhibitor; Cell cycle inhibitor,rigosertib,,,,0,"['Estybon (capsule, myelodysplastic syndrome/solid tumor)', 'rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors),/SymBio', 'rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors), Onconova/SymBio', 'ON-01910 sodium (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'rigosertib', 'Novonex (capsule, myelodysplastic syndrome/solid tumor)', 'SyB-1101 (oral, MDS)', 'Novonex (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'ONO-106 (capsule, myelodysplastic syndrome/solid tumor)', 'rigosertib sodium', 'Estybon (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'ON-01910.Na (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'ON-01910Na', 'ON-1910Na', 'ONO-106 (capsule, myelodysplastic syndrome/solid tumor), Onconova', 'Estybon', 'ON-01910.Na (capsule, myelodysplastic syndrome/solid tumor)', 'ON-1910 sodium', 'ON-01910.Na', 'SyB C-1101', 'SyB-1101 (oral, MDS), SymBio', 'rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors),/', 'Novonex', 'ON-01910 sodium (capsule, myelodysplastic syndrome/solid tumor)']",,NER_API,[],0
CryoStim,Immunostimulant; Immuno-oncology therapy; Immune checkpoint stimulant,CryoStim,,CryoStim,cryostim,fexact,"['CryoStim', 'in-situ therapeutic cancer vaccine (disseminated metastatic tumors)', 'AlloStim (intratumoral formulation, metastatic tumors)']",CryoStim,fexact,"['cryostim', 'in situ therapeutic cancer vaccine disseminated metastatic tumors', 'allostim intratumoral formulation metastatic tumors']",correct_mapping
AT-7519,Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 5 inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Cell cycle inhibitor,AT-7519,,AT-7519,at 7519,fexact,"['AT-381', 'CDK2 inhibitors', 'AT-3424', 'AT-3409', 'AT-4720', 'cyclin dependent kinase-2 inhibitors', 'AT-3851', 'AT-7519', 'AT-7519M', 'AT-1772', 'CDK2 inhibitors (cancer)', 'AT-660', 'AT-9211', 'AT-2035', 'AT-3864', 'AT-3969']",AT-7519,fexact,"['at 381', 'cdk2 inhibitors', 'at 3424', 'at 3409', 'at 4720', 'cyclin dependent kinase 2 inhibitors', 'at 3851', 'at 7519', 'at 7519m', 'at 1772', 'cdk2 inhibitors cancer', 'at 660', 'at 9211', 'at 2035', 'at 3864', 'at 3969']",correct_mapping
"asparaginase, pegylated, Enzon",Protein synthesis inhibitor; Asparaginase stimulant; Apoptosis stimulant,asparaginase,Enzon,asparaginase,asparaginase,fexact,"['Spectrila', 'asparaginase']",asparaginase,fexact,"['spectrila', 'asparaginase']",correct_mapping
"fluphenazine hydrochloride, Corridor Pharmaceuticals-1",5 Hydroxytryptamine receptor antagonist,fluphenazine hydrochloride,Corridor Pharmaceuticals-1,,,0,['fluphenazine hydrochloride'],,0,[],0
ARQ-621,Kinesin inhibitor,ARQ-621,,ARQ-621,arq 621,fexact,"['ARQ-300RP', 'ARQ-621', 'Eg5 kinesin-like protein inhibitors (cancer)']",ARQ-621,fexact,"['arq 300rp', 'arq 621', 'eg5 kinesin like protein inhibitors cancer']",correct_mapping
TAK-901,Aurora kinase inhibitor,TAK-901,,TAK-901,tak 901,fexact,"['aurora B kinase inhibitor (cancer, iv)', 'TAK-901']",TAK-901,fexact,"['aurora b kinase inhibitor cancer iv', 'tak 901']",correct_mapping
antilymphocyte serum,Immunosuppressant,antilymphocyte serum,,,,0,['antilymphocyte serum'],,0,[],0
ondansetron (IV),5 Hydroxytryptamine 3 receptor antagonist,ondansetron,,ondansetron,ondansetron,fexact,"['GR-38032X', 'SN-307', 'Zofran ODT', 'ondansetron', 'Zopram', 'GG-032', 'Ramesin', 'Zophran', 'Zofran', 'ondansetron hydrochloride', 'GG-032X', 'Zofran Zydis', 'Zamanol', 'Zophren', 'GR-38032F', 'GR-38032', 'GR-C507/75', 'Zofran Konserveret']",ondansetron,fexact,"['gr 38032x', 'sn 307', 'zofran odt', 'ondansetron', 'zopram', 'gg 032', 'ramesin', 'zophran', 'zofran', 'ondansetron hydrochloride', 'gg 032x', 'zofran zydis', 'zamanol', 'zophren', 'gr 38032f', 'gr 38032', 'gr c507 75', 'zofran konserveret']",correct_mapping
givinostat (capsule),Interleukin 1b antagonist; Interleukin 6 receptor antagonist; Tumour necrosis factor alpha antagonist; Histone deacetylase inhibitor,givinostat,,givinostat,givinostat,fexact,"['givinostat', 'ITF-2357']",givinostat,fexact,"['givinostat', 'itf 2357']",correct_mapping
milatuzumab-doxorubicin,DNA synthesis inhibitor; DNA topoisomerase II inhibitor,milatuzumab-doxorubicin,,,,0,['milatuzumab-doxorubicin'],,0,[],0
mesna,Unidentified pharmacological activity,mesna,,"mesna, Adherex",mesna,fexact,"['mesna, Adherex', 'mesna', 'uromitexan']","mesna, Adherex",fexact,"['mesna adherex', 'mesna', 'uromitexan']",correct_mapping
mycophenolate mofetil (tablet),Immunosuppressant; Inosine monophosphate dehydrogenase inhibitor,mycophenolate mofetil,,mycophenolate mofetil,mycophenolate mofetil,fexact,"['mycophenolate mofetil hydrochloride', 'ME-MPA', 'CellCept Cap', 'mycophenolate mofetil', 'RS-61443', 'R-99, Roche', 'R-99', 'mycofenolate mofetil', 'CellCept', 'Munoloc', 'RS-6143', 'MMF']",mycophenolate mofetil,fexact,"['mycophenolate mofetil hydrochloride', 'me mpa', 'cellcept cap', 'mycophenolate mofetil', 'rs 61443', 'r 99 roche', 'r 99', 'mycofenolate mofetil', 'cellcept', 'munoloc', 'rs 6143', 'mmf']",correct_mapping
peginterferon alfa-2b,Interferon alpha 2b agonist,peginterferon alfa-2b,,peginterferon alfa-2b,peginterferon alfa 2b,fexact,"['PEG-Intron', 'PEG-IFN alfa-2b', 'Sch-54031', 'SCH-054031', 'Pegetron', 'Sylatron', 'Cylatron', 'PEG-interferon alfa 2b,/Schering-Plough', 'ViraferonPeg', 'peginterferon alfa-2b', 'PegIntron', 'Redipen', 'PEG-Intron and Rebetol combination', 'PEG-interferon alfa 2b,/', 'PEG-interferon alfa-2b and ribavirin combination']",peginterferon alfa-2b,fexact,"['peg intron', 'peg ifn alfa 2b', 'sch 54031', 'sch 054031', 'pegetron', 'sylatron', 'cylatron', 'peg interferon alfa 2b schering plough', 'viraferonpeg', 'peginterferon alfa 2b', 'pegintron', 'redipen', 'peg intron and rebetol combination', 'peg interferon alfa 2b', 'peg interferon alfa 2b and ribavirin combination']",correct_mapping
samalizumab,Immunostimulant; CD200 antagonist,samalizumab,,samalizumab,samalizumab,fexact,"['ALXN-6000', 'CD200 checkpoint inhibitor (cancer)', 'anti-CD200 mAb (CLL, multiple myeloma)', 'samalizumab']",samalizumab,fexact,"['alxn 6000', 'cd200 checkpoint inhibitor cancer', 'anti cd200 mab cll multiple myeloma', 'samalizumab']",correct_mapping
riviciclib,Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cell cycle inhibitor,riviciclib,,P-276-00,riviciclib,fexact,"['CDK4 inhibitor (iv, cancer), Piramal', 'P-276-00', 'P-664-02', 'riviciclib', 'CDK4 inhibitor (cancer), Nicholas Piramal', 'P-276', 'CDK4 inhibitor (iv, cancer), NPIL Research & Development', 'CDK4 inhibitor (iv, cancer)']",P-276-00,fexact,"['cdk4 inhibitor iv cancer piramal', 'p 276 00', 'p 664 02', 'riviciclib', 'cdk4 inhibitor cancer nicholas piramal', 'p 276', 'cdk4 inhibitor iv cancer npil research development', 'cdk4 inhibitor iv cancer']",correct_mapping
mylovenge,Immunostimulant,mylovenge,,APC-8020,mylovenge,fexact,"['dendritic cell therapy (myeloma/amyloidosis/lymphoma)', 'APC-80200', 'Mylovenge', 'APC-8020']",APC-8020,fexact,"['dendritic cell therapy myeloma amyloidosis lymphoma', 'apc 80200', 'mylovenge', 'apc 8020']",correct_mapping
"aldesleukin, Novartis-2",Interleukin 2 agonist; Immunostimulant; T cell stimulant,aldesleukin,Novartis-2,aldesleukin,aldesleukin,fexact,"['aldesleukin', 'Proleukin', 'recombinant IL-2', 'rhIL-2', 'Macrolin IL-2', 'NSC-373364']",aldesleukin,fexact,"['aldesleukin', 'proleukin', 'recombinant il 2', 'rhil 2', 'macrolin il 2', 'nsc 373364']",correct_mapping
"interferon gamma, unspecified",Immunostimulant; Interferon receptor agonist,interferon gamma,unspecified,Actimmune,interferon gamma,fexact,"['Actimmune', 'interferon gamma-1b,/', 'Immukine', 'Imukin', 'interferon gamma, Connective Therapeutics', 'interferon gamma-1b, Horizon/Clinigen', 'Immukin', 'interferon gamma, Connetics', 'DK-1001, THERAMetrics', 'DK-1001, mondoBIOTECH', 'DasKloster 1001-01', 'interferon (gamma1b)', 'interferon (gamma1b), Daiichi', 'interferon (gamma1b), Toray', 'interferon gamma-1b, Horizon/', 'interferon (gamma1b), Genentech', 'interferon gamma-1b', 'interferon gamma', 'Imuforgamma', 'Imukine']",Actimmune,fexact,"['actimmune', 'interferon gamma 1b', 'immukine', 'imukin', 'interferon gamma connective therapeutics', 'interferon gamma 1b horizon clinigen', 'immukin', 'interferon gamma connetics', 'dk 1001 therametrics', 'dk 1001 mondobiotech', 'daskloster 1001 01', 'interferon gamma1b', 'interferon gamma1b daiichi', 'interferon gamma1b toray', 'interferon gamma 1b horizon', 'interferon gamma1b genentech', 'interferon gamma 1b', 'interferon gamma', 'imuforgamma', 'imukine']",correct_mapping
GCS-100 (IV),Vascular endothelial growth factor (VEGF)receptor antagonist; Caspase 9 stimulant; Protein kinase B inhibitor; Angiogenesis inhibitor; Apoptosis stimulant; Galectin-3 antagonist,GCS-100,,,,0,"['GCS-100 (intravenous, cancer), Solana Therapeutics', 'GCS-100 (iv)', 'GCS-100 (intravenous, cancer), GlycoGenesys', 'NCCG, IGG', 'GCS-100 (intravenous, cancer)', 'GCS-100 (intravenous, cancer), Prospect Therapeutics', 'GCS-100LE', 'GCS-100', 'GCS-100 (oral, cancer)', 'NCCG, SafeScience', 'LJPC-101', 'GCS-100 (sc, end stage renal disease/renal transplantation/cancer)', 'GCS-100 (oral)', 'GBC-590', 'GCS-100 (iv, end stage renal disease/renal transplantation/cancer)', 'GCS-100 (sc, end stage renal disease/renal transplantation)', 'GCS-100 (iv, end stage renal disease/renal transplantation/cancer), La Jolla Pharmaceutical']",,Drug_API_mapping,[],0
palonosetron (IV),5 Hydroxytryptamine 3 receptor antagonist,palonosetron,,palanosetron hydrochloride,palonosetron,fexact,"['RS-25259-197', 'RS-42358', 'Paloxi', 'palonosetron', 'RS-25259-007', 'Aloxi', 'Onicit', 'palanosetron hydrochloride']",palanosetron hydrochloride,fexact,"['rs 25259 197', 'rs 42358', 'paloxi', 'palonosetron', 'rs 25259 007', 'aloxi', 'onicit', 'palanosetron hydrochloride']",correct_mapping
ENMD-2076 (oral),Colony stimulating factor 1 receptor antagonist; Aurora kinase inhibitor; C-kit inhibitor; EphA receptor kinase inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor kinase inhibitor; Src inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor; Immuno-oncology therapy,ENMD-2076,,ENMD-2076,enmd 2076,fexact,"['ENMD-981693', 'MKC-1693', 'ENMD-2076', 'MKC-1260', 'aurora kinase inhibitors (oral, cancer)', 'aurora kinase inhibitors (cancer)', 'aurora kinase inhibitor (cancer)', 'aurora kinase inhibitor (cancer), Miikana', 'aurora kinase inhibitors (oral, cancer), EntreMed', 'aurora kinase inhibitors (cancer), Miikana']",ENMD-2076,fexact,"['enmd 981693', 'mkc 1693', 'enmd 2076', 'mkc 1260', 'aurora kinase inhibitors oral cancer', 'aurora kinase inhibitors cancer', 'aurora kinase inhibitor cancer', 'aurora kinase inhibitor cancer miikana', 'aurora kinase inhibitors oral cancer entremed', 'aurora kinase inhibitors cancer miikana']",correct_mapping
AVE1642,Insulin-like growth factor 1 antagonist,AVE1642,,VRDN-001,ave 1642,fuzzy,"['ZB-001', 'EM-164', 'anti-insulin-like growth factor-1 receptor antibody, sanofi-aventis', 'anti-insulin-like growth factor-1 receptor antibody', 'AVE-1642', 'anti-insulin-like growth factor-1 receptor antibody (iv, thyroid eye disease) Viridian Therapeutics', 'anti-insulin-like growth factor-1 receptor antibody, ImmunoGen', 'VRDN-001', 'anti-IGF-1 receptor antibody (cancer), sanofi-aventis', 'anti-IGF-1 receptor antibody (cancer), ImmunoGen', 'anti-IGF-1 receptor antibody (cancer)']",VRDN-001,fexact,"['zb 001', 'em 164', 'anti insulin like growth factor 1 receptor antibody sanofi aventis', 'anti insulin like growth factor 1 receptor antibody', 'ave 1642', 'anti insulin like growth factor 1 receptor antibody iv thyroid eye disease viridian therapeutics', 'anti insulin like growth factor 1 receptor antibody immunogen', 'vrdn 001', 'anti igf 1 receptor antibody cancer sanofi aventis', 'anti igf 1 receptor antibody cancer immunogen', 'anti igf 1 receptor antibody cancer']",incorrect_mapping
"pneumococcal vaccine, Ochsner",Immunostimulant,pneumococcal vaccine,Ochsner,,,0,['pneumococcal vaccine'],,0,[],0
Idarubicin,Radical formation stimulant; DNA topoisomerase I inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,Idarubicin,,,,0,"['idarubicin', 'idarubicin (nanoparticle, acute myelogenous leukemia)', 'idarubicin (nanoparticle, AML)', 'idarubicin NP']",,NER_API,[],0
dacetuzumab,CD40 agonist; Apoptosis stimulant; Immuno-oncology therapy; Immune checkpoint stimulant,dacetuzumab,,dacetuzumab,dacetuzumab,fexact,"['SGN-40', 'SGN-18', 'SGN-14', 'dacetuzumab', 'PRO-64553', 'huS2C6', 'SGN-12', 'anti-CD40 mAbs (iv, NHL/MM/CLL), Seattle Genetics/', 'RG-3636', 'anti-CD40 humanized monoclonal antibodies (iv, non-Hodgkin lymphoma/multiple myeloma/ chronic lymphocytic leukemia), Seattle Genetics/', 'SGN-11']",dacetuzumab,fexact,"['sgn 40', 'sgn 18', 'sgn 14', 'dacetuzumab', 'pro 64553', 'hus2c6', 'sgn 12', 'anti cd40 mabs iv nhl mm cll seattle genetics', 'rg 3636', 'anti cd40 humanized monoclonal antibodies iv non hodgkin lymphoma multiple myeloma chronic lymphocytic leukemia seattle genetics', 'sgn 11']",correct_mapping
alemtuzumab,Immunosuppressant; CD52 antagonist,alemtuzumab,,alemtuzumab,alemtuzumab,fexact,"['BAY-86-5045', 'GZ-402673', 'CAMPATH-1H', 'Lemtrada', 'LDP-03', 'MabCampath', 'CAMPATH-1', 'CAMPATH', 'anti-CD52 mAb, Millennium//', 'alemtuzumab', 'anti-CD52 mAb, Millennium//Schering', 'DE-04188', 'ZK-217699', 'MabCampath-1H', 'anti-CD52 mAb, Millennium/ILEX/Schering']",alemtuzumab,fexact,"['bay 86 5045', 'gz 402673', 'campath 1h', 'lemtrada', 'ldp 03', 'mabcampath', 'campath 1', 'campath', 'anti cd52 mab millennium', 'alemtuzumab', 'anti cd52 mab millennium schering', 'de 04188', 'zk 217699', 'mabcampath 1h', 'anti cd52 mab millennium ilex schering']",correct_mapping
XL-228,Fibroblast growth factor receptor 1 antagonist; Fibroblast growth factor receptor 2 antagonist; Fibroblast growth factor receptor 3 antagonist; Abl receptor tyrosine kinase inhibitor; Aurora kinase inhibitor; IGF-1 receptor tyrosine kinase inhibitor; Src inhibitor,XL-228,,XL-228,xl 228,fexact,"['XL-228', 'insulin-like growth factor 1 receptor kinase inhibitors', 'IGF1R kinase inhibitors (iv, cancer)']",XL-228,fexact,"['xl 228', 'insulin like growth factor 1 receptor kinase inhibitors', 'igf1r kinase inhibitors iv cancer']",correct_mapping
laromustine,DNA inhibitor; O6-alkylguanine-DNA alkyltransferase inhibitor,laromustine,,laromustine,laromustine,fexact,"['SHP, Vion', 'laromustine', 'alkylating agents, Vion', 'VN-40101M', 'sulfonyl hydrazine prodrugs, Vion', 'VNP-4090-CE', 'Cloretazine', 'alkylating agents', 'sulfonyl hydrazine prodrugs', '90CE', 'SHP', 'Onrigin', 'VNP-40101M', 'NTO-1152']",laromustine,fexact,"['shp vion', 'laromustine', 'alkylating agents vion', 'vn 40101m', 'sulfonyl hydrazine prodrugs vion', 'vnp 4090 ce', 'cloretazine', 'alkylating agents', 'sulfonyl hydrazine prodrugs', '90ce', 'shp', 'onrigin', 'vnp 40101m', 'nto 1152']",correct_mapping
abexinostat (capsule),Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,abexinostat,,abexinostat,abexinostat,fexact,"['CRA-024781', 'abexinostat', 'histone deacetylase inhibitors (anticancer), Pharmacyclics', 'HDAC inhibitors (anticancer)', 'CRA-026440', 'histone deacetylase inhibitors (anticancer)', 'S-78454', 'PCI-24781', 'HDAC inhibitors (anticancer), Pharmacyclics', 'CG-781', 'abexinostat hydrochloride']",abexinostat,fexact,"['cra 024781', 'abexinostat', 'histone deacetylase inhibitors anticancer pharmacyclics', 'hdac inhibitors anticancer', 'cra 026440', 'histone deacetylase inhibitors anticancer', 's 78454', 'pci 24781', 'hdac inhibitors anticancer pharmacyclics', 'cg 781', 'abexinostat hydrochloride']",correct_mapping
lexibulin (IV),Microtubule inhibitor; Angiogenesis inhibitor; Tubulin inhibitor,lexibulin,,"lexibulin (iv infusion, cancer)",lexibulin,fexact,"['lexibulin (iv infusion, cancer)', 'CYT-997 (iv infusion, cancer)', 'lexibulin (iv infusion, cancer), YM BioSciences', 'CYT-997', 'lexibulin', 'CYT-997 (iv infusion, cancer), YM BioSciences']","lexibulin (iv infusion, cancer)",fexact,"['lexibulin iv infusion cancer', 'cyt 997 iv infusion cancer', 'lexibulin iv infusion cancer ym biosciences', 'cyt 997', 'lexibulin', 'cyt 997 iv infusion cancer ym biosciences']",correct_mapping
OPB-31121,STAT transcription factor 3 inhibitor,OPB-31121,,OPB-31121,opb 31121,fexact,"['OPB-31121', 'STAT-3 inhibitor (oral, cancer)']",OPB-31121,fexact,"['opb 31121', 'stat 3 inhibitor oral cancer']",correct_mapping
CMV pp65 peptide,Immunostimulant; T cell stimulant,CMV pp65 peptide,,,,0,['CMV pp65 peptide'],,0,[],0
survivin peptides,Immunostimulant,survivin peptides,,,,0,['survivin peptides'],,0,[],0
undisclosed - protein conjugate pneumococcal vaccine,Immunostimulant,undisclosed - protein conjugate pneumococcal vaccine,,,,0,['undisclosed - protein conjugate pneumococcal vaccine'],,0,[],0
CMV N495 peptide vaccine,Immunostimulant,CMV N495 peptide vaccine,,,,0,['CMV N495 peptide vaccine'],,0,[],0
ibritumomab tiuxetan,DNA inhibitor; Apoptosis stimulant; Radiopharmaceutical,ibritumomab tiuxetan,,ibritumomab tiuxetan,ibritumomab tiuxetan,fexact,"['BAY86-5128', 'Zevalin', '90Y-ibritumomab tiuxetan', 'indium-111-anti-CD20', 'indium-111-anti-CD20, IDEC', 'IDEC-Y2B8', 'IDEC-In2B8', '111In-ibritumomab tiuxetan', '111In-anti-CD20', 'SHL-749', '90Y-2B8', '111In-2B8', '90Y-anti-CD20', 'yttrium-90-anti-CD20, IDEC', 'yttrium-90-anti-CD20', '90Y-anti-CD20, IDEC', '111In-anti-CD20, IDEC', 'DE-00749', 'indium-111-ibritumomab tiuxetan', 'ibritumomab tiuxetan', 'yttrium-90-ibritumomab tiuxetan']",ibritumomab tiuxetan,fexact,"['bay86 5128', 'zevalin', '90y ibritumomab tiuxetan', 'indium 111 anti cd20', 'indium 111 anti cd20 idec', 'idec y2b8', 'idec in2b8', '111in ibritumomab tiuxetan', '111in anti cd20', 'shl 749', '90y 2b8', '111in 2b8', '90y anti cd20', 'yttrium 90 anti cd20 idec', 'yttrium 90 anti cd20', '90y anti cd20 idec', '111in anti cd20 idec', 'de 00749', 'indium 111 ibritumomab tiuxetan', 'ibritumomab tiuxetan', 'yttrium 90 ibritumomab tiuxetan']",correct_mapping
natalizumab (IV),Alpha4 integrin antagonist; Alpha4beta1 integrin antagonist; Alpha4beta7 integrin antagonist; Integrin antagonist,natalizumab,,natalizumab,natalizumab,fexact,"['alpha-4/beta1-integrin mAb, Athena', 'BG-00002', 'mAN100226', 'AN-100226', 'VLA-4 mAb, Athena', 'Tysabri', 'Antegren', 'natalizumab', 'natulizumb']",natalizumab,fexact,"['alpha 4 beta1 integrin mab athena', 'bg 00002', 'man100226', 'an 100226', 'vla 4 mab athena', 'tysabri', 'antegren', 'natalizumab', 'natulizumb']",correct_mapping
recombinant human interleukin-6,Immunostimulant,recombinant human interleukin-6,,,,0,['recombinant human interleukin-6'],,0,[],0
"somatropin, Pfizer",Growth hormone receptor agonist,somatropin,Pfizer,,,0,"['somatropin', 'Caretropin', 'DWP-412', 'DWC-20153', 'recombinant somatropin (growth hormone deficiency)', 'rhGH', 'recombinant human growth hormone (growth hormone deficiency)']",,NER_API,[],0
AZD-4877,Kinesin inhibitor,AZD-4877,,AZD-4877,azd 4877,fexact,"['anticancer therapeutic (solid tumors)', 'AZD-4877']",AZD-4877,fexact,"['anticancer therapeutic solid tumors', 'azd 4877']",correct_mapping
holmium-166 DOTMP,DNA inhibitor; Radiopharmaceutical,holmium-166 DOTMP,,,,0,['holmium-166 DOTMP'],,0,[],0
GS-9219,DNA synthesis inhibitor,GS-9219,,rabacfosadine,gs 9219,fexact,"['rabacfosadine', 'PMEG prodrug (cancer)', 'GS-9219', 'VDC-1101']",rabacfosadine,fexact,"['rabacfosadine', 'pmeg prodrug cancer', 'gs 9219', 'vdc 1101']",correct_mapping
"clarithromycin, Abbott",Protein 50S ribosomal subunit inhibitor,clarithromycin,Abbott,clarithromycin,clarithromycin,fexact,"['Biaxin', 'antibiotic A-56268', 'Velcam', 'Macladin', 'Zaclar', 'acladin', 'Cyllind', 'Klacid SR', 'Klaricid XL', 'Kofron', 'Claricid', 'Klacid LA', 'clarithromycin', 'TE-031', 'Clarith', 'A-56268', 'Biclar', 'antibiotic TE-31', 'Klacid', 'Klaricid']",clarithromycin,fexact,"['biaxin', 'antibiotic a 56268', 'velcam', 'macladin', 'zaclar', 'acladin', 'cyllind', 'klacid sr', 'klaricid xl', 'kofron', 'claricid', 'klacid la', 'clarithromycin', 'te 031', 'clarith', 'a 56268', 'biclar', 'antibiotic te 31', 'klacid', 'klaricid']",correct_mapping
"arsenic trioxide, unspecified",Cysteine protease stimulant; Apoptosis stimulant,arsenic trioxide,unspecified,"arsenic trioxide (oral, acute promyelocytic leukemia)",arsenic trioxide,fexact,"['ORH-2014', 'arsenic trioxide', 'SY-2101, Syros Pharmaceuticals', 'sy-2101', 'arsenic trioxide (oral, acute promyelocytic leukemia)']","arsenic trioxide (oral, acute promyelocytic leukemia)",fexact,"['orh 2014', 'arsenic trioxide', 'sy 2101 syros pharmaceuticals', 'sy 2101', 'arsenic trioxide oral acute promyelocytic leukemia']",correct_mapping
darinaparsin (IV),Apoptosis stimulant; NADPH oxidase stimulant,darinaparsin,,"darinaparsin (iv, cancer)",darinaparsin,fexact,"['organic arsenic derivatives (cancer)', 'ZIO-101 (iv, cancer)', 'darinaparsin', 'arsenic derivative, MD Anderson', 'darinaparsin (iv, cancer)', 'organic arsenicals (cancer), ZIOPHARM', 'Z-101, ZIOPHARM', 'arsenic derivative', 'organic arsenicals (cancer)', 'SP-02L', 'Z-101', 'Zinapar', 'ZIO-101 (iv, cancer), ZIOPHARM', 'organic arsenic derivatives (cancer), ZIOPHARM', 'arsenic derivative, MD Anderson Cancer Center', 'S-dimethylarsino-glutathione', 'darinaparsin (iv, cancer), ZIOPHARM', 'ZIO-101', 'SGLU1', 'darinaparsin (iv, cancer), Solasia Pharma', 'MER-1']","darinaparsin (iv, cancer)",fexact,"['organic arsenic derivatives cancer', 'zio 101 iv cancer', 'darinaparsin', 'arsenic derivative md anderson', 'darinaparsin iv cancer', 'organic arsenicals cancer ziopharm', 'z 101 ziopharm', 'arsenic derivative', 'organic arsenicals cancer', 'sp 02l', 'z 101', 'zinapar', 'zio 101 iv cancer ziopharm', 'organic arsenic derivatives cancer ziopharm', 'arsenic derivative md anderson cancer center', 's dimethylarsino glutathione', 'darinaparsin iv cancer ziopharm', 'zio 101', 'sglu1', 'darinaparsin iv cancer solasia pharma', 'mer 1']",correct_mapping
milatuzumab (IV),CD74 antagonist; Immuno-oncology therapy,milatuzumab,,milatuzumab,milatuzumab,fexact,"['hLL1', 'MelanomaCide', 'milatuzumab', 'IMMU-115', 'MyelomaCide Y-90', 'LL1', 'hCD74 antibody (mutilple myeloma/ melanoma)', 'MyelomaCide']",milatuzumab,fexact,"['hll1', 'melanomacide', 'milatuzumab', 'immu 115', 'myelomacide y 90', 'll1', 'hcd74 antibody mutilple myeloma melanoma', 'myelomacide']",correct_mapping
plasma exchange,Immunosuppressant; Immunostimulant,plasma exchange,,,,0,['plasma exchange'],,0,[],0
5-azacitidine,DNA synthesis inhibitor; DNA methylase inhibitor; RNA synthesis inhibitor,5-azacitidine,,"azacytidine (inhaled aerosol, lung cancer)",5 azacitidine,fexact,"['azacitidine', 'azacytidine (inhaled aerosol, lung cancer)', '5-azacytidine (inhaled aerosol, lung cancer)', '5-azacitidine']","azacytidine (inhaled aerosol, lung cancer)",fexact,"['azacitidine', 'azacytidine inhaled aerosol lung cancer', '5 azacytidine inhaled aerosol lung cancer', '5 azacitidine']",correct_mapping
"noscapine, Cougar",Bradykinin B2 receptor antagonist; Microtubule inhibitor; Tubulin inhibitor; Apoptosis stimulant,noscapine,Cougar,noscapine (cancer),noscapine,fexact,"['noscapine (cancer)', 'CB-3304', 'noscapine', 'noscapine (cancer), Emory University']",noscapine (cancer),fexact,"['noscapine cancer', 'cb 3304', 'noscapine', 'noscapine cancer emory university']",correct_mapping
CST-101,Not applicable,CST-101,,CST-101,cst 101,fexact,"['Neukoplast', 'CST-101', 'aNK cells (cancer), NantKwest', 'ZRx-101', 'aNK cells (cancer)', 'activated natural killer cells (cancer)', 'activated natural killer cells (cancer), NantKwest', 'NK-92 cell-based therapy (cancer), ZelleRx']",CST-101,fexact,"['neukoplast', 'cst 101', 'ank cells cancer nantkwest', 'zrx 101', 'ank cells cancer', 'activated natural killer cells cancer', 'activated natural killer cells cancer nantkwest', 'nk 92 cell based therapy cancer zellerx']",correct_mapping
"epoetin beta (once weekly), Roche",Erythropoietin receptor agonist,epoetin beta,Roche,epoetin beta,epoetin beta,fexact,"['Epogin', 'recombinant human erythropoietin, Chugai', 'erythropoietin, Genetics Institute//', 'Marogen', 'rHuEPO, Genetics Inst//', 'erythropoietin, Genetics Institute//Roche', 'epoetin beta, Roche', 'NeoRecormon', 'recombinant human erythropoietin', 'Recormon', 'epoetin beta, Genetics Inst//', 'EPOCH', 'erythropoietin, Genetics Institute/Chugai/Roche', 'RO-2053859', 'rHuEPO, Genetics Inst/Chugai/', 'epoetin beta, Genetics Inst/Chugai/', 'epoetin beta', 'Epogin Subcutaneous Injection Syringe 24000']",epoetin beta,fexact,"['epogin', 'recombinant human erythropoietin chugai', 'erythropoietin genetics institute', 'marogen', 'rhuepo genetics inst', 'erythropoietin genetics institute roche', 'epoetin beta roche', 'neorecormon', 'recombinant human erythropoietin', 'recormon', 'epoetin beta genetics inst', 'epoch', 'erythropoietin genetics institute chugai roche', 'ro 2053859', 'rhuepo genetics inst chugai', 'epoetin beta genetics inst chugai', 'epoetin beta', 'epogin subcutaneous injection syringe 24000']",correct_mapping
choline tetrathiomolybdate,Superoxide dismutase-1 inhibitor; Angiogenesis inhibitor,choline tetrathiomolybdate,,tiomolibdate choline,bis choline tetrathiomolybdate,fuzzy,"['tiomolibdate choline', 'superoxide dismutase 1 inhibitor', 'bis-choline tetrathiomolybdate', 'ATN-224', 'ALXN-1840', 'Decuprate', 'WTX-101', 'angiogenesis inhibitor, Attenuon', 'superoxide dismutase 1 inhibitor, Attenuon', 'tiomolibdate choline (oral, wilson disease/amyotrophic lateral sclerosis)', 'angiogenesis inhibitor']",tiomolibdate choline,fexact,"['tiomolibdate choline', 'superoxide dismutase 1 inhibitor', 'bis choline tetrathiomolybdate', 'atn 224', 'alxn 1840', 'decuprate', 'wtx 101', 'angiogenesis inhibitor attenuon', 'superoxide dismutase 1 inhibitor attenuon', 'tiomolibdate choline oral wilson disease amyotrophic lateral sclerosis', 'angiogenesis inhibitor']",incorrect_mapping
"rhPTH (1-34), unspecified",Parathyroid hormone receptor 1 agonist,rhPTH,unspecified,,,0,"['PTH', 'SHP-634', 'rhPTH', 'Natpara', 'parathyroid hormone, NPS/Shire', 'PTH(1-84), NPS', 'Preotact', 'PREOS', 'rhPTH (1-84)', 'parathyroid hormone,/', 'NPSP-558', 'recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), NPS/Shire', 'recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis),/', 'ALX-1-11', 'recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis),/Shire', 'PTH(1-84)', 'rhPTH, NPS', 'recombinant human parathyroid hormone', 'parathyroid hormone,/Shire', 'parathyroid hormone (sustained release, osteoporosis)', 'Natpar', 'parathyroid hormone', 'TAK-834']",,Drug_API_mapping,[],0
"interferon, Biogen (alpha2b)",Immunosuppressant; Interferon alpha 2b agonist; Protein synthesis inhibitor; Interferon receptor agonist; RNA synthesis inhibitor,interferon,Biogen,,,0,['interferon'],,0,[],0
"COVID-19 vaccine, undisclosed",Immunostimulant,COVID-19 vaccine,undisclosed,AZD-1222,covid 19 vaccine,fexact,"['recombinant viral vector ChAdOx vaccine (2019-nCoV infection), Jenner Institute', 'SII-ChAdOx1 nCoV-19', 'recombinant viral vector ChAdOx vaccine (COVID-19, intramuscular)', 'recombinant viral vector ChAdOx vaccine (COVID-19, intramuscular), Jenner Institute', 'ChAdOX1 SARS2', 'AZD-1222', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19),//', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19), Jenner Institute/UCB/', 'ChAdOx1-S (recombinant)', 'AZN-1222', 'sars-cov-2 vaccine (covid-19), at the university of oxford', 'recombinant viral vector ChAdOx vaccine (2019-nCoV infection)', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19),/UCB/', 'C19VAZ', 'ChAdOx1 nCoV-19', 'SARS-CoV-2 vaccine (COVID-19), The Jenner Institute at the University of Oxford', 'Vaxzevria', 'COVID-19 Vaccine', 'SII-Covishield']",AZD-1222,fexact,"['recombinant viral vector chadox vaccine 2019 ncov infection jenner institute', 'sii chadox1 ncov 19', 'recombinant viral vector chadox vaccine covid 19 intramuscular', 'recombinant viral vector chadox vaccine covid 19 intramuscular jenner institute', 'chadox1 sars2', 'azd 1222', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19 jenner institute ucb', 'chadox1 s recombinant', 'azn 1222', 'sars cov 2 vaccine covid 19 at the university of oxford', 'recombinant viral vector chadox vaccine 2019 ncov infection', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19 ucb', 'c19vaz', 'chadox1 ncov 19', 'sars cov 2 vaccine covid 19 the jenner institute at the university of oxford', 'vaxzevria', 'covid 19 vaccine', 'sii covishield']",correct_mapping
SSCAR-010,T cell stimulant; Immuno-oncology therapy,SSCAR-010,,,,0,['SSCAR-010'],,0,[],0
SSCAR-030,T cell stimulant; Immuno-oncology therapy,SSCAR-030,,,,0,['SSCAR-030'],,0,[],0
belatacept,CD86 antagonist; Immunosuppressant; T cell inhibitor; CD28 antagonist; CD80 antagonist,belatacept,,belatacept,belatacept,fexact,"['belatacept', 'L104EA29YIg', 'Nulojix', 'LEA-29Y', 'BMS-224818', 'belatacept (iv, lung transplant rejection)', 'lymphocyte costimulation/CD28 inhibitor (iv, kidney/heart/lung transplant rejection)', 'LEA-029']",belatacept,fexact,"['belatacept', 'l104ea29yig', 'nulojix', 'lea 29y', 'bms 224818', 'belatacept iv lung transplant rejection', 'lymphocyte costimulation cd28 inhibitor iv kidney heart lung transplant rejection', 'lea 029']",correct_mapping
ABBV-623,Unidentified pharmacological activity,ABBV-623,,ABBV-623,abbv 623,fexact,['ABBV-623'],ABBV-623,fexact,['abbv 623'],correct_mapping
ABBV-992,Unidentified pharmacological activity,ABBV-992,,ABBV-992,abbv 992,fexact,['ABBV-992'],ABBV-992,fexact,['abbv 992'],correct_mapping
tozinameran,Immunostimulant,tozinameran,,tozinameran,tozinameran,fexact,"['lead PF-07302048 vaccine (COVID-19), Pfizer/', 'PF-07302048 program', 'lead PF-07302048 vaccine (COVID-19),/', 'uridine containing mRNA vaccine (COVID-19, lipid nanoparticle, intramuscular),/', 'uridine containing mRNA vaccine (COVID-19, lipid nanoparticle, intramuscular),/Pfizer', 'P2-mutated full spike protein modRNA prime/boost vaccine (COVID-19),/', 'lead BNT-162 vaccine (COVID-19), Pfizer/', 'BNT-162b2', 'P2-mutated full spike protein modRNA prime/boost vaccine (COVID-19),/Pfizer', 'lead BNT-162 vaccine (COVID-19),/', 'BNT-162 program', 'Comirnaty', 'tozinameran']",tozinameran,fexact,"['lead pf 07302048 vaccine covid 19 pfizer', 'pf 07302048 program', 'lead pf 07302048 vaccine covid 19', 'uridine containing mrna vaccine covid 19 lipid nanoparticle intramuscular', 'uridine containing mrna vaccine covid 19 lipid nanoparticle intramuscular pfizer', 'p2 mutated full spike protein modrna prime boost vaccine covid 19', 'lead bnt 162 vaccine covid 19 pfizer', 'bnt 162b2', 'p2 mutated full spike protein modrna prime boost vaccine covid 19 pfizer', 'lead bnt 162 vaccine covid 19', 'bnt 162 program', 'comirnaty', 'tozinameran']",correct_mapping
SCTA-01,Surface glycoprotein (SARS-CoV-2) antagonist,SCTA-01,,SCTA-01,scta 01,fexact,"['SCTA-01', 'anti-SARS-CoV-2 spike protien mAb (COVID-19)', 'neutralizing monoclonal antibody (COVID-19)', 'anti-SARS-CoV-2 spike protien mAb (iv, COVID-19)']",SCTA-01,fexact,"['scta 01', 'anti sars cov 2 spike protien mab covid 19', 'neutralizing monoclonal antibody covid 19', 'anti sars cov 2 spike protien mab iv covid 19']",correct_mapping
talimogene laherparepvec,Granulocyte macrophage colony stimulating factor agonist; Immuno-oncology therapy,talimogene laherparepvec,,talimogene laherparepvec,talimogene laherparepvec,fexact,"['T-VEC', 'OncoVEX therapies (cancer)', 'talminogene laherparepvec', 'Imlygic', 'talimogene laherparepvec', 'OncoVEX-TNF-alpha', 'ICP34.5-null herpes simplex virus-1', 'oncolytic HSV1 therapy expressing GM-CSF (OncoVEX platform, melanoma)', 'OncoVEX-TNF-alpha+GM-CSF', 'OncoVEX', 'ICP34.5-null herpes simplex virus-1, BioVex', 'JS1 34.5-hGMCSF 47-pA-', 'OncoVEX GM-CSF vaccine']",talimogene laherparepvec,fexact,"['t vec', 'oncovex therapies cancer', 'talminogene laherparepvec', 'imlygic', 'talimogene laherparepvec', 'oncovex tnf alpha', 'icp34 5 null herpes simplex virus 1', 'oncolytic hsv1 therapy expressing gm csf oncovex platform melanoma', 'oncovex tnf alpha gm csf', 'oncovex', 'icp34 5 null herpes simplex virus 1 biovex', 'js1 34 5 hgmcsf 47 pa', 'oncovex gm csf vaccine']",correct_mapping
HLX-70,Surface glycoprotein (SARS-CoV-2) antagonist,HLX-70,,HLX-70,hlx 70,fexact,"['SARS-CoV-2 anti-spike glycoprotein fully human monoclonal antibody (COVID-19), Shanghai Henlius Biotech/Shanghai ZJ Bio-Tech/', 'fully human anti-spike protein monoclonal antibody (COVID-19),/Shanghai ZJ Bio-Tech/', 'SARS-CoV-2 anti-spike glycoprotein fully human monoclonal antibody (COVID-19),/Shanghai ZJ Bio-Tech/', 'fully human anti-spike protein monoclonal antibody (covid-19)', 'HLX-70', 'fully human anti-spike protein monoclonal antibody (COVID-19), Shanghai Henlius/Shanghai ZJ Bio-Tech/', 'sars-cov-2 anti-spike glycoprotein fully human monoclonal antibody (covid-19)']",HLX-70,fexact,"['sars cov 2 anti spike glycoprotein fully human monoclonal antibody covid 19 shanghai henlius biotech shanghai zj bio tech', 'fully human anti spike protein monoclonal antibody covid 19 shanghai zj bio tech', 'sars cov 2 anti spike glycoprotein fully human monoclonal antibody covid 19 shanghai zj bio tech', 'fully human anti spike protein monoclonal antibody covid 19', 'hlx 70', 'fully human anti spike protein monoclonal antibody covid 19 shanghai henlius shanghai zj bio tech', 'sars cov 2 anti spike glycoprotein fully human monoclonal antibody covid 19']",correct_mapping
CAEL-101,Unidentified pharmacological activity,CAEL-101,,CAEL-101,cael 101,fexact,"['Amyloid protein deposition inhibitor (iv, ALAmyloidosis) Alexion/Caelum Biosciences', 'Amyloid protein deposition inhibitor (iv, ALAmyloidosis) Alexion/', '[124I]-CAEL-101', '124I-labeled 11-1F4', 'CAEL-101', '124I-labeled 11-1F4, Caelum', '11-1F4', '11-14F']",CAEL-101,fexact,"['amyloid protein deposition inhibitor iv alamyloidosis alexion caelum biosciences', 'amyloid protein deposition inhibitor iv alamyloidosis alexion', '124i cael 101', '124i labeled 11 1f4', 'cael 101', '124i labeled 11 1f4 caelum', '11 1f4', '11 14f']",correct_mapping
"COVID-19 convalescent plasma, unspecified",Immunostimulant,COVID-19 convalescent plasma,unspecified,,,0,['COVID-19 convalescent plasma'],,0,[],0
tolinapant,IAP antagonist,tolinapant,,tolinapant,tolinapant,fexact,"['IAP inhibitors (cancer)', 'tolinapant', 'ASTX-660', 'IAP inhibitors (capsule, oral, cancer/acute myeloid leukemia)', 'AT-IAP']",tolinapant,fexact,"['iap inhibitors cancer', 'tolinapant', 'astx 660', 'iap inhibitors capsule oral cancer acute myeloid leukemia', 'at iap']",correct_mapping
DTRMWXHS-12,Bruton tyrosine kinase inhibitor,DTRMWXHS-12,,DTRMWXHS-12,dtrmwxhs 12,fexact,"['DTRM-12', 'DTRMWXHS-12']",DTRMWXHS-12,fexact,"['dtrm 12', 'dtrmwxhs 12']",correct_mapping
loratadine,Histamine H1 receptor antagonist,loratadine,,loratadine,loratadine,fexact,"['norata', 'Sch-434', 'Fristamin', 'Claritin EZ', 'Claritin-D 24', 'BAY-762211', 'Claritin', 'Clarityn', 'Claritine', 'Clarityne', 'Claritin-D', 'Claritin RediTabs', 'Clarinase', 'Loratidine', 'loratadine', 'Sch-29851', 'Lisino']",loratadine,fexact,"['norata', 'sch 434', 'fristamin', 'claritin ez', 'claritin d 24', 'bay 762211', 'claritin', 'clarityn', 'claritine', 'clarityne', 'claritin d', 'claritin reditabs', 'clarinase', 'loratidine', 'loratadine', 'sch 29851', 'lisino']",correct_mapping
gemtuzumab ozogamicin,DNA inhibitor,gemtuzumab ozogamicin,,gemtuzumab ozogamicin,gemtuzumab ozogamicin,fexact,"['gemtuzumab ozogamicin', 'CMA-676', 'P67.6-MAb conjugate, Wyeth/Celltech', 'calicheamicin MAb conjugate,/', 'WAY-CMA-676', 'Mylotarg', 'CDP-771', 'P67.6-MAb conjugate,/', 'anti-CD33 calicheamicin drug conjugate', 'P67.6-MAb conjugate, Wyeth/', 'calicheamicin MAb conjugate, Wyeth/Celltech', 'calicheamicin MAb conjugate, Wyeth/']",gemtuzumab ozogamicin,fexact,"['gemtuzumab ozogamicin', 'cma 676', 'p67 6 mab conjugate wyeth celltech', 'calicheamicin mab conjugate', 'way cma 676', 'mylotarg', 'cdp 771', 'p67 6 mab conjugate', 'anti cd33 calicheamicin drug conjugate', 'p67 6 mab conjugate wyeth', 'calicheamicin mab conjugate wyeth celltech', 'calicheamicin mab conjugate wyeth']",correct_mapping
"trivalent influenza vaccine, undisclosed",Immunostimulant,trivalent influenza vaccine,undisclosed,,,0,['trivalent influenza vaccine'],,0,[],0
BMS-986207,TIGIT receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,BMS-986207,,ONO-4686,bms 986207,fexact,"['TIGIT checkpoint inhibitor (solid tumor),/Ono', 'TIGIT checkpoint inhibitor (solid tumor/multiple myeloma),/', 'TIGIT checkpoint inhibitor (solid tumor),/', 'TIGIT checkpoint inhibitor (solid tumor/multiple myeloma),/Ono', 'ONO-4686', 'BMS-986207']",ONO-4686,fexact,"['tigit checkpoint inhibitor solid tumor ono', 'tigit checkpoint inhibitor solid tumor multiple myeloma', 'tigit checkpoint inhibitor solid tumor', 'tigit checkpoint inhibitor solid tumor multiple myeloma ono', 'ono 4686', 'bms 986207']",correct_mapping
BR-101801,DNA-dependent protein kinase inhibitor; PI3 kinase delta inhibitor,BR-101801,,BR-101801,br 101801,fexact,"['dual target inhibitor of DNA-PK and P13K delta (DLBCL), Boryung Pharmaceutical', 'BR-101801']",BR-101801,fexact,"['dual target inhibitor of dna pk and p13k delta dlbcl boryung pharmaceutical', 'br 101801']",correct_mapping
"CD22 CAR T cell therapy, PersonGen Biomedicine",T cell stimulant; Immuno-oncology therapy,CD22 CAR T cell therapy,PersonGen Biomedicine,anti-CD22 CAR T-cell therapy,anti cd22 car t cell therapy,fuzzy,['anti-CD22 CAR T-cell therapy'],anti-CD22 CAR T-cell therapy,fexact,['anti cd22 car t cell therapy'],incorrect_mapping
blinatumomab-expanded T cells (BET),T cell stimulant,blinatumomab-expanded T cells,,,,0,['blinatumomab-expanded T cells'],,0,[],0
"varicella zoster vaccine (im), GSK",Immunostimulant,varicella zoster vaccine,GSK,,,0,"['varicella zoster vaccine, SK Bioscience/', 'Sky Varicella', 'varicella zoster vaccine, SK Chemicals', 'varicella zoster vaccine', 'NBP-608', 'varicella zoster vaccine, SK Bioscience', 'SKYZoster', 'SK-NBP608']",,Drug_API_mapping,[],0
COM-902,TIGIT receptor antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,COM-902,,COM-902,com 902,fexact,"['anti-CGEN-15137 antibody (cancer)', 'anti-TIGIT antibody (cancer)', 'COM-902', 'TIGIT checkpoint inhibitor (cancer)']",COM-902,fexact,"['anti cgen 15137 antibody cancer', 'anti tigit antibody cancer', 'com 902', 'tigit checkpoint inhibitor cancer']",correct_mapping
CD38 CAR-T cell therapy,CD38 antagonist; Immuno-oncology therapy,CD38 CAR-T cell therapy,,,,0,['CD38 CAR-T cell therapy'],,0,[],0
tenalisib,PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor,tenalisib,,tenalisib,tenalisib,fexact,"['tenalisib', 'PI3K delta/gamma dual inhibitor (oral, cancer/inflammation)', 'PI3K delta/gamma dual inhibitor (oral, cancer/inflammation), Rhizen', 'RP-6530', 'PI3K delta/gamma dual inhibitor (oral, cancer/inflammation), Rhizen/Icozen', 'PI3K delta/gamma dual inhibitor (oral, cancer/inflammation),/Icozen']",tenalisib,fexact,"['tenalisib', 'pi3k delta gamma dual inhibitor oral cancer inflammation', 'pi3k delta gamma dual inhibitor oral cancer inflammation rhizen', 'rp 6530', 'pi3k delta gamma dual inhibitor oral cancer inflammation rhizen icozen', 'pi3k delta gamma dual inhibitor oral cancer inflammation icozen']",correct_mapping
rivaroxaban,Direct Factor Xa inhibitor; Serine protease inhibitor,rivaroxaban,,rivaroxaban,rivaroxaban,fexact,"['rivaroxaban', 'JNJ-39039039', 'Xarelto', 'Factor Xa inhibitor (thrombosis),/ Ortho-McNeil', 'Xarelto OD', 'BAY-59-7939']",rivaroxaban,fexact,"['rivaroxaban', 'jnj 39039039', 'xarelto', 'factor xa inhibitor thrombosis ortho mcneil', 'xarelto od', 'bay 59 7939']",correct_mapping
methotrexate (IV),Immunosuppressant; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Disease modifying antirheumatic drug,methotrexate,,,,0,"['methotrexate', 'repurposed methotrexate (blood cancer)']",,NER_API,[],0
TG-1701,Bruton tyrosine kinase inhibitor,TG-1701,,edralbrutinib,tg 1701,fexact,"['EBI-1459', 'edralbrutinib', 'SHR-1459', 'TG-1701']",edralbrutinib,fexact,"['ebi 1459', 'edralbrutinib', 'shr 1459', 'tg 1701']",correct_mapping
CMV-MVA triplex vaccine,Immunostimulant,CMV-MVA triplex vaccine,,CMV-MVA Triplex Vaccine,cmv mva triplex vaccine,fexact,"['CMV-MVA Triplex Vaccine', 'cmv vaccine (mva poxvirus vector)', 'CMV-MVA']",CMV-MVA Triplex Vaccine,fexact,"['cmv mva triplex vaccine', 'cmv vaccine mva poxvirus vector', 'cmv mva']",correct_mapping
"immunoglobulin 16.5%, Octapharma",Immunostimulant,immunoglobulin 16.5%,Octapharma,,,0,['immunoglobulin 16.5%'],,0,[],0
MB-106,T cell stimulant; CD20 antagonist; Immuno-oncology therapy,MB-106,,MB-106,mb 106,fexact,"['cd20-specific scfvfc:cd28:cd137:zeda chimeric immunoreceptor t-cell therapy (non-hodgkin lymphoma)', 'CD20-specific scFvFc:CD28:CD137:zeda chimeric immunoreceptor T-cell therapy (non-Hodgkin lymphoma),/Mustang', 'MB-106', 'anti-CD20 T-cell therapy (NHL),/Mustang', 'anti-CD20 T-cell therapy (NHL)', 'anti-cd20 car t-cell therapy (non-hodgkin lymphoma)', 'anti-CD20 CAR T-cell therapy (non-Hodgkin lymphoma),/', 'anti-CD20 CAR T-cell therapy (non-Hodgkin lymphoma),/Mustang', 'anti-CD20 T-cell therapy (NHL),/', 'CD20-specific scFvFc:CD28:CD137:zeda chimeric immunoreceptor T-cell therapy (non-Hodgkin lymphoma),/']",MB-106,fexact,"['cd20 specific scfvfc cd28 cd137 zeda chimeric immunoreceptor t cell therapy non hodgkin lymphoma', 'cd20 specific scfvfc cd28 cd137 zeda chimeric immunoreceptor t cell therapy non hodgkin lymphoma mustang', 'mb 106', 'anti cd20 t cell therapy nhl mustang', 'anti cd20 t cell therapy nhl', 'anti cd20 car t cell therapy non hodgkin lymphoma', 'anti cd20 car t cell therapy non hodgkin lymphoma', 'anti cd20 car t cell therapy non hodgkin lymphoma mustang', 'anti cd20 t cell therapy nhl', 'cd20 specific scfvfc cd28 cd137 zeda chimeric immunoreceptor t cell therapy non hodgkin lymphoma']",correct_mapping
PZ01,T cell stimulant; Immuno-oncology therapy,PZ01,,,,0,['PZ01'],,0,[],0
UCART019,Immuno-oncology therapy; Genome editing,UCART019,,,,0,['UCART019'],,0,[],0
pirtobrutinib,Bruton tyrosine kinase inhibitor,pirtobrutinib,,pirtobrutinib,pirtobrutinib,fexact,"['BTK inhibitor (oral, CLL/NHL),/Eli Lilly/', 'LY-3527727', 'REDX-08608', 'RXC-005', 'pirtobrutinib', 'BTK inhibitor (oral, CLL/NHL),/Eli Lilly/RedX Pharma', 'LOXO-305']",pirtobrutinib,fexact,"['btk inhibitor oral cll nhl eli lilly', 'ly 3527727', 'redx 08608', 'rxc 005', 'pirtobrutinib', 'btk inhibitor oral cll nhl eli lilly redx pharma', 'loxo 305']",correct_mapping
CD20-CAR-T cells,CD20 antagonist; Immuno-oncology therapy,CD20-CAR-T cells,,,,0,['CD20-CAR-T cells'],,0,[],0
"anti-MiHA T cells, SpecificiT Pharma",T cell stimulant; Immuno-oncology therapy,anti-MiHA T cells,SpecificiT Pharma,,,0,['anti-MiHA T cells'],,0,[],0
"CAR-T CD19, Cellular Biomedicine Group",T cell stimulant; Immuno-oncology therapy,CAR-T CD19,Cellular Biomedicine Group,,,0,['CAR-T CD19'],,0,[],0
olanzapine,Alpha 1 adrenoreceptor antagonist; Muscarinic M4 receptor antagonist; Dopamine D1 receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D3 receptor antagonist; Dopamine D4 receptor antagonist; 5 Hydroxytryptamine 2A receptor antagonist; 5 Hydroxytryptamine 2C receptor antagonist; 5 Hydroxytryptamine 3 receptor antagonist; 5 Hydroxytryptamine 6 receptor antagonist; Histamine H1 receptor antagonist,olanzapine,,olanzapine,olanzapine,fexact,"['Olansek', 'Zyprexa', 'Lanzac', 'Zyprexa IM', 'Zyprexa IntraMuscular', 'olanzapine', 'Zyprexa Zydis', 'olanzapine pamoate', 'Zyprexa Velotab', 'ZYPEXA', 'LY-170053', 'Zyprex']",olanzapine,fexact,"['olansek', 'zyprexa', 'lanzac', 'zyprexa im', 'zyprexa intramuscular', 'olanzapine', 'zyprexa zydis', 'olanzapine pamoate', 'zyprexa velotab', 'zypexa', 'ly 170053', 'zyprex']",correct_mapping
"erythropoietin, unspecified",Erythropoietin receptor agonist,erythropoietin,unspecified,epoetin alfa (Epogen),erythropoietin,fexact,"['epoetin alfa', 'Globuren', 'KRN-5702E', 'EPO', 'erythropoietin', 'Erypo', 'Epoade', 'epoetin alfa (Epogen)', 'Epogen', 'Espo']",epoetin alfa (Epogen),fexact,"['epoetin alfa', 'globuren', 'krn 5702e', 'epo', 'erythropoietin', 'erypo', 'epoade', 'epoetin alfa epogen', 'epogen', 'espo']",correct_mapping
HMPL-523,Syk tyrosine kinase inhibitor,HMPL-523,,HMPL-523,hmpl 523,fexact,"['HM-0523', 'HM-029', 'HMPL-281', 'HMPL-523']",HMPL-523,fexact,"['hm 0523', 'hm 029', 'hmpl 281', 'hmpl 523']",correct_mapping
CD19 allogeneic chimeric antigen receptor T cells,CD19 antagonist; Immuno-oncology therapy,CD19 allogeneic chimeric antigen receptor T cells,,,,0,['CD19 allogeneic chimeric antigen receptor T cells'],,0,[],0
Flysyn,Flt-3 antagonist,Flysyn,,Flysyn,flysyn,fexact,"['Flysyn', 'chimeric Fc-optimized anti-FLT3 IgG1 antibody (acute myeloid leukemia)']",Flysyn,fexact,"['flysyn', 'chimeric fc optimized anti flt3 igg1 antibody acute myeloid leukemia']",correct_mapping
ibandronic acid,Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor,ibandronic acid,,ibandronic acid (injectable),ibandronic acid,fexact,"['R-484 (injectable)', 'Bonviva (injectable)', 'Bondenza', 'Ro-200-5450', 'Bondronat', 'Bonviva', 'ibandronic acid (injectable), Roche', 'CT-064', 'ibandronate sodium monohydrate', 'ibandronic acid (injectable)', 'ibandronate sodium', 'ibandronate', 'Boniva (injectable)', 'RG-484 (injectable)', 'BM-210955', 'Bondronat (injectable)', 'Boniva', 'BM-210955NaH2O', 'bisphosphonate, Boehringer Mannheim', 'bisphosphonate', 'ibandronic acid']",ibandronic acid (injectable),fexact,"['r 484 injectable', 'bonviva injectable', 'bondenza', 'ro 200 5450', 'bondronat', 'bonviva', 'ibandronic acid injectable roche', 'ct 064', 'ibandronate sodium monohydrate', 'ibandronic acid injectable', 'ibandronate sodium', 'ibandronate', 'boniva injectable', 'rg 484 injectable', 'bm 210955', 'bondronat injectable', 'boniva', 'bm 210955nah2o', 'bisphosphonate boehringer mannheim', 'bisphosphonate', 'ibandronic acid']",correct_mapping
enoxaparin sodium,Indirect Factor Xa inhibitor; Indirect thrombin inhibitor; Heparin stimulant,enoxaparin sodium,,enoxaparin sodium,enoxaparin sodium,fexact,"['RP-54563', 'PK-10169', 'Lovenox', 'enoxaparin sodium', 'RPY-005', 'Clexane', 'Klexane', 'XRP-4563']",enoxaparin sodium,fexact,"['rp 54563', 'pk 10169', 'lovenox', 'enoxaparin sodium', 'rpy 005', 'clexane', 'klexane', 'xrp 4563']",correct_mapping
birtamimab,Unidentified pharmacological activity,birtamimab,,birtamimab,birtamimab,fexact,"['NEOD-001', 'birtamimab', 'monoclonal antibody therapy (AL amyloidosis), Onclave', 'Hu2A4', 'ELT1-01', 'antibody therapy (AL amyloidosis), Neotope Biosciences', 'monoclonal antibody therapy (AL amyloidosis)']",birtamimab,fexact,"['neod 001', 'birtamimab', 'monoclonal antibody therapy al amyloidosis onclave', 'hu2a4', 'elt1 01', 'antibody therapy al amyloidosis neotope biosciences', 'monoclonal antibody therapy al amyloidosis']",correct_mapping
"clarithromycin, unspecified",Protein 50S ribosomal subunit inhibitor,clarithromycin,unspecified,clarithromycin,clarithromycin,fexact,"['Biaxin', 'antibiotic A-56268', 'Velcam', 'Macladin', 'Zaclar', 'acladin', 'Cyllind', 'Klacid SR', 'Klaricid XL', 'Kofron', 'Claricid', 'Klacid LA', 'clarithromycin', 'TE-031', 'Clarith', 'A-56268', 'Biclar', 'antibiotic TE-31', 'Klacid', 'Klaricid']",clarithromycin,fexact,"['biaxin', 'antibiotic a 56268', 'velcam', 'macladin', 'zaclar', 'acladin', 'cyllind', 'klacid sr', 'klaricid xl', 'kofron', 'claricid', 'klacid la', 'clarithromycin', 'te 031', 'clarith', 'a 56268', 'biclar', 'antibiotic te 31', 'klacid', 'klaricid']",correct_mapping
colesevelam hydrochloride,Cholesterol inhibitor,colesevelam hydrochloride,,colesevelam,colesevelam hydrochloride,fexact,"['Welchol', 'Welchol DM', 'GT31-104HB', 'CholestaGel', 'colesevelam hydrochloride', 'Lodalis', 'colesevelam', 'GT31-104']",colesevelam,fexact,"['welchol', 'welchol dm', 'gt31 104hb', 'cholestagel', 'colesevelam hydrochloride', 'lodalis', 'colesevelam', 'gt31 104']",correct_mapping
AFM-11,CD3 agonist; Immuno-oncology therapy,AFM-11,,AFM-11,afm 11,fexact,"['AFM-11', 'anti-CD19 and anti-CD3 TandAb (B-cell lymphoblastic leukemia)', ""anti-CD3/anti-CD19 tetravalent bispecific T-cell engager (TandAb, non-Hodgkin's lymphoma/acute lymphoblastic leukemia)""]",AFM-11,fexact,"['afm 11', 'anti cd19 and anti cd3 tandab b cell lymphoblastic leukemia', 'anti cd3 anti cd19 tetravalent bispecific t cell engager tandab non hodgkin s lymphoma acute lymphoblastic leukemia']",correct_mapping
vecabrutinib,Bruton tyrosine kinase inhibitor,vecabrutinib,,vecabrutinib,vecabrutinib,fexact,"['vecabrutinib', 'SNS-062', 'vecabrutinib succinate', 'SNS-062 succinate']",vecabrutinib,fexact,"['vecabrutinib', 'sns 062', 'vecabrutinib succinate', 'sns 062 succinate']",correct_mapping
apilimod dimesylate,Phosphatidylinositol 3-phosphate 5-kinase inhibitor,apilimod dimesylate,,,,0,"['apilimod dimesylate (capsule, B-cell non-Hodgkins lymphoma), Lam Therapeutics', 'apilimod', 'LAM-002', 'apilimod mesylate', 'apilimod mesylate (capsule, B-cell non-Hodgkins lymphoma), Lam Therapeutics', 'LAM-002A', 'apilimod dimesylate (capsule, b-cell non-hodgkins lymphoma/chronic lymphocytic leukemia/amyotrophic lateral sclerosis/covid-19)', 'apilimod dimesylate']",,Drug_API_mapping,[],0
MRG-106 (intratumoral),MicroRNA inhibitor,MRG-106,,cobomarsen,mrg 106,fexact,"['cobomarsen', 'M-11667', 'cobomarsen sodium', 'miR-155 inhibitors (hematological malignancies/amyotrophic lateral sclerosis), miRagen Therapeutics', 'MRG-106']",cobomarsen,fexact,"['cobomarsen', 'm 11667', 'cobomarsen sodium', 'mir 155 inhibitors hematological malignancies amyotrophic lateral sclerosis miragen therapeutics', 'mrg 106']",correct_mapping
MRG-106 (IV),MicroRNA inhibitor,MRG-106,,cobomarsen,mrg 106,fexact,"['cobomarsen', 'M-11667', 'cobomarsen sodium', 'miR-155 inhibitors (hematological malignancies/amyotrophic lateral sclerosis), miRagen Therapeutics', 'MRG-106']",cobomarsen,fexact,"['cobomarsen', 'm 11667', 'cobomarsen sodium', 'mir 155 inhibitors hematological malignancies amyotrophic lateral sclerosis miragen therapeutics', 'mrg 106']",correct_mapping
MRG-106 (SC),MicroRNA inhibitor,MRG-106,,cobomarsen,mrg 106,fexact,"['cobomarsen', 'M-11667', 'cobomarsen sodium', 'miR-155 inhibitors (hematological malignancies/amyotrophic lateral sclerosis), miRagen Therapeutics', 'MRG-106']",cobomarsen,fexact,"['cobomarsen', 'm 11667', 'cobomarsen sodium', 'mir 155 inhibitors hematological malignancies amyotrophic lateral sclerosis miragen therapeutics', 'mrg 106']",correct_mapping
tanezumab,Nerve growth factor antagonist,tanezumab,,tanezumab,tanezumab,fexact,"['RI-206', 'recombinant humanized anti-NGF monoclonal (pain), Pfizer/Genentech', 'tanezumab', 'pain therapeutics', 'PF-4383119', 'RI-624', 'm-911', 'muMab 911', 'RN-624', 'PF-04383119', 'recombinant humanized anti-NGF monoclonal (pain), Pfizer/', 'recombinant humanized anti-NGF monoclonal (pain),/', 'pain therapeutics, Pfizer']",tanezumab,fexact,"['ri 206', 'recombinant humanized anti ngf monoclonal pain pfizer genentech', 'tanezumab', 'pain therapeutics', 'pf 4383119', 'ri 624', 'm 911', 'mumab 911', 'rn 624', 'pf 04383119', 'recombinant humanized anti ngf monoclonal pain pfizer', 'recombinant humanized anti ngf monoclonal pain', 'pain therapeutics pfizer']",correct_mapping
"vincristine, Tekmira",Microtubule inhibitor; Tubulin inhibitor; Vinca alkaloid,vincristine,Tekmira,vincristine sulfate (liposomal injection),vincristine,fexact,"['VSLI, Inex', 'transmembrane carrier system (vincristine), Inex', 'vincristine sulfate liposomes for injection, Inex', 'vincristine sulfate (liposomal injection), Talon', 'vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals', 'vincristine sulfate', 'VSLI', 'vincristine sulfate liposomes for injection, Hana', 'vincristine sulfate (liposomal injection), Spectrum /', 'vincristine sulfate (liposomal injection, Optisome)', 'vincristine-TCS, Hana', 'vincristine sulfate (liposomal injection), Spectrum / CASI Pharmaceuticals', 'vincristine', 'vincristine sulfate (liposomal injection), Hana', 'transmembrane carrier system (vincristine)', 'vincristine sulfate (liposomal injection, Optisome), Inex', 'vincristine-TCS, Inex', 'vincristine sulfate (liposomal injection)', 'Marqibo', 'vincristine sulfate liposomes for injection', 'vincristine-TCS', 'Onco-TCS', 'transmembrane carrier system (vincristine), Hana', 'VSLI, Hana', 'vincristine sulfate (liposomal injection),/']",vincristine sulfate (liposomal injection),fexact,"['vsli inex', 'transmembrane carrier system vincristine inex', 'vincristine sulfate liposomes for injection inex', 'vincristine sulfate liposomal injection talon', 'vincristine sulfate liposomal injection spectrum pharmaceuticals', 'vincristine sulfate', 'vsli', 'vincristine sulfate liposomes for injection hana', 'vincristine sulfate liposomal injection spectrum', 'vincristine sulfate liposomal injection optisome', 'vincristine tcs hana', 'vincristine sulfate liposomal injection spectrum casi pharmaceuticals', 'vincristine', 'vincristine sulfate liposomal injection hana', 'transmembrane carrier system vincristine', 'vincristine sulfate liposomal injection optisome inex', 'vincristine tcs inex', 'vincristine sulfate liposomal injection', 'marqibo', 'vincristine sulfate liposomes for injection', 'vincristine tcs', 'onco tcs', 'transmembrane carrier system vincristine hana', 'vsli hana', 'vincristine sulfate liposomal injection']",correct_mapping
gusacitinib,Janus kinase inhibitor; Syk tyrosine kinase inhibitor,gusacitinib,,gusacitinib,gusacitinib,fexact,"['dualSYK/JAK inhibitor (oral tablet, solid tumor/atopic dermatitis/lymphoma/myelofibrosis/eczema)', 'ASN-002 hydrochloride', 'SYK/JAK dual inhibitor (solid tumor)', 'ASN-002', 'gusacitinib', 'gusacitinib hydrochloride']",gusacitinib,fexact,"['dualsyk jak inhibitor oral tablet solid tumor atopic dermatitis lymphoma myelofibrosis eczema', 'asn 002 hydrochloride', 'syk jak dual inhibitor solid tumor', 'asn 002', 'gusacitinib', 'gusacitinib hydrochloride']",correct_mapping
fentanyl,Opioid delta receptor agonist; Opioid kappa receptor agonist; Opioid mu receptor agonist,fentanyl,,"fentanyl (sublingual spray, pain)",fentanyl,fexact,"['fentanyl (sublingual spray, pain), Insys Therapeutics', 'fentanyl', 'fentanyl (sublingual spray, pain), Lunatus', 'Fentanyl SL spray', 'Subsys', 'fentanyl (sublingual spray, pain)']","fentanyl (sublingual spray, pain)",fexact,"['fentanyl sublingual spray pain insys therapeutics', 'fentanyl', 'fentanyl sublingual spray pain lunatus', 'fentanyl sl spray', 'subsys', 'fentanyl sublingual spray pain']",correct_mapping
"morphine, Elan",Opioid delta receptor agonist; Opioid kappa receptor agonist; Opioid mu receptor agonist,morphine,Elan,"morphine (oral SR, Multipor)",morphine,fexact,"['morphine (oral SR, Multipor)', 'morphine (once-daily sustained release)', 'DCV morphine OD', 'morphine (oral SR, Multipor), Tanabe', 'Pguard', 'morphine sulfate anyhdrous', 'morphine (diffuse controlled vesicle technology)', 'morphine (once-daily sustained release), Tanabe', '(-)-morphine', 'morphine', 'TA-2620', 'morphine sulfate', 'Statex SR']","morphine (oral SR, Multipor)",fexact,"['morphine oral sr multipor', 'morphine once daily sustained release', 'dcv morphine od', 'morphine oral sr multipor tanabe', 'pguard', 'morphine sulfate anyhdrous', 'morphine diffuse controlled vesicle technology', 'morphine once daily sustained release tanabe', 'morphine', 'morphine', 'ta 2620', 'morphine sulfate', 'statex sr']",correct_mapping
Methadone,Opioid receptor agonist,Methadone,,,,0,"['heroin addiction therapy,/NIH', 'opiate addiction treatment, Algos/NIH', 'heroin addiction therapy, Algos/NIH', 'methadone', 'methadone + dextromethophan', 'methadone + dextromethorphan,/NIH', 'opiate addiction treatment,/NIH', 'methadone + dextromethorphan, Algos/NIH']",,NER_API,[],0
deferasirox,Chelating agent; Iron absorption inhibitor,deferasirox,,deferasirox,deferasirox,fexact,"['ICL-670A', 'Exjade', 'iron chelator', 'Jadenu', 'ICL-670', 'deferasirox', 'Exjade FCT', 'Jadenu Sprinkle', 'CGP-72670', 'Osveral']",deferasirox,fexact,"['icl 670a', 'exjade', 'iron chelator', 'jadenu', 'icl 670', 'deferasirox', 'exjade fct', 'jadenu sprinkle', 'cgp 72670', 'osveral']",correct_mapping
epoetin alfa,Erythropoietin receptor agonist,epoetin alfa,,epoetin alfa (Epogen),epoetin alfa,fexact,"['epoetin alfa', 'Globuren', 'KRN-5702E', 'EPO', 'erythropoietin', 'Erypo', 'Epoade', 'epoetin alfa (Epogen)', 'Epogen', 'Espo']",epoetin alfa (Epogen),fexact,"['epoetin alfa', 'globuren', 'krn 5702e', 'epo', 'erythropoietin', 'erypo', 'epoade', 'epoetin alfa epogen', 'epogen', 'espo']",correct_mapping
erythrocyte transfusion,Not applicable,erythrocyte transfusion,,,,0,['erythrocyte transfusion'],,0,[],0
thrombocyte transfusion,Unidentified pharmacological activity,thrombocyte transfusion,,,,0,['thrombocyte transfusion'],,0,[],0
immunoglobulin,Immunostimulant,immunoglobulin,,,,0,['immunoglobulin'],,0,[],0
caspofungin acetate,"Cell wall synthesis inhibitor; 1,3-Beta-glucan synthase inhibitor",caspofungin acetate,,caspofungin,caspofungin acetate,fexact,"['Cancidas', 'L-743872', 'MK-0991', 'caspofungin acetate', 'caspofungin', 'Cansidas', 'MK-991']",caspofungin,fexact,"['cancidas', 'l 743872', 'mk 0991', 'caspofungin acetate', 'caspofungin', 'cansidas', 'mk 991']",correct_mapping
ioversol,Not applicable,ioversol,,,,0,['ioversol'],,0,[],0
meloxicam,Prostaglandin synthase inhibitor; Cyclooxygenase 2 inhibitor,meloxicam,,meloxicam,meloxicam,fexact,"['UH-AC-62-XX', 'Movicox', 'meloxicam', 'UH-AE-62-XX', 'Mobec', 'Mobic', 'Mobicox', 'Movalis', 'Movatec']",meloxicam,fexact,"['uh ac 62 xx', 'movicox', 'meloxicam', 'uh ae 62 xx', 'mobec', 'mobic', 'mobicox', 'movalis', 'movatec']",correct_mapping
etanercept,Tumour necrosis factor alpha antagonist,etanercept,,etanercept,etanercept,fexact,"['TNF receptor, Immunex', 'soluble TNF receptor, Amgen', 'etanercept', 'PF-05208752', 'Enbrel Mini', 'Enbrel', 'soluble TNF receptor, Immunex', 'TNF receptor', 'rhu TNFR:Fc', 'Enbrel SureClick', 'TNR-001', 'soluble TNF receptor', 's-TNF-R, AHP']",etanercept,fexact,"['tnf receptor immunex', 'soluble tnf receptor amgen', 'etanercept', 'pf 05208752', 'enbrel mini', 'enbrel', 'soluble tnf receptor immunex', 'tnf receptor', 'rhu tnfr fc', 'enbrel sureclick', 'tnr 001', 'soluble tnf receptor', 's tnf r ahp']",correct_mapping
eltrombopag olamine,Thrombopoietin agonist,eltrombopag olamine,,eltrombopag,eltrombopag olamine,fexact,"['SB-394725', 'hematopoietic growth factor mimetics,/', 'thrombopoietin peptide mimetics,/', '497115', 'hematopoietic growth factor mimetics, Ligand/', 'Revolade', 'hematopoietic growth factor mimetics,/SB', 'SB-497115', 'thrombopoietin peptide mimetics,/Ligand', 'hematopoietic growth factor mimetics, Ligand/SB', 'SB-497115-GR', 'eltrombopag', 'ETB-115', 'Promacta', 'eltrombopag olamine', 'SB-497117GR']",eltrombopag,fexact,"['sb 394725', 'hematopoietic growth factor mimetics', 'thrombopoietin peptide mimetics', '497115', 'hematopoietic growth factor mimetics ligand', 'revolade', 'hematopoietic growth factor mimetics sb', 'sb 497115', 'thrombopoietin peptide mimetics ligand', 'hematopoietic growth factor mimetics ligand sb', 'sb 497115 gr', 'eltrombopag', 'etb 115', 'promacta', 'eltrombopag olamine', 'sb 497117gr']",correct_mapping
voriconazole,Cell wall synthesis inhibitor,voriconazole,,voriconazole,voriconazole,fexact,"['voriconazole', 'Pinup', 'Vfend', 'UK-109496']",voriconazole,fexact,"['voriconazole', 'pinup', 'vfend', 'uk 109496']",correct_mapping
ravuconazole,Cell wall synthesis inhibitor; Sterol demethylase inhibitor,ravuconazole,,ravuconazole,ravuconazole,fexact,"['ER-30346', 'ravuconazole', 'BMS-207147']",ravuconazole,fexact,"['er 30346', 'ravuconazole', 'bms 207147']",correct_mapping
aciclovir,DNA directed DNA polymerase inhibitor,aciclovir,,aciclovir,aciclovir,fexact,"['acyclovir', 'aciclovir', 'Zovir', 'Zovirax']",aciclovir,fexact,"['acyclovir', 'aciclovir', 'zovir', 'zovirax']",correct_mapping
muromonab-CD3,Immunosuppressant; CD3 antagonist,muromonab-CD3,,,,0,"['anti-CD3 murine monoclonal antibody (transplant rejection), Center of Molecular Immunology', 'muromonab-CD3', 'muromonab-cd3 follow-on biologic, /cimab', 'IOR-T3', 'muromonab-CD3 follow-on biologic, The Center of Molecular Immunology/CIMAB', 'anti-CD3 murine monoclonal antibody (transplant rejection)']",,NER_API,[],0
tocladesine,DNA synthesis inhibitor; Cyclic AMP stimulant,tocladesine,,tocladesine,tocladesine,fexact,"['purine ribonucleosides, ICN', 'purine ribonucleosides, Valeant', 'NSC-614491', 'NSC-354258', '8-Cl-cAMP', 'Adenazole', 'tocladesine']",tocladesine,fexact,"['purine ribonucleosides icn', 'purine ribonucleosides valeant', 'nsc 614491', 'nsc 354258', '8 cl camp', 'adenazole', 'tocladesine']",correct_mapping
fluconazole,Cell wall synthesis inhibitor; Sterol demethylase inhibitor,fluconazole,,fluconazole,fluconazole,fexact,"['Diflucan', 'UK-049858', 'Zoltec', 'fluconazole']",fluconazole,fexact,"['diflucan', 'uk 049858', 'zoltec', 'fluconazole']",correct_mapping
iododoxorubicin,DNA topoisomerase II inhibitor,iododoxorubicin,,,,0,"['FCE-21954', '4-IDX', 'FCE-21956', 'Iodo-Dox', 'I-DOX', 'iododoxorubicin']",,NER_API,[],0
idelalisib (tablet),Protein kinase inhibitor; PI3 kinase delta inhibitor; CC chemokine ligand antagonist,idelalisib,,idelalisib,idelalisib,fexact,"['CAL-101', 'PI3K delta inhibitors (inflammation/cancer),/', 'GS-1101', 'lipid kinase inhibitors', 'idelalisib (inflammation/autoimmunity/cancer)', 'p110 delta PI3 kinase inhibitors (inflammation/cancer)', 'idelalisib (inflammation/autoimmunity/cancer), ICOS', 'lipid kinase inhibitors, ICOS', 'Zydelig', 'IC-980033', 'PI3K delta inhibitors (inflammation/cancer), ICOS/', 'P13K delta inhibitors (inflammation/cancer)', 'lipid kinase inhibitors (inflammation/autoimmunity/cancer), ICOS', 'idelalisib', 'p110 delta PI3 kinase inhibitors (inflammation/cancer), ICOS', 'IC-87114', 'lipid kinase inhibitors (inflammation/autoimmunity/cancer)', 'P13K delta inhibitors (inflammation/cancer), Eli Lilly']",idelalisib,fexact,"['cal 101', 'pi3k delta inhibitors inflammation cancer', 'gs 1101', 'lipid kinase inhibitors', 'idelalisib inflammation autoimmunity cancer', 'p110 delta pi3 kinase inhibitors inflammation cancer', 'idelalisib inflammation autoimmunity cancer icos', 'lipid kinase inhibitors icos', 'zydelig', 'ic 980033', 'pi3k delta inhibitors inflammation cancer icos', 'p13k delta inhibitors inflammation cancer', 'lipid kinase inhibitors inflammation autoimmunity cancer icos', 'idelalisib', 'p110 delta pi3 kinase inhibitors inflammation cancer icos', 'ic 87114', 'lipid kinase inhibitors inflammation autoimmunity cancer', 'p13k delta inhibitors inflammation cancer eli lilly']",correct_mapping
VS-4718,Focal adhesion kinase inhibitor,VS-4718,,VS-4718,vs 4718,fexact,"['VS-4718', 'fak program (cancer), verastem', 'focal adhesion kinase program (cancer), Verastem Inc', 'FAK program (cancer), Verastem/Scripps Research Institute/', 'fak program (cancer)', 'focal adhesion kinase/proline-rich tyrosine kinase 2 dual inhibitors (cancer)', 'FAK/PYK2 dual inhibitors (cancer), Verastem', 'VS-5095', 'PND-1186', 'focal adhesion kinase/proline-rich tyrosine kinase 2 dual inhibitors (cancer), Verastem', 'SR-2516', 'FAK/PYK2 dual inhibitors (cancer)']",VS-4718,fexact,"['vs 4718', 'fak program cancer verastem', 'focal adhesion kinase program cancer verastem inc', 'fak program cancer verastem scripps research institute', 'fak program cancer', 'focal adhesion kinase proline rich tyrosine kinase 2 dual inhibitors cancer', 'fak pyk2 dual inhibitors cancer verastem', 'vs 5095', 'pnd 1186', 'focal adhesion kinase proline rich tyrosine kinase 2 dual inhibitors cancer verastem', 'sr 2516', 'fak pyk2 dual inhibitors cancer']",correct_mapping
BI-1206,CD32 antagonist,BI-1206,,BI-1206,bi 1206,fexact,"['BI-1206', 'CD32b checkpoint inhibitor (cancer)', '6G11', 'FcgRIIb checkpoint inhibitor (leukemia/lymphoma)']",BI-1206,fexact,"['bi 1206', 'cd32b checkpoint inhibitor cancer', '6g11', 'fcgriib checkpoint inhibitor leukemia lymphoma']",correct_mapping
"CD19CAR-CD28-CD3zeta-EGFRt-expressing T cells, COH",Immuno-oncology therapy,CD19CAR-CD28-CD3zeta-EGFRt-expressing T cells,COH,,,0,['CD19CAR-CD28-CD3zeta-EGFRt-expressing T cells'],,0,[],0
lexaptepid pegol (IV),Hepcidin inhibitor,lexaptepid pegol,,lexaptepid pegol,lexaptepid pegol,fexact,"['spiegelmer hepcidin inhibitor (inflammation-induced anemia)', 'lexaptepid pegol', 'NOX-H94']",lexaptepid pegol,fexact,"['spiegelmer hepcidin inhibitor inflammation induced anemia', 'lexaptepid pegol', 'nox h94']",correct_mapping
zabinostat,Histone deacetylase inhibitor,zabinostat,,zabinostat,zabinostat,fexact,"['AZD-8025', 'histone deacetylase (HDAC) inhibitor (peripheral T-cell Lymphoma),/', 'histone deacetylase (HDAC) inhibitor (colorectal cancer),/', 'CXD-101', 'histone deacetylase (HDAC) inhibitor (lymphoma),/Nuance Biotech', 'histone deacetylase (HDAC) inhibitor (lymphoma),/', 'histone deacetylase (HDAC) inhibitor (peripheral T-cell Lymphoma),/Nuance Biotech', 'histone deacetylase (HDAC) inhibitor (cancer),/Celleron Therapeutics', 'histone deacetylase (HDAC) inhibitor (colorectal cancer),/Celleron Therapeutics', 'AZD-9468', 'zabinostat', 'histone deacetylase (HDAC) inhibitor (cancer),/']",zabinostat,fexact,"['azd 8025', 'histone deacetylase hdac inhibitor peripheral t cell lymphoma', 'histone deacetylase hdac inhibitor colorectal cancer', 'cxd 101', 'histone deacetylase hdac inhibitor lymphoma nuance biotech', 'histone deacetylase hdac inhibitor lymphoma', 'histone deacetylase hdac inhibitor peripheral t cell lymphoma nuance biotech', 'histone deacetylase hdac inhibitor cancer celleron therapeutics', 'histone deacetylase hdac inhibitor colorectal cancer celleron therapeutics', 'azd 9468', 'zabinostat', 'histone deacetylase hdac inhibitor cancer']",correct_mapping
uprosertib,Protein kinase B inhibitor,uprosertib,,,,0,['uprosertib'],,0,[],0
moxetumomab pasudotox,Protein synthesis inhibitor,moxetumomab pasudotox,,moxetumomab pasudotox,moxetumomab pasudotox,fexact,"['CAT-8015', 'PE38-conjugated anti-CD22 immunotoxin (improved),/CAT/', 'moxetumomab pasudotox-tdfk', 'PE38-conjugated anti-CD22 immunotoxin (improved), Genencor/CAT/', 'moxetumomab pasudotox', 'Lumoxiti', 'GCR-8015']",moxetumomab pasudotox,fexact,"['cat 8015', 'pe38 conjugated anti cd22 immunotoxin improved cat', 'moxetumomab pasudotox tdfk', 'pe38 conjugated anti cd22 immunotoxin improved genencor cat', 'moxetumomab pasudotox', 'lumoxiti', 'gcr 8015']",correct_mapping
HER2-CAR-T cells,T cell stimulant; Immuno-oncology therapy,HER2-CAR-T cells,,,,0,['HER2-CAR-T cells'],,0,[],0
CD33-CAR-T cells,Immuno-oncology therapy,CD33-CAR-T cells,,,,0,['CD33-CAR-T cells'],,0,[],0
milatuzumab (SC),CD74 antagonist; Immuno-oncology therapy,milatuzumab,,milatuzumab,milatuzumab,fexact,"['hLL1', 'MelanomaCide', 'milatuzumab', 'IMMU-115', 'MyelomaCide Y-90', 'LL1', 'hCD74 antibody (mutilple myeloma/ melanoma)', 'MyelomaCide']",milatuzumab,fexact,"['hll1', 'melanomacide', 'milatuzumab', 'immu 115', 'myelomacide y 90', 'll1', 'hcd74 antibody mutilple myeloma melanoma', 'myelomacide']",correct_mapping
sodium bicarbonate (oral),Unidentified pharmacological activity,sodium bicarbonate,,,,0,"['DYV-700', 'sodium bicarbonate', 'sodium bicarbonate (topical transdermal lotion, pain associated with acute gout flare), Dvye Bioscience']",,NER_API,[],0
donor lymphocytes,Immunosuppressant,donor lymphocytes,,,,0,['donor lymphocytes'],,0,[],0
decitabine,DNA methylase inhibitor,decitabine,,decitabine,decitabine,fexact,"['NSC-127716', 'IND-50733', '5-aza-CdR', ""5-aza-2'-deoxycytidine"", '5-aza-2-deoxycytidine', 'decitabine (intravenous, myelodysplastic syndromes/acute myeloid leukemia)', 'Dacogen', 'Dakogen', 'DAC', 'decitabine', 'E-7373', 'decitabine (intravenous, myelodysplastic syndromes/acute myeloid leukemia), Eisai', '5-CdR', '5-azadeoxycytidine', 'AZA-DC', 'JNJ-30979754']",decitabine,fexact,"['nsc 127716', 'ind 50733', '5 aza cdr', '5 aza 2 deoxycytidine', '5 aza 2 deoxycytidine', 'decitabine intravenous myelodysplastic syndromes acute myeloid leukemia', 'dacogen', 'dakogen', 'dac', 'decitabine', 'e 7373', 'decitabine intravenous myelodysplastic syndromes acute myeloid leukemia eisai', '5 cdr', '5 azadeoxycytidine', 'aza dc', 'jnj 30979754']",correct_mapping
ontecizumab,CD248 antagonist,ontecizumab,,ontuxizumab,ontecizumab,fexact,"['anti-endosialin antibody (neovascular disease/cancer), Morphotek', 'anti-tumor endothelial marker 1 antibody  (neovascular disease/cancer)', 'anti-tumor endothelial marker 1 antibody  (neovascular disease/cancer), Morphotek', 'humanized mAb (neovascular disease/cancer)', 'MORAb-004', 'anti-tumor endothelial marker 1 antibody (neovascular disease/cancer)', 'ontecizumab', 'ontuxizumab', 'anti-TEM1 antibody (neovascular disease/cancer), Morphotek', 'humanized mAb (neovascular disease/cancer), Morphotek', 'anti-TEM1 antibody (neovascular disease/cancer)', 'anti-endosialin antibody (neovascular disease/cancer)']",ontuxizumab,fexact,"['anti endosialin antibody neovascular disease cancer morphotek', 'anti tumor endothelial marker 1 antibody neovascular disease cancer', 'anti tumor endothelial marker 1 antibody neovascular disease cancer morphotek', 'humanized mab neovascular disease cancer', 'morab 004', 'anti tumor endothelial marker 1 antibody neovascular disease cancer', 'ontecizumab', 'ontuxizumab', 'anti tem1 antibody neovascular disease cancer morphotek', 'humanized mab neovascular disease cancer morphotek', 'anti tem1 antibody neovascular disease cancer', 'anti endosialin antibody neovascular disease cancer']",correct_mapping
ofatumumab (IV),CD20 antagonist; Immuno-oncology therapy,ofatumumab,,ofatumumab,ofatumumab,fexact,"['anti-CD20 human monoclonal antibody (intravenous), GlaxoSmithKline/', 'HuMax-CD20', 'anti-CD20 human monoclonal antibody (intravenous),/', 'GSK-1841157', 'ofatumumab', '2F2', 'Arzerra']",ofatumumab,fexact,"['anti cd20 human monoclonal antibody intravenous glaxosmithkline', 'humax cd20', 'anti cd20 human monoclonal antibody intravenous', 'gsk 1841157', 'ofatumumab', '2f2', 'arzerra']",correct_mapping
aclarubicin,DNA synthesis inhibitor; Radical formation stimulant; DNA topoisomerase I inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,aclarubicin,,,,0,['aclarubicin'],,0,[],0
"fresh frozen plasma, unspecified",Unidentified pharmacological activity,fresh frozen plasma,unspecified,,,0,['fresh frozen plasma'],,0,[],0
ganciclovir (IV),DNA synthesis inhibitor; DNA directed DNA polymerase inhibitor,ganciclovir,,"ganciclovir (oral), Roche Bioscience",ganciclovir,fexact,"['RS-21592', 'Cymevene', 'ganciclovir (oral), Roche Bioscience', 'Cytovene', 'ganciclovir']","ganciclovir (oral), Roche Bioscience",fexact,"['rs 21592', 'cymevene', 'ganciclovir oral roche bioscience', 'cytovene', 'ganciclovir']",correct_mapping
foscarnet sodium,DNA synthesis inhibitor; RNA directed DNA polymerase inhibitor; DNA directed DNA polymerase inhibitor,foscarnet sodium,,,,0,"['foscarnet\xa0sodium hexahydrate', 'foscarnet sodium', 'Foscavir']",,NER_API,[],0
valganciclovir,DNA synthesis inhibitor; DNA directed DNA polymerase inhibitor,valganciclovir,,valganciclovir,valganciclovir,fexact,"['valganciclovir', 'RG-127', 'RoValcyte', 'Valixa', 'Valcyt', 'Cymeval', 'TA-9070', 'Darilin', 'Valcyte']",valganciclovir,fexact,"['valganciclovir', 'rg 127', 'rovalcyte', 'valixa', 'valcyt', 'cymeval', 'ta 9070', 'darilin', 'valcyte']",correct_mapping
"cytomegalovirus vaccine, DiaVax Biosciences",Immunostimulant,cytomegalovirus vaccine,DiaVax Biosciences,,,0,"['cytomegalovirus vaccine', 'V-160']",,Drug_API_mapping,[],0
atorvastatin (tablet),HMGCoA reductase inhibitor,atorvastatin,,atorvastatin,atorvastatin,fexact,"['atorvastatin', 'Sortis', 'Cardyl', 'Zarator', 'Lipitor', 'YM-548', 'Prevencor', 'Citalor', 'atorvastatin calcium', 'CI 981', 'Lipramar']",atorvastatin,fexact,"['atorvastatin', 'sortis', 'cardyl', 'zarator', 'lipitor', 'ym 548', 'prevencor', 'citalor', 'atorvastatin calcium', 'ci 981', 'lipramar']",correct_mapping
"cefepime, intravenous, unspecified",Cell wall synthesis inhibitor,cefepime,unspecified,cefepime,cefepime,fexact,"['cefepime', 'Axepim', 'Cepimax', 'Maxipime', 'Axepime', 'BMY-28142', 'Maxcef', 'cefepime hydrochloride', 'cefipime']",cefepime,fexact,"['cefepime', 'axepim', 'cepimax', 'maxipime', 'axepime', 'bmy 28142', 'maxcef', 'cefepime hydrochloride', 'cefipime']",correct_mapping
bezlotoxumab,Clostridium difficile toxin B neutraliser,bezlotoxumab,,bezlotoxumab,bezlotoxumab,fexact,"['humanized monoclonal antibody combination (c difficile enterotoxins a and b, ultimab), merck & co/medarex', 'MK-3415 + MK-6072', 'GS-CDA1 + MDX-1388', 'actoxumab + bezlotoxumab', 'MDX-066 + MDX-1388', 'Zinplava', 'humanized monoclonal antibody combination (c difficile enterotoxins a and b, ultimab), merck & co/', 'humanized monoclonal antibody combination (c difficile enterotoxins a and b, ultimab),/', 'C difficile therapy (anti toxin-A and toxin-B antibody combination)', 'MK-3415A', 'MBL-CDA1 + MBL-CDB1', 'bezlotoxumab', 'MDX-1388', 'MBL-CDB1', 'difficile therapy (anti toxin-A and toxin-B antibody combination)', 'CDA-1 + CDB-1', 'MK-6072', 'C difficile therapy (anti toxin-A and toxin-B antibody combination), Medarex']",bezlotoxumab,fexact,"['humanized monoclonal antibody combination c difficile enterotoxins a and b ultimab merck co medarex', 'mk 3415 mk 6072', 'gs cda1 mdx 1388', 'actoxumab bezlotoxumab', 'mdx 066 mdx 1388', 'zinplava', 'humanized monoclonal antibody combination c difficile enterotoxins a and b ultimab merck co', 'humanized monoclonal antibody combination c difficile enterotoxins a and b ultimab', 'c difficile therapy anti toxin a and toxin b antibody combination', 'mk 3415a', 'mbl cda1 mbl cdb1', 'bezlotoxumab', 'mdx 1388', 'mbl cdb1', 'difficile therapy anti toxin a and toxin b antibody combination', 'cda 1 cdb 1', 'mk 6072', 'c difficile therapy anti toxin a and toxin b antibody combination medarex']",correct_mapping
voxtalisib (capsule),mTOR kinase inhibitor; Protein kinase inhibitor; PI3 kinase alpha inhibitor; Cell cycle inhibitor,voxtalisib,,voxtalisib,voxtalisib,fexact,"['voxtalisib', 'phosphoinositide-3 kinase/mTOR inhibitor (cancer)', 'SAR-245409', 'XL-765', 'PI3K/mTOR inhibitor (cancer)', 'PI3K/mTOR inhibitor (cancer), sanofi-aventis']",voxtalisib,fexact,"['voxtalisib', 'phosphoinositide 3 kinase mtor inhibitor cancer', 'sar 245409', 'xl 765', 'pi3k mtor inhibitor cancer', 'pi3k mtor inhibitor cancer sanofi aventis']",correct_mapping
"NYMC X-179A vaccine, New York Medical College",Immunostimulant,NYMC X-179A vaccine,New York Medical College,,,0,['NYMC X-179A vaccine'],,0,[],0
moxifloxacin (capsule),DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,moxifloxacin,,moxifloxacin,moxifloxacin,fexact,"['Actira', 'Avilox', 'moxifloxacin hydrochloride', 'BAY-12-8039', 'Avelox', 'Octegra', 'Avalox', 'moxifloxacin', 'Izilox']",moxifloxacin,fexact,"['actira', 'avilox', 'moxifloxacin hydrochloride', 'bay 12 8039', 'avelox', 'octegra', 'avalox', 'moxifloxacin', 'izilox']",correct_mapping
actoxumab,Clostridium difficile toxin A neutraliser,actoxumab,,actoxumab,actoxumab,fexact,"['CDA-1', 'CDA-1, Medarex', 'MK-3415', 'MBL-CDA1', 'C difficile therapy (toxin A), Medarex', '3D8', 'C difficile therapy (toxin A)', 'MDX-066', 'anti-Clostridium difficile toxin A antibody', 'anti-Clostridium difficile toxin A antibody, Medarex', 'actoxumab']",actoxumab,fexact,"['cda 1', 'cda 1 medarex', 'mk 3415', 'mbl cda1', 'c difficile therapy toxin a medarex', '3d8', 'c difficile therapy toxin a', 'mdx 066', 'anti clostridium difficile toxin a antibody', 'anti clostridium difficile toxin a antibody medarex', 'actoxumab']",correct_mapping
hypertonic saline solution,Unidentified pharmacological activity,hypertonic saline solution,,,,0,['hypertonic saline solution'],,0,[],0
ethanol,Not applicable,ethanol,,,,0,['ethanol'],,0,[],0
edetate calcium disodium,Chelating agent,edetate calcium disodium,,,,0,['edetate calcium disodium'],,0,[],0
ferric carboxymaltose,Iron absorption stimulant,ferric carboxymaltose,,ferric carboxymaltose,ferric carboxymaltose,fexact,"['Injectafer', 'Renegy', 'VIT-45', 'Iroprem', 'Ferinject', 'ferric carboxymaltose', 'Z-213']",ferric carboxymaltose,fexact,"['injectafer', 'renegy', 'vit 45', 'iroprem', 'ferinject', 'ferric carboxymaltose', 'z 213']",correct_mapping
DI-B4,CD19 antagonist; Immuno-oncology therapy,DI-B4,,DI-B4,di b4,fexact,['DI-B4'],DI-B4,fexact,['di b4'],correct_mapping
basiliximab,Interleukin 2 receptor alpha antagonist; Immunosuppressant,basiliximab,,basiliximab,basiliximab,fexact,"['anti-CD25 monoclonal antibody (immunosuppressant)', 'SDZ-CHI-621', 'CHI-621', 'basiliximab', 'Simulect', 'anti-CD25 monoclonal antibody (immunosuppressant), Novartis', 'BSX-003']",basiliximab,fexact,"['anti cd25 monoclonal antibody immunosuppressant', 'sdz chi 621', 'chi 621', 'basiliximab', 'simulect', 'anti cd25 monoclonal antibody immunosuppressant novartis', 'bsx 003']",correct_mapping
undisclosed - inactivated influenza vaccine (split virion),Immunostimulant,undisclosed - inactivated influenza vaccine,,,,0,['undisclosed - inactivated influenza vaccine'],,0,[],0
bismuth,Unidentified pharmacological activity,bismuth,,,,0,"['bismuth, Medeva', 'bismuth', 'bismuth (enteric formulation)']",,Drug_API_mapping,[],0
moxifloxacin (tablet),DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,moxifloxacin,,moxifloxacin,moxifloxacin,fexact,"['Actira', 'Avilox', 'moxifloxacin hydrochloride', 'BAY-12-8039', 'Avelox', 'Octegra', 'Avalox', 'moxifloxacin', 'Izilox']",moxifloxacin,fexact,"['actira', 'avilox', 'moxifloxacin hydrochloride', 'bay 12 8039', 'avelox', 'octegra', 'avalox', 'moxifloxacin', 'izilox']",correct_mapping
2'-F-ara-deoxyuridine,Unidentified pharmacological activity,2'-F-ara-deoxyuridine,,NP-50501,fau 2 f ara deoxyuridine,fuzzy,"['FAU', 'deoxyuracil-beta-D-arabinofuranoside', 'FAU (2-F-Ara-deoxyuridine)', ""2'-fluorodeoxyuracil-beta-D-arabinofuranoside"", 'NSC-678515', 'NP-50501']",NP-50501,fexact,"['fau', 'deoxyuracil beta d arabinofuranoside', 'fau 2 f ara deoxyuridine', '2 fluorodeoxyuracil beta d arabinofuranoside', 'nsc 678515', 'np 50501']",incorrect_mapping
"ciclosporin A, ophthalmic",Immunosuppressant; Calcineurin inhibitor; T cell inhibitor,ciclosporin A,ophthalmic,ciclosporin,cyclosporin a,fuzzy,"['cyclosporin', 'cyclosporin A', 'Sandimmun', 'OLO-400', 'ciclosporin', 'Neoral', 'Sandimmune', 'cyclosporine', 'Sandimmun Neoral']",ciclosporin,fexact,"['cyclosporin', 'cyclosporin a', 'sandimmun', 'olo 400', 'ciclosporin', 'neoral', 'sandimmune', 'cyclosporine', 'sandimmun neoral']",incorrect_mapping
visilizumab,Immunosuppressant; CD3 antagonist; Apoptosis stimulant,visilizumab,,visilizumab,visilizumab,fexact,"['Nuvion', 'visiluzumab', 'anti-CD3 MAb (humanized)', 'SMART anti-CD3 MAb', 'visilizumab', 'SMART anti-CD3 MAb, Protein Design Labs', 'HuM291']",visilizumab,fexact,"['nuvion', 'visiluzumab', 'anti cd3 mab humanized', 'smart anti cd3 mab', 'visilizumab', 'smart anti cd3 mab protein design labs', 'hum291']",correct_mapping
clofarabine,DNA synthesis inhibitor; Ribonucleoside triphosphate reductase inhibitor; DNA repair enzyme inhibitor,clofarabine,,clofarabine (oral),clofarabine,fexact,"['Clolar', 'clofarabine (oral),/', 'clofarabine', 'clofarabine (oral)', 'GZ-393590', 'clofarabine (oral),/ILEX', 'clofarabine (oral), Genzyme', 'SAR-393590']",clofarabine (oral),fexact,"['clolar', 'clofarabine oral', 'clofarabine', 'clofarabine oral', 'gz 393590', 'clofarabine oral ilex', 'clofarabine oral genzyme', 'sar 393590']",correct_mapping
methylprednisolone (injectable),Glucocorticoid agonist,methylprednisolone,,methylprednisolone (Pfizer),methylprednisolone,fexact,"['methylprednisolone sodium succinate', 'methylprednisolone acetate', 'Depo-Medrol', 'DEPO-MEDRONE', 'Solu-Medrol', 'methylprednisolone (Pfizer)', 'PF-00345299', 'methylprednisolone', 'Medrol']",methylprednisolone (Pfizer),fexact,"['methylprednisolone sodium succinate', 'methylprednisolone acetate', 'depo medrol', 'depo medrone', 'solu medrol', 'methylprednisolone pfizer', 'pf 00345299', 'methylprednisolone', 'medrol']",correct_mapping
"varicella-zoster virus vaccine (heat treated), Merck",Immunostimulant,varicella-zoster virus vaccine,Merck,,,0,['varicella-zoster virus vaccine'],,0,[],0
chlorambucil,Immunosuppressant; DNA inhibitor,chlorambucil,,,,0,['chlorambucil'],,0,[],0
fludarabine (oral),DNA synthesis inhibitor; Ribonucleoside diphosphate reductase inhibitor; DNA repair enzyme inhibitor,fludarabine,,fludarabine,fludarabine,fexact,"['Oforta', '2-F-AraAMP', 'SH-537', 'SH-L-573A', 'SHT-586', 'Fludara iv', 'Fludara Oral', 'SH-586', 'fludarabine phosphate', 'BAY-86-4864', 'Beneflur', 'NSC-312887', 'Fludara', 'fludarabine', 'SH-584']",fludarabine,fexact,"['oforta', '2 f araamp', 'sh 537', 'sh l 573a', 'sht 586', 'fludara iv', 'fludara oral', 'sh 586', 'fludarabine phosphate', 'bay 86 4864', 'beneflur', 'nsc 312887', 'fludara', 'fludarabine', 'sh 584']",correct_mapping
bleomycin,DNA inhibitor,bleomycin,,,,0,"['bleomycin A2', 'EPT, Genetronics', 'bleomycin sulfate', 'NSC 125066', 'SECTA', 'bleomycin (intratumoral, EPT)', 'bleomycin (intratumoral, EPT), Genetronics', 'selective electrochemical tumor ablation therapy', 'MedPulser', 'bleomycin (intratumoral, EPT), OncoSec', 'NeoPulse', 'bleomycin B2', 'bleomycin']",,NER_API,[],0
"beclomethasone dipropionate, Soligenix",Immunosuppressant; Glucocorticoid agonist,beclomethasone dipropionate,Soligenix,"beclomethasone dipropionate, (CFC-free)",beclomethasone dipropionate,fexact,"['Qvar Digihaler', 'beclomethasone dipropionate', 'beclomethasone dipropionate (inhaled)', 'Qvar RediHaler', 'Qvar BAI', 'HFA-BDP extrafine aerosol', 'beclometasone (inhaled, CFC-free), Teva', 'beclomethasone dipropionate (Easi-Breathe), Ivax', 'Qvar', 'Aerobec Ventolair', 'beclomethasone dipropionate, (CFC-free), Teva', 'beclomethasone dipropionate, (CFC-free)', 'AeroBec Autohaler', 'beclomethasone dipropionate (Easi-Breathe)', 'beclometasone (inhaled, CFC-free)', 'beclomethasone dipropionate (MDI formulation)', 'TMP-96', 'HFA-134a BDP, HMR']","beclomethasone dipropionate, (CFC-free)",fexact,"['qvar digihaler', 'beclomethasone dipropionate', 'beclomethasone dipropionate inhaled', 'qvar redihaler', 'qvar bai', 'hfa bdp extrafine aerosol', 'beclometasone inhaled cfc free teva', 'beclomethasone dipropionate easi breathe ivax', 'qvar', 'aerobec ventolair', 'beclomethasone dipropionate cfc free teva', 'beclomethasone dipropionate cfc free', 'aerobec autohaler', 'beclomethasone dipropionate easi breathe', 'beclometasone inhaled cfc free', 'beclomethasone dipropionate mdi formulation', 'tmp 96', 'hfa 134a bdp hmr']",correct_mapping
heparin,Serine protease inhibitor; Indirect thrombin inhibitor,heparin,,,,0,"['heparin (oral)', 'heparin oral', 'inhaled mucolytic (CF, PowderHale)', 'Redesca HP', 'heparin (intranasal, Intravail), Intranasal Technology', 'inhaled mucolytic (COPD)', 'heparinoids (oral)', 'low molecular weight heparin biosimilar (injectable, deep vein thrombosis/pulmonary embolism), undisclosed/', 'heparinoids (oral), Emisphere', 'VR-496', 'LMWH biosimilar (injectable,  deep vein thrombosis/pulmonary embolism), undisclosed/', 'E-414 + heparin', 'P-414 + heparin', 'heparin (liquid oral), Emisphere', 'inhaled mucolytic (cystic fibrosis)', 'heparin (inhaled, cystic fibrosis/COPD/asthma, PowderHale)', 'inhaled mucolytic (COPD, PowderHale)', 'heparin (intranasal, Intravail), Intranasal Therapeutics', 'Redesca', 'SNAC + heparin', 'heparin', 'heparin (liquid oral)', 'Heporal']",,Drug_API_mapping,[],0
minocycline-EDTA,Chelating agent,minocycline-EDTA,,,,0,['minocycline-EDTA'],,0,[],0
EBV-specific cytotoxic T lymphocytes,Immunostimulant,EBV-specific cytotoxic T lymphocytes,,,,0,['EBV-specific cytotoxic T lymphocytes'],,0,[],0
lebrikizumab,Interleukin 13 antagonist,lebrikizumab,,lebrikizumab,lebrikizumab,fexact,"['RG-3637', 'anti-IL-13 humanized monoclonal antibody (cancer/asthma)', 'anti-IL-13 (mAb, asthma), Genentech', 'RO-5490255', 'lebri', 'DRM-06', 'MILR-1444A', 'lebrikizumab', 'anti-IL-13 (mAb, asthma)', 'TNX-650', 'anti-IL-13 humanized monoclonal antibody (cancer/asthma), Tanox', 'LY-3650150']",lebrikizumab,fexact,"['rg 3637', 'anti il 13 humanized monoclonal antibody cancer asthma', 'anti il 13 mab asthma genentech', 'ro 5490255', 'lebri', 'drm 06', 'milr 1444a', 'lebrikizumab', 'anti il 13 mab asthma', 'tnx 650', 'anti il 13 humanized monoclonal antibody cancer asthma tanox', 'ly 3650150']",correct_mapping
852A (SC),Immunostimulant; Toll-like receptor 7 agonist,852A,,"852A (intravenous), Pfizer",852a,fexact,"['852A (intravenous), Pfizer', 'TLR-7 agonist (intravenous, cancer), Coley', '852A (cancer),/University of Minnesota', '852A (intravenous)', 'TLR-7 agonist (cancer),/University of Minnesota', '852A', '852A (intravenous), Coley', '3M-001', 'TLR-7 agonist (intravenous, cancer)']","852A (intravenous), Pfizer",fexact,"['852a intravenous pfizer', 'tlr 7 agonist intravenous cancer coley', '852a cancer university of minnesota', '852a intravenous', 'tlr 7 agonist cancer university of minnesota', '852a', '852a intravenous coley', '3m 001', 'tlr 7 agonist intravenous cancer']",correct_mapping
lucatumumab,CD40 antagonist; Immuno-oncology therapy; Immune checkpoint stimulant,lucatumumab,,lucatumumab,lucatumumab,fexact,"['CHIR-12.12', 'anti-CD40 MAbs,/', 'lucatumumab', 'anti-CD40 MAbs, Novartis/Xoma', 'anti-CD40 monoclonal antibodies, Novartis/Xoma', 'HCD-122', '12.12', 'anti-CD40 monoclonal antibodies,/', 'anti-CD40 MAbs,/Xoma', 'anti-CD40 monoclonal antibodies,/Xoma']",lucatumumab,fexact,"['chir 12 12', 'anti cd40 mabs', 'lucatumumab', 'anti cd40 mabs novartis xoma', 'anti cd40 monoclonal antibodies novartis xoma', 'hcd 122', '12 12', 'anti cd40 monoclonal antibodies', 'anti cd40 mabs xoma', 'anti cd40 monoclonal antibodies xoma']",correct_mapping
VTP-195183,Retinoic acid alpha receptor agonist,VTP-195183,,IRX-5183,vtp 195183,fexact,"['IRX-5183 (oral, cancer/autoimmune disease)', 'IRX-5183', 'retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics', 'RARa (oral, cancer/autoimmune disease)', 'IRX-5183 (oral, cancer)', 'IRX-5183 (oral, autoimmune disease)', 'retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease)', 'IRX-5183 (oral, cancer), Io Therapeutics', 'NRX-5183', 'NRX-195183', 'VTP-5183', 'RARa (oral, cancer/autoimmune disease), Io Therapeutics', 'VTP-195183', 'IRX-5183 (oral, autoimmune disease), Io Therapeutics', 'AGN-195183', 'IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics']",IRX-5183,fexact,"['irx 5183 oral cancer autoimmune disease', 'irx 5183', 'retinoic acid receptor alpha agonist oral cancer autoimmune disease io therapeutics', 'rara oral cancer autoimmune disease', 'irx 5183 oral cancer', 'irx 5183 oral autoimmune disease', 'retinoic acid receptor alpha agonist oral cancer autoimmune disease', 'irx 5183 oral cancer io therapeutics', 'nrx 5183', 'nrx 195183', 'vtp 5183', 'rara oral cancer autoimmune disease io therapeutics', 'vtp 195183', 'irx 5183 oral autoimmune disease io therapeutics', 'agn 195183', 'irx 5183 oral cancer autoimmune disease io therapeutics']",correct_mapping
imMucin (intradermal),Immunostimulant; Immuno-oncology therapy,imMucin,,ImMucin,immucin,fexact,"['VXL-100', 'MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/', 'MUC-1 peptide vaccine (cancer),/', 'ImMucin']",ImMucin,fexact,"['vxl 100', 'muc 1 peptide vaccine cancer vaxil biotherapeutics', 'muc 1 peptide vaccine cancer', 'immucin']",correct_mapping
imMucin (SC),Immunostimulant; Immuno-oncology therapy,imMucin,,ImMucin,immucin,fexact,"['VXL-100', 'MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/', 'MUC-1 peptide vaccine (cancer),/', 'ImMucin']",ImMucin,fexact,"['vxl 100', 'muc 1 peptide vaccine cancer vaxil biotherapeutics', 'muc 1 peptide vaccine cancer', 'immucin']",correct_mapping
131I-tositumomab,DNA inhibitor; Apoptosis stimulant; Radiopharmaceutical,131I-tositumomab,,tositumomab,131i tositumomab,fexact,"['131I-anti-B1 therapy', 'Bexxar', 'iodine-131-tositumomab', '131I-tositumomab', 'tositumomab', 'anti-CD20', 'anti-CD20, Coulter', 'iodine-131-anti-B1 therapy', 'anti-B1 antibody, Coulter', 'B-1 therapy', 'anti-B1 antibody']",tositumomab,fexact,"['131i anti b1 therapy', 'bexxar', 'iodine 131 tositumomab', '131i tositumomab', 'tositumomab', 'anti cd20', 'anti cd20 coulter', 'iodine 131 anti b1 therapy', 'anti b1 antibody coulter', 'b 1 therapy', 'anti b1 antibody']",correct_mapping
"sodium stibogluconate (IV), VioQuest","Tyrosine phosphatase 1B inhibitor; Tyrosine phosphatase, non-receptor type 11 inhibitor; Tyrosine phosphatase, non-receptor type 6 inhibitor",sodium stibogluconate,VioQuest,sodium stibogluconate (cancer),sodium stibogluconate,fexact,"['sodium stibogluconate', 'Lenocta', 'sodium stibogluconate (cancer)', 'sodium stibogluconate (cancer), VioQuest', 'VQD-001', 'sodium stibogluconate (cancer), Greenwich']",sodium stibogluconate (cancer),fexact,"['sodium stibogluconate', 'lenocta', 'sodium stibogluconate cancer', 'sodium stibogluconate cancer vioquest', 'vqd 001', 'sodium stibogluconate cancer greenwich']",correct_mapping
siplizumab (IV),CD2 antagonist,siplizumab,,siplizumab,siplizumab,fexact,"['MEDI-507', 'siplizumab', 'TCD-601', 'AlloMune component II']",siplizumab,fexact,"['medi 507', 'siplizumab', 'tcd 601', 'allomune component ii']",correct_mapping
KIR-ligand mismatched haplo-identical natural killer cells,Unidentified pharmacological activity,KIR-ligand mismatched haplo-identical natural killer cells,,,,0,['KIR-ligand mismatched haplo-identical natural killer cells'],,0,[],0
VX-944,Inosine monophosphate dehydrogenase inhibitor,VX-944,,AVN-944,vx 944,fexact,"['IMPDH inhibitor (oral, cancer),/Vertex', 'inosine monophosphate dehydrogenase inhibitor (autoimmune disease/viral infection/cancer), Vertex', 'inosine monophosphate dehydrogenase inhibitor (cancer)', 'IMPDH inhibitor (oral, cancer),/', 'AVN-944', 'IMPDH inhibitor (autoimmune disease/viral infection/cancer), Vertex', 'inosine monophosphate dehydrogenase inhibitor (autoimmune disease/viral infection/cancer)', 'IMPDH inhibitor (autoimmune disease/viral infection/cancer)', 'VX-944']",AVN-944,fexact,"['impdh inhibitor oral cancer vertex', 'inosine monophosphate dehydrogenase inhibitor autoimmune disease viral infection cancer vertex', 'inosine monophosphate dehydrogenase inhibitor cancer', 'impdh inhibitor oral cancer', 'avn 944', 'impdh inhibitor autoimmune disease viral infection cancer vertex', 'inosine monophosphate dehydrogenase inhibitor autoimmune disease viral infection cancer', 'impdh inhibitor autoimmune disease viral infection cancer', 'vx 944']",correct_mapping
"fenretinide, CerRx",Apoptosis stimulant; Retinoic acid receptor agonist,fenretinide,CerRx,"fenretinide (oral, HIV infection), NIAID",fenretinide,fexact,"['RWJ-16434', 'NSC-374551', 'fenretinide (oral)', 'retinoic acid p-hydroxyphenylamine', 'fenretinide (oral, HIV infection), NIAID', '4-HPR', 'fenretinide', 'McN-R-1967']","fenretinide (oral, HIV infection), NIAID",fexact,"['rwj 16434', 'nsc 374551', 'fenretinide oral', 'retinoic acid p hydroxyphenylamine', 'fenretinide oral hiv infection niaid', '4 hpr', 'fenretinide', 'mcn r 1967']",correct_mapping
leuprolide acetate for depot suspension,Luteinizing hormone releasing hormone (LHRH) agonist,leuprolide acetate for depot suspension,,,,0,['leuprolide acetate for depot suspension'],,0,[],0
epratuzumab-Y90,CD22 antagonist; Immuno-oncology therapy; Radiopharmaceutical,epratuzumab-Y90,,yttrium Y 90 epratuzumab,epratuzumab 90y,fuzzy,"['yttrium-90-LymphoCide', '90Y-DOTA-hLL2', '90Y-epratuzumab tetraxetan', 'epratuzumab (radiolabeled)', 'yttrium Y 90 epratuzumab', 'epratuzumab-[111In]', 'yttrium Y 90 epratuzumab tetraxetan', 'IMMU-102', '111In-epratuzumab', 'indium-111-epratuzumab', 'yttrium-90-epratuzumab', 'epratuzumab tetraxetan-[90Y]', 'Y90-epratuzumab', '90Y-LymphoCide', 'epratuzumab-[90Y]', '90Y-epratuzumab']",yttrium Y 90 epratuzumab,fexact,"['yttrium 90 lymphocide', '90y dota hll2', '90y epratuzumab tetraxetan', 'epratuzumab radiolabeled', 'yttrium y 90 epratuzumab', 'epratuzumab 111in', 'yttrium y 90 epratuzumab tetraxetan', 'immu 102', '111in epratuzumab', 'indium 111 epratuzumab', 'yttrium 90 epratuzumab', 'epratuzumab tetraxetan 90y', 'y90 epratuzumab', '90y lymphocide', 'epratuzumab 90y', '90y epratuzumab']",incorrect_mapping
deoxycytidine,Unidentified pharmacological activity,deoxycytidine,,,,0,['deoxycytidine'],,0,[],0
palivizumab,Immunostimulant,palivizumab,,palivizumab,palivizumab,fexact,"['Synagis', 'MEDI-493', 'palivizumab']",palivizumab,fexact,"['synagis', 'medi 493', 'palivizumab']",correct_mapping
"ribavirin, unspecified",Inosine monophosphate dehydrogenase inhibitor,ribavirin,unspecified,ribavirin,ribavirin,fexact,"['SCH-018908', 'Virazid', 'Cotronak', 'Vilona', 'NSC-163039', 'ICN-1229', 'Ro-20-9963', 'tribavirin', 'SCH-18908', 'Rebetol', 'Virazide', 'Ribasphere', 'ribavirin', 'Ribapak', 'Viramid']",ribavirin,fexact,"['sch 018908', 'virazid', 'cotronak', 'vilona', 'nsc 163039', 'icn 1229', 'ro 20 9963', 'tribavirin', 'sch 18908', 'rebetol', 'virazide', 'ribasphere', 'ribavirin', 'ribapak', 'viramid']",correct_mapping
NY-ESO-1 peptide(s),Immunostimulant,NY-ESO-1 peptide,,,,0,['NY-ESO-1 peptide'],,0,[],0
alvespimycin hydrochloride (IV),Heat shock protein 90 antagonist,alvespimycin hydrochloride,,alvespimycin hydrochloride (intravenous),alvespimycin hydrochloride,fexact,"['17-DMAG HCl', 'alvespimycin', 'DMAG', 'NSC-707545', 'BMS-826476', 'alvespimycin hydrochloride', 'alvespimycin hydrochloride (intravenous)', '17-DMAG', 'KOS-1022 (intravenous)', 'KOS-1022']",alvespimycin hydrochloride (intravenous),fexact,"['17 dmag hcl', 'alvespimycin', 'dmag', 'nsc 707545', 'bms 826476', 'alvespimycin hydrochloride', 'alvespimycin hydrochloride intravenous', '17 dmag', 'kos 1022 intravenous', 'kos 1022']",correct_mapping
atiprimod dimaleate,Immunosuppressant; Angiogenesis inhibitor; Apoptosis stimulant; Osteoclast inhibitor; Bone resorption inhibitor,atiprimod dimaleate,,,,0,['atiprimod dimaleate'],,0,[],0
ridaforolimus (IV),Vascular endothelial growth factor (VEGF)receptor antagonist; Immunosuppressant; mTOR kinase inhibitor; Protein kinase inhibitor; Angiogenesis inhibitor; Cell cycle inhibitor,ridaforolimus,,ridaforolimus,ridaforolimus,fexact,"['ridaforolimus (oral, cancer),/', 'ridaforolimus (oral, cancer),/Merck', 'AP-23573 (oral),/', 'AP-23573 (oral),/Merck & Co', 'MK-8669', 'Taltorvic', 'deforolimus', 'Jenzyl', 'deforolimus (oral),/Merck & Co', 'deforolimus (oral),/', 'ridaforolimus', 'AP-23573']",ridaforolimus,fexact,"['ridaforolimus oral cancer', 'ridaforolimus oral cancer merck', 'ap 23573 oral', 'ap 23573 oral merck co', 'mk 8669', 'taltorvic', 'deforolimus', 'jenzyl', 'deforolimus oral merck co', 'deforolimus oral', 'ridaforolimus', 'ap 23573']",correct_mapping
brostallicin,DNA inhibitor; Apoptosis stimulant,brostallicin,,brostallicin,brostallicin,fexact,"['brostallicin', 'PNU-248427', 'PNU-230858', 'PNU-248482', 'PNU-166196A', 'SMi-BX1', 'PNU-166196']",brostallicin,fexact,"['brostallicin', 'pnu 248427', 'pnu 230858', 'pnu 248482', 'pnu 166196a', 'smi bx1', 'pnu 166196']",correct_mapping
"pneumococcal vaccine, undisclosed",Immunostimulant,pneumococcal vaccine,undisclosed,,,0,['pneumococcal vaccine'],,0,[],0
"doxorubicin citrate, Teva",DNA topoisomerase II inhibitor,doxorubicin citrate,Teva,,,0,['doxorubicin citrate'],,0,[],0
"methylprednisolone (oral), unspecified",Corticosteroid agonist,methylprednisolone,unspecified,methylprednisolone (Pfizer),methylprednisolone,fexact,"['methylprednisolone sodium succinate', 'methylprednisolone acetate', 'Depo-Medrol', 'DEPO-MEDRONE', 'Solu-Medrol', 'methylprednisolone (Pfizer)', 'PF-00345299', 'methylprednisolone', 'Medrol']",methylprednisolone (Pfizer),fexact,"['methylprednisolone sodium succinate', 'methylprednisolone acetate', 'depo medrol', 'depo medrone', 'solu medrol', 'methylprednisolone pfizer', 'pf 00345299', 'methylprednisolone', 'medrol']",correct_mapping
gallium maltolate,Ribonucleoside triphosphate reductase inhibitor; Bone resorption inhibitor,gallium maltolate,,gallium maltolate,gallium maltolate,fexact,"['GaM', 'gallium maltolate (oral, glioblastoma multiforme)', 'gallium maltolate', 'gallium maltolate (oral, glioblastoma multiforme), IQ-AI Ltd']",gallium maltolate,fexact,"['gam', 'gallium maltolate oral glioblastoma multiforme', 'gallium maltolate', 'gallium maltolate oral glioblastoma multiforme iq ai ltd']",correct_mapping
Anti-CD45,T cell inhibitor; CD45 antagonist,Anti-CD45,,,,0,"['LM-CD45', 'anti-CD45, Cantab', 'anti-CD45']",,Drug_API_mapping,[],0
2-methoxyestradiol (capsule),Microtubule inhibitor; Caspase 3 stimulant; Angiogenesis inhibitor; Apoptosis stimulant; Hypoxia-inducible factor 1 alpha antagonist; Disease modifying antirheumatic drug,2-methoxyestradiol,,2-methoxyestradiol,2 methoxyestradiol,fexact,"['NSC-650853', '2-ME2', '2-methoxyestradiol', 'Panzem', 'NSC 659853', '2-methoxyestradiol, EntreMed', 'Panzem Capsules']",2-methoxyestradiol,fexact,"['nsc 650853', '2 me2', '2 methoxyestradiol', 'panzem', 'nsc 659853', '2 methoxyestradiol entremed', 'panzem capsules']",correct_mapping
"pyroxamide, Aton Pharma",Histone deacetylase inhibitor; Cell cycle inhibitor,pyroxamide,Aton Pharma,pyroxamide,pyroxamide,fexact,"['NSC-696085', 'pyroxamide']",pyroxamide,fexact,"['nsc 696085', 'pyroxamide']",correct_mapping
RP-323,Protein kinase C stimulant,RP-323,,RP-323,rp 323,fexact,"['12-O-tetra-decanoyl-phorbol-13-acetate', 'TPA', 'RP-323', 'PD-616']",RP-323,fexact,"['12 o tetra decanoyl phorbol 13 acetate', 'tpa', 'rp 323', 'pd 616']",correct_mapping
valspodar (oral),P glycoprotein inhibitor,valspodar,,valspodar,valspodar,fexact,"['SDZ-PSC-833', 'valspodar', 'NSC-648265', 'Amdray', 'SDZ-214-103', 'PSC-833']",valspodar,fexact,"['sdz psc 833', 'valspodar', 'nsc 648265', 'amdray', 'sdz 214 103', 'psc 833']",correct_mapping
semaxanib (IV),VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor,semaxanib,,semaxanib,semaxanib,fexact,"['angiogenesis inhibitors,/', 'FLK-1 RTK antagonists,/Taiho', 'angiogenesis inhibitors,/Taiho', 'aryl hydrocarbon receptor activator/VEGF-2 tyrosine kinase inhibitor,/Taiho', 'aryl hydrocarbon receptor activator/VEGF-2 tyrosine kinase inhibitor,/', 'semaxanib', 'FLK-1 RTK antagonists,/', 'TSU-16', 'SU-5416']",semaxanib,fexact,"['angiogenesis inhibitors', 'flk 1 rtk antagonists taiho', 'angiogenesis inhibitors taiho', 'aryl hydrocarbon receptor activator vegf 2 tyrosine kinase inhibitor taiho', 'aryl hydrocarbon receptor activator vegf 2 tyrosine kinase inhibitor', 'semaxanib', 'flk 1 rtk antagonists', 'tsu 16', 'su 5416']",correct_mapping
ancestim,Stem cell growth factor agonist,ancestim,,ancestim,ancestim,fexact,"['Stemgen', 'SCF', 'ancestim', 'stem cell factor', 'rhSCF']",ancestim,fexact,"['stemgen', 'scf', 'ancestim', 'stem cell factor', 'rhscf']",correct_mapping
KRX-0402,O6-alkylguanine-DNA alkyltransferase inhibitor; DNA repair enzyme inhibitor,KRX-0402,,NSC 637037,krx 0402,fexact,"['Alkylade', 'KRX-0402', 'NSC 637037', 'O6-benzylguanine']",NSC 637037,fexact,"['alkylade', 'krx 0402', 'nsc 637037', 'o6 benzylguanine']",correct_mapping
nelarabine,DNA synthesis inhibitor; T cell inhibitor,nelarabine,,nelarabine,nelarabine,fexact,"['guanine arabinoside prodrug', '506U', 'GW-506U78', 'Atriance', 'ara-G prodrug, Glaxo Wellcome', '506U78', 'ara-G prodrug, GlaxoSmithKline', 'guanine arabinoside prodrug, Glaxo Wellcome', 'Arranon', 'nelarabine', 'NSC-686673', 'ara-G prodrug', 'guanine arabinoside prodrug, GlaxoSmithKline']",nelarabine,fexact,"['guanine arabinoside prodrug', '506u', 'gw 506u78', 'atriance', 'ara g prodrug glaxo wellcome', '506u78', 'ara g prodrug glaxosmithkline', 'guanine arabinoside prodrug glaxo wellcome', 'arranon', 'nelarabine', 'nsc 686673', 'ara g prodrug', 'guanine arabinoside prodrug glaxosmithkline']",correct_mapping
ondansetron (tablet),5 Hydroxytryptamine 3 receptor antagonist,ondansetron,,ondansetron,ondansetron,fexact,"['GR-38032X', 'SN-307', 'Zofran ODT', 'ondansetron', 'Zopram', 'GG-032', 'Ramesin', 'Zophran', 'Zofran', 'ondansetron hydrochloride', 'GG-032X', 'Zofran Zydis', 'Zamanol', 'Zophren', 'GR-38032F', 'GR-38032', 'GR-C507/75', 'Zofran Konserveret']",ondansetron,fexact,"['gr 38032x', 'sn 307', 'zofran odt', 'ondansetron', 'zopram', 'gg 032', 'ramesin', 'zophran', 'zofran', 'ondansetron hydrochloride', 'gg 032x', 'zofran zydis', 'zamanol', 'zophren', 'gr 38032f', 'gr 38032', 'gr c507 75', 'zofran konserveret']",correct_mapping
dolastatin-10,Microtubule inhibitor; Immunostimulant; Tubulin inhibitor,dolastatin-10,,dolastatin-10,dolastatin 10,fexact,"['dolastatin-10', 'NSC-376128']",dolastatin-10,fexact,"['dolastatin 10', 'nsc 376128']",correct_mapping
JNJ-67856633,MALT1 inhibitor,JNJ-67856633,,JNJ-67856633,jnj 67856633,fexact,"['MALT1 inhibitor (oral, B-cell non-Hodgkin lymphoma/chronic lymphocytic leukemia)', 'JNJ-6633', 'JNJ-67856633']",JNJ-67856633,fexact,"['malt1 inhibitor oral b cell non hodgkin lymphoma chronic lymphocytic leukemia', 'jnj 6633', 'jnj 67856633']",correct_mapping
"COVID-19 vaccine, Moderna",Immunostimulant,COVID-19 vaccine,Moderna,AZD-1222,covid 19 vaccine,fexact,"['recombinant viral vector ChAdOx vaccine (2019-nCoV infection), Jenner Institute', 'SII-ChAdOx1 nCoV-19', 'recombinant viral vector ChAdOx vaccine (COVID-19, intramuscular)', 'recombinant viral vector ChAdOx vaccine (COVID-19, intramuscular), Jenner Institute', 'ChAdOX1 SARS2', 'AZD-1222', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19),//', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19), Jenner Institute/UCB/', 'ChAdOx1-S (recombinant)', 'AZN-1222', 'sars-cov-2 vaccine (covid-19), at the university of oxford', 'recombinant viral vector ChAdOx vaccine (2019-nCoV infection)', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19),/UCB/', 'C19VAZ', 'ChAdOx1 nCoV-19', 'SARS-CoV-2 vaccine (COVID-19), The Jenner Institute at the University of Oxford', 'Vaxzevria', 'COVID-19 Vaccine', 'SII-Covishield']",AZD-1222,fexact,"['recombinant viral vector chadox vaccine 2019 ncov infection jenner institute', 'sii chadox1 ncov 19', 'recombinant viral vector chadox vaccine covid 19 intramuscular', 'recombinant viral vector chadox vaccine covid 19 intramuscular jenner institute', 'chadox1 sars2', 'azd 1222', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19 jenner institute ucb', 'chadox1 s recombinant', 'azn 1222', 'sars cov 2 vaccine covid 19 at the university of oxford', 'recombinant viral vector chadox vaccine 2019 ncov infection', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19 ucb', 'c19vaz', 'chadox1 ncov 19', 'sars cov 2 vaccine covid 19 the jenner institute at the university of oxford', 'vaxzevria', 'covid 19 vaccine', 'sii covishield']",correct_mapping
LP-168,Unidentified pharmacological activity,LP-168,,,,0,['LP-168'],,NER_API,[],0
gamma9delta2 T-cells,Immunostimulant,gamma9delta2 T-cells,,,,0,['gamma9delta2 T-cells'],,0,[],0
"COVID-19 vaccine, AstraZeneca",Immunostimulant,COVID-19 vaccine,AstraZeneca,AZD-1222,covid 19 vaccine,fexact,"['recombinant viral vector ChAdOx vaccine (2019-nCoV infection), Jenner Institute', 'SII-ChAdOx1 nCoV-19', 'recombinant viral vector ChAdOx vaccine (COVID-19, intramuscular)', 'recombinant viral vector ChAdOx vaccine (COVID-19, intramuscular), Jenner Institute', 'ChAdOX1 SARS2', 'AZD-1222', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19),//', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19), Jenner Institute/UCB/', 'ChAdOx1-S (recombinant)', 'AZN-1222', 'sars-cov-2 vaccine (covid-19), at the university of oxford', 'recombinant viral vector ChAdOx vaccine (2019-nCoV infection)', 'SARS-CoV-2 spike glycoprotein vaccine (adenoviral vector vaccine, COVID-19),/UCB/', 'C19VAZ', 'ChAdOx1 nCoV-19', 'SARS-CoV-2 vaccine (COVID-19), The Jenner Institute at the University of Oxford', 'Vaxzevria', 'COVID-19 Vaccine', 'SII-Covishield']",AZD-1222,fexact,"['recombinant viral vector chadox vaccine 2019 ncov infection jenner institute', 'sii chadox1 ncov 19', 'recombinant viral vector chadox vaccine covid 19 intramuscular', 'recombinant viral vector chadox vaccine covid 19 intramuscular jenner institute', 'chadox1 sars2', 'azd 1222', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19 jenner institute ucb', 'chadox1 s recombinant', 'azn 1222', 'sars cov 2 vaccine covid 19 at the university of oxford', 'recombinant viral vector chadox vaccine 2019 ncov infection', 'sars cov 2 spike glycoprotein vaccine adenoviral vector vaccine covid 19 ucb', 'c19vaz', 'chadox1 ncov 19', 'sars cov 2 vaccine covid 19 the jenner institute at the university of oxford', 'vaxzevria', 'covid 19 vaccine', 'sii covishield']",correct_mapping
VRC-MARADC087-00-VP,Immunostimulant,VRC-MARADC087-00-VP,,VRC-MARADC087-00-VP,vrc maradc087 00 vp,fexact,"['VRC-MARADC087-00-VP', 'ChAd3-Marburg', 'recombinant adenovirus type-3 vector vaccine (intramuscular, marburg virus infection), //sabin vaccine institute', 'recombinant adenovirus type-3 vector vaccine (intramuscular, marburg virus infection)', 'recombinant adenovirus type-3 vector vaccine (intramuscular, marburg virus infection),//sabin vaccine institute', 'ChAd3-MARV', 'cAd3-Marburg', 'recombinant adenovirus type-3 vector vaccine (intramuscular, Marburg virus infection), National Institute of Allergy and Infectious Diseases//Sabin Vaccine Institute']",VRC-MARADC087-00-VP,fexact,"['vrc maradc087 00 vp', 'chad3 marburg', 'recombinant adenovirus type 3 vector vaccine intramuscular marburg virus infection sabin vaccine institute', 'recombinant adenovirus type 3 vector vaccine intramuscular marburg virus infection', 'recombinant adenovirus type 3 vector vaccine intramuscular marburg virus infection sabin vaccine institute', 'chad3 marv', 'cad3 marburg', 'recombinant adenovirus type 3 vector vaccine intramuscular marburg virus infection national institute of allergy and infectious diseases sabin vaccine institute']",correct_mapping
"cAd3-EBO-S vaccine, Sabin Vaccine Institute",Immunostimulant,cAd3-EBO-S vaccine,Sabin Vaccine Institute,,,0,['cAd3-EBO-S vaccine'],,0,[],0
Xisomab 3G3,Factor XI inhibitor,Xisomab 3G3,,AB-023,xisomab 3g3,fexact,"['AB-023', 'anti-human factor xi mabs (thrombosis/sepsis/myocardial infarction)', 'xisomab 3G3', 'anti-human factor xi mabs (thrombosis/sepsis/myocardial infarction),/vanderbilt university', 'AB-022', '14-E11', 'AXIMAB', 'anti-human Factor XI mAbs (Thrombosis/Sepsis/Myocardial infarction),/Vanderbilt University/Oregon Health Sciences University']",AB-023,fexact,"['ab 023', 'anti human factor xi mabs thrombosis sepsis myocardial infarction', 'xisomab 3g3', 'anti human factor xi mabs thrombosis sepsis myocardial infarction vanderbilt university', 'ab 022', '14 e11', 'aximab', 'anti human factor xi mabs thrombosis sepsis myocardial infarction vanderbilt university oregon health sciences university']",correct_mapping
befovacimab,Tissue factor pathway inhibitor inhibitor,befovacimab,,BAY-1093884,befovacimab,fexact,"['BAY-1093884', 'anti TFPI antibody (hemophilia)', 'anti tissue factor pathway inhibitor (hemophilia)', 'befovacimab']",BAY-1093884,fexact,"['bay 1093884', 'anti tfpi antibody hemophilia', 'anti tissue factor pathway inhibitor hemophilia', 'befovacimab']",correct_mapping
oxycodone,Opioid mu receptor agonist,oxycodone,,,,0,"['oxycodone', 'oxycodone formulated with abuse-deterrent naloxone (sustained release tablet, pain)', 'LY-021702']",,NER_API,[],0
ketorolac,Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor,ketorolac,,ketorolac,ketorolac,fexact,"['Lixidol', 'Droal', 'Toradol', 'Toradol Oral', 'ketorolac', 'Tonum', 'RS-37619', 'BPPC', 'BDPC', 'ketorolac tromethamine', 'Findol', 'Tora-Dol', 'Toratex']",ketorolac,fexact,"['lixidol', 'droal', 'toradol', 'toradol oral', 'ketorolac', 'tonum', 'rs 37619', 'bppc', 'bdpc', 'ketorolac tromethamine', 'findol', 'tora dol', 'toratex']",correct_mapping
CD123-targeted CAR-T cell therapy,Immuno-oncology therapy,CD123-targeted CAR-T cell therapy,,,,0,['CD123-targeted CAR-T cell therapy'],,0,[],0
posaconazole (oral tablet),Cell wall synthesis inhibitor; Sterol demethylase inhibitor,posaconazole,,posaconazole,posaconazole,fexact,"['antifungal, Schering-Plough', 'Noxafil', 'posaconazole', 'Spriafil', 'Sch-56592', 'MK-5592 (oral suspension), Merck & Co', 'MK-5592 (oral suspension)', 'Sch-56984', 'Sch-207962', '056592', 'SCH 056592', 'Sch-56588', 'antifungal', 'Posanol', 'triazole (oral), Schering-Plough', 'triazole (oral)', 'Posaconazole SP']",posaconazole,fexact,"['antifungal schering plough', 'noxafil', 'posaconazole', 'spriafil', 'sch 56592', 'mk 5592 oral suspension merck co', 'mk 5592 oral suspension', 'sch 56984', 'sch 207962', '056592', 'sch 056592', 'sch 56588', 'antifungal', 'posanol', 'triazole oral schering plough', 'triazole oral', 'posaconazole sp']",correct_mapping
CD22-CAR-T cells,CD22 antagonist; Immuno-oncology therapy,CD22-CAR-T cells,,,,0,['CD22-CAR-T cells'],,0,[],0
linperlisib,PI3 kinase delta inhibitor,linperlisib,,linperlisib,linperlisib,fexact,"['YY-20394', 'linperlisib', 'linpulisi']",linperlisib,fexact,"['yy 20394', 'linperlisib', 'linpulisi']",correct_mapping
STI-002,Tumour necrosis factor alpha antagonist,STI-002,,,,0,"['Baileiting', 'infliximab biosimilar, BioMab Pharmaceuticals', 'CMAB-008', 'infliximab biobetter, Mabtech/Sorrento', 'infliximab biosimilar,/Sorrento Therapeutics', 'STI-002', 'infliximab biobetter, Mabtech/', 'infliximab', 'infliximab biosimilar,/']",,NER_API,[],0
RP-4010,Calcium release-activated calcium channel antagonist,RP-4010,,RP-4010,rp 4010,fexact,"['calcium release-activated calcium channel inhibitor (non-Hodgkin lymphoma)', 'calcium release-activated calcium channel inhibitor (non-Hodgkin lymphoma), Rhizen', 'CRAC inhibitor (non-Hodgkin lymphoma), Rhizen', 'CRAC inhibitor (non-Hodgkin lymphoma)', 'RP-4010']",RP-4010,fexact,"['calcium release activated calcium channel inhibitor non hodgkin lymphoma', 'calcium release activated calcium channel inhibitor non hodgkin lymphoma rhizen', 'crac inhibitor non hodgkin lymphoma rhizen', 'crac inhibitor non hodgkin lymphoma', 'rp 4010']",correct_mapping
entospletinib,Syk tyrosine kinase inhibitor,entospletinib,,entospletinib,entospletinib,fexact,"['entospletinib bis-mesylate', 'entospletinib', 'GS-9973', 'Syk inhibitor (rheumatoid arthritis)']",entospletinib,fexact,"['entospletinib bis mesylate', 'entospletinib', 'gs 9973', 'syk inhibitor rheumatoid arthritis']",correct_mapping
polyclonal regulatory T cells,T cell inhibitor,polyclonal regulatory T cells,,,,0,['polyclonal regulatory T cells'],,0,[],0
CT-1530,Bruton tyrosine kinase inhibitor,CT-1530,,CT-1530,ct 1530,fexact,"['Target-3', 'CT-1530', 'leukemia therapy']",CT-1530,fexact,"['target 3', 'ct 1530', 'leukemia therapy']",correct_mapping
KITE-718,T cell stimulant; Immuno-oncology therapy,KITE-718,,KITE-718,kite 718,fexact,"['KITE-718', 'anti-MAGE A3/MAGE A6/HLA-DPB1*0401 TCR T-cell therapy (cancer)', 'MAGE A3/A6 targeting T-cell therapy (cancer)']",KITE-718,fexact,"['kite 718', 'anti mage a3 mage a6 hla dpb1 0401 tcr t cell therapy cancer', 'mage a3 a6 targeting t cell therapy cancer']",correct_mapping
MK-1026,Bruton tyrosine kinase inhibitor,MK-1026,,MK-1026,mk 1026,fexact,"['ARQ-531', 'MK-1026', ""Bruton's tyrosine kinase inhibitors (DLBCL)""]",MK-1026,fexact,"['arq 531', 'mk 1026', 'bruton s tyrosine kinase inhibitors dlbcl']",correct_mapping
icapamespib,Epichaperome inhibitor,icapamespib,,icapamespib,icapamespib,fexact,"['PU-AD', 'icapamespib', ""epichaperome inhibitor (oral, Alzheimer's disease)"", ""epichaperome inhibitor (oral, Alzheimer's disease), Samus Therapeutics"", 'PU-AD dihydrochloride']",icapamespib,fexact,"['pu ad', 'icapamespib', 'epichaperome inhibitor oral alzheimer s disease', 'epichaperome inhibitor oral alzheimer s disease samus therapeutics', 'pu ad dihydrochloride']",correct_mapping
valemetostat,Enhancer of zeste homolog 1 inhibitor; Enhancer of zeste homolog 2 inhibitor,valemetostat,,valemetostat,valemetostat,fexact,"['(R)-OR-S2', 'enhancer of zeste homolog 1/2 dual inhibitor (acute myeloid leukemia)', 'DS-3201b', 'valemetostat', 'OR-S1', 'valemetostat tosylate', 'DS-3201a', 'DS-3201']",valemetostat,fexact,"['r or s2', 'enhancer of zeste homolog 1 2 dual inhibitor acute myeloid leukemia', 'ds 3201b', 'valemetostat', 'or s1', 'valemetostat tosylate', 'ds 3201a', 'ds 3201']",correct_mapping
caspofungin acetate (IV),"Cell wall synthesis inhibitor; 1,3-Beta-glucan synthase inhibitor",caspofungin acetate,,caspofungin,caspofungin acetate,fexact,"['Cancidas', 'L-743872', 'MK-0991', 'caspofungin acetate', 'caspofungin', 'Cansidas', 'MK-991']",caspofungin,fexact,"['cancidas', 'l 743872', 'mk 0991', 'caspofungin acetate', 'caspofungin', 'cansidas', 'mk 991']",correct_mapping
avapritinib,C-kit inhibitor; Platelet-derived growth factor receptor alpha kinase inhib,avapritinib,,avapritinib,avapritinib,fexact,"['avapritinib (GIST/systemic mastocytosis),/CStone Pharmaceuticals', 'avapritinib (GIST/systemic mastocytosis)', 'AYVAKIT', 'avapritinib', 'KIT D816V inhibitor (systemic mastocytosis)', 'BLU-285', 'avapritinib (gist/systemic mastocytosis)']",avapritinib,fexact,"['avapritinib gist systemic mastocytosis cstone pharmaceuticals', 'avapritinib gist systemic mastocytosis', 'ayvakit', 'avapritinib', 'kit d816v inhibitor systemic mastocytosis', 'blu 285', 'avapritinib gist systemic mastocytosis']",correct_mapping
CART-133,Immuno-oncology therapy,CART-133,,CART-33,cart 33,fuzzy,"['anti-CD33 CAR T-cell therapy (leukemia)', 'CART-33']",CART-33,fexact,"['anti cd33 car t cell therapy leukemia', 'cart 33']",incorrect_mapping
propranolol,Beta adrenoreceptor antagonist,propranolol,,,,0,"['repurposed propranolol (cancer), harvard medical school//globalcures', 'repurposed propranolol (cancer), texas tech university', 'propranolol', 'repurposed propranolol (cancer), texas tech university/harvard medical school', 'repurposed propranolol (cancer)', 'repurposed propranolol (cancer), harvard medical school', 'repurposed propranolol (cancer), texas tech university/harvard medical school//globalcures']",,NER_API,[],0
maribavir,Cytomegalovirus UL97 protein kinase inhibitor; Protein kinase inhibitor,maribavir,,maribavir,maribavir,fexact,"['maribavir', 'GW-257406X', 'BW-1263W94', 'GW-1263', 'benzimidavir', 'SHP-620', 'Camvia', 'VP-41263', '1263W94', 'TAK-620']",maribavir,fexact,"['maribavir', 'gw 257406x', 'bw 1263w94', 'gw 1263', 'benzimidavir', 'shp 620', 'camvia', 'vp 41263', '1263w94', 'tak 620']",correct_mapping
Baycip,DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,Baycip,,ciprofloxacin hydrochloride,baycip,fexact,"['Ciprobay', 'Uniflox', 'Ciproxina', 'ciprofloxacin', 'Ciflox', 'BAY-Q-3939', 'Baycip', 'Cipro', 'Ciproxine', 'Ciloxan', 'Ciproxan', 'Ciproxin', 'ciprofloxacin hydrochloride']",ciprofloxacin hydrochloride,fexact,"['ciprobay', 'uniflox', 'ciproxina', 'ciprofloxacin', 'ciflox', 'bay q 3939', 'baycip', 'cipro', 'ciproxine', 'ciloxan', 'ciproxan', 'ciproxin', 'ciprofloxacin hydrochloride']",correct_mapping
moxifloxacin,DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,moxifloxacin,,moxifloxacin,moxifloxacin,fexact,"['Actira', 'Avilox', 'moxifloxacin hydrochloride', 'BAY-12-8039', 'Avelox', 'Octegra', 'Avalox', 'moxifloxacin', 'Izilox']",moxifloxacin,fexact,"['actira', 'avilox', 'moxifloxacin hydrochloride', 'bay 12 8039', 'avelox', 'octegra', 'avalox', 'moxifloxacin', 'izilox']",correct_mapping
piperacillin,Cell wall synthesis inhibitor,piperacillin,,,,0,"['piperacillin sodium + sulbactam sodium (intravenous, bacterial infection)', 'piperacillin', 'sulbactam', 'Yi Tan', 'piperacillin sodium + sulbactam sodium']",,NER_API,[],0
dextromethorphan,NMDA receptor antagonist,dextromethorphan,,,,0,"['dextromethorphan', 'FP-101']",,NER_API,[],0
"stem cell transplantation, unspecified",Not applicable,stem cell transplantation,unspecified,,,0,['stem cell transplantation'],,0,[],0
ofloxacin,DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,ofloxacin,,ofloxacin,ofloxacin,fexact,"['Ocuflox', 'Tarivid', 'ofloxacin', 'Floxin Otic', 'Oflocet', 'Floxin']",ofloxacin,fexact,"['ocuflox', 'tarivid', 'ofloxacin', 'floxin otic', 'oflocet', 'floxin']",correct_mapping
odronextamab,CD3 agonist; Immuno-oncology therapy,odronextamab,,odronextamab,odronextamab,fexact,"['REGN-1979', 'CD20XCD3', 'anti-CD20/anti-CD3 bispecific antibody (cancer)', 'odronextamab', 'anti-CD3/anti-CD20 bispecific T-cell engager (cancer)']",odronextamab,fexact,"['regn 1979', 'cd20xcd3', 'anti cd20 anti cd3 bispecific antibody cancer', 'odronextamab', 'anti cd3 anti cd20 bispecific t cell engager cancer']",correct_mapping
"methotrexate, Zydus",Immunosuppressant; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Disease modifying antirheumatic drug,methotrexate,Zydus,,,0,"['methotrexate', 'repurposed methotrexate (blood cancer)']",,NER_API,[],0
"CAR-T CD20, Cellular Biomedicine Group",T cell stimulant; Immuno-oncology therapy,CAR-T CD20,Cellular Biomedicine Group,,,0,['CAR-T CD20'],,0,[],0
allogeneic CMV specific cytotoxic T lymphocytes,Immunostimulant,allogeneic CMV specific cytotoxic T lymphocytes,,,,0,['allogeneic CMV specific cytotoxic T lymphocytes'],,0,[],0
CMV pp65 specific cytotoxic T lymphocytes,Immunostimulant,CMV pp65 specific cytotoxic T lymphocytes,,,,0,['CMV pp65 specific cytotoxic T lymphocytes'],,0,[],0
"CMV IE-1 specific cytotoxic T lymphocytes, unspecified",Immunostimulant,CMV IE-1 specific cytotoxic T lymphocytes,unspecified,,,0,['CMV IE-1 specific cytotoxic T lymphocytes'],,0,[],0
tafasitamab,CD19 antagonist; Immuno-oncology therapy,tafasitamab,,tafasitamab,tafasitamab,fexact,"['XmAb-5574', 'MOR-208', 'tafasitamab', 'Monjuvi', 'tafasitamab-cxix', 'triple anti-CD19/CD32a activator/CD16a activator (cancer), Xencor', 'triple anti-CD19/CD32a activator/CD16a activator (cancer)', 'anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor', 'XmAb CD19', 'XmAb-CD19', 'ENFORCER antibody', 'triple anti-CD19/FcgRIIa activator/FcgRIIIa activator (cancer), Xencor', 'Minjuvi', 'anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease)', 'MOR-00208', 'triple anti-CD19/FcgRIIa activator/FcgRIIIa activator (cancer)', 'XENP-5574']",tafasitamab,fexact,"['xmab 5574', 'mor 208', 'tafasitamab', 'monjuvi', 'tafasitamab cxix', 'triple anti cd19 cd32a activator cd16a activator cancer xencor', 'triple anti cd19 cd32a activator cd16a activator cancer', 'anti cd19 humanized monoclonal antibody cancer autoimmune disease xencor', 'xmab cd19', 'xmab cd19', 'enforcer antibody', 'triple anti cd19 fcgriia activator fcgriiia activator cancer xencor', 'minjuvi', 'anti cd19 humanized monoclonal antibody cancer autoimmune disease', 'mor 00208', 'triple anti cd19 fcgriia activator fcgriiia activator cancer', 'xenp 5574']",correct_mapping
spebrutinib besylate,Bruton tyrosine kinase inhibitor,spebrutinib besylate,,spebrutinib,spebrutinib besylate,fexact,"['AVL-291', 'Btk inhibitors (cancer)', 'spebrutinib', 'Btk inhibitors (cancer), Celgene', 'CC-90008', 'spebrutinib besylate', 'AVL-101', 'CC-292', 'AVL-292', 'CNX-652']",spebrutinib,fexact,"['avl 291', 'btk inhibitors cancer', 'spebrutinib', 'btk inhibitors cancer celgene', 'cc 90008', 'spebrutinib besylate', 'avl 101', 'cc 292', 'avl 292', 'cnx 652']",correct_mapping
cladribine (IV),Immunosuppressant; Adenosine deaminase inhibitor; DNA synthesis inhibitor,cladribine,,cladribine,cladribine,fexact,"['2-CdA', 'RWJ-26251', '2-chlorodeoxyadenosine', 'NSC-105014F', 'cladribine', 'Litak', 'Leustat', 'Leustatin']",cladribine,fexact,"['2 cda', 'rwj 26251', '2 chlorodeoxyadenosine', 'nsc 105014f', 'cladribine', 'litak', 'leustat', 'leustatin']",correct_mapping
extracorporeal photopheresis,Radical formation stimulant,extracorporeal photopheresis,,,,0,['extracorporeal photopheresis'],,0,[],0
"influenza vaccine, Q-H1N1, adjuvanted, GSK",Immunostimulant,influenza vaccine,GSK,,,0,['influenza vaccine'],,0,[],0
"clodronate disodium, Leiras",Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor,clodronate disodium,Leiras,clodronic acid,clodronate disodium,fexact,"['Clastoban', 'clodronate sodium', 'clodronic acid', 'Bonefos', 'KCO-692', 'clodronate disodium', 'clodronate tetrahydrate', 'Clasteon', 'clodronate disodium, Leiras', 'BAY-94-8393']",clodronic acid,fexact,"['clastoban', 'clodronate sodium', 'clodronic acid', 'bonefos', 'kco 692', 'clodronate disodium', 'clodronate tetrahydrate', 'clasteon', 'clodronate disodium leiras', 'bay 94 8393']",correct_mapping
ATIR,Immunosuppressant,ATIR,,ATIR-101,atir,fexact,"['ATIR', 'alloreactive T cell-depletion therapy (GvHD), Kiadis/', 'TH-9401', 'Theralux extracorporeal photochemotherapy', 'Add-Back of T Cell for Immune Reconstitution', 'alloreactive T cell-depletion therapy (GvHD), Kiadis/ Hospira', 'PDT', 'Add-Back of  Cell for Immune Reconstitution', 'PDT, Theratechnologies', 'TH-9402', 'allodepleted T-cell immunotherapeutics (GvHD)', 'Theralux', 'antileukemics (photoactive)', 'ATIR-101', 'alloreactive T cell-depletion therapy (GvHD),/', 'allodepleted T-cell immunotherapeutics (GvHD), Kiadis Pharma', 'antileukemics (photoactive), Theratechnologies']",ATIR-101,fexact,"['atir', 'alloreactive t cell depletion therapy gvhd kiadis', 'th 9401', 'theralux extracorporeal photochemotherapy', 'add back of t cell for immune reconstitution', 'alloreactive t cell depletion therapy gvhd kiadis hospira', 'pdt', 'add back of cell for immune reconstitution', 'pdt theratechnologies', 'th 9402', 'allodepleted t cell immunotherapeutics gvhd', 'theralux', 'antileukemics photoactive', 'atir 101', 'alloreactive t cell depletion therapy gvhd', 'allodepleted t cell immunotherapeutics gvhd kiadis pharma', 'antileukemics photoactive theratechnologies']",correct_mapping
calaspargase pegol,Protein synthesis inhibitor; Asparaginase stimulant; Apoptosis stimulant,calaspargase pegol,,calaspargase pegol,calaspargase pegol,fexact,"['SHP-663', 'calaspargase pegol-mknl', 'SC-PEG  coli L-asparaginase', 'SC Oncaspar', 'SC-PEG asparaginase', 'Oncaspar-IV', 'SC-PEG E coli L-asparaginase', 'SC-PEG E coli L-asparaginase, Enzon', 'Asparlas', 'calaspargase pegol', 'calaspargase pegol - mknl', 'next generation pegylated asparaginase (solid tumor/lymphoma), Enzon Pharmaceuticals', 'next generation pegylated asparaginase (solid tumor/lymphoma)', 'calaspargase pegol  mknl', 'EZN-2285']",calaspargase pegol,fexact,"['shp 663', 'calaspargase pegol mknl', 'sc peg coli l asparaginase', 'sc oncaspar', 'sc peg asparaginase', 'oncaspar iv', 'sc peg e coli l asparaginase', 'sc peg e coli l asparaginase enzon', 'asparlas', 'calaspargase pegol', 'calaspargase pegol mknl', 'next generation pegylated asparaginase solid tumor lymphoma enzon pharmaceuticals', 'next generation pegylated asparaginase solid tumor lymphoma', 'calaspargase pegol mknl', 'ezn 2285']",correct_mapping
Erwinase (IM),Protein synthesis inhibitor; Asparaginase stimulant; Apoptosis stimulant,Erwinase,,crisantaspase (acute lymphoblastic leukemia),erwinase,fexact,"['crisantaspase (acute lymphoblastic leukemia), Jazz Pharmaceuticals', 'crisantaspase', 'Erwinase', 'crisantaspase (acute lymphoblastic leukemia),/HPA', 'Erwinia chrysanthemi L-asparaginase (acute lymphoblastic leukemia),/HPA', 'Erwinaze', 'crisantaspase (acute lymphoblastic leukemia), OPi/HPA', 'asparaginase (Erwinia chrysanthemi)', 'crisantaspase (acute lymphoblastic leukemia)', 'Erwinia chrysanthemi L-asparaginase (acute lymphoblastic leukemia), OPi/HPA', 'OP-01']",crisantaspase (acute lymphoblastic leukemia),fexact,"['crisantaspase acute lymphoblastic leukemia jazz pharmaceuticals', 'crisantaspase', 'erwinase', 'crisantaspase acute lymphoblastic leukemia hpa', 'erwinia chrysanthemi l asparaginase acute lymphoblastic leukemia hpa', 'erwinaze', 'crisantaspase acute lymphoblastic leukemia opi hpa', 'asparaginase erwinia chrysanthemi', 'crisantaspase acute lymphoblastic leukemia', 'erwinia chrysanthemi l asparaginase acute lymphoblastic leukemia opi hpa', 'op 01']",correct_mapping
veltuzumab (SC),CD20 antagonist; Immuno-oncology therapy,veltuzumab,,veltuzumab,veltuzumab,fexact,"['hA20 antibody', 'hCD20 antibody', 'anti-NHL antibody', 'veltuzumab', 'IMMU-106', 'cA20 antibody']",veltuzumab,fexact,"['ha20 antibody', 'hcd20 antibody', 'anti nhl antibody', 'veltuzumab', 'immu 106', 'ca20 antibody']",correct_mapping
rasburicase,Urate oxidase stimulant,rasburicase,,rasburicase,rasburicase,fexact,"['Elitek', 'Fasturtec', 'urate oxydase', 'SR-29142', 'urate oxidase', 'Rasuritek', 'rasburicase']",rasburicase,fexact,"['elitek', 'fasturtec', 'urate oxydase', 'sr 29142', 'urate oxidase', 'rasuritek', 'rasburicase']",correct_mapping
"epoetin beta, Roche",Erythropoietin receptor agonist,epoetin beta,Roche,epoetin beta,epoetin beta,fexact,"['Epogin', 'recombinant human erythropoietin, Chugai', 'erythropoietin, Genetics Institute//', 'Marogen', 'rHuEPO, Genetics Inst//', 'erythropoietin, Genetics Institute//Roche', 'epoetin beta, Roche', 'NeoRecormon', 'recombinant human erythropoietin', 'Recormon', 'epoetin beta, Genetics Inst//', 'EPOCH', 'erythropoietin, Genetics Institute/Chugai/Roche', 'RO-2053859', 'rHuEPO, Genetics Inst/Chugai/', 'epoetin beta, Genetics Inst/Chugai/', 'epoetin beta', 'Epogin Subcutaneous Injection Syringe 24000']",epoetin beta,fexact,"['epogin', 'recombinant human erythropoietin chugai', 'erythropoietin genetics institute', 'marogen', 'rhuepo genetics inst', 'erythropoietin genetics institute roche', 'epoetin beta roche', 'neorecormon', 'recombinant human erythropoietin', 'recormon', 'epoetin beta genetics inst', 'epoch', 'erythropoietin genetics institute chugai roche', 'ro 2053859', 'rhuepo genetics inst chugai', 'epoetin beta genetics inst chugai', 'epoetin beta', 'epogin subcutaneous injection syringe 24000']",correct_mapping
undisclosed - iron (IV),Iron absorption stimulant,undisclosed - iron,,,,0,['undisclosed - iron'],,0,[],0
MDR1 transduced autologous peripheral blood progenitor cells,Stem cell growth factor agonist,MDR1 transduced autologous peripheral blood progenitor cells,,,,0,['MDR1 transduced autologous peripheral blood progenitor cells'],,0,[],0
(R)-etodolac,Cyclooxygenase 2 inhibitor; Mcl-1 antagonist,etodolac,,,,0,"['Utradol', 'etodolac', 'Lodine XL', 'Lodine SR', 'Hypen', 'Ostelac', 'Lodine', 'ramodar', 'tedolan', 'AY-24236', 'etanal', 'Edolan', 'Osteluc', 'zedolac', 'RAK-591', 'etodolic acid']",,NER_API,[],0
BMS-387032,Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor; Mcl-1 antagonist; Cell cycle inhibitor,BMS-387032,,SNS-032,bms 387032,fexact,"['BMS-387032', 'cyclin-dependent kinase inhibitor (cancer), Sunesis', 'SNS-032']",SNS-032,fexact,"['bms 387032', 'cyclin dependent kinase inhibitor cancer sunesis', 'sns 032']",correct_mapping
rIFN-alpha 1b,Interferon receptor agonist,rIFN-alpha 1b,,,,0,['rIFN-alpha 1b'],,0,[],0
masitinib,Colony stimulating factor 1 receptor antagonist; LYN tyrosine kinase inhibitor; C-kit inhibitor; FGF receptor 3 tyrosine kinase inhibitor; Fyn tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor,masitinib,,masitinib,masitinib,fexact,"['Alsitek', 'Masican', 'Kinaction', 'Masipro', 'Masiviera', 'c-kit inhibitor (mastocytosis/GIST)', 'AB-1010', 'masitinib']",masitinib,fexact,"['alsitek', 'masican', 'kinaction', 'masipro', 'masiviera', 'c kit inhibitor mastocytosis gist', 'ab 1010', 'masitinib']",correct_mapping
"paricalcitol, oral, AbbVie",Vitamin D agonist,paricalcitol,AbbVie,paricalcitol,paricalcitol,fexact,"['paricalcitol (iv), Abbott', 'ABT-358', 'paricalcitol (iv)', 'Zemplar', 'paricalcitol']",paricalcitol,fexact,"['paricalcitol iv abbott', 'abt 358', 'paricalcitol iv', 'zemplar', 'paricalcitol']",correct_mapping
lestaurtinib,Flt-3 antagonist; Janus kinase 2 inhibitor; TrkA tyrosine kinase inhibitor; Apoptosis stimulant,lestaurtinib,,lestaurtinib,lestaurtinib,fexact,"['CEP-701', 'lestaurtinib', 'KT-5555', 'SPM-924', 'NSC-617807']",lestaurtinib,fexact,"['cep 701', 'lestaurtinib', 'kt 5555', 'spm 924', 'nsc 617807']",correct_mapping
defibrotide (oral),Unidentified pharmacological activity,defibrotide,,,,0,['defibrotide'],,0,[],0
defibrotide (IV),Unidentified pharmacological activity,defibrotide,,,,0,['defibrotide'],,0,[],0
"iron sucrose, Vifor Pharma",Iron absorption stimulant,iron sucrose,Vifor Pharma,,,0,"['iron sucrose injection (iron deficiency anemia), Vifor/Luitpold/Galenica/', 'iron sucrose injection (iron deficiency anemia),/Luitpold/Galenica/', 'Venofer', 'iron sucrose injection (iron deficiency anemia), Vifor//Galenica', 'iron sucrose injection (iron deficiency anemia),//Galenica', 'iron sucrose']",,NER_API,[],0
"curcuminoids, Sabinsa",Reducing agent; Free radical scavenger,curcuminoids,Sabinsa,,,0,['curcuminoids'],,0,[],0
talmapimod (capsule),Mitogen-activated protein kinase 14 inhibitor,talmapimod,,talmapimod,talmapimod,fexact,"['p38 MAP kinase inhibitors (inflammation)', 'SCIO-469', 'talmapimod']",talmapimod,fexact,"['p38 map kinase inhibitors inflammation', 'scio 469', 'talmapimod']",correct_mapping
Xcellerate,Immunostimulant; T cell stimulant,Xcellerate,,,,0,['Xcellerate'],,0,[],0
ß-alethine,Immunostimulant,ß-alethine,,,,0,['ß-alethine'],,0,[],0
"dendritic cell vaccine, Celgene",T cell stimulant,dendritic cell vaccine,Celgene,,,0,['dendritic cell vaccine'],,0,[],0
PUVA,Radical formation stimulant,PUVA,,,,0,['PUVA'],,0,[],0
anti-B7 antibodies,T cell inhibitor,anti-B7 antibodies,,,,0,['anti-B7 antibodies'],,0,[],0
forodesine (IV),Immunosuppressant; Purine nucleoside phosphorylase inhibitor,forodesine,,,,0,"['BCX-1777', 'forodesine hydrochloride (intravenous, cancer), BioCryst/ Mundipharma', 'forodesine hydrochloride (intravenous, cancer),/', 'forodesine (intravenous, cancer),/ Mundipharma', 'Immucillin-H', 'forodesine', 'forodesine hydrochloride', 'forodesine (intravenous, cancer),/', 'forodesine (intravenous, cancer), BioCryst/ Mundipharma', 'Fodosine', 'forodesine hydrochloride (intravenous, cancer),/ Mundipharma']",,NER_API,[],0
forodesine (tablet),Immunosuppressant; Purine nucleoside phosphorylase inhibitor,forodesine,,,,0,"['BCX-1777', 'forodesine hydrochloride (intravenous, cancer), BioCryst/ Mundipharma', 'forodesine hydrochloride (intravenous, cancer),/', 'forodesine (intravenous, cancer),/ Mundipharma', 'Immucillin-H', 'forodesine', 'forodesine hydrochloride', 'forodesine (intravenous, cancer),/', 'forodesine (intravenous, cancer), BioCryst/ Mundipharma', 'Fodosine', 'forodesine hydrochloride (intravenous, cancer),/ Mundipharma']",,NER_API,[],0
Wobe-Mucos NEM,Unidentified pharmacological activity,Wobe-Mucos NEM,,,,0,['Wobe-Mucos NEM'],,0,[],0
R-35 (IV),Interleukin 2 receptor antagonist; Immunosuppressant; T cell inhibitor,R-35,,,,0,['R-35'],,0,[],0
dehydroepiandrosterone,Unidentified pharmacological activity,dehydroepiandrosterone,,,,0,"['prasterone sodium sulphate (vaginal atrophy),/', 'prasterone (intra-vaginal, female sexual dysfunction/vaginal atrophy), Endoceutics//', 'Fidelin', 'DHEA (sexual dysfunction/vaginal atrophy)', 'DHEA, Paladin Labs', 'PB-005', '3-beta-hydroxyandrost-5-en-17-one', 'DHEAS, Pharmadigm', 'dehydroepiandrosterone (female sexual dysfunction)', 'DHEA, Neuroscience Pharma', 'DHEA (sexual dysfunction/vaginal atrophy), Endoceutics', 'BAY-86-5314', 'prasterone, Paladin Labs', 'DHEAS', 'synthetic steroid hormones', 'dehydroepiandrosterone, Neuroscience Pharma', 'sodium prasterone sulfate', 'PB-008', 'Vaginorm', 'prasterone (intravaginal, dyspareunia),/', 'DHEA', 'dehydroepiandrosterone (sexual dysfunction/vaginal atrophy),/', 'dehydroepiandrosterone', 'prasterone (intra-vaginal, female sexual dysfunction/vaginal atrophy),//', 'sodium prasterone sulfate (vaginal atrophy), Mayinglong Pharmaceutical/', 'prasterone  (female sexual dysfunction)', 'prasterone (intravaginal, dyspareunia), Endoceutics/', 'dehydroepiandrosterone (sexual dysfunction/vaginal atrophy), Endoceutics/', 'DHEAS, Paradigm', 'sodium prasterone sulfate (vaginal atrophy),/', 'dehydroepiandrosterone (sexual dysfunction/vaginal atrophy)', 'prasterone sodium sulphate (vaginal atrophy), Mayinglong Pharmaceutical/', 'synthetic steroid hormones, Pharmadigm', 'dehydroepiandrosterone, Paradigm', 'DHEA sulfate', 'dehydroepiandrosterone, Paladin Labs', 'prasterone', 'Intrarosa', 'prasterone (intra-vaginal, female sexual dysfunction/vaginal atrophy), Endoceutics/Bayer/', 'dehydroepiandrosterone (sexual dysfunction/vaginal atrophy), Endorecherche', 'INFLAREST']",,Drug_API_mapping,[],0
omacetaxine mepesuccinate (SC),Angiogenesis inhibitor; Apoptosis stimulant,omacetaxine mepesuccinate,,omacetaxine mepesuccinate,omacetaxine mepesuccinate,fexact,"['omacetaxine mepesuccinate', 'NSC-141633', 'homoharringtonine']",omacetaxine mepesuccinate,fexact,"['omacetaxine mepesuccinate', 'nsc 141633', 'homoharringtonine']",correct_mapping
KPT-9274,Nicotinamide phosphoribosyl transferase inhibitor; p21 activated kinase 4 inhibitor,KPT-9274,,KPT-9274,kpt 9274,fexact,"['ATG-019', 'KPT-9331', 'PAK4/NAMPT dual inhibitors (oral, cancer), Karyopharm/', 'KPT-9274', 'PAK4/NAMPT dual inhibitors (oral, cancer),/', 'KPT-7651', 'KPT-9307', 'KPT-7189', 'KPT-6604', 'KPT-8752', 'PAK4/NAMPT dual inhibitors (oral, cancer), Karyopharm Therapeutics', 'KCP-9274', 'PAK4/NAMPT dual inhibitors (oral, cancer)', 'KPT-7523']",KPT-9274,fexact,"['atg 019', 'kpt 9331', 'pak4 nampt dual inhibitors oral cancer karyopharm', 'kpt 9274', 'pak4 nampt dual inhibitors oral cancer', 'kpt 7651', 'kpt 9307', 'kpt 7189', 'kpt 6604', 'kpt 8752', 'pak4 nampt dual inhibitors oral cancer karyopharm therapeutics', 'kcp 9274', 'pak4 nampt dual inhibitors oral cancer', 'kpt 7523']",correct_mapping
"sodium stibogluconate, unspecified",Tyrosine phosphatase 1B inhibitor,sodium stibogluconate,unspecified,sodium stibogluconate (cancer),sodium stibogluconate,fexact,"['sodium stibogluconate', 'Lenocta', 'sodium stibogluconate (cancer)', 'sodium stibogluconate (cancer), VioQuest', 'VQD-001', 'sodium stibogluconate (cancer), Greenwich']",sodium stibogluconate (cancer),fexact,"['sodium stibogluconate', 'lenocta', 'sodium stibogluconate cancer', 'sodium stibogluconate cancer vioquest', 'vqd 001', 'sodium stibogluconate cancer greenwich']",correct_mapping
DVX-201,Natural killer cell stimulant; Immuno-oncology therapy,DVX-201,,,,0,"['DVX-201', 'CAR NK-cell therapy (allogeneic, acute myelogenous leukemia/high risk myelodysplastic syndrome/high risk myelodysplastic / myeloproliferative neoplasms/solid tumors/infectious disease)']",,NER_API,[],0
WU-NK-01,Natural killer cell stimulant; Immuno-oncology therapy,WU-NK-01,,,,0,['WU-NK-01'],,0,[],0
anti-CLL-1 CAR-T cells,T cell stimulant; Immuno-oncology therapy,anti-CLL-1 CAR-T cells,,,,0,['anti-CLL-1 CAR-T cells'],,0,[],0
FHD-286,ATPase inhibitor,FHD-286,,FHD-286,fhd 286,fexact,"['FHD-286', 'allosteric ATPase inhibitor of BRG1 and BRM (oral, acute myeloid leukemia/uveal melanoma)']",FHD-286,fexact,"['fhd 286', 'allosteric atpase inhibitor of brg1 and brm oral acute myeloid leukemia uveal melanoma']",correct_mapping
omacetaxine mepesuccinate,Angiogenesis inhibitor; Apoptosis stimulant,omacetaxine mepesuccinate,,omacetaxine mepesuccinate,omacetaxine mepesuccinate,fexact,"['omacetaxine mepesuccinate', 'NSC-141633', 'homoharringtonine']",omacetaxine mepesuccinate,fexact,"['omacetaxine mepesuccinate', 'nsc 141633', 'homoharringtonine']",correct_mapping
cladribine,Immunosuppressant; Adenosine deaminase inhibitor; DNA synthesis inhibitor,cladribine,,cladribine,cladribine,fexact,"['2-CdA', 'RWJ-26251', '2-chlorodeoxyadenosine', 'NSC-105014F', 'cladribine', 'Litak', 'Leustat', 'Leustatin']",cladribine,fexact,"['2 cda', 'rwj 26251', '2 chlorodeoxyadenosine', 'nsc 105014f', 'cladribine', 'litak', 'leustat', 'leustatin']",correct_mapping
PHI-101,Flt-3 antagonist; Checkpoint kinase 2 inhibitor,PHI-101,,PHI-101,phi 101,fexact,"['Flt3 tyrosine kinase inhibitor (oral, cancer), Pharos', 'Flt3 tyrosine kinase inhibitor (oral, cancer)', 'PHI-101']",PHI-101,fexact,"['flt3 tyrosine kinase inhibitor oral cancer pharos', 'flt3 tyrosine kinase inhibitor oral cancer', 'phi 101']",correct_mapping
glasdegib (oral),Hedgehog pathway inhibitor,glasdegib,,glasdegib,glasdegib,fexact,"['PF-04449913', 'PF-913', 'sonic hedgehog inhibitor (oral/tablet/capsule, cancers)', 'Daurismo', 'glasdegib maleate', 'glasdegib']",glasdegib,fexact,"['pf 04449913', 'pf 913', 'sonic hedgehog inhibitor oral tablet capsule cancers', 'daurismo', 'glasdegib maleate', 'glasdegib']",correct_mapping
ETH-155008,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Pim-3 kinase inhibitor,ETH-155008,,ETH-155008,eth 155008,fexact,"['CDK4/CDK6/PIM/FLT3 inhibitor (cancer/NHL/AML), Shengke Therapeutics', 'ETH-155008']",ETH-155008,fexact,"['cdk4 cdk6 pim flt3 inhibitor cancer nhl aml shengke therapeutics', 'eth 155008']",correct_mapping
homoharringtonine,Apoptosis stimulant,homoharringtonine,,omacetaxine mepesuccinate,homoharringtonine,fexact,"['omacetaxine mepesuccinate', 'NSC-141633', 'homoharringtonine']",omacetaxine mepesuccinate,fexact,"['omacetaxine mepesuccinate', 'nsc 141633', 'homoharringtonine']",correct_mapping
LNK-01002,"Kinase inhibitor, unspecified",LNK-01002,,LNK-01002,lnk 01002,fexact,"['LNK-01002', 'LNK-1000318', 'ras protein inhibitor (oral/capsule/protac), malignant myeloid hematological tumor),//riken', 'ras protein inhibitor (oral/capsule/protac), malignant myeloid hematological tumor), lynk pharmaceuticals//riken', 'ras protein inhibitor (oral/capsule/protac), malignant myeloid hematological tumor)']",LNK-01002,fexact,"['lnk 01002', 'lnk 1000318', 'ras protein inhibitor oral capsule protac malignant myeloid hematological tumor riken', 'ras protein inhibitor oral capsule protac malignant myeloid hematological tumor lynk pharmaceuticals riken', 'ras protein inhibitor oral capsule protac malignant myeloid hematological tumor']",correct_mapping
JNJ-75276617,Menin-MLL inhibitor,JNJ-75276617,,JNJ-75276617,jnj 75276617,fexact,"['JNJ-75276617', 'histone lysine methyltransferase 2A-menin interaction inhibitor (oral, acute leukemiaa/acute myeloid leukemia/acute lymphoblastic leukemia)', 'KMT2A- Menin interaction inhibitor (acute leukemiaa/acute myeloid leukemia/acute lymphoblastic leukemia)']",JNJ-75276617,fexact,"['jnj 75276617', 'histone lysine methyltransferase 2a menin interaction inhibitor oral acute leukemiaa acute myeloid leukemia acute lymphoblastic leukemia', 'kmt2a menin interaction inhibitor acute leukemiaa acute myeloid leukemia acute lymphoblastic leukemia']",correct_mapping
mitoxantrone,Immunosuppressant; DNA topoisomerase II inhibitor,mitoxantrone,,mitoxantrone,mitoxantrone,fexact,"['Ralenova', 'mitoxantrone', 'CL-232315', 'Elsep', 'mitozantrone', 'mitoxantrone hydrochloride', 'Novantrone']",mitoxantrone,fexact,"['ralenova', 'mitoxantrone', 'cl 232315', 'elsep', 'mitozantrone', 'mitoxantrone hydrochloride', 'novantrone']",correct_mapping
"ILT3 chimaeric antigen receptor-T cell therapy, Carbiogene Therapeutics",T cell stimulant; Immuno-oncology therapy,ILT3 chimaeric antigen receptor-T cell therapy,Carbiogene Therapeutics,,,0,['ILT3 chimaeric antigen receptor-T cell therapy'],,0,[],0
Senl_002,CD19 antagonist; Immuno-oncology therapy,Senl_002,,,,0,['Senl_002'],,0,[],0
KITE-222,T cell stimulant; Immuno-oncology therapy,KITE-222,,KITE-222,kite 222,fexact,"['anti-CLL1 CAR T-cell therapy (AML)', 'KITE-796', 'anti-CLL1 CAR T-cell therapy (AML), Gilead', 'anti-CLL1 CAR T-cell therapy (eACT, cancer), Kite/', 'anti-CLL1 CAR T-cell therapy (eACT, cancer),/', 'KITE-222']",KITE-222,fexact,"['anti cll1 car t cell therapy aml', 'kite 796', 'anti cll1 car t cell therapy aml gilead', 'anti cll1 car t cell therapy eact cancer kite', 'anti cll1 car t cell therapy eact cancer', 'kite 222']",correct_mapping
CC-96191,Unidentified pharmacological activity,CC-96191,,CC-96191,cc 96191,fexact,['CC-96191'],CC-96191,fexact,['cc 96191'],correct_mapping
BGB-11417,Bcl2 inhibitor,BGB-11417,,BGB-11417,bgb 11417,fexact,"['Bcl-2 inhibitor (oral film-coated tablets, B-cell lymphomas)', 'BGB-11417']",BGB-11417,fexact,"['bcl 2 inhibitor oral film coated tablets b cell lymphomas', 'bgb 11417']",correct_mapping
IM-73,T cell stimulant; Immuno-oncology therapy,IM-73,,,,0,['IM-73'],,0,[],0
"CD7 CAR-T cell therapy, PersonGen Biomedicine",T cell stimulant; Immuno-oncology therapy,CD7 CAR-T cell therapy,PersonGen Biomedicine,,,0,['CD7 CAR-T cell therapy'],,0,[],0
HMPL-306,Isocitrate dehydrogenase 1 inhibitor; Isocitrate dehydrogenase 2 inhibitor,HMPL-306,,HMPL-306,hmpl 306,fexact,"['IDH 1/2 enzyme inhibitor', 'dual-inhibitor of Isocitrate dehydrogenase 1/2 enzymes', 'HMPL-306']",HMPL-306,fexact,"['idh 1 2 enzyme inhibitor', 'dual inhibitor of isocitrate dehydrogenase 1 2 enzymes', 'hmpl 306']",correct_mapping
DS-1594b,Menin-MLL inhibitor,DS-1594b,,DS-1594,ds 1594b,fexact,"['menin inhibitor (oral, myelodysplastic syndrome/acute lymphoblastic leukemia/acute myelogenous leukemia/chronic myelomonocytic leukemia)', 'DS-1594', 'DS-1594b']",DS-1594,fexact,"['menin inhibitor oral myelodysplastic syndrome acute lymphoblastic leukemia acute myelogenous leukemia chronic myelomonocytic leukemia', 'ds 1594', 'ds 1594b']",correct_mapping
aspacytarabine,DNA synthesis inhibitor,aspacytarabine,,aspacytarabine,aspacytarabine,fexact,"['cytarabine-asparagine conjugate (leukemia)', 'aspacytarabine', 'Astarabine', 'Asp(cytarabine)', 'BST-236']",aspacytarabine,fexact,"['cytarabine asparagine conjugate leukemia', 'aspacytarabine', 'astarabine', 'asp cytarabine', 'bst 236']",correct_mapping
BS-HH-002,Janus kinase inhibitor; Apoptosis stimulant,BS-HH-002,,BS-HH-002.SA,bs hh 002,fexact,"['BS-HH-002', 'BS-HH-002.SA']",BS-HH-002.SA,fexact,"['bs hh 002', 'bs hh 002 sa']",correct_mapping
CFI-400945,Polo-like kinase 4 inhibitor; Immuno-oncology therapy,CFI-400945,,CFI-400945 fumarate,cfi 400945,fexact,"['polo-like kinase 4 (plk4)\xa0inhibitor (oral tablet, advanced cancer/mds/aml/metastatic breast tumor/brain tumor)', 'CFI-400945 fumarate', 'polo-like kinase 4 (PLK4)\xa0inhibitor (oral tablet, advanced cancer/MDS/AML/metastatic breast tumor/brain tumor), The University Health Network', 'polo-like kinase 4 (plk4) inhibitor (oral tablet, advanced cancer/mds/aml/metastatic breast tumor/brain tumor)', 'CFI-440945', '400945', 'polo-like kinase 4 (PLK4) inhibitor (oral tablet, advanced cancer/MDS/AML/metastatic breast tumor/brain tumor), Treadwell Therapeutics/', '945', 'CFI-400945']",CFI-400945 fumarate,fexact,"['polo like kinase 4 plk4 \xa0inhibitor oral tablet advanced cancer mds aml metastatic breast tumor brain tumor', 'cfi 400945 fumarate', 'polo like kinase 4 plk4 \xa0inhibitor oral tablet advanced cancer mds aml metastatic breast tumor brain tumor the university health network', 'polo like kinase 4 plk4 inhibitor oral tablet advanced cancer mds aml metastatic breast tumor brain tumor', 'cfi 440945', '400945', 'polo like kinase 4 plk4 inhibitor oral tablet advanced cancer mds aml metastatic breast tumor brain tumor treadwell therapeutics', '945', 'cfi 400945']",correct_mapping
tamibarotene,Retinoic acid alpha receptor agonist; Retinoic acid beta receptor agonist,tamibarotene,,tamibarotene,tamibarotene,fexact,"['Tamibaro', 'TM-411', 'Amnolake', 'oral tamibarotene (oncological/inflammatory indications), Nippon Shinyaku/R&R/TMRC//Choongwae', 'tamibarotene', 'oral tamibarotene (oncological/inflammatory indications),//TMRC//Choongwae', 'OP-09', 'oral tamibarotene (oncological/inflammatory indications),/R&R/TMRC//Choongwae', 'RR-110', 'oral tamibarotene (oncological/inflammatory indications), Nippon Shinyaku/R&R/TMRC/Innovive/Choongwae', 'INNO-507', 'OMSO-728', 'TOS-80T', 'Amnoid', 'AM-80', 'oral tamibarotene (oncological/inflammatory indications),////Choongwae', 'SY-1425', 'oral tamibarotene (oncological/inflammatory indications), Nippon Shinyaku/R&R/TMRC/CytRx/Choongwae', 'Z-208']",tamibarotene,fexact,"['tamibaro', 'tm 411', 'amnolake', 'oral tamibarotene oncological inflammatory indications nippon shinyaku r r tmrc choongwae', 'tamibarotene', 'oral tamibarotene oncological inflammatory indications tmrc choongwae', 'op 09', 'oral tamibarotene oncological inflammatory indications r r tmrc choongwae', 'rr 110', 'oral tamibarotene oncological inflammatory indications nippon shinyaku r r tmrc innovive choongwae', 'inno 507', 'omso 728', 'tos 80t', 'amnoid', 'am 80', 'oral tamibarotene oncological inflammatory indications choongwae', 'sy 1425', 'oral tamibarotene oncological inflammatory indications nippon shinyaku r r tmrc cytrx choongwae', 'z 208']",correct_mapping
"ceramide nanoliposome, Keystone Nano",Unidentified pharmacological activity,ceramide nanoliposome,Keystone Nano,,,0,['ceramide nanoliposome'],,0,[],0
TBX-2400,Immunostimulant,TBX-2400,,TBX-2400,tbx 2400,fexact,['TBX-2400'],TBX-2400,fexact,['tbx 2400'],correct_mapping
"TAA6 CAR-T cell therapy, PersonGen BioTherapeutics",T cell stimulant; Immuno-oncology therapy,TAA6 CAR-T cell therapy,PersonGen BioTherapeutics,,,0,['TAA6 CAR-T cell therapy'],,0,[],0
SKLB-1028,EGFR antagonist; Abl receptor tyrosine kinase inhibitor; Flt-3 antagonist,SKLB-1028,,SKLB-1028,sklb 1028,fexact,['SKLB-1028'],SKLB-1028,fexact,['sklb 1028'],correct_mapping
flotetuzumab,CD3 agonist; Immuno-oncology therapy,flotetuzumab,,flotetuzumab,flotetuzumab,fexact,"['MGD-006', 'DART 123 (cancer), Servier', 'CD123 x CD3 DART Bi-Specific Antibody', 'anti-CD3/anti-CD123 bispecific T-cell engager (DART, hematological malignancy)', 'S-80880', 'flotetuzumab', 'CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody', 'dart 123 (cancer)']",flotetuzumab,fexact,"['mgd 006', 'dart 123 cancer servier', 'cd123 x cd3 dart bi specific antibody', 'anti cd3 anti cd123 bispecific t cell engager dart hematological malignancy', 's 80880', 'flotetuzumab', 'cd123 x cd3 dual affinity re targeting bi specific antibody', 'dart 123 cancer']",correct_mapping
MANA-312,T cell stimulant; Immuno-oncology therapy,MANA-312,,MANA-312,mana 312,fexact,"['taa-targeted t-cell therapy (prame, survivin, wt1)', 'tumor associated antigen specific t-cells (hodgkin lymphoma)', 'MANA-312']",MANA-312,fexact,"['taa targeted t cell therapy prame survivin wt1', 'tumor associated antigen specific t cells hodgkin lymphoma', 'mana 312']",correct_mapping
quizartinib dihydrochloride,Flt-3 antagonist,quizartinib dihydrochloride,,quizartinib dihydrochloride,quizartinib dihydrochloride,fexact,"['AB-200432', 'ASP-2689', 'quizartinib', 'AC-886', 'Vanflyta', 'AB-530', 'AB-460', 'quizartinib dihydrochloride', 'AB-200382', 'AB-200243', 'Flt3 tyrosine kinase inhibitors', 'AB-200434', 'Flt3 tyrosine kinase inhibitors,/Astellas', 'AB-515', 'Flt3 tyrosine kinase inhibitors,/', 'AC-220']",quizartinib dihydrochloride,fexact,"['ab 200432', 'asp 2689', 'quizartinib', 'ac 886', 'vanflyta', 'ab 530', 'ab 460', 'quizartinib dihydrochloride', 'ab 200382', 'ab 200243', 'flt3 tyrosine kinase inhibitors', 'ab 200434', 'flt3 tyrosine kinase inhibitors astellas', 'ab 515', 'flt3 tyrosine kinase inhibitors', 'ac 220']",correct_mapping
TL-895,Tyrosine kinase inhibitor (TKI),TL-895,,TL-895,tl 895,fexact,"['bruton\xa0tyrosine kinase inhibitor (oral, COVID-19/viral pneumonia)', 'TL-895', 'bruton\xa0tyrosine kinase inhibitor (myelofibrosis)']",TL-895,fexact,"['bruton\xa0tyrosine kinase inhibitor oral covid 19 viral pneumonia', 'tl 895', 'bruton\xa0tyrosine kinase inhibitor myelofibrosis']",correct_mapping
"L-asparaginase, Alize",Asparaginase stimulant,L-asparaginase,Alize,asparaginase,asparaginase,fuzzy,"['Spectrila', 'asparaginase']",asparaginase,fexact,"['spectrila', 'asparaginase']",incorrect_mapping
"natural killer cells, unspecified",Immunostimulant,natural killer cells,unspecified,,,0,['natural killer cells'],,0,[],0
daunorubicin,DNA synthesis inhibitor; Radical formation stimulant; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,daunorubicin,,"doxorubicin (encapsulated nanoparticle, bone cancer)",daunorubicin,fexact,"['doxorubicin (encapsulated nanoparticle, bone cancer)', 'doxorubicin', 'daunorubicin (encapsulated nanoparticle, breast cancer)', 'doxorubicin (encapsulated nanoparticle, breast cancer)', 'IT-143', 'daunorubicin']","doxorubicin (encapsulated nanoparticle, bone cancer)",fexact,"['doxorubicin encapsulated nanoparticle bone cancer', 'doxorubicin', 'daunorubicin encapsulated nanoparticle breast cancer', 'doxorubicin encapsulated nanoparticle breast cancer', 'it 143', 'daunorubicin']",correct_mapping
TAS-1553,Ribonucleoside diphosphate reductase inhibitor,TAS-1553,,TAS-1553,tas 1553,fexact,"['RNR inhibitors (cancer)', 'ribonucleotide reductase inhibitors (cancer)', 'TAS-1553']",TAS-1553,fexact,"['rnr inhibitors cancer', 'ribonucleotide reductase inhibitors cancer', 'tas 1553']",correct_mapping
ALX-148,CD47 antagonist; Immuno-oncology therapy; Signal regulatory protein alpha antagonist,ALX-148,,ALX-148,alx 148,fexact,"['CD47 inhibitor (cancer), Alexo Therapeutics', 'CD47-SIRPalpha interaction inhibitors (cancer), Alexo Therapeutics', 'cd47-sirpalpha interaction inhibitors (myelodysplastic syndrome/acute myelogenous leukemia)', 'ALX-148', 'CD47 checkpoint inhibitor (cancer/acute myelogenous leukemia/), Alexo Therapeutics']",ALX-148,fexact,"['cd47 inhibitor cancer alexo therapeutics', 'cd47 sirpalpha interaction inhibitors cancer alexo therapeutics', 'cd47 sirpalpha interaction inhibitors myelodysplastic syndrome acute myelogenous leukemia', 'alx 148', 'cd47 checkpoint inhibitor cancer acute myelogenous leukemia alexo therapeutics']",correct_mapping
"interferon gamma-1b, unspecified",Interferon receptor agonist; T helper cell stimulant,interferon gamma-1b,unspecified,Actimmune,interferon gamma 1b,fexact,"['Actimmune', 'interferon gamma-1b,/', 'Immukine', 'Imukin', 'interferon gamma, Connective Therapeutics', 'interferon gamma-1b, Horizon/Clinigen', 'Immukin', 'interferon gamma, Connetics', 'DK-1001, THERAMetrics', 'DK-1001, mondoBIOTECH', 'DasKloster 1001-01', 'interferon (gamma1b)', 'interferon (gamma1b), Daiichi', 'interferon (gamma1b), Toray', 'interferon gamma-1b, Horizon/', 'interferon (gamma1b), Genentech', 'interferon gamma-1b', 'interferon gamma', 'Imuforgamma', 'Imukine']",Actimmune,fexact,"['actimmune', 'interferon gamma 1b', 'immukine', 'imukin', 'interferon gamma connective therapeutics', 'interferon gamma 1b horizon clinigen', 'immukin', 'interferon gamma connetics', 'dk 1001 therametrics', 'dk 1001 mondobiotech', 'daskloster 1001 01', 'interferon gamma1b', 'interferon gamma1b daiichi', 'interferon gamma1b toray', 'interferon gamma 1b horizon', 'interferon gamma1b genentech', 'interferon gamma 1b', 'interferon gamma', 'imuforgamma', 'imukine']",correct_mapping
NKX-101,Interleukin 15 agonist; Natural killer cell group 2D stimulant; Immuno-oncology therapy,NKX-101,,NKX-101,nkx 101,fexact,"['allogeneic CAR NK cell therapy (NK cell expansion technology, cancer)', 'allogeneic anti-NKG2D-ligand CAR NK-cell therapy (IL-15 technology, cancer)', 'NKX-101', 'allogeneic CAR NK cell therapy (NK cell expansion technology, hepatocellular carcinoma (HCC)/ intrahepatic cholangiocarcinoma (ICC)/metastatic colorectal cancer (mCRC))']",NKX-101,fexact,"['allogeneic car nk cell therapy nk cell expansion technology cancer', 'allogeneic anti nkg2d ligand car nk cell therapy il 15 technology cancer', 'nkx 101', 'allogeneic car nk cell therapy nk cell expansion technology hepatocellular carcinoma hcc intrahepatic cholangiocarcinoma icc metastatic colorectal cancer mcrc']",correct_mapping
"CD79b chimaeric antigen receptor-T cell therapy, Yake Biotechnology",T cell stimulant; Immuno-oncology therapy,CD79b chimaeric antigen receptor-T cell therapy,Yake Biotechnology,,,0,['CD79b chimaeric antigen receptor-T cell therapy'],,0,[],0
JNJ-74856665,Dihydroorotate dehydrogenase inhibitor,JNJ-74856665,,JNJ-74856665,jnj 74856665,fexact,"['dihydroorotate dehydrogenase inhibitor (oral, acute myeloid leukemia/myelodysplastic syndrome)', 'JNJ-74856665']",JNJ-74856665,fexact,"['dihydroorotate dehydrogenase inhibitor oral acute myeloid leukemia myelodysplastic syndrome', 'jnj 74856665']",correct_mapping
LY-3410738,Isocitrate dehydrogenase 1 inhibitor,LY-3410738,,LY-3410738,ly 3410738,fexact,"['inhibitor selective for mutant IDH1 (IDH1-mutant tumors)', 'mutant IDH1 inhibitor (cancer)', 'LY-3410738']",LY-3410738,fexact,"['inhibitor selective for mutant idh1 idh1 mutant tumors', 'mutant idh1 inhibitor cancer', 'ly 3410738']",correct_mapping
"CD123 CAR-T therapy, Yake Biotechnology",T cell stimulant; Immuno-oncology therapy,CD123 CAR-T therapy,Yake Biotechnology,,,0,['CD123 CAR-T therapy'],,0,[],0
"CD7 CAR-T therapy, Yake Biotechnology",T cell stimulant; Immuno-oncology therapy,CD7 CAR-T therapy,Yake Biotechnology,,,0,['CD7 CAR-T therapy'],,0,[],0
GFH-009,Cyclin-dependent kinase 9 inhibitor,GFH-009,,GFH-009,gfh 009,fexact,"['GFH-009', 'cdk9 inhibitor (intravenous, solid tumor/hematological cancer)']",GFH-009,fexact,"['gfh 009', 'cdk9 inhibitor intravenous solid tumor hematological cancer']",correct_mapping
hypomethylating agents,Unidentified pharmacological activity,hypomethylating agents,,,,0,['hypomethylating agents'],,0,[],0
RO-7283420,CD3 agonist; Immuno-oncology therapy,RO-7283420,,RG-6007,ro 7283420,fexact,"['RG-6007', 'anti-CD3/anti-WT1/anti-HLA-A2 bispecific T-cell engager (AML)', 'RO-7283420', 'HLA-A2-WT1 x CD3 (acute myeloid leukemia)']",RG-6007,fexact,"['rg 6007', 'anti cd3 anti wt1 anti hla a2 bispecific t cell engager aml', 'ro 7283420', 'hla a2 wt1 x cd3 acute myeloid leukemia']",correct_mapping
dociparstat sodium,Elastase inhibitor; Stromal cell-derived factor 1 antagonist; P-selectin antagonist; High mobility group box chromosomal protein 1 antagonist; Factor IV inhibitor,dociparstat sodium,,,,0,"['dociparstat sodium', 'GM-1892']",,NER_API,[],0
EP-0042,Unidentified pharmacological activity,EP-0042,,EP-0042,ep 0042,fexact,['EP-0042'],EP-0042,fexact,['ep 0042'],correct_mapping
pitavastatin,HMGCoA reductase inhibitor,pitavastatin,,pitavastatin,pitavastatin,fexact,"['pitavastatin', 'KN-104', 'Livazo', 'Redevant', 'Pivasta', 'NKS-104', 'P-872441', 'Pitava', '1-PC-002', 'Livalo OD', 'NK-104 (lactone)', 'Alipza', 'NK-104', 'Livalo', 'pitavastatin calcium', 'itavastatin', 'itabastatin', 'nisvastatin']",pitavastatin,fexact,"['pitavastatin', 'kn 104', 'livazo', 'redevant', 'pivasta', 'nks 104', 'p 872441', 'pitava', '1 pc 002', 'livalo od', 'nk 104 lactone', 'alipza', 'nk 104', 'livalo', 'pitavastatin calcium', 'itavastatin', 'itabastatin', 'nisvastatin']",correct_mapping
midostaurin,Protein kinase C inhibitor; C-kit inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor beta kinase inhib; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Cyclin B inbibitor; Cell cycle inhibitor,midostaurin,,midostaurin,midostaurin,fexact,"['PKC-412A', 'PKC-412', 'STI-412', 'Rydapt', 'CGP-41251', 'benzoylstaurosporine', 'midostaurin']",midostaurin,fexact,"['pkc 412a', 'pkc 412', 'sti 412', 'rydapt', 'cgp 41251', 'benzoylstaurosporine', 'midostaurin']",correct_mapping
siremadlin,MDM2 inhibitor,siremadlin,,siremadlin,siremadlin,fexact,"['siremadlin', 'p53-Mdm2 inhibitors (cancer), Novartis Institutes for Biomedical Research', 'HDM-201', 'NVP-HDM-201']",siremadlin,fexact,"['siremadlin', 'p53 mdm2 inhibitors cancer novartis institutes for biomedical research', 'hdm 201', 'nvp hdm 201']",correct_mapping
ivosidenib,Isocitrate dehydrogenase 1 inhibitor,ivosidenib,,ivosidenib,ivosidenib,fexact,"['isocitrate dehydrogenase-1 inhibitor (oral tablet, cancer),/', 'IDH inhibitors (cancer),/Celgene', 'AGI-14100', 'Tibsovo', 'ivosidenib tablets', 'isocitrate dehydrogenase inhibitors (cancer),/', 'IDH', 'IDH inhibitors (cancer),/', 'AGI-16678', 'isocitrate dehydrogenase-1 inhibitor (oral, cancer),/Celgene', 'isocitrate dehydrogenase inhibitors (cancer),/Celgene', 'isocitrate dehydrogenase-1 inhibitor (oral, cancer),/', 'aifunibu', 'AG-120', 'CS-3010', 'IDH-1/IDH-2 inhibitors (cancer),/', 'IDH-1/IDH-2 inhibitors (cancer),/Celgene', 'ivosidenib', 'isocitrate dehydrogenase-1 inhibitor (oral tablet, cancer),/Celgene']",ivosidenib,fexact,"['isocitrate dehydrogenase 1 inhibitor oral tablet cancer', 'idh inhibitors cancer celgene', 'agi 14100', 'tibsovo', 'ivosidenib tablets', 'isocitrate dehydrogenase inhibitors cancer', 'idh', 'idh inhibitors cancer', 'agi 16678', 'isocitrate dehydrogenase 1 inhibitor oral cancer celgene', 'isocitrate dehydrogenase inhibitors cancer celgene', 'isocitrate dehydrogenase 1 inhibitor oral cancer', 'aifunibu', 'ag 120', 'cs 3010', 'idh 1 idh 2 inhibitors cancer', 'idh 1 idh 2 inhibitors cancer celgene', 'ivosidenib', 'isocitrate dehydrogenase 1 inhibitor oral tablet cancer celgene']",correct_mapping
AMG-330,CD3 agonist; Immuno-oncology therapy,AMG-330,,AMG-330,amg 330,fexact,"['MT-114', 'AMG-330', 'eluvixtamab', 'anti-CD3/anti-CD33 bispecific T-cell engager (BiTE/Captisol, cancer)', 'anti-CD3/anti-CD33 bispecific T-cell engager (BiTE/Captisol, cancer), Micromet']",AMG-330,fexact,"['mt 114', 'amg 330', 'eluvixtamab', 'anti cd3 anti cd33 bispecific t cell engager bite captisol cancer', 'anti cd3 anti cd33 bispecific t cell engager bite captisol cancer micromet']",correct_mapping
XY-0206,Unidentified pharmacological activity,XY-0206,,XY-0206,xy 0206,fexact,"['XY-0206', 'flt-3 inhibitor (oral tablet, acute myelogenous leukemia/lung cancer)']",XY-0206,fexact,"['xy 0206', 'flt 3 inhibitor oral tablet acute myelogenous leukemia lung cancer']",correct_mapping
VOR-33,CD33 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,VOR-33,,VOR-33,vor 33,fexact,"['VOR-33', 'anti-CD33 CAR T-cell therapy (cancer/hematological malignancy/AML), Vor BioPharma', 'antigen-modified haematopoietic stem cells (B-celll malignacies), Vor Biophamra', 'anti-cd33 car t-cell therapy (cancer/hematological malignancy/aml)', 'car t-cell therapy (cancer)', 'CAR T-cell therapy (cancer), Vor Biopharma']",VOR-33,fexact,"['vor 33', 'anti cd33 car t cell therapy cancer hematological malignancy aml vor biopharma', 'antigen modified haematopoietic stem cells b celll malignacies vor biophamra', 'anti cd33 car t cell therapy cancer hematological malignancy aml', 'car t cell therapy cancer', 'car t cell therapy cancer vor biopharma']",correct_mapping
SHR-1702,TIM3 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,SHR-1702,,SHR-1702,shr 1702,fexact,"['anti-TIM-3 monoclonal antibody (advanced solid tumors/hematological malignancies)', 'SHR-1702', 'TIM-3 checkpoint inhibitor (advanced solid tumors/hematological malignancies)']",SHR-1702,fexact,"['anti tim 3 monoclonal antibody advanced solid tumors hematological malignancies', 'shr 1702', 'tim 3 checkpoint inhibitor advanced solid tumors hematological malignancies']",correct_mapping
"mycophenolate sodium, unspecified",Immunosuppressant; Inosine monophosphate dehydrogenase inhibitor,mycophenolate sodium,unspecified,enteric-coated mycophenolate sodium,mycophenolate sodium,fexact,"['ERL-080', 'Myfortic', 'enteric-coated mycophenolate sodium', 'mycophenolic acid', 'enteric-coated MPA', 'mycophenolate sodium']",enteric-coated mycophenolate sodium,fexact,"['erl 080', 'myfortic', 'enteric coated mycophenolate sodium', 'mycophenolic acid', 'enteric coated mpa', 'mycophenolate sodium']",correct_mapping
IO-202,Immuno-oncology therapy; Leukocyte immunoglobulin-like receptor B4 antagonist,IO-202,,IO-202,io 202,fexact,"['anti-LILRB4 antibody (AML/CMML/solid tumors),/University of Texas Southwestern Medical Center', 'anti-lilrb4 antibody (aml/cmml/solid tumors)', 'anti-LILRB4 antibody (AML/CMML)', 'IO-202']",IO-202,fexact,"['anti lilrb4 antibody aml cmml solid tumors university of texas southwestern medical center', 'anti lilrb4 antibody aml cmml solid tumors', 'anti lilrb4 antibody aml cmml', 'io 202']",correct_mapping
ZN-d5,Bcl2 inhibitor,ZN-d5,,ZN-d5,zn d5,fexact,"['ZN-d5', 'b-cell lymphoma 2 inhibitor (oral, hematologic malignancies)']",ZN-d5,fexact,"['zn d5', 'b cell lymphoma 2 inhibitor oral hematologic malignancies']",correct_mapping
Cytokine-induced Memory-like NK Cells,Immunostimulant,Cytokine-induced Memory-like NK Cells,,,,0,['Cytokine-induced Memory-like NK Cells'],,0,[],0
D-Peptide,Angiogenesis inhibitor; Apoptosis stimulant,D-Peptide,,,,0,['D-Peptide'],,0,[],0
CB-5339,p97 inhibitor,CB-5339,,CB-5339,cb 5339,fexact,"['valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/advanced solid tumor/non-Hodgkin lymphoma/myelodysplastic syndrome/lymphoma)', 'valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/solid tumor/non-Hodgkin lymphoma/myelodysplastic syndrome), Cleave Therapeutics', 'CB-5339 Tosylate', 'CB-5339', 'valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/solid tumor), Cleave Therapeutics', 'valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/advanced solid tumor/non-Hodgkin lymphoma/myelodysplastic syndrome/lymphoma), Cleave Therapeutics', 'valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/solid tumor/non-Hodgkin lymphoma/myelodysplastic syndrome)', 'valosin-containing protein (VCP)/p97 enzyme inhibitor (oral, acute myeloid leukemia/solid tumor)']",CB-5339,fexact,"['valosin containing protein vcp p97 enzyme inhibitor oral acute myeloid leukemia advanced solid tumor non hodgkin lymphoma myelodysplastic syndrome lymphoma', 'valosin containing protein vcp p97 enzyme inhibitor oral acute myeloid leukemia solid tumor non hodgkin lymphoma myelodysplastic syndrome cleave therapeutics', 'cb 5339 tosylate', 'cb 5339', 'valosin containing protein vcp p97 enzyme inhibitor oral acute myeloid leukemia solid tumor cleave therapeutics', 'valosin containing protein vcp p97 enzyme inhibitor oral acute myeloid leukemia advanced solid tumor non hodgkin lymphoma myelodysplastic syndrome lymphoma cleave therapeutics', 'valosin containing protein vcp p97 enzyme inhibitor oral acute myeloid leukemia solid tumor non hodgkin lymphoma myelodysplastic syndrome', 'valosin containing protein vcp p97 enzyme inhibitor oral acute myeloid leukemia solid tumor']",correct_mapping
SH-1573,Isocitrate dehydrogenase inhibitor,SH-1573,,SH-1573,sh 1573,fexact,['SH-1573'],SH-1573,fexact,['sh 1573'],correct_mapping
CC-90009,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,CC-90009,,CC-90009,cc 90009,fexact,"['cereblon E3 ligase modulator (intravenous, acute myeloid leukemi),/', 'cereblon E3 ligase modulator (iv, acute myeloid leukemi),/Bristol-Myers Squibb', 'cereblon E3 ligase modulator (intravenous, acute myeloid leukemi), Celgene/', 'CC-90009', 'cereblon E3 ligase modulator (iv, acute myeloid leukemi),/']",CC-90009,fexact,"['cereblon e3 ligase modulator intravenous acute myeloid leukemi', 'cereblon e3 ligase modulator iv acute myeloid leukemi bristol myers squibb', 'cereblon e3 ligase modulator intravenous acute myeloid leukemi celgene', 'cc 90009', 'cereblon e3 ligase modulator iv acute myeloid leukemi']",correct_mapping
crisantaspase,Protein synthesis inhibitor; Asparaginase stimulant; Apoptosis stimulant,crisantaspase,,crisantaspase (acute lymphoblastic leukemia),crisantaspase,fexact,"['crisantaspase (acute lymphoblastic leukemia), Jazz Pharmaceuticals', 'crisantaspase', 'Erwinase', 'crisantaspase (acute lymphoblastic leukemia),/HPA', 'Erwinia chrysanthemi L-asparaginase (acute lymphoblastic leukemia),/HPA', 'Erwinaze', 'crisantaspase (acute lymphoblastic leukemia), OPi/HPA', 'asparaginase (Erwinia chrysanthemi)', 'crisantaspase (acute lymphoblastic leukemia)', 'Erwinia chrysanthemi L-asparaginase (acute lymphoblastic leukemia), OPi/HPA', 'OP-01']",crisantaspase (acute lymphoblastic leukemia),fexact,"['crisantaspase acute lymphoblastic leukemia jazz pharmaceuticals', 'crisantaspase', 'erwinase', 'crisantaspase acute lymphoblastic leukemia hpa', 'erwinia chrysanthemi l asparaginase acute lymphoblastic leukemia hpa', 'erwinaze', 'crisantaspase acute lymphoblastic leukemia opi hpa', 'asparaginase erwinia chrysanthemi', 'crisantaspase acute lymphoblastic leukemia', 'erwinia chrysanthemi l asparaginase acute lymphoblastic leukemia opi hpa', 'op 01']",correct_mapping
"MB-102, Mustang Bio",T cell stimulant; Immuno-oncology therapy,MB-102,Mustang Bio,MB-102,mb 102,fexact,"['anti-CD123 CAR T-cell therapy (acute myleloid leukemia)', 'anti-CD123 CAR T-cell therapy (acute myleloid leukemia), Fortress Biotech', 'MB-102', 'anti-CD123 CAR T-cell therapy (acute myeloid leukemia), Mustang Bio', 'anti-cd123 car t-cell therapy (acute myeloid leukemia)', 'anti-CD123 CAR T-cell therapy (acute myeloid leukemia)']",MB-102,fexact,"['anti cd123 car t cell therapy acute myleloid leukemia', 'anti cd123 car t cell therapy acute myleloid leukemia fortress biotech', 'mb 102', 'anti cd123 car t cell therapy acute myeloid leukemia mustang bio', 'anti cd123 car t cell therapy acute myeloid leukemia', 'anti cd123 car t cell therapy acute myeloid leukemia']",correct_mapping
TAS-1440,Lysine (K)-specific demethylase 1A inhibitor,TAS-1440,,TAS-1440,tas 1440,fexact,"['LSD1 inhibitor (oral capsule, AML),/', 'LSD1 inhibitor (oral capsule, AML), Taiho Pharmaceutical/', 'TAS-1440']",TAS-1440,fexact,"['lsd1 inhibitor oral capsule aml', 'lsd1 inhibitor oral capsule aml taiho pharmaceutical', 'tas 1440']",correct_mapping
fedratinib,RET tyrosine kinase inhibitor; Flt-3 antagonist; Janus kinase 2 inhibitor,fedratinib,,fedratinib dihydrochloride monohydrate,fedratinib,fexact,"['dual FLT3/JAK2 inhibitors (myeloproliferative disorders)', 'JAK2 inhibitors (myeloproliferative disorder), TargeGen', 'TG-101193', 'SAR-302503', 'Inrebic', 'fedratinib', 'JAK-2.V617F inhibitors (MPD)', 'fedratinib hydrochloride', 'FLT3/JAK2/Ret inhibitor (myeloproliferative disorders), TargeGen', 'FLT3/JAK2/Ret inhibitor (myeloproliferative disorders)', 'fedratinib dihydrochloride monohydrate', 'JAK2 inhibitors (myeloproliferative disorder)', 'dual FLT3/JAK2 inhibitors (myeloproliferative disorders), TargeGen', 'JAK-2.V617F inhibitors (MPD), TargeGen', 'TG-101348', 'TG-101209']",fedratinib dihydrochloride monohydrate,fexact,"['dual flt3 jak2 inhibitors myeloproliferative disorders', 'jak2 inhibitors myeloproliferative disorder targegen', 'tg 101193', 'sar 302503', 'inrebic', 'fedratinib', 'jak 2 v617f inhibitors mpd', 'fedratinib hydrochloride', 'flt3 jak2 ret inhibitor myeloproliferative disorders targegen', 'flt3 jak2 ret inhibitor myeloproliferative disorders', 'fedratinib dihydrochloride monohydrate', 'jak2 inhibitors myeloproliferative disorder', 'dual flt3 jak2 inhibitors myeloproliferative disorders targegen', 'jak 2 v617f inhibitors mpd targegen', 'tg 101348', 'tg 101209']",correct_mapping
"CD123 CAR-T cells, Chongqing Precision Biotech",T cell stimulant; Immuno-oncology therapy,CD123 CAR-T cells,Chongqing Precision Biotech,anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),cd19 car t cells,fuzzy,"['anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia)', 'cd19 car-t cells']",anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),fexact,"['anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'cd19 car t cells']",incorrect_mapping
ASTX-030,DNA synthesis inhibitor; DNA methylase inhibitor; RNA synthesis inhibitor,ASTX-030,,,,0,"['ASTX-030', 'cedazuridine + azacitidine', 'cedazuridine + azacitidine (fixed-dose combination/oral/tablet formulation, myeloid diseases)']",,NER_API,[],0
cusatuzumab,CD70 antagonist,cusatuzumab,,cusatuzumab,cusatuzumab,fexact,"['anti-CD70 humanized monoclonal antibody (acute myeloid leukemia/myelodysplastic syndrome/hematological malignancies),/', 'JNJ-74494550', 'SIMPLE antibody technology lead (autoimmunity, inflammation, cancer), argenx', 'anti-CD70 humanized monoclonal antibody (cancer),/', 'SIMPLE antibody technology lead (autoimmunity, inflammation, cancer)', 'JNJ-4550', 'anti-CD70 humanized monoclonal antibody (autoimmunity, inflammatory diseases, cancer)', 'anti-CD70 humanized monoclonal antibody (cancer), argenx/', 'anti-CD70 humanized monoclonal antibody (acute myeloid leukemia/myelodysplastic syndrome/hematological malignancies), argenx/', 'cusatuzumab', 'anti-CD70 humanized monoclonal antibody (autoimmunity, inflammatory diseases, cancer), argenx', 'ARGX-110']",cusatuzumab,fexact,"['anti cd70 humanized monoclonal antibody acute myeloid leukemia myelodysplastic syndrome hematological malignancies', 'jnj 74494550', 'simple antibody technology lead autoimmunity inflammation cancer argenx', 'anti cd70 humanized monoclonal antibody cancer', 'simple antibody technology lead autoimmunity inflammation cancer', 'jnj 4550', 'anti cd70 humanized monoclonal antibody autoimmunity inflammatory diseases cancer', 'anti cd70 humanized monoclonal antibody cancer argenx', 'anti cd70 humanized monoclonal antibody acute myeloid leukemia myelodysplastic syndrome hematological malignancies argenx', 'cusatuzumab', 'anti cd70 humanized monoclonal antibody autoimmunity inflammatory diseases cancer argenx', 'argx 110']",correct_mapping
SEA-CD70,CD70 antagonist; Immuno-oncology therapy,SEA-CD70,,SEA-CD70,sea cd70,fexact,['SEA-CD70'],SEA-CD70,fexact,['sea cd70'],correct_mapping
UniCAR-T-CD123,T cell stimulant; Immuno-oncology therapy,UniCAR-T-CD123,,UniCAR02-T-CD123  therapy,unicar t cd123,fexact,"['4-1BB costimulator + peptide-expressing anti-CD123 targeting molecule + anti-peptide CAR T-cell therapy (acute leukemia),/', 'UniCAR-T-CD123', 'TM-123', 'UniCAR02-T-CD123  therapy', 'TM-123 4-1BBL', 'TM-123 + UniCAR-T', '4-1BB costimulator + peptide-expressing anti-CD123 targeting molecule + anti-peptide CAR T-cell therapy (acute leukemia), GEMoaB Monoclonals/']",UniCAR02-T-CD123  therapy,fexact,"['4 1bb costimulator peptide expressing anti cd123 targeting molecule anti peptide car t cell therapy acute leukemia', 'unicar t cd123', 'tm 123', 'unicar02 t cd123 therapy', 'tm 123 4 1bbl', 'tm 123 unicar t', '4 1bb costimulator peptide expressing anti cd123 targeting molecule anti peptide car t cell therapy acute leukemia gemoab monoclonals']",correct_mapping
K-NK003,Natural killer cell stimulant; Immuno-oncology therapy,K-NK003,,K-NK003,k nk003,fexact,"['K-NK003', 'mbIL21-expanded haploidentical NK cells (acute myeloid leukemia/myelodysplastic syndrome)', 'natural killer cell therapy (acute myeloid leukemia)', 'membrane-bound interleukin-21-expanded haploidentical natural killer cells (acute myeloid leukemia/myelodysplastic syndrome)']",K-NK003,fexact,"['k nk003', 'mbil21 expanded haploidentical nk cells acute myeloid leukemia myelodysplastic syndrome', 'natural killer cell therapy acute myeloid leukemia', 'membrane bound interleukin 21 expanded haploidentical natural killer cells acute myeloid leukemia myelodysplastic syndrome']",correct_mapping
JSP-191,C-kit inhibitor,JSP-191,,JSP-191,jsp 191,fexact,"['humanized anti-CD117 monoclonal antibody, Jasper Therapeutics', 'AMG-191', 'humanized anti-CD117 monoclonal antibody', 'JSP-191']",JSP-191,fexact,"['humanized anti cd117 monoclonal antibody jasper therapeutics', 'amg 191', 'humanized anti cd117 monoclonal antibody', 'jsp 191']",correct_mapping
CA-4948,Interleukin-1 receptor associated protein kinase 4 inhibitor,CA-4948,,CA-4948,ca 4948,fexact,"['IRAK4 inhibitors (cancer)', 'IRAK4 inhibitors (anemia),/Curis', 'CA-4948', 'IRAK4 inhibitors (anemia),/', 'AU-4948']",CA-4948,fexact,"['irak4 inhibitors cancer', 'irak4 inhibitors anemia curis', 'ca 4948', 'irak4 inhibitors anemia', 'au 4948']",correct_mapping
Realgar-Indigo naturalis formula,Unidentified pharmacological activity,Realgar-Indigo naturalis formula,,,,0,['Realgar-Indigo naturalis formula'],,0,[],0
HLA-mismatched GCSF mobilized peripheral blood cells,Unidentified pharmacological activity,HLA-mismatched GCSF mobilized peripheral blood cells,,,,0,['HLA-mismatched GCSF mobilized peripheral blood cells'],,0,[],0
NTX-301,DNA methylase inhibitor,NTX-301,,NTX-301,ntx 301,fexact,"['DNMT1 inhibitor (oral, acute myeloid leukemia/myelodysplastic syndromes/chronic myelomonocytic leukemia),/Southern Research Institute', 'dnmt1 inhibitor (oral, acute myeloid leukemia/myelodysplastic syndromes/chronic myelomonocytic leukemia)', 'NTX-301', 'methyl transferase inhibitors (cancer),/', 'methyl transferase inhibitors (cancer),/Southern Research']",NTX-301,fexact,"['dnmt1 inhibitor oral acute myeloid leukemia myelodysplastic syndromes chronic myelomonocytic leukemia southern research institute', 'dnmt1 inhibitor oral acute myeloid leukemia myelodysplastic syndromes chronic myelomonocytic leukemia', 'ntx 301', 'methyl transferase inhibitors cancer', 'methyl transferase inhibitors cancer southern research']",correct_mapping
"CD123-CD33 cCAR-T cells, iCell Gene Therapeutics",T cell stimulant; Immuno-oncology therapy,CD123-CD33 cCAR-T cells,iCell Gene Therapeutics,,,0,['CD123-CD33 cCAR-T cells'],,0,[],0
salsalate,Prostaglandin synthase inhibitor,salsalate,,,,0,"['salsalate (oral/nanoformulation/immediate release, osteoarthrtiis, rheumatoid arthritis, pain), Rhnanopharma', 'salsalate']",,NER_API,[],0
LP-108,Bcl2 inhibitor,LP-108,,LP-108,lp 108,fexact,"['small molecule therapeutic (oral, myelodysplastic syndromes/chronic myelomonocytic leukemia/acute myeloid leukemia/ALL/leukemia), Newave Pharmaceutical', 'Bcl-2 protein inhibitorr (cancer),/', 'LP-108', 'small molecule therapeutic (oral, myelodysplastic syndromes/chronic myelomonocytic leukemia/acute myeloid leukemia)', 'small molecule therapeutic (oral, myelodysplastic syndromes/chronic myelomonocytic leukemia/acute myeloid leukemia/ALL/leukemia)', 'Bcl-2 protein inhibitorr (cancer),/Newave Pharmaceutical', 'small molecule therapeutic (oral, myelodysplastic syndromes/chronic myelomonocytic leukemia/acute myeloid leukemia), Newave Pharmaceutical']",LP-108,fexact,"['small molecule therapeutic oral myelodysplastic syndromes chronic myelomonocytic leukemia acute myeloid leukemia all leukemia newave pharmaceutical', 'bcl 2 protein inhibitorr cancer', 'lp 108', 'small molecule therapeutic oral myelodysplastic syndromes chronic myelomonocytic leukemia acute myeloid leukemia', 'small molecule therapeutic oral myelodysplastic syndromes chronic myelomonocytic leukemia acute myeloid leukemia all leukemia', 'bcl 2 protein inhibitorr cancer newave pharmaceutical', 'small molecule therapeutic oral myelodysplastic syndromes chronic myelomonocytic leukemia acute myeloid leukemia newave pharmaceutical']",correct_mapping
midostaurin (capsule),Protein kinase C inhibitor; C-kit inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor beta kinase inhib; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Cyclin B inbibitor; Cell cycle inhibitor,midostaurin,,midostaurin,midostaurin,fexact,"['PKC-412A', 'PKC-412', 'STI-412', 'Rydapt', 'CGP-41251', 'benzoylstaurosporine', 'midostaurin']",midostaurin,fexact,"['pkc 412a', 'pkc 412', 'sti 412', 'rydapt', 'cgp 41251', 'benzoylstaurosporine', 'midostaurin']",correct_mapping
"methotrexate sodium, Barr Laboratories",Immunosuppressant; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Disease modifying antirheumatic drug,methotrexate sodium,Barr Laboratories,,,0,['methotrexate sodium'],,0,[],0
HAS-CD24,CD24 antagonist,HAS-CD24,,,,0,"['multiple sclerosis therapy', 'HAS-CD24']",,NER_API,[],0
IMGN-632,DNA inhibitor,IMGN-632,,IMGN-632,imgn 632,fexact,"['IMGN-632', 'DGN549/G4723A conjugate (intravenous, acute lymphoblastic leukemia/acute myelogenous leukemia/hematological neoplasm),/Jazz Pharmaceuticals', 'anti-CD123 antibody-drug conjugate (intravenous, acute lymphoblastic leukemia/acute myelogenous leukemia/hematological neoplasm),/Jazz Pharmaceuticals']",IMGN-632,fexact,"['imgn 632', 'dgn549 g4723a conjugate intravenous acute lymphoblastic leukemia acute myelogenous leukemia hematological neoplasm jazz pharmaceuticals', 'anti cd123 antibody drug conjugate intravenous acute lymphoblastic leukemia acute myelogenous leukemia hematological neoplasm jazz pharmaceuticals']",correct_mapping
TAK659,Flt-3 antagonist; Syk tyrosine kinase inhibitor,TAK659,,mivavotinib,tak 659,fuzzy,"['mivavotinib monocitrate', 'mivavotinib', 'TAK-659 citrate', 'mivavotinib citrate', 'TAK-659']",mivavotinib,fexact,"['mivavotinib monocitrate', 'mivavotinib', 'tak 659 citrate', 'mivavotinib citrate', 'tak 659']",incorrect_mapping
ASP-7517,Unidentified pharmacological activity,ASP-7517,,ASP-7517,asp 7517,fexact,"['ASP-7517', 'artificial adjuvant vector cells loaded with WT1 (cancer)']",ASP-7517,fexact,"['asp 7517', 'artificial adjuvant vector cells loaded with wt1 cancer']",correct_mapping
"CD7 chimaeric antigen receptor therapy, Wugen",T cell stimulant; Immuno-oncology therapy,CD7 chimaeric antigen receptor therapy,Wugen,,,0,['CD7 chimaeric antigen receptor therapy'],,0,[],0
PLX-51107,Bromodomain containing 4 inhibitor,PLX-51107,,PLX-51107,plx 51107,fexact,"['PLX-51107', 'BRD4 inhibitors (hematological cancer)']",PLX-51107,fexact,"['plx 51107', 'brd4 inhibitors hematological cancer']",correct_mapping
"stem cell engraftment therapy, Orca Biosystems",Unidentified pharmacological activity,stem cell engraftment therapy,Orca Biosystems,,,0,['stem cell engraftment therapy'],,0,[],0
olutasidenib,Isocitrate dehydrogenase 1 inhibitor,olutasidenib,,olutasidenib,olutasidenib,fexact,"['mIDH1 inhibitor (AML/MDS)', 'mutated isocitrate dehydrogenase 1 inhibitor (oral, AML/MDS)', 'olutasidenib', 'FT-2102']",olutasidenib,fexact,"['midh1 inhibitor aml mds', 'mutated isocitrate dehydrogenase 1 inhibitor oral aml mds', 'olutasidenib', 'ft 2102']",correct_mapping
"CD123 chimaeric antigen receptor therapy, Wuhan Bio-Raid Biotechnology",T cell stimulant; Immuno-oncology therapy,CD123 chimaeric antigen receptor therapy,Wuhan Bio-Raid Biotechnology,,,0,['CD123 chimaeric antigen receptor therapy'],,0,[],0
"CLL1 CAR-T cells,  Shenzhen Geno-Immune Medical Institute",T cell stimulant; Immuno-oncology therapy,CLL1 CAR-T cells, Shenzhen Geno-Immune Medical Institute,,,0,['CLL1 CAR-T cells'],,0,[],0
CYAD-02,T cell stimulant; Immuno-oncology therapy,CYAD-02,,CYAD-02,cyad 02,fexact,"['CYAD-02', 'next generation nkg2d car-t cell therapy', 'anti-mica/micb car t-cell therapy (nkg2d car, cancer)', 'autologous nkg2d t-cell therapy (cancer)']",CYAD-02,fexact,"['cyad 02', 'next generation nkg2d car t cell therapy', 'anti mica micb car t cell therapy nkg2d car cancer', 'autologous nkg2d t cell therapy cancer']",correct_mapping
abatacept,CD86 antagonist; T cell inhibitor; CD80 antagonist; Immune checkpoint inhibitor,abatacept,,abatacept,abatacept,fexact,"['abatacept', 'BMS-188667', 'Orencia', 'ONO-4164IV', 'ONO-4164', 'BMS-188667SC', 'ONO-4164SC', 'BMS-188667IV', 'CTLA4-Ig, BMS', 'BMS-1888667', 'Orenica']",abatacept,fexact,"['abatacept', 'bms 188667', 'orencia', 'ono 4164iv', 'ono 4164', 'bms 188667sc', 'ono 4164sc', 'bms 188667iv', 'ctla4 ig bms', 'bms 1888667', 'orenica']",correct_mapping
quizartinib dihydrochloride (tablet),Flt-3 antagonist,quizartinib dihydrochloride,,quizartinib dihydrochloride,quizartinib dihydrochloride,fexact,"['AB-200432', 'ASP-2689', 'quizartinib', 'AC-886', 'Vanflyta', 'AB-530', 'AB-460', 'quizartinib dihydrochloride', 'AB-200382', 'AB-200243', 'Flt3 tyrosine kinase inhibitors', 'AB-200434', 'Flt3 tyrosine kinase inhibitors,/Astellas', 'AB-515', 'Flt3 tyrosine kinase inhibitors,/', 'AC-220']",quizartinib dihydrochloride,fexact,"['ab 200432', 'asp 2689', 'quizartinib', 'ac 886', 'vanflyta', 'ab 530', 'ab 460', 'quizartinib dihydrochloride', 'ab 200382', 'ab 200243', 'flt3 tyrosine kinase inhibitors', 'ab 200434', 'flt3 tyrosine kinase inhibitors astellas', 'ab 515', 'flt3 tyrosine kinase inhibitors', 'ac 220']",correct_mapping
BTX-A51,Cyclin-dependent kinase 9 inhibitor; Casein kinase 1 inhibitor; Cyclin-dependent kinase 7 inhibitor,BTX-A51,,BTX-A51,btx a51,fexact,"['casein kinase-I alpha inhibitor (myelodysplastic syndrome/AML),/', 'A-86 (BioTheryx)', 'BTX-A51', 'casein kinase-I alpha inhibitor (myelodysplastic syndrome/AML),/ Yissum', 'casein kinase-I alpha inhibitor (myelodysplastic syndrome/AML)', 'A-51', 'casein kinase-I alpha inhibitor (myelodysplastic syndrome/AML), Hebrew University/ Yissum']",BTX-A51,fexact,"['casein kinase i alpha inhibitor myelodysplastic syndrome aml', 'a 86 biotheryx', 'btx a51', 'casein kinase i alpha inhibitor myelodysplastic syndrome aml yissum', 'casein kinase i alpha inhibitor myelodysplastic syndrome aml', 'a 51', 'casein kinase i alpha inhibitor myelodysplastic syndrome aml hebrew university yissum']",correct_mapping
UCART-123,T cell stimulant; Immuno-oncology therapy; Genome editing,UCART-123,,UCART-123,ucart 123,fexact,"['UCART-123', 'anti-CD123 CAR T-cell therapy (AML)']",UCART-123,fexact,"['ucart 123', 'anti cd123 car t cell therapy aml']",correct_mapping
nedisertib,DNA-dependent protein kinase inhibitor,nedisertib,,nedisertib,nedisertib,fexact,"['M-3814', 'peposertib', 'nedisertib', 'MSC-2490484A']",nedisertib,fexact,"['m 3814', 'peposertib', 'nedisertib', 'msc 2490484a']",correct_mapping
VCAR-33,T cell stimulant; Immuno-oncology therapy,VCAR-33,,VCAR-33,vcar 33,fexact,"['anti-cd33 car t-cell therapy (acute myeloid leukemia)', 'CD33CART (VCAR33 construct), Vor Biopharma', 'anti-CD33 CAR T-cell therapy (acute myeloid leukemia),  Vor Biopharma', 'cd33cart (vcar33 construct)', 'VCAR-33', 'CD33CART']",VCAR-33,fexact,"['anti cd33 car t cell therapy acute myeloid leukemia', 'cd33cart vcar33 construct vor biopharma', 'anti cd33 car t cell therapy acute myeloid leukemia vor biopharma', 'cd33cart vcar33 construct', 'vcar 33', 'cd33cart']",correct_mapping
INA-03,Unidentified pharmacological activity,INA-03,,INA-03,ina 03,fexact,['INA-03'],INA-03,fexact,['ina 03'],correct_mapping
interleukin-7,Interleukin 7 agonist,interleukin-7,,,,0,"['BCDF', 'pre-BSF-1, Kodak', 'interleukin-7, Kodak', 'IL-7, Kodak', 'lymphopoietin 1', 'interleukin-7, Ohio State University', 're-B-cell growth factor', 'IL 7', 'NSC-644800', 'lymphopoietin 1, Kodak', 'IL-7', 'interleukin-7, Battelle', 'IL-7, Ohio State University', 'IL-7, Battelle', 'interleukin-7', 'pre-BSF-1']",,Drug_API_mapping,[],0
ONC-201,PI3 kinase inhibitor,ONC-201,,,,0,"['PI3K inhibitors (cancer)', 'ONC-201,/', 'ONC-201, Oncoceutics/', 'ONC-206', 'TIC-10', 'imidazolinopyrimidinones (cancer), Oncoceutics', 'imidazolinopyrimidinones (cancer)', 'ONC-200 series (cancer), Oncoceutics', 'ONC-200 series (cancer)', 'ONC-201, Oncoceutics', 'ONC-201 dihydrochloride', 'PI3K inhibitors (cancer), Oncalis', 'ONC-201, Oncoceutics/ Ohara Pharmaceutical', 'OP-10', 'ONC-201', 'NSC-350625']",,Drug_API_mapping,[],0
ponatinib (capsule),Bcr-Abl inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor kinase inhibitor; TIE-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; Angiogenesis inhibitor; Angiopoietin inhibitor,ponatinib,,ponatinib,ponatinib,fexact,"['dual Abl/Src inhibitors (cancer)', 'ponatinib', 'AP-24534', 'oncogenic kinase inhibitors (cancer)', 'ponatinib hydrochloride', 'Iclusig', 'AP-23464', 'AP-24283']",ponatinib,fexact,"['dual abl src inhibitors cancer', 'ponatinib', 'ap 24534', 'oncogenic kinase inhibitors cancer', 'ponatinib hydrochloride', 'iclusig', 'ap 23464', 'ap 24283']",correct_mapping
JNJ-67571244,CD33 antagonist; CD3 antagonist; Immuno-oncology therapy,JNJ-67571244,,JNJ-67571244,jnj 67571244,fexact,"['CD3xCD33 DuoBody (acute myeloid leukemia/myelodysplastic syndrome),/Genmab', 'JNJ-67571244', 'anti-CD3/anti-CD33 bispecific T-cell engager (acute myeloid leukemia/myelodysplastic syndrome),/Genmab', 'JNJ-1244']",JNJ-67571244,fexact,"['cd3xcd33 duobody acute myeloid leukemia myelodysplastic syndrome genmab', 'jnj 67571244', 'anti cd3 anti cd33 bispecific t cell engager acute myeloid leukemia myelodysplastic syndrome genmab', 'jnj 1244']",correct_mapping
CD25hi Treg depleted DLI,Unidentified pharmacological activity,CD25hi Treg depleted DLI,,,,0,['CD25hi Treg depleted DLI'],,0,[],0
undisclosed - anthracycline,DNA topoisomerase II inhibitor,undisclosed - anthracycline,,,,0,['undisclosed - anthracycline'],,0,[],0
AMG-553,T cell stimulant; Immuno-oncology therapy,AMG-553,,AMG-553,amg 553,fexact,"['AMG-553', 'anti-Flt3 CAR-T cell therapy (acute myeloid leukemia),/Kite Pharma', 'anti-Flt3 CAR-T cell therapy (acute myeloid leukemia),/']",AMG-553,fexact,"['amg 553', 'anti flt3 car t cell therapy acute myeloid leukemia kite pharma', 'anti flt3 car t cell therapy acute myeloid leukemia']",correct_mapping
zelenoleucel,T cell stimulant; Immuno-oncology therapy,zelenoleucel,,MT- 401,zelenoleucel,fexact,"['laap t-cell therapy (all/mds/aml),/ )', 'laap t-cell therapy (all/mds/aml), marker therapeutics/ )', 'zelenoleucel', 'MT- 401']",MT- 401,fexact,"['laap t cell therapy all mds aml', 'laap t cell therapy all mds aml marker therapeutics', 'zelenoleucel', 'mt 401']",correct_mapping
SEL-120,Cyclin-dependent kinase 19 inhibitor; Cyclin-dependent kinase 8 inhibitor; Immuno-oncology therapy,SEL-120,,SEL-120,sel 120,fexact,"['RVU-120', 'haspin kinase/cyclin-dependent kinase-9 inhibitors (cancer), Selvita', 'cdk-8/19 inhibitors (oral, aml/hr-mds)', 'haspin kinase/cyclin-dependent kinase-9 inhibitors (cancer)', 'SEL-120-34', 'SEL120-34A', 'CDK-8 inhibitors (colorectal cancer), Selvita', 'SEL-120', 'cdk-8 inhibitors (colorectal cancer)', 'SEL-120-1', 'CDK-8/19 inhibitors (oral, AML/HR-MDS), Selvita', 'CDK-8/19 inhibitors (oral, AML/HR-MDS)', 'CDK-8 inhibitors (colorectal cancer)']",SEL-120,fexact,"['rvu 120', 'haspin kinase cyclin dependent kinase 9 inhibitors cancer selvita', 'cdk 8 19 inhibitors oral aml hr mds', 'haspin kinase cyclin dependent kinase 9 inhibitors cancer', 'sel 120 34', 'sel120 34a', 'cdk 8 inhibitors colorectal cancer selvita', 'sel 120', 'cdk 8 inhibitors colorectal cancer', 'sel 120 1', 'cdk 8 19 inhibitors oral aml hr mds selvita', 'cdk 8 19 inhibitors oral aml hr mds', 'cdk 8 inhibitors colorectal cancer']",correct_mapping
PRT-543,Protein arginine methyltransferase 5 inhibitor,PRT-543,,PRT-543,prt 543,fexact,"['protein arginine N-methyltransferase 5 inhibitor (oral, solid tumor/hematological malignancies/advanced diffuse large B-cell lymphoma/advanced mantle cell lymphoma/myelodysplastic syndrome/myelofibrosis)', 'PRMT5 inhibitor (oral, solid tumor/hematological malignancies/advanced diffuse large B-cell lymphoma/advanced mantle cell lymphoma/myelodysplastic syndrome/myelofibrosis)', 'PRT-543']",PRT-543,fexact,"['protein arginine n methyltransferase 5 inhibitor oral solid tumor hematological malignancies advanced diffuse large b cell lymphoma advanced mantle cell lymphoma myelodysplastic syndrome myelofibrosis', 'prmt5 inhibitor oral solid tumor hematological malignancies advanced diffuse large b cell lymphoma advanced mantle cell lymphoma myelodysplastic syndrome myelofibrosis', 'prt 543']",correct_mapping
pracinostat,Histone deacetylase inhibitor; Cell cycle inhibitor,pracinostat,,pracinostat,pracinostat,fexact,"['SB-207, Helsinn', 'hdac program (oral, solid tumors/hematological neoplasm)', 'pracinostat', 'histone deacetylase inhibitors (oral, solid tumors), S*Bio Pte Ltd', 'SB-939', 'hdac inhibitors (oral, solid tumors/hematological neoplasm)', 'HDAC inhibitors (oral, solid tumors/hematological neoplasm), S*Bio Pte Ltd', 'SB-869', 'HDAC program (oral, solid tumors/hematological neoplasm), S*Bio Pte Ltd', 'SB-207', 'histone deacetylase inhibitors (oral, solid tumors)']",pracinostat,fexact,"['sb 207 helsinn', 'hdac program oral solid tumors hematological neoplasm', 'pracinostat', 'histone deacetylase inhibitors oral solid tumors s bio pte ltd', 'sb 939', 'hdac inhibitors oral solid tumors hematological neoplasm', 'hdac inhibitors oral solid tumors hematological neoplasm s bio pte ltd', 'sb 869', 'hdac program oral solid tumors hematological neoplasm s bio pte ltd', 'sb 207', 'histone deacetylase inhibitors oral solid tumors']",correct_mapping
blinatumomab (IV),CD3 agonist; Immuno-oncology therapy,blinatumomab,,blinatumomab,blinatumomab,fexact,"['Blincyto', 'blinatumomab', 'blinatumomab (cancer, BiTE),/', 'anti-CD3/anti-CD19 bispecific T-cell engager (BiTE, acute lymphoblastic leukemia),/Astellas', 'MT-103 (cancer, BiTE),/', 'bscCD19xCD3 (cancer, BiTE), Micromet/MedImmune', 'anti-CD3/anti-CD19 bispecific T-cell engager (BiTE, acute lymphoblastic leukemia),/', 'bscCD19xCD3 (cancer, BiTE), Micromet/', 'L01XC19', 'AMG-103', 'MT-103 (cancer, BiTE), Micromet/MedImmune', 'MEDI-538', 'MT-103', 'MT-103, MedImmune', 'MT-103 (cancer, BiTE)', 'bscCD19xCD3 (cancer, BiTE)', 'blinatumomab (cancer, BiTE), Micromet/MedImmune', 'MT-103 (cancer, BiTE), Micromet/', 'blinatumomab (cancer, BiTE), Micromet/', 'CD19XCD3', 'bscCD19xCD3 (cancer, BiTE),/']",blinatumomab,fexact,"['blincyto', 'blinatumomab', 'blinatumomab cancer bite', 'anti cd3 anti cd19 bispecific t cell engager bite acute lymphoblastic leukemia astellas', 'mt 103 cancer bite', 'bsccd19xcd3 cancer bite micromet medimmune', 'anti cd3 anti cd19 bispecific t cell engager bite acute lymphoblastic leukemia', 'bsccd19xcd3 cancer bite micromet', 'l01xc19', 'amg 103', 'mt 103 cancer bite micromet medimmune', 'medi 538', 'mt 103', 'mt 103 medimmune', 'mt 103 cancer bite', 'bsccd19xcd3 cancer bite', 'blinatumomab cancer bite micromet medimmune', 'mt 103 cancer bite micromet', 'blinatumomab cancer bite micromet', 'cd19xcd3', 'bsccd19xcd3 cancer bite']",correct_mapping
autologous multi-lineage potential cells,Immuno-oncology therapy,autologous multi-lineage potential cells,,,,0,['autologous multi-lineage potential cells'],,0,[],0
bisantrene,DNA inhibitor; FTO alpha-ketoglutarate dependent dioxygenase inhibitor,bisantrene,,bisantrene hydrochloride (acute myeloid leukemia),bisantrene,fexact,"['UPI-928', 'bisantrene hydrochloride (acute myeloid leukemia)', 'bisantrene', 'bisantrene hydrochloride (acute myeloid leukemia), Race Oncology', 'CS-1', 'CS-1, Race Oncology', 'bisantrene hydrochloride (acute myeloid leukemia/skin cancer/ovary tumor/breast tumor), Race Oncology', 'bisantrene hydrochloride (acute myeloid leukemia), Update Pharma', 'bisantrene hydrochloride (acute myeloid leukemia/skin cancer/ovary tumor/breast tumor)', 'bisantrene hydrochloride']",bisantrene hydrochloride (acute myeloid leukemia),fexact,"['upi 928', 'bisantrene hydrochloride acute myeloid leukemia', 'bisantrene', 'bisantrene hydrochloride acute myeloid leukemia race oncology', 'cs 1', 'cs 1 race oncology', 'bisantrene hydrochloride acute myeloid leukemia skin cancer ovary tumor breast tumor race oncology', 'bisantrene hydrochloride acute myeloid leukemia update pharma', 'bisantrene hydrochloride acute myeloid leukemia skin cancer ovary tumor breast tumor', 'bisantrene hydrochloride']",correct_mapping
RTX-240,Immunostimulant; T cell stimulant; Natural killer cell stimulant; Immuno-oncology therapy,RTX-240,,RTX-240,rtx 240,fexact,"['rct therapy (solid tumor/aml)', 'mRBC-240', 'dual 4-1bb costimulator + il-15tp red blood cell therapy (solid tumor/aml)', 'rct therapy (solid tumor/aml/melanoma/colorectal cancer)', 'dual 4-1bbl + il-15tp expressing red blood cell therapy (solid tumor/aml)', 'RTX-240', 'RTX-212']",RTX-240,fexact,"['rct therapy solid tumor aml', 'mrbc 240', 'dual 4 1bb costimulator il 15tp red blood cell therapy solid tumor aml', 'rct therapy solid tumor aml melanoma colorectal cancer', 'dual 4 1bbl il 15tp expressing red blood cell therapy solid tumor aml', 'rtx 240', 'rtx 212']",correct_mapping
MAX-40279,Fibroblast growth factor receptor antagonist; Flt-3 antagonist,MAX-40279,,MAX-40279,max 40279,fexact,"['MAX-4', 'dual FLT3/FGFR inhibitor (oral/capsule, acute myelogenous leukemia)', 'MAX-40279-01', 'MAX-40279']",MAX-40279,fexact,"['max 4', 'dual flt3 fgfr inhibitor oral capsule acute myelogenous leukemia', 'max 40279 01', 'max 40279']",correct_mapping
TAK-243,UBA6 inhibitor; UBA1 inhibitor,TAK-243,,TAK-243,tak 243,fexact,"['E1 activating enzyme inhibitors (cancer), Millennium Pharmaceuticals', 'MLN-7243', 'TAK-243', 'ubiquitin activating enzyme 1 inhibitors (cancer), Millennium Pharmaceuticals', 'UBA1 inhibitors (cancer), Millennium Pharmaceuticals']",TAK-243,fexact,"['e1 activating enzyme inhibitors cancer millennium pharmaceuticals', 'mln 7243', 'tak 243', 'ubiquitin activating enzyme 1 inhibitors cancer millennium pharmaceuticals', 'uba1 inhibitors cancer millennium pharmaceuticals']",correct_mapping
OGFT-001,Unidentified pharmacological activity,OGFT-001,,,,0,['OGFT-001'],,0,[],0
"CD123 chimaeric antigen receptor therapy, Hebei Senlang Biotechnology",T cell stimulant; Immuno-oncology therapy,CD123 chimaeric antigen receptor therapy,Hebei Senlang Biotechnology,,,0,['CD123 chimaeric antigen receptor therapy'],,0,[],0
OmnImmune,T cell stimulant; Immuno-oncology therapy,OmnImmune,,TCB-002,omnimmune,fexact,"['OmnImmune', 'TCB-002', 'allogeneic gamma delta T-cell therapy (cancer, viral infection, acute myelogenous leukemia/viral pneumonia/viral infection/bacterial infection/cancer)', 'allogeneic gamma delta T-cell therapy (cancer, viral infection, bacterial infection)']",TCB-002,fexact,"['omnimmune', 'tcb 002', 'allogeneic gamma delta t cell therapy cancer viral infection acute myelogenous leukemia viral pneumonia viral infection bacterial infection cancer', 'allogeneic gamma delta t cell therapy cancer viral infection bacterial infection']",correct_mapping
HM-43239,Flt-3 antagonist; Syk tyrosine kinase inhibitor,HM-43239,,HM-43239,hm 43239,fexact,['HM-43239'],HM-43239,fexact,['hm 43239'],correct_mapping
ICG-144,T cell stimulant; Immuno-oncology therapy,ICG-144,,,,0,['ICG-144'],,0,[],0
PTC-299,Vascular endothelial growth factor (VEGF)receptor antagonist; Dihydroorotate dehydrogenase inhibitor; Angiogenesis inhibitor,PTC-299,,emvododstat,ptc 299,fexact,"['DHODH1 inhibitor (hematological cancer)', 'PTC-VK', 'PTC-299', 'PTC-VJ', 'DHODH inhibitor (hematological cancer)', 'VEGF expression inhibitors (cancer)', 'PTC-WS', 'emvododstat', 'PTC-VG', 'PTC-VH', 'dihydroorotate dehydrogenase inhibitor (hematological cancer)', 'anti-angiogenics (cancer)']",emvododstat,fexact,"['dhodh1 inhibitor hematological cancer', 'ptc vk', 'ptc 299', 'ptc vj', 'dhodh inhibitor hematological cancer', 'vegf expression inhibitors cancer', 'ptc ws', 'emvododstat', 'ptc vg', 'ptc vh', 'dihydroorotate dehydrogenase inhibitor hematological cancer', 'anti angiogenics cancer']",correct_mapping
Minnelide (oral),Heat shock protein 70 antagonist,Minnelide,,triptolide prodrug (pancreatic cancer),minnelide,fexact,"['Minnelide', 'triptolide', 'triptolide prodrug (pancreatic cancer)', 'triptolide prodrug (acute myeloid leukemia)']",triptolide prodrug (pancreatic cancer),fexact,"['minnelide', 'triptolide', 'triptolide prodrug pancreatic cancer', 'triptolide prodrug acute myeloid leukemia']",correct_mapping
brequinar,Dihydroorotate dehydrogenase inhibitor,brequinar,,brequinar,brequinar,fexact,"['NSC-368390', 'CS-2', 'DuP-785', 'brequinar', 'brequinar sodium']",brequinar,fexact,"['nsc 368390', 'cs 2', 'dup 785', 'brequinar', 'brequinar sodium']",correct_mapping
TK-216,FLI1 inhibitor,TK-216,,TK-216,tk 216,fexact,"['TK-216', 'SPH-8216', 'ets-family transcription factor inhibitor (cancer)', 'ets-family transcription factor inhibitor (cancer), Tokalas']",TK-216,fexact,"['tk 216', 'sph 8216', 'ets family transcription factor inhibitor cancer', 'ets family transcription factor inhibitor cancer tokalas']",correct_mapping
fadraciclib (iv),Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor; Mcl-1 antagonist; Cell cycle inhibitor; Cyclin E inhibitor,fadraciclib,,"fadraciclib  (intravenous, advanced cancer)",fadraciclib,fexact,"['fadraciclib', 'CYC-065', 'CYC-065 (intravenous, advanced cancer)', 'fadraciclib  (intravenous, advanced cancer)', 'dual CDK 2/9 inhibitor (advanced cancer)']","fadraciclib  (intravenous, advanced cancer)",fexact,"['fadraciclib', 'cyc 065', 'cyc 065 intravenous advanced cancer', 'fadraciclib intravenous advanced cancer', 'dual cdk 2 9 inhibitor advanced cancer']",correct_mapping
pinometostat,Histone methyltransferase inhibitor,pinometostat,,pinometostat,pinometostat,fexact,"['pinometostat', 'DOT1L inhibitors (mixed lineage leukemia),/GlaxoSmithKline', 'DOT1L inhibitors (leukemia),/GSK', 'EPZ-004777', 'EZ-5676', 'DOT1L inhibitors (leukemia), Epizyme/GSK', 'DOT1L inhibitors (mixed lineage leukemia), Epizyme/GlaxoSmithKline', 'EPZ-5676']",pinometostat,fexact,"['pinometostat', 'dot1l inhibitors mixed lineage leukemia glaxosmithkline', 'dot1l inhibitors leukemia gsk', 'epz 004777', 'ez 5676', 'dot1l inhibitors leukemia epizyme gsk', 'dot1l inhibitors mixed lineage leukemia epizyme glaxosmithkline', 'epz 5676']",correct_mapping
K-NK002,Natural killer cell stimulant; Immuno-oncology therapy,K-NK002,,K-NK002,k nk002,fexact,"['adoptive haploidentical natural killer cell therapy (acute myelogenous leukemia/myelodysplastic syndrome)', 'CSDT002-NK', 'natural killer cell therapy (cancer), Kiadis', 'adoptive haploidentical natural killer cell therapy (acute myelogenous leukemia/myelodysplastic syndrome), Kiadis', 'natural killer cell therapy (cancer)', 'CSTD002-NK', 'K-NK002']",K-NK002,fexact,"['adoptive haploidentical natural killer cell therapy acute myelogenous leukemia myelodysplastic syndrome', 'csdt002 nk', 'natural killer cell therapy cancer kiadis', 'adoptive haploidentical natural killer cell therapy acute myelogenous leukemia myelodysplastic syndrome kiadis', 'natural killer cell therapy cancer', 'cstd002 nk', 'k nk002']",correct_mapping
FN-1501,Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Flt-3 antagonist,FN-1501,,FN-1501,fn 1501,fexact,['FN-1501'],FN-1501,fexact,['fn 1501'],correct_mapping
"anti-CD123 CAR-T cell therapy, Nanjing Legend Biotech",T cell stimulant; Immuno-oncology therapy,anti-CD123 CAR-T cell therapy,Nanjing Legend Biotech,BinD-19,anti cd19 car t cell therapy,fuzzy,"['BinD-19', 'anti-CD19 CAR T-cell therapy']",BinD-19,fexact,"['bind 19', 'anti cd19 car t cell therapy']",incorrect_mapping
211^At-BC8-B10,CD45 antagonist; Immuno-oncology therapy,211^At-BC8-B10,,,,0,['211^At-BC8-B10'],,0,[],0
multivitamin,Reducing agent,multivitamin,,,,0,['multivitamin'],,0,[],0
succimer,Chelating agent,succimer,,,,0,['succimer'],,0,[],0
levofloxacin,DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,levofloxacin,,levofloxacin,levofloxacin,fexact,"['Levoquin', 'Levaquin', 'levofloxacin (injectable, bacterial infection)', 'DR-3355', 'HR-355', 'levofloxacin (oral, bacterial infection)', 'ORF-18489', 'levofloxacin (oral, bacterial infection), Daiichi Seiyaku', 'Cravit', 'levofloxacin', 'levofloxacin (injectable, bacterial infection), Daiichi Sankyo', 'Tavanic', '(S)-ofloxacin', 'Cravit IV', '(-)-ofloxacin', 'DL-8280']",levofloxacin,fexact,"['levoquin', 'levaquin', 'levofloxacin injectable bacterial infection', 'dr 3355', 'hr 355', 'levofloxacin oral bacterial infection', 'orf 18489', 'levofloxacin oral bacterial infection daiichi seiyaku', 'cravit', 'levofloxacin', 'levofloxacin injectable bacterial infection daiichi sankyo', 'tavanic', 's ofloxacin', 'cravit iv', 'ofloxacin', 'dl 8280']",correct_mapping
midostaurin (solution),Protein kinase C inhibitor; C-kit inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor beta kinase inhib; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Cyclin B inbibitor; Cell cycle inhibitor,midostaurin,,midostaurin,midostaurin,fexact,"['PKC-412A', 'PKC-412', 'STI-412', 'Rydapt', 'CGP-41251', 'benzoylstaurosporine', 'midostaurin']",midostaurin,fexact,"['pkc 412a', 'pkc 412', 'sti 412', 'rydapt', 'cgp 41251', 'benzoylstaurosporine', 'midostaurin']",correct_mapping
IM-23,T cell stimulant; Immuno-oncology therapy,IM-23,,IM-23,im 23,fexact,"['IM-23', 'anti-CD123 CAR T-cell therapy (acute myeloid leukemia)']",IM-23,fexact,"['im 23', 'anti cd123 car t cell therapy acute myeloid leukemia']",correct_mapping
edicotinib,Colony stimulating factor 1 receptor antagonist; Immuno-oncology therapy,edicotinib,,edicotinib,edicotinib,fexact,"['FMS inhibitor (oral, inflammatory disease)', 'JNJ-527', 'JNJ-40346527 hydrochloride', 'JNJ-6527', 'edicotinib', 'JNJ-40346527', 'JNJ-244', 'PRV-6527', 'edicotinib hydrochloride']",edicotinib,fexact,"['fms inhibitor oral inflammatory disease', 'jnj 527', 'jnj 40346527 hydrochloride', 'jnj 6527', 'edicotinib', 'jnj 40346527', 'jnj 244', 'prv 6527', 'edicotinib hydrochloride']",correct_mapping
voruciclib,Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cell cycle inhibitor,voruciclib,,voruciclib,voruciclib,fexact,"['CDK4 inhibitor (oral, cancer), NPIL Research & Development', 'CDK4 inhibitor (oral, cancer), Piramal Healthcare', 'P-1446', 'kinase inhibitor (cancer)', 'kinase inhibitor (cancer), Piramal', 'CDK4 inhibitor (oral, cancer), Piramal Life Sciences', 'voruciclib', 'P-1446A-05']",voruciclib,fexact,"['cdk4 inhibitor oral cancer npil research development', 'cdk4 inhibitor oral cancer piramal healthcare', 'p 1446', 'kinase inhibitor cancer', 'kinase inhibitor cancer piramal', 'cdk4 inhibitor oral cancer piramal life sciences', 'voruciclib', 'p 1446a 05']",correct_mapping
AMG-427,CD3 agonist; Immuno-oncology therapy,AMG-427,,AMG-427,amg 427,fexact,"['anti-CD3/anti-FLT3 bispecific T-cell engager (HLE-BiTE, acute myeloid leukemia)', 'AMG-427']",AMG-427,fexact,"['anti cd3 anti flt3 bispecific t cell engager hle bite acute myeloid leukemia', 'amg 427']",correct_mapping
SNDX-5613,Menin-MLL inhibitor,SNDX-5613,,SNDX-5613 sesquifumarate,sndx 5613,fexact,"['SNDX-5613', 'VTP-50469', 'menin-MLL inhibitors (oral, acute leukemia)', 'menin-MLL inhibitors (oral, acute leukemia), Syndax Pharmaceuticals', 'SNDX-5613 sesquifumarate']",SNDX-5613 sesquifumarate,fexact,"['sndx 5613', 'vtp 50469', 'menin mll inhibitors oral acute leukemia', 'menin mll inhibitors oral acute leukemia syndax pharmaceuticals', 'sndx 5613 sesquifumarate']",correct_mapping
quizartinib dihydrochloride (solution),Flt-3 antagonist,quizartinib dihydrochloride,,quizartinib dihydrochloride,quizartinib dihydrochloride,fexact,"['AB-200432', 'ASP-2689', 'quizartinib', 'AC-886', 'Vanflyta', 'AB-530', 'AB-460', 'quizartinib dihydrochloride', 'AB-200382', 'AB-200243', 'Flt3 tyrosine kinase inhibitors', 'AB-200434', 'Flt3 tyrosine kinase inhibitors,/Astellas', 'AB-515', 'Flt3 tyrosine kinase inhibitors,/', 'AC-220']",quizartinib dihydrochloride,fexact,"['ab 200432', 'asp 2689', 'quizartinib', 'ac 886', 'vanflyta', 'ab 530', 'ab 460', 'quizartinib dihydrochloride', 'ab 200382', 'ab 200243', 'flt3 tyrosine kinase inhibitors', 'ab 200434', 'flt3 tyrosine kinase inhibitors astellas', 'ab 515', 'flt3 tyrosine kinase inhibitors', 'ac 220']",correct_mapping
"clifutinib, HEC Pharm",Flt-3 antagonist,clifutinib,HEC Pharm,,,0,['clifutinib'],,0,[],0
AB-110,Not applicable,AB-110,,E-CEL UVEC,ab 110,fexact,"['allogeneic umbilical cord blood-derived cd34-positive hematopoietic stem cells + endothelial cells expressing e4orf1 (e-cel, hematological malignancies)', 'AB-110', 'ab-205', 'E-CEL UVEC', 'allogeneic umbilical cord blood-derived cd34-positive hematopoietic stem cells + endothelial cells expressing e4orf1 (e-cel, hematological malignancies/anal fistula)']",E-CEL UVEC,fexact,"['allogeneic umbilical cord blood derived cd34 positive hematopoietic stem cells endothelial cells expressing e4orf1 e cel hematological malignancies', 'ab 110', 'ab 205', 'e cel uvec', 'allogeneic umbilical cord blood derived cd34 positive hematopoietic stem cells endothelial cells expressing e4orf1 e cel hematological malignancies anal fistula']",correct_mapping
GEM-333,CD3 agonist; T cell stimulant; Immuno-oncology therapy,GEM-333,,GEM-333,gem 333,fexact,"['anti-CD3/anti-CD33 bispecific T-cell engager (AML)', 'anti-CD3/CD33 bispecific mAb (AML),/', 'anti-CD3/CD33 bispecific mAb (AML), GEMoaB/', 'GEM-333']",GEM-333,fexact,"['anti cd3 anti cd33 bispecific t cell engager aml', 'anti cd3 cd33 bispecific mab aml', 'anti cd3 cd33 bispecific mab aml gemoab', 'gem 333']",correct_mapping
BCT-100,Arginase stimulant,BCT-100,,,,0,"['BCT-100', 'rhArg', 'recombinant human arginase (cancer/autoimmune disease/hyperargininemia), BCT', 'recombinant human arginase (cancer), BCT']",,NER_API,[],0
"CMV vaccine, City of Hope",Immunostimulant,CMV vaccine,City of Hope,,,0,"['CMV vaccine', 'cytomegalovirus vaccine,/StressVax']",,Drug_API_mapping,[],0
olvimulogene nanivacirepvec,Immuno-oncology therapy,olvimulogene nanivacirepvec,,olvimulogene nanivacirepvec,olvimulogene nanivacirepvec,fexact,"['GLV-1h68', 'GL-ONC1', 'olvimulogene nanivacirepvec', 'oncolytic vaccinia virus therapy expressing hNIS (cancer)', 'Olvi-Vec', 'recombinant vaccinia virus (injectable, cancer)']",olvimulogene nanivacirepvec,fexact,"['glv 1h68', 'gl onc1', 'olvimulogene nanivacirepvec', 'oncolytic vaccinia virus therapy expressing hnis cancer', 'olvi vec', 'recombinant vaccinia virus injectable cancer']",correct_mapping
dilanubicel,Unidentified pharmacological activity,dilanubicel,,dilanubicel,dilanubicel,fexact,"['dilanubicel', 'NLA-101', 'allogeneic umbilical cord blood cells expanded ex vivo with Notch ligand Delta1']",dilanubicel,fexact,"['dilanubicel', 'nla 101', 'allogeneic umbilical cord blood cells expanded ex vivo with notch ligand delta1']",correct_mapping
SAR-440234,CD3 agonist; Immuno-oncology therapy,SAR-440234,,SAR-440234,sar 440234,fexact,"['SAR-440234', 'anti-CD3/anti-CD123 bispecific T-cell engager (leukemia)']",SAR-440234,fexact,"['sar 440234', 'anti cd3 anti cd123 bispecific t cell engager leukemia']",correct_mapping
BAY-2402234,Dihydroorotate dehydrogenase inhibitor,BAY-2402234,,BAY-2402234,bay 2402234,fexact,"['BAY-2402234', 'DHODH inhibitor (hematological neoplasm)']",BAY-2402234,fexact,"['bay 2402234', 'dhodh inhibitor hematological neoplasm']",correct_mapping
annamycin,DNA inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,annamycin,,Annamycin,annamycin,fexact,"['anthracycline, Aronex', 'Annamycin', 'Annamycin LF', 'Liposomal Annamycin', 'anthracycline, Callisto', 'AR-522', 'anthracycline', 'L-Annamycin']",Annamycin,fexact,"['anthracycline aronex', 'annamycin', 'annamycin lf', 'liposomal annamycin', 'anthracycline callisto', 'ar 522', 'anthracycline', 'l annamycin']",correct_mapping
G-CSF primed mobilized HLA-haploidentical cells,Granulocyte colony stimulating factor agonist,G-CSF primed mobilized HLA-haploidentical cells,,,,0,['G-CSF primed mobilized HLA-haploidentical cells'],,0,[],0
LAM-003,Heat shock protein 90 antagonist,LAM-003,,LAM-003,lam 003,fexact,"['LAM-003', 'HSP90 inhibitor (oral, acute myeloid leukemia), Al Therapeutics', 'immunomodulator (oral, cancer/acute myeloid leukemia), Lam Therapeutics']",LAM-003,fexact,"['lam 003', 'hsp90 inhibitor oral acute myeloid leukemia al therapeutics', 'immunomodulator oral cancer acute myeloid leukemia lam therapeutics']",correct_mapping
ABBV-744,Bromodomain containing 2 inhibitor,ABBV-744,,ABBV-744,abbv 744,fexact,"['BRD4 bromodomain inhibitor (metastatic castration resistant prostate cancer)', 'brd4 bromodomain inhibitor (oral, metastatic castration resistant prostate cancer/myelofibrosis)', 'ABBV-744']",ABBV-744,fexact,"['brd4 bromodomain inhibitor metastatic castration resistant prostate cancer', 'brd4 bromodomain inhibitor oral metastatic castration resistant prostate cancer myelofibrosis', 'abbv 744']",correct_mapping
MG-4101,Natural killer cell stimulant,MG-4101,,MG-4101,mg 4101,fexact,"['allogenic natural killer cell therapy (cancer), morgam', 'allogenic natural killer cell therapy (intravenous, hepatocellular carcinoma/non hodgkin lymphoma), morgam', 'allogeneic natural killer cell therapy (cancer), Mogam/Green Cross', 'allogenic natural killer cell therapy (cancer), Morgam/GC Pharma', 'allogeneic natural killer cell therapy (cancer),/Green Cross', 'allogenic natural killer cell therapy (intravenous, hepatocellular carcinoma/Non Hodgkin lymphoma), Morgam/GC Pharma', 'MG-4101', 'AB-101', 'MG-401']",MG-4101,fexact,"['allogenic natural killer cell therapy cancer morgam', 'allogenic natural killer cell therapy intravenous hepatocellular carcinoma non hodgkin lymphoma morgam', 'allogeneic natural killer cell therapy cancer mogam green cross', 'allogenic natural killer cell therapy cancer morgam gc pharma', 'allogeneic natural killer cell therapy cancer green cross', 'allogenic natural killer cell therapy intravenous hepatocellular carcinoma non hodgkin lymphoma morgam gc pharma', 'mg 4101', 'ab 101', 'mg 401']",correct_mapping
Minnelide (intravenous),Heat shock protein 70 antagonist,Minnelide,,triptolide prodrug (pancreatic cancer),minnelide,fexact,"['Minnelide', 'triptolide', 'triptolide prodrug (pancreatic cancer)', 'triptolide prodrug (acute myeloid leukemia)']",triptolide prodrug (pancreatic cancer),fexact,"['minnelide', 'triptolide', 'triptolide prodrug pancreatic cancer', 'triptolide prodrug acute myeloid leukemia']",correct_mapping
APVO-436,CD3 agonist; Immuno-oncology therapy,APVO-436,,APVO-436,apvo 436,fexact,"['anti-CD3/anti-CD123 bispecific T-cell engager (ADAPTIR, hematological malignancies)', 'APVO-436']",APVO-436,fexact,"['anti cd3 anti cd123 bispecific t cell engager adaptir hematological malignancies', 'apvo 436']",correct_mapping
ASLAN-003,Dihydroorotate dehydrogenase inhibitor; Disease modifying antirheumatic drug,ASLAN-003,,ASLAN-003,aslan 003,fexact,"['DHODH inhibitor (autoimmune disease), Alimirall', 'dihydroorotate dehydrogenase inhibitor (oral, multiple sclerosis/acute myelogenous leukemia/covid-19/dengue/zika virus/breast tumor/hepatocellular carinoma)', 'ASLAN-003', 'LAS-186323', 'DHODH inhibitor (rheumatoid arthritis/multiple sclerosis), Almirall', 'DHODH inhibitor (autoimmune disease)', 'DHODH inhibitor (rheumatoid arthritis/multiple sclerosis)', 'DHODH inhibitor (rheumatoid arthritis/multiple sclerosis/AML)']",ASLAN-003,fexact,"['dhodh inhibitor autoimmune disease alimirall', 'dihydroorotate dehydrogenase inhibitor oral multiple sclerosis acute myelogenous leukemia covid 19 dengue zika virus breast tumor hepatocellular carinoma', 'aslan 003', 'las 186323', 'dhodh inhibitor rheumatoid arthritis multiple sclerosis almirall', 'dhodh inhibitor autoimmune disease', 'dhodh inhibitor rheumatoid arthritis multiple sclerosis', 'dhodh inhibitor rheumatoid arthritis multiple sclerosis aml']",correct_mapping
"APX-001, Amplyx (oral)",glycosylphosphatidylinositol inhibitor,APX-001,Amplyx,,,0,"['E-1210', 'nicotinamide derivatives (glycosylphosphatidylinositol biosynthesis inhibitor), Eisai Co Ltd', 'glycosylphosphatidylinositol biosynthesis inhibitor (fungal infection)', 'anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis),/', 'fosmanogepix (oral, fungal infections),/Pfizer', 'EPI-0010', 'fosmanogepix', 'anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis),/Epitomics', 'anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis),/Apexigen', 'nicotinamide derivatives (glycosylphosphatidylinositol biosynthesis inhibitor)', 'SSS-07', 'APX-001', 'APX-001A', 'fosmanogepix (intravenous, fungal infections),/Pfizer', 'glycosylphosphatidylinositol biosynthesis inhibitor (fungal infection), Eisai', 'APX-001, Apexigen']",,Drug_API_mapping,[],0
"APX-001, Amplyx (iv)",glycosylphosphatidylinositol inhibitor,APX-001,Amplyx,,,0,"['E-1210', 'nicotinamide derivatives (glycosylphosphatidylinositol biosynthesis inhibitor), Eisai Co Ltd', 'glycosylphosphatidylinositol biosynthesis inhibitor (fungal infection)', 'anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis),/', 'fosmanogepix (oral, fungal infections),/Pfizer', 'EPI-0010', 'fosmanogepix', 'anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis),/Epitomics', 'anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis),/Apexigen', 'nicotinamide derivatives (glycosylphosphatidylinositol biosynthesis inhibitor)', 'SSS-07', 'APX-001', 'APX-001A', 'fosmanogepix (intravenous, fungal infections),/Pfizer', 'glycosylphosphatidylinositol biosynthesis inhibitor (fungal infection), Eisai', 'APX-001, Apexigen']",,Drug_API_mapping,[],0
"HA1-specific TCR therapy, HighPassBio",T cell stimulant; Immuno-oncology therapy,HA1-specific TCR therapy,HighPassBio,,,0,['HA1-specific TCR therapy'],,0,[],0
CYC-140,Polo-like kinase 1 inhibitor,CYC-140,,CYC-140,cyc 140,fexact,"['CYC-140', 'Polo-like kinase 1 inhibitors (iv, leukemias)', 'PLK1 inhibitors (iv, cancers)']",CYC-140,fexact,"['cyc 140', 'polo like kinase 1 inhibitors iv leukemias', 'plk1 inhibitors iv cancers']",correct_mapping
NEXI-001,Immuno-oncology therapy,NEXI-001,,NEXI-001,nexi 001,fexact,"['adoptive T-cell therapy (AIM ACT, acute myeloid leukemia/myelodysplastic syndrome)', 'NEXI-001', 'artificial antigen-presenting cell-based adoptive cell therapy (AIM, acute myeloid leukemia/myelodysplasic syndrome)', 'anti-WT1/HLA-A0201 + anti-Prame/HLA-A0201 + anti-Cyclin A1/HLA-A0201 adoptive T-cell therapy (AIM ACT, acute myeloid leukemia/myelodysplastic syndrome)', 'aAPC-based adoptive cell therapy (AIM, acute myeloid leukemia/myelodysplasic syndrome)']",NEXI-001,fexact,"['adoptive t cell therapy aim act acute myeloid leukemia myelodysplastic syndrome', 'nexi 001', 'artificial antigen presenting cell based adoptive cell therapy aim acute myeloid leukemia myelodysplasic syndrome', 'anti wt1 hla a0201 anti prame hla a0201 anti cyclin a1 hla a0201 adoptive t cell therapy aim act acute myeloid leukemia myelodysplastic syndrome', 'aapc based adoptive cell therapy aim acute myeloid leukemia myelodysplasic syndrome']",correct_mapping
G-801,Axl receptor tyrosine kinase inhibitor; Flt-3 antagonist,G-801,,SKI-G-801,g 801,fexact,"['protein kinase inhibitors (cancer), oscotec', 'SKI-G-749', 'G-801', 'flt3 kinase inhibitor (cancer)', 'protein kinase inhibitors (cancer)', 'G-749', 'SKI-G-801']",SKI-G-801,fexact,"['protein kinase inhibitors cancer oscotec', 'ski g 749', 'g 801', 'flt3 kinase inhibitor cancer', 'protein kinase inhibitors cancer', 'g 749', 'ski g 801']",correct_mapping
DCLL-9718S,Unidentified pharmacological activity,DCLL-9718S,,RG-6109,dcll 9718s,fexact,"['anti-CLL-1 antibody-drug conjugate (acute myeloid leukemia)', 'DCLL-9718S', 'RG-6109']",RG-6109,fexact,"['anti cll 1 antibody drug conjugate acute myeloid leukemia', 'dcll 9718s', 'rg 6109']",correct_mapping
Eps8 peptide specific dendritic cell,Immunostimulant,Eps8 peptide specific dendritic cell,,,,0,['Eps8 peptide specific dendritic cell'],,0,[],0
AMG-673,CD3 agonist; Immuno-oncology therapy,AMG-673,,AMG-673,amg 673,fexact,"['anti-CD3/anti-CD33 bispecific T-cell engager (HLE-BiTE, acute myeloid leukemia)', 'AMG-673', 'emerfetamab']",AMG-673,fexact,"['anti cd3 anti cd33 bispecific t cell engager hle bite acute myeloid leukemia', 'amg 673', 'emerfetamab']",correct_mapping
3rd generation CART cells,Immuno-oncology therapy,3rd generation CART cells,,,,0,['3rd generation CART cells'],,0,[],0
GTB-3550,CD33 antagonist; Natural killer cell stimulant; Immuno-oncology therapy,GTB-3550,,OXS-3550,gtb 3550,fexact,"['OXS-3350', '161533 TriKE', 'OXS-3550', 'cd16-il-15-cd33 trispecific killer cell engager (aml/mds/mastocytosis/mast cell leukemia)', 'anti-cd16/anti-cd33/il-15 trispecific immune-cell engager (trike, cancer)', 'anti-CD16/anti-CD33/IL-15 trispecific NK-cell engager (TriKE, cancer), University of Minnesota/New York Medical College/', 'anti-CD16/anti-CD33/IL-15 trispecific immune-cell engager (TriKE, cancer), University of Minnesota/New York Medical College/', 'CD16-IL-15-CD33 Trike', 'anti-cd16/anti-cd33/il-15 trispecific immune-cell engager (trike, cancer), university of minnesota', 'TriKE 161533', '1633 TriKE', 'CD16-IL-15-CD33 trispecific killer cell engager (AML/MDS/mastocytosis/mast cell leukemia), University of Minnesota', 'anti-cd16/anti-cd33/il-15 trispecific nk-cell engager (trike, cancer), university of minnesota', 'anti-cd16/anti-cd33/il-15 trispecific nk-cell engager (trike, cancer)', 'GTB-3550', 'anti-CD16/anti-CD33 antibody + modified IL-15 crosslinker (cancer, TriKE), Oxis International', 'GTB-3550 Trike', '161533']",OXS-3550,fexact,"['oxs 3350', '161533 trike', 'oxs 3550', 'cd16 il 15 cd33 trispecific killer cell engager aml mds mastocytosis mast cell leukemia', 'anti cd16 anti cd33 il 15 trispecific immune cell engager trike cancer', 'anti cd16 anti cd33 il 15 trispecific nk cell engager trike cancer university of minnesota new york medical college', 'anti cd16 anti cd33 il 15 trispecific immune cell engager trike cancer university of minnesota new york medical college', 'cd16 il 15 cd33 trike', 'anti cd16 anti cd33 il 15 trispecific immune cell engager trike cancer university of minnesota', 'trike 161533', '1633 trike', 'cd16 il 15 cd33 trispecific killer cell engager aml mds mastocytosis mast cell leukemia university of minnesota', 'anti cd16 anti cd33 il 15 trispecific nk cell engager trike cancer university of minnesota', 'anti cd16 anti cd33 il 15 trispecific nk cell engager trike cancer', 'gtb 3550', 'anti cd16 anti cd33 antibody modified il 15 crosslinker cancer trike oxis international', 'gtb 3550 trike', '161533']",correct_mapping
T-allo10,Immuno-oncology therapy,T-allo10,,T-allo10,t allo10,fexact,"['tr1 adoptive cell therapy (gvhd)', 'alloantigen-specific IL-10 anergized T cells (intravenous/infusion, GvHD), Stanford University', 'T-allo10', 'alloantigen-specific il-10 anergized t cells (intravenous/infusion, gvhd)']",T-allo10,fexact,"['tr1 adoptive cell therapy gvhd', 'alloantigen specific il 10 anergized t cells intravenous infusion gvhd stanford university', 't allo10', 'alloantigen specific il 10 anergized t cells intravenous infusion gvhd']",correct_mapping
OPB-111077,STAT transcription factor 3 inhibitor,OPB-111077,,OPB-111077,opb 111077,fexact,"['STAT inhibitors (cancer)', 'STAT-3 inhibitor (cancer)', 'OPB-111077']",OPB-111077,fexact,"['stat inhibitors cancer', 'stat 3 inhibitor cancer', 'opb 111077']",correct_mapping
"IGF-methotrexate, IGF Oncology",Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor,IGF-methotrexate,IGF Oncology,,,0,['IGF-methotrexate'],,0,[],0
dexrazoxane,Chelating agent; DNA topoisomerase II inhibitor,dexrazoxane,,dexrazoxane hydrochloride (anthracycline-induced cardiomyopathy),dexrazoxane,fexact,"['dexrazoxane hydrochloride (anthracycline-induced cardiomyopathy)', 'dexrazoxane', 'dexrazoxane hydrochloride']",dexrazoxane hydrochloride (anthracycline-induced cardiomyopathy),fexact,"['dexrazoxane hydrochloride anthracycline induced cardiomyopathy', 'dexrazoxane', 'dexrazoxane hydrochloride']",correct_mapping
Erwinase (IV),Protein synthesis inhibitor; Asparaginase stimulant; Apoptosis stimulant,Erwinase,,crisantaspase (acute lymphoblastic leukemia),erwinase,fexact,"['crisantaspase (acute lymphoblastic leukemia), Jazz Pharmaceuticals', 'crisantaspase', 'Erwinase', 'crisantaspase (acute lymphoblastic leukemia),/HPA', 'Erwinia chrysanthemi L-asparaginase (acute lymphoblastic leukemia),/HPA', 'Erwinaze', 'crisantaspase (acute lymphoblastic leukemia), OPi/HPA', 'asparaginase (Erwinia chrysanthemi)', 'crisantaspase (acute lymphoblastic leukemia)', 'Erwinia chrysanthemi L-asparaginase (acute lymphoblastic leukemia), OPi/HPA', 'OP-01']",crisantaspase (acute lymphoblastic leukemia),fexact,"['crisantaspase acute lymphoblastic leukemia jazz pharmaceuticals', 'crisantaspase', 'erwinase', 'crisantaspase acute lymphoblastic leukemia hpa', 'erwinia chrysanthemi l asparaginase acute lymphoblastic leukemia hpa', 'erwinaze', 'crisantaspase acute lymphoblastic leukemia opi hpa', 'asparaginase erwinia chrysanthemi', 'crisantaspase acute lymphoblastic leukemia', 'erwinia chrysanthemi l asparaginase acute lymphoblastic leukemia opi hpa', 'op 01']",correct_mapping
BAY-1436032,Isocitrate dehydrogenase 1 inhibitor,BAY-1436032,,BAY-1436032,bay 1436032,fexact,"['mIDH-1 inhibitor (cancer)', 'BAY-1436032']",BAY-1436032,fexact,"['midh 1 inhibitor cancer', 'bay 1436032']",correct_mapping
LY-2874455,Fibroblast growth factor receptor antagonist,LY-2874455,,LY-2874455,ly 2874455,fexact,"['LY-2874455', 'FGF receptor inhibitor (cancer)']",LY-2874455,fexact,"['ly 2874455', 'fgf receptor inhibitor cancer']",correct_mapping
"lentiviral CAR-T therapy, Ziopharm",T cell stimulant; Immuno-oncology therapy,lentiviral CAR-T therapy,Ziopharm,,,0,['lentiviral CAR-T therapy'],,0,[],0
"anticancer therapy, Incysus",T cell stimulant; Immuno-oncology therapy,anticancer therapy,Incysus,,,0,['anticancer therapy'],,0,[],0
onvansertib,Polo-like kinase 1 inhibitor,onvansertib,,onvansertib fumarate,onvansertib,fexact,"['NMS-1286937', 'PCM-075', 'pyrazoloquinazoline derivatives (cancer), Nerviano', 'Plk-1 kinase inhibitors (cancer)', 'onvansertib fumarate', 'NMS-P937', 'Polo-like kinase 1 inhibitors', 'onvansertib', 'Plk-1 kinase inhibitors (cancer), Nerviano', 'Polo-like kinase 1 inhibitors, Nerviano', 'Plk-1 kinase inhibitors (oral, cancer), Trovagene', 'NMS-937', 'pyrazoloquinazoline derivatives (cancer)']",onvansertib fumarate,fexact,"['nms 1286937', 'pcm 075', 'pyrazoloquinazoline derivatives cancer nerviano', 'plk 1 kinase inhibitors cancer', 'onvansertib fumarate', 'nms p937', 'polo like kinase 1 inhibitors', 'onvansertib', 'plk 1 kinase inhibitors cancer nerviano', 'polo like kinase 1 inhibitors nerviano', 'plk 1 kinase inhibitors oral cancer trovagene', 'nms 937', 'pyrazoloquinazoline derivatives cancer']",correct_mapping
"rhG-CSF, Synageva BioPharma",Granulocyte colony stimulating factor agonist,rhG-CSF,Synageva BioPharma,filgrastim,rhg csf,fexact,"['CSF', 'r-metHuG-CSF', 'hG-CSF', 'KRN-8601E', 'pluripoietin', 'Neupogen', 'rhG-CSF', 'Nupogen', 'G-CSF', 'filgrastim', 'KRN-8601', 'Grasin', 'filgrastim (HemaGel ER formulation, RxKinetix)', 'Granulokine', 'Neutropoietin', 'CSF-G', 'NSC-614629', 'GRAN']",filgrastim,fexact,"['csf', 'r methug csf', 'hg csf', 'krn 8601e', 'pluripoietin', 'neupogen', 'rhg csf', 'nupogen', 'g csf', 'filgrastim', 'krn 8601', 'grasin', 'filgrastim hemagel er formulation rxkinetix', 'granulokine', 'neutropoietin', 'csf g', 'nsc 614629', 'gran']",correct_mapping
HRAIN-004,T cell stimulant; Immuno-oncology therapy,HRAIN-004,,CD123CAR-41BB-CD3zeta-EGFRt,hrain 004,fexact,"['HRAIN-004', 'anti-CD123 CAR T-cell therapy (acute myeloid leukemia)', 'CD123CAR-41BB-CD3zeta-EGFRt']",CD123CAR-41BB-CD3zeta-EGFRt,fexact,"['hrain 004', 'anti cd123 car t cell therapy acute myeloid leukemia', 'cd123car 41bb cd3zeta egfrt']",correct_mapping
DFP-10917,G2 checkpoint inhibitor,DFP-10917,,radgocitabine,dfp 10917,fexact,"['DFP-10917', 'NS-917', 'radgocitabine']",radgocitabine,fexact,"['dfp 10917', 'ns 917', 'radgocitabine']",correct_mapping
KO-539,Menin-MLL inhibitor,KO-539,,KO-539,ko 539,fexact,"['MI-136', 'KO-539', 'MI-258', 'menin/MLL interaction inhibitor (leukemia), University of Michigan', 'MI-463', 'MIV-6', 'menin/mll interaction inhibitor (leukemia)', 'MI-2-2', 'menin MLL inhibitors (oral, leukemia)', 'KO-382', 'MI-1', 'MI-503']",KO-539,fexact,"['mi 136', 'ko 539', 'mi 258', 'menin mll interaction inhibitor leukemia university of michigan', 'mi 463', 'miv 6', 'menin mll interaction inhibitor leukemia', 'mi 2 2', 'menin mll inhibitors oral leukemia', 'ko 382', 'mi 1', 'mi 503']",correct_mapping
ONO-7475,Axl receptor tyrosine kinase inhibitor; Mer tyrosine kinase inhibitor,ONO-7475,,ONO-7475,ono 7475,fexact,['ONO-7475'],ONO-7475,fexact,['ono 7475'],correct_mapping
tripegfilgrastim,Granulocyte colony stimulating factor agonist,tripegfilgrastim,,lipegfilgrastim (neutropenia),lipegfilgrastim,fuzzy,"['lipegfilgrastim (neutropenia), Neose/', 'biobetter pegfilgastrim', 'XM-22', 'lipegfilgrastim (neutropenia),/', 'lipegfilgrastim (neutropenia)', 'glycoPEGylated G-CSF analogs (sustained release/subcutaneous/protein recombinant, neutropenia)', 'Lonquex', 'glycoPEGylated G-CSF analogs (neutropenia), Neose/', 'glycoPEGylated G-CSF analogs (neutropenia),/', 'GlycoPEG-(Met-des-1-Ala-des-37-Val-des-38-Ser-des-39-Glu)-GCSF', 'lipegfilgrastim']",lipegfilgrastim (neutropenia),fexact,"['lipegfilgrastim neutropenia neose', 'biobetter pegfilgastrim', 'xm 22', 'lipegfilgrastim neutropenia', 'lipegfilgrastim neutropenia', 'glycopegylated g csf analogs sustained release subcutaneous protein recombinant neutropenia', 'lonquex', 'glycopegylated g csf analogs neutropenia neose', 'glycopegylated g csf analogs neutropenia', 'glycopeg met des 1 ala des 37 val des 38 ser des 39 glu gcsf', 'lipegfilgrastim']",incorrect_mapping
allogeneic double negative T cells,Unidentified pharmacological activity,allogeneic double negative T cells,,,,0,['allogeneic double negative T cells'],,0,[],0
"mitoxantrone hydrochloride, unspecified",Immunosuppressant; DNA topoisomerase II inhibitor,mitoxantrone hydrochloride,unspecified,mitoxantrone,mitoxantrone hydrochloride,fexact,"['Ralenova', 'mitoxantrone', 'CL-232315', 'Elsep', 'mitozantrone', 'mitoxantrone hydrochloride', 'Novantrone']",mitoxantrone,fexact,"['ralenova', 'mitoxantrone', 'cl 232315', 'elsep', 'mitozantrone', 'mitoxantrone hydrochloride', 'novantrone']",correct_mapping
talacotuzumab,Interleukin 3 receptor antagonist,talacotuzumab,,talacotuzumab,talacotuzumab,fexact,"['talacotuzumab', 'therapeutic leukaemia antibody (AML)', 'anti-CD123 mAb (acute myelogenous leukemia)', 'anti-IL3R alpha chain mAb (AML)', 'CSL-360', 'JNJ-56022473', 'CD-123', 'CSL-362', 'anti-CD123 mAb (acute myelogenous leukemia), Janssen', '7G3', 'anti-IL3R alpha chain mAb (AML), Janssen']",talacotuzumab,fexact,"['talacotuzumab', 'therapeutic leukaemia antibody aml', 'anti cd123 mab acute myelogenous leukemia', 'anti il3r alpha chain mab aml', 'csl 360', 'jnj 56022473', 'cd 123', 'csl 362', 'anti cd123 mab acute myelogenous leukemia janssen', '7g3', 'anti il3r alpha chain mab aml janssen']",correct_mapping
"Apretero, Hetero Laboratories",Neurokinin 1 receptor antagonist,Apretero,Hetero Laboratories,,,0,['Apretero'],,0,[],0
AMV-564,CD3 agonist; Immuno-oncology therapy,AMV-564,,AMV-564,amv 564,fexact,"['AMV-564', 'anti-CD3/anti-CD33 bispecific T-cell engager (cancer),/Janssen', 'anti-CD3/anti-CD33 bispecific T-cell engager (cancer),/']",AMV-564,fexact,"['amv 564', 'anti cd3 anti cd33 bispecific t cell engager cancer janssen', 'anti cd3 anti cd33 bispecific t cell engager cancer']",correct_mapping
PF-06747143,CXC chemokine receptor 4 antagonist,PF-06747143,,PF-06747143,pf 06747143,fexact,['PF-06747143'],PF-06747143,fexact,['pf 06747143'],correct_mapping
"anti-CD33 CAR-pNK cells, PersonGen Biomedicine",T cell stimulant; Immuno-oncology therapy,anti-CD33 CAR-pNK cells,PersonGen Biomedicine,,,0,['anti-CD33 CAR-pNK cells'],,0,[],0
BI-836858,CD33 antagonist; Immuno-oncology therapy,BI-836858,,BI-836858,bi 836858,fexact,"['mAb 33.1, Boehringer Ingelheim RCV', 'BI-836858', 'Fc-engineered IgG1 mAb to CD33 (acute myelogenous leukemia), Boehringer Ingelheim RCV']",BI-836858,fexact,"['mab 33 1 boehringer ingelheim rcv', 'bi 836858', 'fc engineered igg1 mab to cd33 acute myelogenous leukemia boehringer ingelheim rcv']",correct_mapping
donor-derived WT1-CTL,Immuno-oncology therapy,donor-derived WT1-CTL,,,,0,['donor-derived WT1-CTL'],,0,[],0
donor-derived P-CTL,Immuno-oncology therapy,donor-derived P-CTL,,,,0,['donor-derived P-CTL'],,0,[],0
sertraline hydrochloride,5 Hydroxytryptamine uptake inhibitor,sertraline hydrochloride,,sertraline,sertraline hydrochloride,fexact,"['CP-51974', 'J Zoloft', 'Besitran', 'Serad', 'sertraline HCl', 'CP-519741', 'Lustral', 'Aremis', 'Gladem', 'sertraline hydrochloride', 'Serlain', 'Zoloft', 'Tatig', 'sertraline']",sertraline,fexact,"['cp 51974', 'j zoloft', 'besitran', 'serad', 'sertraline hcl', 'cp 519741', 'lustral', 'aremis', 'gladem', 'sertraline hydrochloride', 'serlain', 'zoloft', 'tatig', 'sertraline']",correct_mapping
luxeptinib,Bruton tyrosine kinase inhibitor; Aurora kinase inhibitor; Flt-3 antagonist,luxeptinib,,luxeptinib,luxeptinib,fexact,"['Brutons tyrosine kinase/Spleen tyrosine kinase/VEGFR-2 inhibitors (cancer/rheumatoid arthritis)', ""CG'806"", 'Btk/Syk/VEGFR-2 inhibitors (cancer/rheumatoid arthritis)', 'Brutons tyrosine kinase/Spleen tyrosine kinase/VEGFR-2 inhibitors (cancer/rheumatoid arthritis), CrystalGenomics', 'Btk/Syk/VEGFR-2 inhibitors (oral, cancer)', 'FLT3/BTK kinase inhibitor (cancer), CrystalGenomics/', 'Btk/Syk/VEGFR-2 inhibitors (cancer/rheumatoid arthritis), CrystalGenomics', 'CG-026806', 'CG-026828', 'CG-806', 'FLT3/BTK kinase inhibitor (cancer),/', 'Btk/Syk/VEGFR-2 inhibitors (oral, cancer), CrystalGenomics', 'luxeptinib']",luxeptinib,fexact,"['brutons tyrosine kinase spleen tyrosine kinase vegfr 2 inhibitors cancer rheumatoid arthritis', 'cg 806', 'btk syk vegfr 2 inhibitors cancer rheumatoid arthritis', 'brutons tyrosine kinase spleen tyrosine kinase vegfr 2 inhibitors cancer rheumatoid arthritis crystalgenomics', 'btk syk vegfr 2 inhibitors oral cancer', 'flt3 btk kinase inhibitor cancer crystalgenomics', 'btk syk vegfr 2 inhibitors cancer rheumatoid arthritis crystalgenomics', 'cg 026806', 'cg 026828', 'cg 806', 'flt3 btk kinase inhibitor cancer', 'btk syk vegfr 2 inhibitors oral cancer crystalgenomics', 'luxeptinib']",correct_mapping
ASP-1235,Immuno-oncology therapy,ASP-1235,,ASP-1235,asp 1235,fexact,"['AGS-62P1', 'ASP-1235']",ASP-1235,fexact,"['ags 62p1', 'asp 1235']",correct_mapping
oNKord,Natural killer cell stimulant; Immuno-oncology therapy,oNKord,,GTA-002,onkord,fexact,"['ex vivo-generated NK cells derived from CD34+ hematopoietic cells (AML)', 'oNKord', 'GTA-002']",GTA-002,fexact,"['ex vivo generated nk cells derived from cd34 hematopoietic cells aml', 'onkord', 'gta 002']",correct_mapping
prexigebersen,Growth factor receptor-bound protein 2 inhibitor,prexigebersen,,prexigebersen,prexigebersen,fexact,"['growth factor-bound protein-2 modulator (liposomal, cancer)', 'prexigebersen', 'BP-1001', 'L-Grb-2 (cancer)', 'Liposomal Grb-2', 'BP-100-1.01', 'liposomal Grb-2 modulator (cancer)', 'L-Grb-2']",prexigebersen,fexact,"['growth factor bound protein 2 modulator liposomal cancer', 'prexigebersen', 'bp 1001', 'l grb 2 cancer', 'liposomal grb 2', 'bp 100 1 01', 'liposomal grb 2 modulator cancer', 'l grb 2']",correct_mapping
bomedemstat,Lysine (K)-specific demethylase 1A inhibitor,bomedemstat,,bomedemstat bis-tosylate,bomedemstat,fexact,"['IMG-7289', 'lysine-specific histone demethylase-1 inhibitors (myeloproliferative disorder)', 'bomedemstat bis-tosylate', 'lsd1 inhibitors (myeloproliferative disorder)', 'IMG-98', 'bomedemstat']",bomedemstat bis-tosylate,fexact,"['img 7289', 'lysine specific histone demethylase 1 inhibitors myeloproliferative disorder', 'bomedemstat bis tosylate', 'lsd1 inhibitors myeloproliferative disorder', 'img 98', 'bomedemstat']",correct_mapping
IDH-305,Isocitrate dehydrogenase 1 inhibitor,IDH-305,,IDH-305,idh 305,fexact,"['IDH-1 inhibitor (cancer)', 'IDH-305']",IDH-305,fexact,"['idh 1 inhibitor cancer', 'idh 305']",correct_mapping
"vincristine sulfate (IV), unspecified",Microtubule inhibitor; Vinca alkaloid,vincristine sulfate,unspecified,vincristine sulfate (liposomal injection),vincristine sulfate,fexact,"['VSLI, Inex', 'transmembrane carrier system (vincristine), Inex', 'vincristine sulfate liposomes for injection, Inex', 'vincristine sulfate (liposomal injection), Talon', 'vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals', 'vincristine sulfate', 'VSLI', 'vincristine sulfate liposomes for injection, Hana', 'vincristine sulfate (liposomal injection), Spectrum /', 'vincristine sulfate (liposomal injection, Optisome)', 'vincristine-TCS, Hana', 'vincristine sulfate (liposomal injection), Spectrum / CASI Pharmaceuticals', 'vincristine', 'vincristine sulfate (liposomal injection), Hana', 'transmembrane carrier system (vincristine)', 'vincristine sulfate (liposomal injection, Optisome), Inex', 'vincristine-TCS, Inex', 'vincristine sulfate (liposomal injection)', 'Marqibo', 'vincristine sulfate liposomes for injection', 'vincristine-TCS', 'Onco-TCS', 'transmembrane carrier system (vincristine), Hana', 'VSLI, Hana', 'vincristine sulfate (liposomal injection),/']",vincristine sulfate (liposomal injection),fexact,"['vsli inex', 'transmembrane carrier system vincristine inex', 'vincristine sulfate liposomes for injection inex', 'vincristine sulfate liposomal injection talon', 'vincristine sulfate liposomal injection spectrum pharmaceuticals', 'vincristine sulfate', 'vsli', 'vincristine sulfate liposomes for injection hana', 'vincristine sulfate liposomal injection spectrum', 'vincristine sulfate liposomal injection optisome', 'vincristine tcs hana', 'vincristine sulfate liposomal injection spectrum casi pharmaceuticals', 'vincristine', 'vincristine sulfate liposomal injection hana', 'transmembrane carrier system vincristine', 'vincristine sulfate liposomal injection optisome inex', 'vincristine tcs inex', 'vincristine sulfate liposomal injection', 'marqibo', 'vincristine sulfate liposomes for injection', 'vincristine tcs', 'onco tcs', 'transmembrane carrier system vincristine hana', 'vsli hana', 'vincristine sulfate liposomal injection']",correct_mapping
"etoposide (oral), unspecified",DNA inhibitor; DNA topoisomerase II inhibitor; DNA repair enzyme inhibitor; Cell cycle inhibitor,etoposide,unspecified,etoposide phosphate,etoposide,fexact,"['Etopophos', 'Eposin', 'NSC-141540', 'etopofos', 'Eposide', 'Nexvep', 'etoposide', 'Vepesid', 'BMY-40481', 'VP-16-213', 'VP-16', 'etoposide phosphate']",etoposide phosphate,fexact,"['etopophos', 'eposin', 'nsc 141540', 'etopofos', 'eposide', 'nexvep', 'etoposide', 'vepesid', 'bmy 40481', 'vp 16 213', 'vp 16', 'etoposide phosphate']",correct_mapping
H3B-8800,RNA splicing inhibitor,H3B-8800,,H3B-8800,h3b 8800,fexact,"['6-deoxypladienolide', 'H3B-8800', 'anticancer program', 'SF3B1 modulators (cancer), H3 Biomedicine', 'SF3B1 modulators (cancer)', 'anticancer program, H3 Biomedicine']",H3B-8800,fexact,"['6 deoxypladienolide', 'h3b 8800', 'anticancer program', 'sf3b1 modulators cancer h3 biomedicine', 'sf3b1 modulators cancer', 'anticancer program h3 biomedicine']",correct_mapping
NPMW-peptide vaccine,Immunostimulant; Immuno-oncology therapy,NPMW-peptide vaccine,,,,0,['NPMW-peptide vaccine'],,0,[],0
SEL-24-A1,Flt-3 antagonist; Pim-1 kinase inhibitor,SEL-24-A1,,,,0,"['SEL-24-A1', 'SEL-24-20', 'first generation SEL-24 compounds (cancer)', 'Pim-1 kinase inhibitors (cancer)', 'multikinase inhibitor (cancer)', 'SEL-24-11', 'SEL-24-1']",,NER_API,[],0
"anti-CD7 CAR-pNK cells, PersonGen Biomedicine",T cell stimulant; Immuno-oncology therapy,anti-CD7 CAR-pNK cells,PersonGen Biomedicine,,,0,['anti-CD7 CAR-pNK cells'],,0,[],0
ATIR-101,Immunosuppressant,ATIR-101,,ATIR-101,atir 101,fexact,"['ATIR', 'alloreactive T cell-depletion therapy (GvHD), Kiadis/', 'TH-9401', 'Theralux extracorporeal photochemotherapy', 'Add-Back of T Cell for Immune Reconstitution', 'alloreactive T cell-depletion therapy (GvHD), Kiadis/ Hospira', 'PDT', 'Add-Back of  Cell for Immune Reconstitution', 'PDT, Theratechnologies', 'TH-9402', 'allodepleted T-cell immunotherapeutics (GvHD)', 'Theralux', 'antileukemics (photoactive)', 'ATIR-101', 'alloreactive T cell-depletion therapy (GvHD),/', 'allodepleted T-cell immunotherapeutics (GvHD), Kiadis Pharma', 'antileukemics (photoactive), Theratechnologies']",ATIR-101,fexact,"['atir', 'alloreactive t cell depletion therapy gvhd kiadis', 'th 9401', 'theralux extracorporeal photochemotherapy', 'add back of t cell for immune reconstitution', 'alloreactive t cell depletion therapy gvhd kiadis hospira', 'pdt', 'add back of cell for immune reconstitution', 'pdt theratechnologies', 'th 9402', 'allodepleted t cell immunotherapeutics gvhd', 'theralux', 'antileukemics photoactive', 'atir 101', 'alloreactive t cell depletion therapy gvhd', 'allodepleted t cell immunotherapeutics gvhd kiadis pharma', 'antileukemics photoactive theratechnologies']",correct_mapping
MDG-1011,T cell stimulant; Immuno-oncology therapy,MDG-1011,,MDG-1011,mdg 1011,fexact,"['MDG-1011', 'anti-PRAME/HLA-A*0201 TCR T-cell therapy (hematological cancers)', 'MDG-1014']",MDG-1011,fexact,"['mdg 1011', 'anti prame hla a 0201 tcr t cell therapy hematological cancers', 'mdg 1014']",correct_mapping
tranylcypromine,Monoamine oxidase A inhibitor; Monoamine oxidase B inhibitor,tranylcypromine,,,,0,['tranylcypromine'],,0,[],0
JNJ-63709178,Interleukin 3 agonist; CD3 agonist; Immuno-oncology therapy,JNJ-63709178,,JNJ-63709178,jnj 63709178,fexact,"['JNJ-63709178', 'JNJ-9178', 'anti-CD3/anti-CD123 bispecific T-cell engager (DuoBody, acute myeloid leukemia)', 'CNTO-9958']",JNJ-63709178,fexact,"['jnj 63709178', 'jnj 9178', 'anti cd3 anti cd123 bispecific t cell engager duobody acute myeloid leukemia', 'cnto 9958']",correct_mapping
OTS-167 (IV),Maternal embryonic leucine zipper kinase inhibitor,OTS-167,,,,0,"['OTSSP-167', 'OTS-167 (oral, breast cancer)', 'MELK inhibitor (oral, neuroblastoma)', 'OTS-167', 'MELK inhibitor (oral, neuroblastoma/solid tumor/ovarian cancer)', 'MELK inhibitor (oral/iv, cancer)']",,NER_API,[],0
nintedanib (tablet),LYN tyrosine kinase inhibitor; FGF receptor tyrosine kinase inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Src inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor,nintedanib,,nintedanib,nintedanib,fexact,"['angiokinase inhibitors (cancer)', 'Vargatef', 'FGF/PDGF/VEGF receptor kinase inhibitors (cancer)', 'intedanib', 'Ofev', 'WeiJiaTe', 'nintedanib esylate', 'nintedanib ethanesulfonate', 'BIBF-1120 ES', 'nintedanib', 'Ofeb', 'BIBF-1120', 'Cyendiv']",nintedanib,fexact,"['angiokinase inhibitors cancer', 'vargatef', 'fgf pdgf vegf receptor kinase inhibitors cancer', 'intedanib', 'ofev', 'weijiate', 'nintedanib esylate', 'nintedanib ethanesulfonate', 'bibf 1120 es', 'nintedanib', 'ofeb', 'bibf 1120', 'cyendiv']",correct_mapping
BPX-701,T cell stimulant; Immuno-oncology therapy,BPX-701,,BPX-701,bpx 701,fexact,"['BPX-701', 'anti-PRAME/HLA-A*0201 TCR T-cell therapy (cancer), Leiden University Medical Center/', 'anti-prame/hla-a*0201 tcr t-cell therapy (cancer)']",BPX-701,fexact,"['bpx 701', 'anti prame hla a 0201 tcr t cell therapy cancer leiden university medical center', 'anti prame hla a 0201 tcr t cell therapy cancer']",correct_mapping
CC-90002,CD47 antagonist; Immuno-oncology therapy,CC-90002,,CC-90002,cc 90002,fexact,"['CD47 checkpoint inhibitor (cancer),/', 'CD47 checkpoint inhibitor (cancer), INHIBRx/', 'INBRX-103', 'CC-90002', 'Ca ImmRx', 'CD47 checkpoint inhibitor (cancer), INHIBRx/Celgene', 'Ca ImmunoRx Ab']",CC-90002,fexact,"['cd47 checkpoint inhibitor cancer', 'cd47 checkpoint inhibitor cancer inhibrx', 'inbrx 103', 'cc 90002', 'ca immrx', 'cd47 checkpoint inhibitor cancer inhibrx celgene', 'ca immunorx ab']",correct_mapping
IRX-5183,Retinoic acid alpha receptor agonist,IRX-5183,,IRX-5183,irx 5183,fexact,"['IRX-5183 (oral, cancer/autoimmune disease)', 'IRX-5183', 'retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics', 'RARa (oral, cancer/autoimmune disease)', 'IRX-5183 (oral, cancer)', 'IRX-5183 (oral, autoimmune disease)', 'retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease)', 'IRX-5183 (oral, cancer), Io Therapeutics', 'NRX-5183', 'NRX-195183', 'VTP-5183', 'RARa (oral, cancer/autoimmune disease), Io Therapeutics', 'VTP-195183', 'IRX-5183 (oral, autoimmune disease), Io Therapeutics', 'AGN-195183', 'IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics']",IRX-5183,fexact,"['irx 5183 oral cancer autoimmune disease', 'irx 5183', 'retinoic acid receptor alpha agonist oral cancer autoimmune disease io therapeutics', 'rara oral cancer autoimmune disease', 'irx 5183 oral cancer', 'irx 5183 oral autoimmune disease', 'retinoic acid receptor alpha agonist oral cancer autoimmune disease', 'irx 5183 oral cancer io therapeutics', 'nrx 5183', 'nrx 195183', 'vtp 5183', 'rara oral cancer autoimmune disease io therapeutics', 'vtp 195183', 'irx 5183 oral autoimmune disease io therapeutics', 'agn 195183', 'irx 5183 oral cancer autoimmune disease io therapeutics']",correct_mapping
vadastuximab talirine,DNA inhibitor,vadastuximab talirine,,vadastuximab talirine,vadastuximab talirine,fexact,"['vadastuximab', 'SGN-CD33A', 'h2H12ec-SGD-1910', 'CD33-targeted ADC (AML), Seattle Genetics', '33A', 'SGD-1882', 'vadastuximab talirine', 'CD33-targeted antibody-drug conjugate (acute myeloid leukemia), Seattle Genetics']",vadastuximab talirine,fexact,"['vadastuximab', 'sgn cd33a', 'h2h12ec sgd 1910', 'cd33 targeted adc aml seattle genetics', '33a', 'sgd 1882', 'vadastuximab talirine', 'cd33 targeted antibody drug conjugate acute myeloid leukemia seattle genetics']",correct_mapping
SGN-CD123A,Interleukin 3 receptor antagonist,SGN-CD123A,,SGN-CD123A,sgn cd123a,fexact,"['CD123-targeted antibody drug conjugate (acute myelogenous leukemia), Seattle Genetics', 'SGN-CD123A']",SGN-CD123A,fexact,"['cd123 targeted antibody drug conjugate acute myelogenous leukemia seattle genetics', 'sgn cd123a']",correct_mapping
RNA CART123 cells,Interleukin 3 receptor antagonist; Immuno-oncology therapy,RNA CART123 cells,,,,0,"['anti-CD123 CAR T cell therapy (acute myeloid leukemia),/University of Pennsylvania', 'anti-cd123 car t cell therapy (acute myeloid leukemia)', 'CART123 cells', 'JEZ-567', 'autologous anti-CD123 CAR T-cells expressing tandem TCR zeta and 4-1BB costimulatory domains (acute myeloid leukemia),/University of Pennsylvania', 'autologous anti-cd123 car t-cells expressing tandem tcr zeta and 4-1bb costimulatory domains (acute myeloid leukemia)']",,Drug_API_mapping,[],0
triciribine phosphate,Protein kinase B inhibitor,triciribine phosphate,,,,0,"['triciribine phosphate (iv, cancer)', 'triciribine phosphate', 'triciribine (iv, cancer)', 'TCN-P', 'Akt phosphorylation inhibitor (cancer)', 'Akt phosphorylation inhibitor (cancer), Greenwich', 'triciribine (iv, breast/ovarian cancer/AML)', 'TCN', 'triciribine phosphate monohydrate', 'PTX-200, Prescient', 'tricyclic nucleoside (cancer)', 'PTX-002, Prescient', 'VQD-002 (iv, cancer)', 'triciribine', 'TCN-PM', 'triciribine phosphate (iv, cancer), Cahaba', 'triciribine (iv, breast/ovarian cancer/AML), Prescient', 'PTX-002', 'API-2', 'triciribine phosphate (iv, cancer), VioQuest', 'tricyclic nucleoside (cancer), Greenwich', 'VD-0002', 'PTX-200', 'triciribine (iv, cancer), VioQuest', 'VQD-002 (iv, cancer), VioQuest']",,NER_API,[],0
AGS-67E,Tubulin inhibitor; CD37 antagonist,AGS-67E,,AGS-67E,ags 67e,fexact,"['anti-CD37 IgG2 mAb (cancer),/Seattle Genetics', 'AGS-67E']",AGS-67E,fexact,"['anti cd37 igg2 mab cancer seattle genetics', 'ags 67e']",correct_mapping
FF-10101,Flt-3 antagonist,FF-10101,,FF-10101,ff 10101,fexact,"['FF-10101', 'FF-10101-01']",FF-10101,fexact,"['ff 10101', 'ff 10101 01']",correct_mapping
pegzilarginase,Arginase stimulant,pegzilarginase,,pegzilarginase,pegzilarginase,fexact,"['pegzilarginase', 'L-arginine degrading enzymes (cancer), University of Texas System', 'engineered human arginase-1 enzyme (cancer/hyperargininemia)', 'l-arginine degrading enzymes (cancer)', 'L-arginine degrading enzymes (cancer)', 'AERase', 'Co-ArgI-PEG', 'AEB-1102']",pegzilarginase,fexact,"['pegzilarginase', 'l arginine degrading enzymes cancer university of texas system', 'engineered human arginase 1 enzyme cancer hyperargininemia', 'l arginine degrading enzymes cancer', 'l arginine degrading enzymes cancer', 'aerase', 'co argi peg', 'aeb 1102']",correct_mapping
"WT1-TCR cell therapy, Cell Medica",T cell stimulant; Immuno-oncology therapy,WT1-TCR cell therapy,Cell Medica,,,0,['WT1-TCR cell therapy'],,0,[],0
vibecotamab,CD3 agonist; Immuno-oncology therapy,vibecotamab,,vibecotamab,vibecotamab,fexact,"['XmAb-14045', 'anti-CD3/anti-CD123 bispecific T-cell engager (FcRn-mediated half-life extension, hematological malignancy), Xencor/', 'vibecotamab', 'bispecific antibody program (CD3 x CD123 target, acute myelogenous leukemia), Xencor/', 'bispecific antibody program (CD3 x CD123 target, acute myelogenous leukemia),/', 'anti-CD3/anti-CD123 bispecific T-cell engager (FcRn-mediated half-life extension, hematological malignancy),/', 'SQZ-622']",vibecotamab,fexact,"['xmab 14045', 'anti cd3 anti cd123 bispecific t cell engager fcrn mediated half life extension hematological malignancy xencor', 'vibecotamab', 'bispecific antibody program cd3 x cd123 target acute myelogenous leukemia xencor', 'bispecific antibody program cd3 x cd123 target acute myelogenous leukemia', 'anti cd3 anti cd123 bispecific t cell engager fcrn mediated half life extension hematological malignancy', 'sqz 622']",correct_mapping
thioguanine,DNA synthesis inhibitor,thioguanine,,,,0,"['6-thioguanine (oral/extended release, inflammatory disease)', 'thioguanine (oral/extended release, inflammatory disease), University of Queensland', 'thioguanine', '6-thioguanine', 'tioguanine', '6-thioguanine (oral/extended release, inflammatory disease), University of Queensland', 'thioguanine (oral/extended release, inflammatory disease)']",,NER_API,[],0
cabazitaxel,Microtubule inhibitor; Taxane,cabazitaxel,,cabazitaxel,cabazitaxel,fexact,"['cabazitaxel', '116258', 'Jevtana', 'taxoid (cancer), sanofi-aventis', '106258', 'TXD-258', 'RPR-116258A', 'XRP-6258']",cabazitaxel,fexact,"['cabazitaxel', '116258', 'jevtana', 'taxoid cancer sanofi aventis', '106258', 'txd 258', 'rpr 116258a', 'xrp 6258']",correct_mapping
"mercaptopurine, unspecified",Immunosuppressant,mercaptopurine,unspecified,"mercaptopurine (oral suspension, acute lymphoblastic leukemia)",mercaptopurine,fexact,"['mercaptopurine (oral suspension, acute lymphoblastic leukemia), Nova', 'mercaptopurine (oral suspension, acute lymphoblastic leukemia),/', 'Allmercap', 'Purixan', 'mercaptopurine (oral suspension, acute lymphoblastic leukemia)', 'mercaptopurine', 'mercaptopurine (oral suspension, acute lymphoblastic leukemia), Nova/', 'Xaluprine']","mercaptopurine (oral suspension, acute lymphoblastic leukemia)",fexact,"['mercaptopurine oral suspension acute lymphoblastic leukemia nova', 'mercaptopurine oral suspension acute lymphoblastic leukemia', 'allmercap', 'purixan', 'mercaptopurine oral suspension acute lymphoblastic leukemia', 'mercaptopurine', 'mercaptopurine oral suspension acute lymphoblastic leukemia nova', 'xaluprine']",correct_mapping
imatinib mesilate (tablet),Bcr-Abl inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Apoptosis stimulant,imatinib mesilate,,imatinib,imatinib mesilate,fexact,"['Ruvise', 'QTI-517', 'Gleevec', 'CGP-57148B', 'Glivec', 'CGP-57148', 'Abl tyrosine protein kinase inhibitors', 'STI-571A', 'Abl tyrosine protein kinase inhibitors, Novartis', 'CGS-57148', 'imatinib mesylate', 'imatinib mesilate', 'QTI-571', 'STI-571', 'NSC-716051', 'imatinib']",imatinib,fexact,"['ruvise', 'qti 517', 'gleevec', 'cgp 57148b', 'glivec', 'cgp 57148', 'abl tyrosine protein kinase inhibitors', 'sti 571a', 'abl tyrosine protein kinase inhibitors novartis', 'cgs 57148', 'imatinib mesylate', 'imatinib mesilate', 'qti 571', 'sti 571', 'nsc 716051', 'imatinib']",correct_mapping
FT-1101,BET protein inhibitor,FT-1101,,CC-95775,ft 1101,fexact,"['CC-95775', 'pan-BET inhibitor (oral, hematological/solid tumors), Celgene', 'pan-BET inhibitor (oral, hematological/solid tumors)', 'FT-1101']",CC-95775,fexact,"['cc 95775', 'pan bet inhibitor oral hematological solid tumors celgene', 'pan bet inhibitor oral hematological solid tumors', 'ft 1101']",correct_mapping
Hu8F4,Unidentified pharmacological activity,Hu8F4,,Hu-8F4,hu 8f4,fuzzy,"['anti-pr1/hla-a2 monoclonal antibody (iv, acute myeloid leukemia)', 'h8F4', 'Hu-8F4']",Hu-8F4,fexact,"['anti pr1 hla a2 monoclonal antibody iv acute myeloid leukemia', 'h8f4', 'hu 8f4']",incorrect_mapping
MiHA-loaded PD-L-silenced DC vaccine,Immunostimulant,MiHA-loaded PD-L-silenced DC vaccine,,,,0,['MiHA-loaded PD-L-silenced DC vaccine'],,0,[],0
"asparaginase, unspecified",Asparaginase stimulant,asparaginase,unspecified,asparaginase,asparaginase,fexact,"['Spectrila', 'asparaginase']",asparaginase,fexact,"['spectrila', 'asparaginase']",correct_mapping
Omidubicel,Not applicable,Omidubicel,,omidubicel,omidubicel,fexact,"['haematopoietic stem cell therapy (hematological malignancy/autoimmune/metabolic disease)', 'CordIn', 'omidubicel', 'NiCord']",omidubicel,fexact,"['haematopoietic stem cell therapy hematological malignancy autoimmune metabolic disease', 'cordin', 'omidubicel', 'nicord']",correct_mapping
8-chloro-adenosine,RNA synthesis inhibitor,8-chloro-adenosine,,"nucleoside analogs (iv, cancer)",8 chloro adenosine,fexact,"['nucleoside analogs (iv, cancer)', '8-chloro-adenosine', '8-Cl-Ado']","nucleoside analogs (iv, cancer)",fexact,"['nucleoside analogs iv cancer', '8 chloro adenosine', '8 cl ado']",correct_mapping
lentivirus transduced B7.1 and IL-2 expressing AML blasts,Interleukin 2 receptor agonist; Immunostimulant; T cell stimulant,lentivirus transduced B7.1 and IL-2 expressing AML blasts,,,,0,['lentivirus transduced B7.1 and IL-2 expressing AML blasts'],,0,[],0
vorasidenib,Isocitrate dehydrogenase 1 inhibitor; Isocitrate dehydrogenase 2 inhibitor,vorasidenib,,vorasidenib citrate,vorasidenib,fexact,"['AGI-23088', 'AG-881 hemicitrate hemihydrate', 'vorasidenib citrate', 'AG-881', 'vorasidenib', 'AGI-0023088', 'AG-881 citrate']",vorasidenib citrate,fexact,"['agi 23088', 'ag 881 hemicitrate hemihydrate', 'vorasidenib citrate', 'ag 881', 'vorasidenib', 'agi 0023088', 'ag 881 citrate']",correct_mapping
AVR ONC-01,Interleukin 12 agonist; Immuno-oncology therapy,AVR ONC-01,,,,0,['AVR ONC-01'],,0,[],0
combretastatin A-1 diphosphate,Angiogenesis inhibitor; Tubulin inhibitor,combretastatin A-1 diphosphate,,OXi-4503,combretastatin a1 diphosphate,fuzzy,"['CA1P dipotassium', 'OXi-4503', 'second-generation VTA (OXi-4503), OXiGENE', 'Combretastatin A1 diphosphate', 'OXi-4500', 'Combretastatin A1 diphosphate dipotassium', 'CA1P']",OXi-4503,fexact,"['ca1p dipotassium', 'oxi 4503', 'second generation vta oxi 4503 oxigene', 'combretastatin a1 diphosphate', 'oxi 4500', 'combretastatin a1 diphosphate dipotassium', 'ca1p']",incorrect_mapping
hydrocortisone,Corticosteroid agonist,hydrocortisone,,,,0,"['ATRS-1902', 'hydrocortisone (adrenal crisis rescue, auto-injector technology)', 'hydrocortisone']",,NER_API,[],0
blood-derived circulating progenitor cells,Not applicable,blood-derived circulating progenitor cells,,,,0,['blood-derived circulating progenitor cells'],,0,[],0
"danorubicin, Galen",Radical formation stimulant; DNA topoisomerase II inhibitor; RNA synthesis inhibitor,danorubicin,Galen,"doxorubicin (encapsulated nanoparticle, bone cancer)",daunorubicin,fuzzy,"['doxorubicin (encapsulated nanoparticle, bone cancer)', 'doxorubicin', 'daunorubicin (encapsulated nanoparticle, breast cancer)', 'doxorubicin (encapsulated nanoparticle, breast cancer)', 'IT-143', 'daunorubicin']","doxorubicin (encapsulated nanoparticle, bone cancer)",fexact,"['doxorubicin encapsulated nanoparticle bone cancer', 'doxorubicin', 'daunorubicin encapsulated nanoparticle breast cancer', 'doxorubicin encapsulated nanoparticle breast cancer', 'it 143', 'daunorubicin']",incorrect_mapping
pexidartinib (capsule),Colony stimulating factor 1 receptor antagonist; C-kit inhibitor; Flt-3 antagonist; Immuno-oncology therapy,pexidartinib,,,,0,"['PLX-3397', 'pexidartinib hydrochloride  (cancer/inflammatory disease)', 'Fms/Kit/Flt-3-ITD inhibitor (cancer/inflammatory disease), Plexxikon', 'pexidartinib hydrochloride  (cancer/inflammatory disease), Plexxikon', 'Fms/Kit/Flt-3-ITD inhibitor (cancer/inflammatory disease)', 'Turalio', 'PLX3397 hydrochloride', 'FP-113', 'pexidartinib hydrochloride', 'pexidartinib']",,NER_API,[],0
IMGN-779,Unidentified pharmacological activity,IMGN-779,,IMGN-779,imgn 779,fexact,"['anti-CD33 antibody-drug conjugate (AML)', 'DNA-alkylating payload/anti-CD33 antibody (AML) conjugate', 'IMGN-779', 'DGN-462/Z4681A (AML) conjugate']",IMGN-779,fexact,"['anti cd33 antibody drug conjugate aml', 'dna alkylating payload anti cd33 antibody aml conjugate', 'imgn 779', 'dgn 462 z4681a aml conjugate']",correct_mapping
vitamin D3,Vitamin D agonist,vitamin D3,,,,0,['vitamin D3'],,0,[],0
FLX-925,Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Flt-3 antagonist,FLX-925,,FLX-925,flx 925,fexact,"['AMG-925', 'FLX-925']",FLX-925,fexact,"['amg 925', 'flx 925']",correct_mapping
peginterferon alfa-2a (SC),Interferon alpha 2A agonist; Interferon receptor agonist,peginterferon alfa-2a,,peginterferon alfa-2a,peginterferon alfa 2a,fexact,"['pegylated IFN alpha-2a, Roche', 'Pegferon', '25-8310/000', 'Ro-25-8310', 'Ro 25-8310/000', 'interferon (pegylated, alpha-2a), Roche', 'PEG-IFN-alpha-2a, Roche', 'Pegasys', 'peginterferon alfa-2a, Chugai', 'PEG-IFN-alpha-2a', 'pegylated IFN alpha-2a, Roche/Ascletis BioScience', 'PEG-IFN-alfa-2a', 'pegylated IFN alpha-2a,/Ascletis BioScience', 'pegylated IFN alpha-2a, Chugai', 'RG-442', 'polyethylene glycol interferon alfa-2a', 'Pegasys ProClick', 'PEG-IFN-alfa-2a, Chugai', 'peginterferon alfa-2a', 'pegylated IFN alpha-2a', 'polyethylene glycol interferon alfa-2a, Roche', 'R-420', 'peginterferon alfa-2a, Roche', 'R-442', 'interferon (pegylated, alpha-2a)']",peginterferon alfa-2a,fexact,"['pegylated ifn alpha 2a roche', 'pegferon', '25 8310 000', 'ro 25 8310', 'ro 25 8310 000', 'interferon pegylated alpha 2a roche', 'peg ifn alpha 2a roche', 'pegasys', 'peginterferon alfa 2a chugai', 'peg ifn alpha 2a', 'pegylated ifn alpha 2a roche ascletis bioscience', 'peg ifn alfa 2a', 'pegylated ifn alpha 2a ascletis bioscience', 'pegylated ifn alpha 2a chugai', 'rg 442', 'polyethylene glycol interferon alfa 2a', 'pegasys proclick', 'peg ifn alfa 2a chugai', 'peginterferon alfa 2a', 'pegylated ifn alpha 2a', 'polyethylene glycol interferon alfa 2a roche', 'r 420', 'peginterferon alfa 2a roche', 'r 442', 'interferon pegylated alpha 2a']",correct_mapping
TCR alfa beta T-cell depletion,T cell stimulant; Immuno-oncology therapy,TCR alfa beta T-cell depletion,,,,0,['TCR alfa beta T-cell depletion'],,0,[],0
INCB-052793,Janus kinase 1 inhibitor,INCB-052793,,INCB-52793,incb 052793,fexact,"['INCB-52793', 'INCB-052793', 'JAK-1 inhibitor (oral tablet, advanced malignancies)']",INCB-52793,fexact,"['incb 52793', 'incb 052793', 'jak 1 inhibitor oral tablet advanced malignancies']",correct_mapping
"BET inhibitor, Zenith Epigenetics",BET protein inhibitor,BET inhibitor,Zenith Epigenetics,,,0,['BET inhibitor'],,0,[],0
MEN-1112,Bone marrow stromal cell antigen 1 antagonist,MEN-1112,,OX-001,men 1112,fexact,"['OBT-357', 'anti-CD157 mAb (BioWa ADCC/intravenous, acute myeloid leukemia), Menarini/', 'MEN-1112', 'OX-357', 'anti-CD157 mAb (BioWa ADCC/intravenous, acute myeloid leukemia),/', 'OX-001', 'mAbs (BioWa ADCC, acute myeloid leukemia), Menarini/', 'mAbs (BioWa ADCC, acute myeloid leukemia),/']",OX-001,fexact,"['obt 357', 'anti cd157 mab biowa adcc intravenous acute myeloid leukemia menarini', 'men 1112', 'ox 357', 'anti cd157 mab biowa adcc intravenous acute myeloid leukemia', 'ox 001', 'mabs biowa adcc acute myeloid leukemia menarini', 'mabs biowa adcc acute myeloid leukemia']",correct_mapping
maraviroc,CC chemokine receptor 5 antagonist; Chemokine receptor antagonist,maraviroc,,maraviroc,maraviroc,fexact,"['UK-395859', 'UK-382055', 'UK-427857', 'CCR5 antagonist (rheumatoid arthritis)', 'CCR5 antagonists (HIV infection)', 'maraviroc', 'UK-378995', 'Celsentri', 'UK-440103', 'Selzentry', 'DIN-02299844', 'UK-408030', 'CCR5 antagonist (Coronavirus disease 19 infection/ respiratory distress syndrome), ViiV Healthcare', 'UK-370907', 'UK-179645', 'CCR5 antagonist (Coronavirus disease 19 infection/ respiratory distress syndrome)', 'UK-107543', 'UK-374503', 'UK-372677', 'UK-418526']",maraviroc,fexact,"['uk 395859', 'uk 382055', 'uk 427857', 'ccr5 antagonist rheumatoid arthritis', 'ccr5 antagonists hiv infection', 'maraviroc', 'uk 378995', 'celsentri', 'uk 440103', 'selzentry', 'din 02299844', 'uk 408030', 'ccr5 antagonist coronavirus disease 19 infection respiratory distress syndrome viiv healthcare', 'uk 370907', 'uk 179645', 'ccr5 antagonist coronavirus disease 19 infection respiratory distress syndrome', 'uk 107543', 'uk 374503', 'uk 372677', 'uk 418526']",correct_mapping
FF-10501-01,Unidentified pharmacological activity,FF-10501-01,,FF-10501 hydrate,ff 10501 01,fexact,"['FF-10501-01', 'FF-10501 hydrate', 'FF-10501']",FF-10501 hydrate,fexact,"['ff 10501 01', 'ff 10501 hydrate', 'ff 10501']",correct_mapping
LOP-628,C-kit inhibitor,LOP-628,,LOP-628,lop 628,fexact,"['c-KIT antibody-drug conjugate (cancer)', 'c-KIT ADC (cancer)', 'LOP-628']",LOP-628,fexact,"['c kit antibody drug conjugate cancer', 'c kit adc cancer', 'lop 628']",correct_mapping
KHK-2823,Interleukin 3 receptor antagonist; Immunostimulant; Immuno-oncology therapy,KHK-2823,,KHK-2823,khk 2823,fexact,['KHK-2823'],KHK-2823,fexact,['khk 2823'],correct_mapping
E-6201,Flt-3 antagonist; Mitogen-activated protein kinase kinase 1 inhibitor; Mitogen-activated protein kinase kinase kinase 1 inhibitor,E-6201,,,,0,"['ER-803064', 'E-6201 (intravenous, cancer)', 'E-6201 (hematological malignancies), Strategia Therapeutics', 'JSI-1187', 'E-6201', 'E-6201 (hematological malignancies),/', 'E-6201 (hematological malignancies), Strategia Therapeutics/JS InnoPharm', 'E-6201 (hematological malignancies), Strategia Therapeutics/', 'E-6201 (topical, psoriasis)', 'MEK-1 inhibitor (topical, psoriasis)', 'E-6201 (AML)', 'E-6201 (hematological malignancies)', 'E-6201 (AML), Strategia Therapeutics', 'MEK-1 inhibitor (intravenous, cancer)']",,Drug_API_mapping,[],0
inecalcitol,Vitamin D agonist,inecalcitol,,,,0,"['TX-527', 'vitamin D analogs, Catholic University of Leuven', 'TX-522', 'inecalcitol', 'inecalcitol (oral, cancer/psoriasis)', 'inecalcitol (oral, hyperthyroidism)', 'vitamin D analogs, KULeuven', 'inecalcitol (oral, prostate cancer/psoriasis)']",,NER_API,[],0
"ribavirin (oral), unspecified",Inosine monophosphate dehydrogenase inhibitor,ribavirin,unspecified,ribavirin,ribavirin,fexact,"['SCH-018908', 'Virazid', 'Cotronak', 'Vilona', 'NSC-163039', 'ICN-1229', 'Ro-20-9963', 'tribavirin', 'SCH-18908', 'Rebetol', 'Virazide', 'Ribasphere', 'ribavirin', 'Ribapak', 'Viramid']",ribavirin,fexact,"['sch 018908', 'virazid', 'cotronak', 'vilona', 'nsc 163039', 'icn 1229', 'ro 20 9963', 'tribavirin', 'sch 18908', 'rebetol', 'virazide', 'ribasphere', 'ribavirin', 'ribapak', 'viramid']",correct_mapping
CVT-DC-01,T cell stimulant; Preferential antigen of melanoma inhibitor; Immuno-oncology therapy,CVT-DC-01,,FDC-101,cvt dc 01,fexact,"['dendritic cell based vaccine (prostate cancer),/Max Delbruck Center', 'dendritic cell based vaccine (prostate cancer), Helmholtz Zentrum Munchen/Max Delbruck Center', 'CVT-DC-01', 'dendritic cell based vaccine (prostate cancer)', 'dendritic cell based vaccine (prostate cancer), Medigene', 'dendritic cell based vaccine (prostate cancer), Trianta', 'FDC-101', 'dendritic cell based vaccine (acute myeloid leukemia/prostate cancer),/', 'dendritic cell based vaccine (acute myeloid leukemia/prostate cancer), Medigene/']",FDC-101,fexact,"['dendritic cell based vaccine prostate cancer max delbruck center', 'dendritic cell based vaccine prostate cancer helmholtz zentrum munchen max delbruck center', 'cvt dc 01', 'dendritic cell based vaccine prostate cancer', 'dendritic cell based vaccine prostate cancer medigene', 'dendritic cell based vaccine prostate cancer trianta', 'fdc 101', 'dendritic cell based vaccine acute myeloid leukemia prostate cancer', 'dendritic cell based vaccine acute myeloid leukemia prostate cancer medigene']",correct_mapping
RG-7775,MDM2 inhibitor,RG-7775,,RG-7775,rg 7775,fexact,"['RG-7775', 'RO-6839921', 'MDM2 antagonist (iv prodrug, acute myelogenous leukemia)']",RG-7775,fexact,"['rg 7775', 'ro 6839921', 'mdm2 antagonist iv prodrug acute myelogenous leukemia']",correct_mapping
IGN-523,L-type amino acid transporter 1 inhibitor,IGN-523,,IGN-523,ign 523,fexact,"['anti-AML-01 to AML-08 mAb (acute myelogenous leukemia)', 'IGN-523']",IGN-523,fexact,"['anti aml 01 to aml 08 mab acute myelogenous leukemia', 'ign 523']",correct_mapping
SG-2000,DNA inhibitor; Caspase 3 stimulant,SG-2000,,SG-2000,sg 2000,fexact,"['SP-2001', 'NSC-D694501', 'NSC-694501', 'NCI-694501', 'SG-2000', 'BN-2629', 'SJG-136']",SG-2000,fexact,"['sp 2001', 'nsc d694501', 'nsc 694501', 'nci 694501', 'sg 2000', 'bn 2629', 'sjg 136']",correct_mapping
autologous umbilical cord blood transfusion,Unidentified pharmacological activity,autologous umbilical cord blood transfusion,,,,0,['autologous umbilical cord blood transfusion'],,0,[],0
"omega-3 fatty acids, Fresenius",Omega 3 fatty acid stimulant,omega-3 fatty acids,Fresenius,,,0,"['omega-3 acid ethyl esters 90', 'Lotriga', 'Seacor', 'omega-3 fatty acids, Pronova', 'GSK-2212836', 'Omacor', 'Esapent', 'TAK-085', 'Eskim', 'K-85', 'Lovaza', 'omega-3 fatty acids', 'Zodin', 'doconexent ethyl + icosapent ethyl', 'omega-3-acid ethyl esters']",,Drug_API_mapping,[],0
LOR-253,Angiogenesis inhibitor; Myc inhibitor; Kruppel-like factor 4 stimulant; G-quadruplex stabiliser,LOR-253,,APTO-253,lor 253,fexact,"['APTO-253 HCl', 'APTO-253', 'LOR-253 HCl', 'LT-253', 'ML-series (anticancer), Lorus', 'ML-133', 'ML-series (anticancer)', 'LOR-253']",APTO-253,fexact,"['apto 253 hcl', 'apto 253', 'lor 253 hcl', 'lt 253', 'ml series anticancer lorus', 'ml 133', 'ml series anticancer', 'lor 253']",correct_mapping
OCV-501,Immunostimulant,OCV-501,,OCV-501,ocv 501,fexact,"['OCV-501', 'graunimotide']",OCV-501,fexact,"['ocv 501', 'graunimotide']",correct_mapping
DCP-001,Immunostimulant,DCP-001,,DCP-001,dcp 001,fexact,"['allogeneic dendritic cell vaccine (intradermal, acute myelogenous leukemia/multiple myeloma)', 'allogeneic dendritic cell vaccine (intradermal, acute myelogenous leukemia)', 'DCP-001', 'DCOne vaccine (intradermal, acute myelogenous leukemia/multiple myeloma)', 'DCOne vaccine (intradermal, acute myelogenous leukemia)']",DCP-001,fexact,"['allogeneic dendritic cell vaccine intradermal acute myelogenous leukemia multiple myeloma', 'allogeneic dendritic cell vaccine intradermal acute myelogenous leukemia', 'dcp 001', 'dcone vaccine intradermal acute myelogenous leukemia multiple myeloma', 'dcone vaccine intradermal acute myelogenous leukemia']",correct_mapping
"mesenchymal precursor cells, allogenic, BMT, Mesoblast",Not applicable,mesenchymal precursor cells,Mesoblast,,,0,"['MPC-300-IV', 'mesenchymal precursor cells (iv, diabetes/inflammation)', 'mesenchymal precursor cells']",,Drug_API_mapping,[],0
WT1:126-134 peptide,Immunostimulant,WT1 126-134 peptide,,,,0,['WT1 126-134 peptide'],,0,[],0
Montanide ISA-51 VG,Immunostimulant,Montanide ISA-51 VG,,,,0,['Montanide ISA-51 VG'],,0,[],0
GSK-2130579A,Immunostimulant,GSK-2130579A,,GSK-2130579A,gsk 2130579a,fexact,"['WT1 ASCI', 'WT1 vaccine', 'WT1 antigen specific cancer immunotherapeutic', 'leukemia vaccine', 'GSK-2130579A']",GSK-2130579A,fexact,"['wt1 asci', 'wt1 vaccine', 'wt1 antigen specific cancer immunotherapeutic', 'leukemia vaccine', 'gsk 2130579a']",correct_mapping
"acadesine, Advancell",B-cell inhibitor; AMPK stimulant; Apoptosis stimulant; Adenosine release stimulant,acadesine,Advancell,,,0,"['GP-1-110', 'Acadesube', 'acadesine', 'ARA-100', 'AIC-riboside', 'Protara', 'AICAR', 'SCH-900395', 'Arasine', 'AICA riboside']",,NER_API,[],0
GVAX,Granulocyte macrophage colony stimulating factor agonist; Immunostimulant; Immuno-oncology therapy,GVAX,,,,0,"['enistimagene setitucel + damistimagene matitucel', 'DE-125', 'Colon  tumor vaccine', 'enistimagene setitucel', 'GVAX', 'GM-CSF-producing cell vaccine (intradermal, cancer),/ Takeda', 'GM-K562', 'GM-CSF-producing cell vaccine (intradermal, cancer),/', 'CG1940/CG8711', 'GM-CSF-producing cell vaccine (intradermal, cancer), Cell Genesys/ Takeda', 'damistimagene matitucel', 'DE-125B', 'Bystander GVAX', 'GVAX Pancreas', 'GM-CSF-producing cell vaccine (intradermal, cancer), BioSante/', 'vaccine (intradermal, cancer), Somatix', 'GM-CSF-producing cell vaccine (intradermal, cancer), Aduro', 'Colon cancer tumor vaccine', 'CG-8123', 'GVAX Pancreas Panc 10.05', 'GM-CSF-producing cell vaccine (intradermal, cancer), BioSante/Takeda', 'GVAX Pancreas Panc 6.03']",,NER_API,[],0
"histamine dihydrochloride, EpiCept",Histamine H2 receptor agonist; NADPH oxidase 2 inhibitor,histamine dihydrochloride,EpiCept,"histamine dihydrochloride (subcutaneous, cancer)",histamine dihydrochloride,fexact,"['Maxamine', 'histamine dihydrochloride (subcutaneous), Meda', 'histamine', 'histamine dihydrochloride (subcutaneous, cancer), Meda/', 'histamine dihydrochloride (subcutaneous), Maxim', 'histamine dihydrochloride (subcutaneous, cancer),/', 'histamine dihydrochloride (subcutaneous, cancer)', 'histamine dihydrochloride (subcutaneous, cancer), Immune Pharmaceuticals', 'histamine dihydrochloride', 'Ceplene', 'EpiLeukin', 'histamine dihydrochloride (subcutaneous)']","histamine dihydrochloride (subcutaneous, cancer)",fexact,"['maxamine', 'histamine dihydrochloride subcutaneous meda', 'histamine', 'histamine dihydrochloride subcutaneous cancer meda', 'histamine dihydrochloride subcutaneous maxim', 'histamine dihydrochloride subcutaneous cancer', 'histamine dihydrochloride subcutaneous cancer', 'histamine dihydrochloride subcutaneous cancer immune pharmaceuticals', 'histamine dihydrochloride', 'ceplene', 'epileukin', 'histamine dihydrochloride subcutaneous']",correct_mapping
MCLA-117,CD3 agonist; T cell stimulant; Immuno-oncology therapy,MCLA-117,,MCLA-117,mcla 117,fexact,"['bispecific human antibodies targeting CD3 and CLEC12A (Biclonics, AML)', 'Fc-silenced anti-CD3/anti-CLEC12A bispecific T-cell engager (Bioclonics ENGAGE, acute myeloid leukemia/myelodysplastic syndrome)', 'MCLA-117']",MCLA-117,fexact,"['bispecific human antibodies targeting cd3 and clec12a biclonics aml', 'fc silenced anti cd3 anti clec12a bispecific t cell engager bioclonics engage acute myeloid leukemia myelodysplastic syndrome', 'mcla 117']",correct_mapping
GNKG-168,Immunostimulant; Toll-like receptor 9 agonist,GNKG-168,,GNKG-168,gnkg 168,fexact,['GNKG-168'],GNKG-168,fexact,['gnkg 168'],correct_mapping
indisulam,Cyclin-dependent kinase inhibitor; DNA topoisomerase II inhibitor; p21 stimulant; p53 stimulant; Sulfonamide antibiotic; Cell cycle inhibitor,indisulam,,indisulam,indisulam,fexact,"['ER-35744', 'indisulam', 'E-7070', 'sulfonamide indisulam analogs']",indisulam,fexact,"['er 35744', 'indisulam', 'e 7070', 'sulfonamide indisulam analogs']",correct_mapping
levetiracetam,Acetylcholine receptor agonist,levetiracetam,,levetiracetam (oral),levetiracetam,fexact,"['L-059', 'levetiracetam (oral), UCB', 'UCB-L060', 'Keppra', 'levetiracepam', 'Keppra Dry Syrup', 'levetiracetam (oral)', 'levetiracetam', 'UCB-L059']",levetiracetam (oral),fexact,"['l 059', 'levetiracetam oral ucb', 'ucb l060', 'keppra', 'levetiracepam', 'keppra dry syrup', 'levetiracetam oral', 'levetiracetam', 'ucb l059']",correct_mapping
R7112 (oral),MDM2 inhibitor,R7112,,RG-7112,r 7112,fuzzy,"['RG-7112', 'MDM2 antagonist (solid tumor/hematological neoplasm)', 'R-7112', 'RO-5045337']",RG-7112,fexact,"['rg 7112', 'mdm2 antagonist solid tumor hematological neoplasm', 'r 7112', 'ro 5045337']",incorrect_mapping
conventional T lymphocytes,Immunostimulant,conventional T lymphocytes,,,,0,['conventional T lymphocytes'],,0,[],0
RG-7356,CD44 antagonist; Apoptosis stimulant; Chondroitin sulfate proteoglycan inhibitor,RG-7356,,RG-7356,rg 7356,fexact,"['AR-001 series', 'anti-CD44 mAb (cancer)', '(ch)ARH460-16-2-IgG2', '(ch)ARH460-16-2-IgG1', 'ARH460-16-2', 'chimeric ARH460-16-2-IgG1', 'RO-5429083', 'H460-16-2', 'anti-CD44 antibody (cancer)', 'RG-7356', 'anti-CD44 mAb (cancer), Roche', 'muARH460-16-2', 'chimeric ARH460-16-2-IgG2', 'chARH460-16-2']",RG-7356,fexact,"['ar 001 series', 'anti cd44 mab cancer', 'ch arh460 16 2 igg2', 'ch arh460 16 2 igg1', 'arh460 16 2', 'chimeric arh460 16 2 igg1', 'ro 5429083', 'h460 16 2', 'anti cd44 antibody cancer', 'rg 7356', 'anti cd44 mab cancer roche', 'muarh460 16 2', 'chimeric arh460 16 2 igg2', 'charh460 16 2']",correct_mapping
WT-2725,Immunostimulant; T cell stimulant,WT-2725,,WT-2725,wt 2725,fexact,['WT-2725'],WT-2725,fexact,['wt 2725'],correct_mapping
PRI-724 (oral),Beta-catenin antagonist,PRI-724,,PRI-724,pri 724,fexact,"['PRI-724', 'OP-724', 'wnt inhibitor (iv, cancer), Prism Biolab/', 'C-28, Prism Biolab Corporation', 'CBP/beta-catenin inhibitor (cancer), Prism Biolab/']",PRI-724,fexact,"['pri 724', 'op 724', 'wnt inhibitor iv cancer prism biolab', 'c 28 prism biolab corporation', 'cbp beta catenin inhibitor cancer prism biolab']",correct_mapping
thioridazine,Dopamine receptor antagonist,thioridazine,,,,0,['thioridazine'],,0,[],0
eryaspase,Asparaginase stimulant,eryaspase,,,,0,"['eryaspase', 'L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor)', 'ERY-ASP', 'Graspa', 'ERY-001']",,Drug_API_mapping,[],0
FT-1050,Unidentified pharmacological activity,FT-1050,,ProTmune,ft 1050,fexact,"['dexamethasone', 'FT-4145', 'ProTmune', 'FT-1050 + FT-4145 modulated mPB (hematologic malignancies)', 'dmPGE2', 'dmPGE2 + dexamethasone modulated mobilized peripheral blood (hematologic malignancies)', 'FT-1050']",ProTmune,fexact,"['dexamethasone', 'ft 4145', 'protmune', 'ft 1050 ft 4145 modulated mpb hematologic malignancies', 'dmpge2', 'dmpge2 dexamethasone modulated mobilized peripheral blood hematologic malignancies', 'ft 1050']",correct_mapping
AKN-028,C-kit inhibitor; Flt-3 antagonist,AKN-028,,,,0,"['Flt3 tyrosine kinase inhibitor (AML),/Swedish Orphan Biovitrum/Karolinska', 'AKN-028']",,NER_API,[],0
AZD-1208,Pim-1 kinase inhibitor; Pim-2 kinase inhibitor; Pim-3 kinase inhibitor,AZD-1208,,AZD-1208,azd 1208,fexact,"['pim kinase inhibitor (cancer)', 'AZD-1208']",AZD-1208,fexact,"['pim kinase inhibitor cancer', 'azd 1208']",correct_mapping
MAGE -A1 peptide pulsed dendritic cells,Immunostimulant,MAGE -A1 peptide pulsed dendritic cells,,,,0,['MAGE -A1 peptide pulsed dendritic cells'],,0,[],0
MAGE- A3 peptide pulsed dendritic cells,Immunostimulant,MAGE- A3 peptide pulsed dendritic cells,,,,0,['MAGE- A3 peptide pulsed dendritic cells'],,0,[],0
choline magnesium trisalicylate,Unidentified pharmacological activity,choline magnesium trisalicylate,,,,0,"['CM-Sal', 'choline magnesium trisalicylate (intrathecal), Neurorecovery', 'choline magnesium trisalicylate', 'choline magnesium trisalicylate (intrathecal)']",,Drug_API_mapping,[],0
MK-8242,Unidentified pharmacological activity,MK-8242,,MK-8242,mk 8242,fexact,"['MK-8242', 'SCH-900242']",MK-8242,fexact,"['mk 8242', 'sch 900242']",correct_mapping
birinapant,IAP antagonist,birinapant,,birinapant,birinapant,fexact,"['NSC-756502', 'TL-32711', 'TL-132711', 'birinapant', 'Smac mimetics (cancer), TetraLogic', 'inhibitor of apoptosis protein antagonists (cancer), TetraLogic', 'XIAP antagonists (cancer)', 'GT-13065', 'XIAP antagonists (cancer), TetraLogic', 'inhibitor  apoptosis protein antagonists (cancer)', 'inhibitor of apoptosis protein antagonists (cancer)', 'Smac mimetics (cancer)']",birinapant,fexact,"['nsc 756502', 'tl 32711', 'tl 132711', 'birinapant', 'smac mimetics cancer tetralogic', 'inhibitor of apoptosis protein antagonists cancer tetralogic', 'xiap antagonists cancer', 'gt 13065', 'xiap antagonists cancer tetralogic', 'inhibitor apoptosis protein antagonists cancer', 'inhibitor of apoptosis protein antagonists cancer', 'smac mimetics cancer']",correct_mapping
tirbanibulin,Src inhibitor; Tubulin polymerization inhibitor,tirbanibulin,,tirbanibulin,tirbanibulin,fexact,"['KX2-391 (oral, cancer), Kinex/Hanmi', 'tirbanibulin (oral, actinic keratosis/cancer)', 'tirbanibulin mesylate', 'KX-01', 'KX2-305', 'KX2-391', 'KX-1136', 'src kinase inhibitors (oral, cancer), Kinex/ Hanmi', 'src kinase inhibitors (oral, cancer), Kinex/', 'KX2-377', 'KX-1136-b', 'KX1-174', 'tirbanibulin', 'KX-305', 'KX-2377', 'KX2-391 (oral, cancer), Kinex/', 'tirbanibulin (oral, actinic keratosis/cancer), Chongqing Jingdong', 'src kinase inhibitors (cancer), Kinex', 'KX1-002']",tirbanibulin,fexact,"['kx2 391 oral cancer kinex hanmi', 'tirbanibulin oral actinic keratosis cancer', 'tirbanibulin mesylate', 'kx 01', 'kx2 305', 'kx2 391', 'kx 1136', 'src kinase inhibitors oral cancer kinex hanmi', 'src kinase inhibitors oral cancer kinex', 'kx2 377', 'kx 1136 b', 'kx1 174', 'tirbanibulin', 'kx 305', 'kx 2377', 'kx2 391 oral cancer kinex', 'tirbanibulin oral actinic keratosis cancer chongqing jingdong', 'src kinase inhibitors cancer kinex', 'kx1 002']",correct_mapping
plerixafor (IV),CXC chemokine receptor 4 antagonist; Chemokine receptor antagonist,plerixafor,,plerixafor,plerixafor,fexact,"['plerixafor octahydrochloride', 'AMD-3100', 'SDZ-SID-791', 'SID-791', 'Mozobil', 'GZ316455', 'JM-3100', 'plerixafor']",plerixafor,fexact,"['plerixafor octahydrochloride', 'amd 3100', 'sdz sid 791', 'sid 791', 'mozobil', 'gz316455', 'jm 3100', 'plerixafor']",correct_mapping
AMG-900,Aurora kinase inhibitor,AMG-900,,AMG-900,amg 900,fexact,['AMG-900'],AMG-900,fexact,['amg 900'],correct_mapping
trans-2-en sodium valproate,GABA receptor agonist; Voltage-gated sodium channel antagonist; Histone deacetylase inhibitor,trans-2-en sodium valproate,,,,0,['trans-2-en sodium valproate'],,0,[],0
donor-specific leukocyte transfusion,Immunosuppressant,donor-specific leukocyte transfusion,,,,0,['donor-specific leukocyte transfusion'],,0,[],0
tigecycline (iv),Protein 30S ribosomal subunit inhibitor,tigecycline,,"tigecycline (iv infusion, acute myeloid leukemia), UHN",tigecycline,fexact,"['tigecycline', 'tigecycline (iv infusion, acute myeloid leukemia), Stem Cell Therapeutics', 'tigecycline (iv infusion, acute myeloid leukemia)', 'tigecycline (iv infusion, acute myeloid leukemia), UHN', 'tigecycline (iv infusion, acute myeloid leukemia), Trillium Therapeutics']","tigecycline (iv infusion, acute myeloid leukemia), UHN",fexact,"['tigecycline', 'tigecycline iv infusion acute myeloid leukemia stem cell therapeutics', 'tigecycline iv infusion acute myeloid leukemia', 'tigecycline iv infusion acute myeloid leukemia uhn', 'tigecycline iv infusion acute myeloid leukemia trillium therapeutics']",correct_mapping
"WT1 DNA vaccine, University of Southampton",Immunostimulant,WT1 DNA vaccine,University of Southampton,,,0,['WT1 DNA vaccine'],,0,[],0
elacytarabine,DNA synthesis inhibitor; RNA synthesis inhibitor,elacytarabine,,"elacytarabine (intravenous, cancer), Clavis",elacytarabine,fexact,"['Elacyt', 'ara-C analogs, Norsk Hydro', 'elacytarabine (intravenous, cancer), Clavis', 'ELACYT (intravenous, cancer), Clavis', 'CP-4055 (intravenous, cancer), Clavis', 'P-4055', 'ara-C analogs', 'CP-4055', 'elacytarabine']","elacytarabine (intravenous, cancer), Clavis",fexact,"['elacyt', 'ara c analogs norsk hydro', 'elacytarabine intravenous cancer clavis', 'elacyt intravenous cancer clavis', 'cp 4055 intravenous cancer clavis', 'p 4055', 'ara c analogs', 'cp 4055', 'elacytarabine']",correct_mapping
CNDO-109,Immunostimulant; Natural killer cell stimulant,CNDO-109,,CNDO-109-activated allogeneic NK cell therapy (cancer),cndo 109,fexact,"['natural killer cell activator (cancer immunotherapy), Royal Free Hospital/ Coronado', 'CNDO-109-activated allogeneic NK cell therapy (cancer), Coronado', 'CNDO-109-AANK cells (cancer), Coronado', 'CNDO-109-activated allogeneic NK cell therapy (cancer)', 'CNDO-109', 'CNDO-102']",CNDO-109-activated allogeneic NK cell therapy (cancer),fexact,"['natural killer cell activator cancer immunotherapy royal free hospital coronado', 'cndo 109 activated allogeneic nk cell therapy cancer coronado', 'cndo 109 aank cells cancer coronado', 'cndo 109 activated allogeneic nk cell therapy cancer', 'cndo 109', 'cndo 102']",correct_mapping
methotrexate (tablet),Immunosuppressant; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Disease modifying antirheumatic drug,methotrexate,,,,0,"['methotrexate', 'repurposed methotrexate (blood cancer)']",,NER_API,[],0
LY-2090314,Glycogen synthase kinase 3 inhibitor; Protein kinase inhibitor,LY-2090314,,LY-2090314,ly 2090314,fexact,"['GSK3-beta inhibitor (cancer)', 'glycogen synthase kinase-3 inhibitors', 'GSK-3 inhibitors (type 2 diabetes, cancer)', 'LY-2090314']",LY-2090314,fexact,"['gsk3 beta inhibitor cancer', 'glycogen synthase kinase 3 inhibitors', 'gsk 3 inhibitors type 2 diabetes cancer', 'ly 2090314']",correct_mapping
Yttrium 90 AHN-12,CD45 antagonist,Yttrium 90 AHN-12,,,,0,['Yttrium 90 AHN-12'],,0,[],0
clofarabine (tablet),DNA synthesis inhibitor; Ribonucleoside triphosphate reductase inhibitor; DNA repair enzyme inhibitor,clofarabine,,clofarabine (oral),clofarabine,fexact,"['Clolar', 'clofarabine (oral),/', 'clofarabine', 'clofarabine (oral)', 'GZ-393590', 'clofarabine (oral),/ILEX', 'clofarabine (oral), Genzyme', 'SAR-393590']",clofarabine (oral),fexact,"['clolar', 'clofarabine oral', 'clofarabine', 'clofarabine oral', 'gz 393590', 'clofarabine oral ilex', 'clofarabine oral genzyme', 'sar 393590']",correct_mapping
effector T lymphocytes,Immunostimulant,effector T lymphocytes,,,,0,['effector T lymphocytes'],,0,[],0
autologous dendritic cells (ID),Immunostimulant,autologous dendritic cells,,,,0,['autologous dendritic cells'],,0,[],0
Thiarabine,DNA synthesis inhibitor; DNA directed DNA polymerase inhibitor,Thiarabine,,VP-701,thiarabine,fexact,"['VP-700 series, Virium', 'VP-700 series', 'VP-700 series, Macrochem', 'VP-700 series, Access', 'GS-7836', 'SR-9025', '4-thio-beta-D-arabinofuranosylcytosine', 'vp-700 series', '4-thio-araC', 'Thiarabine', 'T-araC', 'OSI-7836', 'VP-701', 'VP-700 series, Southern Research Institute']",VP-701,fexact,"['vp 700 series virium', 'vp 700 series', 'vp 700 series macrochem', 'vp 700 series access', 'gs 7836', 'sr 9025', '4 thio beta d arabinofuranosylcytosine', 'vp 700 series', '4 thio arac', 'thiarabine', 't arac', 'osi 7836', 'vp 701', 'vp 700 series southern research institute']",correct_mapping
cyproheptadine,5 Hydroxytryptamine 2 receptor antagonist; Histamine H1 receptor antagonist,cyproheptadine,,,,0,['cyproheptadine'],,0,[],0
ilorasertib (oral),Aurora kinase inhibitor; VEGFR tyrosine kinase inhibitor,ilorasertib,,ilorasertib,ilorasertib,fexact,"['multikinase inhibitor (acute myeloid leukemia)', 'A-968660', 'ilorasertib', 'Aurora/VEGFR/PDGFR kinase inhibitor (acute myeloid leukemia), Abbott', 'Aurora/VEGFR/PDGFR kinase inhibitor (cancer)', 'Aurora/VEGFR/PDGFR kinase inhibitor (cancer), Abbott', 'Aurora/VEGFR/PDGFR kinase inhibitor (acute myeloid leukemia)', 'ABT-348', 'multikinase inhibitor (acute myeloid leukemia), Abbott']",ilorasertib,fexact,"['multikinase inhibitor acute myeloid leukemia', 'a 968660', 'ilorasertib', 'aurora vegfr pdgfr kinase inhibitor acute myeloid leukemia abbott', 'aurora vegfr pdgfr kinase inhibitor cancer', 'aurora vegfr pdgfr kinase inhibitor cancer abbott', 'aurora vegfr pdgfr kinase inhibitor acute myeloid leukemia', 'abt 348', 'multikinase inhibitor acute myeloid leukemia abbott']",correct_mapping
ilorasertib (IV),Aurora kinase inhibitor; VEGFR tyrosine kinase inhibitor,ilorasertib,,ilorasertib,ilorasertib,fexact,"['multikinase inhibitor (acute myeloid leukemia)', 'A-968660', 'ilorasertib', 'Aurora/VEGFR/PDGFR kinase inhibitor (acute myeloid leukemia), Abbott', 'Aurora/VEGFR/PDGFR kinase inhibitor (cancer)', 'Aurora/VEGFR/PDGFR kinase inhibitor (cancer), Abbott', 'Aurora/VEGFR/PDGFR kinase inhibitor (acute myeloid leukemia)', 'ABT-348', 'multikinase inhibitor (acute myeloid leukemia), Abbott']",ilorasertib,fexact,"['multikinase inhibitor acute myeloid leukemia', 'a 968660', 'ilorasertib', 'aurora vegfr pdgfr kinase inhibitor acute myeloid leukemia abbott', 'aurora vegfr pdgfr kinase inhibitor cancer', 'aurora vegfr pdgfr kinase inhibitor cancer abbott', 'aurora vegfr pdgfr kinase inhibitor acute myeloid leukemia', 'abt 348', 'multikinase inhibitor acute myeloid leukemia abbott']",correct_mapping
MK-8776,Checkpoint kinase 1 inhibitor,MK-8776,,SCH-900776,mk 8776,fexact,"['CHK-1 inhibitor (cancer), Schering-Plough', 'CHK-1 inhibitor (cancer)', 'checkpoint kinase 1 inhibitor (cancer), Schering-Plough', 'SCH-900776', 'MK-8776', 'checkpoint kinase 1 inhibitor (cancer)']",SCH-900776,fexact,"['chk 1 inhibitor cancer schering plough', 'chk 1 inhibitor cancer', 'checkpoint kinase 1 inhibitor cancer schering plough', 'sch 900776', 'mk 8776', 'checkpoint kinase 1 inhibitor cancer']",correct_mapping
"amonafide malate, Antisoma",DNA topoisomerase II inhibitor; RNA synthesis inhibitor,amonafide malate,Antisoma,amonafide L- malate,amonafide l malate,fuzzy,"['amonafide L-malate (iv, cancer)', 'XLS-001', 'amonafide L- malate', 'AS-1413', 'Xanafide']",amonafide L- malate,fexact,"['amonafide l malate iv cancer', 'xls 001', 'amonafide l malate', 'as 1413', 'xanafide']",incorrect_mapping
IPI-493,Heat shock protein 90 antagonist,IPI-493,,IPI-493,ipi 493,fexact,"['IPI-493', 'Hsp 90 inhibitors (oral, cancer)', '17-amino-geldanamycin', '17-AG', 'IPI-504']",IPI-493,fexact,"['ipi 493', 'hsp 90 inhibitors oral cancer', '17 amino geldanamycin', '17 ag', 'ipi 504']",correct_mapping
4SC-203,Aurora kinase inhibitor; Flt-3 antagonist; Protein kinase inhibitor; VEGFR tyrosine kinase inhibitor,4SC-203,,4SC-203,4sc 203,fexact,"['SC-71710', '4SC-203', 'angiogenesis inhibitor (iv, AML)', '4iP active agent (cancer),/ProQinase', 'protein kinase inhibitor (iv, AML)']",4SC-203,fexact,"['sc 71710', '4sc 203', 'angiogenesis inhibitor iv aml', '4ip active agent cancer proqinase', 'protein kinase inhibitor iv aml']",correct_mapping
barasertib,Aurora kinase inhibitor; Protein kinase inhibitor; Mitotic inhibitor,barasertib,,barasertib,barasertib,fexact,"['AZD-1152-hQPA', 'AZD-1152', 'barasertib', 'AZD-1152-hydroxyQPA', 'aurora kinase inhibitors']",barasertib,fexact,"['azd 1152 hqpa', 'azd 1152', 'barasertib', 'azd 1152 hydroxyqpa', 'aurora kinase inhibitors']",correct_mapping
ammonium trichlorotellurate (IV),Interleukin 17 antagonist; Interleukin 17 receptor antagonist; Interleukin 18 antagonist; Interleukin 1beta converting enzyme inhibitor; Alpha4beta1 integrin antagonist; Alphavbeta3 integrin antagonist,ammonium trichlorotellurate,,,,0,['ammonium trichlorotellurate'],,0,[],0
BC8-SA conjugate,CD45 antagonist,BC8-SA conjugate,,,,0,['BC8-SA conjugate'],,0,[],0
111In-biotin,Unidentified pharmacological activity,111In-biotin,,,,0,['111In-biotin'],,0,[],0
90Y-biotin,Unidentified pharmacological activity,90Y-biotin,,,,0,['90Y-biotin'],,0,[],0
ciclopirox olamine,Membrane permeability inhibitor; Chelating agent,ciclopirox olamine,,"ciclopirox olamine (oral, hematological malignancies)",ciclopirox olamine,fexact,"['ciclopirox olamine (oral, hematological malignancies)', 'ciclopirox olamine', 'BTX-10504']","ciclopirox olamine (oral, hematological malignancies)",fexact,"['ciclopirox olamine oral hematological malignancies', 'ciclopirox olamine', 'btx 10504']",correct_mapping
SAR-103168,Src inhibitor,SAR-103168,,SAR-103168,sar 103168,fexact,['SAR-103168'],SAR-103168,fexact,['sar 103168'],correct_mapping
cenersen,Apoptosis stimulant; p53 inhibitor,cenersen,,cenersen,cenersen,fexact,"['OL(1)p53', 'EL-625', 'cenersen', 'cenersen sodium', 'p53 antisense oligonucleotide (cancer)', 'Aezea']",cenersen,fexact,"['ol 1 p53', 'el 625', 'cenersen', 'cenersen sodium', 'p53 antisense oligonucleotide cancer', 'aezea']",correct_mapping
autologous dendritic cells (IV),Immunostimulant,autologous dendritic cells,,,,0,['autologous dendritic cells'],,0,[],0
QN-165,Apoptosis stimulant; Cell cycle inhibitor,QN-165,,QN-165,qn 165,fexact,"['nucleolin inhibitors (iv, acute myeloid leukemia)', 'nucleolin inhibitor (AML, RCC, pancreatic cancer, viral infections, SARS-CoV-2 infection), Qualigen Therapeutics', 'anticancer aptamers', 'GRO-26B', 'nucleolin inhibitor (viral infection), Qualigen Therapeutics', 'nucleolin inhibitor (AML, RCC, pancreatic cancer, viral infections, SARS-CoV-2 infection)', 'anticancer aptamers, Aptamera', 'AGRO-100', 'nucleolin inhibitor (viral infection)', 'AGRO-100 derivatives', 'QN-165', 'ACT-GRO-777', 'nucleolin inhibitors (cancer), Aptamera', 'nucleolin inhibitors (cancer)', 'AS-1411', 'AGRO-100 derivatives, Aptamera']",QN-165,fexact,"['nucleolin inhibitors iv acute myeloid leukemia', 'nucleolin inhibitor aml rcc pancreatic cancer viral infections sars cov 2 infection qualigen therapeutics', 'anticancer aptamers', 'gro 26b', 'nucleolin inhibitor viral infection qualigen therapeutics', 'nucleolin inhibitor aml rcc pancreatic cancer viral infections sars cov 2 infection', 'anticancer aptamers aptamera', 'agro 100', 'nucleolin inhibitor viral infection', 'agro 100 derivatives', 'qn 165', 'act gro 777', 'nucleolin inhibitors cancer aptamera', 'nucleolin inhibitors cancer', 'as 1411', 'agro 100 derivatives aptamera']",correct_mapping
IMC-EB10,Flt-3 antagonist,IMC-EB10,,EB-10,imc eb10,fexact,"['IMC-EB10', 'EB-10-MMAF', 'IMC-NC7', 'anti-Flt3 (monoclonal antibody, leukemia)', 'A2IN', 'D4-3', 'EB-10']",EB-10,fexact,"['imc eb10', 'eb 10 mmaf', 'imc nc7', 'anti flt3 monoclonal antibody leukemia', 'a2in', 'd4 3', 'eb 10']",correct_mapping
LM-061,"Kinase inhibitor, unspecified",LM-061,,LM-061,lm 061,fexact,"['LM-061', 'kinase inhibitor (oral, advanced tumor/hematologic malignancy)']",LM-061,fexact,"['lm 061', 'kinase inhibitor oral advanced tumor hematologic malignancy']",correct_mapping
eltrombopag olamine (tablet),Thrombopoietin agonist,eltrombopag olamine,,eltrombopag,eltrombopag olamine,fexact,"['SB-394725', 'hematopoietic growth factor mimetics,/', 'thrombopoietin peptide mimetics,/', '497115', 'hematopoietic growth factor mimetics, Ligand/', 'Revolade', 'hematopoietic growth factor mimetics,/SB', 'SB-497115', 'thrombopoietin peptide mimetics,/Ligand', 'hematopoietic growth factor mimetics, Ligand/SB', 'SB-497115-GR', 'eltrombopag', 'ETB-115', 'Promacta', 'eltrombopag olamine', 'SB-497117GR']",eltrombopag,fexact,"['sb 394725', 'hematopoietic growth factor mimetics', 'thrombopoietin peptide mimetics', '497115', 'hematopoietic growth factor mimetics ligand', 'revolade', 'hematopoietic growth factor mimetics sb', 'sb 497115', 'thrombopoietin peptide mimetics ligand', 'hematopoietic growth factor mimetics ligand sb', 'sb 497115 gr', 'eltrombopag', 'etb 115', 'promacta', 'eltrombopag olamine', 'sb 497117gr']",correct_mapping
CD19CAR-CD3Zeta-4-1BB-Expressing Allogeneic T-Lymphocyte Cells,T cell stimulant; Immuno-oncology therapy,CD19CAR-CD3Zeta-4-1BB-Expressing Allogeneic T-Lymphocyte Cells,,,,0,['CD19CAR-CD3Zeta-4-1BB-Expressing Allogeneic T-Lymphocyte Cells'],,0,[],0
murine CART19,CD19 antagonist; Immuno-oncology therapy,murine CART19,,,,0,['murine CART19'],,0,[],0
luspatercept,Transforming growth factor beta antagonist,luspatercept,,luspatercept,luspatercept,fexact,"['growth and differentiation factor (GDF) protein-based therapy (anemia associated with myelodysplastic syndrome)', 'luspatercept', 'ACE-536', 'luspatercept-aamt', 'GDF ligands and receptors modulator (anemia associated with myelodysplastic syndrome),/ Celgene', 'GDF ligands and receptors modulator (anemia)', 'Anemia therapy', 'ACE-536d', 'RAP-536', 'REBLOZYL', 'GDF ligands and receptors modulator (anemia associated with myelodysplastic syndrome),/']",luspatercept,fexact,"['growth and differentiation factor gdf protein based therapy anemia associated with myelodysplastic syndrome', 'luspatercept', 'ace 536', 'luspatercept aamt', 'gdf ligands and receptors modulator anemia associated with myelodysplastic syndrome celgene', 'gdf ligands and receptors modulator anemia', 'anemia therapy', 'ace 536d', 'rap 536', 'reblozyl', 'gdf ligands and receptors modulator anemia associated with myelodysplastic syndrome']",correct_mapping
"enzyme inhibitor, unspecified",Unidentified pharmacological activity,enzyme inhibitor,unspecified,,,0,['enzyme inhibitor'],,0,[],0
neostigmine,Acetylcholinesterase inhibitor,neostigmine,,,,0,['neostigmine'],,0,[],0
glasdegib,Hedgehog pathway inhibitor,glasdegib,,glasdegib,glasdegib,fexact,"['PF-04449913', 'PF-913', 'sonic hedgehog inhibitor (oral/tablet/capsule, cancers)', 'Daurismo', 'glasdegib maleate', 'glasdegib']",glasdegib,fexact,"['pf 04449913', 'pf 913', 'sonic hedgehog inhibitor oral tablet capsule cancers', 'daurismo', 'glasdegib maleate', 'glasdegib']",correct_mapping
ponatinib (tablet),Bcr-Abl inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor kinase inhibitor; TIE-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; Angiogenesis inhibitor; Angiopoietin inhibitor,ponatinib,,ponatinib,ponatinib,fexact,"['dual Abl/Src inhibitors (cancer)', 'ponatinib', 'AP-24534', 'oncogenic kinase inhibitors (cancer)', 'ponatinib hydrochloride', 'Iclusig', 'AP-23464', 'AP-24283']",ponatinib,fexact,"['dual abl src inhibitors cancer', 'ponatinib', 'ap 24534', 'oncogenic kinase inhibitors cancer', 'ponatinib hydrochloride', 'iclusig', 'ap 23464', 'ap 24283']",correct_mapping
letermovir,CMV terminase inhibitor,letermovir,,letermovir,letermovir,fexact,"['Prevymis', 'BAY-73-6327-N', 'AIC-001', 'AIC-246', 'letermovir', 'antiviral therapy', 'BAY-73-6327', 'MK-8228', 'non-nucleosidic terminase inhibitor (oral, HCMV infection)']",letermovir,fexact,"['prevymis', 'bay 73 6327 n', 'aic 001', 'aic 246', 'letermovir', 'antiviral therapy', 'bay 73 6327', 'mk 8228', 'non nucleosidic terminase inhibitor oral hcmv infection']",correct_mapping
olverembatinib,Bcr-Abl inhibitor; C-kit inhibitor,olverembatinib,,olverembatinib dimesylate,olverembatinib,fexact,"['Bcr-Abl inhibitors (chronic myeloid leukemia), Guangzhou Shunjian Biomedical Technology', 'olverembatinib dimethanesulfonate', 'Bcr-Abl inhibitors (chronic myeloid leukemia), Guangzhou Institutes of Biomedicine and Health', 'HQP-1351', 'bcr-abl inhibitors (chronic myeloid leukemia)', 'GIBH-824', 'olverembatinib', 'APG-1351', 'olverembatinib dimesylate', 'D-824', 'GZD-824']",olverembatinib dimesylate,fexact,"['bcr abl inhibitors chronic myeloid leukemia guangzhou shunjian biomedical technology', 'olverembatinib dimethanesulfonate', 'bcr abl inhibitors chronic myeloid leukemia guangzhou institutes of biomedicine and health', 'hqp 1351', 'bcr abl inhibitors chronic myeloid leukemia', 'gibh 824', 'olverembatinib', 'apg 1351', 'olverembatinib dimesylate', 'd 824', 'gzd 824']",correct_mapping
inotuzumab ozogamicin,DNA inhibitor,inotuzumab ozogamicin,,inotuzumab ozogamicin,inotuzumab ozogamicin,fexact,"['LL-E33288-gamma1-Br', 'non-Hodgkins lymphoma therapy,/', 'PF-5208773', 'antibody-calicheamicin conjugates,/', 'Hu3S193-CM, Wyeth', 'antibody-calicheamicin conjugates, Celltech/Wyeth-Ayerst', 'calicheamicin-beta1', 'calicheamicin-gamma1-I', 'anti-CD22 MAb-caliceamicin,/', 'calicheamicin-gamma-1', 'inotuzumab ozogamicin', 'antibody-calicheamicin conjugates,/Wyeth-Ayerst', 'LL-E33288-gamma1-I', 'CMC-544', 'Cal-7411C7', 'antibody-calicheamicin conjugates, Celltech/', 'non-Hodgkins lymphoma therapy, Wyeth/UCB', 'Hu3S193-CM', 'anti-CD22 MAb-caliceamicin, Wyeth/', 'antibody-calicheamicin conjugates, Celltech/UCB', 'non-Hodgkins lymphoma therapy,/Celltech', 'calicheamicin-gamma1-Br', 'antibody-calicheamicin conjugates, Celltech/Wyeth', 'L-E33288', 'LL-33288', 'non-Hodgkins lymphoma therapy, Wyeth/Celltech', 'Besponsa', 'anti-CD22 MAb-caliceamicin, Wyeth/UCB', 'antibody-calicheamicin conjugates,/Wyeth', 'calicheamicin-beta1-Br', 'non-Hodgkins lymphoma therapy, Wyeth/', 'anti-CD22 MAb-caliceamicin, Wyeth/Celltech', 'calicheamicin-alpha2', 'anti-CD22 MAb-caliceamicin,/Celltech']",inotuzumab ozogamicin,fexact,"['ll e33288 gamma1 br', 'non hodgkins lymphoma therapy', 'pf 5208773', 'antibody calicheamicin conjugates', 'hu3s193 cm wyeth', 'antibody calicheamicin conjugates celltech wyeth ayerst', 'calicheamicin beta1', 'calicheamicin gamma1 i', 'anti cd22 mab caliceamicin', 'calicheamicin gamma 1', 'inotuzumab ozogamicin', 'antibody calicheamicin conjugates wyeth ayerst', 'll e33288 gamma1 i', 'cmc 544', 'cal 7411c7', 'antibody calicheamicin conjugates celltech', 'non hodgkins lymphoma therapy wyeth ucb', 'hu3s193 cm', 'anti cd22 mab caliceamicin wyeth', 'antibody calicheamicin conjugates celltech ucb', 'non hodgkins lymphoma therapy celltech', 'calicheamicin gamma1 br', 'antibody calicheamicin conjugates celltech wyeth', 'l e33288', 'll 33288', 'non hodgkins lymphoma therapy wyeth celltech', 'besponsa', 'anti cd22 mab caliceamicin wyeth ucb', 'antibody calicheamicin conjugates wyeth', 'calicheamicin beta1 br', 'non hodgkins lymphoma therapy wyeth', 'anti cd22 mab caliceamicin wyeth celltech', 'calicheamicin alpha2', 'anti cd22 mab caliceamicin celltech']",correct_mapping
nalbuphine,Opioid mu receptor antagonist; Opioid kappa receptor agonist,nalbuphine,,,,0,"['nalbuphine', 'nalbuphine (oral, pain)', 'Huai Te Tong Bao', 'PHN-131']",,NER_API,[],0
TC-110,T cell stimulant; Immuno-oncology therapy,TC-110,,TC-110,tc 110,fexact,"['FMC-63-TCR fusion protein T-cell therapy (TRuC, hematological cancer), TCR2\xa0Therapeutics', 'anti-CD19 TCR T-cell therapy (TRuC, hematological cancer), TCR2\xa0Therapeutics', 'TC-110', 'CD19-TRuC-T cells (hematological cancer)']",TC-110,fexact,"['fmc 63 tcr fusion protein t cell therapy truc hematological cancer tcr2\xa0therapeutics', 'anti cd19 tcr t cell therapy truc hematological cancer tcr2\xa0therapeutics', 'tc 110', 'cd19 truc t cells hematological cancer']",correct_mapping
alovudine,Nucleoside reverse transcriptase inhibitor,alovudine,,,,0,"['MIV-310', 'FLT', 'alovudine', 'FddThd', 'CL 184824']",,NER_API,[],0
asciminib,Bcr-Abl inhibitor,asciminib,,asciminib,asciminib,fexact,"['asciminib hydrochloride', 'allosteric Bcr-Abl inhibitor (CML/ALL)', 'asciminib', 'ABL-001']",asciminib,fexact,"['asciminib hydrochloride', 'allosteric bcr abl inhibitor cml all', 'asciminib', 'abl 001']",correct_mapping
navitoclax (tablet),Bcl2 inhibitor; Apoptosis stimulant; Bcl-XL inhibitor,navitoclax,,navitoclax,navitoclax,fexact,"['cancer therapeutics (Bcl-2/Bcl-xL inhibitors)', 'Bax modulators (anticancer), Idun/', 'Bax modulators (anticancer),/', 'ABT-263', 'A-438744', 'A-371191', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors),/Idun', 'navitoclax dihydrochloride', 'Bcl-2/Bcl-xL inhibitors (anticancer),/Idun', 'RG-7433', 'Bcl-2/Bcl-xL inhibitors (anticancer), Abbott/Idun', 'Bax modulators (anticancer), Idun/Abbott', 'Bcl-2/Bcl-xL inhibitors (anticancer),/', 'Bcl-2/Bcl-xL inhibitors (anticancer)', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors),/', 'navitoclax', 'A-385358', 'Bax modulators (anticancer, oral), Abbott', 'Bax modulators (anticancer, oral)', 'A-855071.0', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott/Idun', 'A-317267', 'Bcl-2/Bcl-xL inhibitors (anticancer), Abbott', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott']",navitoclax,fexact,"['cancer therapeutics bcl 2 bcl xl inhibitors', 'bax modulators anticancer idun', 'bax modulators anticancer', 'abt 263', 'a 438744', 'a 371191', 'cancer therapeutics bcl 2 bcl xl inhibitors idun', 'navitoclax dihydrochloride', 'bcl 2 bcl xl inhibitors anticancer idun', 'rg 7433', 'bcl 2 bcl xl inhibitors anticancer abbott idun', 'bax modulators anticancer idun abbott', 'bcl 2 bcl xl inhibitors anticancer', 'bcl 2 bcl xl inhibitors anticancer', 'cancer therapeutics bcl 2 bcl xl inhibitors', 'navitoclax', 'a 385358', 'bax modulators anticancer oral abbott', 'bax modulators anticancer oral', 'a 855071 0', 'cancer therapeutics bcl 2 bcl xl inhibitors abbott idun', 'a 317267', 'bcl 2 bcl xl inhibitors anticancer abbott', 'cancer therapeutics bcl 2 bcl xl inhibitors abbott']",correct_mapping
huJCAR014,CD19 antagonist; Immuno-oncology therapy,huJCAR014,,,,0,['huJCAR014'],,0,[],0
AUTO-1,T cell stimulant; Immuno-oncology therapy,AUTO-1,,AUTO-1,auto 1,fexact,"['AUTO-1', 'anti-cd19 scfv-car (b-cell leukemia)', 'anti-CD19 CAR T-cell therapy (B-cell leukemia),/University College London', 'anti-CD19 scFv-CAR (B-cell leukemia),/University College London', 'anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia/Burkitts lymphoma), University College London/', 'anti-cd19 car t-cell therapy (acute lymphoblastic leukemia/burkitts lymphoma)', 'anti-cd19 car t-cell therapy (b-cell leukemia)', 'CD19CAT-41BBZ CAR T-cells']",AUTO-1,fexact,"['auto 1', 'anti cd19 scfv car b cell leukemia', 'anti cd19 car t cell therapy b cell leukemia university college london', 'anti cd19 scfv car b cell leukemia university college london', 'anti cd19 car t cell therapy acute lymphoblastic leukemia burkitts lymphoma university college london', 'anti cd19 car t cell therapy acute lymphoblastic leukemia burkitts lymphoma', 'anti cd19 car t cell therapy b cell leukemia', 'cd19cat 41bbz car t cells']",correct_mapping
posaconazole,Cell wall synthesis inhibitor; Sterol demethylase inhibitor,posaconazole,,posaconazole,posaconazole,fexact,"['antifungal, Schering-Plough', 'Noxafil', 'posaconazole', 'Spriafil', 'Sch-56592', 'MK-5592 (oral suspension), Merck & Co', 'MK-5592 (oral suspension)', 'Sch-56984', 'Sch-207962', '056592', 'SCH 056592', 'Sch-56588', 'antifungal', 'Posanol', 'triazole (oral), Schering-Plough', 'triazole (oral)', 'Posaconazole SP']",posaconazole,fexact,"['antifungal schering plough', 'noxafil', 'posaconazole', 'spriafil', 'sch 56592', 'mk 5592 oral suspension merck co', 'mk 5592 oral suspension', 'sch 56984', 'sch 207962', '056592', 'sch 056592', 'sch 56588', 'antifungal', 'posanol', 'triazole oral schering plough', 'triazole oral', 'posaconazole sp']",correct_mapping
"clofarabine, Betta Pharmaceuticals",DNA synthesis inhibitor; Ribonucleoside triphosphate reductase inhibitor; DNA repair enzyme inhibitor,clofarabine,Betta Pharmaceuticals,clofarabine (oral),clofarabine,fexact,"['Clolar', 'clofarabine (oral),/', 'clofarabine', 'clofarabine (oral)', 'GZ-393590', 'clofarabine (oral),/ILEX', 'clofarabine (oral), Genzyme', 'SAR-393590']",clofarabine (oral),fexact,"['clolar', 'clofarabine oral', 'clofarabine', 'clofarabine oral', 'gz 393590', 'clofarabine oral ilex', 'clofarabine oral genzyme', 'sar 393590']",correct_mapping
amlodipine,L-type calcium channel antagonist,amlodipine,,amlodipine,amlodipine,fexact,"['amlodipine', 'Astudal', 'Istin', 'Norvas', 'Norvasc', 'amlodipine besylate', 'K-48340', 'amlodipine besilate', 'Amlodine', 'UK-4834026', 'Amlogin', 'Amlodin', 'Amlor']",amlodipine,fexact,"['amlodipine', 'astudal', 'istin', 'norvas', 'norvasc', 'amlodipine besylate', 'k 48340', 'amlodipine besilate', 'amlodine', 'uk 4834026', 'amlogin', 'amlodin', 'amlor']",correct_mapping
candesartan (tablet),Angiotensin II 1 antagonist,candesartan,,candesartan,candesartan,fexact,"['Tiadyl', 'TCV-116', 'Atacand', 'Bliopress', 'Blopres', 'Amias', 'Parapres', 'candesartan', 'candesartan cilexetil', 'Blopress', 'H-212/91', 'candesartan cilexetil (hypertension/cardiac failure), AstraZeneca/Cheplapharm', 'candesartan cilexetil (hypertension/cardiac failure),/Cheplapharm', 'candesartan cilexetil (hypertension/cardiac failure),/', 'Kenzen']",candesartan,fexact,"['tiadyl', 'tcv 116', 'atacand', 'bliopress', 'blopres', 'amias', 'parapres', 'candesartan', 'candesartan cilexetil', 'blopress', 'h 212 91', 'candesartan cilexetil hypertension cardiac failure astrazeneca cheplapharm', 'candesartan cilexetil hypertension cardiac failure cheplapharm', 'candesartan cilexetil hypertension cardiac failure', 'kenzen']",correct_mapping
tomaralimab,Toll-like receptor 2 antagonist,tomaralimab,,tomaralimab,tomaralimab,fexact,"['OPN-305', 'OPN-301', 'tomaralimab', 'toll-like receptor specific monoclonal antibodies (inflammatory diseases)', 'TLR-specific mAbs (kidney transplant rejection)']",tomaralimab,fexact,"['opn 305', 'opn 301', 'tomaralimab', 'toll like receptor specific monoclonal antibodies inflammatory diseases', 'tlr specific mabs kidney transplant rejection']",correct_mapping
deferasirox (dispersible tablet),Chelating agent; Iron absorption inhibitor,deferasirox,,deferasirox,deferasirox,fexact,"['ICL-670A', 'Exjade', 'iron chelator', 'Jadenu', 'ICL-670', 'deferasirox', 'Exjade FCT', 'Jadenu Sprinkle', 'CGP-72670', 'Osveral']",deferasirox,fexact,"['icl 670a', 'exjade', 'iron chelator', 'jadenu', 'icl 670', 'deferasirox', 'exjade fct', 'jadenu sprinkle', 'cgp 72670', 'osveral']",correct_mapping
desferrioxamine mesylate,Chelating agent; Iron absorption inhibitor,desferrioxamine mesylate,,deferoxamine mesylate,deferoxamine mesylate,fuzzy,"['deferoxamine mesylate', 'Desferal']",deferoxamine mesylate,fexact,"['deferoxamine mesylate', 'desferal']",incorrect_mapping
isavuconazonium chloride,Cell wall synthesis inhibitor,isavuconazonium chloride,,Cresemba,isavuconazonium chloride,fexact,"['RO-0098557', 'antifungals', 'BAL-8557 (intravenous)', 'isavuconazonium chloride/sulfate (intravenous),/', 'Cresemba', 'BAL-8557', 'antifungals, Basilea', 'isavuconazonium chloride/sulfate (intravenous), Basilea/Astellas', 'isavuconazonium sulfate', 'isavuconazonium chloride', 'isavuconazonium chloride/sulfate (intravenous), Basilea/', 'BAL-8557 (intravenous), Basilea', 'BAL-8349', 'isavuconazole', 'AK-1820', 'isavuconazonium']",Cresemba,fexact,"['ro 0098557', 'antifungals', 'bal 8557 intravenous', 'isavuconazonium chloride sulfate intravenous', 'cresemba', 'bal 8557', 'antifungals basilea', 'isavuconazonium chloride sulfate intravenous basilea astellas', 'isavuconazonium sulfate', 'isavuconazonium chloride', 'isavuconazonium chloride sulfate intravenous basilea', 'bal 8557 intravenous basilea', 'bal 8349', 'isavuconazole', 'ak 1820', 'isavuconazonium']",correct_mapping
micafungin sodium,"1,3-Beta-glucan synthase inhibitor",micafungin sodium,,micafungin,micafungin sodium,fexact,"['Mycamine', 'micafungin', 'Funguard', 'FK-463', 'micafungin sodium']",micafungin,fexact,"['mycamine', 'micafungin', 'funguard', 'fk 463', 'micafungin sodium']",correct_mapping
lintuzumab,CD33 antagonist; Immuno-oncology therapy,lintuzumab,,lintuzumab,lintuzumab,fexact,"['HuM195', 'SMART M195', 'Zamyl', 'humanized M195', 'SGN-33', 'Humanized M195', 'anti-CD33 mAb (leukemia), Seattle Genetics', 'KB-195', 'M-195', 'lintuzumab', 'M195 (humanized), Protein Design Labs']",lintuzumab,fexact,"['hum195', 'smart m195', 'zamyl', 'humanized m195', 'sgn 33', 'humanized m195', 'anti cd33 mab leukemia seattle genetics', 'kb 195', 'm 195', 'lintuzumab', 'm195 humanized protein design labs']",correct_mapping
chlorhexidine gluconate (CHG) impregnated cloths,Membrane integrity inhibitor,chlorhexidine gluconate  impregnated cloths,,,,0,['chlorhexidine gluconate  impregnated cloths'],,0,[],0
NKCARCD19,CD19 antagonist,NKCARCD19,,,,0,['NKCARCD19'],,0,[],0
"cyclosporine, unspecified",Immunosuppressant; Calcineurin inhibitor; T cell inhibitor,cyclosporine,unspecified,ciclosporin,cyclosporine,fexact,"['cyclosporin', 'cyclosporin A', 'Sandimmun', 'OLO-400', 'ciclosporin', 'Neoral', 'Sandimmune', 'cyclosporine', 'Sandimmun Neoral']",ciclosporin,fexact,"['cyclosporin', 'cyclosporin a', 'sandimmun', 'olo 400', 'ciclosporin', 'neoral', 'sandimmune', 'cyclosporine', 'sandimmun neoral']",correct_mapping
denintuzumab,Tubulin polymerization inhibitor,denintuzumab,,,,0,['denintuzumab'],,0,[],0
Undisclosed - levofloxacin (tablet),DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,Undisclosed - levofloxacin,,,,0,['Undisclosed - levofloxacin'],,0,[],0
undisclosed - levofloxacin (IV),DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor,undisclosed - levofloxacin,,,,0,['undisclosed - levofloxacin'],,0,[],0
Combotox,Protein synthesis inhibitor,Combotox,,Combotox,combotox,fexact,"['IMTOX 22', 'anti CD22/N97A', 'ricin-conjugated anti-CD22 and anti-CD19', 'anti CD19 + anti CD22/N97A', 'Combotox', 'anti CD22/ricin', 'IgG-RFB4-dgA and IgG-HD37-dgA']",Combotox,fexact,"['imtox 22', 'anti cd22 n97a', 'ricin conjugated anti cd22 and anti cd19', 'anti cd19 anti cd22 n97a', 'combotox', 'anti cd22 ricin', 'igg rfb4 dga and igg hd37 dga']",correct_mapping
"cytarabine, injectable, Sicor",DNA synthesis inhibitor,cytarabine,Sicor,,,0,"['cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/', 'DepoFoam (cytarabine)', 'DepoCyt', 'NS-101', 'Savedar', 'cytarabine (sustained release, DepoFoam), SkyePharma', 'DTC-101', 'cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical', 'Cytosar-U', 'cytarabine (SR formulation), DepoTech/', 'Cytosar', 'cytarabine', 'DepoCyte', 'cytarabine (sustained release, DepoFoam),/Sigma-Tau/Pfizer/', 'cytarabine (sustained release, DepoFoam),///', 'Ara-C', 'cytarabine (sustained release, DepoFoam),/Sigma-Tau//']",,NER_API,[],0
epratuzumab,CD22 antagonist; Immuno-oncology therapy,epratuzumab,,epratuzumab,epratuzumab,fexact,"['IMMU-103', 'epratuzumab', 'LymphoCide', 'humanized LL2 antibody, UCB', 'CDP-3194', 'lymphoma antibody, UCB', 'hCD22 antibody (iv, NHL/ALL/SLE), UCB/', 'hCD22 antibody (iv, NHL/ALL/SLE),/', 'hCD22 antibody, Immunomedics', 'humanized LL2 antibody', 'hLL2, UCB', 'lymphoma antibody', 'hLL2', 'hCD22 antibody (iv, NHL/ALL/SLE), UCB/Immunomedics', 'lymphoma antibody, Immunomedics', 'hLL2, Immunomedics', 'epratuzumab (humanized anti-CD22)', 'hCD22 antibody', 'humanized LL2 antibody, Immunomedics', 'AMG-412']",epratuzumab,fexact,"['immu 103', 'epratuzumab', 'lymphocide', 'humanized ll2 antibody ucb', 'cdp 3194', 'lymphoma antibody ucb', 'hcd22 antibody iv nhl all sle ucb', 'hcd22 antibody iv nhl all sle', 'hcd22 antibody immunomedics', 'humanized ll2 antibody', 'hll2 ucb', 'lymphoma antibody', 'hll2', 'hcd22 antibody iv nhl all sle ucb immunomedics', 'lymphoma antibody immunomedics', 'hll2 immunomedics', 'epratuzumab humanized anti cd22', 'hcd22 antibody', 'humanized ll2 antibody immunomedics', 'amg 412']",correct_mapping
"quetiapine fumarate, SR",Alpha 1 adrenoreceptor antagonist; Alpha 2 adrenoreceptor antagonist; Dopamine D1 receptor antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 1A receptor antagonist; 5 Hydroxytryptamine 2 receptor antagonist; Histamine H1 receptor antagonist,quetiapine fumarate,SR,quetiapine fumarate (once-daily sustained release tablet),quetiapine fumarate,fexact,"['Seroquel XRO', 'quetiapine', 'quetiapine fumarate (once-daily sustained release tablet)', 'FK-949E', 'Bipresso', 'Seroquel XR', 'Seroquel SR', 'quetiapine fumarate (once-daily sustained release tablet), AstraZeneca', 'Xeroquel LP', 'Seroquel ER', 'quetiapine XR', 'quetiapine fumarate']",quetiapine fumarate (once-daily sustained release tablet),fexact,"['seroquel xro', 'quetiapine', 'quetiapine fumarate once daily sustained release tablet', 'fk 949e', 'bipresso', 'seroquel xr', 'seroquel sr', 'quetiapine fumarate once daily sustained release tablet astrazeneca', 'xeroquel lp', 'seroquel er', 'quetiapine xr', 'quetiapine fumarate']",correct_mapping
adalimumab (SC),Immunosuppressant; Tumour necrosis factor alpha antagonist,adalimumab,,adalimumab,adalimumab,fexact,"['Humira', 'Humira Pen', 'anti-TNF-alpha antibody,/CAT', 'Trudexa', 'D2E7', 'MAb (anti-TNF-alpha), humanized, Knoll/CAT', 'LU 200134', 'MAb (anti-TNF-alpha), humanized,/CAT', 'ABT-D2E7', 'undisclosed biosimilar (rheumatoid arthritis), Tanvex BioPharma', 'Raheara', 'adalimumab', 'anti-TNF-alpha antibody, Knoll/CAT']",adalimumab,fexact,"['humira', 'humira pen', 'anti tnf alpha antibody cat', 'trudexa', 'd2e7', 'mab anti tnf alpha humanized knoll cat', 'lu 200134', 'mab anti tnf alpha humanized cat', 'abt d2e7', 'undisclosed biosimilar rheumatoid arthritis tanvex biopharma', 'raheara', 'adalimumab', 'anti tnf alpha antibody knoll cat']",correct_mapping
hydrochlorothiazide,Thiazide diuretic,hydrochlorothiazide,,,,0,['hydrochlorothiazide'],,0,[],0
pregabalin (capsule),Calcium channel antagonist,pregabalin,,pregabalin,pregabalin,fexact,"['pregabalin', 'Lyrica', 'Lyrica Capsules', 'PD-144723', 'Lyrica OD Tablets', 'S-isobutylGABA', 'PGB', 'CI-1008']",pregabalin,fexact,"['pregabalin', 'lyrica', 'lyrica capsules', 'pd 144723', 'lyrica od tablets', 's isobutylgaba', 'pgb', 'ci 1008']",correct_mapping
autologous AML-reactive T cells,Immunostimulant,autologous AML-reactive T cells,,,,0,['autologous AML-reactive T cells'],,0,[],0
vortioxetine,5 Hydroxytryptamine 1D receptor antagonist; 5 Hydroxytryptamine 3 receptor antagonist; 5 Hydroxytryptamine 7 receptor antagonist; 5 Hydroxytryptamine uptake inhibitor; 5 Hydroxytryptamine 1B receptor agonist; 5 Hydroxytryptamine 1A receptor agonist,vortioxetine,,vortioxetine hydrobromide,vortioxetine,fexact,"['vortioxetine hydrochloride', 'Brintellix', 'Trintellix', 'vortioxetine', 'Lu-AA21004', 'vortioxetine hydrobromide']",vortioxetine hydrobromide,fexact,"['vortioxetine hydrochloride', 'brintellix', 'trintellix', 'vortioxetine', 'lu aa21004', 'vortioxetine hydrobromide']",correct_mapping
KW-2449,Fibroblast growth factor receptor 1 antagonist; Abl receptor tyrosine kinase inhibitor; Aurora kinase inhibitor; Flt-3 antagonist,KW-2449,,KW-2449,kw 2449,fexact,"['tumor antigen-specific mAb (cancer)', 'tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo', 'tumor antigen-specific monoclonal antibody (cancer)', 'KW-2449']",KW-2449,fexact,"['tumor antigen specific mab cancer', 'tumor antigen specific monoclonal antibody cancer kyowa hakko kogyo', 'tumor antigen specific monoclonal antibody cancer', 'kw 2449']",correct_mapping
prednisolone (IV),Arachidonic acid inhibitor; Glucocorticoid agonist,prednisolone,,,,0,"['prednisolone', 'prednisolone (oral controlled release formulation/csds)', 'prednisolone (oral controlled release formulation/colon specific drug delivery system)']",,NER_API,[],0
FPI-01,Immunostimulant,FPI-01,,WT1-CTL,fpi 01,fexact,"['WT-1 analog peptide vaccine (acute myeloid leukemia/mesothelioma/cancer), Formula Pharmaceuticals Inc(US)/ Memorial Sloan-Kettering Cancer Center', 'WT-1 therapeutic vaccine (cancer)', 'FPI-01', 'WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals', 'WT1-CTL', 'wt-1 analog peptide vaccine (acute myeloid leukemia/mesothelioma/cancer), (us)', 'wt-1 analog peptide vaccine (acute myeloid leukemia/mesothelioma/cancer), (us)/ memorial sloan-kettering cancer center', 'ATA-520']",WT1-CTL,fexact,"['wt 1 analog peptide vaccine acute myeloid leukemia mesothelioma cancer formula pharmaceuticals inc us memorial sloan kettering cancer center', 'wt 1 therapeutic vaccine cancer', 'fpi 01', 'wt 1 therapeutic vaccine cancer formula pharmaceuticals', 'wt1 ctl', 'wt 1 analog peptide vaccine acute myeloid leukemia mesothelioma cancer us', 'wt 1 analog peptide vaccine acute myeloid leukemia mesothelioma cancer us memorial sloan kettering cancer center', 'ata 520']",correct_mapping
NRX-5183,Retinoid X receptor agonist,NRX-5183,,IRX-5183,nrx 5183,fexact,"['IRX-5183 (oral, cancer/autoimmune disease)', 'IRX-5183', 'retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics', 'RARa (oral, cancer/autoimmune disease)', 'IRX-5183 (oral, cancer)', 'IRX-5183 (oral, autoimmune disease)', 'retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease)', 'IRX-5183 (oral, cancer), Io Therapeutics', 'NRX-5183', 'NRX-195183', 'VTP-5183', 'RARa (oral, cancer/autoimmune disease), Io Therapeutics', 'VTP-195183', 'IRX-5183 (oral, autoimmune disease), Io Therapeutics', 'AGN-195183', 'IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics']",IRX-5183,fexact,"['irx 5183 oral cancer autoimmune disease', 'irx 5183', 'retinoic acid receptor alpha agonist oral cancer autoimmune disease io therapeutics', 'rara oral cancer autoimmune disease', 'irx 5183 oral cancer', 'irx 5183 oral autoimmune disease', 'retinoic acid receptor alpha agonist oral cancer autoimmune disease', 'irx 5183 oral cancer io therapeutics', 'nrx 5183', 'nrx 195183', 'vtp 5183', 'rara oral cancer autoimmune disease io therapeutics', 'vtp 195183', 'irx 5183 oral autoimmune disease io therapeutics', 'agn 195183', 'irx 5183 oral cancer autoimmune disease io therapeutics']",correct_mapping
olmesartan medoxomil,Angiotensin II 1 antagonist,olmesartan medoxomil,,olmesartan medoxomil,olmesartan medoxomil,fexact,"['Openvas', 'Olmeta', 'CS-866DM', 'olmesartan medoxomil', 'Olmetec', 'Votum', 'Benitec', 'Olmetec OD', 'Benicar', 'CS-866', 'Benetor', 'Benevas', 'Olmes', 'Olvance', 'R-88536', 'CS-866RN']",olmesartan medoxomil,fexact,"['openvas', 'olmeta', 'cs 866dm', 'olmesartan medoxomil', 'olmetec', 'votum', 'benitec', 'olmetec od', 'benicar', 'cs 866', 'benetor', 'benevas', 'olmes', 'olvance', 'r 88536', 'cs 866rn']",correct_mapping
BI-811283,Aurora kinase inhibitor,BI-811283,,BI-811283,bi 811283,fexact,"['BI-811283', 'aurora B kinase inhibitor (cancer)']",BI-811283,fexact,"['bi 811283', 'aurora b kinase inhibitor cancer']",correct_mapping
"cordycepin, OncoVista",DNA inhibitor; RNA synthesis inhibitor,cordycepin,OncoVista,OVI-123,cordycepin,fexact,"['Cordycepin (acute lymphoid leukemia ),/', 'Cordycepin', 'Cordycepin (acute lymphoid leukemia ), OncoVista/', 'Cordycepin (acute lymphoid leukemia), OXiGENE', 'Cordycepin (ALL), OXiGENE', 'OVI-123']",OVI-123,fexact,"['cordycepin acute lymphoid leukemia', 'cordycepin', 'cordycepin acute lymphoid leukemia oncovista', 'cordycepin acute lymphoid leukemia oxigene', 'cordycepin all oxigene', 'ovi 123']",correct_mapping
L-asparaginase,Unidentified pharmacological activity,L-asparaginase,,asparaginase,asparaginase,fuzzy,"['Spectrila', 'asparaginase']",asparaginase,fexact,"['spectrila', 'asparaginase']",incorrect_mapping
"amsacrine, Parke-Davis",DNA topoisomerase II inhibitor,amsacrine,Parke-Davis,,,0,['amsacrine'],,0,[],0
cenplacel-L,Not applicable,cenplacel-L,,,,0,"['cenplacel', 'cenplacel-L', 'PDA-001', 'placenta-derived stem cell therapy (cancer/immune disorder/inflammatory disorder)', 'cenplacel', 'cenplacel-L', 'PDA-001', 'placenta-derived stem cell therapy (cancer/immune disorder/inflammatory disorder)']",,NER_API,[],0
IMGN-633,Microtubule inhibitor,IMGN-633,,,,0,['IMGN-633'],,0,[],0
"pegylated interferon alpha-2b, unspecified",Interferon receptor agonist,pegylated interferon alpha-2b,unspecified,,,0,['pegylated interferon alpha-2b'],,0,[],0
EZN-2232,Immunostimulant,EZN-2232,,recombinant human mannan-binding lectin (infection prevention),ezn 2232,fexact,"['MBL replacement therapy, NatImmune', 'recombinant human mannan-binding protein, NatImmune/Enzon', 'recombinant human mannan-binding lectin (infection prevention)', 'rhMBL, NatImmune/Enzon', 'rhMBL, NatImmune', 'rhMBL, NatImmune/', 'recombinant human mannan-binding protein, NatImmune/', 'recombinant human mannan-binding lectin (infection prevention), Helion', 'EZN-2232']",recombinant human mannan-binding lectin (infection prevention),fexact,"['mbl replacement therapy natimmune', 'recombinant human mannan binding protein natimmune enzon', 'recombinant human mannan binding lectin infection prevention', 'rhmbl natimmune enzon', 'rhmbl natimmune', 'rhmbl natimmune', 'recombinant human mannan binding protein natimmune', 'recombinant human mannan binding lectin infection prevention helion', 'ezn 2232']",correct_mapping
alemtuzumab (SC),Immunosuppressant; CD52 antagonist,alemtuzumab,,alemtuzumab,alemtuzumab,fexact,"['BAY-86-5045', 'GZ-402673', 'CAMPATH-1H', 'Lemtrada', 'LDP-03', 'MabCampath', 'CAMPATH-1', 'CAMPATH', 'anti-CD52 mAb, Millennium//', 'alemtuzumab', 'anti-CD52 mAb, Millennium//Schering', 'DE-04188', 'ZK-217699', 'MabCampath-1H', 'anti-CD52 mAb, Millennium/ILEX/Schering']",alemtuzumab,fexact,"['bay 86 5045', 'gz 402673', 'campath 1h', 'lemtrada', 'ldp 03', 'mabcampath', 'campath 1', 'campath', 'anti cd52 mab millennium', 'alemtuzumab', 'anti cd52 mab millennium schering', 'de 04188', 'zk 217699', 'mabcampath 1h', 'anti cd52 mab millennium ilex schering']",correct_mapping
flutamide,Androgen receptor antagonist,flutamide,,,,0,['flutamide'],,0,[],0
stem cell factor (SCF),Stem cell growth factor agonist,stem cell factor,,ancestim,stem cell factor,fexact,"['Stemgen', 'SCF', 'ancestim', 'stem cell factor', 'rhSCF']",ancestim,fexact,"['stemgen', 'scf', 'ancestim', 'stem cell factor', 'rhscf']",correct_mapping
mafosfamide,DNA inhibitor; DNA synthesis inhibitor,mafosfamide,,,,0,"['mafosfamide', 'Z-7557']",,NER_API,[],0
tandutinib,C-kit inhibitor; Flt-3 antagonist; Platelet-derived growth factor receptor kinase inhibitor,tandutinib,,tandutinib,tandutinib,fexact,"['C2403-47', 'MLN-0518', 'MLN-518', 'anti-Flt3 program, Millennium', 'anti-Flt3 program', 'CT-53518', 'tandutinib']",tandutinib,fexact,"['c2403 47', 'mln 0518', 'mln 518', 'anti flt3 program millennium', 'anti flt3 program', 'ct 53518', 'tandutinib']",correct_mapping
aminophylline,Adenosine A1 receptor antagonist; Adenosine A2a receptor antagonist; Phosphodiesterase inhibitor,aminophylline,,,,0,['aminophylline'],,0,[],0
JNK-401,JNK inhibitor,JNK-401,,JNK-401,jnk 401,fexact,"['JNK-401', 'CC-401']",JNK-401,fexact,"['jnk 401', 'cc 401']",correct_mapping
LOR-2040,Ribonucleoside triphosphate reductase inhibitor,LOR-2040,,LOR-2040,lor 2040,fexact,"['GTI-2040', 'R2 ribonucleotide reductase mRNA antisense oligo, Lorus', 'LOR-2040']",LOR-2040,fexact,"['gti 2040', 'r2 ribonucleotide reductase mrna antisense oligo lorus', 'lor 2040']",correct_mapping
"aminopterin (tablet), Syntrix",DNA synthesis inhibitor; Dihydrofolate reductase inhibitor,aminopterin,Syntrix,aminopterin (oral),aminopterin,fexact,"['aminopterin, University of Texas/', 'NSC-739', 'aminopterin (oral)', 'aminopterin (oral), Syntrix Biosystems', 'Aminopterin', 'aminopterin,/', 'LD-aminopterin', 'aminotrexate, Syntrix Biosystems', 'aminopterin, University of Medicine & Dentistry of New Jersey', 'aminotrexate']",aminopterin (oral),fexact,"['aminopterin university of texas', 'nsc 739', 'aminopterin oral', 'aminopterin oral syntrix biosystems', 'aminopterin', 'aminopterin', 'ld aminopterin', 'aminotrexate syntrix biosystems', 'aminopterin university of medicine dentistry of new jersey', 'aminotrexate']",correct_mapping
yttrium Y 90 humanized monoclonal antibody M195,Unidentified pharmacological activity,yttrium Y 90 humanized monoclonal antibody M195,,,,0,['yttrium Y 90 humanized monoclonal antibody M195'],,0,[],0
valspodar,P glycoprotein inhibitor,valspodar,,valspodar,valspodar,fexact,"['SDZ-PSC-833', 'valspodar', 'NSC-648265', 'Amdray', 'SDZ-214-103', 'PSC-833']",valspodar,fexact,"['sdz psc 833', 'valspodar', 'nsc 648265', 'amdray', 'sdz 214 103', 'psc 833']",correct_mapping
omacetaxine mepesuccinate (IV),Angiogenesis inhibitor; Apoptosis stimulant,omacetaxine mepesuccinate,,omacetaxine mepesuccinate,omacetaxine mepesuccinate,fexact,"['omacetaxine mepesuccinate', 'NSC-141633', 'homoharringtonine']",omacetaxine mepesuccinate,fexact,"['omacetaxine mepesuccinate', 'nsc 141633', 'homoharringtonine']",correct_mapping
apolizumab,Apoptosis stimulant; MHC Class II antagonist,apolizumab,,apolizumab,apolizumab,fexact,"['SMART 1D10 MAb, Protein Design Labs', 'apolizumab', 'Remitogen', 'hu 1D10', 'SMART anti-B cell lymphoma', 'Hu1D10']",apolizumab,fexact,"['smart 1d10 mab protein design labs', 'apolizumab', 'remitogen', 'hu 1d10', 'smart anti b cell lymphoma', 'hu1d10']",correct_mapping
raltitrexed,Thymidylate synthase inhibitor,raltitrexed,,raltitrexed,raltitrexed,fexact,"['raltitrexed', 'D-1694', 'ICI-D-1694', 'TDX', 'ZD-1694', 'Tomudex']",raltitrexed,fexact,"['raltitrexed', 'd 1694', 'ici d 1694', 'tdx', 'zd 1694', 'tomudex']",correct_mapping
BMS-214662,Farnesyltransferase inhibitor,BMS-214662,,BMS-214662,bms 214662,fexact,"['BMS-206635', 'BMS-186511', 'BMS-214662', 'BMS-193269', 'Ras farnesyl transferase inhibitors, BMS']",BMS-214662,fexact,"['bms 206635', 'bms 186511', 'bms 214662', 'bms 193269', 'ras farnesyl transferase inhibitors bms']",correct_mapping
Leridistim,Granulocyte macrophage colony stimulating factor agonist; Interleukin 3 agonist,Leridistim,,,,0,"['MPO-1', 'SC-70935', 'MPO', 'leridistim', 'myelopoietin (1)']",,NER_API,[],0
remestemcel-L,Not applicable,remestemcel-L,,remestemcel-L,remestemcel l,fexact,"['human mesenchyma stem cell therapy (graft vesus host disease)', 'OTI-010', 'mesenchymal stem cell therapy (graft verses host disease)', 'mesenchymal stem cell therapy (bone marrow transplant peripheral blood support), Osiris', 'Ryoncil', 'mesenchymal stem cell therapy (GvHD)', 'MSC therapy (GvHD),/ Mochida', 'mesenchymal stem cell therapy (graft verses host disease), Osiris', 'MSC therapy (GvHD), Osiris', 'MSC therapy (graft verses host disease), Osiris', 'mesenchymal stem cell therapy (bone marrow transplant peripheral blood support)', 'MSC therapy (bone marrow transplant peripheral blood support)', 'MSC therapy (bone marrow transplant peripheral blood support), Osiris', 'Prochymal', 'MSC-100-IV', 'mesenchymal stem cell therapy (GvHD), Osiris', 'Temcell HS', 'MSC therapy (GvHD),/', 'JR-031', 'JR-0301', 'MSC therapy (GvHD)', 'MSC therapy (graft verses host disease)', 'JR-031EB', 'remestemcel-L', 'Allogen']",remestemcel-L,fexact,"['human mesenchyma stem cell therapy graft vesus host disease', 'oti 010', 'mesenchymal stem cell therapy graft verses host disease', 'mesenchymal stem cell therapy bone marrow transplant peripheral blood support osiris', 'ryoncil', 'mesenchymal stem cell therapy gvhd', 'msc therapy gvhd mochida', 'mesenchymal stem cell therapy graft verses host disease osiris', 'msc therapy gvhd osiris', 'msc therapy graft verses host disease osiris', 'mesenchymal stem cell therapy bone marrow transplant peripheral blood support', 'msc therapy bone marrow transplant peripheral blood support', 'msc therapy bone marrow transplant peripheral blood support osiris', 'prochymal', 'msc 100 iv', 'mesenchymal stem cell therapy gvhd osiris', 'temcell hs', 'msc therapy gvhd', 'jr 031', 'jr 0301', 'msc therapy gvhd', 'msc therapy graft verses host disease', 'jr 031eb', 'remestemcel l', 'allogen']",correct_mapping
zosuquidar trihydrochloride,P glycoprotein inhibitor,zosuquidar trihydrochloride,,zosuquidar,zosuquidar trihydrochloride,fexact,"['KAN-979', 'LY-395598', 'LY-395599', 'LY-389551', 'zosuquidar trihydrochloride', 'zosuquidar', 'LY-335979', 'LY-395597', 'multidrug resistance inhibitor', 'RS-33295-198']",zosuquidar,fexact,"['kan 979', 'ly 395598', 'ly 395599', 'ly 389551', 'zosuquidar trihydrochloride', 'zosuquidar', 'ly 335979', 'ly 395597', 'multidrug resistance inhibitor', 'rs 33295 198']",correct_mapping
Ologo,Angiogenesis stimulant,Ologo,,,,0,"['OLOGO, Caladrius', 'CLBS14-NORDA', 'CD34+ stem cell therapy (coronary artery disease),/', 'CD34+ stem cell therapy (myocardial ischemia), Caladrius Biosciences', 'CD34+ stem cell therapy, Northwestern University/', 'CD34+ stem cell therapy (myocardial ischemia), Shire', 'cd34+ stem cell therapy (myocardial ischemia/peripheral arterial occlusive disease)', 'CLBS-14', 'CD34+ stem cell therapy (myocardial ischemia/peripheral arterial occlusive disease), Northwestern University/', 'OLOGO', 'CD34+ stem cell therapy (myocardial ischemia)', 'CD34+ stem cell therapy (coronary artery disease), Northwestern/', 'cd34+ stem cell therapy', 'CLBS-14, Caladrius Biosciences']",,Drug_API_mapping,[],0
BM-41,Unidentified pharmacological activity,BM-41,,BM-4,bm 41,fexact,"['BM-4', 'BM-41']",BM-4,fexact,"['bm 4', 'bm 41']",correct_mapping
TQB-2928,CD47 antagonist; Immuno-oncology therapy; Signal regulatory protein alpha antagonist,TQB-2928,,TQB-2928,tqb 2928,fexact,"['CD47 checkpoint inhibitor/SIRPa checkpoint inhibitor (solid tumors/hematologic malignancies)', 'CD47-SIRPalpha interaction inhibitors (solid tumors/hematologic malignancies)', 'TQB-2928']",TQB-2928,fexact,"['cd47 checkpoint inhibitor sirpa checkpoint inhibitor solid tumors hematologic malignancies', 'cd47 sirpalpha interaction inhibitors solid tumors hematologic malignancies', 'tqb 2928']",correct_mapping
seclidemstat,Lysine (K)-specific demethylase 1A inhibitor,seclidemstat,,seclidemstat,seclidemstat,fexact,"['seclidemstat', 'SP-2577', 'seclidemstat mesylate', 'LSD1 reversible inhibitor (oral tablet, cancer)']",seclidemstat,fexact,"['seclidemstat', 'sp 2577', 'seclidemstat mesylate', 'lsd1 reversible inhibitor oral tablet cancer']",correct_mapping
"ToleroVax, REGiMMUNE",CD1D agonist,ToleroVax,REGiMMUNE,RGI-2001,tolerovax,fexact,"['RGI-7000', 'RGI-2001', 'ToleroVax', 'T-cell modulator (transplant rejection/autoimmune disease)', 'krn-7000, liposomal formulation (autoimmune disease)', 'Multivax platform', 'KRN-7000']",RGI-2001,fexact,"['rgi 7000', 'rgi 2001', 'tolerovax', 't cell modulator transplant rejection autoimmune disease', 'krn 7000 liposomal formulation autoimmune disease', 'multivax platform', 'krn 7000']",correct_mapping
NMS-P948,Colony stimulating factor 1 receptor antagonist; C-kit inhibitor; Flt-3 antagonist; Immuno-oncology therapy,NMS-P948,,NMS-088,nms p948,fexact,"['NMS-03592088', 'NMS-P088', 'NMS-088', 'dual Flt3/Kit inhibitor (cancer)', 'NMS-P948']",NMS-088,fexact,"['nms 03592088', 'nms p088', 'nms 088', 'dual flt3 kit inhibitor cancer', 'nms p948']",correct_mapping
PRGN-3006,Interleukin 15 agonist; CD33 antagonist; T cell stimulant; Immuno-oncology therapy,PRGN-3006,,PRGN-3006,prgn 3006,fexact,"['PRGN-3006 UltraCAR-T', 'non-viral adoptive CAR T-cell therapy with mbIL15 (acute myeloid leukemia/higher risk myelodysplastic syndrome)', 'CAR T-cell therapy/IL-15 (non-viral Sleeping Beauty/UltraCAR-T, acute myeloid leukemia/higher risk myelodysplastic syndrome)', 'PRGN-3006', 'CAR T-cell therapy co-expressing membrane-bound IL-15 (acute myelogenous leukemia/myelodysplastic syndrome)']",PRGN-3006,fexact,"['prgn 3006 ultracar t', 'non viral adoptive car t cell therapy with mbil15 acute myeloid leukemia higher risk myelodysplastic syndrome', 'car t cell therapy il 15 non viral sleeping beauty ultracar t acute myeloid leukemia higher risk myelodysplastic syndrome', 'prgn 3006', 'car t cell therapy co expressing membrane bound il 15 acute myelogenous leukemia myelodysplastic syndrome']",correct_mapping
azercabtagene zapreleucel,T cell stimulant; Immuno-oncology therapy,azercabtagene zapreleucel,,azercabtagene zapreleucel,azercabtagene zapreleucel,fexact,"['allogeneic CAR T-cell therapy (ARCUS, cancer),/ Precision BioSciences', 'anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia),/Shire', 'anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia),/', 'azercabtagene zapreleucel', 'allogeneic CAR T-cell therapy (ARCUS, cancer), Shire/', 'PBCAR-0191', 'allogeneic CAR T-cell therapy (ARCUS, cancer), Shire/Precision BioSciences', 'anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia), Precision BioSciences/Shire', 'allogeneic CAR T-cell therapy (ARCUS, cancer),/']",azercabtagene zapreleucel,fexact,"['allogeneic car t cell therapy arcus cancer precision biosciences', 'anti cd19 car t cell therapy acute lymphoblastic leukemia shire', 'anti cd19 car t cell therapy acute lymphoblastic leukemia', 'azercabtagene zapreleucel', 'allogeneic car t cell therapy arcus cancer shire', 'pbcar 0191', 'allogeneic car t cell therapy arcus cancer shire precision biosciences', 'anti cd19 car t cell therapy acute lymphoblastic leukemia precision biosciences shire', 'allogeneic car t cell therapy arcus cancer']",correct_mapping
ApoGraft,Not applicable,ApoGraft,,,,0,['ApoGraft'],,0,[],0
T-cell depleted PBSC,Not applicable,T-cell depleted PBSC,,,,0,['T-cell depleted PBSC'],,0,[],0
Tebrazid,Unidentified pharmacological activity,Tebrazid,,,,0,['Tebrazid'],,0,[],0
linezolid,Protein 50S ribosomal subunit inhibitor; Protein synthesis inhibitor,linezolid,,linezolid,linezolid,fexact,"['PNU-100766', 'Zyvoxa', 'PNU-10766SS', 'PNU-10766', 'Gabriox', 'Zyvoxid', 'U-100766', 'linezolid', 'PNU-766-INF-0026', 'MDL 100766', 'Zyvox']",linezolid,fexact,"['pnu 100766', 'zyvoxa', 'pnu 10766ss', 'pnu 10766', 'gabriox', 'zyvoxid', 'u 100766', 'linezolid', 'pnu 766 inf 0026', 'mdl 100766', 'zyvox']",correct_mapping
delamanid,Cell wall synthesis inhibitor,delamanid,,delamanid,delamanid,fexact,"['2-nitroimidazole derivatives (tuberculosis), Otsuka', 'nitro-dihydroimidazo-oxazole derivatives (tuberculosis)', '2-nitroimidazole derivatives (tuberculosis)', 'nitro-dihydroimidazo-oxazole derivatives (tuberculosis), Otsuka', 'delamanid', 'Deltyba', 'OPC-67683']",delamanid,fexact,"['2 nitroimidazole derivatives tuberculosis otsuka', 'nitro dihydroimidazo oxazole derivatives tuberculosis', '2 nitroimidazole derivatives tuberculosis', 'nitro dihydroimidazo oxazole derivatives tuberculosis otsuka', 'delamanid', 'deltyba', 'opc 67683']",correct_mapping
candesartan,Angiotensin II 1 antagonist,candesartan,,candesartan,candesartan,fexact,"['Tiadyl', 'TCV-116', 'Atacand', 'Bliopress', 'Blopres', 'Amias', 'Parapres', 'candesartan', 'candesartan cilexetil', 'Blopress', 'H-212/91', 'candesartan cilexetil (hypertension/cardiac failure), AstraZeneca/Cheplapharm', 'candesartan cilexetil (hypertension/cardiac failure),/Cheplapharm', 'candesartan cilexetil (hypertension/cardiac failure),/', 'Kenzen']",candesartan,fexact,"['tiadyl', 'tcv 116', 'atacand', 'bliopress', 'blopres', 'amias', 'parapres', 'candesartan', 'candesartan cilexetil', 'blopress', 'h 212 91', 'candesartan cilexetil hypertension cardiac failure astrazeneca cheplapharm', 'candesartan cilexetil hypertension cardiac failure cheplapharm', 'candesartan cilexetil hypertension cardiac failure', 'kenzen']",correct_mapping
UCART-19,T cell stimulant; Immuno-oncology therapy; Genome editing,UCART-19,,UCART-19,ucart 19,fexact,"['UCART-19', 'anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Servier/', 'allogeneic T-cell therapy (leukemia)', 'allogeneic T-cell therapy (leukemia), Cellectis', 'S-68587', 'anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia)', 'anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), Servier/Pfizer']",UCART-19,fexact,"['ucart 19', 'anti cd19 car t cell therapy b cell acute lymphoblastic leukemia servier', 'allogeneic t cell therapy leukemia', 'allogeneic t cell therapy leukemia cellectis', 's 68587', 'anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'anti cd19 car t cell therapy b cell acute lymphoblastic leukemia servier pfizer']",correct_mapping
bosutinib (tablet),Abl receptor tyrosine kinase inhibitor; Bcr-Abl inhibitor; Src inhibitor; Apoptosis stimulant,bosutinib,,bosutinib,bosutinib,fexact,"['SKI-971', 'PF-05208763', 'PF-5208763', 'Src kinase inhibitors (oral)', 'Bcr-Abl kinase inhibitors, Wyeth', 'Src kinase inhibitors (oral), Wyeth', 'SKI-758', 'Bosulif', 'SKI-606', 'Boslif', 'SKI-015', 'Bcr-Abl kinase inhibitors, Pfizer', 'Bcr-Abl kinase inhibitors', 'Src kinase inhibitors (oral), Wyeth-Ayerst', 'Src kinase inhibitors (oral), Pfizer', 'bosutinib']",bosutinib,fexact,"['ski 971', 'pf 05208763', 'pf 5208763', 'src kinase inhibitors oral', 'bcr abl kinase inhibitors wyeth', 'src kinase inhibitors oral wyeth', 'ski 758', 'bosulif', 'ski 606', 'boslif', 'ski 015', 'bcr abl kinase inhibitors pfizer', 'bcr abl kinase inhibitors', 'src kinase inhibitors oral wyeth ayerst', 'src kinase inhibitors oral pfizer', 'bosutinib']",correct_mapping
brexucabtagene autoleucel,T cell stimulant; Immuno-oncology therapy,brexucabtagene autoleucel,,brexucabtagene autoleucel,brexucabtagene autoleucel,fexact,"['anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma), Kite Pharma', 'brexucabtagene autoleucel', 'eACT (cancer), Kite Pharma', 'Brexu-cel', 'Tecartus', 'KTE-X19', 'eACT (cancer)', 'anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma)']",brexucabtagene autoleucel,fexact,"['anti cd19 car t cell therapy non hodgkin lymphoma kite pharma', 'brexucabtagene autoleucel', 'eact cancer kite pharma', 'brexu cel', 'tecartus', 'kte x19', 'eact cancer', 'anti cd19 car t cell therapy non hodgkin lymphoma']",correct_mapping
pasireotide,Somatostatin receptor 1 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 3 agonist; Somatostatin receptor 5 agonist,pasireotide,,pasireotide diaspartate,pasireotide,fexact,"[""somatostatin analog (neuroendocrine tumors/acromegaly/Cushing's disease)"", 'SOM-230B', 'Signifor', 'pasireotide', 'pasireotide diaspartate', 'SOM-230']",pasireotide diaspartate,fexact,"['somatostatin analog neuroendocrine tumors acromegaly cushing s disease', 'som 230b', 'signifor', 'pasireotide', 'pasireotide diaspartate', 'som 230']",correct_mapping
sitagliptin phosphate,Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue,sitagliptin phosphate,,sitagliptin,sitagliptin phosphate,fexact,"['dipeptidyl peptidase IV inhibitors, Merck & Co', 'ONO-5345', 'sitagliptin phosphate monohydrate', 'Glactiv', 'Januvia', 'DPP-IV inhibitors', 'dipeptidyl peptidase IV inhibitors', 'DPP-IV inhibitors, Merck & Co', 'sitagliptin phosphate', 'sitagliptin', 'Xelevia', 'Ristaben', 'Tesavel', 'MK-0431', 'ONO-5435', 'MK-431']",sitagliptin,fexact,"['dipeptidyl peptidase iv inhibitors merck co', 'ono 5345', 'sitagliptin phosphate monohydrate', 'glactiv', 'januvia', 'dpp iv inhibitors', 'dipeptidyl peptidase iv inhibitors', 'dpp iv inhibitors merck co', 'sitagliptin phosphate', 'sitagliptin', 'xelevia', 'ristaben', 'tesavel', 'mk 0431', 'ono 5435', 'mk 431']",correct_mapping
Mirabegron,Beta 3 adrenoreceptor agonist,Mirabegron,,mirabegron,mirabegron,fexact,"['YM-178', 'mirabegron', 'EB-178', 'solifenacin + mirabegron', 'beta-3 adrenoceptor agonists (diabetes/obesity)', 'Betanis', 'YM-178 OCAS', 'Myrbetriq', 'Betmiga', 'YM-178 OCAS-X', 'YM-178 OCAS-M', 'mirabegron OCAS', 'beta-3 adrenoceptor agonists (diabetes/obesity), Yamanouchi']",mirabegron,fexact,"['ym 178', 'mirabegron', 'eb 178', 'solifenacin mirabegron', 'beta 3 adrenoceptor agonists diabetes obesity', 'betanis', 'ym 178 ocas', 'myrbetriq', 'betmiga', 'ym 178 ocas x', 'ym 178 ocas m', 'mirabegron ocas', 'beta 3 adrenoceptor agonists diabetes obesity yamanouchi']",correct_mapping
momelotinib,Activin receptor-like kinase 2 inhibitor; Janus kinase 1 inhibitor; Janus kinase 2 inhibitor,momelotinib,,momelotinib,momelotinib,fexact,"['JAK2 tyrosine kinase inhibitors (cardiovascular disease)', 'JAK2 tyrosine kinase inhibitors (cancer/cardiovascular disease/myeloproliferative disorder)', 'JAK tyrosine kinase inhibitors (cardiovascular disease),/Myomatrix', 'CYT-387', 'JAK2 tyrosine kinase inhibitors (cardiovascular disease),/Myomatrix', 'GS-0387', 'momelotinib', 'momelotinib dihydrochloride']",momelotinib,fexact,"['jak2 tyrosine kinase inhibitors cardiovascular disease', 'jak2 tyrosine kinase inhibitors cancer cardiovascular disease myeloproliferative disorder', 'jak tyrosine kinase inhibitors cardiovascular disease myomatrix', 'cyt 387', 'jak2 tyrosine kinase inhibitors cardiovascular disease myomatrix', 'gs 0387', 'momelotinib', 'momelotinib dihydrochloride']",correct_mapping
JCAR-014,T cell stimulant; Immuno-oncology therapy,JCAR-014,,JCAR-014,jcar 014,fexact,"['anti-CD19 autologous T-cell therapy (B-cell malignancies)', 'anti-CD19 CAR autologous T-cell therapy (B-cell malignancies)', 'anti-CD19 CAR T-cell therapy (cancer)', 'anti-CD19 CAR autologous T-cell therapy (B-cell malignancies), NCI', 'anti-CD19 CAR T-cell therapy (cancer), Juno Therapeutics', 'JCAR-014', 'anti-CD19 CAR T-cell therapy (B-cell malignancies)', 'anti-CD19 autologous T-cell therapy (B-cell malignancies), National Cancer Institute', 'anti-CD19 CAR T-cell therapy (B-cell malignancies), NCI']",JCAR-014,fexact,"['anti cd19 autologous t cell therapy b cell malignancies', 'anti cd19 car autologous t cell therapy b cell malignancies', 'anti cd19 car t cell therapy cancer', 'anti cd19 car autologous t cell therapy b cell malignancies nci', 'anti cd19 car t cell therapy cancer juno therapeutics', 'jcar 014', 'anti cd19 car t cell therapy b cell malignancies', 'anti cd19 autologous t cell therapy b cell malignancies national cancer institute', 'anti cd19 car t cell therapy b cell malignancies nci']",correct_mapping
insulin glargine,Long-acting insulin,insulin glargine,,insulin glargine,insulin glargine,fexact,"['Lantus SoloStar', 'Hoe-901', 'recombinant insulin analog', 'Lantus AllSTAR', 'Lantus', 'Lantus ClikSTAR', 'Optisulin', 'insulin glargine', 'U100', 'Gla-100']",insulin glargine,fexact,"['lantus solostar', 'hoe 901', 'recombinant insulin analog', 'lantus allstar', 'lantus', 'lantus clikstar', 'optisulin', 'insulin glargine', 'u100', 'gla 100']",correct_mapping
insulin glulisine (SC),Rapid-acting insulin,insulin glulisine,,insulin glulisine,insulin glulisine,fexact,"['HMR-1153', 'Apidra', 'HMR-1423', 'Glulisine', 'Apidra ClikStar', '1964', 'insulin glulisine', 'Apidra SoloStar', 'insulin analogs', 'Shorant', 'HMR-1964']",insulin glulisine,fexact,"['hmr 1153', 'apidra', 'hmr 1423', 'glulisine', 'apidra clikstar', '1964', 'insulin glulisine', 'apidra solostar', 'insulin analogs', 'shorant', 'hmr 1964']",correct_mapping
undisclosed - insulin,Insulin receptor agonist,undisclosed - insulin,,,,0,['undisclosed - insulin'],,0,[],0
"asparaginase, recombinant, Medac",Protein synthesis inhibitor; Asparaginase stimulant; Apoptosis stimulant,asparaginase,Medac,asparaginase,asparaginase,fexact,"['Spectrila', 'asparaginase']",asparaginase,fexact,"['spectrila', 'asparaginase']",correct_mapping
"asparaginase, Medac",Asparaginase stimulant,asparaginase,Medac,asparaginase,asparaginase,fexact,"['Spectrila', 'asparaginase']",asparaginase,fexact,"['spectrila', 'asparaginase']",correct_mapping
CYT107,Interleukin 7 agonist; Immunostimulant,CYT107,,CYT-107,cyt 107,fuzzy,"['CYT-99007', 'CYT-107', 'interleukin-7, Cytheris', 'Glycosylated rhIL-7', 'IL-7, Cytheris', 'glyco-rhIL-7']",CYT-107,fexact,"['cyt 99007', 'cyt 107', 'interleukin 7 cytheris', 'glycosylated rhil 7', 'il 7 cytheris', 'glyco rhil 7']",incorrect_mapping
lovastatin,HMGCoA reductase inhibitor,lovastatin,,lovastatin,lovastatin,fexact,"['lovastatin', 'Mevacor']",lovastatin,fexact,"['lovastatin', 'mevacor']",correct_mapping
famotidine (IV),Histamine H2 receptor antagonist,famotidine,,famotidine,famotidine,fexact,"['Quamatel', 'Pepcid Complete', 'famotidine', 'Gaster OD', 'Pepcid', 'YM-1170', 'Famodine']",famotidine,fexact,"['quamatel', 'pepcid complete', 'famotidine', 'gaster od', 'pepcid', 'ym 1170', 'famodine']",correct_mapping
busulfan (intrathecal),DNA inhibitor,busulfan,,Busulfex,busulfan,fexact,"['busulfan, MD Anderson', 'KRN-246', 'KER-246', 'Myleran', 'busulfan, Orphan Medical', 'Busilvex', 'busulfan', 'Busulfex', 'Busulfanex']",Busulfex,fexact,"['busulfan md anderson', 'krn 246', 'ker 246', 'myleran', 'busulfan orphan medical', 'busilvex', 'busulfan', 'busulfex', 'busulfanex']",correct_mapping
"leukaemia vaccine, MD Anderson",Immunostimulant,leukaemia vaccine,MD Anderson,GSK-2130579A,leukemia vaccine,fuzzy,"['WT1 ASCI', 'WT1 vaccine', 'WT1 antigen specific cancer immunotherapeutic', 'leukemia vaccine', 'GSK-2130579A']",GSK-2130579A,fexact,"['wt1 asci', 'wt1 vaccine', 'wt1 antigen specific cancer immunotherapeutic', 'leukemia vaccine', 'gsk 2130579a']",incorrect_mapping
EM-1421 (IV),Cyclin-dependent kinase 1 inhibitor; Apoptosis stimulant; Survivin inhibitor; Cell cycle inhibitor,EM-1421,,"terameprocol (injectable, cancer, influenza)",em 1421,fexact,"['methylated NDGA,/BioCure', 'methylated NDGAs, Johns Hopkins', 'Mal.4', 'EM-1421', 'terameprocol', 'terameprocol (injectable, cancer, influenza)', 'methylated NDGAs', 'methylated NDGA,/', 'methylated NDGA, Johns Hopkins/BioCure', 'nordihydroguaiaretic acid derivatives', 'methylated NDGA, Johns Hopkins/', 'M4N']","terameprocol (injectable, cancer, influenza)",fexact,"['methylated ndga biocure', 'methylated ndgas johns hopkins', 'mal 4', 'em 1421', 'terameprocol', 'terameprocol injectable cancer influenza', 'methylated ndgas', 'methylated ndga', 'methylated ndga johns hopkins biocure', 'nordihydroguaiaretic acid derivatives', 'methylated ndga johns hopkins', 'm4n']",correct_mapping
ALD-151,Not applicable,ALD-151,,ALD-151,ald 151,fexact,"['ALDHbr Umbilical Cord Blood Cells', 'ALD-151', 'stem cell therapy (leukemia), Nuo Therapeutics', 'stem cell therapy (leukemia)']",ALD-151,fexact,"['aldhbr umbilical cord blood cells', 'ald 151', 'stem cell therapy leukemia nuo therapeutics', 'stem cell therapy leukemia']",correct_mapping
CSL-360,Interleukin 3 receptor antagonist,CSL-360,,talacotuzumab,csl 360,fexact,"['talacotuzumab', 'therapeutic leukaemia antibody (AML)', 'anti-CD123 mAb (acute myelogenous leukemia)', 'anti-IL3R alpha chain mAb (AML)', 'CSL-360', 'JNJ-56022473', 'CD-123', 'CSL-362', 'anti-CD123 mAb (acute myelogenous leukemia), Janssen', '7G3', 'anti-IL3R alpha chain mAb (AML), Janssen']",talacotuzumab,fexact,"['talacotuzumab', 'therapeutic leukaemia antibody aml', 'anti cd123 mab acute myelogenous leukemia', 'anti il3r alpha chain mab aml', 'csl 360', 'jnj 56022473', 'cd 123', 'csl 362', 'anti cd123 mab acute myelogenous leukemia janssen', '7g3', 'anti il3r alpha chain mab aml janssen']",correct_mapping
Indium 111 AHN-12,CD45 antagonist,Indium 111 AHN-12,,,,0,['Indium 111 AHN-12'],,0,[],0
GM-CSF secreting leukemia cell vaccine,Granulocyte macrophage colony stimulating factor agonist; Immunostimulant; Immuno-oncology therapy,GM-CSF secreting leukemia cell vaccine,,,,0,['GM-CSF secreting leukemia cell vaccine'],,0,[],0
troxacitabine,DNA directed DNA polymerase inhibitor,troxacitabine,,troxacitabine,troxacitabine,fexact,"['BCH-4556', 'SPD-758', 'troxacitabine', 'L-OddC', 'Troxatyl']",troxacitabine,fexact,"['bch 4556', 'spd 758', 'troxacitabine', 'l oddc', 'troxatyl']",correct_mapping
CB-001,Stem cell growth factor agonist,CB-001,,CB-001,cb 001,fexact,"['CB-001', 'stem cells']",CB-001,fexact,"['cb 001', 'stem cells']",correct_mapping
pixantrone,DNA inhibitor; DNA topoisomerase II inhibitor,pixantrone,,Pixuvri,pixantrone,fexact,"['Pixuvri', ""second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis), Roche/ Cell Therapeutics"", ""second-generation anthracenedione analog (iv, non hodgkin's lymphoma/ multiple sclerosis), roche"", 'pixantrone dimaleate', ""second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis), CTI BioPharma Corp"", ""second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis),/ Cell Therapeutics"", ""second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis), Cell Therapeutics"", 'BBR-2778', ""second-generation anthracenedione analog (iv, non hodgkin's lymphoma/ multiple sclerosis)"", 'pixantrone', ""second-generation anthracenedione analog (iv, non Hodgkin's lymphoma/ multiple sclerosis), Roche/CTI BioPharma Corp""]",Pixuvri,fexact,"['pixuvri', 'second generation anthracenedione analog iv non hodgkin s lymphoma multiple sclerosis roche cell therapeutics', 'second generation anthracenedione analog iv non hodgkin s lymphoma multiple sclerosis roche', 'pixantrone dimaleate', 'second generation anthracenedione analog iv non hodgkin s lymphoma multiple sclerosis cti biopharma corp', 'second generation anthracenedione analog iv non hodgkin s lymphoma multiple sclerosis cell therapeutics', 'second generation anthracenedione analog iv non hodgkin s lymphoma multiple sclerosis cell therapeutics', 'bbr 2778', 'second generation anthracenedione analog iv non hodgkin s lymphoma multiple sclerosis', 'pixantrone', 'second generation anthracenedione analog iv non hodgkin s lymphoma multiple sclerosis roche cti biopharma corp']",correct_mapping
DT388GMCSF,Unidentified pharmacological activity,DT388GMCSF,,DTGM,dt388 gm csf,fuzzy,"['truncated diphtheria toxin-GM-CSF, Univ South Carolina', 'DTGM', 'DT388-GM-CSF']",DTGM,fexact,"['truncated diphtheria toxin gm csf univ south carolina', 'dtgm', 'dt388 gm csf']",incorrect_mapping
Flt3 ligand,Platelet-derived growth factor receptor agonist,Flt3 ligand,,CDX-301,flt 3 ligand,fuzzy,"['Flt3L', 'Flt-3/Flk-2 ligand', 'Flt-3 ligand (sc, cancer, NSCLC, stem cell transplantation, B-cell lymphoma, metastatic melanoma, autoimmune disease/prostate cancer)', 'Flt-3 ligand', 'Flt-3 ligand (sc, cancer/NSCLC/stem cell transplantation/B-cell lymphoma/metastatic melanoma/autoimmune disease/pancreatic ductal adenocarcinoma)', 'Flt-3 ligand (stem cell mobilizer)', 'Mobista', 'Mobist', 'CDX-301', 'Flt-3/Flk-2 ligand, Immunex', 'Flt-3 ligand (stem cell mobilizer), Viacell', 'Flt-3 ligand, Immunex', 'Flt-3 ligand (sc, cancer, NSCLC, stem cell transplantation, B-cell lymphoma, metastatic melanoma, autoimmune disease)', 'Moblsta', 'Flt-3 ligand, Amgen', 'rhuFlt3L']",CDX-301,fexact,"['flt3l', 'flt 3 flk 2 ligand', 'flt 3 ligand sc cancer nsclc stem cell transplantation b cell lymphoma metastatic melanoma autoimmune disease prostate cancer', 'flt 3 ligand', 'flt 3 ligand sc cancer nsclc stem cell transplantation b cell lymphoma metastatic melanoma autoimmune disease pancreatic ductal adenocarcinoma', 'flt 3 ligand stem cell mobilizer', 'mobista', 'mobist', 'cdx 301', 'flt 3 flk 2 ligand immunex', 'flt 3 ligand stem cell mobilizer viacell', 'flt 3 ligand immunex', 'flt 3 ligand sc cancer nsclc stem cell transplantation b cell lymphoma metastatic melanoma autoimmune disease', 'moblsta', 'flt 3 ligand amgen', 'rhuflt3l']",incorrect_mapping
MK-0752,Protease/peptidase inhibitor; Secretase gamma inhibitor; Notch pathway inhibitor,MK-0752,,MK-0752,mk 0752,fexact,"['Notch signalling pathway inhibitor', 'MK-0752', 'MK-752', 'c-7617']",MK-0752,fexact,"['notch signalling pathway inhibitor', 'mk 0752', 'mk 752', 'c 7617']",correct_mapping
R-XK469,DNA topoisomerase II inhibitor; Cell cycle inhibitor,R-XK469,,,,0,['R-XK469'],,0,[],0
Atgam,Immunosuppressant,Atgam,,Equine antithymocyte immunoglobulin,atgam,fexact,"['PF-06462700', 'lymphocyte immune globulin, anti-thymocyte globulin (equine), Pharmacia & Upjohn', 'Atgam', 'lymphocyte immune globulin, anti-thymocyte globulin (equine)', 'anti-thymocyte equine immunoglobulin C-15 (aplastic anemia)', 'Equine antithymocyte immunoglobulin']",Equine antithymocyte immunoglobulin,fexact,"['pf 06462700', 'lymphocyte immune globulin anti thymocyte globulin equine pharmacia upjohn', 'atgam', 'lymphocyte immune globulin anti thymocyte globulin equine', 'anti thymocyte equine immunoglobulin c 15 aplastic anemia', 'equine antithymocyte immunoglobulin']",correct_mapping
B43-genistein,Tyrosine kinase inhibitor (TKI),B43-genistein,,B43-genistein,b43 genistein,fexact,['B43-genistein'],B43-genistein,fexact,['b43 genistein'],correct_mapping
Traumeel S,Unidentified pharmacological activity,Traumeel S,,,,0,['Traumeel S'],,0,[],0
lintuzumab-gelonin,Protein synthesis inhibitor,lintuzumab-gelonin,,,,0,['lintuzumab-gelonin'],,0,[],0
HuM195-Bi-213,DNA inhibitor; CD33 antagonist; Radiopharmaceutical,HuM195-Bi-213,,213Bi-lintuzumab,hum 195 bi 213,fuzzy,"['bismuth-213-HuM195', 'alpha-particle-emitting radioisotope-linked lintuzumab', 'SMART bismuth-213-M195', 'SMART Y90-M195', 'SMART 213Bi-M195', 'yttrium-90-HuM195', 'Y90-HuM195', 'HuM-195-Bi-213', 'Bismab-A', '213Bi-lintuzumab', '213Bi-HuM195']",213Bi-lintuzumab,fexact,"['bismuth 213 hum195', 'alpha particle emitting radioisotope linked lintuzumab', 'smart bismuth 213 m195', 'smart y90 m195', 'smart 213bi m195', 'yttrium 90 hum195', 'y90 hum195', 'hum 195 bi 213', 'bismab a', '213bi lintuzumab', '213bi hum195']",incorrect_mapping
sodium salicylate,Prostaglandin synthase inhibitor,sodium salicylate,,,,0,['sodium salicylate'],,0,[],0
RFT5-SMPT-dgA,T cell inhibitor,RFT5-SMPT-dgA,,,,0,['RFT5-SMPT-dgA'],,0,[],0
trimetrexate (IV),Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor,trimetrexate,,trimetrexate,trimetrexate,fexact,"['NSC-249008', 'NSC-328564', 'CI-898', 'NSC-352122', 'trimetrexate', 'TMQ', 'NeuTrexin', 'trimetrexate glucuronate', 'JB-11']",trimetrexate,fexact,"['nsc 249008', 'nsc 328564', 'ci 898', 'nsc 352122', 'trimetrexate', 'tmq', 'neutrexin', 'trimetrexate glucuronate', 'jb 11']",correct_mapping
trimetrexate (oral),Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor,trimetrexate,,trimetrexate,trimetrexate,fexact,"['NSC-249008', 'NSC-328564', 'CI-898', 'NSC-352122', 'trimetrexate', 'TMQ', 'NeuTrexin', 'trimetrexate glucuronate', 'JB-11']",trimetrexate,fexact,"['nsc 249008', 'nsc 328564', 'ci 898', 'nsc 352122', 'trimetrexate', 'tmq', 'neutrexin', 'trimetrexate glucuronate', 'jb 11']",correct_mapping
TP-0184,Bone morphogenetic protein receptor type IA inhibitor; Activin receptor-like kinase 2 inhibitor,TP-0184,,TP-0184,tp 0184,fexact,"['TP-0184', 'ALK2 inhibitor (oral, solid tumors), Tolero Pharmaceuticals', 'ALK2 inhibitor (oral, solid tumors)', 'itacnosertib', 'ALK2 inhibitors (anemia), Tolero Pharmaceuticals', 'ALK2 inhibitors (anemia)']",TP-0184,fexact,"['tp 0184', 'alk2 inhibitor oral solid tumors tolero pharmaceuticals', 'alk2 inhibitor oral solid tumors', 'itacnosertib', 'alk2 inhibitors anemia tolero pharmaceuticals', 'alk2 inhibitors anemia']",correct_mapping
"candesartan cilexetil, CJ Cheiljedang",Angiotensin II 1 antagonist,candesartan cilexetil,CJ Cheiljedang,candesartan,candesartan cilexetil,fexact,"['Tiadyl', 'TCV-116', 'Atacand', 'Bliopress', 'Blopres', 'Amias', 'Parapres', 'candesartan', 'candesartan cilexetil', 'Blopress', 'H-212/91', 'candesartan cilexetil (hypertension/cardiac failure), AstraZeneca/Cheplapharm', 'candesartan cilexetil (hypertension/cardiac failure),/Cheplapharm', 'candesartan cilexetil (hypertension/cardiac failure),/', 'Kenzen']",candesartan,fexact,"['tiadyl', 'tcv 116', 'atacand', 'bliopress', 'blopres', 'amias', 'parapres', 'candesartan', 'candesartan cilexetil', 'blopress', 'h 212 91', 'candesartan cilexetil hypertension cardiac failure astrazeneca cheplapharm', 'candesartan cilexetil hypertension cardiac failure cheplapharm', 'candesartan cilexetil hypertension cardiac failure', 'kenzen']",correct_mapping
"CD45RA-depleted allogeneic peripheral blood mononuclear cells, unspecified",Not applicable,CD45RA-depleted allogeneic peripheral blood mononuclear cells,unspecified,,,0,['CD45RA-depleted allogeneic peripheral blood mononuclear cells'],,0,[],0
Gardasil 9,Immunostimulant,Gardasil 9,,Gardasil 9,gardasil 9,fexact,"['Gardasil 9', '9vHPV', '9-valent HPV vaccine', '9-valent HPV vaccine, Merck', 'human papillomavirus vaccine (nonavalent)', 'human papillomavirus vaccine (nonavalent), Merck & Co', 'V-503']",Gardasil 9,fexact,"['gardasil 9', '9vhpv', '9 valent hpv vaccine', '9 valent hpv vaccine merck', 'human papillomavirus vaccine nonavalent', 'human papillomavirus vaccine nonavalent merck co', 'v 503']",correct_mapping
"arsenic trioxide, Syros Pharmaceuticals",Cysteine protease stimulant; Apoptosis stimulant,arsenic trioxide,Syros Pharmaceuticals,"arsenic trioxide (oral, acute promyelocytic leukemia)",arsenic trioxide,fexact,"['ORH-2014', 'arsenic trioxide', 'SY-2101, Syros Pharmaceuticals', 'sy-2101', 'arsenic trioxide (oral, acute promyelocytic leukemia)']","arsenic trioxide (oral, acute promyelocytic leukemia)",fexact,"['orh 2014', 'arsenic trioxide', 'sy 2101 syros pharmaceuticals', 'sy 2101', 'arsenic trioxide oral acute promyelocytic leukemia']",correct_mapping
"HIV-1 vaccine, Crucell-3",Immunostimulant,HIV-1 vaccine,Crucell-3,,,0,['HIV-1 vaccine'],,0,[],0
"HIV vaccine, MVA, Crucell",Immunostimulant,HIV vaccine,Crucell,Gardasil,hpv vaccine,fuzzy,"['human papilloma virus vaccine,/Merck & Co', 'human papilloma virus vaccine,/', 'HPV vaccine (quadrivalent), Sanofi Pasteur MSD/', 'Silgard', 'V-501', 'HPV vaccine,/', 'HPV vaccine,/Merck & Co', 'V-501, Uniquest', 'human papillomavirus vaccine,/', 'human papillomavirus vaccine,/Merck & Co', 'HPV vaccine (quadrivalent), Aventis Pasteur MSD/', 'hpv vaccine (quadrivalent)', 'HPV vaccine (quadrivalent), Merck & Co', 'HPV vaccine (quadrivalent)', 'Gardasil']",Gardasil,fexact,"['human papilloma virus vaccine merck co', 'human papilloma virus vaccine', 'hpv vaccine quadrivalent sanofi pasteur msd', 'silgard', 'v 501', 'hpv vaccine', 'hpv vaccine merck co', 'v 501 uniquest', 'human papillomavirus vaccine', 'human papillomavirus vaccine merck co', 'hpv vaccine quadrivalent aventis pasteur msd', 'hpv vaccine quadrivalent', 'hpv vaccine quadrivalent merck co', 'hpv vaccine quadrivalent', 'gardasil']",incorrect_mapping
lenzilumab,Granulocyte macrophage colony stimulating factor antagonist,lenzilumab,,lenzilumab,lenzilumab,fexact,"['anti-GM-CSF mAb (autoimmune disease),/KaloBios', 'anti-GM-CSF mAb (neurotoxicity drug-induced/chronic myelomonocytic leukemia/COVID-19 pneumonia/graft versus host disease/diffuse large B-cell lymphoma)', 'KB-002', 'KB-003', 'lenzilumab', 'anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios', 'anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios']",lenzilumab,fexact,"['anti gm csf mab autoimmune disease kalobios', 'anti gm csf mab neurotoxicity drug induced chronic myelomonocytic leukemia covid 19 pneumonia graft versus host disease diffuse large b cell lymphoma', 'kb 002', 'kb 003', 'lenzilumab', 'anti gm csf mab autoimmune disease ludwig kalobios', 'anti gm csf mab inflammatory disease rheumatoid arthritis asthma kalobios']",correct_mapping
eculizumab,Complement factor C5 inhibitor,eculizumab,,eculizumab,eculizumab,fexact,"['eculizumab', 'h5G1.1scFv', 'C5 complement inhibitor (2)', '5G1.1', 'Soliris', 'h5G1.1']",eculizumab,fexact,"['eculizumab', 'h5g1 1scfv', 'c5 complement inhibitor 2', '5g1 1', 'soliris', 'h5g1 1']",correct_mapping
undisclosed - immunosuppressive drug,Immunosuppressant,undisclosed - immunosuppressive drug,,,,0,['undisclosed - immunosuppressive drug'],,0,[],0
"umbilical cord blood stem cells, unspecified",Not applicable,umbilical cord blood stem cells,unspecified,,,0,['umbilical cord blood stem cells'],,0,[],0
"human placental derived stem cells, unspecified",Not applicable,human placental derived stem cells,unspecified,,,0,['human placental derived stem cells'],,0,[],0
teniposide,DNA inhibitor; DNA topoisomerase II inhibitor; DNA repair enzyme inhibitor; Mitotic inhibitor,teniposide,,,,0,['teniposide'],,0,[],0
trazodone,Alpha 1 adrenoreceptor antagonist; 5 Hydroxytryptamine uptake inhibitor; Histamine H1 receptor antagonist,trazodone,,,,0,"['repurposed trazodone hydrochloride (neurodegenerative diseases)', 'trazodone hydrochloride', 'trazodone']",,NER_API,[],0
paroxetine,5 Hydroxytryptamine uptake inhibitor,paroxetine,,,,0,['paroxetine'],,0,[],0
undisclosed - benzodiazepine,Benzodiazepine receptor agonist,undisclosed - benzodiazepine,,,,0,['undisclosed - benzodiazepine'],,0,[],0
buspirone,5 Hydroxytryptamine 1A receptor agonist,buspirone,,,,0,"['buspirone hydrochloride', 'BuSpar', 'buspirone', 'buspirone hydrochloride (extended release formulation, anxiety/schizophrenia)', 'Buspirone ER', 'buspirone (extended release formulation, anxiety/schizophrenia)']",,NER_API,[],0
sertraline hydrochloride (tablet),5 Hydroxytryptamine uptake inhibitor,sertraline hydrochloride,,sertraline,sertraline hydrochloride,fexact,"['CP-51974', 'J Zoloft', 'Besitran', 'Serad', 'sertraline HCl', 'CP-519741', 'Lustral', 'Aremis', 'Gladem', 'sertraline hydrochloride', 'Serlain', 'Zoloft', 'Tatig', 'sertraline']",sertraline,fexact,"['cp 51974', 'j zoloft', 'besitran', 'serad', 'sertraline hcl', 'cp 519741', 'lustral', 'aremis', 'gladem', 'sertraline hydrochloride', 'serlain', 'zoloft', 'tatig', 'sertraline']",correct_mapping
probiotic therapy,Microbiome modulator,probiotic therapy,,,,0,['probiotic therapy'],,0,[],0
OXS-1550,Translation elongation factor 2 inhibitor,OXS-1550,,OXS-1550,oxs 1550,fexact,"['DT-2219', 'antibody-drug conjugate targeting CD19/CD22 (B-cell malignancies/non-Hodgkins lymphoma)', 'GTB-1550', 'antibody-drug conjugate targeting CD19/CD22 (B-cell malignancies/non-Hodgkins lymphoma), Oxis Biotech', 'OXS-1550', 'DT-2219-ARL']",OXS-1550,fexact,"['dt 2219', 'antibody drug conjugate targeting cd19 cd22 b cell malignancies non hodgkins lymphoma', 'gtb 1550', 'antibody drug conjugate targeting cd19 cd22 b cell malignancies non hodgkins lymphoma oxis biotech', 'oxs 1550', 'dt 2219 arl']",correct_mapping
WT1:187-195 peptide,Immunostimulant,WT1 187-195 peptide,,,,0,['WT1 187-195 peptide'],,0,[],0
WT1:37-45 peptide,Immunostimulant,WT1 37-45 peptide,,,,0,['WT1 37-45 peptide'],,0,[],0
invimestrocel,Not applicable,invimestrocel,,,,0,"['multipotent adult progenitor cell therapy (multiple sclerosis)', 'somatic stem cell regenerative therapy, HEALIOS', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD),//', 'multipotent adult progenitor cell therapy (spinal cord injury/traumatic brain injury)', 'multipotent adult progenitor cell therapy (ischemia/ARDS/ocular diseases), Athersys/ Healios', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD/MS),//', 'somatic stem cell regenerative therapy', 'multipotent adult progenitor cell therapy (multiple sclerosis/ARDS/GvHD/Traumatic brain injury/stroke/spinal cord injury/immune disorder/myocardial infarction/COVID-19/pneumonia/ocular disease), Athersys/Healios', 'multipotent adult progenitor cell therapy (spinal cord injury/traumatic brain injury), Athersys', 'MAPC (ischemia/cerebral palsy), Athersys', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD/MS), Athersys//Pfizer', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy), Athersys/ Healios', 'multipotent adult progenitor cell therapy (ischemia/ARDS/ocular diseases),/ Healios', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy),/', 'multipotent adult progenitor cell therapy (multiple sclerosis/ARDS/GvHD/Traumatic brain injury/stroke/spinal cord injury/immune disorder/myocardial infarction/COVID-19/pneumonia/ocular disease),/', 'MAPC (ischemia/cerebral palsy)', 'multipotent adult progenitor cell therapy (graft versus host disease), Athersys', 'MultiStem (acute respiratory distress syndrome), Athersys', 'multipotent adult progenitor cell therapy (inflammatory bowel disease), Pfizer', 'MultiStem', 'multipotent adult progenitor cell therapy (graft versus host disease)', 'multipotent adult progenitor cell therapy (ischemia/ARDS/ocular diseases),/', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy),/ Healios', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy), Athersys/', 'PF-05285401', 'MAPC (ischemia/cerebral palsy), Athersys/', 'multipotent adult progenitor cell therapy (inflammatory bowel disease)', ""multipotent adult progenitor cell therapy (Parkinson's disease)"", 'multipotent adult progenitor cell therapy (multiple sclerosis), Athersys', 'MAPC (ischemia/cerebral palsy),/', 'HLCM-051', 'multipotent adult progenitor cell therapy (inflammatory bowel disease), Athersys', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD),//Pfizer', 'invimestrocel', 'MultiStem (acute respiratory distress syndrome)', 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys//Pfizer', ""multipotent adult progenitor cell therapy (Parkinson's disease), Athersys"", 'multipotent adult progenitor cell therapy (multiple sclerosis/ARDS/GvHD/Traumatic brain injury/stroke/spinal cord injury/immune disorder/myocardial infarction/COVID-19/pneumonia/ocular disease),/Healios', ""MultiStem (Parkinson's disease), Athersys"", 'multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD/MS),//Pfizer', ""MultiStem (Parkinson's disease)""]",,NER_API,[],0
mRNA-transfected autologous dendritic cells,Immunostimulant,mRNA-transfected autologous dendritic cells,,,,0,['mRNA-transfected autologous dendritic cells'],,0,[],0
"telomerase vaccine, Geron",Telomerase stimulant; Immunostimulant,telomerase vaccine,Geron,,,0,['telomerase vaccine'],,0,[],0
norethindrone,Progesterone receptor agonist,norethindrone,,,,0,['norethindrone'],,0,[],0
Gelclair,Not applicable,Gelclair,,,,0,['Gelclair'],,0,[],0
high dose chemotherapy,Unidentified pharmacological activity,high dose chemotherapy,,,,0,['high dose chemotherapy'],,0,[],0
bafetinib,LYN tyrosine kinase inhibitor; Bcr-Abl inhibitor,bafetinib,,bafetinib,bafetinib,fexact,"['CNS-9', 'NS-187', 'bafetinib', 'INNO-406']",bafetinib,fexact,"['cns 9', 'ns 187', 'bafetinib', 'inno 406']",correct_mapping
"CMV DNA vaccine, bivalent, Vical",Immunostimulant; T cell stimulant,CMV DNA vaccine,Vical,,,0,['CMV DNA vaccine'],,0,[],0
bosutinib (capsule),Abl receptor tyrosine kinase inhibitor; Bcr-Abl inhibitor; Src inhibitor; Apoptosis stimulant,bosutinib,,bosutinib,bosutinib,fexact,"['SKI-971', 'PF-05208763', 'PF-5208763', 'Src kinase inhibitors (oral)', 'Bcr-Abl kinase inhibitors, Wyeth', 'Src kinase inhibitors (oral), Wyeth', 'SKI-758', 'Bosulif', 'SKI-606', 'Boslif', 'SKI-015', 'Bcr-Abl kinase inhibitors, Pfizer', 'Bcr-Abl kinase inhibitors', 'Src kinase inhibitors (oral), Wyeth-Ayerst', 'Src kinase inhibitors (oral), Pfizer', 'bosutinib']",bosutinib,fexact,"['ski 971', 'pf 05208763', 'pf 5208763', 'src kinase inhibitors oral', 'bcr abl kinase inhibitors wyeth', 'src kinase inhibitors oral wyeth', 'ski 758', 'bosulif', 'ski 606', 'boslif', 'ski 015', 'bcr abl kinase inhibitors pfizer', 'bcr abl kinase inhibitors', 'src kinase inhibitors oral wyeth ayerst', 'src kinase inhibitors oral pfizer', 'bosutinib']",correct_mapping
carlecortemcel-L,Not applicable,carlecortemcel-L,,StemEx,carlecortemcel l,fexact,"['donor cord blood stem cells (stem cell transplantation)', 'carlecortemcel-L', 'StemEx']",StemEx,fexact,"['donor cord blood stem cells stem cell transplantation', 'carlecortemcel l', 'stemex']",correct_mapping
banoxantrone,DNA inhibitor; DNA topoisomerase II inhibitor; DNA directed RNA polymerase inhibitor,banoxantrone,,banoxantrone,banoxantrone,fexact,"['AZD-1689', 'banoxantrone', 'AQ4M', 'AQ4', 'AQ4N, AstraZeneca/Novacea', 'AQ4N']",banoxantrone,fexact,"['azd 1689', 'banoxantrone', 'aq4m', 'aq4', 'aq4n astrazeneca novacea', 'aq4n']",correct_mapping
HSK-29116,Bruton tyrosine kinase inhibitor,HSK-29116,,HSK-29116,hsk 29116,fexact,"['PROTAC-BTK degrader (B lymphocyte derived malignancy)', 'HSK-29116', 'Btk-targeted PROTAC protein degrader program (oral powder, B-cell malignancies)', 'HSK-26784']",HSK-29116,fexact,"['protac btk degrader b lymphocyte derived malignancy', 'hsk 29116', 'btk targeted protac protein degrader program oral powder b cell malignancies', 'hsk 26784']",correct_mapping
"CAR7-T cells, Beijing Gaobo Biotechnology",Immuno-oncology therapy,CAR7-T cells,Beijing Gaobo Biotechnology,,,0,['CAR7-T cells'],,0,[],0
GB-261,Immuno-oncology therapy,GB-261,,GB-261,gb 261,fexact,"['bispecific CD3xCD20 targeting antibody (non-Hodgkin lymphoma)', 'anti-CD3/anti-CD20 bispecific T-cell engager (non-Hodgkin lymphoma)', 'GB-261']",GB-261,fexact,"['bispecific cd3xcd20 targeting antibody non hodgkin lymphoma', 'anti cd3 anti cd20 bispecific t cell engager non hodgkin lymphoma', 'gb 261']",correct_mapping
hCD19.IL15.CAR-iNKT,T cell stimulant; CD19 antagonist; Immuno-oncology therapy,hCD19.IL15.CAR-iNKT,,,,0,['hCD19.IL15.CAR-iNKT'],,0,[],0
TG-1801,Immunostimulant; Immuno-oncology therapy,TG-1801,,TG-1801,tg 1801,fexact,"['NI-1701', 'triple CD47 checkpoint inhibitor/anti-CD19/FcR activator (cancer), Novimmune/TG Therapeutics', 'TG-1801', 'triple cd47 checkpoint inhibitor/anti-cd19/fcr activator (cancer), /tg therapeutics', 'triple cd47 checkpoint inhibitor/anti-cd19/fcr activator (cancer),/', 'triple CD47 checkpoint inhibitor/anti-CD19/FcR activator (cancer), Novimmune/', 'kappa-lambda body (cancer), NovImmune']",TG-1801,fexact,"['ni 1701', 'triple cd47 checkpoint inhibitor anti cd19 fcr activator cancer novimmune tg therapeutics', 'tg 1801', 'triple cd47 checkpoint inhibitor anti cd19 fcr activator cancer tg therapeutics', 'triple cd47 checkpoint inhibitor anti cd19 fcr activator cancer', 'triple cd47 checkpoint inhibitor anti cd19 fcr activator cancer novimmune', 'kappa lambda body cancer novimmune']",correct_mapping
SNC-103,Natural killer cell stimulant; Immuno-oncology therapy,SNC-103,,,,0,['SNC-103'],,0,[],0
"universal chimaeric antigen receptor-modified AT-19 cell therapy, Chengdu USino Technology Biology",T cell stimulant; Immuno-oncology therapy,universal chimaeric antigen receptor-modified AT-19 cell therapy,Chengdu USino Technology Biology,,,0,['universal chimaeric antigen receptor-modified AT-19 cell therapy'],,0,[],0
CT-125A,T cell stimulant; Immuno-oncology therapy,CT-125A,,CT-125A,ct 125a,fexact,"['anti-cd5 car t-cell therapy (chronic lymphocytic leukemia/mantle cell lymphoma/diffuse large b-cell lymphoma/follicular lymphoma/peripheral t-cell lymphomas/ b cell lymphoma/t cell lymphoma/anaplastic large cell lymphoma/t-cell large granular lymphocyte leukemia), /shanghai iaso biotechnology', 'anti-cd5 car t-cell therapy (crispr, cd5-positive relapsed/refractory hematopoietic malignancies), /shanghai iaso biotechnology', 'CT-125A', 'anti-cd5 car t-cell therapy (crispr, cd5-positive relapsed/refractory hematopoietic malignancies),/', 'anti-cd5 car t-cell therapy (chronic lymphocytic leukemia/mantle cell lymphoma/diffuse large b-cell lymphoma/follicular lymphoma/peripheral t-cell lymphomas/ b cell lymphoma/t cell lymphoma/anaplastic large cell lymphoma/t-cell large granular lymphocyte leukemia),/', 'RD-125']",CT-125A,fexact,"['anti cd5 car t cell therapy chronic lymphocytic leukemia mantle cell lymphoma diffuse large b cell lymphoma follicular lymphoma peripheral t cell lymphomas b cell lymphoma t cell lymphoma anaplastic large cell lymphoma t cell large granular lymphocyte leukemia shanghai iaso biotechnology', 'anti cd5 car t cell therapy crispr cd5 positive relapsed refractory hematopoietic malignancies shanghai iaso biotechnology', 'ct 125a', 'anti cd5 car t cell therapy crispr cd5 positive relapsed refractory hematopoietic malignancies', 'anti cd5 car t cell therapy chronic lymphocytic leukemia mantle cell lymphoma diffuse large b cell lymphoma follicular lymphoma peripheral t cell lymphomas b cell lymphoma t cell lymphoma anaplastic large cell lymphoma t cell large granular lymphocyte leukemia', 'rd 125']",correct_mapping
RVT-502 (oral),Syk tyrosine kinase inhibitor,RVT-502,,,,0,"['cerdulatinib', 'Syk/JAK multikinase inhibitor (dermatological diseases)', 'DMVT-502', 'cerdulatinib (dermatological diseases)', 'SNV-009', 'RVT-502']",,NER_API,[],0
TQB-3525,Unidentified pharmacological activity,TQB-3525,,,,0,['TQB-3525'],,0,[],0
SARS-CoV-2-derived multi-peptide vaccine,Immunostimulant,SARS-CoV-2-derived multi-peptide vaccine,,,,0,['SARS-CoV-2-derived multi-peptide vaccine'],,0,[],0
CTA-30X,T cell stimulant; Immuno-oncology therapy,CTA-30X,,CTA-101,cta 30x,fexact,"['CTA-30X', 'CTA-301', 'CTA-101 UCART', 'CTA-101', 'anti-CD19/anti-CD22 CAR T-cell therapy (UCAR, B-cell acute lymphoblastic leukemia/diffuse large B-cell lymphoma)']",CTA-101,fexact,"['cta 30x', 'cta 301', 'cta 101 ucart', 'cta 101', 'anti cd19 anti cd22 car t cell therapy ucar b cell acute lymphoblastic leukemia diffuse large b cell lymphoma']",correct_mapping
FCN-338,Bcl2 inhibitor,FCN-338,,FCN-338,fcn 338,fexact,"['FCN-338', 'Bcl-2 inhibitor (oral tablet, hematological cancer),/', 'LOXO-338', 'Bcl-2 inhibitor (oral tablet, hematological cancer), Eli Lilly/', 'Bcl-2 inhibitor (B-cell lymphoma)']",FCN-338,fexact,"['fcn 338', 'bcl 2 inhibitor oral tablet hematological cancer', 'loxo 338', 'bcl 2 inhibitor oral tablet hematological cancer eli lilly', 'bcl 2 inhibitor b cell lymphoma']",correct_mapping
huCART19-IL18,Interleukin 18 agonist; T cell stimulant; Immuno-oncology therapy,huCART19-IL18,,,,0,['huCART19-IL18'],,0,[],0
polatuzumab vedotin,Tubulin inhibitor,polatuzumab vedotin,,polatuzumab vedotin,polatuzumab vedotin,fexact,"['anti-CD79b antibody-acMMAE conjugate (hematological cancer)', 'DCDS-4501A', 'anti-CD79b-mc-vc-PAB-MMAE', 'RG-7596', 'RO-5541077', 'polatuzumab vedotin-piiq', 'anti-CD79b antibody-monomethyl auristatin E conjugate (hematological cancer)', 'anti-CD79b antibody-monomethyl auristatin E conjugate (hematological cancer), Genentech', 'polatuzumab vedotin', 'Polivy', 'anti-CD79b-vedotin', 'anti-CD79b antibody-acMMAE conjugate (hematological cancer), Genentech']",polatuzumab vedotin,fexact,"['anti cd79b antibody acmmae conjugate hematological cancer', 'dcds 4501a', 'anti cd79b mc vc pab mmae', 'rg 7596', 'ro 5541077', 'polatuzumab vedotin piiq', 'anti cd79b antibody monomethyl auristatin e conjugate hematological cancer', 'anti cd79b antibody monomethyl auristatin e conjugate hematological cancer genentech', 'polatuzumab vedotin', 'polivy', 'anti cd79b vedotin', 'anti cd79b antibody acmmae conjugate hematological cancer genentech']",correct_mapping
JNJ-64264681,Bruton tyrosine kinase inhibitor,JNJ-64264681,,JNJ-64264681,jnj 64264681,fexact,"['BTK inhibitor (oral capsule, non-Hodgkin lymphoma/chronic lymphocytic leukemia)', 'BTK inhibitor (oral solution, immune disorder/cancer)', 'JNJ-64264681']",JNJ-64264681,fexact,"['btk inhibitor oral capsule non hodgkin lymphoma chronic lymphocytic leukemia', 'btk inhibitor oral solution immune disorder cancer', 'jnj 64264681']",correct_mapping
NVG-111,T cell stimulant; Immuno-oncology therapy,NVG-111,,NVG-111,nvg 111,fexact,"['NVG-111', 'anti-CD3/anti-ROR1 bispecific T-cell engager (hematological cancer)']",NVG-111,fexact,"['nvg 111', 'anti cd3 anti ror1 bispecific t cell engager hematological cancer']",correct_mapping
ublituximab,CD20 antagonist; Immuno-oncology therapy,ublituximab,,ublituximab,ublituximab,fexact,"['rituximab biobetter, Il Dong', 'anti-CD20 antibody (lymphoma), TG Therapeutics', 'anti-CD20 antibody (lymphoma)', 'Utuxin', 'LFB-R603', 'LABI-R603', 'TG-1011', 'anti-CD20 antibody (lymphoma), LFB/GTC', 'chimeric anti-CD20 antibody (lymphoma), Laboratoire Francais du Fractionnement et des Biotechnologies', 'anti-CD20 antibody (lymphoma),/GTC', 'TG-20', 'ublituximab', 'TGTX-1101', 'TG-1101']",ublituximab,fexact,"['rituximab biobetter il dong', 'anti cd20 antibody lymphoma tg therapeutics', 'anti cd20 antibody lymphoma', 'utuxin', 'lfb r603', 'labi r603', 'tg 1011', 'anti cd20 antibody lymphoma lfb gtc', 'chimeric anti cd20 antibody lymphoma laboratoire francais du fractionnement et des biotechnologies', 'anti cd20 antibody lymphoma gtc', 'tg 20', 'ublituximab', 'tgtx 1101', 'tg 1101']",correct_mapping
umbralisib,Casein kinase 1 inhibitor; PI3 kinase delta inhibitor,umbralisib,,umbralisib,umbralisib,fexact,"['RP-5264', 'Ukoniq', 'RP-5237', 'dual PI3Kdelta/CK1 inhibitor (cancer), TG Therapeutics', 'RP-5307', 'dual PI3Kdelta/CK1 inhibitor (cancer)', 'TGR-1202', 'PI3K delta inhibitors (B-cell lymphoma/hematological cancers),/Rhizen', 'RV-1001', 'TG-1202', 'PI3K delta inhibitors (cancer), Rhizen/', 'PI3K delta inhibitors (cancer),/', 'umbralisib tosylate', 'RP-5152', 'PI3K delta inhibitors (B-cell lymphoma/hematological cancers),/', 'umbralisib']",umbralisib,fexact,"['rp 5264', 'ukoniq', 'rp 5237', 'dual pi3kdelta ck1 inhibitor cancer tg therapeutics', 'rp 5307', 'dual pi3kdelta ck1 inhibitor cancer', 'tgr 1202', 'pi3k delta inhibitors b cell lymphoma hematological cancers rhizen', 'rv 1001', 'tg 1202', 'pi3k delta inhibitors cancer rhizen', 'pi3k delta inhibitors cancer', 'umbralisib tosylate', 'rp 5152', 'pi3k delta inhibitors b cell lymphoma hematological cancers', 'umbralisib']",correct_mapping
orelabrutinib,Bruton tyrosine kinase inhibitor,orelabrutinib,,orelabrutinib,orelabrutinib,fexact,"['Btk inhibitors (cancer/immune disease)', 'yinuokai', 'ICP-022 (mantle cell lymphoma)', 'ICP-022 (chronic lymphocytic leukemia)', 'Bruton tyrosine kinase inhibitors (oral, marginal zone lymphoma)', 'ICP-022 (autoimmune diseases)', 'ICP-022', 'orelabrutinib', 'Bruton tyrosine kinase inhibitors (cancer/immune disease)']",orelabrutinib,fexact,"['btk inhibitors cancer immune disease', 'yinuokai', 'icp 022 mantle cell lymphoma', 'icp 022 chronic lymphocytic leukemia', 'bruton tyrosine kinase inhibitors oral marginal zone lymphoma', 'icp 022 autoimmune diseases', 'icp 022', 'orelabrutinib', 'bruton tyrosine kinase inhibitors cancer immune disease']",correct_mapping
epcoritamab,CD3 agonist; CD20 antagonist; Immuno-oncology therapy,epcoritamab,,epcoritamab,epcoritamab,fexact,"['Duobody-CD3xCD20', 'bispecific CD3xCD20 targeting antibody program (DuoBody, cancer)', 'GEN-3013', 'anti-CD3/anti-CD20 bispecific T-cell engager (DuoBody, cancer), Genmab', 'epcoritamab', 'bispecific CD3xCD20 targeting antibody program (DuoBody, cancer), Genmab', 'anti-CD3/anti-CD20 bispecific T-cell engager (DuoBody, cancer)']",epcoritamab,fexact,"['duobody cd3xcd20', 'bispecific cd3xcd20 targeting antibody program duobody cancer', 'gen 3013', 'anti cd3 anti cd20 bispecific t cell engager duobody cancer genmab', 'epcoritamab', 'bispecific cd3xcd20 targeting antibody program duobody cancer genmab', 'anti cd3 anti cd20 bispecific t cell engager duobody cancer']",correct_mapping
JNJ-75348780 (intravenous),T cell stimulant; Immuno-oncology therapy,JNJ-75348780,,JNJ-75348780,jnj 75348780,fexact,"['JNJ-75348780', 'anti-CD3/anti-CD22 bispecific T-cell engager (B-cell non-Hodgkin lymphoma/chronic lymphocytic leukemia)']",JNJ-75348780,fexact,"['jnj 75348780', 'anti cd3 anti cd22 bispecific t cell engager b cell non hodgkin lymphoma chronic lymphocytic leukemia']",correct_mapping
JNJ-75348780 (subcutaneous),T cell stimulant; Immuno-oncology therapy,JNJ-75348780,,JNJ-75348780,jnj 75348780,fexact,"['JNJ-75348780', 'anti-CD3/anti-CD22 bispecific T-cell engager (B-cell non-Hodgkin lymphoma/chronic lymphocytic leukemia)']",JNJ-75348780,fexact,"['jnj 75348780', 'anti cd3 anti cd22 bispecific t cell engager b cell non hodgkin lymphoma chronic lymphocytic leukemia']",correct_mapping
ZX-101,PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor,ZX-101,,ZX-101A,zx 101,fexact,"['ZX-101', 'PI3K-delta/gamma dual inhibitor (oral, hematologic malignancies/solid tumor)', 'ZX-101A']",ZX-101A,fexact,"['zx 101', 'pi3k delta gamma dual inhibitor oral hematologic malignancies solid tumor', 'zx 101a']",correct_mapping
TAK-940,T cell stimulant; Immuno-oncology therapy,TAK-940,,TAK-940,tak 940,fexact,"['cd19-targeted 19(t2)28z1xx car t-cell therapy (b-cell cancer), /takeda', 'anti-cd19 car t-cell therapy (b-cell cancer), /takeda', 'TAK-940', 'cd19-targeted 19(t2)28z1xx car t-cell therapy (b-cell cancer),/', 'anti-cd19 car t-cell therapy (b-cell cancer),/']",TAK-940,fexact,"['cd19 targeted 19 t2 28z1xx car t cell therapy b cell cancer takeda', 'anti cd19 car t cell therapy b cell cancer takeda', 'tak 940', 'cd19 targeted 19 t2 28z1xx car t cell therapy b cell cancer', 'anti cd19 car t cell therapy b cell cancer']",correct_mapping
cirmtuzumab,Receptor tyrosine kinase-like orphan receptor 1 antagonist; Immuno-oncology therapy,cirmtuzumab,,cirmtuzumab,cirmtuzumab,fexact,"['anti-ROR1 mAbs (cancer), University of California San Diego', 'anti-ror1 mabs (cancer)', 'anti-ROR1 mAbs (cancer)', 'cirmtuzumab', 'UC-961ADC3', 'Cirmtuzumab Vedotin', 'UC-961']",cirmtuzumab,fexact,"['anti ror1 mabs cancer university of california san diego', 'anti ror1 mabs cancer', 'anti ror1 mabs cancer', 'cirmtuzumab', 'uc 961adc3', 'cirmtuzumab vedotin', 'uc 961']",correct_mapping
CC-99282,Angiogenesis inhibitor; Cereblon E3 ubiquitin ligase stimulant,CC-99282,,CC-99282,cc 99282,fexact,['CC-99282'],CC-99282,fexact,['cc 99282'],correct_mapping
"ThisCART19 cell therapy, Fundamenta Therapeutics",T cell stimulant; Immuno-oncology therapy,ThisCART19 cell therapy,Fundamenta Therapeutics,,,0,['ThisCART19 cell therapy'],,0,[],0
duvelisib,PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor,duvelisib,,duvelisib,duvelisib,fexact,"['phosphoinositide-3 kinase delta/gamma (oral, inflammation/respiratory disease/cancer), Intellikine', 'Copiktra', 'duvelisib hydrate (oral, inflammation/respiratory disease/cancer),////', 'phosphoinositide-3 kinase delta/gamma (oral, inflammation/respiratory disease/cancer)', 'INK-055', 'PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer)', 'duvelisib', 'PI3Kdelta/gamma inhibitors (cancer), Yakult', 'duvelisib hydrate (oral, inflammation/respiratory disease/cancer),///Yakult/', 'ABBV-954', 'PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer), Intellikine/', 'PI3Kdelta/gamma inhibitors (cancer),/', 'YHI-1702', 'PI3Kdelta/gamma inhibitors (cancer)', 'duvelisib hydrate (oral, inflammation/respiratory disease/cancer),//Verastem/Yakult/', 'PI3Kdelta/gamma inhibitors (cancer),/Yakult', 'PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer), Intellikine', 'PI3Kdelta/gamma inhibitors (oral, inflammation/cancer), Intellikine// Mundipharma', 'duvelisib hydrate (oral, inflammation/respiratory disease/cancer), Intellikine//Verastem/Yakult/', 'PI3Kdelta/gamma inhibitors (oral, inflammation/cancer),//', 'duvelisib hydrate (oral, inflammation/respiratory disease/cancer), Intellikine/ Infinity/Verastem/Yakult/', 'INK-1197', 'PI3Kdelta/gamma inhibitors (oral, inflammation/cancer),// Mundipharma', 'VS-0145', 'INK-1048', 'PI3K delta/gamma inhibitors (oral, cancer), Infinity/', 'PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer),/', 'PI3Kdelta/gamma inhibitors (cancer), Verastem/Yakult', 'PI3Kdelta/gamma inhibitors (oral, inflammation/cancer), Intellikine/ Infinity/ Mundipharma', 'duvelisib hydrate', 'INK-713', 'PI3K delta/gamma inhibitors (oral, cancer),/', 'PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer), Intellikine/ Infinity', 'IPI-145']",duvelisib,fexact,"['phosphoinositide 3 kinase delta gamma oral inflammation respiratory disease cancer intellikine', 'copiktra', 'duvelisib hydrate oral inflammation respiratory disease cancer', 'phosphoinositide 3 kinase delta gamma oral inflammation respiratory disease cancer', 'ink 055', 'pi3kdelta gamma inhibitors oral inflammation respiratory disease cancer', 'duvelisib', 'pi3kdelta gamma inhibitors cancer yakult', 'duvelisib hydrate oral inflammation respiratory disease cancer yakult', 'abbv 954', 'pi3kdelta gamma inhibitors oral inflammation respiratory disease cancer intellikine', 'pi3kdelta gamma inhibitors cancer', 'yhi 1702', 'pi3kdelta gamma inhibitors cancer', 'duvelisib hydrate oral inflammation respiratory disease cancer verastem yakult', 'pi3kdelta gamma inhibitors cancer yakult', 'pi3kdelta gamma inhibitors oral inflammation respiratory disease cancer intellikine', 'pi3kdelta gamma inhibitors oral inflammation cancer intellikine mundipharma', 'duvelisib hydrate oral inflammation respiratory disease cancer intellikine verastem yakult', 'pi3kdelta gamma inhibitors oral inflammation cancer', 'duvelisib hydrate oral inflammation respiratory disease cancer intellikine infinity verastem yakult', 'ink 1197', 'pi3kdelta gamma inhibitors oral inflammation cancer mundipharma', 'vs 0145', 'ink 1048', 'pi3k delta gamma inhibitors oral cancer infinity', 'pi3kdelta gamma inhibitors oral inflammation respiratory disease cancer', 'pi3kdelta gamma inhibitors cancer verastem yakult', 'pi3kdelta gamma inhibitors oral inflammation cancer intellikine infinity mundipharma', 'duvelisib hydrate', 'ink 713', 'pi3k delta gamma inhibitors oral cancer', 'pi3kdelta gamma inhibitors oral inflammation respiratory disease cancer intellikine infinity', 'ipi 145']",correct_mapping
NX-2127,Bruton tyrosine kinase inhibitor; IKAROS family zinc finger 3 inhibitor,NX-2127,,NX-2127,nx 2127,fexact,"['NX-2127', 'BTK degraders (PROTAC, chronic lymphocytic leukemia), Nurix Therapeutics/NIH', 'BTK degraders (PROTAC, oral, B-cell lymphoma/CLL),/NIH', 'BTK degraders (PROTAC, oral, B-cell lymphoma/CLL), Nurix Therapeutics/NIH', 'BTK degraders (PROTAC, chronic lymphocytic leukemia),/NIH', 'btk targeting protacs (chronic lymphocytic leukemia)', 'btk targeting protacs (chronic lymphocytic leukemia), nurix therapeutics', 'NRX-0492']",NX-2127,fexact,"['nx 2127', 'btk degraders protac chronic lymphocytic leukemia nurix therapeutics nih', 'btk degraders protac oral b cell lymphoma cll nih', 'btk degraders protac oral b cell lymphoma cll nurix therapeutics nih', 'btk degraders protac chronic lymphocytic leukemia nih', 'btk targeting protacs chronic lymphocytic leukemia', 'btk targeting protacs chronic lymphocytic leukemia nurix therapeutics', 'nrx 0492']",correct_mapping
letermovir (IV),CMV terminase inhibitor,letermovir,,letermovir,letermovir,fexact,"['Prevymis', 'BAY-73-6327-N', 'AIC-001', 'AIC-246', 'letermovir', 'antiviral therapy', 'BAY-73-6327', 'MK-8228', 'non-nucleosidic terminase inhibitor (oral, HCMV infection)']",letermovir,fexact,"['prevymis', 'bay 73 6327 n', 'aic 001', 'aic 246', 'letermovir', 'antiviral therapy', 'bay 73 6327', 'mk 8228', 'non nucleosidic terminase inhibitor oral hcmv infection']",correct_mapping
"pCAR-19B cells, Chongqing Precision Biotech",T cell stimulant; Immuno-oncology therapy,pCAR-19B cells,Chongqing Precision Biotech,,,0,['pCAR-19B cells'],,0,[],0
JBH-492,CC chemokine receptor 7 antagonist,JBH-492,,JBH-492,jbh 492,fexact,"['JBH-492', 'anti-CCR7 antibody-drug conjugate (chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma)']",JBH-492,fexact,"['jbh 492', 'anti ccr7 antibody drug conjugate chronic lymphocytic leukemia non hodgkin s lymphoma']",correct_mapping
car.k.28,T cell stimulant; Immuno-oncology therapy,car.k.28,,,,0,['car.k.28'],,0,[],0
CTA-101,T cell stimulant; Immuno-oncology therapy,CTA-101,,CTA-101,cta 101,fexact,"['CTA-30X', 'CTA-301', 'CTA-101 UCART', 'CTA-101', 'anti-CD19/anti-CD22 CAR T-cell therapy (UCAR, B-cell acute lymphoblastic leukemia/diffuse large B-cell lymphoma)']",CTA-101,fexact,"['cta 30x', 'cta 301', 'cta 101 ucart', 'cta 101', 'anti cd19 anti cd22 car t cell therapy ucar b cell acute lymphoblastic leukemia diffuse large b cell lymphoma']",correct_mapping
FT-819,T cell stimulant; Immuno-oncology therapy,FT-819,,FT-819,ft 819,fexact,"['FT-819', 'anti-CD19 CAR T-cell therapy (cancer),/', 'anti-CD19 CAR T-cell therapy (cancer),/Memorial Sloan Kettering Cancer Center', 'TCR-less anti-CD19 TRAC-CAR-TiPSC (cancer),/', 'TCR-less anti-CD19 TRAC-CAR-TiPSC (cancer),/Memorial Sloan Kettering Cancer Center']",FT-819,fexact,"['ft 819', 'anti cd19 car t cell therapy cancer', 'anti cd19 car t cell therapy cancer memorial sloan kettering cancer center', 'tcr less anti cd19 trac car tipsc cancer', 'tcr less anti cd19 trac car tipsc cancer memorial sloan kettering cancer center']",correct_mapping
"anti-CD22 chimaeric antigen receptor, Kecellitics Biotech Company",T cell stimulant; Immuno-oncology therapy,anti-CD22 chimaeric antigen receptor,Kecellitics Biotech Company,,,0,['anti-CD22 chimaeric antigen receptor'],,0,[],0
FT-596,Natural killer cell stimulant; Immuno-oncology therapy,FT-596,,FT-596,ft 596,fexact,"['hncd16-expressing anti-cd19 car nk-cell therapy (cancer)', 'hnCD16-expressing anti-CD19 CAR NK-cell therapy (cancer),/University of California San Diego', 'FT-596', 'CAR19 + hnCD16 + IL-15RF', 'NKCAR-iPSC-NK cells']",FT-596,fexact,"['hncd16 expressing anti cd19 car nk cell therapy cancer', 'hncd16 expressing anti cd19 car nk cell therapy cancer university of california san diego', 'ft 596', 'car19 hncd16 il 15rf', 'nkcar ipsc nk cells']",correct_mapping
XYF19 CAR-T cells,MAP kinase kinase kinase kinase 1 inhibitor; T cell stimulant; CD19 antagonist; Immuno-oncology therapy; Genome editing,XYF19 CAR-T cells,,xyf19 car-t cell therapy,xyf19 car t cells,fexact,"['xyf19 car-t cell therapy, yufan', 'anti-cd19 car t-cell therapy (relapsed or refractory cd19+ leukemia/lymphoma), yufan', 'XYF19 CAR-T cells', 'anti-cd19 car t-cell therapy (crispr/cas9 hpk1 knock-out, relapsed/refractory cd19-positive leukemia/lymphoma), yufan', 'anti-CD19 autologous CAR T-cell therapy (relapsed or refractory CD19+ leukemia/lymphoma), Yufan Biotechnologies', 'anti-cd19 car t-cell therapy (relapsed or refractory cd19+ leukemia/lymphoma)', 'anti-cd19 car t-cell therapy (crispr/cas9 hpk1 knock-out, relapsed/refractory cd19-positive leukemia/lymphoma)', 'anti-CD19 autologous CAR T-cell therapy (relapsed or refractory CD19+ leukemia/lymphoma)', 'xyf19 car-t cell therapy']",xyf19 car-t cell therapy,fexact,"['xyf19 car t cell therapy yufan', 'anti cd19 car t cell therapy relapsed or refractory cd19 leukemia lymphoma yufan', 'xyf19 car t cells', 'anti cd19 car t cell therapy crispr cas9 hpk1 knock out relapsed refractory cd19 positive leukemia lymphoma yufan', 'anti cd19 autologous car t cell therapy relapsed or refractory cd19 leukemia lymphoma yufan biotechnologies', 'anti cd19 car t cell therapy relapsed or refractory cd19 leukemia lymphoma', 'anti cd19 car t cell therapy crispr cas9 hpk1 knock out relapsed refractory cd19 positive leukemia lymphoma', 'anti cd19 autologous car t cell therapy relapsed or refractory cd19 leukemia lymphoma', 'xyf19 car t cell therapy']",correct_mapping
PBCAR20A,T cell stimulant; Immuno-oncology therapy,PBCAR20A,,PBCAR-20A,pbcar 20a,fuzzy,"['PBCAR-20A', 'allogeneic CAR T-cell therapy (ARCUS, Non-Hodgkin lymphoma/chronic lymphocytic leukemia/small lymphocytic leukemia),/Servier', 'anti-CD20 CAR T-cell therapy (ARCUS, Non-Hodgkin lymphoma/chronic lymphocytic leukemia/small lymphocytic leukemia),/Servier', 'allogeneic car t-cell therapy (arcus, non-hodgkin lymphoma/chronic lymphocytic leukemia/small lymphocytic leukemia)', 'anti-cd20 car t-cell therapy (arcus, non-hodgkin lymphoma/chronic lymphocytic leukemia/small lymphocytic leukemia)']",PBCAR-20A,fexact,"['pbcar 20a', 'allogeneic car t cell therapy arcus non hodgkin lymphoma chronic lymphocytic leukemia small lymphocytic leukemia servier', 'anti cd20 car t cell therapy arcus non hodgkin lymphoma chronic lymphocytic leukemia small lymphocytic leukemia servier', 'allogeneic car t cell therapy arcus non hodgkin lymphoma chronic lymphocytic leukemia small lymphocytic leukemia', 'anti cd20 car t cell therapy arcus non hodgkin lymphoma chronic lymphocytic leukemia small lymphocytic leukemia']",incorrect_mapping
ET-019003,T cell stimulant; Immuno-oncology therapy,ET-019003,,ET-019003,et 019003,fexact,"['dual anti-CD19 CAR T-cell therapy/anti-CD19 chimeric signaling receptor ET190L1-CSR T-cell therapy (ARTEMIS antibody-TCR, lymphoma/leukemia)', 'dual anti-CD19 CAR T-cell therapy/anti-CD19 CSR T-cell therapy (ARTEMIS AbTCR, lymphoma/leukemia)', 'ET-019003', 'ET019003-T Cells']",ET-019003,fexact,"['dual anti cd19 car t cell therapy anti cd19 chimeric signaling receptor et190l1 csr t cell therapy artemis antibody tcr lymphoma leukemia', 'dual anti cd19 car t cell therapy anti cd19 csr t cell therapy artemis abtcr lymphoma leukemia', 'et 019003', 'et019003 t cells']",correct_mapping
CAP-100,CC chemokine receptor 7 antagonist,CAP-100,,CAP-100,cap 100,fexact,"['anti-CCR7 monoclonal antibody (cancer),/', 'anti-CCR7 monoclonal antibody (cancer),/Pepscan Systems', 'CAP-100']",CAP-100,fexact,"['anti ccr7 monoclonal antibody cancer', 'anti ccr7 monoclonal antibody cancer pepscan systems', 'cap 100']",correct_mapping
YTB-323,T cell stimulant; Immuno-oncology therapy,YTB-323,,YTB-323,ytb 323,fexact,"['anti-CD19 CAR T-cell therapy (chronic lymphocytic leukemia/small lymphocytic lymphoma/diffuse large B-cell lymphoma)', 'YTB-323']",YTB-323,fexact,"['anti cd19 car t cell therapy chronic lymphocytic leukemia small lymphocytic lymphoma diffuse large b cell lymphoma', 'ytb 323']",correct_mapping
IO-103,PD-L1 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor,IO-103,,IO-103,io 103,fexact,"['Treg modulator 2 (cancer)', 'PD-L1-derived peptide vaccine (cancer)', 'IO-103']",IO-103,fexact,"['treg modulator 2 cancer', 'pd l1 derived peptide vaccine cancer', 'io 103']",correct_mapping
IO-120,Immuno-oncology therapy,IO-120,,,,0,"['PD-L2-derived peptide vaccine (T-win, follicular lymphoma)', 'IO-120']",,NER_API,[],0
"bendamustine hydrochloride, rapid infusion liquid, Eagle Pharmaceuticals",DNA inhibitor; Apoptosis stimulant,bendamustine hydrochloride,Eagle Pharmaceuticals,bendamustine,bendamustine hydrochloride,fexact,"['Cytostasan', 'SDX-105', 'SyB L-0501', 'Benda', 'bendamustine', 'Inno-P08001', 'Treakisym', 'Innomustine', 'SyB L-0501RI', 'Treanda', 'bendamustine hydrochloride', 'Levact', 'Ribomustin', 'SyBL-0501', 'Ribovact', 'Symbenda']",bendamustine,fexact,"['cytostasan', 'sdx 105', 'syb l 0501', 'benda', 'bendamustine', 'inno p08001', 'treakisym', 'innomustine', 'syb l 0501ri', 'treanda', 'bendamustine hydrochloride', 'levact', 'ribomustin', 'sybl 0501', 'ribovact', 'symbenda']",correct_mapping
IOV-2001,Immuno-oncology therapy,IOV-2001,,IOV-2001,iov 2001,fexact,"['peripheral blood lymphocytes (chronic lymphocytic leukemia),/OSUCCC', 'Autologous PBL', 'IOV-2001']",IOV-2001,fexact,"['peripheral blood lymphocytes chronic lymphocytic leukemia osuccc', 'autologous pbl', 'iov 2001']",correct_mapping
zamtocabtagene autoleucel,T cell stimulant; Immuno-oncology therapy,zamtocabtagene autoleucel,,,,0,['zamtocabtagene autoleucel'],,0,[],0
HMPL-689,PI3 kinase delta inhibitor,HMPL-689,,HMPL-689,hmpl 689,fexact,['HMPL-689'],HMPL-689,fexact,['hmpl 689'],correct_mapping
CMD-502,Natural Killer T cell stimulant; Immuno-oncology therapy,CMD-502,,KUR-502,cmd 502,fexact,"['allogeneic car nkt-cell therapy (hematological cancers), cell medica', 'allogeneic car t-cell therapy (hematological cancers), cell medica', 'anti-cd19 car nk-cell therapy (hematological malignancies)', 'CMD-502', 'anchor cells, /cell medica', 'anchor cells', 'anti-cd19 car nk-cell therapy (b-cell lymphoma), /cell medica', 'CD19.CAR-aNKT cells', 'anti-cd19 car nk-cell therapy (hematological malignancies), /kuur therapeutics', 'anti-cd19 car nk-cell therapy (b-cell lymphoma),/cell medica', 'KUR-502', 'anchor cells,/cell medica', 'anchor cells, /kuur therapeutics']",KUR-502,fexact,"['allogeneic car nkt cell therapy hematological cancers cell medica', 'allogeneic car t cell therapy hematological cancers cell medica', 'anti cd19 car nk cell therapy hematological malignancies', 'cmd 502', 'anchor cells cell medica', 'anchor cells', 'anti cd19 car nk cell therapy b cell lymphoma cell medica', 'cd19 car ankt cells', 'anti cd19 car nk cell therapy hematological malignancies kuur therapeutics', 'anti cd19 car nk cell therapy b cell lymphoma cell medica', 'kur 502', 'anchor cells cell medica', 'anchor cells kuur therapeutics']",correct_mapping
"CARvac cell therapy, iCell Gene Therapeutics",T cell stimulant; Immuno-oncology therapy,CARvac cell therapy,iCell Gene Therapeutics,,,0,['CARvac cell therapy'],,0,[],0
XLCART-001,CD19 antagonist; Immuno-oncology therapy,XLCART-001,,XLCART-001,xlcart 001,fexact,"['anti-cd19 car t-cell therapy (r/r b-cell lymphoma)', 'XLCART-001']",XLCART-001,fexact,"['anti cd19 car t cell therapy r r b cell lymphoma', 'xlcart 001']",correct_mapping
SHC-014748M,PI3 kinase delta inhibitor,SHC-014748M,,SHC-014748M,shc 014748m,fexact,"['SHC-014748M', 'SH-748']",SHC-014748M,fexact,"['shc 014748m', 'sh 748']",correct_mapping
"CD19 chimeric antigen receptor T-cell therapy, 3rd generation, Ziopharm",T cell stimulant; Immuno-oncology therapy,CD19 chimeric antigen receptor T-cell therapy,Ziopharm,,,0,['CD19 chimeric antigen receptor T-cell therapy'],,0,[],0
"CD-19 CAR-T cell therapy, Miltenyi Biomedicine",T cell stimulant; Immuno-oncology therapy,CD-19 CAR-T cell therapy,Miltenyi Biomedicine,,,0,['CD-19 CAR-T cell therapy'],,0,[],0
autologous 3rd generation CD19-CART cells,CD19 antagonist; Immuno-oncology therapy,autologous 3rd generation CD19-CART cells,,,,0,['autologous 3rd generation CD19-CART cells'],,0,[],0
MS-553,Protein kinase C beta inhibitor,MS-553,,,,0,"['protein kinase C beta inhibitor (oral, cancer), Mingsight Pharmceuticals', 'protein kinase C beta inhibitor (oral, ocular disease),/', 'MS-553', 'protein kinase C beta inhibitor (oral, ocular disease),/ MingSight Pharmaceutical', 'ophthalmological agents (ocular disease)']",,NER_API,[],0
hyaluronidase,Hyaluronidase stimulant,hyaluronidase,,,,0,"['hyaluronidase', 'orgelase', 'recombinant hyaluronidase']",,NER_API,[],0
rituximab (SC),CD20 antagonist,rituximab,,rituximab biosimilar,rituximab,fexact,"['GP-2013', 'Riximyo', 'Rixathon', 'rituximab biosimilar', 'Rituximab BS', 'rituximab', 'rituximab biosimilar, Sandoz']",rituximab biosimilar,fexact,"['gp 2013', 'riximyo', 'rixathon', 'rituximab biosimilar', 'rituximab bs', 'rituximab', 'rituximab biosimilar sandoz']",correct_mapping
ianalumab,B-cell activator factor receptor antagonist,ianalumab,,ianalumab,ianalumab,fexact,"['B-cell activating factor receptor monoclonal antibody (leukemia/inflammation)', 'ianalumab', 'fully human monoclonal antibodies (HuCAL, inflammation/leukemia), Novartis', 'VAY-736', 'BAFF-R mAb (leukemia/inflammation), Novartis', 'lanalumab', 'NOV-5 program', 'B-cell activating factor receptor monoclonal antibody (leukemia/inflammation), Novartis', 'fully human monoclonal antibodies (HuCAL, inflammation/leukemia)', 'BAFF-R mAb (leukemia/inflammation)']",ianalumab,fexact,"['b cell activating factor receptor monoclonal antibody leukemia inflammation', 'ianalumab', 'fully human monoclonal antibodies hucal inflammation leukemia novartis', 'vay 736', 'baff r mab leukemia inflammation novartis', 'lanalumab', 'nov 5 program', 'b cell activating factor receptor monoclonal antibody leukemia inflammation novartis', 'fully human monoclonal antibodies hucal inflammation leukemia', 'baff r mab leukemia inflammation']",correct_mapping
"ICAR-19 CAR-T cells, Immune Cell Therapy",T cell stimulant; Immuno-oncology therapy,ICAR-19 CAR-T cells,Immune Cell Therapy,,,0,['ICAR-19 CAR-T cells'],,0,[],0
BI-836826,CD37 antagonist; Immuno-oncology therapy,BI-836826,,BI-836826,bi 836826,fexact,"['BI-836826', 'CD37 antibodies (B-cell malignancies)', 'mAb 37.1', 'mAb 37.2']",BI-836826,fexact,"['bi 836826', 'cd37 antibodies b cell malignancies', 'mab 37 1', 'mab 37 2']",correct_mapping
B-001,CD20 antagonist; Immuno-oncology therapy,B-001,,B-001,b 001,fexact,"['B-001', 'anti-CD20 humanized mAb (iv, non-Hodgkin lymphoma)', 'B-001-A']",B-001,fexact,"['b 001', 'anti cd20 humanized mab iv non hodgkin lymphoma', 'b 001 a']",correct_mapping
"anti-CD19 anti-CD20 Bispecific CAR redirected autologous T-cells, Beijing Doing Biomedical Co.",T cell stimulant; Immuno-oncology therapy,anti-CD19 anti-CD20 Bispecific CAR redirected autologous T-cells,Beijing Doing Biomedical Co.,,,0,['anti-CD19 anti-CD20 Bispecific CAR redirected autologous T-cells'],,0,[],0
"human CD19 T cell therapy, HRAIN Biotechnology",CD19 antagonist; Immuno-oncology therapy,human CD19 T cell therapy,HRAIN Biotechnology,,,0,['human CD19 T cell therapy'],,0,[],0
TAK-007,Natural killer cell stimulant; Immuno-oncology therapy,TAK-007,,TAK-007,tak 007,fexact,"['CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell acute lymphocytic leukemia/chronic lymphocytic leukemia/non-Hodgkin lymphoma/diffuse large B-cell/follicular/mantle cell lymphoma), MD Anderson Cancer Center', 'CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell/diffuse large B-cell/follicular/mantle cell lymphoma),/ MD Anderson Cancer Center', 'allogeneic anti-cd19 car nk-cell therapy (membrane-bound il-15, b-cell lymphoma), takeda', 'CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell/diffuse large B-cell/follicular/mantle cell lymphoma)', 'car.cd19-cd28-zeta-2a-icasp9-il15-transduced cb-nk cells (b-cell/diffuse large b-cell/follicular/mantle cell lymphoma)', 'ic9/car.19/il15-transduced cb-nk cells (b-cell lymphoma)', 'CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell/diffuse large B-cell/follicular/mantle cell lymphoma), MD Anderson Cancer Center', 'CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (B-cell/diffuse large B-cell/follicular/mantle cell lymphoma), Takeda', 'allogeneic anti-CD19 CAR NK-cell therapy (membrane-bound IL-15, B-cell lymphoma), Takeda/MD Anderson Cancer Center', 'allogeneic anti-cd19 car nk-cell therapy (membrane-bound il-15, b-cell lymphoma)', 'anti-CD19 CAR NK-cell therapy (B-cell lymphoma), Takeda/MD Anderson Cancer Center', 'car.cd19-cd28-zeta-2a-icasp9-il15-transduced cb-nk cells (cancer)', 'anti-cd19 car nk-cell therapy (b-cell lymphoma)', 'anti-cd19 car nk-cell therapy (b-cell lymphoma), takeda', 'TAK-007', 'car.cd19-cd28-zeta-2a-icasp9-il15-transduced cb-nk cells (b-cell acute lymphocytic leukemia/chronic lymphocytic leukemia/non-hodgkin lymphoma/diffuse large b-cell/follicular/mantle cell lymphoma)', 'iC9/CAR.19/IL15-transduced CB-NK cells (B-cell lymphoma),/MD Anderson Cancer Center', 'CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells (cancer),/ MD Anderson Cancer Center']",TAK-007,fexact,"['car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells b cell acute lymphocytic leukemia chronic lymphocytic leukemia non hodgkin lymphoma diffuse large b cell follicular mantle cell lymphoma md anderson cancer center', 'car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells b cell diffuse large b cell follicular mantle cell lymphoma md anderson cancer center', 'allogeneic anti cd19 car nk cell therapy membrane bound il 15 b cell lymphoma takeda', 'car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells b cell diffuse large b cell follicular mantle cell lymphoma', 'car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells b cell diffuse large b cell follicular mantle cell lymphoma', 'ic9 car 19 il15 transduced cb nk cells b cell lymphoma', 'car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells b cell diffuse large b cell follicular mantle cell lymphoma md anderson cancer center', 'car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells b cell diffuse large b cell follicular mantle cell lymphoma takeda', 'allogeneic anti cd19 car nk cell therapy membrane bound il 15 b cell lymphoma takeda md anderson cancer center', 'allogeneic anti cd19 car nk cell therapy membrane bound il 15 b cell lymphoma', 'anti cd19 car nk cell therapy b cell lymphoma takeda md anderson cancer center', 'car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells cancer', 'anti cd19 car nk cell therapy b cell lymphoma', 'anti cd19 car nk cell therapy b cell lymphoma takeda', 'tak 007', 'car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells b cell acute lymphocytic leukemia chronic lymphocytic leukemia non hodgkin lymphoma diffuse large b cell follicular mantle cell lymphoma', 'ic9 car 19 il15 transduced cb nk cells b cell lymphoma md anderson cancer center', 'car cd19 cd28 zeta 2a icasp9 il15 transduced cb nk cells cancer md anderson cancer center']",correct_mapping
"hTERT DNA vaccine, Invectys",Telomerase stimulant,hTERT DNA vaccine,Invectys,,,0,['hTERT DNA vaccine'],,0,[],0
BNC-105,Angiogenesis inhibitor; Tubulin inhibitor,BNC-105,,BNC-105P,bnc 105p,fuzzy,['BNC-105P'],BNC-105P,fexact,['bnc 105p'],incorrect_mapping
ONO-4059 (tablet),Bruton tyrosine kinase inhibitor,ONO-4059,,tirabrutinib hydrochloride,ono 4059,fexact,"['GS-4059', 'tirabrutinib hydrochloride', 'Btk tyrosine kinase inhibitor (oral/tablet/capsule, B-cell malignancies/autoimmune diseases), Ono Pharmaceutical/', 'ONO-4059', 'Velexbru', 'tirabrutinib', 'Btk tyrosine kinase inhibitor (oral/tablet/capsule, B-cell malignancies/autoimmune diseases),/']",tirabrutinib hydrochloride,fexact,"['gs 4059', 'tirabrutinib hydrochloride', 'btk tyrosine kinase inhibitor oral tablet capsule b cell malignancies autoimmune diseases ono pharmaceutical', 'ono 4059', 'velexbru', 'tirabrutinib', 'btk tyrosine kinase inhibitor oral tablet capsule b cell malignancies autoimmune diseases']",correct_mapping
CD30-CAR-T cells,CD30 antagonist; T cell stimulant; Immuno-oncology therapy,CD30-CAR-T cells,,,,0,['CD30-CAR-T cells'],,0,[],0
plamotamab,CD3 agonist; Immuno-oncology therapy,plamotamab,,plamotamab,plamotamab,fexact,"['plamotamab', 'XmAb-13677', 'bispecific antibody program (CD3 x CD20 target, B-cell malignancies),/', 'XmAb-13676', 'bispecific antibody program (CD3 x CD20 target, B-cell malignancies), Xencor/', 'anti-CD3/anti-CD20 bispecific T-cell engager (B-cell malignancies), Xencor/', 'THG-338', 'anti-CD3/anti-CD20 bispecific T-cell engager (B-cell malignancies),/', 'XENP-13677']",plamotamab,fexact,"['plamotamab', 'xmab 13677', 'bispecific antibody program cd3 x cd20 target b cell malignancies', 'xmab 13676', 'bispecific antibody program cd3 x cd20 target b cell malignancies xencor', 'anti cd3 anti cd20 bispecific t cell engager b cell malignancies xencor', 'thg 338', 'anti cd3 anti cd20 bispecific t cell engager b cell malignancies', 'xenp 13677']",correct_mapping
"alpha CD19-TCRz-CD137 CAR-T cells, Hrain Biotechnology",T cell stimulant; Immuno-oncology therapy,alpha CD19-TCRz-CD137 CAR-T cells,Hrain Biotechnology,,,0,['alpha CD19-TCRz-CD137 CAR-T cells'],,0,[],0
"alpha CD22-TCRz-CD137, Hrain Biotechnology",T cell stimulant; Immuno-oncology therapy,alpha CD22-TCRz-CD137,Hrain Biotechnology,,,0,['alpha CD22-TCRz-CD137'],,0,[],0
ONO-4059 (Capsule),Bruton tyrosine kinase inhibitor,ONO-4059,,tirabrutinib hydrochloride,ono 4059,fexact,"['GS-4059', 'tirabrutinib hydrochloride', 'Btk tyrosine kinase inhibitor (oral/tablet/capsule, B-cell malignancies/autoimmune diseases), Ono Pharmaceutical/', 'ONO-4059', 'Velexbru', 'tirabrutinib', 'Btk tyrosine kinase inhibitor (oral/tablet/capsule, B-cell malignancies/autoimmune diseases),/']",tirabrutinib hydrochloride,fexact,"['gs 4059', 'tirabrutinib hydrochloride', 'btk tyrosine kinase inhibitor oral tablet capsule b cell malignancies autoimmune diseases ono pharmaceutical', 'ono 4059', 'velexbru', 'tirabrutinib', 'btk tyrosine kinase inhibitor oral tablet capsule b cell malignancies autoimmune diseases']",correct_mapping
PCAR-119,T cell stimulant; Immuno-oncology therapy,PCAR-119,,PCAR-119,pcar 119,fexact,"['anti-CD19 CAR-NK cell therapy, PersonGen BioTherapeutics', 'PCAR-119']",PCAR-119,fexact,"['anti cd19 car nk cell therapy persongen biotherapeutics', 'pcar 119']",correct_mapping
PCAR-019,T cell stimulant; Immuno-oncology therapy,PCAR-019,,PCAR-019,pcar 019,fexact,"['BSJAK-001', 'anti-CD19 CAR T-cell therapy (leukemia/lymphoma), PersonGen Anke Cell Technology', 'anti-CD19 CAR T-cell therapy (leukemia/lymphoma)', 'anti-CD19 CAR T-cell therapy (leukemia/lymphoma), PersonGen Biomedicine', 'PCAR-019']",PCAR-019,fexact,"['bsjak 001', 'anti cd19 car t cell therapy leukemia lymphoma persongen anke cell technology', 'anti cd19 car t cell therapy leukemia lymphoma', 'anti cd19 car t cell therapy leukemia lymphoma persongen biomedicine', 'pcar 019']",correct_mapping
dimethyl fumarate,Transcription factor Nrf2 stimulant,dimethyl fumarate,,dimethyl fumarate,dimethyl fumarate,fexact,"['BG-12', 'BG-00012', 'second-generation fumarate derivative (psoriasis), Fumapharm/', 'fumarate derivative (second-generation, psoriasis), Fumapharm/', 'dimethyl fumarate', 'FAG-201', 'Panaclar', 'dimethyl fumarate (oral, psoriasis)', 'Tecfidera']",dimethyl fumarate,fexact,"['bg 12', 'bg 00012', 'second generation fumarate derivative psoriasis fumapharm', 'fumarate derivative second generation psoriasis fumapharm', 'dimethyl fumarate', 'fag 201', 'panaclar', 'dimethyl fumarate oral psoriasis', 'tecfidera']",correct_mapping
"CD19-CAR-T cells, iCarTAB BioMed",Immuno-oncology therapy,CD19-CAR-T cells,iCarTAB BioMed,anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),cd19 car t cells,fexact,"['anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia)', 'cd19 car-t cells']",anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),fexact,"['anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'cd19 car t cells']",correct_mapping
ICTCAR-011,T cell stimulant; Immuno-oncology therapy,ICTCAR-011,,,,0,['ICTCAR-011'],,0,[],0
ibrutinib (tablet),Bruton tyrosine kinase inhibitor,ibrutinib,,ibrutinib,ibrutinib,fexact,"['Btk inhibitor (cancer), Pharmacyclics/', 'JNJ-54179060', 'Yi Ke', 'PCI-32765', 'Btk inhibitors (autoimmune disease, lymphoma), Pharmacyclics', 'Btk inhibitors (autoimmune disease, lymphoma)', 'B-cell associated tyrosine kinase inhibitors (lymphoma, autoimmune disease)', 'B-cell-associated tyrosine kinase inhibitors (lymphoma, autoimmune disease)', 'PCI-45261', 'CRA-032765', 'Imbruvica', 'B-cell-associated tyrosine kinase inhibitor (cancer),/', 'B-cell-associated tyrosine kinase inhibitor (cancer), Pharmacyclics/', 'Btk inhibitor (cancer), Pharmacyclics/Janssen Biotech', 'B-cell-associated tyrosine kinase inhibitors (lymphoma, autoimmune disease), Celera', 'B-cell associated tyrosine kinase inhibitors (lymphoma, autoimmune disease), Pharmacyclics', 'ibrutinib', 'B-cell-associated tyrosine kinase inhibitor (cancer), Pharmacyclics/Janssen Biotech', 'PCI-31523', 'Btk inhibitor (cancer),/']",ibrutinib,fexact,"['btk inhibitor cancer pharmacyclics', 'jnj 54179060', 'yi ke', 'pci 32765', 'btk inhibitors autoimmune disease lymphoma pharmacyclics', 'btk inhibitors autoimmune disease lymphoma', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease', 'pci 45261', 'cra 032765', 'imbruvica', 'b cell associated tyrosine kinase inhibitor cancer', 'b cell associated tyrosine kinase inhibitor cancer pharmacyclics', 'btk inhibitor cancer pharmacyclics janssen biotech', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease celera', 'b cell associated tyrosine kinase inhibitors lymphoma autoimmune disease pharmacyclics', 'ibrutinib', 'b cell associated tyrosine kinase inhibitor cancer pharmacyclics janssen biotech', 'pci 31523', 'btk inhibitor cancer']",correct_mapping
duvortuxizumab,CD3 agonist; Immuno-oncology therapy,duvortuxizumab,,duvortuxizumab,duvortuxizumab,fexact,"['anti-CD3/anti-CD19 bispecific T-cell engager (DART, cancer), MacroGenics/', 'anti-CD3/anti-CD19 bispecific T-cell engager (DART, cancer),/', 'MGD-011', 'duvortuxizumab', 'CD19xCD3 DART antibody (cancer), MacroGenics/', 'CD19xCD3 DART antibody (cancer),/', 'JNJ-64052781']",duvortuxizumab,fexact,"['anti cd3 anti cd19 bispecific t cell engager dart cancer macrogenics', 'anti cd3 anti cd19 bispecific t cell engager dart cancer', 'mgd 011', 'duvortuxizumab', 'cd19xcd3 dart antibody cancer macrogenics', 'cd19xcd3 dart antibody cancer', 'jnj 64052781']",correct_mapping
"alpha CD19-TCRz-CD28 CAR-T cells, Hrain Biotechnology",T cell stimulant; Immuno-oncology therapy,alpha CD19-TCRz-CD28 CAR-T cells,Hrain Biotechnology,,,0,['alpha CD19-TCRz-CD28 CAR-T cells'],,0,[],0
"CD19-CAR T cells, Beijing Doing Biomedical",T cell stimulant; Immuno-oncology therapy,CD19-CAR T cells,Beijing Doing Biomedical,anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),cd19 car t cells,fexact,"['anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia)', 'cd19 car-t cells']",anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),fexact,"['anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'cd19 car t cells']",correct_mapping
ofatumumab,CD20 antagonist; Immuno-oncology therapy,ofatumumab,,ofatumumab,ofatumumab,fexact,"['anti-CD20 human monoclonal antibody (intravenous), GlaxoSmithKline/', 'HuMax-CD20', 'anti-CD20 human monoclonal antibody (intravenous),/', 'GSK-1841157', 'ofatumumab', '2F2', 'Arzerra']",ofatumumab,fexact,"['anti cd20 human monoclonal antibody intravenous glaxosmithkline', 'humax cd20', 'anti cd20 human monoclonal antibody intravenous', 'gsk 1841157', 'ofatumumab', '2f2', 'arzerra']",correct_mapping
MT-3724,Protein synthesis inhibitor,MT-3724,,MT-3724,mt 3724,fexact,"['anti-CD20 engineered toxin bodies (lymphoma)', 'MT-3724', 'anti-CD20 ETBs (lymphoma)']",MT-3724,fexact,"['anti cd20 engineered toxin bodies lymphoma', 'mt 3724', 'anti cd20 etbs lymphoma']",correct_mapping
zandelisib,PI3 kinase delta inhibitor,zandelisib,,zandelisib,zandelisib,fexact,"['delta selective phosphatidylinositol-3-kinase inhibitors (cancer/inflammation)', 'ME-401', 'delta selective phosphatidylinositol-3-kinase inhibitors (cancer/inflammation),/University of Auckland', 'delta selective PI3K inhibitors (cancer/inflammation)', 'PWT-143', 'delta selective PI3K inhibitors (cancer/inflammation),/', 'zandelisib', 'delta selective PI3K inhibitors (cancer/inflammation), Pathway Therapeutics', 'delta selective phosphatidylinositol-3-kinase inhibitors (cancer/inflammation), Pathway Therapeutics/University of Auckland', 'delta selective PI3K inhibitors (cancer/inflammation), MEI Pharma/']",zandelisib,fexact,"['delta selective phosphatidylinositol 3 kinase inhibitors cancer inflammation', 'me 401', 'delta selective phosphatidylinositol 3 kinase inhibitors cancer inflammation university of auckland', 'delta selective pi3k inhibitors cancer inflammation', 'pwt 143', 'delta selective pi3k inhibitors cancer inflammation', 'zandelisib', 'delta selective pi3k inhibitors cancer inflammation pathway therapeutics', 'delta selective phosphatidylinositol 3 kinase inhibitors cancer inflammation pathway therapeutics university of auckland', 'delta selective pi3k inhibitors cancer inflammation mei pharma']",correct_mapping
mosunetuzumab,CD3 agonist; Immuno-oncology therapy,mosunetuzumab,,mosunetuzumab,mosunetuzumab,fexact,"['mosunetuzumab', 'anti-CD3/anti-CD20 bispecific T-cell engager (TDB, B-cell malignancies), Genentech', 'anti-CD3/anti-CD20 bispecific T-cell engager (TDB, B-cell malignancies)', 'T-cell directed bispecific CD20/CD3 targeting compound', 'CD20-TDB', 'T-cell directed bispecific CD20/CD3 targeting compound, Genentech', 'BTCT-4465A', 'RO-7030816', 'RG-7828']",mosunetuzumab,fexact,"['mosunetuzumab', 'anti cd3 anti cd20 bispecific t cell engager tdb b cell malignancies genentech', 'anti cd3 anti cd20 bispecific t cell engager tdb b cell malignancies', 't cell directed bispecific cd20 cd3 targeting compound', 'cd20 tdb', 't cell directed bispecific cd20 cd3 targeting compound genentech', 'btct 4465a', 'ro 7030816', 'rg 7828']",correct_mapping
tirabrutinib,Bruton tyrosine kinase inhibitor,tirabrutinib,,tirabrutinib hydrochloride,tirabrutinib,fexact,"['GS-4059', 'tirabrutinib hydrochloride', 'Btk tyrosine kinase inhibitor (oral/tablet/capsule, B-cell malignancies/autoimmune diseases), Ono Pharmaceutical/', 'ONO-4059', 'Velexbru', 'tirabrutinib', 'Btk tyrosine kinase inhibitor (oral/tablet/capsule, B-cell malignancies/autoimmune diseases),/']",tirabrutinib hydrochloride,fexact,"['gs 4059', 'tirabrutinib hydrochloride', 'btk tyrosine kinase inhibitor oral tablet capsule b cell malignancies autoimmune diseases ono pharmaceutical', 'ono 4059', 'velexbru', 'tirabrutinib', 'btk tyrosine kinase inhibitor oral tablet capsule b cell malignancies autoimmune diseases']",correct_mapping
"ACTR cancer therapy, Unum Therapeutics",Immunostimulant,ACTR cancer therapy,Unum Therapeutics,,,0,['ACTR cancer therapy'],,0,[],0
sotrastaurin,Immunosuppressant; Protein kinase C inhibitor; Protein kinase inhibitor; T cell inhibitor,sotrastaurin,,sotrastaurin,sotrastaurin,fexact,"['PKC inhibitors (transplant rejection)', 'sotrastaurin acetate', 'NVP-AEB-071', 'protein kinase C inhibitors (immunosuppressant)', 'sotrastaurin', 'AEB-071']",sotrastaurin,fexact,"['pkc inhibitors transplant rejection', 'sotrastaurin acetate', 'nvp aeb 071', 'protein kinase c inhibitors immunosuppressant', 'sotrastaurin', 'aeb 071']",correct_mapping
GS-9901,PI3 kinase delta inhibitor,GS-9901,,GS-9901,gs 9901,fexact,['GS-9901'],GS-9901,fexact,['gs 9901'],correct_mapping
ROR1R-CAR-T Cells,Immuno-oncology therapy,ROR1R-CAR-T Cells,,,,0,['ROR1R-CAR-T Cells'],,0,[],0
CD19.CAR-CD28Z T cells,Immuno-oncology therapy,CD19.CAR-CD28Z T cells,,,,0,['CD19.CAR-CD28Z T cells'],,0,[],0
"A6, Angstrom",Angiogenesis inhibitor; CD44 antagonist,A6,Angstrom,,,0,['A6'],,0,[],0
fenebrutinib,Bruton tyrosine kinase inhibitor,fenebrutinib,,fenebrutinib,fenebrutinib,fexact,"['fenebrutinib', 'GDC-0853', 'RG-7845', 'RO-7010939']",fenebrutinib,fexact,"['fenebrutinib', 'gdc 0853', 'rg 7845', 'ro 7010939']",correct_mapping
Oncoquest,Immuno-oncology therapy,Oncoquest,,,,0,['Oncoquest'],,0,[],0
dezapelisib,PI3 kinase delta inhibitor,dezapelisib,,dezapelisib,dezapelisib,fexact,"['PI3K delta inhibitor (1) (B-cell lymphoma)', 'INCB-040093', 'INCB-40093', 'dezapelisib']",dezapelisib,fexact,"['pi3k delta inhibitor 1 b cell lymphoma', 'incb 040093', 'incb 40093', 'dezapelisib']",correct_mapping
NOV-5 (IV),B-cell activator factor receptor antagonist,NOV-5,,,,0,['NOV-5'],,0,[],0
IMMU-114,Unidentified pharmacological activity,IMMU-114,,IMMU-114,immu 114,fexact,"['HLA-DR mAb (cancer)', 'IMMU-114']",IMMU-114,fexact,"['hla dr mab cancer', 'immu 114']",correct_mapping
acalisib,PI3 kinase beta inhibitor; PI3 kinase delta inhibitor,acalisib,,GS-9820,acalisib,fexact,"['CAL-120', 'acalisib', 'PI3K beta and delta inhibitor (solid tumor)', 'GS-9820']",GS-9820,fexact,"['cal 120', 'acalisib', 'pi3k beta and delta inhibitor solid tumor', 'gs 9820']",correct_mapping
"bendamustine, Shandong Lanjin",DNA inhibitor; Apoptosis stimulant,bendamustine,Shandong Lanjin,bendamustine,bendamustine,fexact,"['Cytostasan', 'SDX-105', 'SyB L-0501', 'Benda', 'bendamustine', 'Inno-P08001', 'Treakisym', 'Innomustine', 'SyB L-0501RI', 'Treanda', 'bendamustine hydrochloride', 'Levact', 'Ribomustin', 'SyBL-0501', 'Ribovact', 'Symbenda']",bendamustine,fexact,"['cytostasan', 'sdx 105', 'syb l 0501', 'benda', 'bendamustine', 'inno p08001', 'treakisym', 'innomustine', 'syb l 0501ri', 'treanda', 'bendamustine hydrochloride', 'levact', 'ribomustin', 'sybl 0501', 'ribovact', 'symbenda']",correct_mapping
otlertuzumab,B-cell inhibitor; Apoptosis stimulant,otlertuzumab,,otlertuzumab,otlertuzumab,fexact,"['Tru 16.4', 'CD37 antagonist, Emergent', 'CytoxB37G', 'SMIP-016', 'otlertuzumab', 'SMIP-016-GV', 'TRU-016', 'CD37 antagonist', 'CD37 antagonist, Trubion', 'CD37-SMIP', '16.4', 'G28-1 scFv-Ig']",otlertuzumab,fexact,"['tru 16 4', 'cd37 antagonist emergent', 'cytoxb37g', 'smip 016', 'otlertuzumab', 'smip 016 gv', 'tru 016', 'cd37 antagonist', 'cd37 antagonist trubion', 'cd37 smip', '16 4', 'g28 1 scfv ig']",correct_mapping
stenoparib,Poly ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor; Poly ADP ribose polymerase 1 inhibitor; Tankyrase inhibitor,stenoparib,,stenoparib,stenoparib,fexact,"['PARP1/2 and Tankyrase 1/2 inhibitor (oral, advanced solid tumors/coronavirus disease 19 infection), Oncology Venture US', 'PARP1/2 and Tankyrase 1/2 inhibitor (advanced solid tumors/COVID-19), 2X Oncology', 'E-7449', 'PARP inhibitor (cancer)', '2X-121', 'stenoparib', 'MGI-25036', 'PARP1/2 and Tankyrase 1/2 inhibitor (oral, advanced solid tumors/coronavirus disease 19 infection)', 'stenoparib, Allarity Therapeutics']",stenoparib,fexact,"['parp1 2 and tankyrase 1 2 inhibitor oral advanced solid tumors coronavirus disease 19 infection oncology venture us', 'parp1 2 and tankyrase 1 2 inhibitor advanced solid tumors covid 19 2x oncology', 'e 7449', 'parp inhibitor cancer', '2x 121', 'stenoparib', 'mgi 25036', 'parp1 2 and tankyrase 1 2 inhibitor oral advanced solid tumors coronavirus disease 19 infection', 'stenoparib allarity therapeutics']",correct_mapping
interleukin-2 gene therapy,Interleukin 2 receptor agonist,interleukin-2 gene therapy,,,,0,"['IL-2 gene therapy', 'interleukin-2 gene therapy', 'AC-9401', 'interleukin-2 gene therapy, Chiron Viagene', 'MetaGene']",,Drug_API_mapping,[],0
CD40 ligand gene therapy (Ad-CD154),CD40 ligand agonist,CD40 ligand gene therapy,,,,0,['CD40 ligand gene therapy'],,0,[],0
allogeneic CD19.CAR central memory T cells,T cell stimulant; Immuno-oncology therapy,allogeneic CD19.CAR central memory T cells,,,,0,['allogeneic CD19.CAR central memory T cells'],,0,[],0
AFX-2,Immunostimulant,AFX-2,,,,0,['AFX-2'],,0,[],0
naratuximab emtansine,Microtubule inhibitor; CD37 antagonist,naratuximab emtansine,,DEBIO-1562,naratuximab emtansine,fexact,"['K1753A/DM-1 conjugate (cancer, TAP), ImmunoGen', 'DEBIO-1562', 'K7153A-SMCC-DM1', 'IMGN-529', 'anti-CD37/maytansinoid derivative conjugate (cancer, TAP), ImmunoGen', 'K1753A/DM-1 conjugate (cancer, TAP)', 'naratuximab emtansine', 'anti-CD37/maytansinoid derivative conjugate (cancer, TAP)', 'naratuximab-SMCC-DM1']",DEBIO-1562,fexact,"['k1753a dm 1 conjugate cancer tap immunogen', 'debio 1562', 'k7153a smcc dm1', 'imgn 529', 'anti cd37 maytansinoid derivative conjugate cancer tap immunogen', 'k1753a dm 1 conjugate cancer tap', 'naratuximab emtansine', 'anti cd37 maytansinoid derivative conjugate cancer tap', 'naratuximab smcc dm1']",correct_mapping
cladribine (SC),Immunosuppressant; Adenosine deaminase inhibitor; DNA synthesis inhibitor,cladribine,,cladribine,cladribine,fexact,"['2-CdA', 'RWJ-26251', '2-chlorodeoxyadenosine', 'NSC-105014F', 'cladribine', 'Litak', 'Leustat', 'Leustatin']",cladribine,fexact,"['2 cda', 'rwj 26251', '2 chlorodeoxyadenosine', 'nsc 105014f', 'cladribine', 'litak', 'leustat', 'leustatin']",correct_mapping
19-28z CAR transduced EBV-CTL,Immuno-oncology therapy,19-28z CAR transduced EBV-CTL,,,,0,['19-28z CAR transduced EBV-CTL'],,0,[],0
"pneumococcal vaccine, Lederle",Immunostimulant,pneumococcal vaccine,Lederle,,,0,['pneumococcal vaccine'],,0,[],0
"rituximab (SC), Halozyme",CD20 antagonist,rituximab,Halozyme,rituximab biosimilar,rituximab,fexact,"['GP-2013', 'Riximyo', 'Rixathon', 'rituximab biosimilar', 'Rituximab BS', 'rituximab', 'rituximab biosimilar, Sandoz']",rituximab biosimilar,fexact,"['gp 2013', 'riximyo', 'rixathon', 'rituximab biosimilar', 'rituximab bs', 'rituximab', 'rituximab biosimilar sandoz']",correct_mapping
"azacitidine, Luitpold",DNA synthesis inhibitor; DNA methylase inhibitor; RNA synthesis inhibitor,azacitidine,Luitpold,"azacytidine (inhaled aerosol, lung cancer)",azacitidine,fexact,"['azacitidine', 'azacytidine (inhaled aerosol, lung cancer)', '5-azacytidine (inhaled aerosol, lung cancer)', '5-azacitidine']","azacytidine (inhaled aerosol, lung cancer)",fexact,"['azacitidine', 'azacytidine inhaled aerosol lung cancer', '5 azacytidine inhaled aerosol lung cancer', '5 azacitidine']",correct_mapping
AMG-319,PI3 kinase delta inhibitor,AMG-319,,AMG-319,amg 319,fexact,['AMG-319'],AMG-319,fexact,['amg 319'],correct_mapping
valganciclovir (tablet),DNA synthesis inhibitor; DNA directed DNA polymerase inhibitor,valganciclovir,,valganciclovir,valganciclovir,fexact,"['valganciclovir', 'RG-127', 'RoValcyte', 'Valixa', 'Valcyt', 'Cymeval', 'TA-9070', 'Darilin', 'Valcyte']",valganciclovir,fexact,"['valganciclovir', 'rg 127', 'rovalcyte', 'valixa', 'valcyt', 'cymeval', 'ta 9070', 'darilin', 'valcyte']",correct_mapping
pinatuzumab vedotin,Tubulin inhibitor,pinatuzumab vedotin,,pinatuzumab vedotin,pinatuzumab vedotin,fexact,"['pinatuzumab vedotin', 'anti-CD22-mc-MMAE', 'CD22-targeting antibody-drug conjugate (hematological malignancies)', 'RG-7593', 'anti-CD22-MCC-DM1', 'anti-CD22-MC-MMAF', 'CD22-targeting antibody-drug conjugates (cancer)', 'anti-CD22-mafodotin', 'anti-CD22-mc-vc-PAB-MMAE', 'anti-CD22-SGD-1269', 'DCDT-2980S', 'anti-CD22-MMAE', 'anti-CD22-MC-monomethyl auristatin phenylalanine']",pinatuzumab vedotin,fexact,"['pinatuzumab vedotin', 'anti cd22 mc mmae', 'cd22 targeting antibody drug conjugate hematological malignancies', 'rg 7593', 'anti cd22 mcc dm1', 'anti cd22 mc mmaf', 'cd22 targeting antibody drug conjugates cancer', 'anti cd22 mafodotin', 'anti cd22 mc vc pab mmae', 'anti cd22 sgd 1269', 'dcdt 2980s', 'anti cd22 mmae', 'anti cd22 mc monomethyl auristatin phenylalanine']",correct_mapping
roniciclib (oral solution),Cyclin-dependent kinase inhibitor,roniciclib,,roniciclib,roniciclib,fexact,"['cyclin-dependent kinase inhibitors (anticancer)', 'BAY-1000394', 'CDK inhibitors (anticancer)', 'BAY-80-3000', 'roniciclib']",roniciclib,fexact,"['cyclin dependent kinase inhibitors anticancer', 'bay 1000394', 'cdk inhibitors anticancer', 'bay 80 3000', 'roniciclib']",correct_mapping
BP-100-1.02,Bcl2 inhibitor,BP-100-1.02,,BP-100-1.02,bp 100 1 02,fexact,"['L-Bcl-2', 'BP-100-1.02', 'liposomal bcl-2 (lymphoma/solid tumor)', 'liposomal Bcl-2 (iv, lymphoma/solid tumor/mantle cell lymphoma/peripheral T-cell lymphoma/cutaneous T-cell lymphoma/follicular lymphoma/marginal zone lymphoma/diffuse large cell lymphoma/hodgkin lymphoma/Waldenstrom Macroglobulinemia)', 'liposomal Bcl-2 (lymphoma/solid tumor), MD Anderson Cancer Center', 'BP-1002', 'liposomal Bcl-2 (lymphoma/solid tumor)']",BP-100-1.02,fexact,"['l bcl 2', 'bp 100 1 02', 'liposomal bcl 2 lymphoma solid tumor', 'liposomal bcl 2 iv lymphoma solid tumor mantle cell lymphoma peripheral t cell lymphoma cutaneous t cell lymphoma follicular lymphoma marginal zone lymphoma diffuse large cell lymphoma hodgkin lymphoma waldenstrom macroglobulinemia', 'liposomal bcl 2 lymphoma solid tumor md anderson cancer center', 'bp 1002', 'liposomal bcl 2 lymphoma solid tumor']",correct_mapping
axicabtagene ciloleucel,T cell stimulant; Immuno-oncology therapy,axicabtagene ciloleucel,,axicabtagene ciloleucel,axicabtagene ciloleucel,fexact,"['axicel', 'axicabtagene ciloleucel', 'KTE-C19', 'anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma), Kite Pharma', 'eACT (cancer), Kite Pharma', 'Yescarta', 'axi-cel', 'FKC-876', 'KTE-X19', 'eACT (cancer)', 'anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma)']",axicabtagene ciloleucel,fexact,"['axicel', 'axicabtagene ciloleucel', 'kte c19', 'anti cd19 car t cell therapy non hodgkin lymphoma kite pharma', 'eact cancer kite pharma', 'yescarta', 'axi cel', 'fkc 876', 'kte x19', 'eact cancer', 'anti cd19 car t cell therapy non hodgkin lymphoma']",correct_mapping
lymphomun,CD3 agonist; CD20 antagonist; Immuno-oncology therapy,lymphomun,,FBT-A05,lymphomun,fexact,"['anti-CD20 bivalent monoclonal antibody (B-cell lymphoma, Triomab), Trion/Fresenius', 'trifunctional antibody therapy (blood malignancy), Fresenius/Trion', 'anti-CD3/anti-CD20 T-cell engager (Triomab, hematological cancer), Lindis', 'anti-CD20 bivalent monoclonal antibody (B-cell lymphoma, Triomab),/Fresenius', 'TPBs-05', 'Lymphomun', 'trifunctional antibody therapy (blood malignancy), Fresenius/', 'FBT-A05', 'Bi-20']",FBT-A05,fexact,"['anti cd20 bivalent monoclonal antibody b cell lymphoma triomab trion fresenius', 'trifunctional antibody therapy blood malignancy fresenius trion', 'anti cd3 anti cd20 t cell engager triomab hematological cancer lindis', 'anti cd20 bivalent monoclonal antibody b cell lymphoma triomab fresenius', 'tpbs 05', 'lymphomun', 'trifunctional antibody therapy blood malignancy fresenius', 'fbt a05', 'bi 20']",correct_mapping
navitoclax (oral solution),Bcl2 inhibitor; Apoptosis stimulant; Bcl-XL inhibitor,navitoclax,,navitoclax,navitoclax,fexact,"['cancer therapeutics (Bcl-2/Bcl-xL inhibitors)', 'Bax modulators (anticancer), Idun/', 'Bax modulators (anticancer),/', 'ABT-263', 'A-438744', 'A-371191', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors),/Idun', 'navitoclax dihydrochloride', 'Bcl-2/Bcl-xL inhibitors (anticancer),/Idun', 'RG-7433', 'Bcl-2/Bcl-xL inhibitors (anticancer), Abbott/Idun', 'Bax modulators (anticancer), Idun/Abbott', 'Bcl-2/Bcl-xL inhibitors (anticancer),/', 'Bcl-2/Bcl-xL inhibitors (anticancer)', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors),/', 'navitoclax', 'A-385358', 'Bax modulators (anticancer, oral), Abbott', 'Bax modulators (anticancer, oral)', 'A-855071.0', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott/Idun', 'A-317267', 'Bcl-2/Bcl-xL inhibitors (anticancer), Abbott', 'cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott']",navitoclax,fexact,"['cancer therapeutics bcl 2 bcl xl inhibitors', 'bax modulators anticancer idun', 'bax modulators anticancer', 'abt 263', 'a 438744', 'a 371191', 'cancer therapeutics bcl 2 bcl xl inhibitors idun', 'navitoclax dihydrochloride', 'bcl 2 bcl xl inhibitors anticancer idun', 'rg 7433', 'bcl 2 bcl xl inhibitors anticancer abbott idun', 'bax modulators anticancer idun abbott', 'bcl 2 bcl xl inhibitors anticancer', 'bcl 2 bcl xl inhibitors anticancer', 'cancer therapeutics bcl 2 bcl xl inhibitors', 'navitoclax', 'a 385358', 'bax modulators anticancer oral abbott', 'bax modulators anticancer oral', 'a 855071 0', 'cancer therapeutics bcl 2 bcl xl inhibitors abbott idun', 'a 317267', 'bcl 2 bcl xl inhibitors anticancer abbott', 'cancer therapeutics bcl 2 bcl xl inhibitors abbott']",correct_mapping
undisclosed - cytotoxic treatment,Unidentified pharmacological activity,undisclosed - cytotoxic treatment,,,,0,['undisclosed - cytotoxic treatment'],,0,[],0
"CD19 chimeric antigen receptor T-cell therapy, Ziopharm",T cell stimulant; Immuno-oncology therapy,CD19 chimeric antigen receptor T-cell therapy,Ziopharm,,,0,['CD19 chimeric antigen receptor T-cell therapy'],,0,[],0
ISF-35 (intranodal),CD40 agonist; CD40 ligand agonist; Immuno-oncology therapy; Immune checkpoint stimulant,ISF-35,,ISF-35,isf 35,fexact,"['MEM-40', 'rAd.CD40L', 'ISF-35', 'CD40 costimulator (adenoviral vector, cancer)', 'Ad-ISF35', 'immune stimulating factor 35']",ISF-35,fexact,"['mem 40', 'rad cd40l', 'isf 35', 'cd40 costimulator adenoviral vector cancer', 'ad isf35', 'immune stimulating factor 35']",correct_mapping
"poly-ICLC, Oncovir (intratumoral)",Toll-like receptor 3 agonist,poly-ICLC,Oncovir,Poly-ICLC,poly iclc,fexact,"['Hiltonol', 'interferon inducer (cancer/viral diseases)', 'polyinosinic-polycytidilic acid', 'Poly-ICLC', 'NSC-301463']",Poly-ICLC,fexact,"['hiltonol', 'interferon inducer cancer viral diseases', 'polyinosinic polycytidilic acid', 'poly iclc', 'nsc 301463']",correct_mapping
milatuzumab,CD74 antagonist; Immuno-oncology therapy,milatuzumab,,milatuzumab,milatuzumab,fexact,"['hLL1', 'MelanomaCide', 'milatuzumab', 'IMMU-115', 'MyelomaCide Y-90', 'LL1', 'hCD74 antibody (mutilple myeloma/ melanoma)', 'MyelomaCide']",milatuzumab,fexact,"['hll1', 'melanomacide', 'milatuzumab', 'immu 115', 'myelomacide y 90', 'll1', 'hcd74 antibody mutilple myeloma melanoma', 'myelomacide']",correct_mapping
zidovudine,Nucleoside reverse transcriptase inhibitor,zidovudine,,zidovudine,zidovudine,fexact,"['Retrovir', 'AZT', 'zidovudine']",zidovudine,fexact,"['retrovir', 'azt', 'zidovudine']",correct_mapping
lumiliximab,Immunosuppressant; CD23 antagonist; Apoptosis stimulant,lumiliximab,,lumiliximab,lumiliximab,fexact,"['IDEC-152', 'gomiliximab', 'PRIMATIZED anti-CD23 antibody', 'lumiliximab', 'PRIMATIZED anti-CD23 antibody, IDEC', 'ST-152', 'SI-3401']",lumiliximab,fexact,"['idec 152', 'gomiliximab', 'primatized anti cd23 antibody', 'lumiliximab', 'primatized anti cd23 antibody idec', 'st 152', 'si 3401']",correct_mapping
givinostat,Interleukin 1b antagonist; Interleukin 6 receptor antagonist; Tumour necrosis factor alpha antagonist; Histone deacetylase inhibitor,givinostat,,givinostat,givinostat,fexact,"['givinostat', 'ITF-2357']",givinostat,fexact,"['givinostat', 'itf 2357']",correct_mapping
ISF-35 (IV),CD40 agonist; CD40 ligand agonist; Immuno-oncology therapy; Immune checkpoint stimulant,ISF-35,,ISF-35,isf 35,fexact,"['MEM-40', 'rAd.CD40L', 'ISF-35', 'CD40 costimulator (adenoviral vector, cancer)', 'Ad-ISF35', 'immune stimulating factor 35']",ISF-35,fexact,"['mem 40', 'rad cd40l', 'isf 35', 'cd40 costimulator adenoviral vector cancer', 'ad isf35', 'immune stimulating factor 35']",correct_mapping
yttrium Y 90 anti-CD19 monoclonal antibody BU12,Immunostimulant,yttrium Y 90 anti-CD19 monoclonal antibody BU12,,,,0,['yttrium Y 90 anti-CD19 monoclonal antibody BU12'],,0,[],0
autologous CD20-specific T cells,T cell stimulant; Immuno-oncology therapy,autologous CD20-specific T cells,,,,0,['autologous CD20-specific T cells'],,0,[],0
MDX-1411,CD70 antagonist,MDX-1411,,MDX-1411,mdx 1411,fexact,"['anti-CD70 human monoclonal antibody-drug conjugate (cancer)', 'MDX-1411']",MDX-1411,fexact,"['anti cd70 human monoclonal antibody drug conjugate cancer', 'mdx 1411']",correct_mapping
MDX-1342 (IV),CD19 antagonist; Immuno-oncology therapy,MDX-1342,,MDX-1342,mdx 1342,fexact,"['MDX-1342', 'anti-CD19 (cancer), MDX/BMS', 'anti-CD19 antibody (cancer),/BMS']",MDX-1342,fexact,"['mdx 1342', 'anti cd19 cancer mdx bms', 'anti cd19 antibody cancer bms']",correct_mapping
PRO-131921,CD20 antagonist; Immuno-oncology therapy,PRO-131921,,PRO-131921,pro 131921,fexact,"['anti-CD20 mAb (hematogical cancer)', 'Non-Hodgkin lymphoma agent, Genentech', '3rd generation anti-CD20 mAb (hematological cancer)', 'anti-CD20 mAb (hematogical cancer), Genentech', 'PRO-131921', '3rd generation anti-CD20 mAb (hematological cancer), Genentech', 'third generation anti-CD20 mAb (hematological cancer)', 'third generation anti-CD20 mAb (hematological cancer), Genentech', 'Non-Hodgkin lymphoma agent']",PRO-131921,fexact,"['anti cd20 mab hematogical cancer', 'non hodgkin lymphoma agent genentech', '3rd generation anti cd20 mab hematological cancer', 'anti cd20 mab hematogical cancer genentech', 'pro 131921', '3rd generation anti cd20 mab hematological cancer genentech', 'third generation anti cd20 mab hematological cancer', 'third generation anti cd20 mab hematological cancer genentech', 'non hodgkin lymphoma agent']",correct_mapping
JCAR-015,T cell stimulant; Immuno-oncology therapy,JCAR-015,,vadacabtagene leraleucel,jcar 015,fexact,"['anti-CD19 CAR T-cell therapy (r/r ALL),//MSKCC', 'JCAR-15', '19-28z CAR  cells', 'anti-cd19 car t-cell therapy (cancer)', 'hCD19-targeting T-cell precursors (radiation-induced injury/cancer), MSKCC', 'anti-CD19 CAR T-cell therapy (cancer), Juno/', 'anti-CD19 CAR T-cell therapy (cancer),/', 'hCD19-targeting chimeric receptor-expressing allogeneic T-cell precursors (radiation-induced injury/cancer), Memorial Sloan Kettering', 'anti-CD19 CAR T-cell therapy (cancer), Juno/Celgene', 'anti-CD19 CAR T-cell therapy (r/r ALL), Juno Therapeutics//MSKCC', 'anti-CD19 CAR T-cell therapy (r/r ALL), Juno Therapeutics/Celgene/MSKCC', 'anti-CD19 CAR T-cell therapy (cancer), Memorial Sloan-Kettering Cancer Center', 'JCAR-015', 'vadacabtagene leraleucel']",vadacabtagene leraleucel,fexact,"['anti cd19 car t cell therapy r r all mskcc', 'jcar 15', '19 28z car cells', 'anti cd19 car t cell therapy cancer', 'hcd19 targeting t cell precursors radiation induced injury cancer mskcc', 'anti cd19 car t cell therapy cancer juno', 'anti cd19 car t cell therapy cancer', 'hcd19 targeting chimeric receptor expressing allogeneic t cell precursors radiation induced injury cancer memorial sloan kettering', 'anti cd19 car t cell therapy cancer juno celgene', 'anti cd19 car t cell therapy r r all juno therapeutics mskcc', 'anti cd19 car t cell therapy r r all juno therapeutics celgene mskcc', 'anti cd19 car t cell therapy cancer memorial sloan kettering cancer center', 'jcar 015', 'vadacabtagene leraleucel']",correct_mapping
CD40-ligand,Immunostimulant; T cell stimulant,CD40-ligand,,,,0,['CD40-ligand'],,0,[],0
BsAb 4G7xH22,CD19 antagonist,BsAb 4G7xH22,,,,0,['BsAb 4G7xH22'],,0,[],0
quarfloxacin,RNA synthesis inhibitor; Apoptosis stimulant,quarfloxacin,,itarnafloxin,quarfloxin,fuzzy,"['CX-3385', 'quadruplex DNA oncogene inhibitor (cancer)', 'c-Myc/VEGF oncogene inhibitor (cancer)', 'quarfloxin', 'CX-3543', 'itarnafloxin']",itarnafloxin,fexact,"['cx 3385', 'quadruplex dna oncogene inhibitor cancer', 'c myc vegf oncogene inhibitor cancer', 'quarfloxin', 'cx 3543', 'itarnafloxin']",incorrect_mapping
APO-866,Niacinamide phosphoribosyltransferase inhibitor,APO-866,,daporinad,apo 866,fexact,"['APO-866', 'WK-175', 'FK-866', 'daporinad']",daporinad,fexact,"['apo 866', 'wk 175', 'fk 866', 'daporinad']",correct_mapping
"interferon, Genentech (alpha2a)",Interferon alpha 2A agonist,interferon,Genentech,,,0,['interferon'],,0,[],0
KGEL,Immunostimulant,KGEL,,,,0,['KGEL'],,0,[],0
triciribine phosphate (IV),Protein kinase B inhibitor,triciribine phosphate,,,,0,"['triciribine phosphate (iv, cancer)', 'triciribine phosphate', 'triciribine (iv, cancer)', 'TCN-P', 'Akt phosphorylation inhibitor (cancer)', 'Akt phosphorylation inhibitor (cancer), Greenwich', 'triciribine (iv, breast/ovarian cancer/AML)', 'TCN', 'triciribine phosphate monohydrate', 'PTX-200, Prescient', 'tricyclic nucleoside (cancer)', 'PTX-002, Prescient', 'VQD-002 (iv, cancer)', 'triciribine', 'TCN-PM', 'triciribine phosphate (iv, cancer), Cahaba', 'triciribine (iv, breast/ovarian cancer/AML), Prescient', 'PTX-002', 'API-2', 'triciribine phosphate (iv, cancer), VioQuest', 'tricyclic nucleoside (cancer), Greenwich', 'VD-0002', 'PTX-200', 'triciribine (iv, cancer), VioQuest', 'VQD-002 (iv, cancer), VioQuest']",,NER_API,[],0
CNF-1010,Heat shock protein 90 antagonist,CNF-1010,,tanespimycin (HALT technology),cnf 1010,fexact,"['EC-5', 'EC-71', 'EC4', 'HSP90 modulators (HALT technology)', '17-AAG', 'tanespimycin', 'CNF-1010, Conforma', 'HSP90 modulators (HALT technology), Conforma', 'tanespimycin (HALT technology)', 'EC-69', 'CNF-1010']",tanespimycin (HALT technology),fexact,"['ec 5', 'ec 71', 'ec4', 'hsp90 modulators halt technology', '17 aag', 'tanespimycin', 'cnf 1010 conforma', 'hsp90 modulators halt technology conforma', 'tanespimycin halt technology', 'ec 69', 'cnf 1010']",correct_mapping
MyVax,Immunostimulant,MyVax,,personalized recombinant protein vaccines (cancer),myvax,fexact,"['Xi-20H5', 'MyVax Personalized Immunotherapy', 'recombinant idiotype protein vaccines', 'MyVax', 'personalized recombinant protein vaccines (cancer)', 'recombinant Id immunotherapy', 'non-Hodgkin lymphoma vaccine', 'GTOP-99', 'Xi-3C9', 'B-cell non-Hodgkins lymphoma vaccine', 'vaccine (NHL)']",personalized recombinant protein vaccines (cancer),fexact,"['xi 20h5', 'myvax personalized immunotherapy', 'recombinant idiotype protein vaccines', 'myvax', 'personalized recombinant protein vaccines cancer', 'recombinant id immunotherapy', 'non hodgkin lymphoma vaccine', 'gtop 99', 'xi 3c9', 'b cell non hodgkins lymphoma vaccine', 'vaccine nhl']",correct_mapping
tabelecleucel,T cell stimulant,tabelecleucel,,tabelecleucel,tabelecleucel,fexact,"['EBV-CTL', 'anti-EBV allogeneic  cell therapy (lymphoproliferative disease)', 'anti-EBV allogeneic T cell therapy (lymphoproliferative disease)', 'tabelecleucel', 'tab-cel', 'ATA-129', 'allogeneic EBV-CTL therapy (lymphoproliferative disease)']",tabelecleucel,fexact,"['ebv ctl', 'anti ebv allogeneic cell therapy lymphoproliferative disease', 'anti ebv allogeneic t cell therapy lymphoproliferative disease', 'tabelecleucel', 'tab cel', 'ata 129', 'allogeneic ebv ctl therapy lymphoproliferative disease']",correct_mapping
fenretinide,Apoptosis stimulant; Retinoic acid alpha receptor agonist,fenretinide,,"fenretinide (oral, HIV infection), NIAID",fenretinide,fexact,"['RWJ-16434', 'NSC-374551', 'fenretinide (oral)', 'retinoic acid p-hydroxyphenylamine', 'fenretinide (oral, HIV infection), NIAID', '4-HPR', 'fenretinide', 'McN-R-1967']","fenretinide (oral, HIV infection), NIAID",fexact,"['rwj 16434', 'nsc 374551', 'fenretinide oral', 'retinoic acid p hydroxyphenylamine', 'fenretinide oral hiv infection niaid', '4 hpr', 'fenretinide', 'mcn r 1967']",correct_mapping
CNF-2024,Heat shock protein 90 antagonist,CNF-2024,,BIIB-021,cnf 2024,fexact,"['EC-129', 'EC-141', 'EC-78', 'synthetic Hsp90 inhibitors (cancer), Conforma', 'EC-82, Conforma', 'EC-145, Conforma', 'EC-144', 'EC-146', 'EC-138', 'BIIB-021', 'Hsp90 inhibitors (synthetic, cancer), Conforma', 'EC-82', 'EC-147', 'EC-137', 'Hsp90 inhibitor (cancer), Biogen Idec', 'EC-151', 'CNF-3647', 'Hsp90 inhibitors (synthetic, cancer)', 'CNF-2024', 'synthetic Hsp90 inhibitors (cancer)', 'EC-89', 'EC-145']",BIIB-021,fexact,"['ec 129', 'ec 141', 'ec 78', 'synthetic hsp90 inhibitors cancer conforma', 'ec 82 conforma', 'ec 145 conforma', 'ec 144', 'ec 146', 'ec 138', 'biib 021', 'hsp90 inhibitors synthetic cancer conforma', 'ec 82', 'ec 147', 'ec 137', 'hsp90 inhibitor cancer biogen idec', 'ec 151', 'cnf 3647', 'hsp90 inhibitors synthetic cancer', 'cnf 2024', 'synthetic hsp90 inhibitors cancer', 'ec 89', 'ec 145']",correct_mapping
agatolimod (IV),Immunostimulant; Toll-like receptor 9 agonist,agatolimod,,agatolimod,agatolimod,fexact,"['agatolimod sodium', 'Vaximmune', 'TLR9 agonists', 'CpG-8916', 'CpG-8954', 'PF-676', 'ProMune', 'CpG DNA, CpG ImmunoPharmaceuticals', 'CpG-7909', 'CpG DNA', 'agatolimod', 'PF-3512676']",agatolimod,fexact,"['agatolimod sodium', 'vaximmune', 'tlr9 agonists', 'cpg 8916', 'cpg 8954', 'pf 676', 'promune', 'cpg dna cpg immunopharmaceuticals', 'cpg 7909', 'cpg dna', 'agatolimod', 'pf 3512676']",correct_mapping
SPC-2996,Bcl2 inhibitor; Apoptosis stimulant,SPC-2996,,beclanorsen,spc 2996,fexact,"['SPC-2004', 'SPC-2996', 'anti-Bcl-2 (LNA antisense therapy), Santaris', 'beclanorsen', 'SPC-2993']",beclanorsen,fexact,"['spc 2004', 'spc 2996', 'anti bcl 2 lna antisense therapy santaris', 'beclanorsen', 'spc 2993']",correct_mapping
XL-844,Checkpoint kinase 1 inhibitor; Checkpoint kinase 2 inhibitor,XL-844,,XL-844,xl 844,fexact,['XL-844'],XL-844,fexact,['xl 844'],correct_mapping
etanercept (SC),Tumour necrosis factor alpha antagonist,etanercept,,etanercept,etanercept,fexact,"['TNF receptor, Immunex', 'soluble TNF receptor, Amgen', 'etanercept', 'PF-05208752', 'Enbrel Mini', 'Enbrel', 'soluble TNF receptor, Immunex', 'TNF receptor', 'rhu TNFR:Fc', 'Enbrel SureClick', 'TNR-001', 'soluble TNF receptor', 's-TNF-R, AHP']",etanercept,fexact,"['tnf receptor immunex', 'soluble tnf receptor amgen', 'etanercept', 'pf 05208752', 'enbrel mini', 'enbrel', 'soluble tnf receptor immunex', 'tnf receptor', 'rhu tnfr fc', 'enbrel sureclick', 'tnr 001', 'soluble tnf receptor', 's tnf r ahp']",correct_mapping
Indium In 111 LL2 IgG,CD22 antagonist,Indium In 111 LL2 IgG,,,,0,['Indium In 111 LL2 IgG'],,0,[],0
CEL-031,Phosphodiesterase 2 inhibitor; Phosphodiesterase 5 inhibitor; Angiogenesis inhibitor; Apoptosis stimulant,CEL-031,,CEL-031,cel 031,fexact,"['461', 'CP-461', 'CEL-031', 'cGMP PDE inhibitor, CellPath', 'OSI 461']",CEL-031,fexact,"['461', 'cp 461', 'cel 031', 'cgmp pde inhibitor cellpath', 'osi 461']",correct_mapping
CC-1088,Phosphodiesterase 4 inhibitor; Angiogenesis inhibitor,CC-1088,,CC-1088,cc 1088,fexact,"['lead SelCID (1)', 'CDC-801', 'CC-5048', 'CC-1088', 'CC-801']",CC-1088,fexact,"['lead selcid 1', 'cdc 801', 'cc 5048', 'cc 1088', 'cc 801']",correct_mapping
idiotypic vaccine (CLL),Immunostimulant,idiotypic vaccine,,,,0,['idiotypic vaccine'],,0,[],0
aminolevulinic acid (topical),Oxidizing agent,aminolevulinic acid,,,,0,"['5-aminolevulinic acid (glioma imaging),/ Photonamic', '5-aminolevulinic acid HCl', 'aminolevulinic acid hydrochloride (cancer imaging),/', 'Levulan PDT', 'aminolevulinic acid hydrochloride (cancer imaging),/photonamic', 'Alaglio', 'aminolevulinic acid (nanocolloidal)', 'aminolevulinic acid hydrochloride (glioma imaging),/', 'aminolevulinic acid hydrochloride', 'aminolevulinic acid hydrochloride (glioma imaging), Medac/ Photonamic', 'ALA', '5-ALA', 'aminolevulinic acid (anemia)', 'ALA PDT', 'ALA-photodynamic therapy', 'Levulan Kerastick', 'Alabel', 'aminolevulinic acid (reconstitutable formulation system)', '5-aminolevulinic acid, Draxis', 'aminolevulinic acid', '5-aminolevulinic acid (anemia)', 'aminolevulinic acid hydrochloride, DUSA', 'ALA PDT, DUSA', 'BF-200 ALA', 'aminolevulinic acid, DUSA', 'aminolevulinic acid hydrochloride (cancer imaging), Medac/Photonamic/Nobelpharma/SBI Pharmaceuticals', '5-ala (anemia)', 'ALA-PDT', '5-aminolevulinic acid (glioma imaging),/', 'NPC-07', 'ALA-HCl', '5-aminolevulinic acid (glioma imaging),///', 'ALA-photodynamic therapy (HPV infection)', 'aminolevulinic acid hydrochloride (glioma imaging),/ Photonamic', 'ALA-photodynamic therapy, DUSA', '5-aminolevulinic acid (glioma imaging), Medac/ Photonamic', 'SPP-005', '5-aminolevulinic acid (glioma imaging),/ Photonamic//', '5-aminolevulinic acid (reconstitutable formulation system)', '5-aminolevulinic acid (glioma), Centre Hospitalier Universitaire de Lille', 'Ameluz', '5-aminolevulinic acid', '5-aminolevulinic acid (nanocolloidal), Biofrontera', 'PDL-506', '5-ALA, DUSA', 'aminolevulinic acid hydrochloride (cancer imaging),/Photonamic//SBI Pharmaceuticals', 'aminolevulinic acid hydrochloride (topical, HPV infection)', 'Levulan', 'MC-506/1', 'ALA PDT, Draxis', 'Gliolan', '5-aminolevulinic acid (glioma imaging),/ Photonamic/Nobelpharma/SBI Pharma', '5-aminolevulinic acid (glioma imaging),/ Photonamic//SBI Pharma', 'aminolevulinic acid hydrochloride (cancer imaging),/Photonamic/Nobelpharma/SBI Pharmaceuticals', '5-ALA, Draxis', '5-ALA (RFS)', '5-aminolevulinic acid (glioma imaging), Medac/ Photonamic/Nobelpharma/SBI Pharma', 'ALA-CIN', 'aminolevulinic acid (nanocolloidal), Biofrontera', 'Gleolan', '5-aminolevulinic acid (glioblastoma)', '5-aminolevulinic acid (nanocolloidal)', 'ZK-728878', 'PDG-506A', 'Aila']",,Drug_API_mapping,[],0
"octreotide, LAR, Novartis",Somatostatin receptor agonist,octreotide,Novartis,octreotide acetate (long-acting formulation),octreotide,fexact,"['octreotide acetate (long-acting formulation), Novartis', 'octreotide acetate', 'octreotide pamoate', 'Sandostatin LAR', 'octreotide acetate (long-acting formulation)', 'Sandostatin LP', 'octreotide LAR', 'Sandostatin LAR Depot', 'octreotide']",octreotide acetate (long-acting formulation),fexact,"['octreotide acetate long acting formulation novartis', 'octreotide acetate', 'octreotide pamoate', 'sandostatin lar', 'octreotide acetate long acting formulation', 'sandostatin lp', 'octreotide lar', 'sandostatin lar depot', 'octreotide']",correct_mapping
octreotide (subcutaneous),Somatostatin receptor agonist,octreotide,,octreotide acetate (long-acting formulation),octreotide,fexact,"['octreotide acetate (long-acting formulation), Novartis', 'octreotide acetate', 'octreotide pamoate', 'Sandostatin LAR', 'octreotide acetate (long-acting formulation)', 'Sandostatin LP', 'octreotide LAR', 'Sandostatin LAR Depot', 'octreotide']",octreotide acetate (long-acting formulation),fexact,"['octreotide acetate long acting formulation novartis', 'octreotide acetate', 'octreotide pamoate', 'sandostatin lar', 'octreotide acetate long acting formulation', 'sandostatin lp', 'octreotide lar', 'sandostatin lar depot', 'octreotide']",correct_mapping
"CD7 CAR-T cells, unspecified",Immuno-oncology therapy,CD7 CAR-T cells,unspecified,anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),cd19 car t cells,fuzzy,"['anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia)', 'cd19 car-t cells']",anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),fexact,"['anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'cd19 car t cells']",incorrect_mapping
"Senl-h19 chimaeric antigen receptor-T cell therapy, Hebei Senlang Biotechnology",T cell stimulant; Immuno-oncology therapy,Senl-h19 chimaeric antigen receptor-T cell therapy,Hebei Senlang Biotechnology,,,0,['Senl-h19 chimaeric antigen receptor-T cell therapy'],,0,[],0
CD19-CAR_Lenti T cell,CD19 antagonist; Immuno-oncology therapy,CD19-CAR_Lenti T cell,,,,0,['CD19-CAR_Lenti T cell'],,0,[],0
adult differentiated autologous T-cells,Immuno-oncology therapy,adult differentiated autologous T-cells,,,,0,['adult differentiated autologous T-cells'],,0,[],0
CAR-ITNK cells,Immunostimulant; T cell stimulant; Immuno-oncology therapy,CAR-ITNK cells,,,,0,['CAR-ITNK cells'],,0,[],0
"rituximab, Pfizer",CD20 antagonist; Immuno-oncology therapy,rituximab,Pfizer,rituximab biosimilar,rituximab,fexact,"['GP-2013', 'Riximyo', 'Rixathon', 'rituximab biosimilar', 'Rituximab BS', 'rituximab', 'rituximab biosimilar, Sandoz']",rituximab biosimilar,fexact,"['gp 2013', 'riximyo', 'rixathon', 'rituximab biosimilar', 'rituximab bs', 'rituximab', 'rituximab biosimilar sandoz']",correct_mapping
Senl_007,T cell stimulant; Immuno-oncology therapy,Senl_007,,,,0,['Senl_007'],,0,[],0
Senl_001,T cell stimulant; Immuno-oncology therapy,Senl_001,,SL-1904B,senl_001,fexact,"['SENL-B19', 'Senl_001', 'SL-1904B', 'anti-cd19 car t-cell therapy (b-cell maligancy)']",SL-1904B,fexact,"['senl b19', 'senl_001', 'sl 1904b', 'anti cd19 car t cell therapy b cell maligancy']",correct_mapping
"CD22 chimaeric antigen receptor therapy, Hebei Senlang Biotechnology",T cell stimulant; Immuno-oncology therapy,CD22 chimaeric antigen receptor therapy,Hebei Senlang Biotechnology,,,0,['CD22 chimaeric antigen receptor therapy'],,0,[],0
GC-019F,T cell stimulant; Immuno-oncology therapy,GC-019F,,GC-007F,gc 019f,fexact,"['GC-019F', 'anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia)', 'CD19-F-CAR-T', 'FasT CAR-19', 'GC-007F']",GC-007F,fexact,"['gc 019f', 'anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'cd19 f car t', 'fast car 19', 'gc 007f']",correct_mapping
Senl_1904B,T cell stimulant; Immuno-oncology therapy,Senl_1904B,,,,0,['Senl_1904B'],,0,[],0
blinatumomab (SC),CD3 agonist; Immuno-oncology therapy,blinatumomab,,blinatumomab,blinatumomab,fexact,"['Blincyto', 'blinatumomab', 'blinatumomab (cancer, BiTE),/', 'anti-CD3/anti-CD19 bispecific T-cell engager (BiTE, acute lymphoblastic leukemia),/Astellas', 'MT-103 (cancer, BiTE),/', 'bscCD19xCD3 (cancer, BiTE), Micromet/MedImmune', 'anti-CD3/anti-CD19 bispecific T-cell engager (BiTE, acute lymphoblastic leukemia),/', 'bscCD19xCD3 (cancer, BiTE), Micromet/', 'L01XC19', 'AMG-103', 'MT-103 (cancer, BiTE), Micromet/MedImmune', 'MEDI-538', 'MT-103', 'MT-103, MedImmune', 'MT-103 (cancer, BiTE)', 'bscCD19xCD3 (cancer, BiTE)', 'blinatumomab (cancer, BiTE), Micromet/MedImmune', 'MT-103 (cancer, BiTE), Micromet/', 'blinatumomab (cancer, BiTE), Micromet/', 'CD19XCD3', 'bscCD19xCD3 (cancer, BiTE),/']",blinatumomab,fexact,"['blincyto', 'blinatumomab', 'blinatumomab cancer bite', 'anti cd3 anti cd19 bispecific t cell engager bite acute lymphoblastic leukemia astellas', 'mt 103 cancer bite', 'bsccd19xcd3 cancer bite micromet medimmune', 'anti cd3 anti cd19 bispecific t cell engager bite acute lymphoblastic leukemia', 'bsccd19xcd3 cancer bite micromet', 'l01xc19', 'amg 103', 'mt 103 cancer bite micromet medimmune', 'medi 538', 'mt 103', 'mt 103 medimmune', 'mt 103 cancer bite', 'bsccd19xcd3 cancer bite', 'blinatumomab cancer bite micromet medimmune', 'mt 103 cancer bite micromet', 'blinatumomab cancer bite micromet', 'cd19xcd3', 'bsccd19xcd3 cancer bite']",correct_mapping
GC-007G,T cell stimulant; Immuno-oncology therapy,GC-007G,,GC-007G,gc 007g,fexact,"['GC-007G', 'anti-CD19 allo-CAR-T cells', 'donor-derived anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia)', 'allogeneic anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia)', 'donor CAR-19']",GC-007G,fexact,"['gc 007g', 'anti cd19 allo car t cells', 'donor derived anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'allogeneic anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'donor car 19']",correct_mapping
"immunoglobulin IV, next-gen, Octapharma",Immunostimulant,immunoglobulin IV,Octapharma,,,0,['immunoglobulin IV'],,0,[],0
SHR-2554,Enhancer of zeste homolog 2 inhibitor,SHR-2554,,SHR-2554,shr 2554,fexact,"['EBI-2554', 'SHR-2554']",SHR-2554,fexact,"['ebi 2554', 'shr 2554']",correct_mapping
UCD19 CAR T cells,CD19 antagonist; Immuno-oncology therapy,UCD19 CAR T cells,,anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),cd19 car t cells,fuzzy,"['anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia)', 'cd19 car-t cells']",anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),fexact,"['anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'cd19 car t cells']",incorrect_mapping
CT-RD06,T cell stimulant; Immuno-oncology therapy,CT-RD06,,,,0,['CT-RD06'],,0,[],0
CD19 CD34 CAR transduced T cells,CD19 antagonist; Immuno-oncology therapy,CD19 CD34 CAR transduced T cells,,,,0,['CD19 CD34 CAR transduced T cells'],,0,[],0
PAN-301-1,Immunostimulant; Immuno-oncology therapy,PAN-301-1,,,,0,"['PAN-301-1', 'nanoparticle based vaccine targeting HAAH (cancer), Panacea', 'HAAH-1 lambda', 'SNS-301', 'nanoparticle based vaccine targeting HAAH (cancer/ myelodysplastic syndrome/ prostate tumor/chronic myelomonocytic leukemia/ squamous cell carcinoma/ head and neck tumor)', 'HAAH-3 lambda', 'nanoparticle based vaccine targeting HAAH (cancer)']",,NER_API,[],0
"CD19 CAR-T cell therapy, PersonGen Biomedicine",T cell stimulant; Immuno-oncology therapy,CD19 CAR-T cell therapy,PersonGen Biomedicine,BinD-19,anti cd19 car t cell therapy,fuzzy,"['BinD-19', 'anti-CD19 CAR T-cell therapy']",BinD-19,fexact,"['bind 19', 'anti cd19 car t cell therapy']",incorrect_mapping
LUCAR 20S CAR-T cells,Immuno-oncology therapy,LUCAR 20S CAR-T cells,,,,0,['LUCAR 20S CAR-T cells'],,0,[],0
"CD19 UCAR-Tcell therapy, Shanghai Longyao Biotechnology",T cell stimulant; Immuno-oncology therapy,CD19 UCAR-Tcell therapy,Shanghai Longyao Biotechnology,,,0,['CD19 UCAR-Tcell therapy'],,0,[],0
ICG-132,T cell stimulant; Immuno-oncology therapy,ICG-132,,ICG-132,icg 132,fexact,"['ICG-132', 'CD20-CD19 cCAR', 'dual anti-cd19/anti-cd20 car t-cell therapy (b-cell malignancies)']",ICG-132,fexact,"['icg 132', 'cd20 cd19 ccar', 'dual anti cd19 anti cd20 car t cell therapy b cell malignancies']",correct_mapping
GC-022,T cell stimulant; Immuno-oncology therapy,GC-022,,GC-022,gc 022,fexact,"['GC-022F', 'GC-022', 'dual anti-CD19/anti-CD22 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/Non-Hodgkin Lymphoma)', 'Dual CAR-19-22', 'anti-CD19 + anti-CD22 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/Non-Hodgkin Lymphoma)']",GC-022,fexact,"['gc 022f', 'gc 022', 'dual anti cd19 anti cd22 car t cell therapy b cell acute lymphoblastic leukemia non hodgkin lymphoma', 'dual car 19 22', 'anti cd19 anti cd22 car t cell therapy b cell acute lymphoblastic leukemia non hodgkin lymphoma']",correct_mapping
PMB-101,T cell stimulant; Immuno-oncology therapy,PMB-101,,PMB-101,pmb 101,fexact,"['BAFF-R CAR T-cell therapy (B-cell malignancies), PeproMene', 'BAFF-R CAR T-cell therapy (B-cell malignancies)', 'anti-baff-r car t-cell therapy (b-cell malignancies), /pepromene', 'PMB-101', 'anti-baff-r car t-cell therapy (b-cell malignancies),/', 'anti-tnfrsf13c car t-cell therapy (b-cell malignancies),/', 'baff-r targeted car t-cell therapy (b-cell malignancies), /pepromene', 'anti-tnfrsf13c car t-cell therapy (b-cell malignancies), /pepromene', 'baff-r targeted car t-cell therapy (b-cell malignancies),/']",PMB-101,fexact,"['baff r car t cell therapy b cell malignancies pepromene', 'baff r car t cell therapy b cell malignancies', 'anti baff r car t cell therapy b cell malignancies pepromene', 'pmb 101', 'anti baff r car t cell therapy b cell malignancies', 'anti tnfrsf13c car t cell therapy b cell malignancies', 'baff r targeted car t cell therapy b cell malignancies pepromene', 'anti tnfrsf13c car t cell therapy b cell malignancies pepromene', 'baff r targeted car t cell therapy b cell malignancies']",correct_mapping
ATLCAR.CD30 cells,CD30 antagonist; Immuno-oncology therapy,ATLCAR.CD30 cells,,,,0,['ATLCAR.CD30 cells'],,0,[],0
"HY-004, Juventas Cell Therapy",T cell stimulant; Immuno-oncology therapy,HY-004,Juventas Cell Therapy,,,0,['HY-004'],,NER_API,[],0
KD-019 2nd,T cell stimulant; Immuno-oncology therapy,KD-019 2nd,,,,0,['KD-019 2nd'],,0,[],0
Senl_1904A,T cell stimulant; Immuno-oncology therapy,Senl_1904A,,,,0,['Senl_1904A'],,0,[],0
welgenaleucel,T cell stimulant; Immuno-oncology therapy,welgenaleucel,,UCAR-011,welgenaleucel,fexact,"['welgenaleucel', 'UWC-19', 'anti-cd19 car t-cell therapy (b-cell lymphoma/dlbcl/b-cell all)', 'UCAR-011']",UCAR-011,fexact,"['welgenaleucel', 'uwc 19', 'anti cd19 car t cell therapy b cell lymphoma dlbcl b cell all', 'ucar 011']",correct_mapping
huCART19,T cell stimulant; Immuno-oncology therapy,huCART19,,LXG-250,hucart 19,fuzzy,"['anti-CD19 CAR T-cell therapy (cancer), University of Pennsylvania/', 'anti-cd19 car t-cell therapy (cancer)', 'anti-CD19 CAR-transduced autologous T-cells (second generation, cancer), University of Pennsylvania/', 'anti-cd19 car-transduced autologous t-cells (second generation, cancer)', 'anti-cd19 chimeric antigen receptor t-cells (second generation, cancer)', 'CTL-119', 'huCART-19', 'LXG-250', 'anti-CD19 chimeric antigen receptor T-cells (second generation, cancer), University of Pennsylvania/']",LXG-250,fexact,"['anti cd19 car t cell therapy cancer university of pennsylvania', 'anti cd19 car t cell therapy cancer', 'anti cd19 car transduced autologous t cells second generation cancer university of pennsylvania', 'anti cd19 car transduced autologous t cells second generation cancer', 'anti cd19 chimeric antigen receptor t cells second generation cancer', 'ctl 119', 'hucart 19', 'lxg 250', 'anti cd19 chimeric antigen receptor t cells second generation cancer university of pennsylvania']",incorrect_mapping
HLA mismatched mononuclear cell infusion,Unidentified pharmacological activity,HLA mismatched mononuclear cell infusion,,,,0,['HLA mismatched mononuclear cell infusion'],,0,[],0
"SCIg 20%, CSL",Immunostimulant,SCIg 20%,CSL,,,0,['SCIg 20%'],,0,[],0
CART22-65s cells,CD22 antagonist; Immuno-oncology therapy,CART22-65s cells,,JJO-686,cart22 65s cells,fexact,"['JJO-686', 'anti-CD22 CAR T-cell therapy (B-cell acute lymphoblastic leukemia), University of Pennsylvania/', 'anti-cd22 car t-cell therapy (b-cell acute lymphoblastic leukemia)', 'anti-CD22 scFv TCRz:41BB CAR T-cell therapy', 'CART22-65s cells']",JJO-686,fexact,"['jjo 686', 'anti cd22 car t cell therapy b cell acute lymphoblastic leukemia university of pennsylvania', 'anti cd22 car t cell therapy b cell acute lymphoblastic leukemia', 'anti cd22 scfv tcrz 41bb car t cell therapy', 'cart22 65s cells']",correct_mapping
"CD19-CAR-T cell therapy, Bioceltech Therapeutics",T cell stimulant; Immuno-oncology therapy,CD19-CAR-T cell therapy,Bioceltech Therapeutics,BinD-19,anti cd19 car t cell therapy,fuzzy,"['BinD-19', 'anti-CD19 CAR T-cell therapy']",BinD-19,fexact,"['bind 19', 'anti cd19 car t cell therapy']",incorrect_mapping
CTX-110,T cell stimulant; Immuno-oncology therapy; Genome editing,CTX-110,,CTX-110,ctx 110,fexact,"['CTX-101', 'anti-CD19 CAR T-cell therapy (cancer)', 'CTX-110', '/Cas9 gene-corrected stem autologous cells (cancer)']",CTX-110,fexact,"['ctx 101', 'anti cd19 car t cell therapy cancer', 'ctx 110', 'cas9 gene corrected stem autologous cells cancer']",correct_mapping
SD101 (intratumoral),Toll-like receptor 9 agonist,SD101,,SD-101,sd 101,fuzzy,"['SD-101, TriSalus', 'HCV vaccine (ISS),/Symphony Dynamo', 'HCV vaccine (ISS),/', 'TLR9 agonist (CpG-C class oligodeoxynucleotide vaccine, advanced solid tumors)', 'SD-101', 'TLR9 agonist (CpG-C class oligodeoxynucleotide vaccine, advanced solid tumors), TriSalus', 'HCV-ISS']",SD-101,fexact,"['sd 101 trisalus', 'hcv vaccine iss symphony dynamo', 'hcv vaccine iss', 'tlr9 agonist cpg c class oligodeoxynucleotide vaccine advanced solid tumors', 'sd 101', 'tlr9 agonist cpg c class oligodeoxynucleotide vaccine advanced solid tumors trisalus', 'hcv iss']",incorrect_mapping
BMS-986178,CD134 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,BMS-986178,,BMS-986178,bms 986178,fexact,"['BMS-986178', 'anti-OX40 antibodies (cancer)', 'OX40 costimulator (cancer)']",BMS-986178,fexact,"['bms 986178', 'anti ox40 antibodies cancer', 'ox40 costimulator cancer']",correct_mapping
SJCAR-19,Unidentified pharmacological activity,SJCAR-19,,,,0,['SJCAR-19'],,0,[],0
AUTO-3,T cell stimulant; Immuno-oncology therapy,AUTO-3,,AUTO-3,auto 3,fexact,"['dual anti-CD19/anti-CD22 CAR T-cell therapy (acute lymphocytic leukaemia/diffuse large B-cell lymphoma)', 'AUTO-3']",AUTO-3,fexact,"['dual anti cd19 anti cd22 car t cell therapy acute lymphocytic leukaemia diffuse large b cell lymphoma', 'auto 3']",correct_mapping
"CD19-CART, Shanghai Bioray Laboratory",T cell stimulant; Immuno-oncology therapy,CD19-CART,Shanghai Bioray Laboratory,ICTCAR-003,cd19cart,fuzzy,"['ICTCAR-003', 'anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia/acute lymphocytic leukemia)', 'CD19CART', 'ICT-19G1']",ICTCAR-003,fexact,"['ictcar 003', 'anti cd19 car t cell therapy b cell acute lymphoblastic leukemia acute lymphocytic leukemia', 'cd19cart', 'ict 19g1']",incorrect_mapping
CD19 T-APCs,CD19 antagonist; Immuno-oncology therapy,CD19 T-APCs,,,,0,['CD19 T-APCs'],,0,[],0
BinD-19,T cell stimulant; Immuno-oncology therapy,BinD-19,,BinD-19,bind 19,fexact,"['BinD-19', 'anti-CD19 CAR T-cell therapy']",BinD-19,fexact,"['bind 19', 'anti cd19 car t cell therapy']",correct_mapping
"methotrexate, unspecified",Immunosuppressant; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Disease modifying antirheumatic drug,methotrexate,unspecified,,,0,"['methotrexate', 'repurposed methotrexate (blood cancer)']",,NER_API,[],0
"13-valent pneumococcal conjugate vaccine, undisclosed",Immunostimulant,13-valent pneumococcal conjugate vaccine,undisclosed,,,0,"['conjugate vaccine (streptococcus pneumoniae infection)', 'conjugate vaccine (Streptococcus pneumoniae infection), SK Chemicals', '13vPnC', 'Prevnar 13 Infant', 'Prevnar 13 Adult', 'multivalent pneumococcal vaccines, Wyeth-Lederle', 'Prevnar 13', '11vPnC', '11vPnC, Wyeth-Lederle', '13-valent pneumococcal conjugate', '13vPnC, Wyeth-Lederle', 'PCV', 'PCV-13', 'conjugate vaccine (Streptococcus pneumoniae infection)', 'pneumococcal conjugate vaccine', 'SKYPNEUMO', 'Sky Pneumo', 'NBP-606', 'pneumococcal conjugate vaccine, SK Chemicals', 'Prevenar 13', 'multivalent pneumococcal vaccines, Wyeth', 'PF-05208760', '13-valent pneumococcal conjugate vaccine']",,Drug_API_mapping,[],0
iC9-CAR19 cells,CD19 antagonist; Immuno-oncology therapy,iC9-CAR19 cells,,,,0,"['anti-CD19 CAR-T cell therapy (CaspaCIDe, cancer),/Ospedale Pediatrico Bambino Gesu', 'iC9-CAR19 cells', 'CD19 CAR-T (CaspaCIDe, cancer),/Ospedale Pediatrico Bambino Gesu', 'ATLCAR.CD19']",,Drug_API_mapping,[],0
"CD19-CAR T cell therapy, Takara Bio",T cell stimulant; Immuno-oncology therapy,CD19-CAR T cell therapy,Takara Bio,BinD-19,anti cd19 car t cell therapy,fuzzy,"['BinD-19', 'anti-CD19 CAR T-cell therapy']",BinD-19,fexact,"['bind 19', 'anti cd19 car t cell therapy']",incorrect_mapping
SRF-231,CD47 antagonist; Immuno-oncology therapy,SRF-231,,SRF-231,srf 231,fexact,"['anti-CD47 human monoclonal antibody (cancer), Surface Oncology/', 'anti-cd47 human monoclonal antibody (cancer)', 'CD47 checkpoint inhibitor (cancer), Surface Oncology', 'SRF-231', 'urabrelimab', 'cd47 checkpoint inhibitor (cancer)']",SRF-231,fexact,"['anti cd47 human monoclonal antibody cancer surface oncology', 'anti cd47 human monoclonal antibody cancer', 'cd47 checkpoint inhibitor cancer surface oncology', 'srf 231', 'urabrelimab', 'cd47 checkpoint inhibitor cancer']",correct_mapping
"CD19 chimaeric antigen receptor therapy, Wuhan Si'an Medical Technology",T cell stimulant; CD19 antagonist; Immuno-oncology therapy,CD19 chimaeric antigen receptor therapy,Wuhan Si'an Medical Technology,,,0,['CD19 chimaeric antigen receptor therapy'],,0,[],0
"CART-19, unspecified",CD19 antagonist; Immuno-oncology therapy,CART-19,unspecified,tisagenlecleucel,cart 19,fexact,"['tisagenlecleucel', 'anti-CD19 CAR T-cell therapy (B-cell leukemia/lymphoma), Novartis', 'tisagenlecleucel-T', 'CART-19', 'anti-cd19-car-transduced autologous t cells (b-cell leukemia/lymphoma)', 'CTL-019', 'Kymriah', 'anti-cd19-car-transduced autologous  cells (b-cell leukemia/lymphoma)', 'anti-CD19 CAR T-cell therapy (B-cell leukemia/lymphoma)']",tisagenlecleucel,fexact,"['tisagenlecleucel', 'anti cd19 car t cell therapy b cell leukemia lymphoma novartis', 'tisagenlecleucel t', 'cart 19', 'anti cd19 car transduced autologous t cells b cell leukemia lymphoma', 'ctl 019', 'kymriah', 'anti cd19 car transduced autologous cells b cell leukemia lymphoma', 'anti cd19 car t cell therapy b cell leukemia lymphoma']",correct_mapping
"CD19-CAR-T cells, Shanghai GeneChem",CD19 antagonist; Immuno-oncology therapy,CD19-CAR-T cells,Shanghai GeneChem,anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),cd19 car t cells,fexact,"['anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia)', 'cd19 car-t cells']",anti-cd19 car t-cell therapy (b-cell acute lymphoblastic leukemia),fexact,"['anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'cd19 car t cells']",correct_mapping
loncastuximab tesirine,DNA inhibitor,loncastuximab tesirine,,loncastuximab tesirine,loncastuximab tesirine,fexact,"['loncastuximab tesirine-lpyl', 'Lonca-T', 'loncastuximab tesirine', 'ADCT-402', 'Lonca', 'Zynlonta']",loncastuximab tesirine,fexact,"['loncastuximab tesirine lpyl', 'lonca t', 'loncastuximab tesirine', 'adct 402', 'lonca', 'zynlonta']",correct_mapping
AMG-714,Interleukin 15 antagonist; Immunosuppressant,AMG-714,,AMG-714,amg 714,fexact,"['anti-IL-15 human monoclonal antibody (celiac disease),/', 'AMG-714', 'PRV-015', 'anti-IL-15 human monoclonal antibody (celiac disease),/ Provention Bio', 'HuMax-IL-15', 'anti-IL-15 human MAb (celiac disease),/ Provention Bio', 'anti-IL-15 human MAb (celiac disease/vitiligo),/ Provention Bio', 'human anti-IL-15 MAb, Genmab/', 'human anti-IL-15 MAb,/', 'anti-IL-15 human MAb (celiac disease/vitiligo),/', 'anti-IL-15 human MAb (celiac disease),/']",AMG-714,fexact,"['anti il 15 human monoclonal antibody celiac disease', 'amg 714', 'prv 015', 'anti il 15 human monoclonal antibody celiac disease provention bio', 'humax il 15', 'anti il 15 human mab celiac disease provention bio', 'anti il 15 human mab celiac disease vitiligo provention bio', 'human anti il 15 mab genmab', 'human anti il 15 mab', 'anti il 15 human mab celiac disease vitiligo', 'anti il 15 human mab celiac disease']",correct_mapping
zidovudine (oral tablet),Nucleoside reverse transcriptase inhibitor,zidovudine,,zidovudine,zidovudine,fexact,"['Retrovir', 'AZT', 'zidovudine']",zidovudine,fexact,"['retrovir', 'azt', 'zidovudine']",correct_mapping
"mitoxantrone, CSPC ZhongQi Pharmaceutical",DNA topoisomerase II inhibitor,mitoxantrone,CSPC ZhongQi Pharmaceutical,mitoxantrone,mitoxantrone,fexact,"['Ralenova', 'mitoxantrone', 'CL-232315', 'Elsep', 'mitozantrone', 'mitoxantrone hydrochloride', 'Novantrone']",mitoxantrone,fexact,"['ralenova', 'mitoxantrone', 'cl 232315', 'elsep', 'mitozantrone', 'mitoxantrone hydrochloride', 'novantrone']",correct_mapping
CART-22 cells,Immuno-oncology therapy,CART-22 cells,,,,0,['CART-22 cells'],,0,[],0
Betalutin,DNA inhibitor; Radiopharmaceutical,Betalutin,,lutetium (177Lu) lilotomab satetraxetan,betalutin,fexact,"['lutetium (177Lu) lilotomab satetraxetan', 'Lymrit 37-05', '177Lu-DOTA-tetulomab', '177Lu-tetraxetan-tetulomab', ""177Lu-tetraxetan-tetulomab (non-Hodgkin's lymphoma)"", '177Lu-lilotomab satetraxetan', 'lilotomab satetraxetan-[177Lu]', 'Betalutin', '177Lu-DOTA-HH1', '177Lu-satetraxetan-lilotomab']",lutetium (177Lu) lilotomab satetraxetan,fexact,"['lutetium 177lu lilotomab satetraxetan', 'lymrit 37 05', '177lu dota tetulomab', '177lu tetraxetan tetulomab', '177lu tetraxetan tetulomab non hodgkin s lymphoma', '177lu lilotomab satetraxetan', 'lilotomab satetraxetan 177lu', 'betalutin', '177lu dota hh1', '177lu satetraxetan lilotomab']",correct_mapping
CPI-1205,Enhancer of zeste homolog 2 inhibitor,CPI-1205,,lirametostat,cpi 1205,fexact,"['CPI-1205', 'EZH2 inhibitors (oral formulation, lymphoma/metastatic castration-resistant prostate cancer/melanoma)', 'EZH2 inhibitors (lymphoma)', 'lirametostat']",lirametostat,fexact,"['cpi 1205', 'ezh2 inhibitors oral formulation lymphoma metastatic castration resistant prostate cancer melanoma', 'ezh2 inhibitors lymphoma', 'lirametostat']",correct_mapping
"huCART-19 T cells, Novartis",T cell stimulant; Immuno-oncology therapy,huCART-19 T cells,Novartis,,,0,['huCART-19 T cells'],,0,[],0
JCAR-018,T cell stimulant; Immuno-oncology therapy,JCAR-018,,JCAR-018,jcar 018,fexact,"['anti-CD22 CAR T-cell therapy (hematological malignancies)', 'anti-CD22 CAR', 'JCAR-018', 'anti-CD22 CAR T-cell therapy (hematological malignancies), Juno', 'm971-BBz CAR']",JCAR-018,fexact,"['anti cd22 car t cell therapy hematological malignancies', 'anti cd22 car', 'jcar 018', 'anti cd22 car t cell therapy hematological malignancies juno', 'm971 bbz car']",correct_mapping
Insulin Aspart,Rapid-acting insulin,Insulin Aspart,,insulin aspart,insulin aspart,fexact,"['NN-X14Mix70', 'NovoTwist', 'insulin-x14', 'NovoMix 50 and 70', 'NovoMix FlexPen', 'NN-X14Mix50', 'BIAsp30', 'NovoMix 30 FlexPen', 'Biphasic insulin aspart 30', 'NovoLog Mix', 'NovoRapid Mix', 'NovoLog FlexTouch', 'B28-Asp-insulin', 'NN-X14Mix30', 'NovoRapid FlexPen', 'NovoRapid', 'NovoMix Penfill', 'NovoRapid FlexTouch', 'insulin aspart', 'INA-X14', 'NovoFine', 'NovoMix30', 'NNX-14', 'NovoRapid 30 Mix', 'NN2000-Mix30', 'NovoLog Mix 70/30', 'NovoLog']",insulin aspart,fexact,"['nn x14mix70', 'novotwist', 'insulin x14', 'novomix 50 and 70', 'novomix flexpen', 'nn x14mix50', 'biasp30', 'novomix 30 flexpen', 'biphasic insulin aspart 30', 'novolog mix', 'novorapid mix', 'novolog flextouch', 'b28 asp insulin', 'nn x14mix30', 'novorapid flexpen', 'novorapid', 'novomix penfill', 'novorapid flextouch', 'insulin aspart', 'ina x14', 'novofine', 'novomix30', 'nnx 14', 'novorapid 30 mix', 'nn2000 mix30', 'novolog mix 70 30', 'novolog']",correct_mapping
tenofovir disoproxil fumarate,Nucleotide reverse transcriptase inhibitor,tenofovir disoproxil fumarate,,tenofovir disoproxil fumarate,tenofovir disoproxil fumarate,fexact,"['GSK-548470', 'Tenozet', 'tenofovir DF', 'tenofovir disoproxil fumarate', 'bis(POC)PMPA', 'tenofovir (oral prodrug)', 'Viread', 'TDF', 'oral PMPA prodrug']",tenofovir disoproxil fumarate,fexact,"['gsk 548470', 'tenozet', 'tenofovir df', 'tenofovir disoproxil fumarate', 'bis poc pmpa', 'tenofovir oral prodrug', 'viread', 'tdf', 'oral pmpa prodrug']",correct_mapping
"poly-ICLC, Oncovir",Toll-like receptor 3 agonist,poly-ICLC,Oncovir,Poly-ICLC,poly iclc,fexact,"['Hiltonol', 'interferon inducer (cancer/viral diseases)', 'polyinosinic-polycytidilic acid', 'Poly-ICLC', 'NSC-301463']",Poly-ICLC,fexact,"['hiltonol', 'interferon inducer cancer viral diseases', 'polyinosinic polycytidilic acid', 'poly iclc', 'nsc 301463']",correct_mapping
baltaleucel-T,Lymphocyte stimulant; Immuno-oncology therapy,baltaleucel-T,,baltaleucel-T,baltaleucel t,fexact,"['baltaleucel-T', 'Epstein-Barr virus specific T cells,/', 'Epstein-Barr virus cytotoxic T lymphocytes,/ Cell Medica', 'baltaleucel', 'ebv ctls (ebv-associated lymphoma, nasopharyngeal carcinoma)', 'immunotherapy (EBV-associated lymphoma),/', 'Cytorex EBV', 'immunotherapy (EBV-associated lymphoma), St Jude/', 'Epstein-Barr virus specific T cells, St Jude/', 'EBV CTLs (EBV-associated lymphoma, nasopharyngeal carcinoma),/Kuur Therapeutics', 'EBV CTLs (EBV-associated lymphoma, nasopharyngeal carcinoma),/ Cell Medica', 'GRALE T-cells (EBV-associated lymphoma),/Cell Medica', 'CMD-003']",baltaleucel-T,fexact,"['baltaleucel t', 'epstein barr virus specific t cells', 'epstein barr virus cytotoxic t lymphocytes cell medica', 'baltaleucel', 'ebv ctls ebv associated lymphoma nasopharyngeal carcinoma', 'immunotherapy ebv associated lymphoma', 'cytorex ebv', 'immunotherapy ebv associated lymphoma st jude', 'epstein barr virus specific t cells st jude', 'ebv ctls ebv associated lymphoma nasopharyngeal carcinoma kuur therapeutics', 'ebv ctls ebv associated lymphoma nasopharyngeal carcinoma cell medica', 'grale t cells ebv associated lymphoma cell medica', 'cmd 003']",correct_mapping
"peginterferon alfa-2b, Virchow",Interferon alpha 2b agonist; Interferon receptor agonist,peginterferon alfa-2b,Virchow,peginterferon alfa-2b,peginterferon alfa 2b,fexact,"['PEG-Intron', 'PEG-IFN alfa-2b', 'Sch-54031', 'SCH-054031', 'Pegetron', 'Sylatron', 'Cylatron', 'PEG-interferon alfa 2b,/Schering-Plough', 'ViraferonPeg', 'peginterferon alfa-2b', 'PegIntron', 'Redipen', 'PEG-Intron and Rebetol combination', 'PEG-interferon alfa 2b,/', 'PEG-interferon alfa-2b and ribavirin combination']",peginterferon alfa-2b,fexact,"['peg intron', 'peg ifn alfa 2b', 'sch 54031', 'sch 054031', 'pegetron', 'sylatron', 'cylatron', 'peg interferon alfa 2b schering plough', 'viraferonpeg', 'peginterferon alfa 2b', 'pegintron', 'redipen', 'peg intron and rebetol combination', 'peg interferon alfa 2b', 'peg interferon alfa 2b and ribavirin combination']",correct_mapping
ketoconazole,Cell wall synthesis inhibitor; Sterol demethylase inhibitor,ketoconazole,,ketoconazole,ketoconazole,fexact,"['Nizale', 'Nizoral', 'ketoconazole']",ketoconazole,fexact,"['nizale', 'nizoral', 'ketoconazole']",correct_mapping
"pneumococcal polyvalent polysaccharide vaccine (im), Merck",Immunostimulant,pneumococcal polyvalent polysaccharide vaccine,Merck,,,0,['pneumococcal polyvalent polysaccharide vaccine'],,0,[],0
AZD-3965,Monocarboxylate transporter 1 inhibitor,AZD-3965,,AZD-3965,azd 3965,fexact,"['AZD-3965', 'monocarboxylate transporter-1 inhibitor (cancer),/Cancer Research Technology']",AZD-3965,fexact,"['azd 3965', 'monocarboxylate transporter 1 inhibitor cancer cancer research technology']",correct_mapping
veltuzumab (IV),CD20 antagonist; Immuno-oncology therapy,veltuzumab,,veltuzumab,veltuzumab,fexact,"['hA20 antibody', 'hCD20 antibody', 'anti-NHL antibody', 'veltuzumab', 'IMMU-106', 'cA20 antibody']",veltuzumab,fexact,"['ha20 antibody', 'hcd20 antibody', 'anti nhl antibody', 'veltuzumab', 'immu 106', 'ca20 antibody']",correct_mapping
CD19zeta chimeric receptor EBV specific CTLs,Immuno-oncology therapy,CD19zeta chimeric receptor EBV specific CTLs,,,,0,['CD19zeta chimeric receptor EBV specific CTLs'],,0,[],0
prednisolone (injectable),Corticosteroid agonist,prednisolone,,,,0,"['prednisolone', 'prednisolone (oral controlled release formulation/csds)', 'prednisolone (oral controlled release formulation/colon specific drug delivery system)']",,NER_API,[],0
motolimod (intratumoral),Immunostimulant; Toll-like receptor 8 agonist,motolimod,,motolimod,motolimod,fexact,"['toll-like receptor modulators,/', 'VTX-378', 'toll-like receptor modulators (cancer, allergy), VentiRx/ Celgene', 'motolimod', 'toll-like receptor modulators (cancer, allergy), VentiRx/', 'TLR modulators (cancer, allergy),/', 'VTX-2337', 'TLR modulators (cancer, allergy), VentiRx/', 'toll-like receptor modulators, VentiRx/ Celgene', 'toll-like receptor modulators, VentiRx/', 'toll-like receptor modulators (cancer, allergy), VentiRx/Bristol-Myers Squibb', 'toll-like receptor modulators (cancer, allergy),/']",motolimod,fexact,"['toll like receptor modulators', 'vtx 378', 'toll like receptor modulators cancer allergy ventirx celgene', 'motolimod', 'toll like receptor modulators cancer allergy ventirx', 'tlr modulators cancer allergy', 'vtx 2337', 'tlr modulators cancer allergy ventirx', 'toll like receptor modulators ventirx celgene', 'toll like receptor modulators ventirx', 'toll like receptor modulators cancer allergy ventirx bristol myers squibb', 'toll like receptor modulators cancer allergy']",correct_mapping
imiquimod (cream),Immunostimulant,imiquimod,,imiquimod,imiquimod,fexact,"['MTD-39', 'S-26308', 'MLD-39', 'Zyclara', 'Zartra', 'imiquimod', 'Aldara', 'DZ-2636', 'Beselna Cream', 'Vyloma', 'R-837']",imiquimod,fexact,"['mtd 39', 's 26308', 'mld 39', 'zyclara', 'zartra', 'imiquimod', 'aldara', 'dz 2636', 'beselna cream', 'vyloma', 'r 837']",correct_mapping
undisclosed - influenza vaccine (ID),Immunostimulant,undisclosed - influenza vaccine,,,,0,['undisclosed - influenza vaccine'],,0,[],0
mAb 216,Immunostimulant,mAb 216,,mAb-216,mab 216,fexact,"['HuMab-216', 'mAb-216', 'human monoclonal antibody (b-cell acute lymphoblastic leukemia)']",mAb-216,fexact,"['humab 216', 'mab 216', 'human monoclonal antibody b cell acute lymphoblastic leukemia']",correct_mapping
Resimmune,Translation elongation factor 2 inhibitor,Resimmune,,A-dmDT390-bisFv(UCHT1),resimmune,fexact,"['anti-CD3 scFv immunotoxins,/NIH', 'UCHT1-CRM9', 'A-dmDT390-bisFv(UCHT1)', 'scFv(UCHT1)-PE38', 'anti-CD3 bivalent antibody-diphtheria toxin conjugate (T-cell lymphoma/leukemia),/', 'anti-CD3 bivalent antibody-diphtheria toxin conjugate (T-cell lymphoma/leukemia/melanoma),/', 'anti-CD3 immunotoxins, Novartis/NIH', 'anti-CD3 bivalent antibody-diphtheria toxin conjugate (T-cell lymphoma/leukemia), Angimmune/', 'FN18-CRM9', 'anti-CD3 immunotoxins,/NIH', 'A-dmDT390-sFv', 'anti-CD3 scFv immunotoxins, Novartis/NIH', 'anti-CD3 scFv immunotoxins, NIH/', 'DT-389-scFv(UCHT1)', 'anti-CD3 scFv immunotoxins, NIH/Novartis', 'anti-CD3 bivalent antibody-diphtheria toxin conjugate (T-cell lymphoma/leukemia/melanoma), Angimmune/', 'Resimmune', 'LAX-699']",A-dmDT390-bisFv(UCHT1),fexact,"['anti cd3 scfv immunotoxins nih', 'ucht1 crm9', 'a dmdt390 bisfv ucht1', 'scfv ucht1 pe38', 'anti cd3 bivalent antibody diphtheria toxin conjugate t cell lymphoma leukemia', 'anti cd3 bivalent antibody diphtheria toxin conjugate t cell lymphoma leukemia melanoma', 'anti cd3 immunotoxins novartis nih', 'anti cd3 bivalent antibody diphtheria toxin conjugate t cell lymphoma leukemia angimmune', 'fn18 crm9', 'anti cd3 immunotoxins nih', 'a dmdt390 sfv', 'anti cd3 scfv immunotoxins novartis nih', 'anti cd3 scfv immunotoxins nih', 'dt 389 scfv ucht1', 'anti cd3 scfv immunotoxins nih novartis', 'anti cd3 bivalent antibody diphtheria toxin conjugate t cell lymphoma leukemia melanoma angimmune', 'resimmune', 'lax 699']",correct_mapping
risedronate (once-weekly),Osteoclast inhibitor; Osteoblast stimulant; Bisphosphonate; Bone resorption inhibitor,risedronate,,risedronate sodium,risedronate,fexact,"['Actonel OaM', 'HMR-4003', 'Actonel', 'Actonel EC', 'Benet', 'Actonil', 'risedronic acid', 'NE-58093', 'Libertas 150', 'Residronate', 'risedronate sodium hydrate', 'Optinate', 'risedronate', 'NE-58095', 'NE-58095NF', 'Acrel', 'risedronate sodium']",risedronate sodium,fexact,"['actonel oam', 'hmr 4003', 'actonel', 'actonel ec', 'benet', 'actonil', 'risedronic acid', 'ne 58093', 'libertas 150', 'residronate', 'risedronate sodium hydrate', 'optinate', 'risedronate', 'ne 58095', 'ne 58095nf', 'acrel', 'risedronate sodium']",correct_mapping
amuvatinib hydrochloride,RET tyrosine kinase inhibitor; C-kit inhibitor; Flt-3 antagonist; MET tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; DNA repair enzyme inhibitor; RAD51 expression inhibitor,amuvatinib hydrochloride,,amuvatinib,amuvatinib hydrochloride,fexact,"['amuvatinib', 'MP-470 hydrochloride', 'amuvatinib hydrochloride', 'MP-470']",amuvatinib,fexact,"['amuvatinib', 'mp 470 hydrochloride', 'amuvatinib hydrochloride', 'mp 470']",correct_mapping
perillyl alcohol (oral),Farnesyltransferase inhibitor; Apoptosis stimulant; Cell cycle inhibitor,perillyl alcohol,,,,0,"['NEO-100', 'monoterpenes', 'monoterpene perillyl alcohol (intranasal, glioma)', 'perillyl alcohol, WARF', 'monoterpene perillyl alcohol (intranasal, glioma), NEONC', 'NSC-641066', 'perillyl alcohol']",,Drug_API_mapping,[],0
SGN-30,CD30 antagonist; Immuno-oncology therapy,SGN-30,,SGN-30,sgn 30,fexact,"['SGN-30', 'chimeric mAb cAC10, Seattle Genetics', 'chimeric mAb AC10, Seattle Genetics', 'anti-CD30 mAb (lymphoma), Seattle Genetics']",SGN-30,fexact,"['sgn 30', 'chimeric mab cac10 seattle genetics', 'chimeric mab ac10 seattle genetics', 'anti cd30 mab lymphoma seattle genetics']",correct_mapping
prednisone (parenteral),Corticosteroid agonist,prednisone,,,,0,"['prednisone (oral microcapsule formulation/Optimum, cancer/acute pain), Orbis Biosciences', 'prednisone (oral microcapsule formulation/Optimum, nephrotic syndrome/asthma/bronchiolitis/eczema/atopic dermatitis/cancer), Orbis Biosciences', 'ORB-101', 'prednisone', 'prednisone (oral microcapsule formulation/Optimum, nephrotic syndrome/asthma/bronchiolitis/eczema/atopic dermatitis/cancer)', 'prednisone (oral microcapsule formulation/Optimum, cancer/acute pain)']",,NER_API,[],0
mono-dgA-RFB4,Unidentified pharmacological activity,mono-dgA-RFB4,,,,0,['mono-dgA-RFB4'],,0,[],0
vitespen (intradermal),Immunostimulant,vitespen,,vitespen,vitespen,fexact,"['HSPPC-96-GH', 'Oncophage', 'Prophage M-200', 'Prophage G-200', 'Prophage R-200', 'Prophage M-100', 'gp96 vaccine, Antigenics', 'NP-150', 'Prophage R-100', 'vitespen', 'HSPPC-96', 'Prophage G-100', 'Prophage NP-150', 'HSPPC-96-C']",vitespen,fexact,"['hsppc 96 gh', 'oncophage', 'prophage m 200', 'prophage g 200', 'prophage r 200', 'prophage m 100', 'gp96 vaccine antigenics', 'np 150', 'prophage r 100', 'vitespen', 'hsppc 96', 'prophage g 100', 'prophage np 150', 'hsppc 96 c']",correct_mapping
penclomedine,DNA inhibitor,penclomedine,,penclomedine,penclomedine,fexact,"['penclomedine', 'CRC-88-04', 'NSC-338720', 'penclomidine']",penclomedine,fexact,"['penclomedine', 'crc 88 04', 'nsc 338720', 'penclomidine']",correct_mapping
arginine butyrate,Histone deacetylase inhibitor; Gene expression stimulant; Globin stimulant; Cell cycle inhibitor,arginine butyrate,,,,0,"['arginine butyrate (hematological malignancies), HemaQuest', 'arginine butyrate', 'VX-105', 'HQK-1004']",,Drug_API_mapping,[],0
Mik-beta-1,Interleukin 2 receptor beta antagonist; Immunosuppressant; T cell stimulant,Mik-beta-1,,mik-beta-1,mik beta 1,fexact,"['mik-beta-1', 'anti-CD122 mAb(CLL)']",mik-beta-1,fexact,"['mik beta 1', 'anti cd122 mab cll']",correct_mapping
estramustine phosphate sodium,Microtubule inhibitor; DNA inhibitor; DNA synthesis inhibitor; Estrogen receptor agonist,estramustine phosphate sodium,,,,0,['estramustine phosphate sodium'],,0,[],0
"gamma delta T-cell therapy, PersonGen BioTherapeutics",T cell stimulant; Immuno-oncology therapy,gamma delta T-cell therapy,PersonGen BioTherapeutics,,,0,['gamma delta T-cell therapy'],,0,[],0
flumatinib,Tyrosine kinase inhibitor (TKI),flumatinib,,flumatinib,flumatinib,fexact,"['hausen xin fu', 'flumatinib', 'fumatini mesylate', 'Xinfu', 'HH-GV-678', 'flumatinib mesylate']",flumatinib,fexact,"['hausen xin fu', 'flumatinib', 'fumatini mesylate', 'xinfu', 'hh gv 678', 'flumatinib mesylate']",correct_mapping
CAR-T-CD22,T cell stimulant; Immuno-oncology therapy,CAR-T-CD22,,,,0,['CAR-T-CD22'],,0,[],0
"dexamethasone sodium phosphate, AVM Biotechnology",Unidentified pharmacological activity,dexamethasone sodium phosphate,AVM Biotechnology,,,0,"['ProDex', 'dexamethasone (sustained release liposomal/BioSeizer, osteoarthritis)', 'TLC-599', 'dexamethasone sodium phosphate', 'dexamethasone sodium phosphate (sustained release liposomal/BioSeizer, osteoarthritis pain)', 'dexamethasone']",,NER_API,[],0
TT52CAR19,CD19 antagonist; Immuno-oncology therapy; Genome editing,TT52CAR19,,,,0,['TT52CAR19'],,0,[],0
CD7 UCAR T cells,T cell stimulant; Immuno-oncology therapy,CD7 UCAR T cells,,,,0,['CD7 UCAR T cells'],,0,[],0
GNR-084,T cell stimulant; Immuno-oncology therapy,GNR-084,,GNR-084,gnr 084,fexact,"['GNR-084', 'anti-CD3/anti-CD19 bispecific T-cell engager (IONTAS, B-cell acute lymphoblastic leukemia), IBC Generium']",GNR-084,fexact,"['gnr 084', 'anti cd3 anti cd19 bispecific t cell engager iontas b cell acute lymphoblastic leukemia ibc generium']",correct_mapping
fish oil,Reducing agent; Omega 3 fatty acid stimulant,fish oil,,,,0,['fish oil'],,0,[],0
ET-190,Immunostimulant; CD19 antagonist; Immuno-oncology therapy,ET-190,,ET-190,et 190,fexact,"['ET190L1-ARTEMIS', 'ET190L1-ARTEMIS T cells (hematological cancer)', 'anti-CD19 CAR T-cell therapy (cancer)', 'CD19-ARTEMIS T-cells (cancer)', 'ET-190']",ET-190,fexact,"['et190l1 artemis', 'et190l1 artemis t cells hematological cancer', 'anti cd19 car t cell therapy cancer', 'cd19 artemis t cells cancer', 'et 190']",correct_mapping
GC-007F,T cell stimulant; Immuno-oncology therapy,GC-007F,,GC-007F,gc 007f,fexact,"['GC-019F', 'anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia)', 'CD19-F-CAR-T', 'FasT CAR-19', 'GC-007F']",GC-007F,fexact,"['gc 019f', 'anti cd19 car t cell therapy b cell acute lymphoblastic leukemia', 'cd19 f car t', 'fast car 19', 'gc 007f']",correct_mapping
tenofovir alafenamide,Nucleotide reverse transcriptase inhibitor,tenofovir alafenamide,,tenofovir alafenamide fumarate,tenofovir alafenamide,fexact,"['Vemlidy', 'GS-7340 hemifumarate', 'tenofovir alafenamide fumarate', 'tenofovir alafenamide', 'tenofovir alafenamide monofumarate', 'GS-7340 fumarate', 'GS-7340']",tenofovir alafenamide fumarate,fexact,"['vemlidy', 'gs 7340 hemifumarate', 'tenofovir alafenamide fumarate', 'tenofovir alafenamide', 'tenofovir alafenamide monofumarate', 'gs 7340 fumarate', 'gs 7340']",correct_mapping
EBViNT,CD137 agonist; Immuno-oncology therapy; Immune checkpoint stimulant,EBViNT,,,,0,['EBViNT'],,0,[],0
CD19.CAR-multiVSTs,CD19 antagonist; Immuno-oncology therapy,CD19.CAR-multiVSTs,,,,0,['CD19.CAR-multiVSTs'],,0,[],0
"CD22 chimaeric antigen receptor therapy, Wuhan Bio-Raid Biotechnology",T cell stimulant; Immuno-oncology therapy,CD22 chimaeric antigen receptor therapy,Wuhan Bio-Raid Biotechnology,,,0,['CD22 chimaeric antigen receptor therapy'],,0,[],0
ADCT-602,DNA inhibitor,ADCT-602,,ADCT-602,adct 602,fexact,"['antibody-drug conjugates (cancer/B-cell acute lymphoblastic leukemia),/ Cancer Research Technology', 'ADCT-602', 'Epratuzumab-cys-SG3249', 'hLL2-cys-SG3249', 'antibody-drug conjugates (cancer),/ Cancer Research Technology', 'antibody-drug conjugates (cancer/B-cell acute lymphoblastic leukemia),/', 'antibody-drug conjugates (cancer),/']",ADCT-602,fexact,"['antibody drug conjugates cancer b cell acute lymphoblastic leukemia cancer research technology', 'adct 602', 'epratuzumab cys sg3249', 'hll2 cys sg3249', 'antibody drug conjugates cancer cancer research technology', 'antibody drug conjugates cancer b cell acute lymphoblastic leukemia', 'antibody drug conjugates cancer']",correct_mapping
UCART-22,T cell stimulant; Immuno-oncology therapy,UCART-22,,UCART-22,ucart 22,fexact,"['UCART-22', 'anti-CD22 CAR T-cell therapy (AML/CLL/ALL)']",UCART-22,fexact,"['ucart 22', 'anti cd22 car t cell therapy aml cll all']",correct_mapping
CLL-442,Unidentified pharmacological activity,CLL-442,,CLL-442,cll 442,fexact,"['CLL-442', ""mTOR/PI3K inhibitor (topical cream, Bowen's disease)""]",CLL-442,fexact,"['cll 442', 'mtor pi3k inhibitor topical cream bowen s disease']",correct_mapping
CIK-CAR.CD19,T cell stimulant; Immuno-oncology therapy,CIK-CAR.CD19,,CIK-CAR.CD19,cik car cd19,fexact,"['anti-CD19 CAR cytokine induced killer cell therapy (ALL/NHL), Formula Pharmaceuticals', 'anti-CD19 CAR CIK-cell therapy (ALL/NHL)', 'anti-CD19 CAR CIK-cell therapy (ALL/NHL), Formula Pharmaceuticals', 'CARCIK-CD19', 'anti-CD19 CAR cytokine induced killer cell therapy (ALL/NHL)', 'CIK-CAR.CD19']",CIK-CAR.CD19,fexact,"['anti cd19 car cytokine induced killer cell therapy all nhl formula pharmaceuticals', 'anti cd19 car cik cell therapy all nhl', 'anti cd19 car cik cell therapy all nhl formula pharmaceuticals', 'carcik cd19', 'anti cd19 car cytokine induced killer cell therapy all nhl', 'cik car cd19']",correct_mapping
"IM-19, Immunochina Pharmaceuticals",T cell stimulant; CD19 antagonist; Immuno-oncology therapy,IM-19,Immunochina Pharmaceuticals,IM-19,im 19,fexact,"['anti-CD19 CAR T-cell therapy (leukemia)', 'IM19 CAR-T', 'anti-CD19 CAR T-cell therapy (non-Hodgkin lymphoma/B-cell acute lymphoblastic leukemia), Simcere Pharmaceutical Group/', 'anti-cd19 car t-cell therapy (non-hodgkin lymphoma/b-cell acute lymphoblastic leukemia)', 'IM-19']",IM-19,fexact,"['anti cd19 car t cell therapy leukemia', 'im19 car t', 'anti cd19 car t cell therapy non hodgkin lymphoma b cell acute lymphoblastic leukemia simcere pharmaceutical group', 'anti cd19 car t cell therapy non hodgkin lymphoma b cell acute lymphoblastic leukemia', 'im 19']",correct_mapping
Pegylated recombinant L-asparaginase erwinia chrysanthemi,Unidentified pharmacological activity,Pegylated recombinant L-asparaginase erwinia chrysanthemi,,,,0,['Pegylated recombinant L-asparaginase erwinia chrysanthemi'],,0,[],0
tazemetostat (oral tablet),Enhancer of zeste homolog 2 inhibitor,tazemetostat,,tazemetostat hydrobromide,tazemetostat,fexact,"['EPZ-005687', 'tazemetostat hydrobromide', 'E-7438', 'EZH2 inhibitors (cancer),/', 'tazemetostat', 'EPZ-6438', 'EPZ-5687', 'EZH2 inhibitors (cancer), EpiZyme/', 'Tazverik']",tazemetostat hydrobromide,fexact,"['epz 005687', 'tazemetostat hydrobromide', 'e 7438', 'ezh2 inhibitors cancer', 'tazemetostat', 'epz 6438', 'epz 5687', 'ezh2 inhibitors cancer epizyme', 'tazverik']",correct_mapping
[14C] tazemetostat,Not applicable,[14C] tazemetostat,,,,0,['[14C] tazemetostat'],,0,[],0
Personalized peptide vaccine,Unidentified pharmacological activity,Personalized peptide vaccine,,,,0,['Personalized peptide vaccine'],,0,[],0
apixaban (tablet),Direct Factor Xa inhibitor; Factor Xa inhibitor; Serine protease inhibitor,apixaban,,apixaban,apixaban,fexact,"['razaxaban follow-on compound,/', 'Factor Xa antagonist (follow-on),/Pfizer', 'BMS-562247', 'razaxaban follow-on compound,/Pfizer', 'Eliquis', 'apixaban', 'Factor Xa antagonist (follow-on),/']",apixaban,fexact,"['razaxaban follow on compound', 'factor xa antagonist follow on pfizer', 'bms 562247', 'razaxaban follow on compound pfizer', 'eliquis', 'apixaban', 'factor xa antagonist follow on']",correct_mapping
calcium,Phosphate antagonist,calcium,,,,0,['calcium'],,0,[],0
Gen-Hevac-B (ID),Immunostimulant,Gen-Hevac-B,,,,0,['Gen-Hevac-B'],,0,[],0
"cytarabine, DepoFoam",DNA synthesis inhibitor,cytarabine,DepoFoam,,,0,"['cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/', 'DepoFoam (cytarabine)', 'DepoCyt', 'NS-101', 'Savedar', 'cytarabine (sustained release, DepoFoam), SkyePharma', 'DTC-101', 'cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical', 'Cytosar-U', 'cytarabine (SR formulation), DepoTech/', 'Cytosar', 'cytarabine', 'DepoCyte', 'cytarabine (sustained release, DepoFoam),/Sigma-Tau/Pfizer/', 'cytarabine (sustained release, DepoFoam),///', 'Ara-C', 'cytarabine (sustained release, DepoFoam),/Sigma-Tau//']",,NER_API,[],0
fimepinostat,Histone deacetylase inhibitor; PI3 kinase inhibitor,fimepinostat,,fimepinostat,fimepinostat,fexact,"['HDAC/PI3 kinase inhibitor (oral, cancer)', 'CUDC-907', 'fimepinostat', 'histone deacetylase/phosphatidylinositol-3 kinase inhibitor (oral, cancer)']",fimepinostat,fexact,"['hdac pi3 kinase inhibitor oral cancer', 'cudc 907', 'fimepinostat', 'histone deacetylase phosphatidylinositol 3 kinase inhibitor oral cancer']",correct_mapping
EZN-3042,Apoptosis stimulant; Survivin inhibitor,EZN-3042,,SPC-3042,ezn 3042,fexact,"['ENZ-3042', 'SPC-3042', 'anti-Survivin (LNA antisense therapy), Santaris/', 'EZN-3042']",SPC-3042,fexact,"['enz 3042', 'spc 3042', 'anti survivin lna antisense therapy santaris', 'ezn 3042']",correct_mapping
"HPV vaccine, CSL",Immunostimulant,HPV vaccine,CSL,Gardasil,hpv vaccine,fexact,"['human papilloma virus vaccine,/Merck & Co', 'human papilloma virus vaccine,/', 'HPV vaccine (quadrivalent), Sanofi Pasteur MSD/', 'Silgard', 'V-501', 'HPV vaccine,/', 'HPV vaccine,/Merck & Co', 'V-501, Uniquest', 'human papillomavirus vaccine,/', 'human papillomavirus vaccine,/Merck & Co', 'HPV vaccine (quadrivalent), Aventis Pasteur MSD/', 'hpv vaccine (quadrivalent)', 'HPV vaccine (quadrivalent), Merck & Co', 'HPV vaccine (quadrivalent)', 'Gardasil']",Gardasil,fexact,"['human papilloma virus vaccine merck co', 'human papilloma virus vaccine', 'hpv vaccine quadrivalent sanofi pasteur msd', 'silgard', 'v 501', 'hpv vaccine', 'hpv vaccine merck co', 'v 501 uniquest', 'human papillomavirus vaccine', 'human papillomavirus vaccine merck co', 'hpv vaccine quadrivalent aventis pasteur msd', 'hpv vaccine quadrivalent', 'hpv vaccine quadrivalent merck co', 'hpv vaccine quadrivalent', 'gardasil']",correct_mapping
"AML vaccine, Juvaris BioTherapeutics",Immunostimulant,AML vaccine,Juvaris BioTherapeutics,,,0,['AML vaccine'],,0,[],0
briciclib sodium,Translation initiation factor 4E inhibitor; Apoptosis stimulant; Cyclin D inhibitor,briciclib sodium,,briciclib sodium,briciclib sodium,fexact,"['briciclib', 'cyclin D1 inhibitor (iv prodrug, hematological malignancies)', 'ON-013105.Na', 'ON-013105', 'styryl sulfone (iv prodrug, hematological malignancies)', 'briciclib sodium', '014185']",briciclib sodium,fexact,"['briciclib', 'cyclin d1 inhibitor iv prodrug hematological malignancies', 'on 013105 na', 'on 013105', 'styryl sulfone iv prodrug hematological malignancies', 'briciclib sodium', '014185']",correct_mapping
"COLD-FX, Afexa",Immunostimulant,COLD-FX,Afexa,,,0,['COLD-FX'],,0,[],0
dasatinib (oral suspension),LYN tyrosine kinase inhibitor; Bcr-Abl inhibitor; C-kit inhibitor; EphA receptor kinase inhibitor; Fyn tyrosine kinase inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib; Src inhibitor; Yes tyrosine kinase inhibitor,dasatinib,,dasatinib,dasatinib,fexact,"['NSC-732517', 'Src/Abl kinase inhibitor (cancer), BMS', 'BMS-354825', 'Sprycel', 'Spricel', 'dasatinib (USAN)', 'dasatinib', 'Spraicell']",dasatinib,fexact,"['nsc 732517', 'src abl kinase inhibitor cancer bms', 'bms 354825', 'sprycel', 'spricel', 'dasatinib usan', 'dasatinib', 'spraicell']",correct_mapping
hydrocortisone sodium succinate,Corticosteroid agonist,hydrocortisone sodium succinate,,,,0,['hydrocortisone sodium succinate'],,0,[],0
metformin HCl (oral solution),Biguanide; Gluconeogenesis inhibitor,metformin HCl,,,,0,['metformin HCl'],,0,[],0
L-778123,Farnesyltransferase inhibitor; Geranylgeranyltransferase inhibitor; Mitotic inhibitor,L-778123,,L-778123,l 778123,fexact,"['L-739750', 'L-778123']",L-778123,fexact,"['l 739750', 'l 778123']",correct_mapping
Yttrium Y 90 monoclonal antibody Lym-1,DNA inhibitor,Yttrium Y 90 monoclonal antibody Lym-1,,,,0,['Yttrium Y 90 monoclonal antibody Lym-1'],,0,[],0
aflibercept (SC),Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor,aflibercept,,,,0,"['aflibercept', 'aflibercept biosimilar', 'SCD-411']",,NER_API,[],0
interleukin-3,Interleukin 3 agonist,interleukin-3,,,,0,"['IL-3', 'Allevorin', 'il-3', 'interleukin-3']",,Drug_API_mapping,[],0
elsamitrucin,DNA topoisomerase I inhibitor; DNA topoisomerase II inhibitor,elsamitrucin,,elsamitrucin,elsamitrucin,fexact,"['BMY-28090', 'elsamicin-A', 'BMS-181171', 'Antibiotic BBM 2478A', 'BBM-2478A', 'NSC-369327', 'elsamitrucin']",elsamitrucin,fexact,"['bmy 28090', 'elsamicin a', 'bms 181171', 'antibiotic bbm 2478a', 'bbm 2478a', 'nsc 369327', 'elsamitrucin']",correct_mapping
benzimate,Mitotic inhibitor,benzimate,,,,0,"['AMP-507', 'ATI-0312', 'AMP-500 series (cancer)', 'PG-045', 'FB-645', 'FB-633', 'FB-639', 'FB-651', 'FB-532', 'FB-649', 'FB-655', 'benzimidazole series (cancer)', 'FB-642', 'benzimate', 'PG-026']",,NER_API,[],0
etaracizumab (IV),Angiogenesis inhibitor; Alphavbeta3 integrin antagonist; Integrin antagonist; Apoptosis stimulant,etaracizumab,,etaracizumab,etaracizumab,fexact,"['LM-609', 'Vitaxin', 'Abegrin', 'etaracizumab', 'second generation Vitaxin', 'MEDI-522', 'Vitaxin-2', 'medi-523']",etaracizumab,fexact,"['lm 609', 'vitaxin', 'abegrin', 'etaracizumab', 'second generation vitaxin', 'medi 522', 'vitaxin 2', 'medi 523']",correct_mapping
"interleukin-11, unspecified",Interleukin 11 agonist,interleukin-11,unspecified,pegilodecakin,interleukin 10,fuzzy,"['rHuIL-10', 'LY-3500518', 'interleukin-10, Schering-Plough', 'peg-IL-10', 'ilodecakin', 'IL-10, Schering-Plough', 'IL-10', 'PEGylated human IL-10', 'Tenovil', 'pegilodecakin', 'interleukin-10', 'Sch-52000', 'rHuIL-10, Schering-Plough', 'AM-0010']",pegilodecakin,fexact,"['rhuil 10', 'ly 3500518', 'interleukin 10 schering plough', 'peg il 10', 'ilodecakin', 'il 10 schering plough', 'il 10', 'pegylated human il 10', 'tenovil', 'pegilodecakin', 'interleukin 10', 'sch 52000', 'rhuil 10 schering plough', 'am 0010']",incorrect_mapping
dasiprotimut-T,Immunostimulant,dasiprotimut-T,,,,0,"['Lympreva', 'vaccine (B-cell lymphoma), Stanford University//', 'BiovaxID', 'vaccine (B-cell lymphoma), Biovest', 'vaccine (B-cell lymphoma), Stanford University//Biovest', 'dasiprotimut-T', 'vaccine (b-cell lymphoma)', 'vaccine (B-cell lymphoma)']",,NER_API,[],0
